PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Mandala, S; Hajdu, R; Bergstrom, J; Quackenbush, E; Xie, J; Milligan, J; Thornton, R; Shei, GJ; Card, D; Keohane, C; Rosenbach, M; Hale, J; Lynch, CL; Rupprecht, K; Parsons, W; Rosen, H				Mandala, S; Hajdu, R; Bergstrom, J; Quackenbush, E; Xie, J; Milligan, J; Thornton, R; Shei, GJ; Card, D; Keohane, C; Rosenbach, M; Hale, J; Lynch, CL; Rupprecht, K; Parsons, W; Rosen, H			Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists	SCIENCE			English	Article							SPHINGOSINE 1-PHOSPHATE; FTY720; IMMUNOSUPPRESSANT; PLASMA	Blood lymphocyte numbers, essential for the development of efficient immune responses, are maintained by recirculation through secondary Lymphoid organs. We show that lymphocyte trafficking is altered by the lysophospholipid sphingosine-1-phosphate (S1P) and by a phosphoryl metabolite of the immunosuppressive agent FTY720. Both species were high-affinity agonists of at Least four of the five S1P receptors. These agonists produce lymphopenia in blood and thoracic duct lymph by sequestration of lymphocytes in lymph nodes, but not spleen. S1P receptor agonists induced emptying of lymphoid sinuses by retention of Lymphocytes on the abluminal side of sinus-lining endothelium and inhibition of egress into lymph. Inhibition of lymphocyte recirculation by activation of S1P receptors may result in therapeutically useful immunosuppression.	Merck Res Labs, Dept Immunol & Rheumatol, Rahway, NJ 07055 USA; Merck Res Labs, Dept Pharmacol, Rahway, NJ 07055 USA; Merck Res Labs, Dept Med Chem, Rahway, NJ 07055 USA	Merck & Company; Merck & Company; Merck & Company	Rosen, H (corresponding author), Merck Res Labs, Dept Immunol & Rheumatol, POB 2000, Rahway, NJ 07055 USA.	hugh_rosen@merck.com						Ansel KM, 2001, CURR OPIN IMMUNOL, V13, P172, DOI 10.1016/S0952-7915(00)00201-6; Brinkmann V, 2000, TRENDS PHARMACOL SCI, V21, P49, DOI 10.1016/S0165-6147(99)01419-4; Brinkmann V, 2001, TRANSPLANTATION, V72, P764, DOI 10.1097/00007890-200109150-00002; Butcher EC, 1999, ADV IMMUNOL, V72, P209, DOI 10.1016/S0065-2776(08)60022-X; Chen JK, 1999, CHEM BIOL, V6, P221, DOI 10.1016/S1074-5521(99)80038-6; Chiba K, 1998, J IMMUNOL, V160, P5037; Fukushima N, 2001, ANNU REV PHARMACOL, V41, P507, DOI 10.1146/annurev.pharmtox.41.1.507; Garcia JGN, 2001, J CLIN INVEST, V108, P689, DOI 10.1172/JCI12450; Gowans JL, 1996, IMMUNOL TODAY, V17, P288, DOI 10.1016/0167-5699(96)80547-0; Graler MH, 1999, CURR TOP MICROBIOL, V246, P131; Henning G, 2001, J EXP MED, V194, P1875, DOI 10.1084/jem.194.12.1875; Hla T, 2001, SCIENCE, V294, P1875, DOI 10.1126/science.1065323; Ishii I, 2001, J BIOL CHEM, V276, P33697, DOI 10.1074/jbc.M104441200; Kabarowski JHS, 2001, SCIENCE, V293, P702, DOI 10.1126/science.1061781; Kiuchi M, 2000, J MED CHEM, V43, P2946, DOI 10.1021/jm000173z; Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092-8674(00)81661-X; Liliom K, 2001, BIOCHEM J, V355, P189, DOI 10.1042/0264-6021:3550189; Luo ZJ, 1999, IMMUNOPHARMACOLOGY, V41, P199, DOI 10.1016/S0162-3109(99)00004-1; Mandala SM, 2000, P NATL ACAD SCI USA, V97, P7859, DOI 10.1073/pnas.120146897; Murata N, 2000, BIOCHEM J, V352, P809, DOI 10.1042/0264-6021:3520809; Neumayer HH, 1999, TRANSPLANTATION, V67, pS204, DOI 10.1097/00007890-199904150-00815; Sugiyama A, 2000, JPN J PHARMACOL, V82, P338, DOI 10.1254/jjp.82.338; Sugiyama A, 2000, CARDIOVASC RES, V46, P119, DOI 10.1016/S0008-6363(00)00013-4	23	1343	1439	1	61	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 12	2002	296	5566					346	349		10.1126/science.1070238	http://dx.doi.org/10.1126/science.1070238			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	541TJ	11923495				2022-12-28	WOS:000175000300058
J	Peterson, AT; Ortega-Huerta, MA; Bartley, J; Sanchez-Cordero, V; Soberon, J; Buddemeier, RH; Stockwell, DRB				Peterson, AT; Ortega-Huerta, MA; Bartley, J; Sanchez-Cordero, V; Soberon, J; Buddemeier, RH; Stockwell, DRB			Future projections for Mexican faunas under global climate change scenarios	NATURE			English	Article							SPECIES RANGE; BIODIVERSITY; NICHES	Global climates are changing rapidly, with unexpected consequences(1). Because elements of biodiversity respond intimately to climate as an important driving force of distributional limitation(2), distributional shifts and biodiversity losses are expected(3,4). Nevertheless, in spite of modelling efforts focused on single species(2) or entire ecosystems(5), a few preliminary surveys of fauna-wide effects(6,7), and evidence of climate change-mediated shifts in several species(8,9), the likely effects of climate change on species' distributions remain little known, and fauna-wide or community-level effects are almost completely unexplored(6). Here, using a genetic algorithm and museum specimen occurrence data, we develop ecological niche models for 1,870 species occurring in Mexico and project them onto two climate surfaces modelled for 2055. Although extinctions and drastic range reductions are predicted to be relatively few, species turnover in some local communities is predicted to be high (> 40% of species), suggesting that severe ecological perturbations may result.	Univ Kansas, Museum Nat Hist, Lawrence, KS 66045 USA; Univ Kansas, Dept Geog, Lawrence, KS 66045 USA; Univ Kansas, Kansas Appl Remote Sensing Program, Lawrence, KS 66045 USA; Univ Kansas, Kansas Geol Survey, Lawrence, KS 66045 USA; Univ Nacl Autonoma Mexico, Inst Biol, Dept Zool, Mexico City 04510, DF, Mexico; Univ Nacl Autonoma Mexico, Inst Ecol, Dept Ecol Evolut, Mexico City 04510, DF, Mexico; Univ Calif San Diego, San Diego Supercomp Ctr, La Jolla, CA 92093 USA	University of Kansas; University of Kansas; University of Kansas; University of Kansas; Universidad Nacional Autonoma de Mexico; Universidad Nacional Autonoma de Mexico; University of California System; University of California San Diego	Peterson, AT (corresponding author), Univ Kansas, Museum Nat Hist, Lawrence, KS 66045 USA.		Soberon, Jorge/ABF-1306-2021; Peterson, A. Townsend/I-5697-2013; Soberon, Jorge/N-7444-2015	Soberon, Jorge/0000-0003-2160-4148; Peterson, A. Townsend/0000-0003-0243-2379; Soberon, Jorge/0000-0003-2160-4148				AUSTIN MP, 1990, ECOL MONOGR, V60, P161, DOI 10.2307/1943043; Carson DJ, 1999, Q J ROY METEOR SOC, V125, P1, DOI 10.1002/qj.49712555303; Chapin FS, 2000, NATURE, V405, P234, DOI 10.1038/35012241; Davis AJ, 1998, NATURE, V391, P783, DOI 10.1038/35842; DOBSON A, 1989, TRENDS ECOL EVOL, V4, P64, DOI 10.1016/0169-5347(89)90150-X; Grinnell J, 1917, AM NAT, V51, P115, DOI 10.1086/279591; HOLT RD, 1992, EVOL ECOL, V6, P433, DOI 10.1007/BF02270702; HOUGHTON JT, 2001, IPCC 3 ASSESSMENT RE; Johnston KM, 1997, GLOB CHANGE BIOL, V3, P531, DOI 10.1046/j.1365-2486.1997.00093.x; KOOPOWITZ H, 1994, CONSERV BIOL, V8, P452; LLORENTEBOUSQUE.J, 1997, PAPILIONIDAE PIERIDA; MacArthur R.H., 1972, pvii; Parmesan C, 1996, NATURE, V382, P765, DOI 10.1038/382765a0; Peterson AT, 2001, BIOSCIENCE, V51, P363, DOI 10.1641/0006-3568(2001)051[0363:PSIUEN]2.0.CO;2; Peterson AT, 1999, CONSERV BIOL, V13, P427, DOI 10.1046/j.1523-1739.1999.013002427.x; Peterson AT, 1999, SCIENCE, V285, P1265, DOI 10.1126/science.285.5431.1265; Peterson AT, 1998, IBIS, V140, P288, DOI 10.1111/j.1474-919X.1998.tb04391.x; Peterson AT, 2002, IBIS, V144, pE27, DOI 10.1046/j.0019-1019.2001.00031.x; Peterson AT, 2001, ECOL MODEL, V144, P21, DOI 10.1016/S0304-3800(01)00345-3; Peterson AT, 2001, CONDOR, V103, P599, DOI 10.1650/0010-5422(2001)103[0599:PSGDBO]2.0.CO;2; PETERSON AT, IN PRESS PREDICTING; Price Jeff, 2000, Bird Observer (Arlington), V28, P224; Sala OE, 2000, SCIENCE, V287, P1770, DOI 10.1126/science.287.5459.1770; Sanchez-Cordero V, 2000, P NATL ACAD SCI USA, V97, P7074, DOI 10.1073/pnas.97.13.7074; Soberon J, 1999, TRENDS ECOL EVOL, V14, P291, DOI 10.1016/S0169-5347(99)01617-1; Stockwell D, 1999, INT J GEOGR INF SCI, V13, P143, DOI 10.1080/136588199241391; TOBLER WR, 1979, J AM STAT ASSOC, V74, P519, DOI 10.2307/2286968; Visser ME, 1998, P ROY SOC B-BIOL SCI, V265, P1867, DOI 10.1098/rspb.1998.0514; Woodward FI, 1998, PHILOS T ROY SOC B, V353, P29, DOI 10.1098/rstb.1998.0188	29	606	665	3	181	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 11	2002	416	6881					626	629		10.1038/416626a	http://dx.doi.org/10.1038/416626a			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	539YV	11948349				2022-12-28	WOS:000174901900041
J	Hannah, ME; Hannah, WJ; Hodnett, ED; Chalmers, B; Kung, R; Willan, A; Amankwah, K; Cheng, M; Helewa, M; Hewson, S; Saigal, S; Whyte, H; Gafni, A				Hannah, ME; Hannah, WJ; Hodnett, ED; Chalmers, B; Kung, R; Willan, A; Amankwah, K; Cheng, M; Helewa, M; Hewson, S; Saigal, S; Whyte, H; Gafni, A		Term Breech Trial 3 Month Follow Up	Outcomes at 3 months after planned cesarean vs planned vaginal delivery for breech presentation at term - The international randomized Term Breech Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POSTNATAL DEPRESSION; URINARY-INCONTINENCE; CHILDBIRTH; BIRTH; LABOR; MODE; EXPERIENCES; PREVALENCE; PREGNANCY	Context The Term Breech Trial found a significant reduction in adverse perinatal outcomes without an increased risk of immediate maternal morbidity with planned cesarean delivery compared with planned vaginal birth. No randomized controlled trial of planned cesarean delivery has measured benefits and risks of postpartum outcomes months after the birth. Objective To compare maternal outcomes of planned cesarean delivery and planned vaginal birth at 3 months post partum. Design Follow-up study to the Term Breech Trial, a randomized controlled trial conducted between January 9, 1997, and April 21, 2000. Setting and Participants A total of 1596 of 1940 women from 110 centers worldwide who had a singleton fetus in breech presentation at term responded to a follow-up questionnaire at 3 months post partum. Main Outcome Measures Breastfeeding; infant health; ease of caring for infant and adjusting to being a new mother; sexual relations and relationship with husband/ partner; pain; urinary, flatal, and fecal incontinence; depression; and views regarding childbirth experience and study participation. Results Baseline information was similar for both the cesarean and vaginal delivery groups. Women in the planned cesarean delivery group were less likely to report urinary incontinence than those in the planned vaginal birth group (36/798 [4.5%] vs 58/797 [7.3%]; relative risk, 0.62; 95% confidence interval, 0.41-0.93). Incontinence of flatus was not different between groups but was less of a problem in the planned cesarean delivery group when it occurred (P=.006). There were no differences between groups in other outcomes. Conclusions Planned cesarean delivery for pregnancies with breech presentation at term may result in a lower risk of incontinence and is not associated with an increased risk of other problems for women at 3 months post partum, although the effect on longer-term outcomes is uncertain.	Univ Toronto, Ctr Res Womens Hlth, Maternal Infant & Reprod Hlth Res Unit, Toronto, ON M5G 1N8, Canada; Sunnybrook & Womens Coll Hlth Sci Ctr, Dept Obstet & Gynaecol, Toronto, ON, Canada; Univ Toronto, Ctr Res Womens Hlth, Fac Nursing, Toronto, ON M5G 1N8, Canada; Univ Toronto, Ctr Res Womens Hlth, WHO Collaborating Ctr, Toronto, ON M5G 1N8, Canada; Univ Toronto, Hosp Sick Children, Dept Paediat, Toronto, ON M5G 1N8, Canada; Centenary Hosp, Dept Obstet & Gynaecol, Scarborough, ON, Canada; Univ Manitoba, St Boniface Hosp, Dept Obstet & Gynaecol, Winnipeg, MB, Canada; McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada; McMaster Univ, Dept Paediat, Hamilton, ON, Canada	University of Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University of Toronto; World Health Organization; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Scarborough Hospital; University of Manitoba; Children's Hospital Research Institute of Manitoba; McMaster University; McMaster University	Hannah, ME (corresponding author), Univ Toronto, Ctr Res Womens Hlth, Maternal Infant & Reprod Hlth Res Unit, Suite 751,790 Bay St, Toronto, ON M5G 1N8, Canada.			Helewa, Michael/0000-0001-6792-4951; Chalmers, Beverley/0000-0002-9345-4284				AlMufti R, 1996, LANCET, V347, P544, DOI 10.1016/S0140-6736(96)91176-9; ASTBURY J, 1994, AUST J PUBLIC HEALTH, V18, P176; BROWN S, 1994, BIRTH-ISS PERINAT C, V21, P4, DOI 10.1111/j.1523-536X.1994.tb00909.x; Chalmers B, 1990, INT J PRENATAL PERIN, V1, P229; Cox J. L., 1994, PERINATAL PSYCHIAT U; COX JL, 1987, BRIT J PSYCHIAT, V150, P782, DOI 10.1192/bjp.150.6.782; *DEP HLTH, 2002, DEP HLTH STAT B; Glazener CMA, 1997, BRIT J OBSTET GYNAEC, V104, P330, DOI 10.1111/j.1471-0528.1997.tb11463.x; Hall MH, 1999, LANCET, V354, P776, DOI 10.1016/S0140-6736(05)76016-5; Hannah ME, 2000, LANCET, V356, P1375, DOI 10.1016/S0140-6736(00)02840-3; HANNAH P, 1992, BRIT J PSYCHIAT, V160, P777, DOI 10.1192/bjp.160.6.777; Hodnett ED, 1997, BIRTH-ISS PERINAT C, V24, P214, DOI 10.1111/j.1523-536X.1997.tb00593.x; HOFMEYR GJ, 2001, COCHRANE LIB; Hojberg KE, 1999, BRIT J OBSTET GYNAEC, V106, P842, DOI 10.1111/j.1471-0528.1999.tb08407.x; Jolly J, 1999, BRIT J OBSTET GYNAEC, V106, P227, DOI 10.1111/j.1471-0528.1999.tb08235.x; KENDELL RE, 1981, PSYCHOL MED, V11, P341, DOI 10.1017/S0033291700052156; Lavender T, 1999, BIRTH-ISS PERINAT C, V26, P89, DOI 10.1046/j.1523-536x.1999.00089.x; MacArthur C, 1997, BRIT J OBSTET GYNAEC, V104, P46, DOI 10.1111/j.1471-0528.1997.tb10648.x; Martin J A, 1999, Natl Vital Stat Rep, V47, P1; Meyer S, 1998, OBSTET GYNECOL, V92, P613, DOI 10.1016/S0029-7844(98)00248-8; *MIN PUBL HLTH WOR, 2000, CAN PER HLTH REP 200; Paterson-Brown S, 1998, BMJ-BRIT MED J, V317, P462; Peschers UM, 1997, BRIT J OBSTET GYNAEC, V104, P1004, DOI 10.1111/j.1471-0528.1997.tb12057.x; ROBSON KM, 1981, BRIT J OBSTET GYNAEC, V88, P882, DOI 10.1111/j.1471-0528.1981.tb02223.x; SULTAN AH, 1993, NEW ENGL J MED, V329, P1905, DOI 10.1056/NEJM199312233292601; VIKTRUP L, 1992, OBSTET GYNECOL, V79, P945; Viktrup L, 2001, AM J OBSTET GYNECOL, V185, P82, DOI 10.1067/mob.2001.114501; WHO, 1996, WHO PUBL; Wilson PD, 1996, BRIT J OBSTET GYNAEC, V103, P154, DOI 10.1111/j.1471-0528.1996.tb09668.x	29	180	185	0	23	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 10	2002	287	14					1822	1831		10.1001/jama.287.14.1822	http://dx.doi.org/10.1001/jama.287.14.1822			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	539QJ	11939868				2022-12-28	WOS:000174881700035
J	Rankin, J; Wright, C; Lind, T				Rankin, J; Wright, C; Lind, T			Cross sectional survey of parents' experience and views of the postmortem examination	BRITISH MEDICAL JOURNAL			English	Article							QUALITY; AUTOPSY	Objective To describe parents' experience and views of the postmortem examination after the loss of a baby. Design Cross sectional survey, Setting Hospital with a dedicated bereavement counselling service, Newcastle upon Tyne. Participants 258 women who had attended a bereavement counselling service at the Royal Victoria Infirmary, Newcastle upon Tyne, on at least one occasion after losing a baby, during pregnancy or infancy, between October 1996 and October 2000. Method Self completion postal questionnaire incorporating fixed choice and open ended questions. Main outcome measures Number of respondents who were asked if they would agree to a postmortem examination of their baby, and number who agreed to a postmortem examination; reasons for agreeing and not agreeing to a postmortem examination; quality, of explanation received; number who regretted their decision to give or withhold consent for a postmortem examination. Results 166 (64%) respondents completed the questionnaire. Of these, 148 (89%) had been asked to agree to a postmortem examination on their baby and 120/148 of these respondents (81%) agreed, most of whom recognised benefits resulting from the examination. 101/117 (86%) respondents believed the findings had been explained appropriately. Nine (7%) of the 120 respondents who had agreed to a postmortem examination regretted their decision. Of the respondents who refused an examination, four (14%) had regrets about their decision. Discussion Parents viewed the postmortem examination as a useful and necessary tool in helping to discover the reasons why their baby had died. Simplifying the language used to explain findings may further raise parents' understanding of the,,value of the postmortem examination and ensure that they are satisfied with it. Medical staff involved in consent for postmortem examinations should be fully trained in how to ask for parental consent, the postmortem examination procedure, and how to explain the findings.	Med Sch Newcastle Upon Tyne, Sch Hlth Sci, Dept Epidemiol & Publ Hlth, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Royal Victoria Infirm, Dept Pathol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England; Royal Victoria Infirm, Dept Fetal Med, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England	Newcastle University - UK; Newcastle University - UK; Newcastle University - UK	Rankin, J (corresponding author), Med Sch Newcastle Upon Tyne, Sch Hlth Sci, Dept Epidemiol & Publ Hlth, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.							BECKWITH JB, 1989, PEDIATR CLIN N AM, V36, P29; CARTLIDGE PHT, 1995, BRIT MED J, V310, P155, DOI 10.1136/bmj.310.6973.155; *CHIEF MED OFF, 2000, INT GUID POST MORT E; CHISWICK M, 1995, BRIT MED J, V310, P141, DOI 10.1136/bmj.310.6973.141; Lund JN, 2001, BRIT MED J, V323, P21, DOI 10.1136/bmj.323.7303.21; McHaffie HE, 2001, ARCH DIS CHILD-FETAL, V85, pF4, DOI 10.1136/fn.85.1.F4; MCPHEE SJ, 1986, AM J MED, V80, P665, DOI 10.1016/0002-9343(86)90822-3; RANKIN J, 1999, WOMENS PERCEPTIONS E; *REG MAT SURV OFF, 2000, ANN REP 1999; RUSHTON DI, 1991, BRIT J OBSTET GYNAEC, V98, P624, DOI 10.1111/j.1471-0528.1991.tb13446.x; Vujanic GM, 1998, J CLIN PATHOL, V51, P850, DOI 10.1136/jcp.51.11.850; VUJANIC GM, 1995, J CLIN PATHOL, V48, P998, DOI 10.1136/jcp.48.11.998; Wright C, 1998, BRIT J OBSTET GYNAEC, V105, P24, DOI 10.1111/j.1471-0528.1998.tb09345.x	13	53	53	1	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 6	2002	324	7341					816	818		10.1136/bmj.324.7341.816	http://dx.doi.org/10.1136/bmj.324.7341.816			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	540ZG	11934774	Green Published			2022-12-28	WOS:000174960300015
J	Bennetzen, J				Bennetzen, J			The rice genome - Opening the door to comparative plant biology	SCIENCE			English	Editorial Material							DNA		Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus	Bennetzen, J (corresponding author), Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA.			Bennetzen, Jeffrey/0000-0003-1762-8307				Arumuganathan K, 1991, PLANT MOL BIOL REP, V9, P208, DOI DOI 10.1007/BF02672069; Bennetzen JL, 1997, GENOME RES, V7, P301, DOI 10.1101/gr.7.4.301; Gale MD, 1998, SCIENCE, V282, P656, DOI 10.1126/science.282.5389.656; Goff SA, 2002, SCIENCE, V296, P92, DOI 10.1126/science.1068275; Harushima Y, 1998, GENETICS, V148, P479; HIEI Y, 1994, PLANT J, V6, P271, DOI 10.1046/j.1365-313X.1994.6020271.x; Hirochika H, 1997, PLANT MOL BIOL, V35, P231, DOI 10.1023/A:1005774705893; RAYBURN AL, 1985, AM J BOT, V72, P1610, DOI 10.2307/2443312; Saji S, 2001, GENOME, V44, P32, DOI 10.1139/gen-44-1-32; The Arabidopsis Genome Initiative, 2000, NATURE, V408, P796; Yazaki J, 2000, DNA RES, V7, P367, DOI 10.1093/dnares/7.6.367; Yu J, 2002, SCIENCE, V296, P79, DOI 10.1126/science.1068037	12	58	66	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 5	2002	296	5565					60	+		10.1126/science.1071402	http://dx.doi.org/10.1126/science.1071402			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	539FA	11935009				2022-12-28	WOS:000174858800030
J	Cantrell, RP; Reeves, TG				Cantrell, RP; Reeves, TG			The rice genome - The cereal of the world's poor takes center stage	SCIENCE			English	Editorial Material							DRAFT SEQUENCE		Int Maize & Wheat Improvement Ctr CIMMYT, Mexico City 06600, DF, Mexico; Int Rice Res Inst, Manila, Philippines	CGIAR; International Maize & Wheat Improvement Center (CIMMYT); CGIAR; International Rice Research Institute (IRRI)	Cantrell, RP (corresponding author), Int Rice Res Inst, DAPO Box 7777, Manila, Philippines.	r.cantrell@cgiar.org; t.reeves@cgiar.org						Fischer KS, 2000, SCIENCE, V290, P279, DOI 10.1126/science.290.5490.279; Goff SA, 2002, SCIENCE, V296, P92, DOI 10.1126/science.1068275; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Leung H, 2002, TRENDS PLANT SCI, V7, P139, DOI 10.1016/S1360-1385(01)02226-9; The Arabidopsis Genome Initiative, 2000, NATURE, V408, P796; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Yu J, 2002, SCIENCE, V296, P79, DOI 10.1126/science.1068037	7	58	63	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 5	2002	296	5565					53	53		10.1126/science.1070721	http://dx.doi.org/10.1126/science.1070721			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	539FA	11935006				2022-12-28	WOS:000174858800027
J	Flores, ER; Tsai, KY; Crowley, D; Sengupta, S; Yang, A; McKeon, F; Jacks, T				Flores, ER; Tsai, KY; Crowley, D; Sengupta, S; Yang, A; McKeon, F; Jacks, T			p63 and p73 are required for p53-dependent apoptosis in response to DNA damage	NATURE			English	Article							CENTRAL-NERVOUS-SYSTEM; KINASE C-ABL; INDUCE APOPTOSIS; TUMOR-SUPPRESSOR; IN-VIVO; P53; FAMILY; CELLS; PROTEIN; TARGET	The tumour-suppressor gene p53 is frequently mutated in human cancers and is important in the cellular response to DNA damage(1,2). Although the p53 family members p63 and p73 are structurally related to p53, they have not been directly linked to tumour suppression, although they have been implicated in apoptosis(3-9). Given the similarity between this family of genes and the ability of p63 and p73 to transactivate p53 target genes(10,11), we explore here their role in DNA damage-induced apoptosis. Mouse embryo fibroblasts deficient for one or a combination of p53 family members were sensitized to undergo apoptosis through the expression of the adenovirus E1A oncogene(12-14). While using the E1A system facilitated our ability to perform biochemical analyses, we also examined the functions of p63 and p73 using an in vivo system in which apoptosis has been shown to be dependent on p53. Using both systems, we show here that the combined loss of p63 and p73 results in the failure of cells containing functional p53 to undergo apoptosis in response to DNA damage.	MIT, Dept Biol, Cambridge, MA 02139 USA; MIT, Ctr Canc Res, Cambridge, MA 02139 USA; MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Howard Hughes Med Inst, Chevy Chase, MD 20185 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Harvard University; Massachusetts Institute of Technology (MIT); Harvard University; Harvard Medical School; Howard Hughes Medical Institute	Jacks, T (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.			Tsai, Kenneth/0000-0001-5325-212X				Agami R, 1999, NATURE, V399, P809; Attardi LD, 2000, GENE DEV, V14, P704; Chong MJ, 2000, P NATL ACAD SCI USA, V97, P889, DOI 10.1073/pnas.97.2.889; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; Gong JG, 1999, NATURE, V399, P806; Herzog KH, 1998, SCIENCE, V280, P1089, DOI 10.1126/science.280.5366.1089; Irwin MS, 2001, APOPTOSIS, V6, P17, DOI 10.1023/A:1009663809458; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; Lee Y, 2001, J NEUROSCI, V21, P6687, DOI 10.1523/JNEUROSCI.21-17-06687.2001; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yang ZL, 1999, ACTA GEOL SIN-ENGL, V73, P404; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zaika A, 2001, J BIOL CHEM, V276, P11310, DOI 10.1074/jbc.M005737200	27	689	707	1	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 4	2002	416	6880					560	564		10.1038/416560a	http://dx.doi.org/10.1038/416560a			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	537JY	11932750				2022-12-28	WOS:000174756500050
J	Hetherington, S; Hughes, AR; Mosteller, M; Shortino, D; Baker, KL; Spreen, W; Lai, E; Davies, K; Handley, A; Dow, DJ; Fling, ME; Stocum, M; Bowman, C; Thurmond, LM; Roses, AD				Hetherington, S; Hughes, AR; Mosteller, M; Shortino, D; Baker, KL; Spreen, W; Lai, E; Davies, K; Handley, A; Dow, DJ; Fling, ME; Stocum, M; Bowman, C; Thurmond, LM; Roses, AD			Genetic variations in HLA-B region and hypersensitivity reactions to abacavir	LANCET			English	Article								Hypersensitivity to abacavir affects about 4% of patients who receive the drug for HIV-1 infection. We did a retrospective, case-control study to identify multiple markers in the vicinity of HLA-B associated with hypersensitivity reactions. HLA-B57 was present In 39 (46%) of 84 patients versus four (4%) of 113 controls (p<0.0001). However, because of low numbers of women and other ethnic groups enrolled, these findings relate largely to white men. The lower sensitivity of HLA-B57 for predicting hypersensitivity to abacavir identified in this study compared with a previous report highlights that predictive values for markers will vary across populations. Clinical monitoring and management of hypersensitivity reactions among patients receiving abacavir must remain unchanged.	GlaxoSmithKline, HIV Clin Dev & Med Affairs, Res Triangle Pk, NC 27709 USA; GlaxoSmithKline, Genet Res, Res Triangle Pk, NC 27709 USA; GlaxoSmithKline, Clin Stat, Res Triangle Pk, NC 27709 USA; GlaxoSmithKline, Drug Metab & Pharmacokinet, Res Triangle Pk, NC 27709 USA	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline	Hetherington, S (corresponding author), GlaxoSmithKline, HIV Clin Dev & Med Affairs, 5 Moore Dr, Res Triangle Pk, NC 27709 USA.		Baker-Neblett, Katherine/Y-4823-2019	Baker-Neblett, Katherine/0000-0001-6869-7498				Cao K, 2001, HUM IMMUNOL, V62, P1009, DOI 10.1016/S0198-8859(01)00298-1; Hetherington S, 2001, CLIN THER, V23, P1603, DOI 10.1016/S0149-2918(01)80132-6; Mallal S, 2002, LANCET, V359, P727, DOI 10.1016/S0140-6736(02)07873-X; Pirmohamed M, 2001, TRENDS PHARMACOL SCI, V22, P298, DOI 10.1016/S0165-6147(00)01717-X; Roses AD, 2000, LANCET, V355, P1358, DOI 10.1016/S0140-6736(00)02126-7	5	593	617	0	18	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 30	2002	359	9312					1121	1122		10.1016/S0140-6736(02)08158-8	http://dx.doi.org/10.1016/S0140-6736(02)08158-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	536YJ	11943262				2022-12-28	WOS:000174729200013
J	Pielke, RA				Pielke, RA			Science policy: Policy, politics and perspective - The scientific community must distinguish analysis from advocacy.	NATURE			English	Editorial Material									Univ Colorado, CIRES, Ctr Sci & Techol Policy Res, Boulder, CO 80309 USA	University of Colorado System; University of Colorado Boulder	Pielke, RA (corresponding author), Univ Colorado, CIRES, Ctr Sci & Techol Policy Res, 1333 Grandview Ave, Boulder, CO 80309 USA.								0	51	52	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 28	2002	416	6879					367	368		10.1038/416367a	http://dx.doi.org/10.1038/416367a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	534UX	11919602				2022-12-28	WOS:000174607800019
J	Khaitan, L; Holzman, MD				Khaitan, L; Holzman, MD			Laparoscopic advances in general surgery	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							LONG-TERM MANAGEMENT; ROUX-EN-Y; GASTRIC BYPASS; HERNIA REPAIR; COLECTOMY; OUTCOMES; FUNDOPLICATION; CANCER		Vanderbilt Univ, Med Ctr, Dept Surg, Nashville, TN 37232 USA	Vanderbilt University	Holzman, MD (corresponding author), Vanderbilt Univ, Med Ctr, Dept Surg, D5203 MCN, Nashville, TN 37232 USA.	mike.holzman@mcmail.vanderbilt.edu						Bammer T, 2001, J GASTROINTEST SURG, V5, P42, DOI 10.1016/S1091-255X(01)80012-3; Campos GMR, 1999, J GASTROINTEST SURG, V3, P292; CARJABO MA, 1999, SURG ENDOSC, V13, P250; Chekan EG, 2001, SABISTON TXB SURG BI, P292; Dent J, 2000, BEST PRACT RES CL GA, V14, P811, DOI 10.1053/bega.2000.0126; DeVault KR, 1999, AM J GASTROENTEROL, V94, P1434; DEVLIN HB, 1986, BRIT J SURG, V73, P123, DOI 10.1002/bjs.1800730217; DUBOIS F, 1990, ANN SURG, V211, P60, DOI 10.1097/00000658-199001000-00010; FRANKLIN ME, 1998, AM SURGEON, V64, P1121; Glasgow RE, 1997, SURG ENDOSC-ULTRAS, V11, P108, DOI 10.1007/s004649900308; Grant A, 2000, BRIT J SURG, V87, P860, DOI 10.1046/j.1365-2168.2000.01540.x; HETZEL DJ, 1992, DIGESTION, V51, P35, DOI 10.1159/000200913; Himpens J, 1998, SURG ENDOSC-ULTRAS, V12, P1091, DOI 10.1007/s004649900788; Holzman MD, 1997, SURG ENDOSC, V11, P32, DOI 10.1007/s004649900290; Lafullarde T, 2001, ARCH SURG-CHICAGO, V136, P180, DOI 10.1001/archsurg.136.2.180; Leibl BJ, 1999, LANGENBECK ARCH SURG, V384, P302, DOI 10.1007/s004230050208; Liberman MA, 1996, SURG ENDOSC-ULTRAS, V10, P15, DOI 10.1007/s004649910002; LICHTENSTEIN IL, 1989, AM J SURG, V157, P188, DOI 10.1016/0002-9610(89)90526-6; LICHTENSTEIN IL, 1976, AM J SURG, V132, P307, DOI 10.1016/0002-9610(76)90381-0; Lucas SW, 1999, WORLD J SURG, V23, P350, DOI 10.1007/PL00012309; Metcalf AM, 2000, SURG CLIN N AM, V80, P1321, DOI 10.1016/S0039-6109(05)70227-9; Milsom JW, 1998, J AM COLL SURGEONS, V187, P46, DOI 10.1016/S1072-7515(98)00132-X; NASH JM, 1992, TIME            0325, P52; National Institutes of Health (USA), 1992, American Journal of Clinical Nutrition, V55, p615S; Park A, 1998, SURGERY, V124, P816, DOI 10.1067/msy.1998.92102; PORIES WJ, 1992, AM J CLIN NUTR, V55, P582; RATTNER DW, 1999, LANCET S1, V1, pSI12; Satava R, 2000, SURG ENDOSC-ULTRAS, V14, P417, DOI 10.1007/s004640000200; Satava RM, 1998, UROL CLIN N AM, V25, P93, DOI 10.1016/S0094-0143(05)70436-5; SCHAUER PR, 1993, SURGERY, V114, P389; Schauer PR, 2000, ANN SURG, V232, P515, DOI 10.1097/00000658-200010000-00007; Terry M, 2001, SURG ENDOSC-ULTRAS, V15, P691, DOI 10.1007/s004640080144; Tisminezky B, 2000, Adv Surg, V34, P67; Toy FK, 1998, SURG ENDOSC, V12, P955, DOI 10.1007/s004649900755; *US DEP HHS, 1994, DIG DIS US EP IMP; Weeks JC, 2002, JAMA-J AM MED ASSOC, V287, P321, DOI 10.1001/jama.287.3.321; Wexner SD, 2000, SURG CLIN N AM, V80, P1299, DOI 10.1016/S0039-6109(05)70226-7; Wittgrove AC, 2000, OBES SURG, V10, P233, DOI 10.1381/096089200321643511	38	13	13	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 27	2002	287	12					1502	1505		10.1001/jama.287.12.1502	http://dx.doi.org/10.1001/jama.287.12.1502			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	533VF	11911736				2022-12-28	WOS:000174550400001
J	Liu, SL; Joseph, KS; Kramer, MS; Allen, JC; Sauve, R; Rusen, I; Wen, SW				Liu, SL; Joseph, KS; Kramer, MS; Allen, JC; Sauve, R; Rusen, I; Wen, SW		Fetal Infant Hlth Study Grp Canadi	Relationship of prenatal diagnosis and pregnancy termination to overall infant mortality in Canada	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NEURAL-TUBE DEFECTS; BIRTH-WEIGHT; CONGENITAL-ANOMALIES; MATERNAL SERUM; UNITED-STATES; RECENT TRENDS; FOLIC-ACID; IMPACT; FETAL; RISK	Context Prenatal diagnosis and termination of affected pregnancies can prevent infant deaths due to congenital anomalies, but an effect at the population level has not been shown. Objective To examine the impact of recent changes in congenital anomaly-related fetal and infant deaths on overall population-based infant mortality. Design, Setting, and Subjects Birth cohort-based study of all live births, stillbirths, and infant deaths in Canada (excluding Ontario) for 1991-1998. Main Outcome Measures Cause-specific infant mortality rates and gestational age-specific fetal death rates. Results The birth cohort-based infant mortality rate fluctuated between 6.4 and 6.1 per 1000 live births between 1991 and 1995, then dropped to 5.4 per 1000 in 1996 and 5.5 per 1000 in 1997. The rate of infant death from congenital anomalies was stable between 1991 and 1995 but declined by 21% (95% confidence interval, 19%-32%) from 1.86 per 1000 in 1995 to 1.47 per 1000 in 1996 and 1997. Fetal deaths due to pregnancy termination at 20 to 23 weeks' gestation increased dramatically in 1994, while fetal deaths due to congenital anomalies at 20 to 21 weeks increased in 1995 and subsequently. Provinces/territories with high rates of fetal death due to pregnancy termination/congenital anomalies at 20 to 23 weeks had fewer infant deaths due to congenital anomalies. Conclusion A large decrease in infant deaths due to congenital anomalies was associated with the most recent decline in infant mortality in Canada, suggesting that increases in prenatal diagnosis and pregnancy termination for congenital anomalies are related to decreases in overall infant mortality at the population level.	Hlth Canada, Ctr Healthy Human Dev, Hlth Surveillance & Epidemiol Div, Ottawa, ON K1A 0L2, Canada; Dalhousie Univ, Dept Obstet & Gynecol, Perinatal Epidemiol Res Unit, Halifax, NS, Canada; Dalhousie Univ, Dept Pediat, Perinatal Epidemiol Res Unit, Halifax, NS, Canada; Dalhousie Univ, IWK Hlth Ctr, Div Neonatal Perinatal Med, Halifax, NS, Canada; McGill Univ, Dept Pediat, Montreal, PQ H3A 2T5, Canada; McGill Univ, Dept Epidemiol & Biostat, Montreal, PQ, Canada; Univ Calgary, Dept Paediat, Calgary, AB T2N 1N4, Canada; Univ Calgary, Dept Community Hlth Sci, Calgary, AB, Canada	Health Canada; Dalhousie University; Dalhousie University; Dalhousie University; McGill University; McGill University; University of Calgary; University of Calgary	Liu, SL (corresponding author), Hlth Canada, Ctr Healthy Human Dev, Hlth Surveillance & Epidemiol Div, HPB Bldg 7,Tunneys Pasture AL 0701D, Ottawa, ON K1A 0L2, Canada.	shiliang_liu@ch-sc.gc.ca		Joseph, K.S./0000-0003-2317-5607				Carmichael S L, 1998, Matern Child Health J, V2, P67, DOI 10.1023/A:1022916121368; *CDCP CDC, 1989, MMWR-MORBID MORTAL W, V38, P633; Centers for Disease Control and Prevention (CDC), 1998, MMWR Morb Mortal Wkly Rep, V47, P773; COLE S, 1989, ACTA OBSTET GYN SCAN, V68, P113, DOI 10.3109/00016348909009897; Cragan J D, 1995, MMWR CDC Surveill Summ, V44, P1; Daltveit AK, 1997, PAEDIATR PERINAT EP, V11, P214, DOI 10.1046/j.1365-3016.1997.d01-14.x; DOLK H, 1991, J EPIDEMIOL COMMUN H, V45, P52, DOI 10.1136/jech.45.1.52; DUCHESNE D, 1999, 84214XPE STAT CAN; DWYER T, 1995, PEDIATR ANN, V24, P350, DOI 10.3928/0090-4481-19950701-06; Fair M, 1993, Health Rep, V5, P281; Fair M, 2000, Chronic Dis Can, V21, P8; Forman R, 1996, CLIN INVEST MED, V19, P195; Forrester MB, 1998, AM J EPIDEMIOL, V148, P1206; GOLDENBERG RL, 1983, JAMA-J AM MED ASSOC, V250, P513, DOI 10.1001/jama.250.4.513; Haddow JE, 1998, NEW ENGL J MED, V338, P955, DOI 10.1056/NEJM199804023381404; HEIN HA, 1986, AM J DIS CHILD, V140, P989, DOI 10.1001/archpedi.1986.02140240035021; *HLTH STAT DIV, 1999, 84F210XPB STAT CAN H; *HLTH STAT DIV, 1997, 84210XIB STAT CAN HL; *HLTH STAT DIV, 1997, 84F209XPB STAT CAN H; Joseph KS, 1997, CAN MED ASSOC J, V157, P535; Joseph KS, 1999, PAEDIATR PERINAT EP, V13, P278; Joseph KS, 1996, CAN MED ASSOC J, V155, P1047; Kramer MS, 2000, JAMA-J AM MED ASSOC, V284, P843, DOI 10.1001/jama.284.7.843; Lee K, 2001, OBSTET GYNECOL, V98, P620, DOI 10.1016/S0029-7844(01)01507-1; LIMB CJ, 1994, AM J OBSTET GYNECOL, V170, P1333; Liu SL, 2001, AM J MED GENET, V104, P7, DOI 10.1002/1096-8628(20011115)104:1<7::AID-AJMG10023>3.3.CO;2-2; MORRIS CD, 1991, JAMA-J AM MED ASSOC, V266, P3447, DOI 10.1001/jama.266.24.3447; Permaul-Woods JA, 1999, CAN MED ASSOC J, V161, P381; ROBERTS HE, 1995, PEDIATRICS, V96, P880; SACHS BP, 1995, OBSTET GYNECOL, V85, P941, DOI 10.1016/0029-7844(95)00056-W; SECO A, 1994, J PUBLIC HEALTH MED, V16, P149; SINGH GK, 1995, AM J PUBLIC HEALTH, V85, P957, DOI 10.2105/AJPH.85.7.957; SMITH GD, 1991, ANN NUTR METAB, V35, P53, DOI 10.1159/000177678; Spencer K, 2000, BRIT J OBSTET GYNAEC, V107, P1271, DOI 10.1111/j.1471-0528.2000.tb11619.x; *STAT CAN, 1993, 82549 STAT CAN; Sullivan FM, 2001, PAEDIATR PERINAT EP, V15, P144; *TASK FORC PER HLT, 1994, CMAJ, V151, P159; Turner LA, 1998, CAN MED ASSOC J, V158, P773; Velie EM, 1996, AM J EPIDEMIOL, V144, P473; Wen SW, 2000, TERATOLOGY, V61, P342, DOI 10.1002/(SICI)1096-9926(200005)61:5<342::AID-TERA5>3.0.CO;2-7; Wen SW, 1999, CAN J PUBLIC HEALTH, V90, P316, DOI 10.1007/BF03404519; Wong SL, 1997, J PAEDIATR CHILD H, V33, P226, DOI 10.1111/j.1440-1754.1997.tb01584.x	42	91	96	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 27	2002	287	12					1561	1567		10.1001/jama.287.12.1561	http://dx.doi.org/10.1001/jama.287.12.1561			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	533VF	11911759	Bronze			2022-12-28	WOS:000174550400028
J	Steindler, DA; Pincus, DW				Steindler, DA; Pincus, DW			Stem cells and neuropoiesis in the adult human brain	LANCET			English	Review							MARROW STROMAL CELLS; BONE-MARROW; SUBVENTRICULAR ZONE; SPINAL-CORD; REPLICATIVE SENESCENCE; NEURONAL PRECURSORS; SUBEPENDYMAL ZONE; TRANSPLANTATION; DIFFERENTIATE; NEUROGENESIS	Stem cells in adult tissues have attracted a great deal of interest. These cells are self-renewing and can give rise to diverse progeny. An extraordinary finding was the presence of stem cells in the mature human brain. This tissue was previously believed incapable of generating new neurons, but neuropoiesis Is now an established phenomenon in the adult brains of mammals, including human beings. This persistent neurogenesis has potential therapeutic applications for various neurological disorders as a source for tissue engraftment and as self-repair by a person's own indigenous population of pluripotent cells or biogenic by-products of their proliferation and differentiation.	Univ Florida, Coll Med, Program Stem Cell Biol, McKnight Brain Inst,Dept Neurosci, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Program Stem Cell Biol, McKnight Brain Inst,Dept Neurosurg, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Program Stem Cell Biol, Shands Canc Ctr, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida	Steindler, DA (corresponding author), Univ Florida, Coll Med, Program Stem Cell Biol, McKnight Brain Inst,Dept Neurosci, POB 100244,100 S Newell Dr, Gainesville, FL 32610 USA.	steindler@mbi.ufl.edu	Steindler, Dennis/AAJ-5811-2020		NINDS NIH HHS [NS37556] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037556] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aboody KS, 2000, P NATL ACAD SCI USA, V97, P12846, DOI 10.1073/pnas.97.23.12846; Auerbach JM, 2000, EUR J NEUROSCI, V12, P1696, DOI 10.1046/j.1460-9568.2000.00067.x; Benedetti S, 2000, NAT MED, V6, P447, DOI 10.1038/74710; Bjornson CRR, 1999, SCIENCE, V283, P534, DOI 10.1126/science.283.5401.534; Bouchet LG, 2001, PHYS MED BIOL, V46, P559, DOI 10.1088/0031-9155/46/2/321; Brazelton TR, 2000, SCIENCE, V290, P1775, DOI 10.1126/science.290.5497.1775; BRODKEY JA, 1995, J NEUROSURG, V82, P106, DOI 10.3171/jns.1995.82.1.0106; Brustle O, 1995, NEURON, V15, P1275, DOI 10.1016/0896-6273(95)90007-1; Brustle O, 1999, SCIENCE, V285, P754, DOI 10.1126/science.285.5428.754; Clarke DL, 2000, SCIENCE, V288, P1660, DOI 10.1126/science.288.5471.1660; Costantini LC, 2000, NEUROSCIENCE, V100, P515, DOI 10.1016/S0306-4522(00)00312-2; DEXTER TM, 1977, J CELL PHYSIOL, V91, P335, DOI 10.1002/jcp.1040910303; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Freed CR, 2001, NEW ENGL J MED, V344, P710, DOI 10.1056/NEJM200103083441002; Frimberger AE, 2001, BRIT J HAEMATOL, V112, P644, DOI 10.1046/j.1365-2141.2001.02542.x; Gallo RC, 2000, J HUMAN VIROL, V3, P1; GATES MA, 1995, J COMP NEUROL, V361, P249, DOI 10.1002/cne.903610205; Geschwind DH, 2001, NEURON, V29, P325, DOI 10.1016/S0896-6273(01)00209-4; Gussoni E, 1999, NATURE, V401, P390, DOI 10.1038/43919; HARLEY CB, 1994, COLD SPRING HARB SYM, V59, P307, DOI 10.1101/SQB.1994.059.01.035; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; Jin KL, 2001, P NATL ACAD SCI USA, V98, P4710, DOI 10.1073/pnas.081011098; KIRSCHENBAUM B, 1994, CEREB CORTEX, V4, P576, DOI 10.1093/cercor/4.6.576; Kirschenbaum B, 1999, J NEUROSCI, V19, P2171; Kondo T, 2000, SCIENCE, V289, P1754, DOI 10.1126/science.289.5485.1754; Kondziolka D, 2000, NEUROLOGY, V55, P565, DOI 10.1212/WNL.55.4.565; Kopen GC, 1999, P NATL ACAD SCI USA, V96, P10711, DOI 10.1073/pnas.96.19.10711; Kukekov VG, 1999, EXP NEUROL, V156, P333, DOI 10.1006/exnr.1999.7028; Lacorazza HD, 1996, NAT MED, V2, P424, DOI 10.1038/nm0496-424; Lagasse E, 2000, NAT MED, V6, P1229, DOI 10.1038/81326; Laywell ED, 2000, P NATL ACAD SCI USA, V97, P13883, DOI 10.1073/pnas.250471697; Laywell ED, 1999, EXP NEUROL, V156, P430, DOI 10.1006/exnr.1999.7029; Lewis R, 2000, SCIENTIST, V14, P1; LEWIS RA, 2001, DISCOVERY WINDOWS LI; Liu S, 2000, P NATL ACAD SCI USA, V97, P6126, DOI 10.1073/pnas.97.11.6126; Lois C, 1996, SCIENCE, V271, P978, DOI 10.1126/science.271.5251.978; LOIS C, 1994, SCIENCE, V264, P1145, DOI 10.1126/science.8178174; Lumelsky N, 2001, SCIENCE, V292, P1389, DOI 10.1126/science.1058866; Magavi SS, 2000, NATURE, V405, P951, DOI 10.1038/35016083; Mathon NF, 2001, SCIENCE, V291, P872, DOI 10.1126/science.1056782; Mattson MP, 2000, EXP GERONTOL, V35, P489, DOI 10.1016/S0531-5565(00)00115-7; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; Mezey E, 2000, SCIENCE, V290, P1779, DOI 10.1126/science.290.5497.1779; MORSHEAD CM, 1994, NEURON, V13, P1071, DOI 10.1016/0896-6273(94)90046-9; Palmer TD, 2001, NATURE, V411, P42, DOI 10.1038/35075141; Palmer TD, 2000, J COMP NEUROL, V425, P479, DOI 10.1002/1096-9861(20001002)425:4<479::AID-CNE2>3.0.CO;2-3; Papayannopoulou T, 1997, ACTA HAEMATOL-BASEL, V97, P97; Peck AB, 2001, ANN MED, V33, P186, DOI 10.3109/07853890109002076; Petersen BE, 1999, SCIENCE, V284, P1168, DOI 10.1126/science.284.5417.1168; Phillips RL, 2000, SCIENCE, V288, P1635, DOI 10.1126/science.288.5471.1635; Pincus DW, 1998, ANN NEUROL, V43, P576, DOI 10.1002/ana.410430505; Pincus DW, 1998, NEUROSURGERY, V42, P858, DOI 10.1097/00006123-199804000-00103; Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71; Sakakibara S, 1996, DEV BIOL, V176, P230, DOI 10.1006/dbio.1996.0130; Sanchez-Ramos J, 2000, EXP NEUROL, V164, P247, DOI 10.1006/exnr.2000.7389; Scharfman HE, 2000, J NEUROSCI, V20, P6144, DOI 10.1523/JNEUROSCI.20-16-06144.2000; Scheffler B, 1999, TRENDS NEUROSCI, V22, P348, DOI 10.1016/S0166-2236(99)01416-2; Schumacher JM, 2000, NEUROLOGY, V54, P1042, DOI 10.1212/WNL.54.5.1042; Senior K, 2000, LANCET, V355, P1890, DOI 10.1016/S0140-6736(05)73336-5; Shors TJ, 2001, NATURE, V410, P372, DOI 10.1038/35066584; SLADEK JR, 1988, SCIENCE, V240, P1386, DOI 10.1126/science.3375820; Soderdahl G, 1998, BONE MARROW TRANSPL, V21, P79, DOI 10.1038/sj.bmt.1701039; STEPHANIE JL, 2001, JAMA-J AM MED ASSOC, V285, P1034; SUSLOV ON, 2000, NEUR ABS, V26, P832; Svendsen CN, 1999, TRENDS NEUROSCI, V22, P357, DOI 10.1016/S0166-2236(99)01428-9; Tang DG, 2001, SCIENCE, V291, P868, DOI 10.1126/science.1056780; Tao Y, 1996, J COMP NEUROL, V376, P653, DOI 10.1002/(SICI)1096-9861(19961223)376:4<653::AID-CNE11>3.0.CO;2-N; Thomas LB, 1996, GLIA, V17, P1; TILL JE, 1961, RADIAT RES, V14, P213, DOI 10.2307/3570892; Toma JG, 2001, NAT CELL BIOL, V3, P778, DOI 10.1038/ncb0901-778; Tsai RYL, 2000, J NEUROSCI, V20, P3725, DOI 10.1523/JNEUROSCI.20-10-03725.2000; Uchida N, 2000, P NATL ACAD SCI USA, V97, P14720, DOI 10.1073/pnas.97.26.14720; Wakayama T, 2001, SCIENCE, V292, P740, DOI 10.1126/science.1059399; Wang S, 1998, NAT BIOTECHNOL, V16, P196, DOI 10.1038/nbt0298-196; Weiss R., 2001, WASHINGTON POST 022, pA02; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0; Wirth ED, 2001, J NEUROTRAUM, V18, P911, DOI 10.1089/089771501750451839; Woodbury D, 2000, J NEUROSCI RES, V61, P364, DOI 10.1002/1097-4547(20000815)61:4<364::AID-JNR2>3.0.CO;2-C; Yang XW, 1996, DEVELOPMENT, V122, P555; Zindy F, 1999, P NATL ACAD SCI USA, V96, P13462, DOI 10.1073/pnas.96.23.13462; 2001, AM J ALZHEIMERS DIS, V16, P8	82	72	73	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 23	2002	359	9311					1047	1054		10.1016/S0140-6736(02)08096-0	http://dx.doi.org/10.1016/S0140-6736(02)08096-0			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	534KP	11937201				2022-12-28	WOS:000174585800028
J	Marquet, PA				Marquet, PA			Ecology - Of predators, prey, and power laws	SCIENCE			English	Editorial Material							MAMMALIAN POPULATION-DENSITY; BODY SIZE		Pontificia Univ Catolica Chile, Ctr Adv Studies Ecol & Biodivers, Santiago, Chile	Pontificia Universidad Catolica de Chile	Marquet, PA (corresponding author), Pontificia Univ Catolica Chile, Ctr Adv Studies Ecol & Biodivers, Casilla 114-D, Santiago, Chile.		Marquet, Pablo A/B-7732-2009	Marquet, Pablo A/0000-0001-6369-9339				[Anonymous], 1991, FRACTALS CHAOS POWER; Bak P., 1996, NATURE WORKS SCI SEL; Brown J., 2000, SCALING BIOL; Carbone C, 2002, SCIENCE, V295, P2273, DOI 10.1126/science.1067994; DAMUTH J, 1993, NATURE, V365, P748, DOI 10.1038/365748a0; DAMUTH J, 1981, NATURE, V290, P699, DOI 10.1038/290699a0; Enquist BJ, 1998, NATURE, V395, P163, DOI 10.1038/25977; Enquist BJ, 1999, NATURE, V398, P573, DOI 10.1038/19219; KLEIBER MAX, 1932, HILGARDIA, V6, P315; Lindeman RL, 1942, ECOLOGY, V23, P399, DOI 10.2307/1930126; MARQUET PA, 1990, SCIENCE, V250, P1125, DOI 10.1126/science.250.4984.1125; PETERS RH, 1984, AM NAT, V124, P498, DOI 10.1086/284290; ROBINSON JG, 1986, AM NAT, V128, P665, DOI 10.1086/284596	13	43	46	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 22	2002	295	5563					2229	2230		10.1126/science.1070587	http://dx.doi.org/10.1126/science.1070587			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	534AD	11910100				2022-12-28	WOS:000174561700033
J	Dorian, P; Cass, D; Schwartz, B; Cooper, R; Gelaznikas, R; Barr, A				Dorian, P; Cass, D; Schwartz, B; Cooper, R; Gelaznikas, R; Barr, A			Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HOSPITAL CARDIAC-ARREST; INTRAVENOUS AMIODARONE; BRETYLIUM TOSYLATE; RESUSCITATION; TACHYARRHYTHMIAS; RECURRENT; INCREASE	Background: Lidocaine has been the initial antiarrhythmic drug treatment recommended for patients with ventricular fibrillation that is resistant to conversion by defibrillator shocks. We performed a randomized trial comparing intravenous lidocaine with intravenous amiodarone as an adjunct to defibrillation in victims of out-of-hospital cardiac arrest. Methods: Patients were enrolled if they had out-of-hospital ventricular fibrillation resistant to three shocks, intravenous epinephrine, and a further shock; or if they had recurrent ventricular fibrillation after initially successful defibrillation. They were randomly assigned in a double-blind manner to receive intravenous amiodarone plus lidocaine placebo or intravenous lidocaine plus amiodarone placebo. The primary end point was the proportion of patients who survived to be admitted to the hospital. Results: In total, 347 patients (mean [+/-SD] age, 67+/-14 years) were enrolled. The mean interval between the time at which paramedics were dispatched to the scene of the cardiac arrest and the time of their arrival was 7+/-3 minutes, and the mean interval from dispatch to drug administration was 25+/-8 minutes. After treatment with amiodarone, 22.8 percent of 180 patients survived to hospital admission, as compared with 12.0 percent of 167 patients treated with lidocaine (P=0.009; odds ratio, 2.17; 95 percent confidence interval, 1.21 to 3.83). Among patients for whom the time from dispatch to the administration of the drug was equal to or less than the median time (24 minutes), 27.7 percent of those given amiodarone and 15.3 percent of those given lidocaine survived to hospital admission (P=0.05). Conclusions: As compared with lidocaine, amiodarone leads to substantially higher rates of survival to hospital admission in patients with shock-resistant out-of-hospital ventricular fibrillation. (N Engl J Med 2002;346:884-90.) Copyright (C) 2002 Massachusetts Medical Society.	St Michaels Hosp, Dept Med, Toronto, ON M5B 1W8, Canada; St Michaels Hosp, Dept Emergency Med, Toronto, ON M5B 1W8, Canada; Sunnybrook & Womens Coll, Hlth Sci Ctr, Div Prehosp Care, Toronto, ON, Canada; Univ Hlth Network, Dept Anesthesia, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Dorian, P (corresponding author), St Michaels Hosp, Dept Med, 30 Bond St, Toronto, ON M5B 1W8, Canada.							ANASTASIOUNANA MI, 1994, J AM COLL CARDIOL, V23, P253, DOI 10.1016/0735-1097(94)90528-2; AUPETIT JF, 1995, J CARDIOVASC PHARM, V25, P810, DOI 10.1097/00005344-199505000-00018; Dorian P, 2000, CAN J CARDIOL, V16, p16C; DORIAN P, 1986, J AM COLL CARDIOL, V8, P327, DOI 10.1016/S0735-1097(86)80047-X; Eisenberg MS, 2001, NEW ENGL J MED, V344, P1304, DOI 10.1056/NEJM200104263441707; *EM CARD CAR COMM, 1992, JAMA-J AM MED ASSOC, V268, P2171; HAYNES RE, 1981, AM J CARDIOL, V48, P353, DOI 10.1016/0002-9149(81)90619-6; KENTSCH M, 1988, Intensivmedizin, V25, P70; KOWEY PR, 1995, CIRCULATION, V92, P3255, DOI 10.1161/01.CIR.92.11.3255; Kudenchuk PJ, 1999, NEW ENGL J MED, V341, P871, DOI 10.1056/NEJM199909163411203; Levine JH, 1996, J AM COLL CARDIOL, V27, P67, DOI 10.1016/0735-1097(95)00427-0; OLSON DW, 1984, ANN EMERG MED, V13, P807, DOI 10.1016/S0196-0644(84)80444-8; SCHEINMAN MM, 1995, CIRCULATION, V92, P3264, DOI 10.1161/01.CIR.92.11.3264; van Walraven C, 1998, ANN EMERG MED, V32, P544, DOI 10.1016/S0196-0644(98)70031-9; WEAVER WD, 1990, CIRCULATION, V82, P2027, DOI 10.1161/01.CIR.82.6.2027; 2000, CIRCULATION S1, V102, P112	16	417	446	1	14	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 21	2002	346	12					884	890		10.1056/NEJMoa013029	http://dx.doi.org/10.1056/NEJMoa013029			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	532FR	11907287	Bronze			2022-12-28	WOS:000174464100003
J	Moss, AJ; Zareba, W; Hall, WJ; Klein, H; Wilber, DJ; Cannom, DS; Daubert, JP; Higgins, SL; Brown, MW; Andrews, ML				Moss, AJ; Zareba, W; Hall, WJ; Klein, H; Wilber, DJ; Cannom, DS; Daubert, JP; Higgins, SL; Brown, MW; Andrews, ML		Multicenter Automatic Defibrillato	Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY-ARTERY DISEASE; SUDDEN-DEATH; RISK	Background: Patients with reduced left ventricular function after myocardial infarction are at risk for life-threatening ventricular arrhythmias. This randomized trial was designed to evaluate the effect of an implantable defibrillator on survival in such patients. Methods: Over the course of four years, we enrolled 1232 patients with a prior myocardial infarction and a left ventricular ejection fraction of 0.30 or less. Patients were randomly assigned in a 3:2 ratio to receive an implantable defibrillator (742 patients) or conventional medical therapy (490 patients). Invasive electrophysiological testing for risk stratification was not required. Death from any cause was the end point. Results: The clinical characteristics at base line and the prevalence of medication use at the time of the last follow-up visit were similar in the two treatment groups. During an average follow-up of 20 months, the mortality rates were 19.8 percent in the conventional-therapy group and 14.2 percent in the defibrillator group. The hazard ratio for the risk of death from any cause in the defibrillator group as compared with the conventional-therapy group was 0.69 (95 percent confidence interval, 0.51 to 0.93; P=0.016). The effect of defibrillator therapy on survival was similar in subgroup analyses stratified according to age, sex, ejection fraction, New York Heart Association class, and the QRS interval. Conclusions: In patients with a prior myocardial infarction and advanced left ventricular dysfunction, prophylactic implantation of a defibrillator improves survival and should be considered as a recommended therapy. (N Engl J Med 2002;346:877-83.) Copyright (C) 2002 Massachusetts Medical Society.	Univ Rochester, Med Ctr, Dept Med, Cardiol Unit,Heart Res Follow Up Program, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Biostat, Rochester, NY 14642 USA; Univ Hosp, Div Cardiol, Magdeburg, Germany; Loyola Univ, Med Ctr, Cardiol Unit, Maywood, IL 60153 USA; Hosp Good Samaritan, Cardiol Associates, Los Angeles, CA 90017 USA; Scripps Clin & Hosp, Dept Cardiol, La Jolla, CA USA	University of Rochester; University of Rochester; University Hospital Magdeburg; Loyola University Chicago; Scripps Research Institute	Moss, AJ (corresponding author), Univ Rochester, Med Ctr, Dept Med, Cardiol Unit,Heart Res Follow Up Program, Box 653, Rochester, NY 14642 USA.		Daubert, James P./ABC-1476-2021					Buxton AE, 1999, NEW ENGL J MED, V341, P1882, DOI 10.1056/NEJM199912163412503; Buxton AE, 2000, NEW ENGL J MED, V342, P1937, DOI 10.1056/NEJM200006293422602; Buxton AE, 2000, NEW ENGL J MED, V342, P1300; Cohn JN, 1997, CIRCULATION, V95, P766; COX DR, 1972, J R STAT SOC B, V34, P187; ELLENBOGEN KA, 1990, AM J CARDIOL, V65, P53, DOI 10.1016/0002-9149(90)90025-V; HEALY B, 1989, NEW ENGL J MED, V320, P949, DOI 10.1056/NEJM198904063201432; Hurst TM, 1999, J AM COLL CARDIOL, V34, P402, DOI 10.1016/S0735-1097(99)00194-1; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; McAnulty J, 1997, NEW ENGL J MED, V337, P1576; Moss A. J., 1999, Annals of Noninvasive Electrocardiology, V4, P83, DOI 10.1111/j.1542-474X.1999.tb00369.x; Moss AJ, 1996, NEW ENGL J MED, V335, P1933, DOI 10.1056/NEJM199612263352601; Myerburg RJ, 2001, J CARDIOVASC ELECTR, V12, P369, DOI 10.1046/j.1540-8167.2001.00369.x; Whitehead J, 1997, DESIGN ANAL SEQUENTI	14	4719	4906	2	74	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 21	2002	346	12					877	883		10.1056/NEJMoa013474	http://dx.doi.org/10.1056/NEJMoa013474			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	532FR	11907286				2022-12-28	WOS:000174464100002
J	Steinmetz, LM; Sinha, H; Richards, DR; Spiegelman, JI; Oefner, PJ; McCusker, JH; Davis, RW				Steinmetz, LM; Sinha, H; Richards, DR; Spiegelman, JI; Oefner, PJ; McCusker, JH; Davis, RW			Dissecting the architecture of a quantitative trait locus in yeast	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; GENETIC DISSECTION; COMPLEX TRAITS; LINKAGE	Most phenotypic diversity in natural populations is characterized by differences in degree rather than in kind. Identification of the actual genes underlying these quantitative traits has proved difficult(1-5). As a result, little is known about their genetic architecture. The failures are thought to be due to the different contributions of many underlying genes to the phenotype and the ability of different combinations of genes and environmental factors to produce similar phenotypes(6,7). This study combined genome-wide mapping and a new genetic technique named reciprocal-hemizygosity analysis to achieve the complete dissection of a quantitative trait locus (QTL) in Saccharomyces cerevisiae. A QTL architecture was uncovered that was more complex than expected. Functional linkages both in cis and in trans were found between three tightly linked quantitative trait genes that are neither necessary nor sufficient in isolation. This arrangement of alleles explains heterosis (hybrid vigour), the increased fitness of the heterozygote compared with homozygotes. It also demonstrates a deficiency in current approaches to QTL dissection with implications extending to traits in other organisms, including human genetic diseases.	Duke Univ, Med Ctr, Dept Microbiol, Durham, NC 27710 USA; Stanford Genome Technol Ctr, Palo Alto, CA 94304 USA; Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Biochem, Stanford, CA 94305 USA	Duke University; Stanford University; Stanford University; Stanford University	McCusker, JH (corresponding author), Duke Univ, Med Ctr, Dept Microbiol, Durham, NC 27710 USA.		Sinha, Himanshu/AAT-7853-2021	Sinha, Himanshu/0000-0001-7031-0491; McCusker, John/0000-0002-8803-9131; Steinmetz, Lars/0000-0002-3962-2865				BOEHNKE M, 1994, AM J HUM GENET, V55, P379; CLEMONS KV, 1994, J INFECT DIS, V169, P859, DOI 10.1093/infdis/169.4.859; CODON AC, 1995, APPL ENVIRON MICROB, V61, P630; Darvasi A, 1998, NAT GENET, V18, P19, DOI 10.1038/ng0198-19; Flint J, 2001, NAT REV GENET, V2, P437, DOI 10.1038/35076585; Goldstein AL, 1999, YEAST, V15, P1541, DOI 10.1002/(SICI)1097-0061(199910)15:14<1541::AID-YEA476>3.3.CO;2-B; Herskowitz I, 1991, METHOD ENZYMOL, P132; LANDER ES, 1989, GENETICS, V121, P185; LANDER ES, 1994, SCIENCE, V265, P2037, DOI 10.1126/science.8091226; Mackay TFC, 2001, NAT REV GENET, V2, P11, DOI 10.1038/35047544; Mauricio R, 2001, NAT REV GENET, V2, P370, DOI 10.1038/35072085; MCCUSKER JH, 1994, INFECT IMMUN, V62, P5447, DOI 10.1128/IAI.62.12.5447-5455.1994; MCCUSKER JH, 1994, GENETICS, V136, P1261; MORTIMER RK, 1986, GENETICS, V113, P35; Murphy A, 1999, ENZYME MICROB TECH, V25, P551, DOI 10.1016/S0141-0229(99)00086-1; Niedenthal RK, 1996, YEAST, V12, P773, DOI 10.1002/(SICI)1097-0061(19960630)12:8<773::AID-YEA972>3.3.CO;2-C; Primig M, 2000, NAT GENET, V26, P415, DOI 10.1038/82539; Risch NJ, 2000, NATURE, V405, P847, DOI 10.1038/35015718; Schafer AJ, 1998, NAT BIOTECHNOL, V16, P33, DOI 10.1038/nbt0198-33; Shoemaker DD, 1996, NAT GENET, V14, P450, DOI 10.1038/ng1296-450; Spiegelman JI, 2000, PLANT CELL, V12, P2485, DOI 10.1105/tpc.12.12.2485; Steinmetz LM, 2000, BIOTECHNOL GENET ENG, V17, P109, DOI 10.1080/02648725.2000.10647990; TAWFIK OW, 1989, J CLIN MICROBIOL, V27, P1689, DOI 10.1128/JCM.27.7.1689-1691.1989; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WICKNER RB, 1987, J BACTERIOL, V169, P4941, DOI 10.1128/jb.169.11.4941-4945.1987; Winzeler EA, 1998, SCIENCE, V281, P1194, DOI 10.1126/science.281.5380.1194; Wood V, 2001, COMP FUNCT GENOM, V2, P143, DOI 10.1002/cfg.86	27	403	423	1	47	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 21	2002	416	6878					326	330		10.1038/416326a	http://dx.doi.org/10.1038/416326a			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	532NP	11907579				2022-12-28	WOS:000174482200044
J	Danovaro-Holliday, MC; Wood, AL; LeBaron, CW				Danovaro-Holliday, MC; Wood, AL; LeBaron, CW			Rotavirus vaccine and the news media, 1987-2001	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PUBLIC-HEALTH; MEASLES MUMPS; INTUSSUSCEPTION; IMMUNIZATION; CHILDREN; EFFICACY; INFANTS; SAFETY; TRIAL; PERTUSSIS	Context In August 1998, the US Food and Drug Administration licensed the first vaccine against rotavirus, the most important cause of severe childhood diarrhea. Fourteen months later, amid intense media activity, the vaccine was withdrawn after an association was found with intussusception. Objectives To examine the character of news media stories about rotavirus vaccine before and after intussusception became an issue, to evaluate what prompted the stories, and to assess the extent to which they evoked public reaction, Design and Setting We searched Lexis-Nexis and Video Monitoring Services of America databases for rotavirus vaccine stories from the first US clinical trials (January 1, 1987) until 17 months after withdrawal (March 31, 2001) and examined calls to the National Immunization Hotline during the period in which rotavirus vaccine information was captured (July 1-December 31, 1999). Main Outcome Measures Mention of vaccine benefits and adverse events, classification of stories as positive, negative, or neutral toward the vaccine, story stimuli, and public response. Results We included 280 newspaper (primary subject of analysis), 49 wire service, and 257 television stories. Prior to identification of the intussusception association (January 1, 1987-July 14,1999), 21% of 188 newspaper stories mentioned vaccine adverse events and only 2 stories were negative toward the vaccine. Ninety-nine percent of stories mentioned vaccine benefits. During the period surrounding withdrawal (July 15-December 31, 1999), 93% of 90 stories mentioned adverse events and 77% were negative toward the vaccine. Eighty-four percent mentioned vaccine benefits. The rate of stories per month was 14-fold greater than the preceding period (P < .001); temporal and geographic patterns of media and hotline activity were similar. Thereafter (January 1, 2000-March 31, 2001), only 2 stories focused on rotavirus vaccine. Scientific research or public health actions prompted 80% of stories. Wire service and television stories showed similar patterns. The increase in rotavirus stories in July 1999 was followed by an increase in calls to the National Immunization Hotline regarding rotavirus but not other topics. The number of rotavirus calls that month was 57% higher than for any other childhood vaccine for any month since the hotline began in 1997. Rotavirus calls ceased almost completely after withdrawal of the vaccine in October 1999. Conclusions In response to reports about an adverse event, news media stories about vaccines can change abruptly from positivity to negativity. Since most vaccine stories may be stimulated by research and public health actions, opportunities exist to provide the media with accurate information necessary to avoid the "early idealization-sudden condemnation" pattern seen with rotavirus vaccine.	CDCP, Natl Immunizat Program, Atlanta, GA 30333 USA	Centers for Disease Control & Prevention - USA	Danovaro-Holliday, MC (corresponding author), CDCP, Natl Immunizat Program, Mailstop E-61, Atlanta, GA 30333 USA.	carolina.danovaro@lshtm.ac.uk; clebaron@cdc.gov						*AD HOC GROUP, 1998, LANCET, V351, P955; *ADV COMM IMM PRAC, 1996, MMWR-MORBID MORTAL W, V45, P1; *AM AC PED PUBL HL, 1999, MMWR-MORBID MORTAL W, V48, P563; [Anonymous], 1999, MMWR Recomm Rep, V48, P1; [Anonymous], 2001, MMWR-MORBID MORTAL W, V50, P637; *AUD BUR CIRC, 2001, NAT CIRC DAT BAS REG; BROWN F, 1997, DEV BIOL STANDARIZAT, V89; *CDCP, 1999, M HELD JUN 16 17 ATL; Centers for Disease Control and Prevention (CDC), 1999, MMWR Morb Mortal Wkly Rep, V48, P780; Chen RT, 1998, LANCET, V352, P63, DOI 10.1016/S0140-6736(05)79543-X; CHEN RT, 1998, VACCINES, P1144; Cohn V, 1996, JAMA-J AM MED ASSOC, V276, P1917; Daneman A, 1998, PEDIATR RADIOL, V28, P913, DOI 10.1007/s002470050497; de Semir V, 1998, JAMA-J AM MED ASSOC, V280, P294, DOI 10.1001/jama.280.3.294; DuVernoy TS, 2000, PEDIATRICS, V106, part. no., DOI 10.1542/peds.106.4.e52; Estes M.K., 1996, FIELDS VIROLOGY, P1625; FARRINGTON P, 1995, LANCET, V345, P567, DOI 10.1016/S0140-6736(95)90471-9; Feudtner C, 2001, PEDIATRICS, V107, P1158, DOI 10.1542/peds.107.5.1158; Freed GL, 1996, JAMA-J AM MED ASSOC, V276, P1869, DOI 10.1001/jama.276.23.1869; Frost K, 1997, AM J PUBLIC HEALTH, V87, P842, DOI 10.2105/AJPH.87.5.842; Gangarosa EJ, 1998, LANCET, V351, P356, DOI 10.1016/S0140-6736(97)04334-1; GELLERT GA, 1994, JAMA-J AM MED ASSOC, V271, P1285, DOI 10.1001/jama.271.16.1285; Girardi E, 1998, JAMA-J AM MED ASSOC, V280, P292, DOI 10.1001/jama.280.3.292; GOTHEFORS L, 1989, J INFECT DIS, V159, P753, DOI 10.1093/infdis/159.4.753; Gregorio L, 1997, PEDIATRICS, V99, P738, DOI 10.1542/peds.99.5.738; GRIFFITH AH, 1981, J BIOL STAND, V9, P475, DOI 10.1016/S0092-1157(81)80040-6; Halsey NA, 1999, JAMA-J AM MED ASSOC, V282, P1763, DOI 10.1001/jama.282.18.1763; Halsey NA, 1998, PEDIATRICS, V102, P1483, DOI 10.1542/peds.102.6.1483; HARDING CM, 1985, CHILD CARE HLTH DEV, V11, P21, DOI 10.1111/j.1365-2214.1985.tb00446.x; HIBBS B, 1999, SOC RISK AN ANN M DE; HOWSON CP, 1991, ADV EFFECTS PERTUSSI; *I MED, 1986, NEW VACCINE DEV DIS, V2; Intussusception among recipients of rotavirus vaccine-United States, 1999, MMWR MORB MORTAL WKL, V48, P577; Izenberg N, 1998, CLIN PEDIATR, V37, P275, DOI 10.1177/000992289803700501; Jefferson T, 2000, J EPIDEMIOL COMMUN H, V54, P402, DOI 10.1136/jech.54.6.402; Joensuu J, 1997, LANCET, V350, P1205, DOI 10.1016/S0140-6736(97)05118-0; Kane MA, 1998, VACCINE, V16, pS73, DOI 10.1016/S0264-410X(98)00302-8; KAPIKIAN AZ, 1996, FIELDS VIROLOGY, V2, P1657; Kramarz P, 2001, PEDIATR INFECT DIS J, V20, P410, DOI 10.1097/00006454-200104000-00008; LANDIS JR, 1977, BIOMETRICS, V33, P363, DOI 10.2307/2529786; Leask JA, 1998, AUST NZ J PUBL HEAL, V22, P17, DOI 10.1111/j.1467-842X.1998.tb01140.x; LEBARON CW, 1990, JAMA-J AM MED ASSOC, V264, P983, DOI 10.1001/jama.264.8.983; Mason BW, 2000, J EPIDEMIOL COMMUN H, V54, P473, DOI 10.1136/jech.54.6.473; *MASS MED BUR, 2001, RAD TEL CALL LETT; Miller E, 2001, ARCH DIS CHILD, V84, P227, DOI 10.1136/adc.84.3.227; Moynihan R, 2000, NEW ENGL J MED, V342, P1645, DOI 10.1056/NEJM200006013422206; Murphy TV, 2001, NEW ENGL J MED, V344, P564, DOI 10.1056/NEJM200102223440804; Nasir L, 2000, J FAM PRACTICE, V49, P731; *NAT HLTH COUNC, 1997, AM TALK SCI MED NEWS; NELKIN D, 1985, SOC RES, V52, P625; Offit PA, 1998, J CLIN VIROL, V11, P155, DOI 10.1016/S0928-0197(98)00063-4; Parashar UD, 1998, EMERG INFECT DIS, V4, P561, DOI 10.3201/eid0404.980406; PerezSchael I, 1997, NEW ENGL J MED, V337, P1181, DOI 10.1056/NEJM199710233371701; POKORNY WJ, 1994, PRINCIPLES PRACTICE, P1856; Rennels MB, 1996, PEDIATRICS, V97, P7; Rennels MB, 1998, PEDIATR INFECT DIS J, V17, P924, DOI 10.1097/00006454-199810000-00018; Rennels MB, 2000, PEDIATRICS, V106, P123, DOI 10.1542/peds.106.1.123; Sansom SL, 2001, AM J EPIDEMIOL, V154, P1077, DOI 10.1093/aje/154.11.1077; SINGER E, 1987, J COMMUN, V37, P10; *US BUR CENS, 2001, WORLD POP PROF 1996; *US FDA, 1997, ROT ROT VACC SPONS P; Velazquez FR, 1996, NEW ENGL J MED, V335, P1022, DOI 10.1056/NEJM199610033351404; VESIKARI T, 1990, AM J DIS CHILD, V144, P285, DOI 10.1001/archpedi.1990.02150270035021; VESIKARI T, 1986, J INFECT DIS, V153, P832, DOI 10.1093/infdis/153.5.832; Withdrawal of rotavirus vaccine, 1999, MMWR-MORBID MORTAL W, V48, P1007; Zanardi LR, 2001, PEDIATRICS, V107, DOI 10.1542/peds.107.6.e97; 1999, AHP NEWS 1998; 2001, AAP NEWS         JAN, P6; 2000, AM JOURNALISM REV NE; 2000, MMWR MORB MORTAL WKL, V49, P585	70	41	41	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 20	2002	287	11					1455	1462		10.1001/jama.287.11.1455	http://dx.doi.org/10.1001/jama.287.11.1455			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	532GB	11903035	Bronze, Green Accepted			2022-12-28	WOS:000174465000030
J	Karre, K				Karre, K			Immunology - A perfect mismatch	SCIENCE			English	Editorial Material							NATURAL-KILLER-CELLS; REJECTION; RECEPTORS		Karolinska Inst, Ctr Microbiol & Tumor Biol, Stockholm, Sweden	Karolinska Institutet	Karre, K (corresponding author), Karolinska Inst, Ctr Microbiol & Tumor Biol, Stockholm, Sweden.							Asai O, 1998, J CLIN INVEST, V101, P1835, DOI 10.1172/JCI1268; GIRALT S, 2000, NONMYELOABLATIVE STE; KARLHOFER FM, 1992, NATURE, V358, P66, DOI 10.1038/358066a0; KARRE K, 1986, NATURE, V319, P675, DOI 10.1038/319675a0; Lanier LL, 1998, ANNU REV IMMUNOL, V16, P359, DOI 10.1146/annurev.immunol.16.1.359; Moretta A, 1997, CURR OPIN IMMUNOL, V9, P694, DOI 10.1016/S0952-7915(97)80051-9; OHLEN C, 1989, SCIENCE, V246, P666, DOI 10.1126/science.2814488; Ruggeri L, 2002, SCIENCE, V295, P2097, DOI 10.1126/science.1068440; Wang JW, 2002, SCIENCE, V295, P2094, DOI 10.1126/science.1068438	9	82	91	1	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 15	2002	295	5562					2029	2031		10.1126/science.1070538	http://dx.doi.org/10.1126/science.1070538			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	532AY	11896262				2022-12-28	WOS:000174450500032
J	Bicknell, WJ				Bicknell, WJ			Sounding board - The case for voluntary smallpox vaccination.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Boston Univ, Sch Publ Hlth, Boston, MA 02118 USA	Boston University	Bicknell, WJ (corresponding author), Boston Univ, Sch Publ Hlth, Boston, MA 02118 USA.							Barbera J, 2001, JAMA-J AM MED ASSOC, V286, P2711, DOI 10.1001/jama.286.21.2711; Centers for Disease Control and Prevention, 2001, INT SMALLP RESP PLAN; CHIN J, 2000, CONTROL COMMUNICABLE, P457; Cohen J, 2001, SCIENCE, V294, P985, DOI 10.1126/science.294.5544.985; Fenner F., 1988, SMALLPOX ITS ERRADIC, P1; Henderson DA, 1999, JAMA-J AM MED ASSOC, V281, P2127, DOI 10.1001/jama.281.22.2127; *INT COMM RES, 2001, Q946 INT COMM RES; Meltzer MI, 2001, EMERG INFECT DIS, V7, P959, DOI 10.3201/eid0706.010607; MILLAR JD, 2000, PARADOX PREVENTION M; *NAT TRANSP SAF BO, 2001, REP INJ AM; *NAT VACC PROGR OF, 2001, PAND INFL PAND PAND; OTOOLE T, 2001, SHINING LIGHT DARK W; PETERSEN M, 2001, NY TIMES        0824, pC2; PICARD A, 2001, GLOBE MAIL      1106, P1; Rosenthal SR, 2001, EMERG INFECT DIS, V7, P920, DOI 10.3201/eid0706.010602	15	73	74	0	2	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 25	2002	346	17					1323	1325						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	544GX	11923492				2022-12-28	WOS:000175150800012
J	Kuruvilla, FG; Shamji, AF; Sternson, SM; Hergenrother, PJ; Schreiber, SL				Kuruvilla, FG; Shamji, AF; Sternson, SM; Hergenrother, PJ; Schreiber, SL			Dissecting glucose signalling with diversity-oriented synthesis and small-molecule microarrays	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; URE2P; TOR; PROTEIN; EXPRESSION; REGULATOR; LIGAND; GLN3P	Small molecules that alter protein function provide a means to modulate biological networks with temporal resolution. Here we demonstrate a potentially general and scalable method of identifying such molecules by application to a particular protein, Ure2p, which represses the transcription factors Gln3p and Nil1p(1-3). By probing a high-density microarray of small molecules generated by diversity-oriented synthesis with fluorescently labelled Ure2p, we performed 3,780 protein-binding assays in parallel and identified several compounds that bind Ure2p. One compound, which we call uretupamine, specifically activates a glucose-sensitive transcriptional pathway downstream of Ure2p. Whole-genome transcription profiling and chemical epistasis demonstrate the remarkable Ure2p specificity of uretupamine and its ability to modulate the glucose-sensitive subset of genes downstream of Ure2p. These results demonstrate that diversity-oriented synthesis and small-molecule microarrays can be used to identify small molecules that bind to a protein of interest, and that these small molecules can regulate specific functions of the protein.	Harvard Univ, Dept Chem & Biol Chem, Bauer Ctr Genom Res, Inst Chem & Cell Biol,Howard Hughes Med Inst, Cambridge, MA 02138 USA; Harvard Univ, Dept Biophys, Cambridge, MA 02138 USA	Harvard University; Howard Hughes Medical Institute; Harvard University	Schreiber, SL (corresponding author), Harvard Univ, Dept Chem & Biol Chem, Bauer Ctr Genom Res, Inst Chem & Cell Biol,Howard Hughes Med Inst, 12 Oxford St, Cambridge, MA 02138 USA.			Sternson, Scott/0000-0002-0835-444X	NIGMS NIH HHS [GM-38627] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038627, R01GM038627] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beck T, 1999, NATURE, V402, P689, DOI 10.1038/45287; Bertram PG, 2000, J BIOL CHEM, V275, P35727, DOI 10.1074/jbc.M004235200; Blackwell HE, 2001, CHEM BIOL, V8, P1167, DOI 10.1016/S1074-5521(01)00085-0; Blinder D, 1996, J BACTERIOL, V178, P4734, DOI 10.1128/jb.178.15.4734-4736.1996; BOGONEZ E, 1983, BIOCHIM BIOPHYS ACTA, V733, P234, DOI 10.1016/0005-2736(83)90527-8; Cardenas ME, 1999, GENE DEV, V13, P3271, DOI 10.1101/gad.13.24.3271; Causton HC, 2001, MOL BIOL CELL, V12, P323, DOI 10.1091/mbc.12.2.323; Clemons PA, 2001, CHEM BIOL, V8, P1183, DOI 10.1016/S1074-5521(01)00086-2; COSCHIGANO PW, 1991, MOL CELL BIOL, V11, P822, DOI 10.1128/MCB.11.2.822; Cunningham TS, 2000, J BIOL CHEM, V275, P14408, DOI 10.1074/jbc.275.19.14408; Edskes HK, 2000, P NATL ACAD SCI USA, V97, P6625, DOI 10.1073/pnas.120168697; Edskes HK, 1999, GENETICS, V153, P585; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Hardwick JS, 1999, P NATL ACAD SCI USA, V96, P14866, DOI 10.1073/pnas.96.26.14866; Hergenrother PJ, 2000, J AM CHEM SOC, V122, P7849, DOI 10.1021/ja0014032; KORNBERG HL, 1957, NATURE, V179, P988, DOI 10.1038/179988a0; Kuruvilla FG, 2001, P NATL ACAD SCI USA, V98, P7283, DOI 10.1073/pnas.121186898; KURUVILLA FG, 2002, GENOME BIOL, V3; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; MacBeath G, 1999, J AM CHEM SOC, V121, P7967, DOI 10.1021/ja991083q; Marton MJ, 1998, NAT MED, V4, P1293, DOI 10.1038/3282; NARAHASHI T, 1964, J GEN PHYSIOL, V47, P965, DOI 10.1085/jgp.47.5.965; Schreiber SL, 2000, SCIENCE, V287, P1964, DOI 10.1126/science.287.5460.1964; Shamji AF, 2000, CURR BIOL, V10, P1574, DOI 10.1016/S0960-9822(00)00866-6; Sternson SM, 2001, J AM CHEM SOC, V123, P1740, DOI 10.1021/ja0036108; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170; Wiemann S, 2001, GENOME RES, V11, P422, DOI 10.1101/gr.GR1547R; XU SW, 1995, MOL CELL BIOL, V15, P2321	28	319	355	2	46	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 11	2002	416	6881					653	657		10.1038/416653a	http://dx.doi.org/10.1038/416653a			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	539YV	11948353				2022-12-28	WOS:000174901900048
J	Li, MY; Chen, DL; Shiloh, A; Luo, JY; Nikolaev, AY; Qin, J; Gu, W				Li, MY; Chen, DL; Shiloh, A; Luo, JY; Nikolaev, AY; Qin, J; Gu, W			Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization	NATURE			English	Article							UBIQUITIN SYSTEM; MDM2; PHOSPHORYLATION; ONCOPROTEIN; DEGRADATION; STABILITY; PROTEIN; PROTEASOME; LIGASE	The p53 tumour suppressor is a short-lived protein that is maintained at low levels in normal cells by Mdm2-mediated ubiquitination and subsequent proteolysis(1-3). Stabilization of p53 is crucial for its tumour suppressor function(1-5). However, the precise mechanism by which ubiquitinated p53 levels are regulated in vivo is not completely understood. By mass spectrometry of affinity-purified p53-associated factors, we have identified herpesvirus-associated ubiquitin-specific protease(6) (HAUSP) as a novel p53-interacting protein. HAUSP strongly stabilizes p53 even in the presence of excess Mdm2, and also induces p53-dependent cell growth repression and apoptosis. Significantly, HAUSP has an intrinsic enzymatic activity that specifically deubiquitinates p53 both in vitro and in vivo. In contrast, expression of a catalytically inactive point mutant of HAUSP in cells increases the levels of p53 ubiquitination and destabilizes p53. These findings reveal an important mechanism by which p53 can be stabilized by direct deubiquitination and also imply that HAUSP might function as a tumour suppressor in vivo through the stabilization of p53.	Columbia Univ Coll Phys & Surg, Inst Canc Genet, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Baylor Coll Med, Dept Biochem, Houston, TX 77030 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA	Columbia University; Columbia University; Baylor College of Medicine; Baylor College of Medicine	Gu, W (corresponding author), Columbia Univ Coll Phys & Surg, Inst Canc Genet, 1150 St Nicholas Ave, New York, NY 10032 USA.		Luo, Jianyuan/ABI-7585-2020	Luo, Jianyuan/0000-0001-6057-2914; Nikolaev, Anatoly/0000-0003-2818-5839				Appella E, 2000, PATHOL BIOL, V48, P227; Ashcroft M, 2000, MOL CELL BIOL, V20, P3224, DOI 10.1128/MCB.20.9.3224-3233.2000; Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; Blattner C, 1999, ONCOGENE, V18, P1723, DOI 10.1038/sj.onc.1202480; Chung CH, 1999, BIOCHEM BIOPH RES CO, V266, P633, DOI 10.1006/bbrc.1999.1880; D'Andrea A, 1998, CRIT REV BIOCHEM MOL, V33, P337, DOI 10.1080/10409239891204251; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; Everett RD, 1997, EMBO J, V16, P566, DOI 10.1093/emboj/16.3.566; Freedman DA, 1999, CELL MOL LIFE SCI, V55, P96, DOI 10.1007/s000180050273; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hershko A, 2000, NAT MED, V6, P1073, DOI 10.1038/80384; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Kornitzer D, 2000, J CELL PHYSIOL, V182, P1, DOI 10.1002/(SICI)1097-4652(200001)182:1<1::AID-JCP1>3.0.CO;2-V; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Prives C, 1999, J PATHOL, V187, P112; Rodriguez MS, 2000, MOL CELL BIOL, V20, P8458, DOI 10.1128/MCB.20.22.8458-8467.2000; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Seavey SE, 1999, J VIROL, V73, P7590, DOI 10.1128/JVI.73.9.7590-7598.1999; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; Tolbert D, 2002, MOL CELL BIOL, V22, P370, DOI 10.1128/MCB.22.1.370-377.2002; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wilkinson KD, 2000, SEMIN CELL DEV BIOL, V11, P141, DOI 10.1006/scdb.2000.0164	30	758	799	3	116	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 11	2002	416	6881					648	653		10.1038/nature737	http://dx.doi.org/10.1038/nature737			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	539YV	11923872				2022-12-28	WOS:000174901900047
J	Wei, BQ; Vajtai, R; Jung, Y; Ward, J; Zhang, R; Ramanath, G; Ajayan, PM				Wei, BQ; Vajtai, R; Jung, Y; Ward, J; Zhang, R; Ramanath, G; Ajayan, PM			Organized assembly of carbon nanotubes - Cunning refinements help to customize the architecture of nanotube structures.	NATURE			English	Article							ARRAYS		Rensselaer Polytech Inst, Dept Mat Sci & Engn, Troy, NY 12180 USA; Motorola Phys Sci Res Labs, Tempe, AZ 85284 USA	Rensselaer Polytechnic Institute	Wei, BQ (corresponding author), Rensselaer Polytech Inst, Dept Mat Sci & Engn, Troy, NY 12180 USA.		Ramanath, Ganpati/C-1157-2011; Vajtai, Robert/B-1029-2008; Jung, Yung Joon/L-2032-2013; Wei, Bingqing/A-4525-2008	Ramanath, Ganpati/0000-0002-8718-9760; Vajtai, Robert/0000-0002-3942-8827; Wei, Bingqing/0000-0002-9416-1731				Dresselhaus M. S., 2001, CARBON NANOTUBES SYN; Fan SS, 1999, SCIENCE, V283, P512, DOI 10.1126/science.283.5401.512; Kind H, 1999, ADV MATER, V11, P1285, DOI 10.1002/(SICI)1521-4095(199910)11:15<1285::AID-ADMA1285>3.0.CO;2-J; Li WZ, 1996, SCIENCE, V274, P1701, DOI 10.1126/science.274.5293.1701; Ren ZF, 1998, SCIENCE, V282, P1105, DOI 10.1126/science.282.5391.1105; Schlittler RR, 2001, SCIENCE, V292, P1136, DOI 10.1126/science.1057823; Sen R, 1997, CHEM PHYS LETT, V267, P276, DOI 10.1016/S0009-2614(97)00080-8; Terrones M, 1997, NATURE, V388, P52, DOI 10.1038/40369; Zhang ZJ, 2000, APPL PHYS LETT, V77, P3764, DOI 10.1063/1.1330751	9	464	499	3	133	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 4	2002	416	6880					495	496		10.1038/416495a	http://dx.doi.org/10.1038/416495a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	537JY	11932732				2022-12-28	WOS:000174756500030
J	Kalab, P; Weis, K; Heald, R				Kalab, P; Weis, K; Heald, R			Visualization of a Ran-GTP gradient in interphase and mitotic Xenopus egg extracts	SCIENCE			English	Article							IMPORTIN-ALPHA; NUCLEAR TRANSPORT; PROTEIN IMPORT; BOUND RAN; BINDING; MUTANTS; DOMAIN; BETA	The small guanosine triphosphatase Ran is loaded with guanosine triphosphate (GTP) by the chromatin-bound guanine nucleotide exchange factor RCC1 and releases import cargoes in the nucleus during interphase. In mitosis, Ran-GTP promotes spindle assembly around chromosomes by locally discharging cargoes that regulate microtubule dynamics and organization. We used fluorescence resonance energy transfer-based biosensors to visualize gradients of Ran-GTP and liberated cargoes around chromosomes in mitotic Xenopus egg extracts. Both gradients were required to assemble and maintain spindle structure. During interphase, Ran-GTP was highly enriched in the nucleoplasm, and a steep concentration difference between nuclear and cytoplasmic Ran-GTP was established, providing evidence for a Ran-GTP gradient surrounding chromosomes throughout the cell cycle.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Weis, K (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 229 Stanley Hall, Berkeley, CA 94720 USA.		Weis, Karsten/F-5719-2011; Kalab, Petr/B-2478-2009; Ding, Cheng-Qiang/B-6287-2011	Weis, Karsten/0000-0001-7224-925X; Heald, Rebecca/0000-0001-6671-6528				Carazo-Salas RE, 1999, NATURE, V400, P178, DOI 10.1038/22133; Catimel B, 2001, J BIOL CHEM, V276, P34189, DOI 10.1074/jbc.M103531200; Cingolani G, 1999, NATURE, V399, P221, DOI 10.1038/20367; Dasso M, 2001, CELL, V104, P321, DOI 10.1016/S0092-8674(01)00218-5; Gordon GW, 1998, BIOPHYS J, V74, P2702, DOI 10.1016/S0006-3495(98)77976-7; Gorlich D, 1996, EMBO J, V15, P1810, DOI 10.1002/j.1460-2075.1996.tb00530.x; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Gruss OJ, 2001, CELL, V104, P83, DOI 10.1016/S0092-8674(01)00193-3; Hetzer M, 2000, MOL CELL, V5, P1013, DOI 10.1016/S1097-2765(00)80266-X; Kalab P, 1999, CURR BIOL, V9, P481, DOI 10.1016/S0960-9822(99)80213-9; KALAB P, UNPUB; Kobe B, 1999, NAT STRUCT BIOL, V6, P388, DOI 10.1038/7625; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; Nachury MV, 2001, CELL, V104, P95, DOI 10.1016/S0092-8674(01)00194-5; Ohba T, 1999, SCIENCE, V284, P1356, DOI 10.1126/science.284.5418.1356; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; SCHLENSTEDT G, 1995, EMBO J, V14, P5367, DOI 10.1002/j.1460-2075.1995.tb00221.x; Tsien RY, 1998, SCIENCE, V280, P1954, DOI 10.1126/science.280.5371.1954; Vetter IR, 1999, NATURE, V398, P39, DOI 10.1038/17969; Weis K, 1996, EMBO J, V15, P7120, DOI 10.1002/j.1460-2075.1996.tb01103.x; Wiese C, 2001, SCIENCE, V291, P653, DOI 10.1126/science.1057661; Wilde A, 1999, SCIENCE, V284, P1359, DOI 10.1126/science.284.5418.1359; Xia ZP, 2001, BIOPHYS J, V81, P2395, DOI 10.1016/S0006-3495(01)75886-9; Zhang CM, 2000, SCIENCE, V288, P1429, DOI 10.1126/science.288.5470.1429; Zhang CM, 1999, J CELL SCI, V112, P2453	26	412	420	0	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 29	2002	295	5564					2452	2456		10.1126/science.1068798	http://dx.doi.org/10.1126/science.1068798			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	536QD	11923538				2022-12-28	WOS:000174712600056
J	Shang, YF; Brown, M				Shang, YF; Brown, M			Molecular determinants for the tissue specificity of SERMs	SCIENCE			English	Article							HUMAN ESTROGEN-RECEPTOR; PROMOTER-CONTEXT; C-MYC; ACTIVATION; TRANSCRIPTION; COACTIVATOR; CANCER; GENE; 4-HYDROXYTAMOXIFEN; ANTIESTROGEN	Selective estrogen receptor modulators (SERMs) mimic estrogen action in certain tissues while opposing it in others. The therapeutic effectiveness of SERMS such as tamoxifen and raloxifene in breast cancer depends on their antiestrogenic activity. In the uterus, however, tamoxifen is estrogenic. Here, we show that both tamoxifen and raloxifene induce the recruitment of corepressors to target gene promoters in mammary cells. In endometrial cells, tamoxifen, but not raloxifene, acts like estrogen by stimulating the recruitment of coactivators to a subset of genes. The estrogen-like activity of tamoxifen in the uterus requires a high level of steroid receptor coactivator 1 (SRC-1) expression. Thus cell type- and promoter-specific differences in coregulator recruitment determine the cellular response to SERMs.	Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Brown, M (corresponding author), Dana Farber Canc Inst, Dept Adult Oncol, 44 Binney St, Boston, MA 02115 USA.		Brown, Myles/B-6906-2008; Brown, Myles/AAX-5332-2021	Brown, Myles/0000-0002-8213-1658	NATIONAL CANCER INSTITUTE [R01CA057374] Funding Source: NIH RePORTER; NCI NIH HHS [CA57374] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUGEREAU P, 1994, MOL ENDOCRINOL, V8, P693, DOI 10.1210/me.8.6.693; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Chen HW, 2001, CURR OPIN CELL BIOL, V13, P218, DOI 10.1016/S0955-0674(00)00200-3; DUBIK D, 1992, ONCOGENE, V7, P1587; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; Glass CK, 2000, GENE DEV, V14, P121; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; Hu X, 2000, TRENDS ENDOCRIN MET, V11, P6, DOI 10.1016/S1043-2760(99)00215-5; Jackson TA, 1997, MOL ENDOCRINOL, V11, P693, DOI 10.1210/me.11.6.693; Jordan VC, 2001, J NATL CANCER I, V93, P1449, DOI 10.1093/jnci/93.19.1449; Lemon BD, 1999, CURR OPIN GENET DEV, V9, P499, DOI 10.1016/S0959-437X(99)00010-6; METZGER D, 1992, NUCLEIC ACIDS RES, V20, P2813, DOI 10.1093/nar/20.11.2813; Nasi S, 2001, FEBS LETT, V490, P153, DOI 10.1016/S0014-5793(01)02118-4; PHAM TA, 1992, MOL ENDOCRINOL, V6, P1043, DOI 10.1210/me.6.7.1043; Schraml P, 1999, CLIN CANCER RES, V5, P1966; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Smith CL, 1997, MOL ENDOCRINOL, V11, P657, DOI 10.1210/me.11.6.657; Tremblay A, 1999, MOL CELL, V3, P513, DOI 10.1016/S1097-2765(00)80479-7; Tsuchiya F, 2001, BIOCHEM BIOPH RES CO, V284, P2, DOI 10.1006/bbrc.2001.4892; TZUKERMAN MT, 1994, MOL ENDOCRINOL, V8, P21, DOI 10.1210/me.8.1.21; UMAYAHARA Y, 1994, J BIOL CHEM, V269, P16433; Watanabe T, 1998, MOL CELL BIOL, V18, P442, DOI 10.1128/MCB.18.1.442; Webb P, 1998, MOL ENDOCRINOL, V12, P1605, DOI 10.1210/me.12.10.1605; Williams JA, 1999, EXP MOL PATHOL, V67, P135, DOI 10.1006/exmp.1999.2289; Yu H, 2000, JNCI-J NATL CANCER I, V92, P1472, DOI 10.1093/jnci/92.18.1472	28	919	974	2	61	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 29	2002	295	5564					2465	2468		10.1126/science.1068537	http://dx.doi.org/10.1126/science.1068537			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	536QD	11923541				2022-12-28	WOS:000174712600060
J	Scully, KM; Rosenfeld, MG				Scully, KM; Rosenfeld, MG			Development - Pituitary development: Regulatory codes in mammalian organogenesis	SCIENCE			English	Review							ANTERIOR-PITUITARY; NEURAL PLATE; IN-VIVO; HORMONE DEFICIENCY; GLAND DEVELOPMENT; RATHKES-POUCH; CELL-TYPES; GENE; PIT-1; TRANSCRIPTION	During mammalian pituitary gland development, distinct cell types emerge from a common primordium. Appearance of specific cell types occurs in response to opposing signaling gradients that emanate from distinct organizing centers. These signals induce expression of interacting transcriptional regulators, including DNA binding-dependent activators and DNA binding-independent transrepressors, in temporally and spatially overlapping patterns. Together they synergistically regulate precursor proliferation and induction of distinct cell types. Terminal cell type differentiation requires selective gene activation strategies and long-term active repression, mediated by cell type-specific and promoter-specific recruitment of coregulatory complexes. These mechanisms imply the potential for flexibility in the ultimate identity of differentiated cell types.	Univ Calif San Diego, Sch Med, Howard Hughes Med Inst, La Jolla, CA 92093 USA	Howard Hughes Medical Institute; University of California System; University of California San Diego	Rosenfeld, MG (corresponding author), Univ Calif San Diego, Sch Med, Howard Hughes Med Inst, 9500 Gilman Dr,Room 345, La Jolla, CA 92093 USA.							Akita S, 1997, J CLIN INVEST, V99, P2462, DOI 10.1172/JCI119430; Altaba ARI, 1999, TRENDS GENET, V15, P418, DOI 10.1016/S0168-9525(99)01840-5; Bentley CA, 1999, ENDOCRINE, V10, P171, DOI 10.1385/ENDO:10:2:171; Bousquet C, 2000, J CLIN INVEST, V106, P1417, DOI 10.1172/JCI11182; Bousquet C, 1999, J BIOL CHEM, V274, P10723, DOI 10.1074/jbc.274.16.10723; Bradford AP, 1997, MOL CELL BIOL, V17, P1065, DOI 10.1128/MCB.17.3.1065; COULY G, 1988, DEVELOPMENT, V103, P101; Dasen JS, 2001, GENE DEV, V15, P3193, DOI 10.1101/gad.932601; Dasen JS, 1999, CELL, V97, P587, DOI 10.1016/S0092-8674(00)80770-9; Dasen JS, 2001, ANNU REV NEUROSCI, V24, P327, DOI 10.1146/annurev.neuro.24.1.327; De Moerlooze L, 2000, DEVELOPMENT, V127, P483; EAGLESON GW, 1990, J NEUROBIOL, V21, P427, DOI 10.1002/neu.480210305; Edlund T, 1999, CELL, V96, P211, DOI 10.1016/S0092-8674(00)80561-9; Ericson J, 1997, CELL, V90, P169, DOI 10.1016/S0092-8674(00)80323-2; Ericson J, 1998, DEVELOPMENT, V125, P1005; Gage PJ, 1996, MOL ENDOCRINOL, V10, P1570, DOI 10.1210/me.10.12.1570; Gage PJ, 1999, DEVELOPMENT, V126, P4643; Gallardo ME, 1999, GENOMICS, V61, P82, DOI 10.1006/geno.1999.5916; Gleiberman AS, 1999, DEV BIOL, V213, P340, DOI 10.1006/dbio.1999.9386; GODFREY P, 1993, NAT GENET, V4, P227, DOI 10.1038/ng0793-227; Gordon DF, 1997, J BIOL CHEM, V272, P24339, DOI 10.1074/jbc.272.39.24339; Hermesz E, 1996, DEVELOPMENT, V122, P41; HOWARD PW, 1995, J BIOL CHEM, V270, P20930, DOI 10.1074/jbc.270.36.20930; Kimura S, 1996, GENE DEV, V10, P60, DOI 10.1101/gad.10.1.60; Kioussi C, 1999, P NATL ACAD SCI USA, V96, P14378, DOI 10.1073/pnas.96.25.14378; Lamolet B, 2001, CELL, V104, P849, DOI 10.1016/S0092-8674(01)00282-3; Lanctot C, 1999, DEVELOPMENT, V126, P1805; Lawrence PA, 1996, CELL, V85, P951, DOI 10.1016/S0092-8674(00)81297-0; Lee SL, 1996, SCIENCE, V273, P1219, DOI 10.1126/science.273.5279.1219; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; Lin CR, 1999, NATURE, V401, P279, DOI 10.1038/45803; LIN SC, 1993, NATURE, V364, P208, DOI 10.1038/364208a0; Liu JX, 2001, P NATL ACAD SCI USA, V98, P8674, DOI 10.1073/pnas.141234898; Maira M, 1999, MOL CELL BIOL, V19, P7549; Martinez-Barbera JP, 2000, DEV BIOL, V223, P422, DOI 10.1006/dbio.2000.9757; Pfaff SL, 1996, CELL, V84, P309, DOI 10.1016/S0092-8674(00)80985-X; Poulin G, 2000, MOL CELL BIOL, V20, P4826, DOI 10.1128/MCB.20.13.4826-4837.2000; Rubenstein JLR, 1998, ANNU REV NEUROSCI, V21, P445, DOI 10.1146/annurev.neuro.21.1.445; Scully KM, 2000, SCIENCE, V290, P1127, DOI 10.1126/science.290.5494.1127; Semina EV, 1996, NAT GENET, V14, P392, DOI 10.1038/ng1296-392; Sheng HZ, 1999, TRENDS GENET, V15, P236, DOI 10.1016/S0168-9525(99)01742-4; Sheng HZ, 1997, SCIENCE, V278, P1809, DOI 10.1126/science.278.5344.1809; Sheng HZ, 1996, SCIENCE, V272, P1004, DOI 10.1126/science.272.5264.1004; Shewchuk BM, 1999, J BIOL CHEM, V274, P35725, DOI 10.1074/jbc.274.50.35725; Smith ST, 1996, DEVELOPMENT, V122, P3141; Sornson MW, 1996, NATURE, V384, P327, DOI 10.1038/384327a0; Szeto DP, 1996, P NATL ACAD SCI USA, V93, P7706, DOI 10.1073/pnas.93.15.7706; Takuma N, 1998, DEVELOPMENT, V125, P4835; Treier M, 1998, GENE DEV, V12, P1691, DOI 10.1101/gad.12.11.1691; Treier M, 2001, DEVELOPMENT, V128, P377; Watkins-Chow DE, 1998, TRENDS GENET, V14, P284, DOI 10.1016/S0168-9525(98)01476-0; Wu W, 1998, NAT GENET, V18, P147, DOI 10.1038/ng0298-147; Xu L, 1998, NATURE, V395, P301, DOI 10.1038/26270; Zhao LP, 2001, DEVELOPMENT, V128, P147	54	284	291	1	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 22	2002	295	5563					2231	2235		10.1126/science.1062736	http://dx.doi.org/10.1126/science.1062736			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	534AD	11910101				2022-12-28	WOS:000174561700034
J	Asfaw, B; Gilbert, WH; Beyene, Y; Hart, WK; Renne, PR; WoldeGabriel, G; Vrba, ES; White, TD				Asfaw, B; Gilbert, WH; Beyene, Y; Hart, WK; Renne, PR; WoldeGabriel, G; Vrba, ES; White, TD			Remains of Homo erectus from bouri, Middle Awash, Ethiopia	NATURE			English	Article							PLEISTOCENE; CLADISTICS; SPECIATION; HOMINIDS; CRANIUM; RECORD	The genesis, evolution and fate of Homo erectus have been explored palaeontologically since the taxon's recognition in the late nineteenth century. Current debate(1) is focused on whether early representatives from Kenya and Georgia should be classified as a separate ancestral species ('H. ergaster')(2-4), and whether H. erectus was an exclusively Asian species lineage that went extinct(5,6). Lack of resolution of these issues has obscured the place of H. erectus in human evolution. A hominid calvaria and postcranial remains recently recovered from the Dakanihylo Member of the Bouri Formation, Middle Awash, Ethiopia, bear directly on these issues. These similar to1.0-million-year (Myr)-old Pleistocene sediments contain abundant early Acheulean stone tools and a diverse vertebrate fauna that indicates a predominantly savannah environment. Here we report that the 'Daka' calvaria's metric and morphological attributes centre it firmly within H. erectus. Daka's resemblance to Asian counterparts indicates that the early African and Eurasian fossil hominids represent demes of a widespread palaeospecies. Daka's anatomical intermediacy between earlier and later African fossils provides evidence of evolutionary change. Its temporal and geographic position indicates that African H. erectus was the ancestor of Homo sapiens.	Rift Valley Res Serv, Addis Ababa, Ethiopia; Univ Calif Berkeley, VLSB, Museum Vertebrate Zool, Lab Human Evolutionary Studies, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Integrat Biol, Berkeley, CA 94720 USA; Minist Youth Sports & Culture, Dept Anthropol & Archaeol ARCCH, Addis Ababa, Ethiopia; Miami Univ, Dept Geol, Oxford, OH 45056 USA; Berkeley Geochronol Ctr, Berkeley, CA 94709 USA; Univ Calif Berkeley, Dept Earth & Planetary Sci, Berkeley, CA 94720 USA; Univ Calif Los Alamos Natl Lab, Los Alamos, NM 87545 USA; Yale Univ, Dept Geol & Geophys, New Haven, CT 06511 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley; University System of Ohio; Miami University; Berkeley Geochronolgy Center; University of California System; University of California Berkeley; United States Department of Energy (DOE); Los Alamos National Laboratory; Yale University	Asfaw, B (corresponding author), Rift Valley Res Serv, POB 5717, Addis Ababa, Ethiopia.			Renne, Paul/0000-0003-1769-5235				Abbate E, 1998, NATURE, V393, P458, DOI 10.1038/30954; Aguirre E., 2000, Human Evolution, V15, P51, DOI 10.1007/BF02436234; Ambrose SH, 2001, SCIENCE, V291, P1748, DOI 10.1126/science.1059487; Andrews P., 1984, Courier Forschungsinstitut Senckenberg, V69, P167; Bar-Yosef O, 1999, ANTHROPOLOGIE, V37, P51; BRAUER G, 1992, J HUM EVOL, V22, P79, DOI 10.1016/0047-2484(92)90032-5; CLARKE R, 2001, INT J ANTHR, V15, P185; de Heinzelin J, 1999, SCIENCE, V284, P625; DEHEINZELIN J, 2000, ANN SCI GEOL, V104; DELSON E, 1985, NATURE, V316, P762, DOI 10.1038/316762a0; GABUNIA L, 2001, ARCHAEOL ETHNOL ANTH, V2, P128; Groves C., 1989, THEORY HUMAN PRIMATE; Harrison Terry, 1993, P345; Howell FC, 1999, J ANTHROPOL RES, V55, P191, DOI 10.1086/jar.55.2.3631209; KALB JE, 1982, NATURE, V298, P17, DOI 10.1038/298017a0; KENNEDY GE, 1991, J HUM EVOL, V20, P375, DOI 10.1016/0047-2484(91)90006-H; KRAMER A, 1993, AM J PHYS ANTHROPOL, V91, P161, DOI 10.1002/ajpa.1330910203; Larick R, 2001, P NATL ACAD SCI USA, V98, P4866, DOI 10.1073/pnas.081077298; Lovejoy CO, 1999, P NATL ACAD SCI USA, V96, P13247, DOI 10.1073/pnas.96.23.13247; Martinez I, 1997, J HUM EVOL, V33, P283, DOI 10.1006/jhev.1997.0155; OLSEN JW, 1999, ANTHROPOLOGIE, V37, P89; Rightmire G. P., 1990, EVOLUTION HOMO ERECT; Rightmire GP, 1996, J HUM EVOL, V31, P21; Rightmire GP, 1998, AM J PHYS ANTHROPOL, V106, P61, DOI 10.1002/(SICI)1096-8644(199805)106:1<61::AID-AJPA5>3.3.CO;2-U; Schwartz JH, 2000, SCIENCE, V289, P55; TRINKAUS E, 1990, AM J PHYS ANTHROPOL, V83, P1, DOI 10.1002/ajpa.1330830102; TURNER A, 1989, J HUM EVOL, V18, P115, DOI 10.1016/0047-2484(89)90066-3; Vrba E. S., 1997, Palaeontologia Africana, V34, P127; Walker A., 1993, NARIOKOTOME HOMO ERE; WOOD BA, 1996, KOOBI FORA RES PROJE, V4	30	187	199	1	53	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 21	2002	416	6878					317	320		10.1038/416317a	http://dx.doi.org/10.1038/416317a			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	532NP	11907576				2022-12-28	WOS:000174482200041
J	May, LD; Lefkowitch, JH; Kram, MT; Rubin, DE				May, LD; Lefkowitch, JH; Kram, MT; Rubin, DE			Mixed hepatocellular-cholestatic liver injury after pioglitazone therapy	ANNALS OF INTERNAL MEDICINE			English	Article							PATIENT; ROSIGLITAZONE; GLITAZONES	Background: Ploglitazone is an oral hypoglycemic agent in the thiazolidinedione class. only one case of hepatotoxicity related to this agent has previously been reported. Objective: To report the clinical course of a patient with hepatitis after therapy with pioglitazone. Design: case report. Setting: A community hospital. Patient: A 49-year-old diabetic man taking pioglitazone, 30 mg/d. Intervention: Discontinuation of pioglitazone therapy. Measurements: serum aminotransferase and bilirubin levels, standard blood tests for causes of hepatitis and cirrhosis other than drug toxicity, and liver biopsy. Results: After 6 months of pioglitazone therapy, significant hepatic dysfunction developed. Blood tests excluded viral, metabolic, and autoimmune disorders. Liver biopsy showed mixed hepatocellular-cholestatic injury compatible with drug toxicity. After treatment with pioglitazone was discontinued, liver enzyme values returned to normal. Conclusion: Patients receiving pioglitazone may develop serious liver injury and should be observed for evidence of hepatitis.	Good Samaritan Hosp, Suffern, NY 10901 USA; Columbia Presbyterian Med Ctr, New York, NY 10032 USA	Columbia University; NewYork-Presbyterian Hospital	May, LD (corresponding author), Gastrointestinal Associates Rockland, 500 New Hempstead Rd, New City, NY 10956 USA.							Aithal PG, 1999, GUT, V44, P731, DOI 10.1136/gut.44.5.731; Al-Salman J, 2000, ANN INTERN MED, V132, P121, DOI 10.7326/0003-4819-132-2-200001180-00006; [Anonymous], 2000, PHYS DESK REF, p[3088, 3094]; Forman LM, 2000, ANN INTERN MED, V132, P118, DOI 10.7326/0003-4819-132-2-200001180-00005; Gale EAM, 2001, LANCET, V357, P1870, DOI 10.1016/S0140-6736(00)04960-6; Kohlroser J, 2000, AM J GASTROENTEROL, V95, P272; Krische D, 2000, WESTERN J MED, V173, P54, DOI 10.1136/ewjm.173.1.54; Maeda K, 2001, ANN INTERN MED, V135, P306, DOI 10.7326/0003-4819-135-4-200108210-00029; Scheen AJ, 2001, DIABETES METAB, V27, P305; ZIMMERMAN HJ, 1999, ADVERSE EFFECTS DRUG, P77	10	114	122	1	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 19	2002	136	6					449	452		10.7326/0003-4819-136-6-200203190-00008	http://dx.doi.org/10.7326/0003-4819-136-6-200203190-00008			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	531AU	11900497				2022-12-28	WOS:000174393100004
J	Phillips, MR; Li, XY; Zhang, YP				Phillips, MR; Li, XY; Zhang, YP			Suicide rates in China, 1995-99	LANCET			English	Article							HEALTH; WOMEN	Background A wide range of suicide rates are reported for China because official mortality data are based on an unrepresentative sample and because different reports adjust crude rates in different ways. We aimed to present an accurate picture of the current pattern of suicide in China on the basis of conservative estimates of suicide rates in different population cohorts. Methods Suicide rates by sex, 5-year age-group, and region (urban or rural) reported in mortality data for 1995-99 provided by the Chinese Ministry of Health were adjusted according to an estimated rate of unreported deaths and projected to the corresponding population. Findings We estimated a mean annual suicide rate of 23 per 100 000 and a total of 287 000 suicide deaths per year. Suicide accounted for 3.6% of all deaths in China and was the fifth most important cause of death. Among young adults 15-34 years of age, suicide was the leading cause of death, accounting for 19% of all deaths. The rate in women was 25% higher than in men, mainly because of the large number of suicides in young rural women. Rural rates were three times higher than urban rates-a difference that remained true for both sexes, for all age-groups, and over time. Interpretation Suicide is a major public-health problem for China that is only gradually being recognised. The unique pattern of suicides in China is widely acknowledged, so controversy about the overall suicide rate should not delay the development and testing of China-specific suicide-prevention programmes.	Beijing Hui Long Guan Hosp, Beijing Suicide Res & Prevent Ctr, Beijing 100096, Peoples R China; Harvard Univ, Sch Med, Dept Social Med, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Phillips, MR (corresponding author), Beijing Hui Long Guan Hosp, Beijing Suicide Res & Prevent Ctr, Beijing 100096, Peoples R China.	phillips@public3.bta.net.cn	Phillips, Michael Robert/AAE-7585-2021; Zhang, Xiao/V-9027-2017	Phillips, Michael Robert/0000-0002-5973-2439; Zhang, Xiao/0000-0002-2932-5875				[Anonymous], 1995, WORLD MENTAL HLTH PR; [Anonymous], 1999, WORLD HLTH REPORT 19; [Anonymous], 1996, GLOBAL BURDEN DIS CO; *BEIJ HUI LONG GUA, 2000, CHIN MENT HLTH J, V14, P295; Bhugra D, 1999, PSYCHOL MED, V29, P1125, DOI 10.1017/S0033291799008910; BROWN P, 1997, NEW SCI         0322, P34; Cantor C., 2000, INT HDB SUICIDE ATTE, P9; CHENG ATA, 2000, INT HDB SUICIDE ATTE, P29; *CHIN BUR STAT, 1996, CHIN POP STAT YB; CHONG M, 1995, CHINESE SOC MENTAL H, P209; Harwood D., 2000, INT HDB SUICIDE ATTE, P275; Hawton K, 2000, BRIT J PSYCHIAT, V177, P484, DOI 10.1192/bjp.177.6.484; He ZX, 1997, ARCH SUICIDE RES, V3, P81, DOI 10.1023/A:1009649332566; He ZX, 1999, PERCEPT MOTOR SKILL, V89, P898, DOI 10.2466/PMS.89.7.898-898; HEISE LL, 1994, SOC SCI MED, V39, P1165, DOI 10.1016/0277-9536(94)90349-2; Ji JL, 2001, HARVARD REV PSYCHIAT, V9, P1; Lee Sing, 2000, CHINESE SOC CHANGE C; Lester D., 2000, WHY PEOPLE KILL THEM; Li X, 2001, CHIN J EPIDEMIOL, V22, P281; Lopez A., 2000, 9 WHO GPE; *MIN HLTH DEP DIS, 1997, ANN REP CHIN DIS SUR; *MIN HLTH DEP EP P, 1992, ANN REP DIS SURV SYS; Murray CJL., 1996, GLOBAL HLTH STAT COM, V1996; PEARSON V, 1995, SOC SCI MED, V41, P1159, DOI 10.1016/0277-9536(94)00424-R; Phillips MR, 1999, CULT MED PSYCHIAT, V23, P25, DOI 10.1023/A:1005462530658; Prichard C., 1996, ACTA PSYCHIAT SCAND, V93, P362; Qin P, 2001, ACTA PSYCHIAT SCAND, V103, P117, DOI 10.1034/j.1600-0447.2001.00008.x; Sartorius N, 1995, Int Psychogeriatr, V7, P301, DOI 10.1017/S1041610295002055; Tam R, 1998, TRANSCULT PSYCHIATRY, V35, P235, DOI 10.1177/136346159803500204; *WHO, 1990, WORLD HLTH STAT ANN; WHO, 2001, WORLD HLTH REPORT 20; WHO, 1995, WORLD HLTH STAT ANN; *WHO, 1993, WHO HLTH STAT ANN; *WHO, 1989, WORLD HLTH STAT ANN; Yin D, 2000, CHIN MENT HLTH J, V14, P4; YOSHIMATSU K, 1992, SUICIDAL BEHAV ASIA, P15	36	587	736	2	65	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 9	2002	359	9309					835	840		10.1016/S0140-6736(02)07954-0	http://dx.doi.org/10.1016/S0140-6736(02)07954-0			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	529YV	11897283				2022-12-28	WOS:000174329600011
J	Vilchez, RA; Madden, CR; Kozinetz, CA; Halvorson, SJ; White, ZS; Jorgensen, JL; Finch, CJ; Butel, JS				Vilchez, RA; Madden, CR; Kozinetz, CA; Halvorson, SJ; White, ZS; Jorgensen, JL; Finch, CJ; Butel, JS			Association between simian virus 40 and non-Hodgkin lymphoma	LANCET			English	Article							HUMAN MESOTHELIOMAS; BK-VIRUS; SIMIAN-VIRUS-40; SV40; DISEASE; LYMPHOCYTES; INFECTIONS; SEQUENCES; TUMORS; BRAIN	Background Non-Hodgkin lymphoma has increased in frequency over the past 30 years, and is a common cancer in HIV-1-infected patients. Although no definite risk factors have emerged, a viral cause has been postulated. Polyomaviruses are known to infect human beings and to induce tumours in laboratory animals. We aimed to identify which one of the three polyomaviruses able to infect human beings (simian virus 40 [SV40], JC virus, and BK virus) was associated with non-Hodgkin lymphoma. Methods We analysed systemic non-Hodgkin lymphoma from 76 HIV-1-infected and 78 HIV-1-uninfected patients, and nonmalignant lymphoid samples from 79 HIV-1-positive and 107 HIV-1-negative patients without tumours; 54 colon and breast carcinoma samples served as cancer controls. We used PCR followed by Southern blot hybridisation and DNA sequence analysis to detect DNAs of polyomaviruses and herpesviruses. Findings Polyomavirus T antigen sequences, all of which were SV40-specific, were detected in 64 (42%) of 154 non-Hodgkin lymphomas, none of 186 non-malignant lymphoid samples, and none of 54 control cancers. This difference was similar for HIV-1-infected patients and HIV-1-uninfected patients alike. Few tumours were positive for both SV40 and Epstein-Barr virus. Human herpesvirus, type 8 was not detected. SV40 sequences were found most frequently in diffuse large B-cell and follicular-type lymphomas. Interpretation SV40 is significantly associated with some types of non-Hodgkin lymphoma. These results add lymphomas to the types of human cancers associated with SV40.	Baylor Coll Med, Dept Med, Infect Dis Sect, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA; Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Baylor Coll Med, Baylor Ctr AIDS Res, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Vilchez, RA (corresponding author), Baylor Coll Med, Dept Med, Infect Dis Sect, BCM 286,Room N1319,1 Baylor Plaza, Houston, TX 77030 USA.			Butel, Janet/0000-0002-6876-3245	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI036211] Funding Source: NIH RePORTER; NIAID NIH HHS [AI36211] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		*AM CANC SOC, 2001, CANC FACTS FIG 2001; BERGSAGEL DJ, 1992, NEW ENGL J MED, V326, P988, DOI 10.1056/NEJM199204093261504; Brielmeier M, 1996, J GEN VIROL, V77, P2807, DOI 10.1099/0022-1317-77-11-2807; Butel JS, 1999, JNCI-J NATL CANCER I, V91, P119, DOI 10.1093/jnci/91.2.119; Butel JS, 2000, CARCINOGENESIS, V21, P405, DOI 10.1093/carcin/21.3.405; Carbone M, 1997, NAT MED, V3, P908, DOI 10.1038/nm0897-908; Chan PKS, 2000, J CLIN MICROBIOL, V38, P2772, DOI 10.1128/JCM.38.7.2772-2773.2000; Chatterjee M, 2000, J MED VIROL, V60, P353, DOI 10.1002/(SICI)1096-9071(200003)60:3&lt;353::AID-JMV16&gt;3.0.CO;2-R; CICALA C, 1992, VIROLOGY, V190, P475, DOI 10.1016/0042-6822(92)91237-O; COE JE, 1975, J NATL CANCER I, V54, P269, DOI 10.1093/jnci/54.1.269; David H, 2001, CANCER LETT, V162, P57, DOI 10.1016/S0304-3835(00)00628-5; DIAMANDOPOULOS GT, 1972, SCIENCE, V176, P173, DOI 10.1126/science.176.4031.173; GEARD L, 2001, J ACQ IMMUN DEF SYND, V26, P182; Imperiale MJ, 2000, VIROLOGY, V267, P1, DOI 10.1006/viro.1999.0092; Jafar S, 1998, J MED VIROL, V54, P276, DOI 10.1002/(SICI)1096-9071(199804)54:4<276::AID-JMV7>3.0.CO;2-1; Jaffe ES, 1999, AM J CLIN PATHOL, V111, pS8; Jaffe ES, 2001, WHO CLASSIFICATION T; Lednicky JA, 1998, DEV BIOL STAND, V94, P155; MARKOWITZ RB, 1993, J INFECT DIS, V167, P13, DOI 10.1093/infdis/167.1.13; Martini F, 1998, INT J CANCER, V78, P669, DOI 10.1002/(SICI)1097-0215(19981209)78:6<669::AID-IJC1>3.0.CO;2-B; Monaco MCG, 1996, J VIROL, V70, P7004, DOI 10.1128/JVI.70.10.7004-7012.1996; Rizzo P, 1999, CHEST, V116, p470S, DOI 10.1378/chest.116.suppl_3.470S; Rizzo P, 1999, CANCER RES, V59, P6103; ROLLISON DE, 2001, HUMAN POLYOMAVIRUSES, P561; Shiramizu B, 2000, J ACQ IMMUN DEF SYND, V23, pA34; Shivapurkar N, 2002, LANCET, V359, P851, DOI 10.1016/S0140-6736(02)07921-7; Shivapurkar N, 2000, INT J CANCER, V85, P743, DOI 10.1002/(SICI)1097-0215(20000301)85:5<743::AID-IJC24>3.3.CO;2-V; Vilchez RA, 2002, J ACQ IMMUN DEF SYND, V29, P109, DOI 10.1097/00042560-200202010-00001; Waheed I, 1999, CANCER RES, V59, P6068; Zhen HN, 1999, CANCER, V86, P2124, DOI 10.1002/(SICI)1097-0142(19991115)86:10<2124::AID-CNCR34>3.0.CO;2-D	31	163	165	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 9	2002	359	9309					817	823		10.1016/S0140-6736(02)07950-3	http://dx.doi.org/10.1016/S0140-6736(02)07950-3			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	529YV	11897278				2022-12-28	WOS:000174329600006
J	Woychik, NA; Hampsey, M				Woychik, NA; Hampsey, M			The RNA polymerase II machinery: Structure illuminates function	CELL			English	Review							GENERAL TRANSCRIPTION FACTORS; START SITE SELECTION; PREINITIATION COMPLEX; TERMINAL DOMAIN; DNA-BINDING; CRYSTAL-STRUCTURE; FACTOR TFIIB; PROMOTER; YEAST; MEDIATOR	Essential components of the eukaryotic transcription apparatus include RNA polymerase 11, a common set of initiation factors, and a Mediator complex that transmits regulatory information to the enzyme. In-sights into mechanisms of transcription have been gained by three-dimensional structures for many of these factors and their complexes, especially for yeast RNA polymerase II at atomic resolution.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Mol Genet & Microbiol, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center	Hampsey, M (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA.	michael.hampsey@umdnj.edu			NIGMS NIH HHS [GM 55736, GM 39484] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039484, R29GM039484] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andel F, 1999, SCIENCE, V286, P2153, DOI 10.1126/science.286.5447.2153; Asturias FJ, 1997, J MOL BIOL, V272, P536, DOI 10.1006/jmbi.1997.1273; Asturias FJ, 1999, SCIENCE, V283, P985, DOI 10.1126/science.283.5404.985; Bell SD, 1999, P NATL ACAD SCI USA, V96, P13662, DOI 10.1073/pnas.96.24.13662; Bhoite LT, 2001, GENE DEV, V15, P2457, DOI 10.1101/gad.921601; Borggrefe T, 2001, J BIOL CHEM, V276, P47150, DOI 10.1074/jbc.M109581200; Brand M, 1999, SCIENCE, V286, P2151, DOI 10.1126/science.286.5447.2151; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; Carlson M, 1997, ANNU REV CELL DEV BI, V13, P1, DOI 10.1146/annurev.cellbio.13.1.1; Chang MP, 1999, MOL CELL BIOL, V19, P1056; Chang WH, 2000, CELL, V102, P609, DOI 10.1016/S0092-8674(00)00083-0; Cho EJ, 1999, J BIOL CHEM, V274, P25807, DOI 10.1074/jbc.274.36.25807; Cramer P, 2000, SCIENCE, V288, P640, DOI 10.1126/science.288.5466.640; Cramer Patrick, 2001, Science (Washington D C), V292, P1863, DOI 10.1126/science.1059493; Dantonel JC, 1999, TRENDS BIOCHEM SCI, V24, P335, DOI 10.1016/S0968-0004(99)01436-X; Dotson MR, 2000, P NATL ACAD SCI USA, V97, P14307, DOI 10.1073/pnas.260489497; Douziech M, 2000, MOL CELL BIOL, V20, P8168, DOI 10.1128/MCB.20.21.8168-8177.2000; Dvir A, 2001, CURR OPIN GENET DEV, V11, P209, DOI 10.1016/S0959-437X(00)00181-7; Ebright RH, 2000, J MOL BIOL, V304, P687, DOI 10.1006/jmbi.2000.4309; Evans R, 2001, GENE DEV, V15, P2945, DOI 10.1101/gad.206901; Faitar SL, 2001, MOL CELL BIOL, V21, P4427, DOI 10.1128/MCB.21.14.4427-4440.2001; Forget D, 1997, P NATL ACAD SCI USA, V94, P7150, DOI 10.1073/pnas.94.14.7150; Freiman RN, 2001, SCIENCE, V293, P2084, DOI 10.1126/science.1061935; Fu JH, 1999, CELL, V98, P799, DOI 10.1016/S0092-8674(00)81514-7; Gaiser F, 2000, J MOL BIOL, V302, P1119, DOI 10.1006/jmbi.2000.4110; Gnatt AL, 2001, SCIENCE, V292, P1876, DOI 10.1126/science.1059495; Green MR, 2000, TRENDS BIOCHEM SCI, V25, P59, DOI 10.1016/S0968-0004(99)01527-3; Groft CM, 1998, P NATL ACAD SCI USA, V95, P9117, DOI 10.1073/pnas.95.16.9117; Grossmann JG, 2001, BIOCHEMISTRY-US, V40, P6267, DOI 10.1021/bi0028946; Hahn S, 1998, CELL, V95, P579, DOI 10.1016/S0092-8674(00)81625-6; Hampsey M, 1999, CURR OPIN GENET DEV, V9, P132, DOI 10.1016/S0959-437X(99)80020-3; Hawkes NA, 2000, CURR BIOL, V10, P273, DOI 10.1016/S0960-9822(00)00363-8; Hawkes NA, 1999, J BIOL CHEM, V274, P14337, DOI 10.1074/jbc.274.20.14337; Hayashi F, 1998, BIOCHEMISTRY-US, V37, P7941, DOI 10.1021/bi9801098; Holmes MC, 2000, SCIENCE, V288, P867, DOI 10.1126/science.288.5467.867; Jensen GJ, 1998, EMBO J, V17, P2353, DOI 10.1017/S1431927600024983; Kamada K, 2001, P NATL ACAD SCI USA, V98, P3115, DOI 10.1073/pnas.051631098; Kang JS, 2001, J BIOL CHEM, V276, P42003, DOI 10.1074/jbc.M105961200; Kayukawa K, 1999, GENE, V234, P139, DOI 10.1016/S0378-1119(99)00164-X; Kim TK, 2000, SCIENCE, V288, P1418, DOI 10.1126/science.288.5470.1418; Kim TK, 1997, P NATL ACAD SCI USA, V94, P12268, DOI 10.1073/pnas.94.23.12268; Klug A, 2001, SCIENCE, V292, P1844, DOI 10.1126/science.1062384; KOLODZIEJ PA, 1990, MOL CELL BIOL, V10, P1915, DOI 10.1128/MCB.10.5.1915; Lagrange T, 1998, GENE DEV, V12, P34, DOI 10.1101/gad.12.1.34; Leuther KK, 1996, CELL, V85, P773, DOI 10.1016/S0092-8674(00)81242-8; Maillet I, 1999, J BIOL CHEM, V274, P22586, DOI 10.1074/jbc.274.32.22586; Malik S, 2000, TRENDS BIOCHEM SCI, V25, P277, DOI 10.1016/S0968-0004(00)01596-6; Minakhin L, 2001, P NATL ACAD SCI USA, V98, P892, DOI 10.1073/pnas.98.3.892; Miyao T, 2001, J BIOL CHEM, V276, P46408, DOI 10.1074/jbc.M107012200; Murray S, 2001, MOL CELL BIOL, V21, P4089, DOI 10.1128/MCB.21.13.4089-4096.2001; Myer VE, 1998, J BIOL CHEM, V273, P27757, DOI 10.1074/jbc.273.43.27757; Myers LC, 2000, ANNU REV BIOCHEM, V69, P729, DOI 10.1146/annurev.biochem.69.1.729; Naar AM, 2001, ANNU REV BIOCHEM, V70, P475, DOI 10.1146/annurev.biochem.70.1.475; Nikolov DB, 1997, P NATL ACAD SCI USA, V94, P15, DOI 10.1073/pnas.94.1.15; Nouraini S, 1996, MOL CELL BIOL, V16, P5985; Okuda M, 2000, EMBO J, V19, P1346, DOI 10.1093/emboj/19.6.1346; Orlicky SM, 2001, J BIOL CHEM, V276, P10097, DOI 10.1074/jbc.M003165200; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Park JM, 2001, MOL CELL, V8, P9, DOI 10.1016/S1097-2765(01)00296-9; Proudfoot NJ, 2002, CELL, V108, P501, DOI 10.1016/S0092-8674(02)00617-7; Rachez C, 2001, CURR OPIN CELL BIOL, V13, P274, DOI 10.1016/S0955-0674(00)00209-X; Ranish JA, 1999, GENE DEV, V13, P49, DOI 10.1101/gad.13.1.49; Reinberg D, 1998, COLD SPRING HARB SYM, V63, P83, DOI 10.1101/sqb.1998.63.83; Robert F, 1998, MOL CELL, V2, P341, DOI 10.1016/S1097-2765(00)80278-6; Schultz P, 2000, CELL, V102, P599, DOI 10.1016/S0092-8674(00)00082-9; Selleck W, 2001, NAT STRUCT BIOL, V8, P695, DOI 10.1038/90408; Steitz TA, 1998, NATURE, V391, P231, DOI 10.1038/34542; Tan Q, 2000, GENE DEV, V14, P339; Todone F, 2001, MOL CELL, V8, P1137, DOI 10.1016/S1097-2765(01)00379-3; Tsai FTF, 2000, EMBO J, V19, P25, DOI 10.1093/emboj/19.1.25; Verrijzer CP, 1996, TRENDS BIOCHEM SCI, V21, P338, DOI 10.1016/0968-0004(96)10044-X; WEIL PA, 1979, CELL, V18, P469; Woychik NA, 1998, COLD SPRING HARB SYM, V63, P311, DOI 10.1101/sqb.1998.63.311; Zhang D, 2001, SCIENCE, V292, P1153, DOI 10.1126/science.1059188; ZHANG J, 1991, J BIOL CHEM, V266, P2297; Zhu WL, 1996, NAT STRUCT BIOL, V3, P122, DOI 10.1038/nsb0296-122	76	200	205	1	30	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 22	2002	108	4					453	463		10.1016/S0092-8674(02)00646-3	http://dx.doi.org/10.1016/S0092-8674(02)00646-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	524XW	11909517	Bronze			2022-12-28	WOS:000174039000004
J	Frey, SE; Couch, RB; Tacket, CO; Treanor, JJ; Wolff, M; Newman, FK; Atmar, RL; Edelman, R; Nolan, CM; Belshe, RB				Frey, SE; Couch, RB; Tacket, CO; Treanor, JJ; Wolff, M; Newman, FK; Atmar, RL; Edelman, R; Nolan, CM; Belshe, RB		Natl Inst Allergy Infect Dis Small	Clinical responses to undiluted and diluted smallpox vaccine	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VIRUS	Background: To evaluate the potential to increase the supply of smallpox vaccine (vaccinia virus), we compared the response to vaccination with 10(8.1), 10(7.2), and 10(7.0) plaque-forming units (pfu) of vaccinia virus per milliliter. Methods: In this randomized, single-blind, prospective study, 680 adults who had not been previously immunized were inoculated intradermally with undiluted vaccine (mean titer, 10(8.1) pfu per milliliter), a 1:5 dilution, or a 1:10 dilution of vaccinia virus with use of a bifurcated needle, and the site was covered with a semipermeable dressing. Subjects were monitored for vesicle formation (an indicator of the success of vaccination) and adverse events for 56 days after immunization. Results: Success rates did not differ significantly among the groups and ranged from 97.1 to 99.1 percent after the first vaccination. Both the undiluted and diluted vaccines were reactogenic. In addition to the formation of pustules, common adverse events included the formation of satellite lesions, regional lymphadenopathy, fever, headache, nausea, muscle aches, fatigue, and chills consistent with the presence of an acute viral illness. Generalized and localized rashes, including two cases of erythema multiforme, were also observed. Conclusions: When given by a bifurcated needle, vaccinia virus vaccine can be diluted to a titer as low as 10(7.0) pfu per milliliter (approximately 10,000 pfu per dose) and induce local viral replication and vesicle formation in more than 97 percent of persons.	St Louis Univ, Hlth Sci Ctr, Sch Med,Dept Med,Div Infect Dis & Immunol, Natl Inst Allergy & Infect Dis,Vaccine & Treatmen, St Louis, MO 63110 USA; Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA; Univ Maryland, Sch Med, Ctr Vaccine Dev, Baltimore, MD 21201 USA; Univ Rochester, Sch Med & Dent, Rochester, NY USA; Emmes Corp, Rockville, MD USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Saint Louis University; Baylor College of Medicine; University System of Maryland; University of Maryland Baltimore; University of Rochester; Emmes Corporation	Belshe, RB (corresponding author), St Louis Univ, Hlth Sci Ctr, Sch Med,Dept Med,Div Infect Dis & Immunol, Natl Inst Allergy & Infect Dis,Vaccine & Treatmen, 3635 Vista Ave,FDT-8N, St Louis, MO 63110 USA.		Atmar, Robert/AFQ-5392-2022	Atmar, Robert/0000-0001-9989-6772	NCRR NIH HHS [M01-RR00188] Funding Source: Medline; NIAID NIH HHS [N01-AI-45257, N01-AI-45150, N01-AI-85342, N01-AI-65298, AI-45248, N01-AI-15448] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000188] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R43AI045257, N01AI085342, N01AI045248, N01AI065298] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		[Anonymous], 2001, MMWR-MORBID MORTAL W, V50, P1; CHERRY JD, 1977, J INFECT DIS, V135, P145, DOI 10.1093/infdis/135.1.145; CONNOR JD, 1977, J INFECT DIS, V135, P167, DOI 10.1093/infdis/135.1.167; *CYTEL SOFTW, 1995, STATX 3 WIND STAT SO; FEERY BJ, 1977, MED J AUSTRALIA, V2, P180, DOI 10.5694/j.1326-5377.1977.tb114544.x; FREED ER, 1972, AM J MED, V52, P411, DOI 10.1016/0002-9343(72)90031-9; Frey SE, 2002, NEW ENGL J MED, V346, P1275, DOI 10.1056/NEJMoa013431; FULGINITI VA, 1968, BIRTH DEFECTS ORIG A, V5, P129; GRAHAM BS, 1992, J INFECT DIS, V166, P244, DOI 10.1093/infdis/166.2.244; Henderson DA, 1999, SCIENCE, V283, P1279, DOI 10.1126/science.283.5406.1279; HOLANDER M, 1973, NONPARAMETRIC STAT M, P115; KATZ JB, 1987, J BIOL STAND, V15, P389, DOI 10.1016/S0092-1157(87)80013-6; LANE JM, 1970, J INFECT DIS, V122, P303, DOI 10.1093/infdis/122.4.303; OCONNELL CJ, 1964, ANN INTERN MED, V60, P282, DOI 10.7326/0003-4819-60-2-282; REDFIELD RR, 1987, NEW ENGL J MED, V316, P673, DOI 10.1056/NEJM198703123161106; SINCLAIR MC, 1972, SOUTHERN MED J, V65, P41, DOI 10.1097/00007611-197201000-00008	16	198	200	0	3	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 25	2002	346	17					1265	1274		10.1056/NEJMoa020534	http://dx.doi.org/10.1056/NEJMoa020534			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	544GX	11923490				2022-12-28	WOS:000175150800002
J	Osterloh, A; Amico, L; Falci, G; Fazio, R				Osterloh, A; Amico, L; Falci, G; Fazio, R			Scaling of entanglement close to a quantum phase transition	NATURE			English	Article							MODEL	Classical phase transitions occur when a physical system reaches a state below a critical temperature characterized by macroscopic order(1). Quantum phase transitions occur at absolute zero; they are induced by the change of an external parameter or coupling constant(2), and are driven by quantum fluctuations. Examples include transitions in quantum Hall systems(3), localization in Si-MOSFETs (metal oxide silicon field-effect transistors; ref. 4) and the superconductor-insulator transition in two-dimensional systems(5,6). Both classical and quantum critical points are governed by a diverging correlation length, although quantum systems possess additional correlations that do not have a classical counterpart. This phenomenon, known as entanglement, is the resource that enables quantum computation and communication(8). The role of entanglement at a phase transition is not captured by statistical mechanics-a complete classification of the critical many-body state requires the introduction of concepts from quantum information theory(9). Here we connect the theory of critical phenomena with quantum information by exploring the entangling resources of a system close to its quantum critical point. We demonstrate, for a class of one-dimensional magnetic systems, that entanglement shows scaling behaviour in the vicinity of the transition point.	INFM, NEST, I-56126 Pisa, Italy; Dipartimento Metodol Fis & Chim, I-95125 Catania, Italy; Scuola Normale Super Pisa, I-56126 Pisa, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); Scuola Normale Superiore di Pisa	Fazio, R (corresponding author), INFM, NEST, Piazza Cavaliezi 7, I-56126 Pisa, Italy.	fazio@sns.it	Fazio, Rosario/M-1742-2013; Osterloh, Andreas/C-5533-2009; Falci, Giuseppe/J-4556-2012	Fazio, Rosario/0000-0002-7793-179X; Osterloh, Andreas/0000-0001-8455-8789; Falci, Giuseppe/0000-0001-5842-2677; Amico, Luigi/0000-0002-9024-5727				Arnesen MC, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.017901; Barber M. N., 1983, PHASE TRANSITIONS CR, V8, P146; BAROUCH E, 1971, PHYS REV A-GEN PHYS, V3, P786, DOI 10.1103/PhysRevA.3.786; Bell J. S., 1987, SPEAKABLE UNSPEAKABL; Bennett CH, 1996, PHYS REV A, V54, P3824, DOI 10.1103/PhysRevA.54.3824; Bennett CH, 1996, PHYS REV A, V53, P2046, DOI 10.1103/PhysRevA.53.2046; Brooke J, 1999, SCIENCE, V284, P779, DOI 10.1126/science.284.5415.779; Dur W, 2000, PHYS REV A, V62, DOI 10.1103/PhysRevA.62.062314; Goldenfeld N., 2019, LECT PHASE TRANSITIO, DOI [https://doi.org/10.1201/9780429493492, DOI 10.1201/9780429493492]; Gunlycke D, 2001, PHYS REV A, V64, DOI 10.1103/PhysRevA.64.042302; HAVILAND DB, 1989, PHYS REV LETT, V62, P2180, DOI 10.1103/PhysRevLett.62.2180; LIEB E, 1961, ANN PHYS-NEW YORK, V16, P407, DOI 10.1016/0003-4916(61)90115-4; Nielsen Michael A., 2002, QUANTUM COMPUTATION; O'Connor KM, 2001, PHYS REV A, V63, DOI 10.1103/PhysRevA.63.052302; OSBORNE TJ, 2001, QUANTPH0109024; Preskill J, 2000, J MOD OPTIC, V47, P127, DOI 10.1080/095003400148097; Sachdev S., 2000, QUANTUM PHASE TRANSI; Sondhi SL, 1997, REV MOD PHYS, V69, P315, DOI 10.1103/RevModPhys.69.315; VANDERZANT HSJ, 1992, PHYS REV LETT, V69, P2971, DOI 10.1103/PhysRevLett.69.2971; Vedral V, 1997, PHYS REV LETT, V78, P2275, DOI 10.1103/PhysRevLett.78.2275; Wang XG, 2001, PHYS REV A, V64, DOI 10.1103/PhysRevA.64.012313; Wootters WK, 1998, PHYS REV LETT, V80, P2245, DOI 10.1103/PhysRevLett.80.2245	24	1518	1529	7	173	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 11	2002	416	6881					608	610		10.1038/416608a	http://dx.doi.org/10.1038/416608a			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	539YV	11948343	Green Submitted			2022-12-28	WOS:000174901900035
J	Markowitz, JA				Markowitz, JA			Cord	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material															NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS002974] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 10	2002	287	14					1773	1774		10.1001/jama.287.14.1773	http://dx.doi.org/10.1001/jama.287.14.1773			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	539QJ	11939838				2022-12-28	WOS:000174881700001
J	Toomre, J				Toomre, J			Solar physics - Order amidst turbulence	SCIENCE			English	Editorial Material							DIFFERENTIAL ROTATION; CONVECTION ZONE; DYNAMICS; INTERIOR		Univ Colorado, Dept Astrophys & Planetary Sci, Boulder, CO 80309 USA	University of Colorado System; University of Colorado Boulder	Toomre, J (corresponding author), Univ Colorado, Dept Astrophys & Planetary Sci, Boulder, CO 80309 USA.							Beer J, 1998, SOL PHYS, V181, P237, DOI 10.1023/A:1005026001784; BRUN AS, IN PRESS ASTROPHYS J; Charbonneau P, 1997, ASTROPHYS J, V486, P502, DOI 10.1086/304485; Gilman PA, 2000, SOL PHYS, V192, P27, DOI 10.1023/A:1005280502744; Gough DO, 1998, NATURE, V394, P755, DOI 10.1038/29472; HABER DA, IN PRESS ASTROPHYS J; Howe R, 2000, SCIENCE, V287, P2456, DOI 10.1126/science.287.5462.2456; Schou J, 1998, ASTROPHYS J, V505, P390, DOI 10.1086/306146; SPIEGEL EA, 1992, ASTRON ASTROPHYS, V265, P106; Thompson MJ, 1996, SCIENCE, V272, P1300, DOI 10.1126/science.272.5266.1300; Tobias SM, 2001, ASTROPHYS J, V549, P1183, DOI 10.1086/319448; Vorontsov SV, 2002, SCIENCE, V296, P101, DOI 10.1126/science.1069190; WEISS NO, 1994, LECT SOLAR PLANETARY, P59	13	13	13	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 5	2002	296	5565					64	65		10.1126/science.1070979	http://dx.doi.org/10.1126/science.1070979			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	539FA	11935010				2022-12-28	WOS:000174858800031
J	Kato, T				Kato, T			Self-assembly of phase-segregated liquid crystal structures	SCIENCE			English	Article							MICRO-SEGREGATION; ANISOTROPIC GELS; LIGHT-SCATTERING; IONIC LIQUIDS; PHYSICAL GELS; AGGREGATION; COMPLEXES; BEHAVIOR; ACID; POLYMERIZATION	Additional functionality can be incorporated into liquid crystalline materials by using phase segregation and self-assembly. Intermolecular interactions such as hydrogen bonding and ionic interactions play key roles in the formation of these complex structures. One-, two-, and three-dimensional phase-segregated structures on various scales of length are formed by self-assembty of a variety of partially incompatible molecules. Such structures can enhance anisotropic properties such as ionic conductivity.	Univ Tokyo, Sch Engn, Dept Chem & Biotechnol, Bunkyo Ku, Tokyo 1138656, Japan	University of Tokyo	Kato, T (corresponding author), Univ Tokyo, Sch Engn, Dept Chem & Biotechnol, Bunkyo Ku, Tokyo 1138656, Japan.	kato@chiral.t.u-tokyo.ac.jp	Kato, Takashi/Q-8050-2016	Kato, Takashi/0000-0002-0571-0883				Abdallah DJ, 2000, ADV MATER, V12, P1237; Abetz V, 2000, SUPRAMOLECULAR POLYMERS, P215; ADAM D, 1994, NATURE, V371, P141, DOI 10.1038/371141a0; ALEXANDER C, 1994, MACROMOL SYMP, V77, P283, DOI 10.1002/masy.19940770130; Baars MWPL, 2000, ADV MATER, V12, P715, DOI 10.1002/(SICI)1521-4095(200005)12:10<715::AID-ADMA715>3.0.CO;2-2; BODEN N, 1995, PHYS REV B, V52, P13274, DOI 10.1103/PhysRevB.52.13274; Bonhote P, 1996, INORG CHEM, V35, P1168, DOI 10.1021/ic951325x; Brunsveld L, 2001, CHEM REV, V101, P4071, DOI 10.1021/cr990125q; CRAWFORD GP, 1996, LIQID CRYSTALS COMPL; Dardel B, 2001, J MATER CHEM, V11, P2814, DOI 10.1039/b103798f; Demus D., 2011, HDB LIQUID CRYSTALS; Elsasser R, 2001, ANGEW CHEM INT EDIT, V40, P2688, DOI 10.1002/1521-3773(20010716)40:14<2688::AID-ANIE2688>3.0.CO;2-S; Evans E, 1996, SCIENCE, V273, P933, DOI 10.1126/science.273.5277.933; FAIRHURST CE, 1998, HDB LIQUID CRYSTALS, V3, pCH7; Furue H, 1999, JPN J APPL PHYS 1, V38, P5660, DOI 10.1143/JJAP.38.5660; Goodby JW, 1999, CURR OPIN SOLID ST M, V4, P361, DOI 10.1016/S1359-0286(99)00035-2; Guymon CA, 1997, SCIENCE, V275, P57, DOI 10.1126/science.275.5296.57; HAAREN JH, 1998, CHEM IND, P1017; HIKMET RAM, 1992, ADV MATER, V4, P679, DOI 10.1002/adma.19920041014; Hillmyer MA, 1996, SCIENCE, V271, P976, DOI 10.1126/science.271.5251.976; KAJIYAMA T, 1989, CHEM LETT, P813, DOI 10.1246/cl.1989.813; Kanie K, 2001, J MATER CHEM, V11, P2875, DOI 10.1039/b103168f; KATO T, 1989, J AM CHEM SOC, V111, P8533, DOI 10.1021/ja00204a044; Kato T, 1998, ADV MATER, V10, P606, DOI 10.1002/(SICI)1521-4095(199805)10:8<606::AID-ADMA606>3.0.CO;2-T; Kato T, 2000, STRUCT BOND, V96, P95; KATO T, 1994, ANGEW CHEM INT EDIT, V33, P1644, DOI 10.1002/anie.199416441; Klok HA, 2002, MACROMOLECULES, V35, P746, DOI 10.1021/ma010907x; Lehn JM, 2000, SUPRAMOLECULAR POLYMERS, P615; Luyten MC, 1998, MACROMOLECULES, V31, P9160, DOI 10.1021/ma9808833; Meeker SP, 2000, PHYS REV E, V61, pR6083, DOI 10.1103/PhysRevE.61.R6083; Mizoshita N, 1999, CHEM COMMUN, P781, DOI 10.1039/a901035a; Mizoshita N, 1999, ADV MATER, V11, P392, DOI 10.1002/(SICI)1521-4095(199903)11:5<392::AID-ADMA392>3.0.CO;2-Q; Mizoshita N, 2002, CHEM COMMUN, P428, DOI 10.1039/b111380c; MIZOSHITA N, UNPUB; Muthukumar M, 1997, SCIENCE, V277, P1225, DOI 10.1126/science.277.5330.1225; Ohtake T, 2000, CHEM MATER, V12, P782, DOI 10.1021/cm990706w; PERCEC V, 1993, J CHEM SOC PERK T 2, P2381, DOI 10.1039/p29930002381; Percec V, 1998, J AM CHEM SOC, V120, P11061, DOI 10.1021/ja9819007; Radler JO, 1998, LANGMUIR, V14, P4272, DOI 10.1021/la980360o; Radler JO, 1997, SCIENCE, V275, P810, DOI 10.1126/science.275.5301.810; Ruokolainen J, 1998, SCIENCE, V280, P557, DOI 10.1126/science.280.5363.557; Sautter A, 2001, ANGEW CHEM INT EDIT, V40, P4425, DOI 10.1002/1521-3773(20011203)40:23<4425::AID-ANIE4425>3.0.CO;2-Z; Slack NL, 1998, MACROMOLECULES, V31, P8503, DOI 10.1021/ma980901g; Smith RC, 1997, J AM CHEM SOC, V119, P4092, DOI 10.1021/ja963837w; Tschierske C, 2001, J MATER CHEM, V11, P2647, DOI 10.1039/b102914m; Tschierske C, 1998, J MATER CHEM, V8, P1485, DOI 10.1039/a800946e; van Boxtel MCW, 2000, ADV MATER, V12, P753, DOI 10.1002/(SICI)1521-4095(200005)12:10<753::AID-ADMA753>3.0.CO;2-V; Warriner HE, 1996, SCIENCE, V271, P969, DOI 10.1126/science.271.5251.969; Welton T, 1999, CHEM REV, V99, P2071, DOI 10.1021/cr980032t; YAMADA M, 1995, MACROMOLECULES, V28, P50, DOI 10.1021/ma00105a006; Yamamoto J, 2001, NATURE, V409, P321, DOI 10.1038/35053035; YANG DK, 1992, APPL PHYS LETT, V60, P3102, DOI 10.1063/1.106765; Yoshio M, 2002, ADV MATER, V14, P351, DOI 10.1002/1521-4095(20020304)14:5<351::AID-ADMA351>3.0.CO;2-D; Yu SJM, 1997, NATURE, V389, P167, DOI 10.1038/38254; Zhang LF, 1996, SCIENCE, V272, P1777, DOI 10.1126/science.272.5269.1777; Zheng YG, 2000, J MATER CHEM, V10, P69, DOI 10.1039/a903000j; Zimmerman N, 1998, CHEM IND-LONDON, P604	57	814	833	6	387	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 29	2002	295	5564					2414	2418		10.1126/science.1070967	http://dx.doi.org/10.1126/science.1070967			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	536QD	11923528				2022-12-28	WOS:000174712600044
J	Klug, A				Klug, A			Retrospective: Structural biology and biochemistry - Max Perutz (1914-2002)	SCIENCE			English	Biographical-Item									MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Klug, A (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.								0	6	7	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 29	2002	295	5564					2382	2383		10.1126/science.1071406	http://dx.doi.org/10.1126/science.1071406			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	536QD	11923516				2022-12-28	WOS:000174712600032
J	Krojer, T; Garrido-Franco, M; Huber, R; Ehrmann, M; Clausen, T				Krojer, T; Garrido-Franco, M; Huber, R; Ehrmann, M; Clausen, T			Crystal structure of DegP (HtrA) reveals a new protease-chaperone machine	NATURE			English	Article							ESCHERICHIA-COLI; SERINE-PROTEASE; QUALITY-CONTROL; PROTEINS; PDZ; RECOGNITION; TEMPERATURE; PROTEOLYSIS; RESOLUTION; DOMAIN	Molecular chaperones and proteases monitor the folded state of other proteins. In addition to recognizing non-native conformations, these quality control factors distinguish substrates that can be refolded from those that need to be degraded(1). To investigate the molecular basis of this process, we have solved the crystal structure of DegP (also known as HtrA), a widely conserved heat shock protein that combines refolding and proteolytic activities(2). The DegP hexamer is formed by staggered association of trimeric rings. The proteolytic sites are located in a central cavity that is only accessible laterally. The mobile side-walls are constructed by twelve PDZ domains, which mediate the opening and closing of the particle and probably the initial binding of substrate. The inner cavity is lined by several hydrophobic patches that may act as docking sites for unfolded polypeptides. In the chaperone conformation, the protease domain of DegP exists in an inactive state, in which substrate binding in addition to catalysis is abolished.	Max Planck Inst Biochem, Abt Strukturforsch, D-82152 Martinsried, Germany; Cardiff Univ, Sch Biosci, Cardiff CF10 3US, S Glam, Wales	Max Planck Society; Cardiff University	Clausen, T (corresponding author), Max Planck Inst Biochem, Abt Strukturforsch, Klopferspitz 18A, D-82152 Martinsried, Germany.		Ehrmann, Michael/A-7307-2012; Krojer, Tobias/ABE-3829-2021	Ehrmann, Michael/0000-0002-1927-260X; Clausen, Tim/0000-0003-1582-6924; Krojer, Tobias/0000-0003-0661-0814				Bochtler M, 1997, P NATL ACAD SCI USA, V94, P6070, DOI 10.1073/pnas.94.12.6070; Brandstetter H, 2001, NATURE, V414, P466, DOI 10.1038/35106609; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cabral JHM, 1996, NATURE, V382, P649, DOI 10.1038/382649a0; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Gottesman S, 1997, GENE DEV, V11, P815, DOI 10.1101/gad.11.7.815; Gray CW, 2000, EUR J BIOCHEM, V267, P5699, DOI 10.1046/j.1432-1327.2000.01589.x; Groll M, 2000, NAT STRUCT BIOL, V7, P1062, DOI 10.1038/80992; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Larsen CN, 1997, CELL, V91, P431, DOI 10.1016/S0092-8674(00)80427-4; Liao DI, 2000, NAT STRUCT BIOL, V7, P749, DOI 10.1038/78973; LIPINSKA B, 1990, J BACTERIOL, V172, P1791, DOI 10.1128/jb.172.4.1791-1797.1990; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Misra R, 2000, J BACTERIOL, V182, P4882, DOI 10.1128/JB.182.17.4882-4888.2000; Pallen MJ, 1997, MOL MICROBIOL, V26, P209, DOI 10.1046/j.1365-2958.1997.5601928.x; PERONA JJ, 1995, PROTEIN SCI, V4, P337; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Spiess C, 1999, CELL, V97, P339, DOI 10.1016/S0092-8674(00)80743-6; STRAUCH KL, 1989, J BACTERIOL, V171, P2689, DOI 10.1128/jb.171.5.2689-2696.1989; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; SWAMY KHS, 1983, ARCH BIOCHEM BIOPHYS, V224, P543, DOI 10.1016/0003-9861(83)90242-4; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; WOOTTON JC, 1989, PROTEIN ENG, V2, P535, DOI 10.1093/protein/2.7.535; Zumbrunn J, 1996, FEBS LETT, V398, P187, DOI 10.1016/S0014-5793(96)01229-X; [No title captured]	30	332	342	1	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 28	2002	416	6879					455	459		10.1038/416455a	http://dx.doi.org/10.1038/416455a			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	534UX	11919638				2022-12-28	WOS:000174607800053
J	Brunner, HR; Gavras, H				Brunner, HR; Gavras, H			Angiotensin blockade for hypertension: a promise fulfilled	LANCET			English	Editorial Material							MYOCARDIAL-INFARCTION; FAILURE; RENIN; ALDOSTERONE; INHIBITION; MORTALITY; CAPTOPRIL; SURVIVAL; LOSARTAN		CHU Vaudois, Div Hypertens & Vasc Med, CH-1011 Lausanne, Switzerland; Boston Univ, Med Ctr, Boston, MA USA	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Boston University	Brunner, HR (corresponding author), CHU Vaudois, Div Hypertens & Vasc Med, CH-1011 Lausanne, Switzerland.	Hans-R.Brunner@chuv.hospvd.ch						[Anonymous], 1997, ARCH INTERN MED, V157, P2413; Brenner BM, 2001, NEW ENGL J MED, V345, P861, DOI 10.1056/NEJMoa011161; BRUNNER HR, 1973, LANCET, V2, P1045; BRUNNER HR, 1972, NEW ENGL J MED, V286, P441, DOI 10.1056/NEJM197203022860901; GAVRAS H, 1971, LANCET, V2, P19; GAVRAS H, 1977, JAMA-J AM MED ASSOC, V238, P880, DOI 10.1001/jama.238.8.880; GAVRAS H, 1974, PROG CARDIOVASC DIS, V17, P39, DOI 10.1016/0033-0620(74)90037-1; Gress TW, 2000, NEW ENGL J MED, V342, P905, DOI 10.1056/NEJM200003303421301; Lewis EJ, 2001, NEW ENGL J MED, V345, P851, DOI 10.1056/NEJMoa011303; LEWIS EJ, 1993, NEW ENGL J MED, V329, P1456, DOI 10.1056/NEJM199311113292004; MacMahon S, 2001, LANCET, V358, P1033, DOI 10.1016/S0140-6736(01)06178-5; *MCR WORK PART, 1985, BMJ-BRIT MED J, V291, P97; NICKLAS JM, 1992, NEW ENGL J MED, V327, P685; Parving HH, 2001, NEW ENGL J MED, V345, P870, DOI 10.1056/NEJMoa011489; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; Pitt B, 2000, LANCET, V355, P1582, DOI 10.1016/S0140-6736(00)02213-3; Yusuf S, 2000, NEW ENGL J MED, V342, P145	17	36	38	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 23	2002	359	9311					990	992		10.1016/S0140-6736(02)08062-5	http://dx.doi.org/10.1016/S0140-6736(02)08062-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	534KP	11937175				2022-12-28	WOS:000174585800002
J	Briffa, KR; Osborn, TJ				Briffa, KR; Osborn, TJ			Paleoclimate - Blowing hot and cold	SCIENCE			English	Editorial Material							TEMPERATURES; MILLENNIUM; CENTURIES		Univ E Anglia, Climat Res Unit, Norwich NR4 7TJ, Norfolk, England	University of East Anglia	Briffa, KR (corresponding author), Univ E Anglia, Climat Res Unit, Norwich NR4 7TJ, Norfolk, England.		Osborn, Timothy/AAK-9279-2020; Osborn, Timothy/E-9740-2011; Briffa, Keith/C-8834-2009	Osborn, Timothy/0000-0001-8425-6799; Osborn, Timothy/0000-0001-8425-6799; 				[Anonymous], 2001, CLIMATE CHANGE 2001; Briffa KR, 2001, J GEOPHYS RES-ATMOS, V106, P2929, DOI 10.1029/2000JD900617; Briffa KR, 2000, QUATERNARY SCI REV, V19, P87, DOI 10.1016/S0277-3791(99)00056-6; Crowley TJ, 2000, AMBIO, V29, P51, DOI 10.1579/0044-7447-29.1.51; Esper J, 2002, SCIENCE, V295, P2250, DOI 10.1126/science.1066208; Huang SP, 2000, NATURE, V403, P756, DOI 10.1038/35001556; Jones PD, 1998, HOLOCENE, V8, P455, DOI 10.1191/095968398667194956; Mann ME, 1999, GEOPHYS RES LETT, V26, P759, DOI 10.1029/1999GL900070; Overpeck J, 1997, SCIENCE, V278, P1251, DOI 10.1126/science.278.5341.1251	9	101	110	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 22	2002	295	5563					2227	2228		10.1126/science.1069486	http://dx.doi.org/10.1126/science.1069486			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	534AD	11910098				2022-12-28	WOS:000174561700031
J	Rogers, KC				Rogers, KC			Nuclear research - The past and future of university research reactors	SCIENCE			English	Editorial Material									Stevens Inst Technol, Hoboken, NJ 07030 USA	Stevens Institute of Technology	Rogers, KC (corresponding author), Stevens Inst Technol, Hoboken, NJ 07030 USA.							Adams M.L., 2000, FUTURE U NUCL ENG PR; Bernard JA, 2000, NUCL TECHNOL, V131, P379, DOI 10.13182/NT00-A3123; CORRADINI M, 2000, DOE PROGRAM U RES TR; *DOE OFF NUCL EN S, 2001, INN NUCL INFR ED RES; EISENHOWER DD, 1953, US DEP STATE PUBL, V5314; LONG RL, 2001, REPORT U RES REACTOR; *NAT RES COUNC, 1999, COOP STEW MAN NAT MU; OLEARY HR, 1994, CONDITION STATUS U R; PEREZ PB, 2000, U RES REACTORS CRITI; SHIRLEY DA, 1988, U RES REACTORS US TH	10	1	1	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 22	2002	295	5563					2217	2218		10.1126/science.1070936	http://dx.doi.org/10.1126/science.1070936			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	534AD	11910093				2022-12-28	WOS:000174561700024
J	Bell, RE; Studinger, M; Tikku, AA; Clarke, GKC; Gutner, MM; Meertens, C				Bell, RE; Studinger, M; Tikku, AA; Clarke, GKC; Gutner, MM; Meertens, C			Origin and fate of Lake Vostok water frozen to the base of the East Antarctic ice sheet	NATURE			English	Article								The subglacial Lake Vostok may be a unique reservoir of genetic material and it may contain organisms with distinct adaptations(1-3), but it has yet to be explored directly. The lake and the overlying ice sheet are closely linked, as the ice-sheet thickness drives the lake circulation, while melting and freezing at the ice-sheet base will control the flux of water, biota and sediment through the lake(4-7). Here we present a reconstruction of the ice flow trajectories for the Vostok core site, using ice-penetrating radar data and Global Positioning System (GPS) measurements of surface ice velocity. We find that the ice sheet has a significant along-lake flow component, persistent since the Last Glacial Maximum. The rates at which ice is frozen (accreted) to the base of the ice sheet are greatest at the shorelines, and the accreted ice layer is subsequently transported out of the lake. Using these new flow field and velocity measurements, we estimate the time for ice to traverse Lake Vostok to be 16,000-20,000 years. We infer that most Vostok ice analysed to date was accreted to the ice sheet close to the western shoreline, and is therefore not representative of open lake conditions. From the amount of accreted lake water we estimate to be exported along the southern shoreline, the lake water residence time is about 13,300 years.	Columbia Univ, Lamont Doherty Earth Observ, Palisades, NY 10964 USA; Univ British Columbia, Dept Earth & Ocean Sci, Vancouver, BC V6T 1Z4, Canada; Yale Univ, Dept Geol & Geophys, New Haven, CT 06511 USA; UNAVCO, UCAR Facil, Boulder, CO 80307 USA	Columbia University; University of British Columbia; Yale University	Bell, RE (corresponding author), Columbia Univ, Lamont Doherty Earth Observ, Palisades, NY 10964 USA.			Studinger, Michael/0000-0003-1265-4741; Meertens, Charles/0000-0003-1811-0307				CARSLAW HS, 1959, CONDUCTION HEAT SOLI, P285; Fujita S, 1999, J GEOPHYS RES-SOL EA, V104, P13013, DOI 10.1029/1999JB900034; Jean-Baptiste P, 2001, NATURE, V411, P460, DOI 10.1038/35078045; JEZEK K, 2001, RAMPAMM 1 SAR IMAGE; Jouzel J, 1999, SCIENCE, V286, P2138, DOI 10.1126/science.286.5447.2138; Kapitsa AP, 1996, NATURE, V381, P684, DOI 10.1038/381684a0; Karl DM, 1999, SCIENCE, V286, P2144, DOI 10.1126/science.286.5447.2144; Kwok R, 2000, J GLACIOL, V46, P689, DOI 10.3189/172756500781832710; POPOV SV, 1998, INT WORKSH LAK VOST, P26; POPOV SV, 2001, MAT GLYATSIOLOGICHES, V90, P206; Priscu JC, 1999, SCIENCE, V286, P2141, DOI 10.1126/science.286.5447.2141; Siegert MJ, 2000, NATURE, V403, P643, DOI 10.1038/35001049; Siegert MJ, 2001, NATURE, V414, P603, DOI 10.1038/414603a; WHILLANS IM, 1976, NATURE, V264, P152, DOI 10.1038/264152a0; Wuest A, 2000, OCEAN MODEL, V2, P29, DOI 10.1016/S1463-5003(00)00007-X	15	101	107	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 21	2002	416	6878					307	310		10.1038/416307a	http://dx.doi.org/10.1038/416307a			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	532NP	11907573				2022-12-28	WOS:000174482200038
J	Simonson, AB; Lake, JA				Simonson, AB; Lake, JA			The transorientation hypothesis for codon recognition during protein synthesis	NATURE			English	Article							ESCHERICHIA-COLI RIBOSOME; PHENYLALANINE TRANSFER-RNA; AMINOACYL-TRANSFER-RNA; ELONGATION-FACTOR TU; EF-TU; ANGSTROM RESOLUTION; A-SITE; SUBUNIT; MECHANISM; BINDING	During decoding, a codon of messenger RNA is matched with its cognate aminoacyl-transfer RNA and the amino acid carried by the tRNA is added to the growing protein chain. Here we propose a molecular mechanism for the decoding phase of translation: the transorientation hypothesis. The model incorporates a newly identified tRNA binding site and utilizes a flip between two tRNA anticodon loop structures, the 5'-stacked and the 3'-stacked conformations. The anticodon loop acts as a three-dimensional hinge permitting rotation of the tRNA about a relatively fixed codon-anticodon pair. This rotation, driven by a conformational change in elongation factor Tu involving GTP hydrolysis, transorients the incoming tRNA into the A site from the D site of initial binding and decoding, where it can be proofread and accommodated. The proposed mechanisms are compatible with the known structures, conformations and functions of the ribosome and its component parts including tRNAs and EF-Tu, in both the GTP and GDP states.	Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Lake, JA (corresponding author), Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA.							ABDULKARIM F, 1994, FEBS LETT, V352, P118, DOI 10.1016/0014-5793(94)00937-6; Abel K, 1996, STRUCTURE, V4, P1153, DOI 10.1016/S0969-2126(96)00123-2; Agrawal RK, 1996, SCIENCE, V271, P1000, DOI 10.1126/science.271.5251.1000; Agrawal RK, 1998, P NATL ACAD SCI USA, V95, P6134, DOI 10.1073/pnas.95.11.6134; Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; Briones E, 1998, J BIOL CHEM, V273, P31956, DOI 10.1074/jbc.273.48.31956; CARBON J, 1974, J MOL BIOL, V85, P371, DOI 10.1016/0022-2836(74)90439-2; Carter AP, 2000, NATURE, V407, P340, DOI 10.1038/35030019; CRICK FHC, 1976, ORIGINS LIFE EVOL B, V7, P389, DOI 10.1007/BF00927934; CUNDLIFFE E, 1906, STRUCTURE FUNCTION G, P586; Dickerson RE, 1997, BIOPOLYMERS, V44, P361, DOI 10.1002/(SICI)1097-0282(1997)44:4<361::AID-BIP4>3.0.CO;2-X; Eiler S, 1999, EMBO J, V18, P6532, DOI 10.1093/emboj/18.22.6532; FULLER W, 1967, NATURE, V215, P817, DOI 10.1038/215817a0; Garrett R. A., 2000, RIBOSOME STRUCTURE F; GEFTER ML, 1969, J MOL BIOL, V39, P145, DOI 10.1016/0022-2836(69)90339-8; GUPTA SL, 1971, BIOCHEMISTRY-US, V10, P4410, DOI 10.1021/bi00800a010; HARADA F, 1975, NUCLEIC ACIDS RES, V2, P865, DOI 10.1093/nar/2.6.865; HOPFIELD JJ, 1974, P NATL ACAD SCI USA, V71, P4135, DOI 10.1073/pnas.71.10.4135; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KLUG A, 1979, J MOL BIOL, V131, P669, DOI 10.1016/0022-2836(79)90196-7; KURLAND CG, 1992, ANNU REV GENET, V26, P29, DOI 10.1146/annurev.ge.26.120192.000333; LADNER JE, 1975, P NATL ACAD SCI USA, V72, P4414, DOI 10.1073/pnas.72.11.4414; LAKE JA, 1977, P NATL ACAD SCI USA, V74, P1903, DOI 10.1073/pnas.74.5.1903; Markus MA, 1997, NAT STRUCT BIOL, V4, P70, DOI 10.1038/nsb0197-70; NIERHAUS KH, 1990, BIOCHEMISTRY-US, V29, P4997, DOI 10.1021/bi00473a001; NISSEN P, 1995, SCIENCE, V270, P1464, DOI 10.1126/science.270.5241.1464; NOLLER HF, 1992, SCIENCE, V256, P1416, DOI 10.1126/science.1604315; Pape T, 1998, EMBO J, V17, P7490, DOI 10.1093/emboj/17.24.7490; Polekhina G, 1996, STRUCTURE, V4, P1141, DOI 10.1016/S0969-2126(96)00122-0; QUIGLEY GJ, 1975, NUCLEIC ACIDS RES, V2, P2329, DOI 10.1093/nar/2.12.2329; Schluenzen F, 2000, CELL, V102, P615, DOI 10.1016/S0092-8674(00)00084-2; Schweisguth DC, 1997, J MOL BIOL, V267, P505, DOI 10.1006/jmbi.1996.0903; Song HW, 1999, J MOL BIOL, V285, P1245, DOI 10.1006/jmbi.1998.2387; Stark H, 1997, NATURE, V389, P403, DOI 10.1038/38770; STOEFFLER G, 1980, Journal of Biological Chemistry, V255, P10517; STRYCHARZ WA, 1978, J MOL BIOL, V126, P123, DOI 10.1016/0022-2836(78)90355-8; TAL J, 1975, NUCLEIC ACIDS RES, V2, P1073, DOI 10.1093/nar/2.7.1073; THACH SS, 1971, P NATL ACAD SCI USA, V68, P1791, DOI 10.1073/pnas.68.8.1791; Vogeley L, 2001, J BIOL CHEM, V276, P17149, DOI 10.1074/jbc.M100017200; Wimberly BT, 2000, NATURE, V407, P327, DOI 10.1038/35030006; Wimberly BT, 1999, CELL, V97, P491, DOI 10.1016/S0092-8674(00)80759-X; WOESE C, 1970, NATURE, V226, P817, DOI 10.1038/226817a0; WREDE P, 1979, P NATL ACAD SCI USA, V76, P3289, DOI 10.1073/pnas.76.7.3289; Yusupov MM, 2001, SCIENCE, V292, P883, DOI 10.1126/science.1060089; ZAUG AJ, 1986, SCIENCE, V231, P470, DOI 10.1126/science.3941911	45	14	15	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 21	2002	416	6878					281	285		10.1038/416281a	http://dx.doi.org/10.1038/416281a			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	532NP	11907568				2022-12-28	WOS:000174482200032
J	Waxman, HA				Waxman, HA			The future of the global tobacco treaty negotiations	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							SMOKING; RESTRICTIONS; CHILDREN; CAMEL		US House Representatives, Washington, DC 20515 USA		Waxman, HA (corresponding author), US House Representatives, Washington, DC 20515 USA.							BETTCHER D, 2001, WHONMHTF1014; Biener L, 2000, BRIT MED J, V321, P351, DOI 10.1136/bmj.321.7257.351; BRODY JE, 1991, NY TIMES        1211, pD22; CONNOLLY GN, 1992, MONOGR NCI, V12, P29; DIFRANZA JR, 1991, JAMA-J AM MED ASSOC, V266, P3149, DOI 10.1001/jama.266.22.3149; Farkas AJ, 1999, TOB CONTROL, V8, P261, DOI 10.1136/tc.8.3.261; Fichtenberg CM, 2000, NEW ENGL J MED, V343, P1772, DOI 10.1056/NEJM200012143432406; FISCHER PM, 1991, JAMA-J AM MED ASSOC, V266, P3145, DOI 10.1001/jama.266.22.3145; HILL DA, 1988, IMPLICATIONS PESTICI; HUNT AR, 2001, WALL ST J       0117, pA15; *I MED, 2001, CLAR SMOK ASS SCI BA; Kaufman M, 2001, WASHINGTON POST 0802, pA01; KLUGER R, 1996, ASHES ASHES AM 100 Y; Lantz PM, 2000, TOB CONTROL, V9, P47, DOI 10.1136/tc.9.1.47; LAUGESEN M, 1991, BRIT J ADDICT, V86, P1343, DOI 10.1111/j.1360-0443.1991.tb01710.x; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; NICKERSON C, 2001, BOSTON GLOBE    0814, pA1; PARKER J, 2001, WORLD TOBACCO   0701, P41; Roemer R., 1993, WHO LEGISLATIVE ACTI, V2nd; SHILMONCZYK BA, 1993, NEW ENGL J MED, V3256, P1665; TAYLOR AL, 1996, WHOPSA966; WARNER KE, 1986, JAMA-J AM MED ASSOC, V255, P1028, DOI 10.1001/jama.255.8.1028; WAXMAN HA, 2001, COMMUNICATION   1119; WAXMAN HA, 2001, COMMUNICATION   0802; WHITE RD, 2001, LOS ANGELES TIM 1119, pC2; *WHO, 2001, UNPUB 2 M WORK GROUP; *WHO, 2001, WHO FRAM CONV TOB CO; *WHO, 2001, UNPUB 3 M THURSD 3 M; *WHO, 1999, A52VR9 WHO; *WHO, 2001, UNPUB 2 M TUESD 1 MA; *WHO, 2000, UNPUB WHO FRAM CONV; *WHO, 2001, UNPUB M WORK GROUP 2; *WHO, 2001, UNPUB 1 M WORK GROUP; *WHO, 2001, UNPUB 3 M WEDN 2 MAY; *WHO, 2001, UNPUB 3 M WORK GROUP; *WHO, 1995, INT STRAT TOB CONTR; World Bank, 1999, CURB EP GOV EC TOB C; World Health Organization, 2001, AFCTCINB22 WHO; *WORLD TRAD ORG, 2001, WTMIN01DECW2	39	20	20	0	2	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 21	2002	346	12					936	939		10.1056/NEJMsb020030	http://dx.doi.org/10.1056/NEJMsb020030			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	532FR	11907296				2022-12-28	WOS:000174464100012
J	Ronsmans, C; Van Damme, W; Filippi, V; Pittrof, R				Ronsmans, C; Van Damme, W; Filippi, V; Pittrof, R			Need for caesarean sections in west Africa	LANCET			English	Letter									Univ London London Sch Hyg & Trop Med, Infect Dis Epidemiol Unit, London WC1E 7HT, England; Med Sans Frontieres, Phnom Penh, Cambodia	University of London; London School of Hygiene & Tropical Medicine	Ronsmans, C (corresponding author), Univ London London Sch Hyg & Trop Med, Infect Dis Epidemiol Unit, Keppel St, London WC1E 7HT, England.		Van Damme, Wim/F-7404-2011	Van Damme, Wim/0000-0002-6344-3007; Van Lerberghe, Wim/0000-0001-9966-6563				DEBROUWERE V, 1998, BESOINS OBSTET NONCO; Dumont A, 2001, LANCET, V358, P1328, DOI 10.1016/S0140-6736(01)06414-5; *MOMA GROUP, 1998, MORB MAT AFR OUEST R; Prual A, 2000, B WORLD HEALTH ORGAN, V78, P593	4	10	10	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 16	2002	359	9310					974	974		10.1016/S0140-6736(02)07992-8	http://dx.doi.org/10.1016/S0140-6736(02)07992-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	531AE	11918935				2022-12-28	WOS:000174391700037
J	Hansen, PL; Wagner, JB; Helveg, S; Rostrup-Nielsen, JR; Clausen, BS; Topsoe, H				Hansen, PL; Wagner, JB; Helveg, S; Rostrup-Nielsen, JR; Clausen, BS; Topsoe, H			Atom-resolved imaging of dynamic shape changes in supported copper nanocrystals	SCIENCE			English	Article							STRUCTURAL-CHANGES; METHANOL SYNTHESIS; SURFACE SCIENCE; PARTICLES; CATALYSTS; HREM; DIFFRACTION; SIMULATION; CONVERSION; CLUSTERS	In situ transmission electron microscopy is used to obtain atom-resolved images of copper nanocrystals on different supports. These are catalysts for methanol synthesis and hydrocarbon conversion processes for fuel cells. The nanocrystals undergo dynamic reversible shape changes in response to changes in the gaseous environment. For zinc oxide-supported samples, the changes are caused both by adsorbate-induced changes in surface energies and by changes in the interfacial energy. For copper nanocrystals supported on silica, the support has negligible influence on the structure. Nanoparticle dynamics must be included in the description of catalytic and other properties of nanomaterials. In situ microscopy offers possibilities for obtaining the relevant atomic-scale insight.	Haldor Topsoe Res Labs, DK-2800 Lyngby, Denmark; Univ Copenhagen, NBlfAFG, DK-2100 Copenhagen O, Denmark	Haldor Topsoe; University of Copenhagen	Hansen, PL (corresponding author), Haldor Topsoe Res Labs, Nymollevej 55, DK-2800 Lyngby, Denmark.	plh@topsoe.dk	Helveg, Stig/AAD-8603-2021; Wagner, Jakob Birkedal/M-5371-2019; Helveg, Stig/O-7513-2018; Wagner, Jakob B./H-5392-2011	Helveg, Stig/0000-0002-0328-8295; Wagner, Jakob Birkedal/0000-0002-2945-0190; Wagner, Jakob B./0000-0002-2945-0190				Alivisatos AP, 1996, SCIENCE, V271, P933, DOI 10.1126/science.271.5251.933; BAKER RTK, 1972, J PHYS E SCI INSTRUM, V5, P793, DOI 10.1088/0022-3735/5/8/024; Bernal S, 1998, ULTRAMICROSCOPY, V72, P135, DOI 10.1016/S0304-3991(98)00009-6; BOCCUZZI F, 1985, SURF SCI, V156, P933, DOI 10.1016/0039-6028(85)90269-9; Boyes ED, 1997, ULTRAMICROSCOPY, V67, P219, DOI 10.1016/S0304-3991(96)00099-X; Campbell CT, 1997, SURF SCI REP, V27, P1, DOI 10.1016/S0167-5729(96)00011-8; Campbell CT, 2001, SCIENCE, V294, P1471, DOI 10.1126/science.1066253; Clausen BS, 1994, TOP CATAL, V1, P367, DOI 10.1007/BF01492289; Clausen BS, 1998, ADV CATAL, V42, P315, DOI 10.1016/S0360-0564(08)60630-6; DATYE AK, 1997, HDB HETEROGENEOUS CA, V2, P493; DUMESIC JA, 1975, J CATAL, V37, P513, DOI 10.1016/0021-9517(75)90186-4; Dumesic JA., 1977, ADV CATAL, V26, P121, DOI [10.1016/S0360-0564(08)60071-1, DOI 10.1016/S0360-0564(08)60071-1]; El-Sayed MA, 2001, ACCOUNTS CHEM RES, V34, P257, DOI 10.1021/ar960016n; ERTL G, 1997, HDB HETEROGENEOUS CA, V4, P1856; FINKLE AL, 1968, INVEST UROL, V6, P26; Grunwaldt JD, 2000, J CATAL, V194, P452, DOI 10.1006/jcat.2000.2930; Gunter MM, 2001, CATAL LETT, V71, P37, DOI 10.1023/A:1016696022840; Hansen J. B., 1997, HDB HETEROGENEOUS CA, V4, P1856; Hansen KH, 1999, PHYS REV LETT, V83, P4120, DOI 10.1103/PhysRevLett.83.4120; Hansen TW, 2001, SCIENCE, V294, P1508, DOI 10.1126/science.1064399; Henry CR, 1998, SURF SCI REP, V31, P235; Jaeger NI, 2001, SCIENCE, V293, P1601, DOI 10.1126/science.1064595; JEFFERSON DA, 1988, NATURE, V332, P617, DOI 10.1038/332617a0; Jensen JR, 2000, J NANOPART RES, V2, P363, DOI 10.1023/A:1010099900370; Jin RC, 2001, SCIENCE, V294, P1901, DOI 10.1126/science.1066541; Niemantsverdriet J.W., 2000, SPECTROSCOPY CATALYS; Ovesen CV, 1997, J CATAL, V168, P133, DOI 10.1006/jcat.1997.1629; Rostrup-Nielsen JR, 2001, PHYS CHEM CHEM PHYS, V3, P283, DOI 10.1039/b004660o; Somorjai G. A, 1999, CATTECH, V3, P84; STADELMANN PA, 1987, ULTRAMICROSCOPY, V21, P131, DOI 10.1016/0304-3991(87)90080-5; STOCKMANN RM, 1995, J MOL CATAL A-CHEM, V102, P147, DOI 10.1016/1381-1169(95)00111-5; Thomas JM, 1999, ANGEW CHEM INT EDIT, V38, P3589; THOMAS JM, 1999, TOPICS CATALYSIS, V8; Topsoe NY, 1999, J MOL CATAL A-CHEM, V141, P95, DOI 10.1016/S1381-1169(98)00253-2; Urban J, 1997, CATAL LETT, V49, P101, DOI 10.1023/A:1019080516212; Vitos L, 1998, SURF SCI, V411, P186, DOI 10.1016/S0039-6028(98)00363-X; WAGNER JA, UNPUB; Wulff G, 1901, Z KRYSTALLOGR MINERA, V34, P449, DOI 10.1524/zkri.1901.34.1.449	38	957	970	27	667	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 15	2002	295	5562					2053	2055		10.1126/science.1069325	http://dx.doi.org/10.1126/science.1069325			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	532AY	11896271				2022-12-28	WOS:000174450500041
J	Fersht, AR; Daggett, V				Fersht, AR; Daggett, V			Protein folding and unfolding at atomic resolution	CELL			English	Review							NUCLEATION-CONDENSATION MECHANISM; MOLECULAR-DYNAMICS SIMULATION; PHI-VALUE ANALYSIS; TRANSITION-STATE; CHYMOTRYPSIN INHIBITOR-2; ENGINEERED PROTEINS; ENERGY LANDSCAPE; DENATURED STATE; COOPERATIVE FORMATION; SECONDARY STRUCTURE	Experiment and simulation are now conspiring to give atomic-level descriptions of protein folding relevant to folding, misfolding, trafficking, and degradation in the cell. We are on the threshold of predicting those protein folding events using simulation that has been carefully benchmarked by experiment.	Univ Cambridge, Dept Chem, Cambridge CB2 1EW, England; Univ Cambridge, MRC, Ctr Prot Engn, Cambridge CB2 1EW, England; Univ Washington, Dept Med Chem, Seattle, WA 98195 USA	University of Cambridge; University of Cambridge; University of Washington; University of Washington Seattle	Fersht, AR (corresponding author), Univ Cambridge, Dept Chem, Lensfield Rd, Cambridge CB2 1EW, England.	arf25@cam.ac.uk; daggett@u.washington.edu	Fersht, Alan R/B-2189-2008		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM050789, R01GM050789] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 50789] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBER T, 1987, NATURE, V330, P41, DOI 10.1038/330041a0; Best RB, 2001, BIOPHYS J, V81, P2344, DOI 10.1016/S0006-3495(01)75881-X; Bond CJ, 1997, P NATL ACAD SCI USA, V94, P13409, DOI 10.1073/pnas.94.25.13409; BRYNGELSON JD, 1995, PROTEINS, V21, P167, DOI 10.1002/prot.340210302; CAFLISCH A, 1995, J MOL BIOL, V252, P672, DOI 10.1006/jmbi.1995.0528; CAFLISCH A, 1994, P NATL ACAD SCI USA, V91, P1746, DOI 10.1073/pnas.91.5.1746; Corrales FJ, 1996, P NATL ACAD SCI USA, V93, P4509, DOI 10.1073/pnas.93.9.4509; DAGGETT V, 1992, P NATL ACAD SCI USA, V89, P5142, DOI 10.1073/pnas.89.11.5142; Daggett V, 1996, J MOL BIOL, V257, P430, DOI 10.1006/jmbi.1996.0173; Daggett V, 2000, CURR OPIN STRUC BIOL, V10, P160, DOI 10.1016/S0959-440X(00)00062-2; Daggett V, 1998, J AM CHEM SOC, V120, P12740, DOI 10.1021/ja981558y; DAGGETT V, 2000, MECH PROTEIN FOLDING, P175; Eaton WA, 1997, CURR OPIN STRUC BIOL, V7, P10, DOI 10.1016/S0959-440X(97)80003-6; Ferguson N, 2001, P NATL ACAD SCI USA, V98, P13008, DOI 10.1073/pnas.221467398; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; FERSHT A, 1999, PROTEIN SCI GUIDE EN; FERSHT AR, 1994, P NATL ACAD SCI USA, V91, P10426, DOI 10.1073/pnas.91.22.10426; FERSHT AR, 1987, BIOCHEMISTRY-US, V26, P6030, DOI 10.1021/bi00393a013; FERSHT AR, 1986, NATURE, V322, P284, DOI 10.1038/322284a0; FERSHT AR, 1995, P NATL ACAD SCI USA, V92, P10869, DOI 10.1073/pnas.92.24.10869; FERSHT AR, 1992, J MOL BIOL, V224, P771, DOI 10.1016/0022-2836(92)90561-W; Fersht AR, 1997, CURR OPIN STRUC BIOL, V7, P3, DOI 10.1016/S0959-440X(97)80002-4; Fowler SB, 2001, STRUCTURE, V9, P355, DOI 10.1016/S0969-2126(01)00596-2; GAY GD, 1995, P NATL ACAD SCI USA, V92, P3683, DOI 10.1073/pnas.92.9.3683; GRAY TE, 1993, EMBO J, V12, P4145, DOI 10.1002/j.1460-2075.1993.tb06098.x; Grosman C, 2000, NATURE, V403, P773, DOI 10.1038/35001586; Huang SH, 1999, NAT STRUCT BIOL, V6, P1132; ITZHAKI LS, 1995, J MOL BIOL, V254, P260, DOI 10.1006/jmbi.1995.0616; JACKSON SE, 1991, BIOCHEMISTRY-US, V30, P10428, DOI 10.1021/bi00107a010; Jager M, 2001, J MOL BIOL, V311, P373, DOI 10.1006/jmbi.2001.4873; KARPLUS M, 1994, PROTEIN SCI, V3, P650; Kazmirski SL, 2001, P NATL ACAD SCI USA, V98, P4349, DOI 10.1073/pnas.071054398; KIM PS, 1982, ANNU REV BIOCHEM, V51, P459, DOI 10.1146/annurev.bi.51.070182.002331; Ladurner AG, 1998, P NATL ACAD SCI USA, V95, P8473, DOI 10.1073/pnas.95.15.8473; Lazaridis T, 1997, SCIENCE, V278, P1928, DOI 10.1126/science.278.5345.1928; Lee C, 2001, MOL CELL, V7, P627, DOI 10.1016/S1097-2765(01)00209-X; Li AJ, 1998, J MOL BIOL, V275, P677, DOI 10.1006/jmbi.1997.1484; LI AJ, 1994, P NATL ACAD SCI USA, V91, P10430, DOI 10.1073/pnas.91.22.10430; Li AJ, 1996, J MOL BIOL, V257, P412, DOI 10.1006/jmbi.1996.0172; Li L, 2001, P NATL ACAD SCI USA, V98, P13014, DOI 10.1073/pnas.241378398; MATOUSCHEK A, 1989, NATURE, V340, P122, DOI 10.1038/340122a0; MATTHEWS JM, 1995, BIOCHEMISTRY-US, V34, P6805, DOI 10.1021/bi00020a027; Mayor U, 2000, P NATL ACAD SCI USA, V97, P13518, DOI 10.1073/pnas.250473497; MCCAMMON JA, 1977, NATURE, V267, P585, DOI 10.1038/267585a0; Neira JL, 1999, J MOL BIOL, V285, P1309, DOI 10.1006/jmbi.1998.2249; Neira JL, 1997, J MOL BIOL, V268, P185, DOI 10.1006/jmbi.1997.0932; Oliveberg M, 2001, CURR OPIN STRUC BIOL, V11, P94, DOI 10.1016/S0959-440X(00)00171-8; Onuchic JN, 2000, ADV PROTEIN CHEM, V53, P87; OTZEN DE, 1994, P NATL ACAD SCI USA, V91, P10422, DOI 10.1073/pnas.91.22.10422; PTITSYN OB, 1987, J PROTEIN CHEM, V6, P273; SERRANO L, 1992, J MOL BIOL, V224, P805, DOI 10.1016/0022-2836(92)90563-Y; Shakhnovich E, 1996, NATURE, V379, P96, DOI 10.1038/379096a0; Shea JE, 2001, ANNU REV PHYS CHEM, V52, P499, DOI 10.1146/annurev.physchem.52.1.499; SHORTLE D, 1986, J CELL BIOCHEM, V30, P281, DOI 10.1002/jcb.240300402; Shortle D, 2001, SCIENCE, V293, P487, DOI 10.1126/science.1060438; Vendruscolo M, 2001, NATURE, V409, P641, DOI 10.1038/35054591; Weissman JS, 1996, CELL, V84, P481, DOI 10.1016/S0092-8674(00)81293-3; Wong KB, 2000, J MOL BIOL, V296, P1257, DOI 10.1006/jmbi.2000.3523; YANAGAWA H, 1993, J BIOL CHEM, V268, P5861; Zagrovic B, 2001, J MOL BIOL, V313, P151, DOI 10.1006/jmbi.2001.5033	60	403	412	0	46	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 22	2002	108	4					573	582		10.1016/S0092-8674(02)00620-7	http://dx.doi.org/10.1016/S0092-8674(02)00620-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	524XW	11909527	Bronze			2022-12-28	WOS:000174039000014
J	Kloc, M; Zearfoss, NR; Etkin, LD				Kloc, M; Zearfoss, NR; Etkin, LD			Mechanisms of subcellular mRNA localization	CELL			English	Review							LOCAL PROTEIN-SYNTHESIS; GERM PLASM COMPONENT; BINDING PROTEIN; TRANSLATIONAL REGULATION; DROSOPHILA OOGENESIS; XENOPUS-OOCYTES; BETA-ACTIN; DEPENDENT TRANSLATION; STRUCTURAL ELEMENTS; AXIS SPECIFICATION	Localization of RNA is a widespread and efficient way to target gene products to a specific region of a cell or embryo. This strategy of posttranscriptional gene regulation utilizes a variety of distinct mechanisms to regulate the movement and anchoring of different transcripts.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Etkin, LD (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, 1515 Holcombe Blvd, Houston, TX 77030 USA.	Ide@mdanderson.org	Kloc, Malgorzata/AAF-6982-2020		NCI NIH HHS [5T32 CA 09299-23] Funding Source: Medline; NICHD NIH HHS [HD 07325-17] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009299] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aakalu G, 2001, NEURON, V30, P489, DOI 10.1016/S0896-6273(01)00295-1; Ainger K, 1997, J CELL BIOL, V138, P1077, DOI 10.1083/jcb.138.5.1077; ARNIKURA R, 2001, P NATL ACAD SCI USA, V98, P9133; Bashirullah A, 1998, ANNU REV BIOCHEM, V67, P335, DOI 10.1146/annurev.biochem.67.1.335; Bashirullah A, 1999, EMBO J, V18, P2610, DOI 10.1093/emboj/18.9.2610; Bassell G J, 2001, Results Probl Cell Differ, V34, P41; Bergsten SE, 1999, DEVELOPMENT, V126, P659; Bergsten SE, 2001, DEVELOPMENT, V128, P427; Bohl F, 2000, EMBO J, V19, P5514, DOI 10.1093/emboj/19.20.5514; Broadus J, 1997, CURR BIOL, V7, P827, DOI 10.1016/S0960-9822(06)00370-8; Bullock SL, 2001, NATURE, V414, P611, DOI 10.1038/414611a; Carrera P, 2000, MOL CELL, V5, P181, DOI 10.1016/S1097-2765(00)80414-1; Castagnetti S, 2000, DEVELOPMENT, V127, P1063; Cha BJ, 2001, CELL, V106, P35, DOI 10.1016/S0092-8674(01)00419-6; Chan AP, 1999, DEVELOPMENT, V126, P4943; Chang JS, 1999, DEV BIOL, V215, P91, DOI 10.1006/dbio.1999.9444; Chartrand P, 1999, CURR BIOL, V9, P333, DOI 10.1016/S0960-9822(99)80144-4; Chartrand P, 2001, ANNU REV CELL DEV BI, V17, P297, DOI 10.1146/annurev.cellbio.17.1.297; Clark IE, 2000, CURR BIOL, V10, P1311, DOI 10.1016/S0960-9822(00)00754-5; Cooperstock RL, 2001, INT REV CYTOL, V203, P541; Cote CA, 1999, MOL CELL, V4, P431, DOI 10.1016/S1097-2765(00)80345-7; Crucs S, 2000, MOL CELL, V5, P457, DOI 10.1016/S1097-2765(00)80440-2; Dahanukar A, 1999, MOL CELL, V4, P209, DOI 10.1016/S1097-2765(00)80368-8; Deshler JO, 1997, SCIENCE, V276, P1128, DOI 10.1126/science.276.5315.1128; Deshler JO, 1998, CURR BIOL, V8, P489, DOI 10.1016/S0960-9822(98)70200-3; DING D, 1993, MOL CELL BIOL, V13, P3773, DOI 10.1128/MCB.13.6.3773; Dollar G, 2002, DEVELOPMENT, V129, P517; Ferrandon D, 1997, EMBO J, V16, P1751, DOI 10.1093/emboj/16.7.1751; Gavis ER, 1996, DEVELOPMENT, V122, P2791; Gonzalez I, 1999, CURR BIOL, V9, P337, DOI 10.1016/S0960-9822(99)80145-6; Groisman I, 2000, CELL, V103, P435, DOI 10.1016/S0092-8674(00)00135-5; Gunkel N, 1998, GENE DEV, V12, P1652, DOI 10.1101/gad.12.11.1652; Havin L, 1998, GENE DEV, V12, P1593, DOI 10.1101/gad.12.11.1593; Heasman J, 2001, DEV BIOL, V240, P377, DOI 10.1006/dbio.2001.0495; HILL MA, 1993, J CELL BIOL, V122, P825, DOI 10.1083/jcb.122.4.825; Husi H, 2000, NAT NEUROSCI, V3, P661, DOI 10.1038/76615; Jankovics F, 2001, GENETICS, V158, P1177; Jansen RP, 2001, NAT REV MOL CELL BIO, V2, P247, DOI 10.1038/35067016; Kang HJ, 1996, SCIENCE, V273, P1402, DOI 10.1126/science.273.5280.1402; Kiebler MA, 2000, NEURON, V25, P19, DOI 10.1016/S0896-6273(00)80868-5; KIMHA J, 1995, CELL, V81, P403, DOI 10.1016/0092-8674(95)90393-3; King ML, 1999, BIOESSAYS, V21, P546, DOI 10.1002/(SICI)1521-1878(199907)21:7<546::AID-BIES3>3.0.CO;2-Z; KISLAUSKIS EH, 1993, J CELL BIOL, V123, P165, DOI 10.1083/jcb.123.1.165; Kloc M, 2000, DEV BIOL, V217, P221, DOI 10.1006/dbio.1999.9554; KLOC M, 1994, SCIENCE, V265, P1101, DOI 10.1126/science.7520603; Kloc M, 2002, DEV BIOL, V241, P79, DOI 10.1006/dbio.2001.0488; Kloc M, 2001, DIFFERENTIATION, V67, P80, DOI 10.1046/j.1432-0436.2001.067003080.x; Kloc M, 2001, INT REV CYTOL, V203, P63; Kobayashi S, 1998, CURR BIOL, V8, P1117, DOI 10.1016/S0960-9822(98)70466-X; Kwon S, 1999, J CELL BIOL, V147, P247, DOI 10.1083/jcb.147.2.247; Lie YS, 1999, DEVELOPMENT, V126, P4989; Lie YS, 1999, DEVELOPMENT, V126, P1129; Lipshitz HD, 2000, CURR OPIN GENET DEV, V10, P476, DOI 10.1016/S0959-437X(00)00116-7; Long RM, 2000, EMBO J, V19, P6592, DOI 10.1093/emboj/19.23.6592; MacArthur H, 1999, MECH DEVELOP, V84, P75, DOI 10.1016/S0925-4773(99)00075-1; Macdonald P, 2001, CURR OPIN CELL BIOL, V13, P326, DOI 10.1016/S0955-0674(00)00215-5; Macdonald PM, 1998, MOL CELL BIOL, V18, P3788, DOI 10.1128/MCB.18.7.3788; MAHONE M, 1995, EMBO J, V14, P2043, DOI 10.1002/j.1460-2075.1995.tb07196.x; Markesich DC, 2000, DEVELOPMENT, V127, P559; Mayford M, 1996, SCIENCE, V274, P1678, DOI 10.1126/science.274.5293.1678; Mendez R, 2001, NAT REV MOL CELL BIO, V2, P521, DOI 10.1038/35080081; Micklem DR, 2000, EMBO J, V19, P1366, DOI 10.1093/emboj/19.6.1366; Mowry KL, 1999, FASEB J, V13, P435, DOI 10.1096/fasebj.13.3.435; Norvell A, 1999, GENE DEV, V13, P864, DOI 10.1101/gad.13.7.864; Otero LJ, 2001, RNA, V7, P1753; Palacios IM, 2001, ANNU REV CELL DEV BI, V17, P569, DOI 10.1146/annurev.cellbio.17.1.569; Pinkstaff JK, 2001, P NATL ACAD SCI USA, V98, P2770, DOI 10.1073/pnas.051623398; Richter JD, 2001, P NATL ACAD SCI USA, V98, P7069, DOI 10.1073/pnas.111146498; Roegiers F, 2000, TRENDS CELL BIOL, V10, P220, DOI 10.1016/S0962-8924(00)01767-0; Ross AF, 1997, MOL CELL BIOL, V17, P2158, DOI 10.1128/MCB.17.4.2158; Saffman EE, 1998, MOL CELL BIOL, V18, P4855, DOI 10.1128/MCB.18.8.4855; SALLES FJ, 1994, SCIENCE, V266, P1996, DOI 10.1126/science.7801127; Saunders C, 1999, MOL CELL, V3, P43, DOI 10.1016/S1097-2765(00)80173-2; SERANO T, 1995, DEVELOPMENT, V121, P3809; Seydoux G, 2001, INT REV CYTOL, V203, P139; Shulman JM, 2000, CELL, V101, P377, DOI 10.1016/S0092-8674(00)80848-X; Smibert CA, 1999, RNA, V5, P1535, DOI 10.1017/S1355838299991392; Steward O, 2001, NEURON, V30, P227, DOI 10.1016/S0896-6273(01)00275-6; Steward O, 2001, P NATL ACAD SCI USA, V98, P7062, DOI 10.1073/pnas.131146398; Steward O, 2001, ANNU REV NEUROSCI, V24, P299, DOI 10.1146/annurev.neuro.24.1.299; Steward O, 1998, NEURON, V21, P741, DOI 10.1016/S0896-6273(00)80591-7; Takizawa PA, 2000, P NATL ACAD SCI USA, V97, P5273, DOI 10.1073/pnas.080585897; Thio GL, 2000, DEV BIOL, V221, P435, DOI 10.1006/dbio.2000.9690; Tomancak P, 2000, NAT CELL BIOL, V2, P458, DOI 10.1038/35017101; Wilhelm JE, 2000, P NATL ACAD SCI USA, V97, P13132, DOI 10.1073/pnas.97.24.13132; Wilkie GS, 2001, CELL, V105, P209, DOI 10.1016/S0092-8674(01)00312-9; Wu L, 1998, NEURON, V21, P1129, DOI 10.1016/S0896-6273(00)80630-3; Yaniv K, 2001, INT REV CYTOL, V203, P521; YISRAELI JK, 1990, DEVELOPMENT, V108, P289; Zhang HL, 2001, NEURON, V31, P261, DOI 10.1016/S0896-6273(01)00357-9; Zhao WM, 2001, EMBO J, V20, P2315, DOI 10.1093/emboj/20.9.2315; Zhou Y, 1996, DEVELOPMENT, V122, P2947	92	254	261	0	19	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 22	2002	108	4					533	544		10.1016/S0092-8674(02)00651-7	http://dx.doi.org/10.1016/S0092-8674(02)00651-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	524XW	11909524	Bronze			2022-12-28	WOS:000174039000011
J	McKenna, NJ; O'Malley, BW				McKenna, NJ; O'Malley, BW			Combinatorial control of gene expression by nuclear receptors and coregulators	CELL			English	Review							THYROID-HORMONE RECEPTOR; TRANSCRIPTIONAL COACTIVATOR CBP; HUMAN GLUCOCORTICOID RECEPTOR; HUMAN ESTROGEN-RECEPTOR; HISTONE ACETYLTRANSFERASE; DEPENDENT TRANSACTIVATION; REGULATED TRANSCRIPTION; STEROID-RECEPTORS; ONCOPROTEIN E1A; CO-REPRESSOR	The nuclear receptor (NR) superfamily of transcription factors regulates gene expression in response to endocrine signaling, and recruitment of coregulators affords these receptors considerable functional flexibility. We will place historical aspects of NR research in context with current opinions on their mechanism of signal transduction, and we will speculate upon future trends in the field.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine	O'Malley, BW (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.	berto@bcm.tmc.edu		McKenna, Neil/0000-0001-6689-0104				Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; BAGCHI MK, 1992, ENDOCR REV, V13, P525, DOI 10.1210/er.13.3.525; BANIAHMAD A, 1995, MOL CELL BIOL, V15, P76, DOI 10.1128/MCB.15.1.76; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Boonyaratanakornkit V, 2001, MOL CELL, V8, P269, DOI 10.1016/S1097-2765(01)00304-5; Caira F, 2000, J BIOL CHEM, V275, P5308, DOI 10.1074/jbc.275.8.5308; CAVAILLES V, 1994, P NATL ACAD SCI USA, V91, P10009, DOI 10.1073/pnas.91.21.10009; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Chen SY, 2000, J BIOL CHEM, V275, P30106, DOI 10.1074/jbc.M005418200; de Mora JF, 2000, MOL CELL BIOL, V20, P5041, DOI 10.1128/MCB.20.14.5041-5047.2000; Endoh H, 1999, MOL CELL BIOL, V19, P5363; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Feng WJ, 1998, SCIENCE, V280, P1747, DOI 10.1126/science.280.5370.1747; Fondell JD, 1996, P NATL ACAD SCI USA, V93, P8329, DOI 10.1073/pnas.93.16.8329; FOWAN BG, 2000, J BIOL CHEM, V275, P4475; Freeman BC, 2001, TRENDS BIOCHEM SCI, V26, P285, DOI 10.1016/S0968-0004(01)01834-5; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; Giguere V, 1999, ENDOCR REV, V20, P689, DOI 10.1210/er.20.5.689; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; Graham JD, 2000, J STEROID BIOCHEM, V74, P255, DOI 10.1016/S0960-0760(00)00101-1; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Herzig S, 2001, NATURE, V413, P179, DOI 10.1038/35093131; HOLLENBERG SM, 1985, NATURE, V318, P635, DOI 10.1038/318635a0; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Hong SH, 2000, MOL CELL BIOL, V20, P6612, DOI 10.1128/MCB.20.17.6612-6625.2000; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Hu X, 1999, NATURE, V402, P93, DOI 10.1038/47069; Ito M, 2000, MOL CELL, V5, P683, DOI 10.1016/S1097-2765(00)80247-6; Iwasaki T, 2001, J BIOL CHEM, V276, P33375, DOI 10.1074/jbc.M101517200; JENSEN EV, 1962, RECENT PROG HORM RES, V18, P387; Jepsen K, 2000, CELL, V102, P753, DOI 10.1016/S0092-8674(00)00064-7; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Katzenellenbogen BS, 2000, RECENT PROG HORM RES, V55, P163; Knutti D, 2001, P NATL ACAD SCI USA, V98, P9713, DOI 10.1073/pnas.171184698; Ko L, 2002, MOL CELL BIOL, V22, P357, DOI 10.1128/MCB.22.1.357-369.2002; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Lanz RB, 1999, CELL, V97, P17, DOI 10.1016/S0092-8674(00)80711-4; Lavinsky RM, 1998, P NATL ACAD SCI USA, V95, P2920, DOI 10.1073/pnas.95.6.2920; LEE JW, 1995, MOL ENDOCRINOL, V9, P243; Lee SK, 1999, J BIOL CHEM, V274, P34283, DOI 10.1074/jbc.274.48.34283; Lewis JD, 2000, SCIENCE, V288, P1385, DOI 10.1126/science.288.5470.1385; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; Lonard DM, 2000, MOL CELL, V5, P939, DOI 10.1016/S1097-2765(00)80259-2; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; Mahajan MA, 2000, MOL CELL BIOL, V20, P5048, DOI 10.1128/MCB.20.14.5048-5063.2000; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; McKenna NJ, 1998, P NATL ACAD SCI USA, V95, P11697, DOI 10.1073/pnas.95.20.11697; McNally JG, 2000, SCIENCE, V287, P1262, DOI 10.1126/science.287.5456.1262; MEANS AR, 1972, P NATL ACAD SCI USA, V69, P1146, DOI 10.1073/pnas.69.5.1146; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; Monsalve M, 2000, MOL CELL, V6, P307, DOI 10.1016/S1097-2765(00)00031-9; Montano MM, 1999, P NATL ACAD SCI USA, V96, P6947, DOI 10.1073/pnas.96.12.6947; Muller JM, 2000, EMBO J, V19, P359, DOI 10.1093/emboj/19.3.359; Naar AM, 2001, ANNU REV BIOCHEM, V70, P475, DOI 10.1146/annurev.biochem.70.1.475; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nawaz Z, 1999, MOL CELL BIOL, V19, P1182; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Norris JD, 1999, SCIENCE, V285, P744, DOI 10.1126/science.285.5428.744; OMALLEY BW, 1968, P NATL ACAD SCI USA, V60, P1527, DOI 10.1073/pnas.60.4.1527; ONATE SA, 1995, SCIENCE, V270, P1354; PAYVAR F, 1982, J CELL BIOCHEM, V19, P241, DOI 10.1002/jcb.240190305; PETRIJ F, 1995, NATURE, V376, P348, DOI 10.1038/376348a0; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Rachez C, 1998, GENE DEV, V12, P1787, DOI 10.1101/gad.12.12.1787; Rogatsky I, 2001, EMBO J, V20, P6071, DOI 10.1093/emboj/20.21.6071; Rosenfeld MG, 2001, J BIOL CHEM, V276, P36865, DOI 10.1074/jbc.R100041200; SCHRADER WT, 1977, J BIOL CHEM, V252, P299; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shi YH, 2001, GENE DEV, V15, P1140, DOI 10.1101/gad.871201; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131; Smith CL, 1997, MOL ENDOCRINOL, V11, P657, DOI 10.1210/me.11.6.657; SPELSBERG TC, 1971, J BIOL CHEM, V246, P4188; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Stenoien DL, 2001, NAT CELL BIOL, V3, P15, DOI 10.1038/35050515; Takeshita A, 1996, ENDOCRINOLOGY, V137, P3594, DOI 10.1210/en.137.8.3594; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Wang HB, 2001, SCIENCE, V293, P853, DOI 10.1126/science.1060781; Wang ZY, 2000, P NATL ACAD SCI USA, V97, P13549, DOI 10.1073/pnas.260463097; Windahl SH, 1999, J STEROID BIOCHEM, V71, P93, DOI 10.1016/S0960-0760(99)00128-4; WRANGE O, 1984, J BIOL CHEM, V259, P4534; Xu JM, 2000, P NATL ACAD SCI USA, V97, P6379, DOI 10.1073/pnas.120166297; Xu JM, 1998, SCIENCE, V279, P1922, DOI 10.1126/science.279.5358.1922; Xu W, 2001, SCIENCE, V294, P2507, DOI 10.1126/science.1065961; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050; YOSHINAGA SK, 1992, SCIENCE, V258, P1598, DOI 10.1126/science.1360703; Zhu YJ, 2000, J BIOL CHEM, V275, P13510, DOI 10.1074/jbc.275.18.13510	102	1179	1220	2	97	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 22	2002	108	4					465	474		10.1016/S0092-8674(02)00641-4	http://dx.doi.org/10.1016/S0092-8674(02)00641-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	524XW	11909518	Bronze			2022-12-28	WOS:000174039000005
J	Ramakrishnan, V				Ramakrishnan, V			Ribosome structure and the mechanism of translation	CELL			English	Review							ELONGATION-FACTOR-G; AMINOACYL-TRANSFER-RNA; ESCHERICHIA-COLI RIBOSOME; INITIATION-FACTOR IF3; PEPTIDYL-TRANSFER-RNA; CONFORMATIONAL SWITCH; CRYSTAL-STRUCTURE; MESSENGER-RNA; 70S RIBOSOME; FACTOR TU	The publication of crystal structures of the 50S and 30S ribosomal subunits and the intact 70S ribosome is revolutionizing our understanding of protein synthesis. This review is an attempt to correlate the structures with biochemical and genetic data to identify the gaps and limits in our current knowledge of the mechanisms involved in translation.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Ramakrishnan, V (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.	ramak@mrc-lmb.cam.ac.uk		Ramakrishnan, V/0000-0002-4699-2194				AEVARSSON A, 1994, EMBO J, V13, P3669, DOI 10.1002/j.1460-2075.1994.tb06676.x; Agrawal RK, 1999, J BIOL CHEM, V274, P8723, DOI 10.1074/jbc.274.13.8723; Agrawal RK, 2000, J CELL BIOL, V150, P447, DOI 10.1083/jcb.150.3.447; Agrawal RK, 1998, P NATL ACAD SCI USA, V95, P6134, DOI 10.1073/pnas.95.11.6134; Agrawal RK, 1999, NAT STRUCT BIOL, V6, P643, DOI 10.1038/10695; Agrawal RK, 1999, CURR OPIN STRUC BIOL, V9, P215, DOI 10.1016/S0959-440X(99)80031-1; Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; Bayfield MA, 2001, P NATL ACAD SCI USA, V98, P10096, DOI 10.1073/pnas.171319598; BELITSINA NV, 1981, FEBS LETT, V131, P289, DOI 10.1016/0014-5793(81)80387-0; BIOU V, 1995, EMBO J, V14, P4056, DOI 10.1002/j.1460-2075.1995.tb00077.x; Borowski C, 1996, P NATL ACAD SCI USA, V93, P4202, DOI 10.1073/pnas.93.9.4202; BRETSCHER MS, 1968, NATURE, V218, P675, DOI 10.1038/218675a0; Brodersen DE, 2000, CELL, V103, P1143, DOI 10.1016/S0092-8674(00)00216-6; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Carter AP, 2001, SCIENCE, V291, P498, DOI 10.1126/science.1057766; Carter AP, 2000, NATURE, V407, P340, DOI 10.1038/35030019; CRICK FHC, 1966, J MOL BIOL, V19, P548, DOI 10.1016/S0022-2836(66)80022-0; CZWORKOWSKI J, 1994, EMBO J, V13, P3661, DOI 10.1002/j.1460-2075.1994.tb06675.x; Dabrowski M, 1998, J BIOL CHEM, V273, P32793, DOI 10.1074/jbc.273.49.32793; Dallas A, 2001, MOL CELL, V8, P855, DOI 10.1016/S1097-2765(01)00356-2; DAVIES J, 1964, P NATL ACAD SCI USA, V51, P883, DOI 10.1073/pnas.51.5.883; Doherty EA, 2001, NAT STRUCT BIOL, V8, P339, DOI 10.1038/86221; Feinberg JS, 2001, P NATL ACAD SCI USA, V98, P11120, DOI 10.1073/pnas.211184098; Fourmy D, 1996, SCIENCE, V274, P1367, DOI 10.1126/science.274.5291.1367; Frank J, 2000, NATURE, V406, P318, DOI 10.1038/35018597; Frolova LY, 1999, RNA, V5, P1014, DOI 10.1017/S135583829999043X; Gabashvili IS, 1999, EMBO J, V18, P6501, DOI 10.1093/emboj/18.22.6501; GARCIA C, 1995, J MOL BIOL, V254, P247, DOI 10.1006/jmbi.1995.0615; GARCIA C, 1995, EUR J BIOCHEM, V228, P395, DOI 10.1111/j.1432-1033.1995.tb20276.x; GAVRILOVA LP, 1976, J MOL BIOL, V101, P537, DOI 10.1016/0022-2836(76)90243-6; Green R, 1997, ANNU REV BIOCHEM, V66, P679, DOI 10.1146/annurev.biochem.66.1.679; GUALERZI CO, 1990, BIOCHEMISTRY-US, V29, P5881, DOI 10.1021/bi00477a001; HAMPL H, 1981, J BIOL CHEM, V256, P2284; Harms J, 2001, CELL, V107, P679, DOI 10.1016/S0092-8674(01)00546-3; HARTZ D, 1990, GENE DEV, V4, P1790, DOI 10.1101/gad.4.10.1790; HOPFIELD JJ, 1974, P NATL ACAD SCI USA, V71, P4135, DOI 10.1073/pnas.71.10.4135; Ito K, 2000, NATURE, V403, P680, DOI 10.1038/35001115; Janosi L, 1996, ADV BIOPHYS, V32, P121, DOI 10.1016/0065-227X(96)84743-5; Joseph S, 1998, EMBO J, V17, P3478, DOI 10.1093/emboj/17.12.3478; KAJI A, 2001, IN PRESS COLD SPRING; Karimi R, 1999, MOL CELL, V3, P601, DOI 10.1016/S1097-2765(00)80353-6; Khaitovich P, 1999, P NATL ACAD SCI USA, V96, P85, DOI 10.1073/pnas.96.1.85; Kisselev LL, 2000, TRENDS BIOCHEM SCI, V25, P561, DOI 10.1016/S0968-0004(00)01669-8; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRUGER K, 1982, CELL, V31, P147, DOI 10.1016/0092-8674(82)90414-7; La Teana A, 2001, RNA, V7, P1173, DOI 10.1017/S1355838201010366; LILL R, 1989, EMBO J, V8, P3933, DOI 10.1002/j.1460-2075.1989.tb08574.x; Lodmell JS, 1997, SCIENCE, V277, P1262, DOI 10.1126/science.277.5330.1262; McCutcheon JP, 1999, P NATL ACAD SCI USA, V96, P4301, DOI 10.1073/pnas.96.8.4301; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MOAZED D, 1989, NATURE, V342, P142, DOI 10.1038/342142a0; MOAZED D, 1986, CELL, V47, P985, DOI 10.1016/0092-8674(86)90813-5; Muth GW, 2000, SCIENCE, V289, P947, DOI 10.1126/science.289.5481.947; Muth GW, 2001, RNA, V7, P1403; NIERHAUS KH, 1980, BIOCHEM INT, V1, P185; NIERHAUS KH, 1990, BIOCHEMISTRY-US, V29, P4997, DOI 10.1021/bi00473a001; NINIO J, 1975, BIOCHIMIE, V57, P587, DOI 10.1016/S0300-9084(75)80139-8; NISSEN P, 1995, SCIENCE, V270, P1464, DOI 10.1126/science.270.5241.1464; Nissen P, 2001, P NATL ACAD SCI USA, V98, P4899, DOI 10.1073/pnas.081082398; NOLLER HF, 1992, SCIENCE, V256, P1416, DOI 10.1126/science.1604315; Ogle JM, 2001, SCIENCE, V292, P897, DOI 10.1126/science.1060612; Pape T, 1998, EMBO J, V17, P7490, DOI 10.1093/emboj/17.24.7490; Pape T, 1999, EMBO J, V18, P3800, DOI 10.1093/emboj/18.13.3800; Pape T, 2000, NAT STRUCT BIOL, V7, P104; Peske F, 2000, MOL CELL, V6, P501, DOI 10.1016/S1097-2765(00)00049-6; Petrelli D, 2001, EMBO J, V20, P4560, DOI 10.1093/emboj/20.16.4560; Piepenburg O, 2000, BIOCHEMISTRY-US, V39, P1734, DOI 10.1021/bi992331y; Pioletti M, 2001, EMBO J, V20, P1829, DOI 10.1093/emboj/20.8.1829; Polacek N, 2001, NATURE, V411, P498, DOI 10.1038/35078113; POTAPOV AP, 1982, FEBS LETT, V146, P5, DOI 10.1016/0014-5793(82)80693-5; POWERS T, 1994, J MOL BIOL, V235, P156, DOI 10.1016/S0022-2836(05)80023-3; Ramakrishnan V, 2001, CURR OPIN STRUC BIOL, V11, P144, DOI 10.1016/S0959-440X(00)00184-6; Rodnina MV, 1997, NATURE, V385, P37, DOI 10.1038/385037a0; Rodnina MV, 1999, P NATL ACAD SCI USA, V96, P9586, DOI 10.1073/pnas.96.17.9586; Roll-Mecak A, 2000, CELL, V103, P781, DOI 10.1016/S0092-8674(00)00181-1; Schluenzen F, 2000, CELL, V102, P615, DOI 10.1016/S0092-8674(00)00084-2; SCHMEING TM, 2002, IN PRESS NAT STRUCT; Selmer M, 1999, SCIENCE, V286, P2349, DOI 10.1126/science.286.5448.2349; Sette M, 1997, EMBO J, V16, P1436, DOI 10.1093/emboj/16.6.1436; Song HW, 2000, CELL, V100, P311, DOI 10.1016/S0092-8674(00)80667-4; Spahn CMT, 1998, BIOL CHEM, V379, P753; Stark H, 2000, CELL, V100, P301, DOI 10.1016/S0092-8674(00)80666-2; Stark H, 1997, NATURE, V389, P403, DOI 10.1038/38770; Thompson J, 2001, P NATL ACAD SCI USA, V98, P9002, DOI 10.1073/pnas.151257098; Tomsic J, 2000, EMBO J, V19, P2127, DOI 10.1093/emboj/19.9.2127; van Heel M, 2000, CURR OPIN STRUC BIOL, V10, P259, DOI 10.1016/S0959-440X(00)00077-4; VanLoock MS, 2000, J MOL BIOL, V304, P507, DOI 10.1006/jmbi.2000.4213; Velichutina IV, 2000, RNA, V6, P1174, DOI 10.1017/S1355838200000637; Vestergaard B, 2001, MOL CELL, V8, P1375, DOI 10.1016/S1097-2765(01)00415-4; Vocadlo DJ, 2001, NATURE, V412, P835, DOI 10.1038/35090602; Vogeley L, 2001, J BIOL CHEM, V276, P17149, DOI 10.1074/jbc.M100017200; WELCH M, 1995, BIOCHEMISTRY-US, V34, P385, DOI 10.1021/bi00002a001; Wilson KS, 2000, NAT STRUCT BIOL, V7, P866, DOI 10.1038/82818; Wilson KS, 1998, CELL, V92, P131, DOI 10.1016/S0092-8674(00)80905-8; Wimberly BT, 2000, NATURE, V407, P327, DOI 10.1038/35030006; Wower J, 2000, J BIOL CHEM, V275, P37887, DOI 10.1074/jbc.M005031200; YONATH AE, 1980, BIOCHEM INT, V1, P428; Yoshizawa S, 1999, SCIENCE, V285, P1722, DOI 10.1126/science.285.5434.1722; Yusupov MM, 2001, SCIENCE, V292, P883, DOI 10.1126/science.1060089; Yusupova GZ, 2001, CELL, V106, P233, DOI 10.1016/S0092-8674(01)00435-4; ZAUG AJ, 1983, NATURE, V301, P578, DOI 10.1038/301578a0; Zavialov AV, 2001, CELL, V107, P115, DOI 10.1016/S0092-8674(01)00508-6; ZUCKER FH, 1986, BIOCHEMISTRY-US, V25, P3682, DOI 10.1021/bi00360a031	105	567	587	2	168	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 22	2002	108	4					557	572		10.1016/S0092-8674(02)00619-0	http://dx.doi.org/10.1016/S0092-8674(02)00619-0			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	524XW	11909526	Bronze			2022-12-28	WOS:000174039000013
J	Reed, R; Hurt, E				Reed, R; Hurt, E			A conserved rnRNA export machinery coupled to pre-mRNA splicing	CELL			English	Review							NUCLEAR-PORE COMPLEX; NONSENSE-MEDIATED DECAY; HNRNP-LIKE PROTEINS; BINDING-PROTEIN; NUCLEOCYTOPLASMIC TRANSPORT; POLY(A)(+) RNA; CYTOPLASMIC FIBRILS; STRUCTURAL BASIS; POLYMERASE-II; YEAST HOMOLOG	Recent advances have led to a new understanding of how mRNAs are exported from the nucleus to the cytoplasm. This process requires a heterodimeric mRNA export receptor that is part of an elaborate machinery conserved from yeast to humans. Export of mRNAs is coupled to upstream steps in gene expression, such as pre-mRNA splicing, and to downstream events, including nonsense-mediated decay.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Heidelberg Univ, Biochem Zentrum Heidelberg, D-69120 Heidelberg, Germany	Harvard University; Harvard Medical School; Ruprecht Karls University Heidelberg	Hurt, E (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.	robin_reed@hms.harvard.edu; cg5@ix.urz.uni-heidelberg.de	Ed Hurt, Dr./AAE-8874-2019	Ed Hurt, Dr./0000-0002-4535-8255				Allen NPC, 2001, J BIOL CHEM, V276, P29268, DOI 10.1074/jbc.M102629200; Bachi A, 2000, RNA, V6, P136, DOI 10.1017/S1355838200991994; Bayliss R, 2000, CELL, V102, P99, DOI 10.1016/S0092-8674(00)00014-3; Bear J, 1999, MOL CELL BIOL, V19, P6306; Bentley D, 1999, CURR OPIN CELL BIOL, V11, P347, DOI 10.1016/S0955-0674(99)80048-9; Braun IC, 2001, J BIOL CHEM, V276, P20536, DOI 10.1074/jbc.M100400200; Brennan CM, 2000, J CELL BIOL, V151, P1, DOI 10.1083/jcb.151.1.1; Brodsky AS, 2000, RNA, V6, P1737, DOI 10.1017/S1355838200001059; BROWN JA, 1995, J BIOL CHEM, V270, P7411, DOI 10.1074/jbc.270.13.7411; Bruhn L, 1997, GENE DEV, V11, P640, DOI 10.1101/gad.11.5.640; Bullock TL, 1996, J MOL BIOL, V260, P422, DOI 10.1006/jmbi.1996.0411; Caceres JF, 1998, GENE DEV, V12, P55, DOI 10.1101/gad.12.1.55; Clouse KN, 2001, NAT CELL BIOL, V3, P97, DOI 10.1038/35050625; Conti E, 2001, CURR OPIN CELL BIOL, V13, P310, DOI 10.1016/S0955-0674(00)00213-1; Daneholt B, 1997, CELL, V88, P585, DOI 10.1016/S0092-8674(00)81900-5; Feng YC, 2001, P NATL ACAD SCI USA, V98, P875, DOI 10.1073/pnas.021558098; Fleckner J, 1997, GENE DEV, V11, P1864, DOI 10.1101/gad.11.14.1864; Fribourg S, 2001, MOL CELL, V8, P645, DOI 10.1016/S1097-2765(01)00348-3; Gallouzi IE, 2001, SCIENCE, V294, P1895, DOI 10.1126/science.1064693; Gatfield D, 2001, CURR BIOL, V11, P1716, DOI 10.1016/S0960-9822(01)00532-2; Gilbert W, 2001, RNA, V7, P302, DOI 10.1017/S1355838201002369; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Graveley BR, 2000, RNA, V6, P1197, DOI 10.1017/S1355838200000960; Gruter P, 1998, MOL CELL, V1, P649, DOI 10.1016/S1097-2765(00)80065-9; Guzik BW, 2001, MOL CELL BIOL, V21, P2545, DOI 10.1128/MCB.21.7.2545-2554.2001; Herold A, 2000, MOL CELL BIOL, V20, P8996, DOI 10.1128/MCB.20.23.8996-9008.2000; Hilleren P, 2001, RNA, V7, P753, DOI 10.1017/S1355838201010147; Hirose Y, 2000, GENE DEV, V14, P1415; Hodge CA, 1999, EMBO J, V18, P5778, DOI 10.1093/emboj/18.20.5778; Huang YQ, 2001, MOL CELL, V7, P899, DOI 10.1016/S1097-2765(01)00233-7; Hurwitz ME, 1998, P NATL ACAD SCI USA, V95, P11241, DOI 10.1073/pnas.95.19.11241; Izaurralde E, 1997, J CELL BIOL, V137, P27, DOI 10.1083/jcb.137.1.27; Jensen TH, 2001, CURR BIOL, V11, P1711, DOI 10.1016/S0960-9822(01)00529-2; Jensen TH, 2001, MOL CELL, V7, P887, DOI 10.1016/S1097-2765(01)00232-5; KADOWAKI T, 1994, MOL BIOL CELL, V5, P1253, DOI 10.1091/mbc.5.11.1253; Kang YB, 1999, GENE DEV, V13, P1126, DOI 10.1101/gad.13.9.1126; Katahira J, 1999, EMBO J, V18, P2593, DOI 10.1093/emboj/18.9.2593; Kataoka N, 2000, MOL CELL, V6, P673, DOI 10.1016/S1097-2765(00)00065-4; Kessler MM, 1997, GENE DEV, V11, P2545, DOI 10.1101/gad.11.19.2545; Kim VN, 2001, SCIENCE, V293, P1832, DOI 10.1126/science.1062829; Kim VN, 2001, EMBO J, V20, P2062, DOI 10.1093/emboj/20.8.2062; Kistler AL, 2001, GENE DEV, V15, P42, DOI 10.1101/gad.851301; Kraemer D, 1997, P NATL ACAD SCI USA, V94, P9119, DOI 10.1073/pnas.94.17.9119; Le Hir H, 2000, EMBO J, V19, P6860, DOI 10.1093/emboj/19.24.6860; Le Hir H, 2001, EMBO J, V20, P4987, DOI 10.1093/emboj/20.17.4987; Lee MS, 1996, GENE DEV, V10, P1233, DOI 10.1101/gad.10.10.1233; Lei EP, 2001, GENE DEV, V15, P1771, DOI 10.1101/gad.892401; Libri D, 2001, GENE DEV, V15, P36, DOI 10.1101/gad.852101; Luo MJ, 2001, NATURE, V413, P644, DOI 10.1038/35098106; Luo MJ, 1999, P NATL ACAD SCI USA, V96, P14937, DOI 10.1073/pnas.96.26.14937; Lykke-Andersen J, 2001, SCIENCE, V293, P1836, DOI 10.1126/science.1062786; Lykke-Andersen J, 2000, CELL, V103, P1121, DOI 10.1016/S0092-8674(00)00214-2; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Mayeda A, 1999, EMBO J, V18, P4560, DOI 10.1093/emboj/18.16.4560; Mili S, 2001, MOL CELL BIOL, V21, P7307, DOI 10.1128/MCB.21.21.7307-7319.2001; Murphy R, 1996, NATURE, V383, P357, DOI 10.1038/383357a0; Murphy R, 1996, MOL BIOL CELL, V7, P1921, DOI 10.1091/mbc.7.12.1921; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; Ohno M, 2000, CELL, V101, P187, DOI 10.1016/S0092-8674(00)80829-6; Otero GC, 1998, J VIROL, V72, P9889, DOI 10.1128/JVI.72.12.9889-9896.1998; PEELMAN LJ, 1995, GENOMICS, V26, P210, DOI 10.1016/0888-7543(95)80203-X; Pemberton LF, 1998, CURR OPIN CELL BIOL, V10, P392, DOI 10.1016/S0955-0674(98)80016-1; Portman DS, 1997, RNA, V3, P527; Proudfoot NJ, 2002, CELL, V108, P501, DOI 10.1016/S0092-8674(02)00617-7; Reed R, 2001, NAT CELL BIOL, V3, pE201, DOI 10.1038/ncb0901-e201; Rodrigues JP, 2001, P NATL ACAD SCI USA, V98, P1030, DOI 10.1073/pnas.98.3.1030; Rout MP, 2000, J CELL BIOL, V148, P635, DOI 10.1083/jcb.148.4.635; Ruiz-Echevarria MJ, 1998, EMBO J, V17, P575, DOI 10.1093/emboj/17.2.575; Santos-Rosa H, 1998, MOL CELL BIOL, V18, P6826, DOI 10.1128/MCB.18.11.6826; Schmitt C, 1999, EMBO J, V18, P4332, DOI 10.1093/emboj/18.15.4332; Schmitt I, 2001, J BIOL CHEM, V276, P42355, DOI 10.1074/jbc.M103916200; Segref A, 1997, EMBO J, V16, P3256, DOI 10.1093/emboj/16.11.3256; Shen EC, 2000, J BIOL CHEM, V275, P23718, DOI 10.1074/jbc.M002312200; Snay-Hodge CA, 1998, EMBO J, V17, P2663, DOI 10.1093/emboj/17.9.2663; Stewart M, 2001, FEBS LETT, V498, P145, DOI 10.1016/S0014-5793(01)02489-9; Strahm Y, 1999, EMBO J, V18, P5761, DOI 10.1093/emboj/18.20.5761; Strasser K, 2000, J CELL BIOL, V150, P695, DOI 10.1083/jcb.150.4.695; Strasser K, 2001, NATURE, V413, P648, DOI 10.1038/35098113; Strasser K, 2000, EMBO J, V19, P410, DOI 10.1093/emboj/19.3.410; Stutz F, 2000, RNA, V6, P638, DOI 10.1017/S1355838200000078; Tan W, 2000, RNA, V6, P1762, DOI 10.1017/S1355838200000832; Tseng SSL, 1998, EMBO J, V17, P2651, DOI 10.1093/emboj/17.9.2651; Vasu SK, 2001, CURR OPIN CELL BIOL, V13, P363, DOI 10.1016/S0955-0674(00)00221-0; Virbasius CMA, 1999, MOL CELL, V4, P219, DOI 10.1016/S1097-2765(00)80369-X; Warner JR, 2001, CELL, V107, P133, DOI 10.1016/S0092-8674(01)00531-1; Watkins JL, 1998, P NATL ACAD SCI USA, V95, P6779, DOI 10.1073/pnas.95.12.6779; Yang J, 2001, MOL CELL, V8, P397, DOI 10.1016/S1097-2765(01)00303-3; Yoon JH, 2000, MOL CELL BIOL, V20, P8767, DOI 10.1128/MCB.20.23.8767-8782.2000; York JD, 1999, SCIENCE, V285, P96, DOI 10.1126/science.285.5424.96; Yun CY, 2000, J CELL BIOL, V150, P707, DOI 10.1083/jcb.150.4.707; Zenklusen D, 2001, MOL CELL BIOL, V21, P4219, DOI 10.1128/MCB.21.13.4219-4232.2001; Zhang M, 2001, GENE DEV, V15, P30, DOI 10.1101/gad.851701; Zhou ZL, 2000, NATURE, V407, P401, DOI 10.1038/35030160	93	316	327	0	21	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 22	2002	108	4					523	531		10.1016/S0092-8674(02)00627-X	http://dx.doi.org/10.1016/S0092-8674(02)00627-X			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	524XW	11909523	Bronze			2022-12-28	WOS:000174039000010
J	Breman, JG; Henderson, DA				Breman, JG; Henderson, DA			Current concepts - Diagnosis and management of smallpox	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							VIRUS EXCRETION; MONKEYPOX VIRUS; INFECTION; COMPLICATIONS; VACCINATION; RESPONSES; CIDOFOVIR; VACCINIA; MICE; PCR		NIH, Fogarty Int Ctr, Bethesda, MD 20892 USA; Johns Hopkins Univ, Baltimore, MD USA	National Institutes of Health (NIH) - USA; NIH Fogarty International Center (FIC); Johns Hopkins University	Breman, JG (corresponding author), NIH, Fogarty Int Ctr, 16 Ctr Dr,MSC 6705,Bldg 16,Rm 214, Bethesda, MD 20892 USA.	jbreman@nih.gov						Alibek K, 1999, BIOHAZARD CHILLING T; [Anonymous], 2001, MMWR Recomm Rep, V50, P1; BEDSON HS, 1963, J PATHOL BACTERIOL, V85, P1, DOI 10.1002/path.1700850102; Bray M, 2000, J INFECT DIS, V181, P10, DOI 10.1086/315190; Breman JG, 2000, EMERGING INFECTIONS 4, P45; BREMAN JG, 1980, NEW ENGL J MED, V303, P1263, DOI 10.1056/NEJM198011273032204; BULLER RML, 1991, MICROBIOL REV, V55, P80, DOI 10.1128/MMBR.55.1.80-122.1991; Centers for Disease Control and Prevention, 2001, INT SMALLP RESP PLAN; DIXON C.W, 1962, SMALLPOX; Esposito Joseph J., 1995, P1131; FENNER F, 1996, VIROLOGY, V2, P2673; Franz DR, 1997, JAMA-J AM MED ASSOC, V278, P399, DOI 10.1001/jama.278.5.399; Frey SE, 2002, NEW ENGL J MED, V346, P1265, DOI 10.1056/NEJMoa020534; Frey SE, 2002, NEW ENGL J MED, V346, P1275, DOI 10.1056/NEJMoa013431; HARPER GJ, 1961, J HYG-CAMBRIDGE, V59, P479, DOI 10.1017/S0022172400039176; HEINER GG, 1971, AM J EPIDEMIOL, V94, P252, DOI 10.1093/oxfordjournals.aje.a121319; Henderson DA, 1999, SCIENCE, V283, P1279, DOI 10.1126/science.283.5406.1279; Henderson DA, 1999, JAMA-J AM MED ASSOC, V281, P2127, DOI 10.1001/jama.281.22.2127; HENDERSON DA, 1999, VACCINES, P74; HUQ F, 1976, B WORLD HEALTH ORGAN, V54, P710; Ibrahim MS, 1997, MOL CELL PROBE, V11, P143, DOI 10.1006/mcpr.1996.0093; Institute of Medicine, 1999, ASS FUT SCI NEED LIV; JEZEK Z, 1988, ACTA TROP, V45, P297; Jezek Z, 1988, HUMAN MONKEYPOX; Jezek Z., 1988, MONOGRAPHS VIROLOGY, V17; KNIGHT JC, 1995, PCR PROTOCOLS DIAGNO, P297; Lalezari JP, 1997, ANN INTERN MED, V126, P257, DOI 10.7326/0003-4819-126-4-199702150-00001; LANE JM, 1970, J INFECT DIS, V122, P303, DOI 10.1093/infdis/122.4.303; LANE JM, 1969, NEW ENGL J MED, V281, P1201, DOI 10.1056/NEJM196911272812201; MACK TM, 1972, AM J EPIDEMIOL, V95, P169, DOI 10.1093/oxfordjournals.aje.a121382; MARSDEN JP, 1948, B HYG, V23, P735; Meltzer MI, 2001, EMERG INFECT DIS, V7, P959, DOI 10.3201/eid0706.010607; Moss B., 1996, FIELDS VIROLOGY, P2637; Nakano JH, 1989, DIAGNOSTIC PROCEDURE, P453; Neubauer H, 1998, J VIROL METHODS, V74, P201, DOI 10.1016/S0166-0934(98)00099-8; O'Toole T, 1999, EMERG INFECT DIS, V5, P540, DOI 10.3201/eid0504.990416; Rao AR, 1972, SMALLPOX; REDFIELD RR, 1987, NEW ENGL J MED, V316, P673, DOI 10.1056/NEJM198703123161106; ROBERTS JA, 1962, BRIT J EXP PATHOL, V43, P451; ROPP SL, 1995, J CLIN MICROBIOL, V33, P2069, DOI 10.1128/JCM.33.8.2069-2076.1995; Rosenthal SR, 2001, EMERG INFECT DIS, V7, P920, DOI 10.3201/eid0706.010602; SARKAR JK, 1973, B WORLD HEALTH ORGAN, V48, P523; SARKAR JK, 1973, B WORLD HEALTH ORGAN, V48, P517; SHCHELKUNOV SN, 1995, VIRUS RES, V36, P107, DOI 10.1016/0168-1702(94)00113-Q; SIMPSON REH, 1952, LANCET, V263, P549; Smee DF, 2001, ANTIVIR CHEM CHEMOTH, V12, P71, DOI 10.1177/095632020101200105; STRANO AJ, 1976, PATHOLOGY TROPICAL E, V1, P65; WEHRLE PF, 1970, B WORLD HEALTH ORGAN, V43, P669; Zaucha GM, 2001, LAB INVEST, V81, P1581, DOI 10.1038/labinvest.3780373	49	245	259	2	27	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 25	2002	346	17					1300	1308		10.1056/NEJMra020025	http://dx.doi.org/10.1056/NEJMra020025			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	544GX	11923491				2022-12-28	WOS:000175150800008
J	Brennan, TA				Brennan, TA			Luxury primary care - Market innovation or threat to access?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							HEALTH; CAPITATION; JUSTICE		Brigham & Womens Hosp, Clin PBB 3, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital	Brennan, TA (corresponding author), Brigham & Womens Hosp, Clin PBB 3, 75 Francis St, Boston, MA 02115 USA.							BELLUCK P, 2002, NY TIMES        1204, pA1; Brennan T, 2002, LANCET, V359, P520, DOI 10.1016/s0140-6736(02)07684-5; BRENNAN TA, 1988, DUKE LAW J, V1, P29; BRENNAN TA, 1991, JUST DOCTORING MED E; COLBY DC, 1995, J HEALTH POLIT POLIC, V20, P49, DOI 10.1215/03616878-20-1-49; Daniels N, 1999, DAEDALUS, V128, P215; Emanuel EJ, 2000, HASTINGS CENT REP, V30, P8, DOI 10.2307/3528040; Fairchild DG, 2000, ACAD MED, V75, P980, DOI 10.1097/00001888-200010000-00009; Federman AD, 2001, J GEN INTERN MED, V16, P668, DOI 10.1046/j.1525-1497.2001.01028.x; Gandhi TK, 2000, J GEN INTERN MED, V15, P149, DOI 10.1046/j.1525-1497.2000.04199.x; Haas JS, 2000, J GEN INTERN MED, V15, P122, DOI 10.1046/j.1525-1497.2000.02219.x; Hall M A, 1997, Georgia Law Rev, V31, P511; HAVIGHURST C, 1999, HLTH LAW POLICY; HAVIGHURST CC, 1986, J HEALTH POLIT POLIC, V11, P697, DOI 10.1215/03616878-11-4-697; HAVIGHURST CC, 1995, HLTH CARE CHOICES PR; JACKSON C, 2001, AM MED NEWS     0917; MANGO PD, 2002, MCKINSEY Q, V2, P4; Mechanic D, 2001, NEW ENGL J MED, V344, P198, DOI 10.1056/NEJM200101183440307; MOREIM EH, 2001, HOLDING HLTH CARE AC; Pearson SD, 1998, NEW ENGL J MED, V339, P689, DOI 10.1056/NEJM199809033391009; Sussman AJ, 2001, ACAD MED, V76, P693, DOI 10.1097/00001888-200107000-00009; 2002, BOSTON GLOBE    0108, pD8	22	34	34	0	2	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 11	2002	346	15					1165	1168		10.1056/NEJM200204113461513	http://dx.doi.org/10.1056/NEJM200204113461513			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	539PX	11948279				2022-12-28	WOS:000174880600012
J	Rosenberg, IH				Rosenberg, IH			Perspective: Fish - Food to calm the heart.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Tufts Univ, Friedman Sch Nutr Sci & Policy, Boston, MA 02111 USA	Tufts University	Rosenberg, IH (corresponding author), Tufts Univ, Friedman Sch Nutr Sci & Policy, Boston, MA 02111 USA.								0	26	36	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 11	2002	346	15					1102	1103		10.1056/NEJM200204113461502	http://dx.doi.org/10.1056/NEJM200204113461502			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	539PX	11948268				2022-12-28	WOS:000174880600001
J	Hozumi, T; Eisenberg, M; Sugioka, K; Kokkirala, AR; Watanabe, H; Teragaki, M; Yoshikawa, J; Homma, S				Hozumi, T; Eisenberg, M; Sugioka, K; Kokkirala, AR; Watanabe, H; Teragaki, M; Yoshikawa, J; Homma, S			Change in coronary flow reserve on transthoracic Doppler echocardiography after a single high-fat meal in young healthy men	ANNALS OF INTERNAL MEDICINE			English	Article							ARTERY-DISEASE; NONINVASIVE ASSESSMENT; ENDOTHELIAL FUNCTION; VASODILATOR RESERVE; VELOCITY RESERVE; HEART-DISEASE; BLOOD-FLOW; METABOLISM	Background: High-fat meals and elevated triglyceride levels are associated with cardiovascular disease. In recent studies of brachial artery vasoactivity, a single high-fat meal reduced endothelial function in young healthy men. It is unknown whether coronary microcirculation is affected after high-fat meals. Objective: To evaluate change in coronary flow reserve after a single high-fat meal. Design: Controlled interventional study. Setting: University hospitals. Patients: 15 young healthy men (mean age [+/-SD], 29 +/- 4 years). Intervention: Coronary flow reserve was determined by using transthoracic Doppler echocardiography before and after consumption of a high-fat meal in all 15 men and before and after consumption of a low-fat meal in 5 of 15 men. Measurements: coronary flow reserve, lipid levels, and hemodynamic characteristics. Results: in all men, triglycerlde levels increased significantly from baseline 5 hours after the high-fat meal, from 1.1 mmol/L to 2.8 mmol/L (100 mg/dL to 250 mg/dL (P < 0.001). Average coronary flow reserve was 4.02 before and 3.30 5 hours after the high-fat meal (decrease, 18% [95% Cl, 13% to 23%]). In the 5 men who received both meals, mean coronary flow reserve decreased by 0.79 after the high-fat meal and increased by 0.07 after the low-fat meal (difference, -0.86 [Cl, -1.36 to -0.37); P = 0.03). Mean triglyceride levels increased by 1.6 mmol/L (140 mg/dL after the high-fat meal and 0.1 mmol/L (10 mg/dL after the low-fat meal (difference, 1.5 mmol/L (C], 0.3 to 2.7 mmol/L], 130 mg/dL [Cl, 23 to 236 mg/dL]; P = 0.03). Conclusions: Coronary flow reserve decreased after a single high-fat meal in young healthy men. High-fat meals may be detrimental to coronary microcirculation.	Osaka City Univ, Sch Med, Dept Internal Med 1, Abeno Ku, Osaka 5458585, Japan; Columbia Univ, New York, NY USA	Osaka Metropolitan University; Columbia University	Hozumi, T (corresponding author), Osaka City Univ, Sch Med, Dept Internal Med 1, Abeno Ku, 1-4-3 Asahi Machi, Osaka 5458585, Japan.	thozumi@med.osaka-u.cu.ac.jp			NCRR NIH HHS [RR-00645] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000645] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Akasaka T, 1997, J AM COLL CARDIOL, V30, P935, DOI 10.1016/S0735-1097(97)00242-8; Fard A, 2000, ARTERIOSCL THROM VAS, V20, P2039, DOI 10.1161/01.ATV.20.9.2039; GROOT PHE, 1991, ARTERIOSCLER THROMB, V11, P653, DOI 10.1161/01.ATV.11.3.653; HOFFMAN JIE, 1984, CIRCULATION, V70, P153, DOI 10.1161/01.CIR.70.2.153; Hozumi T, 1998, CIRCULATION, V97, P1557, DOI 10.1161/01.CIR.97.16.1557; Hozumi T, 1998, J AM COLL CARDIOL, V32, P1251, DOI 10.1016/S0735-1097(98)00389-1; KERN MJ, 1991, J AM COLL CARDIOL, V18, P718, DOI 10.1016/0735-1097(91)90795-B; KLOCKE FJ, 1987, CIRCULATION, V76, P1183, DOI 10.1161/01.CIR.76.6.1183; Lundman P, 1997, CIRCULATION, V96, P3266; MARCUS M, 1981, CIRC RES, V49, P877, DOI 10.1161/01.RES.49.4.877; MARCUS ML, 1987, CIRCULATION, V76, P245, DOI 10.1161/01.CIR.76.2.245; MILLER DD, 1994, CIRCULATION, V89, P2150, DOI 10.1161/01.CIR.89.5.2150; PATSCH JR, 1992, ARTERIOSCLER THROMB, V12, P1336, DOI 10.1161/01.ATV.12.11.1336; Plotnick GD, 1997, JAMA-J AM MED ASSOC, V278, P1682, DOI 10.1001/jama.278.20.1682; SHEKELLE RB, 1981, NEW ENGL J MED, V304, P65, DOI 10.1056/NEJM198101083040201; Vogel RA, 1997, AM J CARDIOL, V79, P350, DOI 10.1016/S0002-9149(96)00760-6; WILSON RF, 1985, CIRCULATION, V72, P82, DOI 10.1161/01.CIR.72.1.82	17	34	35	1	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 2	2002	136	7					523	528		10.7326/0003-4819-136-7-200204020-00009	http://dx.doi.org/10.7326/0003-4819-136-7-200204020-00009			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	536CA	11926787				2022-12-28	WOS:000174682100004
J	Gross, C; Zhuang, XX; Stark, K; Ramboz, S; Oosting, R; Kirby, L; Santarelli, L; Beck, S; Hen, R				Gross, C; Zhuang, XX; Stark, K; Ramboz, S; Oosting, R; Kirby, L; Santarelli, L; Beck, S; Hen, R			Serotonin(1A) receptor acts during development to establish normal anxiety-like behaviour in the adult	NATURE			English	Article							MONOAMINE-OXIDASE; MICE; EXPRESSION; RAT; BINDING; DEPLETION; MEDIATE; MODELS; EXCESS	Serotonin is implicated in mood regulation, and drugs acting via the serotonergic system are effective in treating anxiety and depression. Specifically, agonists of the serotonin(1A) receptor have anxiolytic properties, and knockout mice lacking this receptor show increased anxiety-like behaviour. Here we use a tissue-specific, conditional rescue strategy to show that expression of the serotonin(1A) receptor primarily in the hippocampus and cortex, but not in the raphe nuclei, is sufficient to rescue the behavioural phenotype of the knockout mice. Furthermore, using the conditional nature of these transgenic mice, we suggest that receptor expression during the early postnatal period, but not in the adult, is necessary for this behavioural rescue. These findings show that postnatal developmental processes help to establish adult anxiety-like behaviour. In addition, the normal role of the serotonin(1A) receptor during development may be different from its function when this receptor is activated by therapeutic intervention in adulthood.	Columbia Univ, Ctr Neurobiol & Behav, New York, NY 10032 USA; Childrens Hosp Philadelphia, Dept Pediat, Philadelphia, PA 19104 USA	Columbia University; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Hen, R (corresponding author), Columbia Univ, Ctr Neurobiol & Behav, New York, NY 10032 USA.	rh95@columbia.edu			NIMH NIH HHS [R21 MH099488, P01 MH048125, RC1 MH089800] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P01MH048125, R21MH099488, RC1MH089800] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Bayer KU, 1999, MOL BRAIN RES, V70, P147, DOI 10.1016/S0169-328X(99)00131-X; Caldji C, 1998, P NATL ACAD SCI USA, V95, P5335, DOI 10.1073/pnas.95.9.5335; Cao BJ, 1997, PHARMACOL BIOCHEM BE, V58, P593, DOI 10.1016/S0091-3057(97)00279-7; Cases O, 1996, NEURON, V16, P297, DOI 10.1016/S0896-6273(00)80048-3; Coplan JD, 1995, PSYCHIAT CLIN N AM, V18, P727, DOI 10.1016/S0193-953X(18)30020-0; Durig J, 2000, NEUROREPORT, V11, P833, DOI 10.1097/00001756-200003200-00035; FEIGHNER JP, 1989, PSYCHOPATHOLOGY, V22, P21, DOI 10.1159/000284623; Fletcher A, 1996, BEHAV BRAIN RES, V73, P337; Gross C, 2000, BIOL PSYCHIAT, V48, P1157, DOI 10.1016/S0006-3223(00)01041-6; Haring JH, 1999, DEV BRAIN RES, V114, P269, DOI 10.1016/S0165-3806(99)00032-2; Heisler LK, 1998, P NATL ACAD SCI USA, V95, P15049, DOI 10.1073/pnas.95.25.15049; HOHMANN CF, 1988, DEV BRAIN RES, V43, P163, DOI 10.1016/0165-3806(88)90163-0; KENDLER KS, 1992, ARCH GEN PSYCHIAT, V49, P109; Kistner A, 1996, P NATL ACAD SCI USA, V93, P10933, DOI 10.1073/pnas.93.20.10933; KUNG MP, 1995, J PHARMACOL EXP THER, V272, P429; LIDOV HGW, 1982, BRAIN RES BULL, V8, P389, DOI 10.1016/0361-9230(82)90077-6; Luscher C, 1997, NEURON, V19, P687, DOI 10.1016/S0896-6273(00)80381-5; MARTIN KF, 1992, BRIT J PHARMACOL, V107, P15, DOI 10.1111/j.1476-5381.1992.tb14457.x; Mayford M, 1996, SCIENCE, V274, P1678, DOI 10.1126/science.274.5293.1678; Menard J, 1999, NEUROSCI BIOBEHAV R, V23, P591, DOI 10.1016/S0149-7634(98)00056-6; MITCHELL JB, 1990, DEV BRAIN RES, V55, P231, DOI 10.1016/0165-3806(90)90204-C; Parks CL, 1998, P NATL ACAD SCI USA, V95, P10734, DOI 10.1073/pnas.95.18.10734; Ramboz S, 1998, P NATL ACAD SCI USA, V95, P14476, DOI 10.1073/pnas.95.24.14476; Sibille E, 2000, J NEUROSCI, V20, P2758; TWEED JL, 1989, BRIT J PSYCHIAT, V154, P823, DOI 10.1192/bjp.154.6.823; Upton AL, 1999, J NEUROSCI, V19, P7007, DOI 10.1523/JNEUROSCI.19-16-07007.1999; Yan W, 1997, DEV BRAIN RES, V98, P185, DOI 10.1016/S0165-3806(96)00175-7; Yan W, 1997, DEV BRAIN RES, V98, P177, DOI 10.1016/S0165-3806(96)00176-9	28	697	720	0	44	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 28	2002	416	6879					396	400		10.1038/416396a	http://dx.doi.org/10.1038/416396a			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	534UX	11919622				2022-12-28	WOS:000174607800037
J	Wernsdorfer, W; Aliaga-Alcalde, N; Hendrickson, DN; Christou, G				Wernsdorfer, W; Aliaga-Alcalde, N; Hendrickson, DN; Christou, G			Exchange-biased quantum tunnelling in a supramolecular dimer of single-molecule magnets	NATURE			English	Article							HIGH-SPIN MOLECULES; HYDROGEN-BONDS; MAGNETIZATION; COMPLEXES; PROTEINS; FERRITIN; GOLD(I); CLUSTER	Various present and future specialized applications of magnets require monodisperse, small magnetic particles, and the discovery of molecules that can function as nanoscale magnets was an important development in this regard(1-3). These molecules act as single-domain magnetic particles that, below their blocking temperature, exhibit magnetization hysteresis, a classical property of macroscopic magnets. Such 'single-molecule magnets' (SMMs)(4) straddle the interface between classical and quantum mechanical behaviour because they also display quantum tunnelling of magnetization(5,6) and quantum phase interference(7). Quantum tunnelling of magnetization can be advantageous for some potential applications of SMMs, for example, in providing the quantum superposition of states required for quantum computing(8). However, it is a disadvantage in other applications, such as information storage, where it would lead to information loss. Thus it is important to both understand and control the quantum properties of SMMs. Here we report a supramolecular SMM dimer in which antiferromagnetic coupling between the two components results in quantum behaviour different from that of the individual SMMs. Our experimental observations and theoretical analysis suggest a means of tuning the quantum tunnelling of magnetization in SMMs. This system may also prove useful for studying quantum tunnelling of relevance to mesoscopic antiferromagnets.	Univ Florida, Dept Chem, Gainesville, FL 32611 USA; Lab Louis Neel, CNRS, F-38042 Grenoble, France; Univ Calif San Diego, Dept Chem, La Jolla, CA 92093 USA	State University System of Florida; University of Florida; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); University of California System; University of California San Diego	Christou, G (corresponding author), Univ Florida, Dept Chem, Gainesville, FL 32611 USA.	christou@chem.ufl.edu	Aliaga-Alcalde, Núria/ABI-6678-2020; Aliaga-Alcalde, Núria/H-5886-2011; Wernsdorfer, Wolfgang/M-2280-2016; Christou, George/A-3072-2014	Aliaga-Alcalde, Núria/0000-0003-1080-3862; Aliaga-Alcalde, Núria/0000-0003-1080-3862; Wernsdorfer, Wolfgang/0000-0003-4602-5257; 				Andres H, 2000, J AM CHEM SOC, V122, P12469, DOI 10.1021/ja0009424; Aubin SMJ, 1998, CHEM COMMUN, P803, DOI 10.1039/a800586i; Aubin SMJ, 1998, J AM CHEM SOC, V120, P839, DOI 10.1021/ja973384a; Aubin SMJ, 1998, J AM CHEM SOC, V120, P4991, DOI 10.1021/ja974241r; Aubin SMJ, 1996, J AM CHEM SOC, V118, P7746, DOI 10.1021/ja960970f; Aullon G, 1998, CHEM COMMUN, P653, DOI 10.1039/a709014e; AWSCHALOM DD, 1992, PHYS REV LETT, V68, P3092, DOI 10.1103/PhysRevLett.68.3092; BARBARA B, 1990, PHYS LETT A, V145, P205, DOI 10.1016/0375-9601(90)90682-E; Boskovic C, 2001, J AM CHEM SOC, V123, P9914, DOI 10.1021/ja016341+; Carlin R. L., 1986, MAGNETOCHEMISTRY; Christou G, 2000, MRS BULL, V25, P66, DOI 10.1557/mrs2000.226; Desiraju G. R., 1989, CRYSTAL ENG DESIGN O; Desiraju GR, 1996, ACCOUNTS CHEM RES, V29, P441, DOI 10.1021/ar950135n; Freytag M, 2000, CHEM COMMUN, P277, DOI 10.1039/a907523b; Friedman JR, 1996, PHYS REV LETT, V76, P3830, DOI 10.1103/PhysRevLett.76.3830; GIDER S, 1995, SCIENCE, V268, P77, DOI 10.1126/science.7701343; HENDRICKSON DN, 1992, J AM CHEM SOC, V114, P2455, DOI 10.1021/ja00033a022; Jeffrey G.A., 2012, HYDROGEN BONDING BIO; Jones PG, 1998, CHEM COMMUN, P2307, DOI 10.1039/a803905d; Leuenberger MN, 2001, NATURE, V410, P789, DOI 10.1038/35071024; Raymo FM, 2001, J AM CHEM SOC, V123, P9264, DOI 10.1021/ja010443i; Sangregorio C, 1997, PHYS REV LETT, V78, P4645, DOI 10.1103/PhysRevLett.78.4645; SESSOLI R, 1993, NATURE, V365, P141, DOI 10.1038/365141a0; SESSOLI R, 1993, J AM CHEM SOC, V115, P1804, DOI 10.1021/ja00058a027; Tejada J, 1996, SCIENCE, V272, P424; Thomas L, 1996, NATURE, V383, P145, DOI 10.1038/383145a0; WEMPLE MW, 1993, INORG CHEM, V32, P2025, DOI 10.1021/ic00062a026; Wernsdorfer W, 1999, SCIENCE, V284, P133, DOI 10.1126/science.284.5411.133; Wernsdorfer W, 2001, ADV CHEM PHYS, V118, P99, DOI 10.1002/9780470141786.ch3; Xu CF, 1996, ORGANOMETALLICS, V15, P3972, DOI 10.1021/om960355k	30	867	875	11	292	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 28	2002	416	6879					406	409		10.1038/416406a	http://dx.doi.org/10.1038/416406a			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	534UX	11919625				2022-12-28	WOS:000174607800040
J	Wiesen, AR; Littell, CT				Wiesen, AR; Littell, CT			Relationship between prepregnancy anthrax vaccination and pregnancy and birth outcomes among US army women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BIOLOGICAL WARFARE; HEALTH; SAFETY	Context Substantial concern surrounds the potential health effects of the anthrax vaccine, particularly the-potential adverse effects on reproductive processes. Objective To determine whether receipt of anthrax vaccination by reproductive-aged women has an effect on pregnancy rates. Design, Setting, and Patients Cohort study, based on information from a computer database, of women aged 17 to 44 years who were stationed at Fort Stewart, Ga, or Hunter Army Airfield, Ga, from January 1999 through March 2000. Main Outcome Measures Pregnancy and birth rates and adverse birth outcomes. Results Of a total of 4092 women, 3136 received at least 1 dose of the anthrax vaccine. There was a total of 513 pregnancies, with 385 following at least 1 dose of anthrax vaccine. The pregnancy rate ratio (before and after adjustment for marital status, race, and age) comparing vaccinated with unvaccinated women was 0.94 (95% confidence interval [CI], 0.8-1.2; P=.60). There were 353 live births and 25 pregnancies lost to follow-up. The birth odds ratio after anthrax vaccination (before and after adjustment for marital status and age) was 0.9 (95% CI, 0.5-1.4; P=.55). After adjusting for age, the odds ratio for adverse birth outcome after receiving at least 1 dose of anthrax vaccination was 0.9 (95% CI, 0.4-2.4; P=.88). However, this study did not have sufficient power to detect adverse birth outcomes. Conclusion Anthrax vaccination had no effect on pregnancy and birth rates or adverse birth outcomes.	Madigan Army Med Ctr, Dept Prevent Med, MCHJ PV, Tacoma, WA 98431 USA	Madigan Army Medical Center	Wiesen, AR (corresponding author), Madigan Army Med Ctr, Dept Prevent Med, MCHJ PV, Tacoma, WA 98431 USA.	andrew.wiesen@amedd.army.mil						*ADV COMM IMM PRAC, 1994, MMWR-MORBID MORTAL W, V43, P20; American College of obstetricians and gynecologists, 1993, INT J GYNECOL OBSTET, V40, P69; [Anonymous], 2000, MMWR Recomm Rep, V49, P1; Biological products, 1985, FED REGISTER, V50, P51002; BRACHMAN PS, 1962, AM J PUBLIC HEALTH N, V52, P632, DOI 10.2105/AJPH.52.4.632; *CDCP, 2000, MMWR-MORBID MORTAL W, V49, P341; Chin J., 2000, CONTROL COMMUNICABLE, V17th, P20; Christopher GW, 1997, JAMA-J AM MED ASSOC, V278, P412, DOI 10.1001/jama.278.5.412; Demicheli V, 1998, VACCINE, V16, P880, DOI 10.1016/S0264-410X(98)00023-1; Dixon TC, 1999, NEW ENGL J MED, V341, P815, DOI 10.1056/NEJM199909093411107; Friedlander AM, 1999, JAMA-J AM MED ASSOC, V282, P2104, DOI 10.1001/jama.282.22.2104; GRABENSTEIN JD, 1999, HOSP PHARM, V34, P949; GRABENSTEIN JD, 1999, HOSP PHARM, V34, P959; GRABENSTEIN JD, 1999, HOSP PHARM, V34, P955; HOLMES LB, 1999, OSKIS PEDIAT PRINCIP, P136; Inglesby TV, 1999, JAMA-J AM MED ASSOC, V281, P1735, DOI 10.1001/jama.281.18.1735; MALDONADO G, 1993, AM J EPIDEMIOL, V138, P923, DOI 10.1093/oxfordjournals.aje.a116813; MARDEN PM, 1964, J PEDIATR-US, V64, P357, DOI 10.1016/S0022-3476(64)80188-8; Mazzuchi JF, 2000, AVIAT SPACE ENVIR MD, V71, P260; MCNEIL D, 1996, EPIDEMIOLOGICAL RES, P170; *MI BIOL PROD I, 1999, ANTHR VACC ADS PACK; Pile JC, 1998, ARCH INTERN MED, V158, P429, DOI 10.1001/archinte.158.5.429; Sohl B, 1998, AVERYS DIS NEWBORN, P90; Stoll B. J., 2000, NELSON TXB PEDIAT, P477; VENTURA SJ, 1996, MONTHLY VITAL STAT R, V44; Walker M, 1998, AVERYS DIS NEWBORN, P144; WHITE CS, 1974, ANN INTERN MED, V81, P594, DOI 10.7326/0003-4819-81-5-594; 1989, MODEL BUILDING STRAT, P82	28	33	37	1	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 27	2002	287	12					1556	1560		10.1001/jama.287.12.1556	http://dx.doi.org/10.1001/jama.287.12.1556			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	533VF	11911758				2022-12-28	WOS:000174550400027
J	Bienfang, DC; Karluk, D; Buchbinder, BR; Toker, DE; Durand, ML; Hedley-Whyte, ET; Scully, RE				Bienfang, DC; Karluk, D; Buchbinder, BR; Toker, DE; Durand, ML; Hedley-Whyte, ET; Scully, RE			An 80-year-old woman with sudden unilateral blindness - Mucormycosis, rhino-orbital.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							RHINOCEREBRAL MUCORMYCOSIS; DIALYSIS PATIENTS; DEFEROXAMINE; MANAGEMENT; INFECTION; SURVIVAL; THERAPY; IRON; RISK		Brigham & Womens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Bienfang, DC (corresponding author), Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.		Newman-Toker, David/C-6083-2008; Hedley-Whyte, E Tessa/AAJ-9975-2021	Newman-Toker, David/0000-0003-2789-4115; Hedley-Whyte, E Tessa/0000-0002-1687-8905				ABE F, 1990, MYCOPATHOLOGIA, V110, P87, DOI 10.1007/BF00446996; ABRAMSON E, 1967, ANN INTERN MED, V66, P735, DOI 10.7326/0003-4819-66-4-735; BACHOR R, 1986, MYCOSES, V29, P497; BOELAERT JR, 1987, ANN INTERN MED, V107, P782, DOI 10.7326/0003-4819-107-5-782_2; BRENNAN RO, 1983, AM J CLIN PATHOL, V80, P98, DOI 10.1093/ajcp/80.1.98; DOWNIE JA, 1993, J CLIN NEURO-OPHTHAL, V13, P27; FERRY AP, 1983, OPHTHALMOLOGY, V90, P1096, DOI 10.1016/S0161-6420(83)80052-9; GALETTA SL, 1990, ANN NEUROL, V28, P103, DOI 10.1002/ana.410280121; GOODILL JJ, 1987, NEW ENGL J MED, V317, P54; Johnson, 2000, OPHTHALMOL CLIN N AM, V13, DOI [10.1016/S0896-1549(05)70222-4, DOI 10.1016/S0896-1549(05)70222-4]; SLADE MP, 1991, AM J OPHTHALMOL, V112, P594, DOI 10.1016/S0002-9394(14)76864-3; VEIS JH, 1987, ANN INTERN MED, V107, P258, DOI 10.7326/0003-4819-107-2-258_1; VLASVELD LT, 1991, NEPHRON, V57, P487, DOI 10.1159/000186358; YOHAI RA, 1994, SURV OPHTHALMOL, V39, P3, DOI 10.1016/S0039-6257(05)80041-4	14	7	7	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 21	2002	346	12					924	929		10.1056/NEJMcpc020009	http://dx.doi.org/10.1056/NEJMcpc020009			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	532FR	11907293				2022-12-28	WOS:000174464100009
J	Lenders, JWM; Pacak, K; Walther, MM; Linehan, WM; Mannelli, M; Friberg, P; Keiser, HR; Goldstein, DS; Eisenhofer, G				Lenders, JWM; Pacak, K; Walther, MM; Linehan, WM; Mannelli, M; Friberg, P; Keiser, HR; Goldstein, DS; Eisenhofer, G			Biochemical diagnosis of pheochromocytoma - Which test is best?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LIQUID-CHROMATOGRAPHY; PLASMA METANEPHRINES; ELECTROCHEMICAL DETECTION; URINARY CATECHOLAMINES; METABOLISM; 3,4-DIHYDROXYPHENYLGLYCOL; NOREPINEPHRINE; CURVES	Context Diagnosis of pheochromocytoma depends on biochemical evidence of catecholamine production by the tumor. However, the best test to establish the diagnosis has not been determined. Objective To determine the biochemical test or combination of tests that provides the best method for diagnosis of pheochromocytoma. Design, Setting, and Participants Multicenter cohort study of patients tested for pheochromocytoma at 4 referral centers between 1994 and 2001. The analysis included 214 patients in whom the diagnosis of pheochromocytoma was confirmed and 644 patients who were determined to not have the tumor, Main Outcome Measures Test sensitivity and specificity, receiver operating characteristic curves, and positive and negative predictive values at different pretest prevalences using plasma free metanephrines, plasma catecholamines, urinary catecholamines, urinary total and fractionated metanephrines, and urinary vanillylmandelic acid. Results Sensitivities of plasma free metanephrines (99% [95% confidence interval {CI}, 96%-100%]) and urinary fractionated metanephrines (97% [95% CI 92%-99%]) were higher than those for plasma catecholamines (84% [95% CI, 78%-89%]), urinary catecholamines (86% [95% CI, 80%-91%]), urinary total metanephrines (77% [95% CI, 68%-85%]), and urinary vanillylmandelic acid (64% [95% CI, 55%-71%]). Specificity was highest for urinary vanillylmandelic acid (95% [95% CI, 93%-97%]) and urinary total metanephrines (93% [95% CI, 89%-97%]); intermediate for plasma free metanephrines (89% [95% CI, 87%-92%]), urinary catecholamines (88% [95% CI, 85%-91%]), and plasma catecholamines (81% [95% CI, 78%-84%]); and lowest for urinary fractionated metanephrines (69% [95% CI, 64%-72%]). Sensitivity and specificity values at different upper reference limits were highest for plasma free metanephrines using receiver operating characteristic curves. Combining different tests did not improve the diagnostic yield beyond that of a single test of plasma free metanephrines. Conclusion Plasma free metanephrines provide the best test for excluding or confirming pheochromocytoma and should be the test of first choice for diagnosis of the tumor.	St Radboud Univ, Dept Internal Med, Med Ctr, NL-6500 HB Nijmegen, Netherlands; Univ Florence, Dept Clin Pathophysiol, Florence, Italy; Sahlgrens Univ Hosp, Dept Clin Physiol, S-41345 Gothenburg, Sweden; NICHHD, Pediat & Reprod Endocrinol Branch, NIH, Bethesda, MD 20892 USA; NCI, Urol Oncol Branch, NIH, Bethesda, MD 20892 USA; NHLBI, Hypertens Endocrine Branch, NIH, Bethesda, MD 20892 USA; NINCDS, Clin Neuroendocrinol Sect, NIH, Bethesda, MD 20892 USA	Radboud University Nijmegen; University of Florence; Sahlgrenska University Hospital; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Lenders, JWM (corresponding author), St Radboud Univ, Dept Internal Med, Med Ctr, Geert Grooteplein Zuid 8,POB 9101, NL-6500 HB Nijmegen, Netherlands.		Lenders, J.W.M./L-4487-2015; Eisenhofer, Graeme/AAU-9829-2021	Lenders, J.W.M./0000-0002-7658-4466; Eisenhofer, Graeme/0000-0002-8601-9903; Mannelli, Massimo/0000-0002-8001-9857	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS002979] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BECK JR, 1986, ARCH PATHOL LAB MED, V110, P13; BRAVO EL, 1979, NEW ENGL J MED, V301, P682, DOI 10.1056/NEJM197909273011302; BRAVO EL, 1981, NEW ENGL J MED, V305, P623, DOI 10.1056/NEJM198109103051107; BRAVO EL, 1994, ENDOCR REV, V15, P356, DOI 10.1210/er.15.3.356; DUNCAN MW, 1988, NEW ENGL J MED, V319, P136, DOI 10.1056/NEJM198807213190303; EISENHOFER G, 1995, CLIN SCI, V88, P533, DOI 10.1042/cs0880533; EISENHOFER G, 1995, J CLIN ENDOCR METAB, V80, P3009, DOI 10.1210/jc.80.10.3009; Eisenhofer G, 1999, NEW ENGL J MED, V340, P1872, DOI 10.1056/NEJM199906173402404; Eisenhofer G, 1998, J CLIN ENDOCR METAB, V83, P2175, DOI 10.1210/jc.83.6.2175; EISENHOFER G, 1986, CLIN CHEM, V32, P2030; Eisenhofer G, 2001, Rev Endocr Metab Disord, V2, P297, DOI 10.1023/A:1011572617314; Eisenhofer G, 2001, CLIN CHEM, V47, P988; Eisenhofer G, 1996, J NEUROCHEM, V66, P1565; Gardet V, 2001, J HYPERTENS, V19, P1029, DOI 10.1097/00004872-200106000-00006; GERLO EAM, 1994, CLIN CHEM, V40, P250; GOLDSTEIN DS, 1984, J CHROMATOGR, V311, P148, DOI 10.1016/S0378-4347(00)84701-5; GROSSMAN E, 1991, HYPERTENSION, V17, P733, DOI 10.1161/01.HYP.17.6.733; HANLEY JA, 1983, RADIOLOGY, V148, P839, DOI 10.1148/radiology.148.3.6878708; Hernandez FC, 2000, CLIN BIOCHEM, V33, P649; Heron E, 1996, ANN INTERN MED, V125, P300, DOI 10.7326/0003-4819-125-4-199608150-00008; LENDERS JWM, 1995, ANN INTERN MED, V123, P101, DOI 10.7326/0003-4819-123-2-199507150-00004; LENDERS JWM, 1993, CLIN CHEM, V39, P97; MANGER WM, 1993, CLEV CLIN J MED, V60, P365; MANNELLI M, 1989, J ENDOCRINOL INVEST, V12, P739, DOI 10.1007/BF03350050; Mannelli M, 1999, EUR J ENDOCRINOL, V141, P619, DOI 10.1530/eje.0.1410619; MOYER TP, 1979, CLIN CHEM, V25, P256; Pacak K, 2001, ANN INTERN MED, V134, P315, DOI 10.7326/0003-4819-134-4-200102200-00016; PAUKER SG, 1992, NEW ENGL J MED, V327, P1009, DOI 10.1056/NEJM199210013271407; PEASTON RT, 1993, J CLIN PATHOL, V46, P734, DOI 10.1136/jcp.46.8.734; PISANO JJ, 1962, CLIN CHIM ACTA, V7, P285, DOI 10.1016/0009-8981(62)90022-0; PISANO JJ, 1960, CLIN CHIM ACTA, V5, P406; Raber W, 2000, ARCH INTERN MED, V160, P2957, DOI 10.1001/archinte.160.19.2957; VANDERHOORN FAJ, 1989, J CHROMATOGR-BIOMED, V487, P17, DOI 10.1016/S0378-4347(00)83003-0; Walther MM, 1999, J UROLOGY, V162, P659, DOI 10.1097/00005392-199909010-00004; Witteles RM, 2000, ARCH INTERN MED, V160, P2521, DOI 10.1001/archinte.160.16.2521; YOUNG MJ, 1989, J GEN INTERN MED, V4, P273, DOI 10.1007/BF02597394	36	761	821	0	43	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 20	2002	287	11					1427	1434		10.1001/jama.287.11.1427	http://dx.doi.org/10.1001/jama.287.11.1427			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	532GB	11903030				2022-12-28	WOS:000174465000025
J	Nishimura, M; Somerville, S				Nishimura, M; Somerville, S			Plant biology - Resisting attack	SCIENCE			English	Editorial Material							DISEASE RESISTANCE; ARABIDOPSIS; GENE		Carnegie Inst Washington, Dept Plant Biol, Stanford, CA 94305 USA	Carnegie Institution for Science	Nishimura, M (corresponding author), Carnegie Inst Washington, Dept Plant Biol, 290 Panama St, Stanford, CA 94305 USA.			Nishimura, Marc Tad/0000-0003-4666-6900				Austin MJ, 2002, SCIENCE, V295, P2077, DOI 10.1126/science.1067747; Azevedo C, 2002, SCIENCE, V295, P2073, DOI 10.1126/science.1067554; BOWLING SA, 1994, PLANT CELL, V6, P1845, DOI 10.1105/tpc.6.12.1845; Bowling SA, 1997, PLANT CELL, V9, P1573, DOI 10.1105/tpc.9.9.1573; BOYLES DC, 1998, P NATL ACAD SCI USA, V95, P15849; DIETRICH RA, 1994, CELL, V77, P565, DOI 10.1016/0092-8674(94)90218-6; Dietrich RA, 1997, CELL, V88, P685, DOI 10.1016/S0092-8674(00)81911-X; Frye CA, 2001, P NATL ACAD SCI USA, V98, P373, DOI 10.1073/pnas.011405198; Glazebrook J, 2001, CURR OPIN PLANT BIOL, V4, P301, DOI 10.1016/S1369-5266(00)00177-1; Gray WM, 2001, NATURE, V414, P271, DOI 10.1038/35104500; Kitagawa K, 1999, MOL CELL, V4, P21, DOI 10.1016/S1097-2765(00)80184-7; MUSKETT PR, IN PRESS PLANT CELL; Schwechheimer C, 2001, SCIENCE, V292, P1379, DOI 10.1126/science.1059776; Shirasu K, 1999, CELL, V99, P355, DOI 10.1016/S0092-8674(00)81522-6; TOR M, IN PRESS PLANT CELL; TORNERO P, IN PRESS PLANT CELL; Warren RF, 1999, GENETICS, V152, P401	17	11	13	1	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 15	2002	295	5562					2032	2033		10.1126/science.1070443	http://dx.doi.org/10.1126/science.1070443			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	532AY	11896264				2022-12-28	WOS:000174450500034
J	Sobel, J; Khan, AS; Swerdlow, DL				Sobel, J; Khan, AS; Swerdlow, DL			Threat of a biological terrorist attack on the US food supply: the CDC perspective	LANCET			English	Article							PUBLIC-HEALTH; ESCHERICHIA-COLI; OUTBREAK; SALMONELLOSIS; SURVEILLANCE; INFECTIONS; DISEASE	Deliberate contamination of food with biological agents has already been perpetrated in the USA. The US food supply is Increasingly characterised by centralised production and wide distribution of products. Deliberate contamination of a commercial food product could cause an outbreak of disease, with many illnesses dispersed over wide geographical areas. Dependent on the biological agent and contaminated food, such an outbreak could either present as a slow, diffuse, and initially unremarkable increase in sporadic cases, or as an explosive epidemic suddenly producing many illnesses. Preparedness for a bioterrorist event affecting the food supply, therefore, entails augmentation of the traditional public-health infrastructure to enhance disease surveillance, accelerate capacity of laboratory detection, rapidly investigate and control outbreaks, and develop capacity for response to mass-casualty disasters.	Ctr Dis Control & Prevent, Foodborne & Diarrheal Dis Branch, Div Bacterial & Mycot Dis, Natl Ctr Infect Dis, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Bioterrorism Preparedness & Response Program, Natl Ctr Infect Dis, Atlanta, GA 30333 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Sobel, J (corresponding author), Ctr Dis Control & Prevent, Foodborne & Diarrheal Dis Branch, Div Bacterial & Mycot Dis, Natl Ctr Infect Dis, MS-A38,1600 Clifton Rd, Atlanta, GA 30333 USA.	jsobel@cdc.gov						[Anonymous], 1997, Morbidity and Mortality Weekly Report, V46, P777; [Anonymous], 2000, MMWR Recomm Rep, V49, P1; [Anonymous], 1995, CONTROL COMMUNICABLE; BEAN NH, 1992, AM J PUBLIC HEALTH, V82, P1273, DOI 10.2105/AJPH.82.9.1273; Bennish Michael L., 1994, P229; BLASER MJ, 1982, REV INFECT DIS, V4, P1096; Carus WS, 1999, BIOL WEAPONS LIMITIN, P211; *CDC, 2002, MMWR MORBIDITY MORTA; *CDCP, 1998 ANN REP; Centers for Disease Control and Prevention, 1998, HDB EPID CLIN LAB WO; Centers for Disease Control and Prevention, 1998, MMWR MORB MORTAL WKL, V48, P69; Centers for Disease Control and Prevention (CDC), 2001, MMWR Morb Mortal Wkly Rep, V50, P941; Dixon TC, 1999, NEW ENGL J MED, V341, P815, DOI 10.1056/NEJM199909093411107; DUPONT HL, 1989, J INFECT DIS, V159, P1126, DOI 10.1093/infdis/159.6.1126; EITZEN ME, 1997, MED ASPECTS CHEM BIO, P437; EKEUS R, 1991, REPORT SECRETARY GEN; Franz DR., 1997, TXB MILITARY MED 1, P603; GRIFFIN PM, 1994, RECENT ADV VEROCYTOT; GRIGG B, 1989, FDA CONSUMER     JUL, P7; HATHEWAY CL, 1990, CLIN MICROBIOL REV, V3, P66, DOI 10.1128/CMR.3.1.66-98.1990; HEDBERG CW, 1994, CLIN INFECT DIS, V18, P671, DOI 10.1093/clinids/18.5.671; Hennessy TW, 1996, NEW ENGL J MED, V334, P1281, DOI 10.1056/NEJM199605163342001; Hutwagner LC, 1997, EMERG INFECT DIS, V3, P395, DOI 10.3201/eid0303.970322; *I MED, 1999, COMM R D NEEDS IMPR; KADLEC RP, 1999, BIOL WEAPONS LIMITIN, P95; Khan AS, 2000, LANCET, V356, P1179, DOI 10.1016/S0140-6736(00)02769-0; Kolavic SA, 1997, JAMA-J AM MED ASSOC, V278, P396, DOI 10.1001/jama.278.5.396; Mahon BE, 1997, J INFECT DIS, V175, P876, DOI 10.1086/513985; Mead PS, 1998, LANCET, V352, P1207, DOI 10.1016/S0140-6736(98)01267-7; Mermin JH, 1999, AM J EPIDEMIOL, V150, P797; PHILLS JA, 1972, NEW ENGL J MED, V286, P965, DOI 10.1056/NEJM197205042861802; RYAN CA, 1987, JAMA-J AM MED ASSOC, V258, P3269, DOI 10.1001/jama.258.22.3269; Shapiro RL, 1997, JAMA-J AM MED ASSOC, V278, P433, DOI 10.1001/jama.278.5.433; SIVAPALASINGAM S, 2000, 49 ANN EP INT SERV E; Stephenson J, 1997, JAMA-J AM MED ASSOC, V277, P1337, DOI 10.1001/jama.277.17.1337; Swaminathan B, 2001, EMERG INFECT DIS, V7, P382; SWERDLOW D, 1998, EMERGING INFECT, V2; TAUXE RV, 1992, JAMA-J AM MED ASSOC, V267, P1388, DOI 10.1001/jama.267.10.1388; Tilden J, 1996, AM J PUBLIC HEALTH, V86, P1142, DOI 10.2105/AJPH.86.8_Pt_1.1142; Torok TJ, 1997, JAMA-J AM MED ASSOC, V278, P389, DOI 10.1001/jama.278.5.389; *US GEN ACC OFF, 1999, RCED003 US GEN ACC O; *WHO, 1970, HLTH ASP CHEM BIOL W, P113	42	72	76	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 9	2002	359	9309					874	880		10.1016/S0140-6736(02)07947-3	http://dx.doi.org/10.1016/S0140-6736(02)07947-3			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	529YV	11897303				2022-12-28	WOS:000174329600031
J	Soderblom, LA; Becker, TL; Bennett, G; Boice, DC; Britt, DT; Brown, RH; Buratti, BJ; Isbell, C; Giese, B; Hare, T; Hicks, MD; Howington-Kraus, E; Kirk, RL; Lee, M; Nelson, RM; Oberst, J; Owen, TC; Rayman, MD; Sandel, BR; Stern, SA; Thomas, N; Yelle, RV				Soderblom, LA; Becker, TL; Bennett, G; Boice, DC; Britt, DT; Brown, RH; Buratti, BJ; Isbell, C; Giese, B; Hare, T; Hicks, MD; Howington-Kraus, E; Kirk, RL; Lee, M; Nelson, RM; Oberst, J; Owen, TC; Rayman, MD; Sandel, BR; Stern, SA; Thomas, N; Yelle, RV			Observations of comet 19P/Borrelly by the Miniature Integrated Camera and Spectrometer Aboard Deep Space 1	SCIENCE			English	Article							NUCLEUS; PHOTOMETRY; 253-MATHILDE; HALLEY; IMAGES	The nucleus of the Jupiter-family comet 19P/Borrelly was closely observed by the Miniature Integrated Camera and Spectrometer aboard the Deep Space I spacecraft on 22 September 2001. The 8-kilometer-long body is highly variegated on a scale of 200 meters, exhibiting large albedo variations (0.01 to 0.03) and complex geologic relationships. Short-wavelength infrared spectra (1.3 to 2.6 micrometers) show a slope toward the red and a hot, dry surface (less than or equal to345 kelvin, with no trace of water ice or hydrated minerals), consistent with similar to10% or less of the surface actively sublimating. Borrelly's coma exhibits two types of dust features: fans and highly collimated jets. At encounter, the near-nucleus coma was dominated by a prominent dust jet that resolved into at least three smaller jets emanating from a broad basin in the middle of the nucleus. Because the major dust jet remained fixed in orientation, it is evidently aligned near the rotation axis of the nucleus.	US Geol Survey, Flagstaff, AZ 86001 USA; SW Res Inst, San Antonio, TX 78238 USA; Univ Tennessee, Dept Geol Sci, Knoxville, TN 37996 USA; Univ Arizona, Lunar & Planetary Lab, Dept Planetary Sci, Tucson, AZ 85721 USA; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; DLR, Inst Space Sensor Technol & Planetary Explorat, D-12489 Berlin, Germany; Univ Hawaii, Inst Astron, Honolulu, HI 96822 USA; SW Res Inst, Dept Space Studies, Boulder, CO 80302 USA; Max Planck Inst Aeron, D-37191 Katlenburg Lindau, Germany	United States Department of the Interior; United States Geological Survey; Southwest Research Institute; University of Tennessee System; University of Tennessee Knoxville; University of Arizona; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); Helmholtz Association; German Aerospace Centre (DLR); University of Hawaii System; Max Planck Society	Soderblom, LA (corresponding author), US Geol Survey, 2255 N Gemini Dr, Flagstaff, AZ 86001 USA.		; Thomas, Nicolas/G-4693-2015; Boice, Daniel/C-4831-2018	Hare, Trent/0000-0001-8842-389X; Thomas, Nicolas/0000-0002-0146-0071; Boice, Daniel/0000-0001-6423-3768				AHearn MF, 1995, ICARUS, V118, P223, DOI 10.1006/icar.1995.1190; BEAUCHAMP PM, 1994, P 8 ANN AIAA UT STAT; BORRELLY ALN, COMET 19P BORRELLY D; BURATTI BJ, 1995, ICARUS, V115, P219, DOI 10.1006/icar.1995.1093; Clark BE, 1999, ICARUS, V140, P53, DOI 10.1006/icar.1999.6124; Cruikshank DP, 1998, ICARUS, V135, P389, DOI 10.1006/icar.1998.5997; Farinella P., 2000, Protostars and planets 4, P1255; HANNER MS, 1985, ICARUS, V62, P97, DOI 10.1016/0019-1035(85)90174-5; HUEBNER WF, 1987, SCIENCE, V237, P628, DOI 10.1126/science.237.4815.628; *IAU, 1998, 31664 IAU; KELLER HU, 1987, ASTRON ASTROPHYS, V187, P807; Knollenberg J, 1996, EARTH MOON PLANETS, V72, P103, DOI 10.1007/BF00117509; KONNO I, 1995, ICARUS, V116, P77; Lamy PL, 1998, ASTRON ASTROPHYS, V337, P945; MARSDEN BG, 2001, 7771 IAU; MITCHELL DL, 1987, SCIENCE, V237, P626, DOI 10.1126/science.237.4815.626; MUELLER B, 2001, B AM ASTRON SOC, V33, P1090; OCKERT ME, 1987, J GEOPHYS RES, V92, P14969, DOI 10.1029/JA092iA13p14969; RAUER H, 1999, B AM ASTRON SOC, V31, P1131; Rayman MD, 2001, ACTA ASTRONAUT, V48, P693, DOI 10.1016/S0094-5765(01)00044-3; Rayman MD, 2000, ACTA ASTRONAUT, V47, P475, DOI 10.1016/S0094-5765(00)00087-4; SODERBLOM LA, 2000, P DS1 TECHN VAL S PA; TEDESCO EF, 1989, ASTRON J, V97, P580, DOI 10.1086/115007; VEEDER GJ, 1987, ASTRON J, V94, P169, DOI 10.1086/114460; Veverka J, 1997, SCIENCE, V278, P2109, DOI 10.1126/science.278.5346.2109; WEISSMAN PR, 1986, NATURE, V320, P242, DOI 10.1038/320242a0	26	170	171	1	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 10	2002	296	5570					1087	1091		10.1126/science.1069527	http://dx.doi.org/10.1126/science.1069527			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	551MG	11934989				2022-12-28	WOS:000175565000044
J	Suzuki, N; Suzuki, S; Duncan, GS; Millar, DG; Wada, T; Mirtsos, C; Takada, H; Wakeham, A; Itie, A; Li, SY; Penninger, JM; Wesche, H; Ohashi, PS; Mak, TW; Yeh, WC				Suzuki, N; Suzuki, S; Duncan, GS; Millar, DG; Wada, T; Mirtsos, C; Takada, H; Wakeham, A; Itie, A; Li, SY; Penninger, JM; Wesche, H; Ohashi, PS; Mak, TW; Yeh, WC			Severe impairment of interleukin-1 and Toll-like receptor signalling in mice lacking IRAK-4	NATURE			English	Article							SIGNALING PATHWAYS; KINASE; MYD88; DEFICIENCY; PROTEIN; FAMILY; GENE; RESPONSES; ADAPTER; MEMBER	Toll-like receptors (TLRs), which recognize pathogen-associated molecular patterns, and members of the pro-inflammatory interleukin-1 receptor (IL-1R) family, share homologies in their cytoplasmic domains called Toll/IL-1R/plant R gene homology (TIR) domains(1-3). Intracellular signalling mechanisms mediated by TIRs are similar(4), with MyD88 (refs 5-8) and TRAF6 (refs 9, 10) having critical roles. Signal transduction between MyD88 and TRAF6 is known to involve the serine-threonine kinase IL-1 receptor-associated kinase 1 (IRAK-1)(11) and two homologous proteins, IRAK-2 (ref. 12) and IRAK-M-13. However, the physiological functions of the IRAK molecules remain unclear, and gene-targeting studies have shown that IRAK-1 is only partially required for IL-1R and TLR signalling(14,15). Here we show by gene-targeting that IRAK-4, an IRAK molecule closely related to the Drosophila Pelle protein 16, is indispensable for the responses of animals and cultured cells to IL-1 and ligands that stimulate various TLRs. IRAK-4-deficient animals are completely resistant to a lethal dose of lipopolysaccharide (LPS). In addition, animals lacking IRAK-4 are severely impaired in their responses to viral and bacterial challenges. Our results indicate that IRAK-4 has an essential role in innate immunity.	Univ Toronto, Ontario Canc Inst, Amgen Inst, Toronto, ON M5G 2C1, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2C1, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Immunol, Toronto, ON M5G 2M9, Canada; Tularik Inc, San Francisco, CA 94080 USA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto; University of Toronto	Yeh, WC (corresponding author), Univ Toronto, Ontario Canc Inst, Amgen Inst, 620 Univ Ave,Suite 706, Toronto, ON M5G 2C1, Canada.		Duncan, Gordon/AIE-7011-2022; Penninger, Josef M/I-6860-2013	Penninger, Josef M/0000-0002-8194-3777; Ohashi, Pamela S./0000-0003-2915-9317; Millar, Douglas/0000-0002-8640-7148				Adachi O, 1998, IMMUNITY, V9, P143, DOI 10.1016/S1074-7613(00)80596-8; Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Bonnard M, 2000, EMBO J, V19, P4976, DOI 10.1093/emboj/19.18.4976; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Fitzgerald KA, 2001, NATURE, V413, P78, DOI 10.1038/35092578; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Kanakaraj P, 1998, J EXP MED, V187, P2073, DOI 10.1084/jem.187.12.2073; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; LI S, IN PRESS P NATL ACAD; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; Nguyen LT, 1999, IMMUNITY, V11, P379, DOI 10.1016/S1074-7613(00)80113-2; ONEILL HJ, 1963, J GAS CHROMATOGR, V1, P28, DOI 10.1093/chromsci/1.2.28; Orange JS, 1996, J IMMUNOL, V156, P4746; Parnet P, 1996, J BIOL CHEM, V271, P3967; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; SHELTON CA, 1993, CELL, V72, P515, DOI 10.1016/0092-8674(93)90071-W; Shiu SH, 2001, P NATL ACAD SCI USA, V98, P10763, DOI 10.1073/pnas.181141598; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Thomas JA, 1999, J IMMUNOL, V163, P978; Underhill DM, 1999, NATURE, V401, P811, DOI 10.1038/44605; Wasserman SA, 2000, CURR OPIN GENET DEV, V10, P497, DOI 10.1016/S0959-437X(00)00118-0; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Wesche H, 1999, J BIOL CHEM, V274, P19403, DOI 10.1074/jbc.274.27.19403	30	613	707	3	63	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 18	2002	416	6882					750	754		10.1038/nature736	http://dx.doi.org/10.1038/nature736			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	542FU	11923871				2022-12-28	WOS:000175033500045
J	Albert, CM; Campos, H; Stampfer, MJ; Ridker, PM; Manson, JE; Willett, WC; Ma, J				Albert, CM; Campos, H; Stampfer, MJ; Ridker, PM; Manson, JE; Willett, WC; Ma, J			Blood levels of long-chain n-3 fatty acids and the risk of sudden death.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEART-RATE-VARIABILITY; VENTRICULAR-FIBRILLATION; MYOCARDIAL-INFARCTION; FISH CONSUMPTION; DIETARY-INTAKE; PREVENTION; CURRENTS	Background: Experimental data suggest that long-chain n-3 polyunsaturated fatty acids found in fish have antiarrhythmic properties, and a randomized trial suggested that dietary supplements of n-3 fatty acids may reduce the risk of sudden death among survivors of myocardial infarction. Whether long-chain n-3 fatty acids are also associated with the risk of sudden death in those without a history of cardiovascular disease is unknown. Methods: We conducted a prospective, nested case-control analysis among apparently healthy men who were followed for up to 17 years in the Physicians' Health Study. The fatty-acid composition of previously collected blood was analyzed by gas-liquid chromatography for 94 men in whom sudden death occurred as the first manifestation of cardiovascular disease and for 184 controls matched with them for age and smoking status. Results: Base-line blood levels of long-chain n-3 fatty acids were inversely related to the risk of sudden death both before adjustment for potential confounders (P for trend = 0.004) and after such adjustment (P for trend = 0.007). As compared with men whose blood levels of long-chain n-3 fatty acids were in the lowest quartile, the relative risk of sudden death was significantly lower among men with levels in the third quartile (adjusted relative risk, 0.28; 95 percent confidence interval, 0.09 to 0.87) and the fourth quartile (adjusted relative risk, 0.19; 95 percent confidence interval, 0.05 to 0.71). Conclusions: The n-3 fatty acids found in fish are strongly associated with a reduced risk of sudden death among men without evidence of prior cardiovascular disease.	Brigham & Womens Hosp, Dept Med, Div Prevent Med, Boston, MA 02215 USA; Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA 02215 USA; Brigham & Womens Hosp, Dept Med, Div Cardiovasc Med, Boston, MA 02215 USA; Massachusetts Gen Hosp, Dept Med, Div Cardiovasc, Boston, MA 02114 USA; Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	Albert, CM (corresponding author), Brigham & Womens Hosp, Dept Med, Div Prevent Med, 900 Commonwealth Ave E, Boston, MA 02215 USA.	calbert@partners.org		Albert, Christine/0000-0002-2081-1121	NCI NIH HHS [CA-34944, CA-40360] Funding Source: Medline; NHLBI NIH HHS [HL-34595, 1-K08-HL-03783, HL-26490] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040360] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034595, K08HL003783] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Albert CM, 1998, JAMA-J AM MED ASSOC, V279, P23, DOI 10.1001/jama.279.1.23; [Anonymous], 1988, NEW ENGL J MED, V318, P262; BILLMAN GE, 1994, P NATL ACAD SCI USA, V91, P4427, DOI 10.1073/pnas.91.10.4427; Billman GE, 1999, CIRCULATION, V99, P2452, DOI 10.1161/01.CIR.99.18.2452; Christensen JH, 1997, AM J CARDIOL, V79, P1670, DOI 10.1016/S0002-9149(97)00220-8; Christensen JH, 2001, CIRCULATION, V103, P651, DOI 10.1161/01.CIR.103.5.651; Cunnane SC, 1997, J NUTR, V127, P146, DOI 10.1093/jn/127.1.146; *GISSI PREV INV, 2000, LANCET, V357, P642; GUALLAR E, 1995, J AM COLL CARDIOL, V25, P387, DOI 10.1016/0735-1097(94)00370-6; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; HINKLE LE, 1982, CIRCULATION, V65, P457, DOI 10.1161/01.CIR.65.3.457; Jouven X, 2001, CIRCULATION, V104, P756, DOI 10.1161/hc3201.094151; Kang JX, 1996, CIRCULATION, V94, P1774, DOI 10.1161/01.CIR.94.7.1774; KANNEL WB, 1985, J AM COLL CARDIOL, V5, pB141, DOI 10.1016/S0735-1097(85)80545-3; Li YY, 1997, PROSTAGLANDINS, V54, P511, DOI 10.1016/S0090-6980(97)00122-6; MCLENNAN PL, 1992, AM HEART J, V123, P1555, DOI 10.1016/0002-8703(92)90809-A; Nair SSD, 1997, J NUTR, V127, P383, DOI 10.1093/jn/127.3.383; SISCOVICK DS, 1995, JAMA-J AM MED ASSOC, V274, P1363, DOI 10.1001/jama.274.17.1363; Valagussa F, 1999, LANCET, V354, P447, DOI 10.1016/S0140-6736(99)07072-5; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; Xiao YF, 1997, P NATL ACAD SCI USA, V94, P4182, DOI 10.1073/pnas.94.8.4182; Xiao YF, 1998, P NATL ACAD SCI USA, V95, P2680, DOI 10.1073/pnas.95.5.2680; Zeleniuch-Jacquotte A, 2000, EUR J CLIN NUTR, V54, P367, DOI 10.1038/sj.ejcn.1600964; Zock PL, 1997, AM J EPIDEMIOL, V145, P1114, DOI 10.1093/oxfordjournals.aje.a009074; Zock PL, 1996, EUR J CLIN INVEST, V26, P141, DOI 10.1046/j.1365-2362.1996.t01-1-105263.x	25	870	936	2	47	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 11	2002	346	15					1113	1118		10.1056/NEJMoa012918	http://dx.doi.org/10.1056/NEJMoa012918			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	539PX	11948270				2022-12-28	WOS:000174880600003
J	Horrocks, S; Anderson, E; Salisbury, C				Horrocks, S; Anderson, E; Salisbury, C			Systematic review of whether nurse practitioners working in primary care can provide equivalent care to doctors	BRITISH MEDICAL JOURNAL			English	Review							RANDOMIZED CONTROLLED TRIAL; HEALTH OUTCOMES; PHYSICIANS	Objective To determine whether nurse practitioners can provide care at first point of contact equivalent to doctors in a primary care setting. Design Systematic review of randomised controlled trials and prospective observational studies. Data sources Cochrane controlled trials register, specialist register of trials maintained by Cochrane Effective Practice and Organisation of Care Group, Medline, Embase, CINAHL, science citation index, database of abstracts of reviews of effectiveness, national research register, hand searches, and published bibliographies. Included studies Randomised controlled trials and prospective observational studies comparing nurse practitioners and doctors providing care at first point of contact for patients with undifferentiated health problems in a primary care setting and providing data on one or more of the following outcomes: patient satisfaction, health status, costs, and process of care. Results 11 trials and 23 observational studies met all the inclusion criteria. Patients were more satisfied with care by a nurse practitioner (standardised mean difference 0.27,95% confidence interval 0.07 to 0.47). No differences in health status were found. Nurse practitioners had longer consultations (weighted mean difference 3.67 minutes, 2.05 to 5.29) and made more investigations (odds ratio 1.22, 1.02 to 1.46) than did doctors. No differences were found in prescriptions, return consultations, or referrals. Quality of care was in some ways better for nurse practitioner consultations. Conclusion Increasing availability of nurse practitioners in primary care is likely to lead to high levels of patient satisfaction and high quality care.	Univ Bristol, Div Primary Hlth Care, Bristol BS6 6JL, Avon, England; Univ W England, Fac Hlth & Social Care, Bristol BS16 1DD, Avon, England	University of Bristol; University of West England	Salisbury, C (corresponding author), Univ Bristol, Div Primary Hlth Care, Bristol BS6 6JL, Avon, England.		Salisbury, Chris/C-6724-2008	Salisbury, Chris/0000-0002-4378-3960				ASHBURNER L, 1997, NURSE PRACTITIONERS; Brown SA, 1995, NURS RES, V44, P332; BURNIP R, 1976, AM J DIS CHILD, V130, P51, DOI 10.1001/archpedi.1976.02120020053008; CAMPBELL JD, 1990, SOC SCI MED, V30, P1359, DOI 10.1016/0277-9536(90)90316-K; CHAMBERS LW, 1978, INT J EPIDEMIOL, V7, P153, DOI 10.1093/ije/7.2.153; COOPER M, 2001, EVALUATION SAFETY EF; *DEP HLTH, 1999, MAK DIFF STRENGTH NU; *DEP HLTH, 2000, NHS PLAN; Egger M, 2001, SYSTEMATIC REV HLTH; HALLIWELL S, 1999, BIBLIO SKILL MIX PRI; HOCKELMAN RA, 1975, PEDIATRICS, V55, P313; HOLCOMB LO, 2000, CLIN EXCEL NURSE PRA, V4, P172; Juni P, 2001, BMJ-BRIT MED J, V323, P42, DOI 10.1136/bmj.323.7303.42; KERNICK D, 2001, BR J GEN PRACT, V17, P42; Kinnersley P, 2000, BRIT MED J, V320, P1043, DOI 10.1136/bmj.320.7241.1043; Mundinger MO, 2000, JAMA-J AM MED ASSOC, V283, P59, DOI 10.1001/jama.283.1.59; Offredy M, 2000, FAM PRACT, V17, P564, DOI 10.1093/fampra/17.6.564; *ROYAL COLL NURS, 1996, NURS PRACT YOUR QUES; SACKETT DL, 1974, ANN INTERN MED, V80, P137, DOI 10.7326/0003-4819-80-2-137; Sakr M, 1999, LANCET, V354, P1321, DOI 10.1016/S0140-6736(99)02447-2; SCIGISON M, 1998, SKILL MIX PRIMARY CA; SERGISON M, 1998, SKILL MIX PRIMARY CA; Shum C, 2000, BRIT MED J, V320, P1038, DOI 10.1136/bmj.320.7241.1038; SOX HC, 1979, ANN INTERN MED, V91, P459, DOI 10.7326/0003-4819-91-3-459; SPITZER WO, 1974, NEW ENGL J MED, V290, P251, DOI 10.1056/NEJM197401312900506; Venning P, 2000, BMJ-BRIT MED J, V320, P1048, DOI 10.1136/bmj.320.7241.1048; Winter C, 1981, THESIS CALIFORNIA ST; [No title captured]	28	695	705	3	56	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 6	2002	324	7341					819	823		10.1136/bmj.324.7341.819	http://dx.doi.org/10.1136/bmj.324.7341.819			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	540ZG	11934775	Bronze, Green Published			2022-12-28	WOS:000174960300016
J	Maniatis, T; Reed, R				Maniatis, T; Reed, R			An extensive network of coupling among gene expression machines	NATURE			English	Review							RNA-POLYMERASE-II; PRE-MESSENGER-RNA; CARBOXY-TERMINAL DOMAIN; CAP-BINDING COMPLEX; SPLICING FACTOR; CAPPING ENZYME; COMMITMENT COMPLEX; SR PROTEINS; IN-VITRO; P-TEFB		Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard University; Harvard Medical School	Maniatis, T (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA.							Abovich N, 1997, CELL, V89, P403, DOI 10.1016/S0092-8674(00)80221-4; Aranda A, 2001, MOL CELL, V7, P1003, DOI 10.1016/S1097-2765(01)00235-0; Ares M, 1999, RNA, V5, P1138, DOI 10.1017/S1355838299991379; Bachi A, 2000, RNA, V6, P136, DOI 10.1017/S1355838200991994; Barboric M, 2001, MOL CELL, V8, P327, DOI 10.1016/S1097-2765(01)00314-8; Bentley D, 1999, CURR OPIN CELL BIOL, V11, P347, DOI 10.1016/S0955-0674(99)80048-9; BERGET SM, 1995, J BIOL CHEM, V270, P2411, DOI 10.1074/jbc.270.6.2411; Birse CE, 1998, SCIENCE, V280, P298, DOI 10.1126/science.280.5361.298; Calvo O, 2001, MOL CELL, V7, P1013, DOI 10.1016/S1097-2765(01)00236-2; Cho EJ, 1998, GENE DEV, V12, P3482, DOI 10.1101/gad.12.22.3482; Cho EJ, 1997, GENE DEV, V11, P3319, DOI 10.1101/gad.11.24.3319; Cho EJ, 2001, GENE DEV, V15, P3319, DOI 10.1101/gad.935901; Colot HV, 1996, GENE DEV, V10, P1699, DOI 10.1101/gad.10.13.1699; Cook PR, 1999, SCIENCE, V284, P1790, DOI 10.1126/science.284.5421.1790; Corden JL, 1997, TRENDS BIOCHEM SCI, V22, P413, DOI 10.1016/S0968-0004(97)01125-0; Cramer P, 2001, FEBS LETT, V498, P179, DOI 10.1016/S0014-5793(01)02485-1; Cramer P, 1999, MOL CELL, V4, P251, DOI 10.1016/S1097-2765(00)80372-X; Cramer P, 1997, P NATL ACAD SCI USA, V94, P11456, DOI 10.1073/pnas.94.21.11456; Cramer Patrick, 2001, Science (Washington D C), V292, P1863, DOI 10.1126/science.1059493; Custodio N, 1999, EMBO J, V18, P2855, DOI 10.1093/emboj/18.10.2855; Czaplinski K, 1999, BIOESSAYS, V21, P685, DOI 10.1002/(SICI)1521-1878(199908)21:8<685::AID-BIES8>3.0.CO;2-4; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; Dundr M, 2001, BIOCHEM J, V356, P297, DOI 10.1042/0264-6021:3560297; Dye MJ, 2001, CELL, V105, P669, DOI 10.1016/S0092-8674(01)00372-5; EPERON LP, 1988, CELL, V54, P393, DOI 10.1016/0092-8674(88)90202-4; Fong N, 2001, GENE DEV, V15, P1783, DOI 10.1101/gad.889101; Fong YW, 2001, NATURE, V414, P929, DOI 10.1038/414929a; Gall JG, 2001, FEBS LETT, V498, P164, DOI 10.1016/S0014-5793(01)02461-9; Gatfield D, 2001, CURR BIOL, V11, P1716, DOI 10.1016/S0960-9822(01)00532-2; Ge H, 1998, MOL CELL, V2, P751, DOI 10.1016/S1097-2765(00)80290-7; Goldstrohm AC, 2001, GENE, V277, P31, DOI 10.1016/S0378-1119(01)00695-3; Gonzalez CI, 2000, MOL CELL, V5, P489, DOI 10.1016/S1097-2765(00)80443-8; Graveley BR, 1999, CURR BIOL, V9, pR6, DOI 10.1016/S0960-9822(99)80032-3; Graveley BR, 2000, RNA, V6, P1197, DOI 10.1017/S1355838200000960; Gross S, 2001, MOL CELL BIOL, V21, P8045, DOI 10.1128/MCB.21.23.8045-8055.2001; Hentze MW, 1999, CELL, V96, P307, DOI 10.1016/S0092-8674(00)80542-5; Hilleren P, 2001, NATURE, V413, P538, DOI 10.1038/35097110; Hirose Y, 2000, GENE DEV, V14, P1415; Ho CK, 1999, MOL CELL, V3, P405, DOI 10.1016/S1097-2765(00)80468-2; Huang YQ, 2001, MOL CELL, V7, P899, DOI 10.1016/S1097-2765(01)00233-7; Iborra FJ, 1996, J CELL SCI, V109, P1427; Ishigaki Y, 2001, CELL, V106, P607, DOI 10.1016/S0092-8674(01)00475-5; Jensen TH, 2001, CURR BIOL, V11, P1711, DOI 10.1016/S0960-9822(01)00529-2; Jensen TH, 2001, MOL CELL, V7, P887, DOI 10.1016/S1097-2765(01)00232-5; Kadener S, 2001, EMBO J, V20, P5759, DOI 10.1093/emboj/20.20.5759; Kataoka N, 2000, MOL CELL, V6, P673, DOI 10.1016/S1097-2765(00)00065-4; Kessler MM, 1997, GENE DEV, V11, P2545, DOI 10.1101/gad.11.19.2545; Kim JB, 1999, MOL CELL BIOL, V19, P5960; Kim JB, 2001, J BIOL CHEM, V276, P12317, DOI 10.1074/jbc.M010908200; Kim VN, 2001, SCIENCE, V293, P1832, DOI 10.1126/science.1062829; Kim VN, 2001, EMBO J, V20, P2062, DOI 10.1093/emboj/20.8.2062; Komarnitsky P, 2000, GENE DEV, V14, P2452, DOI 10.1101/gad.824700; Lai MC, 1999, J BIOL CHEM, V274, P11832, DOI 10.1074/jbc.274.17.11832; Le Hir H, 2000, EMBO J, V19, P6860, DOI 10.1093/emboj/19.24.6860; Le Hir H, 2000, GENE DEV, V14, P1098; Le Hir H, 2001, EMBO J, V20, P4987, DOI 10.1093/emboj/20.17.4987; Lei EP, 2001, GENE DEV, V15, P1771, DOI 10.1101/gad.892401; Lewis JD, 1996, GENE DEV, V10, P1683, DOI 10.1101/gad.10.13.1683; Luo MJ, 2001, NATURE, V413, P644, DOI 10.1038/35098106; Luo MJ, 1999, P NATL ACAD SCI USA, V96, P14937, DOI 10.1073/pnas.96.26.14937; Lykke-Andersen J, 2001, SCIENCE, V293, P1836, DOI 10.1126/science.1062786; Lykke-Andersen J, 2000, CELL, V103, P1121, DOI 10.1016/S0092-8674(00)00214-2; Maquat LE, 2001, CELL, V104, P173, DOI 10.1016/S0092-8674(01)00202-1; Martinez E, 2001, MOL CELL BIOL, V21, P6782, DOI 10.1128/MCB.21.20.6782-6795.2001; McCracken S, 1998, COLD SPRING HARB SYM, V63, P301, DOI 10.1101/sqb.1998.63.301; McCracken S, 2002, MOL CELL BIOL, V22, P148, DOI 10.1128/MCB.22.1.148-160.2002; McCracken S, 1997, NATURE, V385, P357, DOI 10.1038/385357a0; McCracken S, 1997, GENE DEV, V11, P3306, DOI 10.1101/gad.11.24.3306; Misteli T, 1998, J CELL BIOL, V143, P297, DOI 10.1083/jcb.143.2.297; Misteli T, 1997, NATURE, V387, P523, DOI 10.1038/387523a0; Misteli T, 1999, MOL CELL, V3, P697, DOI 10.1016/S1097-2765(01)80002-2; Monsalve M, 2000, MOL CELL, V6, P307, DOI 10.1016/S1097-2765(00)00031-9; Morris DP, 2000, J BIOL CHEM, V275, P39935, DOI 10.1074/jbc.M004118200; Muhlemann O, 2001, MOL CELL, V8, P33, DOI 10.1016/S1097-2765(01)00288-X; Osheim YN, 1999, MOL CELL, V3, P379, DOI 10.1016/S1097-2765(00)80465-7; Phair RD, 2000, NATURE, V404, P604, DOI 10.1038/35007077; Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128/MCB.20.8.2629-2634.2000; Proudfoot N, 2000, TRENDS BIOCHEM SCI, V25, P290, DOI 10.1016/S0968-0004(00)01591-7; PROUDFOOT NJ, 1989, TRENDS BIOCHEM SCI, V14, P105, DOI 10.1016/0968-0004(89)90132-1; PTASHNE M, 2002, GENES SIGNALS; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Reed R, 2000, CURR OPIN CELL BIOL, V12, P340, DOI 10.1016/S0955-0674(00)00097-1; Reed R, 2001, NAT CELL BIOL, V3, pE201, DOI 10.1038/ncb0901-e201; Robert F, 2002, J BIOL CHEM, V277, P9302, DOI 10.1074/jbc.M110516200; Roberts GC, 1998, NUCLEIC ACIDS RES, V26, P5568, DOI 10.1093/nar/26.24.5568; Schroeder SC, 2000, GENE DEV, V14, P2435, DOI 10.1101/gad.836300; Segref A, 1997, EMBO J, V16, P3256, DOI 10.1093/emboj/16.11.3256; Serin G, 2001, MOL CELL BIOL, V21, P209, DOI 10.1128/MCB.21.1.209-223.2001; Shatkin AJ, 2000, NAT STRUCT BIOL, V7, P838, DOI 10.1038/79583; Sleeman JE, 1999, CURR BIOL, V9, P1065, DOI 10.1016/S0960-9822(99)80475-8; Strasser K, 2001, NATURE, V413, P648, DOI 10.1038/35098113; Taube R, 2002, MOL CELL BIOL, V22, P321, DOI 10.1128/MCB.22.1.321-331.2002; Tran DP, 2001, MOL CELL BIOL, V21, P7495, DOI 10.1128/MCB.21.21.7495-7508.2001; Trigon S, 1998, J BIOL CHEM, V273, P6769, DOI 10.1074/jbc.273.12.6769; Vagner S, 2000, GENE DEV, V14, P403; Wada T, 1998, EMBO J, V17, P7395, DOI 10.1093/emboj/17.24.7395; Wen YX, 1999, GENE DEV, V13, P1774, DOI 10.1101/gad.13.14.1774; Wetterberg I, 2001, EMBO J, V20, P2564, DOI 10.1093/emboj/20.10.2564; Yan D, 1998, MOL CELL BIOL, V18, P5000, DOI 10.1128/MCB.18.9.5000; Zhou ZL, 2000, NATURE, V407, P401, DOI 10.1038/35030160	100	907	945	3	49	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 4	2002	416	6880					499	506		10.1038/416499a	http://dx.doi.org/10.1038/416499a			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	537JY	11932736				2022-12-28	WOS:000174756500034
J	Manfredini, R; Gallerani, M; la Cecilia, O; Boari, B; Fersini, C; Portaluppi, F				Manfredini, R; Gallerani, M; la Cecilia, O; Boari, B; Fersini, C; Portaluppi, F			Circadian pattern in occurrence of renal colic in an emergency department: analysis of patients' notes	BRITISH MEDICAL JOURNAL			English	Article							RHYTHM; RISK		Univ Ferrara, Sch Med, Dept Clin & Expt Med, I-44100 Ferrara, Italy; Univ Ferrara, Sch Specialisat Nephrol, I-44100 Ferrara, Italy; Univ Ferrara, Sch Specialisat Internal Med, I-44100 Ferrara, Italy	University of Ferrara; University of Ferrara; University of Ferrara	Manfredini, R (corresponding author), Univ Ferrara, Sch Med, Dept Clin & Expt Med, Via Savonarola 9, I-44100 Ferrara, Italy.		Manfredini, Roberto/N-3859-2019; Portaluppi, Francesco/H-2206-2012; Manfredini, Roberto/AAJ-5442-2020; Boari, Benedetta/AAB-4792-2022; Manfredini, Roberto/A-3471-2008	Manfredini, Roberto/0000-0002-8364-2601; Portaluppi, Francesco/0000-0002-2948-1579; Boari, Benedetta/0000-0002-9015-7858; Manfredini, Roberto/0000-0002-8364-2601				KOOPMAN MG, 1989, CLIN SCI, V77, P105, DOI 10.1042/cs0770105; Portaluppi F, 1999, CHRONOBIOL INT, V16, P33, DOI 10.3109/07420529908998710; RIGAS B, 1990, J CLIN GASTROENTEROL, V12, P409, DOI 10.1097/00004836-199008000-00011; ROBERT M, 1994, BRIT J UROL, V74, P294, DOI 10.1111/j.1464-410X.1994.tb16613.x; SINGH RK, 1993, EUR UROL, V24, P387	5	13	13	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 30	2002	324	7340					767	767		10.1136/bmj.324.7340.767	http://dx.doi.org/10.1136/bmj.324.7340.767			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	538KY	11923160	Green Published, Bronze			2022-12-28	WOS:000174816200017
J	Bradley, D				Bradley, D			Neuroscience - Moving through the landscape	SCIENCE			English	Editorial Material							DIRECTION; MOTION		Univ Chicago, Dept Psychol, Chicago, IL 60637 USA	University of Chicago	Bradley, D (corresponding author), Univ Chicago, Dept Psychol, 5848 S Univ Ave, Chicago, IL 60637 USA.							Britten KH, 1998, NAT NEUROSCI, V1, P59, DOI 10.1038/259; Froehler MT, 2002, SCIENCE, V295, P2462, DOI 10.1126/science.1067426; Gibson JJ, 1950, PERCEPTION VISUAL WO; SAITO H, 1986, J NEUROSCI, V6, P145; WARREN WH, 1988, NATURE, V336, P162, DOI 10.1038/336162a0	5	0	0	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 29	2002	295	5564					2385	2386		10.1126/science.1070867	http://dx.doi.org/10.1126/science.1070867			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	536QD	11923517				2022-12-28	WOS:000174712600033
J	Whitesides, GM; Grzybowski, B				Whitesides, GM; Grzybowski, B			Self-assembly at all scales	SCIENCE			English	Article							CAPILLARY FORCES; PATTERNS; MILLIMETER; OBJECTS	Self-assembty is the autonomous organization of components into patterns or structures without human intervention. Self-assembling processes are common throughout nature and technology. They involve components from the molecular (crystals) to the planetary (weather systems) scale and many different kinds of interactions. The concept of self-assembly is used increasingly in many disciplines, with a different flavor and emphasis in each.	Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA	Harvard University	Whitesides, GM (corresponding author), Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA.	gwhitesides@gmwgroup.harvard.edu	Grzybowski, Bartosz A/H-5741-2017; Grzybowski, Bartosz/B-7644-2009	Grzybowski, Bartosz/0000-0001-6613-4261				Aizenberg J, 1999, NATURE, V398, P495, DOI 10.1038/19047; Ball P., 1999, SELF MADE TAPESTRY P; Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; Bonabeau E, 2000, NATURE, V406, P39, DOI 10.1038/35017500; Bowden N, 1999, J AM CHEM SOC, V121, P5373, DOI 10.1021/ja983882z; BURNS MM, 1991, SCIENCE, V252, P1049, DOI 10.1126/science.252.5009.1049-a; Clark TD, 2001, J AM CHEM SOC, V123, P7677, DOI 10.1021/ja010634l; De Rosa C, 2000, NATURE, V405, P433, DOI 10.1038/35013018; Desiraju G. R., 1989, CRYSTAL ENG DESIGN O; Gates B, 2001, ADV MATER, V13, P1605, DOI 10.1002/1521-4095(200111)13:21<1605::AID-ADMA1605>3.0.CO;2-9; Gracias DH, 2000, SCIENCE, V289, P1170, DOI 10.1126/science.289.5482.1170; Gracias DH, 2002, ADV MATER, V14, P235, DOI 10.1002/1521-4095(20020205)14:3<235::AID-ADMA235>3.0.CO;2-B; GRZYBOWSKI B, UNPUB; Grzybowski BA, 2000, NATURE, V405, P1033, DOI 10.1038/35016528; Grzybowski BA, 2001, J PHYS CHEM B, V105, P404, DOI 10.1021/jp0026383; Hartgerink JD, 2001, SCIENCE, V294, P1684, DOI 10.1126/science.1063187; Hess B, 2000, NATURWISSENSCHAFTEN, V87, P199, DOI 10.1007/s001140050704; Huang Y, 2001, SCIENCE, V291, P630, DOI 10.1126/science.291.5504.630; Isaacs L, 1999, PER SUPRAMOL CHEM, V4, P1, DOI 10.1002/9780470511497.ch1; Ismagilov RF, 2001, APPL PHYS LETT, V79, P439, DOI 10.1063/1.1384473; JAKUBITH S, 1990, PHYS REV LETT, V65, P3013, DOI 10.1103/PhysRevLett.65.3013; Jones M.N., 1995, MICELLES MONOLAYERS; Loudet JC, 2000, NATURE, V407, P611, DOI 10.1038/35036539; Philp D, 1996, ANGEW CHEM INT EDIT, V35, P1154, DOI 10.1002/anie.199611541; Shapiro JA, 1998, ANNU REV MICROBIOL, V52, P81, DOI 10.1146/annurev.micro.52.1.81; Shimoyama N, 1996, PHYS REV LETT, V76, P3870, DOI 10.1103/PhysRevLett.76.3870; SIMPSON AW, 1972, NATURE, V237, P320, DOI 10.1038/237320a0; Singh R, 1998, J NONLINEAR SCI, V8, P235, DOI 10.1007/s003329900051; Srinivasan U, 2001, J MICROELECTROMECH S, V10, P17, DOI 10.1109/84.911087; vanBlaaderen A, 1997, NATURE, V385, P321, DOI 10.1038/385321a0; Whitesides GM, 1999, SCIENCE, V284, P89, DOI 10.1126/science.284.5411.89; Xia YN, 2000, ADV MATER, V12, P693, DOI 10.1002/(SICI)1521-4095(200005)12:10<693::AID-ADMA693>3.0.CO;2-J	32	5545	5697	72	3251	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 29	2002	295	5564					2418	2421		10.1126/science.1070821	http://dx.doi.org/10.1126/science.1070821			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	536QD	11923529				2022-12-28	WOS:000174712600045
J	Chase, JM; Leibold, MA				Chase, JM; Leibold, MA			Spatial scale dictates the productivity-biodiversity relationship	NATURE			English	Article							SPECIES RICHNESS; PATTERNS; COMMUNITIES	The diversity of life is heterogeneously distributed across the Earth. A primary cause for this pattern is the heterogeneity in the amount of energy, or primary productivity (the rate of carbon fixed through photosynthesis), available to the biota in a given location(1-12). But the shape of the relationship between productivity and species diversity is highly variable(10-14). In many cases, the relationship is 'hump-shaped', where diversity peaks at intermediate productivity(7,9,10,12,10,15-18). In other cases, diversity increases linearly with productivity(4-6,10-12). A possible reason for this discrepancy is that data are often collected at different spatial scales(10,12,14). If the mechanisms that determine species diversity vary with spatial scale, then so would the shape of the productivity-diversity relationship. Here, we present evidence for scale-dependent productivity-diversity patterns in ponds. When the data were viewed at a local scale (among ponds), the relationship was hump-shaped, whereas when the same data were viewed at a regional scale (among watersheds), the relationship was positively linear. This dependence on scale results because dissimilarity in local species composition within regions increased with productivity.	Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA; Univ Chicago, Dept Ecol & Evolut, Chicago, IL 60637 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Chicago	Chase, JM (corresponding author), Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA.	jchase@pitt.edu	B, A/AHB-5155-2022; Bond, Alexander L/A-3786-2010	Chase, Jonathan/0000-0001-5580-4303				ABRAMS PA, 1995, ECOLOGY, V76, P2019, DOI 10.2307/1941677; ABRAMSKY Z, 1984, NATURE, V309, P150, DOI 10.1038/309150a0; BROWN JH, 1981, AM ZOOL, V21, P877; CARPENTER S, 1998, ECOLOGY, V3; CONNELL JH, 1964, AM NAT, V98, P399, DOI 10.1086/282335; CURRIE DJ, 1991, AM NAT, V137, P27, DOI 10.1086/285144; CURRIE DJ, 1987, NATURE, V329, P326, DOI 10.1038/329326a0; Dodson SI, 2000, ECOLOGY, V81, P2662, DOI 10.1890/0012-9658(2000)081[2662:TRILCB]2.0.CO;2; Eaton A. D., 1998, STANDARD METHODS EXA; Gaston KJ, 2000, NATURE, V405, P220, DOI 10.1038/35012228; Gross KL, 2000, OIKOS, V89, P417, DOI 10.1034/j.1600-0706.2000.890301.x; LANDE R, 1996, OIKOS, V76, P393; Law R., 1999, ADV ECOLOGICAL THEOR, P141; Leibold MA, 1999, EVOL ECOL RES, V1, P73; Loreau M, 2000, ECOL LETT, V3, P73, DOI 10.1046/j.1461-0248.2000.00127.x; Lotka A. J., 1956, ELEMENTS MATH BIOL, DOI DOI 10.2307/1909476; MACARTHUR RH, 1965, BIOL REV, V40, P510, DOI 10.1111/j.1469-185X.1965.tb00815.x; MITCHELLOLDS T, 1987, EVOLUTION, V41, P1149, DOI [10.2307/2409084, 10.1111/j.1558-5646.1987.tb02457.x]; Mittelbach GG, 2001, ECOLOGY, V82, P2381, DOI 10.1890/0012-9658(2001)082[2381:WITORB]2.0.CO;2; Ritchie ME, 1999, NATURE, V400, P557, DOI 10.1038/23010; Rosenzweig Michael L., 1995, DOI 10.1017/CBO9780511623387.002; Tilman D., 1993, SPECIES DIVERSITY EC, P12; VITOUSEK PM, 1997, ECOLOGY, V1; Waide RB, 1999, ANNU REV ECOL SYST, V30, P257, DOI 10.1146/annurev.ecolsys.30.1.257; WHITTAKER R H, 1972, Taxon, V21, P213, DOI 10.2307/1218190; Wright David H., 1993, P66	26	582	623	17	355	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 28	2002	416	6879					427	430		10.1038/416427a	http://dx.doi.org/10.1038/416427a			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	534UX	11919631				2022-12-28	WOS:000174607800046
J	Esper, J; Cook, ER; Schweingruber, FH				Esper, J; Cook, ER; Schweingruber, FH			Low-frequency signals in long tree-ring chronologies for reconstructing past temperature variability	SCIENCE			English	Article							MEDIEVAL WARM PERIOD; SUMMER TEMPERATURES; CLIMATE; HOLOCENE; INFERENCES; CANADA	Preserving multicentennial climate variability in long tree-ring records is critically important for reconstructing the full range of temperature variability over the past 1000 years. This allows the putative "Medieval Warm Period" (MWP) to be described and to be compared with 20th-century warming in modeling and attribution studies. We demonstrate that carefully selected tree-ring chronologies from 14 sites in the Northern Hemisphere (NH) extratropics can preserve such coherent large-scale, multicentennial temperature trends if proper methods of analysis are used. In addition, we show that the average of these chronologies supports the large-scale occurrence of the MWP over the NH extratropics.	Lamont Doherty Earth Observ, Palisades, NY 10964 USA; Swiss Fed Res Inst WSL, CH-8903 Birmensdorf, Switzerland	Columbia University; Swiss Federal Institutes of Technology Domain; Swiss Federal Institute for Forest, Snow & Landscape Research	Cook, ER (corresponding author), Lamont Doherty Earth Observ, Palisades, NY 10964 USA.	drdendro@ldeo.columbia.edu	Esper, Jan/O-3127-2018	Esper, Jan/0000-0003-3919-014X				Bond G, 2001, SCIENCE, V294, P2130, DOI 10.1126/science.1065680; Bond G, 1997, SCIENCE, V278, P1257, DOI 10.1126/science.278.5341.1257; BRIFFA KR, 1992, CLIM DYNAM, V7, P111, DOI 10.1007/BF00211153; Briffa KR, 2001, J GEOPHYS RES-ATMOS, V106, P2929, DOI 10.1029/2000JD900617; Briffa KR, 2000, QUATERNARY SCI REV, V19, P87, DOI 10.1016/S0277-3791(99)00056-6; Briffa KR, 1998, NATURE, V391, P678, DOI 10.1038/35596; BRIFFA KR, 1995, NATURE, V376, P156, DOI 10.1038/376156a0; Broecker WS, 2001, SCIENCE, V291, P1497, DOI 10.1126/science.291.5508.1497; Cook E.R., 2013, METHODS DENDROCHRONO; COOK ER, 1995, HOLOCENE, V5, P229, DOI 10.1177/095968369500500211; Crowley TJ, 2000, SCIENCE, V289, P270, DOI 10.1126/science.289.5477.270; Crowley TJ, 2000, AMBIO, V29, P51, DOI 10.1579/0044-7447-29.1.51; D'Arrigo R, 2001, GEOPHYS RES LETT, V28, P543, DOI 10.1029/2000GL011845; Esper J, 2002, HOLOCENE, V12, P267, DOI 10.1191/0959683602hl543rp; ESPER J, IN PRESS TREE RING R; HUGHES MK, 1994, CLIMATIC CHANGE, V26, P109, DOI 10.1007/BF01092410; Jacoby GC, 1996, SCIENCE, V273, P771, DOI 10.1126/science.273.5276.771; Jones PD, 2001, SCIENCE, V292, P662, DOI 10.1126/science.1059126; Jones PD, 1998, HOLOCENE, V8, P455, DOI 10.1191/095968398667194956; Jones PD, 1999, REV GEOPHYS, V37, P173, DOI 10.1029/1999RG900002; LAMARCHE VC, 1974, SCIENCE, V183, P1043, DOI 10.1126/science.183.4129.1043; Lamb HH, 1965, PALAEOGEOGR PALAEOCL, V1, P13, DOI DOI 10.1016/0031-0182(65)90004-0; Lloyd AH, 1997, ECOLOGY, V78, P1199, DOI 10.1890/0012-9658(1997)078[1199:HDOTFI]2.0.CO;2; Luckman BH, 1997, HOLOCENE, V7, P375, DOI 10.1177/095968369700700401; Mann ME, 1999, GEOPHYS RES LETT, V26, P759, DOI 10.1029/1999GL900070; SZEICZ JM, 1995, QUATERNARY RES, V44, P257, DOI 10.1006/qres.1995.1070; [No title captured]	27	1024	1161	8	295	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 22	2002	295	5563					2250	2253		10.1126/science.1066208	http://dx.doi.org/10.1126/science.1066208			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	534AD	11910106				2022-12-28	WOS:000174561700040
J	van Hoof, A; Frischmeyer, PA; Dietz, HC; Parker, R				van Hoof, A; Frischmeyer, PA; Dietz, HC; Parker, R			Exosome-mediated recognition and degradation of mRNAs lacking a termination codon	SCIENCE			English	Article							3 END; PROTEIN; SURVEILLANCE; MECHANISM; INTERACTS; TURNOVER; COMPLEX; SYSTEM	One role of messenger RNA (mRNA) degradation is to maintain the fidelity of gene expression by degrading aberrant transcripts. Recent results show that mRNAs without translation termination codons are unstable in eukaryotic cells. We used yeast mutants to demonstrate that these "nonstop" mRNAs; are degraded by the exosome in a 3'-to-5' direction. The degradation of nonstop transcripts requires the exosome-associated protein Ski7p. Ski7p is closely related to the translation elongation factor EF1A and the translation termination factor eRF3. This suggests that the recognition of nonstop mRNAs involves the binding of Ski7p to an empty aminoacyl-(RNA-binding) site (A site) on the ribosome, thereby bringing the exosome to a mRNA with a ribosome stalled near the 3' end. This system efficiently degrades mRNAs that are prematurely polyadenylated within the coding region and prevents their expression.	Howard Hughes Med Inst, Chevy Chase, MD 20815 USA; Univ Arizona, Dept Mol & Cellular Biol, Tucson, AZ 85721 USA; Johns Hopkins Univ, Sch Med, Inst Med Genet, Baltimore, MD 21205 USA	Howard Hughes Medical Institute; University of Arizona; Johns Hopkins University	van Hoof, A (corresponding author), Howard Hughes Med Inst, 4000 Jones Bridge Rd, Chevy Chase, MD 20815 USA.	ambro@u.arizona.edu; rrparker@u.arizona.edu	Guerrerio, Pamela/S-9360-2019	van Hoof, Ambro/0000-0002-7800-9764				Allmang C, 1999, GENE DEV, V13, P2148, DOI 10.1101/gad.13.16.2148; Anderson JSJ, 1998, EMBO J, V17, P1497, DOI 10.1093/emboj/17.5.1497; Araki Y, 2001, EMBO J, V20, P4684, DOI 10.1093/emboj/20.17.4684; BEELMAN C, 1996, NATURE, V382, P577; Benard L, 1999, J VIROL, V73, P2893, DOI 10.1128/JVI.73.4.2893-2900.1999; Brown JT, 2000, RNA, V6, P449, DOI 10.1017/S1355838200991787; Burkard KTD, 2000, MOL CELL BIOL, V20, P604, DOI 10.1128/MCB.20.2.604-616.2000; Chen CY, 2001, CELL, V107, P451, DOI 10.1016/S0092-8674(01)00578-5; Frischmeyer PA, 2002, SCIENCE, V295, P2258, DOI 10.1126/science.1067338; Hilleren P, 1999, RNA, V5, P711, DOI 10.1017/S1355838299990519; Karzai AW, 2000, NAT STRUCT BIOL, V7, P449; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Mahadevan S, 1997, GENE, V190, P69, DOI 10.1016/S0378-1119(96)00708-1; Mitchell P, 2000, NAT STRUCT BIOL, V7, P843, DOI 10.1038/82817; Mitchell P, 1996, GENE DEV, V10, P502, DOI 10.1101/gad.10.4.502; MUHLRAD D, 1994, GENE DEV, V8, P855, DOI 10.1101/gad.8.7.855; MUHLRAD D, 1995, MOL CELL BIOL, V15, P2145; Muto A, 1998, TRENDS BIOCHEM SCI, V23, P25, DOI 10.1016/S0968-0004(97)01159-6; PULAK R, 1993, GENE DEV, V7, P1885, DOI 10.1101/gad.7.10.1885; SIKORSKI RS, 1989, GENETICS, V122, P19; Tucker M, 2001, CELL, V104, P377, DOI 10.1016/S0092-8674(01)00225-2; van Hoof A, 2000, MOL CELL BIOL, V20, P8230, DOI 10.1128/MCB.20.21.8230-8243.2000; van Hoof A, 1999, CELL, V99, P347, DOI 10.1016/S0092-8674(00)81520-2	23	402	413	2	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 22	2002	295	5563					2262	2264		10.1126/science.1067272	http://dx.doi.org/10.1126/science.1067272			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	534AD	11910110				2022-12-28	WOS:000174561700044
J	Kastrati, A; Mehilli, J; Dirschinger, J; Schricke, U; Neverve, J; Pache, J; Martinoff, S; Neumann, FJ; Nekolla, S; Blasini, R; Seyfarth, M; Schwaiger, M; Schomig, A				Kastrati, A; Mehilli, J; Dirschinger, J; Schricke, U; Neverve, J; Pache, J; Martinoff, S; Neumann, FJ; Nekolla, S; Blasini, R; Seyfarth, M; Schwaiger, M; Schomig, A		STOPAMI-2	Myocardial salvage after coronary stenting plus abciximab versus fibrinolysis plus abciximab in patients with acute myocardial infarction: a randomised trial	LANCET			English	Article							GLYCOPROTEIN IIB/IIIA INHIBITION; INFLAMMATORY RESPONSES; THROMBOLYTIC THERAPY; BALLOON ANGIOPLASTY; REPERFUSION; BLOCKADE; PLACEMENT; QUANTIFICATION; ANTIPLATELET; DYSFUNCTION	Background Patients with acute myocardial infarction might benefit from the addition of glycoprotein IIb/IIIa inhibitors to fibrinolytic or mechanical reperfusion strategies. We compared two strategies, stenting and fibrinolysis, both combined with abciximab, in terms of their ability to salvage myocardium in patients with acute myocardial infarction. Methods We enrolled 162 patients with acute myocardial infarction within 12 h of onset of symptoms, assigning 81 stenting plus abciximab and 81 alteplase plus abciximab. Technetium-99m sestamibi scintigraphy was done at admission and after a median of 11 days to calculate initial perfusion defect, final infarct size, and degree of myocardial salvage. The primary endpoint was the salvage index (the ratio of the degree of myocardial salvage to the initial perfusion defect). Major adverse clinical events within 6 months from randomisation were also compared between the two treatments. Findings Paired scintigraphic measurements were available for 70 patients in the stent group and 71 in the alteplase group. Stenting was associated with greater myocardial salvage than alteplase (median 13.6% [IQR 5.9-23.9] vs 8.0% [2.5-16.0] of the left ventricle; p=0.007). Salvage index was greater in the stent group than in the alteplase group (median 0.60 [0.37-0.82] vs 0.41 [0.13-0.58]; p=0.001). The 6-month mortality rate was 5% (four deaths) in the stent group and 9% (seven deaths) in the alteplase group (relative risk 0.56 [95% CI 0.17-1.88]; p=0.35). Interpretation In patients with acute myocardial infarction, a reperfusion strategy based on stenting with abciximab produced more myocardial salvage than the combination of fibrinolysis plus abciximab. Larger studies are needed to assess whether these effects translate into clinical benefit.	Tech Univ Munich, Deutsch Herzzentrum, D-80636 Munich, Germany; Tech Univ Munich, Klin & Poliklin Nukl Med Rechts der Isar, D-8000 Munich, Germany; Tech Univ Munich, Med Klin Rechts der Isar 1, D-8000 Munich, Germany	German Heart Center Berlin; German Heart Centre Munich; Technical University of Munich; Technical University of Munich; Technical University of Munich	Kastrati, A (corresponding author), Tech Univ Munich, Deutsch Herzzentrum, Lazarettstr 36, D-80636 Munich, Germany.	kastrati@dhm.mhn.de	Nekolla, Stephan G/L-1857-2013; Mehilli, Julinda/F-2629-2016; , Kastrati/Y-2389-2019	Nekolla, Stephan G/0000-0002-8817-1482; schwaiger, markus/0000-0002-2305-7144				Antman EM, 1999, CIRCULATION, V99, P2720, DOI 10.1161/01.CIR.99.21.2720; Beller GA, 2000, CIRCULATION, V101, P1465, DOI 10.1161/01.CIR.101.12.1465; BRAUNWALD E, 1989, CIRCULATION, V79, P441, DOI 10.1161/01.CIR.79.2.441; Califf RM, 2000, AM HEART J, V139, pS33, DOI 10.1067/mhj.2000.104090; Coller BS, 1999, AM HEART J, V138, pS1, DOI 10.1053/hj.1999.v138.99078; Coller BS, 1999, THROMB HAEMOSTASIS, V82, P326; Coller BS, 1997, THROMB HAEMOSTASIS, V78, P730; COLLER BS, 1990, NEW ENGL J MED, V322, P33, DOI 10.1056/NEJM199001043220107; de Lemos JA, 2000, CIRCULATION, V101, P239, DOI 10.1161/01.CIR.101.3.239; Every NR, 1996, NEW ENGL J MED, V335, P1253, DOI 10.1056/NEJM199610243351701; Gassler JP, 1999, CLIN CARDIOL, V22, P20, DOI 10.1002/clc.4960221605; Gawaz M, 1996, CIRCULATION, V93, P229, DOI 10.1161/01.CIR.93.2.229; Gibbons RJ, 2000, CIRCULATION, V101, P101, DOI 10.1161/01.CIR.101.1.101; GIBBONS RJ, 1989, CIRCULATION, V80, P1277, DOI 10.1161/01.CIR.80.5.1277; Kastrati A, 2001, CIRCULATION, V103, P2816; Lefer AM, 1998, CIRCULATION, V98, P1322, DOI 10.1161/01.CIR.98.13.1322; Lincoff AM, 1999, NEW ENGL J MED, V341, P319, DOI 10.1056/NEJM199907293410503; Magid DJ, 2000, JAMA-J AM MED ASSOC, V284, P3131, DOI 10.1001/jama.284.24.3131; Montalescot G, 2001, NEW ENGL J MED, V344, P1895, DOI 10.1056/NEJM200106213442503; NEUMANN FJ, 1995, CIRCULATION, V92, P748, DOI 10.1161/01.CIR.92.4.748; Neumann FJ, 1998, CIRCULATION, V98, P2695, DOI 10.1161/01.CIR.98.24.2695; O'Shea JC, 2001, JAMA-J AM MED ASSOC, V285, P2468, DOI 10.1001/jama.285.19.2468; Ott I, 1998, AM J CARDIOL, V82, P938, DOI 10.1016/S0002-9149(98)00509-8; Roe MT, 2001, J AM COLL CARDIOL, V37, P9, DOI 10.1016/S0735-1097(00)01101-3; Schomig A, 1996, NEW ENGL J MED, V334, P1084, DOI 10.1056/NEJM199604253341702; Schomig A, 2000, NEW ENGL J MED, V343, P385, DOI 10.1056/NEJM200008103430602; Schomig A, 1997, J AM COLL CARDIOL, V29, P28, DOI 10.1016/S0735-1097(96)00450-0; SINUSAS AJ, 1990, CIRCULATION, V82, P1424, DOI 10.1161/01.CIR.82.4.1424; Stone GW, 2000, CIRCULATION, V102, P664; Takehana K, 2001, J NUCL CARDIOL, V8, P40, DOI 10.1067/mnc.2001.110387; Tiefenbrunn AJ, 1998, J AM COLL CARDIOL, V31, P1240, DOI 10.1016/S0735-1097(98)00094-1; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; Topol EJ, 2000, CIRCULATION, V101, P2788; Topol EJ, 2001, LANCET, V357, P1905; Topol EJ, 2000, HEART, V83, P122, DOI 10.1136/heart.83.1.122; VERANI MS, 1988, J AM COLL CARDIOL, V12, P1573, DOI 10.1016/S0735-1097(88)80028-7; Weaver WD, 1997, JAMA-J AM MED ASSOC, V278, P2093, DOI 10.1001/jama.278.23.2093; Zahn R, 2000, J AM COLL CARDIOL, V36, P2064, DOI 10.1016/S0735-1097(00)00981-5	38	166	172	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 16	2002	359	9310					920	925		10.1016/S0140-6736(02)08022-4	http://dx.doi.org/10.1016/S0140-6736(02)08022-4			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	531AE	11918909				2022-12-28	WOS:000174391700009
J	Dorffler-Melly, J; de Jonge, E; de Pont, AC; Meijers, J; Vroom, MB; Buller, HR; Levi, M				Dorffler-Melly, J; de Jonge, E; de Pont, AC; Meijers, J; Vroom, MB; Buller, HR; Levi, M			Bioavailability of subcutaneous low-molecular-weight heparin to patients on vasopressors	LANCET			English	Article							DEEP-VEIN THROMBOSIS; ENOXAPARIN; PREVENTION	Venous thromboembolism is a frequent complication in patients admitted to intensive care units (ICU), despite prophylactic treatment with subcutaneous low-molecular-weight (LMW) heparin. We postulated that poor efficacy of subcutaneous heparin might be due to administration of vasopressors, which could cause impaired peripheral circulation and inadequate systemic bioavailability of the anticoagulant. We compared concentrations of factor Xa activity in three groups of 15 patients: Individuals In ICU who had and had not received vasopressors, and general surgery patients. Those who received vasopressors had lower plasma concentrations of factor-Xa activity than patients in ICU not on vasopressors and postoperative controls. Patients in ICU who take vasopressors could need higher doses of LMW heparin, or a different mode of administration of the drug, to attain adequate thrombosis prophylaxis.	Univ Amsterdam, Acad Med Ctr, Dept Vasc Med Internal Med, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Intens Care, NL-1105 AZ Amsterdam, Netherlands; Inselspital Bern, Div Angiol, CH-3010 Bern, Switzerland	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Bern; University Hospital of Bern	Levi, M (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Vasc Med Internal Med, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.		Levi, Marcel/AAZ-8559-2020; Meijers, J.C.M./S-5981-2019	Meijers, J.C.M./0000-0002-4198-6780				Attia J, 2001, ARCH INTERN MED, V161, P1268, DOI 10.1001/archinte.161.10.1268; Bara L, 1999, BRIT J HAEMATOL, V104, P230, DOI 10.1046/j.1365-2141.1999.01153.x; LEYVRAZ PF, 1991, BRIT MED J, V303, P543, DOI 10.1136/bmj.303.6802.543; Samama MM, 1999, NEW ENGL J MED, V341, P793, DOI 10.1056/NEJM199909093411103	4	149	154	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 9	2002	359	9309					849	850		10.1016/S0140-6736(02)07920-5	http://dx.doi.org/10.1016/S0140-6736(02)07920-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	529YV	11897286				2022-12-28	WOS:000174329600014
J	Moore, MJ				Moore, MJ			Nuclear RNA turnover	CELL			English	Review							DEGRADATION; PROTEIN; EXOSOME	In mammalian cells, significantly more RNA is turned over in the nucleus than in the cytoplasm. However, only recently have we begun to understand the mechanisms and regulation of nuclear RNA decay.	Brandeis Univ, Dept Biochem, Howard Hughes Med Inst, Waltham, MA 02454 USA	Brandeis University; Howard Hughes Medical Institute	Moore, MJ (corresponding author), Brandeis Univ, Dept Biochem, Howard Hughes Med Inst, 415 South St, Waltham, MA 02454 USA.							Bousquet-Antonelli C, 2000, CELL, V102, P765, DOI 10.1016/S0092-8674(00)00065-9; Brennan CM, 2001, CELL MOL LIFE SCI, V58, P266, DOI 10.1007/PL00000854; Burkard KTD, 2000, MOL CELL BIOL, V20, P604, DOI 10.1128/MCB.20.2.604-616.2000; Chen CY, 2001, CELL, V107, P451, DOI 10.1016/S0092-8674(01)00578-5; Clement JQ, 2001, J BIOL CHEM, V276, P16919, DOI 10.1074/jbc.M005104200; Geerlings TH, 2000, RNA, V6, P1698, DOI 10.1017/S1355838200001540; Guhaniyogi J, 2001, GENE, V265, P11, DOI 10.1016/S0378-1119(01)00350-X; Hilleren P, 2001, NATURE, V413, P538, DOI 10.1038/35097110; Iborra FJ, 2001, SCIENCE, V293, P1139, DOI 10.1126/science.1061216; Ishigaki Y, 2001, CELL, V106, P607, DOI 10.1016/S0092-8674(01)00475-5; Jackson DA, 2000, FASEB J, V14, P242, DOI 10.1096/fasebj.14.2.242; Maquat LE, 2001, CELL, V104, P173, DOI 10.1016/S0092-8674(01)00202-1; Mitchell P, 2000, NAT STRUCT BIOL, V7, P843, DOI 10.1038/82817; Muhlemann O, 2001, MOL CELL, V8, P33, DOI 10.1016/S1097-2765(01)00288-X; Mukherjee D, 2002, EMBO J, V21, P165, DOI 10.1093/emboj/21.1.165; Nam K, 1997, MOL CELL BIOL, V17, P809, DOI 10.1128/MCB.17.2.809; van Hoof A, 1999, CELL, V99, P347, DOI 10.1016/S0092-8674(00)81520-2; Wilusz CJ, 2001, GENE DEV, V15, P2781; Xue Y, 2000, MOL CELL BIOL, V20, P4006, DOI 10.1128/MCB.20.11.4006-4015.2000	19	63	68	0	17	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	FEB 22	2002	108	4					431	434		10.1016/S0092-8674(02)00645-1	http://dx.doi.org/10.1016/S0092-8674(02)00645-1			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	524XW	11909514	Bronze			2022-12-28	WOS:000174039000001
J	Frey, SE; Newman, FK; Cruz, J; Shelton, WB; Tennant, JM; Polach, T; Rothman, AL; Kennedy, JS; Wolff, M; Belshe, RB; Ennis, FA				Frey, SE; Newman, FK; Cruz, J; Shelton, WB; Tennant, JM; Polach, T; Rothman, AL; Kennedy, JS; Wolff, M; Belshe, RB; Ennis, FA			Dose-related effects of smallpox vaccine	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							T-LYMPHOCYTES; VIRUS; RESPONSES; BIOTERRORISM; ADULTS	Background: We conducted a double-blind, randomized trial of three dilutions of vaccinia virus vaccine in previously unimmunized adults in order to assess the clinical success rates, humoral responses, and virus-specific activity of cytotoxic T cells and interferon-gamma-producing T cells. Methods: Sixty healthy adults were inoculated intradermally by bifurcated needle with undiluted vaccine (dose, 10(7.8))plaque-forming units [pfu] per milliliter), a 1:10 dilution (dose, 10(6.5) pfu per milliliter), or a 1:100 dilution (dose, 10(5.0) pfu per milliliter); there were 20 subjects in each group. The subjects were monitored with respect to vesicle formation (an indicator of successful vaccination), the viral titer at the time of peak lesion formation, antiviral antibodies, and cellular immune responses. Results: A vaccinia vesicle developed in 19 of the 20 subjects who received undiluted vaccine (95 percent), 14 of the 20 who received the 1:10 dilution (70 percent), and 3 of the 20 who received the 1:100 dilution (15 percent). One month after vaccination, 34 of 36 subjects with vesicles had antibody responses, as compared with only 1 of 24 subjects without clinical evidence of vaccinia virus replication. Vigorous cytotoxic T-cell and interferon-gamma responses occurred in 94 percent of subjects with vesicles, and a cytotoxic T-cell response occurred in only one subject without a vesicle. Conclusions: The vaccinia virus vaccine (which was produced in 1982 or earlier) still has substantial potency when administered by a bifurcated needle to previously unvaccinated adults. Diluting the vaccine reduces the rate of successful vaccination. The development of vesicular skin lesions after vaccination correlates with the induction of the antibody and T-cell responses that are considered essential for clearing vaccinia virus infections.	St Louis Univ, Hlth Sci Ctr, Sch Med,Dept Med,Div Infect Dis & Immunol, Natl Inst Allergy & Infect Dis,Vaccine & Treatmen, St Louis, MO 63110 USA; Univ Massachusetts, Sch Med, Ctr Infect Dis & Vaccine Res, Worcester, MA USA; Emmes Corp, Rockville, MD USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Saint Louis University; University of Massachusetts System; University of Massachusetts Worcester; Emmes Corporation	Frey, SE (corresponding author), St Louis Univ, Hlth Sci Ctr, Sch Med,Dept Med,Div Infect Dis & Immunol, Natl Inst Allergy & Infect Dis,Vaccine & Treatmen, 3635 Vista Ave,FDT-8N, St Louis, MO 63110 USA.			Blevins, Tamara/0000-0003-1955-2641	NIAID NIH HHS [N01-AI-45250] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI045250] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CHERRY JD, 1977, J INFECT DIS, V135, P145, DOI 10.1093/infdis/135.1.145; Co MDT, 2002, VIROLOGY, V293, P151, DOI 10.1006/viro.2001.1255; CONNOR JD, 1977, J INFECT DIS, V135, P167, DOI 10.1093/infdis/135.1.167; Demkowicz WE, 1996, J VIROL, V70, P2627, DOI 10.1128/JVI.70.4.2627-2631.1996; DEMKOWICZ WE, 1993, J VIROL, V67, P1538, DOI 10.1128/JVI.67.3.1538-1544.1993; FULGINITI VA, 1968, BIRTH DEFECTS OAS, V4, P129; GRAHAM BS, 1992, J INFECT DIS, V166, P244, DOI 10.1093/infdis/166.2.244; GREEN S, 1993, J VIROL, V67, P5962, DOI 10.1128/JVI.67.10.5962-5967.1993; Henderson DA, 1999, EMERG INFECT DIS, V5, P491, DOI 10.3201/eid0504.990401; Henderson DA, 1999, EMERG INFECT DIS, V5, P537, DOI 10.3201/eid0504.990415; HOLANDER M, 1973, NONPARAMETRIC STAT M, P115; IACONOCONNORS LC, 1994, CLIN DIAGN LAB IMMUN, V1, P78, DOI 10.1128/CDLI.1.1.78-82.1994; KATZ JB, 1987, J BIOL STAND, V15, P389, DOI 10.1016/S0092-1157(87)80013-6; LANE JM, 1969, NEW ENGL J MED, V281, P1201, DOI 10.1056/NEJM196911272812201; McClain DJ, 1997, J INFECT DIS, V175, P756, DOI 10.1086/513968; Nanan R, 2000, J GEN VIROL, V81, P1313, DOI 10.1099/0022-1317-81-5-1313; OCONNELL CJ, 1964, ANN INTERN MED, V60, P282, DOI 10.7326/0003-4819-60-2-282; REDFIELD RR, 1987, NEW ENGL J MED, V316, P673, DOI 10.1056/NEJM198703123161106; Russell PK, 1999, EMERG INFECT DIS, V5, P531, DOI 10.3201/eid0504.990413; Shalala DE, 1999, EMERG INFECT DIS, V5, P492, DOI 10.3201/eid0504.990402; WHO, 1980, WKLY EPIDEMIOL REC, V55, P148; 1983, MMWR MORB MORTAL WKL, V32, P387	22	154	155	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 25	2002	346	17					1275	1280		10.1056/NEJMoa013431	http://dx.doi.org/10.1056/NEJMoa013431			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	544GX	11923489	Green Published			2022-12-28	WOS:000175150800003
J	Brummelkamp, TR; Bernards, R; Agami, R				Brummelkamp, TR; Bernards, R; Agami, R			A system for stable expression of short interfering RNAs in mammalian cells	SCIENCE			English	Article							GENE	Mammalian genetic approaches to study gene function have been hampered by the lack of toots to generate stable loss-of-function phenotypes efficiently. We report here a new vector system, named pSUPER, which directs the synthesis of small interfering RNAs (siRNAs) in mammalian cells. We show that siRNA expression mediated by this vector causes efficient and specific down-regulation of gene expression, resulting in functional inactivation of the targeted genes. Stable expression of siRNAs using this vector mediates persistent suppression of gene expression, allowing the analysis of loss-of-function phenotypes that develop over longer periods of time. Therefore, the pSUPER vector constitutes a new and powerful system to analyze gene function in a variety of mammalian cell types.	Netherlands Canc Inst, Div Mol Carcinogenesis, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Div Tumor Biol, NL-1066 CX Amsterdam, Netherlands; Ctr Biomed Genet, Utrecht, Netherlands	Netherlands Cancer Institute; Netherlands Cancer Institute	Agami, R (corresponding author), Netherlands Canc Inst, Div Mol Carcinogenesis, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.		agami, reuven/GOG-8289-2022	Agami, Reuven/0000-0002-2848-2473				Agami R, 2000, CELL, V102, P55, DOI 10.1016/S0092-8674(00)00010-6; BAER M, 1990, NUCLEIC ACIDS RES, V18, P97, DOI 10.1093/nar/18.1.97; BRUMMELKAMP TR, UNPUB; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; HUNTER T, 1975, J BIOL CHEM, V250, P409; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Sharp PA, 1999, GENE DEV, V13, P139, DOI 10.1101/gad.13.2.139	7	3654	4895	9	354	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 19	2002	296	5567					550	553		10.1126/science.1068999	http://dx.doi.org/10.1126/science.1068999			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	544UE	11910072	Green Published			2022-12-28	WOS:000175179400052
J	Donnelly, SE; Birtcher, RC; Allen, CW; Morrison, I; Furuya, K; Song, MH; Mitsuishi, K; Dahmen, U				Donnelly, SE; Birtcher, RC; Allen, CW; Morrison, I; Furuya, K; Song, MH; Mitsuishi, K; Dahmen, U			Ordering in a fluid inert gas confined by flat surfaces	SCIENCE			English	Article							LIQUID INTERFACE; HARD-SPHERES; SIMULATION; TEMPERATURE; TRANSITION; ALUMINUM; WALL	High-resolution transmission electron microscopy images of room-temperature fluid xenon in small faceted cavities in aluminum reveal the presence of three well-defined layers within the fluid at each facet. Such interfacial layering of simple liquids has been theoretically predicted, but observational evidence has been ambiguous. Molecular dynamics simulations indicate that the density variation induced by the layering will cause xenon, confined to an approximately cubic cavity of volume approximate to 8 cubic nanometers, to condense into the body-centered cubic phase, differing from the face-centered cubic phase of both bulk solid xenon and solid xenon confined in somewhat larger (greater than or equal to 20 cubic nanometer) tetradecahedral cavities in face-centered cubic metals. Layering at the liquid-solid interface plays an important role in determining physical properties as diverse as the rheological behavior of two-dimensionally confined liquids and the dynamics of crystal growth.	Univ Salford, Inst Mat Res, Joule Phys Lab, Salford M5 4WT, Lancs, England; Argonne Natl Lab, Div Mat Sci, Argonne, IL 60439 USA; Natl Inst Mat Sci, Tsukuba, Ibaraki 305, Japan; LBNL, Natl Ctr Electron Microscopy, Berkeley, CA 94720 USA	University of Salford; United States Department of Energy (DOE); Argonne National Laboratory; National Institute for Materials Science; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory	Donnelly, SE (corresponding author), Univ Salford, Inst Mat Res, Joule Phys Lab, Salford M5 4WT, Lancs, England.		MITSUISHI, Kazutaka/H-2627-2011	Morrison, Ian/0000-0002-6886-1398; Donnelly, Stephen/0000-0002-9749-5550; Mitsuishi, Kazutaka/0000-0002-9361-4057				Birtcher RC, 1999, PHYS REV LETT, V83, P1617, DOI 10.1103/PhysRevLett.83.1617; BONISSENT A, 1977, PHILOS MAG, V35, P67; CAHN JW, 1985, PHYS REV B, V31, P4300, DOI 10.1103/PhysRevB.31.4300; DONNELLY S, UNPUB; DONNELLY SE, 1985, SCIENCE, V230, P1272, DOI 10.1126/science.230.4731.1272; DONNELLY SE, 1985, RADIAT EFF, V90, P47; DONNELLY SE, 1999, P INT CENT S EL I MA, P306; Furuya K, 1999, J MICROSC-OXFORD, V194, P152, DOI 10.1046/j.1365-2818.1999.00451.x; Howe JM, 1996, PHILOS MAG A, V74, P761, DOI 10.1080/01418619608243540; Huisman WJ, 1997, NATURE, V390, P379, DOI 10.1038/37069; ISRAELACHVILI JN, 1992, INTERMOLECULAR FORCE, P261; Kegel WK, 1999, PHYS REV LETT, V83, P5298, DOI 10.1103/PhysRevLett.83.5298; LAIRD BB, 1992, CHEM REV, V92, P1819, DOI 10.1021/cr00016a007; *MACT, TOT RES; PIZZINI S, 1990, PHIL MAG LETT, V61, P223, DOI 10.1080/09500839008202362; PLISCHKE M, 1986, J CHEM PHYS, V84, P2846, DOI 10.1063/1.450311; Refson K, 2000, COMPUT PHYS COMMUN, V126, P310, DOI 10.1016/S0010-4655(99)00496-8; Schmidt M, 1997, PHYS REV E, V55, P7228, DOI 10.1103/PhysRevE.55.7228; Smith W, 1996, J MOL GRAPHICS, V14, P136, DOI 10.1016/S0263-7855(96)00043-4; Spaepen F, 1994, SOLID STATE PHYS, V47, P1, DOI 10.1016/S0081-1947(08)60638-4; TEMPLIER C, 1985, MATER SCI ENG, V69, P63, DOI 10.1016/0025-5416(85)90373-8; Vom Felde A., 1984, PHYS REV LETT, V53, P922, DOI [10.1103/PhysRevLett.53.922, DOI 10.1103/PHYSREVLETT.53.922]; Yu CJ, 1999, PHYS REV LETT, V82, P2326, DOI 10.1103/PhysRevLett.82.2326	23	110	111	0	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 19	2002	296	5567					507	510		10.1126/science.1068521	http://dx.doi.org/10.1126/science.1068521			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	544UE	11910071				2022-12-28	WOS:000175179400039
J	Musser, RO; Hum-Musser, SM; Eichenseer, H; Peiffer, M; Ervin, G; Murphy, JB; Felton, GW				Musser, RO; Hum-Musser, SM; Eichenseer, H; Peiffer, M; Ervin, G; Murphy, JB; Felton, GW			Herbivory: Caterpillar saliva beats plant defences - A new weapon emerges in the evolutionary arms race between plants and herbivores.	NATURE			English	Article									Univ Arkansas, Dept Entomol, Fayetteville, AR 72701 USA; Univ Arkansas, Dept Hort, Fayetteville, AR 72701 USA; Penn State Univ, Dept Entomol, University Pk, PA 16802 USA	University of Arkansas System; University of Arkansas Fayetteville; University of Arkansas System; University of Arkansas Fayetteville; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Musser, RO (corresponding author), Univ Arkansas, Dept Entomol, Fayetteville, AR 72701 USA.		Felton, Gary W./E-8575-2013	Musser, Richard/0000-0002-9331-4249				Alborn HT, 1997, SCIENCE, V276, P945, DOI 10.1126/science.276.5314.945; Eichenseer H, 1999, ARCH INSECT BIOCHEM, V42, P99, DOI 10.1002/(SICI)1520-6327(199909)42:1&lt;99::AID-ARCH10&gt;3.0.CO;2-B; FELTON GW, 1999, INDUCED PLANT DEFENC; Kahl J, 2000, PLANTA, V210, P336, DOI 10.1007/PL00008142; MATTIACCI L, 1995, P NATL ACAD SCI USA, V92, P2036, DOI 10.1073/pnas.92.6.2036; Ribeiro J.M., 1995, REGULATORY MECH INSE; SAUNDERS JA, 1981, J CHROMATOGR, V205, P147, DOI 10.1016/S0021-9673(00)81822-1	7	367	411	5	197	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 11	2002	416	6881					599	600		10.1038/416599a	http://dx.doi.org/10.1038/416599a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	539YV	11948341				2022-12-28	WOS:000174901900029
J	Giorgini, JD; Ostro, SJ; Benner, LAM; Chodas, PW; Chesley, SR; Hudson, RS; Nolan, MC; Klemola, AR; Standish, EM; Jurgens, RF; Rose, R; Chamberlain, AB; Yeomans, DK; Margot, JL				Giorgini, JD; Ostro, SJ; Benner, LAM; Chodas, PW; Chesley, SR; Hudson, RS; Nolan, MC; Klemola, AR; Standish, EM; Jurgens, RF; Rose, R; Chamberlain, AB; Yeomans, DK; Margot, JL			Asteroid 1950 DA's encounter with Earth in 2880: Physical limits of collision probability prediction	SCIENCE			English	Article							CROSSING ASTEROIDS; DYNAMICS	Integration of the orbit of asteroid (29075) 1950 DA, which is based on radar and optical measurements spanning 51 years, reveals a 20-minute interval in March 2880 when there could be a nonnegligible probability of the 1-kilometer object colliding with Earth. Trajectory knowledge remains accurate until then because of extensive astrometric data, an inclined orbit geometry that reduces in-plane perturbations, and an orbit uncertainty space modulated by gravitational resonance. The approach distance uncertainty in 2880 is determined primarily by uncertainty in the accelerations arising from thermal re-radiation of solar energy absorbed by the asteroid. Those accelerations depend on the spin axis, composition, and surface properties of the asteroid, so that refining the collision probability may require direct inspection by a spacecraft.	CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; Washington State Univ, Sch Elect Engn & Comp Sci, Pullman, WA 99164 USA; Arecibo Observ, Arecibo, PR 00612 USA; Univ Calif Santa Cruz, Lick Observ, Santa Cruz, CA 95064 USA; CALTECH, Pasadena, CA 91125 USA	California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); Washington State University; National Aeronautics & Space Administration (NASA); University of California System; University of California Santa Cruz; California Institute of Technology	Giorgini, JD (corresponding author), CALTECH, Jet Prop Lab, 4800 Oak Grove Dr, Pasadena, CA 91109 USA.	Jon.Giorgini@jpl.nasa.gov	Nolan, Michael C/H-4980-2012; Margot, Jean-Luc/A-6154-2012	Nolan, Michael C/0000-0001-8316-0680; Margot, Jean-Luc/0000-0001-9798-1797				BARDWELL CM, 2001, 2001A26 MIN PLAN EL; Bierman G. J., 1977, FACTORIZATION METHOD; Boattini A, 2001, ASTRON ASTROPHYS, V375, P293, DOI 10.1051/0004-6361:20010825; BOTTKE WF, 2001, COMMUNICATION   0531; BOWELL E, 1989, ASTEROIDS 2, P551; CHESLEY SR, IN PRESS ICARUS; CHODAS PW, 1999, 99462 AM ASTR SOC; Giorgini J.D., 1996, AAS DIV PLAN SCI M A; HEISLER J, 1986, ICARUS, V65, P13, DOI 10.1016/0019-1035(86)90060-6; HUDSON RS, 1993, REMOTE SENSING REV, V8, P195, DOI DOI 10.1080/02757259309532195; Innanen KA, 1996, EARTH MOON PLANETS, V72, P1, DOI 10.1007/BF00117494; *JET PROP LAB JPL, 2001, 2001O20 JPL MIN PLAN; JOKIPII JR, 1989, COSMIC WINDS HELIOSP; KLEMOLA AR, 2001, 2001K23 MIN PLAN EL; LAWSON CL, 1995, SIAM CLASSICS APL MA, V15; *LONEOS SKY SURV, 2001, 2001A22 MIN PLAN EL; MILANI A, 1989, ICARUS, V78, P212, DOI 10.1016/0019-1035(89)90174-7; Milani A, 1998, CELEST MECH DYN ASTR, V71, P35, DOI 10.1023/A:1008387200742; Moyer T.D., 1971, 321527 JPL CAL I TEC; Pravec P, 2000, ICARUS, V148, P12, DOI 10.1006/icar.2000.6482; PRAVEC P, 2001, COMMUNICATION   0812; READ M, 2001, 2001F44 MIN PLAN EL; Standish E.M., 1992, EXPLANATORY SUPPLEME, P279; STANDISH EM, 1995, IAU SYMP, V10, P180, DOI 10.1017/S1539299600010893; Vokrouhlicky D, 2000, ICARUS, V148, P118, DOI 10.1006/icar.2000.6469; WIRTANEN CA, 1950, MINOR PLANET CIRC, P416	26	65	67	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 5	2002	296	5565					132	136		10.1126/science.1068191	http://dx.doi.org/10.1126/science.1068191			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	539FA	11935024				2022-12-28	WOS:000174858800045
J	Spitale, JN				Spitale, JN			Planetary science - Asteroid hazard mitigation using the Yarkovsky effect	SCIENCE			English	Article									Univ Arizona, Lunar & Planetary Lab, Tucson, AZ 85719 USA	University of Arizona	Spitale, JN (corresponding author), Univ Arizona, Lunar & Planetary Lab, 1621 E Univ, Tucson, AZ 85719 USA.							Farinella P, 2001, ASTRON ASTROPHYS, V377, P1081, DOI 10.1051/0004-6361:20011054; Hudson RS, 2000, ICARUS, V148, P37, DOI 10.1006/icar.2000.6483; KRING DA, 1993, P 1 ANN S FOSS AR ME, P63; MELOSH HJ, 1993, HAZARDS DUE COMETS A, P1111; Spitale J, 2001, ICARUS, V149, P222, DOI 10.1006/icar.2000.6477; Vokrouhlicky D, 2000, ICARUS, V148, P118, DOI 10.1006/icar.2000.6469	6	24	24	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 5	2002	296	5565					77	77		10.1126/science.1069577	http://dx.doi.org/10.1126/science.1069577			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	539FA	11935016				2022-12-28	WOS:000174858800037
J	Velikov, KP; Christova, CG; Dullens, RPA; van Blaaderen, A				Velikov, KP; Christova, CG; Dullens, RPA; van Blaaderen, A			Layer-by-layer growth of binary colloidal crystals	SCIENCE			English	Article							HARD-SPHERE COLLOIDS; SUPERLATTICE FORMATION; MIXTURES; CRYSTALLIZATION; PARTICLES	We report the growth of binary colloidal crystals with control over the crystal orientation through a simple layer-by-layer process, Well-ordered single binary colloidal crystals with a stoichiometry of large (L) and small (S) particles of LS2 and LS were generated. In addition, we observed the formation of an LS3 superstructure. The structures formed as a result of the templating effect of the first layer and the forces exerted by the surface tension of the drying liquid. By using spheres of different composition, one component can be selectively removed, as is demonstrated in the growth of a hexagonal non-close-packed colloidal crystal.	Univ Utrecht, Debye Inst, NL-3584 CC Utrecht, Netherlands; FOM, Inst Atom & Mol Phys, NL-1098 SJ Amsterdam, Netherlands	Utrecht University; AMOLF	Velikov, KP (corresponding author), Univ Utrecht, Debye Inst, Princetonlaan 5, NL-3584 CC Utrecht, Netherlands.		Velikov, Krassimir/AAB-7516-2020; Velikov, Krassimir/C-4868-2009; van Blaaderen, Alfons/B-6304-2009; van Blaaderen, Alfons/ABB-1370-2020	Velikov, Krassimir/0000-0002-8838-1201; van Blaaderen, Alfons/0000-0003-3090-2753; van Blaaderen, Alfons/0000-0003-3090-2753				BARTLETT P, 1992, PHYS REV LETT, V68, P3801, DOI 10.1103/PhysRevLett.68.3801; DENKOV ND, 1993, NATURE, V361, P26, DOI 10.1038/361026a0; DENKOV ND, 1992, LANGMUIR, V8, P3183, DOI 10.1021/la00048a054; DENTON AR, 1990, PHYS REV A, V42, P7312, DOI 10.1103/PhysRevA.42.7312; Dimitrov AS, 1996, LANGMUIR, V12, P1303, DOI 10.1021/la9502251; ELDRIDGE MD, 1993, NATURE, V365, P35, DOI 10.1038/365035a0; HACHISU S, 1980, NATURE, V283, P188, DOI 10.1038/283188a0; Heni M, 2000, PHYS REV LETT, V85, P3668, DOI 10.1103/PhysRevLett.85.3668; Hunt N, 2000, PHYS REV E, V62, P900, DOI 10.1103/PhysRevE.62.900; Jiang P, 1999, CHEM MATER, V11, P2132, DOI 10.1021/cm990080+; Kiely CJ, 1998, NATURE, V396, P444, DOI 10.1038/24808; Kralchevsky PA, 2001, CURR OPIN COLLOID IN, V6, P383, DOI 10.1016/S1359-0294(01)00105-4; Moessner R, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.224401; MURRAY MJ, 1980, PHILOS MAG A, V42, P721, DOI 10.1080/01418618008239380; OSSEOASARE K, 1990, COLLOID SURFACE, V50, P321, DOI 10.1016/0166-6622(90)80273-7; SANDERS JV, 1978, NATURE, V275, P201, DOI 10.1038/275201a0; Smith J. V., 1982, GEOMETRICAL STRUCTUR; vanBlaaderen A, 1997, NATURE, V385, P321, DOI 10.1038/385321a0; vanBlaaderen A, 1997, ADV MATER, V9, P833, DOI 10.1002/adma.19970091015; Yin YD, 2001, ADV MATER, V13, P267, DOI 10.1002/1521-4095(200102)13:4<267::AID-ADMA267>3.0.CO;2-9	20	344	353	6	220	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 5	2002	296	5565					106	109		10.1126/science.1067141	http://dx.doi.org/10.1126/science.1067141			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	539FA	11935021				2022-12-28	WOS:000174858800042
J	Coopersmith, CM; Stromberg, PE; Dunne, WM; Davis, CG; Amiot, DM; Buchman, TG; Karl, IE; Hotchkiss, RS				Coopersmith, CM; Stromberg, PE; Dunne, WM; Davis, CG; Amiot, DM; Buchman, TG; Karl, IE; Hotchkiss, RS			Inhibition of intestinal epithelial apoptosis and survival in a murine model of pneumonia-induced sepsis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INCREASED GUT PERMEABILITY; MULTIPLE-ORGAN-FAILURE; BACTERIAL TRANSLOCATION; CELL-DEATH; HEMORRHAGIC-SHOCK; IMPROVES SURVIVAL; MESENTERIC LYMPH; BCL-2; ISCHEMIA; LUNG	Context Increased intestinal epithelial apoptosis is present in both human autopsy studies and animal models of sepsis. Whether altering gut apoptosis decreases mortality in sepsis induced by pathogenic bacteria outside the gut is unknown. Objective To determine if decreasing levels of intestinal cell death improves survival in a murine model of Pseudomonas aeruginosa pneumonia-induced sepsis. Design and Materials Prospective study in which transgenic mice that overexpress the antiapoptotic protein Bcl-2 in their intestinal epithelium (n=25) and control littermates (n=26) were subjected to intratracheal injection of P aeruginosa. Main Outcome Measures Survival at:7 postoperative days, compared between the 2 groups. Secondary outcomes included quantification of gut epithelial apoptosis. Results Survival in transgenic mice that overexpress Bcl-2 in the intestinal epithelium was 40% (10/25) compared with 4% (1/26) in control littermates 7 days after intratracheal injection of P aeruginosa (P=.001), with differences in survival noted within 24 hours of surgery. Overexpression of Bcl-2 was associated with a decrease in gut epithelial apoptosis demonstrated by active caspase 3 staining, the terminal deoxynucleotidyltransferase-mediated dUTP nick end-labeling assay, and hematoxylin-eosin staining. Conclusions In this murine model, inhibiting gut epithelial apoptosis by overexpression of Bcl-2 was associated with a survival advantage in P aeruginosa pneumonia-induced sepsis. These results suggest that intestinal epithelial apoptosis may play a role in sepsis-related mortality.	Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Anesthesiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Coopersmith, CM (corresponding author), Washington Univ, Sch Med, Dept Surg, 660 S Euclid Ave,Campus Box 8109, St Louis, MO 63110 USA.	coopersmithc@msnotes.wustl.edu		Buchman, Timothy/0000-0001-7350-5921	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK052574] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055194, R01GM048095, R37GM044118, R01GM044118, R55GM048095] Funding Source: NIH RePORTER; NIDDK NIH HHS [P30 DK52574] Funding Source: Medline; NIGMS NIH HHS [GM48095, GM55194, GM44118] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abreu MT, 2000, GASTROENTEROLOGY, V119, P1524, DOI 10.1053/gast.2000.20232; Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Angus D C, 2001, Crit Care Med, V29, P1303, DOI 10.1097/00003246-200107000-00002; BAKER JW, 1988, J TRAUMA, V28, P896, DOI 10.1097/00005373-198807000-00002; Baue AE, 1996, SHOCK, V6, pS1, DOI 10.1097/00024382-199610001-00002; CARRICO CJ, 1986, ARCH SURG-CHICAGO, V121, P196; Coopersmith CM, 2002, CRIT CARE MED, V30, P195, DOI 10.1097/00003246-200201000-00028; Coopersmith CM, 1999, AM J PHYSIOL-GASTR L, V276, pG677, DOI 10.1152/ajpgi.1999.276.3.G677; Doig CJ, 1998, AM J RESP CRIT CARE, V158, P444, DOI 10.1164/ajrccm.158.2.9710092; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Grotz MRW, 1999, ANN SURG, V229, P478, DOI 10.1097/00000658-199904000-00005; Hassoun HT, 2001, SHOCK, V15, P1, DOI 10.1097/00024382-200115010-00001; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; Hiramatsu M, 1997, SHOCK, V7, P247, DOI 10.1097/00024382-199704000-00002; Hotchkiss RS, 1999, CRIT CARE MED, V27, P1230, DOI 10.1097/00003246-199907000-00002; Hotchkiss RS, 2000, NAT IMMUNOL, V1, P496, DOI 10.1038/82741; Hotchkiss RS, 1999, P NATL ACAD SCI USA, V96, P14541, DOI 10.1073/pnas.96.25.14541; Hotchkiss RS, 1997, CRIT CARE MED, V25, P1298, DOI 10.1097/00003246-199708000-00015; HOTCHKISS RS, 2002, SCIENCE, V294, P1783; JIANG JX, 1995, ANN SURG, V221, P100, DOI 10.1097/00000658-199501000-00012; Koo DJ, 1999, BBA-MOL BASIS DIS, V1454, P289, DOI 10.1016/S0925-4439(99)00045-9; Magnotti LJ, 1998, ANN SURG, V228, P518, DOI 10.1097/00000658-199810000-00008; Magnotti LJ, 1999, ARCH SURG-CHICAGO, V134, P1333, DOI 10.1001/archsurg.134.12.1333; MAINOUS MR, 1995, SHOCK, V4, P193, DOI 10.1097/00024382-199509000-00007; Maloney JP, 2000, NEW ENGL J MED, V343, P1047, DOI 10.1056/NEJM200010053431416; MOORE FA, 1991, J TRAUMA, V31, P629, DOI 10.1097/00005373-199105000-00006; Murphy S L, 2000, Natl Vital Stat Rep, V48, P1; Nicholson DW, 2000, NATURE, V407, P810, DOI 10.1038/35037747; O'Boyle CJ, 1998, GUT, V42, P29, DOI 10.1136/gut.42.1.29; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; STARKE JR, 1987, PEDIATR RES, V22, P698, DOI 10.1203/00006450-198712000-00017; Sun Z, 1998, SCAND J GASTROENTERO, V33, P415; Sun ZW, 1998, SHOCK, V10, P203, DOI 10.1097/00024382-199809000-00009; Unno N, 1998, GASTROENTEROL CLIN N, V27, P289, DOI 10.1016/S0889-8553(05)70004-2; Wang WY, 1998, J SURG RES, V79, P39, DOI 10.1006/jsre.1998.5385; Wheeler AP, 1999, NEW ENGL J MED, V340, P207, DOI 10.1056/NEJM199901213400307; WILMORE DW, 1988, SURGERY, V104, P917; Yu P, 2000, CRIT CARE MED, V28, P2573, DOI 10.1097/00003246-200007000-00065	38	212	232	1	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 3	2002	287	13					1716	1721		10.1001/jama.287.13.1716	http://dx.doi.org/10.1001/jama.287.13.1716			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	536YW	11926897	Bronze			2022-12-28	WOS:000174730300027
J	Anderson, CA; Bushman, BJ				Anderson, CA; Bushman, BJ			Psychology - The effects of media violence on society	SCIENCE			English	Editorial Material							BEHAVIOR		Iowa State Univ, Dept Psychol, Ames, IA 50011 USA	Iowa State University	Anderson, CA (corresponding author), Iowa State Univ, Dept Psychol, Ames, IA 50011 USA.		Anderson, Craig A/I-6447-2012; Bushman, Brad/AAN-6427-2021; Bushman, Brad/ABG-3412-2021	Anderson, Craig A/0000-0001-6353-0023; Bushman, Brad/0000-0002-1266-5101; 				Anderson CA, 2002, ANNU REV PSYCHOL, V53, P27, DOI 10.1146/annurev.psych.53.100901.135231; Anderson CA, 2000, J PERS SOC PSYCHOL, V78, P772, DOI 10.1037//0022-3514.78.4.772; Anderson CA, 2001, PSYCHOL SCI, V12, P353, DOI 10.1111/1467-9280.00366; Bushman BJ, 2001, AM PSYCHOL, V56, P477, DOI 10.1037//0003-066X.56.6-7.477; HUESMANN LR, 1983, J PERS SOC PSYCHOL, V44, P899, DOI 10.1037/0022-3514.44.5.899; HUESMANN LR, 1986, J SOC ISSUES, V42, P125, DOI 10.1111/j.1540-4560.1986.tb00246.x; HUESMANN LR, IN PRESS DEV PSYCHOL; Johnson JG, 2002, SCIENCE, V295, P2468, DOI 10.1126/science.1062929; Robinson TH, 2001, ARCH PEDIAT ADOL MED, V155, P17, DOI 10.1001/archpedi.155.1.17; *SURG GEN SCI ADV, 1972, TEL GROW IMP TEL VIO; *U CAL CTR COMM SO, 1998, NAT TEL VIOL STUD, V3	11	247	252	1	106	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 29	2002	295	5564					2377	+		10.1126/science.1070765	http://dx.doi.org/10.1126/science.1070765			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	536QD	11923513				2022-12-28	WOS:000174712600029
J	Murayama, M; Howe, JM; Hidaka, H; Takaki, S				Murayama, M; Howe, JM; Hidaka, H; Takaki, S			Atomic-level observation of disclination dipoles in mechanically milled, nanocrystalline Fe	SCIENCE			English	Article							X-RAY-DIFFRACTION; ELECTRON-MICROSCOPY; PLASTIC-DEFORMATION; GRAIN-BOUNDARIES; IRON-POWDER; METALS; COPPER	Plastic deformation of materials occurs by the motion of defects known as dislocations and disclinations. High-resolution transmission electron microscopy was used to directly reveal the individual dislocations that constitute partial disclination dipoles in nanocrystalline, body-centered cubic iron that had undergone severe plastic deformation by mechanical milling, The mechanisms by which the formation and migration of such partial disclination dipoles during deformation allow crystalline solids to fragment and rotate at the nanometer level are described. Such rearrangements are important basic phenomena that occur during material deformation, and hence, they may be critical in the formation of nanocrystalline metals by mechanical milling and other deformation processes.	Univ Virginia, Dept Mat Sci & Engn, Charlottesville, VA 22904 USA; Kyushu Univ, Dept Mat Sci & Engn, Fukuoka 8128581, Japan	University of Virginia; Kyushu University	Howe, JM (corresponding author), Univ Virginia, Dept Mat Sci & Engn, Charlottesville, VA 22904 USA.		Murayama, Mitsuhiro/B-3472-2009	Murayama, Mitsuhiro/0000-0003-1965-4891				ANSTIS GR, 1992, DISLOCATIONS SOLIDS, V9, P1; BENJAMIN JS, 1970, METALL TRANS, V1, P2943; Buseck P., 1988, HIGH RESOLUTION TRAN; CHOU TW, 1979, GEOPHYS RES B, V84, P6083; FECHT HJ, 1990, METALL TRANS A, V21, P2333, DOI 10.1007/BF02646980; GLEITER H, 1989, PROG MATER SCI, V33, P233; Hirth J. P., 1972, THEORY DISLOCATIONS; Huang JY, 1997, ACTA MATER, V45, P113, DOI 10.1016/S1359-6454(96)00163-2; Huang JY, 1996, ACTA MATER, V44, P1211, DOI 10.1016/1359-6454(95)00231-6; Hudson SD, 1998, CURR OPIN COLLOID IN, V3, P125, DOI 10.1016/S1359-0294(98)80003-4; JANG JSC, 1990, SCRIPTA METALL MATER, V24, P1599, DOI 10.1016/0956-716X(90)90439-N; Jiang X, 1996, APPL PHYS LETT, V69, P3902, DOI 10.1063/1.117564; Kimura Y, 1999, MATER T JIM, V40, P1149, DOI 10.2320/matertrans1989.40.1149; Kleman M., 1983, POINTS LINES WALLS; MARCINKOWSKI MJ, 1977, PHILOS MAG, V36, P1499, DOI 10.1080/14786437708238530; Michler J, 1998, J APPL PHYS, V83, P187, DOI 10.1063/1.366672; Nazarov AA, 1996, SCRIPTA MATER, V34, P729, DOI 10.1016/1359-6462(95)00573-0; NYE JF, 1983, P ROY SOC LOND A MAT, V387, P105, DOI 10.1098/rspa.1983.0053; Parameswaran V R, 1979, SPECUL SCI TECHNOL, V4, P509; Revesz A, 1996, NANOSTRUCT MATER, V7, P779, DOI 10.1016/S0965-9773(96)00048-7; ROMANOV AE, 1992, DISLOCATIONS SOLIDS, V9, P191; Schiotz J, 1998, NATURE, V391, P561, DOI 10.1038/35328; Schiotz J, 1996, PHIL MAG LETT, V74, P339, DOI 10.1080/095008396180065; Seefeldt M., 2001, Reviews on Advanced Materials Science, V2, P44; SIEGEL RW, 1992, ULTRAMICROSCOPY, V40, P376, DOI 10.1016/0304-3991(92)90135-7; STERN EA, 1995, PHYS REV LETT, V75, P3874, DOI 10.1103/PhysRevLett.75.3874; Wilson PM, 1996, MACROMOLECULES, V29, P842, DOI 10.1021/ma9506748; Zhang K, 1996, J APPL PHYS, V80, P5617, DOI 10.1063/1.363612; Zhao YH, 2001, ACTA MATER, V49, P365, DOI 10.1016/S1359-6454(00)00310-4; ZHU X, 1987, PHYS REV B, V35, P9085, DOI 10.1103/PhysRevB.35.9085	30	230	240	3	117	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 29	2002	295	5564					2433	2435		10.1126/science.1067430	http://dx.doi.org/10.1126/science.1067430			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	536QD	11923534				2022-12-28	WOS:000174712600050
J	Young, JB; Abraham, WT; Stevenson, LW; Horton, DP; Elkayam, U; Bourge, RC				Young, JB; Abraham, WT; Stevenson, LW; Horton, DP; Elkayam, U; Bourge, RC		Publication Comm VMAC Investigato	Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BRAIN NATRIURETIC PEPTIDE; TOLERANCE; MORTALITY; INFUSION	Context Decompensated congestive heart failure (CHF) is the leading hospital discharge diagnosis in patients older than 65 years. Objective To compare the efficacy and safety of intravenous nesiritide, intravenous nitroglycerin, and placebo. Design, Setting, and Patients Randomized, double-blind trial of 489 inpatients with dyspnea at rest from decompensated CHF, including 246 who received pulmonary artery catheterization, that was conducted at 55 community and academic hospitals between October 1999 and July 2000. Interventions Intravenous nesiritide (n=204), intravenous nitroglycerin (n=143), or placebo (n=142) added to standard medications for 3 hours, followed by nesiritide (n=278) or nitroglycerin (n=216) added to standard medication for 24 hours. Main Outcome Measures Change in pulmonary capillary wedge pressure (PCWP) among catheterized patients and patient self-evaluation of dyspnea at 3 hours after initiation of study drug among all patients. Secondary outcomes included comparisons of hemodynamic and clinical effects between nesiritide and nitroglycerin at 24 hours. Results At 3 hours, the mean (SD) decrease in PCWP from baseline was -5.8 (6.5) mm Hg for nesiritide (vs placebo, P<.001; vs nitroglycerin, P=.03), -3.8 (5.3) mm Hg for nitroglycerin (vs placebo, P=.09), and -2 (4.2) mm Hg for placebo. At 3 hours, nesiritide resulted in improvement in dyspnea compared with placebo (P=.03), but there was no significant difference in dyspnea or global clinical status with nesiritide compared with nitroglycerin. At 24 hours, the reduction in PCWP was greater in the nesiritide group (-8.2 mm Hg) than the nitroglycerin group (-6.3 mm Hg), but patients reported no significant differences in dyspnea and only modest improvement in global clinical status. Conclusion When added to standard care in patients hospitalized with acutely decompensated CHF, nesiritide improves hemodynamic function and some self-reported symptoms more effectively than intravenous nitroglycerin or placebo.	Cleveland Clin Fdn, Dept Cardiovasc Med, Cleveland, OH 44195 USA; Univ Kentucky, Lexington, KY USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Scios Inc, Frederick, MD 21701 USA; Los Angeles Cty USC Med Ctr, Los Angeles, CA 90033 USA; Univ Alabama Birmingham, Birmingham, AL USA	Cleveland Clinic Foundation; University of Kentucky; Harvard University; Brigham & Women's Hospital; Scios; University of Alabama System; University of Alabama Birmingham	Young, JB (corresponding author), Cleveland Clin Fdn, Dept Cardiovasc Med, 9500 Euclid Ave F25, Cleveland, OH 44195 USA.							[Anonymous], 1990, Lancet, V336, P1; ARMSTRONG PW, 1983, BRIT J CLIN PHARMACO, V16, P385, DOI 10.1111/j.1365-2125.1983.tb02182.x; BAYLEY S, 1984, INTENS CARE MED, V10, P139, DOI 10.1007/BF00265803; BROPHY JM, 1993, CAN J CARDIOL, V9, P219; Burger AJ, 2000, J AM COLL CARDIOL, V35, p172A; Califf RM, 1997, AM HEART J, V134, P44, DOI 10.1016/S0002-8703(97)70105-4; Chen HH, 2000, J AM COLL CARDIOL, V36, P1706, DOI 10.1016/S0735-1097(00)00911-6; CLARKSON PBM, 1995, CLIN SCI, V88, P159, DOI 10.1042/cs0880159; Colucci WS, 2000, NEW ENGL J MED, V343, P246, DOI 10.1056/NEJM200007273430403; DIES F, 1986, BR J CLIN PRACT S, V40, P37; DUPUIS J, 1990, AM HEART J, V120, P625, DOI 10.1016/0002-8703(90)90021-O; Earl GL, 1998, PHARMACOTHERAPY, V18, P203; FELDMAN AM, 1993, NEW ENGL J MED, V329, P149, DOI 10.1056/NEJM199307153290301; GRAVES E, 1996, 1994 SUMMARY NATL HO, P17; Hobbs R E, 1999, Expert Opin Investig Drugs, V8, P1063, DOI 10.1517/13543784.8.7.1063; Jensen KT, 1999, CLIN SCI, V96, P5, DOI 10.1042/CS19980105; Kirsten R, 1998, CLIN PHARMACOKINET, V35, P9, DOI 10.2165/00003088-199835010-00002; KONSTAM M, 1994, HEART FAILURE EVALUA; Larsen AI, 1997, AM HEART J, V134, P435, DOI 10.1016/S0002-8703(97)70078-4; MASSIE BM, 1993, CIRCULATION, V88, P492, DOI 10.1161/01.CIR.88.2.492; NATARAJAN D, 1988, AM J CARDIOL, V62, P319, DOI 10.1016/0002-9149(88)90236-6; PACKER M, 1991, NEW ENGL J MED, V325, P1468, DOI 10.1056/NEJM199111213252103; PACKER M, 1985, CIRCULATION, V72, P681, DOI 10.1161/01.CIR.72.4.681; PACKER M, 1984, AM J CARDIOL, V54, P1025, DOI 10.1016/S0002-9149(84)80138-1; RAME JE, 2001, OUTCOMES FOLLOWING D; SAMBOL NC, 2001, CLIN PHARMACOL THER, V69, P90; WILLIAMS JF, 1995, J AM COLL CARDIOL, V26, P1376; YOUNG JB, 1984, AM J MED, V76, P27, DOI 10.1016/0002-9343(84)91040-4; Zellner C, 1999, AM J PHYSIOL-HEART C, V276, pH1049, DOI 10.1152/ajpheart.1999.276.3.H1049	29	738	765	1	17	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 27	2002	287	12					1531	1540						10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	533VF	11911755	Bronze			2022-12-28	WOS:000174550400024
J	Beattie, EC; Stellwagen, D; Morishita, W; Bresnahan, JC; Ha, BK; Von Zastrow, M; Beattie, MS; Malenka, RC				Beattie, EC; Stellwagen, D; Morishita, W; Bresnahan, JC; Ha, BK; Von Zastrow, M; Beattie, MS; Malenka, RC			Control of synaptic strength by glial TNF alpha	SCIENCE			English	Article							AMPA RECEPTOR ENDOCYTOSIS; NEURONS; TRANSMISSION	Activity-dependent modulation of synaptic efficacy in the brain contributes to neural circuit development and experience-dependent plasticity. Although glia are affected by activity and ensheathe synapses, their influence on synaptic strength has largely been ignored. Here, we show that a protein produced by glia, tumor necrosis factor alpha (TNFalpha), enhances synaptic efficacy by increasing surface expression of AMPA receptors. Preventing the actions of endogenous TNFalpha has the opposite effects. Thus, the continual presence of TNFalpha is required for preservation of synaptic strength at excitatory synapses. Through its effects on AMPA receptor trafficking, TNFalpha may play roles in synaptic plasticity and modulating responses to neural injury.	Ohio State Univ, Med Ctr, Dept Neurosci, Columbus, OH 43210 USA; Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Nancy Pritzker Lab, Palo Alto, CA 94304 USA; Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA	University System of Ohio; Ohio State University; Stanford University; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Beattie, MS (corresponding author), Ohio State Univ, Med Ctr, Dept Neurosci, Columbus, OH 43210 USA.	beattie.2@osu.edu; malenka@stanford.edu	Beattie, Michael S/A-8953-2009		NIDA NIH HHS [DA00439] Funding Source: Medline; NIMH NIH HHS [MH063394] Funding Source: Medline; NINDS NIH HHS [NS38079, NS 31193] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH063394, R01MH063394] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031193] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Albensi BC, 2000, SYNAPSE, V35, P151; Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; Allison DW, 1998, J NEUROSCI, V18, P2423; Beattie EC, 2000, NAT NEUROSCI, V3, P1291, DOI 10.1038/81823; Beattie MS, 2000, J NEUROTRAUM, V17, P915, DOI 10.1089/neu.2000.17.915; Bezzi P, 2001, CURR OPIN NEUROBIOL, V11, P387, DOI 10.1016/S0959-4388(00)00223-3; Bezzi P, 2001, NAT NEUROSCI, V4, P702, DOI 10.1038/89490; Carroll RC, 2001, NAT REV NEUROSCI, V2, P315, DOI 10.1038/35072500; Cunningham AJ, 1996, NEUROSCI LETT, V203, P17, DOI 10.1016/0304-3940(95)12252-4; Emch GS, 2000, AM J PHYSIOL-GASTR L, V279, pG582, DOI 10.1152/ajpgi.2000.279.3.G582; Haydon PG, 2001, NAT REV NEUROSCI, V2, P185, DOI 10.1038/35058528; Hermann GE, 2001, NEUROBIOL DIS, V8, P590, DOI 10.1006/nbdi.2001.0414; Luscher C, 1999, NEURON, V24, P649, DOI 10.1016/S0896-6273(00)81119-8; Malinow R, 2000, CURR OPIN NEUROBIOL, V10, P352, DOI 10.1016/S0959-4388(00)00099-4; Mauch DH, 2001, SCIENCE, V294, P1354, DOI 10.1126/science.294.5545.1354; Nagler K, 2001, J PHYSIOL-LONDON, V533, P665, DOI 10.1111/j.1469-7793.2001.00665.x; NOBLE M, 1998, CULTURING NERVE CELL, P526; Pfrieger FW, 1997, SCIENCE, V277, P1684, DOI 10.1126/science.277.5332.1684; Solorzano CC, 1997, SHOCK, V7, P427, DOI 10.1097/00024382-199706000-00007; TANCREDI V, 1992, NEUROSCI LETT, V146, P176, DOI 10.1016/0304-3940(92)90071-E; Ullian EM, 2001, SCIENCE, V291, P657, DOI 10.1126/science.291.5504.657; Ventura R, 1999, J NEUROSCI, V19, P6897, DOI 10.1523/JNEUROSCI.19-16-06897.1999; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.neuro.12.1.13	23	995	1032	0	60	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 22	2002	295	5563					2282	2285		10.1126/science.1067859	http://dx.doi.org/10.1126/science.1067859			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	534AD	11910117				2022-12-28	WOS:000174561700051
J	DeMattos, RB; Bales, KR; Cummins, DJ; Paul, SM; Holtzman, DM				DeMattos, RB; Bales, KR; Cummins, DJ; Paul, SM; Holtzman, DM			Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease	SCIENCE			English	Article							DEPOSITION; PEPTIDE; PLAQUES	The deposition of amyloid-beta (Abeta) peptides into amyloid plaques precedes the cognitive dysfunction of Alzheimer's disease (AD) by years. Biomarkers indicative of brain amyloid burden could be useful for identifying individuals at high risk for developing AD. As in AD in humans, baseline plasma Abeta levels in a transgenic mouse model of AD did not correlate with brain amyloid burden. However, after peripheral administration of a monoclonal antibody to Abeta (m266), we observed a rapid increase in plasma Abeta and the magnitude of this increase was highly correlated with amyloid burden in the hippocampus and cortex. This method may be useful for quantifying brain amyloid burden in patients at risk for or those who have been diagnosed with AD.	Eli Lilly & Co, Lilly Res Labs, Neurosci Discovery Res, Indianapolis, IN 46285 USA; Washington Univ, Sch Med, Ctr Study Nervous Syst Injury, St Louis, MO 63110 USA; Washington Univ, Sch Med, Alzheimers Dis Res Ctr, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; Indiana Univ, Sch Med, Dept Pharmacol, Indianapolis, IN 46285 USA; Indiana Univ, Sch Med, Dept Toxicol, Indianapolis, IN 46285 USA; Indiana Univ, Sch Med, Dept Psychiat, Indianapolis, IN 46285 USA	Eli Lilly; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis	Paul, SM (corresponding author), Eli Lilly & Co, Lilly Res Labs, Neurosci Discovery Res, Indianapolis, IN 46285 USA.		Paul, Steve/ABE-5400-2020		NATIONAL INSTITUTE ON AGING [R01AG020222] Funding Source: NIH RePORTER; NIA NIH HHS [AG20222] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Breiman L., 1984, CLASSIFICATION REGRE; DeMattos RB, 2001, P NATL ACAD SCI USA, V98, P8850, DOI 10.1073/pnas.151261398; Fishman CE, 2001, J NEUROSCI METH, V108, P145, DOI 10.1016/S0165-0270(01)00381-8; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GhersiEgea JF, 1996, J NEUROCHEM, V67, P880; GomezIsla T, 1996, J NEUROSCI, V16, P4491; Holtzman DM, 2000, P NATL ACAD SCI USA, V97, P2892, DOI 10.1073/pnas.050004797; Ji Y, 2001, J ALZHEIMERS DIS, V3, P23, DOI 10.3233/JAD-2001-3105; Mehta PD, 2000, ARCH NEUROL-CHICAGO, V57, P100, DOI 10.1001/archneur.57.1.100; Morris JC, 1996, NEUROLOGY, V46, P707, DOI 10.1212/WNL.46.3.707; Naslund J, 2000, JAMA-J AM MED ASSOC, V283, P1571, DOI 10.1001/jama.283.12.1571; Price JL, 1999, ANN NEUROL, V45, P358, DOI 10.1002/1531-8249(199903)45:3<358::AID-ANA12>3.0.CO;2-X; Price JL, 2001, ARCH NEUROL-CHICAGO, V58, P1395, DOI 10.1001/archneur.58.9.1395; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Shibata M, 2000, J CLIN INVEST, V106, P1489, DOI 10.1172/JCI10498; Yamaguchi H, 2001, J NEUROPATH EXP NEUR, V60, P731, DOI 10.1093/jnen/60.7.731	17	477	532	0	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 22	2002	295	5563					2264	2267		10.1126/science.1067568	http://dx.doi.org/10.1126/science.1067568			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	534AD	11910111				2022-12-28	WOS:000174561700045
J	Lambert, DM; Ritchie, PA; Millar, CD; Holland, B; Drummond, AJ; Baroni, C				Lambert, DM; Ritchie, PA; Millar, CD; Holland, B; Drummond, AJ; Baroni, C			Rates of evolution in ancient DNA from Adelie penguins	SCIENCE			English	Article							MITOCHONDRIAL-DNA; ANTARCTICA	Well-preserved subfossil bones of Adelie penguins, Pygoscelis adeliae, underlie existing and abandoned nesting colonies in Antarctica. These bones, dating back to more than 7000 years before the present, harbor some of the best-preserved ancient DNA yet discovered. From 96 radiocarbon-aged bones, we report large numbers of mitochondrial haplotypes, some of which appear to be extinct, given the 380 living birds sampled. We demonstrate DNA sequence evolution through time and estimate the rate of evolution of the hypervariable region I using a Markov chain Monte Carlo integration and a least-squares regression analysis. our calculated rates of evolution are approximately two to seven times higher than previous indirect phylogenetic estimates.	Massey Univ, Inst Mol Biosci, Palmerston North, New Zealand; Massey Univ, Inst Fundamental Sci, Palmerston North, New Zealand; Univ Auckland, Sch Biol Sci, Auckland 1, New Zealand; Univ Pisa, Dipartimento Sci Terra, I-56126 Pisa, Italy; CNR, Ctr Studio Geol Strutturale, I-56126 Pisa, Italy	Massey University; Massey University; University of Auckland; University of Pisa; Consiglio Nazionale delle Ricerche (CNR)			Baroni, Carlo/D-8184-2012; Millar, Craig/B-5168-2009; Holland, Barbara/G-1646-2013; Drummond, Alexei J/A-3209-2010	Baroni, Carlo/0000-0001-5905-4650; Holland, Barbara/0000-0002-4628-7938; Drummond, Alexei J/0000-0003-4454-2576; Lambert, David/0000-0002-5821-3637; Ritchie, Peter/0000-0002-8351-7931				Bandelt HJ, 2000, MOL PHYLOGENET EVOL, V16, P8, DOI 10.1006/mpev.2000.0792; BARONI C, 1991, QUATERNARY RES, V36, P157, DOI 10.1016/0033-5894(91)90023-X; BARONI C, 1994, GEOLOGY, V22, P23, DOI 10.1130/0091-7613(1994)022<0023:APRAHP>2.3.CO;2; BROWN WM, 1979, P NATL ACAD SCI USA, V76, P1967, DOI 10.1073/pnas.76.4.1967; CANN RL, 1987, NATURE, V325, P31, DOI 10.1038/325031a0; FELSENSTEIN J, 1992, GENET RES, V59, P139, DOI 10.1017/S0016672300030354; Hadly EA, 1998, P NATL ACAD SCI USA, V95, P6893, DOI 10.1073/pnas.95.12.6893; Leonard JA, 2000, P NATL ACAD SCI USA, V97, P1651, DOI 10.1073/pnas.040453097; METROPOLIS N, 1953, J CHEM PHYS, V21, P1087, DOI 10.1063/1.1699114; Parsons TJ, 1997, NAT GENET, V15, P363, DOI 10.1038/ng0497-363; Petit JR, 1999, NATURE, V399, P429, DOI 10.1038/20859; SHIELDS GF, 1987, J MOL EVOL, V24, P212, DOI 10.1007/BF02111234	12	232	239	0	127	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 22	2002	295	5563					2270	2273		10.1126/science.1068105	http://dx.doi.org/10.1126/science.1068105			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	534AD	11910113				2022-12-28	WOS:000174561700047
J	Maquat, LE				Maquat, LE			Molecular biology - Skiing toward nonstop mRNA decay	SCIENCE			English	Editorial Material							SACCHAROMYCES-CEREVISIAE; MESSENGER-RNA		Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, Rochester, NY 14642 USA	University of Rochester	Maquat, LE (corresponding author), Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, 601 Elmwood Ave,Box 712, Rochester, NY 14642 USA.			Maquat, Lynne/0000-0002-2789-2075				Araki Y, 2001, EMBO J, V20, P4684, DOI 10.1093/emboj/20.17.4684; Benard L, 1999, J VIROL, V73, P2893, DOI 10.1128/JVI.73.4.2893-2900.1999; Butler JS, 2002, TRENDS CELL BIOL, V12, P90, DOI 10.1016/S0962-8924(01)02225-5; Flynn JM, 2001, P NATL ACAD SCI USA, V98, P10584, DOI 10.1073/pnas.191375298; Frischmeyer PA, 2002, SCIENCE, V295, P2258, DOI 10.1126/science.1067338; GILDEN R, 2001, MOL MICROBIOL, V42, P879; Karzai AW, 2001, P NATL ACAD SCI USA, V98, P3040, DOI 10.1073/pnas.051628298; Maquat LE, 2001, CELL, V104, P173, DOI 10.1016/S0092-8674(01)00202-1; Mitchell P, 2000, NAT STRUCT BIOL, V7, P843, DOI 10.1038/82817; Nakamura Y, 2001, J MOL EVOL, V53, P282, DOI 10.1007/s002390010218; Roche ED, 2001, J BIOL CHEM, V276, P28509, DOI 10.1074/jbc.M103864200; Tucker M, 2000, ANNU REV BIOCHEM, V69, P571, DOI 10.1146/annurev.biochem.69.1.571; van Hoof A, 2002, SCIENCE, V295, P2262, DOI 10.1126/science.1067272; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Wang ZR, 2001, CELL, V107, P751, DOI 10.1016/S0092-8674(01)00592-X	15	32	34	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 22	2002	295	5563					2221	2222		10.1126/science.1071285	http://dx.doi.org/10.1126/science.1071285			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	534AD	11910094				2022-12-28	WOS:000174561700027
J	McNamara, AK; van Keken, PE; Karato, SI				McNamara, AK; van Keken, PE; Karato, SI			Development of anisotropic structure in the Earth's lower mantle by solid-state convection	NATURE			English	Article							SEISMIC ANISOTROPY; CONSTRAINTS; ORIGIN	Seismological observations reveal highly anisotropic patches at the bottom of the Earth's lower mantle, whereas the bulk of the mantle has been observed to be largely isotropic(1-4). These patches have been interpreted to correspond to areas where subduction has taken place in the past or to areas where mantle plumes are upwelling, but the underlying cause for the anisotropy is unknown-both shape-preferred orientation of elastically heterogenous materials(5) and lattice-preferred orientation of a homogeneous material(6-8) have been proposed. Both of these mechanisms imply that large-strain deformation occurs within the anisotropic regions, but the geodynamic implications of the mechanisms differ. Shape-preferred orientation would imply the presence of large elastic (and hence chemical) heterogeneity whereas lattice-preferred orientation requires deformation at high stresses. Here we show, on the basis of numerical modelling incorporating mineral physics of elasticity and development of lattice-preferred orientation, that slab deformation in the deep lower mantle can account for the presence of strong anisotropy in the circum-Pacific region. In this model-where development of the mineral fabric (the alignment of mineral grains) is caused solely by solid-state deformation of chemically homogeneous mantle material-anisotropy is caused by large-strain deformation at high stresses, due to the collision of subducted slabs with the core-mantle boundary.	Univ Michigan, Dept Geol Sci, Ann Arbor, MI 48109 USA; Yale Univ, Dept Geol & Geophys, New Haven, CT 06520 USA	University of Michigan System; University of Michigan; Yale University	McNamara, AK (corresponding author), Univ Michigan, Dept Geol Sci, 1006 CC Little Bldg, Ann Arbor, MI 48109 USA.	mcnamar@umich.edu	McNamara, Allen/P-3144-2014	McNamara, Allen/0000-0003-3866-9503				Frost H.J., 1982, DEFORMATION MECH MAP; ITA J, 1994, J GEOPHYS RES-SOL EA, V99, P15919, DOI 10.1029/94JB00852; JARVIS GT, 1980, J FLUID MECH, V96, P515, DOI 10.1017/S002211208000225X; Karato S, 1998, EARTH PLANETS SPACE, V50, P1019, DOI 10.1186/BF03352196; Karato SI, 1998, PURE APPL GEOPHYS, V151, P565, DOI 10.1007/s000240050130; Karki BB, 1997, AM MINERAL, V82, P51; Kendall J., 2000, GEOPHYSICS MONOGRAPH, V117, P133; Kendall JM, 1996, NATURE, V381, P409, DOI 10.1038/381409a0; Lay T, 1998, GEODYNAMICS, V28, P299; Lay T, 1998, NATURE, V392, P461, DOI 10.1038/33083; LEITCH AM, 1991, EARTH PLANET SC LETT, V102, P213, DOI 10.1016/0012-821X(91)90009-7; Mainprice D., 2000, EARTHS DEEP INTERIOR, P237, DOI [10.1029/GM117p0237, DOI 10.1029/GM117P0237]; McNamara AK, 2001, EARTH PLANET SC LETT, V191, P85, DOI 10.1016/S0012-821X(01)00405-8; Mitrovica JX, 1997, J GEOPHYS RES-SOL EA, V102, P2751, DOI 10.1029/96JB03175; POLLACK HN, 1993, REV GEOPHYS, V31, P267, DOI 10.1029/93RG01249; RAMBERG H, 1975, TECTONOPHYSICS, V28, P1, DOI 10.1016/0040-1951(75)90058-X; Ritsema J, 2000, GEOPHYS RES LETT, V27, P1041, DOI 10.1029/1999GL011037; Spencer A. J. M., 1980, CONTINUUM MECH; Stixrude L, 1998, GEODYNAMICS, V28, P83; Tackley PJ, 2000, GEOCHEM GEOPHY GEOSY, V1; van Keken P, 2001, PHYS EARTH PLANET IN, V124, P119, DOI 10.1016/S0031-9201(01)00195-9; Yamazaki D, 2001, AM MINERAL, V86, P385; YAMAZAKI D, IN PRESS PHYS EARTH; ZHANG SQ, 1995, NATURE, V375, P774, DOI 10.1038/375774a0	24	114	115	1	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 21	2002	416	6878					310	314		10.1038/416310a	http://dx.doi.org/10.1038/416310a			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	532NP	11907574	Green Published			2022-12-28	WOS:000174482200039
J	Saether, BE; Engen, S; Matthysen, E				Saether, BE; Engen, S; Matthysen, E			Demographic characteristics and population dynamical patterns of solitary birds	SCIENCE			English	Article							LIFE-HISTORY VARIATION; ENVIRONMENTAL STOCHASTICITY; STRATEGIES; EXTINCTION; ABUNDANCE; DENSITY; GROWTH; TIME	In birds and many other animals, there are large interspecific differences in the magnitude of annual variation in population size, Using time-series data on populations of solitary bird species, we found that fluctuations in population size of solitary birds were affected by the deterministic characteristics of the population dynamics as well as the stochastic factors. In species with highly variable populations, annual variation in recruitment was positively related to the return rate of adults between successive breeding seasons. In stable populations, more recruits were found in years with low return rates of breeding adults. This identifies a gradient, associated with the position of the species along a "slow-fast" continuum of life history variation, from highly variable populations with a recruitment-driven demography to stable, strongly density-regulated populations with a survival-restricted demography. These results suggest that patterns in avian population fluctuations can be predicted from a knowledge of life-history characteristics and/or temporal variation in certain demographic traits.	Norwegian Univ Sci & Technol, Dept Zool, N-7491 Trondheim, Norway; Norwegian Univ Sci & Technol, Dept Math Sci, N-7491 Trondheim, Norway; Univ Instelling Antwerp, Dept Biol, Lab Anim Ecol, B-2610 Antwerp, Belgium	Norwegian University of Science & Technology (NTNU); Norwegian University of Science & Technology (NTNU); University of Antwerp	Saether, BE (corresponding author), Norwegian Univ Sci & Technol, Dept Zool, N-7491 Trondheim, Norway.	bernt-erik.sather@chembio.ntnu.no						Aanes S, 2002, ECOL APPL, V12, P281, DOI 10.1890/1051-0761(2002)012[0281:SHSOWP]2.0.CO;2; ARCESE P, 1992, ECOLOGY, V73, P805, DOI 10.2307/1940159; ARINO A, 1995, EVOL ECOL, V9, P429, DOI 10.1007/BF01237765; Bjornstad ON, 2001, SCIENCE, V293, P638, DOI 10.1126/science.1062226; Charnov Eric L., 1993, P1; Coulson T, 2001, SCIENCE, V292, P1528, DOI 10.1126/science.292.5521.1528; Diserud OH, 2000, AM NAT, V155, P497, DOI 10.1086/303339; Engen S, 1998, BIOMETRICS, V54, P840, DOI 10.2307/2533838; ENGEN S, UNPUB; Fowler C.W., 1987, Current Mammalogy, V1, P401; FOWLER CW, 1988, EVOL ECOL, V2, P197, DOI 10.1007/BF02214283; FOWLER CW, 1981, ECOLOGY, V62, P602, DOI 10.2307/1937727; GILPIN ME, 1973, P NATL ACAD SCI USA, V70, P3590, DOI 10.1073/pnas.70.12.3590; LANDE R, IN PRESS AM NAT; Lewontin R. C., 1965, P77; May R, 1999, PHILOS T R SOC B, V354, P1951, DOI 10.1098/rstb.1999.0534; Newton I., 1998, POPULATION LIMITATIO; PIANKA ER, 1970, AM NAT, V104, P592, DOI 10.1086/282697; Pimm S.L., 1991, BALANCE NATURE; PROMISLOW DEL, 1990, J ZOOL, V220, P417, DOI 10.1111/j.1469-7998.1990.tb04316.x; Royama T., 1992, Analytical population dynamics.; Saether BE, 2000, ECOLOGY, V81, P642, DOI 10.2307/177366; Saether BE, 2000, P ROY SOC B-BIOL SCI, V267, P621, DOI 10.1098/rspb.2000.1047; Saether BE, 1998, AM NAT, V151, P441, DOI 10.1086/286131; SOUTHWOOD TRE, 1977, J ANIM ECOL, V46, P337	25	128	129	1	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 15	2002	295	5562					2070	2073						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	532AY	11896278				2022-12-28	WOS:000174450500048
J	Luise, C; Jermy, K; May, C; Costello, G; Collins, WP; Bourne, TH				Luise, C; Jermy, K; May, C; Costello, G; Collins, WP; Bourne, TH			Outcome of expectant management of spontaneous first trimester miscarriage: observational study	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objectives To evaluate the uptake and outcome of expectant management of spontaneous first trimester miscarriage in an early pregnancy assessment unit. Participants 1096 consecutive patients with a diagnosis of spontaneous first trimester miscarriage. Methods Each miscarriage was classified as complete, incomplete, missed, or anembryonic on the basis of ultrasonography. Women who needed treatment were given the choice of expectant management or surgical evacuation of retained products of conception under general anaesthesia. Women undergoing expectant management were checked a few days after transvaginal bleeding had stopped, or they were monitored at weekly intervals for four weeks. Main outcome measures A complete miscarriage (absence of transvaginal bleeding and endometrial thickness < 15 min), the number of women completing their miscarriage within each week of management, and complications (excessive pain or transvaginal bleeding necessitating hospital admission or clinical evidence of infection). Results Two patients with molar pregnancies were excluded, and 37% of the remainder (408/1094) were classified as leaving had a complete miscarriage. 70% (478/686) of women with retained products of conception chose expect ant management; of these, 27 (6%) were lost to follow up. A successful outcome without surgical intervention was seen in 81% of cases (367/451). The rate of spontaneous completion was 91% (201/221) for those cases classified as incomplete miscarriage, 76% (105/138) for missed miscarriage, and 66% (61/92) for anembryonic pregnancy. 70% of women completed their miscarriage within 14 days of classification (84% for incomplete miscarriage and 52% for missed miscarriage and anembryonic pregnancy). Conclusions Most women with retained products of conception chose expectant management. Ultrasonography can be used to advise patients on the likelihood that their miscarriage will complete spontaneously within a given time.	St George Hosp, Early Pregnancy Gynaecol Ultrasound & Minimal Acc, London SW17 0RE, England; Kings Coll Hosp London, Gys Kings & St Thomas Sch Med, Acad Dept Obstet & Gynaecol, London SE5 9PJ, England	St Georges University London; King's College Hospital NHS Foundation Trust; King's College Hospital	Bourne, TH (corresponding author), St George Hosp, Early Pregnancy Gynaecol Ultrasound & Minimal Acc, London SW17 0RE, England.	tbourne@gynae-scanning.com	Bourne, Tom/I-6478-2012	Bourne, Tom/0000-0003-1421-6059				Jurkovic D, 1998, BRIT J OBSTET GYNAEC, V105, P670, DOI 10.1111/j.1471-0528.1998.tb10184.x; MACKENZIE IZ, 1978, LANCET, V2, P566; Nielsen S, 1999, BRIT J OBSTET GYNAEC, V106, P804, DOI 10.1111/j.1471-0528.1999.tb08401.x; *RCR RCOG WORK PAR, 1996, EARL PREGN ASS; Schwarzler P, 1999, HUM REPROD, V14, P1341, DOI 10.1093/humrep/14.5.1341; STEER C, 1989, BRIT MED J, V299, P1317, DOI 10.1136/bmj.299.6711.1317	6	111	115	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 13	2002	324	7342					873	875		10.1136/bmj.324.7342.873	http://dx.doi.org/10.1136/bmj.324.7342.873			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	542PA	11950733	Green Published, Bronze			2022-12-28	WOS:000175052200017
J	Castellsague, X; Bosch, FX; Munoz, N; Meijer, CJLM; Shah, KV; de Sanjose, S; Eluf-Neto, J; Ngelangel, CA; Chichareon, S; Smith, JS; Herrero, R; Moreno, V; Franceschi, S				Castellsague, X; Bosch, FX; Munoz, N; Meijer, CJLM; Shah, KV; de Sanjose, S; Eluf-Neto, J; Ngelangel, CA; Chichareon, S; Smith, JS; Herrero, R; Moreno, V; Franceschi, S		Int Agency Res Canc Multicenter Ce	Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; CARCINOMA IN-SITU; RISK-FACTORS; HIV-INFECTION; NEOPLASIA; POPULATION; COLOMBIA; DISEASES; SPAIN; MEN	Background: It is uncertain whether male circumcision reduces the risks of penile human papillomavirus (HPV) infection in the man and of cervical cancer in his female partner. Methods: We pooled data on 1913 couples enrolled in one of seven case-control studies of cervical carcinoma in situ and cervical cancer in five countries. Circumcision status was self-reported, and the accuracy of the data was confirmed by physical examination at three study sites. The presence or absence of penile HPV DNA was assessed by a polymerase-chain-reaction assay in 1520 men and yielded a valid result in the case of 1139 men (74.9 percent). Results: Penile HPV was detected in 166 of the 847 uncircumcised men (19.6 percent) and in 16 of the 292 circumcised men (5.5 percent). After adjustment for age at first intercourse, lifetime number of sexual partners, and other potential confounders, circumcised men were less likely than uncircumcised men to have HPV infection (odds ratio, 0.37; 95 percent confidence interval, 0.16 to 0.85). Monogamous women whose male partners had six or more sexual partners and were circumcised had a lower risk of cervical cancer than women whose partners were uncircumcised (adjusted odds ratio, 0.42; 95 percent confidence interval, 0.23 to 0.79). Results were similar in the subgroup of men in whom circumcision was confirmed by medical examination. Conclusions: Male circumcision is associated with a reduced risk of penile HPV infection and, in the case of men with a history of multiple sexual partners, a reduced risk of cervical cancer in their current female partners.	Inst Catala Oncol, Serv Epidemiol, Barcelona 08907, Spain; Inst Catala Oncol, Registre Canc, Barcelona 08907, Spain; Int Agcy Res Canc, F-69372 Lyon, France; Free Univ Amsterdam Hosp, Amsterdam, Netherlands; Johns Hopkins Univ, Baltimore, MD USA; Univ Sao Paulo, Sao Paulo, Brazil; Univ Philippines, Philippine Gen Hosp, Manila, Philippines; Prince Songkla Univ, Fac Med, Hat Yai, Thailand; Proyecto Epidemiol Guanacaste, San Jose, Costa Rica	Catalan Institute of Oncology; Catalan Institute of Oncology; World Health Organization; International Agency for Research on Cancer (IARC); Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Johns Hopkins University; Universidade de Sao Paulo; University of the Philippines System; University of the Philippines Manila; Prince of Songkla University	Castellsague, X (corresponding author), Inst Catala Oncol, Serv Epidemiol, Gran Via S-N,Km 2-7, Barcelona 08907, Spain.	xcastellsague@ico.scs.es	JOSÉ, FRANCESC XAVIER BOSCH/J-6339-2012; franceschi, silvia/M-2452-2014; Pique, Xavier Castellsagué/N-5795-2014; Moreno, Victor/A-1697-2010; Eluf-Neto, Jose/B-2522-2009; de Sanjosé Llongueras, Silvia/H-6339-2014	JOSÉ, FRANCESC XAVIER BOSCH/0000-0002-7172-3412; franceschi, silvia/0000-0003-4181-8071; Pique, Xavier Castellsagué/0000-0002-0802-3595; Moreno, Victor/0000-0002-2818-5487; Eluf-Neto, Jose/0000-0001-7504-2115; 				Aynaud O, 1999, BJU INT, V84, P57; BOON ME, 1989, CANCER, V64, P559, DOI 10.1002/1097-0142(19890715)64:2<559::AID-CNCR2820640234>3.0.CO;2-A; Bosch FX, 1996, JNCI-J NATL CANCER I, V88, P1060, DOI 10.1093/jnci/88.15.1060; BOSCH FX, 1993, CANCER EPIDEM BIOMAR, V2, P415; BOSCH FX, 1992, INT J CANCER, V52, P750, DOI 10.1002/ijc.2910520514; BOSCH FX, 1995, JNCI-J NATL CANCER I, V87, P796, DOI 10.1093/jnci/87.11.796; BRINTON LA, 1989, INT J CANCER, V44, P199, DOI 10.1002/ijc.2910440202; BRINTON LA, 1991, INT J CANCER, V47, P504, DOI 10.1002/ijc.2910470406; CAMERON DW, 1989, LANCET, V2, P403; Castellsague X, 1997, J INFECT DIS, V176, P353, DOI 10.1086/514052; Chichareon S, 1998, J NATL CANCER I, V90, P50, DOI 10.1093/jnci/90.1.50; COOK LS, 1994, AM J PUBLIC HEALTH, V84, P197, DOI 10.2105/AJPH.84.2.197; COOK LS, 1993, GENITOURIN MED, V69, P262; DONOVAN B, 1994, GENITOURIN MED, V70, P317; ELUFNETO J, 1994, BRIT J CANCER, V69, P114, DOI 10.1038/bjc.1994.18; HILDESHEIM A, 1994, J INFECT DIS, V169, P235, DOI 10.1093/infdis/169.2.235; HOLLY EA, 1993, J NATL CANCER I, V85, P2, DOI 10.1093/jnci/85.1.2; HUSMAN AMD, 1994, INT J CANCER, V56, P802, DOI 10.1002/ijc.2910560607; HUSSAIN LA, 1995, IMMUNOLOGY, V85, P475; Hutchinson J., 1855, MED TIMES GAZETTE, VII, P542, DOI DOI 10.1056/NEJM185608280550404; *IARC, 1995, IARC MON EV CARC RIS, V64; JACOBS MV, 1995, J CLIN MICROBIOL, V33, P901, DOI 10.1128/JCM.33.4.901-905.1995; KJAER SK, 1991, INT J CANCER, V48, P39; Lavreys L, 1999, J INFECT DIS, V180, P330, DOI 10.1086/314884; MADEN C, 1993, JNCI-J NATL CANCER I, V85, P19, DOI 10.1093/jnci/85.1.19; Melbye M, 1998, SEMIN CANCER BIOL, V8, P307, DOI 10.1006/scbi.1998.0081; MORENO V, 1995, CANCER EPIDEM BIOMAR, V4, P459; Munoz N, 1996, JNCI-J NATL CANCER I, V88, P1068, DOI 10.1093/jnci/88.15.1068; MUNOZ N, 1992, INT J CANCER, V52, P743, DOI 10.1002/ijc.2910520513; MUNOZ N, 1993, CANCER EPIDEM BIOMAR, V2, P423; Ngelangel C, 1998, JNCI-J NATL CANCER I, V90, P43, DOI 10.1093/jnci/90.1.43; O'Farrell N, 2000, INT J STD AIDS, V11, P137, DOI 10.1258/0956462001915480; ORIEL JD, 1971, BRIT J VENER DIS, V47, P1; PARKER SW, 1983, MED J AUSTRALIA, V2, P288, DOI 10.5694/j.1326-5377.1983.tb122467.x; Quinn TC, 2000, NEW ENGL J MED, V342, P921, DOI 10.1056/NEJM200003303421303; SCHOEN EJ, 1990, NEW ENGL J MED, V322, P1308, DOI 10.1056/NEJM199005033221810; Szabo R, 2000, BRIT MED J, V320, P1592, DOI 10.1136/bmj.320.7249.1592; Tseng HF, 2001, CANCER CAUSE CONTROL, V12, P267, DOI 10.1023/A:1011266405062; Urassa M, 1997, AIDS, V11, P73, DOI 10.1097/00002030-199701000-00011; Van Howe RS, 1998, PEDIATR INFECT DIS J, V17, P1, DOI 10.1097/00006454-199801000-00002; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; Weiss GN, 1997, PEDIATR INFECT DIS J, V16, P727, DOI 10.1097/00006454-199708000-00002; WILSON RA, 1947, CAN MED ASSOC J, V56, P54; 1966, LANCET, V1, P137	44	480	512	0	37	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 11	2002	346	15					1105	1112		10.1056/NEJMoa011688	http://dx.doi.org/10.1056/NEJMoa011688			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	539PX	11948269	Green Published			2022-12-28	WOS:000174880600002
J	Hulot, G; Eymin, C; Langlais, B; Mandea, M; Olsen, N				Hulot, G; Eymin, C; Langlais, B; Mandea, M; Olsen, N			Small-scale structure of the geodynamo inferred from Oersted and Magsat satellite data	NATURE			English	Article							GEOMAGNETIC REVERSAL PATHS; PAST 5 MYR; SECULAR VARIATION; TORSIONAL OSCILLATIONS; ANGULAR-MOMENTUM; MAGNETIC-FIELD; CORE SURFACE; EARTHS CORE; INNER-CORE; OUTER-CORE	The 'geodynamo' in the Earth's liquid outer core produces a magnetic field that dominates the large and medium length scales of the magnetic field observed at the Earth's surface(1,2). Here we use data from the currently operating Danish Oersted(3) satellite, and from the US Magsat(2) satellite that operated in 1979/80, to identify and interpret variations in the magnetic field over the past 20 years, down to length scales previously inaccessible. Projected down to the surface of the Earth's core, we found these variations to be small below the Pacific Ocean, and large at polar latitudes and in a region centred below southern Africa. The flow pattern at the surface of the core that we calculate to account for these changes is characterized by a westward flow concentrated in retrograde polar vortices and an asymmetric ring where prograde vortices are correlated with highs (and retrograde vortices with lows) in the historical (400-year average) magnetic field(4,5). This pattern is analogous to those seen in a large class of numerical dynamo simulations(6), except for its longitudinal asymmetry. If this asymmetric state was reached often in the past, it might account for several persistent patterns observed in the palaeomagnetic field(7-10). We postulate that it might also be a state in which the geodynamo operates before reversing.	Inst Phys Globe, Dept Geomagnetisme & Paleomagnetisme, CNRS, UMR 7577, F-75252 Paris 05, France; Danish Space Res Inst, Ctr Planetary Sci, DK-2100 Copenhagen, Denmark	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Technical University of Denmark	Hulot, G (corresponding author), Inst Phys Globe, Dept Geomagnetisme & Paleomagnetisme, CNRS, UMR 7577, 4 Pl Jussieu,B89,Tour 24, F-75252 Paris 05, France.	gh@ipgp.jussieu.fr	Hulot, Gauthier/A-5627-2011; Langlais, Benoit/O-6650-2019; Olsen, Nils/H-1822-2011; MANDEA, Mioara/E-4892-2012; Olsen, Nils/AAZ-1044-2021; Langlais, Benoit/K-5366-2012	Langlais, Benoit/0000-0001-5207-304X; Olsen, Nils/0000-0003-1132-6113; Olsen, Nils/0000-0003-1132-6113; Langlais, Benoit/0000-0001-5207-304X				[Anonymous], 1996, MAGNETIC FIELD EARTH; BLOXHAM J, 1991, REV GEOPHYS, V29, P97, DOI 10.1029/90RG02470; BLOXHAM J, 1989, PHILOS T R SOC A, V329, P415, DOI 10.1098/rsta.1989.0087; Carlut J, 1998, GEOPHYS J INT, V134, P527, DOI 10.1046/j.1365-246x.1998.00577.x; CONSTABLE C, 1992, NATURE, V358, P230, DOI 10.1038/358230a0; Constable CG, 2000, PHILOS T R SOC A, V358, P991, DOI 10.1098/rsta.2000.0570; DORMY E, 2000, GEOCHEM GEOPHY GEOSY, V1; GLATZMAIER GA, 1995, PHYS EARTH PLANET IN, V91, P63, DOI 10.1016/0031-9201(95)03049-3; GUBBINS D, 1993, NATURE, V362, P51, DOI 10.1038/362051a0; GUBBINS D, 1987, NATURE, V325, P509, DOI 10.1038/325509a0; GUBBINS D, 1993, NATURE, V365, P829, DOI 10.1038/365829a0; HULOT G, 1992, GEOPHYS J INT, V108, P224, DOI 10.1111/j.1365-246X.1992.tb00852.x; Hulot G, 1996, PHYS EARTH PLANET IN, V95, P37, DOI 10.1016/0031-9201(95)03106-5; JACKSON A, 1993, GEOPH MONOG SERIES, V72, P97; Jackson A, 2000, PHILOS T ROY SOC A, V358, P957, DOI 10.1098/rsta.2000.0569; JAULT D, 1988, NATURE, V333, P353, DOI 10.1038/333353a0; KUANG W, 1998, GEODYN SER, V28, P187; LANGEL RA, 1998, MAGNETIC FIELD EARTH; LANGLAIS B, IN PRESS PHYS EARTH; LEMOUEL JL, 1984, NATURE, V311, P734, DOI 10.1038/311734a0; NEUBERT T, 2001, EOS T AGU, V82, P87; Olsen N, 1999, SURV GEOPHYS, V20, P309, DOI 10.1023/A:1006611303582; Olson P, 1999, J GEOPHYS RES-SOL EA, V104, P10383, DOI 10.1029/1999JB900013; Olson P, 1999, NATURE, V402, P170, DOI 10.1038/46017; Pais A, 2000, PHYS EARTH PLANET IN, V118, P291, DOI 10.1016/S0031-9201(99)00161-2; Purucker M, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2001GL013645; Rau S, 2000, GEOPHYS J INT, V141, P485, DOI 10.1046/j.1365-246x.2000.00097.x; ROBERTS PH, 1965, J GEOMAGN GEOELECTR, V17, P137, DOI 10.5636/jgg.17.137; Tarits P, 2000, GEOPHYS RES LETT, V27, P4009, DOI 10.1029/1999GL011249; Zatman S, 1997, NATURE, V388, P760, DOI 10.1038/41987	30	227	230	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 11	2002	416	6881					620	623		10.1038/416620a	http://dx.doi.org/10.1038/416620a			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	539YV	11948347				2022-12-28	WOS:000174901900039
J	Leadbetter, EA; Rifkin, IR; Hohlbaum, AM; Beaudette, BC; Shlomchik, MJ; Marshak-Rothstein, A				Leadbetter, EA; Rifkin, IR; Hohlbaum, AM; Beaudette, BC; Shlomchik, MJ; Marshak-Rothstein, A			Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors	NATURE			English	Article							CUTTING EDGE; CPG-DNA; GENE; AUTOANTIBODY; DISRUPTION; EXPRESSION; LUPUS; MICE	Autoreactive B cells are present in the lymphoid tissues of healthy individuals, but typically remain quiescent. When this homeostasis is perturbed, the formation of self-reactive antibodies can have serious pathological consequences. B cells expressing an antigen receptor specific for self-immunoglobulin-g (IgG) make a class of autoantibodies known as rheumatoid factor (RF). Here we show that effective activation of RF+ B cells is mediated by IgG2a-chromatin immune complexes and requires the synergistic engagement of the antigen receptor and a member of the MyD88-dependent Toll-like receptor (TLR) family. Inhibitor studies implicate TLR9. These data establish a critical link between the innate and adaptive immune systems in the development of systemic autoimmune disease and explain the preponderance of autoantibodies reactive with nucleic acid-protein particles. The unique features of this dual-engagement pathway should facilitate the development of therapies that specifically target autoreactive B cells.	Boston Univ, Sch Med, Dept Microbiol, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA; Yale Univ, Sch Med, Dept Lab Med, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT 06520 USA	Boston University; Boston University; Yale University; Yale University	Marshak-Rothstein, A (corresponding author), Boston Univ, Sch Med, Dept Microbiol, Boston, MA 02118 USA.	amrothst@bu.edu	Shlomchik, Mark J./AAN-6189-2020	Shlomchik, Mark J./0000-0002-2152-0959; Rifkin, Ian/0000-0002-2674-3991; Beaudette-Zlatanova, Britte/0000-0002-1585-0409				Adachi O, 1998, IMMUNITY, V9, P143, DOI 10.1016/S1074-7613(00)80596-8; Ahearn JM, 1996, IMMUNITY, V4, P251, DOI 10.1016/S1074-7613(00)80433-1; Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; BELL DA, 1991, CLIN IMMUNOL IMMUNOP, V60, P13, DOI 10.1016/0090-1229(91)90108-M; BELL DA, 1990, J CLIN INVEST, V85, P1487, DOI 10.1172/JCI114595; BENAROCH P, 1995, EMBO J, V14, P37, DOI 10.1002/j.1460-2075.1995.tb06973.x; Bickerstaff MCM, 1999, NAT MED, V5, P694, DOI 10.1038/9544; Botto M, 1998, NAT GENET, V19, P56, DOI 10.1038/ng0598-56; CARTER RH, 1988, J IMMUNOL, V141, P457; EMLEN W, 1992, J IMMUNOL, V148, P3042; ESDAILE J, 1991, NEW ENGL J MED, V324, P150; Furst DE, 1999, ARTHRITIS RHEUM, V42, P357, DOI 10.1002/1529-0131(199902)42:2<357::AID-ANR19>3.0.CO;2-J; Hacker H, 2000, J EXP MED, V192, P595, DOI 10.1084/jem.192.4.595; Hacker H, 1998, EMBO J, V17, P6230, DOI 10.1093/emboj/17.21.6230; Hannum LG, 1996, J EXP MED, V184, P1269, DOI 10.1084/jem.184.4.1269; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Horng T, 2001, NAT IMMUNOL, V2, P835, DOI 10.1038/ni0901-835; JACOBSON BA, 1994, J IMMUNOL, V152, P4489; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; LENART P, 2001, ANTISENSE NUCLEIC A, V4, P247; Li M, 2001, J IMMUNOL, V166, P7128, DOI 10.4049/jimmunol.166.12.7128; Massari P, 2002, J IMMUNOL, V168, P1533, DOI 10.4049/jimmunol.168.4.1533; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; MOLLER G, 1972, CELL IMMUNOL, V4, P416, DOI 10.1016/0008-8749(72)90043-3; Monestier M, 1996, MOL IMMUNOL, V33, P89, DOI 10.1016/0161-5890(95)00115-8; Napirei M, 2000, NAT GENET, V25, P177, DOI 10.1038/76032; Rifkin IR, 2000, J IMMUNOL, V165, P1626, DOI 10.4049/jimmunol.165.3.1626; Scott RS, 2001, NATURE, V411, P207, DOI 10.1038/35075603; SHLOMCHIK MJ, 1993, INT IMMUNOL, V5, P1329, DOI 10.1093/intimm/5.10.1329; SHLOMCHIK MJ, 1987, NATURE, V328, P805, DOI 10.1038/328805a0; Singal R, 1999, BLOOD, V93, P4059, DOI 10.1182/blood.V93.12.4059; TAN EM, 1989, ADV IMMUNOL, V44, P93, DOI 10.1016/S0065-2776(08)60641-0; THEOFILOPOULOS AN, 1985, J EXP MED, V162, P1, DOI 10.1084/jem.162.1.1; Wang HW, 1999, J EXP MED, V190, P639, DOI 10.1084/jem.190.5.639; WILLIAM J, UNPUB EVOLUTION AUTO; WOLFOWICZ CB, 1988, CLIN IMMUNOL IMMUNOP, V46, P382, DOI 10.1016/0090-1229(88)90057-8; Yi AK, 1998, J IMMUNOL, V160, P4755; Zeng D, 2000, J IMMUNOL, V164, P5000, DOI 10.4049/jimmunol.164.10.5000	39	1483	1563	1	60	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 11	2002	416	6881					603	607		10.1038/416603a	http://dx.doi.org/10.1038/416603a			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	539YV	11948342				2022-12-28	WOS:000174901900034
J	Kosak, ST; Skok, JA; Medina, KL; Riblet, R; Le Beau, MM; Fisher, AG; Singh, H				Kosak, ST; Skok, JA; Medina, KL; Riblet, R; Le Beau, MM; Fisher, AG; Singh, H			Subnuclear compartmentalization of immunoglobulin loci during lymphocyte development	SCIENCE			English	Article							V(D)J RECOMBINATION; CENTROMERIC HETEROCHROMATIN; HISTONE ACETYLATION; CHROMATIN; LOCALIZATION; RECEPTOR; ORGANIZATION; ASSOCIATION; NUCLEUS; MICE	Immunoglobulin (Ig) loci are selectively activated for transcription and rearrangement during B lymphocyte development. Using fluorescence in situ hybridization, we show that Ig heavy (H) and Igkappa Loci are preferentially positioned at the nuclear periphery in hematopoietic progenitors and pro-T cells but are centrally configured in pro-B nuclei. The inactive loci at the periphery do not associate with centromeric heterochromatin. Upon localization away from the nuclear periphery in pro-B cells, the IgH locus appears to undergo large-scale compaction. We suggest that subnuclear positioning represents a novel means of regulating transcription and recombination of IgH and Igkappa loci during lymphocyte development.	Univ Chicago, Dept Mol Genet & Cell Biol, Howard Hughes Med Inst, Chicago, IL 60637 USA; Univ Chicago, Dept Med, Chicago, IL 60637 USA; Hammersmith Hosp, Imperial Coll Sch Med, MRC, Clin Sci Ctr,Lymphocyte Dev Grp, London W12 0NN, England; Torrey Pines Inst Mol Studies, San Diego, CA 92121 USA	Howard Hughes Medical Institute; University of Chicago; University of Chicago; Imperial College London; Torrey Pines Institute for Molecular Studies, California	Singh, H (corresponding author), Univ Chicago, Dept Mol Genet & Cell Biol, Howard Hughes Med Inst, 920 E 58th St, Chicago, IL 60637 USA.		Skok, Jane/ABF-7249-2020	Skok, Jane/0000-0002-4145-1516	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007183] Funding Source: NIH RePORTER; NIGMS NIH HHS [5T32GM07183] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andrulis ED, 1998, NATURE, V394, P592, DOI 10.1038/29100; Brown KE, 1997, CELL, V91, P845, DOI 10.1016/S0092-8674(00)80472-9; Chowdhury D, 2001, EMBO J, V20, P6394, DOI 10.1093/emboj/20.22.6394; Cockell M, 1999, CURR OPIN GENET DEV, V9, P199, DOI 10.1016/S0959-437X(99)80030-6; COMINGS DE, 1980, HUM GENET, V53, P131, DOI 10.1007/BF00273484; Corcoran AE, 1998, NATURE, V391, P904, DOI 10.1038/36122; Croft JA, 1999, J CELL BIOL, V145, P1119, DOI 10.1083/jcb.145.6.1119; Csink AK, 1996, NATURE, V381, P529, DOI 10.1038/381529a0; Francastel C, 1999, CELL, V99, P259, DOI 10.1016/S0092-8674(00)81657-8; Gotzmann J, 1999, CRIT REV EUKAR GENE, V9, P257, DOI 10.1615/CritRevEukarGeneExpr.v9.i3-4.100; KOSAK ST, UNPUB; McBlane F, 2000, CURR BIOL, V10, P483, DOI 10.1016/S0960-9822(00)00449-8; McMurry MT, 2000, SCIENCE, V287, P495, DOI 10.1126/science.287.5452.495; PESCHON JJ, 1994, J EXP MED, V180, P1955, DOI 10.1084/jem.180.5.1955; Roth DB, 2000, CELL, V103, P699, DOI 10.1016/S0092-8674(00)00173-2; SCHATZ DG, 1992, ANNU REV IMMUNOL, V10, P359, DOI 10.1146/annurev.iy.10.040192.002043; Skok JA, 2001, NAT IMMUNOL, V2, P848, DOI 10.1038/ni0901-848; Sleckman BP, 1996, ANNU REV IMMUNOL, V14, P459, DOI 10.1146/annurev.immunol.14.1.459; StanhopeBaker P, 1996, CELL, V85, P887, DOI 10.1016/S0092-8674(00)81272-6; YANCOPOULOS GD, 1985, CELL, V40, P271, DOI 10.1016/0092-8674(85)90141-2	20	556	568	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 5	2002	296	5565					158	162		10.1126/science.1068768	http://dx.doi.org/10.1126/science.1068768			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	539FA	11935030				2022-12-28	WOS:000174858800053
J	O'Dowd, CD; Aalto, P; Hameri, K; Kulmala, M; Hoffmann, T				O'Dowd, CD; Aalto, P; Hameri, K; Kulmala, M; Hoffmann, T			Aerosol formation - Atmospheric particles from organic vapours	NATURE			English	Article							FOREST		Univ Helsinki, Dept Phys Sci, Div Atmospher Sci, FIN-00014 Helsinki, Finland; Natl Univ Ireland Univ Coll Galway, Dept Expt Phys, Galway, Ireland; Finnish Inst Occupat Hlth, FIN-00250 Helsinki, Finland; Inst Spectrochem & Appl Spect, D-44139 Dortmund, Germany	University of Helsinki; Ollscoil na Gaillimhe-University of Galway; Finnish Institute of Occupational Health	O'Dowd, CD (corresponding author), Univ Helsinki, Dept Phys Sci, Div Atmospher Sci, POB 64, FIN-00014 Helsinki, Finland.		Aalto, Pasi P/A-1539-2009; Hoffmann, Thorsten/A-7490-2012; Kulmala, Markku T/I-7671-2016; O'Dowd, Colin D/K-8904-2012	Aalto, Pasi P/0000-0001-8826-9108; Kulmala, Markku T/0000-0003-3464-7825; O'Dowd, Colin D/0000-0002-3068-2212; Hameri, Kaarle/0000-0003-2667-2174; Hoffmann, Thorsten/0000-0003-0939-271X				Birmili W, 2000, GEOPHYS RES LETT, V27, P2205, DOI 10.1029/1999GL011334; HOFFMANN T, 1999, EUROTRAC NEWSLETT, V21, P12; Kavouras IG, 1998, NATURE, V395, P683, DOI 10.1038/27179; Kulmala M, 2001, TELLUS B, V53, P324, DOI 10.1034/j.1600-0889.2001.d01-24.x; Leaitch WR, 1999, J GEOPHYS RES-ATMOS, V104, P8095, DOI 10.1029/1998JD100012; Makela JM, 1997, GEOPHYS RES LETT, V24, P1219, DOI 10.1029/97GL00920; Marti JJ, 1996, AEROSOL SCI TECH, V25, P214, DOI 10.1080/02786829608965392	7	307	314	2	117	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 4	2002	416	6880					497	498		10.1038/416497a	http://dx.doi.org/10.1038/416497a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	537JY	11932734				2022-12-28	WOS:000174756500032
J	Young, NS				Young, NS			Acquired aplastic anemia	ANNALS OF INTERNAL MEDICINE			English	Review							BONE-MARROW-TRANSPLANTATION; COLONY-STIMULATING FACTOR; PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA; HIGH-DOSE CYCLOPHOSPHAMIDE; ANTITHYMOCYTE GLOBULIN; NON-A; ANTILYMPHOCYTE GLOBULIN; MALIGNANT-TUMORS; PARVOVIRUS B19; EUROPEAN GROUP	In aplastic anemia, hematopoiesis fails: Blood cell counts are extremely low, and the bone marrow appears empty. The pathophysiology of aplastic anemia is now believed to be immune-mediated, with active destruction of blood-forming cells by lymphocytes. The aberrant immune response may be triggered by environmental exposures, such as to chemicals and drugs or viral infections and, perhaps, endogenous antigens generated by genetically altered bone marrow cells. In patients with post-hepatitis aplastic anemia, antibodies to the known hepatitis viruses are absent; the unknown infectious agent may be more common in developing countries, where aplastic anemia occurs more frequently than it does in the West. The syndrome paroxysmal nocturnal hemoglobinuria (PNH) is intimately related to aplastic anemia because many patients with bone marrow failure have an increased population of abnormal cells. In PNH, an entire class of proteins is not displayed on the cell surface because of an acquired X-chromosome gene mutation. The PNH cells may have a selective advantage in resisting immune attack. In contrast, the disease myelodysplasia can be confused with aplasia and can also evolve from aplastic anemia. The occurrence of cytogenetic abnormalities in patients years after presentation implies that genomic instability is a feature of this immune-mediated disease. Aplastic anemia can be effectively treated by stem-cell transplantation or immunosuppressive therapy, Transplantation is curative but is best used for younger patients who have histocompatible sibling donors. Antithymocyte globulin and cyclosporine restore hematopoiesis in approximately two thirds of patients. However, recovery of blood cell count is often incomplete, recurrent pancytopenia. requires retreatment, and some patients develop late complications (especially myelodysplasia).	NHLBI, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Young, NS (corresponding author), NHLBI, NIH, Bldg 10,Room 7C103,9000 Rockville Pike, Bethesda, MD 20892 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL002315, ZIAHL002315] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alter MJ, 1997, NEW ENGL J MED, V336, P741, DOI 10.1056/NEJM199703133361101; ANDERSON KC, 1990, NEW ENGL J MED, V323, P315; Bacigalupo A, 2000, SEMIN HEMATOL, V37, P69, DOI 10.1016/S0037-1963(00)90031-3; Bacigalupo A, 2000, ACTA HAEMATOL-BASEL, V103, P19, DOI 10.1159/000041000; BACIGALUPO A, 1995, BLOOD, V85, P1348, DOI 10.1182/blood.V85.5.1348.bloodjournal8551348; Ball SE, 1998, BLOOD, V91, P3582; Barrett J, 2000, SEMIN HEMATOL, V37, P15; Bessho M, 1997, EUR J HAEMATOL, V58, P265; Brodsky RA, 1996, BLOOD, V87, P491, DOI 10.1182/blood.V87.2.491.bloodjournal872491; Brodsky RA, 2001, ANN INTERN MED, V135, P477, DOI 10.7326/0003-4819-135-7-200110020-00006; Brown KE, 1997, ANNU REV MED, V48, P59; Brown KE, 1997, NEW ENGL J MED, V336, P1059, DOI 10.1056/NEJM199704103361504; CHEN G, 2002, IN PRESS EXP HEMATOL; Chen R, 2000, J CLIN INVEST, V106, P689, DOI 10.1172/JCI8328; Corwin AL, 1996, T ROY SOC TROP MED H, V90, P647, DOI 10.1016/S0035-9203(96)90418-6; Curtis RE, 1997, NEW ENGL J MED, V336, P897, DOI 10.1056/NEJM199703273361301; Deeg HJ, 1998, BLOOD, V91, P3637; Di Bona E, 1999, BRIT J HAEMATOL, V107, P330, DOI 10.1046/j.1365-2141.1999.01693.x; Dunn DE, 1999, ANN INTERN MED, V131, P401, DOI 10.7326/0003-4819-131-6-199909210-00002; Ehrlich P, 1888, CHARITE ANN, V13, P300; Frickhofen N, 2000, SEMIN HEMATOL, V37, P56, DOI 10.1053/shem.2000.0370056; Genestier L, 1998, BLOOD, V91, P2360, DOI 10.1182/blood.V91.7.2360.2360_2360_2368; Gluckman E, 1998, BLOOD, V92, p376A; Horowitz MM, 2000, SEMIN HEMATOL, V37, P30; Issaragrisil S, 1999, AM J HEMATOL, V61, P164, DOI 10.1002/(SICI)1096-8652(199907)61:3<164::AID-AJH2>3.0.CO;2-R; KAUFMAN DW, 1992, DRUG ETIOLOGY AGRANU; KERNAN NA, 1993, NEW ENGL J MED, V328, P593, DOI 10.1056/NEJM199303043280901; KOJIMA S, 1994, BLOOD, V83, P1474; Kurzrock R., 1997, Blood, V90, p173A; Maciejewski JP, 2001, BLOOD, V98, P3513, DOI 10.1182/blood.V98.13.3513; Margolis D, 1996, BRIT J HAEMATOL, V94, P65, DOI 10.1046/j.1365-2141.1996.d01-1772.x; Margolis DA, 2000, SEMIN HEMATOL, V37, P43; MARSH JCW, 1993, BRIT J HAEMATOL, V84, P731, DOI 10.1111/j.1365-2141.1993.tb03153.x; MARSH JCW, 1994, LANCET, V344, P172, DOI 10.1016/S0140-6736(94)92763-4; Merion RM, 1998, TRANSPLANTATION, V65, P1481, DOI 10.1097/00007890-199806150-00013; MOLLDREM J, IN PRESS ANN INTERN; NAJEAN Y, 1990, BLOOD, V76, P2222; Raghavachar A., 1997, Blood, V90, p439A; Rochling FA, 1997, HEPATOLOGY, V25, P478; Rosenfeld SJ, 2001, BLOOD, V98, p749A; ROSENFELD SJ, 1995, BLOOD, V85, P3058, DOI 10.1182/blood.V85.11.3058.bloodjournal85113058; Safadi R, 2001, BONE MARROW TRANSPL, V27, P183, DOI 10.1038/sj.bmt.1702749; Sieff CA, 2000, BRIT J HAEMATOL, V111, P30, DOI 10.1046/j.1365-2141.2000.02263.x; Sloand E. M., 1997, Blood, V90, p20B; SOCIE G, 1993, NEW ENGL J MED, V329, P1152, DOI 10.1056/NEJM199310143291603; SOCIE G, 1991, BLOOD, V78, P277; Sokal EM, 1998, LANCET, V352, P1739, DOI 10.1016/S0140-6736(98)06165-0; STORB R, 1994, BLOOD, V84, P941, DOI 10.1182/blood.V84.3.941.941; Tisdale JF, 2000, LANCET, V356, P1554, DOI 10.1016/S0140-6736(00)03126-3; Tisdale JF, 2001, BLOOD, V98, p223A; Tsai TW, 1997, ADV INTERNAL MED, V42, P423; TZAKIS AG, 1988, NEW ENGL J MED, V319, P393, DOI 10.1056/NEJM198808183190702; WITHERSPOON RP, 1989, NEW ENGL J MED, V321, P784, DOI 10.1056/NEJM198909213211203; Wolk A, 1998, BLOOD, V92, p158A; YANG C, 1991, Chinese Medical Sciences Journal, V6, P203; Young NS, 2000, SEMIN HEMATOL, V37, P3, DOI 10.1016/S0037-1963(00)90026-X; Young NS, 2000, J CLIN INVEST, V106, P637, DOI 10.1172/JCI11002; Young NS, 1997, NEW ENGL J MED, V336, P1365, DOI 10.1056/NEJM199705083361906; YOUNG NS, 1995, BLOOD, V85, P3367, DOI 10.1182/blood.V85.12.3367.bloodjournal85123367; YOUNG NS, 2002, IN PRESS MYELODYSPLA; Young NS, 1994, APLASTIC ANEMIA ACQU, P100; Zeng WH, 2001, J CLIN INVEST, V108, P765, DOI 10.1172/JCI12687	62	212	231	0	15	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 2	2002	136	7					534	546		10.7326/0003-4819-136-7-200204020-00011	http://dx.doi.org/10.7326/0003-4819-136-7-200204020-00011			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	536CA	11926789				2022-12-28	WOS:000174682100006
J	Brodlie, M; Laing, IA; Keeling, JW; McKenzie, KJ				Brodlie, M; Laing, IA; Keeling, JW; McKenzie, KJ			Ten years of neonatal autopsies in tertiary referral centre: retrospective study	BRITISH MEDICAL JOURNAL			English	Article							PERINATAL AUTOPSY; POSTMORTEM EXAMINATION; EXPERIENCE; FAMILIES; YIELD	Objectives To measure the neonatal autopsy rate at a tertiary referral centre and identify trends over the past decade. To identify factors that may influence the likelihood of consent being given for autopsy. To examine any discordance between diagnoses before death and at autopsy. Design Retrospective review of patients' records. Setting Tertiary neonatal referral centre affiliated to university. Outcome measures Sex, gestational age, birth weight, type of delivery, and length of stay in neonatal unit for baby. Maternal age, marital status, history of previous pregnancies, and details of who requested permission for autopsy. Concordance between diagnoses before death and at autopsy. Results An autopsy was performed in 209/314 (67%) cases. New information was obtained in 50 (26%) autopsies. In six (3%) cases this information was crucial for future counselling. In 145 (74%) there was complete concordance between the clinical cause of death and the findings at autopsy. From 1994 onwards the autopsy rate in the neonatal unit fell. The only significant factor associated with consent for autopsy was increased gestational age. Conclusions Important extra information can be gained at neonatal autopsies. This should help parents to make an informed decision when they are asked to give permission for their baby to have an autopsy. These findings are of particular relevance in view of the recent negative publicity surrounding neonatal autopsies and the general decline in the neonatal autopsy rate over the decade studied.	Neonatal Unit, Edinburgh EH3 9YW, Midlothian, Scotland; Royal Hosp Sick Children, Dept Paediat Pathol, Edinburgh EH9 1LW, Midlothian, Scotland		Laing, IA (corresponding author), Neonatal Unit, Simpson Mem Matern Pavil, Edinburgh EH3 9YW, Midlothian, Scotland.			Brodlie, Malcolm/0000-0003-4591-8299				BECKWITH JB, 1989, PEDIATR CLIN N AM, V36, P29; BERGER LR, 1978, CLIN PEDIATR, V17, P445, DOI 10.1177/000992287801700511; BERTHRONG M, 1984, ARCH PATHOL LAB MED, V108, P506; BROWN HG, 1984, ARCH PATHOL LAB MED, V108, P446; BURROWS S, 1975, JAMA-J AM MED ASSOC, V233, P441, DOI 10.1001/jama.233.5.441; CRAFT H, 1986, AM J DIS CHILD, V140, P1260, DOI 10.1001/archpedi.1986.02140260062027; Dhar V, 1998, J PEDIATR-US, V132, P75, DOI 10.1016/S0022-3476(98)70488-3; DORSEY DB, 1977, AM J CLIN PATHOL, V69, P217; GOLDMAN L, 1983, NEW ENGL J MED, V308, P1000, DOI 10.1056/NEJM198304283081704; HIRSCH CS, 1984, ARCH PATHOL LAB MED, V108, P513; Hunter M, 2001, BRIT MED J, V322, P255, DOI 10.1136/bmj.322.7281.255; KEELING JW, 1987, FETAL NEONATAL PATHO; KHONG TY, 1995, MED J AUSTRALIA, V162, P469, DOI 10.5694/j.1326-5377.1995.tb140007.x; Kircher T L, 1992, JAMA, V267, P1268; Kumar P, 2000, ARCH PEDIAT ADOL MED, V154, P38; LANDEFELD CS, 1988, NEW ENGL J MED, V318, P1249, DOI 10.1056/NEJM198805123181906; MANISCALCO WM, 1982, AM J DIS CHILD, V136, P781, DOI 10.1001/archpedi.1982.03970450023005; MEIER PR, 1986, OBSTET GYNECOL, V67, P349; PORTER HJ, 1987, J CLIN PATHOL, V40, P180, DOI 10.1136/jcp.40.2.180; REYNOLDS RC, 1978, AM J CLIN PATHOL, V69, P220; ROWE J, 1978, PEDIATRICS, V62, P166; SALLER DN, 1995, JAMA-J AM MED ASSOC, V273, P663, DOI 10.1001/jama.273.8.663; VALDESDAPENA M, 1984, ARCH PATHOL LAB MED, V108, P497; VANMARTER LJ, 1987, AM J DIS CHILD, V141, P149, DOI 10.1001/archpedi.1987.04460020039023	24	86	88	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 30	2002	324	7340					761	763		10.1136/bmj.324.7340.761	http://dx.doi.org/10.1136/bmj.324.7340.761			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	538KY	11923158	Bronze, Green Published			2022-12-28	WOS:000174816200015
J	Afzal, NA; Albert, D; Thomas, AL; Thomson, M				Afzal, NA; Albert, D; Thomas, AL; Thomson, M			A child with oesophageal strictures	LANCET			English	Editorial Material							ESOPHAGEAL		Royal Free Hosp, Ctr Paediat Gastroenterol, London NW3 2QG, England; Great Ormond St Childrens Hosp, London NW3 2QG, England	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust	Thomson, M (corresponding author), Royal Free Hosp, Ctr Paediat Gastroenterol, Pond St, London NW3 2QG, England.							ANDERSON KD, 1990, NEW ENGL J MED, V323, P637, DOI 10.1056/NEJM199009063231004; Broto J, 1999, PEDIATR SURG INT, V15, P323, DOI 10.1007/s003830050591; Panieri E, 1998, PEDIATR SURG INT, V13, P336, DOI 10.1007/s003830050333; RAHBAR R, ANN OTOL RHINOL LARY, V110, P1; Ward RF, 1998, INT J PEDIATR OTORHI, V44, P221, DOI 10.1016/S0165-5876(98)00061-5	5	31	32	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 23	2002	359	9311					1032	1032		10.1016/S0140-6736(02)08095-9	http://dx.doi.org/10.1016/S0140-6736(02)08095-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	534KP	11937184				2022-12-28	WOS:000174585800011
J	Campion, EW				Campion, EW			Perspective - Specialized care for elderly patients	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																			0	18	18	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 21	2002	346	12					874	874		10.1056/NEJM200203213461202	http://dx.doi.org/10.1056/NEJM200203213461202			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	532FR	11907285				2022-12-28	WOS:000174464100001
J	Stuhlinger, MC; Abbasi, F; Chu, JW; Lamendola, C; McLaughlin, TL; Cooke, JP; Reaven, GM; Tsao, PS				Stuhlinger, MC; Abbasi, F; Chu, JW; Lamendola, C; McLaughlin, TL; Cooke, JP; Reaven, GM; Tsao, PS			Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MEDIATED GLUCOSE DISPOSAL; STAGE RENAL-DISEASE; ASYMMETRIC DIMETHYLARGININE; ENDOTHELIAL DYSFUNCTION; PLASMA-CONCENTRATIONS; HYPERTENSION; PREDICTOR; ADHERENCE; CELLS; ADMA	Context Increased levels of asymmetric dimethylarginine (ADMA) are associated with endothelial dysfunction and increased risk of cardiovascular disease. Several cardiovascular risk factors are associated with reduced sensitivity to insulin, but elevated ADMA concentrations have not been fully linked to the metabolic syndrome. Objective To evaluate the relationship between insulin sensitivity and plasma ADMA concentrations, and to determine whether a pharmacological treatment that increases insulin sensitivity would also modulate ADMA concentrations. Design, Setting, and Subjects Cross-sectional study, containing a nonrandomized controlled trial component, of 64 healthy volunteers without diabetes (42 women, 22 men; 48 with normal blood pressure and 16 with hypertension), which was conducted at a university medical center between October 2000 and July 2001. Intervention Rosiglitazone (4 mg/d for 4 weeks and then 4 mg twice daily for 8 weeks), an insulin-sensitizing agent, was given to 7 insulin-resistant subjects with hypertension. These subjects were studied before and after 12-week treatment. Main Outcome Measures Insulin sensitivity measured by the insulin suppression test, and fasting plasma levels of low-density lipoprotein cholesterol, triglycerides, high-density lipoprotein cholesterol, glucose, insulin, and ADMA concentrations. Results Plasma ADMA concentrations were positively correlated with impairment of insulin-mediated glucose disposal in nondiabetic, normotensive subjects (r = 0.73; P < .001). Consistent with the metabolic syndrome, ADMA levels were also positively correlated with fasting triglyceride levels (r = 0.52; P < .001) but not with low-density lipoprotein cholesterol levels (r = 0.19; P = .20). Plasma ADMA concentrations increased in insulin-resistant subjects independent of hypertension. Pharmacological treatment improved insulin sensitivity and reduced mean (SD) plasma ADMA concentrations from 1.50 (0.30) to 1.05 (0.33) pmol/L (P = .001). Conclusion A significant relationship exists between insulin resistance and plasma concentrations of ADMA. Pharmacological intervention with rosiglitazone enhanced insulin sensitivity and reduced ADMA levels. Increases in plasma ADMA concentrations may contribute to the endothelial dysfunction observed in insulin-resistant patients.	Stanford Univ, Div Cardiovasc Med, Sch Med, Falk Cardiovasc Res Ctr, Stanford, CA 94305 USA	Stanford University	Tsao, PS (corresponding author), Stanford Univ, Div Cardiovasc Med, Sch Med, Falk Cardiovasc Res Ctr, 300 Pasteur Dr, Stanford, CA 94305 USA.	ptsao@stanford.edu		Cooke, John/0000-0003-0033-9138	NCRR NIH HHS [M01-RR00070] Funding Source: Medline; NHLBI NIH HHS [R01 HL08506, R01 HL62889, R01 HL-58638] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000070] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062889, R01HL008506] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abbasi F, 2001, AM J CARDIOL, V88, P1201, DOI 10.1016/S0002-9149(01)02063-X; Abbasi F, 1999, ARTERIOSCL THROM VAS, V19, P2818, DOI 10.1161/01.ATV.19.11.2818; Balletshofer BM, 2000, CIRCULATION, V101, P1780, DOI 10.1161/01.CIR.101.15.1780; Boger RH, 1998, CIRCULATION, V98, P1842, DOI 10.1161/01.CIR.98.18.1842; Boger RH, 1997, CIRCULATION, V95, P2068, DOI 10.1161/01.CIR.95.8.2068; Boger RH, 2000, CIRC RES, V87, P99, DOI 10.1161/01.RES.87.2.99; Boger RH, 2001, CLIN SCI, V100, P161, DOI 10.1042/CS20000173; Carantoni M, 1997, DIABETES CARE, V20, P1462, DOI 10.2337/diacare.20.9.1462; Chan JR, 2000, ARTERIOSCL THROM VAS, V20, P1040, DOI 10.1161/01.ATV.20.4.1040; Chen NG, 1999, J CLIN ENDOCR METAB, V84, P3485, DOI 10.1210/jc.84.10.3485; Chen NG, 1999, CIRCULATION, V100, P940, DOI 10.1161/01.CIR.100.9.940; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Fard A, 2000, ARTERIOSCL THROM VAS, V20, P2039, DOI 10.1161/01.ATV.20.9.2039; Ferri C, 1997, EXP CLIN ENDOCR DIAB, V105, P38, DOI 10.1055/s-0029-1211794; Fleck C, 2001, KIDNEY INT, V59, pS14, DOI 10.1046/j.1523-1755.2001.59780014.x; Gavin JR, 1997, DIABETES CARE, V20, P1183; GINSBERG H, 1975, J CLIN INVEST, V55, P454, DOI 10.1172/JCI107951; GREENFIELD MS, 1981, DIABETES, V30, P387, DOI 10.2337/diabetes.30.5.387; HAGER SR, 1989, AM J KIDNEY DIS, V14, P272, DOI 10.1016/S0272-6386(89)80201-X; HARRISON DG, 1993, J CLIN INVEST, V91, P1, DOI 10.1172/JCI116156; Higashi Y, 1997, HYPERTENSION, V29, P280, DOI 10.1161/01.HYP.29.1.280; Kielstein JT, 1999, J AM SOC NEPHROL, V10, P594; Leiper J, 1999, CARDIOVASC RES, V43, P542, DOI 10.1016/S0008-6363(99)00162-5; MacAllister RJ, 1996, BRIT J PHARMACOL, V119, P1533, DOI 10.1111/j.1476-5381.1996.tb16069.x; MacAllister RJ, 1996, NEPHROL DIAL TRANSPL, V11, P2449, DOI 10.1093/oxfordjournals.ndt.a027213; Miyazaki H, 1999, CIRCULATION, V99, P1141, DOI 10.1161/01.CIR.99.9.1141; Petrie JR, 1996, CIRCULATION, V93, P1331, DOI 10.1161/01.CIR.93.7.1331; Pettersson A, 1997, J CHROMATOGR B, V692, P257, DOI 10.1016/S0378-4347(96)00525-7; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Schroder M, 2001, KIDNEY INT, V59, pS19, DOI 10.1046/j.1523-1755.2001.59780019.x; Segarra G, 1999, STROKE, V30, P2206, DOI 10.1161/01.STR.30.10.2206; SHEN DC, 1988, J CLIN ENDOCR METAB, V66, P580, DOI 10.1210/jcem-66-3-580; Steinberg HO, 1996, J CLIN INVEST, V97, P2601, DOI 10.1172/JCI118709; Stuhlinger MC, 2001, CIRCULATION, V104, P2569, DOI 10.1161/hc4601.098514; Surdacki A, 1999, J CARDIOVASC PHARM, V33, P652, DOI 10.1097/00005344-199904000-00020; Valkonen VP, 2001, LANCET, V358, P2127, DOI 10.1016/S0140-6736(01)07184-7; VALLANCE P, 1992, J CARDIOVASC PHARM, V20, pS60, DOI 10.1097/00005344-199204002-00018; VALLANCE P, 1992, LANCET, V339, P572; Vallance P, 2001, LANCET, V358, P2096, DOI 10.1016/S0140-6736(01)07229-4; Yeni-Komshian H, 2000, DIABETES CARE, V23, P171, DOI 10.2337/diacare.23.2.171; Yip J, 1998, J CLIN ENDOCR METAB, V83, P2773, DOI 10.1210/jc.83.8.2773; Zavaroni I, 1999, METABOLISM, V48, P989, DOI 10.1016/S0026-0495(99)90195-6; Zoccali C, 2001, LANCET, V358, P2113, DOI 10.1016/S0140-6736(01)07217-8	44	480	509	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 20	2002	287	11					1420	1426		10.1001/jama.287.11.1420	http://dx.doi.org/10.1001/jama.287.11.1420			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	532GB	11903029	Bronze			2022-12-28	WOS:000174465000024
J	Van Dijk, D; Jansen, EWL; Hijman, R; Nierich, AP; Diephuis, JC; Moons, KGM; Lahpor, JR; Borst, C; Keizer, AMA; Nathoe, HM; Grobbee, DE; De Jaegere, PPT; Kalkman, CJ				Van Dijk, D; Jansen, EWL; Hijman, R; Nierich, AP; Diephuis, JC; Moons, KGM; Lahpor, JR; Borst, C; Keizer, AMA; Nathoe, HM; Grobbee, DE; De Jaegere, PPT; Kalkman, CJ		Octopus Study Grp	Cognitive outcome after off-pump and on-pump coronary artery bypass graft surgery - A randomized trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARDIOPULMONARY BYPASS; DYSFUNCTION; OCTOPUS; STROKE; SELECTION; DESIGN; BRAIN; HEART	Context Coronary artery bypass graft (CABG) surgery is associated with a decline in cognitive function, which has largely been attributed to the use of cardiopulmonary bypass (on-pump procedures). Cardiac stabilizers facilitate CABG surgery without use of cardiopulmonary bypass (off-pump procedures) and should reduce the cognitive decline associated with on-pump procedures. Objective To compare the effect of CABG surgery with (on-pump) and without (off-pump) cardiopulmonary bypass on cognitive outcome. Design and Setting Randomized controlled trial conducted in the Netherlands of CABG surgery patients enrolled from March 1998 through August 2000, with 3- and 12-month follow-up. Participants and Intervention Patients scheduled for their first CABG surgery (mean age, 61 years; n = 281) were randomly assigned to off-pump surgery (n = 142) or on-pump surgery (n = 139). Main Outcome Measures Cognitive outcome at 3 and 12 months, which was determined by psychologists (blinded for randomization) who administered 10 neuropsychological tests before and after surgery. Quality of life, stroke rate, and all-cause mortality at 3 and 12 months were secondary outcome measures. Results Cognitive outcome could be determined at 3 months in 248 patients. Cognitive decline occurred in 21% in the off-pump group and 29% in the on-pump group (relative risk [RR], 0.65; 95% confidence interval [CI], 0.36-1.16; P = .15). The overall standardized change score (le, improvement of cognitive performance) was 0.19 in the off-pump vs 0.13 in the on-pump group (P = .03). At 12 months, cognitive decline occurred in 30.8% in the off-pump group and 33.6% in the on-pump group (RR, 0.88 95% CI, 0.52-1.49; P = .69), The overall standardized change score was 0.19 in the off-pump vs 0.12 in the on-pump group (P = .09). No statistically significant differences were observed between the on-pump and off-pump groups in quality of life, stroke rate, or all-cause mortality at 3 and 12 months. Conclusion Patients who received their first CABG surgery without cardiopulmonary bypass had improved cognitive outcomes 3 months after the procedure, but the effects were limited and became negligible at 12 months.	Univ Med Ctr, Dept Anaesthesiol, NL-3508 GA Utrecht, Netherlands; Univ Med Ctr, Dept Cardiothorac Surg, NL-3508 GA Utrecht, Netherlands; Univ Med Ctr, Dept Psychiat, NL-3508 GA Utrecht, Netherlands; Univ Med Ctr, Dept Cardiol, NL-3508 GA Utrecht, Netherlands; Univ Med Ctr, Julius Ctr Patient Oriented Res, NL-3508 GA Utrecht, Netherlands; Weezenlanden Hosp, Isala Clin, Dept Thorac Anaesthesiol, Zwolle, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Isala Clinics	Kalkman, CJ (corresponding author), Univ Med Ctr, Dept Anaesthesiol, POB 85500,HpN E03-511, NL-3508 GA Utrecht, Netherlands.	c.j.kalkman@azu.nl	Kalkman, Cor/O-3215-2019; Grobbee, Diederick/C-7651-2014	Kalkman, Cor/0000-0002-8372-6960; Grobbee, Diederick/0000-0003-4472-4468				Arrowsmith JE, 1998, STROKE, V29, P2357, DOI 10.1161/01.STR.29.11.2357; Berger VW, 1999, CONTROL CLIN TRIALS, V20, P319, DOI 10.1016/S0197-2456(99)00014-8; Borst C, 1996, J AM COLL CARDIOL, V27, P1356, DOI 10.1016/0735-1097(96)00039-3; Diegeler A, 2000, ANN THORAC SURG, V69, P1162, DOI 10.1016/S0003-4975(99)01574-X; Grigore AM, 2001, ANESTHESIOLOGY, V95, P1110, DOI 10.1097/00000542-200111000-00014; HARRIS DN, 1993, LANCET, V342, P586, DOI 10.1016/0140-6736(93)91412-F; Hart JC, 2000, ANN THORAC SURG, V70, P1017, DOI 10.1016/S0003-4975(00)01799-9; Hartman GS, 1996, ANESTH ANALG, V83, P701, DOI 10.1097/00000539-199610000-00007; Jansen EWL, 1998, J THORAC CARDIOV SUR, V116, P60, DOI 10.1016/S0022-5223(98)70243-0; Lachin JM, 1999, CONTROL CLIN TRIALS, V20, P408, DOI 10.1016/S0197-2456(99)00022-7; Lloyd CT, 2000, J THORAC CARDIOV SUR, V119, P148, DOI 10.1016/S0022-5223(00)70230-3; Mahanna EP, 1996, ANN THORAC SURG, V61, P1342, DOI 10.1016/0003-4975(95)01095-5; Moller JT, 1998, LANCET, V351, P857, DOI 10.1016/S0140-6736(97)07382-0; MURKIN JM, 1995, J THORAC CARDIOV SUR, V110, P349, DOI 10.1016/S0022-5223(95)70230-X; MURKIN JM, 1995, ANN THORAC SURG, V59, P1289, DOI 10.1016/0003-4975(95)00106-U; Newman MF, 1996, CIRCULATION, V94, P74; Newman MF, 2001, NEW ENGL J MED, V344, P395, DOI 10.1056/NEJM200102083440601; NEWMAN SP, 1995, ANN THORAC SURG, V59, P1351, DOI 10.1016/0003-4975(95)00215-7; Nierich AP, 2000, ANN THORAC SURG, V70, P466, DOI 10.1016/S0003-4975(00)01561-7; Rasmussen LS, 2001, ACTA ANAESTH SCAND, V45, P275, DOI 10.1034/j.1399-6576.2001.045003275.x; Ricci M, 2000, ANN THORAC SURG, V69, P1471, DOI 10.1016/S0003-4975(00)01238-8; Roach GW, 1996, NEW ENGL J MED, V335, P1857, DOI 10.1056/NEJM199612193352501; STUMP DA, 1995, ANN THORAC SURG, V59, P1340, DOI 10.1016/0003-4975(95)00108-W; Stump DA, 2000, ANN THORAC SURG, V70, P1782, DOI 10.1016/S0003-4975(00)02202-5; van Dijk D, 2001, CIRCULATION, V104, P1761, DOI 10.1161/hc4001.097036; van Dijk D, 2000, J THORAC CARDIOV SUR, V120, P632, DOI 10.1067/mtc.2000.108901; van Dijk D, 2000, CONTROL CLIN TRIALS, V21, P595, DOI 10.1016/S0197-2456(00)00103-3; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WILLIAMS A, 1990, HEALTH POLICY, V16, P199	30	392	396	0	19	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 20	2002	287	11					1405	1412		10.1001/jama.287.11.1405	http://dx.doi.org/10.1001/jama.287.11.1405			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	532GB	11903027	Bronze			2022-12-28	WOS:000174465000022
J	Schulz, KF; Grimes, DA				Schulz, KF; Grimes, DA			Unequal group sizes in randomised trials: guarding against guessing	LANCET			English	Review							CLINICAL-TRIALS; QUALITY; BIAS	We cringe at the pervasive notion that a randomised trial needs to yield equal sample sizes in the comparison groups. Unfortunately, that conceptual misunderstanding can lead to bias by investigators who force equality, especially if by non-scientific means. In simple, unrestricted, randomised trials (analogous to repeated coin-tossing), the sizes of groups should indicate random variation. In other words, some discrepancy between the numbers in the comparison groups would be expected. The appeal of equal group sizes in a simple randomised controlled trial is cosmetic, not scientific. Moreover, other randomisation schemes, termed restricted randomisation, force equality by departing from simple randomisation. Forcing equal group sizes, however, potentially harms the unpredictability of treatment assignments, especially when using permuted-block randomisation in non-double-blinded trials. Diminished unpredictability can allow bias to creep into a trial. Overall, investigators underuse simple randomisation and overuse fixed-block randomisation. For non-double-blinded trials larger than 200 participants, investigators should use simple randomisation more often and accept moderate disparities in group sizes. Such unpredictability reflects the essence of randomness. We endorse the generation of mildly unequal group sizes and encourage an appreciation of such Inequalities. For non-double-blinded randomised controlled trials with a sample size of less than 200 overall or within any principal stratum or subgroup, urn randomisation enhances unpredictability compared with blocking. A simpler alternative, our mixed randomisation approach, attains unpredictability within the context of the currently understood simple randomisation and permuted-block methods. Simple randomisation contributes the unpredictability whereas permuted-block randomisation contributes the balance, but avoids the perfect balance that can result in selection bias.	Family Hlth Int, Res Triangle Pk, NC 27709 USA		Schulz, KF (corresponding author), Family Hlth Int, POB 13950, Res Triangle Pk, NC 27709 USA.	KSchulz@fhi.org						Adetugbo K, 2000, ARCH DERMATOL, V136, P381, DOI 10.1001/archderm.136.3.381; Altman DG, 2001, ANN INTERN MED, V134, P663, DOI 10.7326/0003-4819-134-8-200104170-00012; ALTMAN DG, 1990, LANCET, V335, P149, DOI 10.1016/0140-6736(90)90014-V; Altman DG, 1991, PRACTICAL STAT MED R; Berger VW, 1999, CONTROL CLIN TRIALS, V20, P319, DOI 10.1016/S0197-2456(99)00014-8; BERGER VW, 2001, CONTROL CLIN TRIALS, V22, pS43; CATES W, 1978, OBSTET GYNECOL, V52, P493; FRIEDMAN LM, 1996, FUNDAMENTALS CLIN TR; KEIRSE MJNC, 1994, BIRTH-ISS PERINAT C, V21, P111, DOI 10.1111/j.1523-536X.1994.tb00246.x; LACHIN JM, 1988, CONTROL CLIN TRIALS, V9, P289, DOI 10.1016/0197-2456(88)90045-1; LACHIN JM, 1988, CONTROL CLIN TRIALS, V9, P365, DOI 10.1016/0197-2456(88)90049-9; LACHIN JM, 1988, CONTROL CLIN TRIALS, V9, P312, DOI 10.1016/0197-2456(88)90046-3; MATTS JP, 1988, CONTROL CLIN TRIALS, V9, P327, DOI 10.1016/0197-2456(88)90047-5; Meinert CL., 1986, CLIN TRIALS DESIGN C; Moher D, 1998, LANCET, V352, P609, DOI 10.1016/S0140-6736(98)01085-X; Moher D, 2001, LANCET, V357, P1191, DOI 10.1016/S0140-6736(00)04337-3; MOSTELLER F, 1980, CONTROL CLIN TRIALS, V1, P37, DOI 10.1016/S0197-2456(80)80006-7; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; Pocock SJ., 2013, CLIN TRIALS PRACTICA; SCHULZ KF, 1994, JAMA-J AM MED ASSOC, V272, P125, DOI 10.1001/jama.272.2.125; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V274, P1456; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Schulz KF, 2002, LANCET, V359, P614, DOI 10.1016/S0140-6736(02)07750-4; Schulz KF, 2002, LANCET, V359, P515, DOI 10.1016/S0140-6736(02)07683-3; WEI LJ, 1988, CONTROL CLIN TRIALS, V9, P345, DOI 10.1016/0197-2456(88)90048-7	25	145	147	1	10	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 16	2002	359	9310					966	970		10.1016/S0140-6736(02)08029-7	http://dx.doi.org/10.1016/S0140-6736(02)08029-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	531AE	11918933				2022-12-28	WOS:000174391700035
J	Grimes, DA; Schulz, KF				Grimes, DA; Schulz, KF			Uses and abuses of screening tests	LANCET			English	Review							BREAST-CANCER; ABSENTEEISM; MAMMOGRAPHY	Screening tests are ubiquitous in contemporary practice, yet the principles of screening are widely misunderstood. Screening is the testing of apparently well people to find those at increased risk of having a disease or disorder. Although an earlier diagnosis generally has intuitive appeal, earlier might not always be better, or worth the cost. Four terms describe the validity of a screening test: sensitivity, specificity, and predictive value of positive and negative results. For tests with continuous variables-eg, blood glucose-sensitivity and specificity are inversely related; where the cutoff for abnormal is placed should indicate the clinical effect of wrong results. The prevalence of disease in a population affects screening test performance: in low-prevalence settings, even very good tests have poor predictive value positives. Hence, knowledge of the approximate prevalence of disease is a prerequisite to interpreting screening test results. Tests are often done in sequence, as is true for syphilis and HIV-1 infection. Lead-time and length biases distort the apparent value of screening programmes; randomised controlled trials are the only way to avoid these biases. Screening can improve health; strong indirect evidence links cervical cytology programmes to declines in cervical cancer mortality. However, inappropriate application or interpretation of screening tests can rob people of their perceived health, initiate harmful diagnostic testing, and squander health-care resources.	Family Hlth Int, Res Triangle Pk, NC 27709 USA		Grimes, DA (corresponding author), Family Hlth Int, POB 13950, Res Triangle Pk, NC 27709 USA.	dgrimes@fhi.org						[Anonymous], 1995, JAMA, V273, P491; BEGG CB, 1987, STAT MED, V6, P411, DOI 10.1002/sim.4780060402; *CAN TASK FORC PER, 1994, CAN GUID CLIN PREV C; CUCKLE HS, 1984, ANTENATAL NEONATAL S, P1; Enkin M, 2000, KEIRSE CHALMERS; Feig DS, 1998, AM J OBSTET GYNECOL, V178, P386, DOI 10.1016/S0002-9378(98)80030-6; FEINSTEIN AR, 1975, CLIN PHARMACOL THER, V17, P104; Gabbe S, 1998, OBSTET GYNECOL, V91, P643, DOI 10.1016/S0029-7844(98)00019-2; Gotzsche PC, 2000, LANCET, V355, P129, DOI 10.1016/S0140-6736(99)06065-1; GRIFFITH CS, 1990, AM J OBSTET GYNECOL, V162, P615, DOI 10.1016/0002-9378(90)90969-E; HAYNES RB, 1978, NEW ENGL J MED, V299, P741, DOI 10.1056/NEJM197810052991403; Hennekens C.H., 1987, EPIDEMIOLOGY MED; Horton R, 2001, LANCET, V358, P1284, DOI 10.1016/S0140-6736(01)06452-2; Lang T., 1997, REPORT STAT MED ANNO, DOI 10.1097/00006205-199705000-00022; Myers ER, 2000, OBSTET GYNECOL, V96, P645, DOI 10.1016/S0029-7844(00)00979-0; Olsen O, 2001, LANCET, V358, P1340, DOI 10.1016/S0140-6736(01)06449-2; Riegelman R. K., 1989, STUDYING STUDY TESTI; Sackett DL, 1991, CLIN EPIDEMIOLOGY BA, V2nd; Sawaya GF, 1999, OBSTET GYNECOL, V94, P307, DOI 10.1016/S0029-7844(99)00289-6; TAYLOR DW, 1981, CLIN INVEST MED, V4, P173; US Preventive Services Task Force, 1996, GUID CLIN PREV SERV, P18; WALD N, 1989, BRIT J OBSTET GYNAEC, V96, P389, DOI 10.1111/j.1471-0528.1989.tb02411.x; YERUSHALMY J, 1947, PUBLIC HEALTH REP, V62, P1432, DOI 10.2307/4586294; YOUDEN WJ, 1950, CANCER-AM CANCER SOC, V3, P32, DOI 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3	24	360	373	2	25	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 9	2002	359	9309					881	884		10.1016/S0140-6736(02)07948-5	http://dx.doi.org/10.1016/S0140-6736(02)07948-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	529YV	11897304				2022-12-28	WOS:000174329600032
J	Kontoyiannis, DP; Lewis, RE				Kontoyiannis, DP; Lewis, RE			Antifungal drug resistance of pathogenic fungi	LANCET			English	Review							CANDIDA-KRUSEI INFECTION; AMPHOTERICIN-B; FLUCONAZOLE RESISTANCE; ASPERGILLUS-FUMIGATUS; CROSS-RESISTANCE; AIDS PATIENTS; AZOLE RESISTANCE; CELL-WALL; ITRACONAZOLE RESISTANCE; MOLECULAR MECHANISMS	Pathogenic fungi have many complex mechanisms of resistance to antifungal drugs. Information about the clinical, cellular, and molecular factors contributing to antifungal-drug resistance continues to accumulate. We critically review the diagnosis, epidemiology, and mechanisms of antifungal drug resistance of pathogenic fungi. Better understanding of this resistance should assist in developing better detection strategies for preventing and treating refractory mycoses In the future.	Univ Texas, MD Anderson Canc Ctr, Dept Infect Dis Infect Control & Employee Hlth, Houston, TX 77030 USA; Univ Houston, Coll Pharm, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Houston System; University of Houston	Kontoyiannis, DP (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Infect Dis Infect Control & Employee Hlth, 1515 Holcombe Blvd, Houston, TX 77030 USA.	dkontoyi@mdanderson.org	Lewis, Russell E/A-4616-2015	Lewis, Russell E/0000-0002-2002-4339	NCI NIH HHS [CA-16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alexander BD, 1997, DRUGS, V54, P657, DOI 10.2165/00003495-199754050-00002; Aller AI, 2000, ANTIMICROB AGENTS CH, V44, P1544, DOI 10.1128/AAC.44.6.1544-1548.2000; Alves Sydney H., 1997, Revista do Instituto de Medicina Tropical de Sao Paulo, V39, P359, DOI 10.1590/S0036-46651997000600010; Anaissie EJ, 1998, CLIN INFECT DIS, V26, P1264, DOI 10.1086/516359; Andes D, 2001, ANTIMICROB AGENTS CH, V45, P922, DOI 10.1128/AAC.45.3.922-926.2001; Barchiesi F, 1997, EUR J CLIN MICROBIOL, V16, P601, DOI 10.1007/BF02447925; Barchiesi F, 2000, ANTIMICROB AGENTS CH, V44, P1578, DOI 10.1128/AAC.44.6.1578-1584.2000; Bekersky I, 1999, PHARMACEUT RES, V16, P1694, DOI 10.1023/A:1018997730462; BENYAACOV R, 1994, ANTIMICROB AGENTS CH, V38, P648, DOI 10.1128/AAC.38.4.648; Bouchara JP, 2000, J MED MICROBIOL, V49, P977, DOI 10.1099/0022-1317-49-11-977; Calvet HM, 1997, ANTIMICROB AGENTS CH, V41, P535, DOI 10.1128/AAC.41.3.535; Cartledge JD, 1997, AIDS, V11, P1839, DOI 10.1097/00002030-199715000-00008; CASADEVALL A, 1993, ANTIMICROB AGENTS CH, V37, P1383, DOI 10.1128/AAC.37.6.1383; Clancy CJ, 1999, ANTIMICROB AGENTS CH, V43, P1289, DOI 10.1128/AAC.43.5.1289; Cross EW, 2000, MICROB DRUG RESIST, V6, P155, DOI 10.1089/107662900419474; Dannaoui E, 2001, J ANTIMICROB CHEMOTH, V47, P333, DOI 10.1093/jac/47.3.333; Dasbach EJ, 2000, CLIN INFECT DIS, V31, P1524, DOI 10.1086/317487; DEBONO M, 1994, ANNU REV MICROBIOL, V48, P471, DOI 10.1146/annurev.mi.48.100194.002351; Denning DW, 1997, EUR J CLIN MICROBIOL, V16, P261, DOI 10.1007/BF01695630; Denning DW, 1997, ANTIMICROB AGENTS CH, V41, P1364, DOI 10.1128/AAC.41.6.1364; DICK JD, 1980, ANTIMICROB AGENTS CH, V18, P158, DOI 10.1128/AAC.18.1.158; Duswald KH, 1997, MYCOSES, V40, P267, DOI 10.1111/j.1439-0507.1997.tb00231.x; Edmond MB, 1999, CLIN INFECT DIS, V29, P239, DOI 10.1086/520192; Fekete-Forgacs K, 2000, MYCOSES, V43, P273, DOI 10.1046/j.1439-0507.2000.00587.x; Fichtenbaum CJ, 1998, CLIN INFECT DIS, V26, P556, DOI 10.1086/514571; FRANCIS P, 1992, CLIN INFECT DIS, V15, P1003, DOI 10.1093/clind/15.6.1003; GEBER A, 1995, ANTIMICROB AGENTS CH, V39, P2708, DOI 10.1128/AAC.39.12.2708; Georgopapadakou NH, 2001, EXPERT OPIN INV DRUG, V10, P269, DOI 10.1517/13543784.10.2.269; Ghannoum MA, 1996, J CLIN MICROBIOL, V34, P489, DOI 10.1128/JCM.34.3.489-495.1996; Ghannoum MA, 1999, CLIN MICROBIOL REV, V12, P501, DOI 10.1128/CMR.12.4.501; Graybill JR, 1998, ANTIMICROB AGENTS CH, V42, P2938, DOI 10.1128/AAC.42.11.2938; Groll AH, 1998, ADV PHARMACOL, V44, P343, DOI 10.1016/S1054-3589(08)60129-5; Harousseau JL, 2000, ANTIMICROB AGENTS CH, V44, P1887, DOI 10.1128/AAC.44.7.1887-1893.2000; Henry KW, 1999, ANTIMICROB AGENTS CH, V43, P1968, DOI 10.1128/AAC.43.8.1968; Hiemenz JW, 1996, CLIN INFECT DIS, V22, pS133, DOI 10.1093/clinids/22.Supplement_2.S133; Hoban DJ, 1999, ANTIMICROB AGENTS CH, V43, P1463, DOI 10.1128/AAC.43.6.1463; KARYOTAKIS NC, 1993, J INFECT DIS, V168, P1311, DOI 10.1093/infdis/168.5.1311; Kelly SL, 1997, FEBS LETT, V400, P80, DOI 10.1016/S0014-5793(96)01360-9; Kontoyiannis DP, 2001, PHARMACOTHERAPY, V21, p175S, DOI 10.1592/phco.21.12.175S.34506; KURTZ MB, 1994, ANTIMICROB AGENTS CH, V38, P1480, DOI 10.1128/AAC.38.7.1480; Latge JP, 1999, CLIN MICROBIOL REV, V12, P310, DOI 10.1128/CMR.12.2.310; LAW D, 1994, J ANTIMICROB CHEMOTH, V34, P659, DOI 10.1093/jac/34.5.659; Lee SC, 2000, ANTIMICROB AGENTS CH, V44, P2715, DOI 10.1128/AAC.44.10.2715-2718.2000; Lewis RE, 2001, PHARMACOTHERAPY, V21, p149S, DOI 10.1592/phco.21.12.149S.34505; Loffler J, 2000, FEMS MICROBIOL LETT, V185, P59, DOI 10.1016/S0378-1097(00)00071-9; Lopez-Ribot JL, 1998, ANTIMICROB AGENTS CH, V42, P2932, DOI 10.1128/AAC.42.11.2932; Louie A, 1998, ANTIMICROB AGENTS CH, V42, P1105, DOI 10.1128/AAC.42.5.1105; Lyman CA, 1999, EUR J CLIN MICROBIOL, V18, P213, DOI 10.1007/s100960050262; Lynch ME, 1996, J MED VET MYCOL, V34, P337; Lyons CN, 2000, ANTIMICROB AGENTS CH, V44, P2296, DOI 10.1128/AAC.44.9.2296-2303.2000; Maenza JR, 1996, J INFECT DIS, V173, P219, DOI 10.1093/infdis/173.1.219; Marichal P, 1997, ANTIMICROB AGENTS CH, V41, P2229, DOI 10.1128/AAC.41.10.2229; Marr KA, 2001, ANTIMICROB AGENTS CH, V45, P52, DOI 10.1128/AAC.45.1.52-59.2001; Martins MD, 1998, CLIN INFECT DIS, V27, P1291, DOI 10.1086/515006; McNeil MM, 2001, CLIN INFECT DIS, V33, P641, DOI 10.1086/322606; Mondon P, 1999, ANTIMICROB AGENTS CH, V43, P1856, DOI 10.1128/AAC.43.8.1856; Moore CB, 2000, J INFECTION, V41, P203, DOI 10.1053/jinf.2000.0747; Moran GP, 1998, ANTIMICROB AGENTS CH, V42, P1819, DOI 10.1128/AAC.42.7.1819; Muller FMC, 1999, J CLIN MICROBIOL, V37, P3405; NAKAMURA K, 2000, INT C ANT AG CHEM TO, P392; *NAT COMM CLIN LAB, 1999, REF METH BROTH DIL A; Neely MN, 2000, EUR J CLIN MICROBIOL, V19, P897, DOI 10.1007/s100960000395; Nguyen MH, 1998, J INFECT DIS, V177, P425, DOI 10.1086/514193; Orni-Wasserlauf R, 1999, CLIN INFECT DIS, V29, P1592, DOI 10.1086/313546; Orozco AS, 1998, ANTIMICROB AGENTS CH, V42, P2645, DOI 10.1128/AAC.42.10.2645; Osherov N, 2001, J ANTIMICROB CHEMOTH, V48, P75, DOI 10.1093/jac/48.1.75; Perea S, 2001, ANTIMICROB AGENTS CH, V45, P2676, DOI 10.1128/AAC.45.10.2676-2684.2001; PEREA S, 2000, INT C ANT AG CHEM TO, P393; Perepnikhatka V, 1999, J BACTERIOL, V181, P4041, DOI 10.1128/JB.181.13.4041-4049.1999; Perfect JR, 1999, DRUG RESIST UPDATE, V2, P259, DOI 10.1054/drup.1999.0090; Pfaller MA, 1996, J CLIN MICROBIOL, V34, P1691, DOI 10.1128/JCM.34.7.1691-1693.1996; Pfaller MA, 1999, DIAGN MICR INFEC DIS, V33, P217, DOI 10.1016/S0732-8893(98)00160-6; Pfaller MA, 1996, CLIN INFECT DIS, V22, pS89, DOI 10.1093/clinids/22.Supplement_2.S89; Polak A, 1991, Prog Drug Res, V37, P181; Polak A, 1999, MYCOSES, V42, P355, DOI 10.1046/j.1439-0507.1999.00475.x; POWDERLY WG, 1988, AM J MED, V84, P826, DOI 10.1016/0002-9343(88)90059-9; PRASAD R, 1995, CURR GENET, V27, P320, DOI 10.1007/BF00352101; Redding S W, 2000, Spec Care Dentist, V20, P178, DOI 10.1111/j.1754-4505.2000.tb00015.x; Rex JH, 2001, CLIN MICROBIOL REV, V14, P643, DOI 10.1128/CMR.14.4.643-658.2001; REX JH, 1995, ANTIMICROB AGENTS CH, V39, P40, DOI 10.1128/AAC.39.1.40; Rex JH, 1997, CLIN INFECT DIS, V24, P235, DOI 10.1093/clinids/24.2.235; REX JH, 1995, ANTIMICROB AGENTS CH, V39, P1, DOI 10.1128/AAC.39.1.1; Rocco TR, 2000, ARCH SURG-CHICAGO, V135, P160, DOI 10.1001/archsurg.135.2.160; Rodriguez-Adrian LJ, 1998, CLIN INFECT DIS, V26, P1270, DOI 10.1086/516364; Sanglard D, 1999, ANTIMICROB AGENTS CH, V43, P2753, DOI 10.1128/AAC.43.11.2753; Sanglard D, 1996, ANTIMICROB AGENTS CH, V40, P2300, DOI 10.1128/AAC.40.10.2300; SANGLARD D, 1995, ANTIMICROB AGENTS CH, V39, P2378, DOI 10.1128/AAC.39.11.2378; Sanglard D, 1997, MICROBIOL-UK, V143, P405, DOI 10.1099/00221287-143-2-405; Sanglard D, 2001, ANTIMICROB AGENTS CH, V45, P1174, DOI 10.1128/AAC.45.4.1174-1183.2001; Schorling SR, 2000, CRIT REV MICROBIOL, V26, P59, DOI 10.1080/10408410091154183; Seo K, 1999, MICROBIOL IMMUNOL, V43, P1017, DOI 10.1111/j.1348-0421.1999.tb01231.x; Sheehan DJ, 1999, CLIN MICROBIOL REV, V12, P40, DOI 10.1128/CMR.12.1.40; Shlaes DM, 1997, CLIN INFECT DIS, V25, P584, DOI 10.1086/513766; Sobel JD, 2001, J INFECT DIS, V183, P286, DOI 10.1086/317936; SOKOLANDERSON M, 1988, ANTIMICROB AGENTS CH, V32, P702, DOI 10.1128/AAC.32.5.702; Soll DR, 2000, CLIN MICROBIOL REV, V13, P332, DOI 10.1128/CMR.13.2.332-370.2000; Stevens DA, 1998, CLIN INFECT DIS, V26, P1266, DOI 10.1086/516362; Taylor BN, 2000, J INFECT DIS, V182, P955, DOI 10.1086/315768; The National Committee for Clinical Laboratory Standard, 1997, M27A NCCLS; Tobin MB, 1997, GENE, V200, P11, DOI 10.1016/S0378-1119(97)00281-3; Tumbarello M, 1996, J ANTIMICROB CHEMOTH, V38, P691, DOI 10.1093/jac/38.4.691; Uzun O, 2000, ANN ONCOL, V11, P1517, DOI 10.1023/A:1008308923252; van Burik JAH, 1998, MEDICINE, V77, P246, DOI 10.1097/00005792-199807000-00003; van de Hulst HC, 1998, ANNU REV ASTRON ASTR, V36, P1, DOI 10.1146/annurev.astro.36.1.1; Vanden Bossche H, 1994, Trends Microbiol, V2, P393, DOI 10.1016/0966-842X(94)90618-1; Vargas K, 2000, J CLIN MICROBIOL, V38, P3595, DOI 10.1128/JCM.38.10.3595-3607.2000; Venkateswarlu K, 1996, ANTIMICROB AGENTS CH, V40, P2443, DOI 10.1128/AAC.40.11.2443; WALSH TJ, 1990, J CLIN MICROBIOL, V28, P1616, DOI 10.1128/JCM.28.7.1616-1622.1990; Walsh TJ, 2001, ANTIMICROB AGENTS CH, V45, P3487, DOI 10.1128/AAC.45.12.3487-3496.2001; Wheat J, 1997, ANTIMICROB AGENTS CH, V41, P410, DOI 10.1128/AAC.41.2.410; WHELAN WL, 1984, ANTIMICROB AGENTS CH, V26, P570, DOI 10.1128/AAC.26.4.570; WHELAN WL, 1987, CRIT REV MICROBIOL, V15, P45, DOI 10.3109/10408418709104447; White MH, 1997, CLIN INFECT DIS, V24, P1129, DOI 10.1086/513661; White TC, 1997, ANTIMICROB AGENTS CH, V41, P1482, DOI 10.1128/AAC.41.7.1482; White TC, 1998, CLIN MICROBIOL REV, V11, P382, DOI 10.1128/CMR.11.2.382; WINGARD JR, 1991, NEW ENGL J MED, V325, P1274, DOI 10.1056/NEJM199110313251803; WOODS RA, 1968, NATURE, V218, P369, DOI 10.1038/218369a0; Xu JP, 2001, ANTIMICROB AGENTS CH, V45, P420, DOI 10.1128/AAC.45.2.420-427.2001; Yoon SA, 1999, ANTIMICROB AGENTS CH, V43, P836, DOI 10.1128/AAC.43.4.836	119	315	337	5	54	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 30	2002	359	9312					1135	1144		10.1016/S0140-6736(02)08162-X	http://dx.doi.org/10.1016/S0140-6736(02)08162-X			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	536YJ	11943280				2022-12-28	WOS:000174729200030
J	Winkens, R; Dinant, GJ				Winkens, R; Dinant, GJ			Evidence base of diagnostic research - Rational, cost effective use of investigations in clinical practice	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTITIONERS; CARE; FEEDBACK; EDUCATION; AUDITS; TESTS		Univ Hosp, Dept Gen Practice, NL-6200 MD Maastricht, Netherlands; Univ Hosp, Transmural Care Unit, NL-6200 MD Maastricht, Netherlands; Maastricht Univ, Dept Gen Practice, NL-6200 MD Maastricht, Netherlands	Maastricht University; Maastricht University; Maastricht University	Winkens, R (corresponding author), Univ Hosp, Dept Gen Practice, NL-6200 MD Maastricht, Netherlands.							BUNTINX F, 1993, FAM PRACT, V10, P219, DOI 10.1093/fampra/10.2.219; Campbell MK, 2000, FAM PRACT, V17, P192, DOI 10.1093/fampra/17.2.192; Davis D, 1999, JAMA-J AM MED ASSOC, V282, P867, DOI 10.1001/jama.282.9.867; Dinant GJ vWM, 1994, HUISARTS WETENSCHAP, V37, P202; EVERETT GD, 1983, ARCH INTERN MED, V143, P942, DOI 10.1001/archinte.143.5.942; GEIJER RMM, 1999, NHG STANDAARDEN HUIS, V1; Grol R, 1997, BRIT MED J, V315, P418, DOI 10.1136/bmj.315.7105.418; Knottnerus JA, 1997, BRIT MED J, V315, P1109; Smith R., 1992, AUDIT ACTION; SMITHUIS LO, 1994, HUISARTS WETENSCHAP, V37, P464; THOMAS S, 1996, NHG STANDAARDEN HUIS, V2; TIERNEY WM, 1990, NEW ENGL J MED, V322, P1499, DOI 10.1056/NEJM199005243222105; VANDERWEIJDEN T, 1991, CLIN TRIALS PRACTICA; Winkens RAG, 1997, J CLIN EPIDEMIOL, V50, P435, DOI 10.1016/S0895-4356(96)00422-2; Winkens RAG, 1996, BRIT MED J, V312, P490, DOI 10.1136/bmj.312.7029.490; WONES RG, 1987, MED CARE, V25, P78, DOI 10.1097/00005650-198701000-00009; ZAAT JOM, 1992, MED CARE, V30, P189, DOI 10.1097/00005650-199203000-00001	17	64	69	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 30	2002	324	7340					783	785		10.1136/bmj.324.7340.783	http://dx.doi.org/10.1136/bmj.324.7340.783			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	538KY	11924663	Green Published			2022-12-28	WOS:000174816200023
J	Matsumoto, M; Saito, S; Ohmine, I				Matsumoto, M; Saito, S; Ohmine, I			Molecular dynamics simulation of the ice nucleation and growth process leading to water freezing	NATURE			English	Article							HYDROGEN-BOND NETWORK; LIQUID WATER; HOMOGENEOUS NUCLEATION; REARRANGEMENT DYNAMICS; SUPERCOOLED WATER; FLUCTUATION; TRANSITIONS; PERSPECTIVE; RELAXATION; SCATTERING	Upon cooling, water freezes to ice. This familiar phase transition occurs widely in nature, yet unlike the freezing of simple liquids(1-3), it has never been successfully simulated on a computer. The difficulty lies with the fact that hydrogen bonding between individual water molecules yields a disordered three-dimensional hydrogen-bond network whose rugged and complex global potential energy surface(4-6) permits a large number of possible network configurations. As a result, it is very challenging to reproduce the freezing of 'real' water into a solid with a unique crystalline structure. For systems with a limited number of possible disordered hydrogen-bond network structures, such as confined water, it is relatively easy to locate a pathway from a liquid state to a crystalline structure(7-9). For pure and spatially unconfined water, however, molecular dynamics simulations of freezing are severely hampered by the large number of possible network configurations that exist. Here we present a molecular dynamics trajectory that captures the molecular processes involved in the freezing of pure water. We find that ice nucleation occurs once a sufficient number of relatively long-lived hydrogen bonds develop spontaneously at the same location to forma fairly compact initial nucleus. The initial nucleus then slowly changes shape and size until it reaches a stage that allows rapid expansion, resulting in crystallization of the entire system.	Nagoya Univ, Dept Chem, Chikusa Ku, Nagoya, Aichi 4648602, Japan	Nagoya University	Ohmine, I (corresponding author), Nagoya Univ, Dept Chem, Chikusa Ku, Nagoya, Aichi 4648602, Japan.		Saito, Shinji/B-9746-2019; MATSUMOTO, Masakazu/B-1495-2011	Saito, Shinji/0000-0003-4982-4820; MATSUMOTO, Masakazu/0000-0002-6799-6813				Abraham F.F, 1974, HOMOGENEOUS NUCL THE; Ball KD, 1996, SCIENCE, V271, P963, DOI 10.1126/science.271.5251.963; BARTELL LS, 1995, J PHYS CHEM-US, V99, P1080, DOI 10.1021/j100004a005; Dobson Christopher M., 1999, Current Opinion in Structural Biology, V9, P92, DOI 10.1016/S0959-440X(99)80012-8; Koga K, 2000, NATURE, V408, P564, DOI 10.1038/35046035; Kramer B, 1999, J CHEM PHYS, V111, P6521, DOI 10.1063/1.479946; Matsumoto M, 1996, J CHEM PHYS, V104, P2705, DOI 10.1063/1.471664; Metzler R, 2000, PHYS REP, V339, P1, DOI 10.1016/S0370-1573(00)00070-3; Mishima O, 1998, NATURE, V396, P329, DOI 10.1038/24540; Nada H, 1996, J CRYST GROWTH, V169, P587, DOI 10.1016/S0022-0248(96)00444-7; OHMINE I, 1993, CHEM REV, V93, P2545, DOI 10.1021/cr00023a011; OHMINE I, 1988, J CHEM PHYS, V89, P5852, DOI 10.1063/1.455536; Ohmine I, 1999, ACCOUNTS CHEM RES, V32, P741, DOI 10.1021/ar970161g; OHMINE I, 1995, J PHYS CHEM-US, V99, P6767, DOI 10.1021/j100018a004; Onuchic JN, 1997, ANNU REV PHYS CHEM, V48, P545, DOI 10.1146/annurev.physchem.48.1.545; SAITO S, 1995, J CHEM PHYS, V102, P3566, DOI 10.1063/1.468580; SASAI M, 1992, J CHEM PHYS, V96, P3045, DOI 10.1063/1.461950; SASAI M, 1990, J CHEM PHYS, V93, P7329, DOI 10.1063/1.459406; Sastry S, 1996, PHYS REV E, V53, P6144, DOI 10.1103/PhysRevE.53.6144; STEINHARDT PJ, 1983, PHYS REV B, V28, P784, DOI 10.1103/PhysRevB.28.784; STILLINGER FH, 1984, SCIENCE, V225, P983, DOI 10.1126/science.225.4666.983; Svishchev IM, 1996, J AM CHEM SOC, V118, P649, DOI 10.1021/ja951624l; SWOPE WC, 1990, PHYS REV B, V41, P7042, DOI 10.1103/PhysRevB.41.7042; WALRAFEN GE, 1989, J PHYS CHEM-US, V93, P2909, DOI 10.1021/j100345a014; WEISSMAN MB, 1988, REV MOD PHYS, V60, P537, DOI 10.1103/RevModPhys.60.537; Wolde P. R. t, 1997, SCIENCE, V277, P1975	26	662	672	25	492	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 28	2002	416	6879					409	413		10.1038/416409a	http://dx.doi.org/10.1038/416409a			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	534UX	11919626				2022-12-28	WOS:000174607800041
J	Bosch, J; Yusuf, S; Pogue, J; Sleight, P; Lonn, E; Rangoonwala, B; Davies, R; Ostergren, J; Probstfield, J				Bosch, J; Yusuf, S; Pogue, J; Sleight, P; Lonn, E; Rangoonwala, B; Davies, R; Ostergren, J; Probstfield, J		HOPE Investigators	Use of ramipril in preventing stroke: double blind randomised trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BLOOD-PRESSURE; ASSOCIATION	Objective To determine the effect of the angiotensin converting enzyme inhibitor ramipril on the secondary prevention of stroke. Design Randomised controlled trial with 2 x 2 factorial design. Setting 267 hospitals in 19 countries. Participants 9297 patients with vascular disease or diabetes plus an additional risk factor, followed for 4.5 years as part of the HOPE study. Outcome measures Stroke (confirmed by computed tomography or magnetic resonance imaging when available), transient ischaemic attack, and cognitive function. Blood pressure was recorded at entry to the study, after 2 years, and at the end of the study. Results Reduction in blood pressure was modest (3.8 nun Hg systolic and 2.8 mm Hg diastolic). The relative risk of any stroke was reduced by 32% (156 v 226) in the ramipril group compared with the placebo group, and the relative risk of fatal stroke was reduced by 61% (17 v 44). Benefits were consistent across baseline blood pressures, drugs used, and subgroups defined by the presence or absence of previous stroke, coronary artery disease, peripheral arterial disease, diabetes, or hypertension. Significantly fewer patients on ramipril had cognitive or functional impairment. Conclusion Ramipril reduces the incidence of stroke in patients at high risk, despite a modest reduction in blood pressure.	McMaster Univ, Canadian Cardiovasc Collaborat, Hamilton, ON L8L 2X2, Canada; John Radcliffe Hosp, Dept Cardiac, Oxford OX3 9DU, England; Univ Ottawa, Inst Heart, Ottawa, ON K1Y 4W7, Canada; Karolinska Inst, SE-17177 Stockholm, Sweden; Univ Washington, Seattle, WA 98104 USA	McMaster University; University of Oxford; University of Ottawa; University of Ottawa Heart Institute; Karolinska Institutet; University of Washington; University of Washington Seattle	Bosch, J (corresponding author), McMaster Univ, Canadian Cardiovasc Collaborat, 237 Barton St E, Hamilton, ON L8L 2X2, Canada.	jackie@ccc.mcmaster.ca	Bosch, Jacqueline/AAP-6910-2021	Bosch, Jacqueline/0000-0001-6292-4207; Yusuf, Salim/0000-0003-4776-5601				Adler AI, 2000, BMJ-BRIT MED J, V321, P412, DOI 10.1136/bmj.321.7258.412; ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; Goldstein LB, 2001, STROKE, V32, P280, DOI 10.1161/01.STR.32.1.280; *HEART STROK FDN C, 2001, PREV STROK; Helgason CM, 1997, CIRCULATION, V96, P701; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LONN EM, 1994, CIRCULATION, V90, P2056, DOI 10.1161/01.CIR.90.4.2056; Lonn EM, 2001, CIRCULATION, V103, P919; Lopez Alan D., 1996, GLOBAL BURDEN DIS CO; MacMahon S, 2001, LANCET, V358, P1033, DOI 10.1016/S0140-6736(01)06178-5; Mindlen F, 1996, CAN J CARDIOL, V12, P127; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; Neal B, 1995, J HYPERTENS, V13, P1869, DOI 10.1097/00004872-199512010-00068; WILHELMSEN L, 1979, CLIN SCI, V57, pS455, DOI 10.1042/cs057455s; Yusuf S, 2000, NEW ENGL J MED, V342, P154, DOI 10.1056/NEJM200001203420302; Yusuf S, 2000, NEW ENGL J MED, V342, P145	17	267	284	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 23	2002	324	7339					699	702		10.1136/bmj.324.7339.699	http://dx.doi.org/10.1136/bmj.324.7339.699			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	535ML	11909785	Green Published, Bronze			2022-12-28	WOS:000174648200016
J	Ely, JW; Osheroff, JA; Ebell, MH; Chambliss, ML; Vinson, DC; Stevermer, JJ; Pifer, EA				Ely, JW; Osheroff, JA; Ebell, MH; Chambliss, ML; Vinson, DC; Stevermer, JJ; Pifer, EA			Obstacles to answering doctors' questions about patient care with evidence: qualitative study	BRITISH MEDICAL JOURNAL			English	Article							CLINICAL QUESTIONS; INFORMATION NEEDS; PHYSICIANS; PRACTITIONERS; LANSOPRAZOLE; ESOPHAGITIS; MULTICENTER; OMEPRAZOLE	Objective To describe the obstacles encountered when attempting to answer doctors' questions with evidence. Design Qualitative study. Setting General practices in Iowa. Participants 9 academic generalist doctors, 14 family doctors, and 2 medical librarians. Main outcome measure A taxonomy of obstacles encountered while searching for evidence based answers to doctors' questions. Results 59 obstacles were encountered and organised according to the five steps in asking and answering questions: recognise a gap in knowledge, formulate a question, search for relevant information, formulate an answer, and use the answer to direct patient care. Six obstacles were considered particularly salient by the investigators and practising doctors: the excessive time required to find information; difficulty modifying the original question, which was often vague and open to interpretation; difficulty selecting an optimal strategy to search for information; failure of a seemingly appropriate resource to cover die topic; uncertainty about how to know when all the relevant evidence has been found so that the search can stop; and inadequate synthesis of multiple bits of evidence into a clinically useful statement. Conclusions Many obstacles are encountered when asking and answering questions about how to care for patients. Addressing these obstacles could lead to better patient care by improving clinically oriented information resources.	Univ Iowa, Coll Med, Dept Family Med, Iowa City, IA 52242 USA; Praxis Press, New York, NY 10010 USA; Michigan State Univ, Dept Family Practice, E Lansing, MI 48824 USA; Moses Cone Hosp Family Med Residency, Greensboro, NC 27401 USA; Univ Missouri, Sch Med, Columbia, MO 65212 USA; Univ Penn, Div Gen Internal Med, Philadelphia, PA 19104 USA	University of Iowa; Michigan State University; Moses Cone Memorial Hospital; University of Missouri System; University of Missouri Columbia; University of Pennsylvania	Ely, JW (corresponding author), Univ Iowa, Coll Med, Dept Family Med, Iowa City, IA 52242 USA.		Greiver, Michelle/N-8764-2015	Greiver, Michelle/0000-0001-8957-0285	NLM NIH HHS [R01 LM007179, 1R01LM07179-01] Funding Source: Medline; NATIONAL LIBRARY OF MEDICINE [R01LM007179] Funding Source: NIH RePORTER	NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		Armstrong E C, 1999, WMJ, V98, P25; Bergus GR, 2000, ARCH FAM MED, V9, P541, DOI 10.1001/archfami.9.6.541; Chambliss ML, 1996, J FAM PRACTICE, V43, P140; COVELL DG, 1985, ANN INTERN MED, V103, P596, DOI 10.7326/0003-4819-103-4-596; Crabtree BF., 1999, DOING QUALITATIVE RE, V2nd ed; Davidoff F, 2000, ANN INTERN MED, V132, P996, DOI 10.7326/0003-4819-132-12-200006200-00012; Davison GC, 1997, J CONSULT CLIN PSYCH, V65, P950, DOI 10.1037/0022-006X.65.6.950; Ebell M, 1999, J Am Board Fam Pract, V12, P225; Ely JW, 2000, BRIT MED J, V321, P429, DOI 10.1136/bmj.321.7258.429; Ely JW, 1999, BRIT MED J, V319, P358, DOI 10.1136/bmj.319.7206.358; Feinstein AR, 1997, AM J MED, V103, P529, DOI 10.1016/S0002-9343(97)00244-1; Fozi K, 2000, Med J Malaysia, V55, P486; Freeman AC, 2001, BRIT MED J, V323, P1100, DOI 10.1136/bmj.323.7321.1100; GORMAN PN, 1995, J AM SOC INFORM SCI, V46, P729, DOI 10.1002/(SICI)1097-4571(199512)46:10<729::AID-ASI3>3.0.CO;2-2; GORMAN PN, 1995, MED DECIS MAKING, V15, P113, DOI 10.1177/0272989X9501500203; Guyatt GH, 2000, BRIT MED J, V320, P954, DOI 10.1136/bmj.320.7240.954; HATLEBAKK JG, 1993, SCAND J GASTROENTERO, V28, P224, DOI 10.3109/00365529309096076; Hersh WR, 1998, JAMA-J AM MED ASSOC, V280, P1307, DOI 10.1001/jama.280.15.1307; OSHEROFF JA, 1993, B MED LIBR ASSOC, V81, P11; OSHEROFF JA, 1991, ANN INTERN MED, V114, P576, DOI 10.7326/0003-4819-114-7-576; Richter JE, 2000, ARCH INTERN MED, V160, P1803, DOI 10.1001/archinte.160.12.1803; Sackett D. L., 1997, EVIDENCE BASED MED P; Simon H.A., 1993, PROTOCOL ANAL VERBAL; SONTAG SJ, 1992, GASTROENTEROLOGY, V102, P109, DOI 10.1016/0016-5085(92)91790-B; WILLIAMSON JW, 1989, ANN INTERN MED, V110, P151, DOI 10.7326/0003-4819-110-2-151; WILSON SR, 1989, UNPUB USE CRITICAL I	26	236	245	0	13	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 23	2002	324	7339					710	713		10.1136/bmj.324.7339.710	http://dx.doi.org/10.1136/bmj.324.7339.710			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	535ML	11909789	Green Published, Bronze			2022-12-28	WOS:000174648200020
J	Isaakidis, P; Swingler, GH; Pienaar, E; Volmink, J; Ioannidis, JPA				Isaakidis, P; Swingler, GH; Pienaar, E; Volmink, J; Ioannidis, JPA			Relation between burden of disease and randomised evidence in sub-Saharan Africa: survey of research	BRITISH MEDICAL JOURNAL			English	Article							INSTITUTES-OF-HEALTH; GLOBAL BURDEN; PUBLICATION; COUNTRIES	Objective To evaluate whether the amount of randomised clinical research on various medical conditions is related to the burden of disease and health needs of the local populations in sub-Saharan Africa. Design Construction and analysis of comprehensive database of randomised controlled trials in sub-Saharan Africa based on Medline, the Cochrane Controlled Trials Register, and several African databases. Setting Sub-Saharan Africa. Main outcome measures Number of trials and randomised subjects for each category of disease in the global burden of disease taxonomy; ratios of disability adjusted life years (DALYs) per amount of randomised evidence. Results 1179 eligible randomised controlled trials were identified. The number of trials published each year increased over time. Almost half of the trials (n = 565) had been done in South Africa. There was relatively good correlation between the estimated burden of disease at year 2000 and the number of trials performed (r = 0.53, P = 0.024) and the number of participants randomised (r = 0.68, P = 0.002). However, some conditions-for example, injuries (over 20 000 DALYs per patient ever randomised)-were more neglected than others. Conclusion Despite recent improvements, few clinical trials are done in sub-Saharan Africa. Clinical research in this part of the world should focus more evenly on the major contributors to burden of disease.	Univ Ioannina, Sch Med, Dept Hyg & Epidemiol, Clin Trials & Evidence Based Med Unit, GR-45110 Ioannina, Greece; S African MRC, S African Cochrane Ctr, Cape Town, South Africa	University of Ioannina; South African Medical Research Council	Ioannidis, JPA (corresponding author), Univ Ioannina, Sch Med, Dept Hyg & Epidemiol, Clin Trials & Evidence Based Med Unit, GR-45110 Ioannina, Greece.		Swaibu, Ramadhani A/H-3164-2011; Ioannidis, John P. A./G-9836-2011	Isaakidis, Petros/0000-0002-7881-1554				[Anonymous], 1996, GLOBAL BURDEN DIS CO; Costello A, 2000, BRIT MED J, V321, P827, DOI 10.1136/bmj.321.7264.827; EASTERBROOK PJ, 1991, LANCET, V337, P867, DOI 10.1016/0140-6736(91)90201-Y; Fraser DW, 2000, B WORLD HEALTH ORGAN, V78, P1054; Gross CP, 1999, NEW ENGL J MED, V340, P1881, DOI 10.1056/NEJM199906173402406; Horton R, 2000, LANCET, V355, P2231, DOI 10.1016/S0140-6736(00)02414-4; Horton R, 2000, LANCET, V356, P1044, DOI 10.1016/S0140-6736(00)02721-5; Ioannidis JPA, 1998, JAMA-J AM MED ASSOC, V279, P281, DOI 10.1001/jama.279.4.281; Krug EG, 2000, AM J PUBLIC HEALTH, V90, P523, DOI 10.2105/AJPH.90.4.523; Lee K, 2000, BRIT MED J, V321, P775, DOI 10.1136/bmj.321.7264.775; Logie DE, 1997, BRIT MED J, V315, P1444, DOI 10.1136/bmj.315.7120.1444; MSAMANGA GI, 1997, NEW ENGL J MED, V337, P801; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; OLKIN I, 1995, STAT MED, V14, P457, DOI 10.1002/sim.4780140507; TAYLOR D, 1986, SOC SCI MED, V22, P1141, DOI 10.1016/0277-9536(86)90180-2; Trouiller P, 1999, LANCET, V354, P164, DOI 10.1016/S0140-6736(05)75299-5; *UN STAT DIV, 1992, MONTHL B STAT, V7; Varmus H, 1999, NEW ENGL J MED, V340, P1914, DOI 10.1056/NEJM199906173402411; Walt G, 1998, LANCET, V351, P434, DOI 10.1016/S0140-6736(97)05546-3; Wolffers I, 1998, LANCET, V351, P1652, DOI 10.1016/S0140-6736(97)10237-9; Yusuf S, 1998, BRIT MED J, V317, P1669, DOI 10.1136/bmj.317.7174.1669	21	71	73	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 23	2002	324	7339					702	705		10.1136/bmj.324.7339.702	http://dx.doi.org/10.1136/bmj.324.7339.702			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	535ML	11909786	Green Published, Bronze			2022-12-28	WOS:000174648200017
J	Lindholm, LH; Ibsen, H; Dahlof, B; Devereux, RB; Beevers, G; de Faire, U; Fyhrquist, F; Julius, S; Kjeldsen, SE; Kristiansson, K; Lederballe-Pedersen, O; Nieminen, MS; Omvik, P; Oparil, S; Wedel, H; Aurup, P; Edelman, J; Snapinn, S				Lindholm, LH; Ibsen, H; Dahlof, B; Devereux, RB; Beevers, G; de Faire, U; Fyhrquist, F; Julius, S; Kjeldsen, SE; Kristiansson, K; Lederballe-Pedersen, O; Nieminen, MS; Omvik, P; Oparil, S; Wedel, H; Aurup, P; Edelman, J; Snapinn, S		LIFE study grp	Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol	LANCET			English	Article							LEFT-VENTRICULAR HYPERTROPHY; BLOOD-PRESSURE; RISK-FACTORS; EVENTS; MELLITUS; OUTCOMES; DISEASE	Background The most suitable anti hypertensive drug to reduce the risk of cardiovascular disease in patients with hypertension and diabetes is unclear. In prespecified analyses, we compared the effects of losartan and atenolol on cardiovascular morbidity and mortality in diabetic patients. Interpretation Losartan was more effective than atenolol in reducing cardiovascular morbidity and mortality as well as mortality from all causes in patients with hypertension, diabetes, and LVH. Losartan seems to have benefits beyond blood pressure reduction. Methods As part of the LIFE study, in a double-masked, randomised, parallel-group trial, we assigned a group of 1195 patients with diabetes, hypertension, and signs of left-ventricular hypertrophy (LVH) on electrocardiograms losartan-based or atenolol-based treatment. Mean age of patients was 67 years (SD 7) and mean blood pressure 177/96 mm Hg (14/10) after placebo run-in. We followed up patients for at least 4 years (mean 4.7 years [1.1]). We used Cox regression analysis with baseline Framingham risk score and electrocardiogram-LVH as covariates to compare the effects of the drugs on the primary composite endpoint of cardiovascular morbidity and mortality (cardiovascular death, stroke, or myocardial infarction). Findings Mean blood pressure fell to 146/79 mm Hg (17/11) in losartan patients and 148/79 mm Hg (19/11) in atenolol patients. The primary endpoint occurred in 103 patients assigned losartan (n = 586) and 139 assigned atenolol (n = 609); relative risk 0.76 (95% CI 0.58-0.98), p = 0.031. 38 and 61 patients in the losartan and atenolol groups, respectively, died from cardiovascular disease; 0.63 (0.42-0.95), p = 0.028. Mortality from all causes was 63 and 104 in losartan and atenolol groups, respectively; 0.61 (0.45-0.84), p = 0.002. Interpretation Losartan was more effective than atenolol in reducing cardiovascular morbidity and mortality as well as mortality from all causes in patients with hypertension, diabetes, and LVH. Losartan seems to have benefits beyond blood pressure reduction.	Univ Umea Hosp, Dept Publ Hlth & Clin Med, SE-90185 Umea, Sweden; Glostrup Univ Hosp, Glostrup, Denmark; Sahlgrens Univ Hosp, Gothenburg, Sweden; Cornell Med Ctr, New York, NY USA; City Hosp, Birmingham, W Midlands, England; Karolinska Univ Hosp, Stockholm, Sweden; Univ Helsinki, Cent Hosp, FIN-00014 Helsinki, Finland; Univ Michigan, Ann Arbor, MI 48109 USA; Ullevaal Univ Hosp, Oslo, Norway; Merck Res Labs Scandinavia, Stockholm, Sweden; Viborg Hosp, Viborg, Denmark; Haukeland Hosp, N-5021 Bergen, Norway; Univ Alabama Birmingham, Birmingham, AL USA; Nord Sch Publ Hlth, Gothenburg, Sweden; Merck Res Labs, West Point, PA USA	Umea University; University of Copenhagen; Sahlgrenska University Hospital; Cornell University; University of Birmingham; Karolinska Institutet; Karolinska University Hospital; University of Helsinki; Helsinki University Central Hospital; University of Michigan System; University of Michigan; University of Oslo; Merck & Company; Aarhus University; University of Alabama System; University of Alabama Birmingham; Merck & Company	Lindholm, LH (corresponding author), Univ Umea Hosp, Dept Publ Hlth & Clin Med, SE-90185 Umea, Sweden.	larsh.lindholm@fammed.umu.se						*AM DIAB ASS, 2002, DIABETES CARE S1, V25, pS85, DOI DOI 10.2337/DIACARE.25.2007.S85; ANDERSON KM, 1991, CIRCULATION, V83, P356, DOI 10.1161/01.CIR.83.1.356; Bella JN, 2001, AM J CARDIOL, V87, P1260, DOI 10.1016/S0002-9149(01)01516-8; Brenner BM, 2001, NEW ENGL J MED, V345, P861, DOI 10.1056/NEJMoa011161; Brown MJ, 2000, LANCET, V356, P366, DOI 10.1016/S0140-6736(00)02527-7; Chalmers J, 1999, J HYPERTENS, V17, P151; Curb JD, 1996, JAMA-J AM MED ASSOC, V276, P1886, DOI 10.1001/jama.276.23.1886; Dahlof B, 1997, AM J HYPERTENS, V10, P705; Dahlof B, 2002, LANCET, V359, P995, DOI 10.1016/S0140-6736(02)08089-3; Dahlof B, 1998, HYPERTENSION, V32, P989, DOI 10.1161/01.HYP.32.6.989; Devereux RB, 2000, CIRCULATION, V101, P2271, DOI 10.1161/01.CIR.101.19.2271; Estacio RO, 1998, NEW ENGL J MED, V338, P645, DOI 10.1056/NEJM199803053381003; Gerstein HC, 2000, LANCET, V355, P253; Hansson L, 2000, LANCET, V356, P359, DOI 10.1016/S0140-6736(00)02526-5; Hansson L, 1999, LANCET, V353, P611, DOI 10.1016/S0140-6736(98)05012-0; Hansson L, 1998, LANCET, V351, P1755, DOI 10.1016/S0140-6736(98)04311-6; KANNEL WB, 1979, CIRCULATION, V59, P8, DOI 10.1161/01.CIR.59.1.8; Kjeldsen SE, 2000, AM J HYPERTENS, V13, P899, DOI 10.1016/S0895-7061(00)00280-6; Lewis EJ, 2001, NEW ENGL J MED, V345, P851, DOI 10.1056/NEJMoa011303; Lindholm LH, 2000, J HYPERTENS, V18, P1671, DOI 10.1097/00004872-200018110-00020; Liu JE, 2000, J AM COLL CARDIOL, V35, p263A; Palmieri V, 2001, CIRCULATION, V103, P102; STAMLER J, 1993, DIABETES CARE, V16, P434, DOI 10.2337/diacare.16.2.434; Stearne MR, 1998, BRIT MED J, V317, P713; Tatti P, 1998, DIABETES CARE, V21, P597, DOI 10.2337/diacare.21.4.597; Tuomilehto J, 1999, NEW ENGL J MED, V340, P677, DOI 10.1056/NEJM199903043400902; Weir MR, 1999, AM J HYPERTENS, V12, p205S; *WHO STUD GROUP, 1985, TECHN REP SER WHO, V727; Yusuf S, 2000, NEW ENGL J MED, V342, P145; Zimmet P, 2001, NATURE, V414, P782, DOI 10.1038/414782a	30	1095	1161	0	38	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 23	2002	359	9311					1004	1010		10.1016/S0140-6736(02)08090-X	http://dx.doi.org/10.1016/S0140-6736(02)08090-X			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	534KP	11937179				2022-12-28	WOS:000174585800006
J	Carmo-Fonseca, M				Carmo-Fonseca, M			The contribution of nuclear compartmentalization to gene regulation	CELL			English	Review							BETA-GLOBIN LOCUS; LIVING CELLS; CENTROMERIC HETEROCHROMATIN; CHROMOSOME TERRITORIES; NUCLEOLAR-LOCALIZATION; TRANSCRIPTION FACTORS; IN-VIVO; CHROMATIN; DNA; ORGANIZATION	Recent developments in live-cell imaging are challenging our stereotyped view of the fixed cell nucleus. The emerging picture is that nuclear processes may rely on a constant flow of molecules between dynamic compartments created by relatively immobile binding or assembly sites. This article discusses current views on the origins of nuclear compartments and their roles in gene expression.	Univ Lisbon, Fac Med, Inst Mol Med, P-1649028 Lisbon, Portugal	Universidade de Lisboa	Carmo-Fonseca, M (corresponding author), Univ Lisbon, Fac Med, Inst Mol Med, Av Prof Egas Moniz, P-1649028 Lisbon, Portugal.			Carmo-Fonseca, Maria/0000-0002-3402-7143				Adachi M, 2000, J CELL BIOL, V148, P849, DOI 10.1083/jcb.148.5.849; Ahmad K, 2001, CELL, V104, P839, DOI 10.1016/S0092-8674(01)00281-1; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Billiard J, 2001, J BIOL CHEM, V276, P15354, DOI 10.1074/jbc.M009973200; Brown KE, 1999, MOL CELL, V3, P207, DOI 10.1016/S1097-2765(00)80311-1; Brown KE, 1997, CELL, V91, P845, DOI 10.1016/S0092-8674(00)80472-9; Buchholz F, 2000, EMBO REP, V1, P133, DOI 10.1093/embo-reports/kvd027; Burgess SM, 1999, GENE DEV, V13, P1871, DOI 10.1101/gad.13.14.1871; Carmo-Fonseca M, 2000, NAT CELL BIOL, V2, pE107, DOI 10.1038/35014078; Cartwright P, 2000, CELL MOL LIFE SCI, V57, P1193, DOI 10.1007/PL00000759; Carvalho C, 2001, MOL BIOL CELL, V12, P3563, DOI 10.1091/mbc.12.11.3563; Cha JHJ, 2000, TRENDS NEUROSCI, V23, P387, DOI 10.1016/S0166-2236(00)01609-X; Cheng TH, 2000, GENE DEV, V14, P452; Cobb BS, 2000, GENE DEV, V14, P2146, DOI 10.1101/gad.816400; Collins EC, 2000, EMBO REP, V1, P127, DOI 10.1093/embo-reports/kvd021; Cremer T, 2001, NAT REV GENET, V2, P292, DOI 10.1038/35066075; Custodio N, 1999, EMBO J, V18, P2855, DOI 10.1093/emboj/18.10.2855; Cyert MS, 2001, J BIOL CHEM, V276, P20805, DOI 10.1074/jbc.R100012200; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Eilbracht J, 2001, P NATL ACAD SCI USA, V98, P3849, DOI 10.1073/pnas.071042298; Fardaei M, 2001, NUCLEIC ACIDS RES, V29, P2766, DOI 10.1093/nar/29.13.2766; Ferreira J, 1997, J CELL BIOL, V139, P1597, DOI 10.1083/jcb.139.7.1597; Festenstein R, 1999, NAT GENET, V23, P457, DOI 10.1038/70579; Francastel C, 1999, CELL, V99, P259, DOI 10.1016/S0092-8674(00)81657-8; Francastel C, 2001, P NATL ACAD SCI USA, V98, P12120, DOI 10.1073/pnas.211444898; Frey MR, 2001, J CELL BIOL, V154, P499, DOI 10.1083/jcb.200105084; Gall JG, 2000, ANNU REV CELL DEV BI, V16, P273, DOI 10.1146/annurev.cellbio.16.1.273; Galy V, 2000, NATURE, V403, P108, DOI 10.1038/47528; Gerasimova TI, 2000, MOL CELL, V6, P1025, DOI 10.1016/S1097-2765(00)00101-5; Godfrey K. R., 1983, COMPARTMENTAL MODELS; Goodson ML, 2001, J BIOL CHEM, V276, P18513, DOI 10.1074/jbc.M008066200; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Graef IA, 2001, CURR OPIN GENET DEV, V11, P505, DOI 10.1016/S0959-437X(00)00225-2; Gunawardena S, 2000, CURR BIOL, V10, P285, DOI 10.1016/S0960-9822(00)00360-2; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; Henderson BR, 2000, NAT CELL BIOL, V2, P653, DOI 10.1038/35023605; Hennig W, 1999, CHROMOSOMA, V108, P1, DOI 10.1007/s004120050346; Heun P, 2001, J CELL BIOL, V152, P385, DOI 10.1083/jcb.152.2.385; Houtsmuller AB, 1999, SCIENCE, V284, P958, DOI 10.1126/science.284.5416.958; Jans DA, 2000, BIOESSAYS, V22, P532, DOI 10.1002/(SICI)1521-1878(200006)22:6<532::AID-BIES6>3.0.CO;2-O; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; Kimura H, 2001, J CELL BIOL, V153, P1341, DOI 10.1083/jcb.153.7.1341; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; Korgaonkar C, 2002, MOL CELL BIOL, V22, P196, DOI 10.1128/MCB.22.1.196-206.2002; Kourmouli N, 2000, EMBO J, V19, P6558, DOI 10.1093/emboj/19.23.6558; Kuge S, 2001, MOL CELL BIOL, V21, P6139, DOI 10.1128/MCB.21.18.6139-6150.2001; Lehembre F, 2001, ONCOGENE, V20, P1, DOI 10.1038/sj.onc.1204063; Lever MA, 2000, NATURE, V408, P873, DOI 10.1038/35048603; Li BR, 2001, J BIOL CHEM, V276, P46480, DOI 10.1074/jbc.C100388200; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; Lohrum MAE, 2000, NAT CELL BIOL, V2, P179, DOI 10.1038/35004057; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; Lundgren M, 2000, CELL, V103, P733, DOI 10.1016/S0092-8674(00)00177-X; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; McMorrow T, 2000, EMBO J, V19, P4986, DOI 10.1093/emboj/19.18.4986; Miller JW, 2000, EMBO J, V19, P4439, DOI 10.1093/emboj/19.17.4439; Miska EA, 2001, NUCLEIC ACIDS RES, V29, P3439, DOI 10.1093/nar/29.16.3439; Misteli T, 2000, NATURE, V408, P877, DOI 10.1038/35048610; Misteli T, 2001, SCIENCE, V291, P843, DOI 10.1126/science.291.5505.843; Misteli T, 1997, NATURE, V387, P523, DOI 10.1038/387523a0; Misteli T, 1999, MOL CELL, V3, P697, DOI 10.1016/S1097-2765(01)80002-2; MONNERON A, 1969, J ULTRA MOL STRUCT R, V27, P266, DOI 10.1016/S0022-5320(69)80017-1; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; Neilson J, 2001, CURR OPIN IMMUNOL, V13, P346, DOI 10.1016/S0952-7915(00)00225-9; Ohno M, 2000, CELL, V101, P187, DOI 10.1016/S0092-8674(00)80829-6; Orr HT, 2001, GENE DEV, V15, P925, DOI 10.1101/gad.888401; Pederson T, 2000, MOL BIOL CELL, V11, P799, DOI 10.1091/mbc.11.3.799; Polioudaki H, 2001, EMBO REP, V2, P920, DOI 10.1093/embo-reports/kve199; Qumsiyeh MB, 1999, CELL MOL LIFE SCI, V55, P1129, DOI 10.1007/s000180050362; Rosin-Arbesfeld R, 2000, NATURE, V406, P1009, DOI 10.1038/35023016; Rothery P, 1993, MODELS BIOL MATH STA; Sabbattini P, 2001, EMBO J, V20, P2812, DOI 10.1093/emboj/20.11.2812; Sadoni N, 1999, J CELL BIOL, V146, P1211, DOI 10.1083/jcb.146.6.1211; Schubeler D, 2000, GENE DEV, V14, P940; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Smith KP, 1999, J CELL BIOL, V144, P617, DOI 10.1083/jcb.144.4.617; Stanford NP, 2000, EMBO J, V19, P6546, DOI 10.1093/emboj/19.23.6546; Steffan JS, 2001, NATURE, V413, P739, DOI 10.1038/35099568; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Tapscott SJ, 2001, SCIENCE, V293, P816, DOI 10.1126/science.1063517; Thoma F, 1999, EMBO J, V18, P6585, DOI 10.1093/emboj/18.23.6585; Tumbar T, 2001, NAT CELL BIOL, V3, P134, DOI 10.1038/35055033; Vazquez J, 2001, CURR BIOL, V11, P1227, DOI 10.1016/S0960-9822(01)00390-6; Volker M, 2001, MOL CELL, V8, P213, DOI 10.1016/S1097-2765(01)00281-7; Volpi EV, 2000, J CELL SCI, V113, P1565; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Wente SR, 2000, SCIENCE, V288, P1374, DOI 10.1126/science.288.5470.1374; Xiao Z, 2001, J BIOL CHEM, V276, P39404, DOI 10.1074/jbc.M103117200; Yang J, 1999, EMBO J, V18, P2174, DOI 10.1093/emboj/18.8.2174; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2; Zhang YP, 2001, SCIENCE, V292, P1910, DOI 10.1126/science.1058637; Zhao X, 2001, J BIOL CHEM, V276, P35042, DOI 10.1074/jbc.M105086200; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032; Zhu J, 2000, CELL MOL LIFE SCI, V57, P411, DOI 10.1007/PL00000703; Zoghbi HY, 2000, ANNU REV NEUROSCI, V23, P217, DOI 10.1146/annurev.neuro.23.1.217	96	155	159	0	9	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	FEB 22	2002	108	4					513	521		10.1016/S0092-8674(02)00650-5	http://dx.doi.org/10.1016/S0092-8674(02)00650-5			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	524XW	11909522	Bronze			2022-12-28	WOS:000174039000009
J	Bradbury, EJ; Moon, LDF; Popat, RJ; King, VR; Bennett, GS; Patel, PN; Fawcett, JW; McMahon, SB				Bradbury, EJ; Moon, LDF; Popat, RJ; King, VR; Bennett, GS; Patel, PN; Fawcett, JW; McMahon, SB			Chondroitinase ABC promotes functional recovery after spinal cord injury	NATURE			English	Article							NEURITE GROWTH-INHIBITORS; SULFATE PROTEOGLYCANS; REACTIVE ASTROCYTES; SENSORY AXONS; GLIAL SCAR; CNS; REGENERATION; EXPRESSION; OUTGROWTH; NEUROCAN	The inability of axons to regenerate after a spinal cord injury in the adult mammalian central nervous system (CNS) can lead to permanent paralysis. At sites of CNS injury, a glial scar develops, containing extracellular matrix molecules including chondroitin sulphate proteoglycans (CSPGs)(1,2). CSPGs are inhibitory to axon growth in vitro(3-5), and regenerating axons stop at CSPG-rich regions in vivo(6). Removing CSPG glycosaminoglycan (GAG) chains attenuates CSPG inhibitory activity(7-10). To test the functional effects of degrading chondroitin sulphate (CS)-GAG after spinal cord injury, we delivered chondroitinase ABC (ChABC) to the lesioned dorsal columns of adult rats. We show that intrathecal treatment with ChABC degraded CS-GAG at the injury site, upregulated a regeneration-associated protein in injured neurons, and promoted regeneration of both ascending sensory projections and descending corticospinal tract axons. ChABC treatment also restored post-synaptic activity below the lesion after electrical stimulation of corticospinal neurons, and promoted functional recovery of locomotor and proprioceptive behaviours. Our results demonstrate that CSPGs are important inhibitory molecules in vivo and suggest that their manipulation will be useful for treatment of human spinal injuries.	Kings Coll London, Ctr Res Neurosci, Sensory Funct Grp, London SE1 1UL, England; Univ Cambridge, Dept Physiol, Cambridge CB2 2PY, England; Univ Cambridge, Ctr Brain Repair, Cambridge CB2 2PY, England; Queen Mary Univ London, St Bartholomews & Royal London Sch Med & Dent, Dept Neurosci, London E1 4NS, England	University of London; King's College London; University of Cambridge; University of Cambridge; University of London; Queen Mary University London	Bradbury, EJ (corresponding author), Kings Coll London, Ctr Res Neurosci, Sensory Funct Grp, Hodgkin Bldg,Guys Campus,London Bridge, London SE1 1UL, England.	elizabeth.bradbury@kcl.ac.uk	Moon, Lawrence/C-4906-2008	Moon, Lawrence/0000-0001-9622-0312; McMahon, Stephen/0000-0003-4656-5536; Bradbury, Elizabeth/0000-0003-4252-0234; Fawcett, James/0000-0002-7990-4568				Asher RA, 2000, J NEUROSCI, V20, P2427; Bradbury EJ, 1999, EUR J NEUROSCI, V11, P3873, DOI 10.1046/j.1460-9568.1999.00809.x; Bradbury EJ, 2000, TRENDS PHARMACOL SCI, V21, P389, DOI 10.1016/S0165-6147(00)01536-4; BREGMAN BS, 1995, NATURE, V378, P498, DOI 10.1038/378498a0; CHONG MS, 1994, J NEUROSCI, V14, P4375; Davies SJA, 1999, J NEUROSCI, V19, P5810, DOI 10.1523/JNEUROSCI.19-14-05810.1999; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; Fidler PS, 1999, J NEUROSCI, V19, P8778, DOI 10.1523/JNEUROSCI.19-20-08778.1999; Fitch MT, 1999, CNS REGENERATION BAS, P55; Hill CE, 2001, EXP NEUROL, V171, P153, DOI 10.1006/exnr.2001.7734; Jones LL, 2001, J PHYSIOL-LONDON, V533, P83, DOI 10.1111/j.1469-7793.2001.0083b.x; Karim F, 2001, BRAIN RES REV, V36, P204, DOI 10.1016/S0165-0173(01)00096-0; KUNKELBAGDEN E, 1993, EXP NEUROL, V119, P153, DOI 10.1006/exnr.1993.1017; LEVINE JM, 1994, J NEUROSCI, V14, P4716; McKeon RJ, 1999, J NEUROSCI, V19, P10778, DOI 10.1523/JNEUROSCI.19-24-10778.1999; MCKEON RJ, 1991, J NEUROSCI, V11, P3398; MCKEON RJ, 1995, EXP NEUROL, V136, P32, DOI 10.1006/exnr.1995.1081; Moon LDF, 2001, NAT NEUROSCI, V4, P465, DOI 10.1038/87415; MORI M, 1990, J COMP NEUROL, V299, P167, DOI 10.1002/cne.902990204; Murray M, 1997, Adv Neurol, V72, P219; Murray M, 2001, NEUROSCIENTIST, V7, P28, DOI 10.1177/107385840100700107; Niederost BP, 1999, J NEUROSCI, V19, P8979, DOI 10.1523/JNEUROSCI.19-20-08979.1999; Pasterkamp RJ, 2001, EUR J NEUROSCI, V13, P457, DOI 10.1046/j.0953-816X.2000.01398.x; Plant GW, 2001, MOL CELL NEUROSCI, V17, P471, DOI 10.1006/mcne.2000.0948; Ramer MS, 2000, NATURE, V403, P312, DOI 10.1038/35002084; Ramer MS, 2000, SPINAL CORD, V38, P449, DOI 10.1038/sj.sc.3101055; SMITHTHOMAS LC, 1994, J CELL SCI, V107, P1687; Thallmair M, 1998, NAT NEUROSCI, V1, P124, DOI 10.1038/373; Wall PD, 1997, J NEUROPHYSIOL, V78, P860, DOI 10.1152/jn.1997.78.2.860; Zuo J, 1998, EXP NEUROL, V154, P654, DOI 10.1006/exnr.1998.6951	30	1768	1883	7	242	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 11	2002	416	6881					636	640		10.1038/416636a	http://dx.doi.org/10.1038/416636a			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	539YV	11948352				2022-12-28	WOS:000174901900044
J	Tamaskar, P; McGinnis, RA				Tamaskar, P; McGinnis, RA			Declining student interest in psychiatry	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MEDICAL-SCHOOL; CHOICE; SPECIALTY; CAREER		Med Coll Ohio, Toledo, OH 43699 USA		Tamaskar, P (corresponding author), Med Coll Ohio, Toledo, OH 43699 USA.							Coodin S, 2001, PSYCHIATR REHABIL J, V24, P299, DOI 10.1037/h0095082; Feifel D, 1999, AM J PSYCHIAT, V156, P1397; LEE EK, 1995, AM J PSYCHIAT, V152, P1066; *NAT MENT HLTH ADV, 1993, AM J PSYCHIAT, V150, P1450; PAIVA REA, 1982, J MED EDUC, V57, P666; SIERLES FS, 1995, AM J PSYCHIAT, V152, P1416; Stoudemire A, 2000, PSYCHOSOMATICS, V41, P204, DOI 10.1176/appi.psy.41.3.204; U.S. Department of Health and Human Services, 1999, MENT HLTH REP SURG	8	16	17	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 10	2002	287	14					1859	1859		10.1001/jama.287.14.1859	http://dx.doi.org/10.1001/jama.287.14.1859			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	539QJ	11939877	hybrid			2022-12-28	WOS:000174881700043
J	Bhatti, MA; Seville, MTA				Bhatti, MA; Seville, MTA			Hematogenous anaerobic osteomyelitis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									King Faisal Specialist Hosp & Res Ctr, Jeddah 21499, Saudi Arabia; Aurora Baycare Med Ctr, Green Bay, WI 54308 USA	King Faisal Specialist Hospital & Research Center	Bhatti, MA (corresponding author), King Faisal Specialist Hosp & Res Ctr, Jeddah 21499, Saudi Arabia.								0	4	4	0	2	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 4	2002	346	14					1060	1060		10.1056/NEJMicm990899	http://dx.doi.org/10.1056/NEJMicm990899			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	536YL	11932473				2022-12-28	WOS:000174729400005
J	Trotter, JF; Wachs, M; Everson, GT; Kam, I				Trotter, JF; Wachs, M; Everson, GT; Kam, I			Medical progress - Adult-to-adult transplantation of the right hepatic lobe from a living donor	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							LIVER-TRANSPLANTATION; ANASTOMOSIS; FULMINANT; FAILURE; GRAFTS		Univ Colorado, Hlth Sci Ctr, Div Gastroenterol & Hepatol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Div Transplant Surg, Denver, CO USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Trotter, JF (corresponding author), Univ Colorado, Hlth Sci Ctr, Div Gastroenterol & Hepatol, 4200 E 9th Ave,B-154, Denver, CO 80262 USA.							Abecassis M, 2000, JAMA-J AM MED ASSOC, V284, P2919; Adams M, 2000, LIVER TRANSPLANT, V6, P815; Alexander JW, 1996, CLIN TRANSPLANT, V10, P1; Bak T, 2001, LIVER TRANSPLANT, V7, P680, DOI 10.1053/jlts.2001.26509; Broelsch CE, 2000, LIVER TRANSPLANT, V6, pS64, DOI 10.1053/jlts.2000.19015; Cotler SJ, 2001, LIVER TRANSPLANT, V7, P335, DOI 10.1053/jlts.2001.22755; Cronin DC, 2001, NEW ENGL J MED, V344, P1633, DOI 10.1056/NEJM200105243442112; Fan ST, 2000, ARCH SURG-CHICAGO, V135, P336, DOI 10.1001/archsurg.135.3.336; Gridelli B, 2000, NEW ENGL J MED, V343, P404, DOI 10.1056/NEJM200008103430606; Hirano I, 2000, LIVER TRANSPLANT, V6, P250, DOI 10.1016/S1527-6465(00)80023-4; Imamura H, 2000, J Hepatobiliary Pancreat Surg, V7, P380, DOI 10.1007/s005340070033; Kaneko T, 2000, TRANSPLANTATION, V70, P982, DOI 10.1097/00007890-200009270-00018; Lee KH, 2000, LIVER TRANSPLANT, V6, P387, DOI 10.1053/lv.2000.6810; Lo CM, 1997, ANN SURG, V226, P261, DOI 10.1097/00000658-199709000-00005; Marcos A, 2000, ANN SURG, V231, P824, DOI 10.1097/00000658-200006000-00006; Marcos A, 2000, LIVER TRANSPLANT, V6, pS59, DOI 10.1053/jlts.2000.19011; Marcos A, 2000, TRANSPLANTATION, V69, P1375, DOI 10.1097/00007890-200004150-00028; Marcos A, 1999, TRANSPLANTATION, V68, P798, DOI 10.1097/00007890-199909270-00012; Marcos A, 2000, LIVER TRANSPLANT, V6, P3, DOI 10.1002/lt.500060117; Marcos A, 2000, TRANSPLANTATION, V69, P2410, DOI 10.1097/00007890-200006150-00034; Marcos A, 2000, TRANSPLANTATION, V69, P2202, DOI 10.1097/00007890-200005270-00044; Marcos A, 2000, LIVER TRANSPLANT, V6, P296, DOI 10.1053/lv.2000.6354; Miwa S, 1999, HEPATOLOGY, V30, P1521, DOI 10.1002/hep.510300621; Renz J F, 2000, Liver Transpl, V6, P367, DOI 10.1053/lv.2000.8151; Renz JF, 2000, LIVER TRANSPLANT, V6, pS73, DOI 10.1053/jlts.2000.18686; Renz JF, 2000, SEMIN LIVER DIS, V20, P411, DOI 10.1055/s-2000-13153; Rinella ME, 2001, LIVER TRANSPLANT, V7, P409, DOI 10.1053/jlts.2001.23787; Schiano TD, 2001, HEPATOLOGY, V33, P3, DOI 10.1053/jhep.2001.21489; Shapiro RS, 2000, LIVER TRANSPLANT, V6, pS77, DOI 10.1053/jlts.2000.19014; STRONG RW, 1990, NEW ENGL J MED, V322, P1505, DOI 10.1056/NEJM199005243222106; Strong RW, 1999, LIVER TRANSPLANT SUR, V5, P536, DOI 10.1002/lt.500050613; Testa G, 2000, LIVER TRANSPLANT, V6, P710, DOI 10.1053/jlts.2000.18706; Todo S, 2000, LIVER TRANSPLANT, V6, pS66, DOI 10.1053/jlts.2000.19009; Trotter JF, 2000, LIVER TRANSPLANT, V6, pS52, DOI 10.1053/jlts.2000.18685; Trotter JF, 2000, LIVER TRANSPLANT, V6, P290, DOI 10.1053/lv.2000.6351; Trotter JF, 2001, LIVER TRANSPLANT, V7, P485, DOI 10.1053/jlts.2001.24646; *UN NETW ORG SHAR, 2001, 2000 ANN REP SCI REG; Wachs ME, 1998, TRANSPLANTATION, V66, P1313, DOI 10.1097/00007890-199811270-00008; YAMAOKA Y, 1994, TRANSPLANTATION, V57, P1127, DOI 10.1097/00007890-199404150-00024	39	344	352	0	9	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 4	2002	346	14					1074	1082		10.1056/NEJMra011629	http://dx.doi.org/10.1056/NEJMra011629			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	536YL	11932476				2022-12-28	WOS:000174729400009
J	Psaty, BM; Smith, NL; Heekbert, SR; Vos, HL; Lemaitre, RN; Reiner, AP; Siscovick, DS; Bis, J; Lumley, T; Longstreth, WT; Rosendaal, FR				Psaty, BM; Smith, NL; Heekbert, SR; Vos, HL; Lemaitre, RN; Reiner, AP; Siscovick, DS; Bis, J; Lumley, T; Longstreth, WT; Rosendaal, FR			Diuretic therapy, the alpha-adducin gene variant, and the risk of myocardial infarction or stroke in persons with treated hypertension	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BLOOD-PRESSURE; ENVIRONMENT INTERACTION; JAPANESE POPULATION; MOLECULAR-GENETICS; LINKAGE ANALYSIS; CANDIDATE GENES; HEALTH OUTCOMES; ASSOCIATION; POLYMORPHISM; PHARMACOGENOMICS	Context A genetic variant in alpha-adducin has been associated with renal sodium reabsorption and salt-sensitive hypertension, Whether this genetic variant modifies the effect of diuretic therapy on the incidence of myocardial infarction (MI) and stroke is unknown. Objectives To estimate the interaction between alpha-adducin and diuretic therapy on the risk of MI or stroke. Specifically, we hypothesized that in participants with treated hypertension, the risk of MI or stroke associated with diuretic use would be lower in carriers of the adducin variant than in carriers of the adducin wild-type genotype. Design, Setting, and Participants Population-based case-control study of patients enrolled in a health maintenance organization, treated pharmacologically for hypertension, and genotyped as homozygous carriers of the adducin wild-type genotype or carriers of 1 or 2 copies of the Trp460 variant allele. Cases had a first nonfatal MI (n = 206) or stroke (n = 117) between January 1995 and December 1998. Controls (n=715) were a stratified random sample of pharmacologically treated hypertensive patients who were matched to MI cases by age, sex, and calendar year. Main Outcome Measure Risk of the combined outcome of first nonfatal MI or stroke. Results The adducin variant was present in more than one third of the participants. Among the 653 carriers of the adducin wild-type genotype, diuretic therapy was not associated with the risk of MI or stroke (odds ratio [OR], 1.09; 95% confidence interval [CI], 0.78-1.52). Among the 385 carriers of the adducin variant allele, diuretic therapy was associated with a lower risk of the combined outcome of MI and stroke than other anti hypertensive therapies (OR, 0.49; 95% Cl, 0.32-0.77). The OR in carriers of the adducin variant was less than half of the OR in carriers of the wild-type genotype (P=.005). The case-control synergy index (SI) was 0.45 (95% Cl, 0.26-0.79) for the combined outcome of MI and stroke. The point estimates of the diuretic-adducin interaction were similar in separate analyses of MI (SI, 0.41; 95% Cl, 0.21-0.80) and stroke (SI, 0.53; 95% Cl, 0.24-1.19). The diuretic-adducin interaction was not confounded by traditional cardiovascular risk factors, was specific to diuretic therapy but not present for other major anti hypertensive drug classes, and did not differ substantially between subgroups defined by age, sex, race, diabetes, and history of cardiovascular disease. Conclusions In carriers of the adducin variant, diuretic therapy was associated with a lower risk of combined MI or stroke than other antihypertensive therapies. If these findings are confirmed in other studies, this large subgroup of the hypertensive population may be especially likely to benefit from low-dose diuretic therapy.	Univ Washington, Dept Epidemiol, Cardiovasc Hlth Res Unit, Seattle, WA 98101 USA; Univ Washington, Dept Med, Seattle, WA 98101 USA; Univ Washington, Dept Biostat, Seattle, WA 98101 USA; Univ Washington, Dept Biostat, Seattle, WA 98101 USA; Univ Washington, Dept Neurol, Seattle, WA 98101 USA; Univ Washington, Dept Hlth Serv, Seattle, WA 98101 USA; Leiden Univ, Med Ctr, Dept Hematol, Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Clin Epidemiol, Leiden, Netherlands	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Psaty, BM (corresponding author), Univ Washington, Dept Epidemiol, Cardiovasc Hlth Res Unit, 1730 Minor Ave,Suite 1360, Seattle, WA 98101 USA.		Rosendaal, Frits/Q-3842-2017	Rosendaal, Frits/0000-0003-2558-7496	NHLBI NIH HHS [HL40628, HL60739, HL43201] Funding Source: Medline; NIA NIH HHS [AG09556] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040628, R01HL043201, R01HL060739, R29HL040628] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG009556] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bianchi G, 2000, AM J HYPERTENS, V13, P739, DOI 10.1016/S0895-7061(00)00241-7; Black HR, 1997, ARCH INTERN MED, V157, P2413; Boerwinkle E, 2000, AM J HYPERTENS, V13, P734, DOI 10.1016/S0895-7061(00)00243-0; Bray MS, 2000, AM J HYPERTENS, V13, P699, DOI 10.1016/S0895-7061(00)00242-9; Breslow N. E., 1980, IARC SCI PUBLICATION, V32; BURT VL, 1995, HYPERTENSION, V25, P305, DOI 10.1161/01.HYP.25.3.305; Corvol P, 1999, HYPERTENSION, V33, P1324, DOI 10.1161/01.HYP.33.6.1324; Cusi D, 1998, KIDNEY INT, V54, P328, DOI 10.1046/j.1523-1755.1998.00007.x; Cusi D, 1997, LANCET, V349, P1353, DOI 10.1016/S0140-6736(97)01029-5; Ferrandi M, 2000, ACTA PHYSIOL SCAND, V168, P187; Ferrari P, 1998, CURR OPIN NEPHROL HY, V7, P217, DOI 10.1097/00041552-199803000-00012; Ferrari Patrizia, 1995, P1261; Furberg CD, 2000, JAMA-J AM MED ASSOC, V283, P1967; Glorioso N, 1999, HYPERTENSION, V34, P649, DOI 10.1161/01.HYP.34.4.649; Green SA, 1995, PULM PHARMACOL, V8, P1, DOI 10.1006/pulp.1995.1001; Halushka MK, 1999, NAT GENET, V22, P239, DOI 10.1038/10297; Housman D, 1998, NAT BIOTECHNOL, V16, P492, DOI 10.1038/nbt0698-492; Ishikawa K, 1998, AM J HYPERTENS, V11, P502, DOI 10.1016/S0895-7061(97)00486-X; Ives Diane G., 1995, Annals of Epidemiology, V5, P278, DOI 10.1016/1047-2797(94)00093-9; Kamitani A, 1998, HYPERTENSION, V32, P138, DOI 10.1161/01.HYP.32.1.138; Kato N, 1998, HYPERTENSION, V31, P730, DOI 10.1161/01.HYP.31.3.730; Khoury M, 1993, FUNDAMENTALS GENETIC; Khoury MJ, 1996, AM J EPIDEMIOL, V144, P207; Lazarou J, 1998, JAMA-J AM MED ASSOC, V279, P1200, DOI 10.1001/jama.279.15.1200; Lifton RP, 1996, SCIENCE, V272, P676, DOI 10.1126/science.272.5262.676; Luft FC, 1998, J HYPERTENS, V16, P1871, DOI 10.1097/00004872-199816121-00004; Manunta P, 1998, KIDNEY INT, V53, P1471, DOI 10.1046/j.1523-1755.1998.00931.x; Matsuoka Y, 2000, CELL MOL LIFE SCI, V57, P884, DOI 10.1007/PL00000731; MAY DG, 1994, J CLIN PHARMACOL, V34, P881, DOI 10.1002/j.1552-4604.1994.tb04001.x; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Morimoto A, 1997, LANCET, V350, P1734, DOI 10.1016/S0140-6736(97)05189-1; PEARCE N, 1993, INT J EPIDEMIOL, V22, P1189, DOI 10.1093/ije/22.6.1189; Perna A, 2000, KIDNEY INT, V57, P274, DOI 10.1046/j.1523-1755.2000.00818.x; Price T R, 1993, Ann Epidemiol, V3, P504; Province MA, 2000, AM J HYPERTENS, V13, P710, DOI 10.1016/S0895-7061(99)00282-4; Psaty BM, 1999, JAMA-J AM MED ASSOC, V282, P786, DOI 10.1001/jama.282.8.786; Psaty BM, 1997, JAMA-J AM MED ASSOC, V277, P739, DOI 10.1001/jama.277.9.739; Psaty BM, 2000, J HUM HYPERTENS, V14, P95, DOI 10.1038/sj.jhh.1000943; PSATY BM, 1995, JAMA-J AM MED ASSOC, V274, P620, DOI 10.1001/jama.274.8.620; Psaty BM, 2001, JAMA-J AM MED ASSOC, V285, P906, DOI 10.1001/jama.285.7.906; Rieder M J, 2000, Curr Hypertens Rep, V2, P44, DOI 10.1007/s11906-000-0057-4; Rieder MJ, 1999, NAT GENET, V22, P59, DOI 10.1038/8760; Schlesselman JJ, 1982, CASE CONTROL STUDIES; SMITH PG, 1984, INT J EPIDEMIOL, V13, P356, DOI 10.1093/ije/13.3.356; SMITH RL, 1986, XENOBIOTICA, V16, P361, DOI 10.3109/00498258609050244; Tamaki S, 1998, HYPERTENS RES-CLIN E, V21, P29, DOI 10.1291/hypres.21.29; Turner ST, 2000, CIRCULATION, V102, P40; Yang QH, 1997, AM J EPIDEMIOL, V146, P713	48	169	180	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 3	2002	287	13					1680	1689		10.1001/jama.287.13.1680	http://dx.doi.org/10.1001/jama.287.13.1680			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	536YW	11926892	Bronze			2022-12-28	WOS:000174730300022
J	Caro, GMM; Meierhenrich, UJ; Schutte, WA; Barbier, B; Segovia, AA; Rosenbauer, H; Thiemann, WHP; Brack, A; Greenberg, JM				Caro, GMM; Meierhenrich, UJ; Schutte, WA; Barbier, B; Segovia, AA; Rosenbauer, H; Thiemann, WHP; Brack, A; Greenberg, JM			Amino acids from ultraviolet irradiation of interstellar ice analogues	NATURE			English	Article							COMET HALLEY; DUST; HYDROCARBONS; MIXTURES; SPACE; LIFE	Amino acids are the essential molecular components of living organisms on Earth, but the proposed mechanisms for their spontaneous generation have been unable to account for their presence in Earth's early history(1). The delivery of extraterrestrial organic compounds has been proposed as an alternative to generation on Earth(2-5), and some amino acids have been found in several meteorites(6-9). Here we report the detection of amino acids in the room-temperature residue of an interstellar ice analogue that was ultraviolet-irradiated in a high vacuum at 12 K. We identified 16 amino acids; the chiral ones showed enantiomeric separation. Some of the identified amino acids are also found in meteorites. Our results demonstrate that the spontaneous generation of amino acids in the interstellar medium is possible, supporting the suggestion that prebiotic molecules could have been delivered to the early Earth by cometary dust, meteorites or interplanetary dust particles.	Ctr Biophys Mol, F-45160 Olivet, France; Leiden Observ, Raymond & Beverly Sackler Lab Astrophys, NL-2300 RA Leiden, Netherlands; Univ Bremen, Dept Phys Chem, D-28359 Bremen, Germany; Max Planck Inst Aeron, D-37189 Katlenburg Lindau, Germany	Leiden University; Leiden University - Excl LUMC; University of Bremen; Max Planck Society	Meierhenrich, UJ (corresponding author), Ctr Biophys Mol, Rue Charles Sadron, F-45160 Olivet, France.		Muñoz, Guillermo M/L-6370-2014; Meierhenrich, Uwe J/A-1643-2008	Muñoz, Guillermo M/0000-0001-7003-7368; Meierhenrich, Uwe J/0000-0001-6422-3930; Arcones, Almudena/0000-0002-6995-3032				Abe I, 1996, J CHROMATOGR A, V722, P221, DOI 10.1016/0021-9673(95)00506-4; BARNUN A, 1983, J GEOPHYS RES-OCEANS, V88, P6662, DOI 10.1029/JC088iC11p06662; Bernstein MP, 1999, SCIENCE, V283, P1135, DOI 10.1126/science.283.5405.1135; BERNSTEIN MP, 1995, ASTROPHYS J, V454, P327, DOI 10.1086/176485; Brack A, 1999, ADV SPACE RES-SERIES, V24, P417, DOI 10.1016/S0273-1177(99)00457-3; BRIGGS R, 1992, ORIGINS LIFE EVOL B, V22, P287, DOI 10.1007/BF01810858; Caro GMM, 2001, ASTRON ASTROPHYS, V367, P347, DOI 10.1051/0004-6361:20000341; CARO GMM, UNPUB ASTRON ASTROPH; CHYBA C, 1992, NATURE, V355, P125, DOI 10.1038/355125a0; Cronin JR, 1997, SCIENCE, V275, P951, DOI 10.1126/science.275.5302.951; Ehrenfreund P, 1999, ASTRON ASTROPHYS, V350, P240; Ehrenfreund P, 2001, P NATL ACAD SCI USA, V98, P2138, DOI 10.1073/pnas.051502898; Engel MH, 2001, PRECAMBRIAN RES, V106, P35, DOI 10.1016/S0301-9268(00)00123-6; GERAKINES PA, 1995, ASTRON ASTROPHYS, V296, P810; Gerakines PA, 1999, ASTROPHYS J, V522, P357, DOI 10.1086/307611; Gibb EL, 2001, ASTROPHYS J, V558, P702, DOI 10.1086/322291; Greenberg J., 1982, COMETS, P131; GREENBERG JM, 1972, EXTRAIT MEMOIRES SOC, P425; GREENBERG JM, 1986, GALAXY SOLAR SYSTEM, P103; HUANG ZH, 1993, J CHROMATOGR, V635, P271, DOI 10.1016/0021-9673(93)80370-N; Irvine W. M., 2000, Protostars and planets 4, P1159; JENNISKENS P, 1993, ASTRON ASTROPHYS, V273, P583; JOHNS RB, 1970, PHOTOCHEM PHOTOBIOL, V12, P405, DOI 10.1111/j.1751-1097.1970.tb06071.x; KISSEL J, 1987, NATURE, V326, P755, DOI 10.1038/326755a0; Kobayashi K, 1999, ADV SPACE RES, V23, P401, DOI 10.1016/S0273-1177(99)00065-4; KVENVOLDEN K, 1970, NATURE, V228, P923, DOI 10.1038/228923a0; Meierhenrich U, 1999, CHIRALITY, V11, P575, DOI 10.1002/(SICI)1520-636X(1999)11:7<575::AID-CHIR10>3.0.CO;2-P; Mennella V, 2001, ASTRON ASTROPHYS, V367, P355, DOI 10.1051/0004-6361:20000340; MILLER SL, 1953, SCIENCE, V117, P528, DOI 10.1126/science.117.3046.528; ORO J, 1961, NATURE, V190, P389, DOI 10.1038/190389a0; WEBER P, 1985, NATURE, V316, P403, DOI 10.1038/316403a0	31	617	623	4	149	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 28	2002	416	6879					403	406		10.1038/416403a	http://dx.doi.org/10.1038/416403a			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	534UX	11919624				2022-12-28	WOS:000174607800039
J	Shore, B				Shore, B			Sir Raymond Firth (1901-2002) - Obituary	NATURE			English	Biographical-Item									Emory Univ, Dept Anthropol, Atlanta, GA 30322 USA	Emory University	Shore, B (corresponding author), Emory Univ, Dept Anthropol, Atlanta, GA 30322 USA.							FIRTH R, PUBLICATION LIST	1	0	0	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 28	2002	416	6879					384	384		10.1038/416384a	http://dx.doi.org/10.1038/416384a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	534UX	11919616				2022-12-28	WOS:000174607800031
J	Stone, GW; Grines, CL; Cox, DA; Garcia, E; Tcheng, JE; Griffin, JJ; Guagliumi, G; Stuckey, T; Turco, M; Carroll, JD; Rutherford, BD; Lansky, AJ				Stone, GW; Grines, CL; Cox, DA; Garcia, E; Tcheng, JE; Griffin, JJ; Guagliumi, G; Stuckey, T; Turco, M; Carroll, JD; Rutherford, BD; Lansky, AJ		Controlled Abciximab Device Invest	Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IIB/IIIA RECEPTOR BLOCKADE; TRANSLUMINAL CORONARY ANGIOPLASTY; CONVENTIONAL BALLOON ANGIOPLASTY; THROMBOLYTIC THERAPY; VENTRICULAR-FUNCTION; ARTERY DISEASE; RISK PATIENTS; PILOT TRIAL; IMPLANTATION; PLACEMENT	Background: As compared with thrombolytic therapy, primary percutaneous transluminal coronary angioplasty (PTCA) in acute myocardial infarction reduces the rates of death, reinfarction, and stroke, but recurrent ischemia, restenosis, and reocclusion of the infarct-related artery remain problematic. When used in combination with PTCA, coronary stenting and platelet glycoprotein IIb/IIIa inhibitors may further improve outcomes. Methods: Using a 2-by-2 factorial design, we randomly assigned 2082 patients with acute myocardial infarction to undergo PTCA alone (518 patients), PTCA plus abciximab therapy (528), stenting alone with the MultiLink stent (512), or stenting plus abciximab therapy (524). Results: Normal flow was restored in the target vessel in 94.5 to 96.9 percent of patients and did not vary according to the reperfusion strategy. At six months, the primary end point - a composite of death, reinfarction, disabling stroke, and ischemia-driven revascularization of the target vessel - had occurred in 20.0 percent of patients after PTCA, 16.5 percent after PTCA plus abciximab, 11.5 percent after stenting, and 10.2 percent after stenting plus abciximab (P<0.001). There were no significant differences among the groups in the rates of death, stroke, or reinfarction; the difference in the incidence of the primary end point was due entirely to differences in the rates of target-vessel revascularization (ranging from 15.7 percent after PTCA to 5.2 percent after stenting plus abciximab, P<0.001). The rate of angiographically established restenosis was 40.8 percent after PTCA and 22.2 percent after stenting (P<0.001), and the respective rates of reocclusion of the infarcted-related artery were 11.3 percent and 5.7 percent (P=0.01), both independent of abciximab use. Conclusions: At experienced centers, stent implantation (with or without abciximab therapy) should be considered the routine reperfusion strategy. (N Engl J Med 2002;346:957-66.) Copyright (C) 2002 Massachusetts Medical Society.	Cardiovasc Res Fdn, New York, NY 10022 USA; Lenox Hill Heart & Vasc Inst, New York, NY USA; William Beaumont Hosp, Royal Oak, MI 48072 USA; Mid Carolina Cardiol, Charlotte, NC USA; Hosp Gen Gregorio Maranon, Madrid, Spain; Duke Clin Res Inst, Durham, NC USA; Virginia Beach Gen Hosp, Virginia Beach, VA USA; Osped Riuniti Bergamo, I-24100 Bergamo, Italy; Moses Cone Mem Hosp, Greensboro, NC USA; Doylestown Hosp, Doylestown, PA USA; Univ Colorado, Hlth Sci Ctr, Denver, CO USA; St Lukes Hosp, Kansas City, MO USA	Cardiovascular Research Foundation (CRF); Lenox Hill Heart & Vascular Institute of New York; Beaumont Health; General University Gregorio Maranon Hospital; Duke University; Ospedali Riuniti di Bergamo; Moses Cone Memorial Hospital; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Saint Luke's Hospital - Missouri	Stone, GW (corresponding author), Cardiovasc Res Fdn, 55 E 59th St,6th Fl, New York, NY 10022 USA.		Guagliumi, Giulio/K-8006-2016					Antoniucci D, 1998, J AM COLL CARDIOL, V31, P1234, DOI 10.1016/S0735-1097(98)00097-7; Belli G, 2000, CATHETER CARDIO INTE, V50, P362, DOI 10.1002/1522-726X(200007)50:3<362::AID-CCD22>3.3.CO;2-8; BLACKWELDER WC, 1982, CONTROL CLIN TRIALS, V3, P345, DOI 10.1016/0197-2456(82)90024-1; Brener SJ, 1998, CIRCULATION, V98, P734, DOI 10.1161/01.CIR.98.8.734; Carrozza JP, 1998, J AM COLL CARDIOL, V31, P50, DOI 10.1016/S0735-1097(97)00426-9; *CLOP UNST ANG PRE, 2001, NEW ENGL J MED, V345, P1716; *CLOP UNST ANG PRE, 2001, NEW ENGL J MED, V345, P1506; DEBOER MJ, 1995, AM J CARDIOL, V76, P830, DOI 10.1016/S0002-9149(99)80238-0; DODGE HT, 1960, AM HEART J, V60, P762, DOI 10.1016/0002-8703(60)90359-8; Erbel R, 1999, HERZ, V24, P558, DOI 10.1007/BF03044228; FISCHMAN DL, 1994, NEW ENGL J MED, V331, P496, DOI 10.1056/NEJM199408253310802; Grines CL, 1998, J AM COLL CARDIOL, V31, P967, DOI 10.1016/S0735-1097(98)00031-X; Grines CL, 1999, NEW ENGL J MED, V341, P1949, DOI 10.1056/NEJM199912233412601; Herrmann HC, 2000, J AM COLL CARDIOL, V36, P1489, DOI 10.1016/S0735-1097(00)00923-2; Hochman JS, 1999, NEW ENGL J MED, V341, P625, DOI 10.1056/NEJM199908263410901; Kereiakes DJ, 1999, AM J CARDIOL, V84, P1385, DOI 10.1016/S0002-9149(99)00581-0; Lansky A, 1999, TXB INTERVENTIONAL C, P725; LEE ET, 1992, STAT METHODS SURVIVA, P126; Lefkovits J, 1996, AM J CARDIOL, V77, P1045, DOI 10.1016/S0002-9149(96)00128-2; Maillard L, 2000, J AM COLL CARDIOL, V35, P1729, DOI 10.1016/S0735-1097(00)00612-4; Montalescot G, 2001, NEW ENGL J MED, V344, P1895, DOI 10.1056/NEJM200106213442503; Neumann FJ, 2000, J AM COLL CARDIOL, V35, P915, DOI 10.1016/S0735-1097(99)00635-X; Neumann FJ, 1998, CIRCULATION, V98, P2695, DOI 10.1161/01.CIR.98.24.2695; Nunn CM, 1999, J AM COLL CARDIOL, V33, P640, DOI 10.1016/S0735-1097(98)00622-6; Rodriguez A, 1998, AM J CARDIOL, V81, P1286, DOI 10.1016/S0002-9149(98)00154-4; Ross AM, 1999, J AM COLL CARDIOL, V34, P1954, DOI 10.1016/S0735-1097(99)00444-1; Saito S, 1996, J AM COLL CARDIOL, V28, P74, DOI 10.1016/0735-1097(96)00125-8; Saito S, 1999, CATHETER CARDIO INTE, V48, P262, DOI 10.1002/(SICI)1522-726X(199911)48:3<262::AID-CCD5>3.0.CO;2-4; Serruys PW, 1998, Int J Cardiovasc Intervent, V1, P19; SERRUYS PW, 1994, NEW ENGL J MED, V331, P489, DOI 10.1056/NEJM199408253310801; SHEEHAN FH, 1986, CIRCULATION, V74, P293, DOI 10.1161/01.CIR.74.2.293; Stone GW, 1997, J AM COLL CARDIOL, V29, P1459, DOI 10.1016/S0735-1097(97)00088-0; Stone GW, 1999, CIRCULATION, V99, P1548, DOI 10.1161/01.CIR.99.12.1548; STONE GW, 1995, J AM COLL CARDIOL, V26, P66, DOI 10.1016/0735-1097(95)00138-P; Stone GW, 2001, CIRCULATION, V104, P636, DOI 10.1161/hc3101.093701; Stone GW, 2000, J AM COLL CARDIOL, V35, P605, DOI 10.1016/S0735-1097(99)00605-1; Stone GW, 1997, J AM COLL CARDIOL, V29, P901, DOI 10.1016/S0735-1097(97)00041-7; Suryapranata H, 1998, CIRCULATION, V97, P2502, DOI 10.1161/01.CIR.97.25.2502; Wakatsuki T, 2000, J AM COLL CARDIOL, V35, P1835, DOI 10.1016/S0735-1097(00)00632-X; Weaver WD, 1998, JAMA-J AM MED ASSOC, V279, P1876; Yusuf S, 2001, NEW ENGL J MED, V345, P494; Zijlstra F, 1999, NEW ENGL J MED, V341, P1413, DOI 10.1056/NEJM199911043411901	42	931	1013	0	16	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 28	2002	346	13					957	966		10.1056/NEJMoa013404	http://dx.doi.org/10.1056/NEJMoa013404			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	534UY	11919304				2022-12-28	WOS:000174608600002
J	Alrajhi, AA; Ibrahim, EA; De Vol, EB; Khairat, M; Faris, RM; Maguire, JH				Alrajhi, AA; Ibrahim, EA; De Vol, EB; Khairat, M; Faris, RM; Maguire, JH			Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							OPERATION DESERT-STORM; CLINICAL-EXPERIENCE; STEROL BIOSYNTHESIS; SAUDI-ARABIA; KETOCONAZOLE; ITRACONAZOLE; VETERANS; EFFICACY; TROPICA; KUWAIT	Background: Whereas certain oral antifungal azoles are well documented to have activity against leishmania, data on the efficacy of fluconazole for leishmaniasis are limited. We conducted a controlled trial in Saudi Arabia of fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major. Methods: This randomized, double-blind, placebo-controlled trial assessed the efficacy of oral fluconazole, in a dose of 200 mg daily for six weeks, in the treatment of parasitologically confirmed cutaneous leishmaniasis. The primary outcome measure was the time to the complete healing of all lesions. Results: A total of 106 patients were assigned to receive fluconazole, and 103 patients were assigned to receive placebo. Follow-up data were available for 80 and 65 patients, respectively. At the three-month follow-up, healing of lesions was complete for 63 of the 80 patients in the fluconazole group (79 percent) and 22 of the 65 patients in the placebo group (34 percent; relative risk of complete healing, 2.33 [95 percent confidence interval, 1.63 to 3.33]). According to an intention-to-treat analysis, the rates of healing were 59 percent and 22 percent, respectively (relative risk, 2.76 [95 percent confidence interval, 1.84 to 4.12]). Sodium stibogluconate was offered to 11 patients in the fluconazole group who returned for follow-up (14 percent) and 33 of those in the placebo group (51 percent) in whom oral treatment was judged to have failed. According to a Kaplan-Meier analysis, the time to healing was shorter for the fluconazole group (median, 8.5 weeks, as compared with 11.2 weeks in the placebo group; P<0.001 by the log-rank test). Side effects were mild and similar in both groups. Conclusions: A six-week course of oral fluconazole is a safe and useful treatment for cutaneous leishmaniasis caused by L. major. (N Engl J Med 2002;346:891-5.) Copyright (C) 2002 Massachusetts Medical Society.	King Faisal Specialist Hosp & Res Ctr, Dept Med, Infect Dis Sect, MBC 46, Riyadh 11211, Saudi Arabia; Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Div Infect Dis, Boston, MA 02115 USA; Minist Hlth Saudi Arabia, Riyadh, Saudi Arabia; King Faisal Specialist Hosp & Res Ctr, Dept Biostat Epidemiol & Sci Comp, Riyadh 11211, Saudi Arabia	King Faisal Specialist Hospital & Research Center; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; King Faisal Specialist Hospital & Research Center	Alrajhi, AA (corresponding author), King Faisal Specialist Hosp & Res Ctr, Dept Med, Infect Dis Sect, MBC 46, POB 3354, Riyadh 11211, Saudi Arabia.		Alrajhi, Abdulrahman A/Q-4359-2019					ALBANESE G, 1989, ARCH DERMATOL, V125, P1540, DOI 10.1001/archderm.125.11.1540; ALFOUZAN AS, 1991, INT J DERMATOL, V30, P519, DOI 10.1111/j.1365-4362.1991.tb04878.x; ALSALEH QA, 1995, INT J DERMATOL, V34, P495, DOI 10.1111/j.1365-4362.1995.tb00622.x; BEACH DH, 1988, MOL BIOCHEM PARASIT, V31, P149, DOI 10.1016/0166-6851(88)90166-1; BERMAN JD, 1987, J PARASITOL, V73, P671, DOI 10.2307/3282158; BERMAN JD, 1981, AM J TROP MED HYG, V30, P566, DOI 10.4269/ajtmh.1981.30.566; Berman JD, 1997, CLIN INFECT DIS, V24, P684, DOI 10.1093/clind/24.4.684; BRAMMER KW, 1990, REV INFECT DIS, V12, pS318; CONTI R, 1983, REV INFECT DIS, V5, pS600; DEDET JP, 1986, T ROY SOC TROP MED H, V80, P176, DOI 10.1016/0035-9203(86)90239-7; DOGRA J, 1990, INT J DERMATOL, V29, P661, DOI 10.1111/j.1365-4362.1990.tb02593.x; EVENPAZ Z, 1982, INT J DERMATOL, V21, P110, DOI 10.1111/j.1365-4362.1982.tb00517.x; HART DT, 1989, MOL BIOCHEM PARASIT, V33, P123, DOI 10.1016/0166-6851(89)90026-1; IBRAHIM EA, 1994, T ROY SOC TROP MED H, V88, P39, DOI 10.1016/0035-9203(94)90488-X; KREUTZER RD, 1993, AM J TROP MED HYG, V49, P357, DOI 10.4269/ajtmh.1993.49.357; KUBBA R, 1986, SAUDI MED J, V7, P596; Lwanga SK, 1991, SAMPLE SIZE DETERMIN; MAGILL AJ, 1993, NEW ENGL J MED, V328, P1383, DOI 10.1056/NEJM199305133281904; *MIN HLTH, 1991, ANN HLTH REP 1991; Momeni AZ, 1996, ARCH DERMATOL, V132, P784, DOI 10.1001/archderm.132.7.784; NAVIN TR, 1992, J INFECT DIS, V165, P528, DOI 10.1093/infdis/165.3.528; NORTON SA, 1992, ARCH DERMATOL, V128, P83, DOI 10.1001/archderm.128.1.83; OHL CA, 1993, MIL MED, V158, P726, DOI 10.1093/milmed/158.11.726; PETERS W, 1985, T ROY SOC TROP MED H, V79, P831, DOI 10.1016/0035-9203(85)90130-0; RIOUX JA, 1990, ANN PARASIT HUM COMP, V65, P111, DOI 10.1051/parasite/1990653111; SAENZ RE, 1990, AM J MED, V89, P147, DOI 10.1016/0002-9343(90)90292-L; Sundar S, 1996, LANCET, V348, P614, DOI 10.1016/S0140-6736(05)64828-3; Taylor A.E.R., 1987, IN VITRO METHODS PAR; Torrus D, 1996, J ANTIMICROB CHEMOTH, V37, P1042, DOI 10.1093/jac/37.5.1042; WEINRAUCH L, 1983, ARCH DERMATOL RES, V275, P353, DOI 10.1007/BF00417211; WILDFEUER A, 1994, MYCOSES, V37, P127, DOI 10.1111/j.1439-0507.1994.tb00788.x; World Health Organization, 1996, WORLD HLTH REP 1996, P50	32	223	233	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 21	2002	346	12					891	895		10.1056/NEJMoa011882	http://dx.doi.org/10.1056/NEJMoa011882			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	532FR	11907288	Bronze			2022-12-28	WOS:000174464100004
J	Fleetwood, IG; Steinberg, GK				Fleetwood, IG; Steinberg, GK			Arteriovenous malformations	LANCET			English	Review							GAMMA-KNIFE RADIOSURGERY; INTRACRANIAL VASCULAR MALFORMATIONS; COMBINED ENDOVASCULAR EMBOLIZATION; LINEAR-ACCELERATOR RADIOSURGERY; SIMPLE RISK PREDICTIONS; NATURAL-HISTORY; MULTIMODALITY TREATMENT; STEREOTAXIC RADIOSURGERY; SURGICAL RESECTION; PREOPERATIVE EMBOLIZATION	Arteriovenous malformations of the brain are congenital vascular lesions that affect 0.01-0.50% of the population, and are generally present in patients aged 20-40 years. The usual clinical presentations are haemorrhage, seizures, progressive neurological deficit, or headache. Results of natural history studies have shown a yearly haemorrhage rate of 1-4%. Frequency of rebleeding has increased over the years, and several factors that increase risk of haemorrhage have been identified. Although substantial, the morbidity associated with haemorrhages could be less than previously thought. Over the past decade, great advances have been made in application of endovascular embolisation techniques, stereotactic radiosurgery, and microsurgery, allowing effective multidisciplinary treatment of arteriovenous malformations, including those previously deemed to be untreatable. Increasing attention has been paid to management of flow-related aneurysms associated with these malformations. Finally, many reports of recurrent arteriovenous malformations have coincided with new theories regarding the embryogenesis of these disorders and laboratory work suggesting their proliferative potential.	Stanford Univ, Dept Neurosurg, Stanford, CA 94305 USA; Stanford Univ, Stanford Stroke Ctr, Stanford, CA 94305 USA	Stanford University; Stanford University	Steinberg, GK (corresponding author), Stanford Univ, Dept Neurosurg, Room R281,Edwards Bldg,300 Pasteur Dr, Stanford, CA 94305 USA.	gsteinberg@stanford.edu		Steinberg, Gary/0000-0001-6374-1058				Alkadhi H, 2000, AM J NEURORADIOL, V21, P1423; [Anonymous], NEUROLOGICAL ASPECTS; Berman MF, 2000, NEUROSURGERY, V47, P389, DOI 10.1097/00006123-200008000-00023; Brown RD, 1996, J NEUROSURG, V85, P29, DOI 10.3171/jns.1996.85.1.0029; Brown RD, 2000, NEUROSURGERY, V46, P1024, DOI 10.1097/00006123-200004000-00055; BROWN RD, 1988, J NEUROSURG, V68, P352, DOI 10.3171/jns.1988.68.3.0352; Caldarelli M, 1997, J Neurosurg Sci, V41, P315; Chang SD, 1998, NEUROL MED-CHIR, V38, P200, DOI 10.2176/nmc.38.suppl_200; Chang SD, 2000, NEUROSURGERY, V47, P397; Cockroft KM, 1998, NEUROSURG CLIN N AM, V9, P565; COLOMBO F, 1994, NEUROSURGERY, V34, P14; CRAWFORD PM, 1986, J NEUROL NEUROSUR PS, V49, P1, DOI 10.1136/jnnp.49.1.1; DAWSON RC, AJNR AM J NEURORADIO, V11, P857; DERUTY R, 1993, ACTA NEUROCHIR, V123, P101, DOI 10.1007/BF01401864; DERUTY R, 1995, NEUROL RES, V17, P169, DOI 10.1080/01616412.1995.11740307; Deveikis JP, 1998, NEUROIMAG CLIN N AM, V8, P401; DIAS MS, 1990, NEUROSURGERY, V27, P855, DOI 10.1227/00006123-199012000-00001; Duong DH, 1999, NEW ENGL J MED, V340, P1812; Duong DH, 1998, STROKE, V29, P1167, DOI 10.1161/01.STR.29.6.1167; Eisenschenk S, 1998, STEREOT FUNCT NEUROS, V71, P51, DOI 10.1159/000029648; Ellis TL, 1998, J NEUROSURG, V89, P104, DOI 10.3171/jns.1998.89.1.0104; Falkson CB, 1997, BRIT J NEUROSURG, V11, P12; Finnerty JJ, 1999, AM J OBSTET GYNECOL, V181, P296, DOI 10.1016/S0002-9378(99)70551-X; Firlik AD, 1998, NEUROSURGERY, V43, P1223, DOI 10.1097/00006123-199811000-00124; FLEETWOO IG, 2002, IN PRESS NEUROLOGICA; FLEETWOOD IG, 2002, IN PRESS MANAGEMENT; FLEETWOOD IG, 2002, ENDOVASCULAR THERAPY; Flickinger JC, 2000, INT J RADIAT ONCOL, V46, P1143, DOI 10.1016/S0360-3016(99)00513-1; Flickinger JC, 1999, INT J RADIAT ONCOL, V44, P67, DOI 10.1016/S0360-3016(98)00518-5; FOURNIER D, 1991, J NEUROSURG, V75, P228, DOI 10.3171/jns.1991.75.2.0228; Friedman WA, 1996, J NEUROSURG, V84, P912, DOI 10.3171/jns.1996.84.6.0912; FRIEDMAN WA, 1995, J NEUROSURG, V82, P180, DOI 10.3171/jns.1995.82.2.0180; Gabriel EM, 1996, J NEUROSURG, V84, P879, DOI 10.3171/jns.1996.84.5.0879; Gallina P, 1998, NEUROSURGERY, V42, P996, DOI 10.1097/00006123-199805000-00024; Gao EZ, 1997, NEUROSURGERY, V41, P1345, DOI 10.1097/00006123-199712000-00020; Gerszten PC, 1996, PEDIATR NEUROSURG, V24, P139, DOI 10.1159/000121030; Gobin YP, 1996, J NEUROSURG, V85, P19, DOI 10.3171/jns.1996.85.1.0019; GRAF CJ, 1983, J NEUROSURG, V58, P331, DOI 10.3171/jns.1983.58.3.0331; GUO WY, 1993, ACTA NEUROCHIR, V121, P212, DOI 10.1007/BF01809278; GUO WY, 1993, ACTA RADIOL, V34, P600; HAMILTON MG, 1994, NEUROSURGERY, V34, P2; Hara M, 1998, MINIM INVAS NEUROSUR, V41, P40, DOI 10.1055/s-2008-1052014; Hartmann A, 1998, STROKE, V29, P931, DOI 10.1161/01.STR.29.5.931; Hartmann A, 2000, STROKE, V31, P2361, DOI 10.1161/01.STR.31.10.2361; HEIKKINEN ER, 1989, STEREOT FUNCT NEUROS, V53, P157, DOI 10.1159/000099532; Henkes H, 1998, NEUROL RES, V20, P479; HEROS RC, 1990, NEUROSURGERY, V26, P570, DOI 10.1227/00006123-199004000-00003; Hino A, 1999, SURG NEUROL, V52, P156, DOI 10.1016/S0090-3019(99)00060-9; Hofmeister C, 2000, STROKE, V31, P1307, DOI 10.1161/01.STR.31.6.1307; Hoh BL, 2000, NEUROSURGERY, V47, P346, DOI 10.1097/00006123-200008000-00015; Hongo K, 2000, J CLIN NEUROSCI, V7, P88; ITOYAMA Y, 1989, J NEUROSURG, V71, P805, DOI 10.3171/jns.1989.71.6.0805; JAFAR JJ, 1993, J NEUROSURG, V78, P60, DOI 10.3171/jns.1993.78.1.0060; KADER A, 1994, NEUROSURGERY, V34, P801, DOI 10.1227/00006123-199405000-00003; Kader A, 1996, J NEUROSURG, V85, P14, DOI 10.3171/jns.1996.85.1.0014; Karlsson B, 1999, INT J RADIAT ONCOL, V43, P313, DOI 10.1016/S0360-3016(98)00396-4; Karlsson B, 2001, INT J RADIAT ONCOL, V49, P1045, DOI 10.1016/S0360-3016(00)01432-2; Kihlstrom L, 1997, J NEUROSURG, V86, P589, DOI 10.3171/jns.1997.86.4.0589; Kim MS, 1999, STEREOT FUNCT NEUROS, V72, P168, DOI 10.1159/000056453; KONDZIOLKA D, 1995, NEUROSURGERY, V37, P851, DOI 10.1227/00006123-199511000-00001; KONDZIOLKA D, 1992, CAN J NEUROL SCI, V19, P40, DOI 10.1017/S0317167100042517; Kurita H, 1998, J NEUROL NEUROSUR PS, V65, P648, DOI 10.1136/jnnp.65.5.648; Kwon Y, 2000, J NEUROSURG, V93, P104, DOI 10.3171/jns.2000.93.supplement_3.0104; Langer DJ, 1998, NEUROSURGERY, V42, P481, DOI 10.1097/00006123-199803000-00008; Lasjaunias P, 1997, Interv Neuroradiol, V3, P275; LATCHAW RE, 1995, NEUROSURGERY, V37, P619, DOI 10.1227/00006123-199510000-00003; LAWTON MT, 1995, NEUROSURGERY, V37, P29, DOI 10.1227/00006123-199507000-00004; Lazar RM, 2000, NEUROPSYCHOLOGIA, V38, P1325, DOI 10.1016/S0028-3932(00)00054-3; Leblanc R, 1995, STEREOT FUNCT NEUROS, V65, P60, DOI 10.1159/000098898; Lindqvist M, 2000, NEUROSURGERY, V46, P803, DOI 10.1097/00006123-200004000-00006; LUNSFORD LD, 1991, J NEUROSURG, V75, P512, DOI 10.3171/jns.1991.75.4.0512; Malik GM, 1996, SURG NEUROL, V46, P106, DOI 10.1016/0090-3019(96)00084-5; Mansmann U, 2000, NEUROSURGERY, V46, P272, DOI 10.1097/00006123-200002000-00004; MARKS MP, 1991, AM J NEURORADIOL, V12, P489; MARKS MP, 1990, RADIOLOGY, V176, P807, DOI 10.1148/radiology.176.3.2389040; MARKS MP, 1992, RADIOLOGY, V183, P355, DOI 10.1148/radiology.183.2.1561335; MARKS MP, AJNR AM J NEURORADIO, V14, P297; Martin N, 1990, INTRACRANIAL VASCULA, P1; Martin N A, 2000, Clin Neurosurg, V46, P295; Mast H, 1997, LANCET, V350, P1065, DOI 10.1016/S0140-6736(97)05390-7; Mattle HP, 2000, J NEUROL, V247, P917, DOI 10.1007/s004150070047; McCormick W., 1984, INTRACRANIAL ARTERIO, P44, DOI 10.1016/S1042-3680(18)30174-8; Meisel HJ, 2000, NEUROSURGERY, V46, P793, DOI 10.1097/00006123-200004000-00004; Merland J J, 1986, Acta Radiol Suppl, V369, P621; Miyachi S, 2000, J CLIN NEUROSCI, V7, P82, DOI 10.1054/jocn.2000.0718; Miyamoto S, 2000, NEUROSURGERY, V46, P589, DOI 10.1097/00006123-200003000-00013; Miyawaki L, 1999, INT J RADIAT ONCOL, V44, P1089, DOI 10.1016/S0360-3016(99)00102-9; Mizoi K, 1998, NEUROL MED-CHIR, V38, P186, DOI 10.2176/nmc.38.suppl_186; Morgan MK, 1999, J NEUROSURG, V90, P695, DOI 10.3171/jns.1999.90.4.0695; Mullan S, 1996, J NEUROSURG, V85, P1, DOI 10.3171/jns.1996.85.1.0001; Nagashima H, 2000, J CLIN NEUROSCI, V7, P86; NAGATA S, 1991, ACTA NEUROCHIR, V112, P37, DOI 10.1007/BF01402452; NAKSTAD PH, 1994, NEURORADIOLOGY, V36, P410, DOI 10.1007/BF00612131; Nataf F, 1997, NEURORADIOLOGY, V39, P52, DOI 10.1007/s002340050367; Norris JS, 1999, J NEUROSURG, V90, P673, DOI 10.3171/jns.1999.90.4.0673; Ogilvy CS, 2001, CIRCULATION, V103, P2644; ONDRA SL, 1990, J NEUROSURG, V73, P387, DOI 10.3171/jns.1990.73.3.0387; PASQUALIN A, 1991, NEUROSURGERY, V29, P358, DOI 10.1227/00006123-199109000-00004; Paulsen RD, 1999, NEUROSURGERY, V44, P479, DOI 10.1097/00006123-199903000-00022; Paulsen RD, 1999, NEUROSURGERY, V44, P991, DOI 10.1097/00006123-199905000-00031; PERATA HJ, 1994, J NEUROSURG, V80, P631, DOI 10.3171/jns.1994.80.4.0631; PERRET G, 1966, J NEUROSURG, V25, P467, DOI 10.3171/jns.1966.25.4.0467; Perret G, 1969, INTRACRANIAL ANEURYS, P200; PIEPGRAS DG, 1993, J NEUROSURG, V78, P5, DOI 10.3171/jns.1993.78.1.0005; Pollock BE, 1998, NEUROSURGERY, V42, P1239, DOI 10.1097/00006123-199806000-00020; Pollock BE, 1996, NEUROSURGERY, V38, P318, DOI 10.1097/00006123-199602000-00016; Pollock BE, 1996, STROKE, V27, P1, DOI 10.1161/01.STR.27.1.1; Pollock BE, 1996, NEUROSURGERY, V38, P652, DOI 10.1227/00006123-199604000-00004; Redekop G, 1998, J NEUROSURG, V89, P539, DOI 10.3171/jns.1998.89.4.0539; Rodriguez-Arias C, 2000, CHILD NERV SYST, V16, P363, DOI 10.1007/s003810050532; Santoro A, 2000, J NEUROSURG, V93, P1082, DOI 10.3171/jns.2000.93.6.1082; Schaller C, 1998, J NEUROL NEUROSUR PS, V65, P547, DOI 10.1136/jnnp.65.4.547; Schlienger M, 2000, INT J RADIAT ONCOL, V46, P1135, DOI 10.1016/S0360-3016(99)00523-4; SCHUMACHER M, 1991, NEURORADIOLOGY, V33, P101, DOI 10.1007/BF00588243; SHI XE, 1993, CHINESE MED J-PEKING, V106, P851; SISTI MB, 1993, J NEUROSURG, V79, P653, DOI 10.3171/jns.1993.79.5.0653; SOLOMON RA, 1986, J NEUROSURG, V64, P857, DOI 10.3171/jns.1986.64.6.0857; Sonstein WJ, 1996, J NEUROSURG, V85, P838, DOI 10.3171/jns.1996.85.5.0838; SPETZLER RF, 1992, J NEUROSURG, V76, P918, DOI 10.3171/jns.1992.76.6.0918; SPETZLER RF, 1986, J NEUROSURG, V65, P476, DOI 10.3171/jns.1986.65.4.0476; Steinberg Gary K., 1997, P727; STEINBERG GK, 1990, NEW ENGL J MED, V323, P96, DOI 10.1056/NEJM199007123230205; STEINER L, 1992, J NEUROSURG, V77, P1, DOI 10.3171/jns.1992.77.1.0001; TERBRUGGE KG, 1987, CAN J NEUROL SCI, V14, P70; Thompson RC, 1998, NEUROSURGERY, V43, P202, DOI 10.1097/00006123-199808000-00006; TURJMAN F, 1995, NEUROSURGERY, V37, P856, DOI 10.1227/00006123-199511000-00002; U HS, 1992, SURG NEUROL, V38, P192; VANALPHEN HAM, 1986, NEUROSURG REV, V9, P77; Vikingstad EM, 2000, NEUROSURGERY, V47, P562, DOI 10.1097/00006123-200009000-00004; VINUELA F, 1991, J NEUROSURG, V75, P856, DOI 10.3171/jns.1991.75.6.0856; Vymazal J, 1999, STEREOT FUNCT NEUROS, V72, P175, DOI 10.1159/000056454; Wautier MP, 1999, BLOOD, V94, P2020, DOI 10.1182/blood.V94.6.2020.418a23_2020_2028; WILKINS RH, 1985, NEUROSURGERY, V16, P421, DOI 10.1227/00006123-198503000-00026; WILLINSKY R, 1988, J NEURORADIOLOGY, V15, P225; Wong S. H., 1997, Annals Academy of Medicine Singapore, V26, P475; Yakes WF, 1997, NEUROSURGERY, V40, P1145, DOI 10.1097/00006123-199706000-00005; YAMADA S, 1990, J NEUROSURG, V72, P418, DOI 10.3171/jns.1990.72.3.0418; YAMAMOTO Y, 1995, J NEUROSURG, V83, P832, DOI 10.3171/jns.1995.83.5.0832; YASARGIL MG, 1987, AVM BRAIN HIST EMBRY; YEH HS, 1993, J NEUROSURG, V78, P12, DOI 10.3171/jns.1993.78.1.0012; Zhao JZ, 2000, J CLIN NEUROSCI, V7, P54, DOI 10.1054/jocn.2000.0713; Zimmerman G, 2000, J NEUROSURG, V92, P39, DOI 10.3171/jns.2000.92.1.0039	142	272	279	2	22	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 9	2002	359	9309					863	873		10.1016/S0140-6736(02)07946-1	http://dx.doi.org/10.1016/S0140-6736(02)07946-1			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	529YV	11897302				2022-12-28	WOS:000174329600030
J	Ying, QL; Nichols, J; Evans, EP; Smith, AG				Ying, QL; Nichols, J; Evans, EP; Smith, AG			Changing potency by spontaneous fusion	NATURE			English	Article							EMBRYONIC STEM-CELLS; MARROW; BRAIN; BLOOD; HYBRIDIZATION; EXPRESSION	Recent reports have suggested that mammalian stem cells residing in one tissue may have the capacity to produce differentiated cell types for other tissues and organs(1-9). Here we define a mechanism by which progenitor cells of the central nervous system can give rise to non-neural derivatives. Cells taken from mouse brain were co-cultured with pluripotent embryonic stem cells. Following selection for a transgenic marker carried only by the brain cells, undifferentiated stem cells are recovered in which the brain cell genome has undergone epigenetic reprogramming. However, these cells also carry a transgenic marker and chromosomes derived from the embryonic stem cells. Therefore the altered phenotype does not arise by direct conversion of brain to embryonic stem cell but rather through spontaneous generation of hybrid cells. The tetraploid hybrids exhibit full pluripotent character, including multilineage contribution to chimaeras. We propose that transdetermination consequent to cell fusion 10 could underlie many observations otherwise attributed to an intrinsic plasticity of tissue stem cells(9).	Univ Edinburgh, Ctr Genome Res, Edinburgh EH9 3JQ, Midlothian, Scotland; Univ Oxford, Dept Zool, Oxford OX1 3PS, England	University of Edinburgh; University of Oxford	Smith, AG (corresponding author), Univ Edinburgh, Ctr Genome Res, Kings Bldg,W Mains Rd, Edinburgh EH9 3JQ, Midlothian, Scotland.	austin.smith@ed.ac.uk		Nichols, Jennifer/0000-0002-8650-1388; Smith, Austin/0000-0002-3029-4682				AKESON EC, 1996, GENETIC VARIANTS STR, P1506; BAIN G, 1995, DEV BIOL, V168, P342, DOI 10.1006/dbio.1995.1085; BARSKI G, 1961, J NATL CANCER I, V26, P1269; Bjornson CRR, 1999, SCIENCE, V283, P534, DOI 10.1126/science.283.5401.534; Blau HM, 2001, CELL, V105, P829, DOI 10.1016/S0092-8674(01)00409-3; Brazelton TR, 2000, SCIENCE, V290, P1775, DOI 10.1126/science.290.5497.1775; Clarke DL, 2000, SCIENCE, V288, P1660, DOI 10.1126/science.288.5471.1660; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; Ephrussi Boris, 1972, HYBRIDIZATION SOMATI; Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528; Galli R, 2000, NAT NEUROSCI, V3, P986, DOI 10.1038/79924; GARDNER RL, 1988, J CELL SCI, P11; Krause DS, 2001, CELL, V105, P369, DOI 10.1016/S0092-8674(01)00328-2; Lagasse E, 2000, NAT MED, V6, P1229, DOI 10.1038/81326; LUPTON SD, 1991, MOL CELL BIOL, V11, P3374, DOI 10.1128/MCB.11.6.3374; Mezey E, 2000, SCIENCE, V290, P1779, DOI 10.1126/science.290.5497.1779; MOUNTFORD P, 1994, P NATL ACAD SCI USA, V91, P4303, DOI 10.1073/pnas.91.10.4303; MOUNTFORD PS, 1995, TRENDS GENET, V11, P179, DOI 10.1016/S0168-9525(00)89040-X; NAGY A, 1990, DEVELOPMENT, V110, P815; Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9; Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Pratt T, 2000, DEV BIOL, V228, P19, DOI 10.1006/dbio.2000.9935; ROBERTSON E, 1987, TERATOCARCINOMA EMBR; Smith A, 2001, COLD SPRING HARBOR M, P205; Smith AG., 1991, J TISSUE CULT METHOD, V13, P89, DOI [10.1007/BF01666137, DOI 10.1007/BF01666137, 10.1007/bf01666137]; SORIEUL S, 1961, NATURE, V190, P653, DOI 10.1038/190653b0; Tada M, 2001, CURR BIOL, V11, P1553, DOI 10.1016/S0960-9822(01)00459-6; Yeom YI, 1996, DEVELOPMENT, V122, P881	29	1193	1321	0	55	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 4	2002	416	6880					545	548		10.1038/nature729	http://dx.doi.org/10.1038/nature729			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	537JY	11932748	Green Published			2022-12-28	WOS:000174756500046
J	Hernandez-Diaz, S				Hernandez-Diaz, S			Iatrogenic legacy from diethylstilbestrol exposure	LANCET			English	Editorial Material							ASSOCIATION; FERTILITY; MICE		Boston Univ, Sch Publ Hlth, Slone Epidemiol Unit, Brookline, MA 02446 USA	Boston University	Hernandez-Diaz, S (corresponding author), Boston Univ, Sch Publ Hlth, Slone Epidemiol Unit, Brookline, MA 02446 USA.							DIECKMANN WJ, 1953, AM J OBSTET GYNECOL, V66, P1062; GILL WB, 1979, J UROLOGY, V122, P36, DOI 10.1016/S0022-5347(17)56240-0; GIUSTI RM, 1995, ANN INTERN MED, V122, P778, DOI 10.7326/0003-4819-122-10-199505150-00008; HENDERSON BE, 1976, PEDIATRICS, V58, P505; HERBST AL, 1971, NEW ENGL J MED, V284, P878, DOI 10.1056/NEJM197104222841604; Hussain N, 2002, PEDIATRICS, V109, P473, DOI 10.1542/peds.109.3.473; Kaufman RH, 2000, OBSTET GYNECOL, V96, P483, DOI 10.1016/S0029-7844(00)00959-5; MCLACHLAN JA, 1975, SCIENCE, V190, P991, DOI 10.1126/science.242076; Newbold RR, 1998, CARCINOGENESIS, V19, P1655, DOI 10.1093/carcin/19.9.1655; Palmer JR, 2001, AM J EPIDEMIOL, V154, P316, DOI 10.1093/aje/154.4.316; WALKER BE, 1995, INT J CANCER, V61, P249, DOI 10.1002/ijc.2910610218; WILCOX AJ, 1995, NEW ENGL J MED, V332, P1411, DOI 10.1056/NEJM199505253322104	12	9	13	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 30	2002	359	9312					1081	1082		10.1016/S0140-6736(02)08126-6	http://dx.doi.org/10.1016/S0140-6736(02)08126-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	536YJ	11943252				2022-12-28	WOS:000174729200003
J	Hernandez-Nunez, A; Fernandez-Herrera, J; Buceta, LR; Garcia-Diez, A				Hernandez-Nunez, A; Fernandez-Herrera, J; Buceta, LR; Garcia-Diez, A			Trichomegaly following treatment with interferon alpha-2b	LANCET			English	Editorial Material									Hosp Univ Princesa, Dept Dermatol, Madrid 28006, Spain	Hospital de La Princesa	Buceta, LR (corresponding author), Hosp Univ Princesa, Dept Dermatol, Madrid 28006, Spain.								0	25	25	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 30	2002	359	9312					1107	1107		10.1016/S0140-6736(02)08153-9	http://dx.doi.org/10.1016/S0140-6736(02)08153-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	536YJ	11943258	Bronze			2022-12-28	WOS:000174729200009
J	Huynh, WU; Dittmer, JJ; Alivisatos, AP				Huynh, WU; Dittmer, JJ; Alivisatos, AP			Hybrid nanorod-polymer solar cells	SCIENCE			English	Article							CONJUGATED POLYMERS; PHOTOVOLTAIC CELLS; CDSE NANOCRYSTALS; ELECTRON-TRANSFER; TRANSPORT; DEVICES	We demonstrate that semiconductor nanorods can be used to fabricate readily processed and efficient hybrid solar cells together with polymers. By controlling nanorod length, we can change the distance on which electrons are transported directly through the thin film device. Tuning the band gap by altering the nanorod radius enabled us to optimize the overlap between the absorption spectrum of the cell and the solar emission spectrum. A photovoltaic device consisting of 7-nanometer by 60-nanometer CdSe nanorods and the conjugated polymer poly-3(hexylthiophene) was assembled from solution with an external quantum efficiency of over 54% and a monochromatic power conversion efficiency of 6.9% under 0.1 milliwatt per square centimeter illumination at 515 nanometers. Under Air Mass (A.M.) 1.5 Global solar conditions, we obtained a power conversion efficiency of 1.7%.	Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Mat Sci, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Alivisatos, AP (corresponding author), Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA.		chen, jia/F-8731-2011; Alivisatos, Paul/N-8863-2015	Alivisatos, Paul/0000-0001-6895-9048				Alivisatos AP, 1996, SCIENCE, V271, P933, DOI 10.1126/science.271.5251.933; BASSLER H, 1994, MOL CRYST LIQ CRYS A, V252, P11, DOI 10.1080/10587259408038206; Bozano L, 1999, APPL PHYS LETT, V74, P1132, DOI 10.1063/1.123959; Dittmer JJ, 2000, ADV MATER, V12, P1270, DOI 10.1002/1521-4095(200009)12:17<1270::AID-ADMA1270>3.0.CO;2-8; Ginger DS, 1999, PHYS REV B, V59, P10622, DOI 10.1103/PhysRevB.59.10622; Green MA, 2001, PROG PHOTOVOLTAICS, V9, P287, DOI 10.1002/pip.389; Greenham NC, 1996, PHYS REV B, V54, P17628, DOI 10.1103/PhysRevB.54.17628; Huynh WU, 1999, ADV MATER, V11, P923, DOI 10.1002/(SICI)1521-4095(199908)11:11<923::AID-ADMA923>3.0.CO;2-T; OREGAN B, 1991, NATURE, V353, P737, DOI 10.1038/353737a0; Peng XG, 2000, NATURE, V404, P59, DOI 10.1038/35003535; Peng ZA, 2001, J AM CHEM SOC, V123, P183, DOI 10.1021/ja003633m; Rehm JM, 1996, J PHYS CHEM-US, V100, P9577, DOI 10.1021/jp960155m; Roman LS, 1997, ADV MATER, V9, P1164, DOI 10.1002/adma.19970091508; Shaheen SE, 2001, APPL PHYS LETT, V78, P841, DOI 10.1063/1.1345834; Sirringhaus H, 1998, SCIENCE, V280, P1741, DOI 10.1126/science.280.5370.1741; YU G, 1995, SCIENCE, V270, P1789, DOI 10.1126/science.270.5243.1789	16	4689	4863	16	1771	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 29	2002	295	5564					2425	2427		10.1126/science.1069156	http://dx.doi.org/10.1126/science.1069156			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	536QD	11923531				2022-12-28	WOS:000174712600047
J	Blagosklonny, MV; Pardee, AB				Blagosklonny, MV; Pardee, AB			Conceptual biology: Unearthing the gems	NATURE			English	Editorial Material									New York Med Coll, Brander Canc Res Inst, Hawthorne, NY 10532 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA	New York Medical College; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Blagosklonny, MV (corresponding author), New York Med Coll, Brander Canc Res Inst, Hawthorne, NY 10532 USA.							Blagosklonny MV, 1997, ONCOGENE, V15, P1889, DOI 10.1038/sj.onc.1201374; Bray D, 2001, NATURE, V412, P863, DOI 10.1038/35091132; Goodman AB, 1998, P NATL ACAD SCI USA, V95, P7240, DOI 10.1073/pnas.95.13.7240; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Weinberg RA, 2001, TRENDS BIOCHEM SCI, V26, P207, DOI 10.1016/S0968-0004(01)01823-0	5	62	67	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 28	2002	416	6879					373	373		10.1038/416373a	http://dx.doi.org/10.1038/416373a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	534UX	11919607	Bronze			2022-12-28	WOS:000174607800024
J	Krajinovic, M; Costea, I; Chiasson, S				Krajinovic, M; Costea, I; Chiasson, S			Polymorphism of the thymidylate synthase gene and outcome of acute lymphoblastic leukaemia	LANCET			English	Article								Interindividual variability In response to methotrexate could be caused by variable concentrations of thymidylate synthase. We Investigated the possible association between a tandem-repeat polymorphism in the thymidylate synthase promoter, of which a triple repeat Is associated with Increased expression of thymidylate synthase, and outcome of acute lymphoblastic leukaemia in 205 children treated with methotrexate. We obtained DNA samples from buccal epithelial cells, peripheral blood, or bone marrow In remission, and analysed them for the polymorphism by PCR amplification. Individuals who were homozygous for the triple repeat had a poorer outlook than those with other genotypes (odds ratio 4.1, 95% CI 1.9-9.0, p = 0.001). Genotyping of thymidylate synthase might make It possible to Individualise treatment for patients with acute lymphoblastic leukaemia.	Hop St Justine, Ctr Rech, Serv Hematol Oncol, Montreal, PQ H3T 1C5, Canada; Univ Montreal, Dept Pediat, Montreal, PQ H3C 3J7, Canada	Universite de Montreal; Universite de Montreal	Krajinovic, M (corresponding author), Hop St Justine, Ctr Rech, Serv Hematol Oncol, 3175 Cote St Catherine, Montreal, PQ H3T 1C5, Canada.							HORIE N, 1995, CELL STRUCT FUNCT, V20, P191, DOI 10.1247/csf.20.191; Iacopetta B, 2001, BRIT J CANCER, V85, P827, DOI 10.1054/bjoc.2001.2007; Kawakami K, 1999, ANTICANCER RES, V19, P3249; Rots MG, 2000, LEUKEMIA, V14, P2166, DOI 10.1038/sj.leu.2401943; Welsh SJ, 2000, CLIN CANCER RES, V6, P2538	5	135	143	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 23	2002	359	9311					1033	1034		10.1016/S0140-6736(02)08065-0	http://dx.doi.org/10.1016/S0140-6736(02)08065-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	534KP	11937185				2022-12-28	WOS:000174585800012
J	Yang, QH; Rasmussen, SA; Friedman, JM				Yang, QH; Rasmussen, SA; Friedman, JM			Mortality associated with Down's syndrome in the USA from 1983 to 1997: a population-based study	LANCET			English	Article							DEATH; SURVIVAL; INDIVIDUALS; LEUKEMIA	Background Down's syndrome is the most frequently identified cause of mental retardation, but information about mortality and comorbidity in people with Down's syndrome is limited. Methods We used data from US death certificates from 1983 to 1997 to calculate median age at death and standardised mortality odds ratios (SMORs) for common medical disorders in people with Down's syndrome. Findings Of 17 897 people reported to have Down's syndrome, median age at death increased from 25 years in 1983 to 49 years in 1997, an average increase of 1.7 years per year studied (p < 0.0001). Median age at death was significantly lower in black people and people of other races than in white people with Down's syndrome. As expected, death certificates with a diagnosis of Down's syndrome were more likely to list congenital heart defects (SMOR 29.1, 95% CI 27.8-30.4), dementia (21.2, 19.6-22.7), hypothyroidism (20.3, 18.5-22.3), or leukaemia (1.6, 1.4-1.8) than were those that did not report Down's syndrome. By contrast, malignant neoplasms other than leukaemia were listed on death certificates of people with Down's syndrome less than one-tenth as often as expected (0.07, 0.06-0.08). A strikingly low SMOR for malignancy was associated with Down's syndrome at all ages, in both sexes, and for all common tumour types except leukaemia and testicular cancer. Interpretation Identification of factors responsible for the racial differences recorded could facilitate further improvement in survival of people with Down's syndrome. Reduced exposure to environmental factors that contribute to cancer risk, tumour-suppressor genes on chromosome 21, or a slower rate of replication or higher likelihood of apoptosis in Down's syndrome cells, could be possible reasons for paucity of cancer in people with Down's syndrome.	Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30341 USA; Univ British Columbia, Dept Med Genet, Vancouver, BC, Canada	Centers for Disease Control & Prevention - USA; University of British Columbia	Yang, QH (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, 4770 Buford Highway,MS F-45, Atlanta, GA 30341 USA.	qyang@cdc.gov		Friedman, Jan/0000-0002-7482-9570; Rasmussen, Sonja/0000-0002-0574-4928				[Anonymous], 2000, TERATOLOGY, V61, P86; BAIRD PA, 1988, LANCET, V2, P1354; BAIRD PA, 1988, AM J HUM GENET, V43, P239; BELL JA, 1989, J MED GENET, V26, P764, DOI 10.1136/jmg.26.12.764; Bishop J, 1997, AM J EPIDEMIOL, V145, P134; Boker LK, 2001, INT J CANCER, V93, P741, DOI 10.1002/ijc.1383; *CDCP, 1994, MMWR-MORBID MORTAL W, V43, P617; Conover W.J., 1999, PRACTICAL NONPARAMET, V350; COOLEY WC, 1991, CLIN PEDIATR, V30, P233, DOI 10.1177/000992289103000407; Forrester MB, 1998, AM J EPIDEMIOL, V148, P1206; Frid C, 1999, J INTELL DISABIL RES, V43, P234, DOI 10.1046/j.1365-2788.1999.00198.x; GITTELSOHN A, 1979, AM J PUBLIC HEALTH, V69, P680, DOI 10.2105/AJPH.69.7.680; HASLAM RHA, 1992, J CHILD NEUROL, V7, P304, DOI 10.1177/088307389200700312; Hasle H, 2000, LANCET, V355, P165, DOI 10.1016/S0140-6736(99)05264-2; Hattori M, 2000, NATURE, V405, P311, DOI 10.1038/35012518; Hayes C, 1997, INT J EPIDEMIOL, V26, P822, DOI 10.1093/ije/26.4.822; ISRAEL RA, 1986, AM J EPIDEMIOL, V124, P161, DOI 10.1093/oxfordjournals.aje.a114375; KULLER LH, 1995, AM J PUBLIC HEALTH, V85, P1198, DOI 10.2105/AJPH.85.9.1198; Leonard S, 2000, PAEDIATR PERINAT EP, V14, P163; Lloyd-Jones DM, 1998, ANN INTERN MED, V129, P1020, DOI 10.7326/0003-4819-129-12-199812150-00005; MIETTINEN OS, 1981, AM J EPIDEMIOL, V114, P144, DOI 10.1093/oxfordjournals.aje.a113161; MULCAHY MT, 1979, CLIN GENET, V16, P103; *NAT CTR HLTH STAT, 1986, PUBL US DAT TAP DOC; Record RG, 1955, BRIT J PREV SOC MED, V9, P10; Rothman K., 1998, MODERN EPIDEMIOLOGY; Satge D, 1998, AM J MED GENET, V78, P207, DOI 10.1002/(SICI)1096-8628(19980707)78:3<207::AID-AJMG1>3.3.CO;2-Q; Sawa A, 1999, J NEURAL TRANSM-SUPP, P87; SCHNEIDER EL, 1972, P SOC EXP BIOL MED, V141, P1092; SCHOLL T, 1982, DEV MED CHILD NEUROL, V24, P817; SEGAL DJ, 1974, J CELL PHYSIOL, V83, P85, DOI 10.1002/jcp.1040830112; SMITH GF, 1984, JAMA-J AM MED ASSOC, V251, P229, DOI 10.1001/jama.251.2.229; SMITH KR, 1995, EPIDEMIOLOGY, V6, P55, DOI 10.1097/00001648-199501000-00011; SORLIE PD, 1995, AM J PUBLIC HEALTH, V85, P949, DOI 10.2105/AJPH.85.7.949; Yasui K, 1999, AM J MED GENET, V84, P406, DOI 10.1002/(SICI)1096-8628(19990611)84:5<406::AID-AJMG4>3.3.CO;2-W	34	540	552	1	28	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 23	2002	359	9311					1019	1025		10.1016/S0140-6736(02)08092-3	http://dx.doi.org/10.1016/S0140-6736(02)08092-3			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	534KP	11937181				2022-12-28	WOS:000174585800008
J	Herlihy, CR; Eckert, CG				Herlihy, CR; Eckert, CG			Genetic cost of reproductive assurance in a self-fertilizing plant	NATURE			English	Article							INBREEDING DEPRESSION; CROSS-FERTILIZATION; SYSTEM EVOLUTION; MATING SYSTEM; INFERENCES; ECOLOGY	The transition from outcrossing to self-fertilization is one of the most common evolutionary trends in plants(1). Reproductive assurance, where self-fertilization ensures seed production when pollinators and/or potential mates are scarce, is the most long-standing and most widely accepted explanation for the evolution of selfing(2-8), but there have been few experimental tests of this hypothesis. Moreover, many apparently adaptive floral mechanisms that ensure the autonomous production of selfed seed might use ovules that would have otherwise been outcrossed. This seed discounting is costly if selfed offspring are less viable than their outcrossed counterparts, as often happens. The fertility benefit of reproductive assurance has never been examined in the light of seed discounting. Here we combine experimental measures of reproductive assurance with marker-gene estimates of self-fertilization, seed discounting and inbreeding depression to show that, during 2 years in 10 Ontario populations of Aquilegia canadensis (Ranunculaceae), reproductive assurance through self-fertilization increases seed production, but this benefit is greatly outweighed by severe seed discounting and inbreeding depression.	Queens Univ, Dept Biol, Kingston, ON K7L 3N6, Canada	Queens University - Canada	Eckert, CG (corresponding author), Queens Univ, Dept Biol, Kingston, ON K7L 3N6, Canada.	eckertc@biology.queensu.ca						BAKER HG, 1955, EVOLUTION, V9, P347, DOI 10.2307/2405656; Barrett SCH, 1996, PHILOS T R SOC B, V351, P1271, DOI 10.1098/rstb.1996.0110; CHARLESWORTH D, 1987, ANNU REV ECOL SYST, V18, P237, DOI 10.1146/annurev.es.18.110187.001321; Cruden R.W., 1989, EVOLUTIONARY ECOLOGY, P171; Darwin CR, 1876, EFFECTS CROSS SELF F; Eckert CG, 1998, AM J BOT, V85, P919, DOI 10.2307/2446357; Fisher RA, 1941, ANN EUGENIC, V11, P53, DOI 10.1111/j.1469-1809.1941.tb02272.x; Griffin SR, 2000, AM J BOT, V87, P1246, DOI 10.2307/2656717; Holsinger KE, 1996, EVOL BIOL, V29, P107; Husband BC, 1996, EVOLUTION, V50, P54, DOI [10.1111/j.1558-5646.1996.tb04472.x, 10.2307/2410780]; JAIN SK, 1976, ANNU REV ECOL SYST, V7, P469, DOI 10.1146/annurev.es.07.110176.002345; JARNE P, 1993, ANNU REV ECOL SYST, V24, P441, DOI 10.1146/annurev.es.24.110193.002301; LANDE R, 1994, EVOLUTION, V48, P965, DOI 10.1111/j.1558-5646.1994.tb05286.x; Lloyd D. G., 1980, Demography and evolution in plant populations., P67; LLOYD DG, 1992, INT J PLANT SCI, V153, P370, DOI 10.1086/297041; LLOYD DG, 1992, INT J PLANT SCI, V153, P358, DOI 10.1086/297040; MACIOR LW, 1978, OIKOS, V30, P452, DOI 10.2307/3543340; Mavraganis K, 2001, OIKOS, V95, P300, DOI 10.1034/j.1600-0706.2001.950212.x; Morgan MT, 1997, AM NAT, V150, P618, DOI 10.1086/286085; Morgan MT, 1997, TRENDS ECOL EVOL, V12, P231, DOI 10.1016/S0169-5347(97)01045-8; PIPER JG, 1984, NATURE, V310, P50, DOI 10.1038/310050a0; PIPER JG, 1986, HEREDITY, V56, P207, DOI 10.1038/hdy.1986.33; RITLAND K, 1990, J HERED, V81, P235; RITLAND K, 1990, EVOLUTION, V44, P1230, DOI 10.1111/j.1558-5646.1990.tb05227.x; Routley MB, 1999, HEREDITY, V82, P518, DOI 10.1038/sj.hdy.6885220; Schoen DJ, 1996, PHILOS T R SOC B, V351, P1281, DOI 10.1098/rstb.1996.0111; SCHOEN DJ, 1992, INT J PLANT SCI, V153, P381, DOI 10.1086/297042; SCHOEN DJ, 1991, EVOLUTION, V45, P1651, DOI [10.1111/j.1558-5646.1991.tb02670.x, 10.2307/2409786]; Stebbins G.L., 1974, FLOWERING PLANTS EVO, DOI 10.4159/harvard.9780674864856; YAHARA T, 1992, EVOLUTION, V46, P557, DOI [10.2307/2409872, 10.1111/j.1558-5646.1992.tb02059.x]	30	247	258	0	75	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAR 21	2002	416	6878					320	323		10.1038/416320a	http://dx.doi.org/10.1038/416320a			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	532NP	11907577				2022-12-28	WOS:000174482200042
J	Malaty, HM; El-Kasabany, A; Graham, DY; Miller, CC; Reddy, SG; Srinivasan, SR; Yamaoka, Y; Berenson, GS				Malaty, HM; El-Kasabany, A; Graham, DY; Miller, CC; Reddy, SG; Srinivasan, SR; Yamaoka, Y; Berenson, GS			Age at acquisition of Helicobacter pylori infection: a follow-up study from infancy to adulthood	LANCET			English	Article							SOCIOECONOMIC-STATUS; DIAGNOSTIC-TESTS; GASTRIC-CANCER; UNITED-STATES; CHILDREN; CHILDHOOD; EPIDEMIOLOGY; ADOLESCENTS; POPULATION; PREVALENCE	Background Helicobacter pylori infection is common worldwide, but the time of acquisition is unclear. We investigated this issue in a cohort of children selected retrospectively from a population followed up for 21 years. Methods We monitored 224 children (99 black, 125 white; 110 male, 114 female) from 1975-76 (ages 1-3 years) to 1995-96. H pylori status was assessed by presence of serum IgG antibodies. Findings 18 (8.0%) children at age 1-3 years had H pylori antibodies (13% black vs 4% white children, p=0.008). By age 18-23 years, the prevalence of the infection was 24.5% (43% black vs 8% white participants, p<0.0001). Of the 206 children not infected at baseline, 40 (19%) became infected by age 21-23. The crude incidence rate per year was 1.4% for the whole cohort, ranging from 2.1% at 4-5 years and 1.5% at age 7-9 years to 0.3% at 21-23 years. The seroconversion rate was higher among black than among white children (relative risk 3.3, 95% CI 1.8-6.2, p=0.001). The median age for seroconversion was 7.5 years for both races. Nine of the 58 seropositive children cleared the infection during follow-up. The rate of seroreversion per year was 1.1%; it was highest among children at age 4-5 years (2.2% vs 0.2% at ages 18-19). Interpretation Most newly acquired H pylori infections happened before age 10 years. Treatment and preventive strategies should be aimed at children in this age-group.	Vet Affairs Med Ctr, Dept Med, Houston, TX 77030 USA; Vet Affairs Med Ctr, Dept Mol Virol & Microbiol, Houston, TX 77030 USA; Baylor Coll Med, Houston, TX 77030 USA; Tulane Sch Publ Hlth, Tulane Ctr Cardiovasc Hlth, New Orleans, LA USA; Univ Texas, Sch Med, Dept Surg, Houston, TX USA	Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Baylor College of Medicine; Tulane University; University of Texas System	Malaty, HM (corresponding author), Vet Affairs Med Ctr, Dept Med, 111D,2002 Holcombe Blvd, Houston, TX 77030 USA.		Graham, David/AAL-2165-2021	Yamaoka, Yoshio/0000-0002-1222-5819				ASHORN M, 1995, SCAND J GASTROENTERO, V30, P876, DOI 10.3109/00365529509101594; BAMFORD KB, 1993, GUT, V34, P1348, DOI 10.1136/gut.34.10.1348; CHONG SKF, 1995, PEDIATRICS, V96, P211; Correa P, 1996, CANCER EPIDEM BIOMAR, V5, P477; CRANSTROM M, 1997, J CLIN MICROBIOL, V35, P468; EVANS DJ, 1989, GASTROENTEROLOGY, V96, P1004, DOI 10.1016/0016-5085(89)91616-8; FORMAN D, 1991, BRIT MED J, V302, P1302, DOI 10.1136/bmj.302.6788.1302; GRAHAM DY, 1991, GASTROENTEROLOGY, V100, P1495, DOI 10.1016/0016-5085(91)90644-Z; Graham DY, 1991, HELICOBACTER PYLORI, P97; GRAHAM DY, 1991, J GASTROEN HEPATOL, V6, P97; Khanna B, 1998, J INFECT DIS, V178, P460, DOI 10.1086/515634; KLEIN PD, 1994, AM J GASTROENTEROL, V89, P2196; KUIPERS EJ, 1993, LANCET, V342, P328, DOI 10.1016/0140-6736(93)91473-Y; Kumagai T, 1998, J INFECT DIS, V178, P717, DOI 10.1086/515376; Malaty HM, 1999, CLIN INFECT DIS, V28, P279, DOI 10.1086/515105; Malaty HM, 1996, AM J EPIDEMIOL, V143, P257, DOI 10.1093/oxfordjournals.aje.a008736; MALATY HM, 1994, ANN INTERN MED, V120, P982, DOI 10.7326/0003-4819-120-12-199406150-00002; Malaty HM, 2001, CLIN INFECT DIS, V32, P1387, DOI 10.1086/320148; MALATY HM, 1991, SCAND J GASTROENTERO, V26, P927, DOI 10.3109/00365529108996244; MALATY HM, 1992, GASTROENTEROLOGY, V103, P813, DOI 10.1016/0016-5085(92)90011-M; MALATY HM, 1994, GUT, V35, P742, DOI 10.1136/gut.35.6.742; MEGRAUD F, 1989, J CLIN MICROBIOL, V27, P1870; MENDALL MA, 1992, LANCET, V339, P896, DOI 10.1016/0140-6736(92)90931-R; PARSONNET J, 1995, ALIMENT PHARM THERAP, V9, P45; Pickoff AS, 1995, AM J MED SCI, V310, pS1, DOI 10.1097/00000441-199512000-00001; Snyder JD, 1999, CAN J GASTROENTEROL, V13, P585, DOI 10.1155/1999/304679; Staat MA, 1996, J INFECT DIS, V174, P1120, DOI 10.1093/infdis/174.5.1120; TEH BH, 1994, ANTICANCER RES, V14, P1389; TYTGAT GNJ, 1993, GASTROENTEROL INT, V6, P76	29	283	296	2	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 16	2002	359	9310					931	935		10.1016/S0140-6736(02)08025-X	http://dx.doi.org/10.1016/S0140-6736(02)08025-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	531AE	11918912				2022-12-28	WOS:000174391700012
J	Begg, CB; Riedel, ER; Bach, PB; Kattan, MW; Schrag, D; Warren, JL; Scardino, PT				Begg, CB; Riedel, ER; Bach, PB; Kattan, MW; Schrag, D; Warren, JL; Scardino, PT			Variations in morbidity after radical prostatectomy.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HOSPITAL VOLUME; RETROPUBIC PROSTATECTOMY; PANCREATIC RESECTION; COMPLICATION RATES; COLORECTAL-CANCER; BREAST-CANCER; OUTCOMES; MORTALITY; SURVIVAL; SURGERY	Background: Recent studies of surgery for cancer have demonstrated variations in outcomes among hospitals and among surgeons. We sought to examine variations in morbidity after radical prostatectomy for prostate cancer. Methods: We used the Surveillance, Epidemiology, and End Results-Medicare linked data base to evaluate health-related outcomes after radical prostatectomy. The rates of postoperative complications, late urinary complications (strictures or fistulas 31 to 365 days after the procedure), and long-term incontinence (more than 1 year after the procedure) were inferred from the Medicare claims records of 11,522 patients who underwent prostatectomy between 1992 and 1996. These rates were analyzed in relation to hospital volume and surgeon volume (the number of procedures performed at individual hospitals and by individual surgeons, respectively). Results: Neither hospital volume nor surgeon volume was significantly associated with surgery-related death. Significant trends in the relation between volume and outcome were observed with respect to postoperative complications and late urinary complications. Postoperative morbidity was lower in very-high-volume hospitals than in low-volume hospitals (27 percent vs. 32 percent, P=0.03) and was also lower when the prostatectomy was performed by very-high-volume surgeons than when it was performed by low-volume surgeons (26 percent vs. 32 percent, P<0.001). The rates of late urinary complications followed a similar pattern. Results for long-term preservation of continence were less clear-cut. In a detailed analysis of the 159 surgeons who had a high or very high volume of procedures, wide surgeon-to-surgeon variations in these clinical outcomes were observed, and they were much greater than would be predicted on the basis of chance or observed variations in the case mix. Conclusions: In men undergoing prostatectomy, the rates of postoperative and late urinary complications are significantly reduced if the procedure is performed in a high-volume hospital and by a surgeon who performs a high number of such procedures.	Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, Hlth Outcomes Res Grp, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Urol, New York, NY 10021 USA; NCI, Appl Res Branch, Bethesda, MD 20892 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Begg, CB (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, Hlth Outcomes Res Grp, 1275 York Ave,Box 44, New York, NY 10021 USA.		Kattan, Michael/AAF-9735-2021	Kattan, Michael/0000-0002-3840-4161; Schrag, Deborah/0000-0002-4334-5717				Allison PD, 1999, LOGISTIC REGRESSION, P179; Bach PB, 2001, NEW ENGL J MED, V345, P181, DOI 10.1056/NEJM200107193450306; Begg CB, 1998, JAMA-J AM MED ASSOC, V280, P1747, DOI 10.1001/jama.280.20.1747; Benoit RM, 2000, UROLOGY, V56, P116, DOI 10.1016/S0090-4295(00)00539-2; Best A E, 1999, J Med Syst, V23, P175, DOI 10.1023/A:1020515419714; Birkmeyer JD, 1999, SURGERY, V126, P178, DOI 10.1016/S0039-6060(99)70152-2; Birkmeyer JD, 2001, SURGERY, V130, P415, DOI 10.1067/msy.2001.117139; Catalona WJ, 1999, J UROLOGY, V162, P433, DOI 10.1016/S0022-5347(05)68578-3; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Davidson PJT, 1996, EUR UROL, V29, P168; Dillioglugil O, 1997, J UROLOGY, V157, P1760, DOI 10.1016/S0022-5347(01)64856-0; Dudley RA, 2000, JAMA-J AM MED ASSOC, V283, P1159, DOI 10.1001/jama.283.9.1159; Ellison LM, 2000, J UROLOGY, V163, P867, DOI 10.1016/S0022-5347(05)67821-4; Glasgow RE, 1996, WESTERN J MED, V165, P294; GORDON TA, 1995, ANN SURG, V221, P43, DOI 10.1097/00000658-199501000-00005; Heinzer H, 1997, UROL INT, V59, P30, DOI 10.1159/000283013; Hermanek P, 1996, EUR J SURG ONCOL, V22, P213, DOI 10.1016/S0748-7983(96)80004-7; Hewitt M, 1999, ENSURING QUALITY CAN; Hillner BE, 2000, J CLIN ONCOL, V18, P2327, DOI 10.1200/JCO.2000.18.11.2327; HOSMER DW, 1989, APPL LOGISTIC REGRES; Klabunde CN, 2000, J CLIN EPIDEMIOL, V53, P1258, DOI 10.1016/S0895-4356(00)00256-0; Lawthers AG, 2000, MED CARE, V38, P785, DOI 10.1097/00005650-200008000-00003; LEEFELDSTEIN A, 1994, JAMA-J AM MED ASSOC, V271, P1163, DOI 10.1001/jama.271.15.1163; LIEBERMAN MD, 1995, ANN SURG, V222, P638, DOI 10.1097/00000658-199511000-00006; Mettlin C, 1997, CA-CANCER J CLIN, V47, P265, DOI 10.3322/canjclin.47.5.265; Mettlin C, 1997, CA-CANCER J CLIN, V47, P325; Parry JM, 1999, BRIT J SURG, V86, P475, DOI 10.1046/j.1365-2168.1999.01064.x; Patti M G, 1998, J Gastrointest Surg, V2, P186, DOI 10.1016/S1091-255X(98)80011-5; Potosky AL, 2000, JNCI-J NATL CANCER I, V92, P1582, DOI 10.1093/jnci/92.19.1582; POTOSKY AL, 1993, MED CARE, V31, P732; POTOSKY AL, IN PRESS MED CARE; RIES LAG, 1997, NIH PUBLICATION; ROMANO PS, 1993, J CLIN EPIDEMIOL, V46, P1075, DOI 10.1016/0895-4356(93)90103-8; ROMANO PS, 1993, J CLIN EPIDEMIOL, V46, P1081; Roohan PJ, 1998, AM J PUBLIC HEALTH, V88, P454, DOI 10.2105/AJPH.88.3.454; Schrag D, 2000, JAMA-J AM MED ASSOC, V284, P3028, DOI 10.1001/jama.284.23.3028; Stanford JL, 2000, JAMA-J AM MED ASSOC, V283, P354, DOI 10.1001/jama.283.3.354; Thompson IM, 1999, J UROLOGY, V162, P107, DOI 10.1097/00005392-199907000-00026; Yao SL, 1999, J NATL CANCER I, V91, P1950, DOI 10.1093/jnci/91.22.1950	39	645	661	0	13	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 11	2002	346	15					1138	1144		10.1056/NEJMsa011788	http://dx.doi.org/10.1056/NEJMsa011788			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	539PX	11948274				2022-12-28	WOS:000174880600007
J	Richey, JE; Melack, JM; Aufdenkampe, AK; Ballester, VM; Hess, LL				Richey, JE; Melack, JM; Aufdenkampe, AK; Ballester, VM; Hess, LL			Outgassing from Amazonian rivers and wetlands as a large tropical source of atmospheric CO2	NATURE			English	Article							CARBON-DIOXIDE; BASIN; TRANSPORT; OXIDATION; EXCHANGE; FORESTS	Terrestrial ecosystems in the humid tropics play a potentially important but presently ambiguous role in the global carbon cycle. Whereas global estimates of atmospheric CO2 exchange indicate that the tropics are near equilibrium or are a source with respect to carbon(1,2), ground-based estimates indicate that the amount of carbon that is being absorbed by mature rainforests is similar to or greater than that being released by tropical deforestation(3,4) (about 1.6 Gt Cyr(-1)). Estimates of the magnitude of carbon sequestration are uncertain, however, depending on whether they are derived from measurements of gas fluxes above forests(5,6) or of biomass accumulation in vegetation and soils(3,7). It is also possible that methodological errors may overestimate rates of carbon uptake or that other loss processes have yet to be identified(3). Here we demonstrate that outgassing (evasion) of CO2 from rivers and wetlands of the central Amazon basin constitutes an important carbon loss process, equal to 1.2 +/- 0.3 Mg Cha(-1) yr(-1). This carbon probably originates from organic matter transported from upland and flooded forests, which is then respired and outgassed downstream. Extrapolated across the entire basin, this flux-at 0.5 Gt Cyr(-1) -is an order of magnitude greater than fluvial export of organic carbon to the ocean(8). From these findings, we suggest that the overall carbon budget of rainforests, summed across terrestrial and aquatic environments, appears closer to being in balance than would be inferred from studies of uplands alone(3,5-6).	Univ Washington, Sch Oceanog, Seattle, WA 98195 USA; Univ Calif Santa Barbara, Inst Computat Earth Syst Sci, Santa Barbara, CA 93106 USA; Ctr Energia Nucl Agr, Piracicaba, SP, Brazil	University of Washington; University of Washington Seattle; University of California System; University of California Santa Barbara	Richey, JE (corresponding author), Univ Washington, Sch Oceanog, Seattle, WA 98195 USA.	jrichey@u.washington.edu	Ballester, Maria V R/K-1926-2013	Ballester, Maria V R/0000-0003-2567-6747; Aufdenkampe, Anthony/0000-0002-5811-6458				[Anonymous], EOS; BARBOSA C, 2000, 9 LAT AM S REM SENS, P1168; CHAMBERS JQ, 2000, FOREST ECOL MANAG, V5348, P1; CLARK JF, 1994, TELLUS B, V46, P274, DOI 10.1034/j.1600-0889.1994.t01-2-00003.x; Cole JJ, 2001, MAR FRESHWATER RES, V52, P101, DOI 10.1071/MF00084; DAVIDSON EA, 1995, TELLUS B, V47, P550, DOI 10.1034/j.1600-0889.47.issue5.3.x; DEGENS ET, 1991, BIOGEOCHEMISTRY MAJO, P323, DOI [DOI 10.1007/B136008, DOI 10.1002/AQC.3270010209]; DEVOL AH, 1987, LIMNOL OCEANOGR, V32, P235, DOI 10.4319/lo.1987.32.1.0235; DEVOL AH, 1995, GLOBAL BIOGEOCHEM CY, V9, P307, DOI 10.1029/95GB01145; GRACE J, 1995, SCIENCE, V270, P778, DOI 10.1126/science.270.5237.778; Gurney KR, 2002, NATURE, V415, P626, DOI 10.1038/415626a; HESS LL, IN PRESS INT J REMOT; Hope D, 2001, LIMNOL OCEANOGR, V46, P847, DOI 10.4319/lo.2001.46.4.0847; KLING GW, 1991, SCIENCE, V251, P298, DOI 10.1126/science.251.4991.298; MacIntyre S, 2002, GEOPH MONOG SERIES, V127, P135; Malhi Y, 1998, J GEOPHYS RES-ATMOS, V103, P31593, DOI 10.1029/98JD02647; Malhi Y, 2000, TRENDS ECOL EVOL, V15, P332, DOI 10.1016/S0169-5347(00)01906-6; McClain M. E., 1996, Archiv fuer Hydrobiologie Supplement, V113, P111; McClain ME, 1997, GLOBAL BIOGEOCHEM CY, V11, P295, DOI 10.1029/97GB01056; Melack J.M., 2001, BIOGEOCHEMISTRY AMAZ, P235; Phillips OL, 1998, SCIENCE, V282, P439, DOI 10.1126/science.282.5388.439; RICHEY JE, 1988, LIMNOL OCEANOGR, V33, P551, DOI 10.4319/lo.1988.33.4.0551; RICHEY JE, 1980, SCIENCE, V207, P1348, DOI 10.1126/science.207.4437.1348; RICHEY JE, 1990, LIMNOL OCEANOGR, V35, P352, DOI 10.4319/lo.1990.35.2.0352; RICHEY JE, IN PRESS BIOSPHERIC; SARMIENTO JL, 1992, NATURE, V356, P589, DOI 10.1038/356589a0; Schimel DS, 2001, NATURE, V414, P169, DOI 10.1038/35102500; Sippel SJ, 1998, INT J REMOTE SENS, V19, P3055, DOI 10.1080/014311698214181; Siqueira P, 2000, IEEE T GEOSCI REMOTE, V38, P2638, DOI 10.1109/36.885210; Telmer K, 1999, CHEM GEOL, V159, P61, DOI 10.1016/S0009-2541(99)00034-0	30	760	822	19	285	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 11	2002	416	6881					617	620		10.1038/416617a	http://dx.doi.org/10.1038/416617a			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	539YV	11948346				2022-12-28	WOS:000174901900038
J	Comforti, E; Chung, YC; Heiblum, M; Umansky, V; Mahalu, D				Comforti, E; Chung, YC; Heiblum, M; Umansky, V; Mahalu, D			Bunching of fractionally charged quasiparticles tunnelling through high-potential barriers	NATURE			English	Article							QUASI-PARTICLE; ELECTRONS; NOISE	Shot noise measurements have been used to measure the charge of quasiparticles in the fractional quantum Hall (FQH) regime(1-3). To induce shot noise in an otherwise noiseless current of quasiparticles, a barrier is placed in its path to cause weak backscattering. The measured shot noise is proportional to the charge of the quasiparticles; for example, at filling factor v = 1/3, noise corresponding to q = e/3 appears. For increasingly opaque barriers, the measured charge increases monotonically, approaching q = e asymptotically(4,5). It was therefore believed that only electrons, or alternatively, three bunched quasiparticles, can tunnel through high-potential barriers encountered by a noiseless current of quasiparticles. Here we investigate the interaction of e/3 quasiparticles with a strong barrier in FQH samples and find that bunching of quasiparticles in the strong backscattering limit depends on the average dilution of the quasiparticle current. For a very dilute current, bunching ceases altogether and the transferred charge approaches q = e/3. This surprising result demonstrates that quasiparticles can tunnel individually through high-potential barriers originally thought to be opaque for them.	Weizmann Inst Sci, Dept Condensed Matter Phys, Braun Ctr Submicron Res, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Heiblum, M (corresponding author), Weizmann Inst Sci, Dept Condensed Matter Phys, Braun Ctr Submicron Res, IL-76100 Rehovot, Israel.		Umansky, Vladimir/P-1334-2019; heiblum, moty/Q-1193-2019	Umansky, Vladimir/0000-0001-5727-2064; 				COMFORTI E, 2001, CONDMAT0112367; dePicciotto R, 1997, NATURE, V389, P162, DOI 10.1038/38241; Griffiths TG, 2000, PHYS REV LETT, V85, P3918, DOI 10.1103/PhysRevLett.85.3918; KANE CL, 1994, PHYS REV LETT, V72, P724, DOI 10.1103/PhysRevLett.72.724; Khlus V. A., 1987, Soviet Physics - JETP, V66, P1243; LESOVIK GB, 1989, JETP LETT+, V49, P592; Oliver WD, 1999, SCIENCE, V284, P299, DOI 10.1126/science.284.5412.299; PANGE RE, 1987, QUANTUM HALL EFFECT; Reznikov M, 1999, NATURE, V399, P238, DOI 10.1038/20384; Saminadayar L, 1997, PHYS REV LETT, V79, P2526, DOI 10.1103/PhysRevLett.79.2526; Schottky W, 1918, ANN PHYS-BERLIN, V57, P541	12	37	37	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 4	2002	416	6880					515	518		10.1038/416515a	http://dx.doi.org/10.1038/416515a			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	537JY	11932739	Green Submitted			2022-12-28	WOS:000174756500037
J	Skegg, DCG				Skegg, DCG			Oral contraceptives, parity, and cervical cancer	LANCET			English	Editorial Material							RISK		Univ Otago, Dept Prevent & Social Med, Dunedin, New Zealand	University of Otago	Skegg, DCG (corresponding author), Univ Otago, Dept Prevent & Social Med, Dunedin, New Zealand.							BOYLE P, 1993, B WORLD HEALTH ORGAN, V71, P669; BRINTON LA, 1989, AM J EPIDEMIOL, V130, P486, DOI 10.1093/oxfordjournals.aje.a115362; BRINTON LA, 1991, CONTRACEPTION, V43, P581, DOI 10.1016/0010-7824(91)90005-Z; Calle EE, 1996, LANCET, V347, P1713, DOI 10.1016/S0140-6736(96)90806-5; Deacon JM, 2000, BRIT J CANCER, V83, P1565, DOI 10.1054/bjoc.2000.1523; *IARC WORK GROUP, 1995, IARC MON EV CARC RIS, V64; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 1999, IARC MON EV CARC RIS, P72; Lacey JV, 1999, CANCER EPIDEM BIOMAR, V8, P1079; MARTIN CE, 1967, AM J PUBLIC HEALTH N, V57, P803, DOI 10.2105/AJPH.57.5.803; Parazzini F, 1998, BRIT J CANCER, V77, P838, DOI 10.1038/bjc.1998.136; Parkin DM, 1999, INT J CANCER, V80, P827, DOI 10.1002/(SICI)1097-0215(19990315)80:6&lt;827::AID-IJC6&gt;3.0.CO;2-P; Peduzzi P, 1996, J CLIN EPIDEMIOL, V49, P1373, DOI 10.1016/S0895-4356(96)00236-3; SCHIFFMAN MH, 1995, CANCER-AM CANCER SOC, V76, P1888, DOI 10.1002/1097-0142(19951115)76:10+<1888::AID-CNCR2820761305>3.0.CO;2-H; SKEGG DCG, 1982, LANCET, V2, P581; SKEGG DCG, 1994, CONTRACEPTION, V49, P435, DOI 10.1016/0010-7824(94)90002-7; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; Woodman CBJ, 2001, LANCET, V357, P1831, DOI 10.1016/S0140-6736(00)04956-4	17	22	28	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 30	2002	359	9312					1080	1081		10.1016/S0140-6736(02)08125-4	http://dx.doi.org/10.1016/S0140-6736(02)08125-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	536YJ	11943251				2022-12-28	WOS:000174729200002
J	Coussens, LM; Fingleton, B; Matrisian, LM				Coussens, LM; Fingleton, B; Matrisian, LM			Cancer therapy - Matrix metalloproteinase inhibitors and cancer: Trials and tribulations	SCIENCE			English	Review							B16-F10 MELANOMA-CELLS; TISSUE INHIBITOR; IN-VIVO; INTESTINAL TUMORIGENESIS; BREAST-CANCER; MICE; CARCINOGENESIS; METASTASIS; EXPRESSION; MARIMASTAT	For at least 30 years, matrix metalloproteinases (MMPs) have been heralded as promising targets for cancer therapy on the basis of their massive up-regulation in malignant tissues and their unique ability to degrade all components of the extracellular matrix. Preclinical studies testing the efficacy of MMP suppression in tumor models were so compelling that synthetic metalloproteinase inhibitors (MPIs) were rapidly developed and routed into human clinical trials. The results of these trials have been disappointing. Here we review the studies that brought MPIs into clinical testing and discuss the design and outcome of the trials in tight of new information about the cellular source, substrates, and mode of action of MMPs at different stages of tumor progression. The important lessons learned from the MPI experience may be of great value for future studies of MPIs and for cancer drug development in general.	Vanderbilt Univ, Dept Canc Biol, Nashville, TN 37232 USA; Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94143 USA	Vanderbilt University; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Matrisian, LM (corresponding author), Vanderbilt Univ, Dept Canc Biol, 221 Kirkland Hall, Nashville, TN 37232 USA.		Coussens, Lisa/ABH-9834-2020		NATIONAL CANCER INSTITUTE [R01CA084360, P01CA072006, P50CA090949, R01CA060867, P30CA068485] Funding Source: NIH RePORTER; NCI NIH HHS [CA72006, P50CA90949, P30CA68485, R01CA60867, R01CA84360] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALVAREZ OA, 1990, J NATL CANCER I, V82, P589, DOI 10.1093/jnci/82.7.589; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Bergers G, 1999, SCIENCE, V284, P808, DOI 10.1126/science.284.5415.808; BIRD J, 1998, CHEM ABSTR 22571, V129; Bramhall SR, 2001, J CLIN ONCOL, V19, P3447, DOI 10.1200/JCO.2001.19.15.3447; Bremer C, 2001, NAT MED, V7, P743, DOI 10.1038/89126; Brown PD, 2000, EXPERT OPIN INV DRUG, V9, P2167, DOI 10.1517/13543784.9.9.2167; Buck TB, 1999, ANN NY ACAD SCI, V878, P732, DOI 10.1111/j.1749-6632.1999.tb07775.x; Cianfrocca M, 2002, J CLIN ONCOL, V20, P153, DOI 10.1200/JCO.20.1.153; Coussens LM, 2000, CELL, V103, P481, DOI 10.1016/S0092-8674(00)00139-2; DARMIENTO J, 1995, MOL CELL BIOL, V15, P5732; DECLERCK YA, 1994, EUR J CANCER, V30A, P2170, DOI 10.1016/0959-8049(94)00460-M; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Druker BJ, 2000, J CLIN INVEST, V105, P3, DOI 10.1172/JCI9083; FIELDING J, 2000, P AN M AM SOC CLIN, V19, pA240; Glasspool RM, 2000, EUR J CANCER, V36, P1661, DOI 10.1016/S0959-8049(00)00154-4; Gore M, 1996, LANCET, V348, P263, DOI 10.1016/S0140-6736(96)24030-9; Goss KJH, 1998, INT J CANCER, V78, P629; Hidalgo M, 2001, JNCI-J NATL CANCER I, V93, P178, DOI 10.1093/jnci/93.3.178; KHOKHA R, 1989, SCIENCE, V243, P947, DOI 10.1126/science.2465572; KHOKHA R, 1994, J NATL CANCER I, V86, P299, DOI 10.1093/jnci/86.4.299; KOOP S, 1994, CANCER RES, V54, P4791; Kruger A, 2001, CANCER RES, V61, P1272; Louie AY, 2000, NAT BIOTECHNOL, V18, P321, DOI 10.1038/73780; Mark D, 2000, EMERGING THERAPEUTIC, V4, P609, DOI DOI 10.1517/14728222.4.5.609; Martin DC, 1996, ONCOGENE, V13, P569; Masson R, 1998, J CELL BIOL, V140, P1535, DOI 10.1083/jcb.140.6.1535; McCawley LJ, 2000, MOL MED TODAY, V6, P149, DOI 10.1016/S1357-4310(00)01686-5; McCawley LJ, 2001, CURR OPIN CELL BIOL, V13, P534, DOI 10.1016/S0955-0674(00)00248-9; Michael M, 1999, J CLIN ONCOL, V17, P1802, DOI 10.1200/JCO.1999.17.6.1802; MONTGOMERY AMP, 1994, CANCER RES, V54, P5467; MOORE M, 2001, P AM SOC CLIN ONCOL, V19, pA240; Nelson AR, 2000, J CLIN ONCOL, V18, P1135, DOI 10.1200/JCO.2000.18.5.1135; Nemunaitis J, 1998, CLIN CANCER RES, V4, P1101; Pozzi A, 2000, P NATL ACAD SCI USA, V97, P2202, DOI 10.1073/pnas.040378497; Pozzi A, 2002, ONCOGENE, V21, P272, DOI 10.1038/sj.onc.1205045; Primrose JN, 1999, BRIT J CANCER, V79, P509, DOI 10.1038/sj.bjc.6690079; REICH R, 1988, CANCER RES, V48, P3307; Rosemurgy A, 1999, AM J CLIN ONCOL-CANC, V22, P247, DOI 10.1097/00000421-199906000-00007; Rudolph-Owen LA, 1998, CANCER RES, V58, P5500; SCHULTZ RM, 1988, CANCER RES, V48, P5539; SLEDGE GW, 1995, J NATL CANCER I, V87, P1546, DOI 10.1093/jnci/87.20.1546; Sternlicht MD, 1999, CELL, V98, P137, DOI 10.1016/S0092-8674(00)81009-0; Stetler-Stevenson WG, 1999, J CLIN INVEST, V103, P1237, DOI 10.1172/JCI6870; StetlerStevenson WG, 1996, AM J PATHOL, V148, P1345; Whittaker M, 1999, CHEM REV, V99, P2735, DOI 10.1021/cr9804543; Wilson CL, 1997, P NATL ACAD SCI USA, V94, P1402, DOI 10.1073/pnas.94.4.1402; WOESSNER JF, 2000, MATRIX METALLOPROTEI; Wynn R L, 1999, Gen Dent, V47, P19	49	2213	2309	4	313	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 29	2002	295	5564					2387	2392		10.1126/science.1067100	http://dx.doi.org/10.1126/science.1067100			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	536QD	11923519				2022-12-28	WOS:000174712600035
J	Abbott, A				Abbott, A			Babies' cancer screens 'not needed'	NATURE			English	News Item																			0	0	0	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 28	2002	416	6879					356	356		10.1038/416356b	http://dx.doi.org/10.1038/416356b			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	534UX	11919591	Bronze			2022-12-28	WOS:000174607800009
J	Cohn, MJ				Cohn, MJ			Evolutionary biology - Lamprey Hox genes and the origin of jaws	NATURE			English	Article							NEURAL CREST; LAMPETRA-JAPONICA; EXPRESSION		Univ Reading, Sch Anim & Microbial Sci, Div Zool, Reading RG6 6AJ, Berks, England	University of Reading	Cohn, MJ (corresponding author), Univ Reading, Sch Anim & Microbial Sci, Div Zool, Reading RG6 6AJ, Berks, England.							Alexandre D, 1996, DEVELOPMENT, V122, P735; Grammatopoulos GA, 2000, DEVELOPMENT, V127, P5355; Horigome N, 1999, DEV BIOL, V207, P287, DOI 10.1006/dbio.1998.9175; Janvier P., 1996, EARLY VERTEBRATES; LANGILLE RM, 1988, DEVELOPMENT, V102, P301; Myojin M, 2001, J EXP ZOOL, V291, P68, DOI 10.1002/jez.6; Neidert AH, 2001, P NATL ACAD SCI USA, V98, P1665, DOI 10.1073/pnas.98.4.1665; NEWTH DR, 1951, J EXP BIOL, V28, P247; Ogasawara M, 2000, DEV BIOL, V223, P399, DOI 10.1006/dbio.2000.9756; Pasqualetti M, 2000, DEVELOPMENT, V127, P5367; Schilling TF, 2001, DEV BIOL, V231, P201, DOI 10.1006/dbio.2000.9997; Trainor PA, 2000, NAT REV NEUROSCI, V1, P116, DOI 10.1038/35039056; Wada H, 1999, DEV BIOL, V213, P131, DOI 10.1006/dbio.1999.9369	13	71	77	3	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 28	2002	416	6879					386	387		10.1038/416386a	http://dx.doi.org/10.1038/416386a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	534UX	11919618				2022-12-28	WOS:000174607800033
J	Galea, S; Ahern, J; Resnick, H; Kilpatrick, D; Bucuvalas, M; Gold, J; Vlahov, D				Galea, S; Ahern, J; Resnick, H; Kilpatrick, D; Bucuvalas, M; Gold, J; Vlahov, D			Psychological sequelae of the September 11 terrorist attacks in New York City.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POSTTRAUMATIC-STRESS-DISORDER; NATIONAL COMORBIDITY SURVEY; MAJOR DEPRESSION; NATURAL DISASTER; SOCIAL SUPPORT; OKLAHOMA-CITY; PREVALENCE; PSYCHOPATHOLOGY; SURVIVORS; SYMPTOMS	Background: The scope of the terrorist attacks of September 11, 2001, was unprecedented in the United States. We assessed the prevalence and correlates of acute post-traumatic stress disorder (PTSD) and depression among residents of Manhattan five to eight weeks after the attacks. Methods: We used random-digit dialing to contact a representative sample of adults living south of 110th Street in Manhattan. Participants were asked about demographic characteristics, exposure to the events of September 11, and psychological symptoms after the attacks. Results: Among 1008 adults interviewed, 7.5 percent reported symptoms consistent with a diagnosis of current PTSD related to the attacks, and 9.7 percent reported symptoms consistent with current depression (with ``current`` defined as occurring within the previous 30 days). Among respondents who lived south of Canal Street (i.e., near the World Trade Center), the prevalence of PTSD was 20.0 percent. Predictors of PTSD in a multivariate model were Hispanic ethnicity, two or more prior stressors, a panic attack during or shortly after the events, residence south of Canal Street, and loss of possessions due to the events. Predictors of depression were Hispanic ethnicity, two or more prior stressors, a panic attack, a low level of social support, the death of a friend or relative during the attacks, and loss of a job due to the attacks. Conclusions: There was a substantial burden of acute PTSD and depression in Manhattan after the September 11 attacks. Experiences involving exposure to the attacks were predictors of current PTSD, and losses as a result of the events were predictors of current depression. In the aftermath of terrorist attacks, there may be substantial psychological morbidity in the population. (N Engl J Med 2002;346:982-7.) Copyright (C) 2002 Massachusetts Medical Society.	New York Acad Med, Ctr Urban Epidemiol Studies, New York, NY 10029 USA; Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA; Med Univ S Carolina, Natl Crime Victims Res & Treatment Ctr, Charleston, SC 29425 USA; Schulman Ronca & Bucuvalas, New York, NY USA; Bellevue Hosp Ctr, New York, NY 10016 USA	New York Academy of Medicine; Columbia University; Medical University of South Carolina; Bellevue Hospital Center	Galea, S (corresponding author), New York Acad Med, Ctr Urban Epidemiol Studies, Rm 556,1216 5th Ave, New York, NY 10029 USA.		Galea, Sandro/GLR-6066-2022	Galea, Sandro/0000-0002-7534-0945; Ahern, Jennifer/0000-0002-3853-9760	NATIONAL INSTITUTE ON DRUG ABUSE [R01DA014219] Funding Source: NIH RePORTER; NIDA NIH HHS [R01 DA14219-01S1] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; BLAZER DG, 1994, AM J PSYCHIAT, V151, P979; *DEP HLTH HUMAN SE, 1999, MENT HLTH REP SURG G; Eaton L, 2001, NY TIMES, pA1; Fothergill A, 1999, DISASTERS, V23, P156, DOI 10.1111/1467-7717.00111; Fullerton CS, 1999, AVIAT SPACE ENVIR MD, V70, P902; Ginexi EM, 2000, AM J COMMUN PSYCHOL, V28, P495, DOI 10.1023/A:1005188515149; Goenjian AK, 2001, AM J PSYCHIAT, V158, P788, DOI 10.1176/appi.ajp.158.5.788; GREEN BL, 1990, J APPL SOC PSYCHOL, V20, P1033, DOI 10.1111/j.1559-1816.1990.tb00388.x; HANSON RF, 1995, J CONSULT CLIN PSYCH, V63, P987, DOI 10.1037/0022-006X.63.6.987; Harvey AG, 1999, J CONSULT CLIN PSYCH, V67, P985, DOI 10.1037/0022-006X.67.6.985; Kawachi I, 2001, J URBAN HEALTH, V78, P458, DOI 10.1093/jurban/78.3.458; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; KILPATRICK DG, 1987, CRIME DELINQUENCY, V33, P479, DOI 10.1177/0011128787033004005; MADAKASIRA S, 1987, J NERV MENT DIS, V175, P286, DOI 10.1097/00005053-198705000-00008; Mazure CM, 2000, AM J PSYCHIAT, V157, P896, DOI 10.1176/appi.ajp.157.6.896; North CS, 1999, JAMA-J AM MED ASSOC, V282, P755, DOI 10.1001/jama.282.8.755; Ortega AN, 2000, AM J PSYCHIAT, V157, P615, DOI 10.1176/appi.ajp.157.4.615; Pole N, 2001, J NERV MENT DIS, V189, P442, DOI 10.1097/00005053-200107000-00005; Resnick H, 1999, J ANXIETY DISORD, V13, P359, DOI 10.1016/S0887-6185(99)00010-9; RESNICK HS, 1993, J CONSULT CLIN PSYCH, V61, P984, DOI 10.1037/0022-006X.61.6.984; ROTHBAUM BO, 1992, J TRAUMA STRESS, V5, P455, DOI 10.1007/BF00977239; RUBONIS AV, 1991, PSYCHOL BULL, V109, P384, DOI 10.1037/0033-2909.109.3.384; Ruef A M, 2000, Cultur Divers Ethnic Minor Psychol, V6, P235, DOI 10.1037/1099-9809.6.3.235; Shah BV, 1997, SUDAAN USERS MANUAL; Shalev AY, 1998, AM J PSYCHIAT, V155, P630, DOI 10.1176/ajp.155.5.630; Shalev AY, 2000, J CLIN PSYCHIAT, V61, P33; SHERBOURNE CD, 1991, SOC SCI MED, V32, P705, DOI 10.1016/0277-9536(91)90150-B; SHORE JH, 1989, J NERV MENT DIS, V177, P681, DOI 10.1097/00005053-198911000-00004; Tucker P, 2000, J BEHAV HEALTH SER R, V27, P406, DOI 10.1007/BF02287822; *US BUR CENS, 2000, STF3A DEP COMM BUR C; 2001, NY TIMES        1226, pB2	32	1192	1212	3	129	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 28	2002	346	13					982	987		10.1056/NEJMsa013404	http://dx.doi.org/10.1056/NEJMsa013404			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	534UY	11919308	Green Published			2022-12-28	WOS:000174608600006
J	Studer, SM; Terry, PB				Studer, SM; Terry, PB			Bronchial cast.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Mt Sinai Med Ctr, New York, NY 10029 USA; Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA	Icahn School of Medicine at Mount Sinai; Johns Hopkins University; Johns Hopkins Medicine	Studer, SM (corresponding author), Mt Sinai Med Ctr, New York, NY 10029 USA.								0	8	8	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 28	2002	346	13					981	981		10.1056/NEJMicm010283	http://dx.doi.org/10.1056/NEJMicm010283			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	534UY	11919307				2022-12-28	WOS:000174608600005
J	Rhodes, M; Newman, C; Read, S				Rhodes, M; Newman, C; Read, S			National service framework for coronary heart disease: audit of English hospitals	BRITISH MEDICAL JOURNAL			English	Article									St Martins Coll, Dept Nursing Studies, Carlisle CA1 2HH, England; Univ Sheffield, No Gen Hosp, Ctr Clin Sci, Sheffield S5 7AU, S Yorkshire, England; Univ Sheffield, Sch Nursing & Midwifery, Sheffield S10 2HL, S Yorkshire, England	University of Cumbria; Northern General Hospital; University of Sheffield; University of Sheffield	Rhodes, M (corresponding author), St Martins Coll, Dept Nursing Studies, Carlisle CA1 2HH, England.							*DEP HLTH, 2000, NAT SERV FRAM COR HE; *NHS CONF, 1999, BINL DIR NHS MAN	2	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 23	2002	324	7339					709	709		10.1136/bmj.324.7339.709	http://dx.doi.org/10.1136/bmj.324.7339.709			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	535ML	11909788	Green Published, Bronze			2022-12-28	WOS:000174648200019
J	Frischmeyer, PA; van Hoof, A; O'Donnell, K; Guerrerio, AL; Parker, R; Dietz, HC				Frischmeyer, PA; van Hoof, A; O'Donnell, K; Guerrerio, AL; Parker, R; Dietz, HC			An mRNA surveillance mechanism that eliminates transcripts lacking termination codons	SCIENCE			English	Article							MESSENGER-RNA TURNOVER; SACCHAROMYCES-CEREVISIAE; POLYADENYLATION SIGNAL; YEAST; GENE; DEGRADATION; SITE; DEADENYLATION; DETERMINANTS; STABILITY	Translation is an important mechanism to monitor the quality of messenger RNAs (mRNAs), as exemplified by the translation-dependent recognition and degradation of transcripts harboring premature termination codons (PTCs) by the nonsense-mediated mRNA decay (NMD) pathway. We demonstrate in yeast that mRNAs lacking all termination codons are as labile as nonsense transcripts. Decay of "nonstop" transcripts in yeast requires translation but is mechanistically distinguished from NMD and the major mRNA turnover pathway that requires deadenylation, decapping, and 5'-to-3' exonucleotytic decay. These data suggest that nonstop decay is initiated when the ribosome reaches the 3' terminus of the message. We demonstrate multiple physiologic sources of nonstop transcripts and conservation of their accelerated decay in mammalian cells. This process regulates the stability and expression of mRNAs that fail to signal translational termination.	Johns Hopkins Univ, Sch Med, Inst Med Genet, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Biophys & Biophys Chem, Baltimore, MD 21205 USA; Univ Arizona, Dept Mol & Cellular Biol, Tucson, AZ 85721 USA; Howard Hughes Med Inst, Coconut Grove, FL 33133 USA	Johns Hopkins University; Johns Hopkins University; University of Arizona; Howard Hughes Medical Institute	Dietz, HC (corresponding author), Johns Hopkins Univ, Sch Med, Inst Med Genet, Baltimore, MD 21205 USA.		Guerrerio, Anthony/T-2632-2019; Guerrerio, Pamela/S-9360-2019	Guerrerio, Anthony/0000-0003-2458-7160; van Hoof, Ambro/0000-0002-7800-9764	NIGMS NIH HHS [GM55239] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055239] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Audibert A, 1998, P NATL ACAD SCI USA, V95, P14302, DOI 10.1073/pnas.95.24.14302; Beelman CA, 1996, NATURE, V382, P642, DOI 10.1038/382642a0; BELGRADER P, 1994, MOL CELL BIOL, V14, P8219, DOI 10.1128/MCB.14.12.8219; Caponigro G, 1996, MICROBIOL REV, V60, P233, DOI 10.1128/MMBR.60.1.233-249.1996; CAPONIGRO G, 1995, GENE DEV, V9, P2421, DOI 10.1101/gad.9.19.2421; CHEN F, 1995, NUCLEIC ACIDS RES, V23, P2614, DOI 10.1093/nar/23.14.2614; CUI Y, 1995, GENE DEV, V9, P423, DOI 10.1101/gad.9.4.423; Graber JH, 1999, P NATL ACAD SCI USA, V96, P14055, DOI 10.1073/pnas.96.24.14055; Graber JH, 1999, NUCLEIC ACIDS RES, V27, P888, DOI 10.1093/nar/27.3.888; HILGER C, 1991, J VIROL, V65, P4284, DOI 10.1128/JVI.65.8.4284-4291.1991; Karzai AW, 2000, NAT STRUCT BIOL, V7, P449; Keiler KC, 1996, SCIENCE, V271, P990, DOI 10.1126/science.271.5251.990; Kessler O, 1996, MOL CELL BIOL, V16, P4426; LEEDS P, 1992, MOL CELL BIOL, V12, P2165, DOI 10.1128/MCB.12.5.2165; MUHLRAD D, 1994, GENE DEV, V8, P855, DOI 10.1101/gad.8.7.855; MUHLRAD D, 1994, NATURE, V370, P578, DOI 10.1038/370578a0; OLDHAM ER, 1993, MOL ENDOCRINOL, V7, P1379, DOI 10.1210/me.7.11.1379; Sparks KA, 1997, MOL CELL BIOL, V17, P4199, DOI 10.1128/MCB.17.8.4199; Sparks KA, 1998, NUCLEIC ACIDS RES, V26, P4676, DOI 10.1093/nar/26.20.4676; Tucker M, 2001, CELL, V104, P377, DOI 10.1016/S0092-8674(01)00225-2; van Hoof A, 2002, SCIENCE, V295, P2262, DOI 10.1126/science.1067272; WANG XM, 1995, MOL CELL BIOL, V15, P1769; WEISS IM, 1994, MOL CELL BIOL, V14, P8123, DOI 10.1128/MCB.14.12.8123; Wolfe CL, 1996, J BIOL CHEM, V271, P4679	24	402	416	0	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 22	2002	295	5563					2258	2261		10.1126/science.1067338	http://dx.doi.org/10.1126/science.1067338			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	534AD	11910109				2022-12-28	WOS:000174561700043
J	Izumi, Y; Xu, L; di Tomaso, E; Fukumura, D; Jain, RK				Izumi, Y; Xu, L; di Tomaso, E; Fukumura, D; Jain, RK			Tumor biology - Herceptin acts as an anti-angiogenic cocktail	NATURE			English	Article									Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiat Oncol,Edwin L Steele Lab, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital	Izumi, Y (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiat Oncol,Edwin L Steele Lab, Boston, MA 02114 USA.		Mieszkowska, Magdalena/O-6753-2017; Jain, Rakesh K/I-1384-2017; Xu, Lei/GRR-9174-2022	Jain, Rakesh K/0000-0001-7571-3548; 	NATIONAL CANCER INSTITUTE [P01CA080124] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA080124] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allgayer H, 2000, J CLIN ONCOL, V18, P2201, DOI 10.1200/JCO.2000.18.11.2201; Bornstein P, 2001, J CLIN INVEST, V107, P929, DOI 10.1172/JCI12749; Fidler IJ, 2001, JNCI-J NATL CANCER I, V93, P1040, DOI 10.1093/jnci/93.14.1040; Fukumura D, 1998, CELL, V94, P715, DOI 10.1016/S0092-8674(00)81731-6; Jain RK, 2001, SCI AM, V285, P38, DOI 10.1038/scientificamerican1201-38; Jain RK, 2001, NAT MED, V7, P987, DOI 10.1038/nm0901-987; JAIN RK, IN PRESS NATURE REV; Kerbel RS, 2000, EUR J CANCER, V36, P1248, DOI 10.1016/S0959-8049(00)00092-7; Nicolini G, 1996, J BIOL CHEM, V271, P30290, DOI 10.1074/jbc.271.47.30290; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Thurston G, 1999, SCIENCE, V286, P2511, DOI 10.1126/science.286.5449.2511; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073	12	507	543	0	36	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 21	2002	416	6878					279	280		10.1038/416279b	http://dx.doi.org/10.1038/416279b			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	532NP	11907566				2022-12-28	WOS:000174482200031
J	Xu, X; Makovicky, PJ; Wang, XL; Norell, MA; You, HL				Xu, X; Makovicky, PJ; Wang, XL; Norell, MA; You, HL			A Ceratopsian dinosaur from China and the early evolution of Ceratopsia	NATURE			English	Article								Ceratopsians (horned dinosaurs) represent one of the last and the most diverse radiations of non-avian dinosaurs(1-4). Although recent systematic work unanimously supports a basal division of Ceratopsia into parrot-like psittacosaurids and frilled neoceratopsians, the early evolution of the group remains poorly understood, mainly owing to its incomplete early fossil record. Here we describe a primitive ceratopsian from China. Cladistic analysis posits this new species as the most basal neoceratopsian. This new taxon demonstrates that some neoceratopsian characters evolved in a more incremental fashion than previously known and also implies mosaic evolution of characters early in ceratopsian history.	Chinese Acad Sci, Inst Vertebrate Paleontol & Paleoanthropol, Beijing 100044, Peoples R China; Field Museum, Chicago, IL 60605 USA; Amer Museum Nat Hist, New York, NY 10024 USA	Chinese Academy of Sciences; Institute of Vertebrate Paleontology & Paleoanthropology, CAS; Field Museum of Natural History (Chicago); American Museum of Natural History (AMNH)	Xu, X (corresponding author), Chinese Acad Sci, Inst Vertebrate Paleontol & Paleoanthropol, Beijing 100044, Peoples R China.			You, Hai-Lu/0000-0003-2203-6461				Bohlin B., 1953, FOSSIL REPTILES MONG; BROWN BARNUM, 1940, ANN NEW YORK ACAD SCI, V40, P133; Chinnery BJ, 1998, J VERTEBR PALEONTOL, V18, P569, DOI 10.1080/02724634.1998.10011085; COOMBS WP, 1982, PALAEONTOLOGY, V25, P89; Dodson P., 1990, P593; DODSON P, 1976, J PALEONTOL, V50, P929; Dodson P, 1997, ENCY DINOSAURS, P473; Dong Zhiming, 1997, P68; Lo Ching-Hua, 1999, Palaeoworld, V11, P328; MAKOVICKY PJ, 2000, MESOZOIC TERRESTRIAL, P243; MARYANSKA T, 1975, Palaeontologia Polonica, V33, P133; SERENO P, 1997, ANN REV EARTH PLANET, V25, P234; Sereno P.C., 1990, P203, DOI 10.1017/CBO9780511608377.018; SERRENO PC, 2000, AGE DINOSAURS RUSSIA, P480; Sternberg CM, 1951, NATIONAL MUSEUM CANA, V123, P225; Swisher C.C., 2001, CHINESE SCI BULL, V46, P2009; Xu Xing, 2000, Vertebrata Palasiatica, V38, P318; Zhao XJ, 1999, J VERTEBR PALEONTOL, V19, P681	18	84	97	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 21	2002	416	6878					314	317		10.1038/416314a	http://dx.doi.org/10.1038/416314a			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	532NP	11907575				2022-12-28	WOS:000174482200040
J	Onder, G; Penninx, BWJH; Balkrishnan, R; Fried, LP; Chaves, PHM; Williamson, J; Carter, C; Di Bari, M; Guralnik, JM; Pahor, M				Onder, G; Penninx, BWJH; Balkrishnan, R; Fried, LP; Chaves, PHM; Williamson, J; Carter, C; Di Bari, M; Guralnik, JM; Pahor, M			Relation between use of angiotensin-converting enzyme inhibitors and muscle strength and physical function in older women: an observational study	LANCET			English	Article							SKELETAL-MUSCLE; HEART-FAILURE; HEALTH; DISABILITY; PERFORMANCE; ASSOCIATION; ACTIVATION; PREVENTION; CYTOKINES; COMMUNITY	Background Angiotensin-converting enzyme (ACE) inhibitors prevent decline in physical function in patients with congestive heart failure (CHF). We aimed to see whether ACE inhibitors also prevent reduction in physical performance and in muscle strength in older women who do not have CHF. Methods We assessed 3-year rates of decline in both knee extensor muscle strength and walking speed in 641 women with hypertension who had participated in the Women's Health and Aging Study. Women were stratified into four groups according to type and duration of antihypertensive drug treatment. 61 had used ACE inhibitors continuously, 133 intermittently, 146 never, and 301 had used other hypertensive drugs either continuously or intermittently. Findings Participants who had taken ACE inhibitors continuously had a lower mean 3-year decline in muscle strength of -1.0 kg (SE 1.1) compared with -3.7 (0.5) kg in continuous/intermittent users of other anti hypertensive drugs (p=0.016) and with -3.9 kg in those who had never used antihypertensives (p=0.026). Muscle strength fell by 3.0 kg in 3 years in both continuous and intermittent users of ACE inhibitors (p=0.096). Mean 3-year decline in walking speed in continuous ACE inhibitor users was -1.7 cm/s compared with -13.6 cm/s in intermittent users of ACE inhibitors (p=0.015), -15.7 cm/s in continuous/intermittent users of other anti hypertensive drugs (p=0.002), and -17.9 cm/s in never users of anti hypertensive drugs (p=0.001). Interpretation ACE inhibitor treatment may halt or slow decline in muscle strength in elderly women with hypertension and without CHF.	Wake Forest Univ, Baptist Med Ctr, Sticht Ctr Aging, Sect Gerontol & Geriatr,Dept Internal Med,Sch Med, Winston Salem, NC 27157 USA; Univ Cattolica Sacro Cuore, Ctr Med Invecchiamento, Rome, Italy; Johns Hopkins Med Inst, Dept Med, Baltimore, MD 21205 USA; Johns Hopkins Med Inst, Dept Epidemiol, Baltimore, MD 21205 USA; NIA, Epidemiol Demog & Biometry Program, Bethesda, MD 20892 USA	Wake Forest University; Wake Forest Baptist Medical Center; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Onder, G (corresponding author), Wake Forest Univ, Baptist Med Ctr, Sticht Ctr Aging, Sect Gerontol & Geriatr,Dept Internal Med,Sch Med, Med Ctr Blvd, Winston Salem, NC 27157 USA.	gonder@wfubmc.edu	Balkrishnan, Rajesh/L-4015-2019; Penninx, Brenda WJH/S-7627-2017; Chaves, Paulo/D-5878-2016; Carter, Christy/A-6828-2011; Carter, Christy/E-6630-2011; DI BARI, MAURO/J-1524-2012	Penninx, Brenda WJH/0000-0001-7779-9672; Chaves, Paulo/0000-0001-8013-7928; DI BARI, MAURO/0000-0002-5514-0524	NATIONAL INSTITUTE ON AGING [P60AG010484, N01AG012112] Funding Source: NIH RePORTER; NIA NIH HHS [N01AG12112, 5P60 AG 10484-07] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bandinelli S, 1999, AGING-CLIN EXP RES, V11, P287, DOI 10.1007/BF03339802; Cohen HJ, 1997, J GERONTOL A-BIOL, V52, pM201, DOI 10.1093/gerona/52A.4.M201; Dagenais GR, 2001, CIRCULATION, V104, P522, DOI 10.1161/hc3001.093502; DE CR, 1995, J CLIN INVEST, V96, P60; Di Bari M, 2000, CIRCULATION, V102, P843; Ferrucci L, 1997, JAMA-J AM MED ASSOC, V277, P728; Ferrucci L, 1999, J AM GERIATR SOC, V47, P639, DOI 10.1111/j.1532-5415.1999.tb01583.x; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gambassi G, 2000, ARCH INTERN MED, V160, P53, DOI 10.1001/archinte.160.1.53; Guralnik JM, 2000, J GERONTOL A-BIOL, V55, pM221, DOI 10.1093/gerona/55.4.M221; Guralnik JM, 1999, J GERONTOL A-BIOL, V54, pM410, DOI 10.1093/gerona/54.8.M410; GURALNIK JM, 2001, WOMENS HLTH AGING ST; Han YQ, 1999, CIRC RES, V84, P695, DOI 10.1161/01.RES.84.6.695; Henriksen EJ, 1999, AM J PHYSIOL-REG I, V277, pR332, DOI 10.1152/ajpregu.1999.277.1.R332; Hespel P, 1996, DIABETES, V45, pS99, DOI 10.2337/diab.45.1.S99; HYATT RH, 1990, AGE AGEING, V19, P330, DOI 10.1093/ageing/19.5.330; Kasper JD, 1999, ANN EPIDEMIOL, V9, P498, DOI 10.1016/S1047-2797(99)00026-5; Kranzhofer R, 1999, ARTERIOSCL THROM VAS, V19, P1623, DOI 10.1161/01.ATV.19.7.1623; LEVENS NR, 1986, J CARDIOVASC PHARM, V8, pS17, DOI 10.1097/00005344-198600101-00005; Moldawer LL, 1997, CANCER-AM CANCER SOC, V79, P1828; Montgomery H, 1999, LANCET, V353, P541, DOI 10.1016/S0140-6736(98)07131-1; Noguchi Y, 1996, SURG TODAY, V26, P467, DOI 10.1007/BF00311551; Parmley William W., 1998, American Journal of Medicine, V105, p27S, DOI 10.1016/S0002-9343(98)00208-3; Peeters ACTM, 1998, IMMUNOLOGY, V94, P376, DOI 10.1046/j.1365-2567.1998.00524.x; PSATY BM, 1992, J CLIN EPIDEMIOL, V45, P683, DOI 10.1016/0895-4356(92)90143-B; Rantanen T, 1999, ARCH PHYS MED REHAB, V80, P130, DOI 10.1016/S0003-9993(99)90109-0; Roubenoff R, 2000, J Nutr Health Aging, V4, P140; Schaufelberger M, 1996, EUR HEART J, V17, P1678; SCHIEFFER B, 1995, AM J PHYSIOL-HEART C, V269, pH1507, DOI 10.1152/ajpheart.1995.269.5.H1507; Schroll M, 1997, AGING-CLIN EXP RES, V9, P143, DOI 10.1007/BF03340140; Ustun TB, 1999, LANCET, V354, P111, DOI 10.1016/S0140-6736(98)07507-2; Vescovo G, 1998, CIRCULATION, V98, P1742, DOI 10.1161/01.CIR.98.17.1742; Visser M, 2000, J AM GERIATR SOC, V48, P381, DOI 10.1111/j.1532-5415.2000.tb04694.x; Williams AG, 2000, NATURE, V403, P614, DOI 10.1038/35001141; Woods D, 2001, J CLIN ENDOCR METAB, V86, P2200, DOI 10.1210/jc.86.5.2200	35	228	235	2	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 16	2002	359	9310					926	930		10.1016/S0140-6736(02)08024-8	http://dx.doi.org/10.1016/S0140-6736(02)08024-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	531AE	11918911				2022-12-28	WOS:000174391700011
J	Ruggeri, L; Capanni, M; Urbani, E; Perruccio, K; Shlomchik, WD; Tosti, A; Posati, S; Rogaia, D; Frassoni, F; Aversa, F; Martelli, MF; Velardi, A				Ruggeri, L; Capanni, M; Urbani, E; Perruccio, K; Shlomchik, WD; Tosti, A; Posati, S; Rogaia, D; Frassoni, F; Aversa, F; Martelli, MF; Velardi, A			Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants	SCIENCE			English	Article							LEUKEMIA; STIMULATION; REJECTION	T cells that accompany allogeneic hematopoietic grafts for treating leukemia enhance engraftment and mediate the graft-versus-leukemia effect. Unfortunatety, alloreactive T cells also cause graft-versus-host disease (GVHD). T cell depletion prevents GVHD but increases the risk of graft rejection and leukemic relapse. in human transplants, we show that donor-versus-recipient natural killer (NK)-cell alloreactivity could eliminate leukemia relapse and graft rejection and protect patients against GVHD. In mice, the pretransplant infusion of alloreactive NK cells obviated the need for high-intensity conditioning and reduced GVHD. NK cell alloreactivity may thus provide a powerful tool. for enhancing the efficacy and safety of allogeneic hematopoietic transplantation.	Univ Perugia, Sch Med, Dept Clin & Expt Med, Sect Hematol & Clin Immunol, I-06100 Perugia, Italy; Yale Univ, Sch Med, Dept Med, Sect Hematol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Sect Oncol, New Haven, CT 06520 USA; Osped San Martino Genova, Dept Hematol, Genoa, Italy	University of Perugia; Yale University; Yale University; University of Genoa; IRCCS AOU San Martino IST	Velardi, A (corresponding author), Univ Perugia, Sch Med, Dept Clin & Expt Med, Sect Hematol & Clin Immunol, I-06100 Perugia, Italy.	velardi@unipg.it	Perruccio, Katia/ABF-8021-2020; Frassoni, Francesco/K-3971-2018	Frassoni, Francesco/0000-0003-1262-0648; Aversa, Franco/0000-0002-8871-6817	NHLBI NIH HHS [HL03979] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AVERSA F, 1994, BLOOD, V84, P3948, DOI 10.1182/blood.V84.11.3948.bloodjournal84113948; Aversa F, 1998, NEW ENGL J MED, V339, P1186, DOI 10.1056/NEJM199810223391702; BACHARLUSTIG E, 1995, NAT MED, V1, P1268, DOI 10.1038/nm1295-1268; BELLONE G, 1993, J EXP MED, V177, P1117, DOI 10.1084/jem.177.4.1117; CICCONE E, 1992, J EXP MED, V175, P709, DOI 10.1084/jem.175.3.709; CICCONE E, 1992, J EXP MED, V176, P963, DOI 10.1084/jem.176.4.963; COLONNA M, 1993, P NATL ACAD SCI USA, V90, P12000, DOI 10.1073/pnas.90.24.12000; COLONNA M, 1993, SCIENCE, V260, P1121, DOI 10.1126/science.8493555; GIRALT S, 2000, NONMYELOABLATIVE STE; KARRE K, 1986, NATURE, V319, P675, DOI 10.1038/319675a0; KOSAKA H, 1992, J EXP MED, V176, P1291, DOI 10.1084/jem.176.5.1291; Lanier LL, 1998, ANNU REV IMMUNOL, V16, P359, DOI 10.1146/annurev.immunol.16.1.359; Martelli MF, 2002, SEMIN HEMATOL, V39, P48, DOI 10.1053/shem.2002.29255; Moretta A, 1997, CURR OPIN IMMUNOL, V9, P694, DOI 10.1016/S0952-7915(97)80051-9; OHLEN C, 1989, SCIENCE, V246, P666, DOI 10.1126/science.2814488; Reisner Y, 1999, IMMUNOL TODAY, V20, P343, DOI 10.1016/S0167-5699(98)01428-5; Ruggeri L, 1999, BLOOD, V94, P333, DOI 10.1182/blood.V94.1.333.413a31_333_339; RUGGERI L, UNPUB; Shlomchik WD, 1999, SCIENCE, V285, P412, DOI 10.1126/science.285.5426.412; STOCKERLGOLDSTE.KE, 1999, HEMATOPOIETIC CELL T, P823; Valiante N M, 1997, Biol Blood Marrow Transplant, V3, P229; Valiante NM, 1997, IMMUNOL REV, V155, P155, DOI 10.1111/j.1600-065X.1997.tb00948.x; Yu YYL, 1996, IMMUNITY, V4, P67, DOI 10.1016/S1074-7613(00)80299-X	23	2446	2613	5	91	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 15	2002	295	5562					2097	2100		10.1126/science.1068440	http://dx.doi.org/10.1126/science.1068440			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	532AY	11896281				2022-12-28	WOS:000174450500056
J	Jenkins, R				Jenkins, R			Addressing suicide as a public-health problem	LANCET			English	Editorial Material									Inst Psychiat, WHO Collaborating Ctr Mental Hlth Res & Training, London SE5 8AF, England	University of London; King's College London	Jenkins, R (corresponding author), Inst Psychiat, WHO Collaborating Ctr Mental Hlth Res & Training, De Crespigny Pk, London SE5 8AF, England.		Jenkins, Rachel/E-4287-2010; Jenkins, Rachel/H-2953-2019	Jenkins, Rachel/0000-0002-2958-0331; Jenkins, Rachel/0000-0002-2958-0331				Charlton J., 1992, Population Trends, P10; *COMM AUSTR, 1994, BETT HLTH OUTC AUSTR; *DEP HLTH, 1999, CM4386; *DEP HLTH, 1994, HLTH NAT KEY AR HDB; Hawton K, 1998, J AFFECT DISORDERS, V50, P269; Jenkins R., 2000, INT HDB SUICIDE ATTE, P597, DOI 10.1002/9780470698976; *MIN HLTH, 1998, NZ YOUTH SUIC PREV S; Murray CJL., 1996, GLOBAL HLTH STAT COM, V1996; MURTHY RS, 2000, INT HDB SUICIDE ATTE, P631; *NAT COUNC SUIC PR, 1996, SUPP SUIC CRIS; National Research and Development Centre for Welfare and Health, 1993, SUIC CAN BE PREV TAR; Pritchard C, 1996, ACTA PSYCHIAT SCAND, V93, P362, DOI 10.1111/j.1600-0447.1996.tb10661.x; RETTERSTOL N, 1995, ITAL J SUICIDOL, V5, P19; Taylor SJ, 1997, ACTA PSYCHIAT SCAND, V95, P457, DOI 10.1111/j.1600-0447.1997.tb10132.x; United Nations, 1996, PREV SUIC GUID FORM; VANDERHOCK W, 1998, SOC SCI MED, V56, P495; World Health Organization, 2000, WORLD HLTH REP 1999; World Health Organization, 1990, CONS STRAT RED SUIC	18	23	30	0	6	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 9	2002	359	9309					813	814		10.1016/S0140-6736(02)07958-8	http://dx.doi.org/10.1016/S0140-6736(02)07958-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	529YV	11897274				2022-12-28	WOS:000174329600003
J	Kaplan, EL				Kaplan, EL			The deceitful heart	LANCET			English	Editorial Material									Univ Minnesota, Sch Med, Dept Pediat, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Kaplan, EL (corresponding author), Univ Minnesota, Sch Med, Dept Pediat, Minneapolis, MN 55455 USA.							*COMM REV JON CRIT, 1965, CIRCULATION, V32, P664; TARANTA A, 1962, ANN INTERN MED, V56, P367, DOI 10.7326/0003-4819-56-3-367	2	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 9	2002	359	9309					834	834		10.1016/S0140-6736(02)07976-X	http://dx.doi.org/10.1016/S0140-6736(02)07976-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	529YV	11897282				2022-12-28	WOS:000174329600010
J	Mead, GM				Mead, GM			Management of oral mucositis associated with cancer chemotherapy	LANCET			English	Editorial Material							COLONY-STIMULATING FACTOR; DOUBLE-BLIND; PREVENTION; PILOCARPINE; TRIAL; HEAD		Royal S Hants Hosp, Dept Med Oncol, Southampton SO14 0YG, Hants, England	University of Southampton; University Hospital Southampton NHS Foundation Trust; Royal South Hants Hospital	Mead, GM (corresponding author), Royal S Hants Hosp, Dept Med Oncol, Southampton SO14 0YG, Hants, England.	Lynn.Mooney@suht.swest.nhs.uk						Awidi A, 2001, EUR J CANCER, V37, P2010, DOI 10.1016/S0959-8049(01)00189-7; Castagna L, 2001, ANN ONCOL, V12, P953, DOI 10.1023/A:1011119721267; Cheng KKF, 2001, EUR J CANCER, V37, P2056, DOI 10.1016/S0959-8049(01)00098-3; CHI KH, 1995, J CLIN ONCOL, V13, P2620, DOI 10.1200/JCO.1995.13.10.2620; CLARKSON JE, 2002, COCHRANE LIB; Dodd MJ, 2000, ORAL SURG ORAL MED O, V90, P39, DOI 10.1067/moe.2000.105713; GABRILOVE JL, 1988, NEW ENGL J MED, V318, P1414, DOI 10.1056/NEJM198806023182202; Hejna M, 2001, EUR J CANCER, V37, P1994, DOI 10.1016/S0959-8049(01)00132-0; Larson PJ, 1998, CANCER NURS, V21, P263, DOI 10.1097/00002820-199808000-00007; LEVEQUE FG, 1993, J CLIN ONCOL, V11, P1124, DOI 10.1200/JCO.1993.11.6.1124; MAHOOD DJ, 1991, J CLIN ONCOL, V9, P449, DOI 10.1200/JCO.1991.9.3.449; SARIS ST, 1999, CANCER, V85, P2103; Sonis ST, 1998, ORAL ONCOL, V34, P39, DOI 10.1016/S1368-8375(97)00053-5; Sprinzl GM, 2001, EUR J CANCER, V37, P2003, DOI 10.1016/S0959-8049(01)00170-8	14	35	35	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 9	2002	359	9309					815	816		10.1016/S0140-6736(02)07960-6	http://dx.doi.org/10.1016/S0140-6736(02)07960-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	529YV	11897276				2022-12-28	WOS:000174329600005
J	Richards, EJ; Elgin, SCR				Richards, EJ; Elgin, SCR			Epigenetic codes for heterochromatin formation and silencing: Rounding up the usual suspects	CELL			English	Review							NUCLEOSOME CORE PARTICLE; HISTONE H3 METHYLATION; DE-NOVO METHYLATION; DNA METHYLATION; FISSION YEAST; CHROMATIN-STRUCTURE; GENE-REGULATION; DROSOPHILA-MELANOGASTER; X-CHROMOSOME; LYSINE 9	Recent results from diverse organisms point to a self-reinforcing network of interactions among the three best-characterized covalent modifications that mark heterochromatin: histone hypoacetylation, histone H3-Lys9 methylation, and cytosine methylation. These modification systems suggest a mechanistic basis for spreading of heterochromatin over large domains and for stable epigenetic inheritance of the silent state. All three modifications used in packaging heterochromatin are also used in stable silencing of euchromatic genes.	Washington Univ, Dept Biol, St Louis, MO 63130 USA	Washington University (WUSTL)	Elgin, SCR (corresponding author), Washington Univ, Dept Biol, 1 Brookings Dr, St Louis, MO 63130 USA.	selgin@bioiogy.wustl.edu	Richards, Eric/E-6866-2012	Richards, Eric/0000-0002-8665-7470; Elgin, Sarah C. R./0000-0002-5176-2510	NICHD NIH HHS [HD 23844] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD023844] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Aagaard L, 1999, EMBO J, V18, P1923, DOI 10.1093/emboj/18.7.1923; ALLSHIRE RC, 1995, GENE DEV, V9, P218, DOI 10.1101/gad.9.2.218; Annunziato AT, 2000, GENE EXPRESSION, V9, P37; Bachman KE, 2001, J BIOL CHEM, V276, P32282, DOI 10.1074/jbc.M104661200; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Bartee L, 2001, GENE DEV, V15, P1753, DOI 10.1101/gad.905701; Bell AC, 2001, SCIENCE, V291, P447, DOI 10.1126/science.291.5503.447; Bender J, 2001, CELL, V106, P129, DOI 10.1016/S0092-8674(01)00441-X; BIRD AP, 1995, TRENDS GENET, V11, P94, DOI 10.1016/S0168-9525(00)89009-5; Boggs BA, 2002, NAT GENET, V30, P73, DOI 10.1038/ng787; BONE JR, 1994, GENE DEV, V8, P96, DOI 10.1101/gad.8.1.96; Brasher SV, 2000, EMBO J, V19, P1587, DOI 10.1093/emboj/19.7.1587; Cervoni N, 2001, J BIOL CHEM, V276, P40778, DOI 10.1074/jbc.M103921200; Chua S, 1997, DIABETES REV, V5, P2; CLARK T, 1983, J COMPUT CHEM, V4, P294, DOI 10.1002/jcc.540040303; Colot V, 1996, CELL, V86, P855, DOI 10.1016/S0092-8674(00)80161-0; Colot V, 1999, BIOESSAYS, V21, P402, DOI 10.1002/(SICI)1521-1878(199905)21:5<402::AID-BIES7>3.3.CO;2-2; Cryderman DE, 1999, EMBO J, V18, P3724, DOI 10.1093/emboj/18.13.3724; Czermin B, 2001, EMBO REP, V2, P915, DOI 10.1093/embo-reports/kve210; Dennis K, 2001, GENE DEV, V15, P2940, DOI 10.1101/gad.929101; Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974; Dobosy JR, 2001, CELL MOL LIFE SCI, V58, P721, DOI 10.1007/PL00000895; Eissenberg JC, 2000, CURR OPIN GENET DEV, V10, P204, DOI 10.1016/S0959-437X(00)00058-7; Ekwall K, 1999, GENETICS, V153, P1153; Ekwall K, 1997, CELL, V91, P1021, DOI 10.1016/S0092-8674(00)80492-4; Ekwall K, 1996, J CELL SCI, V109, P2637; Firestein R, 2000, MOL CELL BIOL, V20, P4900, DOI 10.1128/MCB.20.13.4900-4909.2000; FREEMANCOOK L, 2000, CHROMATIN STRUCTURE, P203; Gaudin V, 2001, DEVELOPMENT, V128, P4847; Gibbons RJ, 2000, NAT GENET, V24, P368, DOI 10.1038/74191; Grewal SIS, 2000, J CELL PHYSIOL, V184, P311, DOI 10.1002/1097-4652(200009)184:3<311::AID-JCP4>3.0.CO;2-D; GREWAL SIS, 2002, IN PRESS CURR OPIN C, V12; Heard E, 2001, CELL, V107, P727, DOI 10.1016/S0092-8674(01)00598-0; HEBBES TR, 1994, EMBO J, V13, P1823, DOI 10.1002/j.1460-2075.1994.tb06451.x; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; Hecht A, 1996, NATURE, V383, P92, DOI 10.1038/383092a0; Henikoff S, 1998, GENETICS, V149, P307; Henikoff S, 2000, BBA-REV CANCER, V1470, pO1, DOI 10.1016/S0304-419X(99)00034-7; HOLLIDAY R, 1975, SCIENCE, V187, P226, DOI 10.1126/science.1111098; Hwang KK, 2001, P NATL ACAD SCI USA, V98, P11423, DOI 10.1073/pnas.211303598; Ivanova AV, 1998, NAT GENET, V19, P192, DOI 10.1038/566; Jacobs SA, 2001, EMBO J, V20, P5232, DOI 10.1093/emboj/20.18.5232; JAMES TC, 1989, EUR J CELL BIOL, V50, P170; Jeddeloh JA, 1999, NAT GENET, V22, P94, DOI 10.1038/8803; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jones PA, 2001, SCIENCE, V293, P1068, DOI 10.1126/science.1063852; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Jost JP, 2001, NUCLEIC ACIDS RES, V29, P4452, DOI 10.1093/nar/29.21.4452; Kouzminova E, 2001, EMBO J, V20, P4309, DOI 10.1093/emboj/20.15.4309; Krude T, 2001, CELL MOL LIFE SCI, V58, P665, DOI 10.1007/PL00000890; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Lindroth AM, 2001, SCIENCE, V292, P2077, DOI 10.1126/science.1059745; Litt MD, 2001, EMBO J, V20, P2224, DOI 10.1093/emboj/20.9.2224; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Macleod D, 1999, NAT GENET, V23, P139, DOI 10.1038/13767; Martienssen RA, 2001, SCIENCE, V293, P1070, DOI 10.1126/science.293.5532.1070; Matzke M, 2001, SCIENCE, V293, P1080, DOI 10.1126/science.1063051; Miao VPW, 2000, J MOL BIOL, V300, P249, DOI 10.1006/jmbi.2000.3864; MIYNARCZYK SK, 2000, CURR BIOL, V10, pR899; Moazed D, 2001, MOL CELL, V8, P489, DOI 10.1016/S1097-2765(01)00340-9; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Nakayama J, 2000, CELL, V101, P307, DOI 10.1016/S0092-8674(00)80840-5; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Noma K, 2001, SCIENCE, V293, P1150, DOI 10.1126/science.1064150; Oakeley EJ, 1997, P NATL ACAD SCI USA, V94, P11721, DOI 10.1073/pnas.94.21.11721; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Papa CM, 2001, PLANT CELL, V13, P1919, DOI 10.1105/tpc.13.8.1919; Pelissier T, 1999, NUCLEIC ACIDS RES, V27, P1625, DOI 10.1093/nar/27.7.1625; Peters AHFM, 2002, NAT GENET, V30, P77, DOI 10.1038/ng789; Peters AHFM, 2001, CELL, V107, P323, DOI 10.1016/S0092-8674(01)00542-6; Ramsahoye BH, 2000, P NATL ACAD SCI USA, V97, P5237, DOI 10.1073/pnas.97.10.5237; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Reik W, 2001, SCIENCE, V293, P1089, DOI 10.1126/science.1063443; Rice JC, 2001, CURR OPIN CELL BIOL, V13, P263, DOI 10.1016/S0955-0674(00)00208-8; Richards EJ, 1997, TRENDS GENET, V13, P319, DOI 10.1016/S0168-9525(97)01199-2; RIGGS AD, 1975, CYTOGENET CELL GENET, V14, P9, DOI 10.1159/000130315; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Rougier N, 1998, GENE DEV, V12, P2108, DOI 10.1101/gad.12.14.2108; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Santos F, 2002, DEV BIOL, V241, P172, DOI 10.1006/dbio.2001.0501; Selker EU, 1997, TRENDS GENET, V13, P296, DOI 10.1016/S0168-9525(97)01201-8; Selker EU, 1998, P NATL ACAD SCI USA, V95, P9430, DOI 10.1073/pnas.95.16.9430; Smith ER, 2000, MOL CELL BIOL, V20, P312, DOI 10.1128/MCB.20.1.312-318.2000; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Struhl K, 1999, CELL, V98, P1, DOI 10.1016/S0092-8674(00)80599-1; Suka N, 2001, MOL CELL, V8, P473, DOI 10.1016/S1097-2765(01)00301-X; Sun FL, 2001, MOL CELL BIOL, V21, P2867, DOI 10.1128/MCB.21.8.2867-2879.2001; Sun FL, 2000, P NATL ACAD SCI USA, V97, P5340, DOI 10.1073/pnas.090530797; Tamaru H, 2001, NATURE, V414, P277, DOI 10.1038/35104508; Tian L, 2001, P NATL ACAD SCI USA, V98, P200, DOI 10.1073/pnas.011347998; TSCHIERSCH B, 1994, EMBO J, V13, P3822, DOI 10.1002/j.1460-2075.1994.tb06693.x; Turner BM, 2000, BIOESSAYS, V22, P836, DOI 10.1002/1521-1878(200009)22:9<836::AID-BIES9>3.0.CO;2-X; Vaute O, 2002, NUCLEIC ACIDS RES, V30, P475, DOI 10.1093/nar/30.2.475; Vogelauer M, 2000, NATURE, V408, P495, DOI 10.1038/35044127; Wang HB, 2001, MOL CELL, V8, P1207, DOI 10.1016/S1097-2765(01)00405-1; Weiler KS, 1995, ANNU REV GENET, V29, P577, DOI 10.1146/annurev.ge.29.120195.003045; White CL, 2001, EMBO J, V20, P5207, DOI 10.1093/emboj/20.18.5207; Xu GL, 1999, NATURE, V402, P187, DOI 10.1038/46052	100	673	706	0	53	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 22	2002	108	4					489	500		10.1016/S0092-8674(02)00644-X	http://dx.doi.org/10.1016/S0092-8674(02)00644-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	524XW	11909520	Bronze			2022-12-28	WOS:000174039000007
J	Gottar, M; Gobert, V; Michel, T; Belvin, M; Duyk, G; Hoffmann, JA; Ferrandon, D; Royet, J				Gottar, M; Gobert, V; Michel, T; Belvin, M; Duyk, G; Hoffmann, JA; Ferrandon, D; Royet, J			The Drosophila immune response against Gram-negative bacteria is mediated by a peptidoglycan recognition protein	NATURE			English	Article							TOLL-LIKE RECEPTORS; INNATE IMMUNITY; DEFICIENCY IMD; HOST-DEFENSE; GENES; ANTIFUNGAL; INFECTION; SILKWORM; REQUIRES; FAMILY	The antimicrobial defence of Drosophila relies largely on the challenge-induced synthesis of an array of potent antimicrobial peptides by the fat body(1,2). The defence against Gram-positive bacteria and natural fungal infections is mediated by the Toll signalling pathway, whereas defence against Gram-negative bacteria is dependent on the Immune deficiency (IMD) pathway(3-18). Loss-of-function mutations in either pathway reduce the resistance to corresponding infections(3,9). The link between microbial infections and activation of these two pathways has remained elusive. The Toll pathway is activated by Gram-positive bacteria through a circulating Peptidoglycan recognition protein (PGRP-SA)(6). PGRPs appear to be highly conserved from insects to mammals, and the Drosophila genome contains 13 members(19-23). Here we report a mutation in a gene coding for a putative transmembrane protein, PGRP-LC, which reduces survival to Gram-negative sepsis but has no effect on the response to Gram-positive bacteria or natural fungal infections. By genetic epistasis, we demonstrate that PGRP-LC acts upstream of the imd gene. The data on PGRP-SA with respect to the response to Gram-positive infections, together with the present report, indicate that the PGRP family has a principal role in sensing microbial infections in Drosophila.	Inst Biol Mol & Cellulaire, CNRS, UPR 9022, F-67084 Strasbourg, France; Exelixis Inc, San Francisco, CA 94083 USA	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Exelixis, Inc.	Ferrandon, D (corresponding author), Inst Biol Mol & Cellulaire, CNRS, UPR 9022, 15 Rue Rene Descartes, F-67084 Strasbourg, France.	D.Ferrandon@ibmc.u-strasbg.fr; J.Royet@ibmc.u-strasbg.fr		FERRANDON, Dominique/0000-0001-7680-7773; Michel, Tatiana/0000-0002-0146-9236				Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Elrod-Erickson M, 2000, CURR BIOL, V10, P781, DOI 10.1016/S0960-9822(00)00569-8; Georgel P, 2001, DEV CELL, V1, P503, DOI 10.1016/S1534-5807(01)00059-4; Hedengren M, 1999, MOL CELL, V4, P827, DOI 10.1016/S1097-2765(00)80392-5; Hoffmann JA, 2002, NAT IMMUNOL, V3, P121, DOI 10.1038/ni0202-121; Jung AC, 2001, BIOTECHNIQUES, V30, P594, DOI 10.2144/01303rr04; Kang DW, 1998, P NATL ACAD SCI USA, V95, P10078, DOI 10.1073/pnas.95.17.10078; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Lemaitre B, 1997, P NATL ACAD SCI USA, V94, P14614, DOI 10.1073/pnas.94.26.14614; LEMAITRE B, 1995, P NATL ACAD SCI USA, V92, P9465, DOI 10.1073/pnas.92.21.9465; Leulier F, 2000, EMBO REP, V1, P353, DOI 10.1093/embo-reports/kvd073; Liu C, 2000, J BIOL CHEM, V275, P24490, DOI 10.1074/jbc.M001239200; Liu C, 2001, J BIOL CHEM, V276, P34686, DOI 10.1074/jbc.M105566200; Lu YR, 2001, GENE DEV, V15, P104, DOI 10.1101/gad.856901; Meng XJ, 1999, GENE DEV, V13, P792, DOI 10.1101/gad.13.7.792; Michel T, 2001, NATURE, V414, P756, DOI 10.1038/414756a; Ochiai M, 1999, J BIOL CHEM, V274, P11854, DOI 10.1074/jbc.274.17.11854; Rutschmann S, 2000, NAT IMMUNOL, V1, P342, DOI 10.1038/79801; Rutschmann S, 2000, IMMUNITY, V12, P569, DOI 10.1016/S1074-7613(00)80208-3; Rutschmann S, 2002, J IMMUNOL, V168, P1542, DOI 10.4049/jimmunol.168.4.1542; Sieling PA, 2002, CURR OPIN MICROBIOL, V5, P70, DOI 10.1016/S1369-5274(02)00288-6; Silverman N, 2000, GENE DEV, V14, P2461, DOI 10.1101/gad.817800; Stoven S, 2000, EMBO REP, V1, P347, DOI 10.1093/embo-reports/kvd072; Tauszig-Delamasure S, 2002, NAT IMMUNOL, V3, P91, DOI 10.1038/ni747; Tzou P, 2002, CURR OPIN MICROBIOL, V5, P102, DOI 10.1016/S1369-5274(02)00294-1; Vidal S, 2001, GENE DEV, V15, P1900, DOI 10.1101/gad.203301; Werner T, 2000, P NATL ACAD SCI USA, V97, P13772, DOI 10.1073/pnas.97.25.13772; Wu LP, 2001, GENETICS, V159, P189; Yoshida H, 1996, J BIOL CHEM, V271, P13854, DOI 10.1074/jbc.271.23.13854	30	509	547	0	83	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 11	2002	416	6881					640	644		10.1038/nature734	http://dx.doi.org/10.1038/nature734			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	539YV	11912488				2022-12-28	WOS:000174901900045
J	Kaminski, A; Rosenkranz, S; Fretwell, HM; Campuzano, JC; Li, Z; Raffy, H; Cullen, WG; You, H; Olson, CG; Varma, CM; Hochst, H				Kaminski, A; Rosenkranz, S; Fretwell, HM; Campuzano, JC; Li, Z; Raffy, H; Cullen, WG; You, H; Olson, CG; Varma, CM; Hochst, H			Spontaneous breaking of time-reversal symmetry in the pseudogap state of a high-T-c superconductor	NATURE			English	Article							PHASE; MODEL; GAP	A change in 'symmetry' is often observed when matter undergoes a phase transition-the symmetry is said to be spontaneously broken. The transition made by underdoped high-transition-temperature (high-T-c) superconductors is unusual, in that it is not a mean-field transition as seen in other superconductors. Rather, there is a region in the phase diagram above the superconducting transition temperature T-c (where phase coherence and superconductivity begin) but below a characteristic temperature T* where a 'pseudogap' appears in the spectrum of electronic excitations(1,2). It is therefore important to establish if T* is just a cross-over temperature arising from fluctuations in the order parameter that will establish superconductivity at T-c (refs 3, 4), or if it marks a phase transition where symmetry is spontaneously broken(5-10). Here we report that, for a material in the pseudogap state, left-circularly polarized photons give a different photocurrent from right-circularly polarized photons. This shows that time-reversal symmetry is spontaneously broken(11) below T*, which therefore corresponds to a phase transition.	Univ Illinois, Dept Phys, Chicago, IL 60607 USA; Argonne Natl Lab, Div Mat Sci, Argonne, IL 60439 USA; Univ Coll Swansea, Dept Phys, Swansea SA2 8PP, W Glam, Wales; Univ Paris 11, Phys Solides Lab, F-91405 Orsay, France; Iowa State Univ, Ames Lab, Ames, IA 50011 USA; Lucent Technol, Bell Labs, Murray Hill, NJ 07974 USA; Univ Wisconsin, Ctr Synchrotron Radiat, Stoughton, WI 53589 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; United States Department of Energy (DOE); Argonne National Laboratory; Swansea University; UDICE-French Research Universities; Universite Paris Saclay; Iowa State University; United States Department of Energy (DOE); Ames National Laboratory; Alcatel-Lucent; Lucent Technologies; AT&T; University of Wisconsin System	Campuzano, JC (corresponding author), Univ Illinois, Dept Phys, Chicago, IL 60607 USA.	jcc@uic.edu	You, Hoydoo/A-6201-2011; Campuzano, Juan Carlos/G-4358-2012; Rosenkranz, Stephan/E-4672-2011	You, Hoydoo/0000-0003-2996-9483; Campuzano, Juan Carlos/0000-0002-2083-4884; Rosenkranz, Stephan/0000-0002-5659-0383				Chakravarty S, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.094503; Ding H, 1996, PHYS REV LETT, V76, P1533, DOI 10.1103/PhysRevLett.76.1533; Ding H, 1996, NATURE, V382, P51, DOI 10.1038/382051a0; DUBS RL, 1985, PHYS REV LETT, V54, P1249, DOI 10.1103/PhysRevLett.54.1249; HOCHST H, 1994, NUCL INSTRUM METH A, V347, P107, DOI 10.1016/0168-9002(94)91864-3; HSU TC, 1991, PHYS REV B, V43, P2866, DOI 10.1103/PhysRevB.43.2866; Ivanov DA, 2000, PHYS REV LETT, V84, P3958, DOI 10.1103/PhysRevLett.84.3958; Loeser AG, 1996, SCIENCE, V273, P325, DOI 10.1126/science.273.5273.325; RANDERIA M, 1992, PHYS REV LETT, V69, P2001, DOI 10.1103/PhysRevLett.69.2001; RANDERIA M, 1995, PHYS REV LETT, V74, P4951, DOI 10.1103/PhysRevLett.74.4951; SIMON ME, 2002, CONDMAT0201036; Tallon JL, 2001, PHYSICA C, V349, P53, DOI 10.1016/S0921-4534(00)01524-0; Varma CM, 1997, PHYS REV B, V55, P14554, DOI 10.1103/PhysRevB.55.14554; Varma CM, 1999, PHYS REV LETT, V83, P3538, DOI 10.1103/PhysRevLett.83.3538; Varma CM, 2000, PHYS REV B, V61, pR3804, DOI 10.1103/PhysRevB.61.R3804; VENUS D, 1993, PHYS REV B, V48, P6144, DOI 10.1103/PhysRevB.48.6144	17	255	260	2	64	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 11	2002	416	6881					610	613		10.1038/416610a	http://dx.doi.org/10.1038/416610a			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	539YV	11948344	Green Submitted			2022-12-28	WOS:000174901900036
J	Lippard, S				Lippard, S			Chemical synthesis: The art of chemistry	NATURE			English	Editorial Material									MIT, Dept Chem, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Lippard, S (corresponding author), MIT, Dept Chem, Cambridge, MA 02139 USA.							DeGrado WF, 1999, ANNU REV BIOCHEM, V68, P779, DOI 10.1146/annurev.biochem.68.1.779; Leininger S, 2000, CHEM REV, V100, P853, DOI 10.1021/cr9601324; Lippard SJ, 2000, CHEM ENG NEWS, V78, P64, DOI 10.1021/cen-v078n032.p064; TAFT KL, 1994, J AM CHEM SOC, V116, P823, DOI 10.1021/ja00082a001; Watton SP, 1997, ANGEW CHEM INT EDIT, V36, P2774, DOI 10.1002/anie.199727741	5	19	58	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 11	2002	416	6881					587	587		10.1038/416587a	http://dx.doi.org/10.1038/416587a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	539YV	11948331	Bronze			2022-12-28	WOS:000174901900020
J	Ramet, M; Manfruelli, P; Pearson, A; Mathey-Prevot, B; Ezekowitz, RAB				Ramet, M; Manfruelli, P; Pearson, A; Mathey-Prevot, B; Ezekowitz, RAB			Functional genomic analysis of phagocytosis and identification of a Drosophila receptor for E-coli	NATURE			English	Article							PEPTIDOGLYCAN RECOGNITION PROTEIN; CELLS; GENE; HEMATOPOIESIS; MELANOGASTER; MECHANISMS; EXPRESSION; REGULATOR; CLONING	The recognition and phagocytosis of microbes by macrophages is a principal aspect of innate immunity that is conserved from insects to humans. Drosophila melanogaster has circulating macrophages that phagocytose microbes similarly to mammalian macrophages(1,2), suggesting that insect macrophages can be used as a model to study cell-mediated innate immunity. We devised a double-stranded RNA interference-based screen in macrophage-like Drosophila S2 cells, and have defined 34 gene products involved in phagocytosis. These include proteins that participate in haemocyte development, vesicle transport, actin cytoskeleton regulation and a cell surface receptor. This receptor, Peptidoglycan recognition protein LC (PGRP-LC), is involved in phagocytosis of Gram-negative but not Gram-positive bacteria. Drosophila humoral immunity also distinguishes between Gram-negative and Gram-positive bacteria through the Imd and Toll pathways, respectively; however, a receptor for the Imd pathway has not been identified. Here we show that PGRP-LC is important for antibacterial peptide synthesis induced by Escherichia coli both in vitro and in vivo. Furthermore, totem mutants, which fail to express PGRP-LC, are susceptible to Gram-negative (E. coli), but not Gram-positive, bacterial infection. Our results demonstrate that PGRP-LC is an essential component for recognition and signalling of Gram-negative bacteria. Furthermore, this functional genomic approach is likely to have applications beyond phagocytosis.	Massachusetts Gen Hosp Children, Lab Dev Immunol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02114 USA; Harvard Univ, Dept Pediat, Dana Faber Canc Inst, Div Pediat Oncol, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute	Ramet, M (corresponding author), Massachusetts Gen Hosp Children, Lab Dev Immunol, 55 Fruit St, Boston, MA 02114 USA.							Aderem A, 1999, ANNU REV IMMUNOL, V17, P593, DOI 10.1146/annurev.immunol.17.1.593; BJERKNES R, 1984, J IMMUNOL METHODS, V72, P229, DOI 10.1016/0022-1759(84)90451-4; FEHON RG, 1994, DEVELOPMENT, V120, P545; Franc NC, 1999, SCIENCE, V284, P1991, DOI 10.1126/science.284.5422.1991; Garin J, 2001, J CELL BIOL, V152, P165, DOI 10.1083/jcb.152.1.165; Hackam DJ, 2001, J BIOL CHEM, V276, P18200, DOI 10.1074/jbc.M102009200; Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107; Imler JL, 2000, CURR OPIN MICROBIOL, V3, P16, DOI 10.1016/S1369-5274(99)00045-4; Imler JL, 2000, J ENDOTOXIN RES, V6, P459, DOI 10.1177/09680519000060060801; Juang JL, 1999, ONCOGENE, V18, P5138, DOI 10.1038/sj.onc.1202911; Kang DW, 1998, P NATL ACAD SCI USA, V95, P10078, DOI 10.1073/pnas.95.17.10078; Kirchhausen T, 2000, NAT REV MOL CELL BIO, V1, P187, DOI 10.1038/35043117; Lanzetti L, 2000, NATURE, V408, P374, DOI 10.1038/35042605; Lebestky T, 2000, SCIENCE, V288, P146, DOI 10.1126/science.288.5463.146; Lee S, 2000, J NEUROSCI, V20, P1096, DOI 10.1523/JNEUROSCI.20-03-01096.2000; Leulier F, 2000, EMBO REP, V1, P353, DOI 10.1093/embo-reports/kvd073; Liu C, 2000, J BIOL CHEM, V275, P24490, DOI 10.1074/jbc.M001239200; Liu C, 2001, J BIOL CHEM, V276, P34686, DOI 10.1074/jbc.M105566200; Lukacsovich T, 2001, GENETICS, V157, P727; Madden K, 1999, DEV BIOL, V213, P301, DOI 10.1006/dbio.1999.9399; Manfruelli P, 1999, EMBO J, V18, P3380, DOI 10.1093/emboj/18.12.3380; Michel T, 2001, NATURE, V414, P756, DOI 10.1038/414756a; Ochiai M, 1999, J BIOL CHEM, V274, P11854, DOI 10.1074/jbc.274.17.11854; Oike Y, 1999, BLOOD, V93, P2771; PEARSON A, 1995, P NATL ACAD SCI USA, V92, P4056, DOI 10.1073/pnas.92.9.4056; Perry DG, 1999, J IMMUNOL, V162, P380; Ramet M, 2001, IMMUNITY, V15, P1027, DOI 10.1016/S1074-7613(01)00249-7; Rehorn KP, 1996, DEVELOPMENT, V122, P4023; RIZKI TM, 1980, EXPERIENTIA, V36, P1223, DOI 10.1007/BF01976142; Tauszig S, 2000, P NATL ACAD SCI USA, V97, P10520, DOI 10.1073/pnas.180130797; Werner T, 2000, P NATL ACAD SCI USA, V97, P13772, DOI 10.1073/pnas.97.25.13772	31	567	585	2	63	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 11	2002	416	6881					644	648		10.1038/nature735	http://dx.doi.org/10.1038/nature735			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	539YV	11912489				2022-12-28	WOS:000174901900046
J	Taylor, WR				Taylor, WR			A 'periodic table' for protein structures	NATURE			English	Article							BETA-SHEET; CLASSIFICATION; PREDICTION; DATABASE	Current structural genomics programs aim systematically to determine the structures of all proteins coded in both human and other genomes, providing a complete picture of the number and variety of protein structures that exist. In the past, estimates have been made on the basis of the incomplete sample of structures currently known. These estimates have varied greatly (between 1,000 and 10,000; see for example refs 1 and 2), partly because of limited sample size but also owing to the difficulties of distinguishing one structure from another. This distinction is usually topological, based on the fold of the protein; however, in strict topological terms (neglecting to consider intra-chain cross-links), protein chains are open strings and hence are all identical. To avoid this trivial result, topologies are determined by considering secondary links in the form of intra-chain hydrogen bonds (secondary structure) and tertiary links formed by the packing of secondary structures. However, small additions to or loss of structure can make large changes to these perceived topologies and such subjective solutions are neither robust nor amenable to automation. Here I formalize both secondary and tertiary links to allow the rigorous and automatic definition of protein topology.	Natl Inst Med Res, Div Math Biol, London NW7 1AA, England	MRC National Institute for Medical Research	Taylor, WR (corresponding author), Natl Inst Med Res, Div Math Biol, Mill Hill, London NW7 1AA, England.	wtaylor@nimr.mrc.ac.uk						CHOTHIA C, 1993, STRUCTURE, V1, P217, DOI 10.1016/0969-2126(93)90010-E; CHOTHIA C, 1990, ANNU REV BIOCHEM, V59, P1007, DOI 10.1146/annurev.bi.59.070190.005043; COHEN FE, 1982, J MOL BIOL, V156, P821, DOI 10.1016/0022-2836(82)90144-9; COHEN FE, 1980, NATURE, V285, P378, DOI 10.1038/285378a0; Eidhammer I, 2000, J COMPUT BIOL, V7, P685, DOI 10.1089/106652701446152; FINKELSTEIN AV, 1987, PROG BIOPHYS MOL BIO, V50, P171, DOI 10.1016/0079-6107(87)90013-7; Hadley C, 1999, STRUCT FOLD DES, V7, P1099, DOI 10.1016/S0969-2126(99)80177-4; Holm L, 1997, NUCLEIC ACIDS RES, V25, P231, DOI 10.1093/nar/25.1.231; JONES DT, 1992, NATURE, V358, P86, DOI 10.1038/358086a0; MURZIN AG, 1988, J MOL BIOL, V204, P749, DOI 10.1016/0022-2836(88)90366-X; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; MURZIN AG, 1994, J MOL BIOL, V236, P1396; Orengo CA, 1997, STRUCTURE, V5, P1093, DOI 10.1016/S0969-2126(97)00260-8; ORENGO CA, 1994, NATURE, V372, P631, DOI 10.1038/372631a0; Taylor WR, 2002, MOL CELL PROTEOMICS, V1, P334, DOI 10.1074/mcp.T200001-MCP200; Taylor WR, 2001, J MOL BIOL, V310, P1135, DOI 10.1006/jmbi.2001.4817; TAYLOR WR, 1994, PROTEINS, V18, P281, DOI 10.1002/prot.340180309; Taylor WR, 2000, BIOCHEM SOC T, V28, P264, DOI 10.1042/bst0280264; Taylor WR, 1999, PROTEIN ENG, V12, P203, DOI 10.1093/protein/12.3.203	20	105	106	1	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 11	2002	416	6881					657	660		10.1038/416657a	http://dx.doi.org/10.1038/416657a			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	539YV	11948354				2022-12-28	WOS:000174901900049
J	Kadan-Lottick, NS; Robison, LL; Gurney, JG; Neglia, JP; Yasui, Y; Hayashi, R; Hudson, M; Greenberg, M; Mertens, AC				Kadan-Lottick, NS; Robison, LL; Gurney, JG; Neglia, JP; Yasui, Y; Hayashi, R; Hudson, M; Greenberg, M; Mertens, AC			Childhood cancer survivors' knowledge about their past diagnosis and treatment - Childhood cancer survivor study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LONG-TERM SURVIVORS; ADOLESCENT CANCER; 5-YEAR SURVIVORS; ADULT SURVIVORS; LATE MORTALITY; MANAGEMENT; NEOPLASMS; CHILDREN; THERAPY; PATIENT	Context Adult survivors of childhood cancer are at risk for adverse effects later in life but may have limited access 10 information about their diagnosis and treatment. This knowledge is necessary to motivate them to seek medical follow-up and to report essential history to health care professionals. Objective To assess knowledge of adult survivors of childhood cancer about their primary cancer diagnosis and associated therapies. Design, Setting, and Participants Cross-sectional survey of 635 consecutive survivors (approximately 5%) drawn from 12156 participants 18 years or older participating in the Childhood Cancer Survivor Study (a multiinstitutional cohort of individuals diagnosed between January 1, 1970, and December 31,1986, at at-rage <21 years, who had survived 5 years from diagnosis). The survey assessed knowledge of their cancer diagnosis and associated therapies in a 3- to 5-minute telephone questionnaire. Main Outcome Measures Responses were compared with medical record data for accuracy, sensitivity, specificity, and positive and negative predictive value. Results Overall, 72% accurately reported their diagnosis with precision and 19% were accurate but not precise. Individuals with central nervous system (CNS) cancer (odds ratio, 5.1; 95% confidence interval, 2.6-9.9) and neuroblastoma (OR, 4.2; 95% CI, 1.8-9.6) were more likely not to know their cancer diagnosis. Participants' accuracy rates for reporting their treatment history was 94% for chemotherapy, 89% for radiation, and 93% for splenectomy. Among those who received anthracyclines, only 30% recalled receiving daunorubicin therapy and 52% recalled receiving doxorubicin therapy, even after prompting with the drugs' names. Among those who received radiotherapy, 70% recalled the site of radiotherapy. History of receiving a written medical summary, attending a long-term follow-up clinic, and anxiety about late effects were not associated with greater, knowledge. Conclusions Important knowledge deficits exist among adult survivors of childhood cancer regarding basic aspects of their diagnosis and treatment. Such deficits could impair survivors' ability to seek and receive appropriate long-term follow-up care.	Univ Minnesota, Sch Med, Dept Pediat, Minneapolis, MN 55455 USA; Fred Hutchinson Canc Res Ctr, Canc Prevent Res Program, Seattle, WA 98104 USA; St Louis Childrens Hosp, St Louis, MO 63178 USA; St Jude Childrens Res Hosp, Memphis, TN 38105 USA; Hosp Sick Children, Toronto, ON M5G 1X8, Canada	University of Minnesota System; University of Minnesota Twin Cities; Fred Hutchinson Cancer Center; St. Louis Children's Hospital; Washington University (WUSTL); St Jude Children's Research Hospital; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Kadan-Lottick, NS (corresponding author), Univ Minnesota, Sch Med, Dept Pediat, 420 Delaware St SE,Mayo Mail Code 715, Minneapolis, MN 55455 USA.	kadan@epi.umn.edu	hayashi, robert james/AAH-2077-2019; Kadan-Lottick, Nina Singh/HGE-5850-2022; Robison, Leslie/N-8122-2018; Yasui, Yutaka/E-2564-2015	hayashi, robert james/0000-0002-1140-1139; Kadan-Lottick, Nina Singh/0000-0002-6857-396X; Yasui, Yutaka/0000-0002-7717-8638; Neglia, Joseph/0000-0002-5525-0598	NCI NIH HHS [U24 CA055727, U24-CA55727] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U24CA055727] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bhatia S, 1996, NEW ENGL J MED, V334, P745, DOI 10.1056/NEJM199603213341201; Blacklay A, 1998, ARCH DIS CHILD, V78, P340, DOI 10.1136/adc.78.4.340; Brigden ML, 2001, AM FAM PHYSICIAN, V63, P499; BYRNE J, 1989, ANN INTERN MED, V110, P400, DOI 10.7326/0003-4819-110-5-400; Eiser C, 1996, ARCH DIS CHILD, V75, P405, DOI 10.1136/adc.75.5.405; Grossi M, 1998, PEDIATR CLIN N AM, V45, P1637, DOI 10.1016/S0031-3955(05)70106-1; Hudson MM, 1997, J CLIN ONCOL, V15, P2205, DOI 10.1200/JCO.1997.15.6.2205; Hudson MM, 1999, INT J CANCER, P138; MEADOWS AT, 1981, LANCET, V2, P1015; Mertens AC, 2001, J CLIN ONCOL, V19, P3163, DOI 10.1200/JCO.2001.19.13.3163; Neglia JP, 2001, J NATL CANCER I, V93, P618, DOI 10.1093/jnci/93.8.618; NICHOLSON HS, 1994, CANCER, V73, P3094; NOVACK DH, 1979, JAMA-J AM MED ASSOC, V241, P897, DOI 10.1001/jama.241.9.897; Oeffinger KC, 1998, J CLIN ONCOL, V16, P2864, DOI 10.1200/JCO.1998.16.8.2864; RIED HL, 1994, SEMIN ROENTGENOL, V29, P6, DOI 10.1016/S0037-198X(05)80068-9; RIES LA, 1999, NIH PUBLICATION; Robison LL, 2002, MED PEDIATR ONCOL, V38, P229, DOI 10.1002/mpo.1316; STEINHERZ LJ, 1992, PEDIATRICS, V89, P942	18	250	252	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 10	2002	287	14					1832	1839		10.1001/jama.287.14.1832	http://dx.doi.org/10.1001/jama.287.14.1832			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	539QJ	11939869	Bronze			2022-12-28	WOS:000174881700036
J	Johnson, TC; Brown, ET; McManus, J; Barry, S; Barker, P; Gasse, F				Johnson, TC; Brown, ET; McManus, J; Barry, S; Barker, P; Gasse, F			A high-resolution paleoclimate record spanning the past 25,000 years in southern East Africa	SCIENCE			English	Article							LAKE MALAWI; TROPICS; SEDIMENTS; CLIMATE	High-resolution profiles of the mass accumulation rate of biogenic silica and other geochemical proxies in two piston cores from northern Lake Malawi provide a climate signal for this part of tropical Africa spanning the past 25,000 years. The biogenic silica mass accumulation rate was low during the relatively dry late Pleistocene, when the river flux of silica to the take was suppressed. Millennial-scale fluctuations, due to upwelling intensity, in the late Pleistocene climate of the Lake Malawi basin appear to have been closely linked to the Northern Hemisphere climate until 11 thousand years ago. Relatively cold conditions in the Northern Hemisphere coincided with more frequent north winds over the Malawi basin, perhaps resulting from a more southward migration of the Intertropical Convergence Zone.	Univ Minnesota, Large Lakes Observ, Duluth, MN 55812 USA; Univ Lancaster, Dept Geog, Lancaster LA1 4YB, England; Univ Aix Marseille 3, CNRS, Ctr European Rech & Enseignement Geosci Environm, F-13545 Aix En Provence, France	University of Minnesota System; University of Minnesota Duluth; Lancaster University; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite	Johnson, TC (corresponding author), Univ Minnesota, Large Lakes Observ, Duluth, MN 55812 USA.	tcj@d.umn.edu	Johnson, Thomas/C-1423-2010; Barker, Philip/J-5938-2012	Barker, Philip/0000-0002-5334-9201; Brown, Erik T/0000-0001-7154-2729				ASPILA KI, 1976, ANALYST, V101, P187, DOI 10.1039/an9760100187; BARRY SL, 2001, THESIS U MINNESOTA; BOOTSMA HA, 1998, WATER QUALITY REPORT; Brown ET, 2000, GEOCHIM COSMOCHIM AC, V64, P3515, DOI 10.1016/S0016-7037(00)00460-9; Chadwick OA, 1999, NATURE, V397, P491, DOI 10.1038/17276; *CLIM VAR PRED CLI, 1999, 161999 WCRP CLIVAR; DEMASTER DJ, 1979, THESIS YALE U; Filippelli GM, 1999, GEOLOGY, V27, P171, DOI 10.1130/0091-7613(1999)027<0171:EOCALD>2.3.CO;2; FINNEY BP, 1991, PALAEOGEOGR PALAEOCL, V85, P351, DOI 10.1016/0031-0182(91)90167-P; Gasse F, 2000, QUATERNARY SCI REV, V19, P189, DOI 10.1016/S0277-3791(99)00061-X; GASSE F, E AFRICAN GREAT LAKE; Harkin D. A., 1955, TANGANYIKA NOTES, V40, P20; JOHNSON TC, 1979, GEOCHIM COSMOCHIM AC, V43, P77, DOI 10.1016/0016-7037(79)90048-6; JOHNSON TC, 1990, AAPG MEMOIR, V50, P113; Johnson TC, 2001, GEOLOGY, V29, P83, DOI 10.1130/0091-7613(2001)029<0083:DROCVS>2.0.CO;2; JOHNSON TC, IN PRESS SEDIMENTATI; LIVINGSTONE DA, 1993, BIOLOGICAL RELATIONSHIPS BETWEEN AFRICA AND SOUTH AMERICA, P455; Nicholson S.E., 1996, LIMNOLOGY CLIMATOLOG, V1st ed., P25, DOI [DOI 10.1201/9780203748978-2, 10.1201/9780203748978-2]; Nicholson SE., 1998, ENV CHANGE RESPONSE, P207, DOI [https://doi.org/10.1007/978-94-017-1437-2_16, DOI 10.1007/978-94-017-1437-2_16]; PATTERSON G, 1995, FISHERY POTENTIAL PR, P1; STUIVER M, 1993, RADIOCARBON, V35, P215, DOI 10.1017/S0033822200013904; Vidal L, 1999, CLIM DYNAM, V15, P909, DOI 10.1007/s003820050321	22	174	184	1	47	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 5	2002	296	5565					113	+		10.1126/science.1070057	http://dx.doi.org/10.1126/science.1070057			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	539FA	11935023				2022-12-28	WOS:000174858800044
J	Teder, P; Vandivier, RW; Jiang, DH; Liang, JR; Cohn, L; Pure, E; Henson, PM; Noble, PW				Teder, P; Vandivier, RW; Jiang, DH; Liang, JR; Cohn, L; Pure, E; Henson, PM; Noble, PW			Resolution of lung inflammation by CD44	SCIENCE			English	Article							HYALURONIC-ACID; TGF-BETA; MACROPHAGES; FIBROSIS; RECEPTOR	Successful repair after tissue injury and inflammation requires resolution of the inflammatory response and removal of extracellular matrix breakdown products. We have examined whether the cell-surface adhesion molecule and hyaluronan receptor CD44 plays a role in resolving lung inflammation. CD44-deficient mice succumb to unremitting inflammation following noninfectious lung injury, characterized by impaired clearance of apoptotic neutrophils, persistent accumulation of hyaluronan fragments at the site of tissue injury, and impaired activation of transforming growth factor-beta(1). This phenotype was partially reversed by reconstitution with CD44(+) cells, thus demonstrating a critical role for this receptor in resolving lung inflammation.	Yale Univ, Sch Med, Dept Med, Pulm & Crit Care Sect, New Haven, CT 06520 USA; VA Connecticut Healthcare Syst, West Haven, CT 06516 USA; Natl Jewish Med & Res Ctr, Dept Pediat, Denver, CO 80206 USA; Ludwig Inst Canc Res, New York, NY 10158 USA; Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA	Yale University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System; National Jewish Health; Ludwig Institute for Cancer Research; The Wistar Institute	Noble, PW (corresponding author), Yale Univ, Sch Med, Dept Med, Pulm & Crit Care Sect, New Haven, CT 06520 USA.	paul.noble@yale.edu	Liang, Carol Jiurong/AAI-4963-2021; Jiang, Dianhua/B-1421-2009	Jiang, Dianhua/0000-0002-4508-3829; Liang, Jiurong/0000-0001-5179-5016	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060539] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL60539] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMSON IYR, 1974, AM J PATHOL, V77, P185; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BARTOLAZZI A, 1994, J EXP MED, V180, P53, DOI 10.1084/jem.180.1.53; DeGrendele HC, 1997, J IMMUNOL, V159, P2549; DeGrendele HC, 1997, SCIENCE, V278, P672, DOI 10.1126/science.278.5338.672; Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112; Guo MML, 1996, ANAL BIOCHEM, V233, P216, DOI 10.1006/abio.1996.0031; Hart SP, 1997, J IMMUNOL, V159, P919; HASLETT C, 1985, AM J PATHOL, V119, P101; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; LEE HG, 1994, ANAL BIOCHEM, V219, P278, DOI 10.1006/abio.1994.1267; McKee CM, 1996, J CLIN INVEST, V98, P2403, DOI 10.1172/JCI119054; MCNEIL JD, 1985, ANN RHEUM DIS, V44, P780, DOI 10.1136/ard.44.11.780; Munger JS, 1999, CELL, V96, P319, DOI 10.1016/S0092-8674(00)80545-0; Rafi-Janajreh AQ, 1999, J IMMUNOL, V163, P1619; RODEN L, 1989, CIBA F SYMP, V143, P60; SAMPSON PM, 1992, J CLIN INVEST, V90, P1492, DOI 10.1172/JCI116017; Schmits R, 1997, BLOOD, V90, P2217, DOI 10.1182/blood.V90.6.2217.2217_2217_2233; UNDERHILL CB, 1993, DEV BIOL, V155, P324, DOI 10.1006/dbio.1993.1032; Yu Q, 1997, J EXP MED, V186, P1985, DOI 10.1084/jem.186.12.1985; Yu Q, 2000, GENE DEV, V14, P163	21	524	547	0	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 5	2002	296	5565					155	158		10.1126/science.1069659	http://dx.doi.org/10.1126/science.1069659			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	539FA	11935029				2022-12-28	WOS:000174858800052
J	Rifai, N; Buring, JE; Lee, IM; Manson, JE; Ridker, PM				Rifai, N; Buring, JE; Lee, IM; Manson, JE; Ridker, PM			Is C-reactive protein specific for vascular disease in women?	ANNALS OF INTERNAL MEDICINE			English	Article							CORONARY-HEART-DISEASE; CARDIOVASCULAR-DISEASE; INFLAMMATION; RISK; CANCER; ATHEROSCLEROSIS; HEALTH; MEN	Background: C-reactive protein (CRP) predicts risk for future cardiovascular events in asymptomatic individuals. However, because CRP also predicts total mortality, its specificity for vascular disease is uncertain. Objective: To compare the predictive value of CRP for cancer and cardiovascular disease, the major determinants of mortality. Design: Prospective, nested case-control study. Setting: The Women's Health Study, an ongoing prospective cohort study involving 28345 U.S. women 45 years of age and older who were healthy at the time of enrollment. Participants: 643 women who subsequently developed cancer or had cardiovascular events; 643 age- and smoking-matched women who remained free of either disease during 58-month follow-up. Measurements: Baseline CRP levels. Results: Little evidence showed that increasing quartiles of baseline CRP predicted incident cancer (adjusted relative risks, 1.0, 1.2, 1.1, and 1.3; P for trend > 0.2). In contrast, increasing quartiles of baseline CRP were a strong marker of risk for future cardiovascular disease (adjusted relative risks, 1.0, 2.9, 3.4, and 5.6; P for trend < 0.001). \ Conclusion: C-reactive protein appears to independently predict cardiovascular events but not cancer.	Harvard Univ, Div Prevent Med, Brigham & Womens Hosp, Sch Med, Boston, MA 02215 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Ridker, PM (corresponding author), Harvard Univ, Div Prevent Med, Brigham & Womens Hosp, Sch Med, 900 Commonwealth Ave E, Boston, MA 02215 USA.	pridker@partners.org	Lee, I-Min/ABD-5409-2021		NHLBI NIH HHS [HL 58755] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058755] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; Danesh J, 2000, BMJ-BRIT MED J, V321, P199, DOI 10.1136/bmj.321.7255.199; Gussekloo J, 2000, ARTERIOSCL THROM VAS, V20, P1047, DOI 10.1161/01.ATV.20.4.1047; Harris TB, 1999, AM J MED, V106, P506, DOI 10.1016/S0002-9343(99)00066-2; Kodama J, 1999, EUR J OBSTET GYN R B, V82, P107, DOI 10.1016/S0301-2115(98)00227-9; Koenig W, 1999, CIRCULATION, V99, P237, DOI 10.1161/01.CIR.99.2.237; Lee IM, 1999, J NATL CANCER I, V91, P2102, DOI 10.1093/jnci/91.24.2102; Maseri A, 1997, NEW ENGL J MED, V336, P1014, DOI 10.1056/NEJM199704033361409; PEPYS MB, 1981, LANCET, V1, P653; Ridker PM, 1998, CIRCULATION, V97, P2007, DOI 10.1161/01.CIR.97.20.2007; Ridker PM, 1997, NEW ENGL J MED, V336, P973, DOI 10.1056/NEJM199704033361401; Ridker PM, 2000, NEW ENGL J MED, V342, P836, DOI 10.1056/NEJM200003233421202; Rifai N, 1999, CLIN CHEM, V45, P2136; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Tracy RP, 1997, ARTERIOSCL THROM VAS, V17, P1121, DOI 10.1161/01.ATV.17.6.1121	15	61	62	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 2	2002	136	7					529	533		10.7326/0003-4819-136-7-200204020-00010	http://dx.doi.org/10.7326/0003-4819-136-7-200204020-00010			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	536CA	11926788				2022-12-28	WOS:000174682100005
J	Hui, JYH; Woo, PCY; Lo, SS; Chan, JCS				Hui, JYH; Woo, PCY; Lo, SS; Chan, JCS			Over-the-counter medication and its effects	LANCET			English	Article									Univ Hong Kong, Queen Mary Hosp, Dept Microbiol, Hong Kong, Hong Kong, Peoples R China; United Christian Hosp, Dept Diagnost Radiol & Organ Imaging, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong; United Christian Hospital	Woo, PCY (corresponding author), Univ Hong Kong, Queen Mary Hosp, Dept Microbiol, Univ Pathol Bldg, Hong Kong, Hong Kong, Peoples R China.		Woo, Patrick Chiu Yat/C-4449-2009	Woo, Patrick Chiu Yat/0000-0001-9401-1832				Duan HQ, 1999, J NAT PROD, V62, P1522, DOI 10.1021/np9902183; Ferraz MB, 1996, SOC SCI MED, V42, P1129, DOI 10.1016/0277-9536(95)00393-2; KIMMERLE R, 1985, AM J MED, V79, P535, DOI 10.1016/0002-9343(85)90046-4; ODRISCOLL J, 1992, BRIT J DERMATOL, V127, P543, DOI 10.1111/j.1365-2133.1992.tb14859.x; SHUSTER S, 1985, BRIT MED J, V291, P38, DOI 10.1136/bmj.291.6487.38	5	7	7	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 30	2002	359	9312					1120	1120		10.1016/S0140-6736(02)08157-6	http://dx.doi.org/10.1016/S0140-6736(02)08157-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	536YJ	11943261				2022-12-28	WOS:000174729200012
J	Froehler, MT; Duffy, CJ				Froehler, MT; Duffy, CJ			Cortical neurons encoding path and place: Where you go is where you are	SCIENCE			English	Article							SUPERIOR TEMPORAL AREA; OPTIC FLOW STIMULI; MST NEURONS; MACAQUE MONKEY; EYE POSITION; DORSAL PART; RESPONSES; MOTION; SENSITIVITY; HIPPOCAMPUS	We recorded neuronal activity in monkey medial superior temporal (MST) cortex during movement on a motorized sled. Most neurons showed a preferred heading direction, but some responded only when that heading was part of a particular path. others responded only when the animal was at a certain place in the room, regardless of its path to that place. Video simulations of the self-movement scene evoked path, but not place, responses. Stationary positioning in the room revealed location preferences that matched place preferences recorded during movement. We conclude that MST encodes heading, path, and place information to support visuospatial orientation.	Univ Rochester, Med Ctr, Dept Neurol, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Neurobiol & Anat, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Ophthalmol, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Brain & Cognit Sci, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Ctr Visual Sci, Rochester, NY 14642 USA	University of Rochester; University of Rochester; University of Rochester; University of Rochester; University of Rochester	Duffy, CJ (corresponding author), Univ Rochester, Med Ctr, Dept Neurol, Rochester, NY 14642 USA.				NEI NIH HHS [EY10287, T2-EY07125C] Funding Source: Medline; NIA NIH HHS [AG17596] Funding Source: Medline; NIGMS NIH HHS [T32-GM07356] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY010287] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007356] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG017596] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Batschelet E., 1981, CIRCULAR STAT BIOL; Bremmer F, 1997, J NEUROPHYSIOL, V77, P944, DOI 10.1152/jn.1997.77.2.944; Clower DM, 2001, J NEUROSCI, V21, P6283, DOI 10.1523/JNEUROSCI.21-16-06283.2001; CRIST CF, 1988, J NEUROSCI METH, V26, P117, DOI 10.1016/0165-0270(88)90160-4; Duffy CJ, 1997, EXP BRAIN RES, V114, P472, DOI 10.1007/PL00005656; DUFFY CJ, 1991, J NEUROPHYSIOL, V65, P1346, DOI 10.1152/jn.1991.65.6.1346; DUFFY CJ, 1995, J NEUROSCI, V15, P5192; Gibson JJ, 1950, PERCEPTION VISUAL WO; GRAZIANO MSA, 1994, J NEUROSCI, V14, P54; Hays AV, 1982, WESCON C P, V2, P1; Inoue Y, 1998, EXP BRAIN RES, V121, P135, DOI 10.1007/s002210050445; JUDGE SJ, 1980, VISION RES, V20, P535, DOI 10.1016/0042-6989(80)90128-5; KOMATSU H, 1988, J NEUROPHYSIOL, V60, P580, DOI 10.1152/jn.1988.60.2.580; Mardia K., 1972, STAT DIRECTIONAL DAT, V37, DOI 10.2307/2984782; MCNAUGHTON BL, 1994, CEREB CORTEX, V4, P27, DOI 10.1093/cercor/4.1.27; MCNAUGHTON BL, 1989, PSYCHOBIOLOGY, V17, P230; Nishijo H, 1997, NEUROSCI LETT, V226, P57, DOI 10.1016/S0304-3940(97)00255-3; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV; OBRIEN HL, 1921, CEREB CORTEX, V11, P1083; ONO T, 1993, J NEUROPHYSIOL, V70, P1516, DOI 10.1152/jn.1993.70.4.1516; ORBAN GA, 1992, P NATL ACAD SCI USA, V89, P2595, DOI 10.1073/pnas.89.7.2595; Paolini M, 2000, J NEUROPHYSIOL, V84, P730, DOI 10.1152/jn.2000.84.2.730; ROBINSON DA, 1963, IEEE T BIO-MED ENG, VBM10, P137, DOI 10.1109/TBMEL.1963.4322822; Rockland KS, 1999, CEREB CORTEX, V9, P232, DOI 10.1093/cercor/9.3.232; ROLLS ET, 1999, HIPPOCAMPAL PARIETAL, pCH17; ROY JP, 1992, J NEUROSCI, V12, P2478; SAITO H, 1986, J NEUROSCI, V6, P145; Schaafsma SJ, 1996, J NEUROPHYSIOL, V76, P4056; Siegel RM, 1997, CEREB CORTEX, V7, P327, DOI 10.1093/cercor/7.4.327; TANAKA K, 1989, J NEUROPHYSIOL, V62, P642, DOI 10.1152/jn.1989.62.3.642	30	52	57	1	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 29	2002	295	5564					2462	2465		10.1126/science.1067426	http://dx.doi.org/10.1126/science.1067426			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	536QD	11923540				2022-12-28	WOS:000174712600059
J	Kind, PC; Mitchell, DE; Ahmed, B; Blakemore, C; Bonhoeffer, T; Sengpiel, F				Kind, PC; Mitchell, DE; Ahmed, B; Blakemore, C; Bonhoeffer, T; Sengpiel, F			Correlated binocular activity guides recovery from monocular deprivation	NATURE			English	Article							VISUAL-CORTEX; SYNAPTIC PLASTICITY; KITTENS; STRABISMUS; EXPERIENCE; AMBLYOPIA; REVERSAL; MONKEYS; PERIOD; CATS	Monocular deprivation (MD) has much more rapid and severe effects on the ocular dominance of neurons in the primary visual cortex (V1) than does binocular deprivation(1). This finding underlies the widely held hypothesis that the developmental plasticity of ocular dominance reflects competitive interactions for synaptic space between inputs from the two eyes(2). According to this view, the relative levels of evoked activity in afferents representing the two eyes determine functional changes in response to altered visual experience. However, if the deprived eye of a monocularly deprived kitten is simply reopened, there is substantial physiological and behavioural recovery, leading to the suggestion that absolute activity levels, or some other noncompetitive mechanisms, determine the degree of recovery from MD3-7. Here we provide evidence that correlated binocular input is essential for such recovery. Recovery is far less complete if the two eyes are misaligned after a period of MD. This is a powerful demonstration of the importance of cooperative, associative mechanisms in the developing visual cortex.	Univ Oxford, Physiol Lab, Oxford OX1 3PT, England; Univ Edinburgh, Dept Biomed Sci, Edinburgh EH8 9XD, Midlothian, Scotland; Dalhousie Univ, Dept Psychol, Halifax, NS B3H 4J1, Canada; Max Planck Inst Neurobiol, D-82152 Munich, Germany; Cardiff Sch Biosci, Cardiff CF10 3US, S Glam, Wales	University of Oxford; University of Edinburgh; Dalhousie University; Max Planck Society; Cardiff University	Kind, PC (corresponding author), Univ Oxford, Physiol Lab, Parks Rd, Oxford OX1 3PT, England.		Bonhoeffer, Tobias/B-9481-2009; Sengpiel, Frank/A-4682-2010	Bonhoeffer, Tobias/0000-0001-7897-6634; Sengpiel, Frank/0000-0002-7060-1851; Blakemore, Colin/0000-0003-2659-7899; Kind, Peter/0000-0002-4256-9639				BIENENSTOCK EL, 1982, J NEUROSCI, V2, P32, DOI 10.1523/jneurosci.02-01-00032.1982; BLAKE R, 1974, INVEST OPHTH VISUAL, V13, P121; BLAKEMORE C, 1981, PROC R SOC SER B-BIO, V213, P399, DOI 10.1098/rspb.1981.0072; BLAKEMORE C, 1974, J PHYSIOL-LONDON, V237, P195, DOI 10.1113/jphysiol.1974.sp010478; BONHOEFFER T, 1995, EUR J NEUROSCI, V7, P1973, DOI 10.1111/j.1460-9568.1995.tb00720.x; Bonhoeffer Tobias, 1996, P55; CLOTHIAUX EE, 1991, J NEUROPHYSIOL, V66, P1785, DOI 10.1152/jn.1991.66.5.1785; Crair MC, 1997, NEURON, V19, P307, DOI 10.1016/S0896-6273(00)80941-1; GIFFIN F, 1978, J PHYSIOL-LONDON, V274, P511, DOI 10.1113/jphysiol.1978.sp012164; GUILLERY RW, 1988, MAKING NERVOUS SYSTE, P356; HUBEL DH, 1965, J NEUROPHYSIOL, V28, P1041, DOI 10.1152/jn.1965.28.6.1041; Kind PC, 1999, CURR BIOL, V9, pR640, DOI 10.1016/S0960-9822(99)80412-6; Kiorpes L, 1998, J NEUROSCI, V18, P6411; KIRKWOOD A, 1995, NATURE, V375, P328, DOI 10.1038/375328a0; MALACH R, 1989, VISUAL NEUROSCI, V3, P267, DOI 10.1017/S0952523800010014; MITCHELL DE, 1988, J PHYSIOL-LONDON, V395, P639, DOI 10.1113/jphysiol.1988.sp016939; MITCHELL DE, 1977, J COMP NEUROL, V176, P53, DOI 10.1002/cne.901760104; Mitchell DE, 1998, CURR BIOL, V8, P1179, DOI 10.1016/S0960-9822(07)00489-7; Mitchell DE, 2001, P NATL ACAD SCI USA, V98, P11662, DOI 10.1073/pnas.201392698; Mitchell DE, 1984, HDB PHYSL 1 1, V3, P507; MOVSHON JA, 1976, J PHYSIOL-LONDON, V261, P175, DOI 10.1113/jphysiol.1976.sp011552; MURPHY KM, 1986, NATURE, V323, P536, DOI 10.1038/323536a0; QUICK MW, 1989, INVEST OPHTH VIS SCI, V30, P1012; Rittenhouse CD, 1999, NATURE, V397, P347, DOI 10.1038/16922; SENGPIEL F, 1994, J NEUROSCI, V14, P6855; WIESEL TN, 1965, J NEUROPHYSIOL, V28, P1029, DOI 10.1152/jn.1965.28.6.1029; WORGOTTER F, 1987, BIOL CYBERN, V57, P349, DOI 10.1007/BF00354980	27	62	65	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 28	2002	416	6879					430	433		10.1038/416430a	http://dx.doi.org/10.1038/416430a			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	534UX	11919632				2022-12-28	WOS:000174607800047
J	Audet, AM; Hartman, EE				Audet, AM; Hartman, EE			A 58-year-old woman dissatisfied with her care, 2 years later	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									Commonwealth Fund, New York, NY 10021 USA	Commonwealth Fund	Audet, AM (corresponding author), Commonwealth Fund, New York, NY 10021 USA.							Aye LS, 2001, JAMA-J AM MED ASSOC, V286, P1311, DOI 10.1001/jama.286.11.1311; Daley J, 2001, JAMA-J AM MED ASSOC, V285, P2629, DOI 10.1001/jama.285.20.2629; Eisenberg L, 2001, JAMA-J AM MED ASSOC, V285, P2639, DOI 10.1001/jama.285.20.2639	3	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 27	2002	287	12					1577	1577		10.1001/jama.287.12.1577	http://dx.doi.org/10.1001/jama.287.12.1577			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	533VF	11911761				2022-12-28	WOS:000174550400030
J	Greenwald, P				Greenwald, P			Science, medicine, and the future - Cancer chemoprevention	BMJ-BRITISH MEDICAL JOURNAL			English	Review							BREAST-CANCER; BETA-CAROTENE; PREVENTION; SUPPLEMENTATION; TAMOXIFEN; PROGRESS		NCI, Div Canc Prevent, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Greenwald, P (corresponding author), NCI, Div Canc Prevent, NIH, 6130 Execut Blvd,Suite 2040, Bethesda, MD 20892 USA.	pg37g@nih.gov						Alberts DS, 1999, CANCER RES, V59, P4743; *ALPH TOC BET CAR, 1994, NEW ENGL J MED, V330, P1020; *AM I CANC RES, 1996, DIET PHYT CANC PREV; Brawley OW, 2000, EUR J CANCER, V36, P1312, DOI 10.1016/S0959-8049(00)00105-2; Clarke M, 1998, LANCET, V351, P1451; Davis JN, 1998, NUTR CANCER, V32, P123, DOI 10.1080/01635589809514730; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; Greenwald P, 2001, CONT CANC RES, P499; GREENWALD P, 1995, CA-CANCER J CLIN, V45, P31, DOI 10.3322/canjclin.45.1.31; Greenwald P, 2001, EUR J CANCER, V37, P948, DOI 10.1016/S0959-8049(01)00070-3; Hennekens CH, 1996, NEW ENGL J MED, V334, P1145, DOI 10.1056/NEJM199605023341801; HO CT, 1994, FOOD PHYTOCHEMICALS, V2; Huang M.-T., 1994, FOOD PHYTOCHEMICALS; Hursting SD, 1999, JNCI-J NATL CANCER I, V91, P215, DOI 10.1093/jnci/91.3.215; Kelloff GJ, 2000, ADV CANCER RES, V78, P199; Kelloff GJ, 2000, CANCER EPIDEM BIOMAR, V9, P127; Kelloff GJ, 1999, EUR J CANCER, V35, P2031, DOI 10.1016/S0959-8049(99)00299-3; Khuri FR, 1997, JNCI-J NATL CANCER I, V89, P199, DOI 10.1093/jnci/89.3.199; Knowles LM, 2000, CARCINOGENESIS, V21, P1129, DOI 10.1093/carcin/21.6.1129; Kucuk O, 2001, CANCER EPIDEM BIOMAR, V10, P861; Langman M, 1998, GUT, V43, P578, DOI 10.1136/gut.43.4.578; Lippman SM, 1998, JNCI-J NATL CANCER I, V90, P1514, DOI 10.1093/jnci/90.20.1514; Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802; Singletary E, 2000, CANCER EPIDEM BIOMAR, V9, P1087; Smith-Warner S. A., 1999, NUTR ONCOLOGY, P153; Urban D, 1999, EUR UROL, V35, P429, DOI 10.1159/000019875; Zhou JR, 1999, J NUTR, V129, P1628, DOI 10.1093/jn/129.9.1628	27	97	101	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 23	2002	324	7339					714	718		10.1136/bmj.324.7339.714	http://dx.doi.org/10.1136/bmj.324.7339.714			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	535ML	11909790	Green Published			2022-12-28	WOS:000174648200021
J	Cohen, HJ; Feussner, JR; Weinberger, M; Carnes, M; Hamdy, RC; Hsieh, F; Phibbs, C; Lavori, P; Courtney, D; Lyles, KW; May, C; McMurtry, C; Pennypacker, L; Smith, DM; Ainslie, N; Hornick, T; Brodkin, K				Cohen, HJ; Feussner, JR; Weinberger, M; Carnes, M; Hamdy, RC; Hsieh, F; Phibbs, C; Lavori, P; Courtney, D; Lyles, KW; May, C; McMurtry, C; Pennypacker, L; Smith, DM; Ainslie, N; Hornick, T; Brodkin, K			A controlled trial of inpatient and outpatient geriatric evaluation and management	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RANDOMIZED CONTROLLED-TRIALS; FUNCTIONAL STATUS; CLINICAL-TRIAL; CARE; HEALTH; OUTCOMES; UNIT; INTERVENTION	Background: Over the past 20 years, both inpatient units and outpatient clinics have developed programs for geriatric evaluation and management. However, the effects of these interventions on survival and functional status remain uncertain. Methods: We conducted a randomized trial involving frail patients 65 years of age or older who were hospitalized at 11 Veterans Affairs medical centers. After their condition had been stabilized, patients were randomly assigned, according to a two-by-two factorial design, to receive either care in an inpatient geriatric unit or usual inpatient care, followed by either care at an outpatient geriatric clinic or usual outpatient care. The interventions involved teams that provided geriatric assessment and management according to Veterans Affairs standards and published guidelines. The primary outcomes were survival and health-related quality of life, measured with the use of the Medical Outcomes Study 36-Item Short-Form General Health Survey (SF-36), one year after randomization. Secondary outcomes were the ability to perform activities of daily living, physical performance, utilization of health services, and costs. Results: A total of 1388 patients were enrolled and followed. Neither the inpatient nor the outpatient intervention had a significant effect on mortality (21 percent at one year overall), nor were there any synergistic effects between the two interventions. At discharge, patients assigned to the inpatient geriatric units had significantly greater improvements in the scores for four of the eight SF-36 subscales, activities of daily living, and physical performance than did those assigned to usual inpatient care. At one year, patients assigned to the outpatient geriatric clinics had better scores on the SF-36 mental health subscale, even after adjustment for the score at discharge, than those assigned to usual outpatient care. Total costs at one year were similar for the intervention and usual-care groups. Conclusions: In this controlled trial, care provided in inpatient geriatric units and outpatient geriatric clinics had no significant effects on survival. There were significant reductions in functional decline with inpatient geriatric evaluation and management and improvements in mental health with outpatient geriatric evaluation and management, with no increase in costs. (N Engl J Med 2002;346:905-12.) Copyright (C) 2002 Massachusetts Medical Society.	Vet Affairs Med Ctr, Durham, NC 27705 USA; Vet Affairs Cent Off, Washington, DC USA; Vet Affairs Med Ctr, Indianapolis, IN USA; Vet Affairs Med Ctr, Madison, WI USA; Vet Affairs Med Ctr, Mountain Home, TN USA; Vet Affairs Cooperat Studies Program Coordinating, Palo Alto, CA USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA)	Cohen, HJ (corresponding author), Vet Affairs Med Ctr, 508 Fulton St, Durham, NC 27705 USA.			Phibbs, Ciaran/0000-0002-4353-3507				Adler LA, 1998, BIOL PSYCHIAT, V43, P868, DOI 10.1016/S0006-3223(97)00027-9; Agostini JV, 2001, AHRQ PUBLICATION, V01-E058; APPLEGATE W, 1991, J AM GERIATR SOC S, V39, P2; APPLEGATE WB, 1990, NEW ENGL J MED, V322, P1572, DOI 10.1056/NEJM199005313222205; Asplund K, 2000, J AM GERIATR SOC, V48, P1381, DOI 10.1111/j.1532-5415.2000.tb02626.x; Bosworth HB, 1999, MED CARE, V37, P1226, DOI 10.1097/00005650-199912000-00006; Boult C, 2001, J AM GERIATR SOC, V49, P351, DOI 10.1046/j.1532-5415.2001.49076.x; Bradley EH, 2000, GERONTOLOGIST, V40, P191, DOI 10.1093/geront/40.2.191; Burns R, 2000, J AM GERIATR SOC, V48, P8, DOI 10.1111/j.1532-5415.2000.tb03021.x; CAMPION EW, 1995, NEW ENGL J MED, V332, P1376, DOI 10.1056/NEJM199505183322012; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; DEYO R, 1991, J AM GERIATR SOC S, V39; Engelhardt JB, 1996, J AM GERIATR SOC, V44, P847, DOI 10.1111/j.1532-5415.1996.tb03747.x; EPSTEIN AM, 1987, ANN INTERN MED, V106, P299, DOI 10.7326/0003-4819-106-2-299; EPSTEIN AM, 1990, JAMA-J AM MED ASSOC, V263, P538, DOI 10.1001/jama.263.4.538; FILLENBAUM GG, 1985, J AM GERIATR SOC, V33, P698, DOI 10.1111/j.1532-5415.1985.tb01779.x; FOZARD J, 1985, VA PRACT, V2, P85; HEINEMANN GD, 1994, INTERDISCIPLINARY HL, P77; Hynes D, 1999, MED CARE, V37, pAS27, DOI 10.1097/00005650-199904002-00005; Kane RA, 1981, ASSESSING ELDERLY PR; KARPPI P, 1995, AGING-CLIN EXP RES, V7, P207, DOI 10.1007/BF03324317; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; KAVISH W, 1996, GENERATIONS      WIN, P54; LANDEFELD CS, 1995, NEW ENGL J MED, V332, P1338, DOI 10.1056/NEJM199505183322006; MCVEY LJ, 1989, ANN INTERN MED, V110, P79, DOI 10.7326/0003-4819-110-1-79; Morishita L, 1998, GERONTOLOGIST, V38, P303, DOI 10.1093/geront/38.3.303; Nikolaus T, 1999, AGE AGEING, V28, P543, DOI 10.1093/ageing/28.6.543; REUBEN DB, 1995, NEW ENGL J MED, V332, P1345, DOI 10.1056/NEJM199505183322007; Reuben DB, 1999, J AM GERIATR SOC, V47, P269, DOI 10.1111/j.1532-5415.1999.tb02988.x; REUBEN DB, 1992, J GERONTOL, V47, pM106, DOI 10.1093/geronj/47.4.M106; REUBEN DB, 1990, J AM GERIATR SOC, V38, P1105, DOI 10.1111/j.1532-5415.1990.tb01373.x; RUBENSTEIN LZ, 1984, NEW ENGL J MED, V311, P1664, DOI 10.1056/NEJM198412273112604; Satish S, 1996, J AM GERIATR SOC, V44, P914, DOI 10.1111/j.1532-5415.1996.tb01860.x; SCHMITT M, 1994, INTERDISCIPLINARY HL, V92, P105; SCHMITT MH, 2000, GERONTOLOGIST S, V40, P343; SILVERMAN M, 1995, J AM GERIATR SOC, V43, P733, DOI 10.1111/j.1532-5415.1995.tb07041.x; Stuck AE, 1999, SOC SCI MED, V48, P445, DOI 10.1016/S0277-9536(98)00370-0; STUCK AE, 1993, LANCET, V342, P1032, DOI 10.1016/0140-6736(93)92884-V; TARLOV AR, 1989, JAMA-J AM MED ASSOC, V262, P925, DOI 10.1001/jama.262.7.925; UNGURU G, 1998, CONSULT PHARM, V13, P553; Ware JE, 1996, JAMA-J AM MED ASSOC, V276, P1039, DOI 10.1001/jama.1996.03540130037027; Weinberger M, 1996, NEW ENGL J MED, V334, P1441, DOI 10.1056/NEJM199605303342206; Weinberger M, 2001, MED CARE, V39, P627, DOI 10.1097/00005650-200106000-00010; Wieland D, 1997, SCAND J SOC MED, V25, P1, DOI 10.1177/140349489702500101; Wieland D, 1996, AGING CLIN EXP RES, V8, P297, DOI 10.1007/BF03339586	45	416	420	0	24	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 21	2002	346	12					905	912		10.1056/NEJMsa010285	http://dx.doi.org/10.1056/NEJMsa010285			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	532FR	11907291				2022-12-28	WOS:000174464100007
J	Catassi, C; Fabiani, E; Corrao, G; Barbato, M; De Renzo, A; Carella, AM; Gabrielli, A; Leoni, P; Carroccio, A; Baldassarre, M; Bertolani, P; Caramaschi, P; Sozzi, M; Guariso, G; Volta, U; Corazza, GR				Catassi, C; Fabiani, E; Corrao, G; Barbato, M; De Renzo, A; Carella, AM; Gabrielli, A; Leoni, P; Carroccio, A; Baldassarre, M; Bertolani, P; Caramaschi, P; Sozzi, M; Guariso, G; Volta, U; Corazza, GR		Italian Working Grp Coeliac Dis No	Risk of non-Hodgkin lymphoma in celiac disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SMALL-BOWEL LYMPHOMA; T-CELL LYMPHOMA; HIGH PREVALENCE; GASTROINTESTINAL-TRACT; SMALL-INTESTINE; ENTEROPATHY; MALIGNANCY; ANTIBODIES; FEATURES; GLUTEN	Context Celiac disease is one of the most common lifelong disorders. Non-Hodgkin lymphoma is a possible complication of celiac disease and may lead to a large portion of lyphoma cases. Objective To quantify the risk for developing non-Hodgkin lymphoma of any primary site associated with celiac disease. Design and Setting Multicenter, case-control study conducted between January 1996 and December 1999 throughout Italy. Patients Cases were older than 20 years (median, 57; range, 20-92 years) with non Hodgkin lymphoma of any primary site and histological type and were recruited at the time of the diagnosis. Controls were healthy adults (2739 men and 2981 women) from the general population. Main Outcome Measure Positive test result for class A serum antiendomysial antibody. Results Celiac disease was diagnosed in 6 (0.92%) of 653 patients with lymphoma. Of the 6 cases, 3 were of B-cell and 3 were of T-cell origin. Four of 6 cases had lymphoma primarily located in the gut. In the control group, 24 (0.42%) had celiac disease. The odds ratio (adjusted for age and sex) for non-Hodgkin lymphoma of any primary site associated with celiac disease was 3.1 (95% confidence interval [CI], 1.3-7.6), 16.9 (95% CI, 7.4-38.7) for gut lymphoma, and 19.2 (95% CI, 7.9-46.6) for T-cell lymphoma, respectively. The risk for non-Hodgkin lymphoma for the overall population, which was adjusted for age and sex, was 0.63% (95% CI, -0.12% to 1.37%). Conclusion Celiac disease is associated with an increased risk for non-Hodgkin lymphoma, especially of T-cell type and primarily localized in the gut. However, the association does not represent a great enough risk to justify early mass screening for celiac disease.	Univ Maryland, Ctr Cardiac Res, Baltimore, MD 21201 USA; Univ Dept Pediat, Ancona, Italy; Univ Dept Internal Med, Ancona, Italy; Univ Dept Hematol, Ancona, Italy; Univ Milan, Dept Stat, Bicocca, Italy; Univ Roma La Sapienza, Dept Pediat Gastroenterol, Rome, Italy; Univ Naples Federico II, Dept Clin Hematol, Naples, Italy; Casa Sollievo Sofferenza Hosp, Dept Hematol, San Giovanni Rotondo, Italy; Univ Hosp Palermo, Div Internal Med, Palermo, Italy; Univ Dept Pediat, Bari, Italy; Univ Dept Clin Med, Verona, Italy; Azienda Policlin, Dept Pediat, Modena, Italy; Natl Canc Ctr, Div Gastroenterol & Digest Endoscopy, Aviano, Italy; Univ Dept Pediat, Padua, Italy; Dept Internal Med, Bologna, Italy; Univ Dept Gastroenterol, Pavia, Italy	University System of Maryland; University of Maryland Baltimore; University of Milan; Sapienza University Rome; University of Naples Federico II; IRCCS Casa Sollievo Della Sofferenza; University of Palermo; Policlinico Paolo Giaccone	Catassi, C (corresponding author), Univ Maryland, Div Pediat Gastroenterol & Nutr, 22 S Greene St,N5W70,Box 140, Baltimore, MD 21201 USA.	catassi@tin.it	Biagi, Federico/G-2812-2011; Corazza, Gino Roberto/K-8500-2016; Carroccio, Antonio/K-4484-2016	Biagi, Federico/0000-0002-2227-4622; Corazza, Gino Roberto/0000-0001-9532-0573; Carroccio, Antonio/0000-0001-8913-7916; Baldassarre, Maria Elisabetta/0000-0003-0590-6664; Guariso, Graziella/0000-0002-3120-5063; Volta, Umberto/0000-0003-3405-3808				Carbone A, 1997, HUM PATHOL, V28, P580, DOI 10.1016/S0046-8177(97)90080-0; CATASSI C, 1994, LANCET, V343, P200, DOI 10.1016/S0140-6736(94)90989-X; Catassi C, 1996, ACTA PAEDIATR, V85, P29, DOI 10.1111/j.1651-2227.1996.tb14244.x; CHAN JKC, 1994, HISTOPATHOLOGY, V25, P517, DOI 10.1111/j.1365-2559.1994.tb01371.x; COLLIN P, 1994, GUT, V35, P1215, DOI 10.1136/gut.35.9.1215; Corazza GR, 1997, SCAND J GASTROENTERO, V32, P917, DOI 10.3109/00365529709011202; Corrao G, 2001, LANCET, V358, P356, DOI 10.1016/S0140-6736(01)05554-4; COUGHLIN SS, 1994, AM J EPIDEMIOL, V18, P51; DAMORE F, 1994, J CLIN ONCOL, V12, P1673, DOI 10.1200/JCO.1994.12.8.1673; Dieterich W, 1997, NAT MED, V3, P797, DOI 10.1038/nm0797-797; DOMIZIO P, 1993, AM J SURG PATHOL, V17, P429, DOI 10.1097/00000478-199305000-00001; EGAN LJ, 1995, J CLIN GASTROENTEROL, V21, P123, DOI 10.1097/00004836-199509000-00012; Fairley NH, 1937, BMJ-BRIT MED J, V1937, P375, DOI 10.1136/bmj.1.3972.375; FISCHBACH W, 1992, CANCER, V70, P1075, DOI 10.1002/1097-0142(19920901)70:5<1075::AID-CNCR2820700511>3.0.CO;2-1; FREEMAN HJ, 1986, GASTROENTEROLOGY, V90, P1992, DOI 10.1016/0016-5085(86)90272-6; Gale J, 2000, J CLIN ONCOL, V18, P795, DOI 10.1200/JCO.2000.18.4.795; GOUGH KR, 1962, GUT, V3, P232, DOI 10.1136/gut.3.3.232; GREENLAND S, 1987, STAT MED, V6, P701, DOI 10.1002/sim.4780060607; Groves FD, 2000, JNCI-J NATL CANCER I, V92, P1240, DOI 10.1093/jnci/92.15.1240; HOLMES GKT, 1989, GUT, V30, P333, DOI 10.1136/gut.30.3.333; Ivarsson A, 1999, J INTERN MED, V245, P63, DOI 10.1046/j.1365-2796.1999.00403.x; Johnston SD, 2000, EUR J GASTROEN HEPAT, V12, P645, DOI 10.1097/00042737-200012060-00012; Jonsson V, 1999, J INTERN MED, V245, P277, DOI 10.1046/j.1365-2796.1999.0443f.x; Kataria, 2016, SAUDI J SPORTS MED, V16, P139; LEONARD JN, 1983, BRIT MED J, V286, P16, DOI 10.1136/bmj.286.6358.16; LOGAN RFA, 1989, GASTROENTEROLOGY, V97, P265, DOI 10.1016/0016-5085(89)90060-7; MARSH MN, 1992, GASTROENTEROLOGY, V102, P330, DOI 10.1016/0016-5085(92)91819-P; MATHUSVLIEGEN EMH, 1994, J INTERN MED, V236, P43, DOI 10.1111/j.1365-2796.1994.tb01118.x; MCCARTHY CF, 1991, EUR J GASTROEN HEPAT, V3, P125; Melnyk A, 1997, BLOOD, V89, P4514, DOI 10.1182/blood.V89.12.4514; Not T, 1998, SCAND J GASTROENTERO, V33, P494; OFARRELLY C, 1986, BRIT MED J, V293, P908, DOI 10.1136/bmj.293.6552.908; OTTER R, 1989, BRIT J CANCER, V60, P745, DOI 10.1038/bjc.1989.351; ROSENBERG SA, 1982, CANCER, V49, P2112; Rostami K, 1999, AM J GASTROENTEROL, V94, P888; Siebert JD, 1999, AM J CLIN PATHOL, V111, P379; SIGURGEIRSSON B, 1994, BRIT MED J, V308, P13, DOI 10.1136/bmj.308.6920.13; Sollid LM, 1998, GASTROENTEROLOGY, V115, P1584, DOI 10.1016/S0016-5085(98)70040-X; SWINSON CM, 1983, LANCET, V1, P111; THOMAS DB, 1992, PUBLIC HLTH PREVENTI, P812; TRIER JS, 1991, NEW ENGL J MED, V325, P1709, DOI 10.1056/NEJM199112123252406; Tutt ANJ, 1997, GUT, V40, P801, DOI 10.1136/gut.40.6.801; Ventura A, 1999, GASTROENTEROLOGY, V117, P297, DOI 10.1053/gast.1999.0029900297; Volta U, 1996, J CLIN GASTROENTEROL, V23, P18, DOI 10.1097/00004836-199607000-00006; Volta U, 2001, DIGEST DIS SCI, V46, P1500, DOI 10.1023/A:1010648122797; WACHOLDER S, 1992, AM J EPIDEMIOL, V135, P1019, DOI 10.1093/oxfordjournals.aje.a116396; WALKERSMITH JA, 1990, ARCH DIS CHILD, V65, P909, DOI 10.1136/adc.65.8.909	47	225	232	0	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 20	2002	287	11					1413	1419		10.1001/jama.287.11.1413	http://dx.doi.org/10.1001/jama.287.11.1413			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	532GB	11903028	Green Published, Bronze			2022-12-28	WOS:000174465000023
J	Floyd, K; Blanc, L; Raviglione, M; Lee, JW				Floyd, K; Blanc, L; Raviglione, M; Lee, JW			Resources required for global tuberculosis control	SCIENCE			English	Article								We estimate that to achieve the World Health Organization's tuberculosis control targets, the 22 high-burden countries (HBCs) that collectively account for approximately 80% of the world's tuberculosis cases require about $1 billion per year during the period 2001 to 2005. A further $0.2 billion per year is needed for low and tower-middle income countries outside the 22 HBCs. There is a resource gap of up to around $300 million per year. Substantial progress in tuberculosis control could be achieved with increased investment that is large in the context of existing spending, but small in the wider context of global health expenditure.	WHO, Stop TB Dept, Communicable Dis Cluster, CH-1211 Geneva 27, Switzerland	World Health Organization	Floyd, K (corresponding author), WHO, Stop TB Dept, Communicable Dis Cluster, CH-1211 Geneva 27, Switzerland.			RAVIGLIONE, Mario/0000-0002-9331-2067				[Anonymous], GLOBAL FUND FIGHT AI; APPAIX O, UNPUB; *COMM MACR HLTH, 2001, MACR HLTH INV HLTH E, P157; Migliori GB, 1999, B WORLD HEALTH ORGAN, V77, P467; Schwartlander B, 2001, SCIENCE, V294, P521; Taylor Z, 2000, INT J TUBERC LUNG D, V4, P931; *UG MIN HLTH, 2001, NAT TUB LEPR PROGR 3; WHO, 2002, EV MALN CHILDR MAN S, P4; World Health Organization, 2000, WHOCDSDENIC20001, P10; 2000, MIN C TUB SUST DEV A; CHAIRS SUMMARY OKINA	11	45	57	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 15	2002	295	5562					2040	2041		10.1126/science.1069771	http://dx.doi.org/10.1126/science.1069771			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	532AY	11896267				2022-12-28	WOS:000174450500037
J	Walczyk, T; von Blanckenburg, F				Walczyk, T; von Blanckenburg, F			Natural iron isotope variations in human blood	SCIENCE			English	Article							ABSORPTION	Isotopic analysis of human blood and liver and muscle tissue indicates that each individual bears a long-term iron (Fe) isotope signature in the blood. Blood and tissue differ slightly in isotopic composition and are depleted by up to 2.6 per mil in Fe-56 relative to Fe-54 when compared to dietary Fe. The Fe-56/Fe-54 isotope ratio in the blood of mates is, on average, lower by 0.3 per mil than that of females. These results suggest that Fe isotope effects in the blood reflect differences in intestinal Fe absorption between individuals and genotypes.	Swiss Fed Inst Technol, Inst Food Sci, Human Nutr Lab, CH-8803 Ruschlikon, Switzerland; Univ Bern, CH-3012 Bern, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Bern	Walczyk, T (corresponding author), Swiss Fed Inst Technol, Inst Food Sci, Human Nutr Lab, Seestr 72, CH-8803 Ruschlikon, Switzerland.		von Blanckenburg, Friedhelm/K-4711-2013	von Blanckenburg, Friedhelm/0000-0002-2964-717X				Anbar AD, 2000, SCIENCE, V288, P126, DOI 10.1126/science.288.5463.126; Andrews NC, 1999, NEW ENGL J MED, V341, P1986, DOI 10.1056/NEJM199912233412607; Beard BL, 1999, SCIENCE, V285, P1889, DOI 10.1126/science.285.5435.1889; Beard BL, 1999, GEOCHIM COSMOCHIM AC, V63, P1653, DOI 10.1016/S0016-7037(99)00089-7; Belshaw NS, 2000, INT J MASS SPECTROM, V197, P191, DOI 10.1016/S1387-3806(99)00245-6; Bullen TD, 2001, GEOLOGY, V29, P699, DOI 10.1130/0091-7613(2001)029<0699:DOSAII>2.0.CO;2; CHARLTON RW, 1983, ANNU REV MED, V34, P55, DOI 10.1146/annurev.me.34.020183.000415; DeMaeyer E, 1985, World Health Stat Q, V38, P302; Matthews A, 2001, EARTH PLANET SC LETT, V192, P81, DOI 10.1016/S0012-821X(01)00432-0; Polyakov VB, 2000, GEOCHIM COSMOCHIM AC, V64, P849, DOI 10.1016/S0016-7037(99)00329-4; Schauble EA, 2001, GEOCHIM COSMOCHIM AC, V65, P2487, DOI 10.1016/S0016-7037(01)00600-7; UREY HC, 1947, J CHEM SOC, P562, DOI 10.1039/jr9470000562; VONBLANCKENBURG F, 2001, J C ABSTR, V6, P688; Walczyk T, 1997, FRESEN J ANAL CHEM, V359, P445, DOI 10.1007/s002160050608; Wessling-Resnick M, 2000, ANNU REV NUTR, V20, P129, DOI 10.1146/annurev.nutr.20.1.129; YIP R, 1996, PRESENT KNOWLEDGE NU	16	161	173	3	73	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 15	2002	295	5562					2065	2066		10.1126/science.1069389	http://dx.doi.org/10.1126/science.1069389			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	532AY	11896276				2022-12-28	WOS:000174450500046
J	Corne, JM; Marshall, C; Smith, S; Schreiber, J; Sanderson, G; Holgate, ST; Johnston, SL				Corne, JM; Marshall, C; Smith, S; Schreiber, J; Sanderson, G; Holgate, ST; Johnston, SL			Frequency, severity, and duration of rhinovirus infections in asthmatic and non-asthmatic individuals: a longitudinal cohort study	LANCET			English	Article							SYMPTOMS; EXACERBATIONS; VIRUSES	Background Rhinovirus infections cause exacerbations of asthma. We postulated that people with asthma are more susceptible to rhinovirus infection than people without the disease and compared the susceptibility of these groups. Methods We recruited 76 cohabiting couples. One person in every couple had atopic asthma and one was healthy. Participants completed daily diary cards of upper-respiratory-tract (URT) and lower-respiratory-tract (LRT) symptoms and measured peak expiratory flow twice daily. Every 2 weeks nasal aspirates were taken and examined for rhinovirus. Mixed models were used to compare risks of infection between groups. We also compared the severity and duration of infections. Findings We analysed 753 samples. Rhinovirus was detected in 10.1% (38/378) of samples from participants with asthma and 8.5% (32/375) of samples from healthy participants. After adjustment for confounding factors, asthma did not significantly increase risk of infection (odds ratio 1.15, 95% CI 0.71-1.87). Groups did not differ in frequency, severity, or duration of URT infections or symptoms associated with rhinovirus infection. First rhinovirus infection was associated more frequently with LRT infection in participants with asthma than in healthy individuals (12 of 28 infections vs four of 23, respectively, p=0.051). Symptoms of LRT associated with rhinovirus infection were significantly more severe (p=0.001) and longer-lasting in participants with asthma than in healthy participants (p=0.005). Interpretation People with atopic asthma are not at greater risk of rhinovirus infection than healthy individuals but suffer from more frequent LRT infections and have more severe and longer-lasting LRT symptoms.	Univ Med, Southampton Gen Hosp, Southampton, Hants, England; Univ London Imperial Coll Sci Technol & Med, Fac Med, Natl Heart & Lung Inst, Dept Epidemiol & Publ Hlth, London, England; Univ London Imperial Coll Sci Technol & Med, Fac Med, Natl Heart & Lung Inst, Dept Resp Med, London, England	University of Southampton; Imperial College London; Imperial College London	Corne, JM (corresponding author), Univ Nottingham Hosp, Queens Med Ctr, Dept Resp Med, Level D,South Block, Nottingham NG7 2UH, England.		Johnston, Sebastian Lennox/I-2423-2012	Johnston, Sebastian Lennox/0000-0003-3009-9200				BURNEY PGJ, 1989, EUR RESPIR J, V2, P940; DOUGLAS RG, 1966, AM REV RESPIR DIS, V94, P159; GREVE JM, 1989, CELL, V56, P839, DOI 10.1016/0092-8674(89)90688-0; GWALTNEY JM, 1966, NEW ENGL J MED, V275, P1261, DOI 10.1056/NEJM196612082752301; Harris JM, 1996, CLIN INFECT DIS, V23, P1287, DOI 10.1093/clinids/23.6.1287; HORN MEC, 1973, CHEST              S, V63, P445; JOHNSTON SL, 1993, J CLIN MICROBIOL, V31, P111, DOI 10.1128/JCM.31.1.111-117.1993; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; Johnston SL, 1996, AM J RESP CRIT CARE, V154, P654, DOI 10.1164/ajrccm.154.3.8810601; Malling HJ., 2003, ALLERGY, V48, P55; MANOLITSAS ND, 1994, EUR RESPIR J, V7, P1439, DOI 10.1183/09031936.94.07081439; NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982; PATTEMORE PK, 1992, CLIN EXP ALLERGY, V22, P325, DOI 10.1111/j.1365-2222.1992.tb03094.x; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0	14	388	410	1	20	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 9	2002	359	9309					831	834		10.1016/S0140-6736(02)07953-9	http://dx.doi.org/10.1016/S0140-6736(02)07953-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	529YV	11897281				2022-12-28	WOS:000174329600009
J	Proudfoot, NJ; Furger, A; Dye, MJ				Proudfoot, NJ; Furger, A; Dye, MJ			Integrating rnRNA processing with transcription	CELL			English	Review							RNA-POLYMERASE-II; PRE-MESSENGER-RNA; SPLICE-SITE SELECTION; C-TERMINAL DOMAIN; VERTEBRATE POLY(A) POLYMERASE; B-CELL DIFFERENTIATION; SMALL NUCLEAR-RNA; POLYADENYLATION FACTOR; CARBOXYL-TERMINUS; EXON DEFINITION	The messenger RNA processing reactions of capping, splicing, and polyadenylation occur cotranscriptionally. They not only influence one another's efficiency and specificity, but are also coordinated by transcription. The phosphorylated CTD of RNA polymerase II provides key molecular contacts with these mRNA processing reactions throughout transcriptional elongation and termination.	Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England	University of Oxford	Proudfoot, NJ (corresponding author), Univ Oxford, Sir William Dunn Sch Pathol, S Parks Rd, Oxford OX1 3RE, England.			Proudfoot, Nicholas/0000-0001-8646-3222				Aranda A, 1999, MOL CELL BIOL, V19, P1251; Aranda A, 2001, MOL CELL, V7, P1003, DOI 10.1016/S1097-2765(01)00235-0; Barilla D, 2001, P NATL ACAD SCI USA, V98, P445, DOI 10.1073/pnas.021545298; Bauren G, 1998, GENE DEV, V12, P2759, DOI 10.1101/gad.12.17.2759; BEELMAN CA, 1995, CELL, V81, P179, DOI 10.1016/0092-8674(95)90326-7; BEYER AL, 1988, GENE DEV, V2, P754, DOI 10.1101/gad.2.6.754; Birse CE, 1997, EMBO J, V16, P3633, DOI 10.1093/emboj/16.12.3633; Birse CE, 1998, SCIENCE, V280, P298, DOI 10.1126/science.280.5361.298; Burge CB, 1999, RNA WORLD, P525; Calvo O, 2001, MOL CELL, V7, P1013, DOI 10.1016/S1097-2765(01)00236-2; Chao LC, 1999, MOL CELL BIOL, V19, P5588; Colgan DF, 1997, GENE DEV, V11, P2755, DOI 10.1101/gad.11.21.2755; Collins CA, 2000, NAT STRUCT BIOL, V7, P850; CONNELLY S, 1988, GENE DEV, V2, P440, DOI 10.1101/gad.2.4.440; Corden JL, 1997, TRENDS BIOCHEM SCI, V22, P413, DOI 10.1016/S0968-0004(97)01125-0; Cramer P, 1997, P NATL ACAD SCI USA, V94, P11456, DOI 10.1073/pnas.94.21.11456; Cramer Patrick, 2001, Science (Washington D C), V292, P1863, DOI 10.1126/science.1059493; Cuello P, 1999, EMBO J, V18, P2867, DOI 10.1093/emboj/18.10.2867; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; Dantonel JC, 1997, NATURE, V389, P399, DOI 10.1038/38763; de Vries H, 2000, EMBO J, V19, P5895, DOI 10.1093/emboj/19.21.5895; Dominski Z, 1999, GENE, V239, P1, DOI 10.1016/S0378-1119(99)00367-4; Dye MJ, 2001, CELL, V105, P669, DOI 10.1016/S0092-8674(01)00372-5; Dye MJ, 1999, MOL CELL, V3, P371, DOI 10.1016/S1097-2765(00)80464-5; Fatica A, 2000, EMBO J, V19, P6218, DOI 10.1093/emboj/19.22.6218; Flaherty SM, 1997, P NATL ACAD SCI USA, V94, P11893, DOI 10.1073/pnas.94.22.11893; Fong N, 2001, GENE DEV, V15, P1783, DOI 10.1101/gad.889101; FU XD, 1995, RNA, V1, P663; Gamberi C, 1997, MOL CELL BIOL, V17, P2587, DOI 10.1128/MCB.17.5.2587; Goldstrohm AC, 2001, GENE, V277, P31, DOI 10.1016/S0378-1119(01)00695-3; Greger IH, 1998, EMBO J, V17, P4771, DOI 10.1093/emboj/17.16.4771; Gunderson SI, 1998, MOL CELL, V1, P255, DOI 10.1016/S1097-2765(00)80026-X; Gunderson SI, 1997, GENE DEV, V11, P761, DOI 10.1101/gad.11.6.761; Henkin TM, 2000, CURR OPIN MICROBIOL, V3, P149, DOI 10.1016/S1369-5274(00)00067-9; Hernandez N, 1992, TRANSCRIPTIONAL REGU, P281; Hirose Y, 1998, NATURE, V395, P93, DOI 10.1038/25786; Hirose Y, 1999, GENE DEV, V13, P1234, DOI 10.1101/gad.13.10.1234; Hirose Y, 2000, GENE DEV, V14, P1415; Ho CK, 1999, MOL CELL, V3, P405, DOI 10.1016/S1097-2765(00)80468-2; Kadener S, 2001, EMBO J, V20, P5759, DOI 10.1093/emboj/20.20.5759; Komarnitsky P, 2000, GENE DEV, V14, P2452, DOI 10.1101/gad.824700; Kramer A, 1996, ANNU REV BIOCHEM, V65, P367, DOI 10.1146/annurev.biochem.65.1.367; KUNKEL GR, 1985, MOL CELL BIOL, V5, P2332, DOI 10.1128/MCB.5.9.2332; LEWIS ED, 1986, P NATL ACAD SCI USA, V22, P8555; Lewis JD, 1997, EUR J BIOCHEM, V247, P461, DOI 10.1111/j.1432-1033.1997.00461.x; LOGAN J, 1987, P NATL ACAD SCI USA, V84, P8306, DOI 10.1073/pnas.84.23.8306; Lou H, 1998, MOL CELL BIOL, V18, P4977, DOI 10.1128/MCB.18.9.4977; MADHANI HD, 1992, CELL, V71, P803, DOI 10.1016/0092-8674(92)90556-R; McCracken S, 1997, NATURE, V385, P357, DOI 10.1038/385357a0; Misteli T, 1998, CURR OPIN CELL BIOL, V10, P323, DOI 10.1016/S0955-0674(98)80007-0; MOORE MJ, 1993, NATURE, V365, P364, DOI 10.1038/365364a0; Morris DP, 2000, J BIOL CHEM, V275, P39935, DOI 10.1074/jbc.M004118200; Newman AJ, 1997, EMBO J, V16, P5797, DOI 10.1093/emboj/16.19.5797; NIWA M, 1992, NATURE, V360, P277, DOI 10.1038/360277a0; O'Mullane L, 1998, MOL CELL BIOL, V18, P7510, DOI 10.1128/MCB.18.12.7510; Osheim YN, 1999, MOL CELL, V3, P379, DOI 10.1016/S1097-2765(00)80465-7; Paule MR, 2000, NUCLEIC ACIDS RES, V28, P1283, DOI 10.1093/nar/28.6.1283; Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128/MCB.20.8.2629-2634.2000; Proudfoot N, 1996, CELL, V87, P779, DOI 10.1016/S0092-8674(00)81982-0; Proudfoot N, 2000, TRENDS BIOCHEM SCI, V25, P290, DOI 10.1016/S0968-0004(00)01591-7; PROUDFOOT NJ, 1989, TRENDS BIOCHEM SCI, V14, P105, DOI 10.1016/0968-0004(89)90132-1; Reines D, 1996, TRENDS BIOCHEM SCI, V21, P351, DOI 10.1016/0968-0004(96)10045-1; Roberts GC, 1998, NUCLEIC ACIDS RES, V26, P5568, DOI 10.1093/nar/26.24.5568; Rodriguez CR, 2000, MOL CELL BIOL, V20, P104, DOI 10.1128/MCB.20.1.104-112.2000; RYAN K, 2002, IN PRESS MOL CELL BI; Sachs AB, 1997, CELL, V89, P831, DOI 10.1016/S0092-8674(00)80268-8; Shatkin AJ, 2000, NAT STRUCT BIOL, V7, P838, DOI 10.1038/79583; SISODIA SS, 1987, MOL CELL BIOL, V7, P3602, DOI 10.1128/MCB.7.10.3602; SMALE ST, 1985, MOL CELL BIOL, V5, P352, DOI 10.1128/MCB.5.2.352; Smith CWJ, 2000, TRENDS BIOCHEM SCI, V25, P381, DOI 10.1016/S0968-0004(00)01604-2; Steinmetz EJ, 2001, NATURE, V413, P327, DOI 10.1038/35095090; SUN JS, 1995, GENE DEV, V9, P843, DOI 10.1101/gad.9.7.843; Takagaki Y, 1998, MOL CELL, V2, P761, DOI 10.1016/S1097-2765(00)80291-9; Takagaki Y, 1996, CELL, V87, P941, DOI 10.1016/S0092-8674(00)82000-0; TANTRAVAHI J, 1993, MOL CELL BIOL, V13, P578, DOI 10.1128/MCB.13.1.578; Tran DP, 2001, MOL CELL BIOL, V21, P7495, DOI 10.1128/MCB.21.21.7495-7508.2001; Vagner S, 2000, GENE DEV, V14, P403; Valadkhan S, 2000, RNA, V6, P206, DOI 10.1017/S1355838200992197; Valadkhan S, 2001, NATURE, V413, P701, DOI 10.1038/35099500; Wahle E, 1999, FEMS MICROBIOL REV, V23, P277, DOI 10.1016/S0168-6445(99)00008-X; Wittschieben BO, 1999, MOL CELL, V4, P123, DOI 10.1016/S1097-2765(00)80194-X; Wu SP, 1999, NATURE, V402, P832, DOI 10.1038/45590; Yonaha M, 2000, EMBO J, V19, P3770, DOI 10.1093/emboj/19.14.3770; Zeng CQ, 2000, MOL CELL BIOL, V20, P8290, DOI 10.1128/MCB.20.21.8290-8301.2000; Zhao J, 1999, MICROBIOL MOL BIOL R, V63, P405, DOI 10.1128/MMBR.63.2.405-445.1999; Zorio DAR, 1999, NATURE, V402, P835, DOI 10.1038/45597	86	827	846	0	54	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	FEB 22	2002	108	4					501	512		10.1016/S0092-8674(02)00617-7	http://dx.doi.org/10.1016/S0092-8674(02)00617-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	524XW	11909521	Bronze			2022-12-28	WOS:000174039000008
J	Mitton-Fry, RM; Anderson, EM; Hughes, TR; Lundblad, V; Wuttke, DS				Mitton-Fry, RM; Anderson, EM; Hughes, TR; Lundblad, V; Wuttke, DS			Conserved structure for single-stranded telomeric DNA recognition	SCIENCE			English	Article							OXYTRICHA MACRONUCLEAR DNA; BINDING-PROTEIN; RAD9 CHECKPOINT; CDC13 PROTEIN; IN-VITRO; MUTANTS; VIVO	The essential Cdc13 protein in the yeast Saccharomyces cerevisiae is a single-stranded telomeric DNA binding protein required for chromosome end protection and telomere replication. Here we report the solution structure of the Cdc13 DNA binding domain in complex with telomeric DNA. The structure reveals the use of a single OB (oligonucleotide/oligosaccharide binding) fold augmented by an unusually large loop for DNA recognition. This OB fold is structurally similar to OB folds found in the ciliated protozoan telomere end-binding protein, although no sequence similarity is apparent between them. The common usage of an OB fold for telomeric DNA interaction demonstrates conservation of end-protection mechanisms among eukaryotes.	Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Interdept Program Cell & Mol Biol, Houston, TX 77030 USA	University of Colorado System; University of Colorado Boulder; Baylor College of Medicine; Baylor College of Medicine	Wuttke, DS (corresponding author), Univ Colorado, Dept Chem & Biochem, Campus Box 215, Boulder, CO 80309 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059414] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM55867, GM59414, R01 GM059414] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baumann P, 2001, SCIENCE, V292, P1171, DOI 10.1126/science.1060036; Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; Booth C, 2001, NUCLEIC ACIDS RES, V29, P4414, DOI 10.1093/nar/29.21.4414; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Classen S, 2001, J MOL BIOL, V314, P1113, DOI 10.1006/jmbi.2000.5191; de Lange T, 2001, SCIENCE, V292, P1075; Diede SJ, 1999, CELL, V99, P723, DOI 10.1016/S0092-8674(00)81670-0; Dietmann S, 2001, NUCLEIC ACIDS RES, V29, P55, DOI 10.1093/nar/29.1.55; Dietmann S, 2001, NAT STRUCT BIOL, V8, P953, DOI 10.1038/nsb1101-953; Evans SK, 1999, SCIENCE, V286, P117, DOI 10.1126/science.286.5437.117; FANG GW, 1993, GENE DEV, V7, P870, DOI 10.1101/gad.7.5.870; Farmer BT, 1996, NAT STRUCT BIOL, V3, P995, DOI 10.1038/nsb1296-995; GARVIK B, 1995, MOL CELL BIOL, V15, P6128; GOTTSCHLING DE, 1986, CELL, V47, P195, DOI 10.1016/0092-8674(86)90442-3; Horvath MP, 2001, J MOL BIOL, V310, P367, DOI 10.1006/jmbi.2001.4766; Horvath MP, 1998, CELL, V95, P963, DOI 10.1016/S0092-8674(00)81720-1; Hughes TR, 2000, P NATL ACAD SCI USA, V97, P6457, DOI 10.1073/pnas.97.12.6457; KLEYWEGT GJ, 1994, ESF CCP4 NEWSLETTER, V31, P9; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Lin JJ, 1996, P NATL ACAD SCI USA, V93, P13760, DOI 10.1073/pnas.93.24.13760; Lingner J, 1997, P NATL ACAD SCI USA, V94, P11190, DOI 10.1073/pnas.94.21.11190; Lustig AJ, 2001, NAT STRUCT BIOL, V8, P297, DOI 10.1038/86157; MITTONFRY RM, IN PRESS J BIOMOL NM; MURZIN AG, 1993, EMBO J, V12, P861, DOI 10.1002/j.1460-2075.1993.tb05726.x; Nugent CI, 1996, SCIENCE, V274, P249, DOI 10.1126/science.274.5285.249; Pennock E, 2001, CELL, V104, P387, DOI 10.1016/S0092-8674(01)00226-4; PRICE CM, 1987, GENE DEV, V1, P783, DOI 10.1101/gad.1.8.783; Shore D, 2001, CURR OPIN GENET DEV, V11, P189, DOI 10.1016/S0959-437X(00)00178-7; SINGER MS, 1994, SCIENCE, V266, P404, DOI 10.1126/science.7545955; WEINERT TA, 1993, GENETICS, V134, P63; [No title captured]	31	168	175	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 5	2002	296	5565					145	147		10.1126/science.1068799	http://dx.doi.org/10.1126/science.1068799			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	539FA	11935027				2022-12-28	WOS:000174858800049
J	Fried, TR; Bradley, EH; Towle, VR; Allore, H				Fried, TR; Bradley, EH; Towle, VR; Allore, H			Understanding the treatment preferences of seriously ill patients	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LIFE-SUSTAINING TREATMENT; DECISION-MAKING; CARE; END; SURVIVAL; OLDER; INTERVENTIONS; PHYSICIANS; PEOPLE; FAMILY	Background: The questions patients are asked about their preferences with regard to life-sustaining treatment usually focus on specific interventions, but the outcomes of treatment and their likelihood affect patients' preferences. Methods: We administered a questionnaire about treatment preferences to 226 persons who were 60 years of age or older and who had a limited life expectancy due to cancer, congestive heart failure, or chronic obstructive pulmonary disease. The study participants were asked whether they would want to receive a given treatment, first when the outcome was known with certainty and then with different likelihoods of an adverse outcome. The outcome without treatment was specified as death from the underlying disease. Results: The burden of treatment (i.e., the length of the hospital stay, extent of testing, and invasiveness of interventions), the outcome, and the likelihood of the outcome all influenced treatment preferences. For a low-burden treatment with the restoration of current health, 98.7 percent of participants said they would choose to receive the treatment (rather than not receive it and die), but 11.2 percent of these participants would not choose the treatment if it had a high burden. If the outcome was survival but with severe functional impairment or cognitive impairment, 74.4 percent and 88.8 percent of these participants, respectively, would not choose treatment. The number of participants who said they would choose treatment declined as the likelihood of an adverse outcome increased, with fewer participants choosing treatment when the possible outcome was functional or cognitive impairment than when it was death. Preferences did not differ according to the primary diagnosis. Conclusions: Advance care planning should take into account patients' attitudes toward the burden of treatment, the possible outcomes, and their likelihood. The likelihood of adverse functional and cognitive outcomes of treatment requires explicit consideration.	Vet Affairs Connecticut Healthcare Syst, Clin Epidemiol Unit, West Haven, CT 06516 USA; Yale Univ, Sch Med, Dept Med, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06510 USA; Yale Univ, Sch Med, Program Aging, New Haven, CT USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System; Yale University; Yale University; Yale University	Fried, TR (corresponding author), Vet Affairs Connecticut Healthcare Syst, Clin Epidemiol Unit, 950 Campbell Ave, West Haven, CT 06516 USA.	terri.fried@yale.edu		Allore, Heather/0000-0001-7685-8175	NATIONAL INSTITUTE ON AGING [P30AG021342] Funding Source: NIH RePORTER; NIA NIH HHS [P30 AG021342] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Allen JP, 1996, JAMA-J AM MED ASSOC, V275, P474; BRETT AS, 1991, JAMA-J AM MED ASSOC, V266, P825, DOI 10.1001/jama.266.6.825; Brundage MD, 1997, J CLIN ONCOL, V15, P330, DOI 10.1200/JCO.1997.15.1.330; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; *CONN HOSP, 1996, SUMM GUID IN ADV CAR; Dales RE, 1999, CHEST, V116, P792, DOI 10.1378/chest.116.3.792; Danis M, 1996, CRIT CARE MED, V24, P1811, DOI 10.1097/00003246-199611000-00009; DANIS M, 1988, JAMA-J AM MED ASSOC, V260, P797, DOI 10.1001/jama.260.6.797; DOUKAS DJ, 1991, J FAM PRACTICE, V32, P145; Finucane TE, 1999, JAMA-J AM MED ASSOC, V282, P1670, DOI 10.1001/jama.282.17.1670; Gazmararian JA, 1999, JAMA-J AM MED ASSOC, V281, P545, DOI 10.1001/jama.281.6.545; GILLICK MR, 1995, ANN INTERN MED, V123, P621, DOI 10.7326/0003-4819-123-8-199510150-00009; Hanson LC, 1997, ANN INTERN MED, V126, P381, DOI 10.7326/0003-4819-126-5-199703010-00007; Inouye SK, 1998, JAMA-J AM MED ASSOC, V279, P1187, DOI 10.1001/jama.279.15.1187; KNAUS WA, 1995, ANN INTERN MED, V122, P191, DOI 10.7326/0003-4819-122-3-199502010-00007; LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179; Lo B, 1999, ANN INTERN MED, V130, P772, DOI 10.7326/0003-4819-130-9-199905040-00018; Lynn J, 1997, J AM GERIATR SOC, V45, P526; Lynn J, 1997, ANN INTERN MED, V126, P97, DOI 10.7326/0003-4819-126-2-199701150-00001; MCNEIL BJ, 1982, NEW ENGL J MED, V306, P1259, DOI 10.1056/NEJM198205273062103; MURPHY DJ, 1994, NEW ENGL J MED, V330, P545, DOI 10.1056/NEJM199402243300807; MURPHY DJ, 1990, J CLIN EPIDEMIOL, V43, pS11, DOI 10.1016/0895-4356(90)90213-9; Navari RI, 2000, JAMA-J AM MED ASSOC, V284, P2449, DOI 10.1001/jama.284.19.2449; Patrick DL, 1997, ANN INTERN MED, V127, P509, DOI 10.7326/0003-4819-127-7-199710010-00002; PEARLMAN RA, 1993, J CLIN ETHIC, V4, P33; PFEIFFER E, 1975, J AM GERIATR SOC, V23, P433, DOI 10.1111/j.1532-5415.1975.tb00927.x; Ratner E, 2001, J AM GERIATR SOC, V49, P778, DOI 10.1046/j.1532-5415.2001.49155.x; Rosenfeld KE, 2000, J GEN INTERN MED, V15, P620, DOI 10.1046/j.1525-1497.2000.06289.x; ROYALL DR, 1992, J AM GERIATR SOC, V40, P1221, DOI 10.1111/j.1532-5415.1992.tb03646.x; SACHS GA, 1995, J AM GERIATR SOC, V43, P553, DOI 10.1111/j.1532-5415.1995.tb06106.x; SCHONWETTER RS, 1993, J GEN INTERN MED, V8, P295, DOI 10.1007/BF02600139; Schwartz LM, 1997, ANN INTERN MED, V127, P966, DOI 10.7326/0003-4819-127-11-199712010-00003; SLEVIN ML, 1990, BRIT MED J, V300, P1458, DOI 10.1136/bmj.300.6737.1458; Steinhauser AE, 2000, JAMA-J AM MED ASSOC, V284, P2476, DOI 10.1001/jama.284.19.2476; Tolle SW, 1999, ANN INTERN MED, V130, P681, DOI 10.7326/0003-4819-130-8-199904200-00015; Tulsky JA, 1998, ANN INTERN MED, V129, P441, DOI 10.7326/0003-4819-129-6-199809150-00003; WU AW, 1995, ANN INTERN MED, V122, P342, DOI 10.7326/0003-4819-122-5-199503010-00004	37	917	923	1	37	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 4	2002	346	14					1061	1066		10.1056/NEJMsa012528	http://dx.doi.org/10.1056/NEJMsa012528			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	536YL	11932474	Bronze			2022-12-28	WOS:000174729400007
J	Schilling, FH; Spix, C; Berthold, F; Erttmann, R; Fehse, N; Hero, B; Klein, G; Sander, J; Schwarz, K; Treuner, J; Zorn, U; Michaelis, J				Schilling, FH; Spix, C; Berthold, F; Erttmann, R; Fehse, N; Hero, B; Klein, G; Sander, J; Schwarz, K; Treuner, J; Zorn, U; Michaelis, J			Neuroblastoma screening at one year of age	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CALCULATING SAMPLE SIZES; TRIALS; AMPLIFICATION; PATTERN; DISEASE; CANCER	Background: Neuroblastoma is the second most common type of childhood tumor. It is not known whether screening for neuroblastoma at one year of age reduces the incidence of metastatic disease or mortality due to neuroblastoma. Methods: We offered urine screening for neuroblastoma at approximately one year of age to 2,581,188 children in 6 of 16 German states from 1995 to 2000. A total of 2,117,600 eligible children in the remaining states served as controls. We compared the two groups in terms of the incidence of disseminated disease and mortality from neuroblastoma. Results: A total of 1,475,773 children (61.2 percent of those who were born between July 1, 1994, and October 31, 1999) underwent screening. In this group, neuroblastoma was detected by screening in 149 children, of whom 3 have died. Fifty-five children who had negative screening tests were subsequently given a diagnosis of neuroblastoma; 14 of these children have died. The screened group and children in the control area had a similar incidence of stage 4 neuroblastoma (3.7 cases per 100,000 screened children [95 percent confidence interval, 2.7 to 4.7] and 3.8 per 100,000 controls [95 percent confidence interval, 2.9 to 4.6]) and a similar rate of death among children with neuroblastoma (1.3 deaths per 100,000 screened children [95 percent confidence interval, 0.7 to 1.8] and 1.2 per 100,000 controls [95 percent confidence interval, 0.7 to 1.7]). Comparison of the screened group and the children in the control area revealed substantial overdiagnosis in the former group (an estimated rate of 7 cases per 100,000 children [95 percent confidence interval, 4.6 to 9.2]); the overdiagnosis rate represents children who had neuroblastoma that was diagnosed by screening but who would not benefit from earlier diagnosis and treatment. Conclusions: The present findings do not support the usefulness of general screening for neuroblastoma at one year of age.	Olga Hosp, Klinikum Stuttgart, D-70176 Stuttgart, Germany; Johannes Gutenberg Univ Mainz, German Childhood Canc Registry, D-6500 Mainz, Germany; Univ Cologne, Childrens Hosp, Cologne, Germany; Univ Hamburg, Univ Hosp Eppendorf, Hamburg, Germany; Landesgesundheitsamt Niedersachsen, Hannover, Germany	General Hospital of N. Ionia Agia Olga; Klinikum Stuttgart; Johannes Gutenberg University of Mainz; University of Cologne; University of Hamburg; University Medical Center Hamburg-Eppendorf	Schilling, FH (corresponding author), Olga Hosp, Klinikum Stuttgart, Bismarckstr 8, D-70176 Stuttgart, Germany.	f.schilling@olgahospital.de						Ambros PF, 2000, NEUROBLASTOMA, P21; BERTHOLD F, 1991, AM J PEDIAT HEMATOL, V13, P8; Berthold F, 1999, J CLIN ONCOL, V17, P1200, DOI 10.1200/JCO.1999.17.4.1200; Berthold F, 2000, DRUGS, V59, P1261, DOI 10.2165/00003495-200059060-00006; Bessho F, 1996, INT J CANCER, V67, P520, DOI 10.1002/(SICI)1097-0215(19960807)67:4<520::AID-IJC10>3.0.CO;2-B; BRODEUR GM, 1993, J CLIN ONCOL, V11, P1466, DOI 10.1200/JCO.1993.11.8.1466; CARLSEN NLT, 1988, ANTICANCER RES, V8, P255; CASAGRANDE JT, 1978, BIOMETRICS, V34, P483, DOI 10.2307/2530613; DANGIO GJ, 1971, LANCET, V1, P1046; DEBERNARDI B, 1995, J CLIN ONCOL, V13, P884, DOI 10.1200/JCO.1995.13.4.884; DEBERNARDI B, 1992, CANCER-AM CANCER SOC, V70, P1625, DOI 10.1002/1097-0142(19920915)70:6<1625::AID-CNCR2820700631>3.0.CO;2-6; ESTEVE, 1995, BRIT J CANCER, V72, P804; Esteve J, 1998, MED PEDIATR ONCOL, V31, P401; ESTEVE J, 1995, BRIT J CANCER, V71, P1125, DOI 10.1038/bjc.1995.219; FLEISS JL, 1980, BIOMETRICS, V36, P343, DOI 10.2307/2529990; HANAWA Y, 1990, MED PEDIATR ONCOL, V18, P472, DOI 10.1002/mpo.2950180607; JARO MA, 1989, J AM STAT ASSOC, V84, P414, DOI 10.2307/2289924; KAATSCH P, 1995, EUR J CANCER, V31A, P993, DOI 10.1016/0959-8049(95)00091-7; Kaneko M, 1998, MED PEDIATR ONCOL, V31, P1, DOI 10.1002/(SICI)1096-911X(199807)31:1<1::AID-MPO1>3.0.CO;2-H; Kawa K, 1999, J CLIN ONCOL, V17, P3216, DOI 10.1200/JCO.1999.17.10.3216; Lastowska M, 2001, J CLIN ONCOL, V19, P3080; Lemieux B, 2000, NEUROBLASTOMA, P265; Maris JM, 1999, J CLIN ONCOL, V17, P2264, DOI 10.1200/JCO.1999.17.7.2264; McIntosh MW, 1999, STAT MED, V18, P2775, DOI 10.1002/(SICI)1097-0258(19991030)18:20<2775::AID-SIM196>3.0.CO;2-I; MILLER AB, 1985, SCREENING CANCER, P3; MILLER AB, 1996, ADV CANC SCREENING, P1; Morrison AS, 1992, SCREENING CHRONIC DI; Moss S, 2001, EVALUATION MONITORIN, P29; Nishi M, 1997, INT J CANCER, V71, P552, DOI 10.1002/(SICI)1097-0215(19970516)71:4<552::AID-IJC8>3.0.CO;2-T; Powell JE, 1998, LANCET, V352, P682, DOI 10.1016/S0140-6736(97)11239-9; PROROK P, 1998, ENCY BIOSTATISTICS, P3976; SANKILA R, 2001, EVALUATION MONITORIN, P233; Sawada T, 1994, Prog Clin Biol Res, V385, P371; Sawada T, 2000, NEUROBLASTOMA, P245; Schilling FH, 2000, NEUROBLASTOMA, P281; SCHILLING FH, 1991, PROG CLIN BIOL RES, V366, P579; Schilling FH, 1998, MED PEDIATR ONCOL, V31, P435, DOI 10.1002/(SICI)1096-911X(199811)31:5<435::AID-MPO9>3.0.CO;2-Y; Spix C, 2001, EUR J CANCER, V37, P722, DOI 10.1016/S0959-8049(01)00003-X; TAKEDA T, 1989, MED PEDIATR ONCOL, V17, P368, DOI 10.1002/mpo.2950170504; TREUNER J, 1995, EUR J CANCER, V31A, P565, DOI 10.1016/0959-8049(95)00034-G; TUCHMAN M, 1987, CLIN BIOCHEM, V20, P173, DOI 10.1016/S0009-9120(87)80116-9; Welch HG, 2000, JAMA-J AM MED ASSOC, V283, P2975, DOI 10.1001/jama.283.22.2975; Woods WG, 1996, LANCET, V348, P1682, DOI 10.1016/S0140-6736(96)06020-5; Woods WG, 1999, MED PEDIATR ONCOL, V33, P360; Woods WG, 2002, NEW ENGL J MED, V346, P1041, DOI 10.1056/NEJMoa012387; Yamamoto K, 1998, J CLIN ONCOL, V16, P1265, DOI 10.1200/JCO.1998.16.4.1265; 1999, MED PEDIAT ONCOL, V33, P357	47	275	279	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 4	2002	346	14					1047	1053		10.1056/NEJMoa012277	http://dx.doi.org/10.1056/NEJMoa012277			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	536YL	11932471				2022-12-28	WOS:000174729400003
J	Terada, N; Hamazaki, T; Oka, M; Hoki, M; Mastalerz, DM; Nakano, Y; Meyer, EM; Morel, L; Petersen, BE; Scott, EW				Terada, N; Hamazaki, T; Oka, M; Hoki, M; Mastalerz, DM; Nakano, Y; Meyer, EM; Morel, L; Petersen, BE; Scott, EW			Bone marrow cells adopt the phenotype of other cells by spontaneous cell fusion	NATURE			English	Article							STEM-CELLS; ES CELLS; IN-VIVO; RECEPTOR; BRAIN; MICE	Recent studies have demonstrated that transplanted bone marrow cells can turn into unexpected lineages including myocytes, hepatocytes, neurons and many others(1). A potential problem, however, is that reports discussing such 'transdifferentiation' in vivo tend to conclude donor origin of transdifferentiated cells on the basis of the existence of donor-specific genes such as Y-chromosome markers(1). Here we demonstrate that mouse bone marrow cells can fuse spontaneously with embryonic stem cells in culture in vitro that contains interleukin-3. Moreover, spontaneously fused bone marrow cells can subsequently adopt the phenotype of the recipient cells, which, without detailed genetic analysis, might be interpreted as 'dedifferentiation' or transdifferentiation.	Univ Florida, Coll Med, Dept Pathol, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Shands Canc Ctr, Program Stem Cell Biol, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Dept Pharmacol, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Dept Mol Genet & Microbiol, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida	Terada, N (corresponding author), Univ Florida, Coll Med, Dept Pathol, Gainesville, FL 32610 USA.							Brazelton TR, 2000, SCIENCE, V290, P1775, DOI 10.1126/science.290.5497.1775; Chiozzi P, 1997, J CELL BIOL, V138, P697, DOI 10.1083/jcb.138.3.697; Clarke DL, 2000, SCIENCE, V288, P1660, DOI 10.1126/science.288.5471.1660; ENELOW RI, 1992, AM J RESP CELL MOL, V6, P57; Everett CA, 1996, ZYGOTE, V4, P59, DOI 10.1017/S0967199400002896; FALZONI S, 1995, J CLIN INVEST, V95, P1207, DOI 10.1172/JCI117770; Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528; Hadjantonakis AK, 1998, MECH DEVELOP, V76, P79, DOI 10.1016/S0925-4773(98)00093-8; Hamazaki T, 2001, FEBS LETT, V497, P15, DOI 10.1016/S0014-5793(01)02423-1; Kawasaki H, 2000, NEURON, V28, P31, DOI 10.1016/S0896-6273(00)00083-0; Kawasome H, 1998, P NATL ACAD SCI USA, V95, P5033, DOI 10.1073/pnas.95.9.5033; Krause DS, 2001, CELL, V105, P369, DOI 10.1016/S0092-8674(01)00328-2; Lagasse E, 2000, NAT MED, V6, P1229, DOI 10.1038/81326; Mezey E, 2000, SCIENCE, V290, P1779, DOI 10.1126/science.290.5497.1779; Minamino T, 1999, P NATL ACAD SCI USA, V96, P15127, DOI 10.1073/pnas.96.26.15127; Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9; Nishimoto M, 1999, MOL CELL BIOL, V19, P5453; PARWARESCH MR, 1986, VIRCHOWS ARCH B, V51, P89, DOI 10.1007/BF02899019; Petersen BE, 1999, SCIENCE, V284, P1168, DOI 10.1126/science.284.5417.1168; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Tada M, 1997, EMBO J, V16, P6510, DOI 10.1093/emboj/16.21.6510; Tada M, 2001, CURR BIOL, V11, P1553, DOI 10.1016/S0960-9822(01)00459-6; Theise ND, 2000, HEPATOLOGY, V32, P11, DOI 10.1053/jhep.2000.9124; Weissman IL, 2000, SCIENCE, V287, P1442, DOI 10.1126/science.287.5457.1442; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0	25	1564	1733	1	65	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 4	2002	416	6880					542	545		10.1038/nature730	http://dx.doi.org/10.1038/nature730			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	537JY	11932747				2022-12-28	WOS:000174756500045
J	Walsh, DM; Klyubin, I; Fadeeva, JV; Cullen, WK; Anwyl, R; Wolfe, MS; Rowan, MJ; Selkoe, DJ				Walsh, DM; Klyubin, I; Fadeeva, JV; Cullen, WK; Anwyl, R; Wolfe, MS; Rowan, MJ; Selkoe, DJ			Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo	NATURE			English	Article							INSULIN-DEGRADING ENZYME; TRANSGENIC MICE; PRECURSOR PROTEIN; SYNAPTIC-TRANSMISSION; ALZHEIMERS-DISEASE; NEURODEGENERATION; FIBRILLOGENESIS; NEUROTOXICITY; A-BETA(1-42); AGGREGATION	Although extensive data support a central pathogenic role for amyloid beta protein (Abeta) in Alzheimer's disease(1), the amyloid hypothesis remains controversial, in part because a specific neurotoxic species of Abeta and the nature of its effects on synaptic function have not been defined in vivo. Here we report that natural oligomers of human Abeta are formed soon after generation of the peptide within specific intracellular vesicles and are subsequently secreted from the cell. Cerebral microinjection of cell medium containing these oligomers and abundant Abeta monomers but no amyloid fibrils markedly inhibited hippocampal long-term potentiation (LTP) in rats in vivo. Immunodepletion from the medium of all Ab species completely abrogated this effect. Pretreatment of the medium with insulin-degrading enzyme, which degrades Abeta monomers but not oligomers, did not prevent the inhibition of LTP. Therefore, Abeta oligomers, in the absence of monomers and amyloid fibrils, disrupted synaptic plasticity in vivo at concentrations found in human brain and cerebrospinal fluid. Finally, treatment of cells with gamma-secretase inhibitors prevented oligomer formation at doses that allowed appreciable monomer production, and such medium no longer disrupted LTP, indicating that synaptotoxic Abeta oligomers can be targeted therapeutically.	Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA; Brigham & Womens Hosp, Ctr Neurol Dis, Boston, MA 02115 USA; Univ Dublin Trinity Coll, Dept Pharmacol & Therapeut, Dublin 2, Ireland; Univ Dublin Trinity Coll, Dept Physiol, Dublin 2, Ireland	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Trinity College Dublin; Trinity College Dublin	Selkoe, DJ (corresponding author), Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA.	dselkoe@rics.bwh.harvard.edu	hu, jenny/AAK-8712-2020	Rowan, Michael Joseph/0000-0002-3867-9536				Chapman PF, 1999, NAT NEUROSCI, V2, P271, DOI 10.1038/6374; Chen GQ, 2000, NATURE, V408, P975, DOI 10.1038/35050103; Chesneau V, 2000, PROTEIN EXPRES PURIF, V19, P91, DOI 10.1006/prep.2000.1217; Chiti F, 1999, P NATL ACAD SCI USA, V96, P3590, DOI 10.1073/pnas.96.7.3590; Chui DH, 1999, NAT MED, V5, P560, DOI 10.1038/8438; DICKSON DW, 1995, NEUROBIOL AGING, V16, P285, DOI 10.1016/0197-4580(95)00013-5; Fitzjohn SM, 2001, J NEUROSCI, V21, P4691, DOI 10.1523/JNEUROSCI.21-13-04691.2001; GETMAN DP, 1993, J MED CHEM, V36, P288, DOI 10.1021/jm00054a014; Hartley DM, 1999, J NEUROSCI, V19, P8876, DOI 10.1523/JNEUROSCI.19-20-08876.1999; Hsia AY, 1999, P NATL ACAD SCI USA, V96, P3228, DOI 10.1073/pnas.96.6.3228; Kim JH, 2001, J NEUROSCI, V21, P1327; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Larson J, 1999, BRAIN RES, V840, P23, DOI 10.1016/S0006-8993(99)01698-4; Lewis J, 2001, SCIENCE, V293, P1487, DOI 10.1126/science.1058189; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; Moechars D, 1999, J BIOL CHEM, V274, P6483, DOI 10.1074/jbc.274.10.6483; Morishima-Kawashima M, 1998, BIOCHEMISTRY-US, V37, P15247, DOI 10.1021/bi981843u; Mucke L, 2000, J NEUROSCI, V20, P4050, DOI 10.1523/jneurosci.20-11-04050.2000; PIKE CJ, 1991, BRAIN RES, V563, P311, DOI 10.1016/0006-8993(91)91553-D; PODLISNY MB, 1995, J BIOL CHEM, V270, P9564, DOI 10.1074/jbc.270.16.9564; Qiu WQ, 1998, J BIOL CHEM, V273, P32730, DOI 10.1074/jbc.273.49.32730; Rochet JC, 2000, CURR OPIN STRUC BIOL, V10, P60, DOI 10.1016/S0959-440X(99)00049-4; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; TERRY RD, 1991, ANN NEUROL, V30, P572, DOI 10.1002/ana.410300410; Walsh DM, 1999, J BIOL CHEM, V274, P25945, DOI 10.1074/jbc.274.36.25945; Walsh DM, 2000, BIOCHEMISTRY-US, V39, P10831, DOI 10.1021/bi001048s; Xia WM, 2000, P NATL ACAD SCI USA, V97, P9299, DOI 10.1073/pnas.97.16.9299; Xia WM, 1997, J BIOL CHEM, V272, P7977, DOI 10.1074/jbc.272.12.7977	30	3453	3657	6	713	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 4	2002	416	6880					535	539		10.1038/416535a	http://dx.doi.org/10.1038/416535a			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	537JY	11932745				2022-12-28	WOS:000174756500043
J	Shavelle, DM; Takasu, J; Budoff, MJ; Mao, SS; Zhao, XQ; O'Brien, KD				Shavelle, DM; Takasu, J; Budoff, MJ; Mao, SS; Zhao, XQ; O'Brien, KD			HMG CoA reductase inhibitor (statin) and aortic valve calcium	LANCET			English	Article							CORONARY-ARTERY DISEASE	There Is no known pharmacological therapy for calcific aortic valvular sclerosis or stenosis. Because leaflet calcification occurs In areas of lipoprotein deposition, we hypothesised that 3-hydroxy-3-methylglutaryl-coenzyme A (HMG COA) reductase Inhibitors (statins) might slow aortic valve calcium (AVC) accumulation. We retrospectively identified 65 patients who had undergone two electron-beam computed tomography scans at a mean (SD) interval of 2.5 (1.6) years. 28 (43%) patients were receiving statins. Patients who were treated with statins had a 62-63% lower median rate of AVC accumulation (p=0.006) and 44-49% fewer statin patients had definite AVC progression (p=0.043). These findings suggest that statins may decrease AVC accumulation.	Univ Washington, Dept Med, Div Cardiol, Seattle, WA 98195 USA; Harbor UCLA Res & Educ Inst, Torrance, CA USA	University of Washington; University of Washington Seattle; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center	O'Brien, KD (corresponding author), Univ Washington, Dept Med, Div Cardiol, 1959 NE Pacific St, Seattle, WA 98195 USA.		O'Brien, Kevin/CAH-4638-2022; O'Brien, Kevin Douglas/HDO-1461-2022; Budoff, Matthew/ABD-5175-2021	O'Brien, Kevin/0000-0002-2293-9196; O'Brien, Kevin Douglas/0000-0002-2293-9196; Budoff, Matthew/0000-0002-9616-1946				Callister TQ, 1998, NEW ENGL J MED, V339, P1972, DOI 10.1056/NEJM199812313392703; Callister TQ, 1998, RADIOLOGY, V208, P807, DOI 10.1148/radiology.208.3.9722864; Kizer JR, 2001, J HEART VALVE DIS, V10, P361; OBrien KD, 1996, ARTERIOSCL THROM VAS, V16, P523, DOI 10.1161/01.ATV.16.4.523; Stewart BF, 1997, J AM COLL CARDIOL, V29, P630, DOI 10.1016/S0735-1097(96)00563-3	5	202	209	0	17	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 30	2002	359	9312					1125	1126		10.1016/S0140-6736(02)08161-8	http://dx.doi.org/10.1016/S0140-6736(02)08161-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	536YJ	11943265				2022-12-28	WOS:000174729200016
J	Thiele, A; Henning, P; Kubischik, M; Hoffmann, KP				Thiele, A; Henning, P; Kubischik, M; Hoffmann, KP			Neural mechanisms of saccadic suppression	SCIENCE			English	Article							EYE-MOVEMENTS; VISUAL PATHWAY; CHANGE-POINT; MOTION; SENSITIVITY; MACAQUE; NEURONS; STRIATE; CORTEX; MST	In normal vision our gaze leaps from detail to detail, resulting in rapid image motion across the retina. Yet we are unaware of such motion, a phenomenon known as saccadic suppression. We recorded neural activity in the middle temporal and middle superior temporal cortical areas during saccades and identical image motion under passive viewing conditions. Some neurons were selectively silenced during saccadic image motion, but responded well to identical external image motion. In addition, a subpopulation of neurons reversed their preferred direction of motion during saccades. Consequently, oppositely directed motion signals annul one another, and motion percepts are suppressed.	Ruhr Univ Bochum, D-44780 Bochum, Germany	Ruhr University Bochum	Hoffmann, KP (corresponding author), Ruhr Univ Bochum, D-44780 Bochum, Germany.			Thiele, Alexander/0000-0003-4894-0213				Bair W, 1998, VISUAL NEUROSCI, V15, P779, DOI 10.1017/S0952523898154160; BRIDGEMAN B, 1975, VISION RES, V15, P719, DOI 10.1016/0042-6989(75)90290-4; BRITTEN KH, 1992, J NEUROSCI, V12, P4745; BURR DC, 1994, NATURE, V371, P511, DOI 10.1038/371511a0; BURR DC, 1982, VISION RES, V22, P479, DOI 10.1016/0042-6989(82)90196-1; BURR DC, 1982, J PHYSIOL-LONDON, V333, P1; CAMPBELL FW, 1978, VISION RES, V18, P1297, DOI 10.1016/0042-6989(78)90219-5; CELEBRINI S, 1994, J NEUROSCI, V14, P4109; COMMENGES D, 1985, STAT MED, V4, P91, DOI 10.1002/sim.4780040113; COMMENGES D, 1986, COMPUT METH PROG BIO, V23, P123, DOI 10.1016/0169-2607(86)90107-0; Derrington AM, 1998, VISUAL NEUROSCI, V15, P875, DOI 10.1017/S0952523898155128; Diamond MR, 2000, J NEUROSCI, V20, P3449, DOI 10.1523/JNEUROSCI.20-09-03449.2000; Fischer WH, 1996, EXP BRAIN RES, V110, P435; Holt E., 1903, HARVARD PSYCHOL STUD, V1, P3; ILG UJ, 1993, VISION RES, V33, P211, DOI 10.1016/0042-6989(93)90159-T; JUDGE SJ, 1980, J NEUROPHYSIOL, V43, P1133, DOI 10.1152/jn.1980.43.4.1133; Leopold DA, 1998, EXP BRAIN RES, V123, P341, DOI 10.1007/s002210050577; MACKAY D, 1970, NATURE, V255, P90; MATIN E, 1974, PSYCHOL BULL, V81, P899, DOI 10.1037/h0037368; MATIN E, 1972, SCIENCE, V178, P179, DOI 10.1126/science.178.4057.179; NODA H, 1975, J PHYSIOL-LONDON, V250, P579, DOI 10.1113/jphysiol.1975.sp011071; Park J, 2001, VISION RES, V41, P3751, DOI 10.1016/S0042-6989(01)00211-5; Ross J, 1996, BEHAV BRAIN RES, V80, P1, DOI 10.1016/0166-4328(96)00012-5; SPERRY RW, 1950, VISION RES, V16, P1185; Thiele A, 1999, EUR J NEUROSCI, V11, P2044, DOI 10.1046/j.1460-9568.1999.00630.x; Treue S, 1996, NATURE, V382, P539, DOI 10.1038/382539a0; VONHOLST E, 1950, NATURWISSENSCHAFTEN, V37, P464, DOI 10.1007/BF00622503	27	186	190	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 29	2002	295	5564					2460	2462		10.1126/science.1068788	http://dx.doi.org/10.1126/science.1068788			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	536QD	11923539	Green Submitted			2022-12-28	WOS:000174712600058
J	Polo, S; Sigismund, S; Faretta, M; Guidi, M; Capua, MR; Bossi, G; Chen, H; De Camilli, P; Di Fiore, PP				Polo, S; Sigismund, S; Faretta, M; Guidi, M; Capua, MR; Bossi, G; Chen, H; De Camilli, P; Di Fiore, PP			A single motif responsible for ubiquitin recognition and monoubiquitination in endocytic proteins	NATURE			English	Article							TYROSINE KINASE SUBSTRATE; 26-S PROTEASE SUBUNIT; SACCHAROMYCES-CEREVISIAE; BINDING; DOMAIN; EPS15; EH; FAMILY	Ubiquitination is a post-translation modification in which ubiquitin chains or single ubiquitin molecules are appended to target proteins, giving rise to poly- or monoubiquitination, respectively(1-4). Polyubiquitination targets proteins for destruction by the proteasome. The role of monoubiquitination is less understood, although a function in membrane trafficking is emerging, at least in yeast(1,3,5). Here we report that a short amino-acid stretch at the carboxy-termini of the monoubiquitinated endocytic proteins Eps15 and eps15R is indispensable for their monoubiquitination. A similar sequence, also required for this modification, is found in other cytosolic endocytic proteins, such as epsins and Hrs. These sequences comprise a protein motif, UIM (ref. 6), which has been proposed to bind to ubiquitin. We confirm this for the UIMs of eps15, eps15R, epsins and Hrs. Thus, the same motif in several endocytic proteins is responsible for ubiquitin recognition and monoubiquitination. Our results predict the existence of a UIM: ubiquitin-based intracellular network. Eps15/eps15R, epsins and Hrs may function as adaptors between ubiquitinated membrane cargo and either the clathrin coat or other endocytic scaffolds. In addition, through their own ubiquitination, they may further contribute to the amplification of this network in the endocytic pathway.	European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy; Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA; IFOM, FIRC Inst Mol Oncol, I-20134 Milan, Italy; Univ Milan, Sch Med, I-20122 Milan, Italy	IRCCS European Institute of Oncology (IEO); Yale University; Howard Hughes Medical Institute; Yale University; IFOM - FIRC Institute of Molecular Oncology; University of Milan	Di Fiore, PP (corresponding author), European Inst Oncol, Dept Expt Oncol, Via Ripamonti 435, I-20141 Milan, Italy.		Faretta, Mario/H-8946-2012; Yang, Chen/G-1379-2010; Di Fiore, Pier Paolo/K-2130-2012; Polo, Simona/P-3509-2014; Sigismund, Sara/H-3687-2017	Faretta, Mario/0000-0003-1678-5781; Di Fiore, Pier Paolo/0000-0002-2252-0950; Sigismund, Sara/0000-0002-1396-4453; Polo, Simona/0000-0001-5536-9399				Avantaggiati ML, 1996, EMBO J, V15, P2236, DOI 10.1002/j.1460-2075.1996.tb00577.x; Beal R, 1996, P NATL ACAD SCI USA, V93, P861, DOI 10.1073/pnas.93.2.861; Benmerah A, 1996, J BIOL CHEM, V271, P12111, DOI 10.1074/jbc.271.20.12111; Burd CG, 1998, MOL CELL, V2, P157, DOI 10.1016/S1097-2765(00)80125-2; Chen H, 1998, NATURE, V394, P793, DOI 10.1038/29555; Coda L, 1998, J BIOL CHEM, V273, P3003, DOI 10.1074/jbc.273.5.3003; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; Dunn R, 2001, J BIOL CHEM, V276, P25974, DOI 10.1074/jbc.M104113200; Dunn R, 2001, MOL BIOL CELL, V12, P421, DOI 10.1091/mbc.12.2.421; Gagny B, 2000, J CELL SCI, V113, P3309; Gaullier JM, 1998, NATURE, V394, P432, DOI 10.1038/28767; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Hicke L, 2001, CELL, V106, P527, DOI 10.1016/S0092-8674(01)00485-8; Hofmann K, 2001, TRENDS BIOCHEM SCI, V26, P347, DOI 10.1016/S0968-0004(01)01835-7; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; Iannolo G, 1997, CANCER RES, V57, P240; Itoh T, 2001, SCIENCE, V291, P1047, DOI 10.1126/science.291.5506.1047; Jensen JP, 1995, J BIOL CHEM, V270, P30408, DOI 10.1074/jbc.270.51.30408; Katzmann DJ, 2001, CELL, V106, P145, DOI 10.1016/S0092-8674(01)00434-2; KOMADA M, 1995, MOL CELL BIOL, V15, P6213; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Patki V, 1998, NATURE, V394, P433, DOI 10.1038/28771; Santolini E, 1999, EXP CELL RES, V253, P186, DOI 10.1006/excr.1999.4694; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; vanDelft S, 1997, J BIOL CHEM, V272, P14013, DOI 10.1074/jbc.272.22.14013; vanNocker S, 1996, MOL CELL BIOL, V16, P6020; Wang GL, 2001, MOL CELL BIOL, V21, P3564, DOI 10.1128/MCB.21.10.3564-3575.2001; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; WONG WT, 1995, P NATL ACAD SCI USA, V92, P9530, DOI 10.1073/pnas.92.21.9530; Young P, 1998, J BIOL CHEM, V273, P5461, DOI 10.1074/jbc.273.10.5461	30	532	539	0	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 28	2002	416	6879					451	455		10.1038/416451a	http://dx.doi.org/10.1038/416451a			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	534UX	11919637				2022-12-28	WOS:000174607800052
J	Molegraaf, HJA; Presura, C; van der Marel, D; Kes, PH; Li, M				Molegraaf, HJA; Presura, C; van der Marel, D; Kes, PH; Li, M			Superconductivity-induced transfer of in-plane spectral weight in Bi2Sr2Ca2O8+delta	SCIENCE			English	Article							HIGH-TEMPERATURE SUPERCONDUCTIVITY; OPTICAL EVIDENCE; ANISOTROPY; YBA2CU3O7-DELTA; CONDUCTIVITY; SUPERFLUID; DENSITY; STATES; COLOR	Optical data are reported on a spectral weight transfer over a broad frequency range of Bi2Sr2CaCu2O8+delta, when this material became superconducting. Using spectroscopic ellipsometry, we observed the removal of a small amount of spectral weight in a broad frequency band from 10(4) cm(-1) to at least 2 x 10(4) cm(-1), due to the onset of superconductivity. We observed a blue shift of the ab-plane plasma frequency when the material became superconducting, indicating that the spectral weight was transferred to the infrared range. our observations are in agreement with models in which superconductivity is accompanied by an increased charge carrier spectral weight. The measured spectral weight transfer is large enough to account for the condensation energy in these compounds.	Univ Groningen, Ctr Mat Sci, NL-9747 AG Groningen, Netherlands; Leiden Univ, Kamerlingh Onnes Lab, NL-2300 RA Leiden, Netherlands	University of Groningen; Leiden University; Leiden University - Excl LUMC	van der Marel, D (corresponding author), Univ Groningen, Ctr Mat Sci, Nijenborgh 4, NL-9747 AG Groningen, Netherlands.		van der Marel, Dirk/G-4618-2012	van der Marel, Dirk/0000-0001-5266-9847				ALEXANDROV S, 1994, HIGH TEMPERATURE SUP; Anderson PW, 1998, SCIENCE, V279, P1196, DOI 10.1126/science.279.5354.1196; ANDERSON PW, 1995, SCIENCE, V268, P1154, DOI 10.1126/science.268.5214.1154; Anderson PW, 2000, PHYSICA C, V341, P9, DOI 10.1016/S0921-4534(00)00378-6; Assaad FF, 1996, PHYS REV LETT, V77, P4592, DOI 10.1103/PhysRevLett.77.4592; Basov DN, 1999, SCIENCE, V283, P49, DOI 10.1126/science.283.5398.49; CHAKRAVARTY S, 1993, SCIENCE, V261, P337, DOI 10.1126/science.261.5119.337; Ding H, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.227001; Emery VJ, 2000, J PHYS CHEM SOLIDS, V61, P467, DOI 10.1016/S0022-3697(99)00338-8; Feng DL, 2000, SCIENCE, V289, P277, DOI 10.1126/science.289.5477.277; FUGOL I, 1993, SOLID STATE COMMUN, V86, P385, DOI 10.1016/0038-1098(93)90863-I; HAN SG, 1990, PHYS REV LETT, V65, P2708, DOI 10.1103/PhysRevLett.65.2708; HIRSCH JE, 1992, PHYSICA C, V201, P347, DOI 10.1016/0921-4534(92)90483-S; HIRSCH JE, 1992, PHYSICA C, V199, P305, DOI 10.1016/0921-4534(92)90415-9; HOLCOMB MJ, 1994, PHYS REV LETT, V73, P2360, DOI 10.1103/PhysRevLett.73.2360; Klein MV, 1999, SCIENCE, V283, P42, DOI 10.1126/science.283.5398.42; Lee PA, 1999, PHYSICA C, V317, P194, DOI 10.1016/S0921-4534(99)00059-3; Leggett AJ, 1996, SCIENCE, V274, P587, DOI 10.1126/science.274.5287.587; Loram JW, 2001, J PHYS CHEM SOLIDS, V62, P59, DOI 10.1016/S0022-3697(00)00101-3; Moler KA, 1998, SCIENCE, V279, P1193, DOI 10.1126/science.279.5354.1193; Pavarini E, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.047003; Quijada MA, 1999, PHYS REV B, V60, P14917, DOI 10.1103/PhysRevB.60.14917; Rubhausen M, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.224514; Stevens CJ, 1997, PHYS REV LETT, V78, P2212, DOI 10.1103/PhysRevLett.78.2212; TAJIMA S, 1993, PHYS REV B, V48, P16164, DOI 10.1103/PhysRevB.48.16164; Tanner DB, 1998, PHYSICA B, V244, P1, DOI 10.1016/S0921-4526(97)00453-5; Tinkham M., 1996, INTRO SUPERCONDUCTIV, V2nd ed.; Tsvetkov AA, 1998, NATURE, V395, P360, DOI 10.1038/26439; van der Eb JW, 2001, PHYS REV LETT, V86, P3407, DOI 10.1103/PhysRevLett.86.3407; VANDERMAREL D, P 10 ANN HTS WORKSH, P357; Yagil Y, 1996, PHYSICA C, V256, P205, DOI 10.1016/0921-4534(95)00665-6	31	259	260	5	48	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 22	2002	295	5563					2239	2241		10.1126/science.1069947	http://dx.doi.org/10.1126/science.1069947			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	534AD	11910103				2022-12-28	WOS:000174561700036
J	Tsujimoto, T; Jeromin, A; Saitoh, N; Roder, JC; Takahashi, T				Tsujimoto, T; Jeromin, A; Saitoh, N; Roder, JC; Takahashi, T			Neuronal calcium sensor 1 and activity-dependent facilitation of P/Q-type calcium currents at presynaptic nerve terminals	SCIENCE			English	Article							CENTRAL SYNAPTIC TRANSMISSION; RAT BRAIN-STEM; BINDING-PROTEIN; DEVELOPMENTAL-CHANGES; TRANSMITTER RELEASE; FREQUENIN; SYSTEM; NCS-1; PHOSPHORYLATION; DROSOPHILA	P/Q-type presynaptic calcium currents (I-pCa) undergo activity-dependent facilitation during repetitive activation at the calyx of the Held synapse. We investigated whether neuronal calcium sensor 1 (NCS-1) may underlie this phenomenon. Direct loading of NCS-1 into the nerve terminal mimicked activity-dependent I-pCa facilitation by accelerating the activation time of I-pCa in a Ca2+-dependent manner. A presynaptically loaded carboxyl-terminal peptide of NCS-1 abolished I-pCa facilitation. These results suggest that residual Ca2+ activates endogenous NCS-1, thereby facilitating I-pCa. Because both P/Q-type Ca2+ channels and NCS-1 are widely expressed in mammalian nerve terminals, NCS-1 may contribute to the activity-dependent synaptic facilitation at many synapses.	Univ Tokyo, Fac Med, Dept Neurophysiol, Tokyo 1130033, Japan; Mt Sinai Hosp, Res Inst, Toronto, ON M5G 1X5, Canada	University of Tokyo; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Tsujimoto, T (corresponding author), Univ Tokyo, Fac Med, Dept Neurophysiol, Tokyo 1130033, Japan.		Oka, Yoshitaka/C-9670-2010; Takahashi, Tomoyuki/G-5951-2015; Roder, John/G-6468-2013	Oka, Yoshitaka/0000-0002-3482-3051; Takahashi, Tomoyuki/0000-0002-8771-7666; 				Ames JB, 2000, BIOCHEMISTRY-US, V39, P12149, DOI 10.1021/bi0012890; Borst JGG, 1998, J PHYSIOL-LONDON, V513, P149, DOI 10.1111/j.1469-7793.1998.149by.x; Bourne Y, 2001, J BIOL CHEM, V276, P11949, DOI 10.1074/jbc.M009373200; Cuttle MF, 1998, J PHYSIOL-LONDON, V512, P723, DOI 10.1111/j.1469-7793.1998.723bd.x; DECASTRO E, 1995, BIOCHEM BIOPH RES CO, V216, P133, DOI 10.1006/bbrc.1995.2601; DeMaria CD, 2001, NATURE, V411, P484, DOI 10.1038/35078091; DODGE FA, 1967, J PHYSIOL-LONDON, V193, P419, DOI 10.1113/jphysiol.1967.sp008367; Forsythe ID, 1998, NEURON, V20, P797, DOI 10.1016/S0896-6273(00)81017-X; Helmchen F, 1997, BIOPHYS J, V72, P1458, DOI 10.1016/S0006-3495(97)78792-7; IKEDA SR, 1991, J PHYSIOL-LONDON, V439, P181, DOI 10.1113/jphysiol.1991.sp018663; Iwasaki S, 2000, J NEUROSCI, V20, P59, DOI 10.1523/JNEUROSCI.20-01-00059.2000; Iwasaki S, 1998, J PHYSIOL-LONDON, V509, P419, DOI 10.1111/j.1469-7793.1998.419bn.x; Kajikawa Y, 2001, P NATL ACAD SCI USA, V98, P8054, DOI 10.1073/pnas.141031298; KASAI H, 1992, J PHYSIOL-LONDON, V448, P189, DOI 10.1113/jphysiol.1992.sp019036; KATZ B, 1967, J PHYSIOL-LONDON, V189, P535, DOI 10.1113/jphysiol.1967.sp008183; Martone ME, 1999, CELL TISSUE RES, V295, P395, DOI 10.1007/s004410051246; NEF S, 1995, J RECEPT SIGNAL TR R, V15, P365, DOI 10.3109/10799899509045227; Olafsson P, 1997, MOL BRAIN RES, V44, P73, DOI 10.1016/S0169-328X(96)00188-X; OLAFSSON P, 1995, P NATL ACAD SCI USA, V92, P8001, DOI 10.1073/pnas.92.17.8001; Paterlini M, 2000, NEUROSCIENCE, V99, P205, DOI 10.1016/S0306-4522(00)00201-3; PONGS O, 1993, NEURON, V11, P15, DOI 10.1016/0896-6273(93)90267-U; RIVOSECCHI R, 1994, J PHYSIOL-LONDON, V474, P223, DOI 10.1113/jphysiol.1994.sp020015; Sage C, 2000, HEARING RES, V150, P70, DOI 10.1016/S0378-5955(00)00183-0; Sakaba T, 2001, NEURON, V32, P1119, DOI 10.1016/S0896-6273(01)00543-8; Schaad NC, 1996, P NATL ACAD SCI USA, V93, P9253, DOI 10.1073/pnas.93.17.9253; TAKAHASHI T, 1993, NATURE, V366, P156, DOI 10.1038/366156a0; Tang YG, 2000, BIOPHYS J, V78, P2735, DOI 10.1016/S0006-3495(00)76819-6; Taschenberger H, 2000, J NEUROSCI, V20, P9162; UCHITEL OD, 1992, P NATL ACAD SCI USA, V89, P3330, DOI 10.1073/pnas.89.8.3330; Wang CY, 2001, NEURON, V32, P99, DOI 10.1016/S0896-6273(01)00434-2	30	176	182	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 22	2002	295	5563					2276	2279		10.1126/science.1068278	http://dx.doi.org/10.1126/science.1068278			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	534AD	11910115				2022-12-28	WOS:000174561700049
J	Madison-Antenucci, S; Grams, J; Hajduk, SL				Madison-Antenucci, S; Grams, J; Hajduk, SL			Editing machines: The complexities of trypanosome RNA editing	CELL			English	Review							MESSENGER-RNA; BRUCEI MITOCHONDRIA; IN-VITRO; PROTEIN; GENE	The assembly and disassembly of ribonucleoprotein complexes containing substrate precursor mRNAs and guide RNAs is crucial to the initiation and propagation of RNA editing. We discuss here the composition of these complexes and how their assembly may regulate RNA editing.	Univ Alabama, Sch Med, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA; Univ Alabama, Sch Dent, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Hajduk, SL (corresponding author), Univ Alabama, Sch Med, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA.			Madison-Antenucci, Susan/0000-0003-1748-9327				BENNE R, 1986, CELL, V46, P819, DOI 10.1016/0092-8674(86)90063-2; Grams J, 2000, EMBO J, V19, P5525, DOI 10.1093/emboj/19.20.5525; Horvath A, 2000, SCIENCE, V287, P1639, DOI 10.1126/science.287.5458.1639; Huang CE, 2001, EMBO J, V20, P4694, DOI 10.1093/emboj/20.17.4694; Kable ML, 1996, SCIENCE, V273, P1189, DOI 10.1126/science.273.5279.1189; Lambert L, 1999, NUCLEIC ACIDS RES, V27, P1429, DOI 10.1093/nar/27.6.1429; Madison-Antenucci S, 1998, EMBO J, V17, P6368, DOI 10.1093/emboj/17.21.6368; McManus MT, 2001, RNA, V7, P167, DOI 10.1017/S1355838201002072; Missel A, 1997, MOL CELL BIOL, V17, P4895, DOI 10.1128/MCB.17.9.4895; Muller UF, 2001, EMBO J, V20, P1394, DOI 10.1093/emboj/20.6.1394; Panigrahi AK, 2001, MOL CELL BIOL, V21, P6833, DOI 10.1128/MCB.21.20.6833-6840.2001; Panigrahi AK, 2001, MOL CELL BIOL, V21, P380, DOI 10.1128/MCB.21.2.380-389.2001; POLLARD VW, 1992, EMBO J, V11, P4429, DOI 10.1002/j.1460-2075.1992.tb05543.x; Rusche LN, 1997, EMBO J, V16, P4069, DOI 10.1093/emboj/16.13.4069; Rusche LN, 2001, MOL CELL BIOL, V21, P979, DOI 10.1128/MCB.21.4.979-989.2001; Schnaufer A, 2001, SCIENCE, V291, P2159, DOI 10.1126/science.1058655; Seiwert SD, 1996, CELL, V84, P831, DOI 10.1016/S0092-8674(00)81062-4; SIMPSON L, 1994, CURR OPIN GENET DEV, V4, P887, DOI 10.1016/0959-437X(94)90075-2; STUART KD, 2001, FRONTIERS MOL BIOL, P1; Vanhamme L, 1998, J BIOL CHEM, V273, P21825, DOI 10.1074/jbc.273.34.21825	20	88	92	0	3	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	FEB 22	2002	108	4					435	438		10.1016/S0092-8674(02)00653-0	http://dx.doi.org/10.1016/S0092-8674(02)00653-0			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	524XW	11909515	Bronze			2022-12-28	WOS:000174039000002
J	Ham, C; Alberti, KGMM				Ham, C; Alberti, KGMM			The medical profession, the public, and the government	BRITISH MEDICAL JOURNAL			English	Article									Dept Hlth, Strategy Unit, London SW1A 2NS, England; Royal Coll Physicians, London NW1 4LE, England	Royal College of Physicians	Ham, C (corresponding author), Dept Hlth, Strategy Unit, London SW1A 2NS, England.							ABEL L, 1959, BMJ S, V4, P109; CHANTLER C, 2001, PATIENTS PROFESSIONA; *COMM ENQ ALL ILL, 1969, CMND3975; *DEP HLTH, 2001, COMM QUAL QUEST EXC; HAM C, 1977, CONFLICTS NHS; HAMPTON JR, 1983, BRIT MED J, V287, P1237, DOI 10.1136/bmj.287.6401.1237; Irvine D, 2001, PATIENTS DOCTORS ALL; Klein Rudolf, 1983, POLITICS NATL HLTH S; Robb B, 1967, SANS EVERYTHING CASE; Salter B, 1999, POLICY POLIT, V27, P143, DOI 10.1332/030557399782227209; Smith R, 2001, BMJ-BRIT MED J, V322, P1073, DOI 10.1136/bmj.322.7294.1073; The Stationary Office, 2001, LEARN BRIST REP PUBL	12	80	84	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 6	2002	324	7341					838	842		10.1136/bmj.324.7341.838	http://dx.doi.org/10.1136/bmj.324.7341.838			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	540ZG	11934780	Green Published			2022-12-28	WOS:000174960300021
J	Baker, VR				Baker, VR			Earth sciences - The study of superfloods	SCIENCE			English	Editorial Material							LATE PLEISTOCENE		Univ Arizona, Dept Hydrol & Water Resources, Tucson, AZ 85721 USA	University of Arizona	Baker, VR (corresponding author), Univ Arizona, Dept Hydrol & Water Resources, Tucson, AZ 85721 USA.							ARKHIPOV SA, 1995, BOREAS, V24, P196; BAKER VR, 1993, SCIENCE, V259, P348, DOI 10.1126/science.259.5093.348; Baker VR, 2001, NATURE, V412, P228, DOI 10.1038/35084172; Bjornstad BN, 2001, J GEOL, V109, P695, DOI 10.1086/323190; BRETZ JH, 1923, J GEOL, V32, P139; Grosswald M.G., 1999, CATACLYSMIC MEGAFLOO; House P. K., 2002, ANCIENT FLOODS MODER; KEHEW AE, 1994, QUATERNARY SCI REV, V13, P859, DOI 10.1016/0277-3791(94)90006-X; OCONNOR JE, 1993, 104 GEOL SOC AM; SHAW J, 1996, GEOMORPHOLOGY SANS F, P182; Teller JT, 1990, PALEOCEANOGRAPHY, V5, P897, DOI 10.1029/PA005i006p00897; Zuffa GG, 2000, J GEOL, V108, P253, DOI 10.1086/314404	12	28	30	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 29	2002	295	5564					2379	2380		10.1126/science.1068448	http://dx.doi.org/10.1126/science.1068448			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	536QD	11923514				2022-12-28	WOS:000174712600030
J	Johnson, JG; Cohen, P; Smailes, EM; Kasen, S; Brook, JS				Johnson, JG; Cohen, P; Smailes, EM; Kasen, S; Brook, JS			Television viewing and aggressive behavior during adolescence and adulthood	SCIENCE			English	Article							MEDIA VIOLENCE	Television viewing and aggressive behavior were assessed over a 17-year interval in a community sample of 707 individuals. There was a significant association between the amount of time spent watching television during adolescence and early adulthood and the likelihood of subsequent aggressive acts against others. This association remained significant after previous aggressive behavior, childhood neglect, family income, neighborhood violence, parental education, and psychiatric disorders were controlled statistically.	Columbia Univ, New York, NY 10032 USA; New York State Psychiat Inst & Hosp, New York, NY 10032 USA; Mt Sinai Med Ctr, New York, NY 10029 USA	Columbia University; New York State Psychiatry Institute; Icahn School of Medicine at Mount Sinai	Johnson, JG (corresponding author), Columbia Univ, 1051 Riverside Dr, New York, NY 10032 USA.	jjohnso@pi.cmpmc.columbia.edu			NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH036971] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA003188] Funding Source: NIH RePORTER; NIDA NIH HHS [DA-03188] Funding Source: Medline; NIMH NIH HHS [MH-36971] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		*AM PSYCH ASS, 1993, SUMM REP AM PSYCH AS; AMMONS RB, 1962, PSYCHOL REP, V11, P111, DOI 10.1177/003329416201100106; Bandura A., 1973, AGGRESSION SOCIAL LE; BIRD HR, 1992, J AM ACAD CHILD PSY, V31, P78, DOI 10.1097/00004583-199201000-00012; Bushman BJ, 2001, AM PSYCHOL, V56, P477, DOI 10.1037//0003-066X.56.6-7.477; Bushman Brad J, 2001, HDB CHILDREN MEDIA, P223; CENTERWALL BS, 1992, JAMA-J AM MED ASSOC, V267, P3059; COHEN P, 1987, J AM ACAD CHILD PSY, V26, P662, DOI 10.1097/00004583-198709000-00009; Cohen P., 1996, LIFE VALUES ADOLESCE; Costello E. J., 1984, TESTING NIMH DIAGNOS; Ellickson P, 1997, AM J PUBLIC HEALTH, V87, P985, DOI 10.2105/AJPH.87.6.985; ERON LD, 1972, AM PSYCHOL, V27, P253, DOI 10.1037/h0033721; Gerbner G., 1994, TELEVISION VIOLENCE; GERBNER G, 1992, VIOLENCE CABLE ORIGI; Goldstein A., 1994, AGGRESSIVE BEHAV, P255; HUESMANN LR, 1988, AGGRESSIVE BEHAV, V14, P13; HUESMANN LR, 1986, J SOC ISSUES, V42, P125, DOI 10.1111/j.1540-4560.1986.tb00246.x; Johnson JG, 2000, J PERS DISORD, V14, P171, DOI 10.1521/pedi.2000.14.2.171; KENNY DA, 1997, HDB SOCIAL PSYCHOL, P233; KOGAN L, 1977, J SOCIAL SERVICE RES, V1, P117, DOI DOI 10.1300/J079V01N02_01; OLEARY KD, 1989, J CONSULT CLIN PSYCH, V57, P263, DOI 10.1037/0022-006X.57.2.263; PAIK H, 1994, COMMUN RES, V21, P516, DOI 10.1177/009365094021004004; PIACENTINI JC, 1992, J ABNORM CHILD PSYCH, V20, P51, DOI 10.1007/BF00927116; Robins L.N., 1991, PSYCHIAT DISORDERS A; Singer MI, 1999, PEDIATRICS, V104, P878, DOI 10.1542/peds.104.4.878; TURNER CW, 1986, J SOC ISSUES, V42, P51, DOI 10.1111/j.1540-4560.1986.tb00242.x	26	219	223	1	65	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 29	2002	295	5564					2468	2471		10.1126/science.1062929	http://dx.doi.org/10.1126/science.1062929			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	536QD	11923542				2022-12-28	WOS:000174712600061
J	Kim, MC; Panstruga, R; Elliott, C; Muller, J; Devoto, A; Yoon, HW; Park, HC; Cho, MJ; Schulze-Lefert, P				Kim, MC; Panstruga, R; Elliott, C; Muller, J; Devoto, A; Yoon, HW; Park, HC; Cho, MJ; Schulze-Lefert, P			Calmodulin interacts with MLO protein to regulate defence against mildew in barley	NATURE			English	Article							POWDERY MILDEW; ALPHA-SUBUNIT; OXIDATIVE BURST; ACTIVATION; RESISTANCE; CALCIUM; GENE; MUTATIONS; RESPONSES; INCREASE	In plants, defence against specific isolates of a pathogen can be triggered by the presence of a corresponding race-specific resistance gene(1), whereas resistance of a more broad-spectrum nature can result from recessive, presumably loss-of-regulatory-function, mutations(2). An example of the latter are mlo mutations in barley, which have been successful in agriculture for the control of powdery mildew fungus (Blumeria graminis f. sp. hordei; Bgh)(3). MLO protein resides in the plasma membrane, has seven transmembrane domains, and is the prototype of a sequence-diversified family unique to plants(4,5), reminiscent of the seven-transmembrane receptors in fungi and animals(5). In animals, these are known as G-protein-coupled receptors and exist in three main families, lacking sequence similarity, that are thought to be an example of molecular convergence(6). MLO seems to function independently of heterotrimeric G proteins. We have identified a domain in MLO that mediates a Ca2+-dependent interaction with calmodulin in vitro. Loss of calmodulin binding halves the ability of MLO to negatively regulate defence against powdery mildew in vivo. We propose a sensor role for MLO in the modulation of defence reactions.	Max Planck Inst Zuchtungsforsch, Dept Plant Microbe Interact, D-50829 Cologne, Germany; Gyeongsang Natl Univ, Plant Mol Biol & Biotechnol Res Ctr, Div Appl Life Sci, BK21 Program, Chinju 660701, South Korea; John Innes Ctr Plant Sci Res, Sainsbury Lab, Norwich NR4 7UH, Norfolk, England	Max Planck Society; Gyeongsang National University; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	Schulze-Lefert, P (corresponding author), Max Planck Inst Zuchtungsforsch, Dept Plant Microbe Interact, Carl von Linne Weg 10, D-50829 Cologne, Germany.	mjcho@nongae.gsnu.ac.kr; schlef@mpiz-koeln.mpg.de	Schulze-Lefert, Paul/B-6707-2011; Bruening, Stefan/B-8505-2011; Schulze-Lefert, Paul/A-7746-2008; Panstruga, Ralph/F-3340-2011; Cho, Moo Je/F-1649-2010; Elliott, Candace/F-1860-2011	Panstruga, Ralph/0000-0002-3756-8957; Elliott, Candace/0000-0002-9174-0244				Aharon GS, 1998, FEBS LETT, V424, P17, DOI 10.1016/S0014-5793(98)00129-X; Apanovitch DM, 1998, J BIOL CHEM, V273, P28597, DOI 10.1074/jbc.273.44.28597; Blume B, 2000, PLANT CELL, V12, P1425, DOI 10.1105/tpc.12.8.1425; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; Bofill-Cardona E, 2000, J BIOL CHEM, V275, P32672, DOI 10.1074/jbc.M002780200; Brzostowski JA, 2001, TRENDS BIOCHEM SCI, V26, P291, DOI 10.1016/S0968-0004(01)01804-7; Buschges R, 1997, CELL, V88, P695, DOI 10.1016/S0092-8674(00)81912-1; Chin D, 2000, TRENDS CELL BIOL, V10, P322, DOI 10.1016/S0962-8924(00)01800-6; Dangl JL, 2001, NATURE, V411, P826, DOI 10.1038/35081161; Devoto A, 1999, J BIOL CHEM, V274, P34993, DOI 10.1074/jbc.274.49.34993; Grant M, 2000, PLANT J, V23, P441, DOI 10.1046/j.1365-313x.2000.00804.x; Jabs T, 1997, P NATL ACAD SCI USA, V94, P4800, DOI 10.1073/pnas.94.9.4800; Jarosch B, 1999, MOL PLANT MICROBE IN, V12, P508, DOI 10.1094/MPMI.1999.12.6.508; JORGENSEN JH, 1992, EUPHYTICA, V63, P141, DOI 10.1007/BF00023919; Kumar J, 2001, PHYTOPATHOLOGY, V91, P127, DOI 10.1094/PHYTO.2001.91.2.127; Lee SH, 1997, J BIOL CHEM, V272, P9252, DOI 10.1074/jbc.272.14.9252; Lein W, 2001, BBA-MOL CELL BIOL L, V1530, P172, DOI 10.1016/S1388-1981(00)00182-7; Ma H, 2001, CURR BIOL, V11, pR869, DOI 10.1016/S0960-9822(01)00519-X; Peterhansel C, 1997, PLANT CELL, V9, P1397, DOI 10.1105/tpc.9.8.1397; Regenfelder E, 1997, EMBO J, V16, P1934, DOI 10.1093/emboj/16.8.1934; Schweizer P, 2000, PLANT J, V24, P895, DOI 10.1046/j.1365-313x.2000.00941.x; Shirasu K, 1999, PLANT J, V17, P293, DOI 10.1046/j.1365-313X.1999.00376.x; Shirasu K, 2000, PLANT MOL BIOL, V44, P371, DOI 10.1023/A:1026552827716; SLEPAK VZ, 1993, J BIOL CHEM, V268, P21889; Stagljar I, 1998, P NATL ACAD SCI USA, V95, P5187, DOI 10.1073/pnas.95.9.5187; WINITZ S, 1994, METHOD ENZYMOL, V237, P321; Xu HX, 1998, PLANT CELL, V10, P585, DOI 10.1105/tpc.10.4.585	27	286	327	2	85	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 28	2002	416	6879					447	450		10.1038/416447a	http://dx.doi.org/10.1038/416447a			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	534UX	11919636				2022-12-28	WOS:000174607800051
J	Medina, JF; Nores, WL; Mauk, MD				Medina, JF; Nores, WL; Mauk, MD			Inhibition of climbing fibres is a signal for the extinction of conditioned eyelid responses	NATURE			English	Article							INFERIOR OLIVE; CEREBELLUM; MECHANISMS; STIMULATION; PREDICTION; FLOCCULUS; BLOCKING; PATHWAY; NEURONS	A fundamental tenet of cerebellar learning theories asserts that climbing fibre afferents from the inferior olive provide a teaching signal that promotes the gradual adaptation of movements(1-3). Data from several forms of motor learning provide support for this tenet(4-8). In pavlovian eyelid conditioning, for example, where a tone is repeatedly paired with a reinforcing unconditioned stimulus like periorbital stimulation, the unconditioned stimulus promotes acquisition of conditioned eyelid responses by activating climbing fibres(9-12). Climbing fibre activity elicited by an unconditioned stimulus is inhibited during the expression of conditioned responses(9-11)-consistent with the inhibitory projection from the cerebellum to inferior olive(6,13). Here, we show that inhibition of climbing fibres serves as a teaching signal for extinction, where learning not to respond is signalled by presenting a tone without the unconditioned stimulus. We used reversible infusion of synaptic receptor antagonists to show that blocking inhibitory input to the climbing fibres prevents extinction of the conditioned response, whereas blocking excitatory input induces extinction. These results, combined with analysis of climbing fibre activity in a computer simulation of the cerebellar-olivary system(14-16), suggest that transient inhibition of climbing fibres below their background level is the signal that drives extinction.	Univ Texas, Sch Med, WM Keck Ctr Neurobiol Learning & Memory, Houston, TX 77030 USA; Univ Texas, Sch Med, Dept Neurobiol & Anat, Houston, TX 77030 USA	University of Texas System; University of Texas System	Mauk, MD (corresponding author), Univ Texas, Sch Med, WM Keck Ctr Neurobiol Learning & Memory, Houston, TX 77030 USA.			Medina, Javier/0000-0001-8708-5315				ALBUS J S, 1971, Mathematical Biosciences, V10, P25, DOI 10.1016/0025-5564(71)90051-4; De Zeeuw CI, 1998, TRENDS NEUROSCI, V21, P391, DOI 10.1016/S0166-2236(98)01310-1; DEMER JL, 1985, BRAIN RES, V346, P22, DOI 10.1016/0006-8993(85)91090-X; Fanselow MS, 1998, NEURON, V20, P625, DOI 10.1016/S0896-6273(00)81002-8; Hesslow G, 1996, EXP BRAIN RES, V110, P36; Hollerman JR, 1998, NAT NEUROSCI, V1, P304, DOI 10.1038/1124; ITO M, 1982, ANNU REV NEUROSCI, V5, P275, DOI 10.1146/annurev.ne.05.030182.001423; KEATING JG, 1995, J NEUROPHYSIOL, V73, P1329, DOI 10.1152/jn.1995.73.4.1329; Kim JJ, 1998, SCIENCE, V279, P570, DOI 10.1126/science.279.5350.570; Lang EJ, 1996, J NEUROPHYSIOL, V76, P255, DOI 10.1152/jn.1996.76.1.255; Linden D J, 1993, Curr Opin Neurobiol, V3, P401, DOI 10.1016/0959-4388(93)90133-J; MARR D, 1969, J PHYSIOL-LONDON, V202, P437, DOI 10.1113/jphysiol.1969.sp008820; MAUK MD, 1986, P NATL ACAD SCI USA, V83, P5349, DOI 10.1073/pnas.83.14.5349; Medina JF, 2000, NAT NEUROSCI, V3, P1205, DOI 10.1038/81486; Medina JF, 2001, J NEUROSCI, V21, P4081, DOI 10.1523/JNEUROSCI.21-11-04081.2001; Medina JF, 2000, J NEUROSCI, V20, P5516, DOI 10.1523/JNEUROSCI.20-14-05516.2000; Ramnani N, 1996, J PHYSIOL-LONDON, V495, P159, DOI 10.1113/jphysiol.1996.sp021581; Raymond JL, 1996, SCIENCE, V272, P1126, DOI 10.1126/science.272.5265.1126; SAKURAI M, 1987, J PHYSIOL-LONDON, V394, P463, DOI 10.1113/jphysiol.1987.sp016881; Schultz W, 2000, ANNU REV NEUROSCI, V23, P473, DOI 10.1146/annurev.neuro.23.1.473; SEARS LL, 1991, BRAIN RES, V545, P114, DOI 10.1016/0006-8993(91)91276-7; Simpson JI, 1996, BEHAV BRAIN SCI, V19, P384, DOI 10.1017/S0140525X00081486; THACH WT, 1992, ANNU REV NEUROSCI, V15, P403, DOI 10.1146/annurev.neuro.15.1.403; Thompson RF, 1998, NEUROBIOL LEARN MEM, V70, P150, DOI 10.1006/nlme.1998.3845; Voogd J, 1998, TRENDS NEUROSCI, V21, P370, DOI 10.1016/S0166-2236(98)01318-6	25	186	188	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 21	2002	416	6878					330	333		10.1038/416330a	http://dx.doi.org/10.1038/416330a			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	532NP	11907580				2022-12-28	WOS:000174482200045
J	Richardson, MI; Wilson, RJ				Richardson, MI; Wilson, RJ			A topographically forced asymmetry in the martian circulation and climate	NATURE			English	Article							MARS; SURFACE; SIMULATION; MODEL	Large seasonal and hemispheric asymmetries in the martian climate system are generally ascribed to variations in solar heating associated with orbital eccentricity(1). As the orbital elements slowly change (over a period of >10(4) years), characteristics of the climate such as dustiness and the vigour of atmospheric circulation are thought to vary(2-5), as should asymmetries in the climate (for example, the deposition of water ice at the northern versus the southern pole). Such orbitally driven climate change might be responsible for the observed layering in Mars' polar deposits by modulating deposition of dust and water ice(3,5,6). Most current theories assume that climate asymmetries completely reverse as the angular distance between equinox and perihelion changes by 180degrees. Here we describe a major climate mechanism that will not precess in this way. We show that Mars' global north-south elevation difference forces a dominant southern summer Hadley circulation that is independent of perihelion timing. The Hadley circulation, a tropical overturning cell responsible for trade winds, largely controls interhemispheric transport of water and the bulk dustiness of the atmosphere(7-11). The topography therefore imprints a strong handedness on climate, with water ice and the active formation of polar layered deposits more likely in the north.	CALTECH, Div Geol & Planetary Sci, Pasadena, CA 91125 USA; NOAA, Geophys Fluid Dynam Lab, Princeton, NJ 08542 USA	California Institute of Technology; National Oceanic Atmospheric Admin (NOAA) - USA	Richardson, MI (corresponding author), CALTECH, Div Geol & Planetary Sci, MC 150-21, Pasadena, CA 91125 USA.	mir@gps.caltech.edu		Richardson, Mark/0000-0001-9633-4141				Clancy RT, 1996, ICARUS, V122, P36, DOI 10.1006/icar.1996.0108; Fenton LK, 2001, J GEOPHYS RES-PLANET, V106, P32885, DOI 10.1029/2000JE001407; Forget F, 1999, J GEOPHYS RES-PLANET, V104, P24155, DOI 10.1029/1999JE001025; HABERLE RM, 1982, ICARUS, V50, P322, DOI 10.1016/0019-1035(82)90129-4; HABERLE RM, 1993, J GEOPHYS RES-PLANET, V98, P3093, DOI 10.1029/92JE02946; HABERLE RM, UNPUB ICARUS; Herkenhoff KE, 2000, ICARUS, V144, P243, DOI 10.1006/icar.1999.6287; Houben H, 1997, J GEOPHYS RES-PLANET, V102, P9069, DOI 10.1029/97JE00046; JAKOSKY BM, 1993, ICARUS, V102, P286, DOI 10.1006/icar.1993.1049; Kieffer H. H., 1992, MARS, P1180; LINDZEN RS, 1988, J ATMOS SCI, V45, P2416, DOI 10.1175/1520-0469(1988)045<2416:HCFZAH>2.0.CO;2; Molnar P, 1999, J GEOPHYS RES-ATMOS, V104, P24265, DOI 10.1029/1999JD900485; Murphy JR, 1995, J GEOPHYS RES-PLANET, V100, P26357, DOI 10.1029/95JE02984; MURRAY BC, 1973, SCIENCE, V180, P638, DOI 10.1126/science.180.4086.638; OORT AH, 1970, MON WEATHER REV, V98, P423, DOI 10.1175/1520-0493(1970)098<0423:OTAVOT>2.3.CO;2; Peixoto J. P., 1992, PHYS CLIMATE, DOI DOI 10.1063/1.2809772; RICHARDSON MI, IN PRESS J GEOPHYS R; RICHARDSON ML, UNPUB J GEOPHYS RES; Smith DE, 1999, SCIENCE, V284, P1495, DOI 10.1126/science.284.5419.1495; Smith DE, 1996, SCIENCE, V271, P184, DOI 10.1126/science.271.5246.184; Thomas P., 1992, MARS, P767; TOON OB, 1980, ICARUS, V44, P552, DOI 10.1016/0019-1035(80)90130-X; Ward W. R., 1992, MARS, P298; WARD WR, 1974, J GEOPHYS RES, V79, P3375, DOI 10.1029/JC079i024p03375; Wilson RJ, 1996, J ATMOS SCI, V53, P1290, DOI 10.1175/1520-0469(1996)053<1290:CMSOTT>2.0.CO;2; Zurek R.W., 1992, MARS, P835	26	101	101	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 21	2002	416	6878					298	301		10.1038/416298a	http://dx.doi.org/10.1038/416298a			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	532NP	11907570				2022-12-28	WOS:000174482200035
J	Nogueira, RG; Sheen, VL				Nogueira, RG; Sheen, VL			Herpes zoster ophthalmicus followed by contralateral hemiparesis.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Brigham & Womens Hosp, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Beth Israel Deaconess Medical Center	Nogueira, RG (corresponding author), Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.				NIMH NIH HHS [K08 MH063886] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [K08MH063886] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))			0	7	7	0	5	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 11	2002	346	15					1127	1127		10.1056/NEJMicm010341	http://dx.doi.org/10.1056/NEJMicm010341			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	539PX	11948272				2022-12-28	WOS:000174880600005
J	Trotter, CL; Edmunds, WJ				Trotter, CL; Edmunds, WJ			Modelling cost effectiveness of meningococcal serogroup C conjugate vaccination campaign in England and Wales	BRITISH MEDICAL JOURNAL			English	Article							DISEASE	Objectives To assess die cost effectiveness of a meningococcal serogroup C conjugate vaccination campaign in 0-17 year olds. Design Cost effectiveness analysis from the perspective of die healthcare provider. Setting England and Wales. Main outcome measure Cost per life year saved. Results In 1998-9, immediately before the introduction of meningococcal C vaccination, die burden of serogroup C disease was considerable, with an estimated 1137 cases in people aged 0-17 years and at least 72 deaths. The vaccination campaign is estimated to have cost between pound126m ($180m, E207m) and pound241 m ($343m, E395m), depending on the price of the vaccine. Under base case assumptions die cost per life year saved from the vaccination campaign is estimated to be pound6259 ($8919, E10 264). School based vaccination was more cost effective than general practice based vaccination because of lower delivery Costs. Immunisation of infants aged under I year was the least cost effective component of the campaign because, although this maximises the life years gained, the three dose schedule required is more expensive than other methods of delivery. Estimates of the cost per life year saved were sensitive to assumptions on the future incidence of disease and the case fatality ratio. Conclusions Meningococcal C vaccination is likely to be more cost effective in all age groups when the incidence of disease is high. It is also more cost effective when given to children aged 1-4 (by general practitioners) and to children and young people aged 5-17 years at school than when administered to infants under 12 months of age or youths aged 16-17 years who are not at school.	Publ Hlth Lab Serv, Ctr Communicable Dis Surveillance, Div Immunizat, London NW9 5EQ, England; City Univ London, Dept Econ, London EC1V 0HB, England	Public Health England; City University London	Trotter, CL (corresponding author), Publ Hlth Lab Serv, Ctr Communicable Dis Surveillance, Div Immunizat, London NW9 5EQ, England.		Trotter, Caroline L/H-5077-2013	Trotter, Caroline/0000-0003-4000-2708				BARAFF LJ, 1993, PEDIATR INFECT DIS J, V12, P389, DOI 10.1097/00006454-199305000-00008; BARBOUR ML, 1995, J INFECT DIS, V171, P93, DOI 10.1093/infdis/171.1.93; Barker R M, 1999, Commun Dis Public Health, V2, P168; Barquet N, 1999, ARCH INTERN MED, V159, P2329, DOI 10.1001/archinte.159.19.2329; BEGG N, 1995, MENINGOCOCCAL DIS, P285; *BRIT MED ASS ROYA, 2000, BRIT NAT FORM, V39; *CDSC, 2001, COMMUN DIS REP WEEKL, V11; *CDSC, 1997, CDR, V7, P393; *CDSC, 1999, COMMUN DIS REP CDR W, V9, P297; *CDSC, 1996, COMMOUN DIS REP CDR, V6, P311; *CHIEF MED OFF CHI, 1999, INTRO IMM GROUP C ME; *DEP HLTH, 1995, POL APPR HLTH; Erickson L, 1998, CLIN INFECT DIS, V26, P1159, DOI 10.1086/520303; Gold MR, 1996, COST EFFECTIVENESS H; Irwin DJ, 1997, J PUBLIC HEALTH MED, V19, P162, DOI 10.1093/oxfordjournals.pubmed.a024604; Miller E, 2001, VACCINE, V20, pS58, DOI 10.1016/S0264-410X(01)00299-7; Netten A.P., 2000, UNIT COSTS HLTH SOCI; Ramsay ME, 2001, LANCET, V357, P195, DOI 10.1016/S0140-6736(00)03594-7; RAMSAY ME, 1997, EUROSURVEILLANCE, V2, P1; Richmond P, 1999, J INFECT DIS, V179, P1569, DOI 10.1086/314753; SALISBURY DM, 1999, IMMINISATION INFECT; SALISLBURY DM, 1999, IMMUNISATION INFECT; Schildkamp RL, 1996, SCAND J INFECT DIS, V28, P47, DOI 10.3109/00365549609027149; Stuart J M, 1997, Commun Dis Rep CDR Rev, V7, pR3; STUARTJM, 1997, COMMUN DIS REP CDR R, V7, pR3; Wylie PAL, 1997, BRIT MED J, V315, P774, DOI 10.1136/bmj.315.7111.774; 2000, CURRENT PROBLEMS PHA, V26, P14	27	53	54	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 6	2002	324	7341					809	812B		10.1136/bmj.324.7341.809	http://dx.doi.org/10.1136/bmj.324.7341.809			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	540ZG	11934772	Green Submitted, Green Accepted, Bronze, Green Published			2022-12-28	WOS:000174960300013
J	Baker, PA				Baker, PA			Paleoclimate - Trans-Atlantic climate connections	SCIENCE			English	Editorial Material									Duke Univ, Nicholas Sch Environm & Earth Sci, Div Earth & Ocean Sci, Durham, NC 27708 USA	Duke University	Baker, PA (corresponding author), Duke Univ, Nicholas Sch Environm & Earth Sci, Div Earth & Ocean Sci, Durham, NC 27708 USA.							Baker PA, 2001, NATURE, V409, P698, DOI 10.1038/35055524; Baker PA, 2001, SCIENCE, V291, P640, DOI 10.1126/science.291.5504.640; Broecker WS, 2001, SCIENCE, V294, P2308, DOI 10.1126/science.1068389; Crowley TJ, 2000, SCIENCE, V289, P270, DOI 10.1126/science.289.5477.270; deMenocal P, 2000, SCIENCE, V288, P2198, DOI 10.1126/science.288.5474.2198; Gasse F, 2000, QUATERNARY SCI REV, V19, P189, DOI 10.1016/S0277-3791(99)00061-X; Hartmann DL, 2002, SCIENCE, V295, P811, DOI 10.1126/science.1068447; Haug GH, 2001, SCIENCE, V293, P1304, DOI 10.1126/science.1059725; HODELL DA, 1991, NATURE, V352, P790, DOI 10.1038/352790a0; Hughen KA, 2000, SCIENCE, V290, P1951, DOI 10.1126/science.290.5498.1951; Johnson TC, 2002, SCIENCE, V296, P113, DOI 10.1126/science.1070057; Johnson TC, 2001, GEOLOGY, V29, P83, DOI 10.1130/0091-7613(2001)029<0083:DROCVS>2.0.CO;2; Peterson LC, 2000, SCIENCE, V290, P1947, DOI 10.1126/science.290.5498.1947; STREETPERROTT FA, 1993, NATURE, V366, P411, DOI 10.1038/366411a0	14	7	7	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 5	2002	296	5565					67	68		10.1126/science.1071162	http://dx.doi.org/10.1126/science.1071162			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	539FA	11935013				2022-12-28	WOS:000174858800034
J	Li, WM; Scott, AP; Siefkes, MJ; Yan, HG; Liu, Q; Yun, SS; Gage, DA				Li, WM; Scott, AP; Siefkes, MJ; Yan, HG; Liu, Q; Yun, SS; Gage, DA			Bile acid secreted by male sea lamprey that acts as a sex pheromone	SCIENCE			English	Article							PETROMYZON-MARINUS; SPAWNING BEHAVIOR; STEROIDS; GOLDFISH; PROSTAGLANDINS; MATURATION; EXCRETION; RELEASE; LAKES	We show that reproductively mature mate sea lampreys release a bile acid that acts as a potent sex pheromone, inducing preference and searching behavior in ovulated female lampreys. The secreted bile acid 7alpha,12alpha,24-trihydroxy-5alpha-cholan-3-one 24-sulfate was released in much higher amounts relative to known vertebrate steroid pheromones and may be secreted through the gills. Hence, the mate of this fish species signals both its reproductive status and location to females by secreting a pheromone that can act over long distances.	Michigan State Univ, Dept Fisheries & Wildlife, E Lansing, MI 48824 USA; Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA; Ctr Environm Fisheries & Aquaculture Sci, Weymouth DT4 8UB, Dorset, England	Michigan State University; Michigan State University; Centre for Environment Fisheries & Aquaculture Science	Li, WM (corresponding author), Michigan State Univ, Dept Fisheries & Wildlife, E Lansing, MI 48824 USA.	Liweim@msu.edu	Li, Weiming/D-9615-2013; li, weiming/E-4652-2011	Li, Weiming/0000-0001-5437-1518; Scott, Alexander Pickering/0000-0002-5540-1317; Yun, Sang Seon/0000-0001-6723-0482				APPLEGATE VC, 1950, 55 US DEP INT FISH W; Barnes S., 1988, BILE ACIDS, V4, P65; Bjerselius R, 2000, CAN J FISH AQUAT SCI, V57, P557, DOI 10.1139/cjfas-57-3-557; Bjerselius R, 1995, P 5 INT S REPR PHYS, P271; CARDE RT, 1995, ANNU REV ENTOMOL, V40, P559, DOI 10.1146/annurev.en.40.010195.003015; DULKA JG, 1987, NATURE, V325, P251, DOI 10.1038/325251a0; Fontaine PR, 1938, B SCO OCEANOGR FR, V97, P1681; HASLEWOOD GA, 1969, BIOCHEM J, V114, P179, DOI 10.1042/bj1140179; KELSO JRM, 2000, N AM J FISH MANAGE, V20, P132; Li, 1994, THESIS U MINNESOTA; LI W, 1995, J GEN PHYSIOL, V105, P567; MANION PJ, 1980, CAN J FISH AQUAT SCI, V37, P1635, DOI 10.1139/f80-211; MAREN TH, 1968, COMP BIOCHEM PHYSIOL, V26, P853, DOI 10.1016/0010-406X(68)90005-4; MASON RT, 1989, SCIENCE, V245, P290, DOI 10.1126/science.2749261; NOVOTNY M, 1986, SCIENCE, V231, P722, DOI 10.1126/science.3945805; PICKERING AD, 1977, CELL TISSUE RES, V180, P1; Rasmussen LEL, 1996, NATURE, V379, P684, DOI 10.1038/379684a0; SCOTT AP, 1994, GEN COMP ENDOCR, V96, P309, DOI 10.1006/gcen.1994.1186; Scott AP, 1997, GEN COMP ENDOCR, V105, P62, DOI 10.1006/gcen.1996.6798; SMITH BR, 1980, CAN J FISH AQUAT SCI, V37, P1780, DOI 10.1139/f80-222; Sorensen Peter W., 1999, P15; SORENSEN PW, 1988, BIOL REPROD, V39, P1039, DOI 10.1095/biolreprod39.5.1039; SVEINSSON T, 1995, ENVIRON BIOL FISH, V42, P253, DOI 10.1007/BF00004919; TEETER J, 1980, CAN J FISH AQUAT SCI, V37, P2123, DOI 10.1139/f80-254; Vermeirssen ELM, 1996, GEN COMP ENDOCR, V101, P180, DOI 10.1006/gcen.1996.0020; YAMAMOTO K, 1986, HEPATOLOGY, V6, P54, DOI 10.1002/hep.1840060111; Yambe H, 1999, J FISH BIOL, V55, P158, DOI 10.1111/j.1095-8649.1999.tb00665.x	27	303	314	1	65	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 5	2002	296	5565					138	141		10.1126/science.1067797	http://dx.doi.org/10.1126/science.1067797			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	539FA	11935026				2022-12-28	WOS:000174858800047
J	Ronald, P; Leung, H				Ronald, P; Leung, H			The rice genome - The most precious things are jade and pearls ...	SCIENCE			English	Editorial Material							SACCHAROMYCES-CEREVISIAE; DRAFT SEQUENCE; EXPRESSION; TOLERANCE; SYSTEM; GENES		Univ Calif Davis, Dept Plant Pathol, Davis, CA 95616 USA; Int Rice Res Inst, Manila, Philippines	University of California System; University of California Davis; CGIAR; International Rice Research Institute (IRRI)	Ronald, P (corresponding author), Univ Calif Davis, Dept Plant Pathol, Davis, CA 95616 USA.	pcronald@ucdavis.edu	Ronald, Pamela/AAK-7664-2020					DellaPenna D, 1999, SCIENCE, V285, P375, DOI 10.1126/science.285.5426.375; Devos KM, 2000, PLANT CELL, V12, P637, DOI 10.1105/tpc.12.5.637; *FAO, 1996, FOOD BAL SHEET; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Goff SA, 2002, SCIENCE, V296, P92, DOI 10.1126/science.1068275; Greco R, 2001, PLANT PHYSIOL, V125, P1175, DOI 10.1104/pp.125.3.1175; He ZH, 2000, TRANSGENIC RES, V9, P223, DOI 10.1023/A:1008992719010; Hirochika H, 2001, CURR OPIN PLANT BIOL, V4, P118, DOI 10.1016/S1369-5266(00)00146-1; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Jaglo-Ottosen KR, 1998, SCIENCE, V280, P104, DOI 10.1126/science.280.5360.104; Jeon JS, 2001, PLANT SCI, V161, P211, DOI 10.1016/S0168-9452(01)00414-9; Kasuga M, 1999, NAT BIOTECHNOL, V17, P287, DOI 10.1038/7036; Kaul S, 2000, NATURE, V408, P796, DOI 10.1038/35048692; Li X, 2001, PLANT J, V27, P235, DOI 10.1046/j.1365-313x.2001.01084.x; Lockhart DJ, 2000, NATURE, V405, P827, DOI 10.1038/35015701; Noble D, 2002, SCIENCE, V295, P1678, DOI 10.1126/science.1069881; Sanchez PA, 2002, SCIENCE, V295, P2019, DOI 10.1126/science.1065256; Serageldin I, 1999, SCIENCE, V285, P387, DOI 10.1126/science.285.5426.387; Tanksley SD, 1997, SCIENCE, V277, P1063, DOI 10.1126/science.277.5329.1063; WEIGEL D, 1995, NATURE, V377, P495, DOI 10.1038/377495a0; Wissuwa M, 2001, PLANT BREEDING, V120, P43, DOI 10.1046/j.1439-0523.2001.00561.x; Yale J, 2001, J BIOL CHEM, V276, P15996, DOI 10.1074/jbc.M008209200; Yu J, 2002, SCIENCE, V296, P79, DOI 10.1126/science.1068037; 1991, ECONOMIST       0309, P83	24	19	30	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 5	2002	296	5565					58	59		10.1126/science.1071337	http://dx.doi.org/10.1126/science.1071337			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	539FA	11935008				2022-12-28	WOS:000174858800029
J	Jordan, R; Gold, L; Cummins, C; Hyde, C				Jordan, R; Gold, L; Cummins, C; Hyde, C			Systematic review and meta-analysis of evidence for increasing numbers of drugs in antiretroviral combination therapy	BMJ-BRITISH MEDICAL JOURNAL			English	Review							PLACEBO-CONTROLLED TRIAL; HIV-INFECTED PATIENTS; IMMUNODEFICIENCY-VIRUS-INFECTION; ZIDOVUDINE PLUS LAMIVUDINE; DOUBLE-BLIND TRIAL; CD4 CELL COUNTS; PREVIOUSLY UNTREATED PATIENTS; RANDOMIZED CONTROLLED-TRIAL; AIDS-RELATED-COMPLEX; OF-LIFE OUTCOMES	Objective To assess the evidence for die effectiveness of increasing numbers of drugs in antiretroviral combination therapy. Design Systematic review, meta-analysis, and meta-regression of fully reported randomised controlled trials. All studies included compared quadruple versus triple therapy, triple versus double therapy, double versus monotherapy, or monotherapy versus placebo or no treatment. Participants Patients with any stage of HIV infection who had not received antiretroviral therapy. Main outcome measures Changes in disease progression or death (clinical outcomes); CD4 count and plasma viral load (surrogate markers). Search strategy Six electronic databases, including Medline, Embase, and the Cochrane Library, searched up to February 2001. Results 54 randomised controlled trials, most of good quality, with 66 comparison groups were included in the analysis. For both die clinical outcomes and surrogate markers, combinations with up to and including three (triple therapy) were progressively and significantly more effective. The odds ratio for disease progression or death for triple therapy compared with double therapy was 0.6 (95% confidence interval 0.5 to 0.8). Heterogeneity in effect sizes was present in many outcomes but was largely related to the drugs used and trial quality. Conclusions Evidence from randomised controlled trials supports the use of triple therapy. Research is needed on the effectiveness of quadruple therapies and the relative effectiveness of specific combinations of drugs.	Univ Birmingham, CDSC W Midlands, Dept Publ Hlth & Epidemiol, Birmingham B15 2TT, W Midlands, England; Univ Birmingham, Hlth Serv Management Ctr, Hlth Econ Facil, Birmingham B15 2RT, W Midlands, England; Univ Birmingham, Inst Child Hlth, Birmingham B4 6NH, W Midlands, England; Univ Birmingham, Dept Publ Hlth & Epidemiol, Birmingham B15 2TT, W Midlands, England	University of Birmingham; University of Birmingham; University of Birmingham; University of Birmingham	Jordan, R (corresponding author), Univ Birmingham, CDSC W Midlands, Dept Publ Hlth & Epidemiol, Birmingham B15 2TT, W Midlands, England.	r.e.jordan@bham.ac.uk	Jordan, Rachel/ABG-1892-2021	Jordan, Rachel/0000-0002-0747-6883; Christopher, Hyde/0000-0002-7349-0616; Gold, Lisa/0000-0002-2733-900X; Cummins, Carole/0000-0001-5464-1944				Aboulker JP, 1999, AIDS, V13, P57, DOI 10.1097/00002030-199901140-00008; Abrams D, 1999, LANCET, V353, P2014, DOI 10.1016/S0140-6736(98)12263-8; [Anonymous], 1996, Lancet, V348, P283; ANTMAN EM, 1992, JAMA-J AM MED ASSOC, V268, P240, DOI 10.1001/jama.268.2.240; Babiker AG, 1999, AIDS, V13, P2209, DOI 10.1097/00002030-199911120-00003; *BHIVA WRIT COMM, 1999, BRIT HIV ASS BHIVA G; *BHIVA WRIT COMM B, 2001, BRIT HIV ASS BHIVA G; *BHIVA WRIT COMM B, 1999, BRIT HIV ASS BHIVA G; BOZZETTE SA, 1995, JAMA-J AM MED ASSOC, V273, P295, DOI 10.1001/jama.273.4.295; Bucciardini R, 2000, AIDS, V14, P2567, DOI 10.1097/00002030-200011100-00020; Carpenter CCJ, 2000, JAMA-J AM MED ASSOC, V283, P381, DOI 10.1001/jama.283.3.381; Carpenter CCJ, 1996, JAMA-J AM MED ASSOC, V276, P146, DOI 10.1001/jama.276.2.146; CASCADE Collaboration, 2000, LANCET, V355, P1158, DOI 10.1016/S0140-6736(00)02069-9; Clarke M. J., 1995, SYSTEMATIC REV, P37; *CONC COORD COMM, 1991, LANCET, V343, P871; Conway B, 2000, CLIN INFECT DIS, V30, pS130, DOI 10.1086/313850; COOPER DA, 1993, NEW ENGL J MED, V329, P297, DOI 10.1056/NEJM199307293290501; DAVEY RT, 1993, P NATL ACAD SCI USA, V90, P5608, DOI 10.1073/pnas.90.12.5608; DOLIN R, 1995, ARCH INTERN MED, V155, P961, DOI 10.1001/archinte.155.9.961; Egger M, 1997, BMJ-BRIT MED J, V315, P1194, DOI 10.1136/bmj.315.7117.1194; ERON JJ, 1995, NEW ENGL J MED, V333, P1662, DOI 10.1056/NEJM199512213332502; Evers S, 1998, J ACQ IMMUN DEF SYND, V17, P143, DOI 10.1097/00042560-199802010-00007; FISCHL MA, 1990, ANN INTERN MED, V112, P727, DOI 10.7326/0003-4819-112-10-727; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; Fisher RI, 1998, ONCOLOGY-NY, V12, P9; Floridia M, 1999, J ACQ IMMUN DEF SYND, V20, P11, DOI 10.1097/00042560-199901010-00002; Floridia M, 1997, J INFECT DIS, V175, P255, DOI 10.1093/infdis/175.2.255; Foudraine NA, 1998, AIDS, V12, P1513, DOI 10.1097/00002030-199812000-00014; Friedland GH, 1999, J ACQ IMMUN DEF SYND, V21, P281, DOI 10.1097/00126334-199908010-00005; GALLANT JE, 1999, MEDSCAPE HIV AIDS S, V5; Garcia F, 1999, AIDS, V13, P2377, DOI 10.1097/00002030-199912030-00009; Gartland M, 2000, AIDS, V14, P367, DOI 10.1097/00002030-200003100-00009; Gatell J, 1999, ANTIVIR THER, V4, P79; Gazzard BG, 1997, LANCET, V349, P1086, DOI 10.1016/S0140-6736(96)12073-0; GILL S, 1991, GENITOURIN MED, V67, P15; Goodgame JC, 2000, ANTIVIR THER, V5, P215; Gries JM, 1997, CLIN PHARMACOL THER, V61, P70, DOI 10.1016/S0009-9236(97)90183-1; HAMILTON JD, 1992, NEW ENGL J MED, V326, P437, DOI 10.1056/NEJM199202133260703; Hammer SM, 1996, NEW ENGL J MED, V335, P1081, DOI 10.1056/NEJM199610103351501; Haubrich R, 1999, AIDS, V13, P2411, DOI 10.1097/00002030-199912030-00013; IOANNIDIS JPA, 1995, ANN INTERN MED, V122, P856, DOI 10.7326/0003-4819-122-11-199506010-00009; Izopet J, 1999, J MED VIROL, V57, P163, DOI 10.1002/(SICI)1096-9071(199902)57:2&lt;163::AID-JMV13&gt;3.0.CO;2-A; Katlama C, 1996, JAMA-J AM MED ASSOC, V276, P118, DOI 10.1001/jama.276.2.118; Kaulen P, 1993, Ger J Ophthalmol, V2, P412; KAZEMPOUR K, 1995, J ACQ IMMUN DEF SYND, V10, pS97; KINLOCHDELOES S, 1995, NEW ENGL J MED, V333, P408, DOI 10.1056/NEJM199508173330702; Kirk O, 1999, AIDS, V13, pF9, DOI 10.1097/00002030-199901140-00002; KOJIMA E, 1995, J INFECT DIS, V171, P1152, DOI 10.1093/infdis/171.5.1152; KOOT M, 1993, J INFECT DIS, V168, P733, DOI 10.1093/infdis/168.3.733; Kuritzkes DR, 1999, AIDS, V13, P685, DOI 10.1097/00002030-199904160-00009; LANE HC, 1989, ANN INTERN MED, V111, P41, DOI 10.7326/0003-4819-111-1-41; Lau J, 1998, LANCET, V351, P123, DOI 10.1016/S0140-6736(97)08468-7; Ledergerber B, 1999, LANCET, V353, P863, DOI 10.1016/S0140-6736(99)01122-8; Lewi David S., 2000, Revista do Instituto de Medicina Tropical de Sao Paulo, V42, P27, DOI 10.1590/S0036-46652000000100005; LEWI DS, 2000, REV INST MED TROP SP, V12, P27; Maguire M, 2000, AIDS, V14, P1195, DOI 10.1097/00002030-200006160-00017; MANNUCCI PM, 1994, BRIT J HAEMATOL, V86, P174, DOI 10.1111/j.1365-2141.1994.tb03270.x; MERIGAN TC, 1991, BLOOD, V78, P900; Mocroft A, 1998, LANCET, V352, P1725, DOI 10.1016/S0140-6736(98)03201-2; Mocroft A, 2000, LANCET, V356, P291, DOI 10.1016/S0140-6736(00)02504-6; Moher D, 1999, LANCET, V354, P1896, DOI 10.1016/S0140-6736(99)04149-5; Molina JM, 1999, J INFECT DIS, V180, P351, DOI 10.1086/314891; Montaner JSG, 1998, JAMA-J AM MED ASSOC, V279, P930, DOI 10.1001/jama.279.12.930; Moyle G J, 1997, Antivir Ther, V2, P229; MULDER JW, 1994, AIDS, V8, P313, DOI 10.1097/00002030-199403000-00004; NHS Centre for Reviews and Dissemination, 1996, 4 CRD U YORK NHS CTR; *NHS CTR REV DISS, 1996, 4 CRD NHS U YORK; Nielsen C, 1996, AIDS, V10, P625, DOI 10.1097/00002030-199606000-00008; Niu MT, 1998, J INFECT DIS, V178, P80, DOI 10.1086/515612; OBrien WA, 1996, NEW ENGL J MED, V334, P426, DOI 10.1056/NEJM199602153340703; Opravil M, 2000, J ACQ IMMUN DEF SYND, V23, P17; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Raboud J M, 1997, Antivir Ther, V2, P237; Revicki DA, 1999, AIDS, V13, P851, DOI 10.1097/00002030-199905070-00016; RICHMAN DD, 1987, NEW ENGL J MED, V317, P192, DOI 10.1056/NEJM198707233170402; Ruxrungtham K, 2000, AIDS, V14, P1375, DOI 10.1097/00002030-200007070-00010; Schooley RT, 1996, J INFECT DIS, V173, P1354, DOI 10.1093/infdis/173.6.1354; SELIGMANN M, 1994, LANCET, V343, P871; Staszewski S, 1997, AIDS, V11, P477, DOI 10.1097/00002030-199704000-00011; Staszewski S, 1999, NEW ENGL J MED, V341, P1865, DOI 10.1056/NEJM199912163412501; Stellbrink HJ, 2000, CLIN DRUG INVEST, V20, P295, DOI 10.2165/00044011-200020050-00001; Stuart JWTC, 1999, AIDS, V13, pF53, DOI 10.1097/00002030-199905070-00001; THOMPSON S, 1991, BMJ-BRIT MED J, V309, P1351; THOMPSON SG, 1994, BMJ-BRIT MED J, V309, P1351, DOI 10.1136/bmj.309.6965.1351; Vella S, 1996, Antivir Ther, V1, P129; VOLBERDING PA, 1995, NEW ENGL J MED, V333, P401, DOI 10.1056/NEJM199508173330701; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; WU AW, 1990, J ACQ IMMUN DEF SYND, V3, P683; WU AW, 1993, J ACQ IMMUN DEF SYND, V6, P452; YARCHOAN R, 1994, J INFECT DIS, V169, P9, DOI 10.1093/infdis/169.1.9; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; 2001, COMPENDIUM BEST AVAI	92	39	40	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 30	2002	324	7340					757	760C		10.1136/bmj.324.7340.757	http://dx.doi.org/10.1136/bmj.324.7340.757			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	538KY	11923157	Green Published, Bronze			2022-12-28	WOS:000174816200014
J	Sharp, D				Sharp, D			Telling the truth about sex	LANCET			English	Editorial Material									The Lancet, London NW1 7BY, England		Sharp, D (corresponding author), The Lancet, London NW1 7BY, England.							COCHRAN W., 1954, STAT PROBLEMS KINSEY; Copas AJ, 2002, SEX TRANSM INFECT, V78, P26, DOI 10.1136/sti.78.1.26; DiClemente RJ, 2001, LANCET, V358, P1828, DOI 10.1016/S0140-6736(01)06878-7; EASTAWAY R, 1999, WHY BUSES COME 3S HI, pCH3; Johnson AM, 2001, LANCET, V358, P1835, DOI 10.1016/S0140-6736(01)06883-0	5	1	1	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 30	2002	359	9312					1084	1084		10.1016/S0140-6736(02)08128-X	http://dx.doi.org/10.1016/S0140-6736(02)08128-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	536YJ	11943254				2022-12-28	WOS:000174729200005
J	Alderson, LM; Gonzalez, RG; Delalle, I; Ciordia, R				Alderson, LM; Gonzalez, RG; Delalle, I; Ciordia, R			A 52-year-old woman with recurrent unsteadiness, slurred speech, and fatigue. Primary lymphoma of the central nervous system.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							PRIMARY CNS LYMPHOMA; VIRUS INFECTION; FEATURES; LESIONS; AIDS		Rhode Isl Hosp, Dept Neurosurg, Providence, RI 02902 USA; Brown Univ, Providence, RI 02912 USA	Lifespan Health Rhode Island; Rhode Island Hospital; Brown University	Alderson, LM (corresponding author), Rhode Isl Hosp, Dept Neurosurg, Providence, RI 02902 USA.			Delalle, Ivana/0000-0002-1873-3064				Al-Yamany M, 1999, J NEURO-ONCOL, V42, P151, DOI 10.1023/A:1006162615774; Alderson L, 1996, J NEUROL NEUROSUR PS, V60, P102, DOI 10.1136/jnnp.60.1.102; BERCIANO J, 1982, J NEUROL SCI, V53, P253, DOI 10.1016/0022-510X(82)90011-9; Corboy JR, 1998, NEUROLOGY, V50, P335, DOI 10.1212/WNL.50.2.335; CORDOLIANI YS, 1992, AM J ROENTGENOL, V159, P841; DALMAU J, 1997, CANC NERVOUS SYSTEM, P674; FISHER M, 1956, NEW ENGL J MED, V255, P57, DOI 10.1056/NEJM195607122550201; FRANCIS GS, 1995, NEUROL CLIN, V13, P147, DOI 10.1016/S0733-8619(18)30065-3; GRAD A, 1989, ARCH NEUROL-CHICAGO, V46, P281, DOI 10.1001/archneur.1989.00520390047014; HOCHBERG FH, 1988, J NEUROSURG, V68, P835, DOI 10.3171/jns.1988.68.6.0835; HOTSON JR, 1982, NEUROLOGY, V32, P31, DOI 10.1212/WNL.32.1.31; ITO H, 1994, NEUROLOGY, V44, P1506, DOI 10.1212/WNL.44.8.1506; JAECKLE KA, 1996, CANC NERVOUS SYSTEM, P361; Johnson BA, 1997, AM J NEURORADIOL, V18, P563; Maher EA, 1999, SEMIN ONCOL, V26, P346; MARKAND ON, 1976, NEUROLOGY, V26, P769, DOI 10.1212/WNL.26.8.769; Nuckols JD, 1999, MODERN PATHOL, V12, P1167; Rolak LA, 1996, OFFICE PRACTICE NEUR, P350; Sedgewick RP, 1972, HDB CLINICAL NEUROLO, V14, P267; STERN BJ, 1985, ARCH NEUROL-CHICAGO, V42, P909, DOI 10.1001/archneur.1985.04060080095022; SUGITA Y, 1988, SURG NEUROL, V30, P148, DOI 10.1016/0090-3019(88)90102-4; Tagliati M, 1998, NEUROLOGY, V50, P244, DOI 10.1212/WNL.50.1.244; VICTOR M, 1959, ARCH NEUROL-CHICAGO, V1, P579, DOI 10.1001/archneur.1959.03840060001001; WEISS S, 1959, NEUROLOGY, V9, P711, DOI 10.1212/WNL.9.11.711	24	0	0	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 28	2002	346	13					1009	1015		10.1056/NEJMcpc010136	http://dx.doi.org/10.1056/NEJMcpc010136			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	534UY	11919311				2022-12-28	WOS:000174608600009
J	Walther, GR; Post, E; Convey, P; Menzel, A; Parmesan, C; Beebee, TJC; Fromentin, JM; Hoegh-Guldberg, O; Bairlein, F				Walther, GR; Post, E; Convey, P; Menzel, A; Parmesan, C; Beebee, TJC; Fromentin, JM; Hoegh-Guldberg, O; Bairlein, F			Ecological responses to recent climate change	NATURE			English	Review							ECOSYSTEM RESPONSE; SOUTHERN-OCEAN; SEA; VARIABILITY; PHENOLOGY; MIGRATION; RED; CONSEQUENCES; DETERMINISM; TEMPERATURE	There is now ample evidence of the ecological impacts of recent climate change, from polar terrestrial to tropical marine environments. The responses of both flora and fauna span an array of ecosystems and organizational hierarchies, from the species to the community levels. Despite continued uncertainty as to community and ecosystem trajectories under global change, our review exposes a coherent pattern of ecological change across systems. Although we are only at an early stage in the projected trends of global warming, ecological responses to recent climate change are already clearly visible.	Univ Hannover, Inst Geobot, D-30167 Hannover, Germany; Penn State Univ, Dept Biol, Mueller Lab 208, University Pk, PA 16802 USA; British Antarctic Survey, NERC, Cambridge CB3 0ET, England; Tech Univ Munich, Dept Ecol, D-85354 Freising Weihenstephan, Germany; Univ Texas, Patterson Labs 141, Austin, TX 78712 USA; Univ Sussex, Sch Biol Sci, Brighton BN1 9QG, E Sussex, England; IFREMER, Ctr Halieut Mediterraneen & Trop, F-34203 Sete, France; Univ Queensland, Ctr Marine Studies, St Lucia, Qld 4072, Australia; Inst Vogelforsch Vogelwarte Helgoland, D-26386 Wilhelmshaven, Germany	Leibniz University Hannover; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; UK Research & Innovation (UKRI); Natural Environment Research Council (NERC); NERC British Antarctic Survey; Technical University of Munich; University of Texas System; University of Texas Austin; University of Sussex; Ifremer; University of Queensland	Walther, GR (corresponding author), Univ Hannover, Inst Geobot, Nienburger Str 17, D-30167 Hannover, Germany.		Hoegh-Guldberg, Ove/H-6169-2011; Convey, Peter/AAV-5728-2020; Hoegh-Guldberg, Ove/ABA-5420-2020; Menzel, Annette/B-1105-2013; Parmesan, Camille/GVT-5674-2022	Hoegh-Guldberg, Ove/0000-0001-7510-6713; Convey, Peter/0000-0001-8497-9903; Hoegh-Guldberg, Ove/0000-0001-7510-6713; Menzel, Annette/0000-0002-7175-2512; Fromentin, Jean-Marc/0000-0002-1496-4332; Parmesan, Camille/0000-0002-1515-274X				Ahas R, 1999, INT J BIOMETEOROL, V42, P119, DOI 10.1007/s004840050094; Alheit J, 1997, FISH OCEANOGR, V6, P130, DOI 10.1046/j.1365-2419.1997.00035.x; Bakun A., 1998, REINVENTING FISHERIE, P331, DOI DOI 10.1007/978-94-011-4433-9_25; Barbraud C, 2001, NATURE, V411, P183, DOI 10.1038/35075554; Barlein F., 2001, CLIMATE 21 CENTURY C, P278; BEEBEE TJC, 1995, NATURE, V374, P219, DOI 10.1038/374219a0; Bergstrom DM, 1999, TRENDS ECOL EVOL, V14, P472, DOI 10.1016/S0169-5347(99)01688-2; Both C, 2001, NATURE, V411, P296, DOI 10.1038/35077063; Bradley NL, 1999, P NATL ACAD SCI USA, V96, P9701, DOI 10.1073/pnas.96.17.9701; Brown BE, 1997, CORAL REEFS, V16, P129; Brown JH, 1997, P NATL ACAD SCI USA, V94, P9729, DOI 10.1073/pnas.94.18.9729; Brown JL, 1999, P NATL ACAD SCI USA, V96, P5565, DOI 10.1073/pnas.96.10.5565; Bryant D., 1998, REEFS RISK MAP BASED; Chisholm JRM, 1995, CR ACAD SCI III-VIE, V318, P1219; Chown SL, 1999, BIOL REV, V74, P87, DOI 10.1017/S000632319800526X; Convey P, 2000, J BIOGEOGR, V27, P1279, DOI 10.1046/j.1365-2699.2000.00512.x; Convey P, 2001, FINGERPRINTS OF CLIMATE CHANGE, P17; Crick HQP, 1999, NATURE, V399, P423, DOI 10.1038/20839; Crick HQP, 1997, NATURE, V388, P526, DOI 10.1038/41453; CUNNINGHAM DM, 1994, EMU, V94, P27, DOI 10.1071/MU9940027; Cushing D.H., 1995, POPULATION PRODUCTIO; Dukes JS, 1999, TRENDS ECOL EVOL, V14, P135, DOI 10.1016/S0169-5347(98)01554-7; Dunn PO, 1999, P ROY SOC B-BIOL SCI, V266, P2487, DOI 10.1098/rspb.1999.0950; Easterling DR, 2000, SCIENCE, V289, P2068, DOI 10.1126/science.289.5487.2068; Epstein PR, 1998, B AM METEOROL SOC, V79, P409, DOI 10.1175/1520-0477(1998)079<0409:BAPSOC>2.0.CO;2; Forchhammer MC, 1998, NATURE, V391, P29, DOI 10.1038/34070; Forchhammer MC, 2001, J ANIM ECOL, V70, P721, DOI 10.1046/j.0021-8790.2001.00532.x; Fromentin JM, 1996, MAR ECOL PROG SER, V134, P111, DOI 10.3354/meps134111; GATTER W, 1992, J ORNITHOL, V133, P427, DOI 10.1007/BF01640470; GLYNN PW, 1991, TRENDS ECOL EVOL, V6, P175, DOI 10.1016/0169-5347(91)90208-F; GRABHERR G, 1994, NATURE, V369, P448, DOI 10.1038/369448a0; Grenfell BT, 1998, NATURE, V394, P674, DOI 10.1038/29291; Harrington R, 1999, TRENDS ECOL EVOL, V14, P146, DOI 10.1016/S0169-5347(99)01604-3; HERSTEINSSON P, 1992, OIKOS, V64, P505, DOI 10.2307/3545168; Hoegh-Guldberg O, 1999, MAR FRESHWATER RES, V50, P839, DOI 10.1071/MF99078; Hoffman A.A., 1997, EXTREME ENV CHANGE E; Holbrook SJ, 1997, ECOL APPL, V7, P1299; Hughes L, 2000, TRENDS ECOL EVOL, V15, P56, DOI 10.1016/S0169-5347(99)01764-4; Huin N, 2000, BIRD STUDY, V47, P22, DOI 10.1080/00063650009461157; Inouye DW, 2000, P NATL ACAD SCI USA, V97, P1630, DOI 10.1073/pnas.97.4.1630; IPCC, 2001, 3 ASSESSMENT REPORT; JANZEN FJ, 1994, P NATL ACAD SCI USA, V91, P7484; Karl TR, 1996, B AM METEOROL SOC, V77, P279, DOI 10.1175/1520-0477(1996)077<0279:IOCCFT>2.0.CO;2; Keeling CD, 1996, NATURE, V382, P146, DOI 10.1038/382146a0; KENNEDY AD, 1995, ANNU REV ECOL SYST, V26, P683, DOI 10.1146/annurev.es.26.110195.003343; Kiesecker JM, 2001, NATURE, V410, P681, DOI 10.1038/35070552; King JC, 1998, ANN GLACIOL, V27, P571; Kullman L, 2001, AMBIO, V30, P72, DOI 10.1639/0044-7447(2001)030[0072:CCWATL]2.0.CO;2; Loeb V, 1997, NATURE, V387, P897, DOI 10.1038/43174; Loya Y, 2001, ECOL LETT, V4, P122, DOI 10.1046/j.1461-0248.2001.00203.x; McCarty JP, 2001, CONSERV BIOL, V15, P320, DOI 10.1046/j.1523-1739.2001.015002320.x; McGowan JA, 1998, SCIENCE, V281, P210, DOI 10.1126/science.281.5374.210; Menzel A, 1999, NATURE, V397, P659, DOI 10.1038/17709; Menzel A, 2001, FINGERPRINTS OF CLIMATE CHANGE, P123; Menzel A, 2001, GLOBAL CHANGE BIOL, V7, P657, DOI 10.1046/j.1365-2486.2001.00430.x; Meshinev T, 2000, PHYTOCOENOLOGIA, V30, P431; Milner JM, 1999, J ANIM ECOL, V68, P1235, DOI 10.1046/j.1365-2656.1999.00366.x; Mumby PJ, 2001, MAR BIOL, V139, P183; Myneni RB, 1997, NATURE, V386, P698, DOI 10.1038/386698a0; Nehring S, 1998, ICES J MAR SCI, V55, P818, DOI 10.1006/jmsc.1998.0389; Nieder J, 2000, CYBIUM, V24, P359; Ottersen G, 2001, OECOLOGIA, V128, P1, DOI 10.1007/s004420100655; Parmesan C, 1999, NATURE, V399, P579, DOI 10.1038/21181; Parmesan C, 1996, NATURE, V382, P765, DOI 10.1038/382765a0; PARMESAN C, EVOLUTION ECOLOGY TA; Pascual M, 1999, ECOLOGY, V80, P2225, DOI 10.1890/0012-9658(1999)080[2225:FITPDS]2.0.CO;2; Pitelka LF, 1997, AM SCI, V85, P464; Planque B, 1999, CAN J FISH AQUAT SCI, V56, P2069, DOI 10.1139/cjfas-56-11-2069; Polovina JJ, 1996, FISH OCEANOGR, V5, P114, DOI 10.1111/j.1365-2419.1996.tb00110.x; Post E, 1999, NATURE, V401, P905, DOI 10.1038/44814; Post E, 1999, ECOLOGY, V80, P1322, DOI 10.1890/0012-9658(1999)080[1322:CVPPAN]2.0.CO;2; Post E, 2001, BMC Ecol, V1, P5, DOI 10.1186/1472-6785-1-5; Post E, 1997, P ROY SOC B-BIOL SCI, V264, P1317, DOI 10.1098/rspb.1997.0182; Pounds JA, 1999, NATURE, V398, P611, DOI 10.1038/19297; PUGH PJA, 1994, ZOOL J LINN SOC-LOND, V110, P207, DOI 10.1111/j.1096-3642.1994.tb02015.x; Reaser JK, 2000, CONSERV BIOL, V14, P1500, DOI 10.1046/j.1523-1739.2000.99145.x; Rhen T, 1998, EVOLUTION, V52, P1514, DOI 10.1111/j.1558-5646.1998.tb02034.x; ROOT TL, 1993, CONSERV BIOL, V7, P256, DOI 10.1046/j.1523-1739.1993.07020256.x; Roy DB, 2000, GLOB CHANGE BIOL, V6, P407, DOI 10.1046/j.1365-2486.2000.00322.x; Saetre GP, 1999, P ROY SOC B-BIOL SCI, V266, P1247, DOI 10.1098/rspb.1999.0770; Sagarin RD, 1999, ECOL MONOGR, V69, P465, DOI 10.1890/0012-9615(1999)069[0465:CRCIAI]2.0.CO;2; Smith R.I.L., 2001, GEOGRAPHIA, V25, P19; Smith RIL, 1996, BIOL CONSERV, V76, P135, DOI 10.1016/0006-3207(95)00099-2; SOUTHWARD AJ, 1995, J THERM BIOL, V20, P127, DOI 10.1016/0306-4565(94)00043-I; Sparks T., 1999, BTO NEWS, V223, P8; Spencer T, 2000, MAR POLLUT BULL, V40, P569, DOI 10.1016/S0025-326X(00)00026-6; Sturm M, 2001, NATURE, V411, P546, DOI 10.1038/35079180; Thomas CD, 1999, NATURE, V399, P213, DOI 10.1038/20335; Visser ME, 1998, P ROY SOC B-BIOL SCI, V265, P1867, DOI 10.1098/rspb.1998.0514; Visser ME, 2001, P ROY SOC B-BIOL SCI, V268, P289, DOI 10.1098/rspb.2000.1363; Walther GR, 2000, PHYTOCOENOLOGIA, V30, P409; Walther GR., 2001, FINGERPRINTS CLIMATE; WARDLE P, 1992, NEW ZEAL J BOT, V30, P303, DOI 10.1080/0028825X.1992.10412909; Wespestad VG, 2000, ICES J MAR SCI, V57, P272, DOI 10.1006/jmsc.2000.0640; Wilkinson C, 2000, STATUS CORAL REEFS W; Woodward F.I., 1987, CLIMATE PLANT DISTRI; Wuethrich B, 2000, SCIENCE, V287, P793, DOI 10.1126/science.287.5454.793	97	6578	7073	186	8169	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 28	2002	416	6879					389	395		10.1038/416389a	http://dx.doi.org/10.1038/416389a			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	534UX	11919621				2022-12-28	WOS:000174607800036
J	Roberts, M; Reich, MR				Roberts, M; Reich, MR			Ethical analysis in public health	LANCET			English	Review								Public-health regularly encounters serious ethical dilemmas, such as rationing scarce resources, influencing individuals to change their behaviour, and limiting freedom to diminish disease transmission. Yet unlike medical ethics, there is no agreed-upon framework for analysing these difficulties. We offer such a framework. It distinguishes three philosophical views, often invoked in public-health discourse: positions based on outcomes (utilitarianism), positions focused on rights and opportunities (liberalism), and views that emphasise character and virtue (communitarianism). We explore critical variations within each approach, and identify practical problems that arise In addressing the ethical dimensions of health policy. We conclude by examining challenges posed by the feminist argument of ethics-of-care and by postmodern views about the nature of ethics. Health professionals need enhanced skills in applied philosophy to improve the coherence, transparency, and quality of public deliberations over ethical Issues inherent in health policy.	Harvard Ctr Populat & Dev Studies, Cambridge, MA 02138 USA; Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	Reich, MR (corresponding author), Harvard Ctr Populat & Dev Studies, 9 Bow St, Cambridge, MA 02138 USA.			Reich, Michael R./0000-0003-3338-0612				Alford W. P., 1995, STEAL BOOK ELEGANT O; Anand S, 1997, J HEALTH ECON, V16, P685, DOI 10.1016/S0167-6296(97)00005-2; [Anonymous], 1999, DEV FREEDOM; [Anonymous], 1993, MORAL IMAGINATION; [Anonymous], 1960, QUEST CERTAINTY STUD; BAIER A, 1994, MORAL PREJUDICES ESS, P21; Beauchamp TL, 2009, PRINCIPLES BIOMEDICA; Bentham Jeremy, 1996, PRINCIPLES MORALS LE; Coughlin SS, 1999, AM J PUBLIC HEALTH, V89, P768, DOI 10.2105/AJPH.89.5.768; DANIELS N, 1985, JUST HLTH CARE; Dworkin Ronald, 1993, McGill Law J, V38, P883; Frankena W., 1973, ETHICS; Gibbard Allan, 1990, WISE CHOICES APT FEE; GRIFFIN J, 1986, WELL EING; HAMPSHIRE S, 1982, UTILITARIANISM BEYON; HARMAN G, 1977, NATURE MORALITY INTR; KANT I, 1956, CRITIQUE PRACTICAL R, P62; Lyotard J. F, 1984, POSTMODERN CONDITION, V10; Margolis H., 1996, DEALING RISK WHY PUB; Moss AR, 2000, AM J PUBLIC HEALTH, V90, P1385, DOI 10.2105/AJPH.90.9.1385; Nagel T, 1988, CONSEQUENTIALISM ITS; Nozick Robert, 1974, ANARCHY STATE UTOPIA; Nussbaum M., 1993, QUALITY LIFE, P242; O'Neill Onora., 1989, CONSTRUCTIONS REASON; Obermeyer CM, 1999, MED ANTHROPOL Q, V13, P79, DOI 10.1525/maq.1999.13.1.79; PEREZSTABLE EJ, 1991, AM J PUBLIC HEALTH, V81, P563, DOI 10.2105/AJPH.81.5.563; Plato, 1987, REPUBLIC, V2nd; Putnam H., 1990, REALISM HUMAN FACE; Rawls J, 1993, POLITICAL LIBERALISM; ROBERTS MJ, 1986, ALTERNATIVE SOCIAL C; Rorty R., 1989, CONTINGENCY IRONY SO; Rorty R, 1993, HUMAN RIGHTS; Rosser R, 1992, MEASURES QUALITY LIF; Sandel M., 1982, LIBERALISM LIMITS JU; Sen A., 1993, QUALITY LIFE; SHENON P, 2000, NY TIMES        0112; STOLBERG SG, 1998, NY TIMES        0227; TAYLOR C, 1988, UTILITARIANISM BEYON; TAYLOR C, 1982, UTILITARIANISM BEYON; WENZ PS, 1986, PRICE HLTH; Williams Bernard, 1973, UTILITARIANISM	41	137	139	1	43	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 23	2002	359	9311					1055	1059		10.1016/S0140-6736(02)08097-2	http://dx.doi.org/10.1016/S0140-6736(02)08097-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	534KP	11937202				2022-12-28	WOS:000174585800029
J	Barouch, LA; Harrison, RW; Skaf, MW; Rosas, GO; Cappola, TP; Kobeissi, ZA; Hobai, IA; Lemmon, CA; Burnett, AL; O'Rourke, B; Rodriguez, ER; Huang, PL; Lima, JAC; Berkowitz, DE; Hare, JM				Barouch, LA; Harrison, RW; Skaf, MW; Rosas, GO; Cappola, TP; Kobeissi, ZA; Hobai, IA; Lemmon, CA; Burnett, AL; O'Rourke, B; Rodriguez, ER; Huang, PL; Lima, JAC; Berkowitz, DE; Hare, JM			Nitric oxide regulates the heart by spatial confinement of nitric oxide synthase isoforms	NATURE			English	Article							CARDIAC-SPECIFIC OVEREXPRESSION; CALCIUM-RELEASE CHANNEL; FUNCTION IN-VIVO; SKELETAL-MUSCLE; INHIBITION; POTENTIATION; HYPERTROPHY; ACTIVATION; RECEPTOR; FAILURE	Subcellular localization of nitric oxide (NO) synthases with effector molecules is an important regulatory mechanism for NO signalling(1). In the heart, NO inhibits L-type Ca2+ channels 2 but stimulates sarcoplasmic reticulum (SR) Ca2+ release(3-5), leading to variable effects on myocardial contractility. Here we show that spatial confinement of specific NO synthase isoforms regulates this process. Endothelial NO synthase (NOS3) localizes to caveolae(6-8), where compartmentalization with beta-adrenergic receptors and L-type Ca2+ channels(9) allows NO to inhibit beta-adrenergic-induced inotropy(8,10). Neuronal NO synthase (NOS1), however, is targeted to cardiac SR11. NO stimulation of SR Ca2+ release via the ryanodine receptor (RyR) in vitro(3,4) suggests that NOS1 has an opposite, facilitative effect on contractility. We demonstrate that NOS1-deficient mice have suppressed inotropic response, whereas NOS3-deficient mice have enhanced contractility, owing to corresponding changes in SR Ca2+ release. Both NOS1(-/-) and NOS3(-/-) mice develop age-related hypertrophy, although only NOS3(-/-) mice are hypertensive. NOS1/3(-/-) double knockout mice have suppressed beta-adrenergic responses and an additive phenotype of marked ventricular remodelling. Thus, NOS1 and NOS3 mediate independent, and in some cases opposite, effects on cardiac structure and function.	Johns Hopkins Med Inst, Dept Med, Div Cardiol, Baltimore, MD 21287 USA; Johns Hopkins Med Inst, Dept Biomed Engn, Baltimore, MD 21287 USA; Johns Hopkins Med Inst, Dept Urol, Baltimore, MD 21287 USA; Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21287 USA; Johns Hopkins Med Inst, Dept Anaesthesiol & Crit Care Med, Baltimore, MD 21287 USA; Massachusetts Gen Hosp, Cardiovasc Res Ctr, Charlestown, MA 02129 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Harvard University; Massachusetts General Hospital	Hare, JM (corresponding author), Johns Hopkins Med Inst, Dept Med, Div Cardiol, Baltimore, MD 21287 USA.		Lemmon, Christopher/GPP-1470-2022	Hobai, Ion/0000-0002-3729-0422; O'Rourke, Brian/0000-0002-5548-4853; Huang, Paul/0000-0002-5436-8658; Lemmon, Christopher/0000-0002-9049-6366				Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; BRENMAN JE, 1995, CELL, V82, P743, DOI 10.1016/0092-8674(95)90471-9; CARCIACARDENA G, 1997, J BIOL CHEM, V272, P25437; Cheng HJ, 2001, CIRC RES, V89, P599, DOI 10.1161/hh1901.098042; Eu JP, 2000, CELL, V102, P499, DOI 10.1016/S0092-8674(00)00054-4; Fang M, 2000, NEURON, V28, P183, DOI 10.1016/S0896-6273(00)00095-7; Feron O, 1998, J BIOL CHEM, V273, P3125, DOI 10.1074/jbc.273.6.3125; Gyurko R, 2000, AM J PHYSIOL-HEART C, V278, pH971, DOI 10.1152/ajpheart.2000.278.3.H971; Hare JM, 2000, CIRC RES, V86, P1085, DOI 10.1161/01.RES.86.10.1085; Hare JM, 1999, NAT MED, V5, P1241, DOI 10.1038/15193; Hare JM, 1998, CIRCULATION, V97, P161, DOI 10.1161/01.CIR.97.2.161; Kanai AJ, 2001, P NATL ACAD SCI USA, V98, P14126, DOI 10.1073/pnas.241380298; KOBZIK L, 1994, NATURE, V372, P546, DOI 10.1038/372546a0; Liu LM, 2001, NATURE, V410, P490, DOI 10.1038/35068596; MERY PF, 1993, J BIOL CHEM, V268, P26286; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; Petroff MGV, 2001, NAT CELL BIOL, V3, P867, DOI 10.1038/ncb1001-867; Schmidt AG, 2000, J MOL CELL CARDIOL, V32, P1735, DOI 10.1006/jmcc.2000.1209; Schwencke C, 1999, MOL ENDOCRINOL, V13, P1061, DOI 10.1210/me.13.7.1061; Son H, 1996, CELL, V87, P1015, DOI 10.1016/S0092-8674(00)81796-1; Stamler JS, 2001, CELL, V106, P675, DOI 10.1016/S0092-8674(01)00495-0; TOPOL EJ, 1985, NEW ENGL J MED, V312, P277, DOI 10.1056/NEJM198501313120504; Varghese P, 2000, J CLIN INVEST, V106, P697, DOI 10.1172/JCI9323; VERDECCHIA P, 1995, J AM COLL CARDIOL, V25, P871, DOI 10.1016/0735-1097(94)00424-O; Xu KY, 1999, P NATL ACAD SCI USA, V96, P657, DOI 10.1073/pnas.96.2.657; Xu L, 1998, SCIENCE, V279, P234, DOI 10.1126/science.279.5348.234; Yang XP, 1999, HYPERTENSION, V34, P24, DOI 10.1161/01.HYP.34.1.24; Zhai J, 2000, J BIOL CHEM, V275, P10538, DOI 10.1074/jbc.275.14.10538	29	629	654	1	40	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 21	2002	416	6878					337	340		10.1038/416337a	http://dx.doi.org/10.1038/416337a			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	532NP	11907582				2022-12-28	WOS:000174482200047
J	Brussee, H; Gasser, R				Brussee, H; Gasser, R			Fistula connecting the left main coronary artery with the right atrium in a marathon runner	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Karl Franzens Univ Graz, A-8036 Graz, Austria	University of Graz	Brussee, H (corresponding author), Karl Franzens Univ Graz, A-8036 Graz, Austria.								0	12	13	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 21	2002	346	12					904	904		10.1056/NEJMicm980664	http://dx.doi.org/10.1056/NEJMicm980664			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	532FR	11907290				2022-12-28	WOS:000174464100006
J	Smith, RP; Schoen, RT; Rahn, DW; Sikand, VK; Nowakowski, J; Parenti, DL; Holman, MS; Persing, DH; Steere, AC				Smith, RP; Schoen, RT; Rahn, DW; Sikand, VK; Nowakowski, J; Parenti, DL; Holman, MS; Persing, DH; Steere, AC			Clinical characteristics and treatment outcome of early Lyme disease in patients with microbiologically confirmed erythema migrans	ANNALS OF INTERNAL MEDICINE			English	Article							BURGDORFERI SENSU-STRICTO; POLYMERASE-CHAIN-REACTION; BORRELIA-BURGDORFERI; SKIN BIOPSIES; CULTURE; SERODIAGNOSIS; INFECTION; DIAGNOSIS; MANIFESTATIONS; AMPLIFICATION	Background: Lyme disease has a wide spectrum of clinical manifestations. Diagnosis is usually based on the clinical and serologic picture rather than on microbiological confirmation. Objective: To examine the clinical presentation and treatment outcome of early Lyme disease in patients with microbiologically confirmed erythema migrans. Design: Observational cohort study. Setting: 31 university-based or clinician-practice sites in 10 endemic states. Participants: 10 936 participants enrolled in a phase III trial of Lyme disease vaccine; 118 participants had erythema migrans in which Borrelia burgdotferi was detected by culture or polymerase chain reaction. Measurements: Clinical characteristics and treatment outcome were noted. Skin biopsies of erythema migrans were performed for culture and detection of B. burgdorferi by polymerase chain reaction; serologic responses were determined by Western blot. Results: The 118 patients with microbiologically confirmed erythema migrans presented a median of 3 days after symptom onset. Early erythema migrans commonly had homogeneous or central redness rather than a peripheral erythema with partial central clearing. The most common associated symptoms were low-grade fever, headache, neck stiffness, arthralgia, myalgia, or fatigue. By convalescence, 65% of patients had positive IgM or IgG antibody responses to B. burgdorferi. Most patients responded promptly to antibiotic treatment. Conclusions: in major endemic areas in the United States, Lyme disease commonly presents as erythema migrans with homogeneous or central redness and nonspecific flu-like symptoms. Clinical outcome is excellent if antibiotic therapy is administered soon after symptom onset.	Maine Med Ctr, Res Inst, Lyme Dis Res Lab, Portland, ME 04102 USA; Yale Univ, Sch Med, New Haven, CT USA; Med Coll Georgia, Augusta, GA 30912 USA; Tufts Univ, Sch Med, Boston, MA 02111 USA; Tufts Univ New England Med Ctr, Boston, MA 02111 USA; New York Med Coll, Valhalla, NY 10595 USA; SmithKline Beecham, Collegeville, PA USA; Corixa Corp, Seattle, WA USA	Maine Medical Center; Yale University; University System of Georgia; Augusta University; Tufts University; Tufts Medical Center; New York Medical College; GlaxoSmithKline; Corixa	Smith, RP (corresponding author), Maine Med Ctr, Res Inst, Lyme Dis Res Lab, 13 Charles St,3rd Floor, Portland, ME 04102 USA.			Steere, Allen/0000-0002-5268-9853				Aguero-Rosenfeld ME, 1999, J CLIN MICROBIOL, V37, P3718, DOI 10.1128/JCM.37.11.3718-3721.1999; [Anonymous], 1995, MMWR MORB MORTAL WKL, V44, P590; BERARDI VP, 1988, J INFECT DIS, V158, P754, DOI 10.1093/infdis/158.4.754; BERGER BW, 1992, J CLIN MICROBIOL, V30, P359, DOI 10.1128/JCM.30.2.359-361.1992; BRADLEY JF, 1994, ANN INTERN MED, V120, P487, DOI 10.7326/0003-4819-120-6-199403150-00007; CAMPBELL GL, 1995, J INFECT DIS, V172, P470, DOI 10.1093/infdis/172.2.470; CLARK JR, 1985, LARYNGOSCOPE, V95, P1341; Dattwyler RJ, 1997, NEW ENGL J MED, V337, P289, DOI 10.1056/NEJM199707313370501; DINERMAN H, 1992, ANN INTERN MED, V117, P281, DOI 10.7326/0003-4819-117-4-281; DRESSLER F, 1993, J INFECT DIS, V167, P392, DOI 10.1093/infdis/167.2.392; ENGERVALL K, 1990, CLIN OTOLARYNGOL, V15, P537, DOI 10.1111/j.1365-2273.1990.tb00795.x; ENGSTROM SM, 1995, J CLIN MICROBIOL, V33, P419, DOI 10.1128/JCM.33.2.419-427.1995; Gerber MA, 1996, NEW ENGL J MED, V335, P1270, DOI 10.1056/NEJM199610243351703; Golde WT, 1998, J CLIN MICROBIOL, V36, P1015, DOI 10.1128/JCM.36.4.1015-1019.1998; James AM, 2001, J INFECT DIS, V183, P1810, DOI 10.1086/320721; Kirkland KB, 1997, ARCH INTERN MED, V157, P2635, DOI 10.1001/archinte.157.22.2635; Klempner MS, 2001, NEW ENGL J MED, V345, P85, DOI 10.1056/NEJM200107123450202; Krause PJ, 1996, JAMA-J AM MED ASSOC, V275, P1657, DOI 10.1001/jama.275.21.1657; Luft BJ, 1996, ANN INTERN MED, V124, P785, DOI 10.7326/0003-4819-124-9-199605010-00002; LUGER SW, 1995, ANTIMICROB AGENTS CH, V39, P661, DOI 10.1128/AAC.39.3.661; MASSAROTTI EM, 1992, AM J MED, V92, P396, DOI 10.1016/0002-9343(92)90270-L; MELCHERS W, 1991, J CLIN MICROBIOL, V29, P2401, DOI 10.1128/JCM.29.11.2401-2406.1991; Nadelman RB, 1996, AM J MED, V100, P502, DOI 10.1016/S0002-9343(95)99915-9; NADELMAN RB, 1995, AM J MED, V98, pS15, DOI 10.1016/S0002-9343(99)80040-0; Nichol G, 1998, ANN INTERN MED, V128, P37, DOI 10.7326/0003-4819-128-1-199801010-00007; NOCTON JJ, 1994, NEW ENGL J MED, V330, P229, DOI 10.1056/NEJM199401273300401; Nowakowski J, 1997, ANN INTERN MED, V127, P130, DOI 10.7326/0003-4819-127-2-199707150-00006; Orloski K A, 2000, MMWR CDC Surveill Summ, V49, P1; Oschmann P, 1998, J NEUROL, V245, P262, DOI 10.1007/s004150050216; PANCHOLI P, 1995, J INFECT DIS, V172, P1007, DOI 10.1093/infdis/172.4.1007; RAHN DW, 1991, ANN INTERN MED, V114, P472, DOI 10.7326/0003-4819-114-6-472; SCHWARTZ I, 1992, J CLIN MICROBIOL, V30, P3082, DOI 10.1128/JCM.30.12.3082-3088.1992; SHRESTHA M, 1985, AM J MED, V78, P235, DOI 10.1016/0002-9343(85)90432-2; STEERE AC, 1983, ANN INTERN MED, V99, P76, DOI 10.7326/0003-4819-99-1-76; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906; Steere AC, 1998, NEW ENGL J MED, V339, P209, DOI 10.1056/NEJM199807233390401; STEERE AC, 1983, ANN INTERN MED, V99, P22, DOI 10.7326/0003-4819-99-1-22; Steere AC, 2001, NEW ENGL J MED, V345, P115, DOI 10.1056/NEJM200107123450207; Strle F, 1999, ANN INTERN MED, V130, P32, DOI 10.7326/0003-4819-130-1-199901050-00006; WORMSER GP, 1992, JAMA-J AM MED ASSOC, V268, P1311, DOI 10.1001/jama.268.10.1311; Wormser GP, 1999, J INFECT DIS, V180, P720, DOI 10.1086/314922	41	156	164	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 19	2002	136	6					421	428		10.7326/0003-4819-136-6-200203190-00005	http://dx.doi.org/10.7326/0003-4819-136-6-200203190-00005			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	531AU	11900494				2022-12-28	WOS:000174393100001
J	Graham, HK				Graham, HK			Painful hip dislocation in cerebral palsy	LANCET			English	Editorial Material									Royal Childrens Hosp, Dept Orthopaed Surg, Parkville, Vic 3052, Australia	Royal Children's Hospital Melbourne	Graham, HK (corresponding author), Royal Childrens Hosp, Dept Orthopaed Surg, Parkville, Vic 3052, Australia.		Graham, Kerr/AAK-4383-2020					BAX M C, 1964, Dev Med Child Neurol, V6, P295; Bjornson KF, 2001, EUR J NEUROL, V8, P183, DOI 10.1046/j.1468-1331.2001.00051.x; Brown J. K., 1989, SEM ORTHOP, V4, P236; COSGROVE AP, 1994, DEV MED CHILD NEUROL, V36, P379; DOBSON F, IN PRESS J BONE JOIN; Goldstein Murray, 2001, Developmental Medicine and Child Neurology, V43, P563, DOI 10.1017/S0012162201001025; Graham HK, 2001, EUR J NEUROL, V8, P30, DOI 10.1046/j.1468-1331.2001.00036.x; Little WJ., 1861, T OBSTET SOC LOND, P293; MACKEITH RC, 1958, LANCET, V1, P61; Owers KL, 2001, J BONE JOINT SURG BR, V83B, P1161, DOI 10.1302/0301-620X.83B8.11266; RANG M, 2000, STORY ORTHOPAEDICS, P229; Scrutton D, 2001, DEV MED CHILD NEUROL, V43, P586, DOI 10.1017/S0012162201001086; ZIV I, 1984, DEV MED CHILD NEUROL, V26, P94	13	38	41	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 16	2002	359	9310					907	908		10.1016/S0140-6736(02)08015-7	http://dx.doi.org/10.1016/S0140-6736(02)08015-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	531AE	11918905				2022-12-28	WOS:000174391700005
J	Beard, C				Beard, C			Paleontology - East of Eden at the Paleocene/Eocene boundary	SCIENCE			English	Editorial Material									Carnegie Museum Nat Hist, Sect Vertebrate Paleontol, Pittsburgh, PA 15213 USA		Beard, C (corresponding author), Carnegie Museum Nat Hist, Sect Vertebrate Paleontol, Pittsburgh, PA 15213 USA.			Beard, K. Christopher/0000-0002-6279-9837				Beard K. Christopher, 1998, Bulletin of Carnegie Museum of Natural History, V34, P5; Beard KC, 1999, B SOC GEOL FR, V170, P697; Bowen GJ, 2002, SCIENCE, V295, P2062, DOI 10.1126/science.1068700; Bowen GJ., 2001, PALEOCENE EOCENE STR, P73; Dickens GR, 1997, GEOLOGY, V25, P259, DOI 10.1130/0091-7613(1997)025<0259:ABOGIT>2.3.CO;2; GINGERICH PD, 2001, U MICHIGAN PAPERS PA, V33, P37; Hooker JJ, 1998, LATE PALEOCENE-EARLY EOCENE CLIMATIC AND BIOTIC EVENTS IN THE MARINE AND TERRESTRIAL RECORDS, P428; Lucas SG, 1998, LATE PALEOCENE-EARLY EOCENE CLIMATIC AND BIOTIC EVENTS IN THE MARINE AND TERRESTRIAL RECORDS, P451; Maas M. C., 1990, GEOL SOC AM SPEC PAP, V243, P71; Wilf P, 1999, SCIENCE, V284, P2153, DOI 10.1126/science.284.5423.2153; Zachos J, 2001, SCIENCE, V292, P686, DOI 10.1126/science.1059412	11	26	28	1	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 15	2002	295	5562					2028	2029		10.1126/science.1070259	http://dx.doi.org/10.1126/science.1070259			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	532AY	11896261				2022-12-28	WOS:000174450500031
J	Liu, MS; Deora, R; Doulatov, SR; Gingery, M; Eiserling, FA; Preston, A; Maskell, DJ; Simons, RW; Cotter, PA; Parkhill, J; Miller, JF				Liu, MS; Deora, R; Doulatov, SR; Gingery, M; Eiserling, FA; Preston, A; Maskell, DJ; Simons, RW; Cotter, PA; Parkhill, J; Miller, JF			Reverse transcriptase-mediated tropism switching in Bordetella bacteriophage	SCIENCE			English	Article							VIRULENCE; REGULON; PROTEIN	Host-pathogen interactions are often driven by mechanisms that promote genetic variability. We have identified a group of temperate bacteriophages that generate diversity in a gene, designated mtd (major tropism determinant), which specifies tropism for receptor molecules on host Bordetella species. Tropism switching is the result of a template-dependent, reverse transcriptase-mediated process that introduces nucleotide substitutions at defined locations within mtd. This cassette-based mechanism is capable of providing a vast repertoire of potential ligand-receptor interactions.	Univ Calif Los Angeles, Dept Microbiol Mol Genet & Immunol, Los Angeles, CA 90095 USA; Univ Cambridge, Dept Clin Vet Med, Ctr Vet Sci, Cambridge CB3 0ES, England; Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA; Sanger Ctr, Cambridge, England	University of California System; University of California Los Angeles; University of Cambridge; University of California System; University of California Santa Barbara; Wellcome Trust Sanger Institute	Miller, JF (corresponding author), Univ Calif Los Angeles, Dept Microbiol Mol Genet & Immunol, Los Angeles, CA 90095 USA.	jfmiller@ucla.edu	Parkhill, Julian/G-4703-2011	Parkhill, Julian/0000-0002-7069-5958; Preston, Andrew/0000-0002-1489-280X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038417, R01AI043986] Funding Source: NIH RePORTER; NIAID NIH HHS [AI38417, AI43986] Funding Source: Medline; NIGMS NIH HHS [GM-08042] Funding Source: Medline; PHS HHS [T32A107323] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AKERLEY BJ, 1995, CELL, V80, P611, DOI 10.1016/0092-8674(95)90515-4; Cotter P.A., 2001, PRINCIPLES BACTERIAL, P620; Cotter PA, 1997, MOL MICROBIOL, V24, P671, DOI 10.1046/j.1365-2958.1997.3821741.x; Deora R, 2001, MOL MICROBIOL, V40, P669, DOI 10.1046/j.1365-2958.2001.02415.x; DOI H, 1991, P NATL ACAD SCI USA, V88, P9282, DOI 10.1073/pnas.88.20.9282; DOULATOV S, UNPUB; Edwards RA, 1998, GENE, V207, P149, DOI 10.1016/S0378-1119(97)00619-7; Gerber AP, 2001, TRENDS BIOCHEM SCI, V26, P376, DOI 10.1016/S0968-0004(01)01827-8; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LEININGER E, 1991, P NATL ACAD SCI USA, V88, P345, DOI 10.1073/pnas.88.2.345; Martinez-Abarca F, 2000, MOL MICROBIOL, V38, P917, DOI 10.1046/j.1365-2958.2000.02197.x; Matsuura M, 1997, GENE DEV, V11, P2910, DOI 10.1101/gad.11.21.2910; SINGER MF, 1995, J BIOL CHEM, V270, P24623, DOI 10.1074/jbc.270.42.24623; Stockbauer KE, 2001, MOL MICROBIOL, V39, P65, DOI 10.1046/j.1365-2958.2001.02191.x; Uhl MA, 1996, EMBO J, V15, P1028, DOI 10.1002/j.1460-2075.1996.tb00440.x	15	168	183	1	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 15	2002	295	5562					2091	2094		10.1126/science.1067467	http://dx.doi.org/10.1126/science.1067467			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	532AY	11896279				2022-12-28	WOS:000174450500054
J	Malkin, D				Malkin, D			Simian virus 40 and non-Hodgkin lymphoma	LANCET			English	Editorial Material							T-ANTIGEN; SIMIAN-VIRUS-40; CELL; INFECTION; DISEASE; MUTANT; INVIVO		Univ Toronto, Hosp Sick Children, Dept Pediat, Div Hematol & Oncol, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Malkin, D (corresponding author), Univ Toronto, Hosp Sick Children, Dept Pediat, Div Hematol & Oncol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	david.malkin@sickkids.on.ca						Butel JS, 1999, JNCI-J NATL CANCER I, V91, P119, DOI 10.1093/jnci/91.2.119; CHEN JD, 1992, ONCOGENE, V7, P1167; CICALA C, 1992, VIROLOGY, V190, P475, DOI 10.1016/0042-6822(92)91237-O; COE JE, 1975, J NATL CANCER I, V54, P269, DOI 10.1093/jnci/54.1.269; Del Valle L, 2002, JNCI-J NATL CANCER I, V94, P267, DOI 10.1093/jnci/94.4.267; DIAMANDO.GT, 1973, JNCI-J NATL CANCER I, V50, P1347, DOI 10.1093/jnci/50.5.1347; EDDY BE, 1962, VIROLOGY, V17, P65, DOI 10.1016/0042-6822(62)90082-X; EVANS AS, 1976, YALE J BIOL MED, V49, P175; Flaegstad T, 1999, CANCER RES, V59, P1160; FRAUMENI JF, 1963, JAMA-J AM MED ASSOC, V185, P713, DOI 10.1001/jama.1963.03060090045016; Malkin D, 2001, ONCOGENE, V20, P4441, DOI 10.1038/sj.onc.1204583; ROBLES MTS, 1994, MOL CELL BIOL, V14, P2686, DOI 10.1128/MCB.14.4.2686; Shah KV, 2000, REV MED VIROL, V10, P31, DOI 10.1002/(SICI)1099-1654(200001/02)10:1<31::AID-RMV260>3.0.CO;2-I; Stubdal H, 1997, MOL CELL BIOL, V17, P4979, DOI 10.1128/MCB.17.9.4979; SYMONDS HS, 1993, MOL CELL BIOL, V13, P3255, DOI 10.1128/MCB.13.6.3255; Zhen HN, 1999, CANCER, V86, P2124, DOI 10.1002/(SICI)1097-0142(19991115)86:10<2124::AID-CNCR34>3.0.CO;2-D	16	8	8	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 9	2002	359	9309					812	813		10.1016/S0140-6736(02)07957-6	http://dx.doi.org/10.1016/S0140-6736(02)07957-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	529YV	11897273				2022-12-28	WOS:000174329600002
J	Nye, MJ				Nye, MJ			Portraits of science - "The most versatile physicist of his generation"	SCIENCE			English	Biographical-Item									Oregon State Univ, Dept Hist, Corvallis, OR 97331 USA	Oregon State University	Nye, MJ (corresponding author), Oregon State Univ, Dept Hist, Corvallis, OR 97331 USA.								0	0	0	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 5	2002	296	5565					49	50		10.1126/science.1069837	http://dx.doi.org/10.1126/science.1069837			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	539FA	11935005				2022-12-28	WOS:000174858800024
J	Bucciantini, M; Giannoni, E; Chiti, F; Baroni, F; Formigli, L; Zurdo, JS; Taddei, N; Ramponi, G; Dobson, CM; Stefani, M				Bucciantini, M; Giannoni, E; Chiti, F; Baroni, F; Formigli, L; Zurdo, JS; Taddei, N; Ramponi, G; Dobson, CM; Stefani, M			Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases	NATURE			English	Article							AMYLOID-BETA-PROTEIN; FIBRIL FORMATION; ALZHEIMERS-DISEASE; PARKINSONS-DISEASE; MTT REDUCTION; SH3 DOMAIN; CELL-DEATH; NEUROTOXICITY; FIBRILLIZATION; ACCELERATION	A range of human degenerative conditions, including Alzheimer's disease, light-chain amyloidosis and the spongiform encephalopathies, is associated with the deposition in tissue of proteinaceous aggregates known as amyloid fibrils or plaques. It has been shown previously that fibrillar aggregates that are closely similar to those associated with clinical amyloidoses can be formed in vitro from proteins not connected with these diseases, including the SH3 domain from bovine phosphatidyl-inositol-3'-kinase and the amino-terminal domain of the Escherichia coli HypF protein. Here we show that species formed early in the aggregation of these non-disease-associated proteins can be inherently highly cytotoxic. This finding provides added evidence that avoidance of protein aggregation is crucial for the preservation of biological function and suggests common features in the origins of this family of protein deposition diseases.	Univ Florence, Dipartimento Sci Biochim, I-50134 Florence, Italy; Univ Florence, Dipartimento Anat Istol & Med Legale, I-50134 Florence, Italy; Univ Cambridge, Dept Chem, Cambridge CB2 1EW, England	University of Florence; University of Florence; University of Cambridge	Stefani, M (corresponding author), Univ Florence, Dipartimento Sci Biochim, Viale Morgagni 50, I-50134 Florence, Italy.		Zurdo, Jesús/C-3110-2015; Giannoni, Elisa/AAE-2092-2020	Zurdo, Jesús/0000-0001-5186-8633; STEFANI, MASSIMO/0000-0002-4490-1922; bucciantini, monica/0000-0002-5243-9301; Giannoni, Elisa/0000-0001-7136-1098; Taddei, Niccolo/0000-0003-2513-1018	Telethon [453/BI, 686] Funding Source: Medline	Telethon(Fondazione Telethon)		Abe K, 1998, NEUROSCI RES, V31, P295, DOI 10.1016/S0168-0102(98)00055-8; BOOKER GW, 1993, CELL, V73, P813, DOI 10.1016/0092-8674(93)90259-S; Butterfield DA, 1999, METHOD ENZYMOL, V309, P746; Chiti F, 1999, P NATL ACAD SCI USA, V96, P3590, DOI 10.1073/pnas.96.7.3590; Chiti F, 2001, PROTEIN SCI, V10, P2541, DOI 10.1110/ps.ps.10201; Clarke G, 2000, NATURE, V406, P195, DOI 10.1038/35018098; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Dobson CM, 2001, PHILOS T R SOC B, V356, P133, DOI 10.1098/rstb.2000.0758; Fandrich M, 2001, NATURE, V410, P165, DOI 10.1038/35065514; Fezoui Y, 2000, NAT STRUCT BIOL, V7, P1095, DOI 10.1038/81937; GLENNER GG, 1974, J HISTOCHEM CYTOCHEM, V22, P1141, DOI 10.1177/22.12.1141; Goldberg MS, 2000, NAT CELL BIOL, V2, pE115, DOI 10.1038/35017124; Guijarro JI, 1998, P NATL ACAD SCI USA, V95, P4224, DOI 10.1073/pnas.95.8.4224; Harper JD, 1997, CHEM BIOL, V4, P951, DOI 10.1016/S1074-5521(97)90303-3; Hartley DM, 1999, J NEUROSCI, V19, P8876, DOI 10.1523/JNEUROSCI.19-20-08876.1999; Hsia AY, 1999, P NATL ACAD SCI USA, V96, P3228, DOI 10.1073/pnas.96.6.3228; Jimenez JL, 1999, EMBO J, V18, P815, DOI 10.1093/emboj/18.4.815; Kelly JW, 1998, CURR OPIN STRUC BIOL, V8, P101, DOI 10.1016/S0959-440X(98)80016-X; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; LEROUX MR, 1999, MECH PROTEIN FOLDING, P364; Li LM, 2000, SCIENCE, V287, P661, DOI 10.1126/science.287.5453.661; Liu YB, 1997, J NEUROCHEM, V69, P581, DOI 10.1046/j.1471-4159.1997.69020581.x; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; Monji A, 2000, NEUROSCI LETT, V278, P81, DOI 10.1016/S0304-3940(99)00899-X; Perutz MF, 2001, NATURE, V412, P143, DOI 10.1038/35084141; Pillot T, 1999, J NEUROCHEM, V73, P1626, DOI 10.1046/j.1471-4159.1999.0731626.x; Sherman MY, 2001, NEURON, V29, P15, DOI 10.1016/S0896-6273(01)00177-5; Sousa MM, 2001, AM J PATHOL, V159, P1993; Sunde M, 1997, ADV PROTEIN CHEM, V50, P123, DOI 10.1016/S0065-3233(08)60320-4; Thomas T, 1996, NATURE, V380, P168, DOI 10.1038/380168a0; Walsh DM, 1999, J BIOL CHEM, V274, P25945, DOI 10.1074/jbc.274.36.25945; Weatherall DJ, 1995, OXFORD TXB MED, V2, P1512; Zhu YJ, 2000, FASEB J, V14, P1244, DOI 10.1096/fasebj.14.9.1244; Zurdo J, 2001, J AM CHEM SOC, V123, P8141, DOI 10.1021/ja016229b	34	2068	2134	3	434	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 4	2002	416	6880					507	511		10.1038/416507a	http://dx.doi.org/10.1038/416507a			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	537JY	11932737				2022-12-28	WOS:000174756500035
J	Gascard, JC; Watson, AJ; Messias, MJ; Olsson, KA; Johannessen, T; Simonsen, K				Gascard, JC; Watson, AJ; Messias, MJ; Olsson, KA; Johannessen, T; Simonsen, K			Long-lived vortices as a mode of deep ventilation in the Greenland Sea	NATURE			English	Article							OCEAN CONVECTION; WINTER; MESOSCALE; FLUID	The Greenland Sea is one of a few sites in the world ocean where convection to great depths occurs(1-4)-a process that forms some of the densest waters in the ocean. But the role of deep convective eddies, which result from surface cooling and mixing across density surfaces followed by geostrophic adjustment(5), has not been fully taken into account in the description of the initiation and growth of convection(6). Here we present tracer, float and hydrographic observations of long-lived (similar to1 year) and compact (similar to5 km core diameter) vortices that reach down to depths of 2 km. The eddies form in winter, near the rim of the Greenland Sea central gyre, and rotate clockwise with periods of a few days. The cores of the observed eddies are constituted from a mixture of modified Atlantic water that is warm and salty with polar water that is cold and fresh. We infer that these submesoscale coherent eddies contribute substantially to the input of Atlantic and polar waters to depths greater than 500 m in the central Greenland Sea.	Univ Paris 06, Lab Oceanog Dynam & Climatol, F-75252 Paris 05, France; Univ E Anglia, Sch Environm Sci, Norwich NR4 7TJ, Norfolk, England; Univ Gothenburg, Dept Analyt & Marine Chem, S-41296 Gothenburg, Sweden; Univ Bergen, Inst Geophys, N-5007 Bergen, Norway; Univ Bergen, Bjerknes Ctr Climate Res, N-5007 Bergen, Norway; Nansen Environm & Remote Sensing Ctr, N-5037 Bergen, Norway	UDICE-French Research Universities; Sorbonne Universite; University of East Anglia; University of Gothenburg; University of Bergen; Bjerknes Centre for Climate Research; University of Bergen; Nansen Environmental & Remote Sensing Center (NERSC)	Gascard, JC (corresponding author), Univ Paris 06, Lab Oceanog Dynam & Climatol, F-75252 Paris 05, France.		Simonsen, Knud/Y-4764-2019; Olsson, K. Anders/B-3982-2008	Simonsen, Knud/0000-0003-0337-9987; Watson, Andrew/0000-0002-9654-8147				GASCARD JC, 1983, J PHYS OCEANOGR, V13, P1779, DOI 10.1175/1520-0485(1983)013<1779:TFOLSW>2.0.CO;2; GILL AE, 1981, J FLUID MECH, V103, P275, DOI 10.1017/S0022112081001341; HEDSTROM K, 1988, J FLUID MECH, V191, P535, DOI 10.1017/S0022112088001697; Legg S, 1998, J PHYS OCEANOGR, V28, P944, DOI 10.1175/1520-0485(1998)028<0944:LODOCB>2.0.CO;2; Lherminier P, 1999, DEEP-SEA RES PT II, V46, P1199, DOI 10.1016/S0967-0645(99)00020-X; LILLY JM, IN PRESS J PHYS OCEA; Marshall J, 1999, REV GEOPHYS, V37, P1, DOI 10.1029/98RG02739; MCWILLIAMS JC, 1988, J PHYS OCEANOGR, V18, P1178, DOI 10.1175/1520-0485(1988)018<1178:VGTBA>2.0.CO;2; Morawitz WML, 1996, J PHYS OCEANOGR, V26, P2316, DOI 10.1175/1520-0485(1996)026<2316:TDOOAD>2.0.CO;2; ROACH AT, 1993, ATMOS OCEAN, V31, P319, DOI 10.1080/07055900.1993.9649474; RUDELS B, 1989, J GEOPHYS RES-OCEANS, V94, P3223, DOI 10.1029/JC094iC03p03223; SCHOTT F, 1993, J GEOPHYS RES-OCEANS, V98, P14401, DOI 10.1029/93JC00658; Straneo F, 1999, J PHYS OCEANOGR, V29, P55, DOI 10.1175/1520-0485(1999)029<0055:COLCDT>2.0.CO;2; Watson AJ, 1999, NATURE, V401, P902, DOI 10.1038/44807	14	75	79	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 4	2002	416	6880					525	527		10.1038/416525a	http://dx.doi.org/10.1038/416525a			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	537JY	11932742				2022-12-28	WOS:000174756500040
J	Gaggiotti, OE; Jones, F; Lee, WM; Amos, W; Harwood, J; Nichols, RA				Gaggiotti, OE; Jones, F; Lee, WM; Amos, W; Harwood, J; Nichols, RA			Patterns of colonization in a metapopulation of grey seals	NATURE			English	Article							POPULATION-STRUCTURE	The colonization of a new habitat is a fundamental process in metapopulation biology(1), but it is difficult to study. The emigration of colonists from established populations might be induced by resource competition owing to high local population density(2,3). Migration distances are also important because they determine the frequency and scale of recolonization and hence the spatial scale of the metapopulation(4). Traditionally, these factors have been investigated with demographic approaches that are labour-intensive and are only possible in amenable species. In many cases, genetic differentiation is minimal, preventing traditional genetic approaches from identifying the source of colonists unambiguously. Here we present a bayesian approach that integrates genetic, demographic and geographic distance data. We apply the method to study the British metapopulation of grey seals, which has been growing at 6% per year over the last few decades(5). Our method reveals differential recruitment to three newly founded colonies and implicates density-dependent dispersal in metapopulation dynamics by using genetic data.	Queen Mary Univ London, Sch Biol Sci, London E1 4NS, England; Univ Cambridge, Dept Zool, Cambridge CB2 3EJ, England; Univ Edinburgh, Inst Cell Anim & Populat Biol, Edinburgh EH9 3JT, Midlothian, Scotland; Univ St Andrews, NERC, Sea Mammal Res Unit, Gatty Marine Lab, St Andrews KY16 8LB, Fife, Scotland	University of London; Queen Mary University London; University of Cambridge; University of Edinburgh; UK Research & Innovation (UKRI); Natural Environment Research Council (NERC); University of St Andrews	Nichols, RA (corresponding author), Queen Mary Univ London, Sch Biol Sci, Mile End Rd, London E1 4NS, England.	r.a.nichols@qmul.ac.uk	Nichols, Richard/B-7732-2008; Gaggiotti, Oscar E/G-2459-2010; Nichols, Richard Alan/T-4773-2019; Jones, Felicity C/AAY-3523-2021	Nichols, Richard/0000-0002-4801-9312; Gaggiotti, Oscar E/0000-0003-1827-1493; Jones, Felicity C/0000-0002-5027-1031				Baker R. R., 1978, EVOLUTIONARY ECOLOGY; Giles BE, 1997, AM NAT, V149, P507, DOI 10.1086/286002; Hanski I, 1998, NATURE, V396, P41, DOI 10.1038/23876; Hanski I., 1999, METAPOPULATION ECOLO; HASTINGS WK, 1970, BIOMETRIKA, V57, P97, DOI 10.1093/biomet/57.1.97; HIBY AR, 1996, NERC NEWS        JAN; Ingvarsson PK, 1998, HEREDITY, V80, P456, DOI 10.1046/j.1365-2540.1998.00306.x; Johnson C. G., 1969, INSECT MIGRATION DIS; METROPOLIS N, 1953, J CHEM PHYS, V21, P1087, DOI 10.1063/1.1699114; MILNER GB, 1985, MAR FISH REV, V47, P1; Pomeroy PP, 2000, ETHOLOGY, V106, P899, DOI 10.1046/j.1439-0310.2000.00610.x; Pritchard JK, 2000, GENETICS, V155, P945; Rannala B, 1997, P NATL ACAD SCI USA, V94, P9197, DOI 10.1073/pnas.94.17.9197; SPIEGELHALTER DJ, IN PRESS J R STAT B, V64; WHITLOCK MC, 1992, AM NAT, V139, P952, DOI 10.1086/285368	15	72	74	0	51	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 28	2002	416	6879					424	427		10.1038/416424a	http://dx.doi.org/10.1038/416424a			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	534UX	11919630				2022-12-28	WOS:000174607800045
J	Afra, D; Baron, B; Bonadonna, G; Curran, WJ; Green, SB; Hildebrand, J; Scott, CB; Shapiro, W; Thomas, D; Trojanowski, T; Urtasun, R; Walker, MD; Burdett, S; Parmar, MKB; Souhami, RL; Stenning, SP; Stewart, LA				Afra, D; Baron, B; Bonadonna, G; Curran, WJ; Green, SB; Hildebrand, J; Scott, CB; Shapiro, W; Thomas, D; Trojanowski, T; Urtasun, R; Walker, MD; Burdett, S; Parmar, MKB; Souhami, RL; Stenning, SP; Stewart, LA		Glioma Meta-analysis Trialists Grp	Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials	LANCET			English	Article							OPERATED ASTROCYTOMAS GRADE-3; RESEARCH-COUNCIL TRIAL; RADIATION-THERAPY; MALIGNANT GLIOMAS; CCNU-CHEMOTHERAPY; BRAIN GLIOMAS; POSTOPERATIVE RADIOTHERAPY; GLIOBLASTOMA; SURVIVAL; DIBROMODULCITOL	Background Trials on the effect of systemic chemotherapy on survival and recurrence in adults with high-grade glioma have had inconclusive results. We undertook a systematic review and meta-analysis to assess the effects of such treatment on survival and recurrence. Methods We did a systematic review and meta-analysis using updated data on individual patients from all available randomised trials that compared radiotherapy alone with radiotherapy plus chemotherapy. Data for 3004 patients from 12 randomised controlled trials were included (11 published and one unpublished). Findings Overall, the results showed significant prolongation of survival associated with chemotherapy, with a hazard ratio of 0.85 (95% CI 0.78-0.91, p < 0.0001) or a 15% relative decrease in the risk of death. This effect is equivalent to an absolute increase in 1-year survival of 6% (95% CI 3-9) from 40% to 46% and a 2-month increase in median survival time (1-3). There was no evidence that the effect of chemotherapy differed in any group of patients defined by age, sex, histology, performance status, or extent of resection. Interpretation This small but clear improvement in survival from chemotherapy encourages further study of drug treatment of these tumours.	MRC, Clin Trials Unit, Meta Anal Grp, London NW1 2DA, England; Natl Inst Neurosurg, Budapest, Hungary; EORTC Data Ctr, Brussels, Belgium; Ist Nazl Tumori, I-20133 Milan, Italy; Thomas Jefferson Univ, Jefferson Med Coll, Philadelphia, PA 19107 USA; Case Western Reserve Univ, Cleveland, OH 44106 USA; Hop Univ Erasme, Brussels, Belgium; Radiat Therapy Oncol Grp, Philadelphia, PA USA; St Josephs Hosp, Barrow Neurol Inst, Phoenix, AZ USA; UCL Royal Free & Univ Coll Med Sch, London, England; Natl Hosp, London WC1N 3BG, England; Sch Med, Lublin, Poland; Univ Alberta, Cross Canc Inst, Edmonton, AB, Canada; NINCDS, Bethesda, MD 20892 USA	Medical Research Council Clinical Trials Unit; European Organisation for Research & Treatment of Cancer; Fondazione IRCCS Istituto Nazionale Tumori Milan; Jefferson University; Case Western Reserve University; Universite Libre de Bruxelles; Radiation Therapy Oncology Group (RTOG); Barrow Neurological Institute; St. Joseph's Hospital and Medical Center; University of London; University College London; UCL Medical School; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; Medical University of Lublin; University of Alberta; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Stewart, LA (corresponding author), MRC, Clin Trials Unit, Meta Anal Grp, 222 Euston Rd, London NW1 2DA, England.	ls@ctu.mrc.ac.uk		Stewart, Lesley/0000-0003-0287-4724				AFRA D, 1983, J NEUROSURG, V59, P106, DOI 10.3171/jns.1983.59.1.0106; BLEEHEN NM, 1991, BRIT J CANCER, V64, P769, DOI 10.1038/bjc.1991.396; BRISMAN R, 1976, ARCH NEUROL-CHICAGO, V33, P745, DOI 10.1001/archneur.1976.00500110013003; CHANG CH, 1983, CANCER, V52, P997, DOI 10.1002/1097-0142(19830915)52:6<997::AID-CNCR2820520612>3.0.CO;2-2; CIANFRIGLIA F, 1980, CANCER, V45, P1289, DOI 10.1002/1097-0142(19800315)45:6<1289::AID-CNCR2820450605>3.0.CO;2-8; Clarke M, 1998, ANN ONCOL, V9, P827, DOI 10.1023/A:1008468705492; DICKERSIN K, 1994, BMJ-BRIT MED J, V309, P1286, DOI 10.1136/bmj.309.6964.1286; DICKERSIN K, 1990, JAMA-J AM MED ASSOC, V263, P1385, DOI 10.1001/jama.263.10.1385; EAGAN RT, 1979, JAMA-J AM MED ASSOC, V241, P2046, DOI 10.1001/jama.241.19.2046; *EARL BREAST CANC, 1990, TREATM EARL BREAST C, V1; *EORTC BRAIN TUM G, 1978, EUR J CANCER, V14, P851; FINE HA, 1993, CANCER, V71, P2585, DOI 10.1002/1097-0142(19930415)71:8<2585::AID-CNCR2820710825>3.0.CO;2-S; GARRETT MJ, 1978, CLIN ONCOL, V4, P71; GREEN SB, 1983, CANCER TREAT REP, V67, P121; HATLEVOLL R, 1985, CANCER, V56, P41, DOI 10.1002/1097-0142(19850701)56:1<41::AID-CNCR2820560108>3.0.CO;2-W; HILDEBRAND J, 1994, NEUROLOGY, V44, P1479, DOI 10.1212/WNL.44.8.1479; HILDEBRAND J, 1981, J NEUROSURG, V55, P27; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KRISTIANSEN K, 1981, CANCER, V47, P649, DOI 10.1002/1097-0142(19810215)47:4<649::AID-CNCR2820470405>3.0.CO;2-W; MULLER H, 1985, CLIN NEUROL NEUROSUR, V87, P167, DOI 10.1016/0303-8467(85)90002-2; PARMAR M, 1995, SURVIVAL ANAL PRACTI; REAGAN TJ, 1976, J NEUROSURG, V44, P186, DOI 10.3171/jns.1976.44.2.0186; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Solero C L, 1979, Cancer Clin Trials, V2, P43; Souhami R, 1995, CANC ITS MANAGEMENT; STENNING SP, 1987, BRIT J CANCER, V56, P89, DOI 10.1038/bjc.1987.161; STEWART LA, 1995, STAT MED, V14, P2057, DOI 10.1002/sim.4780141902; STEWART LA, 1993, LANCET, V341, P984; TAKAKURA K, 1986, J NEUROSURG, V64, P53, DOI 10.3171/jns.1986.64.1.0053; Thomas D, 2001, J CLIN ONCOL, V19, P509, DOI 10.1200/JCO.2001.19.2.509; TROJANOWSKI T, 1988, J NEURO-ONCOL, V6, P285, DOI 10.1007/BF00163714; USHIO Y, 1981, P 7 INT C NEUR SURG, P362; WALKER MD, 1978, J NEUROSURG, V49, P333, DOI 10.3171/jns.1978.49.3.0333; WALKER MD, 1980, NEW ENGL J MED, V303, P1323, DOI 10.1056/NEJM198012043032303; WEIR B, 1976, J NEUROSURG, V45, P129, DOI 10.3171/jns.1976.45.2.0129; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7	36	914	985	1	86	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 23	2002	359	9311					1011	1018						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	534KP	11937180				2022-12-28	WOS:000174585800007
J	Pickup, J; Mattock, M; Kerry, S				Pickup, J; Mattock, M; Kerry, S			Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials	BMJ-BRITISH MEDICAL JOURNAL			English	Article							THERAPY; PUMP; LISPRO; CSII; HYPOGLYCEMIA; RETINOPATHY; MELLITUS; ANALOG	Objective To compare glycaemic control and insulin dosage in people with type 1 diabetes treated by continuous subcutaneous insulin infusion (insulin infusion pump therapy) or optimised insulin injections. Design Meta-analysis of 12 randomised controlled trials. Participants 301 people with type I diabetes allocated to insulin infusion and 299 allocated to insulin injections for between 2.5 and 24 months. Main outcome measures Glycaemic control measured by mean blood glucose concentration and percentage of glycated haemoglobin. Total daily insulin dose. Results Mean blood glucose concentration was lower in people receiving continuous subcutaneous insulin infusion compared with those receiving insulin injections (standardised mean difference 0.56, 95% confidence interval 0.35 to 0.77), equivalent to a difference of 1.0 mmol/l. The percentage of glycated haemoglobin was also lower in people receiving insulin infusion (0.44. 0.20 to 0.69), equivalent to a difference of 0.5%. Blood glucose concentrations were less variable during insulin infusion. This improved control during insulin infusion was achieved with an average reduction of 14% in insulin dose (difference in total daily insulin dose 0.58, 0,34 to 0.83), equivalent to 7.58 units/day. Conclusions Glycaemic control is better during continuous subcutaneous insulin infusion compared with optimised injection therapy, and less insulin is needed to achieve this level of strict control. The difference in control between die two methods is small but should reduce the risk of microvascular complications.	Guys Hosp, Guys Kings & St Thomass Hosp Sch Med, Dept Chem Pathol, Metab Unit, London SE1 9RT, England; St Helier Hosp, SW Thames Inst Renal Res, Carshalton SM5 1AA, Surrey, England; Univ London St Georges Hosp, Sch Med, Dept Gen Practice & Primary Care, London SW17 0RE, England	Guy's & St Thomas' NHS Foundation Trust; St Helier Hospital; St Georges University London	Pickup, J (corresponding author), Guys Hosp, Guys Kings & St Thomass Hosp Sch Med, Dept Chem Pathol, Metab Unit, London SE1 9RT, England.	john.pickup@kcl.ac.uk						[Anonymous], 1996, DIABETES, V45, P1289; BAK JF, 1987, DIABETES RES CLIN EX, V6, P155; BECKNIELSEN H, 1984, DIABETES, V33, P832, DOI 10.2337/diabetes.33.9.832; BENDING JJ, 1985, AM J MED, V79, P685, DOI 10.1016/0002-9343(85)90518-2; Bode BW, 1996, DIABETES CARE, V19, P324, DOI 10.2337/diacare.19.4.324; Boland EA, 1999, DIABETES CARE, V22, P1779, DOI 10.2337/diacare.22.11.1779; CARTA Q, 1986, DIABETES METAB, V12, P121; COUSTAN DR, 1986, JAMA-J AM MED ASSOC, V255, P631, DOI 10.1001/jama.255.5.631; DAHLJORGENSEN K, 1986, BRIT MED J, V293, P1195, DOI 10.1136/bmj.293.6556.1195; DEBEAUFORT CE, 1989, DIABETIC MED, V6, P766; *DUSS STUD GROUP, 1990, DIABETES NUTR METAB, V3, P203; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; EICHNER HL, 1988, DIABETES NUTR METAB, V1, P283; FUI SNT, 1986, DIABETES CARE, V9, P221, DOI 10.2337/diacare.9.3.221; GONEN B, 1979, DIABETES, V28, P749, DOI 10.2337/diabetes.28.8.749; Hanaire-Broutin H, 2000, DIABETES CARE, V23, P1232, DOI 10.2337/diacare.23.9.1232; HELVE E, 1987, ACTA MED SCAND, V221, P385; HOME PD, 1982, DIABETES CARE, V5, P466, DOI 10.2337/diacare.5.5.466; LAURITZEN T, 1983, DIABETOLOGIA, V24, P326; LAURITZEN T, 1983, LANCET, V1, P200; MARSHALL SM, 1987, DIABETIC MED, V4, P521, DOI 10.1111/j.1464-5491.1987.tb00922.x; MECKLENBURG RS, 1985, DIABETES CARE, V8, P367, DOI 10.2337/diacare.8.4.367; Melki V, 1998, DIABETES CARE, V21, P977, DOI 10.2337/diacare.21.6.977; NATHAN DM, 1982, ANN INTERN MED, V97, P31, DOI 10.7326/0003-4819-97-1-31; NOSADINI R, 1988, DIABETES NUTR METAB, V1, P289; NOSARI I, 1993, DIABETES NUTR METAB, V6, P33; Pickup J, 2001, BMJ-BRIT MED J, V322, P1262, DOI 10.1136/bmj.322.7297.1262; PICKUP JC, 1978, BRIT MED J, V1, P204, DOI 10.1136/bmj.1.6107.204; Pickup JC, 2001, DIFFICULT DIABETES, P205, DOI 10.1002/9780470757109.ch13; Renner R, 1999, DIABETES CARE, V22, P784, DOI 10.2337/diacare.22.5.784; SAURBREY N, 1988, DIABETIC MED, V5, P150, DOI 10.1111/j.1464-5491.1988.tb00962.x; SCHIFFRIN A, 1982, DIABETES, V31, P255, DOI 10.2337/diabetes.31.3.255; SCHIFFRIN AD, 1984, DIABETES CARE, V7, P107, DOI 10.2337/diacare.7.2.107; Schmauss S, 1998, DIABETIC MED, V15, P247, DOI 10.1002/(SICI)1096-9136(199803)15:3<247::AID-DIA547>3.0.CO;2-T; SCHMITZ A, 1989, DAN MED BULL, V36, P176; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SHERWIN RS, 1984, NEW ENGL J MED, V311, P365, DOI 10.1056/NEJM198408093110604; SIMONSON DC, 1985, DIABETES, V34, P80, DOI 10.2337/diab.34.3.S80; Sutton AJAK, 2000, METHODS METAANALYSIS; Zinman B, 1997, DIABETES, V46, P440, DOI 10.2337/diabetes.46.3.440	40	265	272	0	19	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 23	2002	324	7339					705	708		10.1136/bmj.324.7339.705	http://dx.doi.org/10.1136/bmj.324.7339.705			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	535ML	11909787	Bronze, Green Published			2022-12-28	WOS:000174648200018
J	Inagaki, S; Guan, S; Ohsuna, T; Terasaki, O				Inagaki, S; Guan, S; Ohsuna, T; Terasaki, O			An ordered mesoporous organosilica hybrid material with a crystal-like wall structure	NATURE			English	Article							MOLECULAR-SIEVES; ORGANIC GROUPS; FRAMEWORKS; OXIDE	Surfactant-mediated synthesis strategies are widely used to fabricate ordered mesoporous solids(1-6) in the form of metal oxides(7), metals(8), carbon(9) and hybrid organosilicas(10-14). These materials have amorphous pore walls, which could limit their practical utility. In the case of mesoporous metal oxides, efforts to crystallize the framework structure by thermal(15,16) and hydrothermal treatments(17) have resulted in crystallization of only a fraction of the pore walls. Here we report the surfactant-mediated synthesis of an ordered benzene-silica hybrid material; this material has an hexagonal array of mesopores with a lattice constant of 52.5 Angstrom, and crystal-like pore walls that exhibit structural periodicity with a spacing of 7.6 Angstrom along the channel direction. The periodic pore surface structure results from alternating hydrophilic and hydrophobic layers, composed of silica and benzene, respectively. We believe that this material is formed as a result of structure-directing interactions between the benzene-silica precursor molecules, and between the precursor molecules and the surfactants. We expect that other organosilicas and organo-metal oxides can be produced in a similar fashion, to yield a range of hierarchically ordered mesoporous solids with molecular-scale pore surface periodicity.	Toyota Cent Res & Dev Labs Inc, Aichi 4801192, Japan; Tohoku Univ, Mat Res Inst, Sendai, Miyagi 9808577, Japan; Tohoku Univ, Grad Sch Sci, JST, CREST, Sendai, Miyagi 9808578, Japan; Tohoku Univ, Dept Phys, Sendai, Miyagi 9808578, Japan	Toyota Central R&D Labs Inc; Tohoku University; Japan Science & Technology Agency (JST); Tohoku University; Tohoku University	Inagaki, S (corresponding author), Toyota Cent Res & Dev Labs Inc, Aichi 4801192, Japan.		Inagaki, Shinji/M-8168-2018; Terasaki, Osamu/Y-1137-2018	Inagaki, Shinji/0000-0003-0405-5511; Terasaki, Osamu/0000-0001-5803-0817				Asefa T, 1999, NATURE, V402, P867, DOI 10.1038/47229; Attard GS, 1997, SCIENCE, V278, P838, DOI 10.1126/science.278.5339.838; BAGSHAW SA, 1995, SCIENCE, V269, P1242, DOI 10.1126/science.269.5228.1242; BECK JS, 1992, J AM CHEM SOC, V114, P10834, DOI 10.1021/ja00053a020; Cerveau G, 2000, ANGEW CHEM INT EDIT, V39, P4533, DOI 10.1002/1521-3773(20001215)39:24<4533::AID-ANIE4533>3.3.CO;2-#; Corriu RJP, 2000, ANGEW CHEM INT EDIT, V39, P1376, DOI 10.1002/(SICI)1521-3773(20000417)39:8<1376::AID-ANIE1376>3.0.CO;2-S; FIROUZI A, 1995, SCIENCE, V267, P1138, DOI 10.1126/science.7855591; Guan S, 2000, J AM CHEM SOC, V122, P5660, DOI 10.1021/ja000839e; Harmer MA, 1998, ADV MATER, V10, P1255, DOI 10.1002/(SICI)1521-4095(199810)10:15<1255::AID-ADMA1255>3.0.CO;2-T; INAGAKI S, 1993, J CHEM SOC CHEM COMM, P680, DOI 10.1039/c39930000680; Inagaki S, 1999, J AM CHEM SOC, V121, P9611, DOI 10.1021/ja9916658; Joo SH, 2001, NATURE, V412, P169, DOI 10.1038/35084046; KRESGE CT, 1992, NATURE, V359, P710, DOI 10.1038/359710a0; Kruk M, 2001, CHEM MATER, V13, P3169, DOI 10.1021/cm0101069; Lee B, 2001, CHEM COMMUN, P2118, DOI 10.1039/b104516b; Liu Y, 2001, ANGEW CHEM INT EDIT, V40, P1255, DOI 10.1002/1521-3773(20010401)40:7<1255::AID-ANIE1255>3.3.CO;2-L; LOY DA, 1995, CHEM REV, V95, P1431, DOI 10.1021/cr00037a013; Melde BJ, 1999, CHEM MATER, V11, P3302, DOI 10.1021/cm9903935; Stein A, 2000, ADV MATER, V12, P1403, DOI 10.1002/1521-4095(200010)12:19<1403::AID-ADMA1403>3.0.CO;2-X; YANAGISAWA T, 1990, B CHEM SOC JPN, V63, P988, DOI 10.1246/bcsj.63.988; Yang PD, 1998, NATURE, V396, P152; Ying JY, 1999, ANGEW CHEM INT EDIT, V38, P56, DOI 10.1002/(SICI)1521-3773(19990115)38:1/2<56::AID-ANIE56>3.0.CO;2-E	22	1189	1232	4	530	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 21	2002	416	6878					304	307		10.1038/416304a	http://dx.doi.org/10.1038/416304a			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	532NP	11907572				2022-12-28	WOS:000174482200037
J	Xin, HB; Senbonmatsu, T; Cheng, DS; Wang, YX; Copello, JA; Ji, GJ; Collier, ML; Deng, KY; Jeyakumar, LH; Magnuson, MA; Inagami, T; Kotlikoff, MI; Fleischer, S				Xin, HB; Senbonmatsu, T; Cheng, DS; Wang, YX; Copello, JA; Ji, GJ; Collier, ML; Deng, KY; Jeyakumar, LH; Magnuson, MA; Inagami, T; Kotlikoff, MI; Fleischer, S			Oestrogen protects FKBP12.6 null mice from cardiac hypertrophy	NATURE			English	Article							CALCIUM-RELEASE CHANNEL; LEFT-VENTRICULAR HYPERTROPHY; RYANODINE RECEPTOR FUNCTION; FK506 BINDING-PROTEIN; HORMONE REPLACEMENT; SELECTIVE BINDING; SMOOTH-MUSCLE; HEART; COMPLEX; CARDIOMYOPATHY	FK506 binding proteins 12 and 12.6 (FKBP12 and FKBP12.6) are intracellular receptors for the immunosuppressant drug FK506 (ref. 1). The skeletal muscle ryanodine receptor (RyR1) is isolated as a hetero-oligomer with FKBP12 (ref. 2), whereas the cardiac ryanodine receptor (RyR2) more selectively associates with FKBP12.6 (refs 3, 4, 5). FKBP12 modulates Ca2+ release from the sarcoplasmic reticulum in skeletal muscle(6,7) and developmental cardiac defects have been reported in FKBP12-deficient mice(8), but the role of FKBP12.6 in cardiac excitation contraction coupling remains unclear. Here we show that disruption of the FKBP12.6 gene in mice results in cardiac hypertrophy in male mice, but not in females. Female hearts are normal, despite the fact that male and female knockout mice display similar dysregulation of Ca2+ release, seen as increases in the amplitude and duration of Ca2+ sparks and calcium-induced calcium release gain. Female FKBP12.6-null mice treated with tamoxifen, an oestrogen receptor antagonist, develop cardiac hypertrophy similar to that of male mice. We conclude that FKBP12.6 modulates cardiac excitation-contraction coupling and that oestrogen plays a protective role in the hypertrophic response of the heart to Ca2+ dysregulation.	Vanderbilt Univ, Dept Biol Sci, Nashville, TN 37235 USA; Vanderbilt Univ, Dept Biochem, Nashville, TN 37235 USA; Vanderbilt Univ, Dept Physiol & Mol Biophys, Nashville, TN 37235 USA; Vanderbilt Univ, Dept Pharmacol, Nashville, TN 37235 USA; Cornell Univ, Coll Vet Med, Dept Biomed Sci, Ithaca, NY 14853 USA; Univ Penn, Sch Vet Med, Dept Anim Biol, Philadelphia, PA 19104 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Cornell University; University of Pennsylvania	Fleischer, S (corresponding author), Vanderbilt Univ, Dept Biol Sci, 221 Kirkland Hall, Nashville, TN 37235 USA.		Magnuson, Mark/AAY-7172-2021; Magnuson, Mark A/B-1335-2009	Magnuson, Mark/0000-0002-8824-6499; Magnuson, Mark A/0000-0002-8824-6499				ALDAPE RA, 1992, J BIOL CHEM, V267, P16029; Barg S, 1997, AM J PHYSIOL-CELL PH, V272, pC1726, DOI 10.1152/ajpcell.1997.272.5.C1726; BRILLANTES AMB, 1994, CELL, V77, P513, DOI 10.1016/0092-8674(94)90214-3; Collier ML, 2000, J GEN PHYSIOL, V115, P653, DOI 10.1085/jgp.115.5.653; Falvo JV, 2000, MOL CELL BIOL, V20, P2239, DOI 10.1128/MCB.20.6.2239-2247.2000; Fentzke RC, 1997, J AM SOC ECHOCARDIOG, V10, P915, DOI 10.1016/S0894-7317(97)80008-9; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; Gomez AM, 1997, SCIENCE, V276, P800, DOI 10.1126/science.276.5313.800; Hayward CS, 2000, CARDIOVASC RES, V46, P28, DOI 10.1016/S0008-6363(00)00005-5; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; JAYARAMAN T, 1992, J BIOL CHEM, V267, P9474; Kadokami T, 2000, J CLIN INVEST, V106, P589, DOI 10.1172/JCI9307; LAM E, 1995, J BIOL CHEM, V270, P26511, DOI 10.1074/jbc.270.44.26511; LEVY D, 1988, ANN INTERN MED, V108, P7, DOI 10.7326/0003-4819-108-1-7; Lim WK, 1999, AM J CARDIOL, V83, P1132, DOI 10.1016/S0002-9149(99)00029-6; LOUIE EK, 1994, PROG CARDIOVASC DIS, V36, P275, DOI 10.1016/S0033-0620(05)80036-2; Marks AR, 1996, PHYSIOL REV, V76, P631, DOI 10.1152/physrev.1996.76.3.631; Marx SO, 2000, CELL, V101, P365, DOI 10.1016/S0092-8674(00)80847-8; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Pelzer T, 1997, ADV EXP MED BIOL, V432, P83; Shorofsky SR, 1999, CIRC RES, V84, P424, DOI 10.1161/01.RES.84.4.424; Shou WN, 1998, NATURE, V391, P489, DOI 10.1038/35146; TIMERMAN AP, 1995, J BIOL CHEM, V270, P2451, DOI 10.1074/jbc.270.6.2451; Timerman AP, 1996, J BIOL CHEM, V271, P20385, DOI 10.1074/jbc.271.34.20385; TIMERMAN AP, 1993, J BIOL CHEM, V268, P22992; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VANDUYNE GD, 1991, SCIENCE, V252, P839, DOI 10.1126/science.1709302; Wang YX, 1997, P NATL ACAD SCI USA, V94, P14918, DOI 10.1073/pnas.94.26.14918; Xin HB, 1999, J BIOL CHEM, V274, P15315, DOI 10.1074/jbc.274.22.15315	30	242	264	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 21	2002	416	6878					334	337		10.1038/416334a	http://dx.doi.org/10.1038/416334a			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	532NP	11907581				2022-12-28	WOS:000174482200046
J	D'Hondt, S; Rutherford, S; Spivack, AJ				D'Hondt, S; Rutherford, S; Spivack, AJ			Metabolic activity of subsurface life in deep-sea sediments	SCIENCE			English	Article							SULFATE-REDUCING BACTERIA; MARINE-SEDIMENTS; ORGANIC-MATTER; REDUCTION; METHANE; OXIDATION; BIOSPHERE; RATES	Global maps of sulfate and methane in marine sediments reveal two provinces of subsurface metabolic activity: a sulfate-rich open-ocean province, and an ocean-margin province where sulfate is limited to shallow sediments. Methane is produced in both regions but is abundant only in sulfate-depleted sediments. Metabolic activity is greatest in narrow zones of sulfate-reducing methane oxidation along ocean margins. The metabolic rates of subseafloor life are orders of magnitude lower than those of life on Earth's surface. Most microorganisms in subseafloor sediments are either inactive or adapted for extraordinarily low metabolic activity.	Univ Rhode Isl, Grad Sch Oceanog, Narragansett, RI 02882 USA	University of Rhode Island	D'Hondt, S (corresponding author), Univ Rhode Isl, Grad Sch Oceanog, Narragansett, RI 02882 USA.		chen, qi/C-8585-2011					Adler M, 2000, INT J EARTH SCI, V88, P641, DOI 10.1007/s005310050294; Behrenfeld MJ, 1997, LIMNOL OCEANOGR, V42, P1, DOI 10.4319/lo.1997.42.1.0001; BERNER RA, 1980, EARLY DIAGENESIS; Boetius A, 2000, NATURE, V407, P623, DOI 10.1038/35036572; Borowski WS, 1996, GEOLOGY, V24, P655, DOI 10.1130/0091-7613(1996)024<0655:MPWSPI>2.3.CO;2; CANFIELD DE, 1991, AM J SCI, V291, P177, DOI 10.2475/ajs.291.2.177; CRAGG BA, COMMUNICATION; Dickens G, 2001, GEOCHEM GEOPHY GEOSY, V2; FENCHEL T, 1998, BACTERIAL BIOGEOCHEM; FROELICH PN, 1979, GEOCHIM COSMOCHIM AC, V43, P1075, DOI 10.1016/0016-7037(79)90095-4; FRYER P, 1990, P ODP INIT REP, V125, P687; Hinrichs KU, 1999, NATURE, V398, P802, DOI 10.1038/19751; JORGENSEN BB, 1978, GEOMICROBIOL J, V1, P49; KING GM, 1984, GEOMICROBIOL J, V3, P275, DOI 10.1080/01490458409377807; Knoblauch C, 1999, APPL ENVIRON MICROB, V65, P4230; KVENVOLDEN KA, 1993, REV GEOPHYS, V31, P173, DOI 10.1029/93RG00268; Niewohner C, 1998, GEOCHIM COSMOCHIM AC, V62, P455, DOI 10.1016/S0016-7037(98)00055-6; OREMLAND RS, 1982, INITIAL REP DEEP SEA, V64, P759; Parkes RJ, 2000, HYDROGEOL J, V8, P11, DOI 10.1007/PL00010971; PARKES RJ, 1994, NATURE, V371, P410, DOI 10.1038/371410a0; Pilson M. E. Q., 1998, INTRO CHEM SEA; Ravenschlag K, 2000, APPL ENVIRON MICROB, V66, P3592, DOI 10.1128/AEM.66.8.3592-3602.2000; Smith DC, 2000, GEOMICROBIOL J, V17, P207; SPIVACK AJ, 2000, EOS, V81, pF216; TARAFA ME, 1987, INITIAL REP DEEP SEA, V95, P635; TAYLOR B, 1999, P ODP INIT REP, V180, P4; Wellsbury P, 1997, NATURE, V388, P573, DOI 10.1038/41544; Whitman WB, 1998, P NATL ACAD SCI USA, V95, P6578, DOI 10.1073/pnas.95.12.6578	28	384	397	4	125	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 15	2002	295	5562					2067	2070		10.1126/science.1064878	http://dx.doi.org/10.1126/science.1064878			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	532AY	11896277				2022-12-28	WOS:000174450500047
J	Ellis, AS; Johnson, TM; Bullen, TD				Ellis, AS; Johnson, TM; Bullen, TD			Chromium isotopes and the fate of hexavalent chromium in the environment	SCIENCE			English	Article							REDUCTION; GROUNDWATER; BEHAVIOR; CR(VI)	Measurements of chromium (Cr) stable-isotope fractionation in laboratory experiments and natural waters show that lighter isotopes reacted preferentially during Cr(VI) reduction by magnetite and sediments. The Cr-53/Cr-52 ratio of the product was 3.4 +/- 0.1 per mil less than that of the reactant. Cr-53/Cr-52 shifts in water samples indicate the extent of reduction, a critical process that renders toxic Cr(VI) in the environment immobile and less toxic.	Univ Illinois, Dept Geol, Urbana, IL 61801 USA; US Geol Survey, Div Water Resources, Menlo Pk, CA 94025 USA	University of Illinois System; University of Illinois Urbana-Champaign; United States Department of the Interior; United States Geological Survey	Johnson, TM (corresponding author), Univ Illinois, Dept Geol, 245 Nat Hist Bldg, Urbana, IL 61801 USA.	tmjohnsn@uiuc.edu	Johnson, Thomas/A-2740-2008	Johnson, Thomas/0000-0003-1620-1408				ANDERSON LD, 1994, ENVIRON SCI TECHNOL, V28, P178, DOI 10.1021/es00050a025; BARTLETT RJ, 1988, CHROMIUM NATURAL HUM, P267; Blowes DW, 1997, ENVIRON SCI TECHNOL, V31, P3348, DOI 10.1021/es960844b; BOTTCHER J, 1990, J HYDROL, V114, P413, DOI 10.1016/0022-1694(90)90068-9; Buerge IJ, 1998, ENVIRON SCI TECHNOL, V32, P2092, DOI 10.1021/es970932b; CARY EE, 1982, CHROMIUM AIR SOIL NA; GOVINDARAJU K, 1989, GEOSTAND NEWSL, V13; Hoefs J., 1987, STABLE ISOTOPE GEOCH, V3rd; JAMES BR, 1983, J ENVIRON QUAL, V12, P177, DOI 10.2134/jeq1983.00472425001200020005x; JAMES BR, 1984, J ENVIRON QUAL, V13, P67, DOI 10.2134/jeq1984.00472425001300010012x; Johnson TM, 1999, GEOCHIM COSMOCHIM AC, V63, P2775, DOI 10.1016/S0016-7037(99)00279-3; Kortenkamp A, 1996, ARCH BIOCHEM BIOPHYS, V329, P199, DOI 10.1006/abbi.1996.0209; Loyaux-Lawniczak S, 2001, ENVIRON SCI TECHNOL, V35, P1350, DOI 10.1021/es001073l; Lytle CM, 1998, ENVIRON SCI TECHNOL, V32, P3087, DOI 10.1021/es980089x; Makdisi RS, 2000, NATURAL ATTENUATION CONSIDERATIONS AND CASE STUDIES, P185; Robles-Camacho J, 2000, J GEOCHEM EXPLOR, V68, P167, DOI 10.1016/S0375-6742(99)00083-7; ROTARU M, 1992, NATURE, V358, P465, DOI 10.1038/358465a0; Shukolyukov A, 1998, SCIENCE, V282, P927, DOI 10.1126/science.282.5390.927; Thode H.G., 1965, FLUIDS SUBSURFACE, V4; U.S. E.P.A, 1992, SW 846 TEST METH EV; Wittbrodt PR, 1996, ENVIRON SCI TECHNOL, V30, P2470, DOI 10.1021/es950731c	21	360	377	11	206	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 15	2002	295	5562					2060	2062		10.1126/science.1068368	http://dx.doi.org/10.1126/science.1068368			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	532AY	11896274				2022-12-28	WOS:000174450500044
J	Stevens, JL; Cantin, GT; Wang, G; Shevchenko, A; Shevchenko, A; Berk, AJ				Stevens, JL; Cantin, GT; Wang, G; Shevchenko, A; Shevchenko, A; Berk, AJ			Transcription control by E1A and MAP kinase pathway via Sur2 mediator subunit	SCIENCE			English	Article							SERUM RESPONSE ELEMENTS; SIGNALING PATHWAY; COMPLEX; COACTIVATOR; INDUCTION; PROTEIN; TERNARY; GENES	Sur2 is a metazoan Mediator subunit that interacts with the adenovirus E1A protein and functions in a mitogen-activated protein kinase pathway required for vulva development in Caenorhabditis elegans. We generated sur2(-/-) embryonic stem cells to analyze its function as a mammalian Mediator component. Our results show that Sur2 forms a subcomplex of the Mediator with two other subunits, TRAP/Med100 and 95. Knock-out of Sur2 prevents activation by E1A-CR3 and the mitogen-activated protein kinase-regulated ETS transcription factor Elk-1, but not by multiple other transcription factors. These results imply that specific activation domains stimulate transcription by binding to distinct Mediator subunits. Activation by EIIA and Elk-1 requires recruitment of Mediator to a promoter by binding to its Sur2 subunit.	Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; Max Planck Inst Mol Cell Biol & Genet, D-01307 Dresden, Germany; Univ Calif Los Angeles, Dept Microbiol Mol Genet & Immunol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; Max Planck Society; University of California System; University of California Los Angeles	Berk, AJ (corresponding author), Univ Calif Los Angeles, Inst Mol Biol, 611 Charles Young Dr E, Los Angeles, CA 90095 USA.		BERK, ARNOLD/AAF-7052-2020	WANG, Gang/0000-0002-4582-501X	NCI NIH HHS [CA25235] Funding Source: Medline; NIGMS NIH HHS [GM07185] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA025235, R37CA025235] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Boyer TG, 1999, NATURE, V399, P276, DOI 10.1038/20466; Gineitis D, 2001, J BIOL CHEM, V276, P24531, DOI 10.1074/jbc.M102678200; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; Hazzalin CA, 2002, NAT REV MOL CELL BIO, V3, P30, DOI 10.1038/nrm715; Ito M, 2000, MOL CELL, V5, P683, DOI 10.1016/S1097-2765(00)80247-6; JOHANSEN FE, 1995, BBA-REV CANCER, V1242, P1, DOI 10.1016/0304-419X(94)00014-S; Lee DH, 2000, DATA KNOWL ENG, V34, P77, DOI 10.1016/S0169-023X(00)00009-4; Malik S, 2000, TRENDS BIOCHEM SCI, V25, P277, DOI 10.1016/S0968-0004(00)01596-6; MCMAHON SB, 1995, MOL CELL BIOL, V15, P1086; MILTENBERGER RJ, 1993, J BIOL CHEM, V268, P15674; MONTELL C, 1984, CELL, V36, P951, DOI 10.1016/0092-8674(84)90045-X; Myers LC, 2000, ANNU REV BIOCHEM, V69, P729, DOI 10.1146/annurev.biochem.69.1.729; Rachez C, 2001, CURR OPIN CELL BIOL, V13, P274, DOI 10.1016/S0955-0674(00)00209-X; ROEDER RG, COMMUNICATION; SINGH N, 1995, GENE DEV, V9, P2251, DOI 10.1101/gad.9.18.2251; Stevens J. D., UNPUB; Wang G, 2001, MOL CELL BIOL, V21, P4604, DOI 10.1128/MCB.21.14.4604-4613.2001; WANG GC, UNPUB; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; Watson DK, 1997, ONCOGENE, V14, P213, DOI 10.1038/sj.onc.1200839; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5	21	199	208	0	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 26	2002	296	5568					755	758		10.1126/science.1068943	http://dx.doi.org/10.1126/science.1068943			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	546PD	11934987				2022-12-28	WOS:000175281700062
J	Basson, CT; Chow, CM; Scully, RE; Crigler, JF; Aretz, HT				Basson, CT; Chow, CM; Scully, RE; Crigler, JF; Aretz, HT			A 27-year-old woman with two intracardiac masses and a history of endocrinopathy. Cardiac myxomas arising from the left atrium and the mitral-valve apparatus, consistent with Carney complex.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CUTANEOUS PIGMENTED LESIONS; GENETIC-HETEROGENEITY; TUMORS; LENTIGINOSIS; HISTOGENESIS; MUTATIONS; MULTIPLE; HEART		Cornell Univ, Weill Med Coll, Mol Cardiol Lab, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Med, Div Cardiol, New York, NY USA; New York Presbyterian Hosp, New York, NY USA	Cornell University; Cornell University; NewYork-Presbyterian Hospital	Basson, CT (corresponding author), Cornell Univ, Weill Med Coll, Mol Cardiol Lab, New York, NY 10021 USA.							ATHERTON DJ, 1980, BRIT J DERMATOL, V103, P421, DOI 10.1111/j.1365-2133.1980.tb07266.x; Basson CT, 1997, AM J CARDIOL, V79, P994, DOI 10.1016/S0002-9149(97)00033-7; BURKE A, 1996, TUMORS HEART GREAT 3; BURKE AP, 1993, AM J CLIN PATHOL, V100, P671, DOI 10.1093/ajcp/100.6.671; CARNEY JA, 1985, AM J SURG PATHOL, V9, P53, DOI 10.1097/00000478-198501000-00009; CARNEY JA, 1985, MEDICINE, V64, P270, DOI 10.1097/00005792-198507000-00007; Casey M, 2001, J CLIN INVEST, V107, P235, DOI 10.1172/JCI10841C1; Casey M, 1998, CIRCULATION, V98, P2560, DOI 10.1161/01.CIR.98.23.2560; Casey M, 2000, J CLIN INVEST, V106, pR31, DOI 10.1172/JCI10841; CHOMETTE G, 1985, ANN MED INTERNE, V136, P301; ERRICHETTI A, 1994, PRINCIPLES PRACTICE, P1135; FERRANS VJ, 1973, HUM PATHOL, V4, P111, DOI 10.1016/S0046-8177(73)80051-6; Goldstein MM, 1999, AM J MED GENET, V86, P62, DOI 10.1002/(SICI)1096-8628(19990903)86:1<62::AID-AJMG12>3.0.CO;2-1; JOHANSSON L, 1989, ARCH PATHOL LAB MED, V113, P735; Kirschner LS, 2000, HUM MOL GENET, V9, P3037, DOI 10.1093/hmg/9.20.3037; Kirschner LS, 2000, NAT GENET, V26, P89, DOI 10.1038/79238; KOOPMAN RJJ, 1991, HUM GENET, V86, P300; LIE JT, 1989, ARCH PATHOL LAB MED, V113, P724; MCCARTHY PM, 1986, J THORAC CARDIOV SUR, V91, P389; MIRALLES A, 1991, ANN THORAC SURG, V52, P886, DOI 10.1016/0003-4975(91)91241-M; Pucci A, 2000, AM HEART J, V140, P134, DOI 10.1067/mhj.2000.107176; REES JR, 1973, BRIT HEART J, V35, P874; REYNEN K, 1995, NEW ENGL J MED, V333, P1610, DOI 10.1056/NEJM199512143332407; Stratakis CA, 1996, J CLIN INVEST, V97, P699, DOI 10.1172/JCI118467; VANGELDER HM, 1992, ANN THORAC SURG, V53, P419, DOI 10.1016/0003-4975(92)90261-2; Vaughan CJ, 2001, CURR OPIN CARDIOL, V16, P195, DOI 10.1097/00001573-200105000-00007; Vidaillet H J Jr, 1984, Minn Med, V67, P695; WILSHER ML, 1986, AUST NZ J MED, V16, P393, DOI 10.1111/j.1445-5994.1986.tb01196.x	28	16	18	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 11	2002	346	15					1152	1158		10.1056/NEJMcpc010057	http://dx.doi.org/10.1056/NEJMcpc010057			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	539PX	11948276				2022-12-28	WOS:000174880600009
J	Pham, KN; Puertas, AM; Bergenholtz, J; Egelhaaf, SU; Moussaid, A; Pusey, PN; Schofield, AB; Cates, ME; Fuchs, M; Poon, WCK				Pham, KN; Puertas, AM; Bergenholtz, J; Egelhaaf, SU; Moussaid, A; Pusey, PN; Schofield, AB; Cates, ME; Fuchs, M; Poon, WCK			Multiple glassy states in a simple model system	SCIENCE			English	Article							DYNAMIC LIGHT-SCATTERING; COLLOID-POLYMER MIXTURES; SUPERCOOLED LIQUIDS; COUPLING-THEORY; PHASE-BEHAVIOR; TRANSITION; SPHERES; SUSPENSIONS	Experiments, theory, and simulation were used to study glass formation in a simple model system composed of hard spheres with short-range attraction ("sticky hard spheres"). The experiments, using well-characterized colloids, revealed a reentrant glass transition line. Mode-coupling theory calculations and molecular dynamics simulations suggest that the reentrance is due to the existence of two qualitatively different glassy states: one dominated by repulsion (with structural arrest due to caging) and the other by attraction (with structural arrest due to bonding). This picture is consistent with a study of the particle dynamics in the colloid using dynamic light scattering.	Univ Edinburgh, Dept Phys & Astron, Edinburgh EH9 3JZ, Midlothian, Scotland; Univ Almeria, Dept Appl Phys, Almeria 04120, Spain; Univ Gothenburg, Dept Chem, S-41296 Gothenburg, Sweden	University of Edinburgh; Universidad de Almeria; University of Gothenburg	Poon, WCK (corresponding author), Univ Edinburgh, Dept Phys & Astron, Mayfield Rd, Edinburgh EH9 3JZ, Midlothian, Scotland.	w.poon@ed.ac.uk	Pham, Khoa/B-8049-2008; Poon, Wilson/V-3495-2019; Fuchs, Matthias/D-8667-2013; Puertas, Antonio M/K-8962-2014; Schofield, Andrew Bruce/AAV-4862-2020; Poon, Wilson C K/B-5960-2013; Bergenholtz, Johan/D-3538-2009	Pham, Khoa/0000-0002-6234-0903; Poon, Wilson/0000-0003-0760-7940; Fuchs, Matthias/0000-0002-9757-6924; Schofield, Andrew Bruce/0000-0002-8741-856X; Poon, Wilson C K/0000-0003-0760-7940; Bergenholtz, Johan/0000-0001-7403-1350; Puertas Lopez, Antonio Manuel/0000-0003-4127-1424; Egelhaaf, Stefan U./0000-0002-2574-3498				ANGELL CA, 1995, SCIENCE, V267, P1924, DOI 10.1126/science.267.5206.1924; ASAKURA S, 1954, J CHEM PHYS, V22, P1255, DOI 10.1063/1.1740347; BARTSCH E, 1992, J CHEM PHYS, V97, P3950, DOI 10.1063/1.462934; BENGTZELIUS U, 1984, J PHYS C SOLID STATE, V17, P5915, DOI 10.1088/0022-3719/17/33/005; BERNAL JD, 1964, PROC R SOC LON SER-A, V280, P299, DOI 10.1098/rspa.1964.0147; BOLHUIS P, 1994, PHYS REV E, V50, P4880, DOI 10.1103/PhysRevE.50.4880; Dawson K, 2001, PHYS REV E, V63, DOI 10.1103/PhysRevE.63.011401; Franzese G, 2001, NATURE, V409, P692, DOI 10.1038/35055514; Gotze W, 1999, J PHYS-CONDENS MAT, V11, pA1, DOI 10.1088/0953-8984/11/10A/002; HOOVER WG, 1968, J CHEM PHYS, V49, P3609, DOI 10.1063/1.1670641; LEKKERKERKER HNW, 1992, EUROPHYS LETT, V20, P559, DOI 10.1209/0295-5075/20/6/015; Mallamace F, 2000, PHYS REV LETT, V84, P5431, DOI 10.1103/PhysRevLett.84.5431; Mishima O, 2001, J CHEM PHYS, V115, P4199, DOI 10.1063/1.1392365; Poon WCK, 1999, FARADAY DISCUSS, V112, P143, DOI 10.1039/a900664h; Poon WCK, 1995, FARADAY DISCUSS, V101, P65, DOI 10.1039/fd9950100065; Puertas AM, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.098301; PUSEY PN, 1986, NATURE, V320, P340, DOI 10.1038/320340a0; PUSEY PN, 1987, PHYS REV LETT, V59, P2083, DOI 10.1103/PhysRevLett.59.2083; Rudhardt D, 1998, PHYS REV LETT, V81, P1330, DOI 10.1103/PhysRevLett.81.1330; SEGRE PN, 1995, J MOD OPTIC, V42, P1929, DOI 10.1080/09500349514551681; STILLINGER FH, 1995, SCIENCE, V267, P1935, DOI 10.1126/science.267.5206.1935; TSLOK OB, 1998, PHYS REV LETT, V80, P999; VANMEGEN W, 1994, PHYS REV E, V49, P4206, DOI 10.1103/PhysRevE.49.4206; Weeks ER, 2000, SCIENCE, V287, P627, DOI 10.1126/science.287.5453.627; 1995, SCIENCE, V267, P1887	25	646	650	1	160	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 5	2002	296	5565					104	106		10.1126/science.1068238	http://dx.doi.org/10.1126/science.1068238			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	539FA	11935020	Green Submitted			2022-12-28	WOS:000174858800041
J	Reeves, JN; Watson, D; Osborne, JP; Pounds, DA; O'Brien, PT; Short, ADT; Turner, MJL; Watson, MG; Mason, KO; Ehle, M; Schartel, N				Reeves, JN; Watson, D; Osborne, JP; Pounds, DA; O'Brien, PT; Short, ADT; Turner, MJL; Watson, MG; Mason, KO; Ehle, M; Schartel, N			The signature of supernova ejecta in the X-ray afterglow of the gamma-ray burst 011211	NATURE			English	Article							LINE SIGNATURES; ALPHA EMISSION; NEUTRON-STARS; BURSTS; MERGERS; GRB	Now that gamma-ray bursts (GRBs) have been determined to lie at cosmological distances(1), their isotropic burst energies are estimated to be as high as 10(54) erg (ref. 2), making them the most energetic phenomena in the Universe. The nature of the progenitors responsible for the bursts remains, however, elusive. The favoured models range from the merger of two neutron stars in a binary system(3-5) to the collapse of a massive star(6-8). Spectroscopic studies of the afterglow emission could reveal details of the environment of the burst, by indicating the elements present, the speed of the outflow and an estimate of the temperature. Here we report an X-ray spectrum of the afterglow of GRB011211, which shows emission lines of magnesium, silicon, sulphur, argon, calcium and possibly nickel, arising in metal-enriched material with an outflow velocity of the order of one-tenth the speed of light. These observations strongly favour models(30) where a supernova explosion from a massive stellar progenitor precedes the burst event and is responsible for the outflowing matter.	Univ Leicester, Dept Phys & Astron, Xray Astron Grp, Leicester LE1 7RH, Leics, England; UCL, Mullard Space Sci Lab, Dorking RH5 6NT, Surrey, England; XMM Newton SOC, Madrid 28080, Spain	University of Leicester; University of London; University College London	Reeves, JN (corresponding author), Univ Leicester, Dept Phys & Astron, Xray Astron Grp, Univ Rd, Leicester LE1 7RH, Leics, England.	jnr@star.le.ac.uk	Watson, Darach/E-4521-2015	Watson, Darach/0000-0002-4465-8264				Antonelli LA, 2000, ASTROPHYS J, V545, pL39, DOI 10.1086/317328; Ballantyne DR, 2001, ASTROPHYS J, V559, pL83, DOI 10.1086/323906; Bevington PR., 2002, DATA REDUCTION ERROR; Bloom JS, 1999, NATURE, V401, P453, DOI 10.1038/46744; Bulik T, 1999, MON NOT R ASTRON SOC, V309, P629, DOI 10.1046/j.1365-8711.1999.02878.x; BURUD I, 2001, 1213 GCN GRB; EICHLER D, 1989, NATURE, V340, P126, DOI 10.1038/340126a0; Frail DA, 2001, ASTROPHYS J, V562, pL55, DOI 10.1086/338119; FRONTERA F, 2001, 1215 GCN GRB; FRUCHTER A, 2001, 1200 GCN GRB; Fryer CL, 1999, ASTROPHYS J, V526, P152, DOI 10.1086/307992; Hanlon L, 2000, ASTRON ASTROPHYS, V359, P941; HOLLAND S, 2002, UNPUB ASTRON J; Jaasen F, 2001, ASTRON ASTROPHYS, V365, pL1, DOI 10.1051/0004-6361:20000036; KALLMAN TR, 2002, UNPUB ASTROPHYS J; MCLAUGHLIN GC, 2001, UNPUB ASTROPHYS J; MESZAROS P, 2001, ASTROPH0111170; Metzger MR, 1997, NATURE, V387, P878, DOI 10.1038/43132; Mewe R., 1985, Astronomy & Astrophysics Supplement Series, V62, P197; MOCHKOVITCH R, 1993, NATURE, V361, P236, DOI 10.1038/361236a0; Paczynski B, 1998, ASTROPHYS J, V494, pL45, DOI 10.1086/311148; PACZYNSKI B, 1986, APJ, V308, P43; Piro L, 1999, ASTRON ASTROPHYS SUP, V138, P431, DOI 10.1051/aas:1999296; Piro L, 2000, SCIENCE, V290, P955, DOI 10.1126/science.290.5493.955; Rees MJ, 2000, ASTROPHYS J, V545, pL73, DOI 10.1086/317882; SANTOSLLEO M, 2001, 1192 GCN GRB; Vietri M, 1999, ASTROPHYS J, V527, pL43, DOI 10.1086/312386; Weth C, 2000, ASTROPHYS J, V534, P581, DOI 10.1086/308792; Wheeler JC, 2000, ASTROPHYS J, V537, P810, DOI 10.1086/309055; WOOSLEY SE, 1993, ASTROPHYS J, V405, P273, DOI 10.1086/172359	30	198	199	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 4	2002	416	6880					512	515		10.1038/416512a	http://dx.doi.org/10.1038/416512a			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	537JY	11932738				2022-12-28	WOS:000174756500036
J	ten Kate, K				ten Kate, K			Global genetic resources - Science and the convention on biological diversity	SCIENCE			English	Editorial Material									Royal Bot Gardens, Richmond TW9 3AE, Surrey, England	Royal Botanic Gardens, Kew	ten Kate, K (corresponding author), Royal Bot Gardens, Richmond TW9 3AE, Surrey, England.							GLOWKA L, COMMUNICATION; Laird S.A, 2002, BIODIVERSITY TRADITI; *SECR CONV BIOL DI, 2001, GLOB BIOD OUTL 2001; Ten Kate K, 1999, COMMERCIAL USE BIODI; TENKATE K, 2002, C COMM INT PROP RIGH	5	21	21	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 29	2002	295	5564					2371	2372						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	536QD	11923511				2022-12-28	WOS:000174712600024
J	Check, E				Check, E			Alternative therapies leave US commission divided	NATURE			English	News Item																		Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569	1	0	0	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 28	2002	416	6879					355	355		10.1038/416355b	http://dx.doi.org/10.1038/416355b			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	534UX	11919588	Bronze			2022-12-28	WOS:000174607800007
J	Tsai, E				Tsai, E			Should family members be present during cardiopulmonary resuscitation?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							WATCH RESUSCITATION; RELATIVES; ROOM		Kingston Gen Hosp, Dept Pediat, Kingston, ON K7L 2V7, Canada	Queens University - Canada	Tsai, E (corresponding author), Kingston Gen Hosp, Dept Pediat, Watkins 3,76 Stuart St, Kingston, ON K7L 2V7, Canada.							ADAMS S, 1994, BRIT MED J, V308, P1687, DOI 10.1136/bmj.308.6945.1687; Back D, 1994, Nurs Times, V90, P34; Back K J, 1991, Pediatr Nurs, V17, P571; Barratt F, 1998, J ACCID EMERG MED, V15, P109; Bassler P C, 1999, J Nurses Staff Dev, V15, P126, DOI 10.1097/00124645-199905000-00007; Belanger M A, 1997, J Emerg Nurs, V23, P238, DOI 10.1016/S0099-1767(97)90015-5; Boie ET, 1999, ANN EMERG MED, V34, P70, DOI 10.1016/S0196-0644(99)70274-X; Boyd R, 2000, Eur J Emerg Med, V7, P51; Brown J R, 1989, Nursing, V19, P46; Connors P, 1996, Nurs Stand, V10, P42; CRISCI C, 1994, BRIT MED J, V309, P406; DOYLE CJ, 1987, ANN EMERG MED, V16, P673, DOI 10.1016/S0196-0644(87)80069-0; DUBIN WR, 1986, ANN EMERG MED, V15, P54, DOI 10.1016/S0196-0644(86)80488-7; Eichhorn D J, 1996, J Cardiovasc Nurs, V10, P59; *EM NURS ASS, 1995, PRES OPT FAM PRES; *EM NURS ASS, 1998, FAM PRES BEDS INV PR; GOLDSCHMIDT D, 2001, CNN MED NEWS    0504; Gyulay J E, 1989, Issues Compr Pediatr Nurs, V12, P71, DOI 10.3109/01460868909038030; Hanson C, 1992, J Emerg Nurs, V18, P104; Hartley D, 2001, JAMA-J AM MED ASSOC, V285, P380, DOI 10.1001/jama.285.4.380; Jarvis A S, 1998, Intensive Crit Care Nurs, V14, P3, DOI 10.1016/S0964-3397(98)80029-3; Meyers T A, 1998, J Emerg Nurs, V24, P400, DOI 10.1016/S0099-1767(98)70005-4; Meyers TA, 2000, AM J NURS, V100, P32, DOI 10.2307/3521954; Mitchell MH, 1997, J ACCID EMERG MED, V14, P366; Offord R J, 1998, Intensive Crit Care Nurs, V14, P288, DOI 10.1016/S0964-3397(98)80690-3; Osuagwu C C, 1991, J Emerg Nurs, V17, P363; Post H, 1989, Nursing, V19, P43; Rattrie E, 2000, Nurs Stand, V14, P32; Reese V, 1994, Nursing, V24, p32V; REESE V, 1994, NURSING, V24, pV32; Resuscitation Council (UK), 1996, SHOULD REL WITN RES; Robinson SM, 1998, LANCET, V352, P614, DOI 10.1016/S0140-6736(97)12179-1; SCHILLING RJ, 1994, BRIT MED J, V309, P406, DOI 10.1136/bmj.309.6951.406; TULLER D, 2001, NY TIMES        0515, pF6; 2000, CIRCULATION S1, V102, P12	35	47	49	0	4	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 28	2002	346	13					1019	1021		10.1056/NEJM200203283461312	http://dx.doi.org/10.1056/NEJM200203283461312			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	534UY	11919313				2022-12-28	WOS:000174608600011
J	Friedlaender, MM				Friedlaender, MM			The right to sell or buy a kidney: are we failing our patients?	LANCET			English	Editorial Material							RENAL-TRANSPLANTATION; UNITED-STATES; RECIPIENTS; MORTALITY; DONORS		Hadassah Univ Hosp, Serv Nephrol, IL-91120 Jerusalem, Israel; Hadassah Univ Hosp, Hypertens Serv, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem; Hebrew University of Jerusalem	Friedlaender, MM (corresponding author), Hadassah Univ Hosp, Serv Nephrol, POB 12000, IL-91120 Jerusalem, Israel.							Cameron JS, 1999, KIDNEY INT, V55, P724, DOI 10.1046/j.1523-1755.1999.00286.x; DOSSETOR JB, 2000, AM J KIDNEY DIS, V35, P1002; FRIEDLAENDER MM, 1993, LANCET, V342, P1061, DOI 10.1016/0140-6736(93)92922-G; FRIEDLAENDER MM, 1996, INT YB NEPHROLOGY, P153; Frishberg Y, 1998, J AM SOC NEPHROL, V9, P1100; Hariharan S, 2000, NEW ENGL J MED, V342, P605, DOI 10.1056/NEJM200003023420901; Hou S, 2000, KIDNEY INT, V58, P1820, DOI 10.1046/j.1523-1755.2000.00345.x; KASSIRER JP, 1983, NEW ENGL J MED, V308, P898, DOI 10.1056/NEJM198304143081511; NAJARIAN JS, 1992, LANCET, V340, P807, DOI 10.1016/0140-6736(92)92683-7; Neylan JF, 1999, J AM SOC NEPHROL, V10, P2237; OUNIBI W, 1993, J AM SOC NEPHROL, V4, P957; Radcliffe-Richards J, 1998, LANCET, V351, P1950, DOI 10.1016/S0140-6736(97)08211-1; SALAHUDEEN AK, 1990, LANCET, V336, P725, DOI 10.1016/0140-6736(90)92214-3; Steinberg A, 1996, NEPHROL DIAL TRANSPL, V11, P961; WARDEN J, 1989, BRIT MED J, V298, P1670; Wolfe RA, 1999, NEW ENGL J MED, V341, P1725, DOI 10.1056/NEJM199912023412303; 1998, NEPHROL DIAL TRANSPL, V13, P1636	17	81	83	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 16	2002	359	9310					971	973		10.1016/S0140-6736(02)08030-3	http://dx.doi.org/10.1016/S0140-6736(02)08030-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	531AE	11918934				2022-12-28	WOS:000174391700036
J	Sharp, D				Sharp, D			Hot, cold, and now bubble fusion	LANCET			English	Editorial Material									The Lancet, London NW1 7BY, England		Sharp, D (corresponding author), The Lancet, London NW1 7BY, England.							Kennedy D, 2002, SCIENCE, V295, P1793, DOI 10.1126/science.295.5561.1793; PARK B, 2002, BUBBLE FUSION COLLEC; PARK R, 2000, VOODOO SCI; SHAPIRA D, 2002, COMMENTS REPORTED NU; Taleyarkhan RP, 2002, SCIENCE, V295, P1868, DOI 10.1126/science.1067589; TALEYARKHAN RP, COMMENTS SHAPIRA SAL	6	1	1	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 16	2002	359	9310					908	908		10.1016/S0140-6736(02)08016-9	http://dx.doi.org/10.1016/S0140-6736(02)08016-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	531AE	11918906				2022-12-28	WOS:000174391700006
J	Jha, P; Mills, A; Hanson, K; Kumaranayake, L; Conteh, L; Kurowski, C; Nguyen, SN; Cruz, VO; Ranson, K; Vaz, LME; Yu, SC; Morton, O; Sachs, JD				Jha, P; Mills, A; Hanson, K; Kumaranayake, L; Conteh, L; Kurowski, C; Nguyen, SN; Cruz, VO; Ranson, K; Vaz, LME; Yu, SC; Morton, O; Sachs, JD			Improving the health of the global poor	SCIENCE			English	Article								We analyzed the technical basis for a major global program to reduce disease among the poor. Effective interventions exist against the few diseases which most account for excess mortality among the poor. Achieving high coverage of effective interventions requires a well-functioning health system, as well as overcoming a set of financial and nonfinancial constraints. The annual incremental cost would be between $40 billion and $52 billion by 2015 in 83 low-income and sub-Saharan African countries. Such a program is feasible and would avoid millions of child, maternal, and adult deaths annually in poor countries.	WHO, CH-01220 Geneva, Switzerland; World Bank, Washington, DC 20433 USA; Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England; Univ Penn, Philadelphia, PA 19104 USA; Hybrid Vigor Inst, San Francisco, CA USA; Hybrid Vigor Inst, London SE10 8NW, England; Harvard Univ, Ctr Int Dev, Cambridge, MA 02138 USA	World Health Organization; The World Bank; University of London; London School of Hygiene & Tropical Medicine; University of Pennsylvania; Harvard University	Jha, P (corresponding author), WHO, CH-01220 Geneva, Switzerland.		Conteh, Lesong/ABE-9550-2020	Conteh, Lesong/0000-0002-0719-3672; Jha, Prabhat/0000-0001-7067-8341; Mills, Anne/0000-0001-9863-9950				[Anonymous], 1999, WORLD HLTH REPORT 19; [Anonymous], 1996, GLOBAL BURDEN DIS CO; Bloom DE, 2000, SCIENCE, V287, P1207, DOI 10.1126/science.287.5456.1207; Dye C, 1998, LANCET, V352, P1886, DOI 10.1016/S0140-6736(98)03199-7; Fabricant SJ, 1999, INT J HEALTH PLAN M, V14, P179; FAVEAU V, 1990, BRIT MED J, V301, P103; Hanson K., 2001, CONSTRAINTS SCALING; Jha P, 2000, BRIT MED J, V321, P358, DOI 10.1136/bmj.321.7257.358; Kelly PM, 2001, B WORLD HEALTH ORGAN, V79, P111; KRUGMAN P, 2001, NY TIMES        1225, P27; KUMARANAYAKE L, IN PRESS COSTS SCALI; NGUYEN S, 2001, INDIRECT ESTIMATES A; OLIVEIRACRUZ V, 2001, APPROACHES OVERCOMIN; *UN POP DIV, 1998, WORLD POP 1950 2050; *UNAIDS WHO, 2001, AIDS EP UPD DEC 2001; WOLF M, 2002, FINANCIAL TIMES 0109, P13; World Bank, 1998, ASS AID; *WORLD BANK, 1993, WORLD DEV REP 1993 I; World Health Organization, 2000, WORLD HLTH REP 2000; 2001, EC MAGAZINE     1220, P95; 2002, BMJ, V324, P2	21	78	78	1	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 15	2002	295	5562					2036	2039		10.1126/science.295.5562.2036	http://dx.doi.org/10.1126/science.295.5562.2036			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	532AY	11896266				2022-12-28	WOS:000174450500036
J	MacLehose, L; McKee, M; Weinberg, J				MacLehose, L; McKee, M; Weinberg, J			Responding to the challenge of communicable disease in Europe	SCIENCE			English	Review							SURVEILLANCE; RATES	In the 1960s and 1970s, communicable disease seemed a minor threat, Lout since then the emergence of new infections and the reemergence of old diseases has provoked a renewed focus on European communicable disease surveillance and control. A "network approach" among European countries has been successful in detecting some international outbreaks, but management and funding aspects remain unresolved. Surveillance outside the European Union has faced new challenges as a result of economic and political change following the collapse of communism. Subsequently, innovative international surveillance schemes are currently being implemented in the countries of Central and Eastern Europe and the former Soviet Union. The challenge for surveillance in Europe is to ensure that it has the capacity to meet both the needs of today and the diseases of the future.	Univ London London Sch Hyg & Trop Med, European Observ Hlth Care Syst, London WC1E 7HT, England; City Univ London, London EC1V 0HB, England	University of London; London School of Hygiene & Tropical Medicine; City University London	MacLehose, L (corresponding author), Univ London London Sch Hyg & Trop Med, European Observ Hlth Care Syst, Keppel St, London WC1E 7HT, England.		McKee, Marc D/E-2187-2011; Mckee, Martin/E-6673-2018	McKee, Marc D/0000-0001-8349-965X; Mckee, Martin/0000-0002-0121-9683				[Anonymous], 1997, GUNS GERMS STEEL; Bradbury J, 1998, LANCET, V352, P969, DOI 10.1016/S0140-6736(05)61533-4; Brand H., 2000, EVALUATION ARRANGEME; Catchpole M, 2001, LANCET, V358, P1911, DOI 10.1016/S0140-6736(01)06921-5; Davies N., 1996, EUROPE HIST; Decludt B, 2000, LANCET, V356, P2100, DOI 10.1016/S0140-6736(05)74311-7; Desenclos J-C., 1999, Euro Surveill, V4, P58; DESENCLOS JC, 1993, LANCET, V341, P1003, DOI 10.1016/0140-6736(93)91084-Y; Donaldson L., 2002, GETTING AHEAD CURVE; ENGELS F, 1969, CONDITION WORKING CL; FIDLER D, 1999, INT LAW INFECT DIS, P45; Giesecke J, 1998, LANCET, V352, P1308, DOI 10.1016/S0140-6736(98)00042-7; Kazionny B, 2001, LANCET, V358, P1513, DOI 10.1016/S0140-6736(01)06574-6; KEYS D, 1999, CATASTROPHE INVESTIG; Kimerling ME, 1999, INT J TUBERC LUNG D, V3, P451; Lever F, 2001, Euro Surveill, V6, P53; Loytonen M, 1998, SOC SCI MED, V46, P695, DOI 10.1016/S0277-9536(97)00176-7; MacLehose L, 2001, BRIT MED J, V323, P861, DOI 10.1136/bmj.323.7317.861; McKee M, 2000, LANCET, V356, P665, DOI 10.1016/S0140-6736(00)02616-7; McKee M, 2002, HLTH CARE CENTRAL AS; McKee M, 1996, J EUROPEAN SOCIAL PO, V6, P263, DOI DOI 10.1177/095892879600600401; McNeill W., 1976, PLAGUES PEOPLE; *MIN AGR FISH FOOD, 2000, BSE INQ INQ BSE VAR; *OUTBR MAN TEAM, 2001, OUTBREAK LIFE THREAT; Plowman R, 2001, J HOSP INFECT, V47, P198, DOI 10.1053/jhin.2000.0881; Randolph SE, 2001, PHILOS T R SOC B, V356, P1045, DOI 10.1098/rstb.2001.0893; REINTJES R, IN PRESS INT J HYG E; Riedner G, 2000, SEX TRANSM INFECT, V76, P363, DOI 10.1136/sti.76.5.363; SATCHER D, 1995, EMERG INFECT DIS, V1, P1, DOI 10.3201/eid0101.950101; Stoilova Y, 1999, Folia Med (Plovdiv), V41, P73; Tibayrenc M, 2001, B WORLD HEALTH ORGAN, V79, P1094; Tibayrenc M, 1997, NATURE, V389, P433, DOI 10.1038/38861; *UNAIDS WHO, 2001, AIDS EP UPD; Weber W, 2000, LANCET, V356, P1177; Weinberg J, 1999, EUR J PUBLIC HEALTH, V9, P236, DOI 10.1093/eurpub/9.3.236; Weinberg J, 1997, EUR J PUBLIC HEALTH, V7, P454, DOI 10.1093/eurpub/7.4.454; Wheeler JG, 1999, BMJ-BRIT MED J, V318, P1046, DOI 10.1136/bmj.318.7190.1046; *WHO, 2000, WKLY EPIDEMIOL REV, V75, P234; EUROSURVELLANCE WEEK; EUROPEAN PROGRAMME I; 1998, LANCET, V352, P1237	41	35	36	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 15	2002	295	5562					2047	2050		10.1126/science.1070025	http://dx.doi.org/10.1126/science.1070025			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	532AY	11896269				2022-12-28	WOS:000174450500039
J	Celeste, A; Petersen, S; Romanienko, PJ; Fernandez-Capetillo, O; Chen, HT; Sedelnikova, OA; Reina-San-Martin, B; Coppola, V; Meffre, E; Difilippantonio, MJ; Redon, C; Pilch, DR; Olaru, A; Eckhaus, M; Camerini-Otero, RD; Tessarollo, L; Livak, F; Manova, K; Bonner, WM; Nussenzweig, MC; Nussenzweig, A				Celeste, A; Petersen, S; Romanienko, PJ; Fernandez-Capetillo, O; Chen, HT; Sedelnikova, OA; Reina-San-Martin, B; Coppola, V; Meffre, E; Difilippantonio, MJ; Redon, C; Pilch, DR; Olaru, A; Eckhaus, M; Camerini-Otero, RD; Tessarollo, L; Livak, F; Manova, K; Bonner, WM; Nussenzweig, MC; Nussenzweig, A			Genomic instability in mice lacking histone H2AX	SCIENCE			English	Article							DOUBLE-STRAND BREAKS; END-JOINING PATHWAY; ATM-DEFICIENT MICE; DNA-REPAIR; ATAXIA-TELANGIECTASIA; TARGETED DISRUPTION; IONIZING-RADIATION; VERTEBRATE CELLS; RECOMBINATION; STABILITY	Higher order chromatin structure presents a barrier to the recognition and repair of DNA damage. Double-strand breaks (DSBs) induce histone H2AX phosphorylation, which is associated with the recruitment of repair factors to damaged DNA. To help clarify the physiological role of H2AX, we targeted H2AX in mice. Although H2AX is not essential for irradiation-induced cell-cycle checkpoints, H2AX(-/-) mice were radiation sensitive, growth retarded, and immune deficient, and mutant males were infertile. These pleiotropic phenotypes were associated with chromosomal instability, repair defects, and impaired recruitment of Nbs1, 53bp1, and Brca1, but not Rad51, to irradiation-induced foci. Thus, H2AX is critical for facilitating the assembly of specific DNA-repair complexes on damaged DNA.	NCI, Expt Immunol Branch, NIH, Bethesda, MD 20892 USA; NIDDKD, Genet & Biochem Branch, NIH, Bethesda, MD 20892 USA; NIH, Mol Pharmacol Lab, Bethesda, MD 20892 USA; Rockefeller Univ, Howard Hughes Med Inst, Lab Mol Immunol, New York, NY 10021 USA; NIH, Mouse Canc Genet Program, Frederick, MD 20892 USA; NCI, Dept Genet, NIH, Bethesda, MD 20892 USA; Univ Maryland, Sch Med, Dept Microbiol & Immunol, Baltimore, MD 21201 USA; NIH, Vet Resources Program, Natl Ctr Res Resources, Bethesda, MD 20892 USA; Mem Sloan Kettering Canc Ctr, Mol Cytol Core Facil, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; Howard Hughes Medical Institute; Rockefeller University; National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University System of Maryland; University of Maryland Baltimore; National Institutes of Health (NIH) - USA; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Nussenzweig, A (corresponding author), NCI, Expt Immunol Branch, NIH, Bethesda, MD 20892 USA.		Difilippantonio, Michael/AAF-2839-2021; Coppola, Vincenzo/E-2917-2011; Fernandez-Capetillo, Oscar/H-3508-2015; Coppola, Vincenzo/D-5352-2014; Nussenzweig, Michel/AAE-7292-2019; Reina-San-Martin, Bernardo/I-9484-2016	Difilippantonio, Michael/0000-0002-4676-7034; Coppola, Vincenzo/0000-0001-6163-1779; Fernandez-Capetillo, Oscar/0000-0002-2690-6885; Coppola, Vincenzo/0000-0001-6163-1779; Reina-San-Martin, Bernardo/0000-0003-2083-6166; Martin (nee Sedelnikova), Olga/0000-0003-3470-2935	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK052008] Funding Source: NIH RePORTER; Intramural NIH HHS [Z99 CA999999] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Casellas R, 1998, EMBO J, V17, P2404, DOI 10.1093/emboj/17.8.2404; CELESTE A, UNPUB; Chen HT, 2000, SCIENCE, V290, P1962, DOI 10.1126/science.290.5498.1962; Difilippantonio MJ, 2000, NATURE, V404, P510, DOI 10.1038/35006670; Downs JA, 2000, NATURE, V408, P1001, DOI 10.1038/35050000; Ehrenstein MR, 1999, EMBO J, V18, P3484, DOI 10.1093/emboj/18.12.3484; Elson A, 1996, P NATL ACAD SCI USA, V93, P13084, DOI 10.1073/pnas.93.23.13084; Essers J, 2000, EMBO J, V19, P1703, DOI 10.1093/emboj/19.7.1703; Essers J, 1997, CELL, V89, P195, DOI 10.1016/S0092-8674(00)80199-3; Ferguson DO, 2000, P NATL ACAD SCI USA, V97, P6630, DOI 10.1073/pnas.110152897; Gao YJ, 2000, NATURE, V404, P897, DOI 10.1038/35009138; GU Y, 1997, IMMUNITY, V7; Karanjawala ZE, 1999, CURR BIOL, V9, P1501, DOI 10.1016/S0960-9822(00)80123-2; Liyanage M, 2000, BLOOD, V96, P1940, DOI 10.1182/blood.V96.5.1940.h8001940_1940_1946; Mahadevaiah SK, 2001, NAT GENET, V27, P271, DOI 10.1038/85830; Manis JP, 1998, J EXP MED, V187, P2081, DOI 10.1084/jem.187.12.2081; Maser RS, 2001, MOL CELL BIOL, V21, P6006, DOI 10.1128/MCB.21.17.6006-6016.2001; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; Nussenzweig A, 1997, P NATL ACAD SCI USA, V94, P13588, DOI 10.1073/pnas.94.25.13588; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Petersen S, 2001, NATURE, V414, P660, DOI 10.1038/414660a; Redon C, 2002, CURR OPIN GENET DEV, V12, P162, DOI 10.1016/S0959-437X(02)00282-4; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rolink A, 1996, IMMUNITY, V5, P319, DOI 10.1016/S1074-7613(00)80258-7; Schrader CE, 1999, J EXP MED, V190, P323, DOI 10.1084/jem.190.3.323; SHROFF R, COMMUNICATION; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Sonoda E, 1999, MOL CELL BIOL, V19, P5166; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049; Xu Y, 1996, GENE DEV, V10, P2411, DOI 10.1101/gad.10.19.2411; Zhu J, 2001, CURR BIOL, V11, P105, DOI 10.1016/S0960-9822(01)00019-7	33	1065	1101	0	78	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 3	2002	296	5569					922	927		10.1126/science.1069398	http://dx.doi.org/10.1126/science.1069398			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	549KF	11934988	Green Accepted			2022-12-28	WOS:000175442500048
J	Moses, AE; Cohen-Poradosu, R				Moses, AE; Cohen-Poradosu, R			Eczema vaccinatum - A timely reminder	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Hadassah Univ Med Ctr, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem	Moses, AE (corresponding author), Hadassah Univ Med Ctr, IL-91120 Jerusalem, Israel.								0	15	15	0	2	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 25	2002	346	17					1287	1287		10.1056/NEJMicm010892	http://dx.doi.org/10.1056/NEJMicm010892			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	544GX	11923488				2022-12-28	WOS:000175150800005
J	Ray, S; Samuel, T; Hawker, J; Smith, S				Ray, S; Samuel, T; Hawker, J; Smith, S			Hepatitis B immunisation in renal units in the United Kingdom: questionnaire study	BRITISH MEDICAL JOURNAL			English	Article									Birmingham Heartlands Hosp, Ctr Communicable Dis Surveillance, Birmingham B9 5SS, W Midlands, England; Birmingham Heartlands Hosp, Renal Unit, Birmingham B9 5ST, W Midlands, England	Heart of England NHS Foundation Trust; University of Birmingham; Heart of England NHS Foundation Trust; University of Birmingham	Smith, S (corresponding author), Birmingham Heartlands Hosp, Bordesley Green E, Birmingham B9 5ST, W Midlands, England.							*DEP HLTH, 1996, IMM AG INF DIS 1996; JIBANI MM, 1994, NEPHROL DIAL TRANSPL, V9, P1765; *LOND DEP HLTH PUB, IN PRESS DRAFT GOOD; *ROYAL COLL PHYS R, 1997, TREATM AD PAT REN FA, P64	4	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 13	2002	324	7342					877	878		10.1136/bmj.324.7342.877	http://dx.doi.org/10.1136/bmj.324.7342.877			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	542PA	11950735	Green Published, Bronze			2022-12-28	WOS:000175052200020
J	Birkmeyer, JD; Siewers, AE; Finlayson, EVA; Stukel, TA; Lucas, FL; Batista, I; Welch, HG; Wennberg, DE				Birkmeyer, JD; Siewers, AE; Finlayson, EVA; Stukel, TA; Lucas, FL; Batista, I; Welch, HG; Wennberg, DE			Hospital volume and surgical mortality in the United States.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CARDIAC-SURGERY; OPERATIVE MORTALITY; OUTCOMES; CARE; COMORBIDITIES; QUALITY; DEATHS	Background: Although numerous studies suggest that there is an inverse relation between hospital volume of surgical procedures and surgical mortality, the relative importance of hospital volume in various surgical procedures is disputed. Methods: Using information from the national Medicare claims data base and the Nationwide Inpatient Sample, we examined the mortality associated with six different types of cardiovascular procedures and eight types of major cancer resections between 1994 and 1999 (total number of procedures, 2.5 million). Regression techniques were used to describe relations between hospital volume (total number of procedures performed per year) and mortality (in-hospital or within 30 days), with adjustment for characteristics of the patients. Results: Mortality decreased as volume increased for all 14 types of procedures, but the relative importance of volume varied markedly according to the type of procedure. Absolute differences in adjusted mortality rates between very-low-volume hospitals and very-high-volume hospitals ranged from over 12 percent (for pancreatic resection, 16.3 percent vs. 3.8 percent) to only 0.2 percent (for carotid endarterectomy, 1.7 percent vs. 1.5 percent). The absolute differences in adjusted mortality rates between very-low-volume hospitals and very-high-volume hospitals were greater than 5 percent for esophagectomy and pneumonectomy, 2 to 5 percent for gastrectomy, cystectomy, repair of a nonruptured abdominal aneurysm, and replacement of an aortic or mitral valve, and less than 2 percent for coronary-artery bypass grafting, lower-extremity bypass, colectomy, lobectomy, and nephrectomy. Conclusions: In the absence of other information about the quality of surgery at the hospitals near them, Medicare patients undergoing selected cardiovascular or cancer procedures can significantly reduce their risk of operative death by selecting a high-volume hospital.	Dept Vet Affairs Med Ctr, Vet Affairs Outcomes Grp 111B, White River Jct, VT 05009 USA; Dartmouth Hitchcock Med Ctr, Dept Surg, Lebanon, NH 03766 USA; Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Ctr Evaluat Clin Sci, Hanover, NH 03756 USA; Maine Med Ctr, Ctr Outcomes Res & Evaluat, Portland, ME 04102 USA; Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA	Dartmouth College; Dartmouth College; Maine Medical Center; University of California System; University of California San Francisco	Birkmeyer, JD (corresponding author), Dept Vet Affairs Med Ctr, Vet Affairs Outcomes Grp 111B, White River Jct, VT 05009 USA.		Young, Alexander/A-1523-2009	Young, Alexander/0000-0002-9367-9213; Stukel, Therese/0000-0002-2951-1360	AHRQ HHS [R01 HS10141-01] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS010141] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Begg CB, 1998, JAMA-J AM MED ASSOC, V280, P1747, DOI 10.1001/jama.280.20.1747; Birkmeyer J D, 1999, Eff Clin Pract, V2, P277; Birkmeyer JD, 2001, SURGERY, V130, P415, DOI 10.1067/msy.2001.117139; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; COMAROW A, 2000, US NEWS WORLD R 0717, P68; *DEP HLTH HUM SERV, 1998, ICD9CM DEP HLTH HUM; Dudley RA, 2000, JAMA-J AM MED ASSOC, V283, P1159, DOI 10.1001/jama.283.9.1159; Finlayson E V, 2001, Eff Clin Pract, V4, P172; FINLAYSON EVA, 2001, EFF CLIN PRACT, V4, P235; FISHER ES, 1992, AM J PUBLIC HEALTH, V82, P243, DOI 10.2105/AJPH.82.2.243; FLOOD AB, 1984, MED CARE, V22, P98, DOI 10.1097/00005650-198402000-00002; Ghali WA, 1997, JAMA-J AM MED ASSOC, V277, P379, DOI 10.1001/jama.277.5.379; Ghorra S, 1999, ANN SURG, V229, P163, DOI 10.1097/00000658-199902000-00001; Halm E, 2000, IS VOLUME RELATED QU; HANNAN EL, 1989, JAMA-J AM MED ASSOC, V262, P503, DOI 10.1001/jama.262.4.503; HANNAN EL, 1994, ANN THORAC SURG, V58, P1852, DOI 10.1016/0003-4975(94)91726-4; HSIA DC, 1990, NEW ENGL J MED, V322, P1540; IEZZONI LI, 1992, JAMA-J AM MED ASSOC, V267, P2197, DOI 10.1001/jama.267.16.2197; JENCKS SF, 1988, JAMA-J AM MED ASSOC, V260, P2240, DOI 10.1001/jama.260.15.2240; KATZ DJ, 1994, J VASC SURG, V19, P804, DOI 10.1016/S0741-5214(94)70005-2; KELLY JV, 1986, MED CARE, V24, P785, DOI 10.1097/00005650-198609000-00001; Khuri SF, 2001, SURGERY, V130, P429, DOI 10.1067/msy.2001.117138; Laks MP, 2000, NEW ENGL J MED, V342, P1527; LUFT HS, 1979, NEW ENGL J MED, V301, P1364, DOI 10.1056/NEJM197912203012503; MARSA L, 2000, LA TIMES        1016, pS1; McCullagh P., 1989, GEN LINEAR MODELS, V2nd; Pronovost PJ, 1999, JAMA-J AM MED ASSOC, V281, P1310, DOI 10.1001/jama.281.14.1310; ROMANO PS, 1993, J CLIN EPIDEMIOL, V46, P1075, DOI 10.1016/0895-4356(93)90103-8; Russell TR, 2001, SURGERY, V130, P423, DOI 10.1067/msy.2001.117137; Schneider EC, 1998, JAMA-J AM MED ASSOC, V279, P1638, DOI 10.1001/jama.279.20.1638; Taylor DH, 1999, NEW ENGL J MED, V340, P293, DOI 10.1056/NEJM199901283400408; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	32	3734	3784	5	113	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 11	2002	346	15					1128	1137		10.1056/NEJMsa012337	http://dx.doi.org/10.1056/NEJMsa012337			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	539PX	11948273				2022-12-28	WOS:000174880600006
J	Kaplinsky, N; Braun, D; Lisch, D; Hay, A; Hake, S; Freeling, M				Kaplinsky, N; Braun, D; Lisch, D; Hay, A; Hake, S; Freeling, M			Biodiversity (communications arising): Maize transgene results in Mexico are artefacts	NATURE			English	Article									Univ Calif Berkeley, Dept Plant & Microbial Biol, Berkeley, CA 94720 USA; ARS, Ctr Plant Gene Express, USDA, Albany, CA 94710 USA	University of California System; University of California Berkeley; United States Department of Agriculture (USDA)	Kaplinsky, N (corresponding author), Univ Calif Berkeley, Dept Plant & Microbial Biol, Berkeley, CA 94720 USA.		Lisch, Damon/A-9414-2010	Lisch, Damon/0000-0002-8693-8651; Kaplinsky, Nick/0000-0002-1759-1826				CALLIS J, 1987, GENE DEV, V1, P1183, DOI 10.1101/gad.1.10.1183; Chiueh LC, 2001, J FOOD DRUG ANAL, V9, P50; Quist D, 2001, NATURE, V414, P541, DOI 10.1038/35107068; SanMiguel P, 1996, SCIENCE, V274, P765, DOI 10.1126/science.274.5288.765; Zimmermann A, 2000, LEBENSM-WISS TECHNOL, V33, P210, DOI 10.1006/fstl.2000.0637	5	50	58	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 11	2002	416	6881					601	601		10.1038/nature739	http://dx.doi.org/10.1038/nature739			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	539YV	11935145				2022-12-28	WOS:000174901900031
J	Rosenbloom, M				Rosenbloom, M			Chlorpromazine and the psychopharmacologic revolution	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									Columbia Univ, Coll Phys & Surg, New York, NY 10032 USA	Columbia University	Rosenbloom, M (corresponding author), Columbia Univ, Coll Phys & Surg, New York, NY 10032 USA.							Artigues M F, 2000, N C Med J, V61, P90; Ban TA, 2001, PROG NEURO-PSYCHOPH, V25, P709, DOI 10.1016/S0278-5846(01)00160-9; Cancro R, 2000, PSYCHIATR SERV, V51, P333, DOI 10.1176/appi.ps.51.3.333; CORYELL W, 1987, AM J PSYCHIAT, V144, P913; FREEMAN H, 1999, CENTURY PSYCHIAT; JOS CJ, 1985, AM J PSYCHIAT, V142, P660, DOI 10.1176/ajp.142.5.660; LIPTON MA, 1978, PSYCHOPHARMACOLOGY G, P4; Meyer JM, 1997, PSYCHIATR SERV, V48, P1137; Shorter Edward., 1997, HIST PSYCHIAT ERA AS; SNYDER SH, 1996, DRUGS BRAIN; 1976, AM J PSYCHIAT, V27, P505	11	16	17	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 10	2002	287	14					1860	1861		10.1001/jama.287.14.1860	http://dx.doi.org/10.1001/jama.287.14.1860			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	539QJ	11939878	hybrid			2022-12-28	WOS:000174881700044
J	Morris, F; Brady, WJ				Morris, F; Brady, WJ			ABC of clinical electrocardiography - Acute myocardial infarction - Part I	BRITISH MEDICAL JOURNAL			English	Article									No Gen Hosp, Sheffield S5 7AU, S Yorkshire, England; Univ Virginia, Dept Emergency Med, Charlottesville, VA USA	Northern General Hospital; University of Virginia	Morris, F (corresponding author), No Gen Hosp, Sheffield S5 7AU, S Yorkshire, England.								0	34	35	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 6	2002	324	7341					831	834		10.1136/bmj.324.7341.831	http://dx.doi.org/10.1136/bmj.324.7341.831			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	540ZG	11934778	Green Published			2022-12-28	WOS:000174960300019
J	Renehan, AG; Egger, M; Saunders, MP; O'Dwyer, ST				Renehan, AG; Egger, M; Saunders, MP; O'Dwyer, ST			Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trials	BMJ-BRITISH MEDICAL JOURNAL			English	Review							RADICAL SURGERY; RECURRENCE; CARCINOMA; PATTERNS; COLON; SURVEILLANCE; MANAGEMENT; QUALITY	Objective To review die evidence from clinical trials of follow up of patients after curative resection for colorectal cancer. Design Systematic review and meta-analysis of randomised controlled trials of intensive compared with control follow up. Main outcome measures All cause mortality at five years (primary outcome). Rates of recurrence of intraluminal, local, and metastatic disease and metachronous (second colorectal primary) cancers (secondary outcomes). Results Five trials, which included 1342 patients, met the inclusion criteria. Intensive follow up was associated with a reduction in all cause mortality (combined risk ratio 0.81, 95% confidence interval 0.70 to 0.94, P=0.007). The effect was most pronounced in the four extramural detection trials that used computed tomography and frequent measurements of serum carcinoembryonic antigen (risk ratio 0.73, 0.60 to 0.89, P=0.002). Intensive follow up was associated with significantly earlier detection of all recurrences (difference in means 8.5 months, 7.6 to 9.4 months, P < 0.001) and an increased detection rate for isolated local recurrences (risk ratio 1.61, 1.12 to 2.32, P=0.011). Conclusions Intensive follow up after curative resection for colorectal cancer improves survival. Large trials are required to identify which components of intensive follow up are most beneficial.	Christie Hosp NHS Trust, Dept Surg, Manchester M20 4BX, Lancs, England; Univ Bristol, Dept Social Med, MRC, Hlth Serv Res Collaborat, Bristol BS8 2PR, Avon, England; Christie Hosp NHS Trust, Dept Clin Oncol, Manchester M20 4BX, Lancs, England	Christie NHS Foundation Trust; Christie Hospital; University of Bristol; Christie NHS Foundation Trust; Christie Hospital	Renehan, AG (corresponding author), Christie Hosp NHS Trust, Dept Surg, Manchester M20 4BX, Lancs, England.	arenehan@picr.man.ac.uk	Renehan, Andrew/K-5992-2015	Renehan, Andrew/0000-0003-4309-4396; Egger, Matthias/0000-0001-7462-5132				ABULAFI AM, 1994, BRIT J SURG, V81, P7, DOI 10.1002/bjs.1800810106; *ASS COL GREAT BRI, 2001, GUID MAN COL CANC; ATKIN WS, 1993, LANCET, V341, P736, DOI 10.1016/0140-6736(93)90499-7; Barillari P, 1996, DIS COLON RECTUM, V39, P388, DOI 10.1007/BF02054052; BRUINVELS DJ, 1994, ANN SURG, V219, P174, DOI 10.1097/00000658-199402000-00009; BRUINVELS DJ, 1995, EUR J SURG, V161, P827; CUNLIFFE WJ, 1984, BRIT J SURG, V71, P941, DOI 10.1002/bjs.1800711210; Deeks JJ, 2001, SYSTEMATIC REV HLTH, P285, DOI DOI 10.1002/9780470693926.CH15; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Dube S, 1997, DIS COLON RECTUM, V40, P35, DOI 10.1007/BF02055679; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; GHEZZI P, 1994, JAMA-J AM MED ASSOC, V271, P1587, DOI 10.1001/jama.1994.03510440047031; Juni P, 2001, BMJ-BRIT MED J, V323, P42, DOI 10.1136/bmj.323.7303.42; Kjeldsen BJ, 1997, BRIT J SURG, V84, P666; Kjeldsen BJ, 1997, INT J COLORECTAL DIS, V12, P329, DOI 10.1007/s003840050118; Kjeldsen BJ, 1999, SCAND J GASTROENTERO, V34, P509, DOI 10.1080/003655299750026254; KRONBORG O, 1988, SCAND J GASTROENTERO, V23, P159, DOI 10.3109/00365528809096975; Kuchler T, 1999, HEPATO-GASTROENTEROL, V46, P322; LEFEBVRE A, 2001, SYSTEMATIC REV HLTH, P69; LOCKHARTMUMMERY HE, 1972, DIS COLON RECTUM, V15, P261, DOI 10.1007/BF02589884; LOCKHARTMUMMERY HE, 1972, DIS COLON RECTUM, V15, P61; Makela J, 1992, Surg Oncol, V1, P157, DOI 10.1016/0960-7404(92)90029-K; MAKELA JT, 1995, ARCH SURG-CHICAGO, V130, P1062; MALCOLM AW, 1981, SURG GYNECOL OBSTET, V152, P131; MCCALL JL, 1994, DIS COLON RECTUM, V37, P875, DOI 10.1007/BF02052591; Mella J, 1997, ANN ROY COLL SURG, V79, P206; MELLA J, 1979, ANN R COLL SURG ENGL, V79, P2066; NORTHOVER J, 1994, JAMA-J AM MED ASSOC, V272, P31, DOI 10.1001/jama.1994.03520010041025; OHLSSON B, 1995, DIS COLON RECTUM, V38, P619, DOI 10.1007/BF02054122; PHILLIPS RKS, 1984, BRIT J SURG, V71, P604, DOI 10.1002/bjs.1800710813; Pietra N, 1998, DIS COLON RECTUM, V41, P1127, DOI 10.1007/BF02239434; Pisani P, 1999, INT J CANCER, V83, P18, DOI 10.1002/(SICI)1097-0215(19990924)83:1&lt;18::AID-IJC5&gt;3.0.CO;2-M; Renehan AG, 2000, LANCET, V355, P1095, DOI 10.1016/S0140-6736(05)72214-5; Rosen M, 1998, DIS COLON RECTUM, V41, P1116, DOI 10.1007/BF02239433; Schoemaker D, 1998, GASTROENTEROLOGY, V114, P7, DOI 10.1016/S0016-5085(98)70626-2; *SCOTL INT GUID NE, 2002, CLIN GUID COL CANC 1; Thompson SG, 1999, STAT MED, V18, P2693, DOI 10.1002/(SICI)1097-0258(19991030)18:20<2693::AID-SIM235>3.0.CO;2-V; VIRGO KS, 1995, ANN SURG ONCOL, V2, P472, DOI 10.1007/BF02307079; WAGHORN A, 1995, BRIT MED J, V311, P1344, DOI 10.1136/bmj.311.7016.1344; WILLETT CG, 1984, ANN SURG, V200, P685, DOI 10.1097/00000658-198412000-00001	40	421	430	0	12	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 6	2002	324	7341					813	816		10.1136/bmj.324.7341.813	http://dx.doi.org/10.1136/bmj.324.7341.813			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	540ZG	11934773	Green Published, Bronze			2022-12-28	WOS:000174960300014
J	Clutton-Brock, T				Clutton-Brock, T			Behavioral ecology - Breeding together: Kin selection and mutualism in cooperative vertebrates	SCIENCE			English	Review							WHITE-BROWED SCRUBWRENS; SURICATA-SURICATTA; REPRODUCTIVE SUCCESS; SELFISH SENTINELS; HELPING-BEHAVIOR; EVOLUTION; RECIPROCITY; HELPERS; LIONS; SURVIVAL	`In cooperatively breeding vertebrates, nonbreeding helpers raise young produced by dominant breeders. Although the evolution of cooperative breeding has often been,attributed primarily to kin selection (whereby individuals gain "indirect" benefits to their fitness by assisting collateral relatives), there is increasing evidence that helpers can be unrelated to the young they are raising. Recent studies also suggest that the indirect benefits of cooperative behavior may often have been overestimated while the direct benefits of helping to the helper's own fitness have probably been underestimated. It now seems likely that the evolutionary mechanisms maintaining cooperative breeding are diverse and that, in some species, the direct benefits of helping may be sufficient to maintain cooperative societies. The benefits of cooperation in vertebrate societies may consequently show parallels with those in human societies, where cooperation between unrelated individuals is frequent and social institutions are often maintained by generalized reciprocity.	Univ Cambridge, Dept Zool, Cambridge CB2 3EJ, England	University of Cambridge	Clutton-Brock, T (corresponding author), Univ Cambridge, Dept Zool, Downing St, Cambridge CB2 3EJ, England.	thcb@hermes.cam.ac.uk						[Anonymous], 2000, BOWLING ALONE; [Anonymous], 1971, INSECT SOC; AXELROD R, 1981, SCIENCE, V211, P1390, DOI 10.1126/science.7466396; Axelrod Robert, 1994, ANNOTATED BIBLIO EVO; Balshine-Earn S, 1998, BEHAV ECOL, V9, P432, DOI 10.1093/beheco/9.5.432; Bednekoff PA, 1997, AM NAT, V150, P373, DOI 10.1086/286070; Bernasconi G, 1999, TRENDS ECOL EVOL, V14, P477, DOI 10.1016/S0169-5347(99)01722-X; Bernasconi G, 1996, P ROY SOC B-BIOL SCI, V263, P509, DOI 10.1098/rspb.1996.0077; Bourke A. F., 1995, SOCIAL EVOLUTION ANT; Bourke Andrew F.G., 1997, P203; Brown J.L., 1987, HELPING COMMUNAL BRE; Bygott JD., 1979, GREAT APES, P405; Chagnon N.A., 1979, EVOLUTIONARY BIOL HU, P86; Clutton-Brock TH, 2000, P ROY SOC B-BIOL SCI, V267, P301, DOI 10.1098/rspb.2000.1000; Clutton-Brock TH, 1998, P ROY SOC B-BIOL SCI, V265, P2291, DOI 10.1098/rspb.1998.0573; Clutton-Brock TH, 1999, J ANIM ECOL, V68, P672, DOI 10.1046/j.1365-2656.1999.00317.x; Clutton-Brock TH, 2001, SCIENCE, V293, P2446, DOI 10.1126/science.1061274; Clutton-Brock TH, 1999, SCIENCE, V284, P1640, DOI 10.1126/science.284.5420.1640; CLUTTONBROCK TH, 1995, NATURE, V373, P209, DOI 10.1038/373209a0; Cockburn A, 1998, ANNU REV ECOL SYST, V29, P141, DOI 10.1146/annurev.ecolsys.29.1.141; CONNOR RC, 1995, BIOL REV, V34, P1652; Courchamp F, 2000, OIKOS, V91, P311, DOI 10.1034/j.1600-0706.2000.910212.x; Courchamp F, 1999, TRENDS ECOL EVOL, V14, P405, DOI 10.1016/S0169-5347(99)01683-3; CREEL S, 1990, P ROY SOC B-BIOL SCI, V241, P229, DOI 10.1098/rspb.1990.0090; CREEL S, IN PRESS AFRICAN WIL; Crozier R.H., 1996, EVOLUTION SOCIAL INS; Dugatkin L.A., 1997, COOPERATION ANIMALS; DUNN PO, 1995, P ROY SOC B-BIOL SCI, V259, P339, DOI 10.1098/rspb.1995.0050; Emlen S.T., 1991, P301; EMLEN ST, 1988, BEHAV ECOL SOCIOBIOL, V23, P305, DOI 10.1007/BF00300577; GASTON AJ, 1978, AM NAT, V112, P1091, DOI 10.1086/283348; GRINNELL J, 1995, ANIM BEHAV, V49, P95, DOI 10.1016/0003-3472(95)80157-X; HAMILTON WD, 1964, J THEOR BIOL, V7, P1, DOI [10.1016/0022-5193(64)90038-4, 10.1016/0022-5193(64)90039-6]; Heinsohn R, 1999, TRENDS ECOL EVOL, V14, P53, DOI 10.1016/S0169-5347(98)01545-6; HEINSOHN R, 1995, SCIENCE, V269, P1260, DOI 10.1126/science.7652573; HEINSOHN RG, 1991, ANIM BEHAV, V41, P1097, DOI 10.1016/S0003-3472(05)80652-9; Hoeksema JD, 2000, OECOLOGIA, V125, P321, DOI 10.1007/s004420000496; HOKKO H, IN PRESS BEHAV ECOL; JAMIESON IG, 1989, AM NAT, V133, P394, DOI 10.1086/284925; Kokko H, 2001, P ROY SOC B-BIOL SCI, V268, P187, DOI 10.1098/rspb.2000.1349; Komdeur J, 1996, BEHAV ECOL, V7, P326; KROPOTKIN P, 1908, MUTUAL AID; LEONARD ML, 1989, BEHAV ECOL SOCIOBIOL, V25, P357, DOI 10.1007/BF00302993; LIGON JD, 1978, NATURE, V280, P174; Magrath RD, 1997, J ANIM ECOL, V66, P658, DOI 10.2307/5919; Magrath RD, 1997, BEHAV ECOL SOCIOBIOL, V41, P185, DOI 10.1007/s002650050378; Manser MB, 1999, P ROY SOC B-BIOL SCI, V266, P1013, DOI 10.1098/rspb.1999.0737; MULDER RA, 1993, ANIM BEHAV, V45, P830, DOI 10.1006/anbe.1993.1100; NOE R, 1990, ANIM BEHAV, V39, P78, DOI 10.1016/S0003-3472(05)80728-6; PACKER C, 1990, AM NAT, V136, P1, DOI 10.1086/285079; Pusey Anne E., 1997, P254; Queller DC, 1998, BIOSCIENCE, V48, P165, DOI 10.2307/1313262; REEVE HK, 1992, NATURE, V358, P147, DOI 10.1038/358147a0; REYER HU, 1984, ANIM BEHAV, V32, P1163, DOI 10.1016/S0003-3472(84)80233-X; Ridley Matt, 1996, ORIGINS VIRTUE; Roberts G, 1998, P ROY SOC B-BIOL SCI, V265, P427, DOI 10.1098/rspb.1998.0312; Russell AF, 2001, P ROY SOC B-BIOL SCI, V268, P2169, DOI 10.1098/rspb.2001.1790; Strassmann JE, 1997, BEHAV ECOL SOCIOBIOL, V40, P71, DOI 10.1007/s002650050317; West SA, 2001, NATURE, V409, P510, DOI 10.1038/35054057; Wright J, 2001, P ROY SOC B-BIOL SCI, V268, P821, DOI 10.1098/rspb.2000.1574; Zahavi A, 1997, HANDICAP PRINCIPLE M	61	644	656	6	474	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 5	2002	296	5565					69	72		10.1126/science.296.5565.69	http://dx.doi.org/10.1126/science.296.5565.69			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	539FA	11935014				2022-12-28	WOS:000174858800035
J	Frenkel, D				Frenkel, D			Colloidal systems - Playing tricks with designer "atoms"	SCIENCE			English	Editorial Material							HARD; TRANSITION		FOM, Inst Atom & Mol Phys, NL-1098 SJ Amsterdam, Netherlands	AMOLF	Frenkel, D (corresponding author), FOM, Inst Atom & Mol Phys, Kruislaan 407, NL-1098 SJ Amsterdam, Netherlands.	frenkel@amolf.nl	Frenkel, Daan/G-2580-2014	Frenkel, Daan/0000-0002-6362-2021				ALDER BJ, 1957, J CHEM PHYS, V27, P1208, DOI 10.1063/1.1743957; BARTLETT P, 1992, PHYS REV LETT, V68, P3801, DOI 10.1103/PhysRevLett.68.3801; BOLHUIS P, 1994, PHYS REV E, V50, P4880, DOI 10.1103/PhysRevE.50.4880; Dawson K, 2001, PHYS REV E, V63, DOI 10.1103/PhysRevE.63.011401; GAST AP, 1983, J COLLOID INTERF SCI, V96, P251, DOI 10.1016/0021-9797(83)90027-9; Onsager L, 1933, CHEM REV, V13, P73, DOI 10.1021/cr60044a006; ONSAGER L, 1949, ANN NY ACAD SCI, V51, P627, DOI 10.1111/j.1749-6632.1949.tb27296.x; Pham KN, 2002, SCIENCE, V296, P104, DOI 10.1126/science.1068238; PUSEY PN, 1986, NATURE, V320, P340, DOI 10.1038/320340a0; PUSEY PN, 1991, LES HOUCH S, V51, P763; Velikov KP, 2002, SCIENCE, V296, P106, DOI 10.1126/science.1067141; WOOD WW, 1957, J CHEM PHYS, V27, P1207, DOI 10.1063/1.1743956	12	81	82	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 5	2002	296	5565					65	66		10.1126/science.1070865	http://dx.doi.org/10.1126/science.1070865			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	539FA	11935011	Green Submitted			2022-12-28	WOS:000174858800032
J	Grieco, F; van Noordwijk, AJ; Visser, ME				Grieco, F; van Noordwijk, AJ; Visser, ME			Evidence for the effect of learning on timing of reproduction in blue tits	SCIENCE			English	Article							BIRDS	We experimentally show that in blue tits (Parus caeruleus) egg-laying date is causally linked to experience in the previous year. Females that received additional food in the nestling period in one year laid eggs later in the next year compared with the control birds, whatever the degree of synchronization with the natural food abundance in the previous year. As a result, they raised their brood much later than the peak period of nestling food availability in the next year. The response to experience is adaptive for blue tits, which live in heterogeneous habitats where the peak period of food varies, but once settled will breed at the same location for life.	Netherlands Inst Ecol, Ctr Terr Ecol, NL-6666 ZG Heteren, Netherlands	Royal Netherlands Academy of Arts & Sciences; Netherlands Institute of Ecology (NIOO-KNAW)	Grieco, F (corresponding author), Netherlands Inst Ecol, Ctr Terr Ecol, POB 40, NL-6666 ZG Heteren, Netherlands.		Visser, Marcel E/A-9151-2009; van noordwijk, arie/A-8880-2011	Visser, Marcel E/0000-0002-1456-1939; 				GIBB JA, 1963, J ANIM ECOL, V32, P489, DOI 10.2307/2605; Gustafsson L., 1990, NATO ASI Series Series G Ecological Sciences, V24, P235; Hau M, 2000, J EXP ZOOL, V286, P494, DOI 10.1002/(SICI)1097-010X(20000401)286:5<494::AID-JEZ7>3.0.CO;2-3; HOUSTON DC, 1999, P 22 INT ORN C DURB, P52; Lambrechts M.M., 1999, P 22 INT ORN C DURB, P249; Lambrechts MM, 1996, P ROY SOC B-BIOL SCI, V263, P19, DOI 10.1098/rspb.1996.0004; Lessells C.M., 1991, P32; NAGER RG, 1995, AM NAT, V146, P454, DOI 10.1086/285809; Nilsson J-A, 1999, P 22 INT ORN C DURB, P234; PERRINS CM, 1970, IBIS, V112, P242, DOI 10.1111/j.1474-919X.1970.tb00096.x; Thomas DW, 2001, SCIENCE, V291, P2598, DOI 10.1126/science.1057487; TINBERGEN JM, 1994, FUNCT ECOL, V8, P563, DOI 10.2307/2389916	12	77	78	0	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 5	2002	296	5565					136	138		10.1126/science.1068287	http://dx.doi.org/10.1126/science.1068287			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	539FA	11935025				2022-12-28	WOS:000174858800046
J	Anderson, MJ; Dixson, AF				Anderson, MJ; Dixson, AF			Sperm competition - Motility and the midpiece in primates	NATURE			English	Article							DOMESTIC-FOWL; DETERMINES; MOBILITY		Zool Soc San Diego, Ctr Reprod Endangered Species, San Diego, CA 92112 USA	Zoological Society of San Diego	Anderson, MJ (corresponding author), Zool Soc San Diego, Ctr Reprod Endangered Species, POB 120551, San Diego, CA 92112 USA.							Birkhead T, 2000, PROMISCUITY EVOLUTIO; Birkhead TR, 1999, P ROY SOC B-BIOL SCI, V266, P1759, DOI 10.1098/rspb.1999.0843; Birkhead TR, 1998, SPERM COMPETITION SE; CARDULLO RA, 1991, CELL MOTIL CYTOSKEL, V19, P180, DOI 10.1002/cm.970190306; Dixson A.F., 1998, PRIMATE SEXUALITY CO; Froman DP, 1998, BIOL REPROD, V58, P379, DOI 10.1095/biolreprod58.2.379; HARCOURT AH, 1981, NATURE, V293, P55, DOI 10.1038/293055a0; Katz D.F., 1990, P125; Parker G.A., 1984, P1; PURVIS A, 1995, COMPUT APPL BIOSCI, V11, P247; Short R.V., 1979, Advances in the Study of Behavior, V9, P131, DOI 10.1016/S0065-3454(08)60035-2; Smuts B. B., 1987, PRIMATE SOC; WOOLLEY DM, 1967, NATURE, V215, P94, DOI 10.1038/215094a0	13	180	183	1	41	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 4	2002	416	6880					496	496		10.1038/416496a	http://dx.doi.org/10.1038/416496a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	537JY	11932733				2022-12-28	WOS:000174756500031
J	Ziske, CG; Muller, T				Ziske, CG; Muller, T			Partial splenectomy	LANCET			English	Article									Univ Bonn, Med Klin & Poliklin 1, D-53105 Bonn, Germany; Krankenhaus Hofheim am Taunus, Kliniken Main Taunus Kreises, Hofheim, Germany	University of Bonn	Ziske, CG (corresponding author), Univ Bonn, Med Klin & Poliklin 1, Sigmund Freud Str 25, D-53105 Bonn, Germany.								0	8	9	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 30	2002	359	9312					1144	1144		10.1016/S0140-6736(02)08163-1	http://dx.doi.org/10.1016/S0140-6736(02)08163-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	536YJ	11943281				2022-12-28	WOS:000174729200031
J	Hollingsworth, MD				Hollingsworth, MD			Crystal engineering: from structure to function	SCIENCE			English	Article							X-RAY-DIFFRACTION; INCLUSION; GROWTH; RECOGNITION; SYMMETRY; STRESS; SOLIDS; DESIGN	Modern crystal engineering has emerged as a rich discipline whose success requires an iterative process of synthesis, crystallography, crystal structure analysis, and computational methods. By focusing on the molecular recognition events during nucleation and growth, chemists have uncovered new ways of controlling the internal structure and symmetry of crystals and of producing materials with useful chemical and physical properties.	Kansas State Univ, Dept Chem, Manhattan, KS 66506 USA	Kansas State University	Hollingsworth, MD (corresponding author), Kansas State Univ, Dept Chem, Manhattan, KS 66506 USA.	mdholl@ksu.edu						Aakeroy CB, 1999, ANGEW CHEM INT EDIT, V38, P1815, DOI 10.1002/(SICI)1521-3773(19990614)38:12<1815::AID-ANIE1815>3.0.CO;2-S; Aakeroy CB, 1998, J AM CHEM SOC, V120, P8986, DOI 10.1021/ja981122i; Albrecht M, 2000, NATURE, V406, P970, DOI 10.1038/35023107; Auciello O, 1998, PHYS TODAY, V51, P22, DOI 10.1063/1.882324; Bernstein J, 1999, ANGEW CHEM INT EDIT, V38, P3440, DOI 10.1002/(SICI)1521-3773(19991203)38:23<3440::AID-ANIE3440>3.0.CO;2-#; Biradha K, 2000, ANGEW CHEM INT EDIT, V39, P3843, DOI 10.1002/1521-3773(20001103)39:21<3843::AID-ANIE3843>3.0.CO;2-#; BROWN ME, 1995, NATURE, V376, P323, DOI 10.1038/376323a0; BURKE JG, 1966, ORIGINS SCI CRYSTALS, P83; CURTIN DY, 1981, CHEM REV, V81, P525, DOI 10.1021/cr00046a001; Desiraju G., 1999, WEAK HYDROGEN BOND A; DESIRAJU GR, 1995, ANGEW CHEM INT EDIT, V34, P2311, DOI 10.1002/anie.199523111; Dunitz JD, 1999, ACCOUNTS CHEM RES, V32, P677, DOI 10.1021/ar980007+; Eddaoudi M, 2002, SCIENCE, V295, P469, DOI 10.1126/science.1067208; Eddaoudi M, 2002, J AM CHEM SOC, V124, P376, DOI 10.1021/ja017154e; Groth P., 1906, CHEM KRYSTALLOGRAPHI, VI; HARRIS KDM, 1994, J AM CHEM SOC, V116, P3543, DOI 10.1021/ja00087a047; Harris KDM, 2001, ANGEW CHEM INT EDIT, V40, P1626, DOI 10.1002/1521-3773(20010504)40:9<1626::AID-ANIE16260>3.0.CO;2-7; Heringdorf FJMZ, 2001, NATURE, V412, P517, DOI 10.1038/35087532; HOLLINGSWORTH MD, 1993, J AM CHEM SOC, V115, P5881, DOI 10.1021/ja00066a089; Hollingsworth MD, 1996, SCIENCE, V273, P1355, DOI 10.1126/science.273.5280.1355; Hollingsworth MD, 2002, J AM CHEM SOC, V124, P2094, DOI 10.1021/ja010327f; Holman KT, 2001, SCIENCE, V294, P1907, DOI 10.1126/science.1064432; Irie M, 2001, SCIENCE, V291, P1769, DOI 10.1126/science.291.5509.1769; KAHR B, 1992, ANGEW CHEM INT EDIT, V31, P1, DOI 10.1002/anie.199200013; Kahr B, 2001, CHEM REV, V101, P893, DOI 10.1021/cr980088n; KITAIGORODSKII AI, 1961, ORGANIC CHEM CRYSTAL, P233; Kolotuchin SV, 1995, ANGEW CHEM INT EDIT, V34, P2654; Konig O, 1997, J AM CHEM SOC, V119, P10632, DOI 10.1021/ja971945s; Lommerse JPM, 2000, ACTA CRYSTALLOGR B, V56, P697, DOI 10.1107/S0108768100004584; MARDER SR, 1991, SCIENCE, V252, P103, DOI 10.1126/science.252.5002.103; MARDER SR, 1993, ADV MATER, V5, P804, DOI 10.1002/adma.19930051104; McBride J.M., 1989, ANGEW CHEM, V101, P391; MCBRIDE JM, 1986, SCIENCE, V234, P830, DOI 10.1126/science.234.4778.830; Moulton B, 2001, CHEM REV, V101, P1629, DOI 10.1021/cr9900432; RIFANI M, 1995, J AM CHEM SOC, V117, P7572, DOI 10.1021/ja00133a042; Robson R, 2000, J CHEM SOC DALTON, P3735, DOI 10.1039/b003591m; RUSSELL VA, 1994, J AM CHEM SOC, V116, P1941, DOI 10.1021/ja00084a039; SCHMIDT G M J, 1971, Pure and Applied Chemistry, V27, P647; VAIDA M, 1988, SCIENCE, V241, P1475, DOI 10.1126/science.241.4872.1475; Ward MD, 2001, CHEM REV, V101, P1697, DOI 10.1021/cr000020j; Weber T, 2001, ACTA CRYSTALLOGR B, V57, P579, DOI 10.1107/S0108768101005468; WEISSBUCH I, 1991, SCIENCE, V253, P637, DOI 10.1126/science.253.5020.637; Yokoo A, 1998, J OPT SOC AM B, V15, P432, DOI 10.1364/JOSAB.15.000432	43	460	467	0	106	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 29	2002	295	5564					2410	2413						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	536QD	11923527				2022-12-28	WOS:000174712600043
J	Lehn, JM				Lehn, JM			Toward self-organization and complex matter	SCIENCE			English	Article							DYNAMIC COMBINATORIAL CHEMISTRY; MOLECULAR RECOGNITION; SUPRAMOLECULAR CHEMISTRY; ORGANIC-CHEMISTRY; CHEMICAL-SYSTEMS; NANOSTRUCTURES; INFORMATION; COMPUTATION; GENERATION; EVOLUTION	Beyond molecular chemistry based on the covalent bond, supramolecular chemistry aims at developing highly complex chemical systems from components interacting through noncovalent intermolecular forces. Over the past quarter century, supramolecular chemistry has grown into a major field and has fueled numerous developments at the interfaces with biology and physics. Some of the conceptual advances and future challenges are profited here.	Univ Strasbourg 1, ISIS, F-67000 Strasbourg, France; Coll France, F-75005 Paris, France	UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UDICE-French Research Universities; PSL Research University Paris; College de France	Lehn, JM (corresponding author), Univ Strasbourg 1, ISIS, F-67000 Strasbourg, France.	lehn@chimie.u-strasbg.fr						ADLEMAN LM, 1994, SCIENCE, V266, P1021, DOI 10.1126/science.7973651; Atwood J.L., 1996, COMPREHENSIVE SUPRAM, DOI DOI 10.1021/jacs.6b12949; Balzani V, 2000, ANGEW CHEM INT EDIT, V39, P3348, DOI 10.1002/1521-3773(20001002)39:19<3348::AID-ANIE3348>3.0.CO;2-X; Balzani V., 1991, SUPRAMOLECULAR PHOTO; Bard A.J., 1994, INTEGRATED CHEM SYST; Berl V, 2000, CHEM-EUR J, V6, P1938; Brunsveld L, 2001, CHEM REV, V101, P4071, DOI 10.1021/cr990125q; Chandross EA, 1999, CHEM REV, V99, P1641, DOI 10.1021/cr990020n; Chen JH, 2000, P NATL ACAD SCI USA, V97, P1328, DOI 10.1073/pnas.97.4.1328; Cousins GRL, 2000, CURR OPIN CHEM BIOL, V4, P270, DOI 10.1016/S1367-5931(00)00088-0; Czarnik A.W., 1997, CHEMOSENSORS ION MOL; de Silva AP, 2000, J AM CHEM SOC, V122, P3965; Desiraju GR, 1995, CRYSTAL SUPRAMOLECUL, V2; EIGEN M, 1971, NATURWISSENSCHAFTEN, V58, P465, DOI 10.1007/BF00623322; Funeriu DP, 2000, CHEM-EUR J, V6, P2103; Fyfe MCT, 1997, ACCOUNTS CHEM RES, V30, P393, DOI 10.1021/ar950199y; Gokel GW, 2001, CHEM SOC REV, V30, P274, DOI 10.1039/b008667n; Hasenknopf B, 1997, J AM CHEM SOC, V119, P10956, DOI 10.1021/ja971204r; Hasenknopf B, 1998, ANGEW CHEM INT EDIT, V37, P3265, DOI 10.1002/(SICI)1521-3773(19981217)37:23<3265::AID-ANIE3265>3.0.CO;2-B; JORTNER JR, 1997, MOL ELECT; KRAMER R, 1993, P NATL ACAD SCI USA, V90, P5394, DOI 10.1073/pnas.90.12.5394; LAWRENCE DS, 1995, CHEM REV, V95, P2229, DOI 10.1021/cr00038a018; Lehn J.-M., 1995, SUPRAMOLECULAR CHEM; Lehn JM, 2000, CHEM-EUR J, V6, P2097, DOI 10.1002/1521-3765(20000616)6:12<2097::AID-CHEM2097>3.0.CO;2-T; Lehn JM, 2001, SCIENCE, V291, P2331, DOI 10.1126/science.1060066; Lehn JM, 1999, CHEM-EUR J, V5, P2455; LEHN JM, 1990, ANGEW CHEM INT EDIT, V29, P1304, DOI 10.1002/anie.199013041; Lehn JM, 1999, NATO ADV SCI I C-MAT, V527, P287; Leininger S, 2000, CHEM REV, V100, P853, DOI 10.1021/cr9601324; Lindoy L.F., 2000, SELF ASSEMBLY SUPRAM; Marchi-Artzner V, 2001, CHEMPHYSCHEM, V2, P367, DOI 10.1002/1439-7641(20010618)2:6<367::AID-CPHC367>3.0.CO;2-#; MENGER FM, 1995, ANGEW CHEM INT EDIT, V34, P2091, DOI 10.1002/anie.199520911; ORGEL LE, 1995, ACCOUNTS CHEM RES, V28, P109, DOI 10.1021/ar00051a004; Paleos CM, 2001, CHEMBIOCHEM, V2, P305, DOI 10.1002/1439-7633(20010504)2:5<305::AID-CBIC305>3.0.CO;2-9; Philp D, 1996, ANGEW CHEM INT EDIT, V35, P1154, DOI 10.1002/anie.199611541; Prins LJ, 2001, ANGEW CHEM INT EDIT, V40, P2382, DOI 10.1002/1521-3773(20010702)40:13<2382::AID-ANIE2382>3.0.CO;2-G; Quinkert G, 1996, HELV CHIM ACTA, V79, P1260, DOI 10.1002/hlca.19960790504; Robertson A, 2000, CHEM SOC REV, V29, P141, DOI 10.1039/a803602k; Rothemund PWK, 2000, P NATL ACAD SCI USA, V97, P984, DOI 10.1073/pnas.97.3.984; Sauvage, 1999, MOL CATENANES ROTAXA; Service RF, 2001, SCIENCE, V293, P782, DOI 10.1126/science.293.5531.782; Smith VCM, 1996, CHEM COMMUN, P2733, DOI 10.1039/cc9960002733; STODDART JF, 2001, ACCOUNTS CHEM RES, V34, P409; Suarez M, 1998, J AM CHEM SOC, V120, P9526, DOI 10.1021/ja981722h; Swiegers GF, 2000, CHEM REV, V100, P3483, DOI 10.1021/cr990110s; WHITESIDES GM, 1991, SCIENCE, V254, P1312, DOI 10.1126/science.1962191; WHITESIDES GM, 1995, ACCOUNTS CHEM RES, V28, P37, DOI 10.1021/ar00049a006; Yates FE., 1987, SELF ORG SYSTEMS; [No title captured]	49	1973	2001	17	704	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 29	2002	295	5564					2400	2403		10.1126/science.1071063	http://dx.doi.org/10.1126/science.1071063			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	536QD	11923524	Green Submitted			2022-12-28	WOS:000174712600040
J	Miller, MM; Melbourne, T; Johnson, DJ; Sumner, WQ				Miller, MM; Melbourne, T; Johnson, DJ; Sumner, WQ			Periodic slow earthquakes from the Cascadia subduction zone	SCIENCE			English	Article									Cent Washington Univ, Dept Geol Sci, Ellensburg, WA 98926 USA	Central Washington University	Miller, MM (corresponding author), Cent Washington Univ, Dept Geol Sci, Ellensburg, WA 98926 USA.			Miller, M Meghan/0000-0002-7296-0639				ADAMS J, 1990, TECTONICS, V9, P569, DOI 10.1029/TC009i004p00569; ATWATER BF, 1997, 108 US GEOL SURV; Dragert H, 2001, SCIENCE, V292, P1525, DOI 10.1126/science.1060152; DRAGERT H, 1995, GEOPHYS RES LETT, V22, P755, DOI 10.1029/95GL00469; Miller MM, 2001, TECTONICS, V20, P161, DOI 10.1029/2000TC001224; Satake K, 1996, NATURE, V379, P246, DOI 10.1038/379246a0; XIE LL, 1995, GEOPHYS J INT, V121, P117, DOI 10.1111/j.1365-246X.1995.tb03515.x; Yamaguchi DK, 1997, NATURE, V389, P922, DOI 10.1038/40048	8	197	205	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 29	2002	295	5564					2423	2423		10.1126/science.1071193	http://dx.doi.org/10.1126/science.1071193			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	536QD	11923530				2022-12-28	WOS:000174712600046
J	Sumper, M				Sumper, M			A phase separation model for the nanopatterning of diatom biosilica	SCIENCE			English	Article							MESOPOROUS MOLECULAR-SIEVES; MORPHOGENESIS; MORPHOLOGY; SILICA	Diatoms are encased in an intricately patterned wall that consists of amorphous silica. Species-specific fabrication of this ornate biomineral enables taxonomists to identify thousands of diatom species. The molecular mechanisms that control this nanofabrication and generate the diversity of patterns is not well understood. A simple model is described, in which repeated phase separation events during wait biogenesis are assumed to produce self-similar silica patterns in smaller and smaller scales, On the basis of this single assumption, the apparently complex patterns found in the valves of the diatom genus Coscinodiscus can be predicted. Microscopic analysis of valves in statu nascendi from three different Coscinodiscus species supports the conclusions derived from the model.	Univ Regensburg, Lehrstuhl Biochem 1, D-93053 Regensburg, Germany	University of Regensburg	Sumper, M (corresponding author), Univ Regensburg, Lehrstuhl Biochem 1, D-93053 Regensburg, Germany.							DRUM RW, 1964, J ULTRA MOL STRUCT R, V10, P217, DOI 10.1016/S0022-5320(64)80006-X; GORDON R, 1994, INT REV CYTOL, V150, P243; GRIFFITHS G, 1993, FINE STRUCTURE IMMUN; Hasle Grethe Rytter, 1992, Diatom Research, V7, P37; Imhof A, 1997, NATURE, V389, P948, DOI 10.1038/40105; KRESGE CT, 1992, NATURE, V359, P710, DOI 10.1038/359710a0; Kroger N, 1999, SCIENCE, V286, P1129, DOI 10.1126/science.286.5442.1129; Kroger N, 2000, P NATL ACAD SCI USA, V97, P14133, DOI 10.1073/pnas.260496497; Kroger N, 2001, J BIOL CHEM, V276, P26066, DOI 10.1074/jbc.M102093200; Lin HP, 1996, SCIENCE, V273, P765, DOI 10.1126/science.273.5276.765; Mann S, 1996, NATURE, V382, P313, DOI 10.1038/382313a0; MONNIER A, 1993, SCIENCE, V261, P1299, DOI 10.1126/science.261.5126.1299; Pickett-Heaps J., 1990, PROGR PHYCOLOGICAL R, V7, P1; PICKETTHEAPS JD, 1979, BIOL CELLULAIRE, V35, P199; Schacht S, 1996, SCIENCE, V273, P768, DOI 10.1126/science.273.5276.768; SCHMID AMM, 1983, J PHYCOL, V19, P387, DOI 10.1111/j.0022-3646.1983.00387.x; Tanaka H, 1996, PHYS REV LETT, V76, P787, DOI 10.1103/PhysRevLett.76.787; Tomas CR, 1997, IDENTIFYING MARINE P; WIDAWSKI G, 1994, NATURE, V369, P387, DOI 10.1038/369387a0; Yang H, 1997, NATURE, V386, P692, DOI 10.1038/386692a0	20	293	299	2	117	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 29	2002	295	5564					2430	2433		10.1126/science.1070026	http://dx.doi.org/10.1126/science.1070026			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	536QD	11923533				2022-12-28	WOS:000174712600049
J	Bernstein, MP; Dworkin, JP; Sandford, SA; Cooper, GW; Allamandola, LJ				Bernstein, MP; Dworkin, JP; Sandford, SA; Cooper, GW; Allamandola, LJ			Racemic amino acids from the ultraviolet photolysis of interstellar ice analogues	NATURE			English	Article							ALLENDE MINERALS; SOLAR-SYSTEM; DENSE CLOUDS; HYDROGEN; INVENTORY; METHANOL	The delivery of extraterrestrial organic molecules to Earth by meteorites may have been important for the origin and early evolution of life(1). Indigenous amino acids have been found in meteorites(2)-over 70 in the Murchison meteorite alone(3). Although it has been generally accepted that the meteoritic amino acids formed in liquid water(4) on a parent body, the water in the Murchison meteorite is depleted in deuterium(5) relative to the indigenous organic acids(6,7). Moreover, the meteoritical evidence(8) for an excess of laevo-rotatory amino acids is hard to understand in the context of liquid-water reactions on meteorite parent bodies. Here we report a laboratory demonstration that glycine, alanine and serine naturally form from ultraviolet photolysis of the analogues of icy interstellar grains. Such amino acids would naturally have a deuterium excess similar to that seen in interstellar molecular clouds, and the formation process could also result in enantiomeric excesses if the incident radiation is circularly polarized. These results suggest that at least some meteoritic amino acids are the result of interstellar photochemistry, rather than formation in liquid water on an early Solar System body.	SETI Inst, Ctr Study Life Universe, Mountain View, CA 94043 USA; NASA, Ames Res Ctr, Moffett Field, CA 94035 USA	National Aeronautics & Space Administration (NASA); NASA Ames Research Center	Bernstein, MP (corresponding author), SETI Inst, Ctr Study Life Universe, 2035 Landings Dr, Mountain View, CA 94043 USA.	mbernstein@mail.arc.nasa.gov	Dworkin, Jason P./C-9417-2012	Dworkin, Jason P./0000-0002-3961-8997				ALLAMANDOLA LJ, 1988, ICARUS, V76, P225, DOI 10.1016/0019-1035(88)90070-X; ALLAMANDOLA LJ, 1992, ASTROPHYS J, V399, P134, DOI 10.1086/171909; BERNSTEIN MP, 1995, ASTROPHYS J, V454, P327, DOI 10.1086/176485; Bonner WA, 2000, ORIGINS LIFE EVOL B, V30, P513, DOI 10.1023/A:1026571209426; Chiar JE, 2000, ASTROPHYS J, V537, P749, DOI 10.1086/309047; Cronin J R, 1983, Adv Space Res, V3, P5, DOI 10.1016/0273-1177(83)90036-4; Cronin JR, 1997, SCIENCE, V275, P951, DOI 10.1126/science.275.5302.951; CRONIN JR, 1993, NATO ADV SCI INST SE, V416, P209; Ehrenfreund P, 2001, ASTROPHYS J, V550, pL95, DOI 10.1086/319491; Gerakines PA, 1996, ASTRON ASTROPHYS, V312, P289; Irvine WM, 1996, NATURE, V383, P418, DOI 10.1038/383418a0; Kerridge JF, 1999, SPACE SCI REV, V90, P275, DOI 10.1023/A:1005222804192; Lacy JH, 1998, ASTROPHYS J, V501, pL105, DOI 10.1086/311452; LERNER NR, 1995, GEOCHIM COSMOCHIM AC, V59, P1623, DOI 10.1016/0016-7037(95)00068-B; Lerner NR, 1997, GEOCHIM COSMOCHIM AC, V61, P4885, DOI 10.1016/S0016-7037(97)00275-5; MATTHEWS CN, 1967, NATURE, V215, P1230, DOI 10.1038/2151230a0; ORO J, 1961, NATURE, V190, P389, DOI 10.1038/190389a0; Peltzer E T, 1984, Adv Space Res, V4, P69, DOI 10.1016/0273-1177(84)90546-5; PRASAD SS, 1983, ASTROPHYS J, V267, P603, DOI 10.1086/160896; ROBERT F, 1982, GEOCHIM COSMOCHIM AC, V46, P81, DOI 10.1016/0016-7037(82)90293-9; RUBENSTEIN E, 1983, NATURE, V306, P118, DOI 10.1038/306118a0; RUBENSTEIN E, 1999, SCIENCE, V283, P1415; Sandford SA, 1996, METEORIT PLANET SCI, V31, P449, DOI 10.1111/j.1945-5100.1996.tb02088.x; Sorrell WH, 2001, ASTROPHYS J, V555, pL129, DOI 10.1086/322525; TEGLER SC, 1993, ASTROPHYS J, V411, P260, DOI 10.1086/172825; Teixeira TC, 1999, ASTRON ASTROPHYS, V347, pL19; Turner BE, 2001, ASTROPHYS J SUPPL S, V136, P579, DOI 10.1086/322536; WARNECK P, 1962, APPL OPTICS, V1, P721, DOI 10.1364/AO.1.000721; ZHAO MX, 1995, J CHROMATOGR A, V690, P55, DOI 10.1016/0021-9673(94)00927-2	30	601	606	4	144	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 28	2002	416	6879					401	403		10.1038/416401a	http://dx.doi.org/10.1038/416401a			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	534UX	11919623				2022-12-28	WOS:000174607800038
J	Edhouse, J; Morris, F				Edhouse, J; Morris, F			ABC of clinical electrocardiography - Broad complex tachycardia - Part I	BRITISH MEDICAL JOURNAL			English	Article									Stepping Hill Hosp, Stockport SK2 7JE, Lancs, England; No Gen Hosp, Sheffield S5 7AU, S Yorkshire, England	Northern General Hospital	Edhouse, J (corresponding author), Stepping Hill Hosp, Stockport SK2 7JE, Lancs, England.								0	5	5	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 23	2002	324	7339					719	722		10.1136/bmj.324.7339.719	http://dx.doi.org/10.1136/bmj.324.7339.719			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	535ML	11909791	Green Published			2022-12-28	WOS:000174648200022
J	Karim, SA; Karim, QA; Adhikari, M; Cassol, S; Chersich, M; Cooper, P; Coovadia, A; Coovadia, H; Cotton, M; Coutsoudis, A; Hide, W; Hussey, G; Maartens, G; Madhi, S; Martin, D; Pettifor, JM; Rollins, N; Sherman, G; Thula, S; Urban, M; Velaphi, S; Williamson, C				Karim, SA; Karim, QA; Adhikari, M; Cassol, S; Chersich, M; Cooper, P; Coovadia, A; Coovadia, H; Cotton, M; Coutsoudis, A; Hide, W; Hussey, G; Maartens, G; Madhi, S; Martin, D; Pettifor, JM; Rollins, N; Sherman, G; Thula, S; Urban, M; Velaphi, S; Williamson, C			Vertical HIV transmission in South Africa: translating research into policy and practice	LANCET			English	Editorial Material							TO-CHILD TRANSMISSION; COST-EFFECTIVENESS; RANDOMIZED TRIAL; PREVENTION; ZIDOVUDINE; NEVIRAPINE; WOMEN		Univ Natal, ZA-4041 Durban, South Africa; Chris Hani Baragwanath Hosp, Johannesburg, South Africa; Univ Stellenbosch, ZA-7600 Stellenbosch, South Africa; Univ Witwatersrand, ZA-2050 Wits, South Africa; Univ Western Cape, ZA-7535 Bellville, South Africa; Univ Cape Town, ZA-7700 Rondebosch, South Africa	University of Kwazulu Natal; Stellenbosch University; University of Witwatersrand; University of the Western Cape; University of Cape Town	Karim, SA (corresponding author), Univ Natal, ZA-4041 Durban, South Africa.		Hide, Winston Hide/C-7217-2009; Hide, Winston/R-3815-2019; Karim, Salim Safurdeen Abdool/N-5947-2013; Karim, Salim Abdool/AAE-7118-2019; Karim, Salim Abdool/P-3117-2019; Maartens, Gary/F-3836-2014; Hide, Winston A/V-2727-2017; Cotton, Mark/AAQ-9936-2020; Abdool Karim, Quarraisha/GVS-1160-2022; Pettifor, John/M-4579-2019	Hide, Winston Hide/0000-0002-8621-3271; Hide, Winston/0000-0002-8621-3271; Karim, Salim Safurdeen Abdool/0000-0002-4986-2133; Karim, Salim Abdool/0000-0002-4986-2133; Maartens, Gary/0000-0003-3080-6606; Hide, Winston A/0000-0002-8621-3271; Cotton, Mark/0000-0003-2559-6034; Abdool Karim, Quarraisha/0000-0002-0985-477X; Pettifor, John/0000-0003-1155-0334; Urban, Michael/0000-0002-9392-0206; chersich, matthew/0000-0002-4320-9168; , Carolyn/0000-0003-0125-1226				Abdullah MF, 2001, S AFR MED J, V91, P579; Coates TJ, 1996, LANCET, V348, P1143, DOI 10.1016/S0140-6736(96)02307-0; COOVADIA HM, 2001, AIDSCIENCE, V1, P1; Coutsoudis A, 2002, HEALTH POLICY PLANN, V17, P154, DOI 10.1093/heapol/17.2.154; Coutsoudis A, 2001, AIDS, V15, P379, DOI 10.1097/00002030-200102160-00011; Culnane M, 1999, JAMA-J AM MED ASSOC, V281, P151, DOI 10.1001/jama.281.2.151; Eshleman SH, 2001, AIDS, V15, P1951, DOI 10.1097/00002030-200110190-00006; GRAY G, 2000, 13 INT AIDS C DURB S; Guay LA, 1999, LANCET, V354, P795, DOI 10.1016/S0140-6736(99)80008-7; MOODLEY D, 2000, 13 INT AIDS C DURB S; Musoke P, 1999, AIDS, V13, P479, DOI 10.1097/00002030-199903110-00006; OWOR M, 2000, 13 INT AIDS C DURB S; Shaffer N, 1999, LANCET, V353, P773, DOI 10.1016/S0140-6736(98)10411-7; Soderlund N, 1999, BRIT MED J, V318, P1650, DOI 10.1136/bmj.318.7199.1650; Stringer JSA, 2002, AM J PUBLIC HEALTH, V92, P365, DOI 10.2105/AJPH.92.3.365; Sweat M, 2000, LANCET, V356, P113, DOI 10.1016/S0140-6736(00)02447-8; Victora CG, 2000, LANCET, V355, P451, DOI 10.1016/S0140-6736(00)82011-5; Wiktor SZ, 1999, LANCET, V353, P781, DOI 10.1016/S0140-6736(98)10412-9; Wilkinson D, 2000, S AFR MED J, V90, P794	19	11	11	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 23	2002	359	9311					992	993		10.1016/S0140-6736(02)08063-7	http://dx.doi.org/10.1016/S0140-6736(02)08063-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	534KP	11937176				2022-12-28	WOS:000174585800003
J	Snieder, R; Gret, A; Douma, H; Scales, J				Snieder, R; Gret, A; Douma, H; Scales, J			Coda wave interferometry for estimating nonlinear behavior in seismic velocity	SCIENCE			English	Article							MULTIPLE LIGHT-SCATTERING; TEMPORAL-CHANGE; LOMA-PRIETA; EARTHQUAKE; ATTENUATION; CALIFORNIA; ROCKS; ANISOTROPY; DOUBLETS; FAULT	In coda wave interferometry, one records multiply scattered waves at a limited number of receivers to infer changes in the medium over time. With this technique, we have determined the nonlinear dependence of the seismic velocity in granite on temperature and the associated acoustic emissions. This technique can be used in warning mode, to detect the presence of temporal changes in the medium, or in diagnostic mode, where the temporal change in the medium is quantified.	Colorado Sch Mines, Dept Geophys, Golden, CO 80401 USA; Colorado Sch Mines, Ctr Wave Phenomena, Golden, CO 80401 USA	Colorado School of Mines; Colorado School of Mines	Snieder, R (corresponding author), Colorado Sch Mines, Dept Geophys, Golden, CO 80401 USA.							AKI K, 1985, EARTHQUAKE PRED RES, V3, P219; BEROZA GC, 1995, J GEOPHYS RES-SOL EA, V100, P3977, DOI 10.1029/94JB02574; Bokelmann GHR, 2000, J GEOPHYS RES-SOL EA, V105, P23879, DOI 10.1029/2000JB900207; CHOUET B, 1979, GEOPHYS RES LETT, V6, P143, DOI 10.1029/GL006i003p00143; Dodge DA, 1997, J GEOPHYS RES-SOL EA, V102, P24437, DOI 10.1029/97JB02024; FEHLER M, 1988, J GEOPHYS RES-SOLID, V93, P4367, DOI 10.1029/JB093iB05p04367; FOLDY LL, 1945, PHYS REV, V67, P107, DOI 10.1103/PhysRev.67.107; GOT JL, 1990, PURE APPL GEOPHYS, V134, P195, DOI 10.1007/BF00876998; Groenenboom J, 1995, J ACOUST SOC AM, V98, P3482, DOI 10.1121/1.413780; Heckmeier M, 1997, PROG COLL POL SCI S, V104, P12, DOI 10.1007/BF01182409; Hughes D. S., 1956, GEOPHYSICS, V21, P277; Ide JM, 1937, J GEOL, V45, P689, DOI 10.1086/624595; JIN A, 1986, J GEOPHYS RES-SOLID, V91, P665, DOI 10.1029/JB091iB01p00665; JOHNSTON DH, 1980, J GEOPHYS RES, V85, P937, DOI 10.1029/JB085iB02p00937; Kern H, 2001, TECTONOPHYSICS, V338, P113, DOI 10.1016/S0040-1951(01)00128-7; Lagendijk A, 1996, PHYS REP, V270, P143, DOI 10.1016/0370-1573(95)00065-8; LEARY PC, 1979, J GEOPHYS RES, V84, P659, DOI 10.1029/JB084iB02p00659; Li YG, 1998, SCIENCE, V279, P217, DOI 10.1126/science.279.5348.217; MARET G, 1987, Z PHYS B CON MAT, V65, P409, DOI 10.1007/BF01303762; Meredith PG, 2001, GEOPHYS RES LETT, V28, P2105, DOI 10.1029/2000GL012470; Miller V, 2001, SCIENCE, V293, P2231, DOI 10.1126/science.1063463; Nishimura T, 2000, GEOPHYS RES LETT, V27, P269, DOI 10.1029/1999GL005439; PESELNICK L, 1975, J GEOPHYS RES, V80, P3765, DOI 10.1029/JB080i026p03765; POUPINET G, 1984, J GEOPHYS RES, V89, P5719, DOI 10.1029/JB089iB07p05719; RATDOMOPURBO A, 1995, GEOPHYS RES LETT, V22, P775, DOI 10.1029/95GL00302; ROBERTS PM, 1992, J ACOUST SOC AM, V91, P3291, DOI 10.1121/1.402864; SATO H, 1987, J GEOPHYS RES-SOLID, V92, P1356, DOI 10.1029/JB092iB02p01356; SATO H, 1986, J GEOPHYS RES-SOLID, V91, P2049, DOI 10.1029/JB091iB02p02049; SILVER PG, 2001, EOS FALL M S, V82, pF896; Snieder R, 1999, NATO ADV SCI I C-MAT, V531, P405; SNIEDER R, 2000, EOS FALL M S, V81, pF848; Snieder RK, 1998, PHYS REV E, V58, P5668, DOI 10.1103/PhysRevE.58.5668; TSUKUDA T, 1988, PURE APPL GEOPHYS, V128, P261, DOI 10.1007/BF01772600; YONG C, 1980, GEOPHYS RES LETT, V7, P1089, DOI 10.1029/GL007i012p01089; [No title captured]	35	396	417	5	61	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 22	2002	295	5563					2253	2255		10.1126/science.1070015	http://dx.doi.org/10.1126/science.1070015			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	534AD	11910107				2022-12-28	WOS:000174561700041
J	O'Hagan, D; Schaffrath, C; Cobb, SL; Hamilton, JTG; Murphy, CD				O'Hagan, D; Schaffrath, C; Cobb, SL; Hamilton, JTG; Murphy, CD			Biosynthesis of an organofluorine molecule - A fluorinase enzyme has been discovered that catalyses carbon-fluorine bond formation.	NATURE			English	Article							FLUOROACETALDEHYDE		Univ St Andrews, Sch Chem, St Andrews KY16 9ST, Fife, Scotland; Univ St Andrews, Ctr Biomol Sci, St Andrews KY16 9ST, Fife, Scotland; Queens Univ Belfast, Dept Food Sci, Microbial Biochem Sect, Belfast BT9 SPX, Antrim, North Ireland	University of St Andrews; University of St Andrews; Queens University Belfast	O'Hagan, D (corresponding author), Univ St Andrews, Sch Chem, N Haugh, St Andrews KY16 9ST, Fife, Scotland.	dol@st-andrews.ac.uk	Murphy, Cormac D/I-4758-2013; Cobb, Steven L/F-3926-2012	Murphy, Cormac D/0000-0002-2137-3338; Cobb, Steven L/0000-0002-3790-7023; O'Hagan, David/0000-0002-0510-5552				GANI D, 1982, J CHEM SOC PERK T 1, P1197, DOI 10.1039/p19820001197; Gribble GW, 1999, CHEM SOC REV, V28, P335, DOI 10.1039/a900201d; HALL RJ, 1972, NEW PHYTOL, V71, P855, DOI 10.1111/j.1469-8137.1972.tb01965.x; HARPER DB, 1994, NAT PROD REP, V11, P123, DOI 10.1039/np9941100123; Moss SJ, 2000, CHEM COMMUN, P2281, DOI 10.1039/b007261n; Murphy CD, 2001, APPL ENVIRON MICROB, V67, P4919, DOI 10.1128/AEM.67.10.4919-4921; O'Hagan D, 2000, ACS SYM SER, V746, P210; PETERS RA, 1967, NATURE, V216, P80, DOI 10.1038/216080a0; SANADA M, 1986, J ANTIBIOT, V39, P259, DOI 10.7164/antibiotics.39.259	9	303	308	8	133	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 21	2002	416	6878					279	279		10.1038/416279a	http://dx.doi.org/10.1038/416279a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC); Current Chemical Reactions (CCR-EXPANDED)	Science & Technology - Other Topics	532NP	11907567	Bronze			2022-12-28	WOS:000174482200030
J	Hatfull, GF				Hatfull, GF			Microbiology - A tail of two specifi-cities	SCIENCE			English	Editorial Material							EVOLUTION		Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Hatfull, GF (corresponding author), Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA.							Bebenek K, 1999, MUTAT RES-FUND MOL M, V429, P149, DOI 10.1016/S0027-5107(99)00119-0; Cotter P.A., 2001, PRINCIPLES BACTERIAL, P620; DOI H, 1991, P NATL ACAD SCI USA, V88, P9282, DOI 10.1073/pnas.88.20.9282; Gerber AP, 2001, TRENDS BIOCHEM SCI, V26, P376, DOI 10.1016/S0968-0004(01)01827-8; GRUNDY FJ, 1984, VIROLOGY, V134, P296, DOI 10.1016/0042-6822(84)90299-X; Liu MS, 2002, SCIENCE, V295, P2091, DOI 10.1126/science.1067467; Morozova T, 2002, J MOL BIOL, V315, P951, DOI 10.1006/jmbi.2001.5320; SANDMEIER H, 1994, MOL MICROBIOL, V12, P343, DOI 10.1111/j.1365-2958.1994.tb01023.x	8	2	2	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 15	2002	295	5562					2031	2032		10.1126/science.1070586	http://dx.doi.org/10.1126/science.1070586			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	532AY	11896263				2022-12-28	WOS:000174450500033
J	Colman, E; Hedin, R; Swann, J; Orloff, D				Colman, E; Hedin, R; Swann, J; Orloff, D			A brief history of calcitonin	LANCET			English	Article							ESTABLISHED OSTEOPOROSIS; CALCIUM-METABOLISM; SALMON-CALCITONIN; TRIAL		US FDA, Div Metab & Endocrine Drug Prod, Ctr Drug Evaluat & Res, Rockville, MD 20857 USA; US FDA, Div Drug Risk Evaluat 1, Ctr Drug Evaluat & Res, Rockville, MD 20857 USA	US Food & Drug Administration (FDA); US Food & Drug Administration (FDA)	Colman, E (corresponding author), US FDA, Div Metab & Endocrine Drug Prod, Ctr Drug Evaluat & Res, 5600 Fishers Lane, Rockville, MD 20857 USA.	colmane@cder.fda.gov						CANIGGIA A, 1970, CLIN SCI, V38, P397, DOI 10.1042/cs0380397; Chesnut CH, 2000, AM J MED, V109, P267, DOI 10.1016/S0002-9343(00)00490-3; COHN SH, 1971, J CLIN ENDOCR METAB, V33, P719, DOI 10.1210/jcem-33-5-719; COPP DH, 1962, ENDOCRINOLOGY, V70, P638, DOI 10.1210/endo-70-5-638; Cummings SR, 2000, AM J MED, V109, P330, DOI 10.1016/S0002-9343(00)00539-8; *DEP HLTH HUM SERV, 1984, SUMM BAS APPR CALC N; FRIEDMAN J, 1965, SCIENCE, V150, P1465, DOI 10.1126/science.150.3702.1465; GRUBER HE, 1984, METABOLISM, V33, P295, DOI 10.1016/0026-0495(84)90187-2; *IMS HLTH, 2000, NAT PRES AUD PLUS; KANIS JA, 1992, BRIT MED J, V305, P1124, DOI 10.1136/bmj.305.6862.1124; KAPATANOS G, 1997, ACTA ORTHOP SCAND S, V275, P108; Klibanski A, 2001, JAMA-J AM MED ASSOC, V285, P785; *MED EC CO, 2001, PHYS DESK REF; OVERGAARD K, 1992, BRIT MED J, V305, P556, DOI 10.1136/bmj.305.6853.556; REGINSTER JY, 1995, AM J MED, V98, P452, DOI 10.1016/S0002-9343(99)80344-1	15	19	19	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 9	2002	359	9309					885	886		10.1016/S0140-6736(02)07949-7	http://dx.doi.org/10.1016/S0140-6736(02)07949-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	529YV	11897305				2022-12-28	WOS:000174329600033
J	Narlikar, GJ; Fan, HY; Kingston, RE				Narlikar, GJ; Fan, HY; Kingston, RE			Cooperation between complexes that regulate chromatin structure and transcription	CELL			English	Review							HISTONE DEACETYLASE COMPLEXES; TATA-BINDING PROTEIN; NUCLEOSOME MOBILIZATION; COVALENT MODIFICATIONS; REMODELING COMPLEXES; ORDERED RECRUITMENT; ACETYLATION; SWI/SNF; ISWI; ACETYLTRANSFERASE	Chromatin structure creates barriers for each step in eukaryotic transcription. Here we discuss how the activities of two major classes of chromatin-modifying complexes, ATIP-dependent remodeling complexes and HAT or HDAC complexes, might be coordinated to create a DNA template that is accessible to the general transcription apparatus.	Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Kingston, RE (corresponding author), Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.	kingston@frodo.mgh.harvard.edu						Aalfs JD, 2001, J BIOL CHEM, V276, P34270, DOI 10.1074/jbc.M104163200; Agalioti T, 2000, CELL, V103, P667, DOI 10.1016/S0092-8674(00)00169-0; Ahringer J, 2000, TRENDS GENET, V16, P351, DOI 10.1016/S0168-9525(00)02066-7; ALLFREY VG, 1964, P NATL ACAD SCI USA, V51, P786, DOI 10.1073/pnas.51.5.786; Anderson JD, 2001, J MOL BIOL, V307, P977, DOI 10.1006/jmbi.2001.4528; Barbaric S, 2001, EMBO J, V20, P4944, DOI 10.1093/emboj/20.17.4944; Berger SL, 2001, ONCOGENE, V20, P3007, DOI 10.1038/sj.onc.1204324; Boyer LA, 2000, J BIOL CHEM, V275, P18864, DOI 10.1074/jbc.M002810200; Brehm A, 2000, EMBO J, V19, P4332, DOI 10.1093/emboj/19.16.4332; Brown CE, 2001, SCIENCE, V292, P2333, DOI 10.1126/science.1060214; Brown CE, 2000, TRENDS BIOCHEM SCI, V25, P15, DOI 10.1016/S0968-0004(99)01516-9; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Burns LG, 1997, MOL CELL BIOL, V17, P4811, DOI 10.1128/MCB.17.8.4811; Clapier CR, 2001, MOL CELL BIOL, V21, P875, DOI 10.1128/MCB.21.3.875-883.2001; Cosma MP, 1999, CELL, V97, P299, DOI 10.1016/S0092-8674(00)80740-0; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; Deroo BJ, 2001, ONCOGENE, V20, P3039, DOI 10.1038/sj.onc.1204328; Deuring R, 2000, MOL CELL, V5, P355, DOI 10.1016/S1097-2765(00)80430-X; Dilworth FJ, 2000, MOL CELL, V6, P1049, DOI 10.1016/S1097-2765(00)00103-9; Dimova D, 1999, MOL CELL, V4, P75, DOI 10.1016/S1097-2765(00)80189-6; DiRenzo J, 2000, MOL CELL BIOL, V20, P7541, DOI 10.1128/MCB.20.20.7541-7549.2000; Fazzio TG, 2001, MOL CELL BIOL, V21, P6450, DOI 10.1128/MCB.21.19.6450-6460.2001; Gavin I, 2001, MOL CELL, V7, P97, DOI 10.1016/S1097-2765(01)00158-7; Goldmark JP, 2000, CELL, V103, P423, DOI 10.1016/S0092-8674(00)00134-3; Grant PA, 1999, J BIOL CHEM, V274, P5895, DOI 10.1074/jbc.274.9.5895; Guschin D, 2000, BIOCHEMISTRY-US, V39, P5238, DOI 10.1021/bi000421t; Guyon JR, 1999, MOL CELL BIOL, V19, P2088; Guyon JR, 2001, MOL CELL BIOL, V21, P1132, DOI 10.1128/MCB.21.4.1132-1144.2001; Hamiche A, 1999, CELL, V97, P833, DOI 10.1016/S0092-8674(00)80796-5; Hassan AH, 2001, FRONT BIOSCI, V6, pD1054, DOI 10.2741/Hassan; Hassan AH, 2001, CELL, V104, P817, DOI 10.1016/S0092-8674(01)00279-3; Havas K, 2000, CELL, V103, P1133, DOI 10.1016/S0092-8674(00)00215-4; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Ikeda K, 1999, MOL CELL BIOL, V19, P855; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; Ito T, 1999, GENE DEV, V13, P1529, DOI 10.1101/gad.13.12.1529; Jaskelioff M, 2000, MOL CELL BIOL, V20, P3058, DOI 10.1128/MCB.20.9.3058-3068.2000; Kehle J, 1998, SCIENCE, V282, P1897, DOI 10.1126/science.282.5395.1897; Khochbin S, 2001, CURR OPIN GENET DEV, V11, P162, DOI 10.1016/S0959-437X(00)00174-X; Kim J, 1999, IMMUNITY, V10, P345, DOI 10.1016/S1074-7613(00)80034-5; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; Krebs JE, 2000, CELL, V102, P587, DOI 10.1016/S0092-8674(00)00081-7; Krebs JE, 1999, GENE DEV, V13, P1412, DOI 10.1101/gad.13.11.1412; Kuo MH, 2000, MOL CELL, V6, P1309, DOI 10.1016/S1097-2765(00)00129-5; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; Langst G, 2001, MOL CELL, V8, P1085, DOI 10.1016/S1097-2765(01)00397-5; Langst G, 1999, CELL, V97, P843, DOI 10.1016/S0092-8674(00)80797-7; Langst G, 2001, J CELL SCI, V114, P2561; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; Lee KM, 1999, BIOCHEMISTRY-US, V38, P8423, DOI 10.1021/bi990090o; LEE MS, 1991, EMBO J, V10, P607, DOI 10.1002/j.1460-2075.1991.tb07988.x; Lemon B, 2001, NATURE, V414, P924, DOI 10.1038/414924a; Logie C, 1999, BIOCHEMISTRY-US, V38, P2514, DOI 10.1021/bi982109d; Lorch Y, 1999, CELL, V96, P389, DOI 10.1016/S0092-8674(00)80551-6; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; MEERSSEMAN G, 1992, EMBO J, V11, P2951, DOI 10.1002/j.1460-2075.1992.tb05365.x; Mizuguchi G, 2001, J BIOL CHEM, V276, P14773, DOI 10.1074/jbc.M100125200; Moazed D, 2001, MOL CELL, V8, P489, DOI 10.1016/S1097-2765(01)00340-9; Narlikar GJ, 2001, MOL CELL, V8, P1219, DOI 10.1016/S1097-2765(01)00412-9; Neely KE, 1999, MOL CELL, V4, P649, DOI 10.1016/S1097-2765(00)80216-6; Peterson CL, 2000, CURR OPIN GENET DEV, V10, P187, DOI 10.1016/S0959-437X(00)00068-X; Pollard KJ, 1997, MOL CELL BIOL, V17, P6212, DOI 10.1128/MCB.17.11.6212; Reid JL, 2000, MOL CELL, V6, P1297, DOI 10.1016/S1097-2765(00)00128-3; Roberts SM, 1997, GENETICS, V147, P451; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; Schnitzler GR, 2001, MOL CELL BIOL, V21, P8504, DOI 10.1128/MCB.21.24.8504-8511.2001; Schultz DC, 2001, GENE DEV, V15, P428, DOI 10.1101/gad.869501; Sewack GF, 2001, MOL CELL BIOL, V21, P1404, DOI 10.1128/MCB.21.4.1404-1415.2001; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Sif S, 2001, GENE DEV, V15, P603, DOI 10.1101/gad.872801; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; STUDITSKY VM, 1994, CELL, V76, P371, DOI 10.1016/0092-8674(94)90343-3; Sudarsanam P, 2000, P NATL ACAD SCI USA, V97, P3364, DOI 10.1073/pnas.050407197; Suka N, 2001, MOL CELL, V8, P473, DOI 10.1016/S1097-2765(01)00301-X; Sullivan EK, 2001, MOL CELL BIOL, V21, P5826, DOI 10.1128/MCB.21.17.5826-5837.2001; Syntichaki P, 2000, NATURE, V404, P414, DOI 10.1038/35006136; Tong JK, 1998, NATURE, V395, P917, DOI 10.1038/27699; Tse C, 1998, MOL CELL BIOL, V18, P4629, DOI 10.1128/MCB.18.8.4629; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; Vogelauer M, 2000, NATURE, V408, P495, DOI 10.1038/35044127; Wade PA, 1998, CURR BIOL, V8, P843, DOI 10.1016/S0960-9822(98)70328-8; Wang HB, 2001, NUCLEIC ACIDS RES, V29, P2517, DOI 10.1093/nar/29.12.2517; Whitehouse I, 1999, NATURE, V400, P784, DOI 10.1038/23506; WORKMAN JL, 1992, SCIENCE, V258, P1780, DOI 10.1126/science.1465613; Xiao H, 2001, MOL CELL, V8, P531, DOI 10.1016/S1097-2765(01)00345-8; Zhang HS, 2001, ONCOGENE, V20, P3134, DOI 10.1038/sj.onc.1204338; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4	88	1177	1237	2	125	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 22	2002	108	4					475	487		10.1016/S0092-8674(02)00654-2	http://dx.doi.org/10.1016/S0092-8674(02)00654-2			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	524XW	11909519	Bronze			2022-12-28	WOS:000174039000006
J	Drazen, JM				Drazen, JM			Perspective - Smallpox and bioterrorism	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material													Drazen, Jeffrey M/E-5841-2012	Drazen, Jeffrey/0000-0003-2715-9890					0	18	21	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 25	2002	346	17					1262	1263		10.1056/NEJM2e020038	http://dx.doi.org/10.1056/NEJM2e020038			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	544GX	11923485				2022-12-28	WOS:000175150800001
J	Johnson, E				Johnson, E			Phase of matter: The elusive liquid-solid interface	SCIENCE			English	Editorial Material							TRANSMISSION ELECTRON-MICROSCOPY; ALUMINUM; INCLUSIONS; AL		Univ Copenhagen, Niels Bohr Inst, Orsted Lab, DK-2100 Copenhagen O, Denmark	University of Copenhagen; Niels Bohr Institute	Johnson, E (corresponding author), Univ Copenhagen, Niels Bohr Inst, Orsted Lab, Univ Pk 5, DK-2100 Copenhagen O, Denmark.							Allen CW, 1999, J ELECTRON MICROSC, V48, P1025; Dahmen U, 1997, MRS BULL, V22, P49, DOI 10.1557/S0883769400033819; Donnelly SE, 2002, SCIENCE, V296, P507, DOI 10.1126/science.1068521; FRENKEN JWM, 1985, PHYS REV LETT, V54, P134, DOI 10.1103/PhysRevLett.54.134; GREY F, 1990, PHYS REV B, V41, P9519, DOI 10.1103/PhysRevB.41.9519; Howe JM, 1996, PHILOS MAG A, V74, P761, DOI 10.1080/01418619608243540; Huisman WJ, 1997, NATURE, V390, P379, DOI 10.1038/37069; Ishikawa N, 1997, NUCL INSTRUM METH B, V127, P123, DOI 10.1016/S0168-583X(96)00864-6; MIEDEMA AR, 1981, SOLID STATE COMMUN, V39, P1337, DOI 10.1016/0038-1098(81)90239-8; Porter D.A., 1992, PHASE TRANSFORMATION, P45; Reichert H, 2000, NATURE, V408, P839, DOI 10.1038/35048537; Sasaki K, 1997, MATER RES SOC SYMP P, V466, P185; STOLTZE P, 1988, PHYS REV LETT, V61, P440, DOI 10.1103/PhysRevLett.61.440; TEMPLIER C, 1985, MATER SCI ENG, V69, P63, DOI 10.1016/0025-5416(85)90373-8; VOMVELDE A, 1984, PHYS REV LETT, V53, P922; XIAO SQ, 1995, J MICROSC-OXFORD, V180, P61, DOI 10.1111/j.1365-2818.1995.tb03657.x	16	25	26	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 19	2002	296	5567					477	478		10.1126/science.1070400	http://dx.doi.org/10.1126/science.1070400			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	544UE	11910073				2022-12-28	WOS:000175179400028
J	Dent, THS; Sadler, M				Dent, THS; Sadler, M			From guidance to practice: Why NICE is not enough	BRITISH MEDICAL JOURNAL			English	Article									N & Mid Hampshire Hlth Author, Basingstoke RG24 9NB, Hants, England; NHS Direct Hampshire & Isle of Wight, Winchester SO22 5DH, Hants, England		Dent, THS (corresponding author), N & Mid Hampshire Hlth Author, Harness House, Basingstoke RG24 9NB, Hants, England.							[Anonymous], 1991, ASS EFF HLTH TECHN; BENTHAM P, 1998, OLD AGE PSYCHIAT, V12, P7; Best L, 1997, J CLIN EFFECT, V2, P51; BROWNE A, 2000, OBSERVER        1210; Dent THS, 1997, BMJ-BRIT MED J, V315, P1248, DOI 10.1136/bmj.315.7118.1248; HALL C, 2001, DAILY TELEGRAPH 0125; *NAT I CLIN EXC, 2001, WE COND TECHN APPR; *NAT I CLIN EXC, 2000, DRUGS ALZH DIS; *NAT I CLIN EXC, 2000, GUID US ZAN REL TRAT; NEWDICK C, 2001, HLTH SERVICE J, V111, P26; PAYNE N, 1999, CONTROLLING COSTS ST, P118; PITT FA, 1997, USE DONEPEZIL TREATM; *ROYAL COLL PHYS L, 2000, PRESCR COSTL MED; Sculpher M, 2001, BRIT MED J, V322, P943, DOI 10.1136/bmj.322.7292.943; Smith R, 2000, BRIT MED J, V321, P1363, DOI 10.1136/bmj.321.7273.1363; STEIN K, 1997, 69 DEC NHS EX S W; Walley T, 2000, BRIT MED J, V321, P1523, DOI 10.1136/bmj.321.7275.1523; 2001, DRUG THER B, V39, P9	18	34	35	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 6	2002	324	7341					842	845		10.1136/bmj.324.7341.842	http://dx.doi.org/10.1136/bmj.324.7341.842			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	540ZG	11934781	Green Published			2022-12-28	WOS:000174960300022
J	Fang, JC; Kinlay, S; Beltrame, J; Hikiti, H; Wainstein, M; Behrendt, D; Suh, J; Frei, B; Mudge, GH; Selwyn, AP; Ganz, P				Fang, JC; Kinlay, S; Beltrame, J; Hikiti, H; Wainstein, M; Behrendt, D; Suh, J; Frei, B; Mudge, GH; Selwyn, AP; Ganz, P			Effect of vitamins C and E on progression of transplant-associated arteriosclerosis: a randomised trial	LANCET			English	Article							CORONARY-ARTERY-DISEASE; INTRAVASCULAR ULTRASOUND; ALPHA-TOCOPHEROL; ENDOTHELIAL DYSFUNCTION; OXIDATIVE STRESS; ANTIOXIDANT; CHOLESTEROL; REJECTION; ACETYLCHOLINE; PRAVASTATIN	Background Cardiac transplantation is associated with oxidant stress, which may contribute to the development of accelerated coronary arteriosclerosis. We postulated that treatment with antioxidant vitamins C and E would retard the progression of transplant-associated arteriosclerosis. Methods In a double-blind prospective study, 40 patients (0-2 years after cardiac transplantation) were randomly assigned vitamin C 500 mg plus vitamin E 400 IU, each twice daily (n=19), or placebo (n=21) for 1 year. The primary endpoint was the change in average intimal index (plaque area divided by vessel area) measured by intravascular ultrasonography (IVUS). Coronary endothelium-dependent vasoreactivity was assessed with intracoronary acetylcholine infusions. IVUS, coronary vasoreactivity, and vitamin C and E plasma concentrations were assessed at baseline and at 1 year follow-up. All patients received pravastatin. Analyses were by intention to treat. Findings Vitamin C and E concentrations increased in the vitamin group (vitamin C 43 [SD 21] to 103 [43] mumol/L; vitamin E 24 [14] to 65 [27] mumol/L) but did not change in the placebo group (vitamin C 45 [15] vs 43 (16] mumol/L; vitamin E 27 [14] vs 27 [91 mumol/L; p<0.0001 for difference between groups). During 1 year of treatment, the intimal index increased in the placebo group by 8% (SE 2) but did not change significantly in the treatment group (0.8% [1]; p=0.008). Coronary endothelial function remained stable in both groups. Interpretation Supplementation with antoxidant vitamins C and E retards the early progression of transplant-associated coronary arteriosclerosis.	Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA; Oregon State Univ, Linus Pauling Inst, Corvallis, OR 97331 USA	Harvard University; Brigham & Women's Hospital; Oregon State University	Fang, JC (corresponding author), Brigham & Womens Hosp, Div Cardiovasc, 75 Francis St, Boston, MA 02115 USA.	jfang@partners.org	Wainstein, Marco Vugman/AAQ-1248-2020; Beltrame, John/C-1687-2017	Wainstein, Marco Vugman/0000-0002-7284-1453; Beltrame, John/0000-0002-4294-6510; Ganz, Peter/0000-0002-0437-8882	PHS HHS [H149954, H156170, P01 H148743] Funding Source: Medline; NCIRD CDC HHS [IP50 H156985] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NCIRD CDC HHS		Alexander R W, 1998, Trans Am Clin Climatol Assoc, V109, P129; ANDERSON TJ, 1993, CIRCULATION, V88, P1093, DOI 10.1161/01.CIR.88.3.1093; ANDERSON TJ, 1995, NEW ENGL J MED, V332, P488, DOI 10.1056/NEJM199502233320802; BILLINGHAM ME, 1990, PROG CARDIOVASC DIS, V33, P11, DOI 10.1016/0033-0620(90)90036-2; Bulkley GB, 1997, BIOCHEM SOC T, V25, P804, DOI 10.1042/bst0250804; Cai H, 2000, CIRC RES, V87, P840, DOI 10.1161/01.RES.87.10.840; Carr AC, 2000, CIRC RES, V87, P349, DOI 10.1161/01.RES.87.5.349; Davis SF, 1996, CIRCULATION, V93, P457, DOI 10.1161/01.CIR.93.3.457; Dupuis J, 1999, CIRCULATION, V99, P3227, DOI 10.1161/01.CIR.99.25.3227; EGASHIRA K, 1994, CIRCULATION, V89, P2519, DOI 10.1161/01.CIR.89.6.2519; Fang JC, 2000, AM J CARDIOL, V86, P460, DOI 10.1016/S0002-9149(00)00967-X; FISH RD, 1988, J CLIN INVEST, V81, P21, DOI 10.1172/JCI113297; Gerondakis S, 1998, CURR OPIN IMMUNOL, V10, P353, DOI 10.1016/S0952-7915(98)80175-1; Griendling KK, 2000, CIRC RES, V86, P494, DOI 10.1161/01.RES.86.5.494; Hancock WW, 1998, NAT MED, V4, P1392, DOI 10.1038/3982; Holvoet P, 2000, ARTERIOSCL THROM VAS, V20, P698, DOI 10.1161/01.ATV.20.3.698; Kapadia SR, 2000, J HEART LUNG TRANSPL, V19, P167, DOI 10.1016/S1053-2498(99)00128-X; Kinlay S, 1999, CIRCULATION, V100, P219, DOI 10.1161/01.CIR.100.3.219; Kobashigawa J, 2000, J HEART LUNG TRANSPL, V19, P546, DOI 10.1016/S1053-2498(00)00100-5; KOBASHIGAWA JA, 1995, NEW ENGL J MED, V333, P621, DOI 10.1056/NEJM199509073331003; Kunsch C, 1999, CIRC RES, V85, P753, DOI 10.1161/01.RES.85.8.753; LIBBY P, 1994, CLIN TRANSPLANT, V8, P313; LUDMER PL, 1986, NEW ENGL J MED, V315, P1046, DOI 10.1056/NEJM198610233151702; Nagano H, 1997, J CLIN INVEST, V100, P550, DOI 10.1172/JCI119564; Nissen SE, 2001, CIRCULATION, V103, P604, DOI 10.1161/01.CIR.103.4.604; Ohtsuka T, 1996, J BIOL CHEM, V271, P1651, DOI 10.1074/jbc.271.3.1651; Reul RM, 1997, TRANSPLANTATION, V64, P1765, DOI 10.1097/00007890-199712270-00025; SLAKEY D, 1993, TRANSPLANT P, V25, P610; TREASURE CB, 1992, CIRCULATION, V86, P1156, DOI 10.1161/01.CIR.86.4.1156; Valagussa F, 1999, LANCET, V354, P447, DOI 10.1016/S0140-6736(99)07072-5; Wenke K, 1997, CIRCULATION, V96, P1398, DOI 10.1161/01.CIR.96.5.1398; Williams A, 1999, FREE RADICAL RES, V30, P383, DOI 10.1080/10715769900300421; Yeung AC, 1995, J HEART LUNG TRANSPL, V14, pS215; Yusuf S, 2000, NEW ENGL J MED, V342, P154, DOI 10.1056/NEJM200001203420302	34	222	231	0	13	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 30	2002	359	9312					1108	1113		10.1016/S0140-6736(02)08154-0	http://dx.doi.org/10.1016/S0140-6736(02)08154-0			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	536YJ	11943259				2022-12-28	WOS:000174729200010
J	Green, RM; Cusotvic, A; Sanderson, G; Hunter, J; Johnston, SL; Woodcock, A				Green, RM; Cusotvic, A; Sanderson, G; Hunter, J; Johnston, SL; Woodcock, A			Synergism between allergens and viruses and risk of hospital admission with asthma: case-control study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							INDOOR ALLERGENS; EXPOSURE; SENSITIZATION; CHILDREN; EXACERBATIONS; INFLAMMATION; PURIFICATION; INFECTIONS; ANTIBODIES	Objective To investigate the importance of sensitisation and exposure to allergens and viral infection in precipitating acute asthma in adults resulting in admission to hospital. Design Case-control study. Setting Large district general hospital. Participants 60 patients aged 17-50 admitted to hospital over a year with acute asthma, matched with two controls: patients with stable asthma recruited from die outpatient department and patients admitted to hospital with non-respiratory conditions (inpatient controls). Main outcome measures Atopic status (skin testing and total and specific IgE), presence of common respiratory Viruses and atypical bacteria (polymerase chain reaction), dust samples from homes, and exposure to allergens (enzyme linked immunosorbent assay (ELISA): Der p 1, Fel d 1, Can f 1, and Bla g 2). Results Viruses were detected in 31 of 177 patients. The difference in the frequency of viruses detected between the groups was significant (admitted with asthma 26%, stable asthma 18%, inpatient controls 9%; P=0.04). A significantly higher proportion of patients admitted with asthma (66%) were sensitised and exposed to either mite, cat, or dog allergen than patients with stable asthma (37%) and inpatient controls (15%; P < 0.001). Being sensitised and exposed to allergens was all independent associate of the group admitted to hospital (odds ratio 2.3, 95% confidence interval 1.0 to 5.4; P=0.05), whereas the combination of sensitisation, high exposure to one or more allergens, and viral detection considerably increased the risk of being admitted with asthma (8.4, 2.1 to 32.8; P=0.002). Conclusions Allergens and viruses may act together to exacerbate asthma.	Wythenshawe Hosp, NW Lung Ctr, Manchester M23 9LT, Lancs, England; Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Dept Resp Med, London W2 1PG, England; Southampton Gen Hosp, Univ Med, Southampton SO9 6YD, Hants, England	Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital; Imperial College London; University of Southampton	Cusotvic, A (corresponding author), Wythenshawe Hosp, NW Lung Ctr, Manchester M23 9LT, Lancs, England.	acustovic@fs1.with.man.ac.uk	Johnston, Sebastian Lennox/I-2423-2012; Custovic, Adnan/A-2435-2012	Johnston, Sebastian Lennox/0000-0003-3009-9200; Custovic, Adnan/0000-0001-5218-7071; Woodcock, Ashley/0000-0002-5428-8578				Busse WW, 1997, J ALLERGY CLIN IMMUN, V100, P147, DOI 10.1016/S0091-6749(97)70216-1; CALHOUN WJ, 1994, J CLIN INVEST, V94, P2200, DOI 10.1172/JCI117581; Campbell MJ, 1997, BRIT MED J, V315, P1012, DOI 10.1136/bmj.315.7114.1012; CHAPMAN MD, 1988, J IMMUNOL, V140, P812; Chauhan AJ, 2001, LUNG BIOL HEALTH DIS, V154, P221; Custovic A, 1997, AM J RESP CRIT CARE, V155, P94, DOI 10.1164/ajrccm.155.1.9001295; Custovic A, 1996, J ALLERGY CLIN IMMUN, V98, P64, DOI 10.1016/S0091-6749(96)70227-0; DUFF AL, 1993, PEDIATRICS, V92, P535; FRAENKEL DJ, 1995, AM J RESP CRIT CARE, V151, P879; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573, DOI 10.1164/ajrccm/147.3.573; Grunberg K, 1997, AM J RESP CRIT CARE, V156, P609; INGRAM JM, 1995, J ALLERGY CLIN IMMUN, V96, P449, DOI 10.1016/S0091-6749(95)70286-5; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; Johnston SL, 1996, AM J RESP CRIT CARE, V154, P654, DOI 10.1164/ajrccm.154.3.8810601; LEMANSKE RF, 1989, J CLIN INVEST, V83, P1, DOI 10.1172/JCI113843; LUCZYNSKA CM, 1989, J IMMUNOL METHODS, V118, P227, DOI 10.1016/0022-1759(89)90010-0; MILLS TAE, 1997, J ALLERGY CLIN IMMUN, V100, pS1; *NAT ASTHM CAMP, 1999, NAT ASTHM AUD 1999 2, P12; NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982; POLLART SM, 1991, J ALLERGY CLIN IMMUN, V87, P511, DOI 10.1016/0091-6749(91)90010-L; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Simpson A, 1999, AM J RESP CRIT CARE, V160, P45, DOI 10.1164/ajrccm.160.1.9809091; Smith DH, 1997, AM J RESP CRIT CARE, V156, P787, DOI 10.1164/ajrccm.156.3.9611072; Tunnicliffe WS, 1999, EUR RESPIR J, V13, P654, DOI 10.1183/09031936.99.13365499	24	256	267	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 30	2002	324	7340					763	766A		10.1136/bmj.324.7340.763	http://dx.doi.org/10.1136/bmj.324.7340.763			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	538KY	11923159	Green Published, Bronze			2022-12-28	WOS:000174816200016
J	Munoz, N; Franceschi, S; Bosetti, C; Moreno, V; Herrero, R; Smith, JS; Shah, KV; Meijer, CJLM; Bosch, FX				Munoz, N; Franceschi, S; Bosetti, C; Moreno, V; Herrero, R; Smith, JS; Shah, KV; Meijer, CJLM; Bosch, FX		IARC Multicentr Cerv Canc Study Grp	Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study	LANCET			English	Article							CARCINOMA IN-SITU; RISK-FACTORS; INTRAEPITHELIAL NEOPLASIA; INFECTION; PREVALENCE; PREGNANCY; COLOMBIA; GRADE; SPAIN; WOMEN	Background High parity has long been suspected of being associated with an increased risk of cervical cancer, but previous analyses of this association have not taken the strong effect of human papillomavirus (HPV) into account. To assess the role of reproductive factors in the progression from HPV infection to cancer, we did a pooled analysis including only HPV-positive women. Methods We pooled data from eight case-control studies on invasive cervical carcinoma (ICC) and two on in-situ carcinoma (ISC) from four continents. 1465 patients with squamous-cell ICCs, 211 with ISCs, 124 with adenocarcinomas or adenosquamous ICCs, and 255 control women, all positive for HPV DNA by PCR-based assays, were analysed. We calculated pooled odds ratios by means of unconditional multiple logistic regression models, and adjusted them for sexual and non-sexual confounding factors. The 95% Cl were estimated by treating the odds ratio as floating absolute risk. Findings We found a direct association between the number of full-term pregnancies and squamous-cell cancer risk: the odds ratio for seven full-term pregnancies or more was 3.8 (95% Cl 2.7-5-5) compared with nulliparous women, and 2.3 (1.6-3.2) compared with women who had one or two full-term pregnancies. There was no significant association between risk of adenocarcinoma or adenosquamous carcinoma and number of full-term pregnancies. Interpretation High parity increases the risk of squamous-cell carcinoma of the cervix among HPV-positive women. A general decline in parity might therefore partly explain the reduction in cervical cancer recently seen in most countries.	Int Agcy Res Canc, Unit Field & Intervent Studies, F-69372 Lyon 08, France; Ist Ric Farmacol Mario Negri, Milan, Italy; Catalan Inst Oncol, Epidemiol & Canc Registry Serv, Barcelona, Spain; Costa Rica Canc Inst, San Jose, Costa Rica; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Baltimore, MD USA; Free Univ Amsterdam Hosp, Dept Pathol, Amsterdam, Netherlands	World Health Organization; International Agency for Research on Cancer (IARC); Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Catalan Institute of Oncology; Johns Hopkins University; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER	Munoz, N (corresponding author), Int Agcy Res Canc, Unit Field & Intervent Studies, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	munoz@iarc.fr	JOSÉ, FRANCESC XAVIER BOSCH/J-6339-2012; franceschi, silvia/M-2452-2014; Eluf-Neto, Jose/B-2522-2009; bosetti, cristina/AAA-6731-2020; Moreno, Victor/A-1697-2010; Pique, Xavier Castellsagué/N-5795-2014	JOSÉ, FRANCESC XAVIER BOSCH/0000-0002-7172-3412; franceschi, silvia/0000-0003-4181-8071; Eluf-Neto, Jose/0000-0001-7504-2115; bosetti, cristina/0000-0003-2090-4608; Moreno, Victor/0000-0002-2818-5487; Pique, Xavier Castellsagué/0000-0002-0802-3595				Autier P, 1996, BRIT J CANCER, V74, P488, DOI 10.1038/bjc.1996.388; BOSCH FX, 1993, CANCER EPIDEM BIOMAR, V2, P415; BOSCH FX, 1992, INT J CANCER, V52, P750, DOI 10.1002/ijc.2910520514; BOYD JT, 1964, BRIT J CANCER, V18, P419, DOI 10.1038/bjc.1964.49; Breslow N. E., 1980, IARC SCI PUBLICATION, V32; BRINTON LA, 1993, GYNECOL ONCOL, V51, P301, DOI 10.1006/gyno.1993.1294; BRINTON LA, 1989, AM J EPIDEMIOL, V130, P486, DOI 10.1093/oxfordjournals.aje.a115362; ChangClaude J, 1996, GYNECOL ONCOL, V60, P355, DOI 10.1006/gyno.1996.0055; Chaouki N, 1998, INT J CANCER, V75, P546, DOI 10.1002/(SICI)1097-0215(19980209)75:4&lt;546::AID-IJC9&gt;3.0.CO;2-T; Chichareon S, 1998, J NATL CANCER I, V90, P50, DOI 10.1093/jnci/90.1.50; Deacon JM, 2000, BRIT J CANCER, V83, P1565, DOI 10.1054/bjoc.2000.1523; EASTON DF, 1991, STAT MED, V10, P1025, DOI 10.1002/sim.4780100703; ELUFNETO J, 1994, BRIT J CANCER, V69, P114, DOI 10.1038/bjc.1994.18; HILDESHEIM A, 1994, J INFECT DIS, V169, P235, DOI 10.1093/infdis/169.2.235; Hildesheim A, 2001, BRIT J CANCER, V84, P1219, DOI 10.1054/bjoc.2001.1779; HUSMAN AMD, 1995, J MED VIROL, V46, P97, DOI 10.1002/jmv.1890460203; *INT AG RES CANC, 1995, MON EV CARC RISKS H, V64; JACOBS MV, 1995, J CLIN MICROBIOL, V33, P901, DOI 10.1128/JCM.33.4.901-905.1995; Kjellberg L, 2000, BRIT J CANCER, V82, P1332, DOI 10.1054/bjoc.1999.1100; Kruger-Kjaer S, 1998, INT J CANCER, V76, P613, DOI 10.1002/(SICI)1097-0215(19980529)76:5&lt;613::AID-IJC1&gt;3.0.CO;2-T; MANOS MM, 1989, CANCER CEL, V7, P209; Moreno V, 2002, LANCET, V359, P1085, DOI 10.1016/S0140-6736(02)08150-3; MORENO V, 1995, CANCER EPIDEM BIOMAR, V4, P459; MUKHERJEE BN, 1994, INT J CANCER, V59, P476, DOI 10.1002/ijc.2910590408; MUNOZ N, 1992, INT J CANCER, V52, P743, DOI 10.1002/ijc.2910520513; MUNOZ N, 1993, CANCER EPIDEM BIOMAR, V2, P423; Ngelangel C, 1998, JNCI-J NATL CANCER I, V90, P43, DOI 10.1093/jnci/90.1.43; Parazzini F, 1998, BRIT J CANCER, V77, P838, DOI 10.1038/bjc.1998.136; Rolon PA, 2000, INT J CANCER, V85, P486, DOI 10.1002/(SICI)1097-0215(20000215)85:4&lt;486::AID-IJC7&gt;3.0.CO;2-S; Santos C, 2001, BRIT J CANCER, V85, P966, DOI 10.1054/bjoc.2001.1948; SCHNEIDER A, 1987, INT J CANCER, V40, P198, DOI 10.1002/ijc.2910400212; SINGER A, 1975, BRIT J OBSTET GYNAEC, V82, P81, DOI 10.1111/j.1471-0528.1975.tb02204.x; Smith FR, 1931, AM J OBSTET GYNECOL, V21, P18, DOI 10.1016/S0002-9378(31)90837-5; Vizcaino AP, 2000, INT J CANCER, V86, P429, DOI 10.1002/(SICI)1097-0215(20000501)86:3<429::AID-IJC20>3.0.CO;2-D; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F	35	364	397	1	17	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 30	2002	359	9312					1093	1101		10.1016/S0140-6736(02)08151-5	http://dx.doi.org/10.1016/S0140-6736(02)08151-5			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	536YJ	11943256				2022-12-28	WOS:000174729200007
J	Humphrey, D; Duggan, C; Saha, D; Smith, D; Kas, J				Humphrey, D; Duggan, C; Saha, D; Smith, D; Kas, J			Active fluidization of polymer networks through molecular motors	NATURE			English	Article							F-ACTIN; MYOSIN; FILAMENTS; MINIFILAMENTS; REPTATION; DYNAMICS; INVITRO; CHAIN	Entangled polymer solutions and melts exhibit elastic, solid-like resistance to quick deformations and a viscous, fluid-like response to slow deformations. This viscoelastic behaviour reflects the dynamics of individual polymer chains driven by brownian motion(1) : since individual chains can only move in a snake-like fashion through the mesh of surrounding polymer molecules, their diffusive transport, described by reptation(2-4),is so slow that the relaxation of suddenly imposed stress is delayed. Entangled polymer solutions and melts therefore elastically resist deforming motions that occur faster than the stress relaxation time. Here we show that the protein myosin II permits active control over the viscoelastic behaviour of actin filament solutions. We find that when each actin filament in a polymerized actin solution interacts with at least one myosin minifilament, the stress relaxation time of the polymer solution is significantly shortened. We attribute this effect to myosin's action as a 'molecular motor', which allows it to interact with randomly oriented actin filaments and push them through the solution, thus enhancing longitudinal filament motion. By superseding reptation with sliding motion, the molecular motors thus overcome a fundamental principle of complex fluids: that only depolymerization makes an entangled, isotropic polymer solution fluid for quick deformations.	Univ Texas, Ctr Nonlinear Dynam, Austin, TX 78712 USA; Univ Texas, Inst Mol & Cellular Biol, Austin, TX 78712 USA; Univ Texas, Texas Mat Inst, Austin, TX 78712 USA; Univ Texas, Ctr Nano & Mol Sci, Austin, TX 78712 USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin	Kas, J (corresponding author), Univ Texas, Ctr Nonlinear Dynam, Austin, TX 78712 USA.	kas@chaos.ph.utexas.edu		Kas, Josef A./0000-0003-3158-2480				ADELSTEIN RS, 1963, BIOCHEM BIOPH RES CO, V12, P34, DOI 10.1016/0006-291X(63)90409-1; Bray D., 1992, CELL MOVEMENTS; DEGENNES PG, 1971, J CHEM PHYS, V55, P572, DOI 10.1063/1.1675789; Doi M., 1988, THEORY POLYM DYNAMIC; Gupta R.K., 2000, POLYM COMPOSITE RHEO; HONDA H, 1986, J MOL BIOL, V191, P131, DOI 10.1016/0022-2836(86)90428-6; Isambert H, 1996, MACROMOLECULES, V29, P1036, DOI 10.1021/ma946418x; KAS J, 1994, NATURE, V368, P226, DOI 10.1038/368226a0; Kas J, 1996, BIOPHYS J, V70, P609, DOI 10.1016/S0006-3495(96)79630-3; KRON SJ, 1986, P NATL ACAD SCI USA, V83, P6272, DOI 10.1073/pnas.83.17.6272; Liverpool TB, 2001, PHYS REV LETT, V86, P4171, DOI 10.1103/PhysRevLett.86.4171; MACLEANFLETCHER SD, 1980, J CELL BIOL, V85, P414, DOI 10.1083/jcb.85.2.414; MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55; Morse DC, 1998, MACROMOLECULES, V31, P7044, DOI 10.1021/ma980304u; Nedelec FJ, 1997, NATURE, V389, P305, DOI 10.1038/38532; NIEDERMAN R, 1975, J CELL BIOL, V67, P72, DOI 10.1083/jcb.67.1.72; PERKINS TT, 1994, SCIENCE, V264, P819, DOI 10.1126/science.8171335; REISLER E, 1980, J MOL BIOL, V143, P129, DOI 10.1016/0022-2836(80)90127-8; SINARD JH, 1990, J BIOL CHEM, V265, P3654; Straub FB., 1943, STUDIES I MED CHEM U, VIII, P23; Taylor D L, 1979, Int Rev Cytol, V56, P57, DOI 10.1016/S0074-7696(08)61821-5; Verkhovsky AB, 1999, BIOCHEM SOC SYMP, V65, P207; WACHSSTOCK DH, 1994, BIOPHYS J, V66, P801, DOI 10.1016/S0006-3495(94)80856-2	23	242	246	1	63	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 28	2002	416	6879					413	416		10.1038/416413	http://dx.doi.org/10.1038/416413			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	534UX	11919627				2022-12-28	WOS:000174607800042
J	Peters, SE; Foote, M				Peters, SE; Foote, M			Determinants of extinction in the fossil record	NATURE			English	Article							MASS EXTINCTIONS; DIVERSITY; EVOLUTION	The causes of mass extinctions and the nature of biological selectivity at extinction events are central questions in palaeobiology. It has long been recognized, however, that the amount of sedimentary rock available for sampling may bias perceptions of biodiversity(1-7) and estimates of taxonomic rates of evolution(5-8). This problem has been particularly noted with respect to the principal mass extinctions(5-12). Here we use a new compilation of the amount of exposed marine sedimentary rock to predict how the observed fossil record of extinction would appear if the time series of true extinction rates were in fact smooth. Many features of the highly variable record of apparent extinction rates within marine animals can be predicted on the basis of temporal variation in the amount of exposed rock. Although this result is consistent with the possibility that a common geological cause determines both true extinction rates and the amount of exposed rock, it also supports the hypothesis that much of the observed short-term volatility in extinction rates is an artefact of variability in the stratigraphic record.	Univ Chicago, Dept Geophys Sci, Chicago, IL 60637 USA	University of Chicago	Peters, SE (corresponding author), Univ Chicago, Dept Geophys Sci, 5734 S Ellis Ave, Chicago, IL 60637 USA.	sepeters@midway.uchicago.edu	Peters, Shanan E/A-5620-2013	Peters, Shanan E/0000-0002-3346-4317				Alroy J, 2001, P NATL ACAD SCI USA, V98, P6261, DOI 10.1073/pnas.111144698; ALVAREZ LW, 1980, SCIENCE, V208, P1095, DOI 10.1126/science.208.4448.1095; BECKER L, 2001, SCIENCE, V287, P443; Bowring S.A., 1998, GSA TODAY, V8, P1; Foote M, 2001, PALEOBIOLOGY, V27, P602, DOI 10.1666/0094-8373(2001)027<0602:ITPOPO>2.0.CO;2; Foote M, 2000, PALEOBIOLOGY, V26, P74, DOI 10.1666/0094-8373(2000)26[74:OAECOT]2.0.CO;2; FORTEY RA, 1989, PHILOS T ROY SOC B, V325, P327, DOI 10.1098/rstb.1989.0092; GOLONKA J, 2002, SEPM SPECIAL PUBLICA, V27, P11; Hallam A, 1999, EARTH-SCI REV, V48, P217, DOI 10.1016/S0012-8252(99)00055-0; HOLLAND SM, 1995, PALEOBIOLOGY, V21, P92, DOI 10.1017/S0094837300013099; Holland SM, 2000, PALEOBIOLOGY, V26, P148, DOI 10.1666/0094-8373(2000)26[148:TQOTFR]2.0.CO;2; JOHNSON J G, 1974, Geology (Boulder), V2, P479, DOI 10.1130/0091-7613(1974)2<479:EOPF>2.0.CO;2; KEROHER GC, 1967, US GEOL SURV B, V1200, P1; MACLEOD N, 1991, GEOLOGY, V19, P497, DOI 10.1130/0091-7613(1991)019<0497:HDAMEA>2.3.CO;2; Miller AI, 1996, PALEOBIOLOGY, V22, P304, DOI 10.1017/S0094837300016237; Miller AI, 2000, PALEOBIOLOGY, V26, P53, DOI 10.1666/0094-8373(2000)26[53:CAPGD]2.0.CO;2; PATTERSON C, 1987, NATURE, V330, P248, DOI 10.1038/330248a0; PEASE CM, 1988, J THEOR BIOL, V130, P1, DOI 10.1016/S0022-5193(88)80160-7; Peters SE, 2001, PALEOBIOLOGY, V27, P583, DOI 10.1666/0094-8373(2001)027<0583:BITPAR>2.0.CO;2; RAUP D M, 1976, Paleobiology, V2, P289; RAUP DM, 1992, PALEOBIOLOGY, V18, P80, DOI 10.1017/S0094837300012227; RAUP DM, 1978, PALEOBIOLOGY, V4, P1; RAUP DM, 1972, SCIENCE, V177, P1065, DOI 10.1126/science.177.4054.1065; RAUP DM, 1982, SCIENCE, V215, P1501, DOI 10.1126/science.215.4539.1501; Ross CA, 1995, MAR MICROPALEONTOL, V26, P469, DOI 10.1016/0377-8398(95)00010-0; Sepkoski J.J., 1996, GLOBAL EVENT STRATIG, P35, DOI [10.1007/978-3-642-79634-0_4, DOI 10.1007/978-3-642-79634-0_4]; Smith AB, 2001, PALEOBIOLOGY, V27, P241, DOI 10.1666/0094-8373(2001)027<0241:SLCARR>2.0.CO;2; Smith AB, 2001, PHILOS T R SOC B, V356, P351, DOI 10.1098/rstb.2000.0768; SMITH AB, 1988, EVOL BIOL, V23, P127, DOI DOI 10.1007/978-1-4613-1043-3_; VANVALEN LM, 1984, NATURE, V307, P50, DOI 10.1038/307050a0	30	144	149	1	66	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 28	2002	416	6879					420	424		10.1038/416420a	http://dx.doi.org/10.1038/416420a			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	534UX	11919629				2022-12-28	WOS:000174607800044
J	Schlitt, HJ				Schlitt, HJ			Paid non-related living organ donation: Horn of Plenty or Pandora's box?	LANCET			English	Editorial Material							DONORS		Hannover Med Sch, D-30623 Hannover, Germany	Hannover Medical School	Schlitt, HJ (corresponding author), Hannover Med Sch, D-30623 Hannover, Germany.		Schlitt, Hans J./ABG-4368-2020					Cameron JS, 1999, KIDNEY INT, V55, P724, DOI 10.1046/j.1523-1755.1999.00286.x; Matas AJ, 2000, NEW ENGL J MED, V343, P433, DOI 10.1056/NEJM200008103430611; Radcliffe-Richards J, 1998, LANCET, V351, P1950, DOI 10.1016/S0140-6736(97)08211-1; SHEIL R, 1995, TRANSPLANT SOC B, V3, P3; World Health Organization (WHO), 1992, REP DEV AUSP WHO 198, P12	5	17	17	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 16	2002	359	9310					906	907		10.1016/S0140-6736(02)08014-5	http://dx.doi.org/10.1016/S0140-6736(02)08014-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	531AE	11918904				2022-12-28	WOS:000174391700004
J	Dye, C; Williams, BG; Espinal, MA; Raviglione, MC				Dye, C; Williams, BG; Espinal, MA; Raviglione, MC			Erasing the world's slow stain: Strategies to beat muttidrug-resistant tuberculosis	SCIENCE			English	Review							SHORT-COURSE CHEMOTHERAPY; DRUG-RESISTANT; MYCOBACTERIUM-TUBERCULOSIS; MOLECULAR EPIDEMIOLOGY; BEIJING GENOTYPE; TRANSMISSION; NETHERLANDS; NATIONWIDE; DYNAMICS; OUTBREAK	Multidrug-resistant tuberculosis (MDR) is perceived as a growing hazard to human health worldwide. Judgments about the true scale of the problem, and strategies for containing it, need to come from a balanced appraisal of the epidemiological evidence. We conclude in this review that MDR is, and will probably remain, a locally severe problem; that epidemics can be prevented by fully exploiting the potential of standard short-course chemotherapy (SCC) based on cheap and safe first-line drugs; and that best-practice SCC may even reduce the incidence of MDR where it has already become endemic. On the basis of the available, imperfect data, we recommend a three-part response to the threat of MDR: widespread implementation of SCC as the cornerstone of good tuberculosis control, improved resistance testing and surveillance, and the careful introduction of second-line drugs after a sound evaluation of cost, effectiveness, and feasibility.	WHO, CH-1211 Geneva 27, Switzerland	World Health Organization	Dye, C (corresponding author), WHO, CH-1211 Geneva 27, Switzerland.	dyec@who.int	Dye, Christopher/AIC-4659-2022	Dye, Christopher/0000-0002-2957-1793; RAVIGLIONE, Mario/0000-0002-9331-2067; Williams, Brian/0000-0002-3174-4876				Agerton TB, 1999, CLIN INFECT DIS, V29, P85, DOI 10.1086/520187; Anh DD, 2000, EMERG INFECT DIS, V6, P302; [Anonymous], 1998, MMWR Recomm Rep, V47, P1; Becerra MC, 2000, INT J TUBERC LUNG D, V4, P108; BLOWER SM, 1995, NAT MED, V1, P815, DOI 10.1038/nm0895-815; Blower SM, 1996, SCIENCE, V273, P497, DOI 10.1126/science.273.5274.497; Borgdorff MW, 1998, AM J EPIDEMIOL, V147, P187; Cohn DL, 1997, CLIN INFECT DIS, V24, pS121, DOI 10.1093/clinids/24.Supplement_1.S121; CORBETT EL, UNPUB; Crofton J., 1997, WHOTB96210; Davies J, 1996, NATURE, V383, P219, DOI 10.1038/383219a0; DYE C, 2001, R R SOC LONDON B, V268, P45; DYE C, IN PRESS J INFECT DI; Espinal MA, 2000, JAMA-J AM MED ASSOC, V283, P2537, DOI 10.1001/jama.283.19.2537; Espinal MA, 2001, NEW ENGL J MED, V344, P1294, DOI 10.1056/NEJM200104263441706; Espinal MA, 1999, INT J TUBERC LUNG D, V3, P561; Espinal MA, 2001, INT J TUBERC LUNG D, V5, P887; Farmer P, 1998, BRIT MED J, V317, P671, DOI 10.1136/bmj.317.7159.671; Frieden TR, 1996, JAMA-J AM MED ASSOC, V276, P1229, DOI 10.1001/jama.276.15.1229; Garcia-Garcia MD, 2000, ARCH INTERN MED, V160, P630, DOI 10.1001/archinte.160.5.630; Girardi E, 2000, AIDS, V14, pS47; Godfrey-Faussett P, 2000, LANCET, V356, P1066, DOI 10.1016/S0140-6736(00)02730-6; Gupta R, 2001, SCIENCE, V293, P1049, DOI 10.1126/science.1061861; Hong YP, 2000, INT J TUBERC LUNG D, V4, P911; Kam KM, 2001, INT J TUBERC LUNG D, V5, P815; Kruuner A, 2001, J CLIN MICROBIOL, V39, P3339, DOI 10.1128/JCM.39.9.3339-3345.2001; Laserson KF, 2000, INT J TUBERC LUNG D, V4, P673; MAHMOUDI A, 1993, JAMA-J AM MED ASSOC, V270, P65, DOI 10.1001/jama.270.1.65; McCray E, 2000, RESURG EMERGING INFE, V1, P45; Narayanan PR, 2001, INT J TUBERC LUNG D, V5, P40; *NAT TUB I, 1974, B WORLD HEALTH ORGAN, V51, P473; ORDWAY DJ, 1995, INFECT IMMUN, V63, P741, DOI 10.1128/IAI.63.2.741-743.1995; Prodinger WM, 2001, EMERG INFECT DIS, V7, P483, DOI 10.3201/eid0703.017330; SHELLEY PB, 1997, REPRESENTATIVE POETR; SNIDER DE, 1985, AM REV RESPIR DIS, V132, P125; Sonnenberg P, 2000, LANCET, V356, P1930, DOI 10.1016/S0140-6736(05)73482-6; Sreevatsan S, 1997, P NATL ACAD SCI USA, V94, P9869, DOI 10.1073/pnas.94.18.9869; SUAREZ PG, IN PRESS LANCET; Tahaoglu K, 2001, NEW ENGL J MED, V345, P170, DOI 10.1056/NEJM200107193450303; Takiff HE, 2000, RESURG EMERGING INFE, V1, P77; Teixeira L, 2001, INT J TUBERC LUNG D, V5, P321; van Crevel R, 2001, EMERG INFECT DIS, V7, P880; Van Rie A, 2001, J CLIN MICROBIOL, V39, P636, DOI 10.1128/JCM.39.2.636-641.2001; van Soolingen D, 1999, J INFECT DIS, V180, P726, DOI 10.1086/314930; van Soolingen D, 2001, J INTERN MED, V249, P1, DOI 10.1046/j.1365-2796.2001.00772.x; VANDHELDEN P, UNPUB; VANSOOLINGEN D, UNPUB; Vernon A, 1999, LANCET, V353, P1843, DOI 10.1016/S0140-6736(98)11467-8; Vynnycky E, 1998, EPIDEMIOL INFECT, V121, P309, DOI 10.1017/S0950268898001113; WHO, 2000, ANT DRUG RES WORLD; *WHO, 2001, GLOB TUB CONTR	51	255	272	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 15	2002	295	5562					2042	2046		10.1126/science.1063814	http://dx.doi.org/10.1126/science.1063814			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	532AY	11896268				2022-12-28	WOS:000174450500038
J	Chan-Tack, KM				Chan-Tack, KM			Boerhaave's syndrome	LANCET			English	Editorial Material									Univ Missouri, Dept Med, Columbia, MO 65212 USA	University of Missouri System; University of Missouri Columbia	Chan-Tack, KM (corresponding author), Univ Missouri, Dept Med, Columbia, MO 65212 USA.								0	2	2	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 9	2002	359	9309					823	823		10.1016/S0140-6736(02)07951-5	http://dx.doi.org/10.1016/S0140-6736(02)07951-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	529YV	11897279	Bronze			2022-12-28	WOS:000174329600007
J	Davidson, JRT; Gadde, KM; Fairbank, JA; Krishnan, RR; Califf, RM; Binanay, C; Parker, CB; Pugh, N; Hartwell, TD; Vitiello, B; Ritz, L; Severe, J; Cole, JO; de Battista, C; Doraiswamy, PM; Feighner, JP; Keck, P; Kelsey, J; Lin, KM; Londborg, PD; Nemeroff, CB; Schatzberg, AF; Sheehan, DV; Srivastava, RK; Taylor, L; Trivedi, MH; Weisler, RH				Davidson, JRT; Gadde, KM; Fairbank, JA; Krishnan, RR; Califf, RM; Binanay, C; Parker, CB; Pugh, N; Hartwell, TD; Vitiello, B; Ritz, L; Severe, J; Cole, JO; de Battista, C; Doraiswamy, PM; Feighner, JP; Keck, P; Kelsey, J; Lin, KM; Londborg, PD; Nemeroff, CB; Schatzberg, AF; Sheehan, DV; Srivastava, RK; Taylor, L; Trivedi, MH; Weisler, RH		Hypericum Depression Trial Study G	Effect of Hypericum perforatum (St John's wort) in major depressive disorder - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DOUBLE-BLIND; PLACEBO; EFFICACY; SERTRALINE; EXTRACT; AMITRIPTYLINE; METAANALYSIS; MULTICENTER; FLUOXETINE; IMIPRAMINE	Context Extracts of Hypericum perforatum (St John's wort) are widely used for the treatment of depression of varying severity. Their efficacy in major depressive disorder, however, has not been conclusively demonstrated. Objective To test the efficacy and safety of a well-characterized H perforatum extract (L1-160) in major depressive disorder. Design and Setting Double-blind, randomized, placebo-controlled trial conducted in 12 academic and community psychiatric research clinics in the United States. Participants Adult outpatients (n=340) recruited between December 1998 and June 2000 with major depression and a baseline total score on the Hamilton Depression Scale (HAM-D) of at least 20. Interventions Patients were randomly assigned to receive H perforatum, placebo, or sertraline (as an active comparator) for 8 weeks. Based on clinical response, the daily dose of H perforatum could range from 900 to 1500 mg and that of sertraline from 50 to 100 mg. Responders at week 8 could continue blinded treatment for another 18 weeks. Main Outcome Measures Change in the HAM-D total score from baseline to 8 weeks; rates of full response, determined by the HAM-D and Clinical Global Impressions (CGI) scores. Results On the 2 primary outcome measures, neither sertraline nor H perforatum was significantly different from placebo. The random regression parameter estimate for mean (SE) change in HAM-D total score from baseline to week 8 (with a greater decline indicating more improvement) was-9.20 (0.67) (95% confidence interval [CI], -10.51 to -7.89) for placebo vs -8.68 (0.68) (95% CI, -10.01 to -7.35) for H perforatum (P=.59) and -10.53 (0.72) (95% CI, -11.94 to -9.12) for sertraline (P=.18). Full response occurred in 31.9% of the placebo-treated patients vs 23.9% of the H perforatum-treated patients (P=.21) and 24.8% of sertraline-treated patients (P=.26). Sertraline was better than placebo on the CGI improvement scale (P=.02), which was a secondary measure in this study. Adverse-effect profiles for H perforatum and sertraline differed relative to placebo. Conclusion This study fails to support the efficacy of H perforatum in moderately severe major depression. The result may be due to low assay sensitivity of the trial, but the complete absence of trends suggestive of efficacy for H perforatum is noteworthy.	Duke Univ, Med Ctr, Coordinating Ctr, Durham, NC 27710 USA; Res Triangle Inst, Res Triangle Pk, NC 27709 USA; NIMH, Bethesda, MD 20892 USA; Harvard Univ, McLean Hosp, Sch Med, Belmont, MA 02178 USA; Stanford Univ, Palo Alto, CA 94304 USA; Duke Univ, Med Ctr, Durham, NC 27708 USA; Feighner Res Inst, San Diego, CA USA; Univ Cincinnati, Cincinnati, OH 45221 USA; Emory Univ, Sch Med, Atlanta, GA 30303 USA; Univ Calif Los Angeles, Los Angeles, CA 90024 USA; Summit Res Network, Seattle, WA USA; Univ S Florida, Tampa, FL 33612 USA; Eastside Comprehens Med Serv, New York, NY USA; Dean Fdn, Madison, WI USA; Univ Wisconsin, Madison, WI 53706 USA; Univ Texas, SW Med Ctr, Dallas, TX 75235 USA	Duke University; Research Triangle Institute; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); Harvard University; McLean Hospital; Stanford University; Duke University; University System of Ohio; University of Cincinnati; Emory University; University of California System; University of California Los Angeles; State University System of Florida; University of South Florida; University of Wisconsin System; University of Wisconsin Madison; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Davidson, JRT (corresponding author), Duke Univ, Med Ctr, Coordinating Ctr, Box 3812, Durham, NC 27710 USA.	jonathan.davidson@duke.edu	Trivedi, Madhukar/A-9029-2013; Vitiello, Benedetto/AAC-1758-2022; Fairbank, John/F-8972-2013; Gadde, Kishore/N-1963-2017; Sheehan, David V/L-6879-2013	Trivedi, Madhukar/0000-0002-2983-1110; Fairbank, John/0000-0003-2604-7256; Gadde, Kishore/0000-0002-1856-5574; Nemeroff, Charles/0000-0001-7867-1160; Parker, Corette/0000-0002-6822-6845; Pugh, Norma/0000-0003-3052-2232; Sheehan, David V/0000-0002-5118-7050	NIMH NIH HHS [N01MH70007] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [N01MH070007] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; Bech P, 2000, BRIT J PSYCHIAT, V176, P421, DOI 10.1192/bjp.176.5.421; Beck A., 1993, BECK DEPRESSION INVE; BROCKMOELLER J, 1997, PHARMACOPSYCHIATRY, V30, P102; Connor K M, 2001, CNS Spectr, V6, P850; FABRE LF, 1995, BIOL PSYCHIAT, V38, P592, DOI 10.1016/0006-3223(95)00178-8; First M. B., 1997, STRUCTURED CLIN INTE; Guy W., 1976, PUBLICATION ADM, V76-338; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; Kalb R, 2001, PHARMACOPSYCHIATRY, V34, P96, DOI 10.1055/s-2001-14280; Khan A, 2000, ARCH GEN PSYCHIAT, V57, P311, DOI 10.1001/archpsyc.57.4.311; Laakmann G, 1998, PHARMACOPSYCHIATRY, V31, P54, DOI 10.1055/s-2007-979346; Linde K, 1996, BRIT MED J, V313, P253, DOI 10.1136/bmj.313.7052.253; Lydiard RB, 1997, J CLIN PSYCHIAT, V58, P484, DOI 10.4088/JCP.v58n1104; Moncrieff J, 1998, BRIT J PSYCHIAT, V172, P227, DOI 10.1192/bjp.172.3.227; Montgomery SA, 1999, EUR NEUROPSYCHOPHARM, V9, P271, DOI 10.1016/S0924-977X(98)00050-9; Montgomery SA, 2000, PHYTOMEDICINE S11, V7, P7; MORRIS JB, 1974, ARCH GEN PSYCHIAT, V30, P667; Philipp M, 1999, BRIT MED J, V319, P1534, DOI 10.1136/bmj.319.7224.1534; Piscitelli SC, 2000, LANCET, V355, P547, DOI 10.1016/S0140-6736(99)05712-8; REIMHERR FW, 1990, J CLIN PSYCHIAT, V51, P18; Robinson DS, 2000, J CLIN PSYCHOPHARM, V20, P593, DOI 10.1097/00004714-200012000-00001; Ruschitzka F, 2000, LANCET, V355, P548, DOI 10.1016/S0140-6736(99)05467-7; Schrader E, 2000, INT CLIN PSYCHOPHARM, V15, P61, DOI 10.1097/00004850-200015020-00001; Schweizer E, 2001, INT CLIN PSYCHOPHARM, V16, P137, DOI 10.1097/00004850-200105000-00002; Sheehan DV, 1996, INT CLIN PSYCHOPHARM, V11, P89, DOI 10.1097/00004850-199606003-00015; Shelton RC, 2001, JAMA-J AM MED ASSOC, V285, P1978, DOI 10.1001/jama.285.15.1978; Suri RA, 2000, J CLIN PSYCHIAT, V61, P942, DOI 10.4088/JCP.v61n1209; Vorbach EU, 1997, PHARMACOPSYCHIATRY, V30, P81, DOI 10.1055/s-2007-979524; Wagner H, 1994, J Geriatr Psychiatry Neurol, V7 Suppl 1, pS65, DOI 10.1177/089198879400700118; Wheatley D, 1997, PHARMACOPSYCHIATRY, V30, P77, DOI 10.1055/s-2007-979523; Woelk H, 2000, BMJ-BRIT MED J, V321, P536, DOI 10.1136/bmj.321.7260.536; Wonnemann M, 2000, NEUROPSYCHOPHARMACOL, V23, P188, DOI 10.1016/S0893-133X(00)00102-0	33	327	329	1	37	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 10	2002	287	14					1807	1814						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	539QJ	11939866	Bronze			2022-12-28	WOS:000174881700033
J	Kusumoto, FM; Goldschlager, N				Kusumoto, FM; Goldschlager, N			Device therapy for cardiac arrhythmias	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY; IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR; RANDOMIZED-TRIAL; HEART-FAILURE; RISK; PACEMAKER; DISEASE; ATRIAL		Lovelace Med Ctr, Dept Med, Div Cardiol, Electrophysiol & Pacing Serv, Albuquerque, NM 87108 USA; Univ New Mexico, Div Cardiol, Albuquerque, NM 87131 USA; Univ Calif San Francisco, San Francisco Gen Hosp, Dept Med, Div Cardiol, San Francisco, CA USA	University of New Mexico; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco	Kusumoto, FM (corresponding author), Lovelace Med Ctr, Dept Med, Div Cardiol, Electrophysiol & Pacing Serv, 5400 Gibson Blvd SE, Albuquerque, NM 87108 USA.	fred.kusumoto@lovelace.com						ABRAHAM WT, 2001, AM COLL CARD M MARCH; Andersen HR, 1997, LANCET, V350, P1210, DOI 10.1016/S0140-6736(97)03425-9; Atlee JL, 2001, ANESTHESIOLOGY, V95, P1265, DOI 10.1097/00000542-200111000-00034; Bernstein AD, 2001, PACE, V24, P842, DOI 10.1046/j.1460-9592.2001.00842.x; Buxton AE, 1999, NEW ENGL J MED, V341, P1882, DOI 10.1056/NEJM199912163412503; Buxton AE, 2000, NEW ENGL J MED, V342, P1937, DOI 10.1056/NEJM200006293422602; Cazeau S, 2001, NEW ENGL J MED, V344, P873, DOI 10.1056/NEJM200103223441202; Connolly SJ, 1999, J AM COLL CARDIOL, V33, P16, DOI 10.1016/S0735-1097(98)00549-X; Connolly SJ, 2000, CIRCULATION, V101, P1297, DOI 10.1161/01.CIR.101.11.1297; FANANAPAZIR L, 1994, CIRCULATION, V90, P2731, DOI 10.1161/01.CIR.90.6.2731; Gregoratos G, 1998, J AM COLL CARDIOL, V31, P1175; Kappenberger L, 1997, EUR HEART J, V18, P1249; Kenny RAM, 2001, J AM COLL CARDIOL, V38, P1491, DOI 10.1016/S0735-1097(01)01537-6; LAMAS G, 2001, N AM SOC PAC EL M MA; Maron BJ, 1999, CIRCULATION, V99, P2927, DOI 10.1161/01.CIR.99.22.2927; McAnulty J, 1997, NEW ENGL J MED, V337, P1576; Moss AJ, 1996, NEW ENGL J MED, V335, P1933, DOI 10.1056/NEJM199612263352601; Moss AJ, 2002, NEW ENGL J MED, V346, P877, DOI 10.1056/NEJMoa013474; Olshansky B, 2001, CARDIAC PACING FOR THE CLINICIAN, P397; SAKSENA S, 2001, AM COLL CARD M MARCH; Sanders GD, 2001, ANN INTERN MED, V135, P870, DOI 10.7326/0003-4819-135-10-200111200-00007; Skanes AC, 2001, J AM COLL CARDIOL, V38, P167, DOI 10.1016/S0735-1097(01)01326-2; Stellbrink C, 1999, AM J CARDIOL, V83, p143D; Sutton R, 2000, CIRCULATION, V102, P294; Toff WD, 1997, HEART, V78, P221, DOI 10.1136/hrt.78.3.221	25	20	20	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 10	2002	287	14					1848	1852		10.1001/jama.287.14.1848	http://dx.doi.org/10.1001/jama.287.14.1848			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	539QJ	11939871				2022-12-28	WOS:000174881700038
J	Bustamante, CD; Nielsen, R; Sawyer, SA; Olsen, KM; Purugganan, MD; Hartl, DL				Bustamante, CD; Nielsen, R; Sawyer, SA; Olsen, KM; Purugganan, MD; Hartl, DL			The cost of inbreeding in Arabidopsis	NATURE			English	Article							SELECTION; POLYMORPHISM; POPULATIONS; DIVERGENCE; DROSOPHILA; PATTERNS; MUTATION; THALIANA; LOCUS	Population geneticists have long sought to estimate the distribution of selection intensities among genes of diverse function across the genome. Only recently have DNA sequencing and analytical techniques converged to make this possible. Important advances have come from comparing genetic variation within species (polymorphism) with fixed differences between species (divergence)(1,2). These approaches have been used to examine individual genes for evidence of selection. Here we use the fact that the time since species divergence allows combination of data across genes. In a comparison of amino-acid replacements among species of the mustard weed Arabidopsis with those among species of the fruitfly Drosophila, we find evidence for predominantly beneficial gene substitutions in Drosophila but predominantly detrimental substitutions in Arabidopsis. We attribute this difference to the Arabidopsis mating system of partial self-fertilization, which corroborates a prediction of population genetics theory(3-6) that species with a high frequency of inbreeding are less efficient in eliminating deleterious mutations owing to their reduced effective population size.	Harvard Univ, Dept Organism & Evolutionary Biol, Cambridge, MA 02138 USA; Cornell Univ, Dept Biometr, Ithaca, NY 14853 USA; Washington Univ, Dept Math, St Louis, MO 63130 USA; N Carolina State Univ, Dept Genet, Raleigh, NC 27695 USA	Harvard University; Cornell University; Washington University (WUSTL); University of North Carolina; North Carolina State University	Hartl, DL (corresponding author), Harvard Univ, Dept Organism & Evolutionary Biol, 16 Divin Ave, Cambridge, MA 02138 USA.		Nielsen, Rasmus/D-4405-2009	Nielsen, Rasmus/0000-0003-0513-6591; Olsen, Kenneth/0000-0002-8338-3638; Bustamante, Carlos D./0000-0002-4187-7920				ABBOTT RJ, 1989, HEREDITY, V62, P411, DOI 10.1038/hdy.1989.56; AKASHI H, 1995, GENETICS, V139, P1067; Caballero A, 1995, GENET RES, V66, P213, DOI 10.1017/S0016672300034662; CACCONE A, 1988, GENETICS, V118, P671; CHARLESWORTH D, 1993, J HERED, V84, P321, DOI 10.1093/oxfordjournals.jhered.a111351; Gelman A, 1997, BAYESIAN DATA ANAL; Gelman A., 1992, STAT SCI, V7, P457, DOI [10.1214/ss/1177011136, DOI 10.1214/SS/1177011136]; GEMAN S, 1984, IEEE T PATTERN ANAL, V6, P721, DOI 10.1109/TPAMI.1984.4767596; Gilks R, 1996, MARKOV CHAIN MONTE C; HARTL DL, 1994, GENETICS, V138, P227; KONDRASHOV AS, 1994, GENETICS, V136, P1469; Kusaba M, 2001, PLANT CELL, V13, P627, DOI 10.1105/tpc.13.3.627; MCDONALD JH, 1991, NATURE, V351, P652, DOI 10.1038/351652a0; METROPOLIS N, 1953, J CHEM PHYS, V21, P1087, DOI 10.1063/1.1699114; Savolainen O, 2000, MOL BIOL EVOL, V17, P645, DOI 10.1093/oxfordjournals.molbev.a026343; SAWYER SA, 1992, GENETICS, V132, P1161; Wang JL, 1999, GENET RES, V74, P165, DOI 10.1017/S0016672399003900; [No title captured]	18	241	242	0	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 4	2002	416	6880					531	534		10.1038/416531a	http://dx.doi.org/10.1038/416531a			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	537JY	11932744				2022-12-28	WOS:000174756500042
J	Gendreau, MA; DeJohn, C				Gendreau, MA; DeJohn, C			Current concepts - Responding to medical events during commercial airline flights	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CARDIAC-ARREST; AIR-QUALITY; EMERGENCIES; AIRCRAFT; TRAVEL; TUBERCULOSIS; OUTBREAK		Lahey Clin Fdn, Dept Emergency Med, Burlington, MA 01805 USA; FAA, Civil Aerosp Med Inst, Oklahoma City, OK USA	Lahey Hospital & Medical Center	Gendreau, MA (corresponding author), Lahey Clin Fdn, Dept Emergency Med, 41 Mall Rd, Burlington, MA 01805 USA.	mgndru@massmed.org						*AER MED ASS, 1997, MED GUID AIRL TRAV; *AIR TRANSP ASS, 1997, AIR TRANSP ASS MED I; Alexander J K, 1995, Cardiol Clin, V13, P271; AMLER RW, 1982, JAMA-J AM MED ASSOC, V248, P2129, DOI 10.1001/jama.248.17.2129; [Anonymous], 1976, MMWR MORB MORTAL WKL, V25, P317; *AV CONS PROT DIV, 2001, FACT SHEET STEPS TAK; BARRY M, 1989, JAMA-J AM MED ASSOC, V261, P728, DOI 10.1001/jama.261.5.728; Bettes TN, 1999, AM FAM PHYSICIAN, V60, P801; BLUMEN IJ, 1992, CRIT CARE CLIN, V8, P597, DOI 10.1016/S0749-0704(18)30243-4; Cheatham ML, 1999, AM SURGEON, V65, P1160; COLWELL C, 1999, PHYSICIANS WKLY, V16; *CONS UN, 1999, SEEING RED AIR RAG, V15, P15; COTTRELL JJ, 1988, CHEST, V93, P81, DOI 10.1378/chest.93.1.81; CREWDSON J, 1998, CHICAGO TRIBUNE 1122; CUMMINS RO, 1988, JAMA-J AM MED ASSOC, V260, P3668; CUMMINS RO, 1989, JAMA-J AM MED ASSOC, V261, P1295, DOI 10.1001/jama.261.9.1295; *DAN, 2002, DIV AL NETW; DAVIES GRW, 1982, AVIAT SPACE ENVIR MD, V53, P694; DEJOHN CA, 2000, DOTFAAAM0013 FED AV; Donaldson E, 1996, AUST NZ J SURG, V66, P431, DOI 10.1111/j.1445-2197.1996.tb00777.x; Dowdall N, 2000, BRIT MED J, V321, P1336, DOI 10.1136/bmj.321.7272.1336; EberhartPhillips J, 1997, EPIDEMIOL INFECT, V118, P79, DOI 10.1017/S095026889600948X; GILMORE A, 1989, CAN MED ASSOC J, V140, P197; GONG H, 1992, CHEST, V101, P1104, DOI 10.1378/chest.101.4.1104; Goodwin T, 2000, BRIT MED J, V321, P1338, DOI 10.1136/bmj.321.7272.1338; Han HM, 2000, AVIAT SPACE ENV MED, V71, P330; HARDING RM, 1993, AVIATION MED, P30; HEDBERG CW, 1992, JAMA-J AM MED ASSOC, V268, P3208, DOI 10.1001/jama.268.22.3208; Hedouin V, 1998, Med Law, V17, P503; Hocking MB, 1998, AM IND HYG ASSOC J, V59, P446, DOI 10.1080/15428119891010181; Hocking MB, 2000, CHEMOSPHERE, V41, P603, DOI 10.1016/S0045-6535(99)00537-8; HORDINSKY JR, 1991, DOTFAAAM912 FED AV A; Kenyon TA, 1996, NEW ENGL J MED, V334, P933, DOI 10.1056/NEJM199604113341501; Kovac C, 1999, BRIT MED J, V318, P12; KUKJIAN S, 2001, BOSTON GLOBE    1223, pA1; Lien D, 1998, Can Respir J, V5, P95; Lyznicki JM, 2000, AVIAT SPACE ENVIR MD, V71, P832; MCKENAS DK, 2000, AVIATION TODAY   MAR; MOSER MR, 1979, AM J EPIDEMIOL, V110, P1; NewsonSmith MS, 1997, AVIAT SPACE ENVIR MD, V68, P1134; ORourke MF, 1997, CIRCULATION, V96, P2849, DOI 10.1161/01.CIR.96.9.2849; Page RL, 2000, NEW ENGL J MED, V343, P1210, DOI 10.1056/NEJM200010263431702; Parmet AJ, 1999, AVIAT SPACE ENVIR MD, V70, P817; Rayman RB, 1997, AVIAT SPACE ENVIR MD, V68, P432; Rayman RB, 1998, AVIAT SPACE ENVIR MD, V69, P1007; Robertson RM, 2000, NEW ENGL J MED, V343, P1259, DOI 10.1056/NEJM200010263431709; Rosenberg Craig A., 1997, Journal of Emergency Medicine, V15, P159, DOI 10.1016/S0736-4679(96)00314-9; SCHWARTZ GB, 1982, JAMA-J AM MED ASSOC, V247, P1007; *SEL COMM SCI TECH, 2000, 5 SEL COMM SCI TECH; SKJENNA OW, 1991, CAN MED ASSOC J, V144, P287; SPEIZER C, 1989, ANN EMERG MED, V18, P26, DOI 10.1016/S0196-0644(89)80306-3; Thibeault C, 1997, AVIAT SPACE ENVIR MD, V68, P80; *US HOUS REPR SUBC, 1997, MED KITS COMM AIRL; WALLACE WA, 1995, BRIT MED J, V311, P374, DOI 10.1136/bmj.311.7001.374; WICK RL, 1995, AVIAT SPACE ENVIR MD, V66, P220; 2001, CABIN CREW SAFET NOV; 2001, MMWR MORB MORTAL WKL, V50, P485; 1999, BMJ, V318, P672; 1998, CABIN AIR SAFETY OCT	59	117	119	1	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 4	2002	346	14					1067	1073		10.1056/NEJMra012774	http://dx.doi.org/10.1056/NEJMra012774			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	536YL	11932475				2022-12-28	WOS:000174729400008
J	Judson, H; Hayward, BE; Sheridan, E; Bonthron, DT				Judson, H; Hayward, BE; Sheridan, E; Bonthron, DT			A global disorder of imprinting in the human female germ line	NATURE			English	Article							BECKWITH-WIEDEMANN-SYNDROME; METHYLATED CPG ISLAND; HYDATIDIFORM MOLE; SNRPN GENE; LOCUS; TRANSCRIPT; ESTABLISHMENT; PROTEINS; PATTERN; DEFINE	Imprinted genes are expressed differently depending on whether they are carried by a chromosome of maternal or paternal origin. Correct imprinting is established by germline-specific modifications; failure of this process underlies several inherited human syndromes(1-5). All these imprinting control defects are cis-acting, disrupting establishment or maintenance of allele-specific epigenetic modifications across one contiguous segment of the genome. In contrast, we report here an inherited global imprinting defect. This recessive maternal-effect mutation disrupts the specification of imprints at multiple, non-contiguous loci, with the result that genes normally carrying a maternal methylation imprint assume a paternal epigenetic pattern on the maternal allele. The resulting conception is phenotypically indistinguishable from an androgenetic complete hydatidiform mole(6),in which abnormal extra-embryonic tissue proliferates while development of the embryo is absent or nearly so. This disorder offers a genetic route to the identification of trans-acting oocyte factors that mediate maternal imprint establishment.	Univ Leeds, St Jamess Univ Hosp, Mol Med Unit, Leeds LS9 7TF, W Yorkshire, England	Saint James's University Hospital; University of Leeds	Bonthron, DT (corresponding author), Univ Leeds, St Jamess Univ Hosp, Mol Med Unit, Leeds LS9 7TF, W Yorkshire, England.	d.t.bonthron@leeds.ac.uk		Bonthron, David/0000-0001-8132-8179				Bourc'his D, 2001, SCIENCE, V294, P2536, DOI 10.1126/science.1065848; BUITING K, 1995, NAT GENET, V9, P395, DOI 10.1038/ng0495-395; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; El-Maarri O, 2001, NAT GENET, V27, P341, DOI 10.1038/85927; Engemann S, 2000, HUM MOL GENET, V9, P2691, DOI 10.1093/hmg/9.18.2691; Fisher RA, 2000, HUM REPROD, V15, P594, DOI 10.1093/humrep/15.3.594; Gardner RJ, 2000, HUM MOL GENET, V9, P589, DOI 10.1093/hmg/9.4.589; Hayward BE, 2000, HUM MOL GENET, V9, P835, DOI 10.1093/hmg/9.5.835; Hayward BE, 1998, P NATL ACAD SCI USA, V95, P15475, DOI 10.1073/pnas.95.26.15475; Hayward BE, 1998, P NATL ACAD SCI USA, V95, P10038, DOI 10.1073/pnas.95.17.10038; Helwani MN, 1999, HUM GENET, V105, P112, DOI 10.1007/s004390051071; KAJII T, 1977, NATURE, V268, P633, DOI 10.1038/268633a0; Kamiya M, 2000, HUM MOL GENET, V9, P453, DOI 10.1093/hmg/9.3.453; KANEKOISHINO T, 1995, NAT GENET, V11, P52, DOI 10.1038/ng0995-52; Kerjean A, 2000, HUM MOL GENET, V9, P2183, DOI 10.1093/hmg/9.14.2183; Lee MP, 1999, P NATL ACAD SCI USA, V96, P5203, DOI 10.1073/pnas.96.9.5203; Liu J, 2000, MOL CELL BIOL, V20, P5808, DOI 10.1128/MCB.20.16.5808-5817.2000; Liu J, 2000, J CLIN INVEST, V106, P1167, DOI 10.1172/JCI10431; Moglabey YB, 1999, HUM MOL GENET, V8, P667, DOI 10.1093/hmg/8.4.667; Murphy SK, 2001, GENOMICS, V71, P110, DOI 10.1006/geno.2000.6419; Ohta T, 1999, AM J HUM GENET, V64, P397, DOI 10.1086/302233; REIK W, 1995, HUM MOL GENET, V4, P2379, DOI 10.1093/hmg/4.12.2379; Reik W, 2001, NAT GENET, V27, P255, DOI 10.1038/85804; Shemer R, 1997, P NATL ACAD SCI USA, V94, P10267, DOI 10.1073/pnas.94.19.10267; Smilinich NJ, 1999, P NATL ACAD SCI USA, V96, P8064, DOI 10.1073/pnas.96.14.8064; STRAIN L, 1995, NAT GENET, V11, P164, DOI 10.1038/ng1095-164; SUTCLIFFE JS, 1994, NAT GENET, V8, P52, DOI 10.1038/ng0994-52	27	167	173	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 4	2002	416	6880					539	542		10.1038/416539a	http://dx.doi.org/10.1038/416539a			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	537JY	11932746	Green Accepted			2022-12-28	WOS:000174756500044
J	Rubin, MA; Zhou, M; Dhanasekaran, SM; Varambally, S; Barrette, TR; Sanda, MG; Pienta, KJ; Ghosh, D; Chinnaiyan, AM				Rubin, MA; Zhou, M; Dhanasekaran, SM; Varambally, S; Barrette, TR; Sanda, MG; Pienta, KJ; Ghosh, D; Chinnaiyan, AM			alpha-methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DIGITAL RECTAL EXAMINATION; COA RACEMASE; MOLECULAR CLASSIFICATION; ANTIBODY 34-BETA-E12; DIAGNOSIS; ANTIGEN; CYTOKERATIN; CARCINOMA; SPECIMENS; GENETICS	Context Molecular profiling of prostate cancer has led to the identification of candidate biomarkers and regulatory genes. Discoveries from these genome-scale approaches may have applicability in the analysis of diagnostic prostate specimens. Objectives To determine the expression and clinical utility of a-methylacyl coenzyme A racemase (AMACR), a gene identified as being overexpressed in prostate cancer by global profiling strategies. Design Four gene expression data sets from independent DNA microarray analyses were examined to identify genes expressed in prostate cancer (n = 128 specimens). A lead candidate gene, AMACR, was validated at the transcript level by reverse transcriptase polymerase chain reaction (RT-PCR) and at the protein level by immunoblot and immunohistochemical analysis. AMACR levels were examined using prostate cancer tissue microarrays in 342 samples representing different stages of prostate cancer progression. Protein expression was characterized as negative (score=1), weak (2), moderate (3), or strong (4). Clinical utility of AMACR was evaluated using 94 prostate needle biopsy specimens. Main Outcome Measures Messenger RNA transcript and protein levels of AMACR; sensitivity and specificity of AMACR as a tissue biomarker for prostate cancer in needle biopsy specimens. Results Three of 4 independent DNA microarray analyses (n = 128 specimens) revealed significant overexpression of AMACR in prostate cancer (P<.001). AMACR upregulation in prostate cancer was confirmed by both RT-PCR and immunoblot analysis. Immunohistochemical analysis demonstrated an increased expression of AMACR in malignant prostate epithelia relative to benign epithelia. Tissue microarrays to assess AMACR expression in specimens consisting of benign prostate (n = 108 samples), atrophic prostate (n = 26), prostatic intraepithelial neoplasia (n=75), localized prostate cancer (n = 116), and metastatic prostate cancer (n = 17) demonstrated mean AMACR protein staining intensity of 1.31 (95% confidence interval, 1.23-1.40), 2.33 (95% Cl, 2.13-2.52), 2.67 (95% Cl, 2.52-2.81), 3.20 (95% Cl, 3.10-3.28), and 2.50 (95% Cl, 2.20-2.80), respectively (P<.001). Pairwise comparisons demonstrated significant differences in staining intensity between clinically localized prostate cancer compared with benign prostate tissue, with mean expression scores of 3.2 and 1.3, respectively (mean difference, 1.9; 95% Cl, 1.7-2.1; P<.001). Using moderate or strong staining intensity as positive (score=3 or 4), evaluation of AMACR protein expression in 94 prostate needle biopsy specimens demonstrated 97% sensitivity and 100% specificity for detecting prostate cancer. Conclusions AMACR was shown to be overexpressed in prostate cancer using independent experimental methods and prostate cancer specimens. AMACR may be useful in the interpretation of prostate needle biopsy specimens that are diagnostically challenging.	Univ Michigan, Dept Pathol, Sch Med, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Urol, Sch Med, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Internal Med, Sch Med, Ann Arbor, MI 48109 USA; Univ Michigan, Ctr Comprehens Canc, Sch Med, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Rubin, MA (corresponding author), Univ Michigan, Dept Pathol, Sch Med, 1301 Catherine Rd, Ann Arbor, MI 48109 USA.		Sanda, Martin G/B-2023-2015; Sanda, Martin G/A-6202-2013; Pienta, Kenneth/E-7679-2015	Dhanasekaran, saravana mohan/0000-0002-0489-2224; Rubin, Mark/0000-0002-8321-9950; Varambally, Sooryanarayana/0000-0002-2277-1127; Pienta, Kenneth/0000-0002-4138-2186; Ghosh, Debashis/0000-0001-6618-1316	NCI NIH HHS [P50 CA69568] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA069568] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abate-Shen C, 2000, GENE DEV, V14, P2410, DOI 10.1101/gad.819500; Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Bittner M, 2000, NATURE, V406, P536, DOI 10.1038/35020115; Bostwick D G, 1999, Semin Urol Oncol, V17, P222; CATALONA WJ, 1994, J UROLOGY, V151, P1283, DOI 10.1016/S0022-5347(17)35233-3; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Epstein JI, 2001, J UROLOGY, V166, P402, DOI 10.1016/S0022-5347(05)65953-8; Etzioni R, 1999, J NATL CANCER I, V91, P1033, DOI 10.1093/jnci/91.12.1033; Ferdinandusse S, 2000, J LIPID RES, V41, P1890; Ferdinandusse S, 2001, J LIPID RES, V42, P137; Ferdinandusse S, 2000, NAT GENET, V24, P188, DOI 10.1038/72861; GLEASON DF, 1992, HUM PATHOL, V23, P273, DOI 10.1016/0046-8177(92)90108-F; Gleason DF, 1977, UROLOGIC PATHOLOGY P, P171; GLEASON DONALD F., 1966, CANCER CHEMO THERAP REP, V50, P125; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Googe PB, 1997, AM J CLIN PATHOL, V107, P219, DOI 10.1093/ajcp/107.2.219; Hedges LV, 2014, STAT METHODS META AN; Hollenbeck BK, 2000, J UROLOGY, V164, P1583, DOI 10.1016/S0022-5347(05)67033-4; JACOBSEN SJ, 1995, JAMA-J AM MED ASSOC, V274, P1445, DOI 10.1001/jama.274.18.1445; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Kotti TJ, 2000, J BIOL CHEM, V275, P20887, DOI 10.1074/jbc.M002067200; Liotta L, 2000, NAT REV GENET, V1, P48, DOI 10.1038/35049567; Luo J, 2001, CANCER RES, V61, P4683; Maattanen L, 1999, BRIT J CANCER, V79, P1210, DOI 10.1038/sj.bjc.6690194; Magee JA, 2001, CANCER RES, V61, P5692; Manley S, 2001, AM J PATHOL, V159, P837, DOI 10.1016/S0002-9440(10)61759-2; OMALLEY FP, 1990, VIRCHOWS ARCH A, V417, P191, DOI 10.1007/BF01600133; Parsons JK, 2001, UROLOGY, V58, P619, DOI 10.1016/S0090-4295(01)01311-5; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Perrone EE, 2000, JNCI-J NATL CANCER I, V92, P937, DOI 10.1093/jnci/92.11.937; Putzi MJ, 2000, UROLOGY, V56, P828, DOI 10.1016/S0090-4295(00)00776-7; Rubin MA, 2000, CLIN CANCER RES, V6, P1038; Ruijter E, 1999, ENDOCR REV, V20, P22, DOI 10.1210/er.20.1.22; Scheffe H, 1959, ANAL VARIANCE; Schroder FH, 1998, JNCI-J NATL CANCER I, V90, P1817, DOI 10.1093/jnci/90.23.1817; Shah R, 2001, AM J PATHOL, V158, P1767, DOI 10.1016/S0002-9440(10)64132-6; Signoretti S, 2000, AM J PATHOL, V157, P1769, DOI 10.1016/S0002-9440(10)64814-6; Sreekumar A, 2001, CANCER RES, V61, P7585; Welsh JB, 2001, CANCER RES, V61, P5974; WOJNO KJ, 1995, AM J SURG PATHOL, V19, P251, DOI 10.1097/00000478-199503000-00002	41	518	575	0	38	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 3	2002	287	13					1662	1670		10.1001/jama.287.13.1662	http://dx.doi.org/10.1001/jama.287.13.1662			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	536YW	11926890	Bronze			2022-12-28	WOS:000174730300020
J	Moreno, V; Bosch, FX; Munoz, N; Meijer, CJLM; Shah, DV; Valboomers, JMM; Herrero, R; Franceschi, S				Moreno, V; Bosch, FX; Munoz, N; Meijer, CJLM; Shah, DV; Valboomers, JMM; Herrero, R; Franceschi, S		IARC Multicentric Cervical Canc St	Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study	LANCET			English	Article							CARCINOMA IN-SITU; NEOPLASIA; GENOTYPES; COLOMBIA; GRADE; SPAIN	Background Use of oral contraceptives could increase risk of cervical cancer; however the effect of human papillomavirus (HPV), the main cause of cervical cancer, is not usually taken into account. We aimed to assess how use of oral contraceptives affected risk of cervical cancer in women who tested positive for HPV DNA. Methods We pooled data from eight case-control studies of patients with histologically confirmed invasive cervical carcinoma (ICC) and from two studies of patients with carcinoma in situ (ISC). Information about use of oral contraceptives was obtained from personal interviews. Effects were estimated as odds ratios, with logistic-regression models adjusted for possible confounders. Findings 1465 of 1561 (94%) patients with ICC, 211 of 292 (72%) with ISC, and 255 of 1916 (13%) controls were positive for HPV DNA. Compared with never-users, patients who had used oral contraceptives for fewer than 5 years did: not have increased risk of cervical cancer (odds ratio 0.73; 95% CI 0.52-1-03). The odds ratio for use of oral contraceptives was 2.82 (95% Cl 1.46-5-42) for 5-9 years, and 4.03 (2.09-8.02) for use for 10 years or longer, and these risks did not vary by time since first or last use. Interpretation Long-term use of oral contraceptives could be a cofactor that increases risk of cervical carcinoma by up to four-fold in women who are positive for cervical HPV DNA. In the absence of worldwide information about HPV status, extra effort should be made to include long-term users of oral contraceptives in cervical screening programmes.	Hosp Duran & Reynals, Catalan Inst Oncol, Epidemiol & Canc Registry Serv, Barcelona 08903, Spain; Int Agcy Res Canc, Unit Field & Intervent Studies, F-69372 Lyon, France; Free Univ Amsterdam Hosp, Amsterdam, Netherlands; Johns Hopkins Univ, Baltimore, MD USA; Costa Rica Canc Inst, San Jose, Costa Rica	Catalan Institute of Oncology; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Hospital Duran i Reynals; World Health Organization; International Agency for Research on Cancer (IARC); Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Johns Hopkins University	Moreno, V (corresponding author), Hosp Duran & Reynals, Catalan Inst Oncol, Epidemiol & Canc Registry Serv, Gran Via Km 2-7, Barcelona 08903, Spain.	v.moreno@ico.scs.es	Moreno, Victor/A-1697-2010; JOSÉ, FRANCESC XAVIER BOSCH/J-6339-2012; Pique, Xavier Castellsagué/N-5795-2014; franceschi, silvia/M-2452-2014; Eluf-Neto, Jose/B-2522-2009	Moreno, Victor/0000-0002-2818-5487; JOSÉ, FRANCESC XAVIER BOSCH/0000-0002-7172-3412; Pique, Xavier Castellsagué/0000-0002-0802-3595; franceschi, silvia/0000-0003-4181-8071; Eluf-Neto, Jose/0000-0001-7504-2115				Beral V, 1999, BRIT MED J, V318, P96, DOI 10.1136/bmj.318.7176.96; BOSCH FX, 1993, CANCER EPIDEM BIOMAR, V2, P415; BOSCH FX, 1992, INT J CANCER, V52, P750, DOI 10.1002/ijc.2910520514; BOSCH FX, 1995, JNCI-J NATL CANCER I, V87, P796, DOI 10.1093/jnci/87.11.796; Chaouki N, 1998, INT J CANCER, V75, P546, DOI 10.1002/(SICI)1097-0215(19980209)75:4&lt;546::AID-IJC9&gt;3.0.CO;2-T; Chichareon S, 1998, J NATL CANCER I, V90, P50, DOI 10.1093/jnci/90.1.50; Deacon JM, 2000, BRIT J CANCER, V83, P1565, DOI 10.1054/bjoc.2000.1523; DELGADORODRIGUEZ M, 1992, ACTA OBSTET GYN SCAN, V71, P368, DOI 10.3109/00016349209021075; EASTON DF, 1991, STAT MED, V10, P1025, DOI 10.1002/sim.4780100703; ELUFNETO J, 1994, BRIT J CANCER, V69, P114, DOI 10.1038/bjc.1994.18; Franco EL, 1999, JNCI-J NATL CANCER I, V91, P506, DOI 10.1093/jnci/91.6.506; HILDESHEIM A, 1994, J INFECT DIS, V169, P235, DOI 10.1093/infdis/169.2.235; HUSMAN AMD, 1994, INT J CANCER, V56, P802, DOI 10.1002/ijc.2910560607; *INT AG RES CANC, 1999, IARC MON EV CARC RIS, V72; JACOBS MV, 1995, J CLIN MICROBIOL, V33, P901, DOI 10.1128/JCM.33.4.901-905.1995; Kataria, 2016, SAUDI J SPORTS MED, V16, P139; Kruger-Kjaer S, 1998, INT J CANCER, V76, P613, DOI 10.1002/(SICI)1097-0215(19980529)76:5&lt;613::AID-IJC1&gt;3.0.CO;2-T; Lacey JV, 1999, CANCER EPIDEM BIOMAR, V8, P1079; LAVECCHIA C, 1994, CONTRACEPTION, V49, P223; MANOS MM, 1989, CANCER CEL, V7, P209; MORENO V, 1995, CANCER EPIDEM BIOMAR, V4, P459; MUNOZ N, 1992, INT J CANCER, V52, P743, DOI 10.1002/ijc.2910520513; MUNOZ N, 1993, CANCER EPIDEM BIOMAR, V2, P423; NEGRINI BP, 1994, CANCER RES, V30, P4670; Ngelangel C, 1998, JNCI-J NATL CANCER I, V90, P43, DOI 10.1093/jnci/90.1.43; Rolon PA, 2000, INT J CANCER, V85, P486, DOI 10.1002/(SICI)1097-0215(20000215)85:4&lt;486::AID-IJC7&gt;3.0.CO;2-S; Santos C, 2001, BRIT J CANCER, V85, P966, DOI 10.1054/bjoc.2001.1948; SWAN SH, 1982, AM J EPIDEMIOL, V115, P10, DOI 10.1093/oxfordjournals.aje.a113264; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; WALBOOMERS JMM, 1992, DIAGNOSTIC MOL PATHO, P152	30	406	442	2	31	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 30	2002	359	9312					1085	1092		10.1016/S0140-6736(02)08150-3	http://dx.doi.org/10.1016/S0140-6736(02)08150-3			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	536YJ	11943255				2022-12-28	WOS:000174729200006
J	Veronesi, U; Maisonneuve, P; Sacchini, V; Rotmensz, N; Boyle, P				Veronesi, U; Maisonneuve, P; Sacchini, V; Rotmensz, N; Boyle, P		Italian Tamoxifen Study Grp	Tamoxifen for breast cancer among hysterectomised women	LANCET			English	Article							PREVENTION; TRIAL	Tamoxifen is a candidate drug for prevention of breast cancer, although findings from trials have not been consistent. In our extended follow-up (median 81.2 months, IQR 66.0-87.2) of the Italian Tamoxifen Trial, this drug did not significantly protect against breast cancer In women at usual or slightly reduced risk of the disease (p=0.215). Use of hormone replacement therapy Increased risk of breast cancer, and users of such treatment who were randomly allocated to tamoxifen had a rate of breast cancer that was close to that of never-users. So far, no woman has died from breast cancer In this study. Decisions about Introduction of tamoxifen to reduce risk of breast cancer remain Important and open questions.	European Inst Oncol, Div Epidemiol & Biostat, I-20141 Milan, Italy; European Inst Oncol, Div Senol, Milan, Italy	IRCCS European Institute of Oncology (IEO); IRCCS European Institute of Oncology (IEO)	Boyle, P (corresponding author), European Inst Oncol, Div Epidemiol & Biostat, I-20141 Milan, Italy.		Maisonneuve, Patrick/U-9789-2018; Boyle, Peter/A-4380-2014	Maisonneuve, Patrick/0000-0002-5309-4704; Boyle, Peter/0000-0001-6251-0610				Bergman L, 2000, LANCET, V356, P881, DOI 10.1016/S0140-6736(00)02677-5; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; Powles T, 1998, LANCET, V352, P98; Veronesi U, 1999, LANCET, V353, P244, DOI 10.1016/S0140-6736(05)77261-5; Veronesi U, 1998, LANCET, V352, P93	5	108	113	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 30	2002	359	9312					1122	1124		10.1016/S0140-6736(02)08159-X	http://dx.doi.org/10.1016/S0140-6736(02)08159-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	536YJ	11943263				2022-12-28	WOS:000174729200014
J	Frazzetta, TH; Kardong, KV				Frazzetta, TH; Kardong, KV			Biomechanics - Prey attack by a large theropod dinosaur	NATURE			English	Article									Univ Illinois, Dept Anim Biol Ecol Ethol & Evolut, Urbana, IL 61801 USA; Washington State Univ, Sch Biol Sci, Pullman, WA 99164 USA	University of Illinois System; University of Illinois Urbana-Champaign; Washington State University	Frazzetta, TH (corresponding author), Univ Illinois, Dept Anim Biol Ecol Ethol & Evolut, Urbana, IL 61801 USA.		Rayfield, Emily/F-5038-2010	Rayfield, Emily/0000-0002-2618-750X				Ahlberg PE, 1996, NATURE, V381, P61, DOI 10.1038/381061a0; Erickson GM, 1996, NATURE, V382, P706, DOI 10.1038/382706a0; Farlow J.O., 1991, Modern Geology, V16, P161; FARLOW JO, 1976, AM MIDL NAT, V95, P186, DOI 10.2307/2424244; Frazzetta T., 1983, P222; FRAZZETTA TH, 1962, J MORPHOL, V111, P287, DOI 10.1002/jmor.1051110306; FRAZZETTA TH, 1986, EVOLUTIONARY BIOL, P419; MADSEN JH, 1976, B UTAH GEOLOGICAL MI, V109, P1; Rayfield EJ, 2001, NATURE, V409, P1033, DOI 10.1038/35059070; Schwenk Kurt, 2000, P175, DOI 10.1016/B978-012632590-4/50009-5	10	8	8	9	66	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 28	2002	416	6879					387	388		10.1038/416387a	http://dx.doi.org/10.1038/416387a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	534UX	11919619				2022-12-28	WOS:000174607800034
J	Froemke, RC; Dan, Y				Froemke, RC; Dan, Y			Spike-timing-dependent synaptic modification induced by natural spike trains	NATURE			English	Article							LONG-TERM POTENTIATION; PYRAMIDAL CELLS; BARREL CORTEX; NEURONS; PLASTICITY; SYNAPSES; COINCIDENCE; HIPPOCAMPUS; PATTERNS; EFFICACY	The strength of the connection between two neurons can be modified by activity, in a way that depends on the timing of neuronal firing on either side of the synapse(1-10). This spike-timing-dependent plasticity (STDP) has been studied by systematically varying the intervals between pre- and postsynaptic spikes. Here we studied how STDP operates in the context of more natural spike trains. We found that in visual cortical slices the contribution of each pre-/postsynaptic spike pair to synaptic modification depends not only on the interval between the pair, but also on the timing of preceding spikes. The efficacy of each spike in synaptic modification was suppressed by the preceding spike in the same neuron, occurring within several tens of milliseconds. The direction and magnitude of synaptic modifications induced by spike patterns recorded in vivo in response to natural visual stimuli were well predicted by incorporating the suppressive inter-spike interaction within each neuron. Thus, activity-induced synaptic modification depends not only on the relative spike timing between the neurons, but also on the spiking pattern within each neuron. For natural spike trains, the timing of the first spike in each burst is dominant in synaptic modification.	Univ Calif Berkeley, Dept Mol & Cell Biol, Dept Neurobiol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Dan, Y (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, Dept Neurobiol, 229 Stanley Hall, Berkeley, CA 94720 USA.			Froemke, Robert/0000-0002-1230-6811; Dan, Yang/0000-0002-3818-877X				Bi GQ, 1998, J NEUROSCI, V18, P10464, DOI 10.1523/jneurosci.18-24-10464.1998; Boettiger CA, 2001, NEURON, V31, P809, DOI 10.1016/S0896-6273(01)00403-2; CONNORS BW, 1990, TRENDS NEUROSCI, V13, P99, DOI 10.1016/0166-2236(90)90185-D; Debanne D, 1998, J PHYSIOL-LONDON, V507, P237, DOI 10.1111/j.1469-7793.1998.237bu.x; Dobrunz LE, 1999, NEURON, V22, P157, DOI 10.1016/S0896-6273(00)80687-X; Egger V, 1999, NAT NEUROSCI, V2, P1098, DOI 10.1038/16026; Feldman DE, 2000, NEURON, V27, P45, DOI 10.1016/S0896-6273(00)00008-8; GUSTAFSSON B, 1987, J NEUROSCI, V7, P774; Kempter R, 1999, PHYS REV E, V59, P4498, DOI 10.1103/PhysRevE.59.4498; LEVY WB, 1983, NEUROSCIENCE, V8, P791, DOI 10.1016/0306-4522(83)90010-6; Lisman JE, 2001, NEURON, V31, P191, DOI 10.1016/S0896-6273(01)00364-6; Malenka RC, 1999, SCIENCE, V285, P1870, DOI 10.1126/science.285.5435.1870; Markram H, 1997, SCIENCE, V275, P213, DOI 10.1126/science.275.5297.213; Nishiyama M, 2000, NATURE, V408, P584, DOI 10.1038/35046067; Rao RPN, 2001, NEURAL COMPUT, V13, P2221, DOI 10.1162/089976601750541787; Roberts PD, 1999, J COMPUT NEUROSCI, V7, P235, DOI 10.1023/A:1008910918445; Senn W, 2001, NEURAL COMPUT, V13, P35, DOI 10.1162/089976601300014628; Somogyi P, 1998, BRAIN RES REV, V26, P113, DOI 10.1016/S0165-0173(97)00061-1; Song S, 2000, NAT NEUROSCI, V3, P919, DOI 10.1038/78829; Stanley GB, 1999, J NEUROSCI, V19, P8036, DOI 10.1523/jneurosci.19-18-08036.1999; STUART GJ, 1994, NATURE, V367, P69, DOI 10.1038/367069a0; Tsodyks MV, 1997, P NATL ACAD SCI USA, V94, P719, DOI 10.1073/pnas.94.2.719; van Rossum MCW, 2000, J NEUROSCI, V20, P8812; Varela JA, 1997, J NEUROSCI, V17, P7926; Yao HS, 2001, NEURON, V32, P315, DOI 10.1016/S0896-6273(01)00460-3; Zhang LI, 1998, NATURE, V395, P37, DOI 10.1038/25665; ZORUMSKI CF, 1992, PROG NEUROBIOL, V39, P295, DOI 10.1016/0301-0082(92)90020-F; Zucker RS, 1999, CURR OPIN NEUROBIOL, V9, P305, DOI 10.1016/S0959-4388(99)80045-2	28	574	584	5	96	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 28	2002	416	6879					433	438		10.1038/416433a	http://dx.doi.org/10.1038/416433a			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	534UX	11919633				2022-12-28	WOS:000174607800048
J	Stoller, JK				Stoller, JK			Acute exacerbations of chronic obstructive pulmonary disease.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POSITIVE-PRESSURE VENTILATION; SYSTEMIC GLUCOCORTICOIDS; CHEST RADIOGRAPHY; BLOOD-GASES; MANAGEMENT; COPD; AMINOPHYLLINE; APPRAISAL; ADMISSION; CRITERIA		Cleveland Clin Fdn, Dept Pulm & Crit Care Med, Div Med, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Pulm & Crit Care Med, Sect Resp Therapy, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation	Stoller, JK (corresponding author), Cleveland Clin Fdn, Dept Pulm & Crit Care Med, Div Med, A90,9500 Euclid Ave, Cleveland, OH 44195 USA.	stollej@ccf.org						*AM ASS RESP CAR, 1997, RESP CARE, V42, P362; [Anonymous], 1999, CHEST, V116, P521; [Anonymous], 2001, AM J RESP CRIT CARE; ANTHONISEN NR, 1987, ANN INTERN MED, V106, P196, DOI 10.7326/0003-4819-106-2-196; AUBIER M, 1980, AM REV RESPIR DIS, V122, P747, DOI 10.1164/arrd.1980.122.5.747; Bach PB, 2001, ANN INTERN MED, V134, P600, DOI 10.7326/0003-4819-134-7-200104030-00016; CELLI BR, 1995, AM J RESP CRIT CARE, V152, pS77; Connors AF, 1997, AM J RESP CRIT CARE, V155, P386; Davies L, 1999, LANCET, V354, P456, DOI 10.1016/S0140-6736(98)11326-0; EMERMAN CL, 1989, ANN EMERG MED, V18, P523, DOI 10.1016/S0196-0644(89)80837-6; EMERMAN CL, 1993, ANN EMERG MED, V22, P680, DOI 10.1016/S0196-0644(05)81847-5; EMERMAN CL, 1991, CHEST, V99, P595, DOI 10.1378/chest.99.3.595; Ferguson GT, 2000, CHEST, V117, P23; Kanner RE, 2001, AM J RESP CRIT CARE, V164, P358, DOI 10.1164/ajrccm.164.3.2010017; Keenan SP, 1997, CRIT CARE MED, V25, P1685, DOI 10.1097/00003246-199710000-00018; KRAMER N, 1995, AM J RESP CRIT CARE, V151, P1799, DOI 10.1164/ajrccm.151.6.7767523; McCrory DC, 2001, CHEST, V119, P1190, DOI 10.1378/chest.119.4.1190; Mehta S, 2001, AM J RESP CRIT CARE, V163, P540, DOI 10.1164/ajrccm.163.2.9906116; Nava S, 1997, CHEST, V111, P1631, DOI 10.1378/chest.111.6.1631; Niewoehner DE, 1999, NEW ENGL J MED, V340, P1941, DOI 10.1056/NEJM199906243402502; *NY AM LUNG ASS, 2001, FACT SHEET CHRON OBS; Pauwels Romain A., 2001, American Journal of Respiratory and Critical Care Medicine, V163, P1256; Pearson MG, 1997, THORAX, V52, pS1; Plant PK, 2000, LANCET, V355, P1931, DOI 10.1016/S0140-6736(00)02323-0; RICE KL, 1987, ANN INTERN MED, V107, P305, DOI 10.7326/0003-4819-107-2-305; Rodriguez-Roisin R, 2000, CHEST, V117, p398S, DOI 10.1378/chest.117.5_suppl_2.398S; SAINT S, 1995, JAMA-J AM MED ASSOC, V273, P957, DOI 10.1001/jama.273.12.957; Sayiner A, 2001, CHEST, V119, P726, DOI 10.1378/chest.119.3.726; Seemungal TAR, 1998, AM J RESP CRIT CARE, V157, P1418, DOI 10.1164/ajrccm.157.5.9709032; Seemungal TAR, 2000, AM J RESP CRIT CARE, V161, P1608, DOI 10.1164/ajrccm.161.5.9908022; SEIDENFELD JJ, 1984, ANN EMERG MED, V13, P248, DOI 10.1016/S0196-0644(84)80472-2; Sherk PA, 2000, CLIN CHEST MED, V21, P705, DOI 10.1016/S0272-5231(05)70179-9; SIAFAKAS NM, 1995, EUR RESPIR J, V8, P1398, DOI 10.1183/09031936.95.08081398; Snow V, 2001, ANN INTERN MED, V134, P595, DOI 10.7326/0003-4819-134-7-200104030-00015; Stanbrook MB, 2001, CHEST, V119, P675, DOI 10.1378/chest.119.3.675; Stoller J K, 1998, Respir Care Clin N Am, V4, P425; Stoller JK, 1997, CHEST, V111, pS123, DOI 10.1378/chest.111.6_Supplement.123S; TSAI TW, 1993, ANN EMERG MED, V22, P1854; Turner MO, 1997, ARCH INTERN MED, V157, P1736, DOI 10.1001/archinte.157.15.1736; *US CENS BUR, 2000, STAT ABSTR US, P91; WRENN K, 1991, ANN INTERN MED, V115, P241, DOI 10.7326/0003-4819-115-4-241	41	75	80	1	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 28	2002	346	13					988	994		10.1056/NEJMcp012477	http://dx.doi.org/10.1056/NEJMcp012477			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	534UY	11919309				2022-12-28	WOS:000174608600007
J	Paul, RE; George, G				Paul, RE; George, G			Fatal non-cardiogenic pulmonary oedema after intravenous nonionic radiographic contrast	LANCET			English	Article							EDEMA; MEDIA	Life-threatening reactions to radiographic contrast media are rare. We describe a case of fatal non-cardiogenic pulmonary oedema, after use of iopamidol, a widely used, low osmolar, non-ionic, radiographic contrast medium. A woman with a history of bladder tumour who had haematuria was referred for an Intravenous urogram. After intravenous injection of 100 mL iopamidol, the woman became short of breath, and a chest radiograph showed severe pulmonary oedema. She was treated but subsequently died. The pathogenesis of contrast-induced, non-cardiogenic pulmonary oedema is unclear, and treatment differs from that for cardiogenic pulmonary oedema.	Horton Hosp, Dept Accid & Emergency, Banbury OX16 9AL, England		George, G (corresponding author), Horton Hosp, Dept Accid & Emergency, Banbury OX16 9AL, England.							GOLDSMITH SR, 1995, J ALLERGY CLIN IMMUN, V96, P698, DOI 10.1016/S0091-6749(95)70272-5; GREGANTI MA, 1979, RADIOLOGY, V132, P583, DOI 10.1148/132.3.583; KATAYAMA H, 1990, RADIOLOGY, V175, P621, DOI 10.1148/radiology.175.3.2343107; RAMESH S, 1995, ANN ALLERG ASTHMA IM, V75, P308; Urdaneta F, 1999, J CLIN ANESTH, V11, P675, DOI 10.1016/S0952-8180(99)00120-8	5	18	19	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 23	2002	359	9311					1037	1038		10.1016/S0140-6736(02)08068-6	http://dx.doi.org/10.1016/S0140-6736(02)08068-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	534KP	11937188				2022-12-28	WOS:000174585800015
J	Doyle, PS; Bibette, J; Bancaud, A; Viovy, JL				Doyle, PS; Bibette, J; Bancaud, A; Viovy, JL			Self-assembled magnetic matrices for DNA separation chips	SCIENCE			English	Article							ELECTROPHORESIS; ARRAY		Inst Curie, Lab PCC, UMR CNRS IC 168, F-75248 Paris 05, France; MIT, Dept Chem Engn, Cambridge, MA 02139 USA; ESPCI, Lab Colloides & Nanostruct, F-75213 Paris 05, France	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Massachusetts Institute of Technology (MIT); UDICE-French Research Universities; PSL Research University Paris; Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI)	Viovy, JL (corresponding author), Inst Curie, Lab PCC, UMR CNRS IC 168, 26 Rue Ulm, F-75248 Paris 05, France.		bancaud, aurelien/C-3075-2017; Doyle, Patrick S/H-7031-2013	bancaud, aurelien/0000-0002-0308-249X; Doyle, Patrick S/0000-0003-2147-9172; Viovy, Jean-Louis/0000-0002-8223-4040				Han J, 2000, SCIENCE, V288, P1026, DOI 10.1126/science.288.5468.1026; LIU J, 1995, PHYS REV LETT, V74, P2828, DOI 10.1103/PhysRevLett.74.2828; Mayer P, 1997, MAT RES S C, V463, P57; MITNIK L, 1995, SCIENCE, V267, P219, DOI 10.1126/science.7809626; Viovy JL, 2000, REV MOD PHYS, V72, P813, DOI 10.1103/RevModPhys.72.813; VOLKMUTH WD, 1992, NATURE, V358, P600, DOI 10.1038/358600a0	6	431	492	2	91	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 22	2002	295	5563					2237	2237		10.1126/science.1068420	http://dx.doi.org/10.1126/science.1068420			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	534AD	11910102				2022-12-28	WOS:000174561700035
J	Cornuz, J; Humair, JP; Seematter, L; Stoianov, R; van Melle, G; Stalder, H; Pecoud, A				Cornuz, J; Humair, JP; Seematter, L; Stoianov, R; van Melle, G; Stalder, H; Pecoud, A			Efficacy of resident training in smoking cessation: A randomized, controlled trial of a program based on application of behavioral theory and practice with standardized patients	ANNALS OF INTERNAL MEDICINE			English	Article							CONTINUING MEDICAL-EDUCATION; PREVENTIVE MEDICINE; GENERAL-PRACTICE; HEALTH-CARE; PHYSICIANS; INTERVENTIONS; STRATEGIES; TOBACCO; SMOKERS; ADVICE	Background:New educational programs must be developed to improve physicians' skills and effectiveness in counseling patients about smoking cessation. Objective: To assess the efficacy of an educational program based on behavioral theory, active learning methods, and practice with standardized patients in helping patients abstain from smoking and changing physicians' counseling practices. Design: Cluster randomized, controlled trial. Setting: Two general internal medicine clinics in Switzerland. Participants: 35 residents and 251 consecutive smoking patients. Intervention: A training program administered over two half-days, during which physicians learned to provide counseling that matched smokers' motivation to quit and practiced these skills with standardized patients acting as smokers at different stages of change. The control intervention was a didactic session on management of dyslipidemia. Measurements: Self-reported abstinence from smoking at 1 year of follow-up, which was validated by exhaled carbon monoxide testing at one clinic; score of overall quality of counseling based on use of 14 counseling strategies; patient willingness to quit; and daily cigarette consumption. Results: At 1 year of follow-up, abstinence from smoking was significantly higher in the intervention group than in the control group (13% vs. 5%; P = 0.005); this corresponded to a cluster-adjusted odds ratio of 2.8 (95% Cl, 1.4 to 5.5). Residents who received the study training provided better counseling than did those who received the control training (mean score, 4.0 vs. 2.7; P = 0.002). Smokers' willingness to quit was also higher in the intervention group (94% vs. 80%; P = 0.007). A nonsignificant trend toward lower daily cigarette consumption in the intervention group was observed. Conclusion: A training program in smoking cessation administered to physicians that was based on behavioral theory and practice with standardized patients significantly increased the quality of physicians' counseling, smokers' motivation to quit, and rates of abstinence from smoking at 1 year.	Univ Lausanne, Outpatient Clin, Lausanne, Switzerland; Univ Lausanne, Inst Social & Prevent Med, Lausanne, Switzerland; Univ Lausanne Hosp, Lausanne, Switzerland; Univ Hosp Geneva, Geneva, Switzerland	University of Lausanne; University of Lausanne; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Geneva	Cornuz, J (corresponding author), CHU Vaudois, BH 10, CH-1011 Lausanne, Switzerland.	Jacques.Cornuz@chuv.hospvd.ch						Abrams D B, 2000, Nicotine Tob Res, V2, P223; *ARB LIP SCHW GESS, 2000, SCHWEIZ ARZTEZEITUNG, V780, P1593; CALMONTE R, 2000, ENQUETE SUISSE SANTE; CANTOR JC, 1993, JAMA-J AM MED ASSOC, V270, P1035, DOI 10.1001/jama.270.9.1035; Cardozo LJ, 1998, ARCH INTERN MED, V158, P261, DOI 10.1001/archinte.158.3.261; COHEN SJ, 1989, ANN INTERN MED, V110, P648, DOI 10.7326/0003-4819-110-8-648; CORDES DH, 1995, AM J PREV MED, V11, P145, DOI 10.1016/S0749-3797(18)30465-3; Cornuz J, 1997, PREV MED, V26, P292, DOI 10.1006/pmed.1997.0139; Cornuz J, 1996, Tob Control, V5, P149, DOI 10.1136/tc.5.2.149; CORNUZ J, 1999, NICOTINE TOB RES, V1, P190; CROFTON JW, 1994, MED EDUC, V28, P187, DOI 10.1111/j.1365-2923.1994.tb02697.x; CUMMINGS SR, 1989, ANN INTERN MED, V110, P640, DOI 10.7326/0003-4819-110-8-640; CUMMINGS SR, 1989, J GEN INTERN MED, V4, P482, DOI 10.1007/BF02599545; Davis D, 1999, JAMA-J AM MED ASSOC, V282, P867, DOI 10.1001/jama.282.9.867; DAVIS DA, 1995, JAMA-J AM MED ASSOC, V274, P700; Day SJ, 2000, BRIT MED J, V321, P504, DOI 10.1136/bmj.321.7259.504; Diggle PJ, 1994, ANAL LONGITUDINAL DA; Etter J F, 1998, Rev Med Suisse Romande, V118, P515; Ferry LH, 1999, JAMA-J AM MED ASSOC, V282, P825, DOI 10.1001/jama.282.9.825; FLETCHER RH, 1992, ANN INTERN MED, V116, P1094, DOI 10.7326/0003-4819-116-12-1094; GOLDBERG DN, 1994, AM J PREV MED, V10, P267, DOI 10.1016/S0749-3797(18)30578-6; Goldstein MG, 2000, CLIN PRACTICE GUIDEL; Grufferman S, 1999, EPIDEMIOLOGY, V10, P209; HAYWARD RSA, 1991, ANN INTERN MED, V114, P758, DOI 10.7326/0003-4819-114-9-758; Humair JP, 1998, AM J PREV MED, V14, P1, DOI 10.1016/S0749-3797(97)00010-X; HUMAIR JP, 1999, WONCA 99 1 EUR NETW; HUMAIR JP, 2000, AIDEZ PATIENTS ARRET; KOTTKE TE, 1991, J GEN INTERN MED, V6, P94, DOI 10.1007/BF02599400; Lancaster T, 2005, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001292.pub2, 10.1002/14651858.CD001292.pub3]; Lennox AS, 1998, HLTH ED J, V57, P140; LIM JK, 2000, JAMA-J AM MED ASSOC, V283, P2174; MCILVAIN HE, 1992, J FAM PRACTICE, V34, P745; OCKENE JK, 1987, PREV MED, V16, P723, DOI 10.1016/0091-7435(87)90054-5; OCKENE JK, 1988, ARCH INTERN MED, V148, P1039, DOI 10.1001/archinte.148.5.1039; OCKENE JK, 1991, J GEN INTERN MED, V6, P1, DOI 10.1007/BF02599381; PATRICK DL, 1994, AM J PUBLIC HEALTH, V84, P1086, DOI 10.2105/AJPH.84.7.1086; Pololi LH, 1996, J GEN INTERN MED, V11, P545, DOI 10.1007/BF02599603; PROCHASKA JO, 1992, AM PSYCHOL, V47, P1102, DOI 10.1037/0003-066X.47.9.1102; PROCHASKA JO, 1991, CLIN CHEST MED, V12, P727; Quirk M, 1991, Fam Med, V23, P108; Roche AM, 1996, PREV MED, V25, P251, DOI 10.1006/pmed.1996.0054; SILAGY C, 1992, BRIT MED J, V305, P871, DOI 10.1136/bmj.305.6858.871; SILAGY C, 2001, COCHRANE DB SYST REV, V2; Solberg LI, 1996, PREV MED, V25, P259, DOI 10.1006/pmed.1996.0055; STRECHER VJ, 1991, J GEN INTERN MED, V6, P9, DOI 10.1007/BF02599383; Thorndike AN, 1998, JAMA-J AM MED ASSOC, V279, P604, DOI 10.1001/jama.279.8.604; VELICER WF, 1992, PSYCHOL BULL, V111, P23, DOI 10.1037/0033-2909.111.1.23; WALSH JME, 1994, AM J PREV MED, V10, P168, DOI 10.1016/S0749-3797(18)30614-7; Wang Wei-Dean, 1994, Journal of the Formosan Medical Association, V93, P752; WILSON DM, 1988, JAMA-J AM MED ASSOC, V260, P1570, DOI 10.1001/jama.260.11.1570	50	129	129	1	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 19	2002	136	6					429	437		10.7326/0003-4819-136-6-200203190-00006	http://dx.doi.org/10.7326/0003-4819-136-6-200203190-00006			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	531AU	11900495				2022-12-28	WOS:000174393100002
J	Vaughn, DJ; Gignac, GA; Meadows, AT				Vaughn, DJ; Gignac, GA; Meadows, AT			Long-term medical care of testicular cancer survivors	ANNALS OF INTERNAL MEDICINE			English	Review							GERM-CELL CANCER; CISPLATIN-BASED CHEMOTHERAPY; QUALITY-OF-LIFE; CARCINOMA IN-SITU; COMBINATION CHEMOTHERAPY; TESTIS CANCER; LATE RELAPSE; FOLLOW-UP; REPRODUCTIVE HORMONES; GONADAL TOXICITY	Testicular cancer is the most common solid tumor diagnosed in men 20 to 35 years of age. Because of highly effective treatments that may include surgery, chemotherapy, and radiation therapy, most patients become long-term survivors. Health-related issues that confront testicular cancer survivors include the late medical effects of chemotherapy, the late relapse of disease, the development of second cancers, the effect of the disease and treatment on fertility, and the psychosocial consequences. This case-based discussion focuses on the primary care physician's evaluation and management of a long-term survivor of testicular cancer who was previously treated with surgery and chemotherapy.	Univ Penn, Ctr Canc, Leonard & Madlyn Abramson Family Canc Res Inst, Sch Med, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Vaughn, DJ (corresponding author), Univ Penn, Ctr Canc, Leonard & Madlyn Abramson Family Canc Res Inst, Sch Med, 16 Penn Tower,3400 Spruce St, Philadelphia, PA 19104 USA.			Gignac, Gretchen/0000-0001-8532-9558				AASS N, 1990, BRIT J CANCER, V62, P842, DOI 10.1038/bjc.1990.391; AASS N, 1993, BRIT J CANCER, V67, P1113, DOI 10.1038/bjc.1993.204; AASS N, 1991, EUR J CANCER, V27, P1087, DOI 10.1016/0277-5379(91)90298-R; [Anonymous], 1997, J Clin Oncol, V15, P594; Arai Y, 1997, J CLIN ONCOL, V15, P1444, DOI 10.1200/JCO.1997.15.4.1444; Arai Y, 1996, J UROLOGY, V155, P574, DOI 10.1016/S0022-5347(01)66452-8; BAJORIN DF, 1993, J NATL CANCER I, V85, P60, DOI 10.1093/jnci/85.1.60; BANIEL J, 1995, J UROLOGY, V154, P1370, DOI 10.1016/S0022-5347(01)66867-8; BANIEL J, 1995, J CLIN ONCOL, V13, P1170, DOI 10.1200/JCO.1995.13.5.1170; Berger CC, 1996, BRIT J CANCER, V73, P1108, DOI 10.1038/bjc.1996.213; BOKEMEYER C, 1993, J CLIN ONCOL, V11, P1703, DOI 10.1200/JCO.1993.11.9.1703; BOKEMEYER C, 1995, J CLIN ONCOL, V13, P283, DOI 10.1200/JCO.1995.13.1.283; Bokemeyer C, 1996, J CLIN ONCOL, V14, P2923, DOI 10.1200/JCO.1996.14.11.2923; Bokemeyer C, 1998, BRIT J CANCER, V77, P1355, DOI 10.1038/bjc.1998.226; BOSL GJ, 1986, J CLIN ONCOL, V4, P1684, DOI 10.1200/JCO.1986.4.11.1684; BOSL GJ, 2001, CANC PRINCIPLES PRAC, P1491; Brennemann W, 1997, J UROLOGY, V158, P844, DOI 10.1016/S0022-5347(01)64333-7; Christensen TB, 1998, ANN ONCOL, V9, P657, DOI 10.1023/A:1008213515649; DOLL DC, 1986, ANN INTERN MED, V105, P48, DOI 10.7326/0003-4819-105-1-48; DONOHUE JP, 1993, J UROLOGY, V149, P237, DOI 10.1016/S0022-5347(17)36046-9; DOUCHEZ J, 1993, J UROLOGY, V149, P498, DOI 10.1016/S0022-5347(17)36127-X; DRASGA RE, 1983, J CLIN ONCOL, V1, P179, DOI 10.1200/JCO.1983.1.3.179; EINHORN LH, 1981, CANCER RES, V41, P3275; FOSSA SD, 1985, BRIT J UROL, V57, P204, DOI 10.1111/j.1464-410X.1985.tb06425.x; FOSSA SD, 1995, ONCOLOGY-BASEL, V52, P300; FOSSA SD, 2000, COMPREHENSIVE TXB GE, P1045; Gerl A, 1997, ANN ONCOL, V8, P41, DOI 10.1023/A:1008253323854; GIETEMA JA, 1992, ANN INTERN MED, V116, P709, DOI 10.7326/0003-4819-116-9-709; Gietema JA, 2000, LANCET, V355, P1075, DOI 10.1016/S0140-6736(00)02044-4; Gil-Salom M, 1998, J UROLOGY, V160, P2063, DOI 10.1016/S0022-5347(01)62243-2; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; GRITZ ER, 1989, CANCER, V64, P1560, DOI 10.1002/1097-0142(19891001)64:7<1560::AID-CNCR2820640735>3.0.CO;2-B; HAMILTON CR, 1989, EUR J CANCER CLIN ON, V25, P185, DOI 10.1016/0277-5379(89)90006-0; HANSEN SW, 1990, J CLIN ONCOL, V8, P1695, DOI 10.1200/JCO.1990.8.10.1695; HANSEN SW, 1989, J CLIN ONCOL, V7, P1457, DOI 10.1200/JCO.1989.7.10.1457; HANSEN SW, 1992, DAN MED BULL, V39, P391; Hartmann JT, 1999, BRIT J CANCER, V80, P801, DOI 10.1038/sj.bjc.6690424; Hartmann JT, 2000, CANCER-AM CANCER SOC, V88, P2629, DOI 10.1002/1097-0142(20000601)88:11<2629::AID-CNCR27>3.3.CO;2-6; Heidenreich A, 1999, WORLD J UROL, V17, P230, DOI 10.1007/s003450050138; Howell SJ, 1999, J CLIN ONCOL, V17, P1493, DOI 10.1200/JCO.1999.17.5.1493; Jacobsen KD, 1999, BRIT J CANCER, V80, P249, DOI 10.1038/sj.bjc.6690347; JOHNSON DH, 1984, MED PEDIATR ONCOL, V12, P233, DOI 10.1002/mpo.2950120403; JonkerPool G, 1997, CANCER, V80, P454, DOI 10.1002/(SICI)1097-0142(19970801)80:3<454::AID-CNCR13>3.3.CO;2-E; KAASA S, 1991, EUR J CANCER, V27, P1091, DOI 10.1016/0277-5379(91)90299-S; Kollmannsberger C, 1999, INT J CANCER, V83, P860, DOI 10.1002/(SICI)1097-0215(19991210)83:6<860::AID-IJC32>3.0.CO;2-L; Kollmannsberger C, 1998, J CLIN ONCOL, V16, P3386, DOI 10.1200/JCO.1998.16.10.3386; Kollmannsberger C, 1999, SEMIN SURG ONCOL, V17, P275, DOI 10.1002/(SICI)1098-2388(199912)17:4<275::AID-SSU9>3.0.CO;2-U; KREUSER ED, 1986, EUR J CANCER CLIN ON, V22, P289, DOI 10.1016/0277-5379(86)90393-7; Lampe H, 1997, J CLIN ONCOL, V15, P239, DOI 10.1200/JCO.1997.15.1.239; LEDERMAN GS, 1987, J UROLOGY, V137, P1236, DOI 10.1016/S0022-5347(17)44466-1; LEHNE G, 1993, BRIT J CANCER, V68, P555, DOI 10.1038/bjc.1993.385; LEITNER SP, 1986, J CLIN ONCOL, V4, P1500, DOI 10.1200/JCO.1986.4.10.1500; Meinardi MT, 2000, J CLIN ONCOL, V18, P1725, DOI 10.1200/JCO.2000.18.8.1725; Naysmith TE, 1998, HUM REPROD, V13, P3250, DOI 10.1093/humrep/13.11.3250; NICHOLS CR, 1993, J NATL CANCER I, V85, P36, DOI 10.1093/jnci/85.1.36; NICHOLS CR, 1992, J CLIN ONCOL, V10, P760, DOI 10.1200/JCO.1992.10.5.760; OSANTO S, 1992, J CLIN ONCOL, V10, P574, DOI 10.1200/JCO.1992.10.4.574; Ozen H, 1998, J UROLOGY, V159, P1947, DOI 10.1016/S0022-5347(01)63204-X; Petersen PM, 1999, J CLIN ONCOL, V17, P941, DOI 10.1200/JCO.1999.17.3.941; Petersen PM, 1999, J UROLOGY, V161, P822, DOI 10.1016/S0022-5347(01)61781-6; Petersen PM, 1999, ANN ONCOL, V10, P1475, DOI 10.1023/A:1008322909836; RAGHAVAN D, 1994, J CLIN ONCOL, V12, P2284, DOI 10.1200/JCO.1994.12.11.2284; RAGHAVAN D, 1992, J CLIN ONCOL, V10, P1386, DOI 10.1200/JCO.1992.10.9.1386; Rapley EA, 2000, NAT GENET, V24, P197, DOI 10.1038/72877; RIEKER PP, 1990, J CLIN ONCOL, V8, P347, DOI 10.1200/JCO.1990.8.2.347; RIEKER PP, 1985, J CLIN ONCOL, V3, P1117, DOI 10.1200/JCO.1985.3.8.1117; RIEKER PP, 1989, CANCER, V64, P2399, DOI 10.1002/1097-0142(19891201)64:11<2399::AID-CNCR2820641134>3.0.CO;2-P; Rudberg L, 2000, J PSYCHOSOC ONCOL, V18, P19, DOI 10.1300/J077v18n03_02; SENAN S, 1992, EUR J CANCER, V28A, P2084, DOI 10.1016/0959-8049(92)90262-Z; Sharir S, 1999, J UROLOGY, V161, P472, DOI 10.1016/S0022-5347(01)61926-8; SIGG C, 1988, DERMATOLOGICA, V176, P109, DOI 10.1159/000248684; STEPHENSON WT, 1995, J CLIN ONCOL, V13, P2278, DOI 10.1200/JCO.1995.13.9.2278; STOVER DE, 2001, CANC PRINCIPLES PRAC, P2894; STUART NSA, 1990, BRIT J CANCER, V61, P479, DOI 10.1038/bjc.1990.106; Travis LB, 1997, JNCI-J NATL CANCER I, V89, P1429, DOI 10.1093/jnci/89.19.1429; Van Basten JPA, 1999, BJU INT, V84, P671; vanBasten JPA, 1997, J CLIN ONCOL, V15, P2442, DOI 10.1200/JCO.1997.15.6.2442; VANLEEUWEN FE, 1993, J CLIN ONCOL, V11, P415, DOI 10.1200/JCO.1993.11.3.415; VOGELZANG NJ, 1981, ANN INTERN MED, V95, P288, DOI 10.7326/0003-4819-95-3-288; VOGELZANG NJ, 1985, CANCER, V56, P2765, DOI 10.1002/1097-0142(19851215)56:12<2765::AID-CNCR2820561208>3.0.CO;2-2; VOGELZANG NJ, 1980, CANCER TREAT REP, V64, P1159; VONDERMAASE H, 1986, BRIT MED J, V293, P1398, DOI 10.1136/bmj.293.6559.1398; Wanderas EH, 1997, EUR J CANCER, V33, P244; WILLIAMS SD, 1987, NEW ENGL J MED, V316, P1435, DOI 10.1056/NEJM198706043162302	84	35	36	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 19	2002	136	6					463	470		10.7326/0003-4819-136-6-200203190-00010	http://dx.doi.org/10.7326/0003-4819-136-6-200203190-00010			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	531AU	11900499				2022-12-28	WOS:000174393100006
J	Fox, BD				Fox, BD			Crash diet potomania	LANCET			English	Editorial Material							BEER POTOMANIA		Ealing Gen Hosp, Dept Endocrinol, Southall UB1 3HX, Middx, England		Fox, BD (corresponding author), Ealing Gen Hosp, Dept Endocrinol, Southall UB1 3HX, Middx, England.			Fox, Benjamin/0000-0001-6199-668X				Adrogue HJ, 2000, NEW ENGL J MED, V342, P1581, DOI 10.1056/NEJM200005253422107; ANDERSON JW, 1991, AM J GASTROENTEROL, V87, P6; BERL T, 1997, RENAL ELECT DISORDER; Fenves AZ, 1996, CLIN NEPHROL, V45, P61; Thaler SM, 1998, AM J KIDNEY DIS, V31, P1028, DOI 10.1053/ajkd.1998.v31.pm9631849	5	10	10	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 16	2002	359	9310					942	942		10.1016/S0140-6736(02)08027-3	http://dx.doi.org/10.1016/S0140-6736(02)08027-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	531AE	11918914				2022-12-28	WOS:000174391700014
J	Stark, K; Gunther, M; Schonfeld, C; Tullius, SG; Bienzle, U				Stark, K; Gunther, M; Schonfeld, C; Tullius, SG; Bienzle, U			Immunisations in solid-organ transplant recipients	LANCET			English	Review							HEPATITIS-B VACCINE; INFLUENZAE TYPE-B; PNEUMOCOCCAL POLYSACCHARIDE VACCINE; ORTHOTOPIC LIVER-TRANSPLANTATION; CHRONIC-RENAL-FAILURE; IMMUNE-RESPONSE; HEART-TRANSPLANTATION; MYCOPHENOLATE MOFETIL; HEMODIALYSIS-PATIENTS; VARICELLA VACCINE	Solid-organ transplant recipients are at increased risk of various infectious diseases, some of which are vaccine preventable. Immunisations are among the most efficient interventions available. Solid-organ tranplant recipients would greatly benefit from effective immunisations, provided the recommendations are based on a careful risk-benefit analysis in which the effectiveness of the vaccine is weighed against possible adverse reactions, including graft rejection. In this review, we summarise the data from studies on relevant immunisations in solid-organ transplant recipients. The major issues are the immunogenicity and safety of immunisations, the factors associated with poor immune response, and recommendations for immunisation schemes.	Robert Koch Inst, D-10963 Berlin, Germany; Humboldt Univ, Charite, Inst Trop Med, Berlin, Germany; Humboldt Univ, Charite, Dept Gen & Transplantat Surg, Berlin, Germany	Robert Koch Institute; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Stark, K (corresponding author), Robert Koch Inst, Stresemannstr 90, D-10963 Berlin, Germany.							AAGUAARDTILLERY KM, 1994, CELL IMMUNOL, V152, P493; Abramson JS, 2000, PEDIATRICS, V106, P362; Admon D, 1997, VACCINE, V15, P1518, DOI 10.1016/S0264-410X(97)00193-X; Ahman H, 1998, PEDIATR INFECT DIS J, V17, P211, DOI 10.1097/00006454-199803000-00008; ALLISON AC, 1994, TRANSPLANT P, V26, P3205; AMBER IJ, 1990, TRANSPLANTATION, V49, P122, DOI 10.1097/00007890-199001000-00027; Ambrosch F, 2000, VACCINE, V18, P2095, DOI 10.1016/S0264-410X(99)00566-6; Arguedas MR, 2001, HEPATOLOGY, V34, P28, DOI 10.1053/jhep.2001.25883; Balloni A, 1999, VACCINE, V17, P2507, DOI 10.1016/S0264-410X(99)00064-X; Banatvala J, 2000, LANCET, V355, P561, DOI 10.1016/S0140-6736(99)07239-6; Bedos JP, 1996, CLIN INFECT DIS, V22, P63, DOI 10.1093/clinids/22.1.63; Blumberg EA, 1998, J HEART LUNG TRANSPL, V17, P1075; Blumberg EA, 1996, CLIN INFECT DIS, V22, P295, DOI 10.1093/clinids/22.2.295; Blumberg EA, 2001, CLIN INFECT DIS, V32, P307, DOI 10.1086/318482; Broyer M, 1997, PEDIATRICS, V99, P35, DOI 10.1542/peds.99.1.35; BRUGUERA M, 1987, POSTGRAD MED J, V63, P155; Burbach G, 1999, TRANSPLANTATION, V67, P753, DOI 10.1097/00007890-199903150-00019; *CDCP, 1996, MMWR-MORBID MORTAL W, V48, P1; *CDCP, 1999, MMWR-MORBID MORTAL W, V45, P1; CECKA JM, 2000, CLIN TRANSPLANTS 200, P595; Centers for Disease Control and Prevention, 1997, MMWR-MORBID MORTAL W, V46, P1; Chalasani N, 1998, LIVER TRANSPLANT SUR, V4, P128, DOI 10.1002/lt.500040208; Cheng CH, 1997, VACCINE, V15, P1353, DOI 10.1016/S0264-410X(97)00037-6; CHIARAMONTE M, 1995, SCAND J GASTROENTERO, V30, P601, DOI 10.3109/00365529509089796; Chung RT, 2001, AM J TRANSPLANT, V1, P185, DOI 10.1034/j.1600-6143.2001.10214.x; deMattos AM, 1996, AM J KIDNEY DIS, V28, P631, DOI 10.1016/S0272-6386(96)90246-2; Dengler TJ, 1996, DEUT MED WOCHENSCHR, V121, P1519, DOI 10.1055/s-2008-1043177; Dengler TJ, 1998, TRANSPLANTATION, V66, P1340, DOI 10.1097/00007890-199811270-00014; Dickson RC, 1997, GASTROENTEROLOGY, V113, P1668, DOI 10.1053/gast.1997.v113.pm9352871; Duchini A, 2000, LIVER TRANSPLANT, V6, P531, DOI 10.1053/jlts.2000.9738; Edvardsson VO, 1996, CLIN TRANSPLANT, V10, P556; ELION GB, 1993, ANN NY ACAD SCI, V685, P401, DOI 10.1111/j.1749-6632.1993.tb35897.x; ENKE BU, 1997, TRANSPLANTATION, V64, P37; Eskola J, 2001, NEW ENGL J MED, V344, P403, DOI 10.1056/NEJM200102083440602; FARLEY MM, 1992, ANN INTERN MED, V116, P806, DOI 10.7326/0003-4819-116-10-806; FEINSTONE SM, 1999, VACCINES, P650; Flynn JT, 1999, ADV PERIT D, V15, P269; Furth S L, 1997, Pediatr Transplant, V1, P37; Ghio L, 1997, J PEDIATR-US, V130, P987, DOI 10.1016/S0022-3476(97)70288-9; GIRNDT M, 1995, AM J KIDNEY DIS, V26, P454, DOI 10.1016/0272-6386(95)90491-3; GREKAS D, 1993, INT J CLIN PHARM TH, V31, P553; Gunther M, 2001, TRANSPLANTATION, V71, P477; HARDY I, 1991, NEW ENGL J MED, V325, P1545, DOI 10.1056/NEJM199111283252204; Hardy IRB, 1996, LANCET, V347, P1739, DOI 10.1016/S0140-6736(96)90811-9; Hariharan S, 2000, NEW ENGL J MED, V342, P605, DOI 10.1056/NEJM200003023420901; Hayden Frederick G., 1997, American Journal of Medicine, V102, P55, DOI 10.1016/S0002-9343(97)80013-7; Herrera J. L., 1993, Morbidity and Mortality Weekly Report, V42, P1; Horlander JC, 1999, AM J MED SCI, V318, P304, DOI 10.1097/00000441-199911000-00004; Huzly D, 1997, TRANSPLANTATION, V63, P839, DOI 10.1097/00007890-199703270-00008; Jackson L, 1999, JAMA-J AM MED ASSOC, V281, P243, DOI 10.1001/jama.281.3.243; Jiang H, 1999, TRANSPLANT P, V31, P1978, DOI 10.1016/S0041-1345(99)00235-3; KANTOR AB, 1991, IMMUNOL TODAY, V12, P389, DOI 10.1016/0167-5699(91)90136-H; Kazancioglu R, 2000, CLIN TRANSPLANT, V14, P61, DOI 10.1034/j.1399-0012.2000.140111.x; LEFEBURE AF, 1993, VACCINE, V11, P397, DOI 10.1016/0264-410X(93)90278-6; Loinaz C, 1997, HEPATO-GASTROENTEROL, V44, P235; Lottenbach KR, 1999, INFECT IMMUN, V67, P4935, DOI 10.1128/IAI.67.9.4935-4938.1999; Mack D R, 1996, Liver Transpl Surg, V2, P431, DOI 10.1002/lt.500020605; Markowitz JS, 1998, HEPATOLOGY, V28, P585, DOI 10.1002/hep.510280241; MARWICK C, 1995, JAMA-J AM MED ASSOC, V273, P833, DOI 10.1001/jama.1995.03520350015006; McCashland TM, 2000, J INFECT DIS, V181, P757, DOI 10.1086/315245; MOND JJ, 1995, ANNU REV IMMUNOL, V13, P655, DOI 10.1146/annurev.iy.13.040195.003255; Mutimer D, 2000, TRANSPLANTATION, V70, P809, DOI 10.1097/00007890-200009150-00018; OSULLIVAN J, 1993, LANCET, V342, P859, DOI 10.1016/0140-6736(93)92714-5; PARKER DC, 1993, ANNU REV IMMUNOL, V11, P331, DOI 10.1146/annurev.iy.11.040193.001555; Patel R, 1997, CLIN MICROBIOL REV, V10, P86, DOI 10.1128/CMR.10.1.86; Paya CV, 2001, CLIN INFECT DIS, V33, pS47, DOI 10.1086/320904; Pedrazzi C, 1999, Pediatr Transplant, V3, P109, DOI 10.1034/j.1399-3046.1999.00013.x; Pirofski LA, 1998, CLIN MICROBIOL REV, V11, P1; RAND EB, 1993, J PEDIATR-US, V123, P87, DOI 10.1016/S0022-3476(05)81545-8; Rayes N, 2001, TRANSPLANTATION, V71, P96, DOI 10.1097/00007890-200101150-00016; Redd SC, 1999, VACCINES-BASEL, V3rd, P222; Robbins JB, 1996, JAMA-J AM MED ASSOC, V276, P1181, DOI 10.1001/jama.276.14.1181; Roy MJ, 2000, VACCINE, V19, P764, DOI 10.1016/S0264-410X(00)00302-9; SAMUEL D, 1993, NEW ENGL J MED, V329, P1842, DOI 10.1056/NEJM199312163292503; Sanchez-Fructuoso AI, 2000, TRANSPLANTATION, V69, P436, DOI 10.1097/00007890-200002150-00023; Sanchez-Fueyo A, 2000, HEPATOLOGY, V31, P496, DOI 10.1002/hep.510310233; Saunders RN, 2001, KIDNEY INT, V59, P3, DOI 10.1046/j.1523-1755.2001.00460.x; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SCHULMAN SL, 1992, PEDIATR NEPHROL, V6, P187, DOI 10.1007/BF00866312; Segovia R, 2001, LIVER TRANSPLANT, V7, P106, DOI 10.1053/jlts.2001.21457; Sever MS, 1999, NEPHRON, V81, P55, DOI 10.1159/000045246; SHAPIRO ED, 1991, NEW ENGL J MED, V325, P1453, DOI 10.1056/NEJM199111213252101; SMART LE, 1987, J INFECTION, V14, P209, DOI 10.1016/S0163-4453(87)93360-3; Smith KGC, 1998, NEPHROL DIAL TRANSPL, V13, P160, DOI 10.1093/ndt/13.1.160; Soesman NMR, 2000, J MED VIROL, V61, P85, DOI 10.1002/(SICI)1096-9071(200005)61:1&lt;85::AID-JMV14&gt;3.0.CO;2-H; Stark K, 1999, J INFECT DIS, V180, P2014, DOI 10.1086/315125; TAKALA AK, 1990, ARCH INTERN MED, V150, P2573, DOI 10.1001/archinte.150.12.2573; VANTHIEL DH, 1992, DIGEST DIS SCI, V37, P1245, DOI 10.1007/BF01296567; Vento S, 1998, NEW ENGL J MED, V338, P286, DOI 10.1056/NEJM199801293380503; VERSLUIS DJ, 1986, TRANSPLANTATION, V42, P376, DOI 10.1097/00007890-198610000-00009; WAGNER D, 1994, CLIN INVESTIGATOR, V72, P350; WAGNER D, 1992, CLIN INVESTIGATOR, V70, P585; Young MD, 2001, J MED VIROL, V64, P290, DOI 10.1002/jmv.1049; ZAMORA I, 1994, PEDIATR NEPHROL, V8, P190, DOI 10.1007/BF00865476	94	51	53	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 16	2002	359	9310					957	965		10.1016/S0140-6736(02)08028-5	http://dx.doi.org/10.1016/S0140-6736(02)08028-5			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	531AE	11918932				2022-12-28	WOS:000174391700034
J	Komeda, T; Kim, Y; Kawai, M; Persson, BNJ; Ueba, H				Komeda, T; Kim, Y; Kawai, M; Persson, BNJ; Ueba, H			Lateral hopping of molecules induced by excitation of internal vibration mode	SCIENCE			English	Article							SCANNING-TUNNELING-MICROSCOPY; SINGLE-MOLECULE; ROTATIONAL MOTION; PHASE RELAXATION; CO; SURFACE; PD(110); SPECTROSCOPY; TEMPERATURE; DIFFUSION	We demonstrate electron-stimulated migration for carbon monoxide (CO) molecules adsorbed on the Pd(110) surface, which is initiated by the excitation of a high-frequency (HF) vibrational mode (C-O stretching mode) with inelastic tunneling electrons from the tip of scanning tunneling microscopy. The hopping phenomenon, however, cannot be detected for CO/Cu(110), even though the hopping barrier is lower than in the CO/Pd(110) case. A theoretical model, which is based on the anharmonic coupling between tow-frequency modes (the hindered-translational mode related to the lateral hopping) and the HF mode combined with electron-hole pair excitation, can explain why the hopping of CO is observed on Pd(110) but not on Cu(110).	RIKEN, Wako, Saitama 3510198, Japan; Forschungszentrum Julich, IFF, D-52425 Julich, Germany; Toyama Univ, Dept Elect, Gofuku, Toyama 930, Japan	RIKEN; Helmholtz Association; Research Center Julich; University of Toyama	Kawai, M (corresponding author), RIKEN, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	maki@postman.riken.go.jp	Kim, Yousoo/C-6383-2008; Kawai, Maki/AAC-2345-2021; Persson, Bo Nils Johan/I-1548-2013	Kim, Yousoo/0000-0001-7730-0704; Kawai, Maki/0000-0002-7963-6989; Persson, Bo Nils Johan/0000-0003-1535-738X				AVOURIS P, 1995, ACCOUNTS CHEM RES, V28, P95, DOI 10.1021/ar00051a002; Briner BG, 1997, SCIENCE, V278, P257, DOI 10.1126/science.278.5336.257; ELLIS J, 1995, J CHEM PHYS, V102, P5059, DOI 10.1063/1.469555; FEDORUS AG, 1991, SURF SCI, V251, P846, DOI 10.1016/0039-6028(91)91110-J; GERMER TA, 1994, J CHEM PHYS, V101, P1704, DOI 10.1063/1.467792; JANSCH HJ, 1993, J CHEM PHYS, V99, P721, DOI 10.1063/1.465744; Kato H, 2000, J CHEM PHYS, V112, P1925, DOI 10.1063/1.480771; Kato H, 1999, PHYS REV LETT, V82, P1899, DOI 10.1103/PhysRevLett.82.1899; KITAMURA N, 1993, PHYS REV LETT, V71, P2082, DOI 10.1103/PhysRevLett.71.2082; Komeda T, 2001, JPN J APPL PHYS 1, V40, P4403, DOI 10.1143/JJAP.40.4403; Lauhon LJ, 1999, PHYS REV B, V60, pR8525, DOI 10.1103/PhysRevB.60.R8525; PERSSON BNJ, 1985, PHYS REV LETT, V54, P2119, DOI 10.1103/PhysRevLett.54.2119; PERSSON BNJ, IN PRESS SURF SCI; RAVAL R, 1990, CHEM PHYS LETT, V167, P391, DOI 10.1016/0009-2614(90)85019-9; SCHWEIZER E, 1989, SURF SCI, V213, P49, DOI 10.1016/0039-6028(89)90252-5; SHEN TC, 1995, SCIENCE, V268, P1590, DOI 10.1126/science.268.5217.1590; Stipe BC, 1998, SCIENCE, V279, P1907, DOI 10.1126/science.279.5358.1907; Stipe BC, 1998, PHYS REV LETT, V81, P1263, DOI 10.1103/PhysRevLett.81.1263; Stipe BC, 1997, PHYS REV LETT, V78, P4410, DOI 10.1103/PhysRevLett.78.4410; TRENARY M, 1984, SURF SCI, V146, P269, DOI 10.1016/0039-6028(84)90242-5; WADA Y, 1993, J APPL PHYS, V74, P7321, DOI 10.1063/1.354999	21	287	292	1	84	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 15	2002	295	5562					2055	2058		10.1126/science.1069016	http://dx.doi.org/10.1126/science.1069016			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	532AY	11896272				2022-12-28	WOS:000174450500042
J	Lorig, K				Lorig, K			Partnerships between expert patients and physicians	LANCET			English	Editorial Material							SELF-MANAGEMENT PROGRAM; ARTHRITIS; EDUCATION; OUTCOMES		Stanford Univ, Sch Med, Dept Med,Stanford Patient Educ Res Ctr, Div Rheumatol & Immunol, Palo Alto, CA 94304 USA	Stanford University	Lorig, K (corresponding author), Stanford Univ, Sch Med, Dept Med,Stanford Patient Educ Res Ctr, Div Rheumatol & Immunol, Palo Alto, CA 94304 USA.							Barlow JH, 1998, BRIT J RHEUMATOL, V37, P1315; CLARK NM, 1988, GERONTOLOGIST, V28, P491, DOI 10.1093/geront/28.4.491; Corbin J. M., 1988, UNENDING WORK CARE M; Department of Health, 2001, EXP PAT NEW APPR CHR; Hart JT, 1995, J PUBLIC HEALTH MED, V17, P383; LORIG K, 1985, ARTHRITIS RHEUM, V28, P680, DOI 10.1002/art.1780280612; Lorig KR, 1999, MED CARE, V37, P5, DOI 10.1097/00005650-199901000-00003; LORIG KR, 1993, ARTHRITIS RHEUM, V36, P439, DOI 10.1002/art.1780360403; Lorig KR, 2001, MED CARE, V39, P1217, DOI 10.1097/00005650-200111000-00008; Schwarzer R., 1992, SELF EFFICACY THOUGH	10	111	111	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 9	2002	359	9309					814	815		10.1016/S0140-6736(02)07959-X	http://dx.doi.org/10.1016/S0140-6736(02)07959-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	529YV	11897275				2022-12-28	WOS:000174329600004
J	Hu, FB; Bronner, L; Willett, WC; Stampfer, MJ; Rexrode, KM; Albert, CM; Hunter, D; Manson, JE				Hu, FB; Bronner, L; Willett, WC; Stampfer, MJ; Rexrode, KM; Albert, CM; Hunter, D; Manson, JE			Fish and omega-3 fatty acid intake and risk of coronary heart disease in women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FOOD FREQUENCY QUESTIONNAIRE; ALPHA-LINOLENIC ACID; DIETARY-INTAKE; CARDIOVASCULAR-DISEASE; MYOCARDIAL-INFARCTION; CONSUMPTION; DEATH; REPRODUCIBILITY; PREVENTION; GREENLAND	Context Higher consumption of fish and omega-3 fatty acids has been associated with a lower risk of coronary heart disease (CND) in men, but limited data are available regarding women. Objective To examine the association between fish and long-chain omega-3 fatty acid consumption and risk of CHD in women. Design, Setting, and Participants Dietary consumption and follow-up data from 84688 female nurses enrolled in the Nurses' Health Study, aged 34 to 59 years and free from cardiovascular disease and cancer at baseline in 1980, were compared from validated questionnaires completed in 1980, 1984, 1986, 1990, and 1994. Main Outcome Measures Incident nonfatal myocardial infarction and CHD deaths. Results During 16 years of follow-up, there were 1513 incident cases of CHID (484 CHD deaths and 1029 nonfatal myocardial infarctions). Compared with women who rarely ate fish (<1 per month), those with a higher intake of fish had a lower risk of CHD. After adjustment forage, smoking, and other cardiovascular risk factors, the multivariable relative risks (RRs) of CHD were 0.79 (95% confidence interval [CI], 0.64-0.97) for fish consumption 1 to 3 times per month, 0.71 (95% CI, 0.58-0.87) for once per week, 0.69 (95% CI, 0.55-0.88) for 2 to 4 times per week, and 0.66 (95% Cl, 0.50-0.89) for 5 or more times per week (P for trend =.001). Similarly, women with a higher intake of omega-3 fatty acids had a lower risk of CHD, with multivariable RRs of 1.0, 0.93, 0.78, 0.68, and 0.67 (P<.001 for trend) across quintiles of intake. For fish intake and omega-3 fatty acids, the inverse association appeared to be stronger for CHID deaths (multivariate RR for fish consumption 5 times per week, 0.55 [95% Cl, 0.33-0.90] for CHID deaths vs 0.73 [0.51-1.04]) than for nonfatal myocardial infarction. Conclusion Among women, higher consumption of fish and omega-3 fatty acids is associated with a lower risk of CHID, particularly CHID deaths.	Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA USA; Brigham & Womens Hosp, Dept Med, Div Prevent Med, Boston, MA USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol, Boston, MA USA; Duke Univ, Med Ctr, Dept Psychiat, Durham, NC 27710 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Duke University	Hu, FB (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Nutr, 665 Huntington Ave, Boston, MA 02115 USA.		Hu, Frank/C-1919-2013; Rexrode, Kathryn M/I-1177-2018	Albert, Christine/0000-0002-2081-1121; Rexrode, Kathryn/0000-0003-3387-8429	NCI NIH HHS [CA87969] Funding Source: Medline; NHLBI NIH HHS [HL24074, HL34594] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA087969] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034594] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Albert CM, 1998, JAMA-J AM MED ASSOC, V279, P23, DOI 10.1001/jama.279.1.23; ASCHERIO A, 1995, NEW ENGL J MED, V332, P977, DOI 10.1056/NEJM199504133321501; BANG HO, 1976, ACTA MED SCAND, V200, P69; BURING JE, 1996, PREVENTION MYOCARDIA, P308; BURR ML, 1989, LANCET, V2, P757; D'Agostino RB, 1998, STAT MED, V17, P2265, DOI 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B; Daviglus ML, 1997, NEW ENGL J MED, V336, P1046, DOI 10.1056/NEJM199704103361502; De Caterina R, 2000, AM J CLIN NUTR, V71, p213S, DOI 10.1093/ajcn/71.1.213S; de Lorgeril M, 1999, CIRCULATION, V99, P779, DOI 10.1161/01.CIR.99.6.779; DELORGERIL M, 1994, LANCET, V343, P1454, DOI 10.1016/S0140-6736(94)92580-1; FESKANICH D, 1993, J AM DIET ASSOC, V93, P790, DOI 10.1016/0002-8223(93)91754-E; FLEISCHHAUER FJ, 1993, J AM COLL CARDIOL, V21, P982, DOI 10.1016/0735-1097(93)90357-7; GABH Rose, 1982, WHO MONOGRAPH SERIES; Goodfellow J, 2000, J AM COLL CARDIOL, V35, P265, DOI 10.1016/S0735-1097(99)00548-3; HARRIS WS, 1989, J LIPID RES, V30, P785; HIRAI A, 1980, LANCET, V2, P1132; Hu FB, 1999, AM J EPIDEMIOL, V149, P531, DOI 10.1093/oxfordjournals.aje.a009849; Hu FB, 1999, AM J CLIN NUTR, V69, P890; Hu FB, 1997, NEW ENGL J MED, V337, P1491, DOI 10.1056/NEJM199711203372102; HUNTER DJ, 1992, AM J EPIDEMIOL, V135, P418, DOI 10.1093/oxfordjournals.aje.a116302; Iso H, 2001, JAMA-J AM MED ASSOC, V285, P304, DOI 10.1001/jama.285.3.304; KAGAWA Y, 1982, J NUTR SCI VITAMINOL, V28, P441, DOI 10.3177/jnsv.28.441; Kang JX, 1996, CIRCULATION, V94, P1774, DOI 10.1161/01.CIR.94.7.1774; Kang JX, 2000, AM J CLIN NUTR, V71, p202S, DOI 10.1093/ajcn/71.1.202S; KINSELLA JE, 1988, FOOD TECHNOL-CHICAGO, V42, P124; KINSELLA JE, 1987, AM J CARDIOL, V60, pG23, DOI 10.1016/0002-9149(87)90588-1; Krauss RM, 2000, CIRCULATION, V102, P2284; KROMANN N, 1980, ACTA MED SCAND, V208, P401; KROMHOUT D, 1985, NEW ENGL J MED, V312, P1205, DOI 10.1056/NEJM198505093121901; MCLENNAN PL, 1992, AM HEART J, V123, P1555, DOI 10.1016/0002-8703(92)90809-A; MIDDAUGH JP, 1990, AM J PUBLIC HEALTH, V80, P282, DOI 10.2105/AJPH.80.3.282; MORRIS MC, 1995, AM J EPIDEMIOL, V142, P166, DOI 10.1093/oxfordjournals.aje.a117615; Nair SSD, 1997, J NUTR, V127, P383, DOI 10.1093/jn/127.3.383; NEWMAN WP, 1993, LANCET, V341, P1056, DOI 10.1016/0140-6736(93)92413-N; SISCOVICK DS, 1995, JAMA-J AM MED ASSOC, V274, P1363, DOI 10.1001/jama.274.17.1363; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; Therneau T, 1997, P 1 SEATTL S BIOST S, P51; Valagussa F, 1999, LANCET, V354, P447, DOI 10.1016/S0140-6736(99)07072-5; von Schacky C, 2000, AM J CLIN NUTR, V71, p224S, DOI 10.1093/ajcn/71.1.224s; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086	40	701	747	0	56	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 10	2002	287	14					1815	1821		10.1001/jama.287.14.1815	http://dx.doi.org/10.1001/jama.287.14.1815			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	539QJ	11939867	Bronze			2022-12-28	WOS:000174881700034
J	Rhee, I; Bachman, KE; Park, BH; Jair, KW; Yen, RWC; Schuebel, KE; Cui, HM; Feinberg, AP; Lengauer, C; Kinzler, KW; Baylin, SB; Vogelstein, B				Rhee, I; Bachman, KE; Park, BH; Jair, KW; Yen, RWC; Schuebel, KE; Cui, HM; Feinberg, AP; Lengauer, C; Kinzler, KW; Baylin, SB; Vogelstein, B			DNMT1 and DNMT3b cooperate to silence genes in human cancer cells	NATURE			English	Article							DE-NOVO METHYLATION; DNA METHYLATION; CYTOSINE-5 METHYLTRANSFERASES; WILMS-TUMOR; HYPERMETHYLATION; RELAXATION; NEOPLASIA; LETHALITY; TISSUE	Inactivation of tumour suppressor genes is central to the development of all common forms of human cancer(1). This inactivation often results from epigenetic silencing associated with hypermethylation rather than intragenic mutations(2-7). In human cells, the mechanisms underlying locus-specific or global methylation patterns remain unclear(8,9). The prototypic DNA methyltransferase, Dnmt1, accounts for most methylation in mouse cells(10,11), but human cancer cells lacking DNMT1 retain significant genomic methylation and associated gene silencing(12). We disrupted the human DNMT3b gene in a colorectal cancer cell line. This deletion reduced global DNA methylation by less than 3%. Surprisingly, however, genetic disruption of both DNMT1 and DNMT3b nearly eliminated methyltransferase activity, and reduced genomic DNA methylation by greater than 95%. These marked changes resulted in demethylation of repeated sequences, loss of insulin-like growth factor II (IGF2) imprinting, abrogation of silencing of the tumour suppressor gene p16(INK4a), and growth suppression. Here we demonstrate that two enzymes cooperatively maintain DNA methylation and gene silencing in human cancer cells, and provide compelling evidence that such methylation is essential for optimal neoplastic proliferation.	Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Program Human Genet, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Inst Med Genet, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Program Cellular & Mol Med, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins Medicine; Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Baylin, SB (corresponding author), Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA.	sbaylin@jhmi.edu; vogelbe@welch.jhu.edu	Feinberg, Andrew/AAY-7666-2020; Cui, Hengmi/A-2598-2008; jia, xu/A-8386-2016	Feinberg, Andrew/0000-0002-8364-1991	NATIONAL CANCER INSTITUTE [R01CA054358, R37CA054358] Funding Source: NIH RePORTER; NCI NIH HHS [R37 CA054358-12, R37 CA054358, R01 CA054358] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bachman KE, 1999, CANCER RES, V59, P798; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Cui HM, 1998, NAT MED, V4, P1276, DOI 10.1038/3260; Eads CA, 1999, CANCER RES, V59, P2302; FEINBERG AP, 1988, CANCER RES, V48, P1159; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Jackson-Grusby L, 2001, NAT GENET, V27, P31, DOI 10.1038/83730; JUTTERMANN R, 1994, P NATL ACAD SCI USA, V91, P11797, DOI 10.1073/pnas.91.25.11797; KUO KC, 1980, NUCLEIC ACIDS RES, V8, P4763, DOI 10.1093/nar/8.20.4763; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Lyko F, 1999, NAT GENET, V23, P363, DOI 10.1038/15551; Myohanen SK, 1998, CANCER RES, V58, P591; OGAWA O, 1993, NAT GENET, V5, P408, DOI 10.1038/ng1293-408; Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Ponder BAJ, 2001, NATURE, V411, P336, DOI 10.1038/35077207; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; Rhee I, 2000, NATURE, V404, P1003, DOI 10.1038/35010000; Robertson KD, 2000, CARCINOGENESIS, V21, P461, DOI 10.1093/carcin/21.3.461; SANTI DV, 1983, CELL, V33, P9, DOI 10.1016/0092-8674(83)90327-6; Schmutte C, 1996, CANCER RES, V56, P2375; Siegfried Z, 1997, CURR BIOL, V7, pR305, DOI 10.1016/S0960-9822(06)00144-8; STEENMAN MJC, 1994, NAT GENET, V7, P433, DOI 10.1038/ng0794-433; Tycko B, 2000, J CLIN INVEST, V105, P401, DOI 10.1172/JCI9462; Ueijma H, 2000, NAT GENET, V25, P375, DOI 10.1038/78040; Vertino PM, 1996, MOL CELL BIOL, V16, P4555, DOI 10.1128/mcb.16.8.4555; Vogelstein B., 1998, GENETIC BASIS HUMAN	30	975	1042	4	100	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 4	2002	416	6880					552	556		10.1038/416552a	http://dx.doi.org/10.1038/416552a			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	537JY	11932749				2022-12-28	WOS:000174756500048
J	Rahi, JS; Dezateux, C				Rahi, JS; Dezateux, C			Improving the detection of childhood visual problems and eye disorders	LANCET			English	Editorial Material							AMBLYOPIA		Inst Child Hlth, Ctr Paediat Epidemiol & Biostat, London WC1N 1EH, England; Great Ormond St Hosp Sick Children, Dept Ophthalmol, London, England; Inst Ophthalmol, London, England	University of London; University College London; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London	Rahi, JS (corresponding author), Inst Child Hlth, Ctr Paediat Epidemiol & Biostat, 30 Guilford St, London WC1N 1EH, England.		Dezateux, Carol/A-3416-2009	Rahi, Jugnoo/0000-0002-5718-9209; Dezateux, Carol/0000-0001-9787-6276				CAMPOS E, 1995, SURV OPHTHALMOL, V40, P23, DOI 10.1016/S0039-6257(95)80044-1; *CAN TASK FORC PER, 1994, CAN GUID CLIN PREV C; DEWINTER M, 1995, SCREENING CHILD HLTH; DIGUISEPPI C, 2001, ACTA OPHTHALMOL SCAN, V79, P240; Gilbert C, 2001, B WORLD HEALTH ORGAN, V79, P227; HARRARD RA, 1999, SURV OPHTHALMOL, V43, P375; Hartmann EE, 2001, OPHTHALMOLOGY, V108, P479, DOI 10.1016/S0161-6420(00)00588-1; Juttmann R, 2001, BRIT J OPHTHALMOL, V85, P1332, DOI 10.1136/bjo.85.11.1332; Kvarnstrom G, 2001, ACTA OPHTHALMOL SCAN, V79, P240, DOI 10.1034/j.1600-0420.2001.790306.x; Moseley MJ, 1998, BRIT J OPHTHALMOL, V82, P722, DOI 10.1136/bjo.82.7.722; Rahi JS, 1997, BMJ-BRIT MED J, V315, P1247, DOI 10.1136/bmj.315.7118.1247; Rahi JS, 2001, BRIT J OPHTHALMOL, V85, P257, DOI 10.1136/bjo.85.3.257; SMITH LK, 1994, J PUBLIC HEALTH MED, V16, P348; SNOWDON SK, 1997, 9 CRD U YORK NHS CTR; Williams C, 2001, Ophthalmic Epidemiol, V8, P279; WRIGHT C, 2001, PROTOCOL 00PRT 1 MUL	16	7	8	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 30	2002	359	9312					1083	1084		10.1016/S0140-6736(02)08127-8	http://dx.doi.org/10.1016/S0140-6736(02)08127-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	536YJ	11943253				2022-12-28	WOS:000174729200004
J	Kroenke, K				Kroenke, K			A 75-year-old man with depression	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RANDOMIZED CONTROLLED-TRIAL; RECURRENT MAJOR DEPRESSION; PRIMARY-CARE PATIENTS; LATE-LIFE; OLDER-ADULTS; COMPETING DEMANDS; SUICIDAL IDEATION; RISK-FACTOR; SYMPTOMS; PSYCHOTHERAPY		Regenstrief Inst Hlth Care, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Med, Indianapolis, IN USA	Indiana University System; Indiana University-Purdue University Indianapolis; Regenstrief Institute Inc; Indiana University System; Indiana University-Purdue University Indianapolis	Kroenke, K (corresponding author), Regenstrief Inst Hlth Care, RG-6,1050 Wishard Blvd, Indianapolis, IN 46202 USA.	kkroenke@regenstrief.org	anand, amit/A-7222-2009	Kroenke, Kurt/0000-0002-0114-4669				*AG HLTH CAR POL R, 1993, AHCPR PUBL; ALEXOPOULOS GS, 1993, AM J PSYCHIAT, V150, P1693; Alexopoulos GS, 2000, ARCH GEN PSYCHIAT, V57, P285, DOI 10.1001/archpsyc.57.3.285; Alexopoulos GS, 1996, ARCH GEN PSYCHIAT, V53, P305; Alexopoulos GS, 1999, ARCH GEN PSYCHIAT, V56, P1048, DOI 10.1001/archpsyc.56.11.1048; Alexopoulos GS, 1996, J CLIN PSYCHIAT, V57, P14; Ashley RV, 2001, GEN HOSP PSYCHIAT, V23, P3, DOI 10.1016/S0163-8343(00)00118-3; BRIGHT RA, 1992, JAMA-J AM MED ASSOC, V267, P1783; BRODY DS, 1994, J GEN INTERN MED, V9, P569, DOI 10.1007/BF02599285; Brown C, 1995, GEN HOSP PSYCHIAT, V17, P414, DOI 10.1016/0163-8343(95)00072-0; Callahan CM, 2001, MED CARE, V39, P772, DOI 10.1097/00005650-200108000-00004; Callahan CM, 1996, J AM GERIATR SOC, V44, P1205, DOI 10.1111/j.1532-5415.1996.tb01370.x; CALLAHAN CM, IN PRESS MED CARE; CASSEM EH, 1995, PSYCHOSOMATICS, V36, pS2, DOI 10.1016/S0033-3182(95)71698-X; Chiu E, 1999, WPA SER EVID EXPER P, V1, P313; Cole MG, 1999, AM J PSYCHIAT, V156, P1182; Conwell Y, 1996, AM J PSYCHIAT, V153, P1001; Covinsky KE, 1999, ANN INTERN MED, V130, P563, DOI 10.7326/0003-4819-130-7-199904060-00004; de Groot JC, 2000, ARCH GEN PSYCHIAT, V57, P1071, DOI 10.1001/archpsyc.57.11.1071; DeRubeis RJ, 1999, AM J PSYCHIAT, V156, P1007; DIETRICH AJ, 2000, EFF CLIN PRACT, V4, P191; DiMatteo MR, 2000, ARCH INTERN MED, V160, P2101, DOI 10.1001/archinte.160.14.2101; Everson SA, 1998, ARCH INTERN MED, V158, P1133, DOI 10.1001/archinte.158.10.1133; Ford DE, 1998, ARCH INTERN MED, V158, P1422, DOI 10.1001/archinte.158.13.1422; FRASER S, IN PRESS J GEN INTER; FRIEDHOFF AJ, 1992, JAMA-J AM MED ASSOC, V268, P1018, DOI 10.1001/jama.1992.03490080092032; Gerrity MS, 1999, J FAM PRACTICE, V48, P949; Gerson S, 1999, HARVARD REV PSYCHIAT, V7, P1, DOI 10.1093/hrp/7.1.1; HAGGERTY JJ, 1995, ANNU REV MED, V46, P37, DOI 10.1146/annurev.med.46.1.37; Helfand M, 1998, ANN INTERN MED, V129, P144, DOI 10.7326/0003-4819-129-2-199807150-00020; Kamath M, 1996, AM J GERIAT PSYCHIAT, V4, P167, DOI 10.1097/00019442-199621420-00009; Katon W, 1999, ARCH GEN PSYCHIAT, V56, P1109, DOI 10.1001/archpsyc.56.12.1109; Katon W, 1996, ARCH GEN PSYCHIAT, V53, P924; KATON W, 1995, JAMA-J AM MED ASSOC, V273, P1026, DOI 10.1001/jama.273.13.1026; KAY J, 2001, INTEGRATED TREATMENT; Keller MB, 2000, NEW ENGL J MED, V342, P1462, DOI 10.1056/NEJM200005183422001; Klinkman MS, 1997, GEN HOSP PSYCHIAT, V19, P98, DOI 10.1016/S0163-8343(96)00145-4; KOENIG HG, 1995, J AM GERIATR SOC, V43, P472, DOI 10.1111/j.1532-5415.1995.tb06091.x; Kroenke K, 2001, JAMA-J AM MED ASSOC, V286, P2947, DOI 10.1001/jama.286.23.2947; Kroenke K, 1997, ANN INTERN MED, V126, P463, DOI 10.7326/0003-4819-126-6-199703150-00008; Kroenke K, 2000, PSYCHOSOMATICS, V41, P39, DOI 10.1016/S0033-3182(00)71172-8; Kroenke K, 2001, ANN INTERN MED, V134, P418, DOI 10.7326/0003-4819-134-5-200103060-00014; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Lebowitz BD, 1997, JAMA-J AM MED ASSOC, V278, P1186, DOI 10.1001/jama.278.14.1186; LIN EHB, 1995, MED CARE, V33, P67, DOI 10.1097/00005650-199501000-00006; Lyness JM, 1999, J AM GERIATR SOC, V47, P647, DOI 10.1111/j.1532-5415.1999.tb01584.x; Mamdani MM, 2000, AM J PSYCHIAT, V157, P360, DOI 10.1176/appi.ajp.157.3.360; MAYFIELD D, 1974, AM J PSYCHIAT, V131, P1121; McCusker J, 1998, ARCH INTERN MED, V158, P705, DOI 10.1001/archinte.158.7.705; MULROW CD, 1995, ANN INTERN MED, V122, P913, DOI 10.7326/0003-4819-122-12-199506150-00004; Mulrow CD, 2000, AM J MED, V108, P54, DOI 10.1016/S0002-9343(99)00316-2; Musselman DL, 1998, ARCH GEN PSYCHIAT, V55, P580, DOI 10.1001/archpsyc.55.7.580; Ormel J, 1998, J AM GERIATR SOC, V46, P39, DOI 10.1111/j.1532-5415.1998.tb01011.x; PENDERGAST KB, 2000, PHARMACOEPIDEMIOL S1, V9, P101; Reynolds CF, 1996, AM J PSYCHIAT, V153, P1288; Reynolds CF, 1999, JAMA-J AM MED ASSOC, V281, P39, DOI 10.1001/jama.281.1.39; Robinson RG, 2000, JAMA-J AM MED ASSOC, V283, P1607, DOI 10.1001/jama.283.12.1607; Rosenbaum JF, 1998, BIOL PSYCHIAT, V44, P77, DOI 10.1016/S0006-3223(98)00126-7; ROTER DL, 1995, ARCH INTERN MED, V155, P1877, DOI 10.1001/archinte.155.17.1877; Rubenstein LV, 1999, HEALTH AFFAIR, V18, P89, DOI 10.1377/hlthaff.18.5.89; Salloway S, 2002, AM J GERIAT PSYCHIAT, V10, P107, DOI 10.1176/appi.ajgp.10.1.107; Schneider LS, 1996, AM J GERIAT PSYCHIAT, V4, pS51; Schulberg HC, 1999, J CLIN PSYCHIAT, V60, P19; Simon GE, 1999, NEW ENGL J MED, V341, P1329, DOI 10.1056/NEJM199910283411801; Sirey JA, 2001, AM J PSYCHIAT, V158, P479, DOI 10.1176/appi.ajp.158.3.479; Snow V, 2000, ANN INTERN MED, V132, P738, DOI 10.7326/0003-4819-132-9-200005020-00010; Stefanis CN, 1999, WPA SER EVID EXPER P, V1, P1; Tanielian TL, 2000, PSYCHOSOMATICS, V41, P245, DOI 10.1176/appi.psy.41.3.245; Thase ME, 1997, ARCH GEN PSYCHIAT, V54, P1009; Unutzer J, 1999, MILBANK Q, V77, P225, DOI 10.1111/1468-0009.00132; Unutzer J, 1999, AM J GERIAT PSYCHIAT, V7, P235; Unutzer J, 2001, MED CARE, V39, P785, DOI 10.1097/00005650-200108000-00005; Unutzer J, 2000, INT PSYCHOGERIATR, V12, P15, DOI 10.1017/S1041610200006177; Whooley MA, 2000, NEW ENGL J MED, V343, P1942, DOI 10.1056/NEJM200012283432607; Williams JW, 1998, J GEN INTERN MED, V13, P137, DOI 10.1046/j.1525-1497.1998.00032.x; Williams JW, 2000, ANN INTERN MED, V132, P743, DOI 10.7326/0003-4819-132-9-200005020-00011; Williams JW, 2000, JAMA-J AM MED ASSOC, V284, P1519, DOI 10.1001/jama.284.12.1519	77	10	10	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 27	2002	287	12					1568	1576		10.1001/jama.287.12.1568	http://dx.doi.org/10.1001/jama.287.12.1568			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	533VF	11911760				2022-12-28	WOS:000174550400029
J	Bastard, JP; Caron, M; Vidal, H; Jan, V; Auclair, M; Vigouroux, C; Luboinski, J; Laville, M; Malachi, M; Girard, PM; Rozenbaum, W; Levan, P; Capeau, J				Bastard, JP; Caron, M; Vidal, H; Jan, V; Auclair, M; Vigouroux, C; Luboinski, J; Laville, M; Malachi, M; Girard, PM; Rozenbaum, W; Levan, P; Capeau, J			Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance	LANCET			English	Article							ELEMENT-BINDING PROTEIN-1; TNF-ALPHA; PREADIPOCYTE DIFFERENTIATION; DIABETES-MELLITUS; INHIBITOR; LIPODYSTROPHY; HYPERLIPIDEMIA; TROGLITAZONE; APOPTOSIS; INDINAVIR	Background Lipodystrophy is a major side-effect of antiretroviral therapy but its pathophysiology remains elusive. In-vitro studies show that HIV-1-protease inhibitors affect adipocyte differentiation at an early step involving sterol-regulatory-element-binding-protein-1 (SREBP1), but in-vivo studies are lacking. Methods We compared fat morphology and mRNA and protein expression of major adipocyte differentiation markers and cytokines in subcutaneous abdominal adipose tissue from 26 HIV-1-infected patients who developed peripheral lipoatrophy while on protease inhibitors and from 18 HIV-1-seronegative healthy controls. Findings Patients' fat contained a higher proportion of small adipocytes than control fat, together with lower mRNA concentrations of the adipogenic differentiation factors CCAAT-enhancer binding protein (C/EBP) beta and alpha, peroxisome proliferator-activated receptor (PPAR) gamma, and the 1c isoform of SREBP1, with a median decrease of 93% in the latter. The SREBP1 protein concentration was increased 2.6-fold, whereas the PPAR-gamma protein concentration was decreased by 70%. The expression of adipocyte-specific markers, including leptin, was lower in fat from patients than in fat from controls, whereas expression of tumour necrosis factor (TNF) alpha was higher and correlated negatively with the expression of SREBP1c and downstream adipogenic factors. SREBP1c mRNA concentrations correlated negatively, and TNFalpha mRNA concentrations positively, with glycaemia and insulin resistance, but did not correlate with lipid variables. Interpretation The altered differentiation status of peripheral adipocytes in HIV-1-infected patients with antiretroviral-induced lipoatrophy is associated with greatly reduced SREBP1c expression. Since the differentiation factor SREBP1 is rapidly targeted by protease inhibitors in vitro, our results suggest that SREBP1c could be an important mediator of peripheral lipoatrophy in this setting, leading to metabolic alterations such as insulin resistance.	Univ Paris 06, INSERM, U402, F-75012 Paris, France; Tenon Hosp, Dept Biochem, Paris, France; Fac Med R Laennec, INSERM, U449, Lyon, France; Fac Med R Laennec, Human Nutr Res Ctr Lyon, Lyon, France; Rothschild Hosp, Dept Biochem, Paris, France; Rothschild Hosp, Dept Pathol, Paris, France; Rothschild Hosp, Dept Infect Dis, Paris, France; Rothschild Hosp, Dept Plast Surg, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Rothschild - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Rothschild - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Rothschild - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Rothschild - APHP; UDICE-French Research Universities; Sorbonne Universite	Capeau, J (corresponding author), Univ Paris 06, INSERM, U402, 27 Rue Chaligny, F-75012 Paris, France.	capeau@st-antoine.inserm.fr	Vidal, Hubert/M-6674-2017	Vidal, Hubert/0000-0002-9467-0317; Rozenbaum, Willy/0000-0003-1975-3566; Auclair, Martine/0000-0003-3600-1999				Amemiya-Kudo M, 2000, J BIOL CHEM, V275, P31078, DOI 10.1074/jbc.M005353200; Andre P, 1998, P NATL ACAD SCI USA, V95, P13120, DOI 10.1073/pnas.95.22.13120; Arioglu E, 2000, ANN INTERN MED, V133, P263, DOI 10.7326/0003-4819-133-4-200008150-00009; Auboeuf D, 1997, ANAL BIOCHEM, V245, P141, DOI 10.1006/abio.1996.9986; AUKRUST P, 1994, J INFECT DIS, V169, P420, DOI 10.1093/infdis/169.2.420; Caron M, 2001, DIABETES, V50, P1378, DOI 10.2337/diabetes.50.6.1378; CARON M, 2001, ANTIVIR THER S4, V6, P17; Carr A, 1999, LANCET, V353, P2093, DOI 10.1016/S0140-6736(98)08468-2; Carr A, 2000, LANCET, V356, P1423, DOI 10.1016/S0140-6736(00)02854-3; COLEMAN WP, 1991, PLAST RECONSTR SURG, V88, P736, DOI 10.1097/00006534-199110000-00038; Domingo P, 1999, AIDS, V13, P2261, DOI 10.1097/00002030-199911120-00008; Dowell P, 2000, J BIOL CHEM, V275, P41325, DOI 10.1074/jbc.M006474200; Ebihara K, 2001, DIABETES, V50, P1440, DOI 10.2337/diabetes.50.6.1440; Fajas L, 1999, MOL CELL BIOL, V19, P5495; Garg A, 2000, AM J MED, V108, P143, DOI 10.1016/S0002-9343(99)00414-3; Gavrilova O, 2000, J CLIN INVEST, V105, P271, DOI 10.1172/JCI7901; Hirano Y, 2001, J BIOL CHEM, V276, P36431, DOI 10.1074/jbc.M105200200; Jain RG, 2001, ANTIVIR RES, V51, P151, DOI 10.1016/S0166-3542(01)00148-6; Kuhel DG, 2000, CIRCULATION, V102, P360; Kurebayashi S, 2001, ENDOCR J, V48, P249, DOI 10.1507/endocrj.48.249; Miserez AR, 2001, AIDS, V15, P2045, DOI 10.1097/00002030-200110190-00020; Mohamed-Ali V, 1998, INT J OBESITY, V22, P1145, DOI 10.1038/sj.ijo.0800770; Moitra J, 1998, GENE DEV, V12, P3168, DOI 10.1101/gad.12.20.3168; Moller DE, 2000, TRENDS ENDOCRIN MET, V11, P212, DOI 10.1016/S1043-2760(00)00272-1; Moyle G, 2001, AIDS, V15, P413, DOI 10.1097/00002030-200102160-00015; Nolan D, 2001, ANTIVIR THER, V6, P145; Noor MA, 2001, AIDS, V15, pF11, DOI 10.1097/00002030-200105040-00001; Prins JB, 1997, DIABETES, V46, P1939, DOI 10.2337/diabetes.46.12.1939; Purnell JQ, 2000, AIDS, V14, P51, DOI 10.1097/00002030-200001070-00006; Riddle TM, 2001, J BIOL CHEM, V276, P37514, DOI 10.1074/jbc.M104557200; Rosen ED, 2000, GENE DEV, V14, P1293; Shimomura I, 1997, J CLIN INVEST, V99, P838, DOI 10.1172/JCI119247; Shimomura I, 1998, GENE DEV, V12, P3182, DOI 10.1101/gad.12.20.3182; Vidal H, 2000, METH MOL B, V155, P83; Walli R, 2000, RES EXP MED, V199, P253, DOI 10.1007/s004330050123	35	322	327	0	11	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 23	2002	359	9311					1026	1031		10.1016/S0140-6736(02)08094-7	http://dx.doi.org/10.1016/S0140-6736(02)08094-7			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	534KP	11937183				2022-12-28	WOS:000174585800010
J	Hogan, CJ				Hogan, CJ			Cosmology - The beginning of time	SCIENCE			English	Editorial Material							MICROWAVE		Univ Washington, Dept Astron, Seattle, WA 98195 USA; Univ Washington, Dept Phys, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Hogan, CJ (corresponding author), Univ Washington, Dept Astron, Seattle, WA 98195 USA.							Bennett CL, 1996, ASTROPHYS J, V464, pL1, DOI 10.1086/310075; de Bernardis P, 2000, NATURE, V404, P955, DOI 10.1038/35010035; Hogan C., UNPUB; Kamionkowski M, 1999, ANNU REV NUCL PART S, V49, P77, DOI 10.1146/annurev.nucl.49.1.77; KOLB EW, 1990, EARLY UNIVERSE; LIDDLE AR, 1993, PHYS REP, V231, P1, DOI 10.1016/0370-1573(93)90114-S; Linde A. D., 1990, INFLATION QUANTUM CO; Lyth DH, 1999, PHYS REP, V314, P1, DOI 10.1016/S0370-1573(98)00128-8; Rees Martin, 1997, BEGINNING OUR UNIVER; SUSSKIND L, 1995, J MATH PHYS, V36, P6377, DOI 10.1063/1.531249	10	4	4	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 22	2002	295	5563					2223	+		10.1126/science.1070262	http://dx.doi.org/10.1126/science.1070262			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	534AD	11910096				2022-12-28	WOS:000174561700029
J	McDermott, R; Trabesinger, AH; Muck, M; Hahn, EL; Pines, A; Clarke, J				McDermott, R; Trabesinger, AH; Muck, M; Hahn, EL; Pines, A; Clarke, J			Liquid-state NMR and scalar couplings in microtesla magnetic fields	SCIENCE			English	Article							NOBLE-GAS; RESONANCE	We obtained nuclear magnetic resonance (NMR) spectra of liquids in fields of a few microtesla, using prepolarization in fields of a few millitesta and detection with a dc superconducting quantum interference device (SQUID). Because the sensitivity of the SQUID is frequency independent, we enhanced both signal-to-noise ratio and spectral resolution by detecting the NMR signal in extremely tow magnetic fields, where the NMR tines become very narrow even for grossly inhomogeneous measurement fields. In the absence of chemical shifts, proton-phosphorous scalar (J) couplings have been detected, indicating the presence of specific covalent bonds. This observation opens the possibility for "pure J spectroscopy" as a diagnostic tool, for the detection of molecules in low magnetic fields.	Univ Calif Berkeley, Dept Phys, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Mat Sci, Berkeley, CA 94720 USA; Univ Giessen, Inst Appl Phys, D-35392 Giessen, Germany	University of California System; University of California Berkeley; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Justus Liebig University Giessen	McDermott, R (corresponding author), Univ Calif Berkeley, Dept Phys, Berkeley, CA 94720 USA.		Trabesinger, Andreas/J-2008-2016	Trabesinger, Andreas/0000-0003-3078-8399				Abragam A., 1982, NUCL MAGNETISM ORDER; BENE GJ, 1980, PHYS REP, V58, P213, DOI 10.1016/0370-1573(80)90012-5; Blumich B, 1998, MAGN RESON IMAGING, V16, P479, DOI 10.1016/S0730-725X(98)00069-1; CLARKE J, 1906, SQUID SENSORS FUNDAM, P1; Ernst R. R., 1987, PRINCIPLES NUCL MAGN; Garroway AN, 2001, IEEE T GEOSCI REMOTE, V39, P1108, DOI 10.1109/36.927420; Greenberg YS, 1998, REV MOD PHYS, V70, P175, DOI 10.1103/RevModPhys.70.175; HAHN EL, 1950, PHYS REV, V80, P580, DOI 10.1103/PhysRev.80.580; HAPPER W, 1984, PHYS REV A, V29, P3092, DOI 10.1103/PhysRevA.29.3092; KUMAR S, 1995, J MAGN RESON SER B, V107, P252, DOI 10.1006/jmrb.1995.1085; Meriles CA, 2001, SCIENCE, V293, P82, DOI 10.1126/science.1061498; PACKARD M, 1954, PHYS REV, V93, P941; Schlenga K, 1999, APPL PHYS LETT, V75, P3695, DOI 10.1063/1.125432; Seton HC, 1997, MEAS SCI TECHNOL, V8, P198, DOI 10.1088/0957-0233/8/2/015; Slichter C.P., 1990, PRINCIPLES NUCL MAGN; THOMPSON DD, 1961, J CHEM PHYS, V35, P1894, DOI 10.1063/1.1732162; THOMPSON DD, 1962, J CHEM PHYS, V36, P2812, DOI 10.1063/1.1732379; Tseng CH, 1998, PHYS REV LETT, V81, P3785, DOI 10.1103/PhysRevLett.81.3785; ZAX DB, 1985, J CHEM PHYS, V83, P4877, DOI 10.1063/1.449748; ZAX DB, 1984, CHEM PHYS LETT, V106, P550, DOI 10.1016/0009-2614(84)85381-6	20	246	256	1	53	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 22	2002	295	5563					2247	2249		10.1126/science.1069280	http://dx.doi.org/10.1126/science.1069280			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	534AD	11910105				2022-12-28	WOS:000174561700039
J	Zander, M; Madsbad, S; Madsen, JL; Holst, JJ				Zander, M; Madsbad, S; Madsen, JL; Holst, JJ			Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study	LANCET			English	Article							GLUCOSE-TOLERANCE; FAT DISTRIBUTION; WEIGHT-LOSS; 7-36 AMIDE; TEST MEAL; MELLITUS; NIDDM; SECRETION; RESPONSES; OBESITY	Background Glucagon-like peptide 1 (GLP-1) has been proposed as a treatment for type 2 diabetes. We have investigated the long-term effects of continuous administration of this peptide hormone in a 6-week pilot study. Methods 20 patients with type 2 diabetes were alternately assigned continuous subcutaneous infusion of GLP-1 (n=10) or saline (n=10) for 6 weeks. Before (week 0) and at weeks I and 6, they underwent beta-cell function tests (hyperglycaemic clamps), 8 h profiles of plasma glucose, insulin, C-peptide, glucagon, and free fatty acids, and appetite and side-effect ratings on 100 mm visual analogue scales; at weeks 0 and 6 they also underwent dexascanning, measurement of insulin sensitivity (hyperinsulinaemic euglycaemic clamps), haemoglobin A(1c), and fructosamine. The primary endpoints were haemoglobin A(1c) concentration, 8-h profile of glucose concentration in plasma, and beta-cell function (defined as the first-phase response to glucose and the maximum insulin secretory capacity of the cell). Analyses were per protocol. Findings One patient assigned saline was excluded because no veins were accessible. In the remaining nine patients in that group, no significant changes were observed except an increase in fructosamine concentration (p=0.0004). In the GLP-1 group, fasting and 8 h mean plasma glucose decreased by 4.3 mmol/L and 5.5 mmol/L (p<0.0001). Haemoglobin A(1c) decreased by 1.3% (p=0.003) and fructosamine fell to normal values (p=0.0002). Fasting and 8 h mean concentrations of free fatty acids decreased by 30% and 23% (p=0.0005 and 0.01, respectively). Gastric emptying was inhibited, bodyweight decreased by 1.9 kg, and appetite was reduced. Both insulin sensitivity and beta-cell function improved (p=0.003 and p=0.003, respectively). No important side-effects were seen. Interpretation GLP-1 could be a new treatment for type 2 diabetes, though further investigation of the long-term effects of GLP-1 is needed.	Univ Copenhagen, Panum Inst, Dept Med Physiol, DK-2200 Copenhagen N, Denmark; Univ Copenhagen, Hvidovre Hosp, Dept Endocrinol, DK-2650 Hvidovre, Denmark; Univ Copenhagen, Hvidovre Hosp, Dept Clin Physiol, DK-2650 Hvidovre, Denmark; Hvidovre Univ Hosp, Clin Trial Unit, DK-2650 Hvidovre, Denmark	University of Copenhagen; University of Copenhagen; University of Copenhagen; University of Copenhagen	Zander, M (corresponding author), Univ Copenhagen, Hvidovre Hosp, Dept Endocrinol 541, Kettegaards Alle 30, DK-2650 Hvidovre, Denmark.	M.Zander@dadlnet.dk	Holst, Jens/AAA-8022-2022	Holst, Jens Juul/0000-0001-6853-3805; Madsbad, Sten/0000-0002-5017-1815				Boden G, 1997, DIABETES, V46, P3, DOI 10.2337/diabetes.46.1.3; BOGARDUS C, 1986, DIABETES, V35, P1, DOI 10.2337/diabetes.35.1.1; BRUCE DG, 1988, DIABETES, V37, P736, DOI 10.2337/diabetes.37.6.736; Carey DG, 1996, DIABETES, V45, P633, DOI 10.2337/diabetes.45.5.633; Carpentier A, 2000, DIABETES, V49, P399, DOI 10.2337/diabetes.49.3.399; CHAN JM, 1994, DIABETES CARE, V17, P961, DOI 10.2337/diacare.17.9.961; DEACON CF, 1995, DIABETES, V44, P1126, DOI 10.2337/diabetes.44.9.1126; DEACON CF, 1995, J CLIN ENDOCR METAB, V80, P952, DOI 10.1210/jc.80.3.952; DEFRONZO RA, 1979, AM J PHYSIOL, V237, pE214; Edwards CMB, 1999, DIABETES, V48, P86, DOI 10.2337/diabetes.48.1.86; Flint A, 2000, INT J OBESITY, V24, P38, DOI 10.1038/sj.ijo.0801083; Goodpaster BH, 1999, DIABETES, V48, P839, DOI 10.2337/diabetes.48.4.839; HENRY RR, 1993, DIABETES CARE, V16, P21, DOI 10.2337/diacare.16.1.21; KREYMANN B, 1987, LANCET, V2, P1300; Larsen J, 2001, DIABETES CARE, V24, P1416, DOI 10.2337/diacare.24.8.1416; Lugari R, 2000, HORM METAB RES, V32, P424, DOI 10.1055/s-2007-978665; LUZI L, 1989, AM J PHYSIOL, V257, pE241, DOI 10.1152/ajpendo.1989.257.2.E241; Markovic TP, 1998, DIABETES CARE, V21, P687, DOI 10.2337/diacare.21.5.687; Nauck MA, 1996, DIABETOLOGIA, V39, P1546, DOI 10.1007/s001250050613; NAUCK MA, 1993, DIABETOLOGIA, V36, P741, DOI 10.1007/BF00401145; PORTE D, 1991, DIABETES, V40, P166, DOI 10.2337/diabetes.40.2.166; Rachman J, 1996, DIABETES, V45, P1524, DOI 10.2337/diabetes.45.11.1524; RITZEL R, 1995, DIABETOLOGIA, V38, P720, DOI 10.1007/s001250050344; Staehr P, 2001, DIABETES, V50, P1363, DOI 10.2337/diabetes.50.6.1363; Storgaard H, 2001, DIABETES, V50, P2770, DOI 10.2337/diabetes.50.12.2770; Todd JF, 1997, EUR J CLIN INVEST, V27, P533, DOI 10.1046/j.1365-2362.1997.1490691.x; Toft-Nielsen MB, 1999, DIABETES CARE, V22, P1137, DOI 10.2337/diacare.22.7.1137; Turner R, 1996, ANN INTERN MED, V124, P136, DOI 10.7326/0003-4819-124-1_Part_2-199601011-00011; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; Vella A, 2000, DIABETES, V49, P611, DOI 10.2337/diabetes.49.4.611; Wang YH, 1997, J CLIN INVEST, V99, P2883, DOI 10.1172/JCI119482; WARD WK, 1984, J CLIN INVEST, V74, P1318, DOI 10.1172/JCI111542; Willms B, 1996, J CLIN ENDOCR METAB, V81, P327, DOI 10.1210/jc.81.1.327; Xu G, 1999, DIABETES, V48, P2270, DOI 10.2337/diabetes.48.12.2270; YKIJARVINEN H, 1992, ENDOCR REV, V13, P415, DOI 10.1210/er.13.3.415	35	1004	1129	3	66	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 9	2002	359	9309					824	830		10.1016/S0140-6736(02)07952-7	http://dx.doi.org/10.1016/S0140-6736(02)07952-7			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	529YV	11897280				2022-12-28	WOS:000174329600008
J	Makova, KD; Li, WH				Makova, KD; Li, WH			Strong male-driven evolution of DNA sequences in humans and apes	NATURE			English	Article							MUTATION-RATE; NUCLEOTIDE; CHROMOSOME; RATES	Studies of human genetic diseases have suggested a higher mutation rate in males than in females 1 and the male-to-female ratio (alpha) of mutation rate has been estimated from DNA sequence and microsatellite data to be about 4-6 in higher primates(2-5). Two recent studies, however, claim that alpha is only about 2 in humans(6,7). This is even smaller than the estimates (alpha > 4) for carnivores and birds(8,9); humans should have a higher alpha than carnivores and birds because of a longer generation time and a larger sex difference in the number of germ cell cycles. To resolve this issue, we sequenced a noncoding fragment on Y of about 10.4 kilobases (kb) and a homologous region on chromosome 3 in humans, greater apes, and lesser apes. Here we show that our estimate of alpha from the internal branches of the phylogeny is 5.25 (95% confidence interval (CI) 2.44 to infinity), similar to the previous estimates(2-5), but significantly higher than the two recent ones(6,7). In contrast, for the external (short, species-specific) branches, alpha is only 2.23 (95% CI: 1.47-3.84). We suggest that closely related species are not suitable for estimating alpha, because of ancient polymorphism and other factors. Moreover, we provide an explanation for the small estimate of a in a previous study(6). Our study reinstates a high alpha in hominoids and supports the view that DNA replication errors are the primary source of germline mutation.	Univ Chicago, Dept Ecol & Evolut, Chicago, IL 60637 USA	University of Chicago	Li, WH (corresponding author), Univ Chicago, Dept Ecol & Evolut, 1101 E 57th St, Chicago, IL 60637 USA.	whli@uchicago.edu		Li, Wen-Hsiung/0000-0003-1086-1456				Agulnik AI, 1998, HUM MOL GENET, V7, P1371, DOI 10.1093/hmg/7.9.1371; BEGUN DJ, 1992, NATURE, V356, P519, DOI 10.1038/356519a0; Bohossian HB, 2000, NATURE, V406, P622, DOI 10.1038/35020557; Charlesworth B, 2000, PHILOS T R SOC B, V355, P1563, DOI 10.1098/rstb.2000.0717; Crow JF, 2000, NAT REV GENET, V1, P40, DOI 10.1038/35049558; Ellegren H, 1997, NAT GENET, V17, P182, DOI 10.1038/ng1097-182; Ellegren H, 2000, NAT GENET, V24, P400, DOI 10.1038/74249; Erlandsson R, 2000, MOL BIOL EVOL, V17, P804, DOI 10.1093/oxfordjournals.molbev.a026359; Felsenstein J., 2005, PHYLIP PHYLOGENY INF, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; Huang W, 1997, J MOL EVOL, V44, P463, DOI 10.1007/PL00006166; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LI WH, 1977, GENETICS, V85, P331; McVean GT, 1997, NATURE, V386, P388, DOI 10.1038/386388a0; MIYATA T, 1987, COLD SPRING HARB SYM, V52, P863, DOI 10.1101/SQB.1987.052.01.094; Nachman MW, 2000, GENETICS, V156, P297; Saxena R, 2000, GENOMICS, V67, P256, DOI 10.1006/geno.2000.6260; SHIMMIN LC, 1993, J MOL EVOL, V37, P160, DOI 10.1007/BF02407351; Slattery JP, 1998, GENETICS, V148, P1245; TAJIMA F, 1984, MOL BIOL EVOL, V1, P269; XIA X, 2000, DATA ANAL MOL BIOL E	20	180	185	1	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 11	2002	416	6881					624	626		10.1038/416624a	http://dx.doi.org/10.1038/416624a			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	539YV	11948348				2022-12-28	WOS:000174901900040
J	Taylor, AH; Allen, JI; Clark, PA				Taylor, AH; Allen, JI; Clark, PA			Extraction of a weak climatic signal by an ecosystem	NATURE			English	Article							NORTH-SOUTH SHIFTS; GULF-STREAM; DYNAMICS; SEA; ZOOPLANKTON; ABUNDANCE; PLANKTON; ATLANTIC; TEMPERATURE; CARBON	The complexity of ecosystems can cause subtle(1) and chaotic responses to changes in external forcing(2). Although ecosystems may not normally behave chaotically(3), sensitivity to external influences associated with nonlinearity can lead to amplification of climatic signals. Strong correlations between an El Nino index and rainfall and maize yield in Zimbabwe have been demonstrated(4); the correlation with maize yield was stronger than that with rainfall. A second example is the 100,000-year ice-age cycle, which may arise from a weak cycle in radiation through its influence on the concentration of atmospheric CO2 (ref. 5). Such integration of a weak climatic signal has yet to be demonstrated in a realistic theoretical system. Here we use a particular climatic phenomenon-the observed association between plankton populations around the UK and the position of the Gulf Stream(6,7)-as a probe to demonstrate how a detailed marine ecosystem model extracts a weak signal that is spread across different meteorological variables. Biological systems may therefore respond to climatic signals other than those that dominate the driving variables.	Plymouth Marine Lab, Plymouth PL1 3DH, Devon, England; Univ Plymouth, Dept Math & Stat, Plymouth PL4 8AA, Devon, England; Univ Sussex, Dept Geog, Brighton BN1 9SJ, E Sussex, England	Plymouth Marine Laboratory; University of Plymouth; University of Sussex	Taylor, AH (corresponding author), Plymouth Marine Lab, Prospect Pl, Plymouth PL1 3DH, Devon, England.							Allen JI, 1998, MAR POLLUT BULL, V37, P295; Allen JI, 1998, J MARINE SYST, V18, P265, DOI 10.1016/S0924-7963(98)00015-3; Baretta J. W., 1997, J SEA RES, V38, P229; Baretta-Bekker JG, 1998, AQUAT MICROB ECOL, V14, P91, DOI 10.3354/ame014091; BERRYMAN AA, 1989, TRENDS ECOL EVOL, V4, P26, DOI 10.1016/0169-5347(89)90014-1; Blumberg A.F., 1980, MATH MODELLING ESTUA, P203; BROEKHUIZEN N, 1995, NETH J SEA RES, V33, P381, DOI 10.1016/0077-7579(95)90054-3; CANE MA, 1994, NATURE, V370, P204, DOI 10.1038/370204a0; COLEBROOK JM, 1985, MAR BIOL, V84, P261, DOI 10.1007/BF00392495; DROOP MR, 1974, J MAR BIOL ASSOC UK, V54, P825, DOI 10.1017/S002531540005760X; Ebenhoh W, 1997, J SEA RES, V38, P173, DOI 10.1016/S1385-1101(97)00043-9; Frid CLJ, 1996, ICES J MAR SCI, V53, P972, DOI 10.1006/jmsc.1996.0120; GEORGE DG, 1995, NATURE, V378, P139, DOI 10.1038/378139a0; George DG, 2000, FRESHWATER BIOL, V45, P111, DOI 10.1046/j.1365-2427.2000.00673.x; GLOVER R. S., 1967, SYMP ZOOL SOC LONDON, V19, P189; Huisman J, 1999, LIMNOL OCEANOGR, V44, P1781, DOI 10.4319/lo.1999.44.7.1781; HURRELL JW, 1995, SCIENCE, V269, P676, DOI 10.1126/science.269.5224.676; Mysterud A, 2001, NATURE, V410, P1096, DOI 10.1038/35074099; Shackleton NJ, 2000, SCIENCE, V289, P1897, DOI 10.1126/science.289.5486.1897; SUGIHARA G, 1990, PHILOS T R SOC B, V330, P235, DOI 10.1098/rstb.1990.0195; Taylor AH, 1996, INT J CLIMATOL, V16, P559, DOI 10.1002/(SICI)1097-0088(199605)16:5<559::AID-JOC26>3.0.CO;2-Z; TAYLOR AH, 1995, ICES J MAR SCI, V52, P711, DOI 10.1016/1054-3139(95)80084-0; TAYLOR AH, 1992, J MAR BIOL ASSOC UK, V72, P919, DOI 10.1017/S0025315400060161; TAYLOR AH, IN PRESS CHANGING ST	24	140	143	1	42	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 11	2002	416	6881					629	632		10.1038/416629a	http://dx.doi.org/10.1038/416629a			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	539YV	11948350				2022-12-28	WOS:000174901900042
J	Delos Reyes, CM				Delos Reyes, CM			Overcoming pessimism about treatment of addiction	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DRUG-ABUSE; OUTCOMES; ALCOHOL		Case Western Reserve Univ, Sch Med, Cleveland, OH 44109 USA	Case Western Reserve University	Delos Reyes, CM (corresponding author), Case Western Reserve Univ, Sch Med, Cleveland, OH 44109 USA.							Allen JP, 1997, J STUD ALCOHOL, V58, P7; *AM SOC ADD MED, 1998, PRINC ADD MED; CHAPPEL JN, 1977, JAMA-J AM MED ASSOC, V237, P2318, DOI 10.1001/jama.237.21.2318; *DHHS, 2000, IMPR SUBST AB TREATM; Ewing GB, 1999, AM J PREV MED, V17, P62, DOI 10.1016/S0749-3797(99)00032-X; Fleming MF, 1997, JAMA-J AM MED ASSOC, V277, P1039, DOI 10.1001/jama.277.13.1039; Hoffmann NG, 2000, J ADDICT DIS, V19, P1, DOI 10.1300/J069v19n03_01; Hubbard RL, 1997, PSYCHOL ADDICT BEHAV, V11, P261, DOI 10.1037/0893-164X.11.4.261; Isaacson JH, 2000, J STUD ALCOHOL, V61, P912, DOI 10.15288/jsa.2000.61.912; LEWIS DC, 1987, JAMA-J AM MED ASSOC, V257, P2945, DOI 10.1001/jama.257.21.2945; McLellan AT, 2000, JAMA-J AM MED ASSOC, V284, P1689, DOI 10.1001/jama.284.13.1689; National Institute on Drug Abuse, 1999, NIH PUBL; *PLNDP NAT PROJ OF, 2000, POS PAP DRUG POL	13	4	4	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 10	2002	287	14					1857	1857		10.1001/jama.287.14.1857	http://dx.doi.org/10.1001/jama.287.14.1857			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	539QJ	11939875				2022-12-28	WOS:000174881700041
J	Steurer, J; Fischer, JE; Bachmann, LM; Koller, M; ter Riet, G				Steurer, J; Fischer, JE; Bachmann, LM; Koller, M; ter Riet, G			Communicating accuracy of tests to general practitioners: a controlled study	BRITISH MEDICAL JOURNAL			English	Article								Objective To assess the extent to which different forms of summarising diagnostic test information influence general practitioners' ability to estimate disease probabilities. Design Controlled questionnaire study. Setting Three Swiss conferences in continuous medical education. Participants 263 general practitioners. Intervention Questionnaire with multiple choice questions about terms of test accuracy and a clinical vignette with the results of a diagnostic test described in three different ways (test result only, test result plus test sensitivity and specificity, test result plus the positive likelihood ratio presented in plain language). Main outcome measures Doctors' knowledge and application of terms of test accuracy and estimation of disease probability in the clinical vignette. Results The correct definitions for sensitivity and predictive value were chosen by 76% and 61% of the doctors respectively, but only 22% chose the correct answer for the post-test probability of a positive screening test. In the clinical vignette doctors given the test result only overestimated its diagnostic 11 value (median attributed likelihood ratio (aLR) = 9.0, against 2.54 reported in the literature). Providing the scan's sensitivity and specificity reduced the overestimation (median aLR = 6.0) but to a lesser extent than simple wording of the likelihood ratio (median aLR = 3.0). Conclusion Most general practitioners recognised the correct definitions. for sensitivity and positive predictive value but did not apply them correctly. Conveying test accuracy information in simple, non-technical language improved their ability to estimate disease probabilities accurately.	Univ Zurich Hosp, Horten Zentrum Praxisorientierte Forsch & Wissens, CH-8091 Zurich, Switzerland	University of Zurich; University Zurich Hospital	Steurer, J (corresponding author), Univ Zurich Hosp, Horten Zentrum Praxisorientierte Forsch & Wissens, Bolleystr 40,Postfach Nord, CH-8091 Zurich, Switzerland.		Koller, Michael/AEN-1656-2022; Bachmann, Lucas M/C-9686-2011; Riet, Gerben ter/A-6943-2011	Koller, Michael/0000-0001-5574-2341; Riet, Gerben ter/0000-0002-2231-7637				BRONZ L, 2000, SCHWEIZERISCHE ARZNE, V81, P1635; BUNTINX F, 1992, FAM PRACT, V9, P149, DOI 10.1093/fampra/9.2.149; CLARK TJ, IN PRESS OBSTET GYNE; DECKS JJ, 2001, BRIT MED J, V323, P157; Eddy DM, 1982, JUDGMENT UNCERTAINTY, P249; Hoffrage U, 2000, SCIENCE, V290, P2261, DOI 10.1126/science.290.5500.2261; KAHNEMANN D, 2000, CHOICES VALUES FRAM; Lieu TA, 1998, AM J RESP CRIT CARE, V157, P1173, DOI 10.1164/ajrccm.157.4.9708124; McAlister FA, 1999, LANCET, V354, P1721, DOI 10.1016/S0140-6736(99)01174-5; Miettinen OS, 1998, J CLIN EPIDEMIOL, V51, P1293, DOI 10.1016/S0895-4356(98)00127-9; Reid MC, 1998, AM J MED, V104, P374, DOI 10.1016/S0002-9343(98)00054-0; STIELL IG, 1992, ANN EMERG MED, V21, P384, DOI 10.1016/S0196-0644(05)82656-3; van Walraven C, 1998, JAMA-J AM MED ASSOC, V280, P550, DOI 10.1001/jama.280.6.550	13	101	104	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 6	2002	324	7341					824	826		10.1136/bmj.324.7341.824	http://dx.doi.org/10.1136/bmj.324.7341.824			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	540ZG	11934776	Green Published, Bronze			2022-12-28	WOS:000174960300017
J	Goff, SA; Ricke, D; Lan, TH; Presting, G; Wang, RL; Dunn, M; Glazebrook, J; Sessions, A; Oeller, P; Varma, H; Hadley, D; Hutchinson, D; Martin, C; Katagiri, F; Lange, BM; Moughamer, T; Xia, Y; Budworth, P; Zhong, JP; Miguel, T; Paszkowski, U; Zhang, SP; Colbert, M; Sun, WL; Chen, LL; Cooper, B; Park, S; Wood, TC; Mao, L; Quail, P; Wing, R; Dean, R; Yu, YS; Zharkikh, A; Shen, R; Sahasrabudhe, S; Thomas, A; Cannings, R; Gutin, A; Pruss, D; Reid, J; Tavtigian, S; Mitchell, J; Eldredge, G; Scholl, T; Miller, RM; Bhatnagar, S; Adey, N; Rubano, T; Tusneem, N; Robinson, R; Feldhaus, J; Macalma, T; Oliphant, A; Briggs, S				Goff, SA; Ricke, D; Lan, TH; Presting, G; Wang, RL; Dunn, M; Glazebrook, J; Sessions, A; Oeller, P; Varma, H; Hadley, D; Hutchinson, D; Martin, C; Katagiri, F; Lange, BM; Moughamer, T; Xia, Y; Budworth, P; Zhong, JP; Miguel, T; Paszkowski, U; Zhang, SP; Colbert, M; Sun, WL; Chen, LL; Cooper, B; Park, S; Wood, TC; Mao, L; Quail, P; Wing, R; Dean, R; Yu, YS; Zharkikh, A; Shen, R; Sahasrabudhe, S; Thomas, A; Cannings, R; Gutin, A; Pruss, D; Reid, J; Tavtigian, S; Mitchell, J; Eldredge, G; Scholl, T; Miller, RM; Bhatnagar, S; Adey, N; Rubano, T; Tusneem, N; Robinson, R; Feldhaus, J; Macalma, T; Oliphant, A; Briggs, S			A draft sequence of the rice genome (Oryza sativa L. ssp japonica)	SCIENCE			English	Article							INTEGRATED DOCUMENTATION RESOURCE; QUANTITATIVE TRAIT LOCUS; PHOSPHATE TRANSPORTER; PROTEIN FAMILIES; MOLECULAR DISSECTION; COMPARATIVE GENETICS; DEFENSE RESPONSES; ARABIDOPSIS; PLANT; GENES	The genome of the japonica subspecies of rice, an important cereal and model monocot, was sequenced and assembled by whole-genome shotgun sequencing. The assembled sequence covers 93% of the 420-megabase genome. Gene predictions on the assembled sequence suggest that the genome contains 32,000 to 50,000 genes. Homologs of 98% of the known maize, wheat, and barley proteins are found in rice. Synteny and gene homology between rice and the other cereal genomes are extensive, whereas synteny with Arabidopsis is limited. Assignment of candidate rice orthologs to Arabidopsis genes is possible in many cases. The rice genome sequence provides a foundation for the improvement of cereals, our most important crops.	Syngenta, Torrey Mesa Res Inst, San Diego, CA 92121 USA; Bryan Coll, Dayton, TN 37321 USA; No Illinois Univ, Dept Biol Sci, De Kalb, IL 60115 USA; Univ Calif Berkeley, Dept Plant & Microbial Biol, Berkeley, CA 94720 USA; Clemson Univ, Genome Inst, Clemson, SC 29630 USA; Myriad Genet, Salt Lake City, UT 84108 USA	Syngenta; Northern Illinois University; University of California System; University of California Berkeley; Clemson University; Myriad Genetics, Inc	Goff, SA (corresponding author), Syngenta, Torrey Mesa Res Inst, 3115 Merryfield Row, San Diego, CA 92121 USA.	stephen.goff@syngenta.com	Wood, Thomas/GWZ-2481-2022; Wing, Rod A/Z-2885-2019	Wood, Thomas/0000-0001-8962-8571; Wing, Rod A/0000-0001-6633-6226; Cooper, Bret/0000-0003-4915-2200; Lange, Mark/0000-0001-6565-9584; Yu, Yeisoo/0000-0002-8410-0310; Ricke, Darrell/0000-0002-2842-2809; Thomas, Alun/0000-0001-5650-7044; Glazebrook, Jane/0000-0001-5167-736X; Katagiri, Fumiaki/0000-0001-6893-3788				Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Ambrose BA, 2000, MOL CELL, V5, P569, DOI 10.1016/S1097-2765(00)80450-5; Apweiler R, 2000, BIOINFORMATICS, V16, P1145, DOI 10.1093/bioinformatics/16.12.1145; Apweiler R, 2001, NUCLEIC ACIDS RES, V29, P37, DOI 10.1093/nar/29.1.37; Araki T, 2001, CURR OPIN PLANT BIOL, V4, P63, DOI 10.1016/S1369-5266(00)00137-0; Barry GF, 2001, PLANT PHYSIOL, V125, P1164, DOI 10.1104/pp.125.3.1164; Bateman A, 2000, NUCLEIC ACIDS RES, V28, P263, DOI 10.1093/nar/28.1.263; Bennetzen JL, 1997, GENOME RES, V7, P301, DOI 10.1101/gr.7.4.301; Bradley D, 1996, NATURE, V379, P791, DOI 10.1038/379791a0; BUNYA M, 1991, MOL CELL BIOL, V11, P3229, DOI 10.1128/MCB.11.6.3229; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Chandler VL, 2001, PLANT PHYSIOL, V125, P1155, DOI 10.1104/pp.125.3.1155; CHEN M, 2002, PLANT CELL, V14, P1; Chrispeels MJ, 1999, PLANT CELL, V11, P661, DOI 10.1105/tpc.11.4.661; CHUNG YY, 1995, PLANT SCI, V109, P45, DOI 10.1016/0168-9452(95)04153-L; COHLMANN J, 1998, P NATL ACAD SCI USA, V95, P4126; Colasanti J, 1998, CELL, V93, P593, DOI 10.1016/S0092-8674(00)81188-5; Cook RJ, 1998, P NATL ACAD SCI USA, V95, P1993, DOI 10.1073/pnas.95.5.1993; Dangl JL, 2001, NATURE, V411, P826, DOI 10.1038/35081161; Daram P, 1999, PLANT CELL, V11, P2153, DOI 10.1105/tpc.11.11.2153; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, V5, P345; Dixon RA, 2001, NATURE, V411, P843, DOI 10.1038/35081178; DOEBLEY J, 1995, GENETICS, V141, P333; Facchini PJ, 1999, TRENDS PLANT SCI, V4, P382, DOI 10.1016/S1360-1385(99)01476-4; Feuillet C, 1999, P NATL ACAD SCI USA, V96, P8265, DOI 10.1073/pnas.96.14.8265; Flowers TJ, 2000, J EXP BOT, V51, P99, DOI 10.1093/jexbot/51.342.99; Freeling M, 2001, PLANT PHYSIOL, V125, P1191, DOI 10.1104/pp.125.3.1191; Gale M, 2001, NOVART FDN SYMP, V236, P46; Gale MD, 1998, P NATL ACAD SCI USA, V95, P1971, DOI 10.1073/pnas.95.5.1971; Gale MD, 1998, SCIENCE, V282, P656, DOI 10.1126/science.282.5389.656; Gaut BS, 1997, P NATL ACAD SCI USA, V94, P6809, DOI 10.1073/pnas.94.13.6809; Glazebrook J, 2001, CURR OPIN PLANT BIOL, V4, P301, DOI 10.1016/S1369-5266(00)00177-1; GOODMAN HM, 1995, P NATL ACAD SCI USA, V92, P10831, DOI 10.1073/pnas.92.24.10831; Grant D, 2000, P NATL ACAD SCI USA, V97, P4168, DOI 10.1073/pnas.070430597; Grayer RJ, 2001, PHYTOCHEMISTRY, V56, P253, DOI 10.1016/S0031-9422(00)00450-7; HARLAN JR, 1995, LIVING FIELDS OUR AG, P30; Harushima Y, 1998, GENETICS, V148, P479; Havukkala IJ, 1996, CURR OPIN GENET DEV, V6, P711, DOI 10.1016/S0959-437X(96)80025-6; Hofmann K, 1999, NUCLEIC ACIDS RES, V27, P215, DOI 10.1093/nar/27.1.215; Hogenesch JB, 2001, CELL, V106, P413, DOI 10.1016/S0092-8674(01)00467-6; Kang HG, 1998, PLANT MOL BIOL, V38, P1021, DOI 10.1023/A:1006051911291; Kaul S, 2000, NATURE, V408, P796, DOI 10.1038/35048692; Keller B, 2000, TRENDS PLANT SCI, V5, P246, DOI 10.1016/S1360-1385(00)01629-0; Kellogg EA, 1998, P NATL ACAD SCI USA, V95, P2005, DOI 10.1073/pnas.95.5.2005; Khush GS, 1997, PLANT MOL BIOL, V35, P25, DOI 10.1023/A:1005810616885; Ku HM, 2000, P NATL ACAD SCI USA, V97, P9121, DOI 10.1073/pnas.160271297; Kyozuka J, 1998, P NATL ACAD SCI USA, V95, P1979, DOI 10.1073/pnas.95.5.1979; Lan TH, 2000, GENOME RES, V10, P776, DOI 10.1101/gr.10.6.776; Lanceras JC, 2000, DNA RES, V7, P93, DOI 10.1093/dnares/7.2.93; Lange BM, 2000, P NATL ACAD SCI USA, V97, P13172, DOI 10.1073/pnas.240454797; Lee M, 1996, Symp Soc Exp Biol, V50, P31; Lewis S, 2000, CURR OPIN STRUC BIOL, V10, P349, DOI 10.1016/S0959-440X(00)00095-6; Mao L, 2000, GENOME RES, V10, P982, DOI 10.1101/gr.10.7.982; Martinez P, 1998, J BACTERIOL, V180, P2253, DOI 10.1128/JB.180.8.2253-2256.1998; Mathews S, 1996, MOL BIOL EVOL, V13, P1141, DOI 10.1093/oxfordjournals.molbev.a025677; Mayer K, 2001, GENOME RES, V11, P1167, DOI 10.1101/gr.GR-1617R; McCouch SR, 1997, PLANT MOL BIOL, V35, P89, DOI 10.1023/A:1005711431474; McCouch SR, 2001, PLANT PHYSIOL, V125, P152, DOI 10.1104/pp.125.1.152; MCCOUCH SR, 1995, TRENDS GENET, V11, P482, DOI 10.1016/S0168-9525(00)89157-X; Melchinger AE, 1998, GENETICS, V149, P383; Moon YH, 1999, PLANT MOL BIOL, V40, P167, DOI 10.1023/A:1026429922616; Muchhal US, 1996, P NATL ACAD SCI USA, V93, P10519, DOI 10.1073/pnas.93.19.10519; Muse SV, 2000, PLANT MOL BIOL, V42, P25, DOI 10.1023/A:1006319803002; OBRIEN SJ, 1993, NAT GENET, V3, P103, DOI 10.1038/ng0293-103; PATERSON AH, 1995, GENOME RES, V5, P321, DOI 10.1101/gr.5.4.321; Paterson AH, 1996, NAT GENET, V14, P380, DOI 10.1038/ng1296-380; Peng JR, 1999, NATURE, V400, P256, DOI 10.1038/22307; Pichersky E, 2000, TRENDS PLANT SCI, V5, P439, DOI 10.1016/S1360-1385(00)01741-6; Pnueli L, 1998, DEVELOPMENT, V125, P1979; Prescott AG, 1996, ANNU REV PLANT PHYS, V47, P245, DOI 10.1146/annurev.arplant.47.1.245; Presting GG, 2001, NOVART FDN SYMP, V236, P13; Raghothama KG, 2000, TRENDS PLANT SCI, V5, P412, DOI 10.1016/S1360-1385(00)01746-5; Ratcliffe OJ, 1998, DEVELOPMENT, V125, P1609; Rausch C, 2001, NATURE, V414, P462, DOI 10.1038/35106601; Reeves PH, 2000, CURR OPIN PLANT BIOL, V3, P37, DOI 10.1016/S1369-5266(99)00041-2; Riechmann JL, 2000, SCIENCE, V290, P2105, DOI 10.1126/science.290.5499.2105; Sasaki T, 2000, CURR OPIN PLANT BIOL, V3, P138, DOI 10.1016/S1369-5266(99)00047-3; Thornsberry JM, 2001, NAT GENET, V28, P286, DOI 10.1038/90135; Tierens KFMJ, 2001, PLANT PHYSIOL, V125, P1688, DOI 10.1104/pp.125.4.1688; TSUJI J, 1992, PLANT PHYSIOL, V98, P1304, DOI 10.1104/pp.98.4.1304; van Dodeweerd AM, 1999, GENOME, V42, P887, DOI 10.1139/gen-42-5-887; Veldboom LR, 1996, CROP SCI, V36, P1310, DOI 10.2135/cropsci1996.0011183X003600050040x; Venter JC, 1998, SCIENCE, V280, P1540, DOI 10.1126/science.280.5369.1540; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Vision TJ, 2000, SCIENCE, V290, P2114, DOI 10.1126/science.290.5499.2114; WEIGEL D, 1994, CELL, V78, P203, DOI 10.1016/0092-8674(94)90291-7; Wilson WA, 1999, GENETICS, V153, P453; WING RA, 2001, RICE GENETICS, V4, P215; WOLFE KH, 1989, P NATL ACAD SCI USA, V86, P6201, DOI 10.1073/pnas.86.16.6201; XIAO JH, 1995, GENETICS, V140, P745; Yano M, 1997, PLANT MOL BIOL, V35, P145, DOI 10.1023/A:1005764209331; Yano M, 2000, PLANT CELL, V12, P2473, DOI 10.1105/tpc.12.12.2473; Yu J, 2001, CHINESE SCI BULL, V46, P1937, DOI 10.1007/BF02901901; 2000, DICT NATURAL PRODUCT	94	2334	2708	10	419	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 5	2002	296	5565					92	100		10.1126/science.1068275	http://dx.doi.org/10.1126/science.1068275			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	539FA	11935018				2022-12-28	WOS:000174858800039
J	Giardiello, FM; Yang, VW; Hylind, LM; Krush, AJ; Petersen, GM; Trimbath, JD; Piantadosi, S; Garrett, E; Geiman, DE; Hubbard, W; Offerhaus, GJA; Hamilton, SR				Giardiello, FM; Yang, VW; Hylind, LM; Krush, AJ; Petersen, GM; Trimbath, JD; Piantadosi, S; Garrett, E; Geiman, DE; Hubbard, W; Offerhaus, GJA; Hamilton, SR			Primary chemoprevention of familial adenomatous polyposis with sulindac	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RECTAL-CANCER; FAP; CHROMOSOME-5Q21; IDENTIFICATION; NEOPLASIA; GENES; COLON	Background: Familial adenomatous polyposis is caused by a germ-line mutation in the adenomatous polyposis coli gene and is characterized by the development of hundreds of colorectal adenomas and, eventually, colorectal cancer. Nonsteroidal antiinflammatory drugs can cause regression of adenomas, but whether they can prevent adenomas is unknown. Methods: We conducted a randomized, double-blind, placebo-controlled study of 41 young subjects (age range, 8 to 25 years) who were genotypically affected with familial adenomatous polyposis but phenotypically unaffected. The subjects received either 75 or 150 mg of sulindac orally twice a day or identical-appearing placebo tablets for 48 months. The number and size of new adenomas and side effects of therapy were evaluated every four months for four years, and the levels of five major prostaglandins were serially measured in biopsy specimens of normal-appearing colorectal mucosa. Results: After four years of treatment, the average rate of compliance exceeded 76 percent in the sulindac group, and mucosal prostaglandin levels were lower in this group than in the placebo group. During the course of the study, adenomas developed in 9 of 21 subjects (43 percent) in the sulindac group and 11 of 20 subjects in the placebo group (55 percent) (P=0.54). There were no significant differences in the mean number (P=0.69) or size (P=0.17) of polyps between the groups. Sulindac did not slow the development of adenomas, according to an evaluation involving linear longitudinal methods. Conclusions: Standard doses of sulindac did not prevent the development of adenomas in subjects with familial adenomatous polyposis.	Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Ctr Oncol, Baltimore, MD 21205 USA; Mayo Clin, Rochester, MN USA; Univ Amsterdam, Acad Med Ctr, Dept Pathol, NL-1105 AZ Amsterdam, Netherlands; Univ Texas, MD Anderson Canc Ctr, Div Pathol & Lab Med, Houston, TX 77030 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; Mayo Clinic; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; University of Texas System; UTMD Anderson Cancer Center	Giardiello, FM (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA.				NCI NIH HHS [P50 CA062924, R01 CA084197-02, CA 63721, R01 CA084197, CA 53801, P50 CA 62924-04] Funding Source: Medline; NIDDK NIH HHS [R01 DK052230, R01 DK052230-04] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA053801, R01CA084197, P50CA062924, R01CA063721] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052230] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bussey H.J.R., 1975, FAMILIAL POLYPOSIS C; Cruz-Correa MR, 2001, GASTROENTEROLOGY, V120, pA252; Diggle PJ, 1994, ANAL LONGITUDINAL DA; Giardiello FM, 1997, NEW ENGL J MED, V336, P823, DOI 10.1056/NEJM199703203361202; GIARDIELLO FM, 1993, NEW ENGL J MED, V328, P1313, DOI 10.1056/NEJM199305063281805; Giardiello FM, 1998, DIGEST DIS SCI, V43, P311; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; JOSLYN G, 1991, CELL, V66, P600; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; LABAYLE D, 1991, GASTROENTEROLOGY, V101, P635, DOI 10.1016/0016-5085(91)90519-Q; National Cancer Institute, 1998, CANC THER EV PROGR C; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; NIV Y, 1994, GASTROENTEROLOGY, V107, P854, DOI 10.1016/0016-5085(94)90136-8; NUGENT KP, 1993, BRIT J SURG, V80, P1618, DOI 10.1002/bjs.1800801244; *STAT, 1999, STAT STAT SOFTW; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; THORSON AG, 1994, LANCET, V343, P180, DOI 10.1016/S0140-6736(94)90974-1; Tonelli F, 2000, J SURG ONCOL, V74, P15, DOI 10.1002/1096-9098(200005)74:1<15::AID-JSO4>3.0.CO;2-Z; Torrance CJ, 2000, NAT MED, V6, P1024, DOI 10.1038/79534; WADDELL WR, 1989, AM J SURG, V157, P175, DOI 10.1016/0002-9610(89)90442-X; WADDELL WR, 1983, J SURG ONCOL, V24, P83, DOI 10.1002/jso.2930240119; Yang VW, 2000, PROSTAG OTH LIPID M, V60, P83, DOI 10.1016/S0090-6980(99)00054-4; Yang VW, 1998, CANCER RES, V58, P1750	23	269	277	0	5	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 4	2002	346	14					1054	1059		10.1056/NEJMoa012015	http://dx.doi.org/10.1056/NEJMoa012015			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	536YL	11932472	Bronze, Green Accepted, Green Published			2022-12-28	WOS:000174729400004
J	Klip, H; Verloop, J; van Gool, JD; Koster, META; Burger, CW; van Leeuwen, FE				Klip, H; Verloop, J; van Gool, JD; Koster, META; Burger, CW; van Leeuwen, FE		OMEGA Project Grp	Hypospadias in sons of women exposed to diethylstilbestrol in utero: a cohort study	LANCET			English	Article							IN-VITRO FERTILIZATION; CRYPTORCHIDISM; TUMORS; RISK; DESCENDANTS; ABNORMALITIES; EPIDEMIOLOGY; ASSOCIATION; INUTERO	Background Transgenerational effects of diethylstilbestrol (DES) have been reported in animals, but effects in human beings are unknown. Alerted by two case reports, we aimed to establish the risk of hypospadias in the sons of women who were exposed to DES in utero. Methods We did a cohort study of all sons of a Dutch cohort of 16 284 women with a diagnosis of fertility problems. We used a mailed questionnaire assessing late effects of fertility treatment to identify boys with hypospadias. We compared the prevalence rate of hypospadias between boys with and without maternal DES exposure in utero. Findings 16 284 mothers (response rate 67%) reported 8934 sons. The mothers of 205 boys reported DES exposure in utero. Four of these children were reported to have hypospadias. In the remaining 8729 children, only eight cases of hypospadias were reported (prevalence ratio 21.3 [95% Cl 6.5-70.1]). All cases of hypospadias were medically confirmed. Maternal age or fertility treatment did not affect the risk of hypospadias. Children conceived after assisted reproductive techniques such as in-vitro fertilisation were not at increased risk of hypospadias compared with children conceived naturally (1.8, 0.6-5.7). Interpretation Our findings suggest an increased risk of hypospadias in the sons of women exposed to DES in utero. Although the absolute risk of this anomaly is small, this transgenerational effect of DES warrants additional studies.	Netherlands Canc Inst, Dept Epidemiol, NL-1066 CX Amsterdam, Netherlands; Univ Med Ctr Utrecht, Paediat Renal Ctr, Utrecht, Netherlands; Univ Rotterdam Hosp, Dept Obstet & Gynaecol, Rotterdam, Netherlands	Netherlands Cancer Institute; Utrecht University; Utrecht University Medical Center; Erasmus University Rotterdam; Erasmus MC	van Leeuwen, FE (corresponding author), Netherlands Canc Inst, Dept Epidemiol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	fvleeuw@NKI.NL	Rose, Rebecca J/B-7812-2011					AARSKOG D, 1979, NEW ENGL J MED, V300, P75, DOI 10.1056/NEJM197901113000206; Aho M, 2000, ENVIRON HEALTH PERSP, V108, P463, DOI 10.2307/3454389; Akre O, 1999, EPIDEMIOLOGY, V10, P364, DOI 10.1097/00001648-199907000-00005; Baskin LS, 2000, J UROLOGY, V163, P951, DOI 10.1016/S0022-5347(05)67861-5; Bergh T, 1999, LANCET, V354, P1579, DOI 10.1016/S0140-6736(99)04345-7; Canning D A, 1999, J Urol, V161, P366; Dolk H, 1998, LANCET, V351, P770, DOI 10.1016/S0140-6736(05)78924-8; DRISCOLL SG, 1980, OBSTET GYNECOL, V56, P537; GILL WB, 1979, J UROLOGY, V122, P36, DOI 10.1016/S0022-5347(17)56240-0; GIUSTI RM, 1995, ANN INTERN MED, V122, P778, DOI 10.7326/0003-4819-122-10-199505150-00008; HARRIS EL, 1990, EPIDEMIOL REV, V12, P29, DOI 10.1093/oxfordjournals.epirev.a036060; Hatch EE, 1998, JAMA-J AM MED ASSOC, V280, P630, DOI 10.1001/jama.280.7.630; HERBST AL, 1971, NEW ENGL J MED, V284, P878, DOI 10.1056/NEJM197104222841604; KALLEN B, 1986, ACTA PAEDIATR SCAND, P1; MACNAB AJ, 1991, FERTIL STERIL, V56, P918; Moller H, 1999, EPIDEMIOLOGY, V10, P352, DOI 10.1097/00001648-199907000-00003; Newbold RR, 2000, CARCINOGENESIS, V21, P1355, DOI 10.1093/carcin/21.7.1355; Newbold RR, 1998, CARCINOGENESIS, V19, P1655, DOI 10.1093/carcin/19.9.1655; Palmer JR, 2001, AM J EPIDEMIOL, V154, P316, DOI 10.1093/aje/154.4.316; Paulozzi LJ, 1999, ENVIRON HEALTH PERSP, V107, P297, DOI 10.2307/3434597; REEFHUIS J, 2000, EUROCAT REGISTRATION; Silver RI, 1999, J UROLOGY, V161, P1954, DOI 10.1016/S0022-5347(05)68863-5; STENCHEVER MA, 1981, AM J OBSTET GYNECOL, V140, P186, DOI 10.1016/0002-9378(81)90107-1; Strohsnitter WC, 2001, J NATL CANCER I, V93, P545, DOI 10.1093/jnci/93.7.545; TOMATIS L, 1994, JPN J CANCER RES, V85, P443, DOI 10.1111/j.1349-7006.1994.tb02378.x; TURUSOV VS, 1992, INT J CANCER, V50, P131, DOI 10.1002/ijc.2910500126; WALKER BE, 1984, J NATL CANCER I, V73, P133; Weidner IS, 1999, J UROLOGY, V161, P1606, DOI 10.1016/S0022-5347(05)68992-6; WHITEHEAD ED, 1981, J UROLOGY, V125, P47, DOI 10.1016/S0022-5347(17)54895-8; WILCOX AJ, 1995, AM J OBSTET GYNECOL, V173, P835, DOI 10.1016/0002-9378(95)90350-X	30	196	208	0	12	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 30	2002	359	9312					1102	1107		10.1016/S0140-6736(02)08152-7	http://dx.doi.org/10.1016/S0140-6736(02)08152-7			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	536YJ	11943257				2022-12-28	WOS:000174729200008
J	Dennis, C				Dennis, C			Baiting plan to remove fox threat to Tasmanian wildlife	NATURE			English	News Item																			0	9	9	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 28	2002	416	6879					357	357		10.1038/416357b	http://dx.doi.org/10.1038/416357b			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	534UX	11919593	Bronze			2022-12-28	WOS:000174607800011
J	Cuffe, MS; Califf, RM; Adams, KF; Benza, R; Bourge, R; Colucci, WS; Massie, BM; O'Connor, CM; Pina, I; Quigg, R; Silver, MA; Georghiade, M				Cuffe, MS; Califf, RM; Adams, KF; Benza, R; Bourge, R; Colucci, WS; Massie, BM; O'Connor, CM; Pina, I; Quigg, R; Silver, MA; Georghiade, M		OPTIME-CHF Investigators	Short-term intravenous milrinone for acute exacerbation of chronic heart failure - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES; RATES; HOSPITALIZATION; READMISSION; MORTALITY; SURVIVAL; THERAPY; TRENDS	Context Little randomized evidence is available to guide the in-hospital management of patients with an acute exacerbation of chronic heart failure. Although intravenous inotropic therapy usually produces beneficial hemodynamic effects and is labeled for use in the care of such patients, the effect of such therapy on intermediate-term clinical outcomes is uncertain. Objective To prospectively test whether a strategy that includes short-term use of milrinone in addition to standard therapy can improve clinical outcomes of patients hospitalized with an exacerbation of chronic heart failure. Design Prospective, randomized, double-blind, placebo-controlled trial conducted from July 1997 through November 1999. Setting Seventy-eight community and tertiary care hospitals in the United States. Participants A total of 951 patients admitted with an exacerbation of systolic heart failure not requiring intravenous inotropic support (mean age, 65 years; 92% with baseline New York Heart Association class III or IV; mean left ventricular ejection fraction, 23%). Intervention Patients were randomly assigned to receive a 48-hour infusion of either milrinone, 0.5 mug/kg per minute initially (n=477), or saline placebo (n=472). Main Outcome Measure Cumulative days of hospitalization for cardiovascular cause within 60 days following randomization. Results The median number of days hospitalized for cardiovascular causes within 60 days after randomization did not differ significantly between patients given milrinone (6 days) compared with placebo (7 days; P=.71). Sustained hypotension requiring intervention (10.7% vs 3.2%; P<.001) and new atrial arrhythmias (4.6% vs 1.5%; P=.004) occurred more frequently in patients who received milrinone. The milrinone and placebo groups did not differ significantly in in-hospital mortality (3.8% vs 2.3%; P=.19), 60-day mortality (10.3% vs 8.9%; P=.41), or the composite incidence of death or readmission (35.0% vs 35.3%; P=.92) Conclusion These results do not support the routine use of intravenous milrinone as an adjunct to standard therapy in the treatment of patients hospitalized for an exacerbation of chronic heart failure.	Northwestern Univ, Sch Med, Div Cardiol, Chicago, IL 60611 USA; Duke Clin Res Inst, Durham, NC USA; Univ N Carolina, Heart Failure Program, Chapel Hill, NC USA; Univ Alabama Birmingham, Birmingham, AL USA; Boston Univ, Sch Med, Boston, MA 02118 USA; Vet Affairs Med Ctr, San Francisco, CA 94121 USA; Univ Hosp Cleveland, Cleveland, OH 44106 USA; EHS Christ Hosp & Med Ctr, Oak Lawn, IL USA	Northwestern University; Duke University; University of North Carolina; University of North Carolina Chapel Hill; University of Alabama System; University of Alabama Birmingham; Boston University; US Department of Veterans Affairs; Veterans Health Administration (VHA); University Hospitals of Cleveland	Georghiade, M (corresponding author), Northwestern Univ, Sch Med, Div Cardiol, 201 E Huron St,Galter 10-240, Chicago, IL 60611 USA.	m-gheorghiade@northwestern.edu	Benza, Raymond Louis/AAD-4885-2019	Benza, Raymond Louis/0000-0001-9627-6236; Colucci, Wilson/0000-0002-0576-9420				*AM HEART ASS, 1999, 2000 HEART STROK STA; Chin MH, 1996, ARCH INTERN MED, V156, P1814, DOI 10.1001/archinte.156.16.1814; Cuffe MS, 2000, AM HEART J, V139, P15, DOI 10.1016/S0002-8703(00)90303-X; Cusick DA, 1998, AM J CARDIOL, V82, P1060, DOI 10.1016/S0002-9149(98)00557-8; GHALI JK, 1990, ARCH INTERN MED, V150, P769, DOI 10.1001/archinte.150.4.769; Gheorghiade M, 1998, CIRCULATION, V97, P282, DOI 10.1161/01.CIR.97.3.282; Gheorghiade M, 1997, AM J CARDIOL, V80, pH14, DOI 10.1016/S0002-9149(97)00816-3; Haldeman GA, 1999, AM HEART J, V137, P352, DOI 10.1053/hj.1999.v137.95495; Havranek EP, 2001, J CARD FAIL, V7, P153, DOI 10.1054/jcaf.2001.24121; *HLTH CAR FIN ADM, 1999, MEDPAR INP HOSP DAT; HO KKL, 1993, J AM COLL CARDIOL, V22, pA6, DOI 10.1016/0735-1097(93)90455-A; HUGHES MD, 1993, STAT MED, V12, P1651, DOI 10.1002/sim.4780121802; Hunt SA, 2001, J AM COLL CARDIOL, V38, P2101, DOI 10.1016/S0735-1097(01)01683-7; LEE DCS, 1982, NEW ENGL J MED, V306, P699, DOI 10.1056/NEJM198203253061202; LOEB HS, 1993, CIRCULATION, V87, P78; McDermontt MM, 1997, AM HEART J, V134, P901, DOI 10.1016/S0002-8703(97)80013-0; McDermott MM, 1997, AM HEART J, V134, P728, DOI 10.1016/S0002-8703(97)70057-7; Milfred-Laforest SK, 1999, AM J CARDIOL, V84, P894, DOI 10.1016/S0002-9149(99)00461-0; OCONNELL JB, 1994, J HEART LUNG TRANSPL, V13, pS107; PACKER M, 1991, NEW ENGL J MED, V325, P1468, DOI 10.1056/NEJM199111213252103; SCHOCKEN DD, 1992, J AM COLL CARDIOL, V20, P301, DOI 10.1016/0735-1097(92)90094-4; Shipley JB, 1996, AM J MED SCI, V311, P286, DOI 10.1097/00000441-199606000-00011; Stevenson LW, 1998, AM HEART J, V135, pS293, DOI 10.1016/S0002-8703(98)70257-1; SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429; VINSON JM, 1990, J AM GERIATR SOC, V38, P1290, DOI 10.1111/j.1532-5415.1990.tb03450.x	25	755	802	2	19	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 27	2002	287	12					1541	1547		10.1001/jama.287.12.1541	http://dx.doi.org/10.1001/jama.287.12.1541			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	533VF	11911756	Bronze			2022-12-28	WOS:000174550400025
J	Koshland, DE				Koshland, DE			The seven pillars of life	SCIENCE			English	Editorial Material									Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Koshland, DE (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 229 Stanley Hall, Berkeley, CA 94720 USA.								0	132	140	4	80	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 22	2002	295	5563					2215	2216		10.1126/science.1068489	http://dx.doi.org/10.1126/science.1068489			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	534AD	11910092				2022-12-28	WOS:000174561700023
J	Moerman, DE; Jonas, WB				Moerman, DE; Jonas, WB			Deconstructing the placebo effect and finding the meaning response	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							MAMMARY-ARTERY LIGATION; ACUPUNCTURE ANALGESIA; CLINICAL-TRIALS; SURGERY; ANTHROPOLOGY; NALOXONE; SYMBOLS	We provide a new perspective with which to understand what for a half century has been known as the "placebo effect." We argue that, as currently used, the concept includes much that has nothing to do with placebos, confusing the most interesting and important aspects of the phenomenon. We propose a new way to understand those aspects of medical care, plus a broad range of additional human experiences, by focusing on the idea of "meaning," to which people, when they are sick, often respond. We review several of the many areas in medicine in which meaning affects illness or healing and introduce the idea of the "meaning response." We suggest that use of this formulation, rather than the fixation on inert placebos, will probably lead to far greater insight into how treatment works and perhaps to real improvements in human well-being.	Univ Michigan, Dearborn, MI 48128 USA; Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA; Samuel Inst, Bethesda, MD USA	University of Michigan System; University of Michigan; Uniformed Services University of the Health Sciences - USA	Moerman, DE (corresponding author), Univ Michigan Dearborn, Dept Anthropol, 6515 Cherry Hill Rd, Ypsilanti, MI 48198 USA.	dmoerman@umich.edu		Moerman, Daniel E/0000-0003-4742-4049				Ader R, 2001, Adv Mind Body Med, V17, P293; [Anonymous], 1999, DEATH FORETOLD PROPH; Bailar JC, 2001, NEW ENGL J MED, V344, P1630, DOI 10.1056/NEJM200105243442111; BEAUMONT JM, 1997, PLACEBO EFFECTS POEM; BEECHER HK, 1961, JAMA-J AM MED ASSOC, V176, P1102, DOI 10.1001/jama.1961.63040260007008; Beldoch M, 2001, NEW ENGL J MED, V345, P1278; Benedetti F, 1997, PROG NEUROBIOL, V52, P109, DOI 10.1016/S0301-0082(97)00006-3; Benson H.M.D., 1992, RELAXATION RESPONSE; BLACKWELL B, 1972, LANCET, V1, P1279; BLUMHAGEN DW, 1979, ANN INTERN MED, V91, P111, DOI 10.7326/0003-4819-91-1-111; BRANTHWAITE A, 1981, BRIT MED J, V282, P1576, DOI 10.1136/bmj.282.6276.1576; BRODY H, 1980, J FAM PRACTICE, V10, P445; Brody H, 2001, Adv Mind Body Med, V17, P296; Brody H., 2000, PLACEBO RESPONSE YOU; CATTANEO AD, 1970, EUR J CLIN PHARMACOL, V3, P43, DOI 10.1007/BF00560290; CLARK K, 2000, US NEWS WORLD R 0821, P55; COBB LA, 1959, NEW ENGL J MED, V260, P1115, DOI 10.1056/NEJM195905282602204; CURTIS P, 1988, OCCUP MED, V3, P31; de Craen AJM, 1999, BRIT J CLIN PHARMACO, V48, P853, DOI 10.1046/j.1365-2125.1999.00094.x; deCraen AJM, 1996, BRIT MED J, V313, P1624, DOI 10.1136/bmj.313.7072.1624; DESHARNAIS R, 1993, PSYCHOSOM MED, V55, P149, DOI 10.1097/00006842-199303000-00003; DIMOND EG, 1960, AM J CARDIOL, V5, P483, DOI 10.1016/0002-9149(60)90105-3; DiNubile MJ, 2001, NEW ENGL J MED, V345, P1278; EGBERT LD, 1964, NEW ENGL J MED, V270, P825, DOI 10.1056/NEJM196404162701606; Einarson TE, 2001, NEW ENGL J MED, V345, P1277; ERNST E, 1995, BMJ-BRIT MED J, V311, P551, DOI 10.1136/bmj.311.7004.551; Ernst E, 1998, ARCH SURG-CHICAGO, V133, P1187, DOI 10.1001/archsurg.133.11.1187; Evans M, 2000, J MED ETHICS, V26, P188, DOI 10.1136/jme.26.3.188; FISHER S, 1967, DIS NERV SYST, V28, P510; GOTZSCHE PC, 1994, LANCET, V344, P925; Gracely RH, 2000, PROG PAIN RES MANAG, V16, P1045; Greene P J, 2001, Adv Mind Body Med, V17, P298; GRYLL SL, 1978, PSYCHOPHARMACOLOGY, V57, P253, DOI 10.1007/BF00426747; Hahn RA, 1997, PREV MED, V26, P607, DOI 10.1006/pmed.1996.0124; Harrington Anne, 1997, PLACEBO EFFECT INTER; HONZAK R, 1971, ACTIVA NERVOSA SUPER, V13, P190; Hrobjartsson A, 2001, NEW ENGL J MED, V344, P1594, DOI 10.1056/NEJM200105243442106; HUMPHREY N, 2002, MIND MADE FLESH ESSA, pCH19; JOHNSON AG, 1994, LANCET, V344, P1140, DOI 10.1016/S0140-6736(94)90637-8; Jowett B., 1952, DIALOGUES PLATO; Kaptchuk TJ, 2000, J CLIN EPIDEMIOL, V53, P786, DOI 10.1016/S0895-4356(00)00206-7; Kaptchuk TJ, 2001, NEW ENGL J MED, V345, P1277; KIRMAYER LJ, 1993, CULT MED PSYCHIAT, V17, P161, DOI 10.1007/BF01379325; Kirsch I, 2001, Adv Mind Body Med, V17, P307; Kirsch I., 1999, EXPECTANCIES SHAPE E; Kupers R, 2001, NEW ENGL J MED, V345, P1278; Lange RA, 1999, NEW ENGL J MED, V341, P1075, DOI 10.1056/NEJM199909303411410; LEVISTRAUSS C, 1967, EFFECTIVENESS SYMBOL; LIBERMAN RP, 1967, P 5 INT C COLL INT N, P557; Lilford RJ, 2001, NEW ENGL J MED, V345, P1277; Lock M, 1998, PSYCHOSOM MED, V60, P410, DOI 10.1097/00006842-199807000-00005; Lock M.M., 1993, ENCOUNTERS AGING MYT; Macklin R, 1999, NEW ENGL J MED, V341, P992, DOI 10.1056/NEJM199909233411312; MAYER DJ, 1977, BRAIN RES, V121, P368, DOI 10.1016/0006-8993(77)90161-5; McCleary Timothy, 1997, STARS WE KNOW CROW I; McDonald C J, 1983, Stat Med, V2, P417; McDonald CJ, 2001, NEW ENGL J MED, V345, P1276; Miller FG, 2001, NEW ENGL J MED, V345, P1277; Moerman DE, 2000, MED ANTHROPOL Q, V14, P51, DOI 10.1525/maq.2000.14.1.51; MOERMAN DE, 1979, CURR ANTHROPOL, V20, P59, DOI 10.1086/202203; Moerman DE, 1981, ANN NY ACAD SCI, V364, P256, DOI [DOI 10.1111/J.1749-6632.1981.TB34478.X, 10.1111/j.1749-6632.1981.tb34478.x]; Moseley JB, 1996, AM J SPORT MED, V24, P28, DOI 10.1177/036354659602400106; *NIH, 2002, SCI PLAC INT RES AG; PHILLIPS DP, 1993, LANCET, V342, P1142, DOI 10.1016/0140-6736(93)92124-C; POMERANZ B, 1976, LIFE SCI, V19, P1757, DOI 10.1016/0024-3205(76)90084-9; Reynolds T, 2000, ANN INTERN MED, V133, P491, DOI 10.7326/0003-4819-133-6-200009190-00103; RUBIN R, 2001, US TODAY        0116, pD1; RUSSELL G, 1998, PLACEBO EFFECT; SCHAPIRA K, 1970, BMJ-BRIT MED J, V2, P446, DOI 10.1136/bmj.2.5707.446; Shapiro Elaine, 1997, POWERFUL PLACEBO ANC; Spiegel D, 2001, NEW ENGL J MED, V345, P1276; Spiro H, 1998, POWER HOPE DOCTORS P; TALBOT M, 2001, NY TIMES MAGAZI 0109, P34; TALBOT M, 2001, NY TIMES MAGAZI 0109, P44; TALBOT M, 2001, NY TIMES MAGAZI 0109, P58; THOMAS KB, 1987, BRIT MED J, V294, P1200, DOI 10.1136/bmj.294.6581.1200; UHLENHUTH EH, 1966, PSYCHOPHARMACOLOGIA, V9, P392, DOI 10.1007/BF00406450; Wickramasekera I, 2001, Adv Mind Body Med, V17, P309	78	476	482	0	65	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 19	2002	136	6					471	476		10.7326/0003-4819-136-6-200203190-00011	http://dx.doi.org/10.7326/0003-4819-136-6-200203190-00011			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	531AU	11900500				2022-12-28	WOS:000174393100007
J	Bowen, GJ; Clyde, WC; Koch, PL; Ting, SY; Alroy, J; Tsubamoto, T; Wang, YQ; Wang, Y				Bowen, GJ; Clyde, WC; Koch, PL; Ting, SY; Alroy, J; Tsubamoto, T; Wang, YQ; Wang, Y			Mammalian dispersal at the Paleocene/Eocene boundary	SCIENCE			English	Article							MARINE; END	A profound faunal reorganization occurred near the Paleocene/Eocene boundary, when several groups of mammals abruptly appeared on the Holarctic continents. To test the hypothesis that this event featured the dispersal of groups from Asia to North America and Europe, we used isotope stratigraphy, magnetostratigraphy, and quantitative biochronology to constrain the relative age of important Asian faunas. The extinct family Hyaenodontidae appeared in Asia before it did so in North America, and the modern orders Primates, Artiodactyla, and Perissodactyla first appeared in Asia at or before the Paleocene/Eocene boundary. These results are consistent with Asia being a center for early mammalian origination.	Univ Calif Santa Cruz, Dept Earth Sci, Santa Cruz, CA 95064 USA; Univ New Hampshire, Dept Earth Sci, Durham, NH 03824 USA; Louisiana State Univ, Museum Nat Sci, Baton Rouge, LA 70803 USA; Chinese Acad Sci, Inst Vertebrate Paleontol & Paleoanthropol, Beijing 100044, Peoples R China; Univ Calif Santa Barbara, Natl Ctr Ecol Anal & Synth, Santa Barbara, CA 93101 USA; Kyoto Univ, Primate Res Inst, Inuyama, Aichi 4848506, Japan	University of California System; University of California Santa Cruz; University System Of New Hampshire; University of New Hampshire; Louisiana State University System; Louisiana State University; Chinese Academy of Sciences; Institute of Vertebrate Paleontology & Paleoanthropology, CAS; National Center for Ecological Analysis & Synthesis; University of California System; University of California Santa Barbara; Kyoto University	Bowen, GJ (corresponding author), Univ Calif Santa Cruz, Dept Earth Sci, Santa Cruz, CA 95064 USA.	gbowen@es.ucsc.edu	Clyde, William/C-9595-2017; Alroy, John/B-4585-2009; Bowen, Gabriel J/C-1708-2008	Clyde, William/0000-0001-8814-3409; Alroy, John/0000-0002-9882-2111; 				ALROY J, 1994, PALEOBIOLOGY, V20, P191, DOI 10.1017/S0094837300012677; Alroy J, 2000, PALEOBIOLOGY, V26, P707, DOI 10.1666/0094-8373(2000)026<0707:NMFQMP>2.0.CO;2; Bains S, 1999, SCIENCE, V285, P724, DOI 10.1126/science.285.5428.724; Beard KC, 1999, B SOC GEOL FR, V170, P697; BEARD KC, 1998, DAWN AGE MAMMALS ASI, P5; Bowen GJ., 2001, PALEOCENE EOCENE STR, P73; CANDE SC, 1995, J GEOPHYS RES-SOL EA, V100, P6093, DOI 10.1029/94JB03098; Cojan I, 2000, GEOLOGY, V28, P259, DOI 10.1130/0091-7613(2000)028<0259:SCISOT>2.3.CO;2; DASHZEVEG D, 1988, J GEOL SOC LONDON, V145, P473, DOI 10.1144/gsjgs.145.3.0473; Gingerich P.D., 1989, U MICHIGAN PAPERS PA, V28, P1; Gingerich Philip D., 2001, Museum of Paleontology Papers on Paleontology, V33, P37; Hooker JJ, 1998, LATE PALEOCENE-EARLY EOCENE CLIMATIC AND BIOTIC EVENTS IN THE MARINE AND TERRESTRIAL RECORDS, P428; KENNETT JP, 1991, NATURE, V353, P225, DOI 10.1038/353225a0; KOCH PL, 1992, NATURE, V358, P319, DOI 10.1038/358319a0; Lucas SG, 1998, LATE PALEOCENE-EARLY EOCENE CLIMATIC AND BIOTIC EVENTS IN THE MARINE AND TERRESTRIAL RECORDS, P451; Maas M. C., 1990, GEOL SOC AM SPEC PAP, V243, P71; MCKENNA MC, 1983, ANN MO BOT GARD, V70, P459, DOI 10.2307/2992083; Meng Jin, 1998, Bulletin of Carnegie Museum of Natural History, V34, P148; Peters RB, 2000, GEOLOGY, V28, P979, DOI 10.1130/0091-7613(2000)28<979:HCOGGA>2.0.CO;2; Rohl U, 2000, GEOLOGY, V28, P927, DOI 10.1130/0091-7613(2000)28<927:NCFTLP>2.0.CO;2; TING S, 1998, DAWN AGE MAMMALS ASI, P124; WANG Y, 1998, DAWN AGE MAMMALS ASI, P89; Wing Scott L., 1999, WARM CLIMATES EARTH, P197; ZCHOS J, 2001, SCIENCE, V292, P686	24	192	222	0	62	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 15	2002	295	5562					2062	2065		10.1126/science.1068700	http://dx.doi.org/10.1126/science.1068700			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	532AY	11896275				2022-12-28	WOS:000174450500045
J	Arca, M; Zuliani, G; Wilund, K; Campagna, F; Fellin, R; Bertolini, S; Calandra, S; Ricci, G; Glorioso, N; Maioli, M; Pintus, P; Carru, C; Cossu, F; Cohen, J; Hobbs, HH				Arca, M; Zuliani, G; Wilund, K; Campagna, F; Fellin, R; Bertolini, S; Calandra, S; Ricci, G; Glorioso, N; Maioli, M; Pintus, P; Carru, C; Cossu, F; Cohen, J; Hobbs, HH			Autosomal recessive hypercholesterolaemia in Sardinia, Italy, and mutations in ARH: a clinical and molecular genetic analysis	LANCET			English	Article							LOW-DENSITY-LIPOPROTEIN; HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA; LDL-RECEPTOR; BETA-THALASSEMIA; CHOLESTEROL; POPULATION; INTERNALIZATION; ATHEROSCLEROSIS; PATHWAY; DISEASE	Background Autosomal recessive hypercholesterolaemia (ARH) is caused by mutations in a putative adaptor protein called ARH. This recessive disorder, characterised by severe hypercholesterolaemia, xanthomatosis, and premature coronary artery disease, is rare except on the island of Sardinia, Italy. Our aim was to ascertain why ARH is more common on Sardinia than elsewhere. Methods We obtained detailed medical histories, did physical examinations, measured concentrations of lipoproteins, and harvested genomic DNA from 28 Sardinians with ARH from 17 unrelated families. We sequenced the coding regions and consensus splice sites of ARH in probands from these families, and from 40 individuals of non-Sardinian origin who had an autosomal recessive form of hypercholesterolaemia of unknown cause. Findings Two ARH mutations, a frameshift mutation (c432insA) in exon 4 (ARH1) and a nonsense mutation (c65G-->A) in exon 1 (ARH2), were present in all of the 17 unrelated families with ARH. Three of the ARH alleles contained both mutations, as a result of an ancient recombination between ARH1 and ARH2. No regional clustering of the three mutant alleles within Sardinia was apparent. Furthermore, four Italians from the mainland with autosomal recessive hypercholesterolaemia were homozygous for ARH1. Interpretation The small number, high frequency, and dispersed distribution of ARH mutations on Sardinia are consistent with these mutations being ancient and maintained in the Sardinian population because of geographic isolation.	Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, McDermott Ctr Human Growth & Dev, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Ctr Human Nutr, Dallas, TX 75390 USA; Univ Roma La Sapienza, Dept Med Therapy, Rome, Italy; Univ Ferrara, Inst Med 2, I-44100 Ferrara, Italy; Univ Genoa, Dept Internal Med, I-16126 Genoa, Italy; Univ Modena & Reggio Emilia, Dept Biomed Sci, Modena, Italy; Osped Microcitemico, Bone Marrow Transplant Unit, Cagliari, Italy; Brotzu Hosp, Cagliari, Italy; Univ Sassari, Inst Internal Med, Clin Biochem & Metab Dis Unit, I-07100 Sassari, Italy	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Sapienza University Rome; University of Ferrara; University of Genoa; Universita di Modena e Reggio Emilia; University of Sassari	Hobbs, HH (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, 5323 Harry Hines, Dallas, TX 75390 USA.		Pintus, Paolo/AAQ-7789-2021; /V-4899-2019; Carru, Ciriaco/AAI-9996-2021; ARCA, Marcello/AAC-3883-2022	Pintus, Paolo/0000-0002-8666-8399; ARCA, Marcello/0000-0003-3786-0883; Zuliani, Giovanni/0000-0003-0969-3184; Carru, Ciriaco/0000-0002-6985-4907; Cossu, Fausto/0000-0001-5485-2098	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047619, P01HL020948] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL47619, HL20948, HL0360] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bertolini S, 1999, ARTERIOSCL THROM VAS, V19, P408, DOI 10.1161/01.ATV.19.2.408; BILHEIMER DW, 1983, P NATL ACAD SCI-BIOL, V80, P4124, DOI 10.1073/pnas.80.13.4124; BJORKHEM I, 2001, METABOLIC MOL BASES, P2961; BORK P, 1995, CELL, V80, P93; Braunwald E., 2001, HEART DIS TXB CARDIO; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BUJA LM, 1979, AM J PATHOL, V97, P327; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CUCCA F, 1998, FORUM TGRENDS EXP S, P23; DAVIS CG, 1986, CELL, V45, P15, DOI 10.1016/0092-8674(86)90533-7; DEVITA G, 1989, AM J HUM GENET, V44, P233; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; Garcia CK, 2001, SCIENCE, V292, P1394, DOI 10.1126/science.1060458; GOLDSTEIN JL, 1977, ANNU REV BIOCHEM, V46, P897, DOI 10.1146/annurev.bi.46.070177.004341; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; Goldstein JL, 2001, METABOLIC MOL BASES, V8th, P2863; HARADASHIBA M, 1992, ARTERIOSCLER THROMB, V12, P1071, DOI 10.1161/01.ATV.12.9.1071; Hobbs Helen H., 1992, Human Mutation, V1, P445, DOI 10.1002/humu.1380010602; KHACHADURIAN AK, 1973, NUTR METAB, V15, P132; Landschulz KT, 1996, J CLIN INVEST, V98, P984, DOI 10.1172/JCI118883; Linton MF, 1999, J BIOL CHEM, V274, P19204, DOI 10.1074/jbc.274.27.19204; Loudianos G, 1999, HUM MUTAT, V14, P294, DOI 10.1002/(SICI)1098-1004(199910)14:4<294::AID-HUMU4>3.0.CO;2-9; MUNTONI S, 1991, EUR J EPIDEMIOL, V7, P39; Norman D, 1999, J CLIN INVEST, V104, P619, DOI 10.1172/JCI6677; PIAZZA A, 1985, ANN HUM GENET, V49, P47, DOI 10.1111/j.1469-1809.1985.tb01675.x; PIRASTU M, 1987, P NATL ACAD SCI USA, V84, P2882, DOI 10.1073/pnas.84.9.2882; Raal FJ, 2000, ATHEROSCLEROSIS, V150, P421, DOI 10.1016/S0021-9150(99)00435-9; Rendine S, 1997, ANN HUM GENET, V61, P411; ROSATELLI MC, 1992, AM J HUM GENET, V50, P422; Schmidt HHJ, 1998, J CLIN ENDOCR METAB, V83, P2167, DOI 10.1210/jc.83.6.2167; SPOOR CF, 1986, J HUM EVOL, V15, P399, DOI 10.1016/S0047-2484(86)80019-7; STONE NJ, 1974, CIRCULATION, V49, P476, DOI 10.1161/01.CIR.49.3.476; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; WARNICK GR, 1979, CLIN CHEM, V25, P596; Zuliani G, 1999, ARTERIOSCL THROM VAS, V19, P802, DOI 10.1161/01.ATV.19.3.802; ZULIANI G, 1995, EUR J CLIN INVEST, V25, P322, DOI 10.1111/j.1365-2362.1995.tb01709.x	36	108	111	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 9	2002	359	9309					841	847		10.1016/S0140-6736(02)07955-2	http://dx.doi.org/10.1016/S0140-6736(02)07955-2			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	529YV	11897284				2022-12-28	WOS:000174329600012
J	Vaidya, B; Chan, K; Drury, J; Connolly, V				Vaidya, B; Chan, K; Drury, J; Connolly, V			A race to the lab	LANCET			English	Article									James Cook Univ Hosp, Dept Med, Middlesbrough TS4 3BW, Cleveland, England; James Cook Univ Hosp, Dept Biochem, Middlesbrough TS4 3BW, Cleveland, England	James Cook University Hospital; James Cook University Hospital	Vaidya, B (corresponding author), James Cook Univ Hosp, Dept Med, Middlesbrough TS4 3BW, Cleveland, England.		Vaidya, Bijay/AAF-1947-2020	Vaidya, Bijay/0000-0002-2223-0494				Iolascon A, 1999, BLOOD, V93, P3120; MEENAGHAN M, 1985, BIOCHIM BIOPHYS ACTA, V821, P72, DOI 10.1016/0005-2736(85)90155-5; Stewart GW, 1999, BEST PRACT RES CL HA, V12, P707, DOI 10.1053/beha.1999.0049; STEWART GW, 1979, LANCET, V2, P175	4	8	8	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 9	2002	359	9309					848	848		10.1016/S0140-6736(02)07956-4	http://dx.doi.org/10.1016/S0140-6736(02)07956-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	529YV	11897285				2022-12-28	WOS:000174329600013
J	D'Acremont, V; Landry, P; Darioli, R; Stuerchler, D; Pecoud, A; Genton, B				D'Acremont, V; Landry, P; Darioli, R; Stuerchler, D; Pecoud, A; Genton, B			Treatment of imported malaria in an ambulatory setting: prospective study	BRITISH MEDICAL JOURNAL			English	Article									Policlin Med Univ, CH-1005 Lausanne, Switzerland; Swiss Fed Off Publ Hlth, Bern, Switzerland		Genton, B (corresponding author), Policlin Med Univ, CH-1005 Lausanne, Switzerland.			Whitty, Christopher/0000-0002-6076-5027				Evans MRW, 2000, HOSP MED, V61, P162, DOI 10.12968/hosp.2000.61.3.1308; GENTON B, 2001, TRAVELERS MALARIA, P371; HATZ C, 2001, TRAVELERS MALARIA, P431; Kain KC, 1998, CLIN INFECT DIS, V27, P142, DOI 10.1086/514616	4	37	37	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 13	2002	324	7342					875	876		10.1136/bmj.324.7342.875	http://dx.doi.org/10.1136/bmj.324.7342.875			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	542PA	11950734	Green Published, Bronze			2022-12-28	WOS:000175052200018
J	Walsh, BT; Seidman, SN; Sysko, R; Gould, M				Walsh, BT; Seidman, SN; Sysko, R; Gould, M			Placebo response in studies of major depression - Variable, substantial, and growing	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							EXTENDED-RELEASE XR; DOUBLE-BLIND; CLINICAL-TRIALS; ANTIDEPRESSANT EFFICACY; CANADIAN MULTICENTER; ORG-3770 MIRTAZAPINE; HISTORICAL CONTROLS; PATTERN-ANALYSIS; DRUG TRIALS; IMIPRAMINE	Context Intense debate persists about the need for placebo-controlled groups in clinical trials of medications for major depressive disorder (MDD). There is continuing interest in the development of new medications, but because effective antidepressants are already available, ethical concerns have been raised about the need for placebo groups in new trials. Objective To determine whether the characteristics of placebo control groups in antidepressant trials have changed over time. Data Sources and Study Selection We searched MEDLINE and PsychLit for all controlled trials published in English between January 1981 and December 2000 in which adult outpatients with MDD were randomly assigned to receive medication or placebo. Seventy-five trials met our criteria for inclusion. Data Extraction Data were extracted from the articles by 2 of the authors and discrepancies were resolved via discussion and additional review by a third author. Data Synthesis The mean (SD) proportion of patients in the placebo group who responded was 29.7% (8.3%) (range, 12.5%-51.8%). Most studies examined more than a single active medication, and, in the active medication group with the greatest response, the mean (SD) proportion of patients responding was 50.1% (9.0%) (range, 31.6%-70.4%). Both the proportion of patients responding to placebo and the proportion responding to medication were significantly positively correlated with the year of publication (for placebo: n=75; r=0.45; 95% confidence interval [CI], 0.25-0.61; P<.001; for medication: n=75; r=0.26; 95% CI, 0.03-0.46; P=.02). The association between year of publication and response rate was more statistically robust for placebo than medication. Conclusions The response to placebo in published trials of antidepressant medication for MDD is highly variable and often substantial and has increased significantly in recent years, as has the response to medication. These observations support the view that the inclusion of a placebo group has major scientific importance in trials of new antidepressant medications and indicate that efforts should continue to minimize the risks of such studies so that they may be conducted in an ethically acceptable manner.	Columbia Univ Coll Phys & Surg, Dept Psychiat, New York, NY 10032 USA; New York State Psychiat Inst & Hosp, New York, NY 10032 USA	Columbia University; New York State Psychiatry Institute	Walsh, BT (corresponding author), Columbia Univ Coll Phys & Surg, Dept Psychiat, 1051 Riverside Dr,Unit 98, New York, NY 10032 USA.			Gould, Madelyn/0000-0002-2881-9152				Al-Khatib SM, 2001, SCIENCE, V292, P2013, DOI 10.1126/science.1057783; AMSTERDAM JD, 1986, PHARMACOPSYCHIATRY, V19, P115, DOI 10.1055/s-2007-1017167; AMSTERDAM JD, 1989, PHARMACOPSYCHIATRY, V22, P137, DOI 10.1055/s-2007-1014596; World Medical Association, 2013, JAMA, V310, P2191, DOI 10.1001/jama.2013.281053; BAKISH D, 1992, PSYCHOPHARMACOLOGY, V106, pS98, DOI 10.1007/BF02246248; BREMNER JD, 1995, J CLIN PSYCHIAT, V56, P519; BYERLEY WF, 1988, J CLIN PSYCHOPHARM, V8, P112; Charney DS, 2000, BIOL PSYCHIAT, V47, P687, DOI 10.1016/S0006-3223(00)00845-3; CHOUINARD G, 1994, J AFFECT DISORDERS, V32, P105, DOI 10.1016/0165-0327(94)90068-X; CLAGHORN J, 1983, PROG NEURO-PSYCHOPH, V7, P367, DOI 10.1016/0278-5846(83)90125-2; CLAGHORN JL, 1995, J AFFECT DISORDERS, V34, P165, DOI 10.1016/0165-0327(95)00014-E; Claghorn JL, 1996, J CLIN PSYCHOPHARM, V16, P113, DOI 10.1097/00004714-199604000-00003; CLAGHORN JL, 1992, J CLIN PSYCHIAT, V53, P434; Cohen J., 2013, STAT POWER ANAL BEHA, DOI DOI 10.4324/9780203771587; Cohn CK, 1996, J CLIN PSYCHIAT, V57, P15; COHN JB, 1989, INT CLIN PSYCHOPHARM, V4, P313, DOI 10.1097/00004850-198910000-00006; COHN JB, 1985, J CLIN PSYCHIAT, V46, P26; Conti L, 1989, NEW TRENDS EXP CLIN, V5, P221; Cunningham L A, 1997, Ann Clin Psychiatry, V9, P157, DOI 10.3109/10401239709147791; CUNNINGHAM LA, 1994, J CLIN PSYCHOPHARM, V14, P99; DAVIDSON JRT, 1988, ARCH GEN PSYCHIAT, V45, P120; DOMINGUEZ RA, 1985, J CLIN PSYCHIAT, V46, P84; DUNLOP SR, 1990, PSYCHOPHARMACOL BULL, V26, P173; Enserink M, 2000, SCIENCE, V288, P416; Fabre Jr L. F., 1990, J CLIN PSYCHOPHARM, V10, p67S; FABRE LF, 1995, BIOL PSYCHIAT, V38, P592, DOI 10.1016/0006-3223(95)00178-8; FEIGHNER JP, 1989, ACTA PSYCHIAT SCAND, V80, P125, DOI 10.1111/j.1600-0447.1989.tb07190.x; FEIGHNER JP, 1983, JAMA-J AM MED ASSOC, V249, P3057, DOI 10.1001/jama.249.22.3057; FERGUSON JM, 1994, J CLIN PSYCHIAT, V55, P258; FLEISS JL, 1973, EDUC PSYCHOL MEAS, V33, P613, DOI 10.1177/001316447303300309; FONTAINE R, 1994, J CLIN PSYCHIAT, V55, P234; FREIREICH EJ, 1974, CANCER CHEMOTH REP 1, V58, P623; GEHAN EA, 1978, BIOMEDICINE, V28, P13; GELENBERG AJ, 1990, COMPR PSYCHIAT, V31, P307, DOI 10.1016/0010-440X(90)90037-S; GHOSH K, 1999, NEW CLIN DRUG EVAL U; GILLER E, 1984, J CLIN PSYCHIAT, V45, P44; Guy W., 1976, ASSESSMENT MANUAL PS, P218, DOI DOI 10.1186/1471-244X-7-7; HALIKAS JA, 1995, HUM PSYCHOPHARM CLIN, V10, pS125, DOI 10.1002/hup.470100807; HEILIGENSTEIN JH, 1994, J AFFECT DISORDERS, V30, P163, DOI 10.1016/0165-0327(94)90077-9; HORMAZABAL L, 1985, PSYCHOPHARMACOLOGY, V86, P205, DOI 10.1007/BF00431710; Hrobjartsson A, 2001, NEW ENGL J MED, V344, P1594, DOI 10.1056/NEJM200105243442106; ITII TM, 1983, BR J CLIN PHARM S3, V15, pS433; Khan A, 2000, ARCH GEN PSYCHIAT, V57, P311, DOI 10.1001/archpsyc.57.4.311; KHAN A, 1991, NEUROPSYCHOPHARMACOL, V4, P125; KHAN MC, 1995, HUM PSYCHOPHARM CLIN, V10, pS119, DOI 10.1002/hup.470100806; KLEIN DF, 1991, NEUROPSYCHOPHARMACOL, V4, P251; Kraemer HC, 2000, ARCH GEN PSYCHIAT, V57, P327, DOI 10.1001/archpsyc.57.4.327; LAAKMAN G, 1995, PSYCHOPHARMACOLOGY, V120, P109, DOI 10.1007/BF02246151; Lapierre YD, 1998, J CLIN PSYCHOPHARM, V18, P268, DOI 10.1097/00004714-199808000-00002; Leber P, 2000, ARCH GEN PSYCHIAT, V57, P319, DOI 10.1001/archpsyc.57.4.319; Leber P, 2000, BIOL PSYCHIAT, V47, P699, DOI 10.1016/S0006-3223(99)00321-2; LEBER PD, 1989, EPILEPSIA, V30, pS57, DOI 10.1111/j.1528-1157.1989.tb05816.x; Leon AC, 2001, J CLIN PSYCHIAT, V62, P12; LINEBERRY CG, 1990, J CLIN PSYCHIAT, V51, P194; LIPMAN RS, 1986, ARCH GEN PSYCHIAT, V43, P68; Lydiard RB, 1997, J CLIN PSYCHIAT, V58, P484, DOI 10.4088/JCP.v58n1104; MENDELS J, 1986, J CLIN PSYCHIAT, V47, P357; MENDELS J, 1993, PSYCHOPHARMACOL BULL, V29, P169; MERIDETH CH, 1983, ACTA PSYCHIAT SCAND, V68, P70, DOI 10.1111/j.1600-0447.1983.tb11104.x; Michels KB, 2000, ARCH GEN PSYCHIAT, V57, P321, DOI 10.1001/archpsyc.57.4.321; Montgomery SA, 1999, EUR NEUROPSYCHOPHARM, V9, P271, DOI 10.1016/S0924-977X(98)00050-9; MUIJEN M, 1988, ACTA PSYCHIAT SCAND, V78, P384, DOI 10.1111/j.1600-0447.1988.tb06353.x; NAIR NPV, 1995, J AFFECT DISORDERS, V33, P1, DOI 10.1016/0165-0327(94)00047-D; Olfson M, 2002, JAMA-J AM MED ASSOC, V287, P203, DOI 10.1001/jama.287.2.203; OSE E, 1992, PSYCHOPHARMACOLOGY, V106, pS114, DOI 10.1007/BF02246251; PESELOW ED, 1989, BRIT J PSYCHIAT, V155, P667; QUITKIN FM, 1987, ARCH GEN PSYCHIAT, V44, P259; Quitkin FM, 1996, ARCH GEN PSYCHIAT, V53, P785; Quitkin FM, 1999, AM J PSYCHIAT, V156, P829, DOI 10.1176/ajp.156.6.829; REIMHERR FW, 1990, J CLIN PSYCHIAT, V51, P18; REIMHERR FW, 1984, PSYCHOPHARMACOL BULL, V20, P70; RICKELS K, 1991, PHARMACOPSYCHIATRY, V24, P127, DOI 10.1055/s-2007-1014455; RICKELS K, 1985, ARCH GEN PSYCHIAT, V42, P134; RICKELS K, 1987, ARCH GEN PSYCHIAT, V44, P862; Rickels K, 1996, J CLIN PSYCHOPHARM, V16, P212, DOI 10.1097/00004714-199606000-00004; RICKELS K, 1982, INT PHARMACOPSYCHIAT, V17, P73, DOI 10.1159/000468602; RICKELS K, 1995, J CLIN PSYCHIAT, V56, P43; Robinson DS, 2000, J CLIN PSYCHOPHARM, V20, P593, DOI 10.1097/00004714-200012000-00001; ROSNER F, 1987, AM J MED, V82, P283, DOI 10.1016/0002-9343(87)90069-6; Rothman KJ, 2000, BMJ-BRIT MED J, V321, P442, DOI 10.1136/bmj.321.7258.442; ROTHMAN KJ, 1994, NEW ENGL J MED, V331, P394, DOI 10.1056/NEJM199408113310611; Rudolph RL, 1998, J CLIN PSYCHIAT, V59, P116, DOI 10.4088/JCP.v59n0305; Rudolph RL, 1999, J AFFECT DISORDERS, V56, P171, DOI 10.1016/S0165-0327(99)00067-1; Ruether E., 1999, Pharmacopsychiatry, V32, P127; Rush AJ, 1998, J CLIN PSYCHIAT, V59, P73; Schatzberg AF, 2000, J CLIN PSYCHIAT, V61, P31; Schrader E, 1998, HUM PSYCHOPHARM CLIN, V13, P163, DOI 10.1002/(SICI)1099-1077(199804)13:3<163::AID-HUP5>3.3.CO;2-9; SCHWEIZER E, 1994, J CLIN PSYCHIAT, V55, P104; Schweizer E, 1998, J CLIN PSYCHIAT, V59, P175, DOI 10.4088/JCP.v59n0406; Silverstone PH, 1999, J CLIN PSYCHIAT, V60, P22, DOI 10.4088/JCP.v60n0105; SILVERSTONE T, 1994, INT CLIN PSYCHOPHARM, V9, P109, DOI 10.1097/00004850-199400920-00007; SMITH WT, 1990, PSYCHOPHARMACOL BULL, V26, P191; Stahl SM, 2000, BIOL PSYCHIAT, V48, P894, DOI 10.1016/S0006-3223(00)00957-4; Stahl SM, 2001, J CLIN PSYCHIAT, V62, P17; STARK P, 1985, J CLIN PSYCHIAT, V46, P53; Stassen HH, 1996, PHARMACOPSYCHIATRY, V29, P87, DOI 10.1055/s-2007-979551; Stewart A, 1998, J AFFECT DISORDERS, V48, P125, DOI 10.1016/S0165-0327(97)00161-4; STEWART JW, 1989, ARCH GEN PSYCHIAT, V46, P1080; STEWART JW, 1985, ARCH GEN PSYCHIAT, V42, P1148; Temple R, 2000, ANN INTERN MED, V133, P455, DOI 10.7326/0003-4819-133-6-200009190-00014; Thase ME, 1997, J CLIN PSYCHIAT, V58, P393, DOI 10.4088/JCP.v58n0904; THOMPSON C, 1994, INT CLIN PSYCHOPHARM, V9, P21, DOI 10.1097/00004850-199406003-00004; TOLLEFSON GD, 1993, INT CLIN PSYCHOPHARM, V8, P253, DOI 10.1097/00004850-199300840-00008; Tramer MR, 1998, BMJ-BRIT MED J, V317, P875, DOI 10.1136/bmj.317.7162.875; TRIVEDI MH, 1994, NEUROPSYCHOPHARMACOL, V11, P33, DOI 10.1038/npp.1994.63; VERSIANI M, 1989, BRIT J PSYCHIAT, V155, P72, DOI 10.1192/S0007125000297523; WERNICKE JF, 1987, PSYCHOPHARMACOL BULL, V23, P164; WHITE K, 1984, PSYCHOPHARMACOLOGY, V82, P258, DOI 10.1007/BF00427786; WILCOX CS, 1994, INT CLIN PSYCHOPHARM, V9, P271, DOI 10.1097/00004850-199400940-00006; Wilcox CS, 1996, PSYCHOPHARMACOL BULL, V32, P335; WILLIAMS JBW, 1988, ARCH GEN PSYCHIAT, V45, P742; Zitman F G, 1990, Psychopharmacol Ser, V9, P28	112	891	905	1	63	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 10	2002	287	14					1840	1847		10.1001/jama.287.14.1840	http://dx.doi.org/10.1001/jama.287.14.1840			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	539QJ	11939870				2022-12-28	WOS:000174881700037
J	Vorontsov, SV; Christensen-Dalsgaard, J; Schou, J; Strakhov, VN; Thompson, MJ				Vorontsov, SV; Christensen-Dalsgaard, J; Schou, J; Strakhov, VN; Thompson, MJ			Helioseismic measurement of solar torsional oscillations	SCIENCE			English	Article							TEMPORAL VARIATIONS; ROTATION RATE; ZONAL FLOWS	Bands of slower and faster rotation, the so-called torsional oscillations, are observed at the Sun's surface to migrate in latitude over the 11-year solar cycle. Here, we report on the temporal variations of the Sun's internal rotation from solar p-mode frequencies obtained over nearly 6 years by the Michelson Doppler Imager (MDI) instrument on board the Solar and Heliospheric Observatory (SOHO) satellite. The entire solar convective envelope appears to be involved in the torsional oscillations, with phase propagating poleward and equatorward from midlatitudes at all depths throughout the convective envelope.	Univ London Imperial Coll Sci Technol & Med, Blackett Lab, Space & Atmospher Phys Grp, London SW7 2BZ, England; Queen Mary Univ London, Astron Unit, London E1 4NS, England; Moscow Phys Earth Inst, Moscow 123810, Russia; Aarhus Univ, Inst Fys & Astron, DK-8000 Aarhus C, Denmark; Danmarks Grundforskningsfond, Teoret Astrofys Ctr, DK-8000 Aarhus C, Denmark; Stanford Univ, Stanford, CA 94305 USA	Imperial College London; University of London; Queen Mary University London; Russian Academy of Sciences; Schmidt Institute of Physics of the Earth of the Russian Academy of Sciences; Aarhus University; Aarhus University; Danmarks Grundforskningsfond; Stanford University	Thompson, MJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Blackett Lab, Space & Atmospher Phys Grp, Prince Consort Rd, London SW7 2BZ, England.	michael.thompson@ic.ac.uk		Christensen-Dalsgaard, Jorgen/0000-0001-5137-0966				Antia HM, 2000, ASTROPHYS J, V541, P442, DOI 10.1086/309421; Antia HM, 2001, ASTROPHYS J, V559, pL67, DOI 10.1086/323701; CHRISTENSENDALSGAARD J, 1993, MON NOT R ASTRON SOC, V264, P541, DOI 10.1093/mnras/264.3.541; Covas E, 2000, ASTRON ASTROPHYS, V360, pL21; Harvey JW, 1996, SCIENCE, V272, P1284, DOI 10.1126/science.272.5266.1284; HOWARD R, 1980, ASTROPHYS J, V239, pL33, DOI 10.1086/183286; Howe R, 2000, SCIENCE, V287, P2456, DOI 10.1126/science.287.5462.2456; Howe R, 2000, ASTROPHYS J, V533, pL163, DOI 10.1086/312623; LAVELY EM, 1993, ASTROPHYS J, V403, P810, DOI 10.1086/172252; Scherrer PH, 1995, SOL PHYS, V162, P129, DOI 10.1007/BF00733429; Schou J, 1999, ASTROPHYS J, V523, pL181, DOI 10.1086/312279; Schou J, 1998, ASTROPHYS J, V505, P390, DOI 10.1086/306146; STRAKHOV VN, 2001, ESA, P539; Ulrich RK, 2001, ASTROPHYS J, V560, P466, DOI 10.1086/322524	14	160	162	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 5	2002	296	5565					101	103		10.1126/science.1069190	http://dx.doi.org/10.1126/science.1069190			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	539FA	11935019				2022-12-28	WOS:000174858800040
J	Tanaka, M; Munsterberg, A; Anderson, WG; Prescott, AR; Hazon, N; Tickle, C				Tanaka, M; Munsterberg, A; Anderson, WG; Prescott, AR; Hazon, N; Tickle, C			Fin development in a cartilaginous fish and the origin of vertebrate limbs	NATURE			English	Article							APICAL ECTODERMAL RIDGE; POLARIZING ACTIVITY; SONIC-HEDGEHOG; CHICK-EMBRYOS; HOX GENES; EVOLUTION	Recent fossil finds and experimental analysis of chick and mouse embryos highlighted the lateral fin fold theory, which suggests that two pairs of limbs in tetrapods evolved by subdivision of an elongated single fin(1). Here we examine fin development in embryos of the primitive cartilaginous fish, Scyliorhinus canicula (dogfish) using scanning electron microscopy and investigate expression of genes known to be involved in limb positioning, identity and patterning in higher vertebrates. Although we did not detect lateral fin folds in dogfish embryos, Engrailed-1 expression suggests that the body is compartmentalized dorsoventrally. Furthermore, specification of limb identity occurs through the Tbx4 and Tbx5 genes, as in higher vertebrates. In contrast, unlike higher vertebrates, we did not detect Shh transcripts in dogfish fin-buds, although dHand (a gene involved in establishing Shh) is expressed. In S. canicula, the main fin axis seems to lie parallel to the body axis. 'Freeing' fins from the body axis and establishing a separate 'limb' axis has been proposed to be a crucial step in evolution of tetrapod limbs(2,3). We suggest that Shh plays a critical role in this process.	Univ Dundee, Wellcome Trust Bioctr, Div Cell & Dev Biol, Dundee DD1 5EH, Scotland; Univ Dundee, Wellcome Trust Bioctr, Div Cell Biol & Immunol, Dundee DD1 5EH, Scotland; Univ St Andrews, Sch Biol, Div Environm & Evolutionary Biol, Gatty Marine Lab, St Andrews KY16 8LB, Fife, Scotland	University of Dundee; University of Dundee; University of St Andrews	Tanaka, M (corresponding author), Univ Dundee, Wellcome Trust Bioctr, Div Cell & Dev Biol, Dow St, Dundee DD1 5EH, Scotland.		Munsterberg, Andrea E/E-2205-2011; Prescott, Alan/Y-5956-2018; Tanaka, Mikiko/X-1904-2019; Tanaka, Mikiko/B-9329-2015	Munsterberg, Andrea E/0000-0002-4577-4240; Prescott, Alan/0000-0002-0747-7317; Tanaka, Mikiko/0000-0001-8092-8594; Tanaka, Mikiko/0000-0001-8092-8594				Altabef M, 1997, DEVELOPMENT, V124, P4547; Balfour F M, 1876, J Anat Physiol, V11, P128; Balinsky B. I., 1933, ROUXS ARCH, V130, P704; BALLARD WW, 1993, J EXP ZOOL, V267, P318, DOI 10.1002/jez.1402670309; COATES M, 1993, NATURE, V364, P195, DOI 10.1038/364195b0; COATES MI, 1994, DEVELOPMENT, P169; COATES MI, 1995, CURR BIOL, V5, P844, DOI 10.1016/S0960-9822(95)00169-2; Cohn MJ, 2000, NATURE, V406, P953, DOI 10.1038/35023216; COHN MJ, 1995, CELL, V80, P739, DOI 10.1016/0092-8674(95)90352-6; EKKER SC, 1995, CURR BIOL, V5, P44; JARVIK E, 1980, BASIC STRUCTURE EVOL, P109; Kraus P, 2001, MECH DEVELOP, V100, P45, DOI 10.1016/S0925-4773(00)00492-5; KURATANI S, 1997, J COMP NEUROL, V384, P482; Mazan S, 2000, EVOL DEV, V2, P186, DOI 10.1046/j.1525-142x.2000.00062.x; MOYTHOMAS JA, 1936, SCH SCI REV, V36, P592; MUNSTERBERG AE, 1995, GENE DEV, V9, P2911, DOI 10.1101/gad.9.23.2911; Neyt C, 2000, NATURE, V408, P82, DOI 10.1038/35040549; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; Ruvinsky I, 2000, GENETICS, V156, P1249; Schlosser G, 1997, BRAIN BEHAV EVOLUT, V50, P61, DOI 10.1159/000113323; Shu DG, 1999, NATURE, V402, P42, DOI 10.1038/46965; TABIN C, 1993, NATURE, V361, P692, DOI 10.1038/361692a0; Tamura K, 2001, J ANAT, V199, P195, DOI 10.1017/S0021878201008081; Tanaka M, 1998, DEV GROWTH DIFFER, V40, P423; Tanaka M, 2000, DEVELOPMENT, V127, P4011; Thacher J.K., 1877, T CONN ACAD ARTS SCI, V3, P281; TUMPEL S, UNPUB DEV BIOL; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75	28	97	99	1	62	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 4	2002	416	6880					527	531		10.1038/416527a	http://dx.doi.org/10.1038/416527a			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	537JY	11932743	Green Accepted			2022-12-28	WOS:000174756500041
J	Bodary, PF; Westrick, RJ; Wickenheiser, KJ; Shen, YC; Eitzman, DT				Bodary, PF; Westrick, RJ; Wickenheiser, KJ; Shen, YC; Eitzman, DT			Effect of leptin on arterial thrombosis following vascular injury in mice	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; NECROSIS-FACTOR-ALPHA; OBESITY; GENE; RECEPTOR; DISEASE	Context Complications of atherosclerosis are the leading cause of morbidity and mortality in industrialized societies. Obesity has emerged as an independent risk factor for complications of atherosclerotic vascular disease. Leptin, a hormone produced by the adipocyte, increases with obesity and appears to modulate energy balance and food intake. In addition, other actions of leptin have been proposed, including an in vitro effect on platelet aggregation. Thus, the elevated plasma leptin levels in obese individuals may promote vascular thrombosis. Objective To test the hypothesis that leptin contributes to in vivo thrombosis via the leptin receptor. Design and Materials Between September 2000 and September 2001, a vascular thrombosis model was used to test male 10- to 12-week-old mice completely deficient in leptin or the leptin receptor and mice with platelet leptin-receptor deficiency. Main Outcome Measure Time to formation of an occlusive thrombus in the common carotid artery following experimentally induced endothelial injury. Results Following onset of vascular injury, wild-type mice (n=8) formed occlusive thrombosis in a mean (SD) of 42.2 (4.6) minutes, whereas leptin-deficient (n=5) and leptin receptor-deficient mice (n=7) formed occlusive thrombosis in 75.2 (10.1) and 68.6 (10.3) minutes, respectively (leptin deficient vs wild-type mice, P=.008; leptin-receptor-deficient vs wild-type, P=.03). When recombinant murine leptin was administered to leptin-deficient mice (n=4), the time to occlusion was reduced to 41.8 (6.6) minutes (P=.035 vs vehicle control). Following bone marrow transplantation from leptin receptor-deficient (donor) mice to wild-type (recipient) mice, the time to occlusion was prolonged from 22.3 (2.8) minutes in wild-type mice receiving wild-type marrow (n=3) to 56.8 (5.0) minutes in wild-type mice receiving leptin receptor-deficient bone marrow (n=5) (P=.003). Conclusions Leptin contributes to arterial thrombosis following vascular injury in vivo and these prothrombotic effects appear to be mediated through the platelet leptin receptor.	Univ Michigan, Dept Internal Med, Div Cardiol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Eitzman, DT (corresponding author), 7301 MSRB 3,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R43HL035989, R44HL035989] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-36195, HL-35989] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; Eckel RH, 1998, CIRCULATION, V97, P2099, DOI 10.1161/01.CIR.97.21.2099; Eitzman DT, 2000, BLOOD, V95, P577, DOI 10.1182/blood.V95.2.577; Fantuzzi G, 2000, J LEUKOCYTE BIOL, V68, P437; FUSTER V, 1990, CIRCULATION, V82, P47; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Ishizuka T, 1999, DIABETES, V48, P1061, DOI 10.2337/diabetes.48.5.1061; Juhan-Vague I, 2000, ANN MED, V32, P78; LINTON MF, 1995, SCIENCE, V267, P1034, DOI 10.1126/science.7863332; Lundgren CH, 1996, CIRCULATION, V93, P106, DOI 10.1161/01.CIR.93.1.106; Maruyama I, 2000, ANN NY ACAD SCI, V902, P315; Nakata M, 1999, DIABETES, V48, P426, DOI 10.2337/diabetes.48.2.426; Samad F, 1998, P NATL ACAD SCI USA, V95, P7591, DOI 10.1073/pnas.95.13.7591; Samad F, 1999, P NATL ACAD SCI USA, V96, P6902, DOI 10.1073/pnas.96.12.6902; Samad F, 1996, J CLIN INVEST, V97, P37, DOI 10.1172/JCI118404; Wallace AM, 2001, CIRCULATION, V104, P3052, DOI 10.1161/hc5001.101061; Westrick RJ, 2001, CIRCULATION, V103, P3044, DOI 10.1161/hc2501.092492; Winkler UH, 1997, ARCH GYNECOL OBSTET, V261, P25, DOI 10.1007/s004040050193	18	193	207	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 3	2002	287	13					1706	1709		10.1001/jama.287.13.1706	http://dx.doi.org/10.1001/jama.287.13.1706			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	536YW	11926895				2022-12-28	WOS:000174730300025
J	Marek, K; Seibyl, J; Shoulson, I; Holloway, R; Kieburtz, K; McDermott, M; Kamp, C; Shinaman, A; Fahn, S; Lang, A; Weiner, W; Welsh, M				Marek, K; Seibyl, J; Shoulson, I; Holloway, R; Kieburtz, K; McDermott, M; Kamp, C; Shinaman, A; Fahn, S; Lang, A; Weiner, W; Welsh, M		Parkinson Study Grp	Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POSITRON-EMISSION-TOMOGRAPHY; I-123 BETA-CIT; NONHUMAN-PRIMATES; SPECT; ROPINIROLE; AGONIST; PET	Context Pramipexole and levodopa are effective medications to treat motor symptoms of early Parkinson disease (PD). In vitro and animal studies suggest that pramipexole may protect and that levodopa may either protect or damage dopamine neurons. Neuroimaging offers the potential of an objective biomarker of dopamine neuron degeneration in PD patients. Objective To compare rates of dopamine neuron degeneration after initial treatment with pramipexole or levodopa in early PD by means of dopamine transporter imaging using single-photon emission computed tomography (SPECT) with 2beta-carboxymethoxy-3beta(4-iodophenyl)tropane (beta-CIT) labeled with iodine 123. Design Substudy of a parallel-group, double-blind randomized clinical trial. Setting and Patients Eighty-two patients with early PD who were recruited at 17 clinical sites in the United States and Canada and required dopaminergic therapy to treat emerging disability, enrolled between November 1996 and August 1997. Interventions Patients were randomly assigned to receive pramipexole, 0.5 mg 3 times per day with levodopa placebo (n=42), or carbidopa/levodopa, 25/100 mg 3 times per day with pramipexole placebo (n=40). For patients with residual disability, the dosage was escalated during the first 10 weeks, and subsequently, open-label levodopa could be added. After 24 months of follow-up, the dosage of study drug could be further modified. Main Outcome Measures The primary outcome variable was the percentage change from baseline in striatal [I-123]beta-CIT uptake after 46 months. The percentage changes and absolute changes in striatal, putamen, and caudate [I-123]beta-CIT uptake after 22 and 34 months were also assessed. Clinical severity of PD was assessed using the Unified Parkinson Disease Rating Scale (UPDRS) 12 hours off anti-PD medications. Results Sequential SPECT imaging showed a decline in mean (SD) [I-123]beta-CIT striatal uptake from baseline of 10.3% (9.8%) at 22 months, 15.3% (12.8%) at 34 months, and 20.7% (14.4%) at 46 months-approximately 5.2% per year. The mean (SD) percentage loss in striatal [I-123] beta-CIT uptake from baseline was significantly reduced in the pramipexole group compared with the levodopa group: 7.1% (9.0%) vs 13.5% (9.6%) at 22 months (P=.004); 10.9% (11.8%) vs 19.6% (12.4%) at 34 months (P=.009); and 16.0% (13.3%) vs 25.5% (14.1%) at 46 months (P=.01). The percentage loss from baseline in striatal [I-123]beta-CIT uptake was correlated with the change from baseline in UPDRS at the 46-month evaluation (r=-0.40; P=.001). Conclusions Patients initially treated with pramipexole demonstrated a reduction in loss of striatal [I-123]beta-CIT uptake, a marker of dopamine neuron degeneration, compared with those initially treated with levodopa, during a 46-month period. These imaging data highlight the need to further compare imaging and clinical end points of PD progression in long-term studies.	Inst Neurodegenerat Disorders, CALM PD CIT, New Haven, CT 06510 USA; Univ Rochester, Rochester, NY USA; Columbia Univ, CALM PD, New York, NY USA; Toronto Western Hosp, Univ Hlth Network, Toronto, ON M5T 2S8, Canada; Univ Maryland, Baltimore, MD 21201 USA; Univ So Calif, Los Angeles, CA USA	University of Rochester; Columbia University; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University System of Maryland; University of Maryland Baltimore; University of Southern California	Marek, K (corresponding author), Inst Neurodegenerat Disorders, CALM PD CIT, 60 Temple St,Suite 8B, New Haven, CT 06510 USA.	kmarek@indd.org	Lang, Anthony/ABF-8114-2021; anand, amit/A-7222-2009	Marek, Kenneth/0000-0002-4197-5627; Lang, Anthony/0000-0003-1229-3667				Ahlskog JE, 1999, MOVEMENT DISORD, V14, P940, DOI 10.1002/1531-8257(199911)14:6<940::AID-MDS1005>3.0.CO;2-Y; Asenbaum S, 1997, J NUCL MED, V38, P1; BALDWIN RM, 1993, NUCL MED BIOL, V20, P597, DOI 10.1016/0969-8051(93)90028-S; BERNHEIMER H, 1973, J NEUROL SCI, V20, P415, DOI 10.1016/0022-510X(73)90175-5; Booij J, 1997, J NEUROL NEUROSUR PS, V62, P133, DOI 10.1136/jnnp.62.2.133; Brooks DJ, 2000, NEUROLOGY, V54, pA113; Carvey PM, 1997, J NEURAL TRANSM, V104, P209, DOI 10.1007/BF01273182; CHANG LT, 1978, IEEE T NUCL SCI, V25, P638, DOI 10.1109/TNS.1978.4329385; EIDELBERG D, 1995, NEUROLOGY, V45, P1995, DOI 10.1212/WNL.45.11.1995; ELSWORTH JD, 1994, EXP NEUROL, V126, P300, DOI 10.1006/exnr.1994.1068; Fahn S, 1999, ARCH NEUROL-CHICAGO, V56, P529, DOI 10.1001/archneur.56.5.529; Fahn S., 1987, RECENT DEV PARKINSON, P153; FEARNLEY JM, 1991, BRAIN, V114, P2283, DOI 10.1093/brain/114.5.2283; Guttman M, 1997, NEUROLOGY, V48, P1578, DOI 10.1212/WNL.48.6.1578; HOEHN MM, 1967, NEUROLOGY, V17, P427, DOI 10.1212/WNL.17.5.427; Holloway R, 2000, CLIN NEUROPHARMACOL, V23, P34; Iida M, 1999, BRAIN RES, V838, P51, DOI 10.1016/S0006-8993(99)01688-1; INNIS RB, 1993, P NATL ACAD SCI USA, V90, P11965, DOI 10.1073/pnas.90.24.11965; Innis RB, 1999, MOVEMENT DISORD, V14, P436, DOI 10.1002/1531-8257(199905)14:3<436::AID-MDS1008>3.0.CO;2-J; Jennings DL, 2001, NEUROLOGY, V56, pA74; LANGSTON JW, 1992, MOVEMENT DISORD, V7, P2, DOI 10.1002/mds.870070103; LARUELLE M, 1993, SYNAPSE, V13, P295, DOI 10.1002/syn.890130402; Le WD, 2001, DRUG AGING, V18, P389, DOI 10.2165/00002512-200118060-00001; Little R, 1996, BIOMETRICS, V52, P1324, DOI 10.2307/2532847; Marek K, 2000, SCIENCE, V289, P409, DOI 10.1126/science.289.5478.409; Marek K, 2001, NEUROLOGY, V57, P2089, DOI 10.1212/WNL.57.11.2089; Marek KL, 1996, NEUROLOGY, V46, P231, DOI 10.1212/WNL.46.1.231; MCGEER PL, 1988, ANN NEUROL, V24, P574, DOI 10.1002/ana.410240415; Morrish PK, 1998, J NEUROL NEUROSUR PS, V64, P314, DOI 10.1136/jnnp.64.3.314; MURER M, 1998, ANN NEUROL, V43, P392; Nurmi E, 2000, ANN NEUROL, V47, P804, DOI 10.1002/1531-8249(200006)47:6<804::AID-ANA14>3.0.CO;2-F; Nurmi E, 2001, MOVEMENT DISORD, V16, P608, DOI 10.1002/mds.1139; Nutt JG, 1996, ANN NEUROL, V39, P561, DOI 10.1002/ana.410390504; Olanow CW, 1998, ANN NEUROL, V44, pS167; Parkinson Study Group, 2000, JAMA, V284, P1931; PAULUS W, 1991, J NEUROPATH EXP NEUR, V50, P743, DOI 10.1097/00005072-199111000-00006; Pirker W, 2002, MOVEMENT DISORD, V17, P45, DOI 10.1002/mds.1265; Rascol O, 2000, NEW ENGL J MED, V342, P1484, DOI 10.1056/NEJM200005183422004; SAWLE GV, 1994, ARCH NEUROL-CHICAGO, V51, P237, DOI 10.1001/archneur.1994.00540150027011; SEIBYL JP, 1995, ANN NEUROL, V38, P589, DOI 10.1002/ana.410380407; SHOULSON I, 1993, NEW ENGL J MED, V328, P176, DOI 10.1056/NEJM199301213280305; Shoulson I, 1998, SCIENCE, V282, P1072, DOI 10.1126/science.282.5391.1072; van Dyck CH, 2002, AM J GERIAT PSYCHIAT, V10, P36, DOI 10.1176/appi.ajgp.10.1.36	43	592	605	1	29	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 3	2002	287	13					1653	1661						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	536YW	11926889				2022-12-28	WOS:000174730300019
J	Benger, JR; Pearce, AV				Benger, JR; Pearce, AV			Quality improvement report - Simple intervention to improve detection of child abuse in emergency departments	BRITISH MEDICAL JOURNAL			English	Article							NEGLECT	Problem Child abuse is easily overlooked in a busy emergency department. Design Two stage audit of 1000 children before and after introduction of reminder flowchart. Background and setting An emergency department in a suburban teaching hospital seeing about 4000 injured preschool children a year. Key measures for improvement Number of records in which intentional injury was adequately documented and considered and the number of children referred for further assessment before and after introduction of reminder flowchart into emergency department notes. Strategies for change Nurses were asked to insert a reminder flowchart for assessing intentional injury into the notes of A children aged 0-5 years attending the department with any injury and to record the results of checking the child protection register. Effect of change Documentation of all eight indicators that intentional injury had been considered had increased in die second audit. Records of compatibility, of history with injury and consistency of history increased from less than 2% to more than 70% (P < 0.0001). More children were referred for further assessment in the second audit than the first, although the difference was not significant (6 (0.6%) v 14 (1.4%), P = 0.072). The general level of awareness and vigilance increased in the second audit, even for children whose records did not contain the flowchart. Lessons learnt Inclusion of a simple reminder flowchart in the notes of injured preschool children attending the emergency department increases awareness, consideration, and documentation of intentional injury. Rates of referral for further assessment also increase.	Frenchay Hosp, Emergency Dept, Bristol BS16 1LE, Avon, England; Frenchay Hosp, Dept Community Child Hlth, Bristol BS16 1LE, Avon, England		Benger, JR (corresponding author), Bristol Royal Infirm & Gen Hosp, Emergency Dept, Bristol BS2 8BW, Avon, England.			Benger, Jonathan/0000-0001-6131-0916				Benger JR, 2001, EMERG MED J, V18, P172, DOI 10.1136/emj.18.3.172; *BRIT PAED ASS BRI, 1988, JOINT STAT CHILDR AT; Clark KD, 1997, PEDIATR EMERG CARE, V13, P259, DOI 10.1097/00006565-199708000-00005; HOBSON MI, 1994, BURNS, V20, P442, DOI 10.1016/0305-4179(94)90039-6; MCCLAIN PW, 1993, PEDIATRICS, V91, P338; *NAT CTR CHILD AB, 1988, STUD FIND STUD NAT I; Nicol MF, 1999, J ACCID EMERG MED, V16, P77; PLESS IB, 1987, CHILD ABUSE NEGLECT, V11, P193, DOI 10.1016/0145-2134(87)90058-5; SIDEBOTHAM PD, 1997, BRIT MED J, V315, P338; Van Haeringen AR, 1998, CHILD ABUSE NEGLECT, V22, P159, DOI 10.1016/S0145-2134(97)00172-5	10	75	77	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 30	2002	324	7340					780	782		10.1136/bmj.324.7340.780	http://dx.doi.org/10.1136/bmj.324.7340.780			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	538KY	11924662	Green Published			2022-12-28	WOS:000174816200022
J	Fleming, KA				Fleming, KA			Evidence-based cellular pathology	LANCET			English	Editorial Material							CARCINOMA; CANCER; BIOPSY; SPECIMENS; AUDIT		Univ Oxford, John Radcliffe Hosp, Div Med Sci, Med Sch Off, Oxford OX3 9DU, England	University of Oxford	Fleming, KA (corresponding author), Univ Oxford, John Radcliffe Hosp, Div Med Sci, Med Sch Off, Level 3, Oxford OX3 9DU, England.			Fleming, Kenneth/0000-0002-3200-1302				Appleton MAC, 1998, J CLIN PATHOL, V51, P30, DOI 10.1136/jcp.51.1.30; Attanoos RL, 1996, J CLIN PATHOL, V49, P79, DOI 10.1136/jcp.49.1.79; BLENKINSOPP WK, 1981, J CLIN PATHOL, V34, P509, DOI 10.1136/jcp.34.5.509; Bull AD, 1997, J CLIN PATHOL, V50, P138, DOI 10.1136/jcp.50.2.138; Dey P, 1997, J CLIN PATHOL, V50, P829, DOI 10.1136/jcp.50.10.829; Eskew LA, 1997, J UROLOGY, V157, P199, DOI 10.1016/S0022-5347(01)65322-9; Fleming KA, 1996, J PATHOL, V179, P127; LAL N, 1992, GUT, V33, P724, DOI 10.1136/gut.33.6.724; Mainprize KS, 1998, J CLIN PATHOL, V51, P165, DOI 10.1136/jcp.51.2.165; Miller RA, 1997, HUM PATHOL, V28, P999, DOI 10.1016/S0046-8177(97)90050-2; Nathwani BN, 1997, HUM PATHOL, V28, P1097, DOI 10.1016/S0046-8177(97)90065-4; OLSSON R, 1995, J CLIN PATHOL, V48, P933, DOI 10.1136/jcp.48.10.933; Schlemper RJ, 1997, LANCET, V349, P1725, DOI 10.1016/S0140-6736(96)12249-2; SCHWARTZ WB, 1981, NEW ENGL J MED, V305, P917, DOI 10.1056/NEJM198110153051604; Shepherd NA, 1997, J CLIN PATHOL, V50, P266, DOI 10.1136/jcp.50.4.266; Veenhuizen KCW, 1997, J PATHOL, V182, P266, DOI 10.1002/(SICI)1096-9896(199707)182:3<266::AID-PATH812>3.0.CO;2-#; WAGNER BM, 1984, HUM PATHOL, V15, P1	17	13	15	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 30	2002	359	9312					1149	1150		10.1016/S0140-6736(02)08165-5	http://dx.doi.org/10.1016/S0140-6736(02)08165-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	536YJ	11943283				2022-12-28	WOS:000174729200033
J	Cines, DB; Blanchette, VS				Cines, DB; Blanchette, VS			Medical progress: Immune thrombocytopenic purpura.	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							INTRAVENOUS ANTI-D; RANDOMIZED-TRIAL; INTRACRANIAL HEMORRHAGE; AUTOIMMUNE THROMBOCYTOPENIA; ANTIPHOSPHOLIPID ANTIBODIES; NEONATAL THROMBOCYTOPENIA; PREDNISONE THERAPY; PLATELET COUNTS; ORAL PREDNISONE; GAMMA-GLOBULIN		Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Med, Philadelphia, PA 19104 USA; Univ Toronto, Hosp Sick Children, Dept Paediat, Div Haematol & Oncol, Toronto, ON M5G 1X8, Canada	University of Pennsylvania; University of Pennsylvania; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Cines, DB (corresponding author), Univ Penn, Dept Pathol & Lab Med, 513 A Stellar Chance,422 Curie Blvd, Philadelphia, PA 19104 USA.	dcines@mail.med.upenn.edu			NHLBI NIH HHS [HL54500, HL61844, HL07971] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL054500, R01HL061844] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abramson JS, 2000, PEDIATRICS, V106, P362; AHN YS, 1989, ANN INTERN MED, V111, P723, DOI 10.7326/0003-4819-111-9-723; ALBAYRAK D, 1994, J PEDIATR-US, V125, P1004, DOI 10.1016/S0022-3476(05)82024-4; [Anonymous], 1993, MMWR Recomm Rep, V42, P1; Beilin Y, 1997, ANESTH ANALG, V85, P385, DOI 10.1097/00000539-199708000-00025; Berchtold P, 1997, BRIT J HAEMATOL, V96, P477, DOI 10.1046/j.1365-2141.1997.d01-2064.x; BLANCHETTE V, 1994, LANCET, V344, P703, DOI 10.1016/S0140-6736(94)92205-5; Blanchette V, 1998, SEMIN HEMATOL, V35, P36; BLANCHETTE VS, 1993, J PEDIATR-US, V123, P989, DOI 10.1016/S0022-3476(05)80400-7; BoltonMaggs PHB, 1997, LANCET, V350, P620, DOI 10.1016/S0140-6736(97)04143-3; Bowditch RD, 1996, BLOOD, V88, P4579, DOI 10.1182/blood.V88.12.4579.bloodjournal88124579; Brighton TA, 1996, BLOOD, V88, P194; BUCHANAN GR, 1987, EUR J PEDIATR, V146, P107, DOI 10.1007/BF02343213; BUCHANAN GR, 1984, AM J PEDIAT HEMATOL, V6, P355; Burrows R F, 1993, Obstet Gynecol Surv, V48, P781, DOI 10.1097/00006254-199312000-00003; BURROWS RF, 1993, NEW ENGL J MED, V329, P1463, DOI 10.1056/NEJM199311113292005; BUSSEL JB, 1986, PROG HEMOST THROMB, V8, P103; BUSSEL JB, 1987, VOX SANG, V52, P206, DOI 10.1111/j.1423-0410.1987.tb03029.x; Calpin C, 1998, ARCH PEDIAT ADOL MED, V152, P345; CALVERLEY DC, 1992, ANN INTERN MED, V116, P977, DOI 10.7326/0003-4819-116-12-977; Carcao MD, 1998, ACTA PAEDIATR, V87, P71; Chong BH, 2000, SEMIN HEMATOL, V37, P249, DOI 10.1053/shem.2000.8956; Christiaens GCML, 1997, OBSTET GYNECOL, V90, P546, DOI 10.1016/S0029-7844(97)00349-9; Cohen YC, 2000, ARCH INTERN MED, V160, P1630, DOI 10.1001/archinte.160.11.1630; CORTELAZZO S, 1991, BLOOD, V77, P31; DENOTTOLANDER GJ, 1984, SCAND J HAEMATOL, V32, P101; Dickerhoff R, 2000, J PEDIATR-US, V137, P629, DOI 10.1067/mpd.2000.110123; DIFINO SM, 1980, AM J MED, V69, P430, DOI 10.1016/0002-9343(80)90016-9; Diz-Kucukkaya R, 2001, BLOOD, V98, P1760, DOI 10.1182/blood.V98.6.1760; DOAN CA, 1960, ANN INTERN MED, V53, P861, DOI 10.7326/0003-4819-53-5-861; EDEN OB, 1992, ARCH DIS CHILD, V67, P1056, DOI 10.1136/adc.67.8.1056; Emilia G, 2001, BLOOD, V97, P812, DOI 10.1182/blood.V97.3.812; Emmons RVB, 1996, BLOOD, V87, P4068, DOI 10.1182/blood.V87.10.4068.bloodjournal87104068; Escher R, 1998, BRIT J HAEMATOL, V102, P820; FACON T, 1994, BRIT J HAEMATOL, V86, P678, DOI 10.1111/j.1365-2141.1994.tb04810.x; Farrugia A, 2001, TRANSFUSION MED, V11, P63, DOI 10.1046/j.1365-3148.2001.00288.x; FIGUEROA M, 1993, NEW ENGL J MED, V328, P1226, DOI 10.1056/NEJM199304293281703; Fischer P, 1999, BRIT J HAEMATOL, V105, P626, DOI 10.1046/j.1365-2141.1999.01407.x; Fogarty PF, 2001, BLOOD, V98, p442A; Frederiksen H, 1999, BLOOD, V94, P909, DOI 10.1182/blood.V94.3.909.415k02_909_913; Gaines AR, 2000, BLOOD, V95, P2523, DOI 10.1182/blood.V95.8.2523.008k13_2523_2529; GALLI M, 1994, THROMB HAEMOSTASIS, V71, P571; George JN, 2000, SEMIN HEMATOL, V37, P290, DOI 10.1053/shem.2000.8955; George JN, 1996, BLOOD, V88, P3, DOI 10.1182/blood.V88.1.3.3; GEORGE JN, 1994, NEW ENGL J MED, V331, P1207, DOI 10.1056/NEJM199411033311807; GEORGE JN, 1995, WILLIAMS HEMATOLOGY, P1315; GERNSHEIMER T, 1989, NEW ENGL J MED, V320, P974, DOI 10.1056/NEJM198904133201505; Gill KK, 2000, SEMIN HEMATOL, V37, P275, DOI 10.1053/shem.2000.8960; Godeau B, 1997, BRIT J HAEMATOL, V97, P336, DOI 10.1046/j.1365-2141.1997.412687.x; HE RY, 1994, BLOOD, V83, P1024; HERNANDEZ F, 1995, BRIT J HAEMATOL, V90, P473, DOI 10.1111/j.1365-2141.1995.tb05179.x; IMBACH P, 1995, EUR J PEDIATR, V154, pS60, DOI 10.1007/BF02191508; *INF DIS IMM COMM, 1999, PAEDIAT CHILD HLTH, V4, P417; KARPATKIN S, 1981, ANN INTERN MED, V94, P781, DOI 10.7326/0003-4819-94-6-781; Kattamis AC, 1997, J PEDIATR-US, V130, P281, DOI 10.1016/S0022-3476(97)70355-X; KIEFEL V, 1987, BLOOD, V70, P1722; Kuhne T, 1997, J PEDIATR-US, V130, P17, DOI 10.1016/S0022-3476(97)70305-6; KUNICKI TJ, 1992, BLOOD, V80, P1386; KURANA M, 2001, BLOOD, V98, P130; KURATA Y, 1994, THROMB HAEMOSTASIS, V71, P184; LASTER AJ, 1982, NEW ENGL J MED, V307, P1495, DOI 10.1056/NEJM198212093072406; Lee MS, 1998, NEUROLOGY, V50, P1160, DOI 10.1212/WNL.50.4.1160; Letsky EA, 1996, BRIT J HAEMATOL, V95, P21; Lilleyman JS, 1999, BRIT J HAEMATOL, V105, P871, DOI 10.1046/j.1365-2141.1999.14094195.x; LILLEYMAN JS, 1994, ARCH DIS CHILD, V71, P251, DOI 10.1136/adc.71.3.251; Lipp E, 1998, EUR J HAEMATOL, V60, P283; LIPPMAN SM, 1982, AM J MED, V73, P827, DOI 10.1016/0002-9343(82)90773-2; Marmaccio MJ, 2000, SEMIN HEMATOL, V37, P267; MCCRAE KR, 1992, BLOOD, V80, P2697; McMillan R, 1997, ANN INTERN MED, V126, P307, DOI 10.7326/0003-4819-126-4-199702150-00007; McMillan R, 2001, THROMB HAEMOSTASIS, V85, P821; McMillan R, 2000, SEMIN HEMATOL, V37, P239, DOI 10.1016/S0037-1963(00)90102-1; Medeiros D, 1998, J PEDIATR-US, V133, P334, DOI 10.1016/S0022-3476(98)70265-3; Newman GC, 2001, BRIT J HAEMATOL, V112, P1076, DOI 10.1046/j.1365-2141.2001.02627.x; Payne SD, 1997, AM J OBSTET GYNECOL, V177, P149, DOI 10.1016/S0002-9378(97)70454-X; Peleg D, 1999, AM J OBSTET GYNECOL, V180, P645, DOI 10.1016/S0002-9378(99)70286-3; PEREIRA J, 1995, AM J HEMATOL, V50, P173, DOI 10.1002/ajh.2830500305; PICOZZI VJ, 1980, AM J MED, V69, P690, DOI 10.1016/0002-9343(80)90419-2; PIZZUTO J, 1984, BLOOD, V64, P1179; Portielje JEA, 2001, BLOOD, V97, P2549, DOI 10.1182/blood.V97.9.2549; QUIQUANDON I, 1990, BRIT J HAEMATOL, V74, P223, DOI 10.1111/j.1365-2141.1990.tb02569.x; Raife TJ, 1997, BLOOD, V89, P1112, DOI 10.1182/blood.V89.3.1112; ROARKE J, IN PRESS BLOOD; Rosthoj S, 1996, ACTA PAEDIATR, V85, P910, DOI 10.1111/j.1651-2227.1996.tb14183.x; RUDOWSKI WJ, 1985, WORLD J SURG, V9, P422, DOI 10.1007/BF01655277; Saxon BR, 1998, ACTA PAEDIATR, V87, P65; Scaradavou A, 1997, BLOOD, V89, P2689, DOI 10.1182/blood.V89.8.2689; Semple JW, 1996, BLOOD, V87, P4245, DOI 10.1182/blood.V87.10.4245.bloodjournal87104245; SNYDER HW, 1992, BLOOD, V79, P2237; Stasi R, 2001, BLOOD, V98, P952, DOI 10.1182/blood.V98.4.952; STASI R, 1995, AM J MED, V98, P436, DOI 10.1016/S0002-9343(99)80342-8; Tarantino MD, 1999, J PEDIATR-US, V134, P21, DOI 10.1016/S0022-3476(99)70367-7; TAUB JW, 1995, AM J HEMATOL, V48, P104, DOI 10.1002/ajh.2830480207; TCHERNIA G, 1993, BRIT J HAEMATOL, V84, P457, DOI 10.1111/j.1365-2141.1993.tb03101.x; VANHOFF J, 1988, J PEDIATR-US, V113, P563, DOI 10.1016/S0022-3476(88)80654-1; VANLEEUWEN EF, 1982, BLOOD, V59, P23; VERLIN M, 1976, AM J HEMATOL, V1, P97, DOI 10.1002/ajh.2830010111; Vesely S, 2000, J PEDIAT HEMATOL ONC, V22, P55, DOI 10.1097/00043426-200001000-00011; Vidarsson B, 2000, THROMB HAEMOSTASIS, V83, P634, DOI 10.1055/s-0037-1613879; VONDEMBORNE AEGKR, 1988, BRIT MED J, V296, P249, DOI 10.1136/bmj.296.6617.249-a; Warner MN, 1999, BRIT J HAEMATOL, V104, P442, DOI 10.1046/j.1365-2141.1999.01218.x; Watson S, 2000, BLOOD, V96, p438A; WOERNER SJ, 1981, PEDIATRICS, V67, P453	103	902	979	0	33	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 28	2002	346	13					995	1008		10.1056/NEJMra010501	http://dx.doi.org/10.1056/NEJMra010501			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	534UY	11919310				2022-12-28	WOS:000174608600008
J	Elstein, AS; Schwarz, A				Elstein, AS; Schwarz, A			Evidence base of clinical diagnosis - Clinical problem solving and diagnostic decision making: selective review of the cognitive literature	BRITISH MEDICAL JOURNAL			English	Article							CATEGORIES; KNOWLEDGE; JUDGMENT		Univ Illinois, Coll Med, Dept Med Educ, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Elstein, AS (corresponding author), Univ Illinois, Coll Med, Dept Med Educ, Chicago, IL 60612 USA.		Elstein, Arthur/AAI-9222-2020	Schwartz, Alan/0000-0003-3809-6637	NATIONAL LIBRARY OF MEDICINE [R01LM005630] Funding Source: NIH RePORTER; NLM NIH HHS [R01 LM5630] Funding Source: Medline	NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		BARROWS HS, 1983, JAMA-J AM MED ASSOC, V250, P3077, DOI 10.1001/jama.250.22.3077; Bergus G R, 1995, Fam Med, V27, P314; BORDAGE G, 1984, MED EDUC, V18, P406, DOI 10.1111/j.1365-2923.1984.tb01295.x; BORDAGE G, 1999, ACAD MED S, V74, pS318; BROOKS LR, 1991, J EXP PSYCHOL GEN, V120, P278, DOI 10.1037/0096-3445.120.3.278; Chapman Gretchen B., 2000, DECISION MAKING HLTH, P183; Elstein AS, 1999, ACAD MED, V74, P791, DOI 10.1097/00001888-199907000-00012; Elstein AS, 1978, MED PROBLEM SOLVING; FISCHHOFF B, 1993, ANNU REV PUBL HEALTH, V14, P183, DOI 10.1146/annurev.pu.14.050193.001151; Glasziou PP, 2001, DECISION MAKING HLTH; GROEN GJ, 1985, MED EDUC, V19, P95, DOI 10.1111/j.1365-2923.1985.tb01148.x; Gruppen LD, 1997, ACAD MED, V72, P117, DOI 10.1097/00001888-199702000-00012; Kahneman D., 1982, JUDGEMENT UNCERTAINT; Kassirer JP., 2009, LEARNING CLIN REASON; LEMIEUX M, 1992, COGNITIVE SCI, V16, P185, DOI 10.1207/s15516709cog1602_2; Mellers BA, 1998, ANNU REV PSYCHOL, V49, P447, DOI 10.1146/annurev.psych.49.1.447; NORMAN GR, 1992, ACAD MED, V67, pS78, DOI 10.1097/00001888-199210000-00045; PATEL VL, 1986, COGNITIVE SCI, V10, P91, DOI 10.1016/S0364-0213(86)80010-6; REDELMEIER DA, 1995, MED DECIS MAKING, V15, P227, DOI 10.1177/0272989X9501500305; ROSCH E, 1975, COGNITIVE PSYCHOL, V7, P573, DOI 10.1016/0010-0285(75)90024-9; Sackett D. L., 1997, EVIDENCE BASED MED P; Sackett DL, 1991, CLIN EPIDEMIOLOGY BA, V2nd; SCHARTZ A, 2001, NOMOGRAM BAYESS THEO; SCHMIDT HG, 1990, ACAD MED, V65, P611, DOI 10.1097/00001888-199010000-00001; SOX HC, 1988, MD DECISION MAKING; TVERSKY A, 1981, SCIENCE, V211, P453, DOI 10.1126/science.7455683; TVERSKY A, 1992, J RISK UNCERTAINTY, V5, P297, DOI 10.1007/BF00122574; Wallsten T S, 1981, Med Decis Making, V1, P145, DOI 10.1177/0272989X8100100205	28	396	408	0	44	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 23	2002	324	7339					729	732		10.1136/bmj.324.7339.729	http://dx.doi.org/10.1136/bmj.324.7339.729			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	535ML	11909793	Green Published			2022-12-28	WOS:000174648200026
J	Schwartz, TB				Schwartz, TB			Uses of error - Ambylopia and arrogance	LANCET			English	Editorial Material									Rush Med Coll, Chicago, IL 60612 USA	Rush University	Schwartz, TB (corresponding author), Rush Med Coll, Chicago, IL 60612 USA.								0	1	1	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 23	2002	359	9311					1063	1063		10.1016/S0140-6736(02)08099-6	http://dx.doi.org/10.1016/S0140-6736(02)08099-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	534KP	11937204				2022-12-28	WOS:000174585800031
J	Tattersall, R; Tattersall, R				Tattersall, R; Tattersall, R			Pott's puffy tumour	LANCET			English	Editorial Material								A 53-year-old man presented with a 36-h history of drowsiness, Increasing confusion, ataxia, and left-sided weakness. His wife attributed these symptoms to an injury sustained 3 weeks earlier, when he had been climbing the stairs and hit his forehead on the ceiling. He had not lost consciousness at the time, but since then had complained of severe frontal headache and swelling on his forehead. He saw his general practitioner a week after the injury and no neurological deficit was noted. The headache continued and had become much worse at the onset of his presenting symptoms. On examination, the most striking finding was a boggy, erythematous swelling over the right frontal bone. His Glasgow coma score was 12/15 and he did not initially have a fever, but subsequently developed a temperature of 38degreesC. There was no meningism and fundoscopy was normal. Both ears were examined and no abnormality was seen. He had hypertonicity and hyper-reflexia In the left arm and leg, with an upgoing planter response and six beats of clonus. Cardiovascular, respiratory, and abdominal examination showed no abnormality. Laboratory tests showed hyponatraemia (120 mmol/L) and leucocytosts of 19.8 x 10(9)/L (neutrophilia 17.3 x 10(9)/L). Chest radiograph was normal, and he was started on antibiotic and antiviral treatment for presumed Intracerebral sepsis. Computed-tomography scan of the head was done urgently and showed soft tissue swelling over both frontal bones, with soft tissue opacity (probable Infection) of the frontal sinuses. Initially, the right frontal pole had a region of low density, which did not enhance with contrast. Within 12 h he deteriorated further his hemiparesis deepened, Glasgow coma score dropped to 9. and he began to have seizures. He was treated with intravenous phenytoln, sedated, and ventilated. Repast computed-tomography showed extension of the hypodense, non-enhancing area to the left frontal pole, and a 2-3 mm rim of fluid overlong the anterior half of each cerebral hemisphere. He was transferred to the regional neurosurgical centre, where he had a bifrontal craniotomy. The frontal bone was grossly abnormal and osteomyelitic with pus leaking from holes on its surface. A subperiosteal abscess was drained and a 3 mm blackish red membrane (inflamed dura mater) peeled from the cortex. A subdural empyema was then drained and the sinuses washed out. Pus and blood cultures confirmed the causative organism as Streptococcus milleri. Postoperatively, control of intracranial pressure was difficult, and he died alter 5 days. The diagnosis of Pott's puffy tumour-osteomyelitis of the calvarium-was confirmed at necropsy.	Curzon House, Gotham NG11 0HQ, Notts, England		Tattersall, R (corresponding author), Curzon House, Curzon St, Gotham NG11 0HQ, Notts, England.	robert.tattersall@virgin.net						Dobson J, 1972, Ann R Coll Surg Engl, V50, P54; MEDVEI VC, 1974, ROYAL HOSP ST BARTHO, P206; POTT P, 1769, SOME FEW GEN REMARKS, P126; Pott P., 1760, INJURIES HEAD EXTERN, P47; POTT P, 1756, TREATISE RUPTURES, P232; POTT P, 1779, REMARKS KIND PALSY L, P84; Verbon A, 1996, CLIN INFECT DIS, V23, P1305, DOI 10.1093/clinids/23.6.1305	7	36	36	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAR 23	2002	359	9311					1060	1063		10.1016/S0140-6736(02)08098-4	http://dx.doi.org/10.1016/S0140-6736(02)08098-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	534KP	11937203				2022-12-28	WOS:000174585800030
J	Barnes, I; Matheus, P; Shapiro, B; Jensen, D; Cooper, A				Barnes, I; Matheus, P; Shapiro, B; Jensen, D; Cooper, A			Dynamics of Pleistocene population extinctions in Beringian brown bears	SCIENCE			English	Article							URSUS-ARCTOS; MITOCHONDRIAL; PHYLOGEOGRAPHY; SEQUENCES; ORIGINS; COMPLEX	The climatic and environmental changes associated with the last glaciation (90,000 to 10,000 years before the present; 90 to 10 ka B.P.) are an important example of the effects of global climate change on biological diversity. These effects were particularly marked in Beringia (northeastern Siberia, northwestern North America, and the exposed Bering Strait) during the late Pleistocene. To investigate the evolutionary impact of these events, we studied genetic change in the brown bear, Ursus arctos, in eastern Beringia over the past 60,000 years using DNA preserved in permafrost remains. A marked degree of genetic structure is observed in populations throughout this period despite local extinctions, reinvasions, and potential interspecies competition with the short-faced bear, Arctodus simus. The major phylogeographic changes occurred 35 to 21 ka B.P., before the glacial maximum, and little change is observed after this time. Late Pleistocene histories of mammalian taxa may be more complex than those that might be inferred from the fossil record or contemporary DNA sequences atone.	Univ Oxford, Dept Zool, Henry Wellcome Ancient Biomol Ctr, Oxford OX1 3PS, England; Univ Oxford, Inst Biol Anthropol, Oxford OX2 6QS, England; Univ Alaska, Alaska Quaternary Ctr, Fairbanks, AK 99775 USA	University of Oxford; University of Oxford; University of Alaska System; University of Alaska Fairbanks	Cooper, A (corresponding author), Univ Oxford, Dept Zool, Henry Wellcome Ancient Biomol Ctr, S Parks Rd, Oxford OX1 3PS, England.	alan.cooper@zoo.ox.ac.uk	Barnes, Ian C/B-8081-2008; Cooper, Alan/E-8171-2012	Barnes, Ian C/0000-0001-8322-6918; Cooper, Alan/0000-0002-7738-7851				Anderson PH, 2001, QUATERNARY SCI REV, V20, P93, DOI 10.1016/S0277-3791(00)00129-3; Avise J.C., 2000, PHYLOGEOGRAPHY HIST; Brigham-Grette J, 2001, QUATERNARY SCI REV, V20, P15, DOI 10.1016/S0277-3791(00)00134-7; Cooper A, 2001, NATURE, V409, P704, DOI 10.1038/35055536; Flagstad O, 2001, P ROY SOC B-BIOL SCI, V268, P667, DOI 10.1098/rspb.2000.1416; Greenwood AD, 1999, MOL BIOL EVOL, V16, P1466, DOI 10.1093/oxfordjournals.molbev.a026058; Guthrie R.D., 1990, FROZEN FAUNA MAMMOTH; HANNI C, 1994, P NATL ACAD SCI USA, V91, P12336, DOI 10.1073/pnas.91.25.12336; Hewitt GM, 1999, BIOL J LINN SOC, V68, P87, DOI 10.1111/j.1095-8312.1999.tb01160.x; Jensen-Seaman MI, 2001, MOL ECOL, V10, P2241, DOI 10.1046/j.0962-1083.2001.01365.x; KOTILAINEN AT, 1995, NATURE, V377, P323, DOI 10.1038/377323a0; Leonard JA, 2000, P NATL ACAD SCI USA, V97, P1651, DOI 10.1073/pnas.040453097; LISTER AM, 1995, NATURE, V378, P23, DOI 10.1038/378023a0; Mandryk CAS, 2001, QUATERNARY SCI REV, V20, P301, DOI 10.1016/S0277-3791(00)00115-3; Matheus P. E., 1997, THESIS U ALASKA FAIR; Matheus Paul E., 2001, BAR International Series, V944, P79; Matheus PE, 1995, QUATERNARY RES, V44, P447, DOI 10.1006/qres.1995.1090; Matsuhashi T, 1999, MOL BIOL EVOL, V16, P676, DOI 10.1093/oxfordjournals.molbev.a026150; Miller C. M., COMMUNICATION; RANDI E, 1994, HEREDITY, V73, P480, DOI 10.1038/hdy.1994.146; Richards M, 1996, AM J HUM GENET, V59, P185; Stewart JR, 2001, TRENDS ECOL EVOL, V16, P608, DOI 10.1016/S0169-5347(01)02338-2; SWOFFORD DL, 1999, PAUP STAR PHYLOGENET; TABERLET P, 1994, P ROY SOC B-BIOL SCI, V255, P195, DOI 10.1098/rspb.1994.0028; Thomas MG, 2000, P ROY SOC B-BIOL SCI, V267, P2493, DOI 10.1098/rspb.2000.1310; Vila C, 2001, SCIENCE, V291, P474, DOI 10.1126/science.291.5503.474; Waits LP, 1998, CONSERV BIOL, V12, P408, DOI 10.1046/j.1523-1739.1998.96351.x	27	257	270	10	218	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 22	2002	295	5563					2267	2270		10.1126/science.1067814	http://dx.doi.org/10.1126/science.1067814			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	534AD	11910112				2022-12-28	WOS:000174561700046
J	Bortolotti, M; Coccia, G; Grossi, G				Bortolotti, M; Coccia, G; Grossi, G			Red pepper and functional dyspepsia	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter							CAPSAICIN		Univ Bologna, I-40138 Bologna, Italy; Galliera Hosp, I-16136 Genoa, Italy; Policlin S Orsola, I-40138 Bologna, Italy	University of Bologna; Ente Ospedaliero Ospedali Galliera; IRCCS Azienda Ospedaliero-Universitaria di Bologna	Bortolotti, M (corresponding author), Univ Bologna, I-40138 Bologna, Italy.	bortolottim@orsola-malpighi.med.unibo.it						Camilleri M, 1998, GASTROENTEROLOGY, V115, P747, DOI 10.1016/S0016-5085(98)70155-6; HOLZER P, 1991, PHARMACOL REV, V43, P143; LYNN B, 1990, PAIN, V41, P61, DOI 10.1016/0304-3959(90)91110-5; Nyren O, 1992, Pharmacoeconomics, V1, P312; Talley NJ, 1999, ALIMENT PHARM THER, V13, P1135	5	24	28	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 21	2002	346	12					947	948		10.1056/NEJM200203213461219	http://dx.doi.org/10.1056/NEJM200203213461219			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	532FR	11907302				2022-12-28	WOS:000174464100031
J	Auerbach, AD; Goldman, L				Auerbach, AD; Goldman, L			beta-blockers and reduction of cardiac events in noncardiac surgery - Scientific review	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							ACUTE MYOCARDIAL-INFARCTION; PERIPHERAL VASCULAR-SURGERY; CORONARY-ARTERY SURGERY; HIGH-RISK PATIENTS; ELDERLY PATIENTS; CARDIOVASCULAR MORBIDITY; PERIOPERATIVE MORTALITY; PREOPERATIVE ASSESSMENT; HYPERTENSIVE PATIENTS; MEDICAL CONSULTANT	Context Recent studies suggest that perioperatively administered beta-blockers may reduce the risk of adverse cardiac events in patients undergoing major noncardiac surgery. Objective To review the efficacy of perioperative beta-blockade in reducing myocardial ischemia, myocardial infarction, and cardiac or all-cause mortality from randomized trials. Data Sources A MEDLINE and conventional search of English-language articles published since 1980 was performed to gather information related to perioperative cardiac complications and beta-blockade. Reference lists from all relevant articles and published recommendations for perioperative cardiac risk management were reviewed to identify additional studies. Study Selection and Data Extraction Prospective randomized studies (6) were included in the analysis if they discussed the impact of beta-blockade on perioperative cardiac ischemia, myocardial infarction, and mortality for patients undergoing major noncardiac surgery. Articles were examined for elements of trial design, treatment protocols, important biases, and major findings. These elements were then qualitatively compared. Data Synthesis We identified 5 randomized controlled trials: 4 assessed myocardial ischemia and 3 reported myocardial infarction, cardiac, or all-cause mortality. All studies sought to achieve beta-blockade before the induction of anesthesia by titrating doses to a target heart rate. Of studies reporting myocardial ischemia, numbers needed to treat were modest (2.5-6.7). Similarly modest numbers needed to treat were observed in studies reporting a significant impact on cardiac or all-cause mortality (3.2-8.3). The most marked effects were seen in patients at high risk; the sole study reporting a nonsignificant result enrolled patients with low baseline risk. As a group, studies of perioperative beta-blockade have enrolled relatively few carefully selected patients. In addition, differences in treatment protocols leave questions unanswered regarding optimal duration of therapy. Conclusions Despite heterogeneity of trials, a growing literature suggests a benefit of beta-blockade in preventing perioperative cardiac morbidity. Evidence from these trials can be used to formulate an effective clinical approach while definitive trials are awaited.	Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Auerbach, AD (corresponding author), Univ Calif San Francisco, Dept Med, Box 0120, San Francisco, CA 94143 USA.							Adams KF, 2000, PHARMACOTHERAPY, V20, P495, DOI 10.1592/phco.20.6.495.35164; Antunes E, 1993, Rev Port Cardiol, V12, P219; ASHTON CM, 1993, ANN INTERN MED, V118, P504, DOI 10.7326/0003-4819-118-7-199304010-00004; Bayliff CD, 1999, ANN THORAC SURG, V67, P182, DOI 10.1016/S0003-4975(98)01226-0; Belzberg H, 1999, CHEST, V115, p82S, DOI 10.1378/chest.115.suppl_2.82S; Boersma E, 2001, JAMA-J AM MED ASSOC, V285, P1865, DOI 10.1001/jama.285.14.1865; BROWNER WS, 1992, JAMA-J AM MED ASSOC, V268, P228, DOI 10.1001/jama.268.2.228; Collins TC, 1999, ANN SURG, V230, P251, DOI 10.1097/00000658-199908000-00016; CORIAT P, 1986, ANESTHESIOLOGY, V64, P409, DOI 10.1097/00000542-198603000-00031; DETSKY AS, 1986, ARCH INTERN MED, V146, P2131, DOI 10.1001/archinte.146.11.2131; DODDS TM, 1993, ANESTH ANALG, V76, P705; Eagle KA, 1997, CIRCULATION, V96, P1882, DOI 10.1161/01.CIR.96.6.1882; EAGLE KA, 2002, ACC AHA GUIDELINE UP; ELLIS JE, 1994, ANESTH ANALG, V79, P1133; Fallowfield JM, 1996, BRIT MED J, V313, P1486, DOI 10.1136/bmj.313.7070.1486; Feldman T, 2000, NEW ENGL J MED, V342, P1051; Fleisher LA, 2001, NEW ENGL J MED, V345, P1677, DOI 10.1056/NEJMcp002842; FOSTER ED, 1986, ANN THORAC SURG, V41, P42, DOI 10.1016/S0003-4975(10)64494-3; Fox K, 1999, HEART, V82, P383, DOI 10.1136/hrt.82.3.383; Gilbert K, 2000, ANN INTERN MED, V133, P356, DOI 10.7326/0003-4819-133-5-200009050-00011; GILLIGAN DM, 1991, AM J CARDIOL, V68, P766, DOI 10.1016/0002-9149(91)90651-Z; GODET G, 1987, ANESTHESIOLOGY, V66, P241, DOI 10.1097/00000542-198702000-00027; Goldman L, 1987, J Cardiothorac Anesth, V1, P237, DOI 10.1016/S0888-6296(87)80011-X; GOLDMAN L, 1981, ARCH INTERN MED, V141, P193, DOI 10.1001/archinte.141.2.193; Goldman L, 2001, AM J MED, V110, P320, DOI 10.1016/S0002-9343(01)00623-4; GURWITZ JH, 1992, AM J MED, V93, P605, DOI 10.1016/0002-9343(92)90192-E; HAMMON JW, 1984, ANN THORAC SURG, V38, P363, DOI 10.1016/S0003-4975(10)62287-4; Harwood TN, 1999, J CARDIOTHOR VASC AN, V13, P555, DOI 10.1016/S1053-0770(99)90007-1; Hassan SA, 2001, AM J MED, V110, P260, DOI 10.1016/S0002-9343(00)00717-8; Hewer I, 1997, AANA J, V65, P351; JIVEGARD L, 1992, EUR J VASCULAR SURG, V6, P83, DOI 10.1016/S0950-821X(05)80100-8; Juni P, 2001, BMJ-BRIT MED J, V323, P42, DOI 10.1136/bmj.323.7303.42; Juni P, 1999, JAMA-J AM MED ASSOC, V282, P1054, DOI 10.1001/jama.282.11.1054; KHURI SF, 1995, J AM COLL SURGEONS, V180, P519; Krumholz HM, 1999, ANN INTERN MED, V131, P648, DOI 10.7326/0003-4819-131-9-199911020-00003; Krumholz HM, 1998, JAMA-J AM MED ASSOC, V280, P623, DOI 10.1001/jama.280.7.623; LAMB RK, 1988, EUR HEART J, V9, P32; LANDESBERG G, 1993, LANCET, V341, P715, DOI 10.1016/0140-6736(93)90486-Z; LARSEN SF, 1987, EUR HEART J, V8, P179, DOI 10.1093/oxfordjournals.eurheartj.a062246; Lawrence VA, 1995, J GEN INTERN MED, V10, P671, DOI 10.1007/BF02602761; Lee TH, 1999, CIRCULATION, V100, P1043, DOI 10.1161/01.CIR.100.10.1043; Lee TH, 1999, NEW ENGL J MED, V341, P1838, DOI 10.1056/NEJM199912093412410; LItalien GJ, 1996, J AM COLL CARDIOL, V27, P779, DOI 10.1016/0735-1097(95)00566-8; Litwack RS, 2000, NEW ENGL J MED, V342, P1052; MANGANO DT, 1991, J AM COLL CARDIOL, V17, P843, DOI 10.1016/0735-1097(91)90863-5; Mangano DT, 1995, NEW ENGL J MED, V333, P1750, DOI 10.1056/NEJM199512283332607; Mangano DT, 1996, NEW ENGL J MED, V335, P1713, DOI 10.1056/NEJM199612053352301; MANGANO DT, 1997, NEW ENGL J MED, V336, P1452; MERLI GJ, 1993, CLIN CHEST MED, V14, P205; MERLI GJ, 1987, MED CLIN N AM, V71, P353, DOI 10.1016/S0025-7125(16)30844-6; MILLER K, 1993, CLIN ORTHOP RELAT R, P148; MILLER RR, 1975, NEW ENGL J MED, V293, P416, DOI 10.1056/NEJM197508282930902; Oliver MF, 1999, ANESTHESIOLOGY, V91, P951, DOI 10.1097/00000542-199910000-00014; Packer Milton, 2001, American Journal of Medicine, V110, p81S; Palda VA, 1997, ANN INTERN MED, V127, P309, DOI 10.7326/0003-4819-127-4-199708150-00012; PASTERNACK PF, 1989, AM J SURG, V158, P113, DOI 10.1016/0002-9610(89)90357-7; Petros JA, 1997, NEW ENGL J MED, V336, P1452; Poldermans D, 2000, NEW ENGL J MED, V342, P1052; Poldermans D, 2001, EUR HEART J, V22, P1353, DOI 10.1053/euhj.2000.2555; Poldermans D, 1999, NEW ENGL J MED, V341, P1789, DOI 10.1056/NEJM199912093412402; Quintin L, 1996, ANESTH ANALG, V83, P687, DOI 10.1097/00000539-199610000-00005; Raby KE, 1999, ANESTH ANALG, V88, P477, DOI 10.1097/00000539-199903000-00002; RABY KE, 1992, JAMA-J AM MED ASSOC, V268, P222, DOI 10.1001/jama.268.2.222; Radford MJ, 1998, NEW ENGL J MED, V339, P551, DOI 10.1056/NEJM199808203390809; Reich DL, 1999, ANESTH ANALG, V89, P814, DOI 10.1097/00000539-199910000-00002; Reis SE, 1997, NEW ENGL J MED, V336, P1453; Shammash JB, 2001, AM HEART J, V141, P148, DOI 10.1067/mhj.2001.111547; SHOJANIA KG, 2001, PUBLICATION AGENCY H; SMULYAN H, 1982, JAMA-J AM MED ASSOC, V247, P2539, DOI 10.1001/jama.247.18.2539; Soumeral SB, 1997, JAMA-J AM MED ASSOC, V277, P115, DOI 10.1001/jama.277.2.115; STEYERBERG EW, 1995, ARCH INTERN MED, V155, P1998, DOI 10.1001/archinte.155.18.1998; STONE JG, 1988, ANESTHESIOLOGY, V68, P495, DOI 10.1097/00000542-198804000-00004; Stuhmeier KD, 1996, ANESTHESIOLOGY, V85, P706, DOI 10.1097/00000542-199610000-00004; SWEDBERG K, 1980, BRIT HEART J, V44, P134; Urban MK, 2000, ANESTH ANALG, V90, P1257, DOI 10.1097/00000539-200006000-00001; VANZYL AI, 1989, CHEST, V95, P209, DOI 10.1378/chest.95.1.209; Wallace A, 1998, ANESTHESIOLOGY, V88, P7, DOI 10.1097/00000542-199801000-00005; Wang TJ, 1998, ARCH INTERN MED, V158, P1901, DOI 10.1001/archinte.158.17.1901; White CM, 1999, ANN PHARMACOTHER, V33, P1063, DOI 10.1345/aph.18395; Zaugg M, 1999, ANESTHESIOLOGY, V91, P1674, DOI 10.1097/00000542-199912000-00020	80	247	256	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 20	2002	287	11					1435	1444		10.1001/jama.287.11.1435	http://dx.doi.org/10.1001/jama.287.11.1435			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	532GB	11903031				2022-12-28	WOS:000174465000026
J	Dolan, NC; Freund, K; Walsh, J				Dolan, NC; Freund, K; Walsh, J			Update in women's health	ANNALS OF INTERNAL MEDICINE			English	Review							HIGH-DOSE CHEMOTHERAPY; BREAST-CANCER; THERAPY; RESCUE		Northwestern Univ, Sch Med, Chicago, IL USA; Boston Univ, Med Ctr, Boston, MA USA; Univ Calif San Francisco, San Francisco, CA 94143 USA	Northwestern University; Boston University; University of California System; University of California San Francisco	Dolan, NC (corresponding author), NW Med Facil Fdn, Div Gen Internal Med Fac, 675 N St Clair,Suite 18-200, Chicago, IL 60611 USA.	ndo428@northwestern.edu		Freund, Karen/0000-0002-9049-5574				ANTMAN K, 1992, J CLIN ONCOL, V10, P102, DOI 10.1200/JCO.1992.10.1.102; Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0; BEZWODA WR, 1995, J CLIN ONCOL, V13, P2483, DOI 10.1200/JCO.1995.13.10.2483; KENNEDY MJ, 1991, J NATL CANCER I, V83, P920, DOI 10.1093/jnci/83.13.920; Ross RK, 2000, JNCI-J NATL CANCER I, V92, P328, DOI 10.1093/jnci/92.4.328; WILLIAMS SF, 1992, J CLIN ONCOL, V10, P1743, DOI 10.1200/JCO.1992.10.11.1743	6	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 19	2002	136	6					453	462		10.7326/0003-4819-136-6-200203190-00009	http://dx.doi.org/10.7326/0003-4819-136-6-200203190-00009			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	531AU	11900498				2022-12-28	WOS:000174393100005
J	Boers, M				Boers, M			A breathtaking patient	LANCET			English	Editorial Material									Vrije Univ Amsterdam, Med Ctr, Dept Clin Epidemiol & Biostat, NL-1007 MB Amsterdam, Netherlands	Vrije Universiteit Amsterdam	Boers, M (corresponding author), Vrije Univ Amsterdam, Med Ctr, Dept Clin Epidemiol & Biostat, NL-1007 MB Amsterdam, Netherlands.								0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 16	2002	359	9310					919	919		10.1016/S0140-6736(02)08021-2	http://dx.doi.org/10.1016/S0140-6736(02)08021-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	531AE	11918908				2022-12-28	WOS:000174391700008
J	Ho, WS; Ying, SY; Burd, A				Ho, WS; Ying, SY; Burd, A			On the back burner	LANCET			English	Editorial Material									Prince Wales Hosp, Dept Surg, Shatin, Hong Kong, Peoples R China	Chinese University of Hong Kong; Prince of Wales Hospital	Ho, WS (corresponding author), Prince Wales Hosp, Dept Surg, Shatin, Hong Kong, Peoples R China.								0	0	0	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 16	2002	359	9310					925	925		10.1016/S0140-6736(02)08023-6	http://dx.doi.org/10.1016/S0140-6736(02)08023-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	531AE	11918910				2022-12-28	WOS:000174391700010
J	Orphanides, G; Reinberg, D				Orphanides, G; Reinberg, D			A unified theory of gene expression	CELL			English	Review							RNA-POLYMERASE-II; TRANSCRIPTION ELONGATION-FACTOR; UBIQUITIN-PROTEIN LIGASE; MESSENGER-RNA; LARGE SUBUNIT; GLUCOCORTICOID RECEPTOR; HISTONE ACETYLATION; IN-VITRO; P-TEFB; CHROMATIN	The human genome has been called "the blueprint for life." This master plan is realized through the process of gene expression. Recent progress has revealed that many of the steps in the pathway from gene sequence to active protein are connected, suggesting a unified theory of gene expression.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Div Nucleic Acids Enzymol,Howard Hughes Med Inst, Piscataway, NJ 08854 USA; Syngenta Cent Toxicol Lab, Macclesfield SK10 4TJ, Cheshire, England	Howard Hughes Medical Institute; Rutgers State University New Brunswick; Rutgers State University Medical Center; Syngenta	Reinberg, D (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Div Nucleic Acids Enzymol,Howard Hughes Med Inst, Piscataway, NJ 08854 USA.			Reinberg, Danny/0000-0003-4288-2016				ALLIS CD, 1980, CELL, V20, P55; Barboric M, 2001, MOL CELL, V8, P327, DOI 10.1016/S1097-2765(01)00314-8; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Beaudenon SL, 1999, MOL CELL BIOL, V19, P6972; Bhoite LT, 2001, GENE DEV, V15, P2457, DOI 10.1101/gad.921601; Borggrefe T, 2001, J BIOL CHEM, V276, P47150, DOI 10.1074/jbc.M109581200; Bregman DB, 1996, P NATL ACAD SCI USA, V93, P11586, DOI 10.1073/pnas.93.21.11586; Briggs SD, 2001, GENE DEV, V15, P3286, DOI 10.1101/gad.940201; Calvo O, 2001, MOL CELL, V7, P1013, DOI 10.1016/S1097-2765(01)00236-2; Carmo-Fonseca M, 2002, CELL, V108, P513, DOI 10.1016/S0092-8674(02)00650-5; Cheung P, 2000, MOL CELL, V5, P905, DOI 10.1016/S1097-2765(00)80256-7; Cho EJ, 2001, GENE DEV, V15, P3319, DOI 10.1101/gad.935901; Cook PR, 1999, SCIENCE, V284, P1790, DOI 10.1126/science.284.5421.1790; Cosma MP, 2001, MOL CELL, V7, P1213, DOI 10.1016/S1097-2765(01)00266-0; Cramer Patrick, 2001, Science (Washington D C), V292, P1863, DOI 10.1126/science.1059493; Dantonel JC, 1997, NATURE, V389, P399, DOI 10.1038/38763; Davies K, 2001, CELL, V104, P465, DOI 10.1016/S0092-8674(01)00233-1; Dever TE, 2002, CELL, V108, P545, DOI 10.1016/S0092-8674(02)00642-6; Di Croce L, 1999, MOL CELL, V4, P45, DOI 10.1016/S1097-2765(00)80186-0; Dieci G, 1996, CELL, V84, P245, DOI 10.1016/S0092-8674(00)80979-4; Doerks T, 2001, TRENDS BIOCHEM SCI, V26, P145, DOI 10.1016/S0968-0004(00)01769-2; Ferdous A, 2001, MOL CELL, V7, P981, DOI 10.1016/S1097-2765(01)00250-7; Fersht AR, 2002, CELL, V108, P573, DOI 10.1016/S0092-8674(02)00620-7; Fletcher TM, 2000, MOL CELL BIOL, V20, P6466, DOI 10.1128/MCB.20.17.6466-6475.2000; Fong N, 2001, GENE DEV, V15, P1783, DOI 10.1101/gad.889101; Fong YW, 2001, NATURE, V414, P929, DOI 10.1038/414929a; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; Gerber AP, 2001, TRENDS BIOCHEM SCI, V26, P376, DOI 10.1016/S0968-0004(01)01827-8; Gnatt AL, 2001, SCIENCE, V292, P1876, DOI 10.1126/science.1059495; GOZES I, 1977, J BIOL CHEM, V252, P1819; GREENLEAF AL, 1993, TRENDS BIOCHEM SCI, V18, P117, DOI 10.1016/0968-0004(93)90016-G; Hampsey M, 1999, CURR OPIN GENET DEV, V9, P132, DOI 10.1016/S0959-437X(99)80020-3; Heard E, 2001, CELL, V107, P727, DOI 10.1016/S0092-8674(01)00598-0; Hirose Y, 2000, GENE DEV, V14, P1415; Huang YQ, 2001, MOL CELL, V7, P899, DOI 10.1016/S1097-2765(01)00233-7; Huibregtse JM, 1997, P NATL ACAD SCI USA, V94, P3656, DOI 10.1073/pnas.94.8.3656; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Iborra FJ, 2001, SCIENCE, V293, P1139, DOI 10.1126/science.1061216; Ivanov D, 2000, MOL CELL BIOL, V20, P2970, DOI 10.1128/MCB.20.9.2970-2983.2000; Iyer VR, 2001, NATURE, V409, P533, DOI 10.1038/35054095; Jeanmougin F, 1997, TRENDS BIOCHEM SCI, V22, P151, DOI 10.1016/S0968-0004(97)01042-6; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kanazawa S, 2000, IMMUNITY, V12, P61, DOI 10.1016/S1074-7613(00)80159-4; Kim JB, 2001, J BIOL CHEM, V276, P12317, DOI 10.1074/jbc.M010908200; KIM JH, 2002, IN PRESS P NATL ACAD; Kleiman FE, 2001, CELL, V104, P743, DOI 10.1016/S0092-8674(02)07059-9; Kloc M, 2002, CELL, V108, P533, DOI 10.1016/S0092-8674(02)00651-7; Komarnitsky P, 2000, GENE DEV, V14, P2452, DOI 10.1101/gad.824700; LEE KB, 2002, IN PRESS MOL CELL BI; Lefstin JA, 1998, NATURE, V392, P885, DOI 10.1038/31860; LEMAIRE R, 2002, IN PRESS GENES DEV; LIN RL, 1991, GENE DEV, V5, P1601, DOI 10.1101/gad.5.9.1601; Litt MD, 2001, SCIENCE, V293, P2453, DOI 10.1126/science.1064413; Lo WS, 2000, MOL CELL, V5, P917, DOI 10.1016/S1097-2765(00)80257-9; Lonard DM, 2000, MOL CELL, V5, P939, DOI 10.1016/S1097-2765(00)80259-2; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Luo MJ, 1999, P NATL ACAD SCI USA, V96, P14937, DOI 10.1073/pnas.96.26.14937; MADISONANTENUCC.S, 1908, CELL, V108, P435; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; McNally JG, 2000, SCIENCE, V287, P1262, DOI 10.1126/science.287.5456.1262; Mitsui A, 1999, P NATL ACAD SCI USA, V96, P6054, DOI 10.1073/pnas.96.11.6054; Naar AM, 2001, ANNU REV BIOCHEM, V70, P475, DOI 10.1146/annurev.biochem.70.1.475; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Nishioka K, 2001, SCIENCE, V294, P2497, DOI 10.1126/science.1067622; NISHIOKA K, 2002, IN PRESS GENES DEV; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Orphanides G, 1998, CELL, V92, P105, DOI 10.1016/S0092-8674(00)80903-4; Orphanides G, 1999, NATURE, V400, P284, DOI 10.1038/22350; Orphanides G, 2000, NATURE, V407, P471, DOI 10.1038/35035000; Otero G, 1999, MOL CELL, V3, P109, DOI 10.1016/S1097-2765(00)80179-3; Prives C, 2001, CELL, V107, P815, DOI 10.1016/S0092-8674(01)00619-5; Proudfoot NJ, 2002, CELL, V108, P501, DOI 10.1016/S0092-8674(02)00617-7; Ramakrishnan V, 2002, CELL, V108, P557, DOI 10.1016/S0092-8674(02)00619-0; Reed R, 2002, CELL, V108, P523, DOI 10.1016/S0092-8674(02)00627-X; Ren B, 2000, SCIENCE, V290, P2306, DOI 10.1126/science.290.5500.2306; Richards EJ, 2002, CELL, V108, P489, DOI 10.1016/S0092-8674(02)00644-X; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; Roguev A, 2001, EMBO J, V20, P7137, DOI 10.1093/emboj/20.24.7137; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; RYAN K, 2002, IN PRESS MOL CELL BI, V22; Salghetti SE, 2001, SCIENCE, V293, P1651, DOI 10.1126/science.1062079; Shatkin AJ, 2000, NAT STRUCT BIOL, V7, P838, DOI 10.1038/79583; SHUMAN S, 1987, J BIOL CHEM, V262, P12372; Simon I, 2001, CELL, V106, P697, DOI 10.1016/S0092-8674(01)00494-9; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Sun ZW, 1996, MOL CELL BIOL, V16, P1557; Thomson S, 2001, MOL CELL, V8, P1231, DOI 10.1016/S1097-2765(01)00404-X; Tupler R, 2001, NATURE, V409, P832, DOI 10.1038/35057011; Turner BM, 2000, BIOESSAYS, V22, P836, DOI 10.1002/1521-1878(200009)22:9<836::AID-BIES9>3.0.CO;2-X; Uptain SM, 1997, ANNU REV BIOCHEM, V66, P117, DOI 10.1146/annurev.biochem.66.1.117; Urnov FD, 2001, MOL ENDOCRINOL, V15, P1, DOI 10.1210/me.15.1.1; Wada T, 1998, EMBO J, V17, P7395, DOI 10.1093/emboj/17.24.7395; Wada T, 1998, GENE DEV, V12, P343, DOI 10.1101/gad.12.3.343; Wen YX, 1999, GENE DEV, V13, P1774, DOI 10.1101/gad.13.14.1774; Woychik NA, 2002, CELL, V108, P453, DOI 10.1016/S0092-8674(02)00646-3; Wu WH, 1999, GENETICS, V153, P643; Xu W, 2001, SCIENCE, V294, P2507, DOI 10.1126/science.1065961; Yamaguchi Y, 1999, CELL, V97, P41, DOI 10.1016/S0092-8674(00)80713-8; YANOFSKY C, 1988, J BIOL CHEM, V263, P609; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301	102	670	703	0	67	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	FEB 22	2002	108	4					439	451		10.1016/S0092-8674(02)00655-4	http://dx.doi.org/10.1016/S0092-8674(02)00655-4			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	524XW	11909516	Bronze			2022-12-28	WOS:000174039000003
J	Brem, RB; Yvert, G; Clinton, R; Kruglyak, L				Brem, RB; Yvert, G; Clinton, R; Kruglyak, L			Genetic dissection of transcriptional regulation in budding yeast	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; TRANSGRESSIVE SEGREGATION; EXPRESSION; STRAINS; GENOME; S288C	To begin to understand the genetic architecture of natural variation in gene expression, we carried out genetic linkage analysis of genomewide expression patterns in a cross between a laboratory strain and a wild strain of Saccharomyces cerevisiae. Over 1500 genes were differentially expressed between the parent strains. Expression levels of 570 genes were linked to one or more different loci, with most expression levels showing complex inheritance patterns. The loci detected by linkage felt largely into two categories: cis-acting modulators of single genes and trans-acting modulators of many genes. We found eight such trans-acting loci, each affecting the expression of a group of 7 to 94 genes of related function.	Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; Howard Hughes Med Inst, Coconut Grove, FL 33133 USA	Fred Hutchinson Cancer Center; Howard Hughes Medical Institute	Kruglyak, L (corresponding author), Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave N,D4-100, Seattle, WA 98109 USA.			Yvert, Gael/0000-0003-1955-4786	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM064268] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM64268] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brachmann CB, 1998, YEAST, V14, P115; Causton HC, 2001, MOL BIOL CELL, V12, P323, DOI 10.1091/mbc.12.2.323; Cavalieri D, 2000, P NATL ACAD SCI USA, V97, P12369, DOI 10.1073/pnas.210395297; Cherry JM, 1997, NATURE, V387, P67, DOI 10.1038/387s067; CHURCHILL GA, 1994, GENETICS, V138, P963; Colman-Lerner A, 2001, CELL, V107, P739, DOI 10.1016/S0092-8674(01)00596-7; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; DEVICENTE MC, 1993, GENETICS, V134, P585; Fazzio TG, 2001, MOL CELL BIOL, V21, P6450, DOI 10.1128/MCB.21.19.6450-6460.2001; Gaisne M, 1999, CURR GENET, V36, P195, DOI 10.1007/s002940050490; Hughes TR, 2000, CELL, V102, P109, DOI 10.1016/S0092-8674(00)00015-5; Jansen RC, 2001, TRENDS GENET, V17, P388, DOI 10.1016/S0168-9525(01)02310-1; Jin W, 2001, NAT GENET, V29, P389, DOI 10.1038/ng766; Kobayashi O, 1999, CURR GENET, V36, P256, DOI 10.1007/s002940050498; Kron SJ, 1997, TRENDS MICROBIOL, V5, P450, DOI 10.1016/S0966-842X(97)01131-1; Lindgren B. W, 1968, STAT THEORY; MORTIMER RK, 1994, YEAST, V10, P1543, DOI 10.1002/yea.320101203; Primig M, 2000, NAT GENET, V26, P415, DOI 10.1038/82539; Rieseberg LH, 1999, HEREDITY, V83, P363, DOI 10.1038/sj.hdy.6886170; Sandberg R, 2000, P NATL ACAD SCI USA, V97, P11038, DOI 10.1073/pnas.97.20.11038; Winzeler EA, 1998, SCIENCE, V281, P1194, DOI 10.1126/science.281.5380.1194; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359	22	1009	1048	1	80	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 26	2002	296	5568					752	755		10.1126/science.1069516	http://dx.doi.org/10.1126/science.1069516			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	546PD	11923494				2022-12-28	WOS:000175281700061
J	Remuzzi, G; Schieppati, A; Ruggenenti, P				Remuzzi, G; Schieppati, A; Ruggenenti, P			Nephropathy in patients with type 2 diabetes.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONVERTING-ENZYME-INHIBITION; CALCIUM-CHANNEL BLOCKERS; RENAL-FUNCTION; PROGRESSION; MELLITUS; HYPERTENSION; DISEASE; MICROALBUMINURIA; LISINOPRIL; PREVENTION		Mario Negri Inst Pharmacol Res, Clin Res Ctr Rare Dis, I-24100 Bergamo, Italy; Osped Riuniti Bergamo, Nephrol Unit, I-24100 Bergamo, Italy	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Ospedali Riuniti di Bergamo	Schieppati, A (corresponding author), Mario Negri Inst Pharmacol Res, Clin Res Ctr Rare Dis, Via Gavazzeni 11, I-24100 Bergamo, Italy.		Remuzzi, Giuseppe/V-9766-2017	Remuzzi, Giuseppe/0000-0002-6194-3446				Agodoa LY, 2001, JAMA-J AM MED ASSOC, V285, P2719, DOI 10.1001/jama.285.21.2719; American Diabetes Association Clinical Practice Recommendations, 2001, DIABETES CARE S1, V24, pS1; [Anonymous], 1993, Diabetologia, V36, P835; BAKRIS GL, 1991, AM J HYPERTENS, V4, pS487, DOI 10.1093/ajh/4.7.487S; Bakris GL, 2000, AM J KIDNEY DIS, V36, P646, DOI 10.1053/ajkd.2000.16225; Bernheim J, 1996, NEPHROL DIAL TRANSPL, V11, P1; Brenner BM, 2001, NEW ENGL J MED, V345, P861, DOI 10.1056/NEJMoa011161; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Courreges JP, 1997, ARCH MAL COEUR VAISS, V90, P1059; Diabetes Prevention Program Research Group, 2002, NEW ENGL J MED, V346, P393, DOI [10.1056/NEJMoa012512, DOI 10.1056/NEJMOA012512]; Freeman DJ, 2001, CIRCULATION, V103, P357; Fried LF, 2001, KIDNEY INT, V59, P260, DOI 10.1046/j.1523-1755.2001.00487.x; Gaede P, 1999, LANCET, V353, P617, DOI 10.1016/S0140-6736(98)07368-1; Gerstein HC, 2000, LANCET, V355, P253; HANSEN HP, 2001, 14 ANN M COUNT DURH; Hansson L, 1999, LANCET, V353, P611, DOI 10.1016/S0140-6736(98)05012-0; Hansson L, 1998, LANCET, V351, P1755, DOI 10.1016/S0140-6736(98)04311-6; *HEART OUTC PREV E, 2000, LANCET, V356, P860; Lewis EJ, 2001, NEW ENGL J MED, V345, P851, DOI 10.1056/NEJMoa011303; LEWIS EJ, 1993, NEW ENGL J MED, V329, P1456, DOI 10.1056/NEJM199311113292004; Meltzer S, 1998, CAN MED ASSOC J, V159, pS1; Mogensen CE, 2000, BRIT MED J, V321, P1440, DOI 10.1136/bmj.321.7274.1440; Mogensen CE., 2000, KIDNEY HYPERTENSION, P655, DOI 10.1007/978-1-4615-4499-9_49; Mulec H, 1998, NEPHROL DIAL TRANSPL, V13, P651, DOI 10.1093/ndt/13.3.651; *NAT I DIAB DIG KI, 2001, REN DAT SYST USRDS 2; Nielsen FS, 1997, DIABETES, V46, P1182, DOI 10.2337/diabetes.46.7.1182; OHKUBO Y, 1995, DIABETES RES CLIN PR, V28, P103, DOI 10.1016/0168-8227(95)01064-K; ORDONEZ JD, 1989, NEPHRON, V51, P524, DOI 10.1159/000185387; Parving HH, 2001, CURR OPIN NEPHROL HY, V10, P515, DOI 10.1097/00041552-200107000-00006; Parving HH, 2001, NEW ENGL J MED, V345, P870, DOI 10.1056/NEJMoa011489; Ritz E, 1999, NEW ENGL J MED, V341, P1127, DOI 10.1056/NEJM199910073411506; Ritz E, 2000, DIABETES METAB, V26, P54; Ruggenenti P, 1998, J AM SOC NEPHROL, V9, P2096; Ruggenenti P, 1997, CURR OPIN NEPHROL HY, V6, P141, DOI 10.1097/00041552-199703000-00006; Ruggenenti P, 2001, LANCET, V357, P1601, DOI 10.1016/S0140-6736(00)04728-0; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Smith AC, 1998, KIDNEY INT, V54, P889, DOI 10.1046/j.1523-1755.1998.00055.x; Stearne MR, 1998, BMJ-BRIT MED J, V317, P703; Tuomilehto J, 2001, NEW ENGL J MED, V344, P1343, DOI 10.1056/NEJM200105033441801; Turner RC, 1998, LANCET, V352, P854, DOI 10.1016/s0140-6736(98)07037-8; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; *UK PROSP DIAB STU, 1998, LANCET, V352, P1557; WEIDMANN P, 1995, NEPHROL DIAL TRANSPL, V10, P39; Yusuf S, 2000, NEW ENGL J MED, V342, P145; ZELLER K, 1991, NEW ENGL J MED, V324, P78, DOI 10.1056/NEJM199101103240202	45	440	468	2	21	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 11	2002	346	15					1145	1151		10.1056/NEJMcp011773	http://dx.doi.org/10.1056/NEJMcp011773			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	539PX	11948275				2022-12-28	WOS:000174880600008
J	West, SA; Pen, I; Griffin, AS				West, SA; Pen, I; Griffin, AS			Conflict and cooperation - Cooperation and competition between relatives	SCIENCE			English	Review							POPULATION VISCOSITY; INCLUSIVE FITNESS; KIN SELECTION; VISCOUS POPULATIONS; EVOLUTION; RELATEDNESS; DISPERSAL; ALTRUISM; ECOLOGY	Individuals are predicted to. behave more altruistically and less competitively toward their relatives, because they share a relatively high proportion of their genes (e.g., one-half for siblings and one-eighth for cousins). Consequently, by helping a relative reproduce, an individual passes its genes to the next generation, increasing their Darwinian fitness, this idea, termed kin selection, has been applied to a wide range of phenomena in systems ranging from replicating molecules to humans. Nevertheless, competition between relatives can reduce, and even totally negate, the kin-selected benefits of altruism toward relatives. Recent theoretical work has clarified the processes and selective forces underlying this effect and has demonstrated the generality of the effect of competition between relatives.	Univ Edinburgh, Inst Cell Anim & Populat Biol, Edinburgh EH9 3JT, Midlothian, Scotland	University of Edinburgh	West, SA (corresponding author), Univ Edinburgh, Inst Cell Anim & Populat Biol, W Mains Rd, Edinburgh EH9 3JT, Midlothian, Scotland.	stu.west@ed.ac.uk	Pen, Ido/F-2478-2010; West, Stuart A/M-3608-2014; Griffin, Ashleigh/C-6244-2014	West, Stuart A/0000-0003-2152-3153; Griffin, Ashleigh/0000-0001-7674-9825				Bever JD, 2000, HEREDITY, V85, P366, DOI 10.1046/j.1365-2540.2000.00772.x; Boots M, 1999, P ROY SOC B-BIOL SCI, V266, P1933, DOI 10.1098/rspb.1999.0869; Bourke A. F., 1995, SOCIAL EVOLUTION ANT; Chapuisat M, 1997, EVOLUTION, V51, P475, DOI 10.1111/j.1558-5646.1997.tb02435.x; Clutton-Brock T, 2002, SCIENCE, V296, P69, DOI 10.1126/science.296.5565.69; Emlen Stephen T., 1997, P228; Frank, 1998, FDN SOCIAL EVOLUTION; FRANK SA, 1985, EVOLUTION, V39, P949, DOI 10.1111/j.1558-5646.1985.tb00440.x; FRANK SA, 1986, HEREDITY, V56, P351, DOI 10.1038/hdy.1986.56; Gandon S, 1999, P ROY SOC B-BIOL SCI, V266, P2507, DOI 10.1098/rspb.1999.0953; Gompper Matthew E., 1996, P429; Grafen A., 1985, Oxford Surveys in Evolutionary Biology, V2, P28; Grafen A, 1984, BEHAV ECOLOGY EVOLUT, V2, P62; Griffin AS, 2002, TRENDS ECOL EVOL, V17, P15, DOI 10.1016/S0169-5347(01)02355-2; Hamilton W.D., 1979, P167; Hamilton W.D., 1972, Annual Rev Ecol Syst, V3, P193, DOI 10.1146/annurev.es.03.110172.001205; Hamilton W. D., 1975, BIOSOCIAL ANTHR, P133; Hamilton W.D., 1971, MAN BEAST COMP SOCIA, P57; Hamilton W.D., 1996, NARROW ROADS GENE LA, V1; HAMILTON WD, 1963, AM NAT, V97, P354, DOI 10.1086/497114; HAMILTON WD, 1964, J THEOR BIOL, V7, P1, DOI [10.1016/0022-5193(64)90038-4, 10.1016/0022-5193(64)90039-6]; KELLY JK, 1994, THEOR POPUL BIOL, V46, P32, DOI 10.1006/tpbi.1994.1018; KELLY JK, 1992, J THEOR BIOL, V157, P447, DOI 10.1016/S0022-5193(05)80663-0; Mitteldorf J, 2000, J THEOR BIOL, V204, P481, DOI 10.1006/jtbi.2000.2007; MURRAY MG, 1984, J THEOR BIOL, V111, P237, DOI 10.1016/S0022-5193(84)80208-8; Pen I, 2000, P ROY SOC B-BIOL SCI, V267, P2411, DOI 10.1098/rspb.2000.1299; QUELLER DC, 1989, EVOLUTION, V43, P258, DOI [10.2307/2409206, 10.1111/j.1558-5646.1989.tb04226.x]; QUELLER DC, 1994, EVOL ECOL, V8, P70, DOI 10.1007/BF01237667; QUELLER DC, 1992, TRENDS ECOL EVOL, V7, P322, DOI 10.1016/0169-5347(92)90120-Z; Ratnieks FLW, 2001, ANN ZOOL FENN, V38, P201; Read AF, 2001, SCIENCE, V292, P1099, DOI 10.1126/science.1059410; REEVE HK, 1990, P NATL ACAD SCI USA, V87, P2496, DOI 10.1073/pnas.87.7.2496; Taylor PD, 1996, J THEOR BIOL, V180, P27, DOI 10.1006/jtbi.1996.0075; TAYLOR PD, 1992, P ROY SOC B-BIOL SCI, V249, P299, DOI 10.1098/rspb.1992.0118; TAYLOR PD, 1992, EVOL ECOL, V6, P352, DOI 10.1007/BF02270971; Taylor PD, 2000, EVOLUTION, V54, P1135; Thorne BL, 1997, ANNU REV ECOL SYST, V28, P27, DOI 10.1146/annurev.ecolsys.28.1.27; Trivers R. L., 1985, SOCIAL EVOLUTION; van Baalen M, 1998, J THEOR BIOL, V193, P631, DOI 10.1006/jtbi.1998.0730; West SA, 2001, NATURE, V409, P510, DOI 10.1038/35054057; West SA, 2002, P ROY SOC B-BIOL SCI, V269, P685, DOI 10.1098/rspb.2001.1878; WILSON DS, 1992, EVOL ECOL, V6, P331, DOI 10.1007/BF02270969	42	582	601	12	308	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 5	2002	296	5565					72	75		10.1126/science.1065507	http://dx.doi.org/10.1126/science.1065507			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	539FA	11935015	Green Submitted			2022-12-28	WOS:000174858800036
J	Jackson, JP; Lindroth, AM; Cao, XF; Jacobsen, SE				Jackson, JP; Lindroth, AM; Cao, XF; Jacobsen, SE			Control of CpNpG DNA methylation by the KRYPTONITE histone H3 methyltransferase	NATURE			English	Article							LYSINE-9 METHYLATION; EPIGENETIC ALLELES; PROTEIN; MUTATIONS; DOMAINS; CHROMO; SITE; HETEROCHROMATIN; SPECIFICITY	Gene silencing in eukaryotes is associated with the formation of heterochromatin, a complex of proteins and DNA that block transcription. Heterochromatin is characterized by the methylation of cytosine nucleotides of the DNA, the methylation of histone H3 at lysine 9 (H3 Lys 9), and the specific binding of heterochromatin protein 1 (HP1) to methylated H3 Lys 9 (refs 1-7). Although the relationship between these chromatin modifications is generally unknown, in the fungus Neurospora crassa, DNA methylation acts genetically downstream of H3 Lys 9 methylation(8). Here we report the isolation of KRYPTONITE, a methyltransferase gene specific to H3 Lys 9, identified in a mutant screen for suppressors of gene silencing at the Arabidopsis thaliana SUPERMAN (SUP) locus. Loss-of-function kryptonite alleles resemble mutants in the DNA methyltransferase gene CHROMOMETHYLASE3 (CMT3)(9), showing loss of cytosine methylation at sites of CpNpG trinucleotides (where N is A, C, G or T) and reactivation of endogenous retrotransposon sequences. We show that CMT3 interacts with an Arabidopsis homologue of HP1, which in turn interacts with methylated histones. These data suggest that CpNpG DNA methylation is controlled by histone H3 Lys 9 methylation, through interaction of CMT3 with methylated chromatin.	Univ Calif Los Angeles, Dept Mol Cell & Dev Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Jacobsen, SE (corresponding author), Univ Calif Los Angeles, Dept Mol Cell & Dev Biol, Los Angeles, CA 90095 USA.	jacobsen@ucla.edu	Lindroth, Anders M/C-7744-2015; Hu, Ruogu/B-2203-2008; jia, xu/A-8386-2016	Lindroth, Anders M/0000-0002-8291-2745; 				Akhtar A, 2000, NATURE, V407, P405, DOI 10.1038/35030169; ALLSHIRE RC, 1995, GENE DEV, V9, P218, DOI 10.1101/gad.9.2.218; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Bartee L, 2001, GENE DEV, V15, P1753, DOI 10.1101/gad.905701; Baumbusch LO, 2001, NUCLEIC ACIDS RES, V29, P4319, DOI 10.1093/nar/29.21.4319; Finnegan EJ, 1996, P NATL ACAD SCI USA, V93, P8449, DOI 10.1073/pnas.93.16.8449; Gaudin V, 2001, DEVELOPMENT, V128, P4847; Henikoff S, 1998, GENETICS, V149, P307; Ivanova AV, 1998, NAT GENET, V19, P192, DOI 10.1038/566; Jacobs SA, 2001, EMBO J, V20, P5232, DOI 10.1093/emboj/20.18.5232; Jacobsen SE, 1997, SCIENCE, V277, P1100, DOI 10.1126/science.277.5329.1100; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kishimoto N, 2001, PLANT MOL BIOL, V46, P171, DOI 10.1023/A:1010636222327; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Lindroth AM, 2001, SCIENCE, V292, P2077, DOI 10.1126/science.1059745; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Peters AHFM, 2002, NAT GENET, V30, P77, DOI 10.1038/ng789; Peters AHFM, 2001, CELL, V107, P323, DOI 10.1016/S0092-8674(01)00542-6; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Ronemus MJ, 1996, SCIENCE, V273, P654, DOI 10.1126/science.273.5275.654; Soppe WJJ, 2000, MOL CELL, V6, P791, DOI 10.1016/S1097-2765(05)00090-0; Steimer A, 2000, PLANT CELL, V12, P1165, DOI 10.1105/tpc.12.7.1165; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Tachibana M, 2001, J BIOL CHEM, V276, P25309, DOI 10.1074/jbc.M101914200; Tamaru H, 2001, NATURE, V414, P277, DOI 10.1038/35104508; TSCHIERSCH B, 1994, EMBO J, V13, P3822, DOI 10.1002/j.1460-2075.1994.tb06693.x; VONGS A, 1993, SCIENCE, V260, P1926, DOI 10.1126/science.8316832	27	939	1014	0	111	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 4	2002	416	6880					556	560		10.1038/nature731	http://dx.doi.org/10.1038/nature731			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	537JY	11898023				2022-12-28	WOS:000174756500049
J	Crawford, LM				Crawford, LM			New therapy for non-Hodgkin lymphoma	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									US FDA, Off Commissioner Food & Drugs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Crawford, LM (corresponding author), US FDA, Off Commissioner Food & Drugs, HF-1,Room 14-71,5600 Fishers Ln, Rockville, MD 20857 USA.								0	9	9	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 3	2002	287	13					1640	1640		10.1001/jama.287.13.1640-a	http://dx.doi.org/10.1001/jama.287.13.1640-a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	536YW	11926876				2022-12-28	WOS:000174730300005
J	Karlseder, J; Smogorzewska, A; de Lange, T				Karlseder, J; Smogorzewska, A; de Lange, T			Senescence induced by altered telomere state, not telomere loss	SCIENCE			English	Article							LIFE-SPAN; TRF2; CELLS; FIBROBLASTS; EXTENSION; PROTEIN; MUTANT; LENGTH; END; P53	Primary human cells in culture invariably stop dividing and enter a state of growth arrest called replicative senescence. This transition is induced by programmed telomere shortening, but the underlying mechanisms are unclear. Here, we report that overexpression of TRF2, a telomeric DNA binding protein, increased the rate of telomere shortening in primary cells without accelerating senescence. TRF2 reduced the senescence setpoint, defined as telomere length at senescence, from 7 to 4 kilobases. TRF2 protected critically short telomeres from fusion and repressed chromosome-end fusions in presenescent cultures, which explains the ability of TRF2 to delay senescence. Thus, replicative senescence is induced by a change in the protected status of shortened telomeres rather than by a complete loss of telomeric DNA.	Rockefeller Univ, Cell Biol & Genet Lab, New York, NY 10021 USA	Rockefeller University	de Lange, T (corresponding author), Rockefeller Univ, Cell Biol & Genet Lab, 1230 York Ave, New York, NY 10021 USA.		Smogorzewska, Agata/B-8891-2011; de Lange, Titia/B-8263-2011	de Lange, Titia/0000-0002-9267-367X	NCI NIH HHS [CA76027] Funding Source: Medline; NIA NIH HHS [AG16643] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076027] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLSOPP RC, 1995, EXP CELL RES, V220, P194, DOI 10.1006/excr.1995.1306; Bilaud T, 1997, NAT GENET, V17, P236, DOI 10.1038/ng1097-236; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Broccoli D, 1997, NAT GENET, V17, P231, DOI 10.1038/ng1097-231; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; de Lange T, 2002, ONCOGENE, V21, P532, DOI 10.1038/sj.onc.1205080; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; HARA E, 1991, BIOCHEM BIOPH RES CO, V179, P528, DOI 10.1016/0006-291X(91)91403-Y; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; Huffman KE, 2000, J BIOL CHEM, V275, P19719, DOI 10.1074/jbc.M002843200; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; LUNDBLAD V, 1989, CELL, V57, P633, DOI 10.1016/0092-8674(89)90132-3; Makarov VL, 1997, CELL, V88, P657, DOI 10.1016/S0092-8674(00)81908-X; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; Shay JW, 2000, NAT REV MOL CELL BIO, V1, P72, DOI 10.1038/35036093; SINGER MS, 1994, SCIENCE, V266, P404, DOI 10.1126/science.7545955; Smogorzewska A, 2000, MOL CELL BIOL, V20, P1659, DOI 10.1128/MCB.20.5.1659-1668.2000; Stansel RM, 2001, EMBO J, V20, P5532; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0	22	619	643	0	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 29	2002	295	5564					2446	2449		10.1126/science.1069523	http://dx.doi.org/10.1126/science.1069523			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	536QD	11923537				2022-12-28	WOS:000174712600054
J	Faber, J; Shroeder, L; Thill, MP; Jacob, F				Faber, J; Shroeder, L; Thill, MP; Jacob, F			Carcinoma erysipeloides of the neck	LANCET			English	Editorial Material									Hop Reg Nord, Clin St Louis, Dept Internal Med, Ettelbruck, Luxembourg		Faber, J (corresponding author), Hop Reg Nord, Clin St Louis, Dept Internal Med, Ettelbruck, Luxembourg.								0	5	5	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 23	2002	359	9311					1025	1025		10.1016/S0140-6736(02)08093-5	http://dx.doi.org/10.1016/S0140-6736(02)08093-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	534KP	11937182				2022-12-28	WOS:000174585800009
J	Zhang, MD; Schmid, S; Carrington, M; O'Brien, TR				Zhang, MD; Schmid, S; Carrington, M; O'Brien, TR			Antibodies to varicella-zoster virus in blood donors with genetic variance in CC chemokine receptor 5	LANCET			English	Article							HIV-1 INFECTION; ALLELE; AIDS	Carriers of a 32 bp deletion (Delta32) allele of the CC chemokine receptor 5 (CCR5) gene are reported to be more likely to lack antibodies to varicella-zoster virus than CCR5 wild-type individuals. To find out whether CCR5-Delta32 Is associated with the seroprevalence of varicella-zoster virus Infection, we tested blood donors with different CCR5-Delta32 genotypes for varicella-zoster virus IgG. Antibody to varicella-zoster virus was present In 209 (99.5%) of 210 CCR5-Delta32 carriers and exactly the same proportion of CCR5 wild-type Individuals (209 of 210). We have therefore found no evidence that the CCR5-Delta32 allele is associated with decreased seroprevalence of varicella-zoster virus Infection.	NCI, Viral Epidemiol Branch, Div Canc Epidemiol & Genet, Rockville, MD 20852 USA; Ctr Dis Control & Prevent, Atlanta, GA USA; NCI, Intramural Res Support Program, Sci Applicat Int Corp, Frederick, MD 21701 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Centers for Disease Control & Prevention - USA; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC)	O'Brien, TR (corresponding author), NCI, Viral Epidemiol Branch, Div Canc Epidemiol & Genet, 6120 Execut Blvd,MSC 7248, Rockville, MD 20852 USA.				OFFICE OF THE DIRECTOR, NCI [N01CO056000] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-56000] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Carrington M, 1999, HUM MOL GENET, V8, P1939, DOI 10.1093/hmg/8.10.1939; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Nguyen GT, 1999, J ACQ IMMUN DEF SYND, V22, P75, DOI 10.1097/00042560-199909010-00010; Stephens JC, 1998, AM J HUM GENET, V62, P1507, DOI 10.1086/301867; Wiencke JK, 2001, LANCET, V357, P360, DOI 10.1016/S0140-6736(00)03646-1	5	2	4	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 23	2002	359	9311					1034	1036		10.1016/S0140-6736(02)08066-2	http://dx.doi.org/10.1016/S0140-6736(02)08066-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	534KP	11937186				2022-12-28	WOS:000174585800013
J	Schultz, JC				Schultz, JC			How plants fight dirty - Biochemical ecology	NATURE			English	Editorial Material									Penn State Univ, Dept Entomol, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Schultz, JC (corresponding author), Penn State Univ, Dept Entomol, University Pk, PA 16802 USA.		Schultz, Jack C./V-8661-2019	Schultz, Jack/0000-0001-9870-3537				Chiu J, 1999, MOL BIOL EVOL, V16, P826, DOI 10.1093/oxfordjournals.molbev.a026167; EHRLICH PR, 1964, EVOLUTION, V18, P586, DOI 10.2307/2406212; Karban R., 1997, INDUCED RESPONSES HE, DOI 10.7208/chicago/9780226424972.001.0001; Shiu SH, 2001, P NATL ACAD SCI USA, V98, P10763, DOI 10.1073/pnas.181141598	4	34	39	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 21	2002	416	6878					267	267		10.1038/416267a	http://dx.doi.org/10.1038/416267a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	532NP	11907557				2022-12-28	WOS:000174482200023
J	Boutitie, F; Gueyffier, F; Pocock, S; Fagard, R; Boissel, JP				Boutitie, F; Gueyffier, F; Pocock, S; Fagard, R; Boissel, JP		INDANA Project Steering Comm	J-shaped relationship between blood pressure and mortality in hypertensive patients: New insights from a meta-analysis of individual-patient data	ANNALS OF INTERNAL MEDICINE			English	Article							CORONARY-HEART-DISEASE; ISOLATED SYSTOLIC HYPERTENSION; EUROPEAN-WORKING-PARTY; CARDIOVASCULAR-DISEASE; ELDERLY-PATIENTS; FOLLOW-UP; RISK; MORBIDITY; TRIAL; REDUCTION	Background: Population-based longitudinal studies of hypertension have usually shown a continuous and positive relationship between blood pressure and mortality. However, several studies in hypertensive patients receiving treatment have described this relationship as J-shaped, with an increased risk for events in patients with low blood pressure. Objective: To assess the evidence for a J-shaped relationship between blood pressure and mortality and its relation to treatment. Design: Meta-analysis of individual-patient data. Setting,: seven randomized clinical trials from the INDANA (INdividual Data ANalysis of Antihypertensive intervention) database. Patients: 40 233 persons with hypertension (mean follow-up, 3.9 years). Intervention: Primarily beta-blockers or thiazide diuretics versus placebo or no treatment Measurements: Diastolic and systolic blood pressure and number of cardiovascular, noncardiovascular, and all-cause deaths in yearly periods of follow-up. Results: The analysis included data on 1655 deaths (56% cardiovascular). A J-shaped relationship between diastolic blood pressure and risk for death was observed for total and cardiovascular mortality in treated patients (nadir, 84 and 80 mm Hg, respectively) and untreated patients (nadir, 90 and 85 mm Hg, respectively). For noncardiovascular deaths, the relationship was J-shaped in the treated group (nadir, 84 mm Hg) and negative in the control group. Similar results were observed for systolic blood pressure. The presence of patients with wide pulse pressure did not explain these findings. Conclusions: The increased risk for events observed in patients with low blood pressure was not related to antihypertensive treatment and was not specific to blood pressure-related events. Poor health conditions leading to low blood pressure and an increased risk for death probably explain the J-shaped curve.	Univ Lyon 1, F-69365 Lyon, France; London Sch Hyg & Trop Med, London WC1, England; Leuven Univ, Louvain, Belgium	UDICE-French Research Universities; Universite Claude Bernard Lyon 1; University of London; London School of Hygiene & Tropical Medicine; KU Leuven	Boutitie, F (corresponding author), Fac RTH Laennec, Clin Pharmacol Unit EA643, BP 8071, F-69376 Lyon 08, France.	flb@upcl.univ-lyon1.fr	Gueyffier, François/B-8545-2008	Gueyffier, François/0000-0002-9921-0977				Aitkin M., 1989, STAT MODELLING GLIM; ALDERMAN MH, 1989, JAMA-J AM MED ASSOC, V262, P920, DOI 10.1001/jama.262.7.920; Alli C, 1999, ARCH INTERN MED, V159, P1205, DOI 10.1001/archinte.159.11.1205; AMERY A, 1985, LANCET, V1, P1349; [Anonymous], 1991, JAMA, V265, P3255; [Anonymous], 1980, LANCET, V1, P1261; [Anonymous], 1976, JAMA, V235, P825; Bots ML, 1996, ARCH INTERN MED, V156, P843, DOI 10.1001/archinte.156.8.843; Breslow NE., 1987, STAT METHODS CANC RE, P81; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; COOPE J, 1986, BRIT MED J, V293, P1145, DOI 10.1136/bmj.293.6555.1145; COOPER SP, 1988, AM J EPIDEMIOL, V127, P387, DOI 10.1093/oxfordjournals.aje.a114812; CRUICKSHANK JM, 1988, BMJ-BRIT MED J, V297, P1227, DOI 10.1136/bmj.297.6658.1227; CRUICKSHANK JM, 1987, LANCET, V1, P581; DAHLOF B, 1991, LANCET, V338, P1281, DOI 10.1016/0140-6736(91)92589-T; Finney D. J., 1978, STAT METHODS BIOL AS; FLACK JM, 1995, CIRCULATION, V92, P2437, DOI 10.1161/01.CIR.92.9.2437; FLETCHER AE, 1988, J HUM HYPERTENS, V2, P11; FLETCHER AE, 1992, NEW ENGL J MED, V326, P251; GLYNN RJ, 1995, LANCET, V345, P825, DOI 10.1016/S0140-6736(95)92964-9; GOETGHEBEUR EJT, 1995, J ROY STAT SOC A STA, V158, P107, DOI 10.2307/2983406; GREENBERG G, 1985, BMJ-BRIT MED J, V291, P97; Gueyffier F, 1996, J HUM HYPERTENS, V10, P1; GUEYFFIER F, 1995, THERAPIE, V50, P353; Hansson L, 1998, LANCET, V351, P1755, DOI 10.1016/S0140-6736(98)04311-6; HAYES RJ, 1988, STAT MED, V7, P915, DOI 10.1002/sim.4780070903; *HYP DET FOLL UP P, 1979, JAMA-J AM MED ASSOC, V242, P2562; ISLES CG, 1986, J HYPERTENS, V4, P141, DOI 10.1097/00004872-198604000-00003; KANNEL WB, 1971, AM J CARDIOL, V27, P335, DOI 10.1016/0002-9149(71)90428-0; Kannel WB, 1997, AM HEART J, V134, P758, DOI 10.1016/S0002-8703(97)70061-9; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MCCLOSKEY LW, 1992, ARCH INTERN MED, V152, P513, DOI 10.1001/archinte.152.3.513; MEADE TW, 1992, BMJ-BRIT MED J, V304, P405; ODonnell CJ, 1997, CIRCULATION, V95, P1132; PERRY HM, 1978, ANN NY ACAD SCI, V304, P267; PSATY BM, 1992, JAMA-J AM MED ASSOC, V268, P1287, DOI 10.1001/jama.268.10.1287; Psaty BM, 1997, JAMA-J AM MED ASSOC, V277, P739, DOI 10.1001/jama.277.9.739; SAMUELSSON OG, 1990, J HYPERTENS, V8, P547, DOI 10.1097/00004872-199006000-00008; Somes GW, 1999, ARCH INTERN MED, V159, P2004, DOI 10.1001/archinte.159.17.2004; STAESSEN J, 1989, BMJ-BRIT MED J, V298, P1552, DOI 10.1136/bmj.298.6687.1552; STAMLER J, 1989, HYPERTENSION S1, V13, P12	41	236	241	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 19	2002	136	6					438	448		10.7326/0003-4819-136-6-200203190-00007	http://dx.doi.org/10.7326/0003-4819-136-6-200203190-00007			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	531AU	11900496				2022-12-28	WOS:000174393100003
J	Vatta, M; Stetson, SJ; Perez-Verdia, A; Entman, ML; Noon, GP; Torre-Amione, G; Bowles, NE; Towbin, JA				Vatta, M; Stetson, SJ; Perez-Verdia, A; Entman, ML; Noon, GP; Torre-Amione, G; Bowles, NE; Towbin, JA			Molecular remodelling of dystrophin in patients with end-stage cardiomyopathies and reversal in patients on assistance-device therapy	LANCET			English	Article							DILATED CARDIOMYOPATHY; GENE; MUTATIONS; COLLAGEN; HYPERTROPHY; MYOCARDIUM; REGRESSION; APOPTOSIS; SYSTEM	Background Mutations that lead to disruption of cytoskeletal proteins have been recorded in patients with familial dilated cardiomyopathy. We postulated that changes in cytoskeletal and sarcolemmal proteins provide a final common pathway for dilation and contractile dysfuncton in dilated cardiomyopathy. In this study, we investigated the integrity of dystrophin in the myocardium of patients with end-stage heart failure due to ischaemic or dilated cardiomyopathy, and the response to treatment with left-ventricular assistance devices (LVAD). Methods We assessed the expression and integrity of dystrophin in myocardial biopsy samples by immunohistochemistry and westem-blot analysis using antibodies against the amino-terminal, carboxyl-terminal, and midrod domains. We took samples from the myocardia of ten controls, ten patients with dilated cardiomyopathy, ten with ischaemic heart disease, and six with dilated cardiomyopathy who underwent placement of a left-ventricular assistance device for progressive refractory heart failure. Findings Immunohistochemical staining identified a disruption to the amino-terminus of dystrophin in 18 of 20 patients with end-stage cardiomyopathy (dilated or ischaemic), whereas staining with antibodies against other domains of dystrophin was normal. Westem-blot analysis confirmed these observations, suggesting that remodelling of dystrophin is a common pathway for dysfunction of failing cardiomyocytes. Furthermore, this disruption was reversible in four patients after LVAD support. Interpretation Dystrophin remodelling is a useful indicator of left-ventricular function in patients with dilated and ischaemic cardiomyopathy. Our results lend support to the hypothesis that changes in cytoskeletal proteins and, in particular, dystrophin might provide a final common pathway for contractile dysfunction in heart failure and these changes might be reversible by reduction of mechanical stress.	Baylor Coll Med, Dept Pediat, Cardiol Sect, Houston, TX 77030 USA; Baylor Coll Med, Dept Med, Cardiol Sect, Houston, TX 77030 USA; Baylor Coll Med, Dept Med, Cardiovasc Sci Sect, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Winters Ctr Heart Failure Res, Houston, TX 77030 USA; Baylor Coll Med, Gene & Judy Campbell Lab Cardiac Transplant Res, Houston, TX 77030 USA; Baylor Coll Med, Methodist Hosp, DeBakey Heart Ctr, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; The Methodist Hospital System; The Methodist Hospital - Houston; Methodist DeBakey Heart & Vascular Center	Towbin, JA (corresponding author), Baylor Coll Med, Dept Pediat Cardiol, 1 Baylor Plaza,Room 333E, Houston, TX 77030 USA.	jtowbin@bcm.tmc.edu	Towbin, Jeffrey A./J-5595-2019	Towbin, Jeffrey A./0000-0002-6585-714X; Torre-Amione, Guillermo/0000-0001-9950-0416				Association TCCotNYH, 1994, NOMENCLATURE CRITERI, P253; Badorff C, 1999, NAT MED, V5, P320, DOI 10.1038/6543; BISHOP JE, 1990, J MOL CELL CARDIOL, V22, P1157, DOI 10.1016/0022-2828(90)90079-H; Bowles KR, 1996, J CLIN INVEST, V98, P1355, DOI 10.1172/JCI118922; Bruckner BA, 2001, J HEART LUNG TRANSPL, V20, P457, DOI 10.1016/S1053-2498(00)00321-1; Carlson CG, 1998, NEUROBIOL DIS, V5, P3, DOI 10.1006/nbdi.1998.0188; Di Bella I, 2000, EUR J CARDIO-THORAC, V18, P112, DOI 10.1016/S1010-7940(00)00427-9; Fatkin D, 1999, NEW ENGL J MED, V341, P1715, DOI 10.1056/NEJM199912023412302; Hack AA, 1998, J CELL BIOL, V142, P1279, DOI 10.1083/jcb.142.5.1279; Helman DN, 2000, ANN THORAC SURG, V70, P1255, DOI 10.1016/S0003-4975(00)01826-9; Helman DN, 2000, J HEART LUNG TRANSPL, V19, P121, DOI 10.1016/S1053-2498(99)00116-3; Kamisago M, 2000, NEW ENGL J MED, V343, P1688, DOI 10.1056/NEJM200012073432304; LEVIN HR, 1995, CIRCULATION, V91, P2717, DOI 10.1161/01.CIR.91.11.2717; Li DX, 1999, CIRCULATION, V100, P461, DOI 10.1161/01.CIR.100.5.461; MANOLIO TA, 1992, AM J CARDIOL, V69, P1458, DOI 10.1016/0002-9149(92)90901-A; MARIJIANOWSKI MMH, 1995, J AM COLL CARDIOL, V25, P1263, DOI 10.1016/0735-1097(94)00557-7; MICHELS VV, 1993, J MED GENET, V30, P955, DOI 10.1136/jmg.30.11.955; Milasin J, 1996, HUM MOL GENET, V5, P73, DOI 10.1093/hmg/5.1.73; Mogensen J, 1999, J CLIN INVEST, V103, pR39, DOI 10.1172/JCI6460; MUNTONI F, 1993, NEW ENGL J MED, V329, P921, DOI 10.1056/NEJM199309233291304; Narula J, 1999, P NATL ACAD SCI USA, V96, P8144, DOI 10.1073/pnas.96.14.8144; OCONNELL JB, 1994, J HEART LUNG TRANSPL, V13, pS107; Olson TM, 1998, SCIENCE, V280, P750, DOI 10.1126/science.280.5364.750; OrtizLopez R, 1997, CIRCULATION, V95, P2434, DOI 10.1161/01.CIR.95.10.2434; Pauschinger M, 1999, CIRCULATION, V99, P2750, DOI 10.1161/01.CIR.99.21.2750; PUCHTLER H, 1973, BEITR PATHOL, V150, P174, DOI 10.1016/S0005-8165(73)80016-2; PUCHTLER H, 1988, HISTOCHEMISTRY, V88, P243; Thomas CV, 1998, CIRCULATION, V97, P1708, DOI 10.1161/01.CIR.97.17.1708; TOWBIN JA, 1993, CIRCULATION, V87, P1854, DOI 10.1161/01.CIR.87.6.1854; Tsubata S, 2000, J CLIN INVEST, V106, P655, DOI 10.1172/JCI9224; Zafeiridis A, 1998, CIRCULATION, V98, P656, DOI 10.1161/01.CIR.98.7.656	31	136	140	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 16	2002	359	9310					936	941		10.1016/S0140-6736(02)08026-1	http://dx.doi.org/10.1016/S0140-6736(02)08026-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	531AE	11918913				2022-12-28	WOS:000174391700013
J	Loubeyre, P; Occelli, F; LeToullec, R				Loubeyre, P; Occelli, F; LeToullec, R			Optical studies of solid hydrogen to 320 GPa and evidence for black hydrogen	NATURE			English	Article							HIGH-PRESSURE; MOLECULAR-HYDROGEN; MEGABAR PRESSURES; METALLIZATION; DEPENDENCE; DEUTERIUM; EQUATION; STATE; METAL	The quest for metallic hydrogen at high pressures represents a longstanding problem in condensed matter physics(1,2). Recent calculations(3-6) have predicted that solid hydrogen should become a molecular metal at pressures above 300 GPa, before transforming into an alkali metal; but the strong quantum nature of the problem makes the predictions difficult. Over a decade ago, an optical study(7) of hydrogen was made using a diamond anvil cell to reach 250 GPa. However, despite many subsequent efforts, quantitative studies(8-11) at higher pressures have proved difficult and their conclusions controversial. Here we report optical measurements of solid hydrogen up to a pressure of 320 GPa at 100 K. The vibron signature of the H-2 molecule persists to at least 316 GPa; no structural changes are detected above 160 GPa, and solid hydrogen is observed to turn completely opaque at 320 GPa. We measure the absorption edge of hydrogen above 300 GPa, observing features characteristic of a direct electronic bandgap. This is at odds with the most recent theoretical calculations that predict much larger direct transition energies and the closure of an indirect gap(3-6). We predict that metal hydrogen should be observed at about 450 GPa when the direct gap closes.	CEA, Dept Phys Theor & Applicat, F-91680 Bruyeres Le Chatel, France; Univ Paris 06, PMC, F-75252 Paris, France	CEA; UDICE-French Research Universities; Sorbonne Universite	Loubeyre, P (corresponding author), CEA, Dept Phys Theor & Applicat, F-91680 Bruyeres Le Chatel, France.							CARDONA M, 1982, TOP APPL PHYS, V50, P19; Chen NH, 1996, PHYS REV LETT, V76, P1663, DOI 10.1103/PhysRevLett.76.1663; Collins GW, 1998, SCIENCE, V281, P1178, DOI 10.1126/science.281.5380.1178; DASH WC, 1955, PHYS REV, V99, P1151, DOI 10.1103/PhysRev.99.1151; GARCIA H, 1992, PHYS REV B, V45, P9809; GONCHAROV AF, 1995, PHYS REV LETT, V75, P2514, DOI 10.1103/PhysRevLett.75.2514; Goncharov AF, 1998, PHYS REV LETT, V80, P101, DOI 10.1103/PhysRevLett.80.101; Goncharov AF, 2001, P NATL ACAD SCI USA, V98, P14234, DOI 10.1073/pnas.201528198; HEMLEY RJ, 1991, NATURE, V350, P488, DOI 10.1038/350488a0; INOUE K, 1979, SOLID STATE COMMUN, V30, P627, DOI 10.1016/0038-1098(79)90110-8; Johnson KA, 2000, NATURE, V403, P632, DOI 10.1038/35001024; Loubeyre P, 1996, NATURE, V383, P702, DOI 10.1038/383702a0; Maksimov E. G., 1999, Physics-Uspekhi, V42, P1121, DOI 10.1070/PU1999v042n11ABEH000666; MAO HK, 1986, J GEOPHYS RES-SOLID, V91, P4673, DOI 10.1029/JB091iB05p04673; MAO HK, 1989, SCIENCE, V244, P1462, DOI 10.1126/science.244.4911.1462; Nagao K, 1997, PHYS REV B, V56, P2295, DOI 10.1103/PhysRevB.56.2295; Narayana C, 1998, NATURE, V393, P46, DOI 10.1038/29949; NATOLI V, 1995, PHYS REV LETT, V74, P1601, DOI 10.1103/PhysRevLett.74.1601; RUOFF AL, 1991, J APPL PHYS, V69, P6413, DOI 10.1063/1.348845; Stadele M, 2000, PHYS REV LETT, V84, P6070, DOI 10.1103/PhysRevLett.84.6070; VANSTRAATEN J, 1988, PHYS REV B, V37, P6478, DOI 10.1103/PhysRevB.37.6478; Weir ST, 1996, PHYS REV LETT, V76, P1860, DOI 10.1103/PhysRevLett.76.1860; WELBER B, 1975, PHYS REV B, V12, P5729, DOI 10.1103/PhysRevB.12.5729; Wigner E, 1935, J CHEM PHYS, V3, P764, DOI 10.1063/1.1749590	24	351	362	1	75	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 11	2002	416	6881					613	617		10.1038/416613a	http://dx.doi.org/10.1038/416613a			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	539YV	11948345				2022-12-28	WOS:000174901900037
J	Edwards, N; Kornacki, MJ; Silversin, J				Edwards, N; Kornacki, MJ; Silversin, J			Unhappy doctors: what are the causes and what can be done?	BMJ-BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTITIONERS		NHS Confederat, London SW1E 5ER, England; Amicus, Cambridge, MA 02140 USA		Edwards, N (corresponding author), NHS Confederat, London SW1E 5ER, England.							Aiken LH, 1998, QUAL HEALTH CARE, V7, P222, DOI 10.1136/qshc.7.4.222; Ali NY, 2001, BRIT MED J, V323, P782, DOI 10.1136/bmj.323.7316.782; BLACK N, 2002, BRIT MED J, V323, P275; Bosma H, 1997, BRIT MED J, V314, P558, DOI 10.1136/bmj.314.7080.558; Chew M, 2001, MED J AUSTRALIA, V175, P85, DOI 10.5694/j.1326-5377.2001.tb143536.x; DEGELING P, 1998, PROFESSIONAL SUB CUL; EDWARDS N, 2002, PROBLEM UNHAPPY DOCT; Ferriman A, 2001, BRIT MED J, V322, P694, DOI 10.1136/bmj.322.7288.694; Firth-Cozens J, 2000, OCCUP MED-OXFORD, V50, P199, DOI 10.1093/occmed/50.3.199; FirthCozens J, 1997, BRIT MED J, V315, P34, DOI 10.1136/bmj.315.7099.34; Harrison B, 2001, BRIT MED J, V323, P1305, DOI 10.1136/bmj.323.7324.1305; *HLTH POL EC RES U, 2002, FUT HEALTHC WORKF; Kassirer JP, 1998, NEW ENGL J MED, V339, P1543, DOI 10.1056/NEJM199811193392109; Klein R, 2000, J Health Serv Res Policy, V5, P65; McGlone SJ, 2001, MED J AUSTRALIA, V175, P88, DOI 10.5694/j.1326-5377.2001.tb143537.x; Mechanic D, 2001, BRIT MED J, V323, P266, DOI 10.1136/bmj.323.7307.266; Murray A, 2001, J GEN INTERN MED, V16, P451, DOI 10.1007/s11606-001-0040-z; Schein E. H, 1965, ORG PSYCHOL; Sexton JB, 2000, BMJ-BRIT MED J, V320, P745, DOI 10.1136/bmj.320.7237.745; SILVERSIN J, 2000, LEADING PHYSICIANS C; Silversin J, 2002, MED GROUP MANAGEMENT, V47, P54; Smith R, 2001, BMJ-BRIT MED J, V322, P1073, DOI 10.1136/bmj.322.7294.1073; WEST MA, 2002, LINK MANAGEMENT EMPL	23	175	184	0	12	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 6	2002	324	7341					835	838		10.1136/bmj.324.7341.835	http://dx.doi.org/10.1136/bmj.324.7341.835			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	540ZG	11934779	Green Published			2022-12-28	WOS:000174960300020
J	McMichael, AJ				McMichael, AJ			Population, environment, disease, and survival: past patterns, uncertain futures	LANCET			English	Article							PUBLIC-HEALTH; EPIDEMIOLOGY	Societies are exploring what sustainable development means for development choices. Increasingly, we recognise that human population health is not just an input to socioeconomic development, but is an essential outcome, and, over time, a marker of sustainability. There has been recent attention to how stocks of social and human capital precondition gains in population health. However, recognition of how environmental change can limit health and survival has been slower. Over many millennia, disease and longevity profiles in populations: have reflected changes In environmental conditions and, often, excedances of carrying capacity. Today, population growth and the aggregated pressures of consumption and emissions are beginning to impair various global environmental systems. The research tasks In detecting, attributing, and projecting the resultant health effects are complex. Have recent health gains, in part, depended on depleting natural environmental capital? Population health sciences have a crucial contribution to make to the sustainability project.	Australian Natl Univ, Natl Ctr Epidemiol & Populat Hlth, Canberra, ACT 0200, Australia	Australian National University	McMichael, AJ (corresponding author), Australian Natl Univ, Natl Ctr Epidemiol & Populat Hlth, Canberra, ACT 0200, Australia.							[Anonymous], 1989, STORY IODINE DEFICIE; [Anonymous], 1997, GUNS GERMS STEEL; BOYDEN S, 1987, W CIVILIZATION BIOL; Butler CD, 2000, GLOBAL CHANGE HUMAN, V1, P156, DOI DOI 10.1023/A:1010029222095; Epstein PR, 1997, B AM METEOROL SOC, V78, P409; *FOOD AGR ORG, 2001, STAT FOOD AGR; Intergovernmental Panel on Climate Change, 2001, CLIM CHANG 2001 IMP; Kates RW, 2001, SCIENCE, V292, P641, DOI 10.1126/science.1059386; Kovats RS, 2001, PHILOS T R SOC B, V356, P1057, DOI 10.1098/rstb.2001.0894; LEE K, 2001, INT COOPERATION HLTH, P13; Lindgren E, 2001, LANCET, V358, P16, DOI 10.1016/S0140-6736(00)05250-8; LOMBORG J, 2001, SCEPTICAL ENV; McMichael AJ, 2000, B WORLD HEALTH ORGAN, V78, P1067; McMichael AJ, 2000, LANCET, V356, P495, DOI 10.1016/S0140-6736(00)02564-2; McMichael AJ, 2001, ECOSYST HEALTH, V7, P107, DOI 10.1046/j.1526-0992.2001.007002107.x; McMichael AJ, 1999, AM J EPIDEMIOL, V149, P887; MCMICHAEL AJ, 2000, ETHNICITY HLTH, P133; McMichael AJ, 2001, HUMAN FRONTIERS ENV, DOI [10.1017/CBO9781139106924, DOI 10.1017/CBO9781139106924]; McNeill W.H., 1976, PLAGUES PEOPLES, V1st ed.; Pearce N, 1996, AM J PUBLIC HEALTH, V86, P678, DOI 10.2105/AJPH.86.5.678; POWLES JW, IN PRESS ENCY LIFE S; PRENTICE AM, 1995, BRIT MED J, V311, P437, DOI 10.1136/bmj.311.7002.437; REES WE, 2000, ECOLOGICAL INTEGRITY, P139; ROTBERG R, 1985, HUNGER HIST; Trowell H. C., 1981, W DIS THEIR EMERGENC; Vitousek PM, 1997, SCIENCE, V277, P494, DOI 10.1126/science.277.5325.494; World Health Organization, 1999, WORLD HLTH REP MAK D; World Health Organization (WHO), 1990, WHO TECHN REP SER, V797	28	38	39	0	8	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 30	2002	359	9312					1145	1148		10.1016/S0140-6736(02)08164-3	http://dx.doi.org/10.1016/S0140-6736(02)08164-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	536YJ	11943282				2022-12-28	WOS:000174729200032
J	Vanderlinde, ES; Heal, JM; Blumberg, N				Vanderlinde, ES; Heal, JM; Blumberg, N			Autologous transfusion	BRITISH MEDICAL JOURNAL			English	Review							HIP-REPLACEMENT SURGERY; HOMOLOGOUS BLOOD-TRANSFUSIONS; COLORECTAL-CANCER SURGERY; INFECTIOUS COMPLICATIONS; POSTOPERATIVE INFECTION; ALLOGENEIC TRANSFUSION; BACTERIAL-INFECTION; COST-EFFECTIVENESS; DONATION; MULTICENTER		Univ Rochester, Med Ctr, Transfus Med Unit, Transfus Med & Blood Bank, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Pathol & Lab Med, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Med, Rochester, NY 14642 USA	University of Rochester; University of Rochester; University of Rochester	Blumberg, N (corresponding author), Univ Rochester, Med Ctr, Transfus Med Unit, Transfus Med & Blood Bank, Box 608,601 Elmwood Ave, Rochester, NY 14642 USA.							Bae H, 2001, J BONE JOINT SURG BR, V83B, P676, DOI 10.1302/0301-620X.83B5.10560; Bierbaum BE, 1999, J BONE JOINT SURG AM, V81A, P2, DOI 10.2106/00004623-199901000-00002; BIRKMEYER JD, 1993, TRANSFUSION, V33, P544, DOI 10.1046/j.1537-2995.1993.33793325048.x; Blumberg N, 1996, AM J SURG, V171, P324, DOI 10.1016/S0002-9610(97)89635-3; BLUMBERG N, 2000, SCI BASIS TRANSFUSIO, P427; Body SC, 1999, J CARDIOTHOR VASC AN, V13, P410, DOI 10.1016/S1053-0770(99)90212-4; Borghi B, 2000, EUR J ANAESTH, V17, P411, DOI 10.1046/j.1365-2346.2000.00693.x; BULL BS, 1990, BLOOD CELLS, V16, P5; BUSCH ORC, 1993, NEW ENGL J MED, V328, P1372, DOI 10.1056/NEJM199305133281902; Chan ACW, 1998, AM J SURG, V175, P461, DOI 10.1016/S0002-9610(98)00085-3; COUSIN MT, 1994, ANN CHIR, V48, P818; deCastro RM, 1999, AM J OBSTET GYNECOL, V180, P1491, DOI 10.1016/S0002-9378(99)70044-X; Faris PM, 1996, J BONE JOINT SURG AM, V78A, P62, DOI 10.2106/00004623-199601000-00009; Farrer A, 1997, J Vasc Nurs, V15, P111, DOI 10.1016/S1062-0303(97)90028-5; Faught C, 1998, TRANSFUS MED REV, V12, P206, DOI 10.1016/S0887-7963(98)80061-8; Feagan BG, 2000, ANN INTERN MED, V133, P845, DOI 10.7326/0003-4819-133-11-200012050-00008; FERNANDEZ MC, 1992, TRANSFUSION, V32, P318, DOI 10.1046/j.1537-2995.1992.32492263444.x; Forgie MA, 1998, ARCH INTERN MED, V158, P610, DOI 10.1001/archinte.158.6.610; HEALY JC, 1994, ARCH PATHOL LAB MED, V118, P465; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; HEISS MM, 1993, LANCET, V342, P1328, DOI 10.1016/0140-6736(93)92247-Q; HEISS MM, 1994, J CLIN ONCOL, V12, P1859, DOI 10.1200/JCO.1994.12.9.1859; HOWARD HL, 1993, CLIN LAB HAEMATOL, V15, P165; Kinoshita Y, 2000, SURGERY, V127, P185, DOI 10.1067/msy.2000.102048; MEZROW CK, 1992, TRANSFUSION, V32, P27, DOI 10.1046/j.1537-2995.1992.32192116427.x; MURPHY P, 1991, TRANSFUSION, V31, P212, DOI 10.1046/j.1537-2995.1991.31391165169.x; Napier JAF, 1997, BRIT J ANAESTH, V78, P768, DOI 10.1093/bja/78.6.768; Network for the Advancement of Transfusion Alternatives, 2000, TRANSF MED ALT BLOOD; Newman JH, 1997, J BONE JOINT SURG BR, V79B, P630, DOI 10.1302/0301-620X.79B4.7272; Sauaia A, 1999, AM J SURG, V178, P549, DOI 10.1016/S0002-9610(99)00242-1; Shinozuka N, 2000, AM J SURG, V179, P42, DOI 10.1016/S0002-9610(99)00256-1; Spahn DR, 2000, ANESTHESIOLOGY, V93, P242, DOI 10.1097/00000542-200007000-00035; Thomas D, 2001, BRIT J ANAESTH, V86, P669, DOI 10.1093/bja/86.5.669; Thomas MJG, 1996, TRANSFUSION, V36, P626, DOI 10.1046/j.1537-2995.1996.36796323061.x; TRIULZI DJ, 1992, TRANSFUSION, V32, P517, DOI 10.1046/j.1537-2995.1992.32692367194.x; VAMVAKAS EC, 1995, TRANSFUSION, V35, P150, DOI 10.1046/j.1537-2995.1995.35295125738.x; VIGNALI A, 1995, EUR J SURG, V161, P487; [No title captured]	38	68	74	6	15	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 30	2002	324	7340					772	775		10.1136/bmj.324.7340.772	http://dx.doi.org/10.1136/bmj.324.7340.772			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	538KY	11923162	Green Published			2022-12-28	WOS:000174816200019
J	Ikkala, O; ten Brinke, G				Ikkala, O; ten Brinke, G			Functional materials based on self-assembly of polymeric supramolecules	SCIENCE			English	Article							COPOLYMER; POLYANILINE; SURFACTANT; COMPLEXES	Self-assembty of polymeric supramolecules is a powerful too[ for producing functional materials that combine several properties and may respond to external conditions. We illustrate the concept using a comb-shaped architecture. Examples include the hexagonal self-organization of conjugated conducting polymers and the polarized luminance in solid-state films of rodlike polymers obtained by removing the hydrogen-bonded side chains from the aligned thermotropic smectic phase. Hierarchically structured materials obtained by applying different self-organization and recognition principles and directed assembly form a basis for tunable nanoporous materials, smart membranes, preparation of nano-objects, and anisotropic properties, such as proton conductivity.	Aalto Univ, Dept Engn Math & Phys, FIN-02015 Espoo, Finland; Aalto Univ, Ctr New Mat, FIN-02015 Espoo, Finland; Univ Groningen, Dept Polymer Sci, NL-9747 AG Groningen, Netherlands; Univ Groningen, Ctr Mat Sci, NL-9747 AG Groningen, Netherlands	Aalto University; Aalto University; University of Groningen; University of Groningen	Ikkala, O (corresponding author), Aalto Univ, Dept Engn Math & Phys, POB 2200, FIN-02015 Espoo, Finland.	Olli.ikkala@hut.fi; G.ten.Brinke@chem.rug.nl	Ikkala, Olli T./K-7447-2012	Ikkala, Olli T./0000-0002-0470-1889				Antonietti M, 1996, ADV MATER, V8, P41, DOI 10.1002/adma.19960080106; ANTONIETTI M, 1994, MACROMOLECULES, V27, P6007, DOI 10.1021/ma00099a011; BATES FS, 1990, ANNU REV PHYS CHEM, V41, P525, DOI 10.1146/annurev.pc.41.100190.002521; de Moel K, 2001, CHEM MATER, V13, P4580, DOI 10.1021/cm0110932; Edrington AC, 2001, ADV MATER, V13, P421, DOI 10.1002/1521-4095(200103)13:6<421::AID-ADMA421>3.0.CO;2-#; KNAAPILA M, UNPUB APPL PHYS LETT; Kosonen H, 2000, MACROMOLECULES, V33, P8671, DOI 10.1021/ma0010783; Lehn J.-M., 1995, SUPRAMOLECULAR CHEM; Maki-Ontto R, 2002, ADV MATER, V14, P357, DOI 10.1002/1521-4095(20020304)14:5<357::AID-ADMA357>3.0.CO;2-Q; Maki-Ontto R, 2001, ADV MATER, V13, P117, DOI 10.1002/1521-4095(200101)13:2<117::AID-ADMA117>3.0.CO;2-1; Makinen R, 2000, MACROMOLECULES, V33, P3441, DOI 10.1021/ma991127f; Mena-Osteritz E, 2000, ANGEW CHEM INT EDIT, V39, P2680; Muthukumar M, 1997, SCIENCE, V277, P1225, DOI 10.1126/science.277.5330.1225; Park C, 2001, APPL PHYS LETT, V79, P848, DOI 10.1063/1.1389766; Pease AR, 2001, ACCOUNTS CHEM RES, V34, P433, DOI 10.1021/ar000178q; Rehahn M, 1998, ACTA POLYM, V49, P201, DOI 10.1002/(SICI)1521-4044(199805)49:5<201::AID-APOL201>3.3.CO;2-S; Ruokolainen J, 1999, ADV MATER, V11, P777, DOI 10.1002/(SICI)1521-4095(199906)11:9<777::AID-ADMA777>3.0.CO;2-M; Ruokolainen J, 1998, SCIENCE, V280, P557, DOI 10.1126/science.280.5363.557; Safinya CR, 2001, CURR OPIN STRUC BIOL, V11, P440, DOI 10.1016/S0959-440X(00)00230-X; Saito R, 2001, MACROMOLECULES, V34, P4299, DOI 10.1021/ma002115t; Sanger J, 1997, MACROMOLECULES, V30, P7621, DOI 10.1021/ma970709z; Schon JH, 2000, SCIENCE, V289, P599, DOI 10.1126/science.289.5479.599; Schon JH, 2001, NATURE, V410, P189, DOI 10.1038/35065565; Segalman RA, 2001, ADV MATER, V13, P1152, DOI 10.1002/1521-4095(200108)13:15<1152::AID-ADMA1152>3.0.CO;2-5; Sijbesma RP, 1997, SCIENCE, V278, P1601, DOI 10.1126/science.278.5343.1601; Simon PFW, 2001, CHEM MATER, V13, P3464, DOI 10.1021/cm0110674; Sirringhaus H, 1999, NATURE, V401, P685, DOI 10.1038/44359; Stupp SI, 1997, SCIENCE, V276, P384, DOI 10.1126/science.276.5311.384; Thurn-Albrecht T, 2000, SCIENCE, V290, P2126, DOI 10.1126/science.290.5499.2126; Wang LL, 2001, CHEM MATER, V13, P1273, DOI 10.1021/cm000869g; Wosten HAB, 2001, ANNU REV MICROBIOL, V55, P625, DOI 10.1146/annurev.micro.55.1.625; ZHENG WY, 1995, MACROMOL CHEM PHYSIC, V196, P2443, DOI 10.1002/macp.1995.021960803	32	894	911	15	572	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 29	2002	295	5564					2407	2409		10.1126/science.1067794	http://dx.doi.org/10.1126/science.1067794			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	536QD	11923526				2022-12-28	WOS:000174712600042
J	Yamazaki, T; Oda, H				Yamazaki, T; Oda, H			Orbital influence on Earth's magnetic field: 100,000-year periodicity in inclination	SCIENCE			English	Article							GEOMAGNETIC-FIELD; RELATIVE PALEOINTENSITY; SEDIMENTARY RECORDS; SECULAR VARIATION; INTENSITY; KYR; REVERSALS; PACIFIC; CORES	A continuous record of the inclination and intensity of Earth's magnetic field, during the past 2.25 million years, was obtained from a marine sediment core of 42 meters in length. This record reveals the presence of 100,000-year periodicity in inclination and intensity, which suggests that the magnetic field is modulated by orbital eccentricity. The correlation between inclination and intensity shifted from antiphase to in-phase, corresponding to a magnetic polarity change from reversed to normal. To explain the observation, we propose a model in which the strength of the geocentric axial dipole field varies with 100,000-year periodicity, whereas persistent nondipole components do not.	AIST, Geol Survey Japan, Inst Marine Resources & Environm, Tsukuba, Ibaraki 3058567, Japan	National Institute of Advanced Industrial Science & Technology (AIST)	Yamazaki, T (corresponding author), AIST, Geol Survey Japan, Inst Marine Resources & Environm, Tsukuba, Ibaraki 3058567, Japan.		Oda, Hirokuni/L-8005-2018	Oda, Hirokuni/0000-0001-7142-9208				BASSINOT FC, 1994, EARTH PLANET SC LETT, V126, P91, DOI 10.1016/0012-821X(94)90244-5; CANDE SC, 1995, J GEOPHYS RES-SOL EA, V100, P6093, DOI 10.1029/94JB03098; CELAYA MA, 1988, GEOPHYS RES LETT, V15, P52, DOI 10.1029/GL015i001p00052; Channell JET, 1998, NATURE, V394, P464, DOI 10.1038/28833; CREER KM, 1990, PHYS EARTH PLANET IN, V64, P314, DOI 10.1016/0031-9201(90)90046-Z; GUBBINS D, 1993, NATURE, V365, P829, DOI 10.1038/365829a0; Guyodo Y, 1996, EARTH PLANET SC LETT, V143, P23, DOI 10.1016/0012-821X(96)00121-5; Guyodo Y, 2000, EARTH PLANET SC LETT, V184, P109, DOI 10.1016/S0012-821X(00)00313-7; Guyodo Y, 1999, NATURE, V399, P249, DOI 10.1038/20420; Holt JW, 1996, J GEOPHYS RES-SOL EA, V101, P11655, DOI 10.1029/95JB03843; HYODO M, 1984, J GEOMAGN GEOELECTR, V36, P45, DOI 10.5636/jgg.36.45; Johnson CL, 1997, GEOPHYS J INT, V131, P643, DOI 10.1111/j.1365-246X.1997.tb06604.x; Kok YS, 1999, EARTH PLANET SC LETT, V166, P105, DOI 10.1016/S0012-821X(99)00006-0; LEVI S, 1989, EARTH PLANET SC LETT, V92, P219, DOI 10.1016/0012-821X(89)90048-4; LUND SP, 1988, GEOPHYS RES LETT, V15, P1101, DOI 10.1029/GL015i010p01101; Merrill R.T., 1983, EARTHS MAGNETIC FIEL; NEGRINI RM, 1988, EARTH PLANET SC LETT, V87, P173, DOI 10.1016/0012-821X(88)90073-8; Paillard D., 1996, EOS T AM GEOPHYS UN, V77, P379, DOI 10.1029/96EO00259; RAMPINO MR, 1979, GEOLOGY, V7, P584, DOI 10.1130/0091-7613(1979)7<584:PRBCIG>2.0.CO;2; Ruddiman WF, 1989, PALEOCEANOGRAPHY, V4, P353, DOI 10.1029/PA004i004p00353; TAUXE L, 1993, REV GEOPHYS, V31, P319, DOI 10.1029/93RG01771; TAUXE L, 1995, GEOPHYS RES LETT, V22, P2885, DOI 10.1029/95GL03166; Teanby N, 2000, GEOPHYS J INT, V142, P563, DOI 10.1046/j.1365-246x.2000.00180.x; VALET JP, 1993, NATURE, V366, P234, DOI 10.1038/366234a0; Worm HU, 1997, EARTH PLANET SC LETT, V147, P55, DOI 10.1016/S0012-821X(97)00008-3; YAMAZAKI T, 1994, EARTH PLANET SC LETT, V128, P527, DOI 10.1016/0012-821X(94)90168-6; Yamazaki T, 1999, EARTH PLANET SC LETT, V169, P23, DOI 10.1016/S0012-821X(99)00064-3; Yokoyama Y, 2000, EARTH PLANET SC LETT, V181, P7, DOI 10.1016/S0012-821X(00)00199-0	29	85	86	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 29	2002	295	5564					2435	2438		10.1126/science.1068541	http://dx.doi.org/10.1126/science.1068541			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	536QD	11923535				2022-12-28	WOS:000174712600051
J	Klassen, PS; Lowrie, EG; Reddan, DN; DeLong, ER; Coladonato, JA; Szczech, LA; Lazarus, JM; Owen, WF				Klassen, PS; Lowrie, EG; Reddan, DN; DeLong, ER; Coladonato, JA; Szczech, LA; Lazarus, JM; Owen, WF			Association between pulse pressure and mortality in patients undergoing maintenance hemodialysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ISOLATED SYSTOLIC HYPERTENSION; LARGE ARTERY COMPLIANCE; BLOOD-PRESSURE; CARDIOVASCULAR MORTALITY; HEART-FAILURE; RISK; TERM; REFLECTIONS; POPULATION; STIFFNESS	Context Although increased blood pressure is associated with adverse outcomes in the general population, elevated blood pressure is associated with decreased mortality in patients with end-stage renal disease undergoing maintenance hemodialysis. Recent investigations in the general population have demonstrated the predictive utility of pulse pressure (systolic minus diastolic blood pressure), a measure reflecting the pulsatile nature of the cardiac cycle. Objectives To estimate the relationship between pulse pressure and mortality in patients undergoing maintenance hemodialysis and to test our hypothesis that an increasing pulse pressure would be associated with increased risk of death up to 1 year despite the inverse relationship between conventional blood pressure measures and mortality in patients with end-stage renal disease. Design, Setting, and Patients Retrospective cohort investigation of patients with end-stage renal disease undergoing maintenance hemodialysis at 782 hemodialysis facilities throughout the United States. Of 44 069 eligible patients as of January 1, 1998, 37069 with complete demographic data were included in the analyses of clinical and laboratory data collected from October I through December 31, 1997. Patients were followed up through December 31, 1998. Main Outcome Measures The primary study outcome was death at I year. A secondary outcome was the magnitude of the pulse pressure. Results The final patient cohort was similar to national averages with respect to age, sex, race, and diabetic status. Mean (SD) pulse pressures before dialysis were 75.0 (15.0) mm Hg and 66.9 (13.9) mm Hg after dialysis, By the end of the 1-year follow-up, 5731 patients (18.4%) died. After adjusting for level of systolic blood pressure, multivariable Cox proportional hazards modeling showed a direct and consistent relationship between increasing pulse pressure and increasing death risk. Each incremental elevation of 10 mm Hg in postdialysis pulse pressure was associated with a 12% increase in the hazard for death (hazard ratio, 1.12; 95% confidence interval, 1.06-1.18). Postdialysis systolic blood pressure was inversely related to mortality with a 13% decreased hazard for death for each incremental elevation of 10 mm Hg (hazard ratio, 0.87; 95% confidence interval, 0.84-0.90). In a multivariable linear regression model, important variables directly associated with elevated pulse pressure included age, diabetes, white race, female sex, and number of years receiving dialysis (all P<.001). Conclusions Pulse pressure is associated with risk of death in a large, nationally representative sample of patients undergoing maintenance hemodialysis. The recognition of pulse pressure as an important correlate of mortality in patients receiving dialysis highlights the need to investigate the relationship between potential therapeutic implications of conduit vessel function and clinical outcomes in patients with end-stage renal disease.	Duke Univ, Med Ctr, Duke Inst Renal Outcomes Res & Hlth Policy, Dept Med, Durham, NC 27710 USA; Duke Clin Res Inst, Durham, NC USA; Fresenius Med Care N Amer, Lexington, MA USA	Duke University; Duke University	Klassen, PS (corresponding author), Duke Univ, Med Ctr, Duke Inst Renal Outcomes Res & Hlth Policy, Dept Med, Box 3646, Durham, NC 27710 USA.	klass001@mc.duke.edu						Amar J, 2000, KIDNEY INT, V57, P2485, DOI 10.1046/j.1523-1755.2000.00107.x; [Anonymous], 1982, ARTERIAL FUNCTION HL; [Anonymous], 1982, JAMA-J AM MED ASSOC, V247, P633; [Anonymous], 1997, ARCH INTERN MED, V157, P2413; AVOLIO AP, 1986, ARTERIOSCLEROSIS, V6, P166, DOI 10.1161/01.ATV.6.2.166; BARENBROCK M, 1994, KIDNEY INT, V45, P1397, DOI 10.1038/ki.1994.182; Benetos A, 1998, HYPERTENSION, V32, P560, DOI 10.1161/01.HYP.32.3.560; Blacher J, 1998, HYPERTENSION, V32, P570, DOI 10.1161/01.HYP.32.3.570; CAMERON D, 1994, AM J PHYSL 2, V262, pH693; Chae CU, 1999, JAMA-J AM MED ASSOC, V281, P634, DOI 10.1001/jama.281.7.634; DECESARIS R, 1992, AM J HYPERTENS, V5, P624; *DEP HLTH HUM SERV, 1999, 1999 ANN REP ESRD CL; Domanski MJ, 1999, J AM COLL CARDIOL, V33, P951, DOI 10.1016/S0735-1097(98)00679-2; Domanski MJ, 1999, HYPERTENSION, V34, P375, DOI 10.1161/01.HYP.34.3.375; FLACK JM, 1995, CIRCULATION, V92, P2437, DOI 10.1161/01.CIR.92.9.2437; Foley RN, 1998, AM J KIDNEY DIS, V32, pS112, DOI 10.1053/ajkd.1998.v32.pm9820470; Franklin SS, 1999, CIRCULATION, V100, P354, DOI 10.1161/01.CIR.100.4.354; FRANKLIN SS, 1994, AM HEART J, V128, P793, DOI 10.1016/0002-8703(94)90278-X; Girerd X, 1998, J AM COLL CARDIOL, V31, P1064, DOI 10.1016/S0735-1097(98)00043-6; Glynn RJ, 2000, ARCH INTERN MED, V160, P2765, DOI 10.1001/archinte.160.18.2765; HARNETT JD, 1995, KIDNEY INT, V47, P884, DOI 10.1038/ki.1995.132; Heesen WF, 1998, J CARDIOVASC PHARM, V31, P187, DOI 10.1097/00005344-199802000-00003; Herpin D, 1996, THERAPIE, V51, P11; *HYP DET FOLL UP P, 1979, JAMA-J AM MED ASSOC, V242, P2562; KJELSBERG MO, 1982, JAMA-J AM MED ASSOC, V248, P1465; KLASSEN P, 2000, J AM SOC NEPHROL, V11; LONDON GM, 1990, KIDNEY INT, V37, P137, DOI 10.1038/ki.1990.19; London GM, 1997, KIDNEY INT, V51, P1678, DOI 10.1038/ki.1997.233; NEATON JD, 1984, AM HEART J, V108, P759, DOI 10.1016/0002-8703(84)90669-0; Nichols W, 1998, MCDONALDS BLOOD FLOW; NICHOLS WW, 1992, J HYPERTENS, V10, pS73; Owen WF, 1998, JAMA-J AM MED ASSOC, V280, P1764, DOI 10.1001/jama.280.20.1764; PANNIER BM, 1994, AM J HYPERTENS, V7, P168, DOI 10.1093/ajh/7.2.168; Port FK, 1999, AM J KIDNEY DIS, V33, P507, DOI 10.1016/S0272-6386(99)70188-5; Safar ME, 1997, J VASC RES, V34, P67, DOI 10.1159/000159204; Salem MM, 1999, NEPHROL DIAL TRANSPL, V14, P125, DOI 10.1093/ndt/14.1.125; Salem MM, 1996, AM J KIDNEY DIS, V28, P737, DOI 10.1016/S0272-6386(96)90257-7; Sytkowski PA, 1996, CIRCULATION, V93, P697, DOI 10.1161/01.CIR.93.4.697; TING CT, 1995, HYPERTENSION, V26, P524, DOI 10.1161/01.HYP.26.3.524; Tozawa M, 2002, KIDNEY INT, V61, P717, DOI 10.1046/j.1523-1755.2002.00173.x; *US REN DAT SYST, 2000, USRDS 2000 ANN DAT R; WATANABE H, 1993, J AM COLL CARDIOL, V21, P1497, DOI 10.1016/0735-1097(93)90330-4; WESTERHOF N, 1995, J HYPERTENS, V13, P943, DOI 10.1097/00004872-199509000-00002; Zager PG, 1998, KIDNEY INT, V54, P561, DOI 10.1046/j.1523-1755.1998.00005.x	44	325	343	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 27	2002	287	12					1548	1555		10.1001/jama.287.12.1548	http://dx.doi.org/10.1001/jama.287.12.1548			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	533VF	11911757	Bronze			2022-12-28	WOS:000174550400026
J	Gehring, WJ; Willoughby, AR				Gehring, WJ; Willoughby, AR			The medial frontal cortex and the rapid processing of monetary gains and losses	SCIENCE			English	Article							ANTERIOR CINGULATE; ERROR-DETECTION; NEURAL SYSTEM; ACTIVATION; CHOICE	We report the observation of neural processing that occurs within 265 milliseconds after outcome stimuli that inform human participants about gains and losses in a gambling task. A negative-polarity event-related brain potential, probably generated by a medial-frontal region in or near the anterior cingulate cortex, was greater in amplitude when a participant's choice between two alternatives resulted in a toss than when it resulted in a gain. The sensitivity to losses was not simply a reflection of detecting an error; gains did not elicit the medial-frontal activity when the alternative choice would have yielded a greater gain, and losses elicited the activity even when the alternative choice would have yielded a greater loss. Choices made after losses were riskier and were associated with greater toss-related activity than choices made after gains. It follows that medial-frontal computations may contribute to mental states that participate in higher level decisions, including economic choices.	Univ Michigan, Dept Psychol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Gehring, WJ (corresponding author), Univ Michigan, Dept Psychol, 525 E Univ, Ann Arbor, MI 48109 USA.	wgehring@umich.edu						Bargh JA, 2000, PSYCHOL BULL, V126, P925, DOI 10.1037//0033-2909.126.6.925; Bechara A, 1997, SCIENCE, V275, P1293, DOI 10.1126/science.275.5304.1293; Breiter HC, 2001, NEURON, V30, P619, DOI 10.1016/S0896-6273(01)00303-8; Bush G, 2000, TRENDS COGN SCI, V4, P215, DOI 10.1016/S1364-6613(00)01483-2; Cacioppo JT, 1999, ANNU REV PSYCHOL, V50, P191, DOI 10.1146/annurev.psych.50.1.191; Carter CS, 1998, SCIENCE, V280, P747, DOI 10.1126/science.280.5364.747; DEHAENE S, 1994, PSYCHOL SCI, V5, P303, DOI 10.1111/j.1467-9280.1994.tb00630.x; FALKENSTEIN M, 1991, ELECTROEN CLIN NEURO, V78, P447, DOI 10.1016/0013-4694(91)90062-9; Gehring WJ, 2001, J NEUROSCI, V21, P9430, DOI 10.1523/JNEUROSCI.21-23-09430.2001; GEHRING WJ, 1993, PSYCHOL SCI, V4, P385, DOI 10.1111/j.1467-9280.1993.tb00586.x; Gehring WJ, 2000, NAT NEUROSCI, V3, P516, DOI 10.1038/74899; KAHNEMAN D, 1979, ECONOMETRICA, V47, P263, DOI 10.2307/1914185; Kahneman D., 1999, WELL BEING FDN HEDON, P3, DOI DOI 10.7758/9781610443258; Kiehl KA, 2000, PSYCHOPHYSIOLOGY, V37, P216, DOI 10.1111/1469-8986.3720216; Knutson B, 2000, NEUROIMAGE, V12, P20, DOI 10.1006/nimg.2000.0593; Loewenstein GF, 2001, PSYCHOL BULL, V127, P267, DOI 10.1037//0033-2909.127.2.267; Luu P, 2001, CLIN NEUROPHYSIOL, V112, P1295, DOI 10.1016/S1388-2457(01)00559-4; Mellers BA, 2000, PSYCHOL BULL, V126, P910, DOI 10.1037/0033-2909.126.6.910; Menon V, 2001, HUM BRAIN MAPP, V12, P131, DOI 10.1002/1097-0193(200103)12:3<131::AID-HBM1010>3.0.CO;2-C; Miltner WHR, 1997, J COGNITIVE NEUROSCI, V9, P788, DOI 10.1162/jocn.1997.9.6.788; Scherg M, 1990, ADV AUDIOL, P40, DOI DOI 10.1016/J.BSPC.2015.01.004; Schultz W, 1997, SCIENCE, V275, P1593, DOI 10.1126/science.275.5306.1593; TAYLOR SE, 1991, PSYCHOL BULL, V110, P67, DOI 10.1037/0033-2909.110.1.67; Tucker DM, 1999, BIOL PSYCHOL, V50, P103, DOI 10.1016/S0301-0511(99)00005-8; Yates F.J., 1992, RISK TAKING BEHAV, P1; [No title captured]; [No title captured]	27	1311	1366	15	172	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 22	2002	295	5563					2279	2282		10.1126/science.1066893	http://dx.doi.org/10.1126/science.1066893			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	534AD	11910116				2022-12-28	WOS:000174561700050
J	Regan, CK; Craig, SL; Brauman, JI				Regan, CK; Craig, SL; Brauman, JI			Steric effects and solvent effects in ionic reactions	SCIENCE			English	Article							NUCLEOPHILIC DISPLACEMENT-REACTIONS; GAS-PHASE; CHLORIDE-ION; SN2 REACTION; TEMPERATURE-DEPENDENCE; EXCHANGE EQUILIBRIA; AQUEOUS-SOLUTION; METHYL-CHLORIDE; KINETIC-ENERGY; AFFINITIES	Rates of S(N)2 reactions of chloride ion with methyl- and tert-butyl-substituted chloroacetonitrile were measured by using Fourier transform-ion cyclotron resonance spectrometry to follow the isotopic exchange reaction. Barrier heights for these reactions indicate that steric effects in the gas phase are diminished relative to apparent steric effects in solution. We attribute the increased barrier in solution to a solvation effect. Monte Carlo simulations done using statistical perturbation theory confirm that steric hindrance to solvation contributes to S(N)2 barriers in solution.	Stanford Univ, Dept Chem, Stanford, CA 94305 USA; Bryn Mawr Coll, Dept Chem, Bryn Mawr, PA 19010 USA; Duke Univ, Dept Chem, Durham, NC 27708 USA	Stanford University; Bryn Mawr College; Duke University	Brauman, JI (corresponding author), Stanford Univ, Dept Chem, Stanford, CA 94305 USA.		Craig, Stephen/AAP-6717-2020; Craig, Stephen L/D-3484-2011	Craig, Stephen/0000-0002-8810-0369; Craig, Stephen L/0000-0002-8810-0369				BARLOW SE, 1988, J AM CHEM SOC, V110, P7240, DOI 10.1021/ja00229a064; CALDWELL G, 1984, J AM CHEM SOC, V106, P959, DOI 10.1021/ja00316a023; CARMAN RM, 1976, AUST J CHEM, V29, P133, DOI 10.1071/CH9760133; Chabinyc ML, 1998, SCIENCE, V279, P1882, DOI 10.1126/science.279.5358.1882; CHANDRASEKHAR J, 1984, J AM CHEM SOC, V106, P3049, DOI 10.1021/ja00322a059; CHANDRASEKHAR J, 1985, J AM CHEM SOC, V107, P154, DOI 10.1021/ja00287a028; CHANDRASEKHAR J, 1985, J AM CHEM SOC, V107, P2974, DOI 10.1021/ja00296a024; Craig SL, 1997, SCIENCE, V276, P1536, DOI 10.1126/science.276.5318.1536; DAVIS JW, 1978, J ORG CHEM, V43, P3980, DOI 10.1021/jo00414a045; DELAMARE PBD, 1955, J CHEM SOC, P3200, DOI 10.1039/jr9550003200; DEPUY CH, 1990, J AM CHEM SOC, V112, P8650, DOI 10.1021/ja00180a003; Evans AG, 1942, NATURE, V149, P608, DOI 10.1038/149608a0; Gilbert RG., 1990, THEORY UNIMOLECULAR; Gronert S, 2001, CHEM REV, V101, P329, DOI 10.1021/cr9900836; HASE WL, 1994, SCIENCE, V266, P998, DOI 10.1126/science.266.5187.998; HOFMAN AQ, 1875, BER, V8, P61; Hofmann, 1872, CHEM BER, V5, P704; Ingold C.K., 1953, STRUCTURE MECH ORGAN; JORGENSEN WL, 1997, BOSS VERSION 3 8; LARSON JW, 1984, J AM CHEM SOC, V106, P517, DOI 10.1021/ja00315a008; LARSON JW, 1984, CAN J CHEM, V62, P675, DOI 10.1139/v84-113; LARSON JW, 1985, J AM CHEM SOC, V107, P766, DOI 10.1021/ja00290a005; Lowry T. H., 1987, MECH THEORY ORGANIC; Marcus RA, 1997, J PHYS CHEM A, V101, P4072, DOI 10.1021/jp963722e; OLMSTEAD WN, 1977, J AM CHEM SOC, V99, P4219, DOI 10.1021/ja00455a002; PELLERITE MJ, 1983, J AM CHEM SOC, V105, P2672, DOI 10.1021/ja00347a026; RIVEROS JM, 1985, ADV PHYS ORG CHEM, V21, P197, DOI 10.1016/S0065-3160(08)60100-8; StreitwieserJr, 1962, SOLVOLYTIC DISPLACEM; Taft RW, 1956, STERIC EFFECTS ORGAN; VIGGIANO AA, 1994, J AM CHEM SOC, V116, P2213, DOI 10.1021/ja00084a099; WLADKOWSKI BD, 1992, J AM CHEM SOC, V114, P9136, DOI 10.1021/ja00049a055; Zhong ML, 1996, J AM CHEM SOC, V118, P636, DOI 10.1021/ja9502233	32	82	82	6	51	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 22	2002	295	5563					2245	2247		10.1126/science.1068849	http://dx.doi.org/10.1126/science.1068849			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	534AD	11910104				2022-12-28	WOS:000174561700038
J	Edwards, A; Elwyn, G; Mulley, A				Edwards, A; Elwyn, G; Mulley, A			Explaining risks: turning numerical data into meaningful pictures	BMJ-BRITISH MEDICAL JOURNAL			English	Review							DECISION-MAKING; COMMUNICATION		Cardiff Univ, Dept Gen Practice, Llanedeyrn Hlth Ctr, Cardiff CF3 7PN, S Glam, Wales; Massachusetts Gen Hosp, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital	Edwards, A (corresponding author), Cardiff Univ, Dept Gen Practice, Llanedeyrn Hlth Ctr, Cardiff CF3 7PN, S Glam, Wales.	Edwardsag@cf.ac.uk	Elwyn, G./L-4292-2015; Elwyn, Glyn/B-4798-2009	Elwyn, Glyn/0000-0002-0917-6286				Ahl A S, 1993, Rev Sci Tech, V12, P1045; BUDESCU DV, 1988, J EXP PSYCHOL HUMAN, V14, P281, DOI 10.1037/0096-1523.14.2.281; Calman KC, 1997, BMJ-BRIT MED J, V315, P939; COHN LD, 1995, PEDIATRICS, V95, P713; Cosmides L, 1996, COGNITION, V58, P1, DOI 10.1016/0010-0277(95)00664-8; Edwards A, 2000, MED DECIS MAKING, V20, P290, DOI 10.1177/0272989X0002000305; Edwards A, 2001, J HEALTH COMMUN, V6, P61, DOI 10.1080/10810730150501413; Edwards A, 1999, BRIT MED J, V319, P749, DOI 10.1136/bmj.319.7212.749; Elwyn G., 2001, EVIDENCE BASED PATIE, P3; ENDE J, 1989, J GEN INTERN MED, V4, P23, DOI 10.1007/BF02596485; Eysenbach G, 2000, BMJ-BRIT MED J, V320, P1713, DOI 10.1136/bmj.320.7251.1713; FORTIN JM, 2001, BMC MED INFORM DECIS, V1; Gafni A, 1998, SOC SCI MED, V47, P347, DOI 10.1016/S0277-9536(98)00091-4; GAIL MH, 1989, J NATL CANCER I, V81, P1879, DOI 10.1093/jnci/81.24.1879; Glanz K, 1996, JAMA-J AM MED ASSOC, V275, P253, DOI 10.1001/jama.275.3.253; Hart JT, 1996, LANCET, V347, P1606, DOI 10.1016/S0140-6736(96)91083-1; Hindmoor Andrew, 1997, NEW POLIT ECON, V2, P451; Kuhberger A, 1998, ORGAN BEHAV HUM DEC, V75, P23, DOI 10.1006/obhd.1998.2781; Lipkus I M, 1999, J Natl Cancer Inst Monogr, P149; Mazur DJ., 2001, SHARED DECISION MAKI; OCONNOR AM, 2002, COCHRANE LIB; Paling J., 1997, YOUR ARMPITS ALLIGAT; Peshkin BN, 2001, J CLIN ONCOL, V19, P2555, DOI 10.1200/JCO.2001.19.9.2555; Schwartz Lisa M., 1999, Journal of the National Cancer Institute Monographs, P124; Skolbekken JA, 1998, BMJ-BRIT MED J, V316, P1956, DOI 10.1136/bmj.316.7149.1956; SLATER E, 1998, BRIT MED J, V317, P263; Vlek C, 1987, Birth Defects Orig Artic Ser, V23, P171; WILSON D K, 1988, Health Education Research, V3, P161, DOI 10.1093/her/3.2.161; Wood D, 1998, HEART, V80, pS1; Yamagishi K, 1997, APPL COGNITIVE PSYCH, V11, P495, DOI 10.1002/(SICI)1099-0720(199712)11:6<495::AID-ACP481>3.0.CO;2-J	30	426	430	0	32	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 6	2002	324	7341					827	830		10.1136/bmj.324.7341.827	http://dx.doi.org/10.1136/bmj.324.7341.827			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	540ZG	11934777	Green Published			2022-12-28	WOS:000174960300018
J	Serageldin, I				Serageldin, I			The rice genome - World poverty and hunger - the challenge for science	SCIENCE			English	Editorial Material									Lib Alexandria, Bibliotheca Alexandrina, Alexandria 21526, Egypt		Serageldin, I (corresponding author), Lib Alexandria, Bibliotheca Alexandrina, Alexandria 21526, Egypt.							Bronowski J., 1956, SCI HUMAN VALUES, DOI DOI 10.1111/J.1468-2273.1956.TB00909.X; Putnam R.D., 1994, MAKING DEMOCRACY WOR, DOI DOI 10.2307/206637	2	29	33	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 5	2002	296	5565					54	+		10.1126/science.1072035	http://dx.doi.org/10.1126/science.1072035			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	539FA	11935007				2022-12-28	WOS:000174858800028
J	Lollar, BS; Westgate, TD; Ward, JA; Slater, GF; Lacrampe-Couloume, G				Lollar, BS; Westgate, TD; Ward, JA; Slater, GF; Lacrampe-Couloume, G			Abiogenic formation of alkanes in the Earth's crust as a minor source for global hydrocarbon reservoirs	NATURE			English	Article							ISOTOPIC FRACTIONATION; NATURAL-GAS; METHANE; SERPENTINIZATION; REDUCTION; MIGRATION; HYDROGEN; OLIVINE; FLUIDS; CO2	Natural hydrocarbons are largely formed by the thermal decomposition of organic matter (thermogenesis) or by microbial processes (bacteriogenesis). But the discovery of methane at an East Pacific Rise hydrothermal vent(1) and in other crustal fluids supports the occurrence of an abiogenic source of hydrocarbons(2-4). These abiogenic hydrocarbons are generally formed by the reduction of carbon dioxide, a process which is thought to occur during magma cooling(5) and-more commonly-in hydrothermal systems during water-rock interactions, for example involving Fischer-Tropsch reactions and the serpentinization of ultramafic rocks(6-10). Suggestions that abiogenic hydrocarbons make a significant contribution to economic hydrocarbon reservoirs 2 have been difficult to resolve, in part owing to uncertainty in the carbon isotopic signatures for abiogenic versus thermogenic hydrocarbons(4,10). Here, using carbon and hydrogen isotope analyses of abiogenic methane and higher hydrocarbons in crystalline rocks of the Canadian shield, we show a clear distinction between abiogenic and thermogenic hydrocarbons. The progressive isotopic trends for the series of C-1-C-4 alkanes indicate that hydrocarbon formation occurs by way of polymerization of methane precursors. Given that these trends are not observed in the isotopic signatures of economic gas reservoirs, we can now rule out the presence of a globally significant abiogenic source of hydrocarbons.	Univ Toronto, Stable Isotope Lab, Toronto, ON M5S 3B1, Canada	University of Toronto	Lollar, BS (corresponding author), Univ Toronto, Stable Isotope Lab, Toronto, ON M5S 3B1, Canada.	bsl@quartz.geology.utoronto.ca	Lacrampe-Couloume, Georges/P-6093-2019; Slater, Greg/B-5163-2013; Lacrampe-Couloume, Georges/AAW-9291-2020	Slater, Greg/0000-0001-7418-7566; 				ABRAJANO TA, 1990, APPL GEOCHEM, V5, P625, DOI 10.1016/0883-2927(90)90060-I; Berndt ME, 1996, GEOLOGY, V24, P351, DOI 10.1130/0091-7613(1996)024<0351:ROCDSO>2.3.CO;2; BLEEKER W, 1996, CAN J EARTH SCI, V3, P1213; CHARLOU JL, 1993, J GEOPHYS RES-SOL EA, V98, P9625, DOI 10.1029/92JB02047; DESMARAIS DJ, 1981, NATURE, V292, P826, DOI 10.1038/292826a0; DOIG F, 1995, GEOMICROBIOL J, V13, P91, DOI 10.1080/01490459509378008; DOIG F, 1994, THESIS U TORONTO; GIARDINI AA, 1968, SCIENCE, V159, P317, DOI 10.1126/science.159.3812.317; GOLD T, 1979, J PETROL GEOL, V1, P1; HOLLOWAY JR, 1984, GEOLOGY, V12, P455, DOI 10.1130/0091-7613(1984)12<455:GEALMC>2.0.CO;2; Horita J, 1999, SCIENCE, V285, P1055, DOI 10.1126/science.285.5430.1055; Hu GX, 1998, SCI CHINA SER D, V41, P202, DOI 10.1007/BF02932441; JAMES AT, 1983, AAPG BULL, V67, P1176; Jenden P. D., 1993, FUTURE ENERGY GASES, V1570, P31; Kelley DS, 1996, J GEOPHYS RES-SOL EA, V101, P2943, DOI 10.1029/95JB02252; KHITAROV NI, 1979, SOV GEOL, V2, P62; KONNERUPMADSEN J, 1988, B MINERAL, V106, P642; LAIER T, 1995, P 17 INT M ORG GEOCH, P1109; LANCET MS, 1970, SCIENCE, V170, P980, DOI 10.1126/science.170.3961.980; LOLLAR BS, 1994, B CAN PETROL GEOL, V42, P283; McCollom TM, 2001, GEOCHIM COSMOCHIM AC, V65, P3769, DOI 10.1016/S0016-7037(01)00655-X; Pernaton E, 1996, REV I FR PETROL, V51, P635, DOI 10.2516/ogst:1996042; SCHOELL M, 1983, AAPG BULL, V67, P2225; SHERWOODLOLLAR B, 1993, GEOCHIM COSMOCHIM AC, V57, P5087; SHOCK EL, 1995, NATURE, V378, P338, DOI 10.1038/378338a0; VANKO DA, 1991, P OC DRILL PROGR SCI, V0118; WELHAN JA, 1979, GEOPHYS RES LETT, V6, P829, DOI 10.1029/GL006i011p00829; WESTGATE TD, 1998, THESIS U TORONTO; YUEN G, 1984, NATURE, V307, P252, DOI 10.1038/307252a0; Yuen G.U., 1990, LUNAR PLANET SCI, V21, P1367	30	331	345	1	74	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 4	2002	416	6880					522	524		10.1038/416522a	http://dx.doi.org/10.1038/416522a			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	537JY	11932741				2022-12-28	WOS:000174756500039
J	Fanelli, CG; Pampanelli, S; Porcellati, F; Rossetti, P; Brunetti, P; Bolli, GB				Fanelli, CG; Pampanelli, S; Porcellati, F; Rossetti, P; Brunetti, P; Bolli, GB			Administration of neutral protamine Hagedorn insulin at bedtime versus with dinner in type 1 diabetes mellitus to avoid nocturnal hypoglycemia and improve control - A randomized, controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article							BLOOD-GLUCOSE CONTROL; ACTING INSULIN; NPH INSULIN; COGNITIVE FUNCTION; HOE 901; RESPONSES; MANAGEMENT; INDUCTION; INJECTION; GLARGINE	Background: intensive insulin treatment of type I diabetes mellitus increases the risk for nocturnal hypoglycemia. Objective: To demonstrate that splitting the evening insulin regimen reduces the risk for nocturnal hypoglycemia in intensive treatment of type 1 diabetes mellitus. Design: Randomized, open, two-treatment crossover trial in two 4-month periods. Setting: University research center in Italy. Patients: 22 C-peptide-negative persons with type I diabetes mellitus (mean age [+/-SD], 29 +/- 3 years). Interventions: Each patient was randomly assigned to one of two insulin regimens for 4 months and then switched to the other regimen for another 4 months. The two treatment regimens were 1) mixed treatment-a mixture of human regular and neutral protamine Hagedom (NPH) insulin administered before dinner and 2) split treatment-human regular insulin administered at dinner and NPH insulin administered at bedtime. Measurements: Frequency of nocturnal hypoglycemia. Secondary end points were levels of fasting blood glucose and hemoglobin A(1c) and responses to experimental hypoglycemia. Results: During the split-regimen treatment period, patients had fewer episodes of nocturnal hypoglycemia (mean [+/-SE], 0.10 +/- 0.02 episode/patient-day vs. 0.28 +/- 0.04 episode/patientday; P = 0.002), a lower fasting blood glucose level (mean [+/-SE], 7.6 +/- 0.2 mmol/L vs. 8,3 +/- 0.5 mmol/L [137 +/- 4 mg/dL vs. 160 +/- 8 mg/dL]; P = 0.030), less variable fasting blood glucose levels (SD range, 2.0 +/- 0.4 vs. 3.5 +/- 0.6; P = 0.001), and lower hemoglobin A(1c) value (mean [+/-SE], 7.0% +/- 0.11% vs. 7.5% +/- 0.15%; P = 0.004) than during the mixed regimen. Responses to experimental hypoglycemia were better preserved with the split regimen than with the mixed regimen. Conclusion: When the goal of insulin therapy in type 1 diabetes mellitus is near-normoglycemia, splitting the evening insulin treatment regimen into short-acting insulin at dinner and NPH insulin at bedtime reduces the risks for nocturnal hypoglycemia and hypoglycemia unawareness and decreases the hemoglobin A(1c) value compared with mixing short-acting insulin and NPH insulin at dinner.	Univ Perugia, Dept Internal Med, I-06126 Perugia, Italy	University of Perugia	Bolli, GB (corresponding author), Univ Perugia, Dept Internal Med, Via E Dal Pozzo, I-06126 Perugia, Italy.	gbolli@dimisem.med.unipg.it	Rossetti, Paolo/AAE-7268-2022; Rossetti, Paolo/AAB-7071-2020	Rossetti, Paolo/0000-0002-2767-2996; FANELLI, Carmine Giuseppe/0000-0003-4063-158X				[Anonymous], 1997, DIABETES, V46, P271, DOI 10.2337/diab.46.2.271; BENDTSON I, 1992, DIABETOLOGIA, V35, P898, DOI 10.1007/BF00399939; BENDTSON I, 1988, ACTA MED SCAND, V223, P543; BOLLI GB, 1993, DIABETES CARE, V16, P71, DOI 10.2337/diacare.16.3.71; Bolli GB, 1999, DIABETOLOGIA, V42, P1151, DOI 10.1007/s001250051286; CRYER PE, 1992, DIABETES, V41, P255, DOI 10.2337/diabetes.41.3.255; Dawson-Saunders B., 1994, BASIC CLIN BIOSTATIS; DEFEO P, 1986, DIABETOLOGIA, V29, P475, DOI 10.1007/BF00453496; EVERITT BS, 1989, STAT METHODS MED INV, P68; EWING DJ, 1986, CLIN ENDOCRINOL META, V15, P855, DOI 10.1016/S0300-595X(86)80078-0; FANELLI C, 1994, DIABETOLOGIA, V37, P797, DOI 10.1007/BF00404337; FANELLI CG, 1992, J CLIN INVEST, V89, P2005, DOI 10.1172/JCI115809; Fanelli CG, 1998, DIABETES, V47, P1920, DOI 10.2337/diabetes.47.12.1920; FOWELIN J, 1990, METABOLISM, V39, P822, DOI 10.1016/0026-0495(90)90126-W; FRANCIS AJ, 1983, BRIT MED J, V286, P1173, DOI 10.1136/bmj.286.6372.1173; GALE EAM, 1979, LANCET, V1, P1049; HJEMDAHL P, 1979, LIFE SCI, V25, P131, DOI 10.1016/0024-3205(79)90384-9; Home PD, 2000, DIABETIC MED, V17, P762, DOI 10.1046/j.1464-5491.2000.00380.x; KANE K, 1998, DIABETOLOGIA, V41, P322; King P, 1998, DIABETES CARE, V21, P341, DOI 10.2337/diacare.21.3.341; KOHN A, 1985, GUT, V26, P776, DOI 10.1136/gut.26.8.776; KOLLIND M, 1987, ACTA ENDOCRINOL-COP, V116, P314, DOI 10.1530/acta.0.1160314; KUZUYA H, 1977, DIABETES, V26, P22, DOI 10.2337/diabetes.26.1.22; Lalli C, 1999, DIABETES CARE, V22, P468, DOI 10.2337/diacare.22.3.468; Lepore M, 2000, DIABETES, V49, P2142, DOI 10.2337/diabetes.49.12.2142; LEZAK D, 1998, NEUROPSYCHOLOGICAL A, P154; LOWRY O, 1972, FLEXIBLE SYSTEM ENZY, P89; Matyka KA, 2000, J PEDIATR-US, V137, P233, DOI 10.1067/mpd.2000.107186; MCGUIRE EAH, 1976, J APPL PHYSIOL, V41, P565, DOI 10.1152/jappl.1976.41.4.565; MITRAKOU A, 1993, J CLIN ENDOCR METAB, V76, P462, DOI 10.1210/jc.76.2.462; MOBERG E, 1993, SCAND J CLIN LAB INV, V53, P507, DOI 10.3109/00365519309092547; Mohn A, 2000, DIABETES CARE, V23, P557, DOI 10.2337/diacare.23.4.557a; PEAKE GT, 1974, METHOD HORM RADIOIMM, P103; PERRIELLO G, 1990, DIABETOLOGIA, V33, P52, DOI 10.1007/BF00586461; PERRIELLO G, 1988, NEW ENGL J MED, V319, P1233, DOI 10.1056/NEJM198811103191901; Pieber TR, 2000, DIABETES CARE, V23, P157, DOI 10.2337/diacare.23.2.157; Porcellati F, 2001, DIABETOLOGIA, V44, pA208; PRAMMING S, 1985, BRIT MED J, V291, P376, DOI 10.1136/bmj.291.6492.376; Ratner RE, 2000, DIABETES CARE, V23, P639, DOI 10.2337/diacare.23.5.639; SETH J, 1978, CLIN CHIM ACTA, V86, P109, DOI 10.1016/0009-8981(78)90465-5; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; TOWLER DA, 1993, DIABETES, V42, P1791, DOI 10.2337/diabetes.42.12.1791; VENEMAN T, 1993, DIABETES, V42, P1233, DOI 10.2337/diabetes.42.9.1233; Vervoort G, 1996, DIABETIC MED, V13, P794; Winer BJ, 1991, STAT PRINCIPLES EXPT, P497	45	34	37	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 2	2002	136	7					504	514		10.7326/0003-4819-136-7-200204020-00007	http://dx.doi.org/10.7326/0003-4819-136-7-200204020-00007			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	536CA	11926785				2022-12-28	WOS:000174682100002
J	Tauber, AI				Tauber, AI			Puffing ethics into the medical record	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							PALLIATIVE CARE		Boston Univ, Sch Med, Boston, MA 02215 USA; Boston Univ, Ctr Philosophy Hist Sci, Boston, MA 02215 USA	Boston University; Boston University	Tauber, AI (corresponding author), Boston Univ, Sch Med, 745 Commonwealth Ave, Boston, MA 02215 USA.	ait@bu.edu						Barbour A., 1995, CARING PATIENTS CRIT; HUNTER KM, 1994, DOCTORS STORIES NARR; JONSEN AR, 1998, CLIN ETHNICS PRACTIC; Karlawish JHT, 1999, ANN INTERN MED, V130, P835, DOI 10.7326/0003-4819-130-10-199905180-00018; Lo B, 1999, ANN INTERN MED, V130, P744, DOI 10.7326/0003-4819-130-9-199905040-00015; LO B, 1981, ARCH INTERN MED, V141, P1062, DOI 10.1001/archinte.141.8.1062; LO B, 1995, PHILOS BASIS MED PRA; LO B, 1995, RESOLVING ETHICAL DI; MURPHY EA, 1997, UNDERPRINTING MED ET; Pellegrino E., 1981, PHILOS BASIS MED PRA; Spiro HM, 1993, EMPATHY PRACTICE MED; TAUBER AI, 1999, CONFESSIONS MED MAN; Thomasma D C, 1978, Forum Med, V1, P33	13	13	13	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 2	2002	136	7					559	563		10.7326/0003-4819-136-7-200204020-00024	http://dx.doi.org/10.7326/0003-4819-136-7-200204020-00024			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	536CA	11926802				2022-12-28	WOS:000174682100018
J	Reinhoudt, DN; Crego-Calama, M				Reinhoudt, DN; Crego-Calama, M			Synthesis beyond the molecule	SCIENCE			English	Article							NONCOVALENT SYNTHESIS; CHEMISTRY; AMPLIFICATION; RECOGNITION; COMPLEXES; DISCOVERY; CHIRALITY	Weak, noncovalent interactions between molecules control many biological functions. In chemistry, noncovalent interactions are now exploited for the synthesis in solution of large supramolecular aggregates. The aim of these syntheses is not only the creation of a particular structure, but also the introduction of specific chemical functions in these supramolecules.	Univ Twente, MESA Res Inst, Lab Supramol Chem & Technol, NL-7500 AE Enschede, Netherlands; Univ Twente, Fac Chem Technol, NL-7500 AE Enschede, Netherlands	University of Twente; University of Twente	Reinhoudt, DN (corresponding author), Univ Twente, MESA Res Inst, Lab Supramol Chem & Technol, POB 217, NL-7500 AE Enschede, Netherlands.	d.n.reinhoudt@ct.utwente.nl	Reinhoudt, David N/K-4767-2012					Balzani V, 2000, ANGEW CHEM INT EDIT, V39, P3348, DOI 10.1002/1521-3773(20001002)39:19<3348::AID-ANIE3348>3.0.CO;2-X; Bielejewska AG, 2001, J AM CHEM SOC, V123, P7518, DOI 10.1021/ja010664o; Bosman AW, 1999, CHEM REV, V99, P1665, DOI 10.1021/cr970069y; Buschmann H, 2000, ANGEW CHEM INT EDIT, V39, P4033, DOI 10.1002/1521-3773(20001117)39:22<4033::AID-ANIE4033>3.0.CO;2-2; Castelli VV, 2000, CHEM-EUR J, V6, P1193, DOI 10.1002/(SICI)1521-3765(20000403)6:7<1193::AID-CHEM1193>3.3.CO;2-6; Collier CP, 1999, SCIENCE, V285, P391, DOI 10.1126/science.285.5426.391; Cousins GRL, 2001, ANGEW CHEM INT EDIT, V40, P423, DOI 10.1002/1521-3773(20010119)40:2<423::AID-ANIE423>3.0.CO;2-6; CRAM DJ, 1988, ANGEW CHEM INT EDIT, V27, P1009, DOI 10.1002/anie.198810093; CREGOCALAMA M, 2000, ANGEW CHEM INT EDIT, V39, P755; Diederich F., 2000, TEMPLATED ORGANIC SY; Fernandez-Lopez S, 2001, NATURE, V412, P452, DOI 10.1038/35086601; Friggeri A, 2001, J AM CHEM SOC, V123, P6388, DOI 10.1021/ja010257c; Hamuro Y, 1997, ANGEW CHEM INT EDIT, V36, P2680, DOI 10.1002/anie.199726801; Huc I, 1999, EUR J INORG CHEM, P1415; Jimenez MC, 2000, ANGEW CHEM INT EDIT, V39, P3284, DOI 10.1002/1521-3773(20000915)39:18<3284::AID-ANIE3284>3.0.CO;2-7; Lavigne JJ, 2001, ANGEW CHEM INT EDIT, V40, P3118, DOI 10.1002/1521-3773(20010903)40:17<3118::AID-ANIE3118>3.0.CO;2-Y; Lehn J.-M., 1995, SUPRAMOLECULAR CHEM; LEHN JM, 1988, ANGEW CHEM INT EDIT, V27, P89, DOI 10.1002/anie.198800891; Ludwig R, 2000, FRESEN J ANAL CHEM, V367, P103, DOI 10.1007/s002160051611; Luther A, 1998, NATURE, V396, P245, DOI 10.1038/24343; Mammen M, 1998, ANGEW CHEM INT EDIT, V37, P2755; Marty M, 1998, CHEM COMMUN, P2265, DOI 10.1039/a806070c; NICOLAOU KC, 1995, ANGEW CHEM INT EDIT, V34, P2079, DOI 10.1002/anie.199520791; Paraschiv V, 2001, J ORG CHEM, V66, P8297, DOI 10.1021/Jo0105742; PEDERSEN CJ, 1988, ANGEW CHEM INT EDIT, V27, P1021, DOI 10.1002/anie.198810211; Prins LJ, 1999, NATURE, V398, P498, DOI 10.1038/19053; Prins LJ, 2000, NATURE, V408, P181, DOI 10.1038/35041530; Prins LJ, 2001, J AM CHEM SOC, V123, P10153, DOI 10.1021/ja010610e; Ramstrom O, 2002, NAT REV DRUG DISCOV, V1, P26, DOI 10.1038/nrd704; Rivera JM, 1998, SCIENCE, V279, P1021, DOI 10.1126/science.279.5353.1021; Saghatelian A, 2001, NATURE, V409, P797, DOI 10.1038/35057238; Schenning APHJ, 1998, CHEM-EUR J, V4, P871, DOI 10.1002/(SICI)1521-3765(19980515)4:5<871::AID-CHEM871>3.0.CO;2-3; Ungaro R, 1996, PURE APPL CHEM, V68, P1213, DOI 10.1351/pac199668061213; Wallimann P, 1997, CHEM REV, V97, P1567, DOI 10.1021/cr960373b; WHITESIDES GM, 1995, ACCOUNTS CHEM RES, V28, P37, DOI 10.1021/ar00049a006; Zimmerman SC, 1996, SCIENCE, V271, P1095, DOI 10.1126/science.271.5252.1095	36	403	407	3	79	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 29	2002	295	5564					2403	2407		10.1126/science.1069197	http://dx.doi.org/10.1126/science.1069197			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	536QD	11923525				2022-12-28	WOS:000174712600041
J	Santoro, GE; Martonak, R; Tosatti, E; Car, R				Santoro, GE; Martonak, R; Tosatti, E; Car, R			Theory of quantum annealing of an Ising spin glass	SCIENCE			English	Article							COOLING-RATE DEPENDENCE; GROUND-STATE ENERGY; SYSTEMS; OPTIMIZATION; TRANSITION; ALGORITHM; PHASE; MODEL	Probing the lowest energy configuration of a complex system by quantum annealing was recently found to be more effective than its classical, thermal counterpart. By comparing classical and quantum Monte Carlo annealing protocols on the two-dimensional random Ising model (a prototype spin glass), we confirm the superiority of quantum annealing relative to classical annealing. We also propose a theory of quantum annealing based on a cascade of Landau-Zener tunneling events. For both classical and quantum annealing, the residual energy after annealing is inversely proportional to a power of the logarithm of the annealing time, but the quantum case has a larger power that makes it faster.	Scuola Int Super Studi Avanzati, I-34014 Trieste, Italy; Ist Nazl Fis Mat, Unita Ric SISSA, I-34014 Trieste, Italy; Swiss Ctr Sci Comp, CH-6928 Manno, Switzerland; Swiss Fed Inst Technol, Dept Phys Chem, CH-8093 Zurich, Switzerland; Slovak Univ Technol Bratislava, Dept Phys, FEI, Bratislava 81219, Slovakia; Int Ctr Theoret Phys, I-34100 Trieste, Italy; Princeton Univ, Dept Chem, Princeton, NJ 08544 USA; Princeton Univ, Princeton Mat Inst, Princeton, NJ 08544 USA	International School for Advanced Studies (SISSA); Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); International School for Advanced Studies (SISSA); University of Padua; Swiss Federal Institutes of Technology Domain; ETH Zurich; Slovak University of Technology Bratislava; Abdus Salam International Centre for Theoretical Physics (ICTP); Princeton University; Princeton University	Tosatti, E (corresponding author), Scuola Int Super Studi Avanzati, I-34014 Trieste, Italy.	tosatti@sissa.it	Santoro, Giuseppe Ernesto/H-2306-2012; Martoňák, Roman/T-5223-2018	Santoro, Giuseppe Ernesto/0000-0001-6854-4512; Martoňák, Roman/0000-0002-4013-9117				BARAHONA F, 1982, J PHYS A-MATH GEN, V15, P3241, DOI 10.1088/0305-4470/15/10/028; Brooke J, 1999, SCIENCE, V284, P779, DOI 10.1126/science.284.5415.779; CERNY V, 1985, J OPTIMIZ THEORY APP, V45, P41, DOI 10.1007/BF00940812; CHAKRABARTI A, 1989, PHYS REV B, V39, P542, DOI 10.1103/PhysRevB.39.542; Farhi E, 2001, SCIENCE, V292, P472, DOI 10.1126/science.1057726; FINNILA AB, 1994, CHEM PHYS LETT, V219, P343, DOI 10.1016/0009-2614(94)00117-0; FISHER DS, 1986, PHYS REV LETT, V56, P1601, DOI 10.1103/PhysRevLett.56.1601; GREST GS, 1986, PHYS REV LETT, V56, P1148, DOI 10.1103/PhysRevLett.56.1148; HUSE DA, 1986, PHYS REV LETT, V57, P2203, DOI 10.1103/PhysRevLett.57.2203; Kadowaki T, 1998, PHYS REV E, V58, P5355, DOI 10.1103/PhysRevE.58.5355; KIRKPATRICK S, 1983, SCIENCE, V220, P671, DOI 10.1126/science.220.4598.671; Landau L. D., 1977, QUANTUM MECH NONRELA; Lee YH, 2000, J PHYS CHEM A, V104, P86, DOI 10.1021/jp991868i; Lee YH, 2001, J PHYS CHEM A, V105, P459, DOI 10.1021/jp002589u; LIEB E, 1962, J MATH PHYS, V3, P749, DOI 10.1063/1.1724276; OcampoAlfaro P, 1996, PHYS REV E, V53, P1982, DOI 10.1103/PhysRevE.53.1982; RIEGER H, 1994, PHYS REV LETT, V72, P4141, DOI 10.1103/PhysRevLett.72.4141; SUZUKI M, 1976, PROG THEOR PHYS, V56, P1454, DOI 10.1143/PTP.56.1454; THILL MJ, 1995, PHYSICA A, V214, P321, DOI 10.1016/0378-4371(94)00247-Q; WU WH, 1993, PHYS REV LETT, V71, P1919, DOI 10.1103/PhysRevLett.71.1919	21	413	422	1	51	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 29	2002	295	5564					2427	2430		10.1126/science.1068774	http://dx.doi.org/10.1126/science.1068774			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	536QD	11923532	Green Submitted			2022-12-28	WOS:000174712600048
J	Herrington, DM; Howard, TD; Hawkins, GA; Reboussin, DM; Xu, JF; Zheng, SL; Brosnihan, KB; Meyers, DA; Bleecker, ER				Herrington, DM; Howard, TD; Hawkins, GA; Reboussin, DM; Xu, JF; Zheng, SL; Brosnihan, KB; Meyers, DA; Bleecker, ER			Estrogen-receptor polymorphisms and effects of estrogen replacement on high-density lipoprotein cholesterol in women with coronary disease.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BONE-MINERAL DENSITY; DINUCLEOTIDE REPEAT POLYMORPHISM; POSTMENOPAUSAL CAUCASIAN WOMEN; FRAGMENT-LENGTH-POLYMORPHISM; BREAST-CANCER SUSCEPTIBILITY; ATHEROSCLEROSIS-REGRESSION; ENZYMATIC DETERMINATION; SPONTANEOUS-ABORTION; CONTROLLED-TRIAL; ARTERY DISEASE	Background: Sequence variants in the gene encoding estrogen receptor alpha (ER-alpha) may modify the effects of hormone-replacement therapy on levels of high-density lipoprotein (HDL) cholesterol and other outcomes related to estrogen treatment in postmenopausal women. Methods: We characterized 309 women with coronary artery disease who were enrolled in the Estrogen Replacement and Atherosclerosis trial with respect to eight previously described and two newly identified ER-alpha polymorphisms, and we examined the association between these polymorphisms and the response of HDL cholesterol and other lipids to treatment with estrogen alone or estrogen plus progestin. Results: After adjustment for age, race, diabetes status, body-mass index, smoking status, alcohol intake, and frequency of exercise, the 18.9 percent of the women who had the IVS1-401 C/C genotype (i.e., with C on both chromosomes in intervening sequence 1 at position 401 before exon 2) had an increase in the HDL cholesterol level with hormone-replacement therapy that was more than twice the increase observed in the other women (13.1 mg per deciliter vs. 6.0 mg per deciliter, P for treatment-by-genotype interaction = 0.004); this effect was limited to changes in the HDL subfraction 3 (HDL3) (P for interaction = 0.04). Similar patterns of response were observed for three other highly linked ER-alpha intron 1 polymorphisms close to the IVS1-401 site (range of P values for interaction = 0.07 to 0.005). The pattern of increased response of HDL cholesterol in women with the IVS1-401 C/C genotype was evident in both the women receiving estrogen and those receiving estrogen plus progestin, was preserved across racial and ethnic groups, and was significant among women who were compliant with the study medication (P<0.001). Conclusions: Postmenopausal women with coronary disease who have the ER-alpha IVS1-401 C/C genotype, or several other closely related genotypes, have an augmented response of HDL cholesterol to hormone-replacement therapy. (N Engl J Med 2002;346:967-74.) Copyright (C) 2002 Massachusetts Medical Society.	Wake Forest Univ, Bowman Gray Sch Med, Dept Internal Med, Winston Salem, NC 27157 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Pediat, Winston Salem, NC 27157 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Publ Hlth Sci, Winston Salem, NC 27157 USA; Wake Forest Univ, Bowman Gray Sch Med, Hypertens & Vasc Dis Ctr, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center	Herrington, DM (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Internal Med, Med Ctr Blvd, Winston Salem, NC 27157 USA.				NCRR NIH HHS [M01 RR 07122] Funding Source: Medline; NHLBI NIH HHS [HL46488] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR007122] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL046488] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLAIN CC, 1974, CLIN CHEM, V20, P470; ANDERSEN TI, 1994, HUM GENET, V94, P665; ARMANINI D, 1985, NEW ENGL J MED, V313, P1178, DOI 10.1056/NEJM198511073131902; Austin MA, 1998, AM J HUM GENET, V62, P406, DOI 10.1086/301712; BERKOWITZ GS, 1994, AM J OBSTET GYNECOL, V171, P1579, DOI 10.1016/0002-9378(94)90405-7; Brinton EA, 1996, ARTERIOSCL THROM VAS, V16, P431, DOI 10.1161/01.ATV.16.3.431; BURSTEIN M, 1960, CLIN CHIM ACTA, V5, P609, DOI 10.1016/0009-8981(60)90075-9; CASTAGNOLI A, 1987, NUCLEIC ACIDS RES, V15, P866, DOI 10.1093/nar/15.2.866; Del Senno L., 1992, Human Molecular Genetics, V1, P354; Deng HW, 1998, HUM GENET, V103, P576, DOI 10.1007/s004390050872; Deng HW, 2000, J CLIN ENDOCR METAB, V85, P2748, DOI 10.1210/jc.85.8.2748; FOSSATI P, 1982, CLIN CHEM, V28, P2077; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GEHRING U, 1974, CELL, V3, P301, DOI 10.1016/0092-8674(74)90145-7; GERHARD M, 1995, CIRCULATION, V92, P5, DOI 10.1161/01.CIR.92.1.5; GIDEZ LI, 1982, J LIPID RES, V23, P1206; GORDON DJ, 1989, CIRCULATION, V79, P8, DOI 10.1161/01.CIR.79.1.8; Gotoda T, 1997, ARTERIOSCL THROM VAS, V17, P1376, DOI 10.1161/01.ATV.17.7.1376; GRIFFIN JE, 1980, NEW ENGL J MED, V302, P198, DOI 10.1056/NEJM198001243020404; Han K, 1999, OSTEOPOROSIS INT, V9, P290, DOI 10.1007/s001980050150; Han KO, 1997, J CLIN ENDOCR METAB, V82, P991, DOI 10.1210/jc.82.4.991; Hedges YK, 1999, CIRCULATION, V99, P2688, DOI 10.1161/01.CIR.99.20.2688; Herrington DM, 2000, NEW ENGL J MED, V343, P522, DOI 10.1056/NEJM200008243430801; Herrington DM, 2000, CONTROL CLIN TRIALS, V21, P257, DOI 10.1016/S0197-2456(00)00054-4; Herrington DM, 2000, CONTROL CLIN TRIALS, V21, P414; HILL SM, 1989, CANCER RES, V49, P145; Hoshino S, 2000, J BONE MINER METAB, V18, P153, DOI 10.1007/s007740050106; Jeng MH, 1998, ENDOCRINOLOGY, V139, P4164, DOI 10.1210/en.139.10.4164; Kassi EN, 2001, EUR J CLIN INVEST, V31, P86, DOI 10.1046/j.1365-2362.2001.00762.x; Kikuchi T, 2000, ACTA PAEDIATR, V89, P42, DOI 10.1080/080352500750029040; KINNUNEN PKJ, 1984, METHOD ENZYMAT AN, V4, P34; Kobayashi S, 1996, J BONE MINER RES, V11, P306; LEHRER S, 1990, LANCET, V335, P622, DOI 10.1016/0140-6736(90)90410-7; LEHRER S, 1993, HYPERTENSION, V21, P439, DOI 10.1161/01.HYP.21.4.439; *LIP CLIN RES PROG, 1982, MAN CLIN OP, V1; Mack WJ, 1996, ARTERIOSCL THROM VAS, V16, P697, DOI 10.1161/01.ATV.16.5.697; MAHANEY MC, 1995, ARTERIOSCL THROM VAS, V15, P1730, DOI 10.1161/01.ATV.15.10.1730; Matsubara Y, 1997, ARTERIOSCL THROM VAS, V17, P3006, DOI 10.1161/01.ATV.17.11.3006; O'Neil JP, 1998, MUTAT RES-REV MUTAT, V411, P179, DOI 10.1016/S1383-5742(98)00013-1; Ongphiphadhanakul B, 2000, CLIN ENDOCRINOL, V52, P581, DOI 10.1046/j.1365-2265.2000.00979.x; PARL FF, 1989, BREAST CANCER RES TR, V14, P57, DOI 10.1007/BF01805976; PIKE JW, 1984, SCIENCE, V224, P879, DOI 10.1126/science.6326262; PONGLIKITMONGKOL M, 1988, EMBO J, V7, P3385, DOI 10.1002/j.1460-2075.1988.tb03211.x; Robins SJ, 2001, JAMA-J AM MED ASSOC, V285, P1585, DOI 10.1001/jama.285.12.1585; ROESCHLA.P, 1974, Z KLIN CHEM KLIN BIO, V12, P226; SANO M, 1995, BIOCHEM BIOPH RES CO, V217, P378, DOI 10.1006/bbrc.1995.2787; SCHACHTER BS, 1994, AM J EPIDEMIOL, V140, P1144, DOI 10.1093/oxfordjournals.aje.a117216; Schubert EL, 1999, J STEROID BIOCHEM, V71, P21, DOI 10.1016/S0960-0760(99)00126-0; Scohy S, 2000, NUCLEIC ACIDS RES, V28, P3743, DOI 10.1093/nar/28.19.3743; SMITH EP, 1995, NEW ENGL J MED, V332, P131; Sudhir K, 1997, CIRCULATION, V96, P3774; SULLIVAN JM, 1988, ANN INTERN MED, V108, P358, DOI 10.7326/0003-4819-108-3-358; Syvanne M, 1998, CIRCULATION, V98, P1993, DOI 10.1161/01.CIR.98.19.1993; Trinder P., 1969, ANN CLIN BIOCHEM, V6, P24, DOI [10.1177/000456326900600108, DOI 10.1177/000456326900600108]; WATTS GF, 1993, METABOLISM, V42, P1461, DOI 10.1016/0026-0495(93)90199-X; Weir B.S., 1996, GENETIC DATA ANAL; YAICH L, 1992, CANCER RES, V52, P77	58	293	303	0	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 28	2002	346	13					967	974		10.1056/NEJMoa012952	http://dx.doi.org/10.1056/NEJMoa012952			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	534UY	11919305	Bronze			2022-12-28	WOS:000174608600003
J	Lange, RA; Hillis, LD				Lange, RA; Hillis, LD			Perspective: Reperfusion therapy in acute myocardial infarction.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Texas, SW Med Ctr, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Lange, RA (corresponding author), Univ Texas, SW Med Ctr, Dallas, TX 75390 USA.		Lange, Richard/AAM-9594-2021						0	28	32	0	5	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 28	2002	346	13					954	955		10.1056/NEJM200203283461302	http://dx.doi.org/10.1056/NEJM200203283461302			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	534UY	11919303				2022-12-28	WOS:000174608600001
J	Martinez, F; Taylor, B				Martinez, F; Taylor, B			Mantle wedge control on back-arc crustal accretion	NATURE			English	Article							VALU-FA-RIDGE; SOUTHERN LAU BASIN; MELT EXTRACTION; SPREADING RIDGE; MARIANA TROUGH; LITHOSPHERE; PETROGENESIS; EVOLUTION; PACIFIC; WATER	At mid-ocean ridges, plate separation leads to upward advection and pressure-release partial melting of fertile mantle material; the melt is then extracted to the spreading centre and the residual depleted mantle flows horizontally away(1). In back-arc basins, the subducting slab is an important control on the pattern of mantle advection and melt extraction, as well as on compositional and fluid gradients(2). Modelling studies(3) predict significant mantle wedge effects on back-arc spreading processes. Here we show that various spreading centres in the Lau back-arc basin exhibit enhanced, diminished or normal magma supply, which correlates with distance from the arc volcanic front but not with spreading rate. To explain this correlation we propose that depleted upper-mantle material, generated by melt extraction in the mantle wedge, is overturned and re-introduced beneath the back-arc basin by subduction-induced corner flow. The spreading centres experience enhanced melt delivery near the volcanic front, diminished melting within the overturned depleted mantle farther from the corner and normal melting conditions in undepleted mantle farther away. Our model explains fundamental differences in crustal accretion variables between back-arc and mid-ocean settings.	Univ Hawaii Manoa, Hawaii Inst Geophys & Planetol, Honolulu, HI 96822 USA; Univ Hawaii Manoa, Sch Ocean & Earth Sci & Technol, Dept Geol & Geophys, Honolulu, HI 96822 USA	University of Hawaii System; University of Hawaii Manoa; University of Hawaii System; University of Hawaii Manoa	Martinez, F (corresponding author), Univ Hawaii Manoa, Hawaii Inst Geophys & Planetol, Honolulu, HI 96822 USA.							BORTNIKOV NS, 1993, GEOL ORE DEPOSIT+, V35, P476; CHIU JM, 1991, GEOPHYS J INT, V106, P99, DOI 10.1111/j.1365-246X.1991.tb04604.x; CRAWFORD WC, IN PRESS J GEOPHYS R; DAVIES JH, 1992, J GEOPHYS RES-SOL EA, V97, P2037, DOI 10.1029/91JB02571; FOUQUET Y, 1991, NATURE, V349, P778, DOI 10.1038/349778a0; HARDING AJ, 2000, EOS T AGU, V81, pF1115; Hawkins J.W., 1995, BACKARC BASINS, P63; Hergt JM, 1994, P OCEAN DRILLING PRO, P505, DOI DOI 10.2973/0DP.PR0C.SR.135.142.1994; Hirth G, 1996, EARTH PLANET SC LETT, V144, P93, DOI 10.1016/0012-821X(96)00154-9; Hochstaedter AG, 1996, J GEOPHYS RES-SOL EA, V101, P697, DOI 10.1029/95JB02404; Hochstaedter AG, 2000, J GEOPHYS RES-SOL EA, V105, P495, DOI 10.1029/1999JB900125; JENNER GA, 1987, J VOLCANOL GEOTH RES, V32, P209, DOI 10.1016/0377-0273(87)90045-X; KAPPEL ES, 1986, J GEOPHYS RES-SOLID, V91, P13925, DOI 10.1029/JB091iB14p13925; Langmuir C. H., 1992, MANTLE FLOW MELT GEN; MARTINEZ F, 1995, J GEOPHYS RES-SOL EA, V100, P3807, DOI 10.1029/94JB02466; Martinez F, 2000, J GEOPHYS RES-SOL EA, V105, P16591, DOI 10.1029/2000JB900117; Morgan JP, 1997, EARTH PLANET SC LETT, V146, P213, DOI 10.1016/S0012-821X(96)00207-5; PEARCE JA, 1995, VOLCANISM ASS EXTENS, P53; RIBE NM, 1989, GEOPHYS J INT, V98, P85, DOI 10.1111/j.1365-246X.1989.tb05515.x; SCHEIRER DS, 1993, J GEOPHYS RES-SOL EA, V98, P7871, DOI 10.1029/93JB00015; SINHA MC, 1995, J GEOPHYS RES-SOL EA, V100, P15025, DOI 10.1029/95JB01293; SPIEGELMAN M, 1987, EARTH PLANET SC LETT, V83, P137, DOI 10.1016/0012-821X(87)90057-4; STOLPER E, 1994, EARTH PLANET SC LETT, V121, P293, DOI 10.1016/0012-821X(94)90074-4; Taylor B, 1996, EARTH PLANET SC LETT, V144, P35, DOI 10.1016/0012-821X(96)00148-3; Turner IM, 1999, GEOPHYS J INT, V138, P495, DOI 10.1046/j.1365-246X.1999.00883.x; VALLIER TL, 1991, CHEM GEOL, V91, P227, DOI 10.1016/0009-2541(91)90002-9; WIEDICKE M, 1993, J GEOPHYS RES-SOL EA, V98, P11769, DOI 10.1029/93JB00708; WOODHEAD J, 1993, EARTH PLANET SC LETT, V114, P491, DOI 10.1016/0012-821X(93)90078-N; Wright IC, 1996, J GEOPHYS RES-SOL EA, V101, P22071, DOI 10.1029/96JB01761; Zellmer KE, 2001, GEOCHEM GEOPHY GEOSY, V2	30	127	127	1	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 28	2002	416	6879					417	420		10.1038/416417a	http://dx.doi.org/10.1038/416417a			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	534UX	11919628				2022-12-28	WOS:000174607800043
J	Reeves, EP; Lu, H; Lortat-Jacob, H; Messina, CGM; Bolsover, S; Gabella, G; Potma, EO; Warley, A; Roes, J; Segal, AW				Reeves, EP; Lu, H; Lortat-Jacob, H; Messina, CGM; Bolsover, S; Gabella, G; Potma, EO; Warley, A; Roes, J; Segal, AW			Killing activity of neutrophils is mediated through activation of proteases by K+ flux	NATURE			English	Article							BIOLOGICAL DEFENSE-MECHANISMS; CHRONIC GRANULOMATOUS-DISEASE; NADPH OXIDASE; POLYMORPHONUCLEAR LEUKOCYTES; RESPIRATORY BURST; HYDROGEN-PEROXIDE; HOST-DEFENSE; CATHEPSIN-G; MYELOPEROXIDASE; SUPEROXIDE	According to the hitherto accepted view, neutrophils kill ingested microorganisms by subjecting them to high concentrations of highly toxic reactive oxygen species (ROS) and bringing about myeloperoxidase-catalysed halogenation. We show here that this simple scheme, which for many years has served as a satisfactory working hypothesis, is inadequate. We find that mice made deficient in neutrophil-granule proteases but normal in respect of superoxide production and iodinating capacity, are unable to resist staphylococcal and candidal infections. We also show that activation provokes the influx of an enormous concentration of ROS into the endocytic vacuole. The resulting accumulation of anionic charge is compensated for by a surge of K+ ions that cross the membrane in a pH-dependent manner. The consequent rise in ionic strength engenders the release of cationic granule proteins, including elastase and cathepsin G, from the anionic sulphated proteoglycan matrix. We show that it is the proteases, thus activated, that are primarily responsible for the destruction of the bacteria.	UCL, Ctr Mol Med, Dept Physiol, London WC1E 6JJ, England; UCL, Ctr Mol Med, Dept Anat, London WC1E 6JJ, England; UCL, Windeyer Inst Med Sci, London WC1E 6JJ, England; Inst Biol Struct, F-38027 Grenoble, France; Univ Groningen, Ctr Mat Sci, Ultrafast Laser & Spect Lab, NL-9747 AG Groningen, Netherlands; St Thomas Hosp, Rayne Inst, London SE1 7EH, England	University of London; University College London; University of London; University College London; University of London; University College London; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); University of Groningen; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Segal, AW (corresponding author), UCL, Ctr Mol Med, Dept Physiol, 5 Univ St, London WC1E 6JJ, England.	rmhaase@ucl.ac.uk	Reeves, Emer/C-6026-2012; Messina, Carlo/CAG-9260-2022; Lu, Hui/AAB-5476-2021	Lu, Hui/0000-0002-7029-2681; Segal, Anthony/0000-0001-7602-9043; Roes, Jurgen/0000-0003-3235-2345				Aderem A, 1999, ANNU REV IMMUNOL, V17, P593, DOI 10.1146/annurev.immunol.17.1.593; Amos BJ, 1996, EXP PHYSIOL, V81, P623, DOI 10.1113/expphysiol.1996.sp003963; Aratani Y, 1999, INFECT IMMUN, V67, P1828; BABIOR BM, 1973, J CLIN INVEST, V52, P741, DOI 10.1172/JCI107236; BABIOR BM, 1975, J LAB CLIN MED, V85, P235; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P561; Belaaouaj A, 1998, NAT MED, V4, P615, DOI 10.1038/nm0598-615; Brennan ML, 2001, J CLIN INVEST, V107, P419, DOI 10.1172/JCI8797; BUGHANIM HN, 1995, BLOOD, V86, P3575, DOI 10.1182/blood.V86.9.3575.bloodjournal8693575; Clapp LH, 1998, CURR OPIN NEPHROL HY, V7, P91; CROSS AR, 1986, BIOCHEM J, V237, P111, DOI 10.1042/bj2370111; DeCoursey TE, 2000, P NATL ACAD SCI USA, V97, P6885, DOI 10.1073/pnas.100047297; DeCoursey TE, 2001, J BIOL CHEM, V276, P36063, DOI 10.1074/jbc.C100352200; Grogan A, 1997, J CELL SCI, V110, P3071; Guerin I, 2000, INFECT IMMUN, V68, P2655, DOI 10.1128/IAI.68.5.2655-2662.2000; Hall T.A., 1986, PRINCIPLES ANAL ELEC, P219; Hampton MB, 1998, BLOOD, V92, P3007, DOI 10.1182/blood.V92.9.3007.421k47_3007_3017; Hampton MB, 1996, INFECT IMMUN, V64, P3512, DOI 10.1128/IAI.64.9.3512-3517.1996; Henderson LM, 1999, J GEN PHYSIOL, V114, P771, DOI 10.1085/jgp.114.6.771; HENDERSON LM, 1987, BIOCHEM J, V246, P325, DOI 10.1042/bj2460325; INCE C, 1987, BIOCHIM BIOPHYS ACTA, V905, P195, DOI 10.1016/0005-2736(87)90023-X; Jiang Q, 1997, CHEM RES TOXICOL, V10, P1080, DOI 10.1021/tx9700984; Kettle AJ, 2001, BIOCHEMISTRY-US, V40, P10204, DOI 10.1021/bi010940b; KLEBANOFF SJ, 1975, SEMIN HEMATOL, V12, P117; KLEBANOFF SJ, 1977, J LAB CLIN MED, V89, P675; KLEBANOFF SJ, 1971, J CLIN INVEST, V50, P2226, DOI 10.1172/JCI106718; KOLSET SO, 1990, BIOCHIM BIOPHYS ACTA, V1032, P191, DOI 10.1016/0304-419X(90)90004-K; LOVE WD, 1953, J LAB CLIN MED, V41, P351; MANDELL GL, 1974, INFECT IMMUN, V9, P337, DOI 10.1128/IAI.9.2.337-341.1974; Maturana A, 2001, J BIOL CHEM, V276, P30277, DOI 10.1074/jbc.M010438200; McCord JM, 1979, OXYGEN FREE RADICALS, P343; Menegazzi R, 1996, J CELL BIOL, V135, P511, DOI 10.1083/jcb.135.2.511; METCHNIKOFF B, 2002, IMMUNITY INFECT DIS; NANDA A, 1994, J BIOL CHEM, V269, P27280; NANDA A, 1991, P NATL ACAD SCI USA, V88, P10816, DOI 10.1073/pnas.88.23.10816; ODEBERG H, 1975, J CLIN INVEST, V56, P1118, DOI 10.1172/JCI108186; OLSEN RL, 1983, BIOCHEM J, V209, P781, DOI 10.1042/bj2090781; Potma EO, 2001, P NATL ACAD SCI USA, V98, P1577, DOI 10.1073/pnas.031575698; Rizoli SB, 2000, AM J PHYSIOL-CELL PH, V279, pC619, DOI 10.1152/ajpcell.2000.279.3.C619; Sadir R, 2001, J BIOL CHEM, V276, P8288, DOI 10.1074/jbc.M008110200; SBARRA AJ, 1959, J BIOL CHEM, V234, P1355; SEGAL AW, 1979, FEBS LETT, V100, P27, DOI 10.1016/0014-5793(79)81124-2; SEGAL AW, 1978, BIOCHEM BIOPH RES CO, V84, P611, DOI 10.1016/0006-291X(78)90749-0; SEGAL AW, 1981, NATURE, V290, P406, DOI 10.1038/290406a0; STYRT B, 1982, FEBS LETT, V149, P113, DOI 10.1016/0014-5793(82)81083-1; THRASHER AJ, 1994, BBA-MOL BASIS DIS, V1227, P1, DOI 10.1016/0925-4439(94)90100-7; Tkalcevic J, 2000, IMMUNITY, V12, P201, DOI 10.1016/S1074-7613(00)80173-9; Vita Francesca, 1997, Methods in Cell Science, V19, P197, DOI 10.1023/A:1009711726462; WINTERBOURN CC, 1985, BIOCHEM J, V228, P583, DOI 10.1042/bj2280583	49	854	880	2	63	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 21	2002	416	6878					291	297		10.1038/416291a	http://dx.doi.org/10.1038/416291a			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	532NP	11907569				2022-12-28	WOS:000174482200034
J	Gelmon, KA; Olivotto, I				Gelmon, KA; Olivotto, I			The mammography screening debate: time to move on	LANCET			English	Editorial Material							BREAST-CANCER; PROGRAMS; TRIALS; RATES; WOMEN; UK		British Columbia Canc Agcy, Vancouver Canc Ctr, Vancouver, BC V5Z 4E6, Canada; BC Canc Agcy, Vancouver Isl Ctr, Victoria, BC, Canada	British Columbia Cancer Agency; British Columbia Cancer Agency	Gelmon, KA (corresponding author), British Columbia Canc Agcy, Vancouver Canc Ctr, Vancouver, BC V5Z 4E6, Canada.	kgelmon@bccancer.bc.ca						Baltic S, 2001, J NATL CANCER I, V93, P1678, DOI 10.1093/jnci/93.22.1678; BAUM M, 1995, LANCET, V346, P436, DOI 10.1016/S0140-6736(95)92808-1; Black WC, 2002, JNCI-J NATL CANCER I, V94, P167, DOI 10.1093/jnci/94.3.167; Brown P, 2000, BRIT MED J, V321, P849, DOI 10.1136/bmj.321.7265.849; Chu KC, 1996, JNCI-J NATL CANCER I, V88, P1571, DOI 10.1093/jnci/88.21.1571; de Koning HJ, 2000, LANCET, V355, P80, DOI 10.1016/S0140-6736(99)00419-5; Elmore G, 1998, NEW ENGL J MED, V338, P1089, DOI 10.1056/NEJM199804163381601; ERNSTER VL, 1997, NATL CANC I MONOGR, V22, P151; Gotzsche PC, 2000, LANCET, V355, P129, DOI 10.1016/S0140-6736(99)06065-1; HENDRICK RE, 1997, NATL CANCER I MONOGR, V22, P87; Horton R, 2001, LANCET, V358, P1284, DOI 10.1016/S0140-6736(01)06452-2; Juffs HG, 2002, J NATL CANCER I, V94, P156; Kerlikowske K, 2000, WESTERN J MED, V173, P313, DOI 10.1136/ewjm.173.5.313; Kerlikowske K, 1997, J Natl Cancer Inst Monogr, P79; KERLIKOWSKE K, 1995, JAMA-J AM MED ASSOC, V273, P149, DOI 10.1001/jama.273.2.149; MILLER AB, 2000, JNCI-J NATL CANCER I, V92, P1400; NYSTROM L, 1993, LANCET, V341, P973, DOI 10.1016/0140-6736(93)91067-V; Olsen O, 2001, LANCET, V358, P1340, DOI 10.1016/S0140-6736(01)06449-2; Peto R, 2000, LANCET, V355, P1822, DOI 10.1016/S0140-6736(00)02277-7; Shapiro S, 1998, INT J EPIDEMIOL, V27, P735, DOI 10.1093/ije/27.5.735; SMART CR, 1995, CANCER, V75, P1619, DOI 10.1002/1097-0142(19950401)75:7<1619::AID-CNCR2820750711>3.0.CO;2-T; Taubes G, 1997, SCIENCE, V275, P1056, DOI 10.1126/science.275.5303.1056; WRIGHT CJ, 1995, LANCET, V346, P29, DOI 10.1016/S0140-6736(95)92655-0	23	17	19	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 16	2002	359	9310					904	905		10.1016/S0140-6736(02)08012-1	http://dx.doi.org/10.1016/S0140-6736(02)08012-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	531AE	11918902				2022-12-28	WOS:000174391700002
J	Dever, TE				Dever, TE			Gene-specific regulation by general translation factors	CELL			English	Review							EUKARYOTIC INITIATION-FACTORS; CAP-DEPENDENT TRANSLATION; FACTOR 2-ALPHA KINASE; C-TERMINAL DOMAIN; MESSENGER-RNA; PROTEIN-SYNTHESIS; FACTOR EIF2B; RIBOSOME BINDING; ALPHA-SUBUNIT; CELL-SURVIVAL	Protein synthesis is the ultimate step of gene expression and a key control point for regulation. In particular, it enables cells to rapidly manipulate protein production without new mRNA synthesis, processing, or export. Recent studies have enhanced our understanding of the translation initiation process and helped elucidate how modifications of the general translational machinery regulate gene-specific protein production.	NICHHD, Lab Gene Regulat & Dev, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Dever, TE (corresponding author), NICHHD, Lab Gene Regulat & Dev, NIH, Bethesda, MD 20892 USA.	tdever@box-t.nih.gov	Dever, Thomas/GSE-0966-2022	Dever, Thomas/0000-0001-7120-9678	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001010] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001010] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Ali IK, 2001, EMBO J, V20, P4233, DOI 10.1093/emboj/20.15.4233; Anthony C, 2001, J BIOL CHEM, V276, P39645, DOI 10.1074/jbc.M101564200; Asano K, 2000, GENE DEV, V14, P2534, DOI 10.1101/gad.831800; Asano K, 2001, EMBO J, V20, P2326, DOI 10.1093/emboj/20.9.2326; Balachandran S, 2000, IMMUNITY, V13, P129, DOI 10.1016/S1074-7613(00)00014-5; Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; BIOU V, 1995, EMBO J, V14, P4056, DOI 10.1002/j.1460-2075.1995.tb00077.x; Brewer JW, 2000, P NATL ACAD SCI USA, V97, P12625, DOI 10.1073/pnas.220247197; Browning KS, 2001, TRENDS BIOCHEM SCI, V26, P284, DOI 10.1016/S0968-0004(01)01825-4; Calkhoven CF, 2000, GENE DEV, V14, P1920; Chen JJ, 2000, COLD SPRING HARBOR M, V39, P529; Choi SK, 2000, MOL CELL BIOL, V20, P7183, DOI 10.1128/MCB.20.19.7183-7191.2000; Croniger C, 1998, J BIOL CHEM, V273, P31629, DOI 10.1074/jbc.273.48.31629; Cuesta R, 2000, GENE DEV, V14, P1460; De Gregorio E, 1999, EMBO J, V18, P4865, DOI 10.1093/emboj/18.17.4865; Delepine M, 2000, NAT GENET, V25, P406, DOI 10.1038/78085; Dever TE, 1999, TRENDS BIOCHEM SCI, V24, P398, DOI 10.1016/S0968-0004(99)01457-7; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; Donahue TF, 2000, COLD SPRING HARBOR M, V39, P487; Dong JS, 2000, MOL CELL, V6, P269, DOI 10.1016/S1097-2765(00)00028-9; Erickson FL, 2001, GENETICS, V158, P123; Fabian JR, 1997, J BIOL CHEM, V272, P12359, DOI 10.1074/jbc.272.19.12359; Fernandez J, 2002, J BIOL CHEM, V277, P2050, DOI 10.1074/jbc.M109199200; Fletcher CM, 1999, EMBO J, V18, P2631, DOI 10.1093/emboj/18.9.2631; Fletcher CM, 1998, PROTEIN SCI, V7, P1639, DOI 10.1002/pro.5560070720; Gaba A, 2001, EMBO J, V20, P6453, DOI 10.1093/emboj/20.22.6453; Gale M, 1998, PHARMACOL THERAPEUT, V78, P29, DOI 10.1016/S0163-7258(97)00165-4; Geballe AP, 2000, COLD SPRING HARBOR M, V39, P595; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Gingras AC, 2001, GENE DEV, V15, P2852; Gomez E, 2000, MOL CELL BIOL, V20, P3965, DOI 10.1128/MCB.20.11.3965-3976.2000; Goossens A, 2001, J BIOL CHEM, V276, P30753, DOI 10.1074/jbc.M102960200; Griffin E, 2001, NAT MED, V7, P840, DOI 10.1038/89969; Harding HP, 2001, MOL CELL, V7, P1153, DOI 10.1016/S1097-2765(01)00264-7; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Heesom KJ, 2001, CURR BIOL, V11, P1374, DOI 10.1016/S0960-9822(01)00422-5; Hellen CUT, 2001, GENE DEV, V15, P1593, DOI 10.1101/gad.891101; Hentze MW, 1997, SCIENCE, V275, P500, DOI 10.1126/science.275.5299.500; Hershey JWB, 2000, COLD SPRING HARBOR M, V39, P33; Hinnebusch A.G., 1996, TRANSLATIONAL CONTRO, P199; Hinnebusch AG, 2000, COLD SPRING HARBOR M, V39, P185; Jacobson A., 1996, TRANSLATIONAL CONTRO, P505; Johannes G, 1999, P NATL ACAD SCI USA, V96, P13118, DOI 10.1073/pnas.96.23.13118; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kaytor MD, 2001, CELL, V107, P555, DOI 10.1016/S0092-8674(01)00590-6; KOROMILAS AE, 1992, EMBO J, V11, P4153, DOI 10.1002/j.1460-2075.1992.tb05508.x; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Krishnamoorthy T, 2001, MOL CELL BIOL, V21, P5018, DOI 10.1128/MCB.21.15.5018-5030.2001; LAMPHEAR BJ, 1995, J BIOL CHEM, V270, P21975, DOI 10.1074/jbc.270.37.21975; Lee JH, 1999, P NATL ACAD SCI USA, V96, P4342, DOI 10.1073/pnas.96.8.4342; Leegwater PAJ, 2001, NAT GENET, V29, P383, DOI 10.1038/ng764; Leib DA, 2000, P NATL ACAD SCI USA, V97, P6097, DOI 10.1073/pnas.100415697; LODISH HF, 1976, ANNU REV BIOCHEM, V45, P39, DOI 10.1146/annurev.bi.45.070176.000351; LOHMER S, 1993, PLANT CELL, V5, P65, DOI 10.1105/tpc.5.1.65; Lorsch JR, 1999, EMBO J, V18, P6705, DOI 10.1093/emboj/18.23.6705; Lu LR, 2001, MOL CELL BIOL, V21, P7971, DOI 10.1128/MCB.21.23.7971-7980.2001; LUO ZG, 1995, MOL CELL BIOL, V15, P5235; Marcotrigiano J, 1999, MOL CELL, V3, P707, DOI 10.1016/S1097-2765(01)80003-4; McKendrick L, 2001, EUR J BIOCHEM, V268, P5375, DOI 10.1046/j.0014-2956.2001.02478.x; MINICH WB, 1994, P NATL ACAD SCI USA, V91, P7668, DOI 10.1073/pnas.91.16.7668; Mothe-Satney I, 2000, MOL CELL BIOL, V20, P3558, DOI 10.1128/MCB.20.10.3558-3567.2000; Nanduri S, 2000, EMBO J, V19, P5567, DOI 10.1093/emboj/19.20.5567; Natarajan K, 2001, MOL CELL BIOL, V21, P4347, DOI 10.1128/MCB.21.13.4347-4368.2001; Nathan CAO, 1997, ONCOGENE, V15, P579, DOI 10.1038/sj.onc.1201216; Ohlmann T, 1996, EMBO J, V15, P1371, DOI 10.1002/j.1460-2075.1996.tb00479.x; OSSIPOW V, 1993, P NATL ACAD SCI USA, V90, P8219, DOI 10.1073/pnas.90.17.8219; Ostareck DH, 2001, CELL, V104, P281, DOI 10.1016/S0092-8674(01)00212-4; Pap M, 2002, MOL CELL BIOL, V22, P578, DOI 10.1128/MCB.22.2.578-586.2002; Pavitt GD, 1998, GENE DEV, V12, P514, DOI 10.1101/gad.12.4.514; Perrotti D, 2002, NAT GENET, V30, P48, DOI 10.1038/ng791; Pestova TV, 2000, NATURE, V403, P332, DOI 10.1038/35002118; Pestova TV, 1998, GENE DEV, V12, P67, DOI 10.1101/gad.12.1.67; Pestova TV, 1998, NATURE, V394, P854, DOI 10.1038/29703; Pestova TV, 1996, MOL CELL BIOL, V16, P6870; Pestova TV, 1996, MOL CELL BIOL, V16, P6859, DOI 10.1128/mcb.16.12.6859; Phan L, 2001, EMBO J, V20, P2954, DOI 10.1093/emboj/20.11.2954; Polymenis M, 1997, GENE DEV, V11, P2522, DOI 10.1101/gad.11.19.2522; Preiss T, 1998, NATURE, V392, P516, DOI 10.1038/33192; Pyronnet S, 2001, GENE DEV, V15, P2083, DOI 10.1101/gad.889201; Richter JD, 2000, COLD SPRING HARBOR M, V39, P785; Roll-Mecak A, 2001, TRENDS BIOCHEM SCI, V26, P705, DOI 10.1016/S0968-0004(01)02024-2; Rouault TA, 2000, COLD SPRING HARBOR M, V39, P655; Ruiz-Echevarria MJ, 2000, CELL, V101, P741, DOI 10.1016/S0092-8674(00)80886-7; Sachs A, 2000, COLD SPRING HARBOR M, V39, P447; Sattlegger E, 1998, J BIOL CHEM, V273, P20404, DOI 10.1074/jbc.273.32.20404; Scheuner D, 2001, MOL CELL, V7, P1165, DOI 10.1016/S1097-2765(01)00265-9; Shi YG, 1998, MOL CELL BIOL, V18, P7499, DOI 10.1128/MCB.18.12.7499; Spahn CMT, 2001, SCIENCE, V291, P1959, DOI 10.1126/science.1058409; Stojdl DF, 2000, J VIROL, V74, P9580, DOI 10.1128/JVI.74.20.9580-9585.2000; Thompson SR, 2001, P NATL ACAD SCI USA, V98, P12972, DOI 10.1073/pnas.241286698; Tsukiyama-Kohara K, 2001, NAT MED, V7, P1128, DOI 10.1038/nm1001-1128; Welsh GI, 1998, FEBS LETT, V421, P125, DOI 10.1016/S0014-5793(97)01548-2; Wickens M, 2000, COLD SPRING HARBOR M, V39, P295; Wilson JE, 2000, CELL, V102, P511, DOI 10.1016/S0092-8674(00)00055-6; Wilusz CJ, 2001, NAT REV MOL CELL BIO, V2, P237, DOI 10.1038/35067025; Yang RJ, 2000, MOL CELL BIOL, V20, P2706, DOI 10.1128/MCB.20.8.2706-2717.2000	99	578	597	2	42	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 22	2002	108	4					545	556		10.1016/S0092-8674(02)00642-6	http://dx.doi.org/10.1016/S0092-8674(02)00642-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	524XW	11909525	Bronze			2022-12-28	WOS:000174039000012
J	Buneo, CA; Jarvis, MR; Batista, AP; Andersen, RA				Buneo, CA; Jarvis, MR; Batista, AP; Andersen, RA			Direct visuomotor transformations for reaching	NATURE			English	Article							POSTERIOR PARIETAL CORTEX; AREA 5; ARM MOVEMENTS; REPRESENTATION; INFORMATION; LOCATION; PREMOTOR	The posterior parietal cortex (PPC) is thought to have a function in the sensorimotor transformations that underlie visually guided reaching, as damage to the PPC can result in difficulty reaching to visual targets in the absence of specific visual or motor deficits(1). This function is supported by findings that PPC neurons in monkeys are modulated by the direction of hand movement, as well as by visual, eye position and limb position signals(2-9). The PPC could transform visual target locations from retinal coordinates to hand-centred coordinates by combining sensory signals in a serial manner to yield a body-centred representation of target location(10-12), and then subtracting the body-centred location of the hand. We report here that in dorsal area 5 of the PPC, remembered target locations are coded with respect to both the eye and hand. This suggests that the PPC transforms target locations directly between these two reference frames. Data obtained in the adjacent parietal reach region (PRR) indicate that this transformation may be achieved by vectorially subtracting hand location from target location, with both locations represented in eye-centred coordinates.	CALTECH, Div Biol, Pasadena, CA 91125 USA	California Institute of Technology	Andersen, RA (corresponding author), CALTECH, Div Biol, Mail Code 216-76, Pasadena, CA 91125 USA.	anderson@vis.caltech.edu		Batista, Aaron/0000-0002-1719-0061				Andersen R A, 1993, Curr Opin Neurobiol, V3, P171, DOI 10.1016/0959-4388(93)90206-E; ANDERSEN RA, 1985, SCIENCE, V230, P456, DOI 10.1126/science.4048942; Batista AP, 1999, SCIENCE, V285, P257, DOI 10.1126/science.285.5425.257; Battaglia-Mayer A, 2000, J NEUROPHYSIOL, V83, P2374, DOI 10.1152/jn.2000.83.4.2374; Bullock D, 1998, CEREB CORTEX, V8, P48, DOI 10.1093/cercor/8.1.48; Buneo C. A., 1998, Society for Neuroscience Abstracts, V24, P262; Carrozzo M, 1999, EXP BRAIN RES, V129, P201, DOI 10.1007/s002210050890; Deneve S, 2001, NAT NEUROSCI, V4, P826, DOI 10.1038/90541; Desmurget M, 1999, NAT NEUROSCI, V2, P563, DOI 10.1038/9219; Effron B, 1993, INTRO BOOTSTRAP; FLANDERS M, 1992, BEHAV BRAIN SCI, V15, P309, DOI 10.1017/S0140525X00068813; GEORGOPOULOS AP, 1984, EXP BRAIN RES, V54, P446; Graziano MSA, 2000, SCIENCE, V290, P1782, DOI 10.1126/science.290.5497.1782; Henriques DYP, 1998, J NEUROSCI, V18, P1583; JORDAN MI, 1992, COGNITIVE SCI, V16, P307, DOI 10.1207/s15516709cog1603_1; KALASKA JF, 1990, EXP BRAIN RES, V80, P351; KALASKA JF, 1995, CEREB CORTEX, V5, P410, DOI 10.1093/cercor/5.5.410; KALASKA JF, 1983, EXP BRAIN RES, V51, P247; LACQUANITI F, 1995, CEREB CORTEX, V5, P391, DOI 10.1093/cercor/5.5.391; McIntyre J, 1998, J NEUROSCI, V18, P8423, DOI 10.1523/JNEUROSCI.18-20-08423.1998; Moran DW, 1999, J NEUROPHYSIOL, V82, P2676, DOI 10.1152/jn.1999.82.5.2676; PETRIDES M, 1984, J COMP NEUROL, V228, P105, DOI 10.1002/cne.902280110; RONDOT P, 1977, BRAIN, V100, P355, DOI 10.1093/brain/100.2.355; SALINAS E, 1995, J NEUROSCI, V15, P6461; Scott SH, 1997, J NEUROPHYSIOL, V78, P2413, DOI 10.1152/jn.1997.78.5.2413; Snyder LH, 1997, NATURE, V386, P167, DOI 10.1038/386167a0; STRICK PL, 1978, BRAIN RES, V157, P325, DOI 10.1016/0006-8993(78)90035-5; WIESENDANGER R, 1979, NEUROSCIENCE, V4, P747, DOI 10.1016/0306-4522(79)90004-6; Zar JH., 1999, BIOSTAT ANAL, V663rd	29	441	452	0	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 11	2002	416	6881					632	636		10.1038/416632a	http://dx.doi.org/10.1038/416632a			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	539YV	11948351				2022-12-28	WOS:000174901900043
J	Liu, F; Rugheimer, P; Mateeva, E; Savage, DE; Lagally, MG				Liu, F; Rugheimer, P; Mateeva, E; Savage, DE; Lagally, MG			Nanomechanics - Response of a strained semiconductor structure	NATURE			English	Article							COHERENT		Univ Utah, Dept Mat Sci & Engn, Salt Lake City, UT 84112 USA; Univ Wisconsin, Dept Mat Sci & Engn & Phys, Madison, WI 53706 USA; Colorado Sch Mines, Golden, CO 80401 USA	Utah System of Higher Education; University of Utah; University of Wisconsin System; University of Wisconsin Madison; Colorado School of Mines	Liu, F (corresponding author), Univ Utah, Dept Mat Sci & Engn, Salt Lake City, UT 84112 USA.		Sutter, Eli A./AAD-7878-2019	Savage, Donald/0000-0001-8515-4196				Floro JA, 1997, PHYS REV LETT, V79, P3946, DOI 10.1103/PhysRevLett.79.3946; Floro JA, 1999, PHYS REV B, V59, P1990, DOI 10.1103/PhysRevB.59.1990; Johnson HT, 1997, J APPL PHYS, V81, P6081, DOI 10.1063/1.364357; RAFFERTY CS, 1989, APPL PHYS LETT, V54, P1516, DOI 10.1063/1.101384; Stoney GG, 1909, P R SOC LOND A-CONTA, V82, P172, DOI 10.1098/rspa.1909.0021	5	77	80	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 4	2002	416	6880					498	498		10.1038/416498a	http://dx.doi.org/10.1038/416498a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	537JY	11932735	Bronze			2022-12-28	WOS:000174756500033
J	Renner, C; Aeppli, G; Kim, BG; Soh, YA; Cheong, SW				Renner, C; Aeppli, G; Kim, BG; Soh, YA; Cheong, SW			Atomic-scale images of charge ordering in a mixed-valence manganite	NATURE			English	Article							FERROMAGNETISM; TRANSITION; CRYSTAL; PHYSICS	Transition-metal perovskite oxides exhibit a wide range of extraordinary but imperfectly understood phenomena. The best known examples are high-temperature superconductivity in copper oxides(1), and colossal magnetoresistance in manganese oxides ('manganites')(2,3). All of these materials undergo a range of order-disorder transitions associated with changes in charge, spin, orbital and lattice degrees of freedom. Measurements of such order are usually made by diffraction techniques, which detect the ionic cores and the spins of the conduction electrons. Unfortunately, because such techniques are only weakly sensitive to valence electrons and yield superpositions of signals from distinct submicrometre-scale phases, they cannot directly image phase coexistence and charge ordering, two key features of the manganites. Here we present scanning tunnelling microscope measurements of the manganite Bi1-xCaxMnO3. We show that charge ordering and phase separation can be resolved in real space with atomic-scale resolution. By taking together images and current-voltage spectroscopy data we find that charge order correlates with both structural order and the local conductive state (either metallic or insulating). These experiments provide an atomic-scale basis for descriptions(4) of manganites as mixtures of electronically and structurally distinct phases.	NEC Res Inst, Princeton, NJ 08540 USA; Rutgers State Univ, Dept Phys & Astron, Piscataway, NJ 08854 USA	NEC Corporation; Rutgers State University New Brunswick	Renner, C (corresponding author), NEC Res Inst, 4 Independence Way, Princeton, NJ 08540 USA.	renner@research.nj.nec.com	Renner, Christoph/B-6140-2013	Renner, Christoph/0000-0001-9882-681X				Bao W, 1997, PHYS REV LETT, V78, P543, DOI 10.1103/PhysRevLett.78.543; Billinge SJL, 1996, PHYS REV LETT, V77, P715, DOI 10.1103/PhysRevLett.77.715; Biswas A, 1999, PHYS REV B, V59, P5368, DOI 10.1103/PhysRevB.59.5368; Fath M, 1999, SCIENCE, V285, P1540, DOI 10.1126/science.285.5433.1540; HOWALD C, 2001, PHYS REV B, V64; JIN S, 1994, SCIENCE, V264, P413, DOI 10.1126/science.264.5157.413; Kagan MY, 2001, J EXP THEOR PHYS+, V93, P415, DOI 10.1134/1.1402742; Liu HL, 1998, PHYS REV LETT, V81, P4684, DOI 10.1103/PhysRevLett.81.4684; Matzdorf R, 2000, SCIENCE, V289, P746, DOI 10.1126/science.289.5480.746; Millis AJ, 1998, NATURE, V392, P147, DOI 10.1038/32348; Moreo A, 1999, SCIENCE, V283, P2034, DOI 10.1126/science.283.5410.2034; Orenstein J, 2000, SCIENCE, V288, P468, DOI 10.1126/science.288.5465.468; Pan SH, 2001, NATURE, V413, P282, DOI 10.1038/35095012; Radaelli PG, 1999, PHYS REV B, V59, P14440, DOI 10.1103/PhysRevB.59.14440; Radaelli PG, 1997, PHYS REV B, V55, P3015, DOI 10.1103/PhysRevB.55.3015; Su Y, 1999, PHYS REV B, V59, P11687, DOI 10.1103/PhysRevB.59.11687; VONHELMOLT R, 1993, PHYS REV LETT, V71, P2331, DOI 10.1103/PhysRevLett.71.2331; Wei JYT, 1997, PHYS REV LETT, V79, P5150, DOI 10.1103/PhysRevLett.79.5150; Woo H, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.134412	19	208	212	2	94	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 4	2002	416	6880					518	521		10.1038/416518a	http://dx.doi.org/10.1038/416518a			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	537JY	11932740	Green Submitted			2022-12-28	WOS:000174756500038
J	Vitovski, S; Dunkin, KT; Howard, AJ; Sayers, JR				Vitovski, S; Dunkin, KT; Howard, AJ; Sayers, JR			Nontypeable Haemophilus influenzae in carriage and disease - A difference in IgA1 protease activity levels	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMMUNOGLOBULIN A1 PROTEASE; HEMOPHILUS-INFLUENZAE; NEISSERIA-GONORRHOEAE; SEROTYPE-B; PATHOGENESIS; BACTERIA; STRAINS; CELLS; COLONIZATION; GENE	Context Nontypeable Haemophilus influenzae strains form part of the normal flora of the human upper respiratory tract but are also implicated in a wide range of diseases. infections caused by nontypeable H influenzae are major health and socioeconomic burdens. No single bacterial trait has been associated with disease as opposed to colonization. Objectives To compare IgA1 protease activity in nontypeable H influenzae strains isolated from patients with symptomatic Haemophilus infection (sputum, cerebrospinal fluid, blood, or normally sterile tissue) vs strains from throat swabs of asymptomatic carriers and to compare iga gene carriage and variability in nontypeable H influenzae strains. Design and Setting Retrospective study of 63 strains (44 clinical and 19 carriage) collected between 1991 and 2000 and maintained at the Public Health Laboratory, Gwynedd General Hospital, Bangor, Wales. Main Outcome Measures Levels of IgA1 protease activity produced by carriage strains and clinical isolates from symptomatic patients; the determination of the size and sequence of a variable region of the iga gene. Results Bacterial IgA1 protease activity was significantly higher (P<.001) in strains isolated from sputum, blood, cerebrospinal fluid, or normally sterile tissue of symptomatic individuals (median, 155 mU; interquartile range [IQR], 80-220 mU; mean, 169 mU; 95% confidence interval (01, 126-211 mU) than in those isolated from throat swabs of asymptomatic carriers (median, 30 mU; IQR, 15-90 mU; mean, 56 mU; 95% CI, 26-86 mU; assayed on secretory IgA). The iga gene was detected in 97% of all strains examined. Variations in the sizes and sequences of part of the iga genes were also apparent. This variable region encodes a polypeptide linker connecting the protease domain to the &beta;-core autotranslocator, a porelike structure required for secretion of the protease. Conclusions These findings reveal the importance of iga gene variability and expression levels in the establishment of disease phenotype. They identify nontypeable H influenzae IgA1 protease as a virulence factor and as a potential target for the development of new strategies to fight these important pathogens.	Royal Hallamshire Hosp, Div Genome Med, Infect & Immun Grp, Sheffield S10 2RX, S Yorkshire, England; Gwynedd Gen Hosp, Publ Hlth Lab, Bangor, Gwynedd, Wales	University of Sheffield	Sayers, JR (corresponding author), Royal Hallamshire Hosp, Div Genomic Med, Infect & Immun Grp, Sheffield S10 2RX, S Yorkshire, England.		Sayers, Jon R/AAP-6179-2020; Sayers, Jon R/I-8974-2012	Sayers, Jon R/0000-0002-5082-1443; Sayers, Jon R/0000-0002-5082-1443				Brooks GF, 1995, JAWETZ MELNICK ADELB; COOPER MD, 1984, J INFECT DIS, V150, P737, DOI 10.1093/infdis/150.5.737; FALLA TJ, 1993, LANCET, V341, P851, DOI 10.1016/0140-6736(93)93059-A; FARLEY MM, 1986, J INFECT DIS, V154, P752, DOI 10.1093/infdis/154.5.752; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; Foxwell AR, 1998, MICROBIOL MOL BIOL R, V62, P294, DOI 10.1128/MMBR.62.2.294-308.1998; GREISEN K, 1994, J CLIN MICROBIOL, V32, P335, DOI 10.1128/JCM.32.2.335-351.1994; GRIFFISS JM, 1995, MENINGOCOCCAL DIS, P35; HALTER R, 1989, EMBO J, V8, P2737, DOI 10.1002/j.1460-2075.1989.tb08415.x; HARRISON LH, 1987, LANCET, V2, P761; Hauck CR, 1997, FEBS LETT, V405, P86, DOI 10.1016/S0014-5793(97)00163-4; Hopper S, 2000, INFECT IMMUN, V68, P906, DOI 10.1128/IAI.68.2.906-911.2000; KETT K, 1986, J IMMUNOL, V136, P3631; Kilian M, 1996, APMIS, V104, P321, DOI 10.1111/j.1699-0463.1996.tb00724.x; KILIAN M, 1983, INFECT IMMUN, V42, P126, DOI 10.1128/IAI.42.1.126-132.1983; KILIAN M, 1979, INFECT IMMUN, V26, P143, DOI 10.1128/IAI.26.1.143-149.1979; KILLIAN M, 1976, J GEN MICROBIOL, V93, P9; KRAEHENBUHL JP, 1992, PHYSIOL REV, V72, P853, DOI 10.1152/physrev.1992.72.4.853; Lin L, 1997, MOL MICROBIOL, V24, P1083, DOI 10.1046/j.1365-2958.1997.4191776.x; LOMHOLT H, 1992, P NATL ACAD SCI USA, V89, P2120, DOI 10.1073/pnas.89.6.2120; Lorenzen DR, 1999, J EXP MED, V190, P1049, DOI 10.1084/jem.190.8.1049; MANSA B, 1986, INFECT IMMUN, V52, P171, DOI 10.1128/IAI.52.1.171-174.1986; MULKS MH, 1978, NEW ENGL J MED, V299, P973, DOI 10.1056/NEJM197811022991802; MULKS MH, 1994, METHOD ENZYMOL, V235, P543; MUSSER JM, 1986, INFECT IMMUN, V52, P183, DOI 10.1128/IAI.52.1.183-191.1986; POHLNER J, 1995, MOL MICROBIOL, V17, P1073, DOI 10.1111/j.1365-2958.1995.mmi_17061073.x; POULSEN K, 1988, INFECT IMMUN, V56, P987, DOI 10.1128/IAI.56.4.987-992.1988; POULSEN K, 1989, INFECT IMMUN, V57, P3097, DOI 10.1128/IAI.57.10.3097-3105.1989; POULSEN K, 1992, J BACTERIOL, V174, P2913, DOI 10.1128/JB.174.9.2913-2921.1992; REINHOLDT J, 1983, J IMMUNOL METHODS, V63, P367, DOI 10.1016/S0022-1759(83)80010-6; Reinholdt J, 1997, INFECT IMMUN, V65, P4452, DOI 10.1128/IAI.65.11.4452-4459.1997; StGeme JW, 1997, PEDIATR INFECT DIS J, V16, P931, DOI 10.1097/00006454-199710000-00005; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TURK DC, 1984, J MED MICROBIOL, V18, P1, DOI 10.1099/00222615-18-1-1; Vitovski S, 1999, FASEB J, V13, P331, DOI 10.1096/fasebj.13.2.331; WALLACE RJ, 1983, REV INFECT DIS, V5, P123	36	53	54	0	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 3	2002	287	13					1699	1705		10.1001/jama.287.13.1699	http://dx.doi.org/10.1001/jama.287.13.1699			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	536YW	11926894	Bronze			2022-12-28	WOS:000174730300024
J	Cruz, I; Morales, MA; Noguer, I; Rodriguez, A; Alvar, J				Cruz, I; Morales, MA; Noguer, I; Rodriguez, A; Alvar, J			Leishmania in discarded syringes from intravenous drug users	LANCET			English	Article								Needle sharing by Intravenous drug users (IVDUs) has been proposed as providing an alternative, artificial, and anthroponotic cycle for leishmania transmission. We looked for parasites In syringes discarded by IVDUs using two different PCR techniques. Leishmania spp were detected In 65 (52%) of 125 syringes collected In southern Madrid, Spain, In 1998, and In 52 (34%) of 154 collected In southwestern Madrid In 2000-01. We found shared restriction fragment length polymorphisms In 1.2 of 65 positive samples tested, suggesting that syringe sharing can Indeed promote the spread of leishmania clones among IVDUs.	Inst Salud Carlos III, Ctr Nacl Microbiol, Serv Parasitol, WHO Collaborating Ctr Leishmaniasis, Madrid 28220, Spain; Minist Sanidad & Consumo, Secretaria Plan Nacl Sida, Madrid, Spain; Medicos Mundo Espana, Desk Cuarto Mundo, Madrid, Spain	Instituto de Salud Carlos III; Centro Nacional de Microbiologa (CNM)	Alvar, J (corresponding author), Inst Salud Carlos III, Ctr Nacl Microbiol, Serv Parasitol, WHO Collaborating Ctr Leishmaniasis, Madrid 28220, Spain.		Rodriguez-Arenas, M. Angeles/AAE-2705-2021	Rodriguez-Arenas, M. Angeles/0000-0002-8115-054X; Cruz, Israel/0000-0002-2200-2360				Alvar J, 1997, CLIN MICROBIOL REV, V10, P298, DOI 10.1128/CMR.10.2.298; ALVAR J, 1992, LANCET, V339, P264; DESJEUX P, 1998, WHOCTDLEISH989; MOLINA R, 1994, AIDS, V8, P277, DOI 10.1097/00002030-199402000-00024; Morales MA, 2001, T ROY SOC TROP MED H, V95, P104, DOI 10.1016/S0035-9203(01)90352-9	5	95	104	0	12	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 30	2002	359	9312					1124	1125		10.1016/S0140-6736(02)08160-6	http://dx.doi.org/10.1016/S0140-6736(02)08160-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	536YJ	11943264				2022-12-28	WOS:000174729200015
J	Katzenellenbogen, BS; Katzenellenbogen, JA				Katzenellenbogen, BS; Katzenellenbogen, JA			Biomedicine - Defining the "S" in SERMs	SCIENCE			English	Editorial Material							ESTROGEN-RECEPTOR; BREAST-CANCER; TAMOXIFEN; ANTAGONISM; PREVENTION; RESISTANCE		Univ Illinois, Dept Mol & Integrat Physiol, Urbana, IL 61801 USA; Univ Illinois, Dept Cell & Struct Biol, Urbana, IL 61801 USA; Univ Illinois, Coll Med, Urbana, IL 61801 USA; Univ Illinois, Dept Chem, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Katzenellenbogen, BS (corresponding author), Univ Illinois, Dept Mol & Integrat Physiol, Urbana, IL 61801 USA.							Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; Hall JM, 2001, J BIOL CHEM, V276, P36869, DOI 10.1074/jbc.R100029200; Jordan VC, 1999, ENDOCR REV, V20, P253, DOI 10.1210/edrv.20.3.0368; Katzenellenbogen BS, 2001, ANN NY ACAD SCI, V949, P6; Katzenellenbogen BS, 2000, RECENT PROG HORM RES, V55, P163; Katzenellenbogen JA, 1996, MOL ENDOCRINOL, V10, P119, DOI 10.1210/me.10.2.119; McKenna N, 2000, NAT MED, V6, P960, DOI 10.1038/79637; Montano MM, 1999, P NATL ACAD SCI USA, V96, P6947, DOI 10.1073/pnas.96.12.6947; OSBORNE CK, 1994, BREAST CANCER RES TR, V32, P49, DOI 10.1007/BF00666205; Osborne CK, 1998, NEW ENGL J MED, V339, P1609, DOI 10.1056/NEJM199811263392207; Rosenfeld MG, 2001, J BIOL CHEM, V276, P36865, DOI 10.1074/jbc.R100041200; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Smith CL, 2002, MOL CELL BIOL, V22, P525, DOI 10.1128/MCB.22.2.525-535.2002; Sporn MB, 2001, TRENDS MOL MED, V7, P395, DOI 10.1016/S1471-4914(01)02100-1; Xu JM, 2000, P NATL ACAD SCI USA, V97, P6379, DOI 10.1073/pnas.120166297; Xu JM, 1998, SCIENCE, V279, P1922, DOI 10.1126/science.279.5358.1922; Yahata T, 2001, GENE DEV, V15, P2598, DOI 10.1101/gad.906301	19	178	185	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 29	2002	295	5564					2380	2381		10.1126/science.1070442	http://dx.doi.org/10.1126/science.1070442			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	536QD	11923515				2022-12-28	WOS:000174712600031
J	Hakeda-Suzuki, S; Ng, J; Tzu, J; Dietzl, G; Sun, Y; Harms, M; Nardine, T; Luo, LQ; Dickson, BJ				Hakeda-Suzuki, S; Ng, J; Tzu, J; Dietzl, G; Sun, Y; Harms, M; Nardine, T; Luo, LQ; Dickson, BJ			Rac function and regulation during Drosophila development	NATURE			English	Article							CELL-SHAPE CHANGES; ACTIN CYTOSKELETON; MYOBLAST FUSION; AXON GUIDANCE; RHO GTPASES; MORPHOGENESIS; MELANOGASTER; OUTGROWTH; POLARITY; PROTEIN	Rac GTPases regulate the actin cytoskeleton to control changes in cell shape(1,2). To date, the analysis of Rac function during development has relied heavily on the use of dominant mutant isoforms. Here, we use loss-of-function mutations to show that the three Drosophila Rac genes, Rac1, Rac2 and Mtl, have overlapping functions in the control of epithelial morphogenesis, myoblast fusion, and axon growth and guidance. They are not required for the establishment of planar cell polarity, as had been suggested on the basis of studies using dominant mutant isoforms(3,4). The guanine nucleotide exchange factor, Trio, is essential for Rac function in axon growth and guidance, but not for epithelial morphogenesis or myoblast fusion. Different Rac activators thus act in different developmental processes. The specific cellular response to Rac activation may be determined more by the upstream activator than the specific Rac protein involved.	Res Inst Mol Pathol, A-1030 Vienna, Austria; Stanford Univ, Dept Biol Sci, Stanford, CA 94035 USA; Stanford Univ, Program Neurosci, Stanford, CA 94035 USA	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Stanford University; Stanford University	Dickson, BJ (corresponding author), Res Inst Mol Pathol, Dr Bohr Gasse 7, A-1030 Vienna, Austria.	dickson@nt.imp.univie.ac.at	Dickson, Barry/AAE-7632-2019	Dickson, Barry/0000-0003-0715-892X; Ng, Julian/0000-0002-1908-4414; Hakeda-Suzuki, Satoko/0000-0001-8749-1479; Luo, Liqun/0000-0001-5467-9264				Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Awasaki T, 2000, NEURON, V26, P119, DOI 10.1016/S0896-6273(00)81143-5; Bateman J, 2000, NEURON, V26, P93, DOI 10.1016/S0896-6273(00)81141-1; Chang HY, 2000, SCIENCE, V290, P1978, DOI 10.1126/science.290.5498.1978; CHOU TB, 1993, DEVELOPMENT, V119, P1359; Doberstein SK, 1997, J CELL BIOL, V136, P1249, DOI 10.1083/jcb.136.6.1249; Eaton S, 1996, J CELL BIOL, V135, P1277, DOI 10.1083/jcb.135.5.1277; Edwards KA, 1997, DEV BIOL, V191, P103, DOI 10.1006/dbio.1997.8707; Fanto M, 2000, CURR BIOL, V10, P979, DOI 10.1016/S0960-9822(00)00645-X; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HARDEN N, 1995, DEVELOPMENT, V121, P903; HARIHARAN IK, 1995, EMBO J, V14, P292, DOI 10.1002/j.1460-2075.1995.tb07003.x; Jacinto A, 2001, NAT CELL BIOL, V3, pE117, DOI 10.1038/35074643; Jacinto A, 2000, CURR BIOL, V10, P1420, DOI 10.1016/S0960-9822(00)00796-X; Kaufmann N, 1998, DEVELOPMENT, V125, P453; Liebl EC, 2000, NEURON, V26, P107, DOI 10.1016/S0896-6273(00)81142-3; Lundquist EA, 2001, DEVELOPMENT, V128, P4475; Luo LQ, 2000, NAT REV NEUROSCI, V1, P173, DOI 10.1038/35044547; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; Newsome TP, 2000, DEVELOPMENT, V127, P851; Newsome TP, 2000, CELL, V101, P283, DOI 10.1016/S0092-8674(00)80838-7; Ng J, 2002, NATURE, V416, P442, DOI 10.1038/416442a; Rajagopalan S, 2000, CELL, V103, P1033, DOI 10.1016/S0092-8674(00)00207-5; Reddien PW, 2000, NAT CELL BIOL, V2, P131, DOI 10.1038/35004000; Shulman JM, 1998, TRENDS GENET, V14, P452, DOI 10.1016/S0168-9525(98)01584-4; Sone M, 1997, SCIENCE, V275, P543, DOI 10.1126/science.275.5299.543; WAKELAM MJO, 1985, BIOCHEM J, V228, P1; WilliamsMasson EM, 1997, DEVELOPMENT, V124, P2889; Winter CG, 2001, CELL, V105, P81, DOI 10.1016/S0092-8674(01)00298-7; YOUNG PE, 1993, GENE DEV, V7, P29, DOI 10.1101/gad.7.1.29	30	292	295	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 28	2002	416	6879					438	442		10.1038/416438a	http://dx.doi.org/10.1038/416438a			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	534UX	11919634				2022-12-28	WOS:000174607800049
J	Bachtrog, D; Charlesworth, B				Bachtrog, D; Charlesworth, B			Reduced adaptation of a non-recombining neo-Y chromosome	NATURE			English	Article							MOLECULAR EVOLUTION; DROSOPHILA-MIRANDA; DOSAGE-COMPENSATION; SEX; PSEUDOOBSCURA; VARIABILITY; LIKELIHOOD; PROTEIN; HISTORY; GENES	Sex chromosomes are generally believed to have descended from a pair of homologous autosomes. Suppression of recombination between the ancestral sex chromosomes led to the genetic degeneration of the Y chromosome(1). In response, the X chromosome may become dosage-compensated(1,2). Most proposed mechanisms for the degeneration of Y chromosomes involve the rapid fixation of deleterious mutations on the Y-1. Alternatively, Y-chromosome degeneration might be a response to a slower rate of adaptive evolution, caused by its lack of recombination(3). Here we report patterns of DNA polymorphism and divergence at four genes located on the neo-sex chromosomes of Drosophila miranda. We show that a higher rate of protein sequence evolution of the neo-X-linked copy of Cyclin B relative to the neo-Y copy is driven by positive selection, which is consistent with the adaptive hypothesis for the evolution of the Y chromosome(3). In contrast, the neo-Y-linked copies of even-skipped and roundabout show an elevated rate of protein evolution relative to their neo-X homologues, probably reflecting the reduced effectiveness of selection against deleterious mutations in a non-recombining genome(1). Our results provide evidence for the importance of sexual recombination for increasing and maintaining the level of adaptation of a population.	Univ Edinburgh, Inst Cell Anim & Populat Biol, Edinburgh EH9 3JT, Midlothian, Scotland	University of Edinburgh	Bachtrog, D (corresponding author), Univ Edinburgh, Inst Cell Anim & Populat Biol, W Mains Rd, Edinburgh EH9 3JT, Midlothian, Scotland.							Bachtrog D, 2000, CURR BIOL, V10, P1025, DOI 10.1016/S0960-9822(00)00656-4; Barton NH, 1998, SCIENCE, V281, P1986, DOI 10.1126/science.281.5385.1986; Barton NH, 2000, PHILOS T R SOC B, V355, P1553, DOI 10.1098/rstb.2000.0716; Bell G., 1982, MASTERPIECE NATURE; Carvalho AB, 2000, P NATL ACAD SCI USA, V97, P13239, DOI 10.1073/pnas.230438397; Charlesworth B, 2000, PHILOS T R SOC B, V355, P1563, DOI 10.1098/rstb.2000.0717; DAS M, 1982, CHROMOSOMA, V87, P373, DOI 10.1007/BF00327180; Filatov DA, 2000, NATURE, V404, P388, DOI 10.1038/35006057; Fridolfsson AK, 2000, GENETICS, V155, P1903; GETHMANN RC, 1988, J HERED, V79, P344, DOI 10.1093/oxfordjournals.jhered.a110526; Hudson R.R., 1990, Oxford Surveys in Evolutionary Biology, V7, P1; HUDSON RR, 1987, GENETICS, V116, P153; KIMURA M, 1986, NEUTRAL THEORY MOL E; Lahn BT, 2001, NAT REV GENET, V2, P207, DOI 10.1038/35056058; Li W. H, 1997, MOL EVOLUTION; Lynch M, 1998, GENETICA, V102-3, P29, DOI 10.1023/A:1017022522486; Marin I, 2000, BIOESSAYS, V22, P1106, DOI 10.1002/1521-1878(200012)22:12&lt;1106::AID-BIES8&gt;3.0.CO;2-W; MAYNARD SMITH J., 1978, EVOLUTION SEX; MCDONALD JH, 1991, NATURE, V351, P652, DOI 10.1038/351652a0; Orr HA, 1998, GENETICS, V150, P1693; Powell J. R., 1997, PROGR PROSPECTS EVOL; SCHAEFFER SW, 1992, GENETICS, V132, P163; Steinemann M, 1998, GENETICA, V102-3, P409, DOI 10.1023/A:1017058119760; TAJIMA F, 1993, JPN J GENET, V68, P567, DOI 10.1266/jjg.68.567; Wang RL, 1996, GENETICS, V144, P1113; Waters PD, 2001, CYTOGENET CELL GENET, V92, P74, DOI 10.1159/000056872; Weiss G, 1998, GENETICS, V149, P1539; Wright S., 1969, EVOLUTION GENETICS P; Yang ZH, 1997, COMPUT APPL BIOSCI, V13, P555; Yi SJ, 2000, MOL BIOL EVOL, V17, P703, DOI 10.1093/oxfordjournals.molbev.a026349	30	157	160	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 21	2002	416	6878					323	326		10.1038/416323a	http://dx.doi.org/10.1038/416323a			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	532NP	11907578	Green Published			2022-12-28	WOS:000174482200043
J	Johnson, RJ; Herrera-Acosta, J; Schreiner, GF; Rodriguez-Iturbe, B				Johnson, RJ; Herrera-Acosta, J; Schreiner, GF; Rodriguez-Iturbe, B			Mechanisms of disease - Subtle acquired renal injury as a mechanism of salt-sensitive hypertension	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							SMOOTH-MUSCLE-CELLS; BLOOD-PRESSURE; ANGIOTENSIN-II; ARTERIAL-PRESSURE; TUBULOINTERSTITIAL DISEASE; SYMPATHETIC OVERACTIVITY; MEDIATED HYPERTENSION; CYCLOSPORINE-A; SODIUM; KIDNEY		Baylor Coll Med, Div Nephrol, SM-1273,6550 Fannin St, Houston, TX 77030 USA; Inst Nacl Cardiol I Chavez, Dept Nephrol, Mexico City, DF, Mexico; Scios, Sunnyvale, CA USA; Univ Zulia, Univ Hosp, Renal Serv, Maracaibo 4011, Venezuela; Univ Zulia, Univ Hosp, Dept Immunobiol, Maracaibo 4011, Venezuela	Baylor College of Medicine; National Institute of Cardiology - Mexico; Scios	Johnson, RJ (corresponding author), Baylor Coll Med, Div Nephrol, SM-1273,6550 Fannin St, Houston, TX 77030 USA.	rjohnson@bcm.tmc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068607] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052121] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL68607] Funding Source: Medline; NIDDK NIH HHS [DK-52121] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anderson WP, 2000, HYPERTENSION, V36, P648, DOI 10.1161/01.HYP.36.4.648; Andoh TF, 2001, AM J TRANSPLANT, V1, P222, DOI 10.1046/j.1600-6135.ajt10305.x; Andoh TF, 1998, CURR OPIN NEPHROL HY, V7, P265, DOI 10.1097/00041552-199805000-00005; Barton M, 1997, BIOCHEM BIOPH RES CO, V238, P861, DOI 10.1006/bbrc.1997.7394; BAUER JH, 1982, ARCH INTERN MED, V142, P1317, DOI 10.1001/archinte.142.7.1317; BEILIN LJ, 1977, CLIN SCI MOL MED, V52, P111, DOI 10.1042/cs0520111; Bergstrom G, 1998, HYPERTENSION, V31, P1007, DOI 10.1161/01.HYP.31.4.1007; BEVAN AT, 1969, CLIN SCI, V36, P329; BLAES N, 1983, J CELL PHYSIOL, V116, P167, DOI 10.1002/jcp.1041160207; BORST JGG, 1963, LANCET, V1, P677; BRENNER BM, 1988, AM J HYPERTENS, V1, P335, DOI 10.1093/ajh/1.4.335; CALHOUN DA, 1994, HYPERTENSION, V24, P1; Casellas D, 1999, J AM SOC NEPHROL, V10, pS230; CHEN PY, 1991, J CLIN INVEST, V88, P1559, DOI 10.1172/JCI115467; Chiolero A, 2001, NEPHROL DIAL TRANSPL, V16, P452, DOI 10.1093/ndt/16.3.452; CONVERSE RL, 1992, NEW ENGL J MED, V327, P1912, DOI 10.1056/NEJM199212313272704; Cowley AW, 1996, JAMA-J AM MED ASSOC, V275, P1581, DOI 10.1001/jama.275.20.1581; COWLEY AW, 1995, HYPERTENSION, V25, P663, DOI 10.1161/01.HYP.25.4.663; CURTIS JJ, 1988, AM J MED, V85, P134; CURTIS JJ, 1983, NEW ENGL J MED, V309, P1009, DOI 10.1056/NEJM198310273091702; DAHL LK, 1975, CIRC RES, V36, P692, DOI 10.1161/01.RES.36.6.692; DiBona GF, 1997, PHYSIOL REV, V77, P75, DOI 10.1152/physrev.1997.77.1.75; ELLIOTT P, 1988, BRIT MED J, V297, P319; ENG E, 1994, AM J HYPERTENS, V7, P177, DOI 10.1093/ajh/7.2.177; EPSTEIN FH, 1994, ANN NY ACAD SCI, V718, P72; EPSTEIN M, 1976, J LAB CLIN MED, V87, P411; Fine LG, 1998, KIDNEY INT, pS74; Floege J, 1998, J AM SOC NEPHROL, V9, P211; FOX U, 1976, CLIN EXP PHARMACOL P, P71; Franco M, 2001, J AM SOC NEPHROL, V12, P2263, DOI 10.1681/ASN.V12112263; Gallen IW, 1998, AM J KIDNEY DIS, V31, P19, DOI 10.1053/ajkd.1998.v31.pm9428447; GOLDBLATT H, 1947, PHYSIOL REV, V27, P120, DOI 10.1152/physrev.1947.27.1.120; Goldblatt H, 1934, J EXP MED, V59, P347, DOI 10.1084/jem.59.3.347; GomezAlamillo C, 1996, KIDNEY INT, pS129; Griffin KA, 2001, AM J HYPERTENS, V14, P311, DOI 10.1016/S0895-7061(00)01282-6; Gull W W, 1872, Med Chir Trans, V55, P273; GUYTON AC, 1972, AM J MED, V52, P584, DOI 10.1016/0002-9343(72)90050-2; Hall JE, 1996, J HUM HYPERTENS, V10, P633; HENKE F, 1925, HDB SPEZIELLEN PATHO, V6, P368; Hollenberg NK, 2001, NEPHROL DIAL TRANSPL, V16, P38, DOI 10.1093/ndt/16.suppl_6.38; IIMURA O, 1993, ANN NY ACAD SCI, V676, P105, DOI 10.1111/j.1749-6632.1993.tb38729.x; JAFFE D, 1970, ARCH PATHOL, V90, P1; JEUNEMAITRE X, 1992, CELL, V71, P169, DOI 10.1016/0092-8674(92)90275-H; Johnson RJ, 2000, J HYPERTENS, V18, P1497, DOI 10.1097/00004872-200018100-00019; Johnson RJ, 1999, HYPERTENSION, V34, P151, DOI 10.1161/01.HYP.34.1.151; Johnson RJ, 1997, KIDNEY INT, V52, P1169, DOI 10.1038/ki.1997.442; JOHNSON RJ, 1992, HYPERTENSION, V19, P464, DOI 10.1161/01.HYP.19.5.464; Julius S, 1996, CLIN EXP HYPERTENS, V18, P305, DOI 10.3109/10641969609088965; Kang DH, 2001, AM J PHYSIOL-RENAL, V280, pF727, DOI 10.1152/ajprenal.2001.280.4.F727; KAWABE K, 1978, JPN HEART J, V19, P886; Kimura G, 1993, Curr Opin Nephrol Hypertens, V2, P341; Klag MJ, 1996, NEW ENGL J MED, V334, P13, DOI 10.1056/NEJM199601043340103; Kurokawa K, 1996, KIDNEY INT, pS46; Lifton RP, 1996, SCIENCE, V272, P676, DOI 10.1126/science.272.5262.676; Lombardi D, 1999, HYPERTENSION, V33, P1013, DOI 10.1161/01.HYP.33.4.1013; Lombardi DM, 2001, NEPHRON, V87, P66, DOI 10.1159/000045886; Lu CY, 1999, KIDNEY INT, V55, P2157, DOI 10.1046/j.1523-1755.1999.00491.x; LUFT FC, 1979, CIRCULATION, V59, P643, DOI 10.1161/01.CIR.59.4.643; LUKE RG, 1993, HYPERTENSION, V21, P380, DOI 10.1161/01.HYP.21.3.380; Mahomed F.-A., 1879, LANCET, V113, P399; Mahomed F. A., 1879, LANCET, V1, P46; MAHOMED FA, 1879, LANCET, V1, P149; MAHOMED FA, 1879, LANCET, V1, P261; MAHOMED FA, 1879, LANCET, V1, P437; MAHOMED FA, 1879, LANCET, V1, P76; MAI M, 1993, HYPERTENSION, V22, P754, DOI 10.1161/01.HYP.22.5.754; Mattson DL, 1996, HYPERTENSION, V28, P297, DOI 10.1161/01.HYP.28.2.297; MATTSON DL, 1994, AM J PHYSIOL, V266, pH1918, DOI 10.1152/ajpheart.1994.266.5.H1918; MCCABE RD, 1994, AM J HYPERTENS, V7, P346, DOI 10.1093/ajh/7.4.346; Midgley JP, 1996, JAMA-J AM MED ASSOC, V275, P1590, DOI 10.1001/jama.275.20.1590; Moritz AR, 1937, AM J PATHOL, V13, P679; MUIRHEAD EE, 1993, J HYPERTENS, V11, pS53; MUIRHEAD EE, 1994, J HYPERTENS, V12; Mulvany MJ, 1999, CARDIOVASC RES, V41, P9, DOI 10.1016/S0008-6363(98)00289-2; NORRELUND H, 1994, HYPERTENSION, V24, P301, DOI 10.1161/01.HYP.24.3.301; OMVIK P, 1980, HYPERTENSION, V2, P515, DOI 10.1161/01.HYP.2.4.515; PERERA G A, 1955, J Chronic Dis, V1, P33, DOI 10.1016/0021-9681(55)90019-9; PESSINA AC, 1993, AM J KIDNEY DIS, V21, P10, DOI 10.1016/S0272-6386(12)70249-4; PICHLER RH, 1995, J AM SOC NEPHROL, V6, P1186; Quiroz Y, 2001, AM J PHYSIOL-RENAL, V281, pF38, DOI 10.1152/ajprenal.2001.281.1.F38; Rajagopalan S, 1996, J CLIN INVEST, V97, P1916, DOI 10.1172/JCI118623; Ray PE, 2001, KIDNEY INT, V59, P1850, DOI 10.1046/j.1523-1755.2001.0590051850.x; Resnick N, 1997, ADV EXP MED BIOL, V430, P155; Rodriguez-Iturbe B, 2001, KIDNEY INT, V59, P1626, DOI 10.1046/j.1523-1755.2001.0590051626.x; Rodriguez-Iturbe B, 2001, KIDNEY INT, V59, P2222, DOI 10.1046/j.1523-1755.2001.00737.x; Sanai T, 1996, J LAB CLIN MED, V128, P89, DOI 10.1016/S0022-2143(96)90117-1; SEALEY JE, 1988, J HYPERTENS, V6, P763, DOI 10.1097/00004872-198811000-00001; Skov K, 1996, HYPERTENSION, V28, P464, DOI 10.1161/01.HYP.28.3.464; SOMMERS SC, 1958, AM J PATHOL, V34, P685; Suga SI, 2001, AM J PHYSIOL-RENAL, V281, pF620, DOI 10.1152/ajprenal.2001.281.4.F620; Tavares P, 1998, J CARDIOVASC PHARM, V31, P46, DOI 10.1097/00005344-199801000-00007; Thomas SE, 1998, J AM SOC NEPHROL, V9, P231; Thyberg J, 1996, INT REV CYTOL, V169, P183, DOI 10.1016/S0074-7696(08)61987-7; Traube L, 1856, ZUSAMMENHANG HERZ NI; Vaziri ND, 2000, HYPERTENSION, V36, P142, DOI 10.1161/01.HYP.36.1.142; Weinberger MH, 1996, HYPERTENSION, V27, P481, DOI 10.1161/01.HYP.27.3.481; Welch WJ, 2000, AM J PHYSIOL-RENAL, V278, pF769, DOI 10.1152/ajprenal.2000.278.5.F769; Welch WJ, 2001, KIDNEY INT, V59, P230, DOI 10.1046/j.1523-1755.2001.00483.x; Wilson C, 1941, Q J MED, V10, P65; Zhong Z, 1998, AM J PHYSIOL-RENAL, V275, pF595, DOI 10.1152/ajprenal.1998.275.4.F595	100	330	361	0	23	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 21	2002	346	12					913	923		10.1056/NEJMra011078	http://dx.doi.org/10.1056/NEJMra011078			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	532FR	11907292				2022-12-28	WOS:000174464100008
J	Li, XM; Yang, YL; Ashwell, JD				Li, XM; Yang, YL; Ashwell, JD			TNF-RII and c-IAP1 mediate ubiquitination and degradation of TRAF2	NATURE			English	Article							TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; CELL-DEATH; SIGNALING COMPLEX; PROTEIN LIGASE; APOPTOSIS; ACTIVATION; RECEPTOR; MICE; SENSITIVITY	Tumour necrosis factor-alpha (TNF-alpha) is a proinflammatory mediator that exerts its biological functions by binding two TNF receptors (TNF-RI and TNF-RII), which initiate biological responses by interacting with adaptor and signalling proteins. Among the signalling components that associate with TNF receptors are members of the TNF-R-associated factor (TRAF) family(1,2). TRAF2 is required for TNF-alpha-mediated activation of c-Jun N-terminal kinase (JNK), contributes to activation of NF-kappaB, and mediates anti- apoptotic signals(3,4). TNF-RI and TNF-RII signalling complexes also contain the anti- apoptotic ('inhibitor of apoptosis') molecules c-IAP1 and c-IAP2 (refs 5, 6), which also have RING domain-dependent ubiquitin protein ligase (E3) activity(7). The function of IAPs in TNF-R signalling is unknown. Here we show that binding of TNF-alpha to TNF-RII induces ubiquitination and proteasomal degradation of TRAF2. Although c-IAP1 bound TRAF2 and TRAF1 in vitro, it ubiquitinated only TRAF2. Expression of wild-type c-IAP1, but not an E3-defective mutant, resulted in TRAF2 ubiquitination and degradation. Moreover, E3-defective c-IAP1 prevented TNF-alpha-induced TRAF2 degradation and inhibited apoptosis. These findings identify a physiologic role for c-IAP1 and define a mechanism by which TNF-RII-regulated ubiquitin protein ligase activity can potentiate TNF-induced apoptosis.	NCI, Lab Immune Cell Biol, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Ashwell, JD (corresponding author), NCI, Lab Immune Cell Biol, NIH, Bethesda, MD 20892 USA.							Arch RH, 2000, BIOCHEM BIOPH RES CO, V272, P936, DOI 10.1006/bbrc.2000.2873; Brown KD, 2001, J EXP MED, V193, P943, DOI 10.1084/jem.193.8.943; Chan FKM, 2000, IMMUNITY, V13, P419, DOI 10.1016/S1074-7613(00)00041-8; Chan FKM, 2000, EUR J IMMUNOL, V30, P652; Clem RJ, 2001, J BIOL CHEM, V276, P7602, DOI 10.1074/jbc.M010259200; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Duckett CS, 1997, GENE DEV, V11, P2810, DOI 10.1101/gad.11.21.2810; Duckett CS, 1996, EMBO J, V15, P2685, DOI 10.1002/j.1460-2075.1996.tb00629.x; ERICKSON SL, 1994, NATURE, V372, P560, DOI 10.1038/372560a0; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Huang HK, 2000, J BIOL CHEM, V275, P26661; Lee SY, 1997, IMMUNITY, V7, P703, DOI 10.1016/S1074-7613(00)80390-8; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; MEMON SA, 1995, J IMMUNOL METHODS, V180, P15, DOI 10.1016/0022-1759(94)00294-7; Peschon JJ, 1998, J IMMUNOL, V160, P943; Reinhard C, 1997, EMBO J, V16, P1080, DOI 10.1093/emboj/16.5.1080; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; SARIN A, 1995, J IMMUNOL, V155, P3716; Shu HB, 1996, P NATL ACAD SCI USA, V93, P13973, DOI 10.1073/pnas.93.24.13973; Tschopp J, 1999, CURR BIOL, V9, pR381, DOI 10.1016/S0960-9822(99)80233-4; VAN AD, 1996, SCIENCE, V274, P787; Weiss T, 1998, J IMMUNOL, V161, P3136; Weiss T, 1997, J IMMUNOL, V158, P2398; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; ZHENG LX, 1995, NATURE, V377, P348, DOI 10.1038/377348a0	30	387	402	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 21	2002	416	6878					345	349		10.1038/416345a	http://dx.doi.org/10.1038/416345a			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	532NP	11907583	Green Published			2022-12-28	WOS:000174482200049
J	Pearson, H				Pearson, H			Breast-cancer survey sets screening age for women	NATURE			English	News Item																		2002, NATURE, V415, P950	1	0	0	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 21	2002	416	6878					251	251		10.1038/416251b	http://dx.doi.org/10.1038/416251b			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	532NP	11907539	Bronze			2022-12-28	WOS:000174482200008
J	Berry, DC; Knapp, P; Raynor, DK				Berry, DC; Knapp, P; Raynor, DK			Provision of information about drug side-effects to patients	LANCET			English	Article								To make informed decisions about taking medicinal drugs, people need accurate information about side-effects. A European Union guideline now recommends use of qualitative descriptions for five bands of risk, ranging from very rare (affecting <0.01% of the population), to very common (>10%). We did four studies of more than 750 people, whom we asked to estimate the probability of having a side-effect on the basis of qualitative and quantitative descriptions. Our results showed that qualitative descriptions led to gross overestimation of risk. Until further work is done on how patients taking the drugs interpret these terms, the terms should not be used in drug information leaflets.	Univ Reading, Dept Psychol, Reading RG6 6AL, Berks, England; Univ Leeds, Pharm Practice & Med Management Grp, Leeds, W Yorkshire, England	University of Reading; University of Leeds	Berry, DC (corresponding author), Univ Reading, Dept Psychol, Earley Gate, Reading RG6 6AL, Berks, England.			Knapp, Peter/0000-0001-5904-8699				Berry DC, 1997, PSYCHOL HEALTH, V12, P467, DOI 10.1080/08870449708406723; European Commission, 1998, GUID READ LAB PACK L; Raynor DK, 2000, PHARM J, V264, P268	3	107	107	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 9	2002	359	9309					853	854		10.1016/S0140-6736(02)07923-0	http://dx.doi.org/10.1016/S0140-6736(02)07923-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	529YV	11897289				2022-12-28	WOS:000174329600017
J	Lamas-Linares, A; Simon, C; Howell, JC; Bouwmeester, D				Lamas-Linares, A; Simon, C; Howell, JC; Bouwmeester, D			Experimental quantum cloning of single photons	SCIENCE			English	Article							ALWAYS; CANNOT	Although perfect copying of unknown quantum systems is forbidden by the laws of quantum mechanics, approximate cloning is possible. A natural way of realizing quantum cloning of photons is by stimulated emission. In this context, the fundamental quantum limit to the quality of the clones is imposed by the unavoidable presence of spontaneous emission. In our experiment, a single input photon stimulates the emission of additional photons from a source on the basis of parametric down-conversion. This leads to the production of quantum clones with near-optima[ fidelity. We also demonstrate universality of the copying procedure by showing that the same fidelity is achieved for arbitrary input states.	Univ Oxford, Ctr Quantum Computat, Oxford OX1 3PU, England; Univ Calif Santa Barbara, Dept Phys, Santa Barbara, CA 93106 USA	University of Oxford; University of California System; University of California Santa Barbara	Lamas-Linares, A (corresponding author), Univ Oxford, Ctr Quantum Computat, Parks Rd, Oxford OX1 3PU, England.		Simon, Christoph/F-8163-2010	Simon, Christoph/0000-0003-0747-8800				Bechmann-Pasquinucci H, 1999, PHYS REV A, V59, P4238, DOI 10.1103/PhysRevA.59.4238; Bruss D, 1998, PHYS REV LETT, V81, P2598, DOI 10.1103/PhysRevLett.81.2598; Buzek V, 1999, PHYS REV A, V60, pR2626, DOI 10.1103/PhysRevA.60.R2626; Buzek V, 1996, PHYS REV A, V54, P1844, DOI 10.1103/PhysRevA.54.1844; CUMMINS HK, IN PRESS PHYS REV LE; De Martini F, 2000, OPT COMMUN, V179, P581, DOI 10.1016/S0030-4018(00)00611-8; DIEKS D, 1982, PHYS LETT A, V92, P271, DOI 10.1016/0375-9601(82)90084-6; Galvao EF, 2000, PHYS REV A, V62, DOI 10.1103/PhysRevA.62.022301; Gisin N, 2002, REV MOD PHYS, V74, P145, DOI 10.1103/RevModPhys.74.145; HERBERT N, 1982, FOUND PHYS, V12, P1171, DOI 10.1007/BF00729622; Huang YF, 2001, PHYS REV A, V64, DOI 10.1103/PhysRevA.64.012315; KWIAT PG, 1995, PHYS REV LETT, V75, P4337, DOI 10.1103/PhysRevLett.75.4337; MANDEL L, 1983, NATURE, V304, P188, DOI 10.1038/304188a0; MILONNI PW, 1982, PHYS LETT A, V92, P321, DOI 10.1016/0375-9601(82)90899-4; Simon C, 2000, PHYS REV LETT, V84, P2993, DOI 10.1103/PhysRevLett.84.2993; WOOTTERS WK, 1982, NATURE, V299, P802, DOI 10.1038/299802a0	16	219	225	2	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 26	2002	296	5568					712	714		10.1126/science.1068972	http://dx.doi.org/10.1126/science.1068972			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	546PD	11923493	Green Submitted			2022-12-28	WOS:000175281700047
J	Bell, SD; Botting, CH; Wardleworth, BN; Jackson, SP; White, MF				Bell, SD; Botting, CH; Wardleworth, BN; Jackson, SP; White, MF			The interaction of Alba, a conserved archaeal, chromatin protein, with Sir2 and its regulation by acetylation	SCIENCE			English	Article								The conserved Sir2 family of proteins has protein deacetylase activity that is dependent on NAD (the oxidized form of nicotinamide adenine dinucleotide). Although histones are one likely target for the enzymatic activity of eukaryotic Sir2 proteins, little is known about the substrates and roles of prokaryotic Sir2 homologs. We reveal that an archaeal Sir2 homolog interacts specifically with the major archaeal chromatin protein, Alba, and that Alba exists in acetylated and nonacetylated forms. Furthermore, we show that Sir2 can deacetylate Alba and mediate transcriptional repression in a reconstituted in vitro transcription system. These data provide a paradigm for how Sir2 family proteins influence transcription and suggest that modulation of chromatin structure by acetylation arose before the divergence of the archaeal and eukaryotic lineages.	Hutchinson MRC Res Ctr, MRC, Canc Cell Unit, Cambridge CB2 2QH, England; Univ St Andrews, Ctr Biomol Sci, St Andrews KY16 9ST, Fife, Scotland; Wellcome Trust Res Labs, Cambridge CB2 1QR, England; Canc Res Campaign, Inst Canc & Dev Biol, Cambridge CB2 1QR, England; Univ Cambridge, Dept Zool, Cambridge, England	University of St Andrews; Wellcome Trust Sanger Institute; CRUK Cambridge Institute; University of Cambridge	Bell, SD (corresponding author), Hutchinson MRC Res Ctr, MRC, Canc Cell Unit, Hills Rd, Cambridge CB2 2QH, England.		White, Malcolm F/A-6055-2010; Dry, Kate/I-2328-2014; Jackson, Stephen Philip/R-4548-2019	White, Malcolm F/0000-0003-1543-9342; Jackson, Stephen Philip/0000-0001-9317-7937; Bell, Stephen/0000-0002-8474-6592				Bell SD, 1999, MOL CELL, V4, P971, DOI 10.1016/S1097-2765(00)80226-9; Bell SD, 2001, CURR OPIN MICROBIOL, V4, P208, DOI 10.1016/S1369-5274(00)00190-9; Forterre P, 1999, MOL MICROBIOL, V32, P669, DOI 10.1046/j.1365-2958.1999.01366.x; Frye RA, 2000, BIOCHEM BIOPH RES CO, V273, P793, DOI 10.1006/bbrc.2000.3000; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Guarente L, 2000, GENE DEV, V14, P1021; Magill CP, 2001, J BIOL CHEM, V276, P46693, DOI 10.1074/jbc.C100567200; Min JR, 2001, CELL, V105, P269, DOI 10.1016/S0092-8674(01)00317-8; Moazed D, 2001, MOL CELL, V8, P489, DOI 10.1016/S1097-2765(01)00340-9; She Q, 2001, P NATL ACAD SCI USA, V98, P7835, DOI 10.1073/pnas.141222098; Tanny JC, 2001, P NATL ACAD SCI USA, V98, P415, DOI 10.1073/pnas.031563798; Tanny JC, 1999, CELL, V99, P735, DOI 10.1016/S0092-8674(00)81671-2	12	219	237	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 5	2002	296	5565					148	151		10.1126/science.1070506	http://dx.doi.org/10.1126/science.1070506			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	539FA	11935028				2022-12-28	WOS:000174858800050
J	Dinnebier, RE; Gunnarsson, O; Brumm, H; Koch, E; Stephens, PW; Huq, A; Jansen, M				Dinnebier, RE; Gunnarsson, O; Brumm, H; Koch, E; Stephens, PW; Huq, A; Jansen, M			Structure of haloform intercalated C-60 and its influence on superconductive properties	SCIENCE			English	Article							POWDER-DIFFRACTION; FULLERIDES; A3C60; C60	CHCl3 and CHBr3 intercalated C-60 have attracted particular interest after a superconductivity transition temperature (T-c) of up to 117 K was discovered. We have determined the structure using synchrotron x-ray powder-diffraction and found that the expansion of the lattice mainly takes place in one dimension (triclinic b axis), leaving planes of C-60 molecules on an approximately hexagonal, slightly expanded lattice. We have performed tight-binding band structure calculations for the surface layer. In spite of the slight expansion of the layers, for the range of dopings where a large T-c has been observed, the density of states at the Fermi energy is smaller for C-60.2CHCl(3) and C-60.2CHBr(3) than for C-60. This suggests that the lattice expansion alone cannot explain the increase of T-c.	Max Planck Inst Festkorperforsch, D-70569 Stuttgart, Germany; SUNY Stony Brook, Dept Phys & Astron, Stony Brook, NY 11974 USA	Max Planck Society; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Jansen, M (corresponding author), Max Planck Inst Festkorperforsch, Heisenbergstr 1, D-70569 Stuttgart, Germany.		Huq, Ashfia/J-8772-2013	Huq, Ashfia/0000-0002-8445-9649				BILL A, UNPUB; DAVID WIF, 1991, NATURE, V353, P147, DOI 10.1038/353147a0; Dinnebier RE, 1999, POWDER DIFFR, V14, P84, DOI 10.1017/S0885715600010356; FLEMING RM, 1991, NATURE, V352, P787, DOI 10.1038/352787a0; GELFAND MP, 1992, PHYS REV LETT, V68, P1050, DOI 10.1103/PhysRevLett.68.1050; GUNNARSSON O, 1995, PHYS REV LETT, V74, P1875, DOI 10.1103/PhysRevLett.74.1875; GUNNARSSON O, 1991, PHYS REV LETT, V67, P3002, DOI 10.1103/PhysRevLett.67.3002; Gunnarsson O, 1997, REV MOD PHYS, V69, P575, DOI 10.1103/RevModPhys.69.575; HILL RJ, 1994, J APPL CRYSTALLOGR, V27, P802, DOI 10.1107/S0021889894000646; JANSEN M, 1995, Z ANORG ALLG CHEM, V621, P14, DOI 10.1002/zaac.19956210105; JONES ME, 1954, J AM CHEM SOC, V76, P1434, DOI 10.1021/ja01634a089; Langford JI, 1996, REP PROG PHYS, V59, P131, DOI 10.1088/0034-4885/59/2/002; LAOUINI N, 1995, PHYS REV B, V51, P17446, DOI 10.1103/PhysRevB.51.17446; RIETVELD HM, 1969, J APPL CRYSTALLOGR, V2, P65, DOI 10.1107/S0021889869006558; ROSSEINSKY MJ, 1991, PHYS REV LETT, V66, P2830, DOI 10.1103/PhysRevLett.66.2830; SCHLUTER M, 1992, J PHYS CHEM SOLIDS, V53, P1473, DOI 10.1016/0022-3697(92)90240-E; Schon JH, 2000, NATURE, V408, P549, DOI 10.1038/35046008; Schon JH, 2000, SCIENCE, V288, P656, DOI 10.1126/science.288.5466.656; Schon JH, 2001, SCIENCE, V293, P2432, DOI 10.1126/science.1064773; Solovyov LA, 2001, RUSS CHEM B+, V50, P78, DOI 10.1023/A:1009577218609; WAIDMANN G, 1996, THESIS U BONN; Wehrli S, 2001, EUR PHYS J B, V23, P345, DOI 10.1007/s100510170054; Yildirim T, 1996, PHYS REV LETT, V77, P167, DOI 10.1103/PhysRevLett.77.167	23	67	72	1	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 5	2002	296	5565					109	113		10.1126/science.1068344	http://dx.doi.org/10.1126/science.1068344			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	539FA	11935022				2022-12-28	WOS:000174858800043
J	Yu, J; Hu, SN; Wang, J; Wong, GKS; Li, SG; Liu, B; Deng, YJ; Dai, L; Zhou, Y; Zhang, XQ; Cao, ML; Liu, J; Sun, JD; Tang, JB; Chen, YJ; Huang, XB; Lin, W; Ye, C; Tong, W; Cong, LJ; Geng, JN; Han, YJ; Li, L; Li, W; Hu, GQ; Huang, XG; Li, WJ; Li, J; Liu, ZW; Li, L; Liu, JP; Qi, QH; Liu, JS; Li, L; Li, T; Wang, XG; Lu, H; Wu, TT; Zhu, M; Ni, PX; Han, H; Dong, W; Ren, XY; Feng, XL; Cui, P; Li, XR; Wang, H; Xu, X; Zhai, WX; Xu, Z; Zhang, JS; He, SJ; Zhang, JG; Xu, JC; Zhang, KL; Zheng, XW; Dong, JH; Zeng, WY; Tao, L; Ye, J; Tan, J; Ren, XD; Chen, XW; He, J; Liu, DF; Tian, W; Tian, CG; Xia, HG; Bao, QY; Li, G; Gao, H; Cao, T; Wang, J; Zhao, WM; Li, P; Chen, W; Wang, XD; Zhang, Y; Hu, JF; Wang, J; Liu, S; Yang, J; Zhang, GY; Xiong, YQ; Li, ZJ; Mao, L; Zhou, CS; Zhu, Z; Chen, RS; Hao, BL; Zheng, WM; Chen, SY; Guo, W; Li, GJ; Liu, SQ; Tao, M; Wang, J; Zhu, LH; Yuan, LP; Yang, HM				Yu, J; Hu, SN; Wang, J; Wong, GKS; Li, SG; Liu, B; Deng, YJ; Dai, L; Zhou, Y; Zhang, XQ; Cao, ML; Liu, J; Sun, JD; Tang, JB; Chen, YJ; Huang, XB; Lin, W; Ye, C; Tong, W; Cong, LJ; Geng, JN; Han, YJ; Li, L; Li, W; Hu, GQ; Huang, XG; Li, WJ; Li, J; Liu, ZW; Li, L; Liu, JP; Qi, QH; Liu, JS; Li, L; Li, T; Wang, XG; Lu, H; Wu, TT; Zhu, M; Ni, PX; Han, H; Dong, W; Ren, XY; Feng, XL; Cui, P; Li, XR; Wang, H; Xu, X; Zhai, WX; Xu, Z; Zhang, JS; He, SJ; Zhang, JG; Xu, JC; Zhang, KL; Zheng, XW; Dong, JH; Zeng, WY; Tao, L; Ye, J; Tan, J; Ren, XD; Chen, XW; He, J; Liu, DF; Tian, W; Tian, CG; Xia, HG; Bao, QY; Li, G; Gao, H; Cao, T; Wang, J; Zhao, WM; Li, P; Chen, W; Wang, XD; Zhang, Y; Hu, JF; Wang, J; Liu, S; Yang, J; Zhang, GY; Xiong, YQ; Li, ZJ; Mao, L; Zhou, CS; Zhu, Z; Chen, RS; Hao, BL; Zheng, WM; Chen, SY; Guo, W; Li, GJ; Liu, SQ; Tao, M; Wang, J; Zhu, LH; Yuan, LP; Yang, HM			A draft sequence of the rice genome (Oryza sativa L. ssp indica)	SCIENCE			English	Article							TRANSPOSABLE ELEMENTS; ARABIDOPSIS-THALIANA; HUMAN GENES; COMPARATIVE GENETICS; BIALLELIC MARKERS; GRASS GENOMES; CPG ISLANDS; DNA; PLANTS; IDENTIFICATION	We have produced a draft sequence of the rice genome for the most widely cultivated subspecies in China, Oryza sativa L. ssp. indica, by whole-genome shotgun sequencing. The genome was 466 megabases in size, with an estimated 46,022 to 55,615 genes. Functional coverage in the assembled sequences was 92.0%. About 42.2% of the genome was in exact 20-nucleotide oligomer repeats, and most of the transposons were in the intergenic regions between genes. Although 80.6% of predicted Arabidopsis thaliana genes had a homolog in rice, only 49.4% of predicted rice genes had a homolog in A. thaliana. The large proportion of rice genes with no recognizable homologs is due to a gradient in the GC-content of rice coding sequences.	Chinese Acad Sci, Inst Genet, Beijing 100101, Peoples R China; Chinese Acad Sci, Beijing Genom Inst, Ctr Genom & Bioinformat, Beijing 101300, Peoples R China; Zhejiang Univ, Hangzhou Genom Inst, Inst Bioinformat, Key Lab Bioinformat Zhejiang Prov, Hangzhou 310007, Peoples R China; Univ Washington, Dept Med, Genome Ctr, Seattle, WA 98195 USA; Peking Univ, Coll Life Sci, Beijing 100871, Peoples R China; Xi An Jiao Tong Univ, Coll Med, Xian 710061, Peoples R China; Fudan Univ, Shanghai 200433, Peoples R China; Natl Hybrid Rice R&D Ctr, Changsha 410125, Peoples R China; Chinese Acad Sci, Inst Biophys, Lab Bioinformat, Beijing 100101, Peoples R China; Digital China Ltd, Beijing 100080, Peoples R China; Chinese Acad Sci, Inst Comp Technol, Beijing 100080, Peoples R China; Chinese Acad Sci, Inst Theoret Phys, Beijing 100080, Peoples R China	Chinese Academy of Sciences; Beijing Genomics Institute (BGI); Chinese Academy of Sciences; Zhejiang University; University of Washington; University of Washington Seattle; Peking University; Xi'an Jiaotong University; Fudan University; Chinese Academy of Sciences; Institute of Biophysics, CAS; Chinese Academy of Sciences; Institute of Computing Technology, CAS; Chinese Academy of Sciences; Institute of Theoretical Physics, CAS	Yuan, LP (corresponding author), Chinese Acad Sci, Inst Genet, Beijing 100101, Peoples R China.	hyang@genomics.org.cn	Hu, Jianfei/A-4949-2011; Xiong, Yuqing/D-5404-2009; Hong, LU/HDM-0673-2022; Li, Xianran/AAH-1070-2019; Li, Wei/A-8544-2009; WONG, Gane Ka-Shu/G-5784-2013; 郑, 征/C-8514-2011; Bao, Qiyu/AAH-6113-2020; Lu, Hong/F-2744-2015; Li, Xianran/I-5651-2012; Chen, Runsheng/S-9834-2017; Wang, Jun/C-8434-2016; Hu, Songnian/C-6509-2013; Wang, Jun/B-9503-2016	Xiong, Yuqing/0000-0001-5826-3696; WONG, Gane Ka-Shu/0000-0001-6108-5560; Bao, Qiyu/0000-0001-6523-8763; Lu, Hong/0000-0002-4026-4292; Li, Xianran/0000-0002-4252-6911; Chen, Runsheng/0000-0001-6049-8347; Wang, Jun/0000-0002-8540-8931; Wang, Hao/0000-0001-7475-0136; Hu, Songnian/0000-0003-3966-3111; Liu, Jianping/0000-0002-7336-3895; Tao, Lin/0000-0001-7494-4758; Wang, Jun/0000-0002-2113-5874; Li, Wei/0000-0001-9931-5990; Jianfei, Hu/0000-0001-8458-6683; Zhang, Jianguo/0000-0003-0723-1701	NIEHS NIH HHS [1 RO1 ES09909] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009909] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Altschul SF, 1996, METHOD ENZYMOL, V266, P460; Apweiler R, 2001, NUCLEIC ACIDS RES, V29, P44, DOI 10.1093/nar/29.1.44; Arumuganathan K, 1991, PLANT MOL BIOL REP, V9, P208, DOI DOI 10.1007/BF02672069; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Ashikawa I, 2001, PLANT J, V26, P617, DOI 10.1046/j.1365-313x.2001.01062.x; Bennetzen JL, 2000, PLANT CELL, V12, P1021, DOI 10.1105/tpc.12.7.1021; BERGET SM, 1995, J BIOL CHEM, V270, P2411, DOI 10.1074/jbc.270.6.2411; BERNARDI G, 1985, SCIENCE, V228, P953, DOI 10.1126/science.4001930; Bernardi G, 2000, GENE, V259, P31, DOI 10.1016/S0378-1119(00)00441-8; Bevan M, 1999, TRENDS GENET, V15, P211, DOI 10.1016/S0168-9525(99)01744-8; Bevan M, 2001, CURR OPIN PLANT BIOL, V4, P105, DOI 10.1016/S1369-5266(00)00144-8; BIRD AP, 1995, TRENDS GENET, V11, P94, DOI 10.1016/S0168-9525(00)89009-5; BIRNBOIM HC, 1983, METHOD ENZYMOL, V100, P243; Blencowe BJ, 2000, TRENDS BIOCHEM SCI, V25, P106, DOI 10.1016/S0968-0004(00)01549-8; Brendel V, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-3-reviews1005; Brett D, 2000, FEBS LETT, V474, P83, DOI 10.1016/S0014-5793(00)01581-7; Breyne P, 2001, CURR OPIN PLANT BIOL, V4, P136, DOI 10.1016/S1369-5266(00)00149-7; Bureau TE, 1996, P NATL ACAD SCI USA, V93, P8524, DOI 10.1073/pnas.93.16.8524; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; Carels N, 2000, GENETICS, V154, P1819; CHARGAFF E, 1950, EXPERIENTIA, V6, P201, DOI 10.1007/BF02173653; Cho RJ, 1999, NAT GENET, V23, P203, DOI 10.1038/13833; Comai L, 2000, PLANT MOL BIOL, V43, P387, DOI 10.1023/A:1006480722854; Croft L, 2000, NAT GENET, V24, P340, DOI 10.1038/74153; Davenport RJ, 2001, SCIENCE, V291, P807, DOI 10.1126/science.291.5511.2071; Delcher AL, 1999, NUCLEIC ACIDS RES, V27, P4636, DOI 10.1093/nar/27.23.4636; DEVAN M, 2001, CURR OPIN PLANT BIOL, V4, P105; Devos KM, 1999, GENOME RES, V9, P825, DOI 10.1101/gr.9.9.825; Dickson D, 2001, NATURE, V409, P551, DOI 10.1038/35054705; Drenkard E, 2000, PLANT PHYSIOL, V124, P1483, DOI 10.1104/pp.124.4.1483; Eckardt N A, 2000, Plant Cell, V12, P2011; Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186; Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175; Eyre-Walker A, 2001, NAT REV GENET, V2, P549, DOI 10.1038/35080577; Feuillet C, 1999, P NATL ACAD SCI USA, V96, P8265, DOI 10.1073/pnas.96.14.8265; FILIPSKI J, 1973, J MOL BIOL, V80, P177, DOI 10.1016/0022-2836(73)90240-4; FITCH WM, 1970, SYST ZOOL, V19, P99, DOI 10.2307/2412448; Forsdyke DR, 2000, GENE, V261, P127, DOI 10.1016/S0378-1119(00)00472-8; Gale MD, 1998, P NATL ACAD SCI USA, V95, P1971, DOI 10.1073/pnas.95.5.1971; Gale MD, 1998, SCIENCE, V282, P656, DOI 10.1126/science.282.5389.656; Gasteiger E, 2001, Curr Issues Mol Biol, V3, P47; Gautier C, 2000, CURR OPIN GENET DEV, V10, P656, DOI 10.1016/S0959-437X(00)00144-1; Ge S, 1999, P NATL ACAD SCI USA, V96, P14400, DOI 10.1073/pnas.96.25.14400; Goff SA, 1999, CURR OPIN PLANT BIOL, V2, P86, DOI 10.1016/S1369-5266(99)80018-1; Hanke J, 1999, TRENDS GENET, V15, P389, DOI 10.1016/S0168-9525(99)01830-2; Hastings ML, 2001, CURR OPIN CELL BIOL, V13, P302, DOI 10.1016/S0955-0674(00)00212-X; HATANO S, 1992, PLANT SCI, V83, P55, DOI 10.1016/0168-9452(92)90062-Q; ISLAM SA, 1995, PROTEIN ENG, V8, P513, DOI 10.1093/protein/8.6.513; JACOB F, 1977, SCIENCE, V196, P1161, DOI 10.1126/science.860134; Jiang N, 2001, PLANT CELL, V13, P2553, DOI 10.1105/tpc.13.11.2553; Jurka J, 2000, TRENDS GENET, V16, P418, DOI 10.1016/S0168-9525(00)02093-X; Karlin S, 1998, ANNU REV GENET, V32, P185, DOI 10.1146/annurev.genet.32.1.185; Kaul S, 2000, NATURE, V408, P796, DOI 10.1038/35048692; Kennedy SP, 2001, GENOME RES, V11, P1641, DOI 10.1101/gr.190201; Kruglyak L, 1997, NAT GENET, V17, P21, DOI 10.1038/ng0997-21; Kumar A, 1999, ANNU REV GENET, V33, P479, DOI 10.1146/annurev.genet.33.1.479; LANDER E S, 1988, Genomics, V2, P231; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LARSEN F, 1992, GENOMICS, V13, P1095, DOI 10.1016/0888-7543(92)90024-M; Liu H, 2001, GENOME RES, V11, P2020, DOI 10.1101/gr.194501; Long M, 2001, CURR OPIN GENET DEV, V11, P673, DOI 10.1016/S0959-437X(00)00252-5; Lorkovic ZJ, 2000, TRENDS PLANT SCI, V5, P160, DOI 10.1016/S1360-1385(00)01595-8; Lukashin AV, 1998, NUCLEIC ACIDS RES, V26, P1107, DOI 10.1093/nar/26.4.1107; Mao L, 2000, GENOME RES, V10, P982, DOI 10.1101/gr.10.7.982; Martienssen R, 2001, CELL, V105, P571, DOI 10.1016/S0092-8674(01)00382-8; MASTERSON J, 1994, SCIENCE, V264, P421, DOI 10.1126/science.264.5157.421; Mayer K, 2001, GENOME RES, V11, P1167, DOI 10.1101/gr.GR-1617R; Messing J, 1998, P NATL ACAD SCI USA, V95, P2017, DOI 10.1073/pnas.95.5.2017; MESSING J, 2001, TRENDS GENET, V6, P196; Mironov AA, 1999, GENOME RES, V9, P1288, DOI 10.1101/gr.9.12.1288; Modrek B, 2001, NUCLEIC ACIDS RES, V29, P2850, DOI 10.1093/nar/29.13.2850; Nekrutenko A, 2001, TRENDS GENET, V17, P619, DOI 10.1016/S0168-9525(01)02445-3; RICHARDS RI, 1992, CELL, V70, P709, DOI 10.1016/0092-8674(92)90302-S; Rieseberg LH, 1997, ANNU REV ECOL SYST, V28, P359, DOI 10.1146/annurev.ecolsys.28.1.359; Rogic S, 2001, GENOME RES, V11, P817, DOI 10.1101/gr.147901; ROLFE R, 1959, P NATL ACAD SCI USA, V45, P1039, DOI 10.1073/pnas.45.7.1039; SAKATA K, 2000, 4 ANN C COMP GEN, P31; Salamov AA, 2000, GENOME RES, V10, P516, DOI 10.1101/gr.10.4.516; Sambrook J., 2001, MOL CLONING; Sanchez-Fernandez R, 2001, TRENDS PLANT SCI, V6, P347, DOI 10.1016/S1360-1385(01)02038-6; Sasaki T, 2000, CURR OPIN PLANT BIOL, V3, P138, DOI 10.1016/S1369-5266(99)00047-3; SCHLOTTERER C, 1992, NUCLEIC ACIDS RES, V20, P211, DOI 10.1093/nar/20.2.211; Schmidt R, 2000, CURR OPIN PLANT BIOL, V3, P97, DOI 10.1016/S1369-5266(99)00048-5; Smit AFA, 1996, CURR OPIN GENET DEV, V6, P743, DOI 10.1016/S0959-437X(96)80030-X; Sowdhamini R, 1996, FOLD DES, V1, P209, DOI 10.1016/S1359-0278(96)00032-6; SUEOKA N, 1959, NATURE, V183, P1429, DOI 10.1038/1831429a0; Surzycki SA, 2000, P NATL ACAD SCI USA, V97, P245, DOI 10.1073/pnas.97.1.245; Tao Q.Z., 1994, CELL RES, V4, P127; Tarchini R, 2000, PLANT CELL, V12, P381, DOI 10.1105/tpc.12.3.381; TAUTZ D, 1986, NATURE, V322, P652, DOI 10.1038/322652a0; Temnykh S, 2001, GENOME RES, V11, P1441, DOI 10.1101/gr.184001; TEMNYKH S, 1994, NAT GENET, V6, P114; Tenaillon MI, 2001, P NATL ACAD SCI USA, V98, P9161, DOI 10.1073/pnas.151244298; Turcotte K, 2001, PLANT J, V25, P169, DOI 10.1046/j.1365-313x.2001.00945.x; UMEHARA Y, 1995, MOL BREEDING, V1, P79, DOI 10.1007/BF01682091; van Dodeweerd AM, 1999, GENOME, V42, P887, DOI 10.1139/gen-42-5-887; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Vicient CM, 2001, PLANT PHYSIOL, V125, P1283, DOI 10.1104/pp.125.3.1283; WANG GL, 1995, PLANT J, V7, P525, DOI 10.1046/j.1365-313X.1995.7030525.x; WANG J, IN PRESS GENOME RES; Wheelan SJ, 2000, BIOINFORMATICS, V16, P613, DOI 10.1093/bioinformatics/16.7.613; Wong GKS, 2000, GENOME RES, V10, P1672, DOI 10.1101/gr.148900; Wong GKS, 2001, GENOME RES, V11, P1975, DOI 10.1101/gr.202401; WONG GKS, IN PRESS GENOME RES; Yu J, 2001, CHINESE SCI BULL, V46, P1937, DOI 10.1007/BF02901901; YUAN LP, 1997, HYBRID RICE, V1, P1; Zhang, 1997, JIANGSU AGR SCI, V4, P13; Zhang XY, 2001, P NATL ACAD SCI USA, V98, P12572, DOI 10.1073/pnas.211442198	109	2460	2957	21	469	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 5	2002	296	5565					79	92		10.1126/science.1068037	http://dx.doi.org/10.1126/science.1068037			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	539FA	11935017				2022-12-28	WOS:000174858800038
J	Jia, JH; Amanal, K; Wang, GL; Tang, J; Wang, B; Jiang, J				Jia, JH; Amanal, K; Wang, GL; Tang, J; Wang, B; Jiang, J			Shaggy/GSK3 antagonizes Hedgehog signalling by regulating Cubitus interruptus	NATURE			English	Article							PROTEIN-KINASE-A; TRANSCRIPTIONAL ACTIVATOR; SUBCELLULAR-LOCALIZATION; LIMB DEVELOPMENT; GENE-EXPRESSION; REPRESSOR FORMS; DROSOPHILA; PROTEOLYSIS; SUPPRESSOR; COSTAL2	The Drosophila protein Shaggy (Sgg, also known as Zeste-white3, Zw3) and its vertebrate orthologue glycogen synthase kinase 3 (GSK3) are inhibitory components of the Wingless (Wg) and Wnt pathways(1). Here we show that Sgg is also a negative regulator in the Hedgehog (Hh) pathway. In Drosophila, Hh acts both by blocking the proteolytic processing of full-length Cubitus interruptus, Ci (Ci155), to generate a truncated repressor form( Ci75), and by stimulating the activity of accumulated Ci155 (refs 2-6). Loss of sgg gene function results in a cell-autonomous accumulation of high levels of Ci155 and the ectopic expression of Hh-responsive genes including decapentaplegic (dpp) and wg. Simultaneous removal of sgg and Suppressor of fused, Su(fu)(7), results in wing duplications similar to those caused by ectopic Hh signalling. Ci is phosphorylated by GSK3 after a primed phosphorylation by protein kinase A (PKA), and mutating GSK3-phosphorylation sites in Ci blocks its processing and prevents the production of the repressor form. We propose that Sgg/GSK3 acts in conjunction with PKA to cause hyperphosphorylation of Ci, which targets it for proteolytic processing, and that Hh opposes Ci proteolysis by promoting its dephosphorylation.	Univ Texas, SW Med Ctr, Ctr Dev Biol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Div Cell & Mol Biol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Jiang, J (corresponding author), Univ Texas, SW Med Ctr, Ctr Dev Biol, Dallas, TX 75390 USA.			Jia, Jianhang/0000-0002-9313-3843	NIGMS NIH HHS [R01 GM061269] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061269] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altaba ARI, 1999, TRENDS GENET, V15, P418, DOI 10.1016/S0168-9525(99)01840-5; AzaBlanc P, 1997, CELL, V89, P1043, DOI 10.1016/S0092-8674(00)80292-5; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BRAND AH, 1993, DEVELOPMENT, V118, P401; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Chen CH, 1999, CELL, V98, P305, DOI 10.1016/S0092-8674(00)81960-1; Chen Y, 1996, CELL, V87, P553, DOI 10.1016/S0092-8674(00)81374-4; Chen Y, 1999, DEVELOPMENT, V126, P3607; Denef N, 2000, CELL, V102, P521, DOI 10.1016/S0092-8674(00)00056-8; INGHAM PW, 1995, CURR OPIN GENET DEV, V5, P492, DOI 10.1016/0959-437X(95)90054-K; Jiang J, 1998, NATURE, V391, P493, DOI 10.1038/35154; Jiang J, 1996, CELL, V86, P401, DOI 10.1016/S0092-8674(00)80113-0; JIANG J, 1995, CELL, V80, P563, DOI 10.1016/0092-8674(95)90510-3; Kim L, 2000, CURR OPIN GENET DEV, V10, P508, DOI 10.1016/S0959-437X(00)00120-9; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Methot N, 1999, CELL, V96, P819, DOI 10.1016/S0092-8674(00)80592-9; Nash P, 2001, NATURE, V414, P514, DOI 10.1038/35107009; Ohlmeyer JT, 1998, NATURE, V396, P749, DOI 10.1038/25533; PREAT T, 1992, GENETICS, V132, P725; Price MA, 1999, DEVELOPMENT, V126, P4331; Roelink H, 1996, CURR OPIN NEUROBIOL, V6, P33, DOI 10.1016/S0959-4388(96)80006-7; RUEL L, 1993, EMBO J, V12, P1657, DOI 10.1002/j.1460-2075.1993.tb05811.x; Sisson JC, 1997, CELL, V90, P235, DOI 10.1016/S0092-8674(00)80332-3; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; Villavicencio EH, 2000, AM J HUM GENET, V67, P1047, DOI 10.1016/S0002-9297(07)62934-6; Wang GL, 2000, GENE DEV, V14, P2893, DOI 10.1101/gad.843900; Wang GL, 1999, GENE DEV, V13, P2828, DOI 10.1101/gad.13.21.2828; Wang QT, 1999, DEVELOPMENT, V126, P5097; Yost C, 1998, CELL, V93, P1031, DOI 10.1016/S0092-8674(00)81208-8; Zecca M, 1996, CELL, V87, P833, DOI 10.1016/S0092-8674(00)81991-1	30	234	243	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 4	2002	416	6880					548	552		10.1038/nature733	http://dx.doi.org/10.1038/nature733			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	537JY	11912487				2022-12-28	WOS:000174756500047
J	Lotti, M; Nicotera, P				Lotti, M; Nicotera, P			A risky business	NATURE			English	Editorial Material									Univ Padua, Sch Med, I-35128 Padua, Italy; Univ Leicester, MRC, Toxicol Unit, Leicester LE1 9HN, Leics, England	University of Padua; University of Leicester	Lotti, M (corresponding author), Univ Padua, Sch Med, Via Giustiniani 2, I-35128 Padua, Italy.							Berry C, 2001, TRENDS PHARMACOL SCI, V22, P277, DOI 10.1016/S0165-6147(00)01680-1; Gibbons M, 1999, NATURE, V402, pC81, DOI 10.1038/35011576; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Smith LL, 2001, TRENDS PHARMACOL SCI, V22, P281, DOI 10.1016/S0165-6147(00)01714-4; US National Research Council (NRC), 1994, COMM RISK ASS HAZ AI	6	15	16	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 4	2002	416	6880					481	481		10.1038/416481a	http://dx.doi.org/10.1038/416481a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	537JY	11932722	Bronze			2022-12-28	WOS:000174756500022
J	Higashi, MK; Veenstra, DL; Kondo, LML; Wittkowsky, AK; Srinouanprachanh, SL; Farin, FM; Rettie, AE				Higashi, MK; Veenstra, DL; Kondo, LML; Wittkowsky, AK; Srinouanprachanh, SL; Farin, FM; Rettie, AE			Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BLEEDING COMPLICATIONS; CYTOCHROME-P450 CYP2C9; DOSE REQUIREMENT; RISK-FACTORS; POLYMORPHISM; SENSITIVITY; (S)-WARFARIN; ENANTIOMERS; METABOLISM	Context Warfarin is a commonly used anticoagulant that requires careful clinical management to balance the risks of overanticoagulation and bleeding with those of under-anticoagulation and clotting. The principal enzyme involved in warfarin metabolism is CYP2C9, and 2 relatively common variant forms with reduced activity have been identified, CYP2C9*2 and CYP2C93. Patients with these genetic variants have been shown to require lower maintenance doses of warfarin, but a direct association between CYP2C9 genotype and anticoagulation status or bleeding risk has not been established. Objective To determine if CYP2C9*2 and CYP2C9*3 variants are associated with overanticoagulation and bleeding events during warfarin therapy. Design and Setting Retrospective cohort study conducted at 2 anticoagulation clinics based in Seattle, Wash. Participants Two hundred patients receiving long-term warfarin therapy for various indications during April 3, 1990, to May 31, 2001. Only patients with a complete history of warfarin exposure were included, Main Outcome Measures Anticoagulation status, measured by time to therapeutic international normalized ratio (INR), rate of above-range INRs, and time to stable warfarin dosing; and time to serious or life-threatening bleeding events. Results Among 185 patients with analyzable data, 58 (31.4%) had at least 1 variant CYP2C9 allele and 127 (68.6%) had the wild-type (*1/*1) genotype. Mean maintenance dose varied significantly among the 6 genotype groups (*1/*1 [n = 127], *1/*2 [n =28], *1/*3 [n = 18], *2/*2 [n=4], *2/*3 [n=3], *3/*3 [n =5]) (by Kruskall-Wallis test, chi(5)(2) =37.348; P<.001). Compared with patients with the wild-type genotype, patients with at least 1 variant allele had an increased risk of above-range INRs (hazard ratio [HR], 1.40; 95% confidence interval [CI], 1.03-1.90). The variant group also required more me to achieve stable dosing (HR, 0.65; 95% Cl, 0.45-0.94), with a median difference of 95 days (P=.004). In addition, although numbers were small for some genotypes, representing potentially unstable estimates, patients with a variant genotype had a significantly increased risk of a serious or life-threatening bleeding event (HR, 2.39; 95% Cl, 1.18-4.86). Conclusions The results of our study suggest that the CYP2C9*2 and CYP2C9*3 polymorphisms are associated with an increased risk of overanticoagulation and of bleeding events among patients in a warfarin anticoagulation clinic setting, although small numbers in some cases would suggest the need for caution in interpretation. Screening for CYP2C9 variants may allow clinicians to develop dosing protocols and surveillance techniques to reduce the risk of adverse drug reactions in patients receiving warfarin.	Univ Washington, Med Ctr, Pharmaceut Outcomes Res & Policy Program, Seattle, WA 98195 USA; Univ Washington, Med Ctr, Inst Publ Hlth Genet, Seattle, WA 98195 USA; Univ Washington, Med Ctr, Dept Pharm Serv, Seattle, WA 98195 USA; Univ Washington, Ctr Ecogenet & Environm Hlth, Mol Biomarkers Lab, Seattle, WA 98195 USA; Univ Washington, Dept Med Chem, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Veenstra, DL (corresponding author), Univ Washington, Dept Pharm, Box 357630,Hlth Sci Bldg,Room H-375A, Seattle, WA 98195 USA.	veen-stra@u.washington.edu			NIEHS NIH HHS [P30 ES07033] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007033] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aithal GP, 1999, LANCET, V353, P717, DOI 10.1016/S0140-6736(98)04474-2; CLAYTON D, 1998, OXFORD SCI PUBLICATI, P298; Crespi CL, 1997, PHARMACOGENETICS, V7, P203, DOI 10.1097/00008571-199706000-00005; Dickmann LJ, 2001, MOL PHARMACOL, V60, P382, DOI 10.1124/mol.60.2.382; Fihn SD, 1996, ANN INTERN MED, V124, P970, DOI 10.7326/0003-4819-124-11-199606010-00004; FIHN SD, 1993, ANN INTERN MED, V118, P511, DOI 10.7326/0003-4819-118-7-199304010-00005; Furuya H, 1995, PHARMACOGENETICS, V5, P389, DOI 10.1097/00008571-199512000-00008; Haining RL, 1996, ARCH BIOCHEM BIOPHYS, V333, P447, DOI 10.1006/abbi.1996.0414; Harrison L, 1997, ANN INTERN MED, V126, P133, DOI 10.7326/0003-4819-126-2-199701150-00006; Henne KR, 1998, J CHROMATOGR B, V710, P143, DOI 10.1016/S0378-4347(98)00099-1; Hirsh J, 2001, CHEST, V119, p8S, DOI 10.1378/chest.119.1_suppl.8S; Hirsh J, 2001, AM HEART J, V142, pS3, DOI 10.1067/mhj.2001.117031; HOSMER DW, 1999, APPL SURVIVAL ANAL R, P308; HYLEK EM, 1994, ANN INTERN MED, V120, P897, DOI 10.7326/0003-4819-120-11-199406010-00001; INCIARDI JF, 1994, THER DRUG MONIT, V16, P425, DOI 10.1097/00007691-199408000-00015; KHOURY MJ, 1993, FUNDAMENTALS GENETIC, P49; Kimura M, 1998, THER DRUG MONIT, V20, P243, DOI 10.1097/00007691-199806000-00001; KOUDSTAAL PJ, 1995, NEW ENGL J MED, V333, P5; Leung AYH, 2001, BLOOD, V98, P2584, DOI 10.1182/blood.V98.8.2584; Loebstein R, 2001, CLIN PHARMACOL THER, V70, P159, DOI 10.1067/mcp.2001.117444; MCBRIDE R, 1994, LANCET, V343, P687; Nasu K, 1997, PHARMACOGENETICS, V7, P405, DOI 10.1097/00008571-199710000-00011; Phillips KA, 2001, JAMA-J AM MED ASSOC, V286, P2270, DOI 10.1001/jama.286.18.2270; RETTIE AE, 1992, CHEM RES TOXICOL, V5, P54, DOI 10.1021/tx00025a009; Rettie AE, 1999, EPILEPSY RES, V35, P253, DOI 10.1016/S0920-1211(99)00017-0; Stubbins MJ, 1996, PHARMACOGENETICS, V6, P429, DOI 10.1097/00008571-199610000-00007; SullivanKlose TH, 1996, PHARMACOGENETICS, V6, P341, DOI 10.1097/00008571-199608000-00007; Takahashi H, 1998, CLIN PHARMACOL THER, V63, P519, DOI 10.1016/S0009-9236(98)90103-5; Takahashi H, 1998, PHARMACOGENETICS, V8, P365, DOI 10.1097/00008571-199810000-00001; Takanashi K, 2000, PHARMACOGENETICS, V10, P95, DOI 10.1097/00008571-200003000-00001; Taube J, 2000, BLOOD, V96, P1816, DOI 10.1182/blood.V96.5.1816.h8001816_1816_1819; Thompson E. A., 2000, NSF CBMS REGIONAL C, V6; VANDERMEER FJM, 1993, ARCH INTERN MED, V153, P1557, DOI 10.1001/archinte.153.13.1557; Veenstra DL, 2000, AAPS PHARMSCI, V2, part. no.; Weir B.S., 1996, GENETIC DATA ANAL; WITTKOWSKY AK, 2001, APPL THERAPEUTICS CL; Yasar U, 1999, BIOCHEM BIOPH RES CO, V254, P628, DOI 10.1006/bbrc.1998.9992	37	820	882	1	35	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 3	2002	287	13					1690	1698		10.1001/jama.287.13.1690	http://dx.doi.org/10.1001/jama.287.13.1690			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	536YW	11926893	Bronze			2022-12-28	WOS:000174730300023
J	Edhouse, J; Morris, F				Edhouse, J; Morris, F			ABC of clinical electrocardiography - Broad complex tachycardia - Part II	BRITISH MEDICAL JOURNAL			English	Article									Stepping Hill Hosp, Stockport SK2 7JE, Lancs, England; No Gen Hosp, Sheffield S5 7AU, S Yorkshire, England	Northern General Hospital	Edhouse, J (corresponding author), Stepping Hill Hosp, Stockport SK2 7JE, Lancs, England.								0	5	5	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 30	2002	324	7340					776	779		10.1136/bmj.324.7340.776	http://dx.doi.org/10.1136/bmj.324.7340.776			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	538KY	11923163	Green Published			2022-12-28	WOS:000174816200021
J	Thomas, KS; Armstrong, S; Avery, A; Po, ALW; O'Neill, C; Young, S; Williams, HC				Thomas, KS; Armstrong, S; Avery, A; Po, ALW; O'Neill, C; Young, S; Williams, HC			Randomised controlled trial of short bursts of a potent topical corticosteroid versus prolonged use of a mild preparation for children with mild or moderate atopic eczema	BRITISH MEDICAL JOURNAL			English	Article							SEVERITY SCORE; DERMATITIS; MANAGEMENT; CHILDHOOD	Objective To determine whether a three day burst of a potent corticosteroid is more effective than a mild preparation used for seven days in children with mild or moderate atopic eczema. Design Randomised, double blind, parallel group study of 18 weeks' duration. Setting 13 general practices and a teaching hospital in the Nottingham area. Participants 174 children with mild or moderate atopic eczema recruited from general practices and 33 from a hospital outpatient clinic. Interventions 0.1% betamethasone valerate applied for three days followed by the base ointment for four days versus 1% hydrocortisone applied for seven days. Main outcome measures Primary outcomes were total number of scratch-free days and number of relapses. Secondary outcomes were median duration of relapses, number of undisturbed nights, disease severity (six area, six sign atopic dermatitis severity scale), scores on two quality of life measures (children's life quality index and dermatitis family impact questionnaire), and number of patients in whom treatment failed in each arm. Results No differences were found between the two groups. This was consistent for all outcomes. The median number of scratch-free days was 118.0 for the mild group and 117.5 for the potent group (difference 0.5, 95% confidence interval -2.0 to 4.0, P = 0.53). The median number of relapses for both groups was 1.0. Both groups showed clinically important improvements in disease severity mid quality of life compared with baseline. Conclusion A short burst of a potent topical corticosteroid is just as effective as prolonged use of a milder preparation for controlling mild or moderate atopic eczema in children.	Queens Med Ctr, Ctr Evidence Based Dermatol, Nottingham NG7 2UH, England; Queens Med Ctr, Div Gen Practice, Nottingham NG7 2UH, England; Queens Med Ctr, Trent Inst Hlth Serv Res, Nottingham NG12 2HJ, England; Aston Univ, Ctr Evidence Based Pharmacotherapy, Birmingham B4 ET, W Midlands, England; Univ Ulster & Harkness, Sch Publ Policy Law & Econ, Newtownabbey, North Ireland; Guys Hosp, Tissue Viabil Unit, London SE1 1YR, England	University of Nottingham; University of Nottingham; University of Nottingham; Aston University; Ulster University; Guy's & St Thomas' NHS Foundation Trust	Williams, HC (corresponding author), Queens Med Ctr, Ctr Evidence Based Dermatol, Nottingham NG7 2UH, England.			williams, hywel/0000-0002-5646-3093; Avery, Anthony/0000-0001-7591-4438; Thomas, Kim/0000-0001-7785-7465				BerthJones J, 1996, BRIT J DERMATOL, V135, P25, DOI 10.1111/j.1365-2133.1996.tb00706.x; *BRIT MED ASS ROYA, 2000, BRIT NAT FORM, P508; Charman C, 2000, ARCH DERMATOL, V136, P763, DOI 10.1001/archderm.136.6.763; Charman CR, 2000, BRIT J DERMATOL, V142, P931, DOI 10.1046/j.1365-2133.2000.03473.x; Emerson RM, 2000, BRIT J DERMATOL, V142, P288, DOI 10.1046/j.1365-2133.2000.03300.x; Emerson RM, 1998, BRIT J DERMATOL, V139, P73; EMERSON RM, 1997, BR J DERMATOL S50, V137, P19; FISHER G, 1996, AUST J DERMATOL, V37, pS10; Glazenburg E, 2001, J INVEST DERMATOL, V117, P533; Hepburn DJ, 1996, PEDIATR DERMATOL, V13, P239, DOI 10.1111/j.1442-200X.1996.tb02624.x; HOARE C, 2000, HEALTH TECHNOL ASSES, V4, P25; HORNSTEIN O, 1991, HDB ATOPIC ECZEMA, P350; Lawson V, 1998, BRIT J DERMATOL, V138, P107; MCHENRY PM, 1995, BMJ-BRIT MED J, V310, P843, DOI 10.1136/bmj.310.6983.843; *PERS SOC SERV RES, 2000, UN COSTS HLTH SOC CA; Schachner LA, 1996, PEDIATR DERMATOL, V13, P513, DOI 10.1111/j.1525-1470.1996.tb00737.x; Serup J., 1995, HDB NONINVASIVE METH; SILLEVIS S, 2001, INT S AT DERM PORTL; Tsukahara K, 2001, BRIT J DERMATOL, V145, P590, DOI 10.1046/j.1365-2133.2001.04430.x; Van der Meer JB, 1999, BRIT J DERMATOL, V140, P1114; VANONSELEN J, 1998, COMMUNITY NURSE  SEP, P28; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P383, DOI 10.1111/j.1365-2133.1994.tb08530.x; Williams HC, 2000, ATOPIC DERMATITIS EP, P41, DOI 10.1017/CBO9780511545771.005	23	92	97	0	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 30	2002	324	7340					768	771		10.1136/bmj.324.7340.768	http://dx.doi.org/10.1136/bmj.324.7340.768			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	538KY	11923161	Green Published, Green Accepted, Green Submitted			2022-12-28	WOS:000174816200018
J	Wiley, JS; Dao-Ung, LP; Gu, BJ; Sluyter, R; Shemon, AN; Li, CP; Taper, J; Gallo, J; Manoharan, A				Wiley, JS; Dao-Ung, LP; Gu, BJ; Sluyter, R; Shemon, AN; Li, CP; Taper, J; Gallo, J; Manoharan, A			A loss-of-function polymorphic mutation in the cytolytic P2X7 receptor gene and chronic lymphocytic leukaemia: a molecular study	LANCET			English	Article							CELL-DEATH; ATP; ACTIVATION; APOPTOSIS; LEUKEMIA; PERMEABILITY; EXPRESSION; INDUCTION; CHANNELS; P2X(7)	Background Chronic lymphocytic leukaemia (CLL) has a familial incidence nearly three times higher than expected for the general population and one predisposing factor might be an inherited failure of mechanisms involved in apoptosis of lymphocytes. Our aim was to ascertain whether or not a defect in a proapoptotic pathway, caused by a single nucleotide polymorphism that results in loss-of-function of P2X7 in healthy individuals, was present in leukaemic 6 lymphocytes of patients with CLL. Methods We extracted genomic DNA from the peripheral blood leucocytes of 36 unrelated individuals with CLL, four individuals with familial CLL, and 46 age-matched controls. We sequenced a PCR product to detect mutations in exon 13 of P2X7. In most patients with CLL, we measured expression and function of the P2X7 receptor by flow cytometry in B lymphocytes and T lymphocytes. Findings The prevalence of the polymorphic mutation and the frequency of the mutant allele were three-fold greater in individuals with CLL than in white, elderly controls. Individuals homozygous for the polymorphic allele had no P2X7 receptor function and heterozygotes had half the mean function of that seen in individuals homozygous for the wildtype allele; amounts of ATP-induced apoptosis varied accordingly. In two families, in which we studied a father-son pair and a sister-sister pair with CLL, loss of P2X7 function arose because of inheritance of one or two 1513A-->C alleles for P2X7. Interpretation Activation of the P2X7 receptor leads to apoptosis of lymphocytes in individuals with CLL, and reduced function of this receptor has an anti-apoptotic effect, resulting in an increase in B-cell numbers. Thus, inheritance of a loss-of-function polymorphic mutation at position 1513 in the P2X7 gene could contribute to the pathogenesis of CLL.	Univ Sydney, Dept Med, Nepean Hosp, Penrith, NSW 2751, Australia; Liverpool Hosp, Dept Haematol, Liverpool, Merseyside, England; Univ New S Wales, St George Hosp, Dept Clin Haematol, Kogarah, NSW, Australia	Nepean Hospital; University of Sydney; St George Hospital; University of New South Wales Sydney	Wiley, JS (corresponding author), Univ Sydney, Dept Med, Nepean Hosp, POB 63, Penrith, NSW 2751, Australia.		Sluyter, Ronald/B-5798-2009	Sluyter, Ronald/0000-0003-4909-686X; Gu, Ben/0000-0001-5500-4453; Wiley, James/0000-0001-9421-4154				Bevan S, 2000, BLOOD, V96, P3982; Bortner CD, 1997, J BIOL CHEM, V272, P32436, DOI 10.1074/jbc.272.51.32436; DAMASHEK W, 1967, BLOOD, V29, P219; Dameshek W, 1929, JAMA-J AM MED ASSOC, V92, P1348, DOI 10.1001/jama.1929.92700420002009b; Di Virgilio F, 2001, BLOOD, V97, P587, DOI 10.1182/blood.V97.3.587; Dohner H, 2000, NEW ENGL J MED, V343, P1910, DOI 10.1056/NEJM200012283432602; DOHNER H, 1995, BLOOD, V85, P1580, DOI 10.1182/blood.V85.6.1580.bloodjournal8561580; Fairbairn IP, 2001, J IMMUNOL, V167, P3300, DOI 10.4049/jimmunol.167.6.3300; Fernando KC, 1999, ARCH BIOCHEM BIOPHYS, V362, P197, DOI 10.1006/abbi.1998.1045; Ferrari D, 1999, FEBS LETT, V447, P71, DOI 10.1016/S0014-5793(99)00270-7; GALTON DAG, 1966, CAN MED ASSOC J, V94, P1005; Gargett CE, 1997, BRIT J PHARMACOL, V122, P911, DOI 10.1038/sj.bjp.0701447; Gu B, 1998, BLOOD, V92, P946; Gu BJ, 2001, J BIOL CHEM, V276, P11135, DOI 10.1074/jbc.M010353200; Gu BJ, 2000, AM J PHYSIOL-CELL PH, V279, pC1189, DOI 10.1152/ajpcell.2000.279.4.C1189; GUNZ FW, 1975, SCAND J HAEMATOL, V15, P117; Humphreys BD, 2000, J BIOL CHEM, V275, P26792; Kim M, 2001, EMBO J, V20, P6347, DOI 10.1093/emboj/20.22.6347; Lammas DA, 1997, IMMUNITY, V7, P433, DOI 10.1016/S1074-7613(00)80364-7; Nicke A, 1998, EMBO J, V17, P3016, DOI 10.1093/emboj/17.11.3016; Nihei OK, 2000, BLOOD, V96, P996, DOI 10.1182/blood.V96.3.996.015k02_996_1005; Rassendren F, 1997, J BIOL CHEM, V272, P5482, DOI 10.1074/jbc.272.9.5482; Rego EM, 2001, J EXP MED, V193, P521, DOI 10.1084/jem.193.4.521; Sharma N, 2000, KIDNEY INT, V57, P803, DOI 10.1046/j.1523-1755.2000.00918.x; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; Stankovic T, 1999, LANCET, V353, P26, DOI 10.1016/S0140-6736(98)10117-4; Wallace RH, 1998, NAT GENET, V19, P366, DOI 10.1038/1252; Wickremasinghe RG, 1999, BLOOD, V93, P3587, DOI 10.1182/blood.V93.11.3587.411k46_3587_3600; Wiernik PH, 2001, BRIT J HAEMATOL, V113, P407, DOI 10.1046/j.1365-2141.2001.02773.x; WILEY JS, 1993, ARCH BIOCHEM BIOPHYS, V305, P54, DOI 10.1006/abbi.1993.1392; WILEY JS, 1989, BLOOD, V73, P1316; ZHENG LM, 1991, J CELL BIOL, V112, P279, DOI 10.1083/jcb.112.2.279	32	128	132	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 30	2002	359	9312					1114	1119		10.1016/S0140-6736(02)08156-4	http://dx.doi.org/10.1016/S0140-6736(02)08156-4			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	536YJ	11943260				2022-12-28	WOS:000174729200011
J	Ovid'ko, IA				Ovid'ko, IA			Materials science - Deformation of nanostructures	SCIENCE			English	Editorial Material							FINE-GRAINED MATERIALS		Russian Acad Sci, Inst Problems Mech Engn, St Petersburg 199178, Russia	Russian Academy of Sciences	Ovid'ko, IA (corresponding author), Russian Acad Sci, Inst Problems Mech Engn, Bolshoj 61,Vas Ostrov, St Petersburg 199178, Russia.							Chow G.-M., 2000, NANOSTRUCTURED FILMS; Gutkin M. Yu., 2001, Reviews on Advanced Materials Science, V2, P80; Gutkin MYu., 2002, J METAST NANOCRYST M, V12, P47, DOI 10.4028/www.scientific.net/jmnm.12.47; Kim HS, 2000, ACTA MATER, V48, P493, DOI 10.1016/S1359-6454(99)00353-5; Kleman M., 1983, POINTS LINES WALLS; Klimanek P, 2001, ADV ENG MATER, V3, P877, DOI 10.1002/1527-2648(200111)3:11<877::AID-ADEM877>3.0.CO;2-L; Koch CC, 1999, MRS BULL, V24, P54, DOI 10.1557/S0883769400051551; Masumura RA, 1998, ACTA MATER, V46, P4527, DOI 10.1016/S1359-6454(98)00150-5; Mayo MJ, 1997, NANOSTRUCT MATER, V9, P717, DOI 10.1016/S0965-9773(97)00158-X; McFadden SX, 1999, NATURE, V398, P684, DOI 10.1038/19486; Mulvaney P, 2001, MRS BULL, V26, P1009, DOI 10.1557/mrs2001.258; Murayama M, 2002, SCIENCE, V295, P2433, DOI 10.1126/science.1067430; Ovid'ko IA, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.046103; Roco M.C, 2000, NANOTECHNOLOGY RES D; *US OFF NAV RES, N000140111020 US OFF	15	221	228	0	48	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 29	2002	295	5564					2386	2386		10.1126/science.1071064	http://dx.doi.org/10.1126/science.1071064			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	536QD	11923518				2022-12-28	WOS:000174712600034
J	Bergqvist, D; Agnelli, G; Cohen, AT; Eldor, A; Nilsson, PE; Le Moigne-Amrani, A; Dietrich-Neto, F				Bergqvist, D; Agnelli, G; Cohen, AT; Eldor, A; Nilsson, PE; Le Moigne-Amrani, A; Dietrich-Neto, F		ENOXACAN II Investigators	Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TOTAL HIP-REPLACEMENT; DOUBLE-BLIND; PROLONGED THROMBOPROPHYLAXIS; PULMONARY-EMBOLISM; HOSPITAL DISCHARGE; THROMBOSIS; HEPARIN; DALTEPARIN; PLACEBO; RISK	Background: Abdominal surgery for cancer carries a high risk of venous thromboembolism, but the optimal duration of postoperative thromboprophylaxis is unknown. Methods: We conducted a double-blind, multicenter trial in which patients undergoing planned curative open surgery for abdominal or pelvic cancer received enoxaparin (40 mg subcutaneously) daily for 6 to 10 days and were then randomly assigned to receive either enoxaparin or placebo for another 21 days. Bilateral venography was performed between days 25 and 31, or sooner if symptoms of venous thromboembolism occurred. The primary end point with respect to efficacy was the incidence of venous thromboembolism between days 25 and 31. The primary safety end point was bleeding during the three-week period after randomization. The patients were followed for three months. Results: The intention-to-treat analysis of efficacy included 332 patients. The rates of venous thromboembolism at the end of the double-blind phase were 12.0 percent in the placebo group and 4.8 percent in the enoxaparin group (P=0.02). This difference persisted at three months (13.8 percent vs. 5.5 percent, P=0.01). Three patients in the enoxaparin group and six in the placebo group died within three months after surgery. There were no significant differences in the rates of bleeding or other complications during the double-blind or follow-up periods. Conclusions: Enoxaparin prophylaxis for four weeks after surgery for abdominal or pelvic cancer is safe and significantly reduces the incidence of venographically demonstrated thrombosis, as compared with enoxaparin prophylaxis for one week. (N Engl J Med 2002;346:975-80.) Copyright (C) 2002 Massachusetts Medical Society.	Acad Hosp, Uppsala, Sweden; Univ Perugia, I-06100 Perugia, Italy; Guys Kings & St Thomas Sch Med, London, England; Tel Aviv Sourasky Med Ctr, Tel Aviv, Israel; Malmo Univ Hosp, Malmo, Sweden; Aventis Pharmaceut, Bridgewater, NJ USA	University of Perugia; University of London; King's College London; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Lund University; Skane University Hospital; Sanofi-Aventis	Bergqvist, D (corresponding author), Univ Uppsala Hosp, Dept Surg, SE-75185 Uppsala, Sweden.							Agnelli G, 1999, BLOOD COAGUL FIBRIN, V10, pS29; Bergqvist D, 1997, BRIT J SURG, V84, P1099; Bergqvist D, 1996, NEW ENGL J MED, V335, P696, DOI 10.1056/NEJM199609053351002; BERGQVIST D, 1985, BRIT J SURG, V72, P105, DOI 10.1002/bjs.1800720211; Bergqvist D, 1999, Value Health, V2, P288, DOI 10.1046/j.1524-4733.1999.24003.x; Cohen AT, 2001, THROMB HAEMOSTASIS, V85, P940; Comp PC, 2001, J BONE JOINT SURG AM, V83A, P336, DOI 10.2106/00004623-200103000-00004; Dahl OE, 1997, THROMB HAEMOSTASIS, V77, P26; Falanga A, 1998, HAEMOSTASIS, V28, P50; FLORDAL PA, 1995, THROMB HAEMOSTASIS, V73, P1096; Geerts WH, 2001, CHEST, V119, p132S, DOI 10.1378/chest.119.1_suppl.132S; HUBER O, 1992, ARCH SURG-CHICAGO, V127, P310; Hull RD, 2000, ARCH INTERN MED, V160, P2208, DOI 10.1001/archinte.160.14.2208; Irani S, 1996, SCHWEIZ MED WSCHR, V126, P386; Lassen MR, 1998, THROMB RES, V89, P281, DOI 10.1016/S0049-3848(98)00018-8; Lausen I, 1998, EUR J SURG, V164, P657; LINDBLAD B, 1991, BRIT MED J, V302, P709, DOI 10.1136/bmj.302.6778.709; MEYER G, 1994, PRESSE MED, V23, P1767; Planes A, 1996, LANCET, V348, P224, DOI 10.1016/S0140-6736(96)01453-5; RICKLES FR, 1983, BLOOD, V62, P14; Ricotta S, 1996, THROMB HAEMOSTASIS, V76, P887; SCURR JH, 1988, BRIT MED J, V297, P28, DOI 10.1136/bmj.297.6640.28; SEVITT S, 1961, BRIT J SURG, V48, P475, DOI 10.1002/bjs.18004821103; Von Tempelhoff GF, 2000, INT J ONCOL, V16, P815	24	754	803	1	12	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 28	2002	346	13					975	980		10.1056/NEJMoa012385	http://dx.doi.org/10.1056/NEJMoa012385			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	534UY	11919306				2022-12-28	WOS:000174608600004
J	Lenzer, J				Lenzer, J			Alteplase for stroke: money and optimistic claims buttress the "brain attack" campaign	BRITISH MEDICAL JOURNAL			English	Article							ACUTE ISCHEMIC STROKE; CONFLICT-OF-INTEREST; THROMBOLYTIC THERAPY; PUBLICATION BIAS; PHYSICIANS; EXPERIENCE; TRIALS		Oak Ridge Journalism, Ellenville, NY 12428 USA		Lenzer, J (corresponding author), Oak Ridge Journalism, Ellenville, NY 12428 USA.							*AAEM WORK GROUP T, POST STAT AM AC EM M; Albers GW, 2000, JAMA-J AM MED ASSOC, V283, P1145, DOI 10.1001/jama.283.9.1145; Allison DB, 1996, INT J OBESITY, V20, P931; *AM HEART ASS COLL, 2000, CIRCULATION S1, V102, P204; American Heart Association, 2000, ANN REP 1999; Angell M, 2000, NEW ENGL J MED, V342, P1516, DOI 10.1056/NEJM200005183422009; Bodenheimer T, 2000, NEW ENGL J MED, V342, P1539, DOI 10.1056/NEJM200005183422024; *CAEP COMM THROMB, POS STAT THROMB THER; Chew LD, 2000, J GEN INTERN MED, V15, P478, DOI 10.1046/j.1525-1497.2000.08014.x; Choudhry NK, 2002, JAMA-J AM MED ASSOC, V287, P612, DOI 10.1001/jama.287.5.612; Clark WM, 2000, STROKE, V31, P811, DOI 10.1161/01.STR.31.4.811; Friedberg M, 1999, JAMA-J AM MED ASSOC, V282, P1453, DOI 10.1001/jama.282.15.1453; Hankey GJ, 1997, MED J AUSTRALIA, V166, P419, DOI 10.5694/j.1326-5377.1997.tb123193.x; Hoffman JR, 2001, ANN EMERG MED, V38, P605, DOI 10.1067/mem.2001.119276; Hoffman JR, 2000, WESTERN J MED, V173, P149, DOI 10.1136/ewjm.173.3.149; Jorgensen HS, 1999, BRIT MED J, V319, P288, DOI 10.1136/bmj.319.7205.288; Katzan IL, 2000, JAMA-J AM MED ASSOC, V283, P1151, DOI 10.1001/jama.283.9.1151; LENZER JL, 2001, MOTHER JONES     JUN; Lexchin J, 1999, WESTERN J MED, V171, P238; Li J, 1998, J Emerg Med, V16, P757; LIBMAN RB, 1995, ARCH NEUROL-CHICAGO, V52, P1119, DOI 10.1001/archneur.1995.00540350113023; LOCKYER B, 1999, WHATS NONPROFITS NAM, P4; Marler JR, 2000, NEUROLOGY, V55, P1649, DOI 10.1212/WNL.55.11.1649; Marsa L., 1997, PRESCRIPTION PROFITS, V160; RENNIE D, 1992, JAMA-J AM MED ASSOC, V267, P411, DOI 10.1001/jama.267.3.411; SOLOMON R, 2001, ACEP NEWS        MAY; Wardlaw JM, 1997, LANCET, V350, P607, DOI 10.1016/S0140-6736(97)03022-5; Welch SJ, 1997, CHEST, V112, P865, DOI 10.1378/chest.112.4.865-a	28	75	76	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 23	2002	324	7339					723	726		10.1136/bmj.324.7339.723	http://dx.doi.org/10.1136/bmj.324.7339.723			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	535ML	11909792	Green Published			2022-12-28	WOS:000174648200023
J	Clapham, DE				Clapham, DE			Signal transduction - Hot and cold TRP ion channels	SCIENCE			English	Editorial Material							CAPSAICIN-RECEPTOR; HEAT		Harvard Univ, Sch Med, Childrens Hosp,Howard Hughes Med Inst, Dept Neurobiol,Cardiovasc Div, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Howard Hughes Medical Institute	Clapham, DE (corresponding author), Harvard Univ, Sch Med, Childrens Hosp,Howard Hughes Med Inst, Dept Neurobiol,Cardiovasc Div, Boston, MA 02115 USA.		Clapham, David/R-5974-2019; Clapham, David/S-1123-2019	Clapham, David/0000-0002-4459-9428				Caterina MJ, 2001, ANNU REV NEUROSCI, V24, P487, DOI 10.1146/annurev.neuro.24.1.487; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Caterina MJ, 1999, NATURE, V398, P436, DOI 10.1038/18906; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; Harteneck C, 2000, TRENDS NEUROSCI, V23, P159, DOI 10.1016/S0166-2236(99)01532-5; MCKERNY DD, 2002, NATURE          0210; Montell C, 2002, MOL CELL, V9, P229, DOI 10.1016/S1097-2765(02)00448-3; PEIER AM, 2002, CELL IMMEDIATE EARLY; Tsavaler L, 2001, CANCER RES, V61, P3760	9	30	38	2	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 22	2002	295	5563					2228	2229		10.1126/science.1070766	http://dx.doi.org/10.1126/science.1070766			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	534AD	11910099				2022-12-28	WOS:000174561700032
J	Giles, J				Giles, J			Diplomats near pact in simmering debate over transgenic foods	NATURE			English	News Item																			0	0	0	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 21	2002	416	6878					252	252		10.1038/416252b	http://dx.doi.org/10.1038/416252b			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	532NP	11907542	Bronze			2022-12-28	WOS:000174482200010
J	Rubin, LJ; Badesch, DB; Barst, RJ; Galie, N; Black, CM; Keogh, A; Pulido, T; Frost, A; Roux, S; Leconte, I; Landzberg, M; Simonneau, G				Rubin, LJ; Badesch, DB; Barst, RJ; Galie, N; Black, CM; Keogh, A; Pulido, T; Frost, A; Roux, S; Leconte, I; Landzberg, M; Simonneau, G		Bosentan Randomized Trial Endothel	Bosentan therapy for pulmonary arterial hypertension	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONTINUOUS INTRAVENOUS EPOPROSTENOL; SYSTEMIC-SCLEROSIS; 6-MINUTE WALK; HEART-FAILURE; PROSTACYCLIN; ENDOTHELIN-1; DISEASE	Background: Endothelin-1 is a potent vasoconstrictor and smooth-muscle mitogen. In a preliminary study, the orally administered dual endothelin-receptor antagonist bosentan improved exercise capacity and cardiopulmonary hemodynamics in patients with pulmonary arterial hypertension. The present trial investigated the effect of bosentan on exercise capacity in a larger number of patients and compared two doses. Methods: In this double-blind, placebo-controlled study, we randomly assigned 213 patients with pulmonary arterial hypertension (primary or associated with connective-tissue disease) to receive placebo or to receive 6.25 mg of bosentan twice daily for 4 weeks followed by either of two doses of bosentan (125 or 250 mg twice daily) for a minimum of 12 weeks. The primary end point was the degree of change in exercise capacity. Secondary end points included the change in the Borg dyspnea index, the change in the World Health Organization (WHO) functional class, and the time to clinical worsening. Results: At week 16, patients treated with bosentan had an improved six-minute walking distance; the mean difference between the placebo group and the combined bosentan groups was 44 m (95 percent confidence interval, 21 to 67; P<0.001). Bosentan also improved the Borg dyspnea index and WHO functional class and increased the time to clinical worsening. Conclusions: The endothelin-receptor antagonist bosentan is beneficial in patients with pulmonary arterial hypertension and is well tolerated at a dose of 125 mg twice daily. Endothelin-receptor antagonism with oral bosentan is an effective approach to therapy for pulmonary arterial hypertension. (N Engl J Med 2002;346:896-903.) Copyright (C) 2002 Massachusetts Medical Society.	Univ Calif San Diego, Div Pulm & Crit Care Med, La Jolla, CA 92037 USA; Univ Colorado, Hlth Sci Ctr, Denver, CO USA; Columbia Presbyterian Med Ctr, Babies & Childrens Hosp, New York, NY 10032 USA; Univ Bologna, Bologna, Italy; Royal Free Hosp, Sch Med, London, England; St Vincents Hosp, Darlinghurst, NSW 2010, Australia; Inst Nacl Cardiol, Mexico City, DF, Mexico; Baylor Coll Med, Houston, TX 77030 USA; Methodist Hosp, Houston, TX 77030 USA; Actelion, Allschwil, Switzerland; Childrens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA; Hop Antoine Beclere, Clamart, France	University of California System; University of California San Diego; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Columbia University; NewYork-Presbyterian Hospital; University of Bologna; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; St Vincents Hospital Sydney; National Institute of Cardiology - Mexico; Baylor College of Medicine; The Methodist Hospital System; The Methodist Hospital - Houston; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Antoine-Beclere - APHP	Rubin, LJ (corresponding author), Univ Calif San Diego, Div Pulm & Crit Care Med, 9300 Campus Point Dr,M-C 7372, La Jolla, CA 92037 USA.		Galie, Nazzareno/F-7004-2014; Simonneau, Gerald/ABE-6614-2020; Kurzyna, Marcin/AAA-1244-2020	Galie, Nazzareno/0000-0003-4271-8670; Kurzyna, Marcin/0000-0002-6746-469X				Badesch DB, 2000, ANN INTERN MED, V132, P425, DOI 10.7326/0003-4819-132-6-200003210-00002; Barst RJ, 1996, NEW ENGL J MED, V334, P296, DOI 10.1056/NEJM199602013340504; BORG GAV, 1982, MED SCI SPORT EXER, V14, P377, DOI 10.1249/00005768-198205000-00012; Channick RN, 2001, LANCET, V358, P1119, DOI 10.1016/S0140-6736(01)06250-X; Chen SJ, 1995, J APPL PHYSIOL, V79, P2122, DOI 10.1152/jappl.1995.79.6.2122; FUSTER V, 1984, CIRCULATION, V70, P580, DOI 10.1161/01.CIR.70.4.580; Galie N., 1996, European Journal of Clinical Investigation, V26, pA48; GIAID A, 1993, NEW ENGL J MED, V328, P1732, DOI 10.1056/NEJM199306173282402; GUYATT GH, 1985, CAN MED ASSOC J, V132, P919; Hoeper MM, 2000, NEW ENGL J MED, V342, P1866, DOI 10.1056/NEJM200006223422503; Krum H, 1999, CIRCULATION, V100, P646; MacLean MR, 1998, PULM PHARMACOL THER, V11, P125, DOI 10.1006/pupt.1998.0126; Miyamoto S, 2000, AM J RESP CRIT CARE, V161, P487, DOI 10.1164/ajrccm.161.2.9906015; Mylona P, 1999, EUR J HEART FAIL, V1, P197, DOI 10.1016/S1388-9842(99)00022-7; Okano Y, 1997, LANCET, V350, P1406; RICH S, 1992, NEW ENGL J MED, V327, P76, DOI 10.1056/NEJM199207093270203; Rich S, 1998, PRIMARY PULMONARY HY; Rubin LJ, 1997, NEW ENGL J MED, V336, P111, DOI 10.1056/NEJM199701093360207; STUPI AM, 1986, ARTHRITIS RHEUM, V29, P515, DOI 10.1002/art.1780290409; UNGERER RG, 1983, AM J MED, V75, P65, DOI 10.1016/0002-9343(83)91169-5; YAMANE K, 1994, INTERNAL MED, V33, P579, DOI 10.2169/internalmedicine.33.579	21	1935	2060	1	89	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 21	2002	346	12					896	903		10.1056/NEJMoa012212	http://dx.doi.org/10.1056/NEJMoa012212			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	532FR	11907289	Bronze			2022-12-28	WOS:000174464100005
J	Auerbach, AD; Goldman, L				Auerbach, AD; Goldman, L			beta-blockers and reduction of cardiac events in noncardiac surgery - Clinical applications	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							ACUTE MYOCARDIAL-INFARCTION; HIGH-RISK PATIENTS; MEDICAL CONSULTANT; CORONARY-DISEASE; VASCULAR-SURGERY; ELDERLY PATIENTS; MORTALITY; ISCHEMIA; INDEX; THERAPY	Recent studies suggest that beta-blockers administered perioperatively may reduce the risk of adverse cardiac events and mortality in patients who have cardiac risk factors and undergo major noncardiac surgery. The objective of this article is to provide practicing physicians with examples of perioperative beta-blocker use in practice by using several hypothetical cases. Although current evidence describing the effectiveness of perioperative beta-blockade may not address all possible clinical situations, it is possible to formulate an evidence-based approach that will maximize benefit to patients. We describe how information from several sources can be used to guide management of patients with limited exercise tolerance, those at highest risk for perioperative cardiac events, patients who are taking beta-blockers long-term, and those with relative contraindications to beta-blockade. Even though fine points of their use remain to be elucidated, perioperative beta-blocker use is important and can be easily applied in practice by any physician involved with the care of patients perioperatively.	Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Auerbach, AD (corresponding author), Univ Calif San Francisco, Dept Med, Box 0120, San Francisco, CA 94143 USA.							ASHTON CM, 1993, ANN INTERN MED, V118, P504, DOI 10.7326/0003-4819-118-7-199304010-00004; Belzberg H, 1999, CHEST, V115, p82S, DOI 10.1378/chest.115.suppl_2.82S; Boersma E, 2001, JAMA-J AM MED ASSOC, V285, P1865, DOI 10.1001/jama.285.14.1865; BROWNER WS, 1992, JAMA-J AM MED ASSOC, V268, P228, DOI 10.1001/jama.268.2.228; Collins TC, 1999, ANN SURG, V230, P251, DOI 10.1097/00000658-199908000-00016; DETSKY AS, 1986, ARCH INTERN MED, V146, P2131, DOI 10.1001/archinte.146.11.2131; EAGLE KA, 2002, ACC AHA GUIDELINE UP; FOSTER ED, 1986, ANN THORAC SURG, V41, P42, DOI 10.1016/S0003-4975(10)64494-3; Gilbert K, 2000, ANN INTERN MED, V133, P356, DOI 10.7326/0003-4819-133-5-200009050-00011; Goldman L, 1987, J Cardiothorac Anesth, V1, P237, DOI 10.1016/S0888-6296(87)80011-X; GOLDMAN L, 1977, NEW ENGL J MED, V297, P845, DOI 10.1056/NEJM197710202971601; GURWITZ JH, 1992, AM J MED, V93, P605, DOI 10.1016/0002-9343(92)90192-E; Hassan SA, 2001, AM J MED, V110, P260, DOI 10.1016/S0002-9343(00)00717-8; KHURI SF, 1995, J AM COLL SURGEONS, V180, P519; Krumholz HM, 1999, ANN INTERN MED, V131, P648, DOI 10.7326/0003-4819-131-9-199911020-00003; Krumholz HM, 1998, JAMA-J AM MED ASSOC, V280, P623, DOI 10.1001/jama.280.7.623; Lawrence VA, 1995, J GEN INTERN MED, V10, P671, DOI 10.1007/BF02602761; Lee TH, 1999, CIRCULATION, V100, P1043, DOI 10.1161/01.CIR.100.10.1043; Lee TH, 1999, NEW ENGL J MED, V341, P1838, DOI 10.1056/NEJM199912093412410; Mangano DT, 1995, NEW ENGL J MED, V333, P1750, DOI 10.1056/NEJM199512283332607; Mangano DT, 1996, NEW ENGL J MED, V335, P1713, DOI 10.1056/NEJM199612053352301; MANGANO DT, 1997, NEW ENGL J MED, V336, P1452; MERLI GJ, 1993, CLIN CHEST MED, V14, P205; MERLI GJ, 1987, MED CLIN N AM, V71, P353, DOI 10.1016/S0025-7125(16)30844-6; Palda VA, 1997, ANN INTERN MED, V127, P309, DOI 10.7326/0003-4819-127-4-199708150-00012; Poldermans D, 1999, NEW ENGL J MED, V341, P1789, DOI 10.1056/NEJM199912093412402; Raby KE, 1999, ANESTH ANALG, V88, P477, DOI 10.1097/00000539-199903000-00002; Radford MJ, 1998, NEW ENGL J MED, V339, P551, DOI 10.1056/NEJM199808203390809; SHOJANIA KG, 2001, PUBLICATION AGENCY H; Soumeral SB, 1997, JAMA-J AM MED ASSOC, V277, P115, DOI 10.1001/jama.277.2.115; STONE JG, 1988, ANESTHESIOLOGY, V68, P495, DOI 10.1097/00000542-198804000-00004; Urban MK, 2000, ANESTH ANALG, V90, P1257, DOI 10.1097/00000539-200006000-00001; White CM, 1999, ANN PHARMACOTHER, V33, P1063, DOI 10.1345/aph.18395	33	82	87	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 20	2002	287	11					1445	1447		10.1001/jama.287.11.1445	http://dx.doi.org/10.1001/jama.287.11.1445			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	532GB	11903032				2022-12-28	WOS:000174465000027
J	Ganote, CE; Armstrong, SC				Ganote, CE; Armstrong, SC			Dystrophin-associated protein complex and heart failure	LANCET			English	Editorial Material							BETA-DYSTROGLYCAN; DOMAIN; PHOSPHORYLATION; CARDIOMYOPATHY; REGION; KINASE		E Tennessee State Univ, James H Quillen Coll Med, Dept Pathol, Johnson City, TN 37614 USA	East Tennessee State University	Armstrong, SC (corresponding author), E Tennessee State Univ, James H Quillen Coll Med, Dept Pathol, Johnson City, TN 37614 USA.							Armstrong SC, 2001, J MOL CELL CARDIOL, V33, P1165, DOI 10.1006/jmcc.2001.1380; Badorff C, 1999, NAT MED, V5, P320, DOI 10.1038/6543; Danialou G, 2001, FASEB J, V15, P1655, DOI 10.1096/fj.01-0030fje; Ikeda Y, 2000, AM J PHYSIOL-HEART C, V278, pH1362, DOI 10.1152/ajpheart.2000.278.4.H1362; Ilsley JL, 2001, CELL SIGNAL, V13, P625, DOI 10.1016/S0898-6568(01)00188-7; Kamogawa Y, 2001, CARDIOVASC RES, V50, P509, DOI 10.1016/S0008-6363(01)00205-X; Megeney LA, 1999, P NATL ACAD SCI USA, V96, P220, DOI 10.1073/pnas.96.1.220; MENKE A, 1991, NATURE, V349, P69, DOI 10.1038/349069a0; Miyazato H, 1997, J MOL CELL CARDIOL, V29, P1217, DOI 10.1006/jmcc.1996.0357; Rentschler S, 1999, BIOL CHEM, V380, P431, DOI 10.1515/BC.1999.057; Russo K, 2000, BIOCHEM BIOPH RES CO, V274, P93, DOI 10.1006/bbrc.2000.3103; SHEMANKO CS, 1995, MOL CELL BIOCHEM, V152, P63; Sotgia F, 2000, J BIOL CHEM, V275, P38048, DOI 10.1074/jbc.M005321200; Sotgia F, 2001, BIOCHEMISTRY-US, V40, P14585, DOI 10.1021/bi011247r; WALSH MP, 1995, BIOCHEMISTRY-US, V34, P5561, DOI 10.1021/bi00016a030	15	8	8	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 16	2002	359	9310					905	906		10.1016/S0140-6736(02)08013-3	http://dx.doi.org/10.1016/S0140-6736(02)08013-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	531AE	11918903				2022-12-28	WOS:000174391700003
J	Nystrom, L; Andersson, I; Bjurstam, N; Frisell, J; Nordenskjold, B; Rutqvist, LE				Nystrom, L; Andersson, I; Bjurstam, N; Frisell, J; Nordenskjold, B; Rutqvist, LE			Long-term effects of mammography screening: updated overview of the Swedish randomised trials	LANCET			English	Article							BREAST-CANCER; FOLLOW-UP; MORTALITY; STOCKHOLM	Background There has been much debate about the value of screening mammography. Here we update the overview of the Swedish randomised controlled trials on mammography screening up to and including 1996. The Kopparberg part of the Two-County trial was not available for the overview, but the continuation of the Malmo trial (MMST II) has been added. The article also contains basic data from the trials that have not been presented before. Methods The trials (n=247 010, invited group 129 750, control group 117 260) have been followed up by record linkage to the Swedish Cancer and Cause of Death Registers. The relative risks (RR) for breast cancer death and mortality were calculated for the invited and the control groups. The trial-specific as well as the age-specific effects were analysed. RRs were calculated by the density method, with total person-time experience of the cohort by time interval of follow-up as a basis for estimating mortality rates. We calculated weighted RRs and 95% CI with the Mantel-Haenszel procedure. Findings The median trial time-the time from randomisation until the first round was completed for the control group or if the control group was not invited, until end of follow-up-was 6.5 years (range 3.0-18.1). The median follow-up time, the time from randomisation, to the end of follow-up, was 15.8 years (5.8-20.2). There were 511 breast cancer deaths in 1864 770 women-years in the invited groups and 584 breast cancer deaths in 1688 440 women-years in the control groups, a significant 21% reduction in breast cancer mortality (RR=0.79, 95% CI 0.70-0.89). The reduction was greatest in the age group 60-69 years at entry (33%). Looking at 5-year age groups, there were statistically significant effects in the age groups 55-59, 60-64, and 65-69 years (RR=0.76, 0.68, and 0.69, respectively). There was a small effect in women 50-54 years at randomisation (RR=0.95). The benefit in terms of cumulative breast cancer mortality started to emerge at about 4 years after randomisation and continued to increase to about 10 years. Thereafter the benefit in absolute terms was maintained throughout the period of observation. The age-adjusted relative risk for the total mortality was 0.98 (0.96-1.00). Interpretation The advantageous effect of breast screening on breast cancer mortality persists after long-term follow-up. The recent criticism against the Swedish randomised controlled trials is misleading and scientifically unfounded.	Umea Univ, Dept Publ Hlth & Clin Med, SE-90185 Umea, Sweden; Malmo Univ, Dept Diagnost Radiol, Malmo, Sweden; Univ Gothenburg, Dept Diagnost Radiol, Gothenburg, Sweden; Huddinge Univ Hosp, Dept Surg, Stockholm, Sweden; Linkoping Univ, Dept Oncol, S-58183 Linkoping, Sweden; Huddinge Univ Hosp, Dept Oncol, Stockholm, Sweden	Umea University; Malmo University; University of Gothenburg; Karolinska Institutet; Linkoping University; Karolinska Institutet	Nystrom, L (corresponding author), Umea Univ, Dept Publ Hlth & Clin Med, SE-90185 Umea, Sweden.	Lennarth.Nystrom@epiph.umu.se						Alexander FE, 1999, LANCET, V353, P1903, DOI 10.1016/S0140-6736(98)07413-3; ANDERSSON I, 1988, BRIT MED J, V297, P943, DOI 10.1136/bmj.297.6654.943; Andersson I, 1997, J Natl Cancer Inst Monogr, P63; Bjurstam N, 1997, CANCER, V80, P2091, DOI 10.1002/(SICI)1097-0142(19971201)80:11<2091::AID-CNCR8>3.0.CO;2-#; BJURSTAM N, 1997, MONOGR NATL CANC I, V22, P53; FRISELL J, 1991, BREAST CANCER RES TR, V18, P49, DOI 10.1007/BF01975443; FRISELL J, 1986, BREAST CANCER RES TR, V8, P45, DOI 10.1007/BF01805924; Gotzsche PC, 2000, LANCET, V355, P129, DOI 10.1016/S0140-6736(99)06065-1; LARSSON LG, 1997, MONOGR NATL CANC I, V22, P57; Nixon R, 2000, J Epidemiol Biostat, V5, P349; NYSTOM L, 1997, J MED SCREEN, V3, P85; NYSTROM L, 1995, ACTA ONCOL, V34, P145, DOI 10.3109/02841869509093948; NYSTROM L, 1993, LANCET, V341, P973, DOI 10.1016/0140-6736(93)91067-V; Tabar L, 2000, RADIOL CLIN N AM, V38, P625, DOI 10.1016/S0033-8389(05)70191-3; TABAR L, 1985, LANCET, V1, P829, DOI 10.1016/S0140-6736(85)92204-4	15	795	824	2	40	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 16	2002	359	9310					909	919		10.1016/S0140-6736(02)08020-0	http://dx.doi.org/10.1016/S0140-6736(02)08020-0			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	531AE	11918907				2022-12-28	WOS:000174391700007
J	Vandenkoornhuyse, P; Baldauf, SL; Leyval, C; Straczek, J; Young, JPW				Vandenkoornhuyse, P; Baldauf, SL; Leyval, C; Straczek, J; Young, JPW			Evolution - Extensive fungal diversity in plant roots	SCIENCE			English	Article									Univ York, Dept Biol, York YO10 5SW, N Yorkshire, England; Ctr Pedol Biol, F-54500 Vandoeuvre Les Nancy, France; Ctr Hosp Univ Nancy, F-54500 Nancy, France	University of York - UK; CHU de Nancy	Vandenkoornhuyse, P (corresponding author), Univ York, Dept Biol, POB 373, York YO10 5SW, N Yorkshire, England.		Young, Peter/C-1446-2012	Young, Peter/0000-0001-5259-4830; Baldauf, Sandra/0000-0003-4485-6671				Arnold AE, 2000, ECOL LETT, V3, P267, DOI 10.1046/j.1461-0248.2000.00159.x; FELSENSTEIN J, 1978, SYST ZOOL, V27, P401, DOI 10.2307/2412923; Tehler A, 2000, MYCOLOGIA, V92, P459, DOI 10.2307/3761505	3	299	330	5	101	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 15	2002	295	5562					2051	2051		10.1126/science.295.5562.2051	http://dx.doi.org/10.1126/science.295.5562.2051			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	532AY	11896270				2022-12-28	WOS:000174450500040
J	Wang, JW; Howson, JM; Ghansah, T; Desponts, C; Ninos, JM; May, SL; Nguyen, KHT; Toyama-Sorimachi, N; Kerr, WG				Wang, JW; Howson, JM; Ghansah, T; Desponts, C; Ninos, JM; May, SL; Nguyen, KHT; Toyama-Sorimachi, N; Kerr, WG			Influence of SHIP on the NK repertoire and allogeneic bone marrow transplantation	SCIENCE			English	Article							TRANSGENIC EXPRESSION; RECEPTOR; CELLS; LY49A; PHOSPHATASE; SHP-1; LEADS; LCK	Natural killer cell (NK) receptors for major histocompatibility complex (MHC) class I influence engraftment and graft-versus-tumor effects after allogeneic bone marrow transplantation. We find that SH2-containing inositol phosphatase (SHIP) influences the repertoire of NK receptors. In adult SHIP-/- mice, the NK compartment is dominated by cells that express two inhibitory receptors capable of binding either self or allogeneic MHC ligands. This promiscuous repertoire has significant functional consequences, because SHIP-/- mice fail to reject fully mismatched allogeneic marrow grafts and show enhanced survival after such transplants. Thus, SHIP plays an important role in two processes that limit the success of allogeneic marrow transplantation: graft rejection and graft-versus-host disease.	Univ S Florida, Program Immunol, H Lee Moffitt Comprehens Canc Ctr & Res Inst, Tampa, FL 33612 USA; Univ S Florida, Dept Interdisciplinary Oncol, Tampa, FL 33612 USA; Univ S Florida, Dept Biochem, Tampa, FL 33612 USA; Tokyo Med & Dent Univ, Dept Immune Regulat, Tokyo 1138150, Japan	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; Tokyo Medical & Dental University (TMDU)	Kerr, WG (corresponding author), Univ S Florida, Program Immunol, H Lee Moffitt Comprehens Canc Ctr & Res Inst, Tampa, FL 33612 USA.		Wang, Jia-Wang/I-4966-2012; Ghansah, Tomar/H-4566-2011; Kerr, William G/B-8616-2015	Kerr, William G/0000-0002-4720-7135	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054767] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS027405] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK54767] Funding Source: Medline; NINDS NIH HHS [P01 NS27405] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Binstadt BA, 1996, IMMUNITY, V5, P629, DOI 10.1016/S1074-7613(00)80276-9; Bolland S, 1999, ADV IMMUNOL, V72, P149, DOI 10.1016/S0065-2776(08)60019-X; Brawand P, 2000, J IMMUNOL, V165, P1871, DOI 10.4049/jimmunol.165.4.1871; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; Daws MR, 1999, IMMUNOLOGY, V97, P656; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; GHANSAH T, UNPUB; Held W, 1996, J EXP MED, V184, P2037, DOI 10.1084/jem.184.5.2037; Helgason CD, 1998, GENE DEV, V12, P1610, DOI 10.1101/gad.12.11.1610; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; Liu QR, 1999, GENE DEV, V13, P786, DOI 10.1101/gad.13.7.786; Lowin-Kropf B, 2000, J IMMUNOL, V165, P91, DOI 10.4049/jimmunol.165.1.91; Marti F, 1998, P NATL ACAD SCI USA, V95, P11810, DOI 10.1073/pnas.95.20.11810; Michaelsson J, 2000, EUR J IMMUNOL, V30, P300; Nakamura MC, 1997, J EXP MED, V185, P673, DOI 10.1084/jem.185.4.673; Nisitani S, 2000, P NATL ACAD SCI USA, V97, P2737, DOI 10.1073/pnas.050583597; Ono M, 1996, NATURE, V383, P263, DOI 10.1038/383263a0; Raulet DH, 1999, CURR OPIN IMMUNOL, V11, P129, DOI 10.1016/S0952-7915(99)80023-5; Shlomchik WD, 1999, SCIENCE, V285, P412, DOI 10.1126/science.285.5426.412; Zajac AJ, 1999, J IMMUNOL, V163, P5526	20	132	145	4	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 15	2002	295	5562					2094	2097		10.1126/science.1068438	http://dx.doi.org/10.1126/science.1068438			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	532AY	11896280				2022-12-28	WOS:000174450500055
J	Etheredge, JA				Etheredge, JA			Misperceptions behind mental health policy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									Texas A&M Univ, Ctr Hlth Sci, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station	Etheredge, JA (corresponding author), Texas A&M Univ, Ctr Hlth Sci, College Stn, TX 77843 USA.							*AM PSYCH ASS, 1999, MENT HLTH PAR ITS T; Hanson KW, 1998, PSYCHIATR SERV, V49, P1059, DOI 10.1176/ps.49.8.1059; *NAT MENT HLTH ADV, 1993, AM J PSYCHIAT, V150, P1450; *SEN COMM FIN, 1965, CISNO89S165800B SEN; SING M, 1998, DHHS PUBL; U.S. Surgeon General's Office, 1999, MENT HLTH REP SURG G	6	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 10	2002	287	14					1858	1858		10.1001/jama.287.14.1858	http://dx.doi.org/10.1001/jama.287.14.1858			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	539QJ	11939876	hybrid			2022-12-28	WOS:000174881700042
J	Surman, OS				Surman, OS			Perspective - The ethics of partial-liver donation	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Massachusetts Gen Hosp, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital	Surman, OS (corresponding author), Massachusetts Gen Hosp, Boston, MA 02114 USA.								0	132	135	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 4	2002	346	14					1038	1038		10.1056/NEJM200204043461402	http://dx.doi.org/10.1056/NEJM200204043461402			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	536YL	11932469				2022-12-28	WOS:000174729400001
J	Moffatt, HK; Shimomura, Y				Moffatt, HK; Shimomura, Y			Spinning eggs - a paradox resolved - An explanation for an odd egg performance is rolled out in time for Easter.	NATURE			English	Article									Univ Cambridge, Dept Appl Math & Theoret Phys, Cambridge CB3 9EW, England; Keio Univ, Dept Phys, Yokohama, Kanagawa 2238521, Japan	University of Cambridge; Keio University	Moffatt, HK (corresponding author), Univ Cambridge, Dept Appl Math & Theoret Phys, Silver St, Cambridge CB3 9EW, England.							BRAAMS CM, 1952, PHYSICA, V18, P503, DOI 10.1016/S0031-8914(52)80051-5; Gray CG, 2000, AM J PHYS, V68, P821, DOI 10.1119/1.1302299; HUGENHOLTZ NM, 1952, PHYSICA, V18, P515, DOI 10.1016/S0031-8914(52)80052-7; Jellett J.H., 1872, TREATISE THEORY FRIC	4	30	31	0	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 28	2002	416	6879					385	386		10.1038/416385a	http://dx.doi.org/10.1038/416385a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	534UX	11919617				2022-12-28	WOS:000174607800032
J	Dahlof, B; Devereux, RB; Kjeldsen, SE; Julius, S; Beevers, G; de Faire, U; Fyhrquist, F; Ibsen, H; Kristiansson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Wedel, H				Dahlof, B; Devereux, RB; Kjeldsen, SE; Julius, S; Beevers, G; de Faire, U; Fyhrquist, F; Ibsen, H; Kristiansson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Wedel, H		LIFE study grp	Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol	LANCET			English	Article							LEFT-VENTRICULAR HYPERTROPHY; CONVERTING-ENZYME-INHIBITOR; ANGIOTENSIN-II; ELECTROCARDIOGRAPHIC IDENTIFICATION; MYOCARDIAL-INFARCTION; BLOOD-PRESSURE; SWEDISH TRIAL; OLD PATIENTS; RISK; EVENTS	Background Blood pressure reduction achieved with beta-blockers and diuretics is the best recorded intervention to date for prevention of cardiovascular morbidity and death in patients with hypertension. Left ventricular hypertrophy (LVH) is a strong independent indicator of risk of cardiovascular morbidity and death. We aimed to establish whether selective blocking of angiotensin 11 improves LVH beyond reducing blood pressure and, consequently, reduces cardiovascular morbidity and death. Methods We did a double-masked, randomised, parallel-group trial in 9:193 participants aged 55-80 years with essential hypertension (sitting blood pressure 160-200/95-115 mm Hg) and LVH ascertained by electrocardiography (ECG). We assigned participants once daily losartan-based or atenolol-based anti hypertensive treatment for at least 4 years and until 1040 patients had a primary cardiovascular event (death, myocardial infarction, or stroke). We used Cox regression analysis to compare regimens. Findings Blood pressure fell by 30.2/16.6 (SD 18.5/10.1) and 29.1/16.8 mm Hg (19.2/10.1) in the losartan and atenolol groups, respectively. The primary composite endpoint occurred in 508 losartan (23.8 per 1000 patient-years) and 588 atenolol patients (27.9 per 1000 patient-years: relative risk 0.87, 95% Cl 0.77-0.98, p = 0.021). 204 losartan and 234 atenolol patients died from cardiovascular disease (0.89, 0.73-1.07, p = 0.206); 232 and 309, respectively, had fatal or non-fatal stroke (0.75, 0.63-0.89, p = 0.001); and myocardial infarction (non-fatal and fatal) occurred in 198 and 188, respectively (1.07, 0.88-1.31, p = 0.491). New-onset diabetes was less frequent with losartan. Interpretation Losartan prevents more cardiovascular morbidity and death than atenolol for a similar reduction in blood pressure and is better tolerated. Losartan seems to confer benefits beyond reduction in blood pressure.	Sahlgrens Univ Hosp, Dept Med, SE-41685 Gothenburg, Sweden; Cornell Med Ctr, New York, NY USA; Ullevaal Univ Hosp, Oslo, Norway; Univ Michigan, Ann Arbor, MI 48109 USA; City Hosp, Birmingham, W Midlands, England; Karolinska Univ Hosp, Stockholm, Sweden; Univ Helsinki, Cent Hosp, FIN-00014 Helsinki, Finland; Glostrup Univ Hosp, Glostrup, Denmark; Merck Res Labs Scandinavia, Stockholm, Sweden; Viborg Hosp, Viborg, Denmark; Umea Univ, S-90187 Umea, Sweden; Haukeland Hosp, N-5021 Bergen, Norway; Univ Alabama Birmingham, Birmingham, AL USA; Nord Sch Publ Hlth, Gothenburg, Sweden	Sahlgrenska University Hospital; Cornell University; University of Oslo; University of Michigan System; University of Michigan; University of Birmingham; Karolinska Institutet; Karolinska University Hospital; University of Helsinki; Helsinki University Central Hospital; University of Copenhagen; Merck & Company; Aarhus University; Umea University; University of Alabama System; University of Alabama Birmingham	Dahlof, B (corresponding author), Sahlgrens Univ Hosp, Dept Med, SE-41685 Gothenburg, Sweden.	bdahlof@scandinavianori.se						ANDERSON KM, 1991, CIRCULATION, V83, P356, DOI 10.1161/01.CIR.83.1.356; [Anonymous], 1986, Lancet, V2, P57; Brenner BM, 2001, NEW ENGL J MED, V345, P861, DOI 10.1056/NEJMoa011161; Brunner HR, 2001, AM J CARDIOL, V87, p3C; CASALE PN, 1987, CIRCULATION, V75, P565, DOI 10.1161/01.CIR.75.3.565; Dahlof B, 2001, AM J HYPERTENS, V14, P174, DOI 10.1016/S0895-7061(00)01257-7; DAHLOF B, 1991, LANCET, V338, P1281, DOI 10.1016/0140-6736(91)92589-T; Dahlof B, 1997, AM J HYPERTENS, V10, P705; Dahlof B, 1998, HYPERTENSION, V32, P989, DOI 10.1161/01.HYP.32.6.989; DAHLOF B, 1995, AM J HYPERTENS, V8, P578, DOI 10.1016/0895-7061(95)00081-Y; DAHLOF B, 1992, AM J HYPERTENS, V5, P95, DOI 10.1093/ajh/5.2.95; Devereux RB, 1996, J HYPERTENS, V14, pS95, DOI 10.1097/00004872-199609002-00018; Devereux RB, 2001, BLOOD PRESSURE, V10, P74, DOI 10.1080/08037050152112050; Hansson L, 1999, LANCET, V353, P611, DOI 10.1016/S0140-6736(98)05012-0; Hansson L, 1999, LANCET, V354, P1751, DOI 10.1016/S0140-6736(99)10327-1; KJEKSHUS JK, 1986, AM J CARDIOL, V57, pF43, DOI 10.1016/0002-9149(86)90888-X; Kjeldsen SE, 2001, BLOOD PRESSURE, V10, P190, DOI 10.1080/08037050152669684; Kjeldsen SE, 2000, AM J HYPERTENS, V13, P899, DOI 10.1016/S0895-7061(00)00280-6; Mathew J, 2001, CIRCULATION, V104, P1615, DOI 10.1161/hc3901.096700; MULROW C, 2001, COCHRANE LIB; Neal B, 2000, LANCET, V356, P1955; NORMAN JE, 1995, J AM COLL CARDIOL, V26, P1022, DOI 10.1016/0735-1097(95)00269-5; OKIN PM, 1995, J AM COLL CARDIOL, V25, P417, DOI 10.1016/0735-1097(94)00371-V; Okin PM, 1996, J AM COLL CARDIOL, V27, P124, DOI 10.1016/0735-1097(95)00421-1; PEDERSEN TR, 1981, NEW ENGL J MED, V304, P801; SCHILLACI G, 1994, AM J CARDIOL, V74, P714, DOI 10.1016/0002-9149(94)90316-6; Timmermans PBMWM, 1999, HYPERTENS RES-CLIN E, V22, P147, DOI 10.1291/hypres.22.147; Verdecchia P, 2001, CIRCULATION, V104, P2039, DOI 10.1161/hc4201.097944; *WHO STUD GROUP, 1985, TECHN REP SER WHO ST, V727; Yusuf S, 2000, NEW ENGL J MED, V342, P145	30	3843	4069	3	184	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 23	2002	359	9311					995	1003		10.1016/S0140-6736(02)08089-3	http://dx.doi.org/10.1016/S0140-6736(02)08089-3			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	534KP	11937178				2022-12-28	WOS:000174585800005
J	Horton, R				Horton, R			The health (and wealth) of nations	LANCET			English	Editorial Material									The Lancet, London NW1 7BY, England		Horton, R (corresponding author), The Lancet, London NW1 7BY, England.								0	5	5	1	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 23	2002	359	9311					993	994		10.1016/S0140-6736(02)08064-9	http://dx.doi.org/10.1016/S0140-6736(02)08064-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	534KP	11937177				2022-12-28	WOS:000174585800004
J	Vaessen, N; Janssen, JA; Heutink, P; Hofman, A; Lamberts, SWJ; Oostra, BA; Pols, HAP; van Duijn, CM				Vaessen, N; Janssen, JA; Heutink, P; Hofman, A; Lamberts, SWJ; Oostra, BA; Pols, HAP; van Duijn, CM			Association between genetic variation in the gene for insulin-like growth factor-I and low birthweight	LANCET			English	Article							DISEASE	Low birthweight Is associated with later risk of type 2 diabetes and related disorders. We aimed to show that a polymorphism In the gone for Insulin-like growth factor-I, which has proved to raise risk of type 2 diabetes and myocardial Infarction, Is associated with low birthweight. We recorded birthweight and obtained DNA for 463 adults. Individuals who did not have the wild-type allele of the polymorphism had a 215 g lower birthweight than those homozygous for this allele (95% CI -4.11 to -10). Our data lend support to the hypothesis that genetic variation affecting fetal growth could account for the association between low birthweight and susceptibility to diabetes and cardiovascular disease In later life.	Erasmus Med Ctr Rotterdam, Ctr Biomed Genet, Dept Epidemiol & Biostat, Genet Epidemiol Unit, NL-3000 DR Rotterdam, Netherlands; Erasmus Med Ctr, Dept Internal Med, Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC	van Duijn, CM (corresponding author), Erasmus Med Ctr Rotterdam, Ctr Biomed Genet, Dept Epidemiol & Biostat, Genet Epidemiol Unit, POB 1738, NL-3000 DR Rotterdam, Netherlands.		Janssen, Joseph A.M.J.L./AAU-5133-2021	Janssen, Joseph A.M.J.L./0000-0002-9363-6408; Heutink, Peter/0000-0001-5218-1737; Van Duijn, Cornelia/0000-0002-2374-9204				BARKER DJP, 1995, MOL MED TODAY, V1, P418, DOI 10.1016/S1357-4310(95)90793-9; Hattersley AT, 1999, LANCET, V353, P1789, DOI 10.1016/S0140-6736(98)07546-1; Hill DJ, 1998, DIABETES CARE, V21, pB60; Petrik J, 1998, ENDOCRINOLOGY, V139, P2994, DOI 10.1210/en.139.6.2994; Vaessen N, 2001, DIABETES, V50, P637, DOI 10.2337/diabetes.50.3.637	5	169	178	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 23	2002	359	9311					1036	1037		10.1016/S0140-6736(02)08067-4	http://dx.doi.org/10.1016/S0140-6736(02)08067-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	534KP	11937187				2022-12-28	WOS:000174585800014
J	Farrar, JM				Farrar, JM			Chemical reactions - Steric and solvent effects in ionic reactions	SCIENCE			English	Editorial Material							PHASE SN2 REACTIONS; DYNAMICS		Univ Rochester, Dept Chem, Rochester, NY 14627 USA	University of Rochester	Farrar, JM (corresponding author), Univ Rochester, Dept Chem, Rochester, NY 14627 USA.							Chabinyc ML, 1998, SCIENCE, V279, P1882, DOI 10.1126/science.279.5358.1882; Craig SL, 1997, SCIENCE, V276, P1536, DOI 10.1126/science.276.5318.1536; CYR DM, 1991, J AM CHEM SOC, V113, P9697, DOI 10.1021/ja00025a059; Gilbert RG., 1990, THEORY UNIMOLECULAR; GRAUL ST, 1991, J AM CHEM SOC, V113, P9696, DOI 10.1021/ja00025a058; HASE WL, 1994, SCIENCE, V266, P998, DOI 10.1126/science.266.5187.998; Hofmann, 1872, CHEM BER, V5, P704; Ingold C.K., 1953, STRUCTURE MECH ORGAN; Marcus RA, 1997, J PHYS CHEM A, V101, P4072, DOI 10.1021/jp963722e; OLMSTEAD WN, 1977, J AM CHEM SOC, V99, P4219, DOI 10.1021/ja00455a002; Regan CK, 2002, SCIENCE, V295, P2245, DOI 10.1126/science.1068849; Taft RW, 1956, STERIC EFFECTS ORGAN; WILBUR JL, 1991, J AM CHEM SOC, V113, P9699, DOI 10.1021/ja00025a060	13	0	0	2	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 22	2002	295	5563					2222	2223		10.1126/science.1069937	http://dx.doi.org/10.1126/science.1069937			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	534AD	11910095				2022-12-28	WOS:000174561700028
J	Shen, Y; Zhou, DJ; Qiu, LY; Lai, XM; Simon, M; Shen, L; Kou, ZC; Wang, QF; Jiang, JM; Estep, J; Hunt, R; Clagett, M; Sehgal, PK; Li, YY; Zeng, XJ; Morita, CT; Brenner, MB; Letvin, NL; Chen, ZW				Shen, Y; Zhou, DJ; Qiu, LY; Lai, XM; Simon, M; Shen, L; Kou, ZC; Wang, QF; Jiang, JM; Estep, J; Hunt, R; Clagett, M; Sehgal, PK; Li, YY; Zeng, XJ; Morita, CT; Brenner, MB; Letvin, NL; Chen, ZW			Adaptive immune response of V gamma 2V delta 2(+) T cells during mycobacterial infections	SCIENCE			English	Article							BACILLUS-CALMETTE-GUERIN; AIRBORNE TUBERCULOSIS; PUBLISHED LITERATURE; EFFICACY; LIGANDS; MICE; METAANALYSIS; VACCINATION; STIMULATION; LYMPHOCYTES	To examine the role of T cell receptor (TCR) in gammadelta T cells in adaptive immunity, a macaque model was used to follow Vgamma2Vdelta2(+) T cell responses to mycobacterial infections. These phosphoantigen-specific gammadelta T cells displayed major expansion during Mycobacterium bovis Bacille Calmette-Guerin (BCG) infection and a clear memory-type response after BCG reinfection. Primary and recall expansions of Vgamma2Vdelta2(+) T cells were also seen during Mycobacterium tuberculosis infection of naive and BCG-vaccinated macaques, respectively. This capacity to rapidly expand coincided with a clearance of BCG bacteremia and immunity to fatal tuberculosis in BCG-vaccinated macaques. Thus, Vgamma2Vdelta2(+) T cells may contribute to adaptive immunity to mycobacterial infections.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, TB Res Unit, Boston, MA 02115 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Viral Pathogenesis, Boston, MA 02115 USA; New England Reg Primate Res Ctr, Southborough, MA 01772 USA; Battelle Mem Inst, Battelle Med Res & Evaluat Facil, Columbus, OH 43201 USA; Univ Iowa, Dept Internal Med, Div Rheumatol, Iowa City, IA 52242 USA; Univ Iowa, Interdisciplinary Grp Immunol, Iowa City, IA 52242 USA; Brigham & Womens Hosp, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Battelle Memorial Institute; University of Iowa; University of Iowa; Harvard University; Brigham & Women's Hospital	Chen, ZW (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, TB Res Unit, Boston, MA 02115 USA.		Morita, Craig T/C-1365-2011	Morita, Craig T/0000-0001-8496-8294	NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR013601] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064560] Funding Source: NIH RePORTER; NCRR NIH HHS [R01 RR013601, R01 RR013601-04, RR13601] Funding Source: Medline; NHLBI NIH HHS [HL64560, R01 HL064560-04, R01 HL064560] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARCLAY WR, 1973, AM REV RESPIR DIS, V107, P351; Bukowski JF, 1999, IMMUNITY, V11, P57, DOI 10.1016/S1074-7613(00)80081-3; BURK MR, 1995, EUR J IMMUNOL, V25, P2052, DOI 10.1002/eji.1830250737; Chen ZW, 2000, J MED PRIMATOL, V29, P143, DOI 10.1034/j.1600-0684.2000.290307.x; COLDITZ GA, 1995, PEDIATRICS, V96, P29; COLDITZ GA, 1994, JAMA-J AM MED ASSOC, V271, P698, DOI 10.1001/jama.271.9.698; CONSTANT P, 1994, SCIENCE, V264, P267, DOI 10.1126/science.8146660; DSouza CD, 1997, J IMMUNOL, V158, P1217; HIROMATSU K, 1992, J EXP MED, V175, P49, DOI 10.1084/jem.175.1.49; ITOHARA S, 1990, NATURE, V343, P754, DOI 10.1038/343754a0; JANICKI BW, 1973, AM REV RESPIR DIS, V107, P359; Kunzmann V, 1999, NEW ENGL J MED, V340, P737, DOI 10.1056/NEJM199903043400914; LADEL CH, 1995, EUR J IMMUNOL, V25, P838, DOI 10.1002/eji.1830250331; Langermans JAM, 2001, P NATL ACAD SCI USA, V98, P11497, DOI 10.1073/pnas.201404898; McMurray DN, 2000, CLIN INFECT DIS, V30, pS210, DOI 10.1086/313885; MOMBAERTS P, 1993, NATURE, V365, P53, DOI 10.1038/365053a0; Moore TA, 2000, J IMMUNOL, V165, P2643, DOI 10.4049/jimmunol.165.5.2643; Morita CT, 2000, SPRINGER SEMIN IMMUN, V22, P191, DOI 10.1007/s002810000042; MORITA CT, 1995, IMMUNITY, V3, P495, DOI 10.1016/1074-7613(95)90178-7; Mukasa A, 1999, J IMMUNOL, V162, P4910; PFEFFER K, 1990, EUR J IMMUNOL, V20, P1175, DOI 10.1002/eji.1830200534; Poquet Y, 1996, RES IMMUNOL, V147, P542, DOI 10.1016/S0923-2494(97)85220-0; RIBI E, 1971, J INFECT DIS, V123, P527, DOI 10.1093/infdis/123.5.527; RODRIGUES LC, 1993, INT J EPIDEMIOL, V22, P1154, DOI 10.1093/ije/22.6.1154; Sciammas R, 1997, J EXP MED, V185, P1969, DOI 10.1084/jem.185.11.1969; Shen Y, 2002, INFECT IMMUN, V70, P869, DOI 10.1128/IAI.70.2.869-877.2002; Shen Y, 2001, J VIROL, V75, P8690, DOI 10.1128/JVI.75.18.8690-8696.2001; TANAKA Y, 1995, NATURE, V375, P155, DOI 10.1038/375155a0; TANAKA Y, 1994, P NATL ACAD SCI USA, V91, P8175, DOI 10.1073/pnas.91.17.8175; Zhou DJ, 1999, J IMMUNOL, V162, P2204	30	299	314	2	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 22	2002	295	5563					2255	2258		10.1126/science.1068819	http://dx.doi.org/10.1126/science.1068819			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	534AD	11910108	Green Accepted			2022-12-28	WOS:000174561700042
J	Gambardella, P; Dallmeyer, A; Maiti, K; Malagoli, MC; Eberhardt, W; Kern, K; Carbone, C				Gambardella, P; Dallmeyer, A; Maiti, K; Malagoli, MC; Eberhardt, W; Kern, K; Carbone, C			Ferromagnetism in one-dimensional monatomic metal chains	NATURE			English	Article							MAGNETIC CIRCULAR-DICHROISM; ORBITAL MAGNETIZATION; SURFACES; CO; NANOSTRUCTURES; ANISOTROPY; FE(110); W(110); MODEL	Two-dimensional systems, such as ultrathin epitaxial films and superlattices, display magnetic properties distinct from bulk materials(1). A challenging aim of current research in magnetism is to explore structures of still lower dimensionality(2-6). As the dimensionality of a physical system is reduced, magnetic ordering tends to decrease as fluctuations become relatively more important(7). Spin lattice models predict that an infinite one-dimensional linear chain with short-range magnetic interactions spontaneously breaks up into segments with different orientation of the magnetization, thereby prohibiting long-range ferromagnetic order at a finite temperature(7-9). These models, however, do not take into account kinetic barriers to reaching equilibrium or interactions with the substrates that support the one-dimensional nanostructures. Here we demonstrate the existence of both short- and long-range ferromagnetic order for one-dimensional monatomic chains of Co constructed on a Pt substrate. We find evidence that the monatomic chains consist of thermally fluctuating segments of ferromagnetically coupled atoms which, below a threshold temperature, evolve into a ferromagnetic long-range-ordered state owing to the presence of anisotropy barriers. The Co chains are characterized by large localized orbital moments and correspondingly large magnetic anisotropy energies compared to two-dimensional films and bulk Co.	Ecole Polytech Fed Lausanne, Inst Phys Nanostruct, CH-1015 Lausanne, Switzerland; Forschungszentrum Julich, Inst Festkorperphys, D-52425 Julich, Germany; Berliner Elektronenspeicherring Gesell Synchrotro, D-12489 Berlin, Germany; Max Planck Inst Festkorperforsch, D-70569 Stuttgart, Germany; CNR, Ist Struttura Mat, I-34012 Trieste, Italy	Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Helmholtz Association; Research Center Julich; Max Planck Society; Consiglio Nazionale delle Ricerche (CNR); Istituto di Struttura della Materia (ISM-CNR)	Gambardella, P (corresponding author), Ecole Polytech Fed Lausanne, Inst Phys Nanostruct, CH-1015 Lausanne, Switzerland.	pietro.gambardella@epfl.ch	Carbone, Carlo/B-2626-2010; Eberhardt, Wolfgang U/L-4406-2013; Gambardella, Pietro/B-1880-2009	Gambardella, Pietro/0000-0003-0031-9217; Carbone, Carlo/0000-0002-8675-7850; Maiti, Kalobaran/0000-0001-5264-7832				BATE G, 1991, J MAGN MAGN MATER, V100, P413, DOI 10.1016/0304-8853(91)90831-T; CHEN CT, 1995, PHYS REV LETT, V75, P152, DOI 10.1103/PhysRevLett.75.152; CRANGLE J, 1965, J APPL PHYS, V36, P921, DOI 10.1063/1.1714264; DEJONGH LJ, 1974, ADV PHYS, V23, P1, DOI 10.1080/00018739700101558; Dorantes-Davila J, 1998, PHYS REV LETT, V81, P208, DOI 10.1103/PhysRevLett.81.208; Durr HA, 1999, PHYS REV B, V59, pR701, DOI 10.1103/PhysRevB.59.R701; ELMERS HJ, 1994, PHYS REV LETT, V73, P898, DOI 10.1103/PhysRevLett.73.898; Frota-Pessoa S, 2000, PHYS REV B, V62, P5293, DOI 10.1103/PhysRevB.62.5293; Gambardella P, 2000, PHYS REV B, V61, P2254, DOI 10.1103/PhysRevB.61.2254; Gambardella P, 2000, SURF SCI, V449, P93, DOI 10.1016/S0039-6028(99)01218-2; Hauschild J, 1998, PHYS REV B, V57, pR677, DOI 10.1103/PhysRevB.57.R677; Himpsel FJ, 1998, ADV PHYS, V47, P511, DOI 10.1080/000187398243519; Ising E, 1925, Z PHYS, V31, P253, DOI 10.1007/BF02980577; Landau L. D., 1959, COURSE THEORETICAL P, V5, P482; LIEB EH, 1906, MATH PHYSICS ONE DIM; MERMIN ND, 1966, PHYS REV LETT, V17, P1133, DOI 10.1103/PhysRevLett.17.1133; Pratzer M, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.127201; ROEDER H, 1993, NATURE, V366, P141; SCHNEIDER CM, 2000, HDB SURFACE SCI, P511; Shen J, 1997, PHYS REV B, V56, P2340, DOI 10.1103/PhysRevB.56.2340; Stamm C, 1998, SCIENCE, V282, P449, DOI 10.1126/science.282.5388.449; Stohr J, 1998, IBM J RES DEV, V42, P73, DOI 10.1147/rd.421.0073; THOLE BT, 1992, PHYS REV LETT, V68, P1943, DOI 10.1103/PhysRevLett.68.1943; TISCHER M, 1995, PHYS REV LETT, V75, P1602, DOI 10.1103/PhysRevLett.75.1602; WEINERT M, 1983, J MAGN MAGN MATER, V38, P23, DOI 10.1016/0304-8853(83)90098-7; WELLER D, 1995, PHYS REV LETT, V75, P3752, DOI 10.1103/PhysRevLett.75.3752; Wernsdorfer W, 1997, PHYS REV LETT, V78, P1791, DOI 10.1103/PhysRevLett.78.1791; WU RQ, 1991, J MAGN MAGN MATER, V99, P71, DOI 10.1016/0304-8853(91)90048-F	28	738	743	0	188	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 21	2002	416	6878					301	304		10.1038/416301a	http://dx.doi.org/10.1038/416301a			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	532NP	11907571				2022-12-28	WOS:000174482200036
J	Citroni, M; Ceppatelli, M; Bini, R; Schettino, V				Citroni, M; Ceppatelli, M; Bini, R; Schettino, V			Laser-induced selectivity for dimerization versus polymerization of butadiene under pressure	SCIENCE			English	Article							SOLID-STATE POLYMERIZATION; PHASE; PHOTOCHEMISTRY; BENZENE; TRANSITIONS; MECHANISM; KINETICS	The pressure-induced chemical reaction of liquid butadiene was studied by Fourier transform infrared spectroscopy in a diamond anvil cell. Dimerization was found to occur above 0.7 gigapascal, giving vinylcyclohexene according to a cyclo-addiction reaction and only a trace amount of polybutadiene forms. By irradiating the high-pressure sample with a few milliwatts of the 488-nanometer argon(+) laser line, the dimerization was completely inhibited, and the rapid formation of pure transpolybutadiene was observed. The use of different excitation wavelength allows us to emphasize the selectivity of the process and to identify the active role of the 2(1)A(g) state in this pressure- and laser-induced chemical reaction.	Univ Florence, Dipartimento Chim, I-50019 Florence, Italy; LENS, I-50019 Florence, Italy; INFM, I-50019 Florence, Italy	University of Florence; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR)	Bini, R (corresponding author), Univ Florence, Dipartimento Chim, Polo Sci,Via Lastruccia 3, I-50019 Florence, Italy.	bini@srv.chim.unifi.it	Citroni, Margherita/P-9341-2016	Citroni, Margherita/0000-0001-8555-1263; BINI, ROBERTO/0000-0002-6746-696X; Ceppatelli, Matteo/0000-0002-0688-5167				Anastas P. T., 1998, GREEN CHEM; AOKI K, 1989, J CHEM PHYS, V91, P778, DOI 10.1063/1.457130; AOYAGI M, 1985, J CHEM PHYS, V83, P1140, DOI 10.1063/1.449477; AOYAGI M, 1989, J AM CHEM SOC, V111, P470, DOI 10.1021/ja00184a010; Avrami M, 1941, J CHEM PHYS, V9, P177, DOI 10.1063/1.1750872; Avrami M, 1939, J CHEM PHYS, V7, P1103, DOI 10.1063/1.1750380; Avrami M., 1940, J CHEM PHYS, V8, P212, DOI [DOI 10.1063/1.1750631, 10.1063/1.1750631]; Bearpark MJ, 1997, J AM CHEM SOC, V119, P709, DOI 10.1021/ja962576n; BENSON SW, 1967, J CHEM PHYS, V46, P4920, DOI 10.1063/1.1840657; Bini R, 1997, REV SCI INSTRUM, V68, P3154, DOI 10.1063/1.1148261; CANSELL F, 1993, J CHEM PHYS, V99, P7300, DOI 10.1063/1.465711; Ceppatelli M, 2000, J CHEM PHYS, V113, P5991, DOI 10.1063/1.1288800; CHADWICK RR, 1991, J CHEM PHYS, V95, P7204, DOI 10.1063/1.461397; Ciabini L, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.085505; Ciabini L, 2002, J CHEM PHYS, V116, P2928, DOI 10.1063/1.1435570; DOERING JP, 1980, J CHEM PHYS, V73, P3617, DOI 10.1063/1.440587; DRICKAMER HG, 1967, SCIENCE, V156, P3779; GALASSO V, 1988, J CHEM PHYS, V89, P4529, DOI 10.1063/1.454793; Gorelli FA, 1999, PHYS REV LETT, V83, P4093, DOI 10.1103/PhysRevLett.83.4093; HALLER I, 1964, J CHEM PHYS, V40, P1992, DOI 10.1063/1.1725433; KOHLER BE, 1993, CHEM REV, V93, P41, DOI 10.1021/cr00017a003; MILLER GH, 1960, J POLYM SCI, V43, P517, DOI 10.1002/pol.1960.1204314221; NETO N, 1967, EUR POLYM J, V3, P645; OLIVUCCI M, 1993, J AM CHEM SOC, V115, P3710, DOI 10.1021/ja00062a042; PRUZAN P, 1990, J CHEM PHYS, V92, P6910, DOI 10.1063/1.458278; Sakashita M, 1996, J PHYS CHEM-US, V100, P9943, DOI 10.1021/jp960306l; WIBERG KB, 1993, J PHYS CHEM-US, V97, P13586, DOI 10.1021/j100153a028; YOO CS, 1986, J PHYS CHEM-US, V90, P6732, DOI 10.1021/j100283a029; Zilberg S, 1999, J PHYS CHEM A, V103, P2364, DOI 10.1021/jp983893e	29	121	122	1	51	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 15	2002	295	5562					2058	2060		10.1126/science.1068451	http://dx.doi.org/10.1126/science.1068451			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	532AY	11896273				2022-12-28	WOS:000174450500043
J	Weinberger, AJ				Weinberger, AJ			Planetary disks - A dusty business	SCIENCE			English	Editorial Material							BETA-PICTORIS		Carnegie Inst Washington, Dept Terr Magnetism, Washington, DC 20015 USA	Carnegie Institution for Science	Weinberger, AJ (corresponding author), Carnegie Inst Washington, Dept Terr Magnetism, 5241 Broad Branch Rd NW, Washington, DC 20015 USA.							Augereau JC, 2001, ASTRON ASTROPHYS, V370, P447, DOI 10.1051/0004-6361:20010199; Aumann H. H., 1984, ASTROPHYS J, V278, P23, DOI 10.1086/184214; Heap SR, 2000, ASTROPHYS J, V539, P435, DOI 10.1086/309188; JAYAWARDHANA R, 2001, ASP C SER, V244; Kalas P, 2002, ASTROPHYS J, V567, P999, DOI 10.1086/338388; KOERNER DW, IN PRESS ASTROPHYS J; Schneider G, 2001, ASTRON J, V121, P525, DOI 10.1086/318050; SCHNEIDER G, UNPUB; SMITH BA, 1984, SCIENCE, V226, P1421, DOI 10.1126/science.226.4681.1421; WILNER DJ, 2001, B AM ASTRON SOC, V33, P1410	10	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 15	2002	295	5562					2027	2028		10.1126/science.1070769	http://dx.doi.org/10.1126/science.1070769			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	532AY	11896260				2022-12-28	WOS:000174450500030
J	Wilson, WD				Wilson, WD			Analyzing biomolecular interactions	SCIENCE			English	Editorial Material							SURFACE; BIOSENSOR		Georgia State Univ, Dept Chem, Atlanta, GA 30303 USA	University System of Georgia; Georgia State University	Wilson, WD (corresponding author), Georgia State Univ, Dept Chem, Atlanta, GA 30303 USA.							Bailly C, 2001, BIOCHEMISTRY-US, V40, P9770, DOI 10.1021/bi0108453; *BIACORE AB, 1998, BIAT HDB; CANTOR CR, 1980, BIOPHYSICAL CHEM, V3; Danelian E, 2000, J MED CHEM, V43, P2083, DOI 10.1021/jm991156g; Davis TM, 2000, ANAL BIOCHEM, V284, P348, DOI 10.1006/abio.2000.4726; FAGERSTAM LG, 1992, J CHROMATOGR, V597, P397, DOI 10.1016/0021-9673(92)80137-J; Lacy ER, 2002, J AM CHEM SOC, V124, P2153, DOI 10.1021/ja016154b; Myszka DG, 2000, METHOD ENZYMOL, V323, P325; Myszyka DG, 1999, J MOL RECOGNIT, V12, P279, DOI 10.1002/(SICI)1099-1352(199909/10)12:5<279::AID-JMR473>3.0.CO;2-3; Nakatani K, 2001, NAT BIOTECHNOL, V19, P51, DOI 10.1038/83505; Rich RL, 2001, ANAL BIOCHEM, V296, P197, DOI 10.1006/abio.2001.5314; Rich RL, 2001, J MOL RECOGNIT, V14, P273, DOI 10.1002/jmr.547; Wang L, 2000, P NATL ACAD SCI USA, V97, P12, DOI 10.1073/pnas.97.1.12	13	153	188	4	67	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 15	2002	295	5562					2103	+		10.1126/science.295.5562.2103	http://dx.doi.org/10.1126/science.295.5562.2103			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	532AY	11896282				2022-12-28	WOS:000174450500057
J	Martin, DF; Sierra-Madero, J; Walmsley, S; Wolitz, RA; Macey, K; Georgiou, P; Robinson, CA; Stempien, MJ				Martin, DF; Sierra-Madero, J; Walmsley, S; Wolitz, RA; Macey, K; Georgiou, P; Robinson, CA; Stempien, MJ		Valganciclovir Study Grp	A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ORAL GANCICLOVIR; PHARMACOKINETICS; AIDS	Background: Valganciclovir is an orally administered prodrug that is rapidly hydrolyzed to ganciclovir. We compared the effects of oral valganciclovir with those of intravenous ganciclovir as induction therapy for newly diagnosed cytomegalovirus retinitis in 160 patients with the acquired immunodeficiency syndrome (AIDS). Methods: The primary end point was photographically determined progression of cytomegalovirus retinitis within four weeks after the initiation of treatment. Secondary end points included the achievement of a prospectively defined satisfactory response to induction therapy and the time to progression of cytomegalovirus retinitis. After four weeks, all patients received valganciclovir as maintenance therapy. Results: Eighty patients were randomly assigned to each treatment group. Of the patients who could be evaluated, 7 of 70 assigned to intravenous ganciclovir (10.0 percent) and 7 of 71 assigned to oral valganciclovir (9.9 percent) had progression of cytomegalovirus retinitis during the first four weeks (difference in proportions, 0.1 percentage point; 95 percent confidence interval, -9.7 to 10.0). Forty-seven of 61 patients (77.0 percent) assigned to intravenous ganciclovir and 46 of 64 (71.9 percent) assigned to valganciclovir had a satisfactory response to induction therapy (difference in proportions, 5.2 percentage points; 95 percent confidence interval, -20.4 to 10.1). The median times to progression of retinitis were 125 days in the group assigned to intravenous ganciclovir and 160 days in the group assigned to oral valganciclovir. The mean values for the area under the curve for the ganciclovir dosage interval were similar at both induction doses and maintenance doses. The frequency and severity of adverse events were similar in the two treatment groups. Conclusions: Orally administered valganciclovir appears to be as effective as intravenous ganciclovir for induction treatment and is convenient and effective for the long-term management of cytomegalovirus retinitis in patients with AIDS.	Emory Univ, Sch Med, Dept Ophthalmol, Atlanta, GA 30322 USA; Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Dept Infect Dis, Mexico City, DF, Mexico; Univ Toronto, Toronto Gen Hosp, Dept Med, Toronto, ON M5G 1L7, Canada; Kaiser Permanente, Dept Ophthalmol, San Francisco, CA USA; Roche Pharmaceut, Welwyn Garden City, Herts, England; Roche Pharmaceut, Palo Alto, CA USA	Emory University; Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran - Mexico; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; Kaiser Permanente; Roche Holding; Roche Holding	Martin, DF (corresponding author), Emory Univ, Sch Med, Dept Ophthalmol, 1365B Clifton Rd NE, Atlanta, GA 30322 USA.	dmart04@emory.edu	Sierra Madero, Juan/AAW-8825-2021	Walmsley, Sharon/0000-0002-3959-5692				Brown F, 1999, CLIN PHARMACOKINET, V37, P167, DOI 10.2165/00003088-199937020-00005; DREW WL, 1995, NEW ENGL J MED, V333, P615, DOI 10.1056/NEJM199509073331002; FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0; GALLANT JE, 1992, J INFECT DIS, V166, P1223, DOI 10.1093/infdis/166.6.1223; HOOVER DR, 1993, NEW ENGL J MED, V329, P1922, DOI 10.1056/NEJM199312233292604; JABS DA, 1994, OPHTHALMOLOGY, V101, P1250; Jung D, 1999, J CLIN PHARMACOL, V39, P800, DOI 10.1177/00912709922008452; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KUPPERMANN BD, 1993, AM J OPHTHALMOL, V115, P575, DOI 10.1016/S0002-9394(14)71453-9; Lalezari JP, 1997, ANN INTERN MED, V126, P257, DOI 10.7326/0003-4819-126-4-199702150-00001; Lalezari JP, 2002, J CLIN VIROL, V24, P67, DOI 10.1016/S1386-6532(01)00229-3; Lewis RA, 1997, ANN INTERN MED, V126, P264, DOI 10.7326/0003-4819-126-4-199702150-00002; MARTIN DF, 1994, ARCH OPHTHALMOL-CHIC, V112, P1531, DOI 10.1001/archopht.1994.01090240037023; Martin DF, 1999, NEW ENGL J MED, V340, P1063, DOI 10.1056/NEJM199904083401402; Musch DC, 1997, NEW ENGL J MED, V337, P83, DOI 10.1056/NEJM199707103370203; PALESTINE AG, 1991, ANN INTERN MED, V115, P665, DOI 10.7326/0003-4819-115-9-665; Pescovitz MD, 2000, ANTIMICROB AGENTS CH, V44, P2811, DOI 10.1128/AAC.44.10.2811-2815.2000; SPECTOR SA, 1993, J INFECT DIS, V168, P557, DOI 10.1093/infdis/168.3.557	18	221	240	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 11	2002	346	15					1119	1126		10.1056/NEJMoa011759	http://dx.doi.org/10.1056/NEJMoa011759			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	539PX	11948271				2022-12-28	WOS:000174880600004
J	Metz, M; Futterer, J				Metz, M; Futterer, J			Biodiversity (communications arising) - Suspect evidence of transgenic contamination	NATURE			English	Article									Univ Washington, Dept Microbiol, Seattle, WA 98195 USA; ETH Zurich, Inst Plant Sci, CH-8092 Zurich, Switzerland	University of Washington; University of Washington Seattle; Swiss Federal Institutes of Technology Domain; ETH Zurich	Metz, M (corresponding author), Univ Washington, Dept Microbiol, Seattle, WA 98195 USA.							Jayaraman KS, 2001, NATURE, V413, P555, DOI 10.1038/35098210; Neto RB, 1999, NATURE, V402, P344, DOI 10.1038/46400; Pawlowski WP, 1998, P NATL ACAD SCI USA, V95, P12106, DOI 10.1073/pnas.95.21.12106; Quist D, 2001, NATURE, V414, P541, DOI 10.1038/35107068	4	61	71	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 11	2002	416	6881					600	601		10.1038/nature738	http://dx.doi.org/10.1038/nature738			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	539YV	11935144				2022-12-28	WOS:000174901900030
J	Seki, M; Narusaka, M; Kamiya, A; Ishida, J; Satou, M; Sakurai, T; Nakajima, M; Enju, A; Akiyama, K; Oono, Y; Muramatsu, M; Hayashizaki, Y; Kawai, J; Carninci, P; Itoh, M; Ishii, Y; Arakawa, T; Shibata, K; Shinagawa, A; Shinozaki, K				Seki, M; Narusaka, M; Kamiya, A; Ishida, J; Satou, M; Sakurai, T; Nakajima, M; Enju, A; Akiyama, K; Oono, Y; Muramatsu, M; Hayashizaki, Y; Kawai, J; Carninci, P; Itoh, M; Ishii, Y; Arakawa, T; Shibata, K; Shinagawa, A; Shinozaki, K			Functional annotation of a full-length Arabidopsis cDNA collection	SCIENCE			English	Article							EXPRESSED SEQUENCE TAGS; TRAPPER-SELECTED CDNAS; CLONING; PLANT; DISCOVERY; THALIANA; SIZE	Full-length complementary DNAs (cDNAs) are essential for the correct annotation of genomic sequences and for the functional analysis of genes and their products. We isolated 155,144 RIKEN Arabidopsis full-length (RAFL) cDNA clones. The 3'-end expressed sequence tags (ESTs) of 155,144 RAFL cDNAs were clustered into 14,668 nonredundant cDNA groups, about 60% of predicted genes. We also obtained 5' ESTs from 14,034 nonredundant cDNA groups and constructed a promoter database. The sequence database of the RAFL cDNAs is useful for promoter analysis and correct annotation of predicted transcription units and gene products. Furthermore, the full-length cDNAs are useful resources for analyses of the expression profiles, functions, and structures of plant proteins.	RIKEN, Tsukuba Inst, Plant Mol Biol Lab, Tsukuba, Ibaraki 3050074, Japan; RIKEN, Genom Sci Ctr, Plant Funct Genom Res Grp, Plant Mutat Explorat Team, Tsukuba, Ibaraki 3050074, Japan; Univ Tsukuba, Masters Program Biosyst Studies, Tsukuba, Ibaraki 3050074, Japan; RIKEN GSC, Yokohama Inst, Lab Genome Explorat Res Grp, Tsurumi Ku, Yokohama, Kanagawa 2300045, Japan; RIKEN, Genome Sci Lab, Wako, Saitama 3510198, Japan	RIKEN; RIKEN; University of Tsukuba; RIKEN; RIKEN	Shinozaki, K (corresponding author), RIKEN, Tsukuba Inst, Plant Mol Biol Lab, 3-1-1 Koyadai, Tsukuba, Ibaraki 3050074, Japan.	sinozaki@rtc.riken.go.jp	shibata, kazuhiro/A-9527-2008; Kawai, Jun/A-6451-2016; Sakurai, Tetsuya/B-2690-2010; Itoh, Masayoshi/N-5363-2015; Hayashizaki, Yoshihide/N-6590-2015; Seki, Motoaki/I-2854-2012; Shinozaki, Kazuo/G-4202-2013; Carninci, Piero/K-1568-2014	Sakurai, Tetsuya/0000-0003-2046-8973; Itoh, Masayoshi/0000-0002-1772-318X; Seki, Motoaki/0000-0001-8288-0467; Shinozaki, Kazuo/0000-0002-6317-9867; Carninci, Piero/0000-0001-7202-7243				Arabidopsis Genome Initiative, 2000, Nature (London), V408, P796, DOI 10.1038/35048692; Asamizu E, 2000, DNA RES, V7, P175, DOI 10.1093/dnares/7.3.175; Bevan M, 1997, PLANT CELL, V9, P476, DOI 10.1105/tpc.9.4.476; Carninci P, 2000, GENOME RES, V10, P1617, DOI 10.1101/gr.145100; Carninci P, 1998, P NATL ACAD SCI USA, V95, P520, DOI 10.1073/pnas.95.2.520; Carninci P, 1996, GENOMICS, V37, P327, DOI 10.1006/geno.1996.0567; Carninci P, 2001, GENOMICS, V77, P79, DOI 10.1006/geno.2001.6601; Carninci P, 1997, DNA Res, V4, P61, DOI 10.1093/dnares/4.1.61; Cooke R, 1996, PLANT J, V9, P101, DOI 10.1046/j.1365-313X.1996.09010101.x; Higo K, 1999, NUCLEIC ACIDS RES, V27, P297, DOI 10.1093/nar/27.1.297; HOFTE H, 1993, PLANT J, V4, P1051, DOI 10.1046/j.1365-313X.1993.04061051.x; Lin XY, 1999, NATURE, V402, P761, DOI 10.1038/45471; Mayer K, 1999, NATURE, V402, P769, DOI 10.1038/47134; Meinke DW, 1998, SCIENCE, V282, P662, DOI 10.1126/science.282.5389.662; NEWMAN T, 1994, PLANT PHYSIOL, V106, P1241, DOI 10.1104/pp.106.4.1241; Riechmann JL, 2000, SCIENCE, V290, P2105, DOI 10.1126/science.290.5499.2105; Seki M, 1998, PLANT J, V15, P707, DOI 10.1046/j.1365-313x.1998.00237.x; Seki M, 2001, PLANT PHYSIOL BIOCH, V39, P211, DOI 10.1016/S0981-9428(01)01244-X; Shibata Y, 2001, BIOTECHNIQUES, V30, P1250, DOI 10.2144/01306st01; White JA, 2000, PLANT PHYSIOL, V124, P1582, DOI 10.1104/pp.124.4.1582	20	524	1720	0	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 5	2002	296	5565					141	145		10.1126/science.1071006	http://dx.doi.org/10.1126/science.1071006			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	539FA	11910074				2022-12-28	WOS:000174858800048
J	Van Swygenhoven, H				Van Swygenhoven, H			Polycrystalline materials - Grain boundaries and dislocations	SCIENCE			English	Editorial Material							NANOCRYSTALLINE; DEFORMATION; DIFFUSION; METALS		Paul Scherrer Inst, CH-5232 Villigen, Switzerland	Swiss Federal Institutes of Technology Domain; Paul Scherrer Institute	Van Swygenhoven, H (corresponding author), Paul Scherrer Inst, CH-5232 Villigen, Switzerland.	helena.vs@psi.ch	Van Swygenhoven, Helena/GZL-0225-2022					Derlet PM, 2002, PHILOS MAG A, V82, P1, DOI 10.1080/01418610110058310; Gumbsch P, 1998, SCIENCE, V279, P1489, DOI 10.1126/science.279.5356.1489; HALL EO, 1951, P PHYS SOC LOND B, V64, P747, DOI 10.1088/0370-1301/64/9/303; Keblinski P, 1999, PHILOS MAG A, V79, P2735, DOI 10.1080/01418619908212021; Koch CC, 1999, MRS BULL, V24, P54, DOI 10.1557/S0883769400051551; PETCH NJ, 1953, STEEL I LONDON, V74, P25; Schiotz J, 1999, PHYS REV B, V60, P11971, DOI 10.1103/PhysRevB.60.11971; Schiotz J, 1998, NATURE, V391, P561, DOI 10.1038/35328; Van Swygenhoven H, 1999, ACTA MATER, V47, P3117, DOI 10.1016/S1359-6454(99)00109-3; Van Swygenhoven H, 2000, PHYS REV B, V62, P831, DOI 10.1103/PhysRevB.62.831; Van Swygenhoven H, 1999, PHYS REV B, V60, P22, DOI 10.1103/PhysRevB.60.22; Van Swygenhoven H, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.224105; WEERTMAN JR, 2001, NANOSTRUCTURED MAT P; Yamakov V, 2002, ACTA MATER, V50, P61, DOI 10.1016/S1359-6454(01)00329-9; Yamakov V, 2001, ACTA MATER, V49, P2713, DOI 10.1016/S1359-6454(01)00167-7; Zeng P, 1998, MAT SCI ENG A-STRUCT, V252, P301, DOI 10.1016/S0921-5093(98)00665-0	16	554	561	3	189	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 5	2002	296	5565					66	67						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	539FA	11935012				2022-12-28	WOS:000174858800033
J	Rickes, S; Ocran, K				Rickes, S; Ocran, K			Porcelain gallbladder	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Univ Hosp Charite, D-10117 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Rickes, S (corresponding author), Univ Hosp Charite, D-10117 Berlin, Germany.								0	5	6	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 4	2002	346	14					E4	E4		10.1056/ENEJMicm010212	http://dx.doi.org/10.1056/ENEJMicm010212			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	536YL	11932468				2022-12-28	WOS:000174729400006
J	Woods, WG; Gao, RN; Shuster, JJ; Robison, LL; Bernstein, M; Weitzman, S; Bunin, G; Levy, I; Brossard, J; Dougherty, G; Tuchman, M; Lemieux, B				Woods, WG; Gao, RN; Shuster, JJ; Robison, LL; Bernstein, M; Weitzman, S; Bunin, G; Levy, I; Brossard, J; Dougherty, G; Tuchman, M; Lemieux, B			Screening of infants and mortality due to neuroblastoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							AGE-SPECIFIC INCIDENCE; CHILDHOOD-CANCER; NEURO-BLASTOMA; UNITED-STATES; NORTH-AMERICA; PROJECT; JAPAN; CHILDREN; TRIALS	Background: Neuroblastoma, the most common extracranial solid tumor that occurs in early childhood, can be identified in the preclinical stages by the detection of catecholamines in the urine. However, it is unknown whether routine screening for neuroblastoma reduces mortality due to this disease. Methods: Through their parents, we offered screening for neuroblastoma at three weeks and six months of age to all 476,654 children born in the province of Quebec, Canada, during a five-year period (May 1, 1989, through April 30, 1994). The participation rate was 92 percent. The rate of death due to neuroblastoma was determined and compared with the rates in several unscreened control populations born during the same period. Results: Among children younger than eight years of age in the Quebec cohort, there were 22 deaths due to neuroblastoma; the cumulative (+/-SE) mortality rate due to neuroblastoma was 4.78+/-1.14 per 100,000 children over a period of nine years. The standardized incidence ratios for death due to neuroblastoma for the Quebec cohort were 1.11 (95 percent confidence interval, 0.64 to 1.92) as compared with a control group in Ontario, Canada; 0.90 (95 percent confidence interval, 0.48 to 1.70) as compared with a control group in Minnesota; 1.40 (95 percent confidence interval, 0.81 to 2.41) as compared with a control group in Florida; and 0.96 (95 percent confidence interval, 0.56 to 1.66) as compared with a control group in the Greater Delaware Valley. The standardized mortality ratio for the Quebec cohort as compared with the rest of Canada was 1.39 (95 percent confidence interval, 0.85 to 2.30); the odds ratio for the comparison with a cohort born in Quebec before the screening program began was 0.98 (95 percent confidence interval, 0.54 to 1.77). Conclusions: Screening infants for neuroblastoma does not appear to reduce mortality due to this disease.	Emory Univ, AFLAC Canc Ctr, Atlanta, GA 30322 USA; Childrens Healthcare Atlanta, Atlanta, GA 30322 USA; Stat Canada, Ottawa, ON, Canada; Univ Florida, Gainesville, FL USA; Univ Minnesota, Minneapolis, MN USA; Hop St Justine, Montreal, PQ H3T 1C5, Canada; Hosp Sick Children, Toronto, ON M5G 1X8, Canada; Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; Canadian Med Assoc, Ottawa, ON, Canada; Ctr Univ Sante Estrie, Sherbrooke, PQ, Canada; Montreal Childrens Hosp, Montreal, PQ H3H 1P3, Canada; Childrens Natl Med Ctr, Washington, DC 20010 USA	Emory University; Children's Healthcare of Atlanta (CHOA); Statistics Canada; State University System of Florida; University of Florida; University of Minnesota System; University of Minnesota Twin Cities; Universite de Montreal; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; McGill University; Children's National Health System	Woods, WG (corresponding author), Emory Univ, AFLAC Canc Ctr, 1405 Clifton Rd NE,Rm 319, Atlanta, GA 30322 USA.		Shuster, Jonathan/ABB-5773-2021; Robison, Leslie/N-8122-2018	Shuster, Jonathan/0000-0001-9499-5616; 	NATIONAL CANCER INSTITUTE [R01CA046907] Funding Source: NIH RePORTER; NCI NIH HHS [CA46907] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ater JL, 1998, CANCER, V82, P1593, DOI 10.1002/(SICI)1097-0142(19980415)82:8<1593::AID-CNCR23>3.0.CO;2-Z; BERNSTEIN ML, 1992, J CLIN ONCOL, V10, P323, DOI 10.1200/JCO.1992.10.2.323; BERNSTEIN ML, 1992, J CLIN ONCOL, V10, P1202; BESSHO F, 1991, J PEDIATR-US, V119, P237, DOI 10.1016/S0022-3476(05)80733-4; Bessho F, 1996, INT J CANCER, V67, P520, DOI 10.1002/(SICI)1097-0215(19960807)67:4<520::AID-IJC10>3.0.CO;2-B; BRESLOW NE, 1987, IARC SCI PUBL, V82, P8; BRODEUR GM, 1992, AM J PEDIAT HEMATOL, V14, P111; Brodeur GM, 2001, MED PEDIATR ONCOL, V36, P157, DOI 10.1002/1096-911X(20010101)36:1<157::AID-MPO1038>3.0.CO;2-F; Castleberry RP, 1997, PEDIATR CLIN N AM, V44, P919, DOI 10.1016/S0031-3955(05)70537-X; Gao RN, 1997, CANCER CAUSE CONTROL, V8, P745, DOI 10.1023/A:1018483405637; KANEKO Y, 1990, J CLIN ONCOL, V8, P2005, DOI 10.1200/JCO.1990.8.12.2005; KRAMER S, 1983, J NATL CANCER I, V70, P49; Lemieux B, 1987, ADV NEONATAL SCREENI, P209; MURPHY SB, 1991, LANCET, V337, P344, DOI 10.1016/0140-6736(91)90957-Q; NISHI M, 1987, CANCER, V60, P433, DOI 10.1002/1097-0142(19870801)60:3<433::AID-CNCR2820600326>3.0.CO;2-H; Ries L.A.G., 1999, CANC INCIDENCE SURVI; Ross JA, 1996, CANCER, V77, P201, DOI 10.1002/(SICI)1097-0142(19960101)77:1<201::AID-CNCR32>3.0.CO;2-7; SAWADA T, 1984, LANCET, V2, P271; Schilling FH, 2002, NEW ENGL J MED, V346, P1047, DOI 10.1056/NEJMoa012277; Suita S, 1998, J PEDIATR SURG, V33, P1674, DOI 10.1016/S0022-3468(98)90607-8; TUCHMAN M, 1990, PEDIATRICS, V86, P765; VOORHESS ML, 1962, J CLIN ENDOCR METAB, V22, P126, DOI 10.1210/jcem-22-2-126; Woods WG, 1996, LANCET, V348, P1682, DOI 10.1016/S0140-6736(96)06020-5; WOODS WG, 1992, PEDIATRICS, V89, P114; WOODS WG, 1992, AM J PEDIAT HEMATOL, V14, P312; Woods WG, 1999, MED PEDIATR ONCOL, V33, P360; WOODS WG, 1992, SCREENING, V1, P273; YAMAMOTO K, 1995, J CLIN ONCOL, V13, P2033, DOI 10.1200/JCO.1995.13.8.2033; Yamamoto K, 1998, J CLIN ONCOL, V16, P1265, DOI 10.1200/JCO.1998.16.4.1265; 1999, MED PEDIAT ONCOL, V33, P357	30	233	239	0	10	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 4	2002	346	14					1041	1046		10.1056/NEJMoa012387	http://dx.doi.org/10.1056/NEJMoa012387			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	536YL	11932470				2022-12-28	WOS:000174729400002
J	Ehrlich, GD; Veeh, R; Wang, X; Costerton, JW; Hayes, JD; Hu, FZ; Daigle, BJ; Ehrlich, MD; Post, JC				Ehrlich, GD; Veeh, R; Wang, X; Costerton, JW; Hayes, JD; Hu, FZ; Daigle, BJ; Ehrlich, MD; Post, JC			Mucosal biofilm formation on middle-ear mucosa in the chinchilla model of otitis media	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							QUORUM-SENSING SIGNALS; PSEUDOMONAS-AERUGINOSA; BACTERIAL BIOFILMS; VIABLE BACTERIA; EFFUSION; CULTURE; ADENOIDECTOMY; MICROSCOPY; PERSISTENT; ENDOTOXIN	Context Chronic otitis media with effusion (OME) has long been considered to be a sterile inflammatory process, The previous application of molecular diagnostic technologies to OME suggests that viable bacteria are present in complex communities known as mucosal biofilms; however, direct imaging evidence of mucosal biofilms associated with OM is lacking. Objective To determine whether biofilm formation occurs in middle-ear mucosa in an experimental model of otitis media. Design and Materials A total of 48 research-grade, young adult chinchillas weighing 500 g were used for 2 series of animal experiments: one to obtain specimens for scanning electron microscopy and the other to obtain specimens for confocal laser scanning microscopy using vital dyes. In each series, 21 animals were bilaterally injected with viable Haemophilus influenzae bacteria and 1 was inoculated to account for expected mortality, Three served as negative controls. Effusions and mucosal specimens were collected from 2 infected animals that were euthanized at 3, 6, 12, and 24 hours and at days 2, 4, 5, 10, 16, and 22 after inoculation. Main Outcome Measures Images were analyzed for biofilm morphology, including presence of microcolony formation and for presence of bacteria on tissue surfaces. Results Scanning electron microscopy demonstrated that biofilm formation was evident in all specimens from animals beginning 1 day after infection and was present through 21 days, Confocal laser scanning microscopy indicated that bacteria within the biofilms are viable. Conclusion These preliminary findings provide evidence that mucosal biofilms form in an experimental model of otitis media and suggest that biofilm formation may be an important factor in the pathogenesis of chronic otitis media with effusion.	Allegheny Singer Res Inst, Ctr Genom Sci, Pittsburgh, PA 15212 USA; MCP Hahnemann Sch Med, Dept Microbiol & Immunol, Philadelphia, PA USA; Montana State Univ, Ctr Biofilm Engn, Bozeman, MT 59717 USA	Drexel University; Montana State University System; Montana State University Bozeman	Ehrlich, GD (corresponding author), Allegheny Singer Res Inst, Ctr Genom Sci, 320 E N Ave, Pittsburgh, PA 15212 USA.		Daigle, Bernie/AAO-5462-2021	Ehrlich, Garth/0000-0003-1140-6594	NIDCD NIH HHS [DC02148, DC04173] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC002148, R01DC004173] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Aul JJ, 1998, ANN OTO RHINOL LARYN, V107, P508; Becker P, 2001, APPL ENVIRON MICROB, V67, P2958, DOI 10.1128/AEM.67.7.2958-2965.2001; Casselbrant ML, 1999, JAMA-J AM MED ASSOC, V282, P2125, DOI 10.1001/jama.282.22.2125; Cook G, 2000, INT J ANTIMICROB AG, V13, P169, DOI 10.1016/S0924-8579(99)00120-X; Costerton JW, 1999, INT J ANTIMICROB AG, V11, P217, DOI 10.1016/S0924-8579(99)00018-7; Costerton JW, 1999, SCIENCE, V284, P1318, DOI 10.1126/science.284.5418.1318; COSTERTON JW, 1995, ANNU REV MICROBIOL, V49, P711, DOI 10.1146/annurev.mi.49.100195.003431; COSTERTON JW, 1978, SCI AM, V238, P86, DOI 10.1038/scientificamerican0178-86; Costerton JW, 2001, SCI AM, V285, P74, DOI 10.1038/scientificamerican0701-74; Costerton JW, 2001, TRENDS MICROBIOL, V9, P50, DOI 10.1016/S0966-842X(00)01918-1; DEMARIA TF, 1984, J CLIN MICROBIOL, V20, P15, DOI 10.1128/JCM.20.1.15-17.1984; Dingman JR, 1998, J CLIN MICROBIOL, V36, P3417, DOI 10.1128/JCM.36.11.3417-3419.1998; DONOGHUE HD, 1991, CARIES RES, V25, P108, DOI 10.1159/000261352; Ehrlich GD, 1999, JAMA-J AM MED ASSOC, V282, P2167, DOI 10.1001/jama.282.22.2167; FITZGERALD G, 1975, J BACTERIOL, V122, P345, DOI 10.1128/JB.122.1.345-346.1975; GATES GA, 1987, NEW ENGL J MED, V317, P1444, DOI 10.1056/NEJM198712033172305; GEESEY GG, 1978, LIMNOL OCEANOGR, V23, P1214, DOI 10.4319/lo.1978.23.6.1214; Hoiby N, 2001, MICROBES INFECT, V3, P23, DOI 10.1016/S1286-4579(00)01349-6; HOYLE BD, 1990, J ANTIMICROB CHEMOTH, V26, P1, DOI 10.1093/jac/26.1.1; Klein JO, 2000, VACCINE, V19, pS2, DOI 10.1016/S0264-410X(00)00271-1; Kreft JU, 2001, MICROBIOL-SGM, V147, P2897, DOI 10.1099/00221287-147-11-2897; Leung JW, 1998, GASTROINTEST ENDOSC, V48, P250, DOI 10.1016/S0016-5107(98)70186-5; Mah TFC, 2001, TRENDS MICROBIOL, V9, P34, DOI 10.1016/S0966-842X(00)01913-2; MAW R, 1993, BMJ-BRIT MED J, V306, P756, DOI 10.1136/bmj.306.6880.756; Miller MB, 2001, ANNU REV MICROBIOL, V55, P165, DOI 10.1146/annurev.micro.55.1.165; Page R C, 1998, Ann Periodontol, V3, P108, DOI 10.1902/annals.1998.3.1.108; Parsek MR, 1999, METHOD ENZYMOL, V310, P43; Parsek MR, 2000, P NATL ACAD SCI USA, V97, P8789, DOI 10.1073/pnas.97.16.8789; Post JC, 2000, JAMA-J AM MED ASSOC, V283, P1544, DOI 10.1001/jama.283.12.1544; POST JC, 1995, JAMA-J AM MED ASSOC, V273, P1598, DOI 10.1001/jama.273.20.1598; Post JC, 1996, AM J OTOLARYNG, V17, P106, DOI 10.1016/S0196-0709(96)90005-8; Potera C, 1999, SCIENCE, V283, P1837, DOI 10.1126/science.283.5409.1837; Rashid MH, 2000, P NATL ACAD SCI USA, V97, P9636, DOI 10.1073/pnas.170283397; Rayner MG, 1998, JAMA-J AM MED ASSOC, V279, P296, DOI 10.1001/jama.279.4.296; ROSENFELD RM, 1992, OTOLARYNG HEAD NECK, V106, P378, DOI 10.1177/019459989210600411; Sauer K, 2002, J BACTERIOL, V184, P1140, DOI 10.1128/jb.184.4.1140-1154.2002; Singh PK, 2000, NATURE, V407, P762, DOI 10.1038/35037627; SIRAKOVA T, 1994, INFECT IMMUN, V62, P2002, DOI 10.1128/IAI.62.5.2002-2020.1994; Sternberg C, 1999, APPL ENVIRON MICROB, V65, P4108; Vroom JM, 1999, APPL ENVIRON MICROB, V65, P3502; Whiteley M, 2001, NATURE, V413, P860, DOI 10.1038/35101627; Williams I, 1999, MICROBIOL-UK, V145, P1325, DOI 10.1099/13500872-145-6-1325; Wimpenny J, 2000, FEMS MICROBIOL REV, V24, P661, DOI 10.1111/j.1574-6976.2000.tb00565.x	43	259	287	0	15	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 3	2002	287	13					1710	1715		10.1001/jama.287.13.1710	http://dx.doi.org/10.1001/jama.287.13.1710			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	536YW	11926896	Green Published, Bronze			2022-12-28	WOS:000174730300026
J	Kim, JH; Skates, SJ; Uede, T; Wong, KK; Schorge, JO; Feltmate, CM; Berkowitz, RS; Cramer, DW; Mok, SC				Kim, JH; Skates, SJ; Uede, T; Wong, KK; Schorge, JO; Feltmate, CM; Berkowitz, RS; Cramer, DW; Mok, SC			Osteopontin as a potential diagnostic biomarker for ovarian cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SECRETED PHOSPHOPROTEIN-I; MESSENGER-RNA; MOLECULAR-CLONING; PROSTATE-CANCER; GENE-EXPRESSION; IDENTIFICATION; MACROPHAGES; BREAST; CELLS; SERUM	Context Development of new biomarkers for ovarian cancer is needed for early detection and disease monitoring. Analyses involving complementary DNA (cDNA) microarray data can be used to identify up-regulated genes in cancer cells, whose products may then be further validated as potential biomarkers. Objective To describe validation studies of an up-regulated gene known as osteopontin, previously identified using a cDNA microarray system. Design, Setting, and Participants Experimental and cross-sectional studies were conducted involving ovarian cancer and healthy human ovarian surface epithelial cell lines and cultures, archival paraffin-embedded ovarian tissue collected between June 1992 and June 2001, and fresh tissue and preoperative plasma from 144 patients evaluated for a pelvic mass between June 1992 and June 2001 in gynecologic oncology services at 2 US academic institutions. Plasma samples from 107 women selected from an epidemiologic study of ovarian cancer initiated between May 1992 and March 1997 were used as healthy controls. Main Outcome Measures Relative messenger RNA expression in cancer cells and fresh ovarian tissue, measured by real-time polymerase chain reaction as 2(-DeltaDeltaCT) (a quantitative value representing the amount of osteopontin expression); osteopontin production, localized and scored in ovarian healthy and tumor tissue with immunohistochemical studies; and amount of osteopontin in patient vs control plasma, measured using an enzyme-linked immunoassay. Results The geometric mean for 2(-DeltaDeltaCT) for osteopontin expression in 5 healthy ovarian epithelial cell cultures was 4.1 compared with 270.4 in 14 ovarian cancer cell lines (P=.03). The geometric mean 2(-DeltaDeltaCT) for osteopontin expression in tissue from 2 healthy ovarian epithelial samples was 9.0 compared with 164.0 in 27 microdissected ovarian tumor tissue samples (P=.06). Immunolocalization of osteopontin showed that tissue samples from 61 patients with invasive ovarian cancer and 29 patients with borderline ovarian tumors expressed higher levels of osteopontin than tissue samples from 6 patients with benign tumors and samples of healthy ovarian epithelium from 3 patients (P=.03). Osteopontin levels in plasma were significantly higher (P<.001) in 51 patients with epithelial ovarian cancer (486.5 ng/mL) compared with those of 107 healthy controls (147.1 ng/mL), 46 patients with benign ovarian disease (254.4 ng/mL), and 47 patients with other gynecologic cancers (260.9 ng/mL). Conclusions Our findings provide evidence for an association between levels of a biomarker, osteopontin, and ovarian cancer and suggest that future research assessing its clinical usefulness would be worthwhile.	Brigham & Womens Hosp, Dept Obstet Gynecol & Reprod Biol, Div Gynecol Oncol, Lab Gynecol Oncol, Boston, MA 02115 USA; St Vincent Hosp, Dept Obstet & Gynecol, Suwon, Kyong Ki Do, South Korea; Catholic Univ Korea, Suwon, Kyong Ki Do, South Korea; Harvard Sch Med, Boston, MA USA; Massachusetts Gen Hosp, Ctr Biostat, Boston, MA USA; Dana Farber Canc Inst, Boston, MA 02115 USA; Dana Farber Harvard Canc Ctr, Boston, MA USA; Hokkaido Univ, Inst Med Genet, Sapporo, Hokkaido, Japan; Texas Childrens Hosp, Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; Univ Texas, SW Med Ctr, Dept Obstet & Gynecol, Dallas, TX USA	Harvard University; Brigham & Women's Hospital; Catholic University of Korea; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Hokkaido University; Baylor College of Medicine; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Mok, SC (corresponding author), Brigham & Womens Hosp, Dept Obstet Gynecol & Reprod Biol, Div Gynecol Oncol, Lab Gynecol Oncol, BL1-447,221 Longwood Ave, Boston, MA 02115 USA.	scmok@rics.bwh.harvard.edu	Wong, K.-k./AAA-6589-2020	Wong, K.-k./0000-0002-0375-6669; Feltmate, Colleen/0000-0002-7700-8575; Jae-Hoon, Kim/0000-0001-6599-7065	NATIONAL CANCER INSTITUTE [U01CA086381] Funding Source: NIH RePORTER; NCI NIH HHS [CA86381] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bull JH, 2001, BRIT J CANCER, V84, P1512, DOI 10.1054/bjoc.2001.1816; Casson AG, 1997, INT J CANCER, V72, P739, DOI 10.1002/(SICI)1097-0215(19970904)72:5<739::AID-IJC6>3.0.CO;2-T; CHACKALAPARAMPIL I, 1985, J VIROL, V53, P841, DOI 10.1128/JVI.53.3.841-850.1985; Chan WY, 2000, AM J PATHOL, V156, P409, DOI 10.1016/S0002-9440(10)64744-X; Cramer DW, 2001, INT J CANCER, V94, P128, DOI 10.1002/ijc.1435; Cramer DW, 2000, CANCER EPIDEM BIOMAR, V9, P95; Crawford HC, 1998, CANCER RES, V58, P5206; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; GIACHELLI C, 1991, BIOCHEM BIOPH RES CO, V177, P867, DOI 10.1016/0006-291X(91)91870-I; Giachelli CM, 1998, AM J PATHOL, V152, P353; GIACHELLI CM, 1995, ANN NY ACAD SCI, V760, P109, DOI 10.1111/j.1749-6632.1995.tb44624.x; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; HOGDALL CK, 1995, GYNECOL ONCOL, V56, P22, DOI 10.1006/gyno.1995.1004; HWANG S, 1994, J BIOL CHEM, V269, P711; Jacobs IJ, 1999, LANCET, V353, P1207, DOI 10.1016/S0140-6736(98)10261-1; Kim Youn Wha, 1998, Journal of Korean Medical Science, V13, P652; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; LIAW L, 1995, J CLIN INVEST, V95, P713, DOI 10.1172/JCI117718; Luo LY, 2001, CLIN CANCER RES, V7, P2372; Maki M, 2000, PATHOL INT, V50, P531, DOI 10.1046/j.1440-1827.2000.01075.x; McKee MD, 1996, ANAT RECORD, V245, P394, DOI 10.1002/(SICI)1097-0185(199606)245:2<394::AID-AR19>3.0.CO;2-K; Mok SC, 2001, J NATL CANCER I, V93, P1458, DOI 10.1093/jnci/93.19.1458; Nau GJ, 1997, P NATL ACAD SCI USA, V94, P6414, DOI 10.1073/pnas.94.12.6414; NEGISHI Y, 1993, GYNECOL ONCOL, V48, P148, DOI 10.1006/gyno.1993.1026; PATARCA R, 1989, J EXP MED, V170, P145, DOI 10.1084/jem.170.1.145; *PE APPL BIOS, 1998, GEN AMP 5700 US MAN, pA9; PRINCE CW, 1987, J BIOL CHEM, V262, P2900; REIS LA, 1998, SEER CANC STAT REV 1; Sandmaier BM, 1999, J IMMUNOTHER, V22, P54, DOI 10.1097/00002371-199901000-00008; SENGER DR, 1989, ANTICANCER RES, V9, P1291; Sgroi DC, 1999, CANCER RES, V59, P5656; Shijubo N, 1999, AM J RESP CRIT CARE, V160, P1269, DOI 10.1164/ajrccm.160.4.9807094; SINGH RP, 1990, J EXP MED, V171, P1931, DOI 10.1084/jem.171.6.1931; SMITH JH, 1987, J CELL BIOCHEM, V34, P13, DOI 10.1002/jcb.240340103; Thalmann GN, 1999, CLIN CANCER RES, V5, P2271; Tiniakos DG, 1998, HUM PATHOL, V29, P1250, DOI 10.1016/S0046-8177(98)90253-2; TSAO SW, 1995, EXP CELL RES, V218, P499, DOI 10.1006/excr.1995.1184; Tuck AB, 1998, INT J CANCER, V79, P502, DOI 10.1002/(SICI)1097-0215(19981023)79:5<502::AID-IJC10>3.0.CO;2-3; Tunio GM, 1998, ARCH PATHOL LAB MED, V122, P1087; Tuxen MK, 1999, GYNECOL ONCOL, V74, P12, DOI 10.1006/gyno.1999.5414; Ue T, 1998, INT J CANCER, V79, P127, DOI 10.1002/(SICI)1097-0215(19980417)79:2<127::AID-IJC5>3.0.CO;2-V; Villaret DB, 2000, LARYNGOSCOPE, V110, P374, DOI 10.1097/00005537-200003000-00008; Weber GF, 1996, SCIENCE, V271, P509, DOI 10.1126/science.271.5248.509; Wong KK, 2001, BIOTECHNIQUES, V30, P670, DOI 10.2144/01303dd05; Xu Y, 1998, JAMA-J AM MED ASSOC, V280, P719, DOI 10.1001/jama.280.8.719; Zhang J, 2001, CANCER LETT, V171, P215, DOI 10.1016/S0304-3835(01)00607-3	48	368	399	1	25	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 3	2002	287	13					1671	1679		10.1001/jama.287.13.1671	http://dx.doi.org/10.1001/jama.287.13.1671			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	536YW	11926891	Bronze			2022-12-28	WOS:000174730300021
J	Ghofrani, HA; Wiedemann, R; Rose, F; Olschewski, H; Schermuly, RT; Weissmann, N; Seeger, W; Grimminger, F				Ghofrani, HA; Wiedemann, R; Rose, F; Olschewski, H; Schermuly, RT; Weissmann, N; Seeger, W; Grimminger, F			Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension	ANNALS OF INTERNAL MEDICINE			English	Article							NITRIC-OXIDE; AEROSOLIZED ILOPROST; PROSTACYCLIN; VASODILATOR	Background: inhalation of the stable prostacyclin analogue iloprost is being studied for treatment of pulmonary hypertension. The selective phosphodiesterase-5 inhibitor sildenafil has been reported to cause pulmonary vasodilatation. Objective: To evaluate the safety and effectiveness of oral sildenafil, alone and in combination with inhaled iloprost, for treatment of pulmonary hypertension. Design: Randomized, controlled, open-label trial. Setting: Intensive care unit. Patients: 30 patients with severe pulmonary arterial hypertension (n = 16), chronic thromboembolic pulmonary hypertension (n = 13), or pulmonary hypertension due to aplasia of the left pulmonary artery (n = 1), all classified as New York Heart Association class III or IV. Intervention: All patients received inhaled nitric oxide and aerosolized iloprost (inhaled dose, 2.8 mug). They were then randomly assigned to receive 12.5 mg of oral sildenafil, 50 mg of sildenafil, 12.5 mg of sildenafil plus inhaled iloprost, or 50 mg of sildenafil plus inhaled iloprost. Measurements: Systemic and pulmonary arterial pressure, pulmonary arterial occlusion pressure, cardiac output, central venous pressure, peripheral arterial oxygen saturation, and arterial and mixed venous blood gases were measured during right-heart catheterization by using a Swan-Ganz catheter. Results: In rank order of pulmonary vasodilatory potency (maximum reduction of pulmonary vascular resistance and increase in cardiac index), 50 mg of sildenafil plus iloprost was most effective, followed by 12.5 mg of sildenafil plus iloprost. Iloprost alone and 50 mg of sildenafil were almost equally effective but were less potent than the combination regimens, and the least potent treatments were 12.5 mg of sildenafil and nitric oxide. In patients who received 50 mg of sildenafil plus iloprost, the maximum change in pulmonary vasodilatory potency was -44.2% (95% Cl, -49.5% to -38.8%), compared with -14.1% (Cl, -19.1% to -9.2%) in response to nitric oxide. With administration of 50 mg of sildenafil plus iloprost, the area under the curve for reduction in pulmonary vasodilatory resistance surpassed that of administration of 50 mg of sildenafil alone and iloprost alone combined, the vasodilatory effect lasted longer than 3 hours, and systemic arterial pressure and arterial oxygenation were maintained. No serious adverse events occurred. Conclusion: Although limited by the small sample and lack of long-term observations, the study shows that oral sildenafill is a potent pulmonary vasodilator that acts synergistically with inhaled iloprost to cause strong pulmonary vasodilatation in both severe pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.	Univ Giessen Hosp, Dept Internal Med, D-35392 Giessen, Germany		Ghofrani, HA (corresponding author), Univ Giessen Hosp, Dept Internal Med, Klinikstr 36, D-35392 Giessen, Germany.	ardeschir.ghofrani@innere.med.uni-giessen.de	Olschewski, Horst/L-3547-2019; Ghofrani, Hossein Ardeschir/AAD-2856-2022; Ghofrani, Ardeschir/AAD-5293-2020	Olschewski, Horst/0000-0002-2834-7466; Ghofrani, Ardeschir/0000-0002-2029-4419; Schermuly, Ralph/0000-0002-5167-6970; Seeger, Werner/0000-0003-1946-0894; Weissmann, Norbert/0000-0003-2675-3871; Grimminger, Friedrich/0000-0001-8725-6276				Abrams D, 2000, Heart, V84, pE4, DOI 10.1136/heart.84.2.e4; AHN HS, 1991, ADV EXP MED BIOL, V308, P191; Barst RJ, 1996, NEW ENGL J MED, V334, P296, DOI 10.1056/NEJM199602013340504; BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; Cheitlin MD, 1999, CIRCULATION, V99, P168, DOI 10.1161/01.CIR.99.1.168; Gessler T, 2001, EUR RESPIR J, V17, P14, DOI 10.1183/09031936.01.17100140; Hoeper MM, 2000, J AM COLL CARDIOL, V35, P176, DOI 10.1016/S0735-1097(99)00494-5; Hoeper MM, 2000, NEW ENGL J MED, V342, P1866, DOI 10.1056/NEJM200006223422503; Olschewski H, 2000, ANN INTERN MED, V132, P435, DOI 10.7326/0003-4819-132-6-200003210-00003; Olschewski H, 1999, AM J RESP CRIT CARE, V160, P600, DOI 10.1164/ajrccm.160.2.9810008; Olschewski H, 1996, ANN INTERN MED, V124, P820, DOI 10.7326/0003-4819-124-9-199605010-00006; PEPKEZABA J, 1991, LANCET, V338, P1173, DOI 10.1016/0140-6736(91)92033-X; Prasad S, 2000, NEW ENGL J MED, V343, P1342, DOI 10.1056/NEJM200011023431814; RABE KF, 1995, AM J PHYSIOL, V266, pL536; RICH S, 2001, WORLD S PRIM PULM HY; SITBON O, 1995, AM J RESP CRIT CARE, V151, P384, DOI 10.1164/ajrccm.151.2.7842196; Weimann J, 2000, ANESTHESIOLOGY, V92, P1702, DOI 10.1097/00000542-200006000-00030; Wensel R, 2000, CIRCULATION, V101, P2388, DOI 10.1161/01.CIR.101.20.2388	18	370	408	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 2	2002	136	7					515	522		10.7326/0003-4819-136-7-200204020-00008	http://dx.doi.org/10.7326/0003-4819-136-7-200204020-00008			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	536CA	11926786				2022-12-28	WOS:000174682100003
J	Whelton, SP; Chin, A; Xin, X; He, J				Whelton, SP; Chin, A; Xin, X; He, J			Effect of aerobic exercise on blood pressure: A meta-analysis of randomized, controlled trials	ANNALS OF INTERNAL MEDICINE			English	Article							PHYSICAL-ACTIVITY; CARDIOVASCULAR-RESPONSES; INTENSITY EXERCISE; MILD HYPERTENSION; PUBLICATION BIAS; WOMEN; MODERATE; PROGRAM; FITNESS; WALKING	Purpose: Physical activity has been associated with reduced blood pressure in observational epidemiologic studies and individual clinical trials. This meta-analysis of randomized, controlled trials was conducted to determine the effect of aerobic exercise on blood pressure. Data Sources: English-language articles published before September 2001. Study Selection: 54 randomized, controlled trials (2419 participants) whose intervention and control groups differed only in aerobic exercise. Data Extraction: Using a standardized protocol and data extraction form, three of the investigators independently abstracted data on study design, sample size, participant characteristics, type of intervention, follow-up duration, and treatment outcomes. Data Synthesis: In a random-effects model, data from each trial were pooled and weighted by the inverse of the total variance. Aerobic exercise was associated with a significant reduction in mean systolic and diastolic blood pressure (-3.84 mm Hg [95% Cl, -4.97 to -2.72 mm Hg] and -2.58 mm Hg [Cl, -3.35 to -1.81 mm Hg], respectively). A reduction in blood pressure was associated with aerobic exercise in hypertensive participants and normotensive participants and in overweight participants and normal-weight participants. Conclusions: Aerobic exercise reduces blood pressure in both hypertensive and normotensive persons. An increase in aerobic physical activity should be considered an important component of lifestyle modification for prevention and treatment of high blood pressure.	Tulane Univ, Sch Publ Hlth & Trop Med, Dept Epidemiol, New Orleans, LA 70112 USA	Tulane University	He, J (corresponding author), Tulane Univ, Sch Publ Hlth & Trop Med, Dept Epidemiol, 1430 Tulane Ave SL18, New Orleans, LA 70112 USA.	jhe@rulane.edu	He, Jiang/AAF-5303-2020	He, Jiang/0000-0002-8286-9652	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060300] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01HL60300] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKINPELU AO, 1990, J HUM HYPERTENS, V4, P74; ALBRIGHT CL, 1992, J PSYCHOSOM RES, V36, P25, DOI 10.1016/0022-3999(92)90111-E; *AM HEART ASS, 1999, 2000 HEART STROK STA; ARROLL B, 1992, J CLIN EPIDEMIOL, V45, P439, DOI 10.1016/0895-4356(92)90093-3; ARROLL B, 1995, NEW ZEAL MED J, V108, P266; Begg C., 1994, HDB RES SYNTHESIS, P399; Blumenthal JA, 2000, ARCH INTERN MED, V160, P1947, DOI 10.1001/archinte.160.13.1947; BLUMENTHAL JA, 1991, JAMA-J AM MED ASSOC, V266, P2098, DOI 10.1001/jama.266.15.2098; BRAITH RW, 1994, AM J CARDIOL, V73, P1124, DOI 10.1016/0002-9149(94)90294-1; Brett SE, 2000, CIRCULATION, V101, P611, DOI 10.1161/01.CIR.101.6.611; Brown MD, 1997, HYPERTENSION, V30, P1549, DOI 10.1161/01.HYP.30.6.1549; COOK NR, 1995, ARCH INTERN MED, V155, P701, DOI 10.1001/archinte.155.7.701; Cooper AR, 2000, BRIT J GEN PRACT, V50, P958; Cutler JA, 1997, AM J CLIN NUTR, V65, P643, DOI 10.1093/ajcn/65.2.643S; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Duey William J., 1998, Ethnicity and Disease, V8, P306; DUNCAN JJ, 1991, JAMA-J AM MED ASSOC, V26, P3295; Duval S, 2000, J AM STAT ASSOC, V95, P89, DOI 10.2307/2669529; Duval S, 2000, BIOMETRICS, V56, P455, DOI 10.1111/j.0006-341X.2000.00455.x; FAGARD RH, 1993, J HYPERTENS, V11, pS47; FOLLMANN D, 1992, J CLIN EPIDEMIOL, V45, P769, DOI 10.1016/0895-4356(92)90054-Q; Gordon NF, 1997, AM J CARDIOL, V79, P763, DOI 10.1016/S0002-9149(96)00864-8; HAMDORF PA, 1992, ARCH PHYS MED REHAB, V73, P603; He J, 1999, AM HEART J, V138, pS211, DOI 10.1016/S0002-8703(99)70312-1; He J, 1999, ARCH INTERN MED, V159, P498, DOI 10.1001/archinte.159.5.498; Higashi Y, 1999, HYPERTENSION, V33, P591, DOI 10.1161/01.HYP.33.1.591; Higashi Y, 1999, CIRCULATION, V100, P1194, DOI 10.1161/01.CIR.100.11.1194; JENNINGS G, 1986, CIRCULATION, V73, P30, DOI 10.1161/01.CIR.73.1.30; JONES DR, 1989, JAMA-J AM MED ASSOC, V261, P3255, DOI 10.1001/jama.261.22.3255; Kelley GA, 1999, PREV MED, V28, P264, DOI 10.1006/pmed.1998.0417; KELLEY GA, 1995, SOUTH MED J, V88, P42, DOI 10.1097/00007611-199501000-00005; KING AC, 1991, JAMA-J AM MED ASSOC, V266, P1535, DOI 10.1001/jama.266.11.1535; KINGWELL BA, 1993, MED J AUSTRALIA, V158, P234, DOI 10.5694/j.1326-5377.1993.tb121740.x; KOKKINOS PF, 1995, NEW ENGL J MED, V333, P1462, DOI 10.1056/NEJM199511303332204; Leon A S, 1996, J Cardiopulm Rehabil, V16, P183, DOI 10.1097/00008483-199605000-00006; LINDHEIM SR, 1994, OBSTET GYNECOL, V83, P167; MARTIN JE, 1990, CIRCULATION, V81, P1560, DOI 10.1161/01.CIR.81.5.1560; MEREDITH IT, 1990, J HYPERTENS, V8, P859, DOI 10.1097/00004872-199009000-00010; MEREDITH IT, 1991, HYPERTENSION, V18, P575, DOI 10.1161/01.HYP.18.5.575; Murphy MH, 1998, MED SCI SPORT EXER, V30, P152, DOI 10.1097/00005768-199801000-00021; NELSON L, 1986, LANCET, V2, P473, DOI 10.1016/S0140-6736(86)90354-5; Okumiya K, 1996, J AM GERIATR SOC, V44, P569, DOI 10.1111/j.1532-5415.1996.tb01444.x; OLUSEYE KA, 1990, J HUM HYPERTENS, V4, P77; POSNER JD, 1992, J AM GERIATR SOC, V40, P1; POTEMPA K, 1995, STROKE, V26, P101, DOI 10.1161/01.STR.26.1.101; RADAELLI A, 1992, J HYPERTENS, V10, P1279, DOI 10.1097/00004872-199210000-00024; Ready AE, 1996, MED SCI SPORT EXER, V28, P1097, DOI 10.1097/00005768-199609000-00004; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; Rice JA, 1998, MATH STAT DATA ANAL; Rogers MW, 1996, J HYPERTENS, V14, P1369, DOI 10.1097/00004872-199611000-00017; Sakai T, 1998, J HUM HYPERTENS, V12, P355, DOI 10.1038/sj.jhh.1000608; SUTER E, 1990, INT J SPORTS MED, V11, P425, DOI 10.1055/s-2007-1024832; URATA H, 1987, HYPERTENSION, V9, P245, DOI 10.1161/01.HYP.9.3.245; VANHOOF R, 1989, AM J CARDIOL, V63, P945, DOI 10.1016/0002-9149(89)90145-8; Wang JS, 1997, J APPL PHYSIOL, V83, P2080, DOI 10.1152/jappl.1997.83.6.2080; WHELTON PK, 1993, ARCH INTERN MED, V153, P186, DOI 10.1001/archinte.153.2.186; Whelton PK, 1997, JAMA-J AM MED ASSOC, V277, P1624, DOI 10.1001/jama.277.20.1624; Whelton PK, 1999, CLIN TRIALS CARDIOVA; WIJNEN JAG, 1994, INT J SPORTS MED, V15, P10, DOI 10.1055/s-2007-1021012; Wing RR, 1998, DIABETES CARE, V21, P350, DOI 10.2337/diacare.21.3.350; Wolz M, 2000, AM J HYPERTENS, V13, P103, DOI 10.1016/S0895-7061(99)00241-1; Xin X, 2001, HYPERTENSION, V38, P1112, DOI 10.1161/hy1101.093424; 1997, ARCH INTERN MED, V157, P2413	63	1185	1270	6	224	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 2	2002	136	7					493	503		10.7326/0003-4819-136-7-200204020-00006	http://dx.doi.org/10.7326/0003-4819-136-7-200204020-00006			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	536CA	11926784				2022-12-28	WOS:000174682100001
J	Dittmar, GAG; Wilkinson, CRM; Jedrzejewski, PT; Finley, D				Dittmar, GAG; Wilkinson, CRM; Jedrzejewski, PT; Finley, D			Role of a ubiquitin-like modification in polarized morphogenesis	SCIENCE			English	Article							PROTEIN CONJUGATION SYSTEM; YEAST	Type I ubiquitin-like proteins constitute a family of protein modifiers. Here we report the identification of a posttranslational protein modifier from Saccharomyces cerevisiae, Hub1. Overexpression of Hub1 resulted in enhanced conjugate formation when its carboxyl-terminal residue was deleted, suggesting that mature Hub1 may be produced by proteolytic processing. In vivo targets of Hub1 conjugation included cell polarity factors Sph1 and Hbt1. In the hub1Delta mutant, the subcellular localization of both Hbt1 and Sph1 was disrupted, and cell polarization during the formation of mating projections was defective. Consistent with these polarization defects, the hub1Delta mutant was deficient in mating.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Northeastern Univ, Barnett Inst, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Northeastern University	Finley, D (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, 240 Longwood Ave, Boston, MA 02115 USA.	daniel_finley@hms.harvard.edu	Dittmar, Gunnar/C-6333-2019; Dittmar, Gunnar/B-6383-2016	Dittmar, Gunnar/0000-0003-3647-8623; Dittmar, Gunnar/0000-0003-3647-8623	NIGMS NIH HHS [GM62663, GM58223] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM058223, R01GM062663] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arkowitz RA, 1997, J CELL BIOL, V138, P17, DOI 10.1083/jcb.138.1.17; DOOLITTLE RF, 1987, URFS ORFS PRIMER ANA; FINLEY D, 1987, CELL, V48, P1035, DOI 10.1016/0092-8674(87)90711-2; Friedmann JS, 2001, GENOMICS, V71, P252, DOI 10.1006/geno.2000.6439; Furukawa K, 2000, J BIOL CHEM, V275, P7462, DOI 10.1074/jbc.275.11.7462; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Hochstrasser M, 2001, CELL, V107, P5, DOI 10.1016/S0092-8674(01)00519-0; Ichimura Y, 2000, NATURE, V408, P488, DOI 10.1038/35044114; Jentsch S, 2000, TRENDS CELL BIOL, V10, P335, DOI 10.1016/S0962-8924(00)01785-2; Johnson ES, 2001, CELL, V106, P735, DOI 10.1016/S0092-8674(01)00491-3; Kawakami T, 2001, EMBO J, V20, P4003, DOI 10.1093/emboj/20.15.4003; Knop M, 1999, YEAST, V15, P963, DOI 10.1002/(SICI)1097-0061(199907)15:10B<963::AID-YEA399>3.0.CO;2-W; Lammer D, 1998, GENE DEV, V12, P914, DOI 10.1101/gad.12.7.914; Liakopoulos D, 1998, EMBO J, V17, P2208, DOI 10.1093/emboj/17.8.2208; Lippincott J, 1998, J CELL BIOL, V143, P1947, DOI 10.1083/jcb.143.7.1947; Lyapina S, 2001, SCIENCE, V292, P1382, DOI 10.1126/science.1059780; Madden K, 1998, ANNU REV MICROBIOL, V52, P687, DOI 10.1146/annurev.micro.52.1.687; Mizushima N, 1998, NATURE, V395, P395, DOI 10.1038/26506; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P732; Roemer T, 1998, J CELL SCI, V111, P479; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673	23	68	74	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 29	2002	295	5564					2442	2446		10.1126/science.1069989	http://dx.doi.org/10.1126/science.1069989			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	536QD	11923536				2022-12-28	WOS:000174712600053
J	Sabadini, R				Sabadini, R			Paleoclimate - Ice sheet collapse and sea level change	SCIENCE			English	Editorial Material									Univ Milan, Dept Earth Sci, Sect Geophys, I-20129 Milan, Italy	University of Milan	Sabadini, R (corresponding author), Univ Milan, Dept Earth Sci, Sect Geophys, I-20129 Milan, Italy.							Cheng MK, 1997, J GEOPHYS RES-SOL EA, V102, P22377, DOI 10.1029/97JB01740; Clark PU, 2002, SCIENCE, V295, P2438; Devoti R, 2001, GEOPHYS RES LETT, V28, P855, DOI 10.1029/2000GL011566; ESA, 1999, THESIS, VESA SP -1233(1); *ESA, 1998, ESA SP; Mitrovica JX, 2001, NATURE, V409, P1026, DOI 10.1038/35059054; Wahr J, 1998, J GEOPHYS RES-SOL EA, V103, P30205, DOI 10.1029/98JB02844	7	1	1	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 29	2002	295	5564					2376	2377		10.1126/science.1070629	http://dx.doi.org/10.1126/science.1070629			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	536QD	11923512				2022-12-28	WOS:000174712600028
J	Ng, J; Nardine, T; Harms, M; Tzu, J; Goldstein, A; Sun, Y; Dietzl, G; Dickson, BJ; Luo, LQ				Ng, J; Nardine, T; Harms, M; Tzu, J; Goldstein, A; Sun, Y; Dietzl, G; Dickson, BJ; Luo, LQ			Rac GTPases control axon growth, guidance and branching	NATURE			English	Article							GTP-BINDING PROTEIN; DROSOPHILA-MELANOGASTER; NEURONAL MORPHOGENESIS; ACTIN POLYMERIZATION; RHO GTPASES; DISTINCT; CDC42; PAK; PROLIFERATION; PURIFICATION	Growth, guidance and branching of axons are all essential processes for the precise wiring of the nervous system. Rho family GTPases transduce extracellular signals to regulate the actin cytoskeleton(1). In particular, Rac has been implicated in axon growth and guidance(2-8). Here we analyse the loss-of-function phenotypes of three Rac GTPases in Drosophila mushroom body neurons. We show that progressive loss of combined Rac1, Rac2 and Mtl activity leads first to defects in axon branching, then guidance, and finally growth. Expression of a Rac1 effector domain mutant that does not bind Pak rescues growth, partially rescues guidance, but does not rescue branching defects of Rac mutant neurons. Mosaic analysis reveals both cell autonomous and non-autonomous functions for Rac GTPases, the latter manifesting itself as a strong community effect in axon guidance and branching. These results demonstrate the central role of Rac GTPases in multiple aspects of axon development in vivo, and suggest that axon growth, guidance and branching could be controlled by differential activation of Rac signalling pathways.	Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA; Stanford Univ, Neurosci Program, Stanford, CA 94305 USA; Res Inst Mol Pathol, A-1030 Vienna, Austria	Stanford University; Stanford University; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Luo, LQ (corresponding author), Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA.		Ng, Julian/C-5747-2009; Dickson, Barry/AAE-7632-2019	Dickson, Barry/0000-0003-0715-892X; Luo, Liqun/0000-0001-5467-9264; Ng, Julian/0000-0002-1908-4414				BENTLEY D, 1986, NATURE, V323, P712, DOI 10.1038/323712a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; Dickson BJ, 2001, CURR OPIN NEUROBIOL, V11, P103, DOI 10.1016/S0959-4388(00)00180-X; Hakeda-Suzuki S, 2002, NATURE, V416, P438, DOI 10.1038/416438a; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HARDEN N, 1995, DEVELOPMENT, V121, P903; HARIHARAN IK, 1995, EMBO J, V14, P292, DOI 10.1002/j.1460-2075.1995.tb07003.x; Hing H, 1999, CELL, V97, P853, DOI 10.1016/S0092-8674(00)80798-9; Ito K, 1997, DEVELOPMENT, V124, P761; ITO K, 1992, DEV BIOL, V149, P134, DOI 10.1016/0012-1606(92)90270-Q; Joneson T, 1996, SCIENCE, V274, P1374, DOI 10.1126/science.274.5291.1374; Kaufmann N, 1998, DEVELOPMENT, V125, P453; KNAUS UG, 1992, J BIOL CHEM, V267, P23575; Kozma R, 1997, MOL CELL BIOL, V17, P1201, DOI 10.1128/MCB.17.3.1201; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Lee T, 1999, DEVELOPMENT, V126, P4065; Lee T, 1999, NEURON, V22, P451, DOI 10.1016/S0896-6273(00)80701-1; Lundquist EA, 2001, DEVELOPMENT, V128, P4475; Luo LQ, 2000, NAT REV NEUROSCI, V1, P173, DOI 10.1038/35044547; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; MARSH L, 1984, J CELL BIOL, V99, P2041, DOI 10.1083/jcb.99.6.2041; Morreale A, 2000, NAT STRUCT BIOL, V7, P384; MOSTELLER RD, 1994, MOL CELL BIOL, V14, P1104, DOI 10.1128/MCB.14.2.1104; Newsome TP, 2000, CELL, V101, P283, DOI 10.1016/S0092-8674(00)80838-7; Owen D, 2000, BIOCHEMISTRY-US, V39, P1243, DOI 10.1021/bi991567z; Scott EK, 2001, NAT NEUROSCI, V4, P359, DOI 10.1038/86006; Wang KH, 1999, CELL, V96, P771, DOI 10.1016/S0092-8674(00)80588-7; Worthylake DK, 2000, NATURE, V408, P682, DOI 10.1038/35047014; YAMADA KM, 1970, P NATL ACAD SCI USA, V66, P1206, DOI 10.1073/pnas.66.4.1206; Zipkin ID, 1997, CELL, V90, P883, DOI 10.1016/S0092-8674(00)80353-0	30	266	271	0	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 28	2002	416	6879					442	447		10.1038/416442a	http://dx.doi.org/10.1038/416442a			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	534UX	11919635				2022-12-28	WOS:000174607800050
J	Carbone, C; Gittleman, JL				Carbone, C; Gittleman, JL			A common rule for the scaling of carnivore density	SCIENCE			English	Article							POPULATION-DENSITY; PLANT ENERGETICS; BODY SIZE; PREY; TERRESTRIAL; ECOLOGY; CONSERVATION; EXTINCTION; PREDATOR; MAMMALS	Population density in plants and animals is thought to scale with size as a result of mass-related energy requirements. Variation in resources, however, naturally limits population density and may alter expected scaling patterns. We develop and test a general model for variation within and between species in population density across the order Carnivora. We find that 10,000 kilograms of prey supports about 90 kilograms of a given species of carnivore, irrespective of body mass, and that the ratio of carnivore number to prey biomass scales to the reciprocal of carnivore mass. Using mass-specific equations of prey productivity, we show that carnivore number per unit prey productivity scales to carnivore mass near -0.75, and that the scaling rule can predict population density across more than three orders of magnitude. The relationship provides a basis for identifying declining carnivore species that require conservation measures.	Zool Soc London, Inst Zool, London NW1 4RY, England; Univ Virginia, Dept Biol, Charlottesville, VA 22904 USA	Zoological Society of London; University of Virginia	Carbone, C (corresponding author), Zool Soc London, Inst Zool, Regents Pk, London NW1 4RY, England.	chris.carbone@ioz.ac.uk						Angerbjorn A, 1999, J ANIM ECOL, V68, P34, DOI 10.1046/j.1365-2656.1999.00258.x; [Anonymous], PATTERNS PROCESSES M; Bailey, 1993, AFRICAN LEOPARD ECOL; BANSE K, 1980, ECOL MONOGR, V50, P355, DOI 10.2307/2937256; Berger J, 2001, SCIENCE, V291, P1036, DOI 10.1126/science.1056466; Bininda-Emonds ORP, 1999, BIOL REV, V74, P143, DOI 10.1017/S0006323199005307; Blackburn TM, 1996, OIKOS, V75, P303, DOI 10.2307/3546254; Brown J.H., 1995, MACROECOLOGY; Brown JH, 2000, SFI S SCI C, P1; Calder WA, 2000, SFI S SCI C, P297; Carbone C, 1999, NATURE, V402, P286, DOI 10.1038/46266; DAMUTH J, 1981, NATURE, V290, P699, DOI 10.1038/290699a0; Damuth JD, 1998, NATURE, V395, P115, DOI 10.1038/25843; Dewar RC, 1999, NATURE, V398, P572, DOI 10.1038/19215; EAST R, 1984, AFR J ECOL, V22, P245, DOI 10.1111/j.1365-2028.1984.tb00700.x; Enquist BJ, 1998, NATURE, V395, P163, DOI 10.1038/25977; Enquist BJ, 1999, NATURE, V398, P573, DOI 10.1038/19219; FARLOW JO, 1976, ECOLOGY, V57, P841, DOI 10.2307/1941052; Fuller TK, 1998, ANIM CONSERV, V1, P153, DOI 10.1111/j.1469-1795.1998.tb00023.x; Fuller TK, 2001, CONSERV BIOL SER, V5, P163; Gittleman JL, 2001, SCIENCE, V291, P997, DOI 10.1126/science.291.5506.997; Hilton-Taylor C., 2000, 2000 IUCN RED LIST T; Hubbell Stephen P., 2001, V32, pi; JEDRZEJEWSKI B, 1998, PREDATION VERTEBRATE; Jobin A, 2000, ACTA THERIOL, V45, P243, DOI 10.4098/AT.arch.00-26; KRUUK H, 1982, J ZOOL, V196, P31; LAURENSON MK, 1995, CONSERV BIOL, V9, P1329, DOI 10.1046/j.1523-1739.1995.9051327.x-i1; Magnani F, 1999, NATURE, V398, P572, DOI 10.1038/19217; Marquet PA, 2000, SCIENCE, V289, P1487, DOI 10.1126/science.289.5484.1487; Mills MGL, 1997, CONSERV BIOL, V11, P1397, DOI 10.1046/j.1523-1739.1997.96252.x; MOLINARIJOBIN A, IN PRESS WILDLIFE BI; ODonoghue M, 1997, OIKOS, V80, P150, DOI 10.2307/3546526; Portner HO, 2008, SCIENCE, V322, P690, DOI 10.1126/science.1163156; Purvis A, 2000, P ROY SOC B-BIOL SCI, V267, P1947, DOI 10.1098/rspb.2000.1234; PURVIS A, 1995, COMPUT APPL BIOSCI, V11, P247; Smallwood KS, 1996, OECOLOGIA, V105, P329, DOI 10.1007/BF00328735; Stirling I, 1995, CAN J FISH AQUAT SCI, V52, P2594, DOI 10.1139/f95-849; VEZINA AF, 1985, OECOLOGIA, V67, P555, DOI 10.1007/BF00790027	38	430	441	3	130	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 22	2002	295	5563					2273	2276		10.1126/science.1067994	http://dx.doi.org/10.1126/science.1067994			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	534AD	11910114				2022-12-28	WOS:000174561700048
J	Hirsch, JE				Hirsch, JE			Superconductivity - The true colors of cuprates	SCIENCE			English	Editorial Material							INTERLAYER; MECHANISM		Univ Calif San Diego, Dept Phys, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Hirsch, JE (corresponding author), Univ Calif San Diego, Dept Phys, La Jolla, CA 92093 USA.		Hirsch, JE E/H-4045-2015	Hirsch, JE E/0000-0001-7175-3497				Anderson PW, 2000, PHYSICA C, V341, P9, DOI 10.1016/S0921-4534(00)00378-6; BARDEEN J, 1957, PHYS REV, V108, P1175, DOI 10.1103/PhysRev.108.1175; Basov DN, 1999, SCIENCE, V283, P49, DOI 10.1126/science.283.5398.49; BEDNORZ JG, 1986, Z PHYS B CON MAT, V64, P189, DOI 10.1007/BF01303701; Carlson EW, 2000, PHYS REV B, V62, P3422, DOI 10.1103/PhysRevB.62.3422; Chakravarty S, 1999, PHYS REV LETT, V82, P2366, DOI 10.1103/PhysRevLett.82.2366; HIRSCH JE, 1989, PHYSICA C, V162, P591, DOI 10.1016/0921-4534(89)91165-9; HIRSCH JE, 1992, PHYSICA C, V201, P347, DOI 10.1016/0921-4534(92)90483-S; Hirsch JE, 2000, PHYS REV B, V62, P15131, DOI 10.1103/PhysRevB.62.15131; Hirschlaff E, 1937, P CAMB PHILOS SOC, V33, P140; HONG XQ, 1992, PHYS REV B, V46, P14702, DOI 10.1103/PhysRevB.46.14702; Loram JW, 2000, PHYSICA C, V341, P831, DOI 10.1016/S0921-4534(00)00706-1; MCCRUM NG, 1954, P PHYS SOC LOND A, V67, P386, DOI 10.1088/0370-1298/67/4/412; Molegraaf HJA, 2002, SCIENCE, V295, P2239, DOI 10.1126/science.1069947; Moler KA, 1998, SCIENCE, V279, P1193, DOI 10.1126/science.279.5354.1193; SANTANDERSYRO AF, UNPUB; Scalapino DJ, 1999, SCIENCE, V284, P1282, DOI 10.1126/science.284.5418.1282; Tinkham M., 1996, INTRO SUPERCONDUCTIV, V2nd ed.; Tsvetkov AA, 1998, NATURE, V395, P360, DOI 10.1038/26439; WHEATLEY JM, 1988, PHYS REV B, V37, P5897, DOI 10.1103/PhysRevB.37.5897	20	55	56	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 22	2002	295	5563					2226	2227		10.1126/science.1070866	http://dx.doi.org/10.1126/science.1070866			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	534AD	11910097				2022-12-28	WOS:000174561700030
